<SEC-DOCUMENT>0001683168-26-002026.txt : 20260319
<SEC-HEADER>0001683168-26-002026.hdr.sgml : 20260319
<ACCEPTANCE-DATETIME>20260319170029
ACCESSION NUMBER:		0001683168-26-002026
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		90
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20260319
DATE AS OF CHANGE:		20260319

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Coeptis Therapeutics Holdings, Inc.
		CENTRAL INDEX KEY:			0001759186
		STANDARD INDUSTRIAL CLASSIFICATION:	FINANCE SERVICES [6199]
		ORGANIZATION NAME:           	09 Crypto Assets
		EIN:				981465952
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39669
		FILM NUMBER:		26775044

	BUSINESS ADDRESS:	
		STREET 1:		105 BRADFORD ROAD, SUITE 420
		CITY:			WEXFORD
		STATE:			PA
		ZIP:			15090
		BUSINESS PHONE:		724-934-6467

	MAIL ADDRESS:	
		STREET 1:		105 BRADFORD ROAD, SUITE 420
		CITY:			WEXFORD
		STATE:			PA
		ZIP:			15090

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Bull Horn Holdings Corp.
		DATE OF NAME CHANGE:	20181115
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>coeptis_i10k-123125.htm
<DESCRIPTION>FORM 10-K FOR DEC 2025
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:coep="http://coeptistx.com/20251231">
<head>
     <title>Coeptis Therapeutics Holdings, Inc. 10-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2025%2D(with%2DECD%2Dand%2DCYD) -->
<!-- Field: Set; Name: xdx; ID: xdx_037_coep_coeptistx.com_20251231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04E_20250101_20251231 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05C_edei%2D%2DDocumentFiscalYearFocus_2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_055_edei%2D%2DEntityCentralIndexKey_0001759186 -->
<!-- Field: Set; Name: xdx; ID: xdx_07D_SO_coeptis__i10k%2D123125.xdxs -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_061_Integer_0_Integer -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000004" name="dei:DocumentFiscalYearFocus">2025</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000005" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000006" name="dei:EntityCentralIndexKey">0001759186</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0368" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_custom_CommonStockSubscribedMember" id="xdx2ixbrl0371" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl0372" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0373" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0375" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:SharesIssuedInConnectionWithSEPAValue" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0380" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:SharesIssuedInConnectionWithSEPAValue" contextRef="From2024-01-012024-12-31_custom_CommonStockSubscribedMember" id="xdx2ixbrl0383" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:SharesIssuedInConnectionWithSEPAValue" contextRef="From2024-01-012024-12-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl0384" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:SharesIssuedInConnectionWithSEPAValue" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0385" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:SharesIssuedInConnectionWithSEPAValue" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0387" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0392" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-012024-12-31_custom_CommonStockSubscribedMember" id="xdx2ixbrl0395" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-012024-12-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl0396" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0397" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0399" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:StockIssuedDuringPeriodValueWarrantsIssuedForCash" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0404" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:StockIssuedDuringPeriodValueWarrantsIssuedForCash" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0405" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:StockIssuedDuringPeriodValueWarrantsIssuedForCash" contextRef="From2024-01-012024-12-31_custom_CommonStockSubscribedMember" id="xdx2ixbrl0407" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:StockIssuedDuringPeriodValueWarrantsIssuedForCash" contextRef="From2024-01-012024-12-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl0408" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:StockIssuedDuringPeriodValueWarrantsIssuedForCash" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0409" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:StockIssuedDuringPeriodValueWarrantsIssuedForCash" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0411" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0414" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0415" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-01-012024-12-31_custom_CommonStockSubscribedMember" id="xdx2ixbrl0417" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-01-012024-12-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl0418" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0419" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0421" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:WarrantsIssuedInExchangeForSubscriptionsReceivable" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0424" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:WarrantsIssuedInExchangeForSubscriptionsReceivable" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0425" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:WarrantsIssuedInExchangeForSubscriptionsReceivable" contextRef="From2024-01-012024-12-31_custom_CommonStockSubscribedMember" id="xdx2ixbrl0427" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:WarrantsIssuedInExchangeForSubscriptionsReceivable" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0429" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:WarrantsIssuedInExchangeForSubscriptionsReceivable" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0431" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:SharesIssuedForConversionOfDebtValue" contextRef="From2024-01-012024-12-31_custom_CommonStockSubscribedMember" id="xdx2ixbrl0437" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:SharesIssuedForConversionOfDebtValue" contextRef="From2024-01-012024-12-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl0438" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:SharesIssuedForConversionOfDebtValue" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0439" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:SharesIssuedForConversionOfDebtValue" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0441" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:StockIssuedDuringPeriodValueOfPreferredShareOffering" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0449" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:StockIssuedDuringPeriodValueOfPreferredShareOffering" contextRef="From2024-01-012024-12-31_custom_CommonStockSubscribedMember" id="xdx2ixbrl0451" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:StockIssuedDuringPeriodValueOfPreferredShareOffering" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0453" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:StockIssuedDuringPeriodValueOfInvestmentsAssignmentAgreements" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0460" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:StockIssuedDuringPeriodValueOfInvestmentsAssignmentAgreements" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0461" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:StockIssuedDuringPeriodValueOfInvestmentsAssignmentAgreements" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0462" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:StockIssuedDuringPeriodValueOfInvestmentsAssignmentAgreements" contextRef="From2024-01-012024-12-31_custom_CommonStockSubscribedMember" id="xdx2ixbrl0463" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:StockIssuedDuringPeriodValueOfInvestmentsAssignmentAgreements" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0465" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:StockIssuedDuringPeriodValueOfInvestmentsAssignmentAgreements" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0467" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:StockIssuedDuringPeriodValuePurchaseOfAssets1" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0470" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:StockIssuedDuringPeriodValuePurchaseOfAssets1" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0471" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:StockIssuedDuringPeriodValuePurchaseOfAssets1" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0472" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:StockIssuedDuringPeriodValuePurchaseOfAssets1" contextRef="From2024-01-012024-12-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl0474" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:StockIssuedDuringPeriodValuePurchaseOfAssets1" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0475" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:StockIssuedDuringPeriodValuePurchaseOfAssets1" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0477" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0480" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0481" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_custom_CommonStockSubscribedMember" id="xdx2ixbrl0483" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl0484" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0485" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0487" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0490" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0491" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31_custom_CommonStockSubscribedMember" id="xdx2ixbrl0493" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl0494" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0495" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0497" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0502" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0503" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0504" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31_custom_CommonStockSubscribedMember" id="xdx2ixbrl0505" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl0506" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0526" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-12-31_custom_CommonStockSubscribedMember" id="xdx2ixbrl0529" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0531" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0533" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:SharesIssuedInConnectionWithSEPAValue" contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0538" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:SharesIssuedInConnectionWithSEPAValue" contextRef="From2025-01-012025-12-31_custom_CommonStockSubscribedMember" id="xdx2ixbrl0541" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:SharesIssuedInConnectionWithSEPAValue" contextRef="From2025-01-012025-12-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl0542" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:SharesIssuedInConnectionWithSEPAValue" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0543" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:SharesIssuedInConnectionWithSEPAValue" contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0545" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0550" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-012025-12-31_custom_CommonStockSubscribedMember" id="xdx2ixbrl0553" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-012025-12-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl0554" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0555" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0557" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:SharesIssuedForInvestmentValue" contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0562" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:SharesIssuedForInvestmentValue" contextRef="From2025-01-012025-12-31_custom_CommonStockSubscribedMember" id="xdx2ixbrl0565" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:SharesIssuedForInvestmentValue" contextRef="From2025-01-012025-12-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl0566" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:SharesIssuedForInvestmentValue" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0567" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:SharesIssuedForInvestmentValue" contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0569" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0586" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0587" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2025-01-012025-12-31_custom_CommonStockSubscribedMember" id="xdx2ixbrl0589" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2025-01-012025-12-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl0590" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0591" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0593" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:StockIssuedDuringPeriodValuePrefundedWarrantsExercise" contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0596" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:StockIssuedDuringPeriodValuePrefundedWarrantsExercise" contextRef="From2025-01-012025-12-31_custom_CommonStockSubscribedMember" id="xdx2ixbrl0599" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:StockIssuedDuringPeriodValuePrefundedWarrantsExercise" contextRef="From2025-01-012025-12-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl0600" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:StockIssuedDuringPeriodValuePrefundedWarrantsExercise" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0601" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:StockIssuedDuringPeriodValuePrefundedWarrantsExercise" contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0603" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:StockIssuedDuringPeriodValueOfPreferredShareOffering" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0609" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:StockIssuedDuringPeriodValueOfPreferredShareOffering" contextRef="From2025-01-012025-12-31_custom_CommonStockSubscribedMember" id="xdx2ixbrl0611" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:StockIssuedDuringPeriodValueOfPreferredShareOffering" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0613" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:StockIssuedDuringPeriodValuePreferredShareConversion" contextRef="From2025-01-012025-12-31_custom_CommonStockSubscribedMember" id="xdx2ixbrl0623" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:StockIssuedDuringPeriodValuePreferredShareConversion" contextRef="From2025-01-012025-12-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl0624" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:StockIssuedDuringPeriodValuePreferredShareConversion" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0625" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:StockIssuedDuringPeriodValuePreferredShareConversion" contextRef="From2025-01-012025-12-31_us-gaap_ParentMember" id="xdx2ixbrl0626" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:StockIssuedDuringPeriodValuePreferredShareConversion" contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0627" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="coep:StockIssuedDuringPeriodValuePreferredShareConversion" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0628" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0634" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-01-012025-12-31_custom_CommonStockSubscribedMember" id="xdx2ixbrl0637" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-01-012025-12-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl0638" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0639" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0641" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0646" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0647" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-012025-12-31_custom_CommonStockSubscribedMember" id="xdx2ixbrl0649" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-012025-12-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl0650" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0651" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0653" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0656" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0657" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0658" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-01-012025-12-31_custom_CommonStockSubscribedMember" id="xdx2ixbrl0659" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-01-012025-12-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl0660" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NumberOfReportableSegments" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl1755" decimals="INF" unitRef="Integer">2</ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="coep-20251231.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2025-01-01to2025-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_CommonStockParValue0.0001PerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:CommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_WarrantsEachWholeWarrantExercisableForOnehalfOfOneShareOfCommonStockFor230.00PerWholeShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantsEachWholeWarrantExercisableForOnehalfOfOneShareOfCommonStockFor230.00PerWholeShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-18">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_SaleMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">coep:SaleMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SaleMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">coep:SaleMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_CommonStockSubscribedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">coep:CommonStockSubscribedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubscriptionReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">coep:SubscriptionReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_ParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_CommonStockSubscribedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">coep:CommonStockSubscribedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SubscriptionReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">coep:SubscriptionReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_ParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_CommonStockSubscribedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">coep:CommonStockSubscribedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SubscriptionReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">coep:SubscriptionReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_ParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_CommonStockSubscribedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">coep:CommonStockSubscribedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_SubscriptionReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">coep:SubscriptionReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_ParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_CommonStockSubscribedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">coep:CommonStockSubscribedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_SubscriptionReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">coep:SubscriptionReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_ParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-12-012024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-12-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_NexGenAIMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">coep:NexGenAIMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_NexGenAIMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">coep:NexGenAIMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_SixCustomersMember_custom_AdvertisingCampaignsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">coep:SixCustomersMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">coep:AdvertisingCampaignsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_AdvertisingCampaignsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">coep:AdvertisingCampaignsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_AdvertisingCampaignsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">coep:AdvertisingCampaignsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_ThreeCustomersMember_custom_WebinarServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">coep:ThreeCustomersMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">coep:WebinarServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_WebinarServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">coep:WebinarServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">coep:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">coep:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">coep:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">coep:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_PreferredStockMember206520625">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember206520625">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_CD38AssetsMember_custom_VyGenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">coep:CD38AssetsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">coep:VyGenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_CD38AssetsMember_custom_VyGenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">coep:CD38AssetsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">coep:VyGenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_CD38AssetsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">coep:CD38AssetsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_CoDevelopmentRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">coep:CoDevelopmentRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_CoDevelopmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">coep:CoDevelopmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_CoDevelopmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">coep:CoDevelopmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_LicenseAgreementMember_custom_PurpleBioTechMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">coep:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">coep:PurpleBioTechMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-09-022021-09-30_custom_LicenseAgreementMember_custom_PurpleBioTechMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">coep:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">coep:PurpleBioTechMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-09-02</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_LicenseAgreementMember_custom_PurpleBioTechMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">coep:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">coep:PurpleBioTechMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_LicenseAgreementMember_custom_PurpleBioTechMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">coep:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">coep:PurpleBioTechMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-10-31_custom_Oct2022ConvertiblePromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">coep:Oct2022ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-262023-10-27_custom_Oct2022ConvertiblePromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">coep:Oct2022ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-26</xbrli:startDate>
        <xbrli:endDate>2023-10-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-142023-12-15_custom_Oct2022ConvertiblePromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">coep:Oct2022ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-14</xbrli:startDate>
        <xbrli:endDate>2023-12-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_Oct2022ConvertiblePromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">coep:Oct2022ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_Dec2023ConvertiblePromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">coep:Dec2023ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-232024-04-24_custom_Dec2023ConvertiblePromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">coep:Dec2023ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-23</xbrli:startDate>
        <xbrli:endDate>2024-04-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_Dec2023ConvertiblePromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">coep:Dec2023ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-17_us-gaap_RelatedPartyMember_custom_April2024UnsecuredNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">coep:April2024UnsecuredNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-162024-04-17_us-gaap_RelatedPartyMember_custom_April2024UnsecuredNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">coep:April2024UnsecuredNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-16</xbrli:startDate>
        <xbrli:endDate>2024-04-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-03_custom_YANote1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">coep:YANote1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_custom_YANote1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">coep:YANote1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012024-10-31_custom_YANote1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">coep:YANote1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-02_custom_YorkvilleConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">coep:YorkvilleConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-012024-11-02_custom_YANote1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">coep:YANote1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-01</xbrli:startDate>
        <xbrli:endDate>2024-11-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_YorkvilleConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">coep:YorkvilleConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_YorkvilleConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">coep:YorkvilleConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_YorkvilleConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">coep:YorkvilleConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_StandbyEquityPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_StandbyEquityPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_StandbyEquityPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-16_custom_YorkvilleConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">coep:YorkvilleConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-152025-01-16_custom_YorkvilleConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">coep:YorkvilleConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-15</xbrli:startDate>
        <xbrli:endDate>2025-01-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_YANote2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">coep:YANote2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_YorkvilleConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">coep:YorkvilleConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_DerivativeLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:DerivativeLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_DerivativeLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:DerivativeLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_MeasurementInputConversionPriceMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_MeasurementInputSharePriceMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-012024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-072020-07-08_custom_EidlLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">coep:EidlLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-07</xbrli:startDate>
        <xbrli:endDate>2020-07-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-07-08_custom_EidlLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">coep:EidlLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-07-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_EidlLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">coep:EidlLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_EidlLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">coep:EidlLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_PublicWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">coep:PublicWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PublicWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">coep:PublicWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_PrivatePlacementWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">coep:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PrivatePlacementWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">coep:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_PublicWarrantsMember_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:PublicWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PublicWarrantsMember_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:PublicWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_PrivatePlacementWarrantsMember_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PrivatePlacementWarrantsMember_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_MeasurementInputExercisePriceMember_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_MeasurementInputExercisePriceMember_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_MeasurementInputSharePriceMember_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_MeasurementInputSharePriceMember_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PrivatePlacementWarrantsMember206522015">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PublicWarrantsMember206522015">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:PublicWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_WarrantLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:WarrantLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_PrivatePlacementWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_PublicWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:PublicWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_WarrantLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:WarrantLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_PrivatePlacementWarrantsMember206522046">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_PublicWarrantsMember206522046">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:PublicWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_WarrantLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:WarrantLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_CommonStockMember206522296">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-152023-06-16_custom_PublicOfferingMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">coep:PublicOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-15</xbrli:startDate>
        <xbrli:endDate>2023-06-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-152023-06-16_custom_PublicOfferingMember_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">coep:PublicOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-15</xbrli:startDate>
        <xbrli:endDate>2023-06-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-152023-06-16_custom_PublicOfferingMember_custom_SeriesAWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">coep:PublicOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:SeriesAWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-15</xbrli:startDate>
        <xbrli:endDate>2023-06-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-152023-06-16_custom_PublicOfferingMember_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">coep:PublicOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-15</xbrli:startDate>
        <xbrli:endDate>2023-06-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-16_custom_PublicOfferingMember_custom_SeriesWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">coep:PublicOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:SeriesWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_PublicOfferingMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">coep:PublicOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-272023-12-28_custom_WarrantNoteSubscriptionReceivablesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantNoteSubscriptionReceivablesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-27</xbrli:startDate>
        <xbrli:endDate>2023-12-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_SNAPBiosciencesIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">coep:SNAPBiosciencesIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-10-012025-12-31_custom_TwoInvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">coep:TwoInvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_TwoInvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">coep:TwoInvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TwoInvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">coep:TwoInvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-122024-06-13_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-12</xbrli:startDate>
        <xbrli:endDate>2024-06-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-302024-07-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-30</xbrli:startDate>
        <xbrli:endDate>2024-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-09-032024-09-04_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-09-03</xbrli:startDate>
        <xbrli:endDate>2024-09-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-12-222024-12-23_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-12-22</xbrli:startDate>
        <xbrli:endDate>2024-12-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-052025-02-06_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-05</xbrli:startDate>
        <xbrli:endDate>2025-02-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-25_custom_ConsultingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">coep:ConsultingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_StockOptionsMember206522468">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">coep:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_StockOptionsMember206522468">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">coep:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-232025-03-24_custom_ColleenDelaneyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">coep:ColleenDelaneyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-23</xbrli:startDate>
        <xbrli:endDate>2025-03-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-24_custom_ColleenDelaneyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">coep:ColleenDelaneyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_ColleenDelaneyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">coep:ColleenDelaneyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-12-012025-12-31_custom_ModificationOfOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">coep:ModificationOfOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-12-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-11-23_custom_CoralInvestmentPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">coep:CoralInvestmentPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-11-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-11-23_custom_CoralInvestmentPartnersMember_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">coep:CoralInvestmentPartnersMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-11-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-11-23_custom_CoralInvestmentPartnersMember_us-gaap_CommonClassBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">coep:CoralInvestmentPartnersMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-11-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-012023-09-30_custom_SubscriptionReceivableSept2023Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">coep:SubscriptionReceivableSept2023Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_SubscriptionReceivableSept2023Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">coep:SubscriptionReceivableSept2023Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SubscriptionReceivableSept2023Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">coep:SubscriptionReceivableSept2023Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-012023-09-30_custom_SubscriptionReceivableSept20232ndMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">coep:SubscriptionReceivableSept20232ndMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_SubscriptionReceivableSept20232ndMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">coep:SubscriptionReceivableSept20232ndMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SubscriptionReceivableSept20232ndMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">coep:SubscriptionReceivableSept20232ndMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_December2023FinancingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">coep:December2023FinancingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_December2023FinancingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">coep:December2023FinancingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_December2023FinancingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">coep:December2023FinancingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-28_custom_February2024FinancingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">coep:February2024FinancingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_February2024FinancingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">coep:February2024FinancingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_February2024FinancingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">coep:February2024FinancingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-292024-11-02_custom_StandbyEquityPurchaseAgreementMember_custom_YorkvilleMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">coep:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">coep:YorkvilleMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-29</xbrli:startDate>
        <xbrli:endDate>2024-11-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-292024-11-02_custom_StandbyEquityPurchaseAgreementMember_custom_YorkvilleMember_custom_StockIssuedForServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">coep:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">coep:YorkvilleMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">coep:StockIssuedForServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-29</xbrli:startDate>
        <xbrli:endDate>2024-11-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-02_custom_StandbyEquityPurchaseAgreementMember_custom_YorkvilleMember_custom_ConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">coep:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">coep:YorkvilleMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">coep:ConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_StandbyEquityPurchaseAgreementMember206522812">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">coep:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">coep:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">coep:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">coep:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">coep:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_WarrantHolder1ExercisePrice59.40Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder1ExercisePrice59.40Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_WarrantHolder1ExercisePrice59.40Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder1ExercisePrice59.40Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_WarrantHolder1ExercisePrice59.40Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder1ExercisePrice59.40Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_WarrantHolder1ExercisePrice118.80Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder1ExercisePrice118.80Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_WarrantHolder1ExercisePrice118.80Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder1ExercisePrice118.80Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_WarrantHolder1ExercisePrice118.80Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder1ExercisePrice118.80Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_WarrantHolder1ExercisePrice296.80Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder1ExercisePrice296.80Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_WarrantHolder1ExercisePrice296.80Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder1ExercisePrice296.80Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_WarrantHolder1ExercisePrice296.80Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder1ExercisePrice296.80Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_WarrantHolder2ExercisePrice59.40Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder2ExercisePrice59.40Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_WarrantHolder2ExercisePrice59.40Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder2ExercisePrice59.40Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_WarrantHolder2ExercisePrice59.40Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder2ExercisePrice59.40Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_WarrantHolder2ExercisePrice296.80Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder2ExercisePrice296.80Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_WarrantHolder2ExercisePrice296.80Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder2ExercisePrice296.80Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_WarrantHolder2ExercisePrice296.80Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder2ExercisePrice296.80Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_WarrantHolder5ExercisePrice59.40Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder5ExercisePrice59.40Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_WarrantHolder5ExercisePrice59.40Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder5ExercisePrice59.40Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_WarrantHolder5ExercisePrice59.40Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder5ExercisePrice59.40Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_WarrantHolder18ExercisePrice178.20Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder18ExercisePrice178.20Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_WarrantHolder18ExercisePrice178.20Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder18ExercisePrice178.20Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_WarrantHolder18ExercisePrice178.20Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder18ExercisePrice178.20Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_WarrantHolder20ExercisePrice50.00Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder20ExercisePrice50.00Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_WarrantHolder20ExercisePrice50.00Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder20ExercisePrice50.00Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_WarrantHolder20ExercisePrice50.00Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder20ExercisePrice50.00Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_WarrantHolder21ExercisePrice38.00Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder21ExercisePrice38.00Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_WarrantHolder21ExercisePrice38.00Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder21ExercisePrice38.00Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_WarrantHolder21ExercisePrice38.00Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder21ExercisePrice38.00Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_SeriesWarrantsAAndBExercisePrice27.20Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:SeriesWarrantsAAndBExercisePrice27.20Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_SeriesWarrantsAAndBExercisePrice27.20Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:SeriesWarrantsAAndBExercisePrice27.20Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SeriesWarrantsAAndBExercisePrice27.20Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:SeriesWarrantsAAndBExercisePrice27.20Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_SeriesAWarrantsExercisePrice27.20Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:SeriesAWarrantsExercisePrice27.20Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_SeriesAWarrantsExercisePrice27.20Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:SeriesAWarrantsExercisePrice27.20Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SeriesAWarrantsExercisePrice27.20Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:SeriesAWarrantsExercisePrice27.20Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_SeriesBWarrantsExercisePrice27.20Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:SeriesBWarrantsExercisePrice27.20Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_SeriesBWarrantsExercisePrice27.20Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:SeriesBWarrantsExercisePrice27.20Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SeriesBWarrantsExercisePrice27.20Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:SeriesBWarrantsExercisePrice27.20Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_WarrantHolder22ExercisePrice25.00Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder22ExercisePrice25.00Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_WarrantHolder22ExercisePrice25.00Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder22ExercisePrice25.00Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_WarrantHolder22ExercisePrice25.00Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder22ExercisePrice25.00Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_WarrantHolder22ExercisePrice28.00Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder22ExercisePrice28.00Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_WarrantHolder22ExercisePrice28.00Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder22ExercisePrice28.00Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_WarrantHolder22ExercisePrice28.00Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder22ExercisePrice28.00Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_WarrantHolder23ExercisePrice25.00Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder23ExercisePrice25.00Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_WarrantHolder23ExercisePrice25.00Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder23ExercisePrice25.00Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_WarrantHolder23ExercisePrice25.00Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder23ExercisePrice25.00Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_WarrantHolder23ExercisePrice28.00Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder23ExercisePrice28.00Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_WarrantHolder23ExercisePrice28.00Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder23ExercisePrice28.00Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_WarrantHolder23ExercisePrice28.00Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder23ExercisePrice28.00Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_WarrantHolder24ExercisePrice28.00Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder24ExercisePrice28.00Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_WarrantHolder24ExercisePrice28.00Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder24ExercisePrice28.00Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_WarrantHolder24ExercisePrice28.00Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder24ExercisePrice28.00Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_PreFundedWarrants2ExercisePrice0.002Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:PreFundedWarrants2ExercisePrice0.002Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_PreFundedWarrants2ExercisePrice0.002Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:PreFundedWarrants2ExercisePrice0.002Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PreFundedWarrants2ExercisePrice0.002Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:PreFundedWarrants2ExercisePrice0.002Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_PreFundedWarrants3ExercisePrice0.002Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:PreFundedWarrants3ExercisePrice0.002Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_PreFundedWarrants3ExercisePrice0.002Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:PreFundedWarrants3ExercisePrice0.002Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PreFundedWarrants3ExercisePrice0.002Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:PreFundedWarrants3ExercisePrice0.002Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_WarrantHolder25ExercisePrice12.00Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder25ExercisePrice12.00Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_WarrantHolder25ExercisePrice12.00Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder25ExercisePrice12.00Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_WarrantHolder25ExercisePrice12.00Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder25ExercisePrice12.00Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_GearTherapeuticsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">coep:GearTherapeuticsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-31_custom_TwoPrivatelyHeldCompaniesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">coep:TwoPrivatelyHeldCompaniesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_NexGenAIAffiliatesNetworkPlatformMember_custom_FivePrivatelyHeldCompaniesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">coep:NexGenAIAffiliatesNetworkPlatformMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">coep:FivePrivatelyHeldCompaniesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_NexGenAIAffiliatesNetworkPlatformMember_custom_ThreePrivatelyHeldCompaniesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">coep:NexGenAIAffiliatesNetworkPlatformMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">coep:ThreePrivatelyHeldCompaniesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-11-012025-12-31_custom_NexGenAIAffiliatesNetworkPlatformMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">coep:NexGenAIAffiliatesNetworkPlatformMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-11-012025-11-30_custom_PrivatelyHeldCompanyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">coep:PrivatelyHeldCompanyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-01</xbrli:startDate>
        <xbrli:endDate>2025-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-11-30_custom_PrivatelyHeldCompanyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">coep:PrivatelyHeldCompanyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-11-012025-12-31_custom_PrivatelyHeldCompanyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">coep:PrivatelyHeldCompanyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_FirstYearExtensionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">coep:FirstYearExtensionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_SecondYearExtensionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">coep:SecondYearExtensionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_MehalickMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">coep:MehalickMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_YeraceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">coep:YeraceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-31_custom_CarTLicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">coep:CarTLicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-292022-08-31_custom_CarTLicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">coep:CarTLicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-29</xbrli:startDate>
        <xbrli:endDate>2022-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_CarTLicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">coep:CarTLicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_FindersFeeAndIndemnityAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">coep:FindersFeeAndIndemnityAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_MasterServicesAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">coep:MasterServicesAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_MasterServicesAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">coep:MasterServicesAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_GearCellTherapyPlatformMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">coep:GearCellTherapyPlatformMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-292023-09-30_custom_AGBioLifeCapitalILPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">coep:AGBioLifeCapitalILPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-29</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-12_custom_AGBioLifeCapitalILPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">coep:AGBioLifeCapitalILPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_AGBioLifeCapitalILPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">coep:AGBioLifeCapitalILPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_AGBioLifeCapitalILPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">coep:AGBioLifeCapitalILPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_BoardOfDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">coep:BoardOfDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-12-182024-12-19_custom_NexGenAISolutionsGroupIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">coep:NexGenAISolutionsGroupIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-12-18</xbrli:startDate>
        <xbrli:endDate>2024-12-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_NexGenAIMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">coep:NexGenAIMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_NexGenAIMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">coep:NexGenAIMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_NexGenAIMember206525843">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">coep:NexGenAIMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_NexGenAIMember206525843">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">coep:NexGenAIMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_BiotechnologySegmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">coep:BiotechnologySegmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_BiotechnologySegmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">coep:BiotechnologySegmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_TechnologySegmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">coep:TechnologySegmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TechnologySegmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">coep:TechnologySegmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_BiotechnologyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">coep:BiotechnologyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_TechnologyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">coep:TechnologyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_BiotechnologyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">coep:BiotechnologyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_TechnologyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759186</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">coep:TechnologyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Integer">
      <xbrli:measure>coep:Integer</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"><a href="#a_001">Table of Contents</a></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_908_edei--DocumentType_c20250101__20251231_zToBjC3jUegl"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000014" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(Mark One)</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 2%; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--DocumentAnnualReport_c20250101__20251231_ziiPJh1dTaY5"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000015" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span></span></td>
    <td style="vertical-align: bottom; width: 98%; font-size: 10pt"><span style="font-size: 10pt"><b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the Fiscal Year Ended <span id="xdx_902_edei--DocumentPeriodEndDate_c20250101__20251231_zubypbmFBhD5"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:datemonthdayyearen" id="Fact000016" name="dei:DocumentPeriodEndDate"><span id="xdx_906_edei--CurrentFiscalYearEndDate_c20250101__20251231_zJHCWkz6qGN4" title="Current Fiscal Year End Date"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:datemonthdayen" id="Fact000018" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric></span>, 2025</ix:nonNumeric></span>
</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Or</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 2%; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--DocumentTransitionReport_c20250101__20251231_zkMjnSESw7Wf"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000019" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></span></td>
    <td style="vertical-align: bottom; width: 98%; font-size: 10pt"><span style="font-size: 10pt"><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the transition period from _____________
to _____________</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Commission File Number: <span id="xdx_90D_edei--EntityFileNumber_c20250101__20251231_zSK5WS5acosc"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000020" name="dei:EntityFileNumber">001-39669</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_900_edei--EntityRegistrantName_c20250101__20251231_zyIOym0gEDTh"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000021" name="dei:EntityRegistrantName">Coeptis Therapeutics Holdings, Inc.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 50%; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_903_edei--EntityIncorporationStateCountryCode_c20250101__20251231_zydOZge7zURf"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt-sec:stateprovnameen" id="Fact000022" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="width: 50%; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_909_edei--EntityTaxIdentificationNumber_c20250101__20251231_z2YcOI5Qpg36"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000023" name="dei:EntityTaxIdentificationNumber">98-1465952</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: center"><span style="font-size: 10pt">(State or other jurisdiction of incorporation or organization)</span></td>
    <td style="font-size: 10pt; text-align: center"><span style="font-size: 10pt">(I.R.S. Employer Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_905_edei--EntityAddressAddressLine1_c20250101__20251231_z5QV3RItmpL3"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000024" name="dei:EntityAddressAddressLine1">105 Bradford Rd</ix:nonNumeric></span>, <span id="xdx_900_edei--EntityAddressAddressLine2_c20250101__20251231_z9ZyV4lKLQ24"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000025" name="dei:EntityAddressAddressLine2">Suite 420</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90A_edei--EntityAddressCityOrTown_c20250101__20251231_zBAZJWp7sq0l"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000026" name="dei:EntityAddressCityOrTown">Wexford</ix:nonNumeric></span>, <span id="xdx_904_edei--EntityAddressStateOrProvince_c20250101__20251231_zWjgIUZSOKdj"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt-sec:stateprovnameen" id="Fact000027" name="dei:EntityAddressStateOrProvince">Pennsylvania</ix:nonNumeric></span> <span id="xdx_90C_edei--EntityAddressPostalZipCode_c20250101__20251231_zhzJp5ktq8gi"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000028" name="dei:EntityAddressPostalZipCode">15090</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of Principal Executive Offices) (Zip Code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s Telephone Number, Including
Area Code): <b>(<span id="xdx_90C_edei--CityAreaCode_c20250101__20251231_zzrJJTXeqit6"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000029" name="dei:CityAreaCode">724</ix:nonNumeric></span>) <span id="xdx_90B_edei--LocalPhoneNumber_c20250101__20251231_zAsAkaXk2Xjj"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000030" name="dei:LocalPhoneNumber">934-6467</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Securities registered pursuant to Section 12(b)
of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 37%; text-align: center"><span style="font-size: 10pt"><b>Title of Each Class</b></span></td>
    <td style="border-bottom: black 1pt solid; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 24%; text-align: center"><span style="font-size: 10pt"><b>Trading Symbol(s)</b></span></td>
    <td style="border-bottom: black 1pt solid; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 37%; text-align: center"><span style="font-size: 10pt"><b>Name of Each Exchange on which Registered</b></span></td></tr>
  <tr>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; vertical-align: top; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_904_edei--Security12bTitle_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_zTlTT8xsWzs6"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_CommonStockParValue0.0001PerShareMember" id="Fact000031" name="dei:Security12bTitle">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90B_edei--TradingSymbol_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_zMwjqOl0gQU1"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_CommonStockParValue0.0001PerShareMember" id="Fact000032" name="dei:TradingSymbol">COEP</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_908_edei--SecurityExchangeName_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_zTEjQRjY7zf4"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_CommonStockParValue0.0001PerShareMember" format="ixt-sec:exchnameen" id="Fact000033" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</b></span></td></tr>
  <tr>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; vertical-align: top; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90C_edei--Security12bTitle_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantsEachWholeWarrantExercisableForOnehalfOfOneShareOfCommonStockFor230.00PerWholeShareMember_zDOOaDV4yyi2"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantsEachWholeWarrantExercisableForOnehalfOfOneShareOfCommonStockFor230.00PerWholeShareMember" id="Fact000034" name="dei:Security12bTitle">Warrants, each whole warrant exercisable for one-half of one share of Common Stock for $230.00 per whole share</ix:nonNumeric></span> </b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_909_edei--TradingSymbol_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantsEachWholeWarrantExercisableForOnehalfOfOneShareOfCommonStockFor230.00PerWholeShareMember_zi1xSTpCYLT9"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantsEachWholeWarrantExercisableForOnehalfOfOneShareOfCommonStockFor230.00PerWholeShareMember" id="Fact000035" name="dei:TradingSymbol">COEPW</ix:nonNumeric></span></b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_908_edei--SecurityExchangeName_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantsEachWholeWarrantExercisableForOnehalfOfOneShareOfCommonStockFor230.00PerWholeShareMember_zdf4KYEXUeH6"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantsEachWholeWarrantExercisableForOnehalfOfOneShareOfCommonStockFor230.00PerWholeShareMember" format="ixt-sec:exchnameen" id="Fact000036" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Indicate by check mark if the registrant is a well-known
seasoned issuer, as defined in Rule 405 of the Securities Act. Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>&#160;
<span id="xdx_900_edei--EntityWellKnownSeasonedIssuer_c20250101__20251231_zqGPuhzrzgr6"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000037" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark if
the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>&#160;
<span id="xdx_907_edei--EntityVoluntaryFilers_c20250101__20251231_zkNn2CWx80Gk"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000038" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. <span id="xdx_902_edei--EntityCurrentReportingStatus_c20250101__20251231_zlhLj9E5mYh9"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000039" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span>&#160; No <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T
(&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit
such files.) <span id="xdx_902_edei--EntityInteractiveDataCurrent_c20250101__20251231_zVq5UwCe9ara"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000040" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span>&#160; No <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging
growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting
company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 52%"><span style="font-size: 10pt">Large accelerated filer&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span></span></td>
    <td style="width: 48%"><span style="font-size: 10pt">Accelerated filer&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><span id="xdx_905_edei--EntityFilerCategory_c20250101__20251231_zVAqQw6naII9"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt-sec:entityfilercategoryen" id="Fact000041" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span>&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif">&#9746;</span></span></td>
    <td><span style="font-size: 10pt">Smaller reporting company&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_edei--EntitySmallBusiness_c20250101__20251231_zM3TgTnsQDDd"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000042" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Emerging growth company&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_edei--EntityEmergingGrowthCompany_c20250101__20251231_zzysSATDDkfe"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000043" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If an emerging growth company,
indicate by a check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_edei--EntityExTransitionPeriod_c20250101__20251231_z7e7yahIT3Wi"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000044" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control
over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that
prepared or issued its audit report. <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_edei--IcfrAuditorAttestationFlag_c20250101__20251231_zTjk2Epoc4ui"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000045" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If securities are registered
pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing
reflect the correction of an error to previously issued financial statements. <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_edei--DocumentFinStmtErrorCorrectionFlag_c20250101__20251231_zwzWRnAwqg4k"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000046" name="dei:DocumentFinStmtErrorCorrectionFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
any of those error corrections are restatements that required a recovery analysis of incentive- based compensation received by any of
the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by a check mark whether
the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>&#160;
No <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_edei--EntityShellCompany_dbF_c20250101__20251231_z8HtTx8OZ5Y6"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000047" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The aggregate market value
of the voting and non-voting common equity held by non-affiliates of the registrant, as of the last business day of the registrant&#8217;s
most recently completed second fiscal quarter, based on the closing sale price of $7.80 reported on the Nasdaq Capital Market was: $<span id="xdx_90A_edei--EntityPublicFloat_iI_c20250630_zoBKEBTiTuI"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2025-06-30" id="Fact000048" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,225,766</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The number of shares outstanding
of each of the registrant&#8217;s classes of common stock as of the latest practicable date was: <span id="xdx_906_edei--EntityCommonStockSharesOutstanding_iI_c20260318_zdiLujyviuw3"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2026-03-18" id="Fact000049" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,223,221</ix:nonFraction></span>
shares of $0.0001 par value common stock outstanding as of March 18, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">&#160;</td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Coeptis Therapeutics Holdings, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Annual Report on Form 10-K for the Year Ended
December 31, 2025</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="a_001"></span><b>TABLE OF CONTENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><b>Item</b></span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><b>Page</b></span></td></tr>
  <tr>
    <td style="vertical-align: bottom; width: 5%; text-align: center">&#160;</td>
    <td style="vertical-align: top; width: 90%; text-align: center"><a href="#a_004"><span style="font-size: 10pt"><b>Part I</b></span></a></td>
    <td style="vertical-align: bottom; width: 5%">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">1.</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#a_005">Business</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">1</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">1A.</span></td>
    <td style="vertical-align: top"><a href="#a_006"><span style="font-size: 10pt">Risk Factors</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">8</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">1B.</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#a_007">Unresolved Staff Comments</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">23</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">1C.</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#a_008">Cybersecurity</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">2</span>3</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2.</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#a_009">Properties</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">23</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">3.</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#a_010">Legal Proceedings</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">23</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">4.</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#a_011">Mine Safety Disclosures</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">23</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><a href="#a_012"><span style="font-size: 10pt"><b>Part II</b></span></a></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">5.</span></td>
    <td style="vertical-align: top"><a href="#a_013"><span style="font-size: 10pt">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">24</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">6.</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#a_014">Selected Financial Data</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">32</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">7.</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#a_015">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">32</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">7A.</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#a_016">Quantitative and Qualitative Disclosures About Market Risk</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">37</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">8.</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#a_017">Financial Statements and Supplementary Data</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">37</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">9.</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#a_018">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">38</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">9A.</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#a_019">Controls and Procedures</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">38</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">9B.</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#a_020">Other Information</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">39</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><b><a href="#a_021">Part III</a></b></span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">10.</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#a_022">Directors, Executive Officers and Corporate Governance</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">40</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">11.</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#a_023">Executive Compensation</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">46</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">12.</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#a_024">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">50</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">13.</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#a_025">Certain Relationships and Related Transactions, and Director Independence</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">51</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">14.</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#a_026">Principal Accountant Fees and Services</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">53</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><a href="#a_027"><span style="font-size: 10pt"><b>Part IV</b></span></a></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">15.</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#a_028">Exhibits and Financial Statement Schedules</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">54</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">16.</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#a_029">Form 10-K Summary</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">54</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">17.</span></td>
    <td style="vertical-align: top"><a href="#a_030"><span style="font-size: 10pt">Exhibit Index</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">55</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">18.</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#a_031">Signatures</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">56</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Value: 1; Name: PageNo -->i<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="a_002"></span>PRESENTATION OF FINANCIAL AND OTHER INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 28, 2022, Coeptis
Therapeutics Holdings, Inc. (&#8220;Coeptis&#8221;, &#8216;&#8216;we&#8217;&#8217;, &#8216;&#8216;us&#8217;&#8217; or the &#8220;Company&#8221;),
formerly Bull Horn Holdings Corp., acquired Coeptis Therapeutics, Inc. (&#8220;Coeptis Sub&#8221;) in an all-stock transaction. The acquisition
of Coeptis Sub was accomplished through a reverse merger of our wholly owned subsidiary BH Merger Sub, Inc. with and into Coeptis Sub,
with Coeptis Sub determined to be the accounting acquirer of us (the &#8220;Merger&#8221;). As such, the historical financial statements
of the registrant for periods prior to October 28, 2022, are those of Coeptis Sub and, in connection with the acquisition, Coeptis Sub&#8217;s
equity was exchanged for shares of our common stock. The acquisition of Coeptis Sub was treated as a &#8220;reverse merger.&#8221; Unless
otherwise stated or the context otherwise requires, the historical business information described in this Annual Report on Form 10-K prior
to consummation of the acquisition of Coeptis Sub is that of Coeptis Sub and, following consummation of the acquisition of Coeptis Sub,
reflects business information of us and Coeptis Sub on a consolidated basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This report includes our audited
consolidated financial statements as of and for the years ended December 31, 2025 and December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="a_003"></span><b>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Annual Report on Form
10-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking
statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of
1933, as amended (the &#8220;Securities Act&#8221;) and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange
Act&#8221;). All statements other than statements of historical facts contained in this Annual Report on Form 10-K are &#8220;forward-looking
statements&#8221; for purposes of federal and state securities laws, including statements regarding our expectations and projections regarding
future developments, operations and financial conditions, and the anticipated impact of our acquisitions, business strategy, and strategic
priorities. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results,
performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the
forward-looking statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In some cases, you can identify
forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221;
&#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221;
&#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative
of these terms or other similar expressions, although not all forward-looking statements contain these words. The forward-looking statements
in this Annual Report on Form 10-K are only predictions and are based largely on our current expectations and projections about future
events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking
statements speak only as of the date of this Annual Report on Form 10-K and are subject to a number of known and unknown risks, uncertainties
and assumptions. Although we believe the expectations reflected in any of our forward-looking statements are reasonable, actual results
could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results
of operations, as well as any forward-looking statements, are subject to change and inherent risks and uncertainties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These forward-looking statements
present our estimates and assumptions only as of the date of this Annual Report on Form 10-K. Accordingly, you are cautioned not to place
undue reliance on forward-looking statements, which speak only as of the dates on which they are made. Except as required by applicable
law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information,
future events, changed circumstances or otherwise. Important factors that could cause actual results to differ materially from those in
the forward-looking statements include, but are not limited to, those summarized below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 93%; text-align: justify"><span style="font-size: 10pt">We may not be able to successfully implement our growth strategy on a timely basis or at all;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We may have difficulties managing our anticipated growth, or we may not grow at all;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We have a history of losses, we expect to incur losses in the future and we may not be able to achieve or maintain profitability;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We may not be able to initiate and complete preclinical studies and clinical trials for our product candidates which could adversely affect our business;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We may not be able to obtain and maintain the third-party relationships that are necessary to develop, commercialize and manufacture some or all of our product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We may encounter difficulties in managing our growth, which could adversely affect our operations;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We need to obtain financing in order to continue our operations;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The drug development and approval process is uncertain, time-consuming and expensive;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Competition in the biotechnology and pharmaceutical industries may result in competing products, superior marketing of other products and lower revenues or profits for us;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Federal laws or regulations on drug importation could make lower cost versions of our future products available, which could adversely affect our revenues, if any;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The regulatory approval process is costly and lengthy, and we may not be able to successfully obtain all required regulatory approvals;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Healthcare reform measures could adversely affect our business;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Protecting and defending against intellectual property claims may have a material adverse effect on our business;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">If we are not able to retain our current senior management team and our scientific advisors or continue to attract and retain qualified scientific, technical and business personnel, our business will suffer;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We may not be able to maintain our listing on the Nasdaq Capital Market;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">There is a substantial doubt about our ability to continue as a going concern; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The other risks identified in this Annual Report on Form 10-K including, without limitation, those under Part I, Item 1A. &#8220;Risk Factors&#8221; and Part II, Item 7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; as such factors may updated from time to time in our other filings with the SEC.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Given these uncertainties,
you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and
assumptions only as of the date of this Annual Report on Form 10-K and, except as required by law, we undertake no obligation to update
or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of
this Annual Report on Form 10-K. We qualify all of our forward-looking statements by these cautionary statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTE REGARDING TRADEMARKS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We own or have rights to use
the trademarks and trade names that we use in conjunction with the operation of our business. Each trademark or trade name of any other
company appearing in this Annual Report on Form 10-K is, to our knowledge, owned by such other company. Solely for convenience, our trademarks
and trade names referred to in this Annual Report on Form 10-K may appear without the &#174; or &#8482; symbols, but those references are
not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of
the applicable licensor to these trademarks and trade names.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="a_004"></span><b>PART I</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%"><span id="a_005"></span><span style="font-size: 10pt"><b>ITEM 1.</b></span></td>
    <td style="width: 90%"><span style="font-size: 10pt"><b>BUSINESS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>As discussed elsewhere
in this Annual Report on Form 10-K, pursuant to the Merger, we acquired our primary operating subsidiary Coeptis Therapeutics, Inc. Since
prior to the Merger the Company was a shell company, the business description below is a description of the Company&#8217;s business based
on our subsidiaries&#8217; operations.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Company History</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration: underline">General</span>. </i>We
were originally incorporated in the British Virgin Islands on November 27, 2018, under the name Bull Horn Holdings Corp. On October 27,
2022, Bull Horn Holdings Corp. domesticated from the British Virgin Islands to the State of Delaware. On October 28, 2022, in connection
with the closing of the Merger, we changed our corporate name from Bull Horn Holdings Corp. to &#8220;Coeptis Therapeutics Holdings, Inc.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration: underline">The Merger Transaction</span>.
</i>On October 28, 2022, a wholly owned subsidiary of Bull Horn Holdings Corp., merged with and into Coeptis Therapeutics, Inc., with
Coeptis Therapeutics, Inc. as the surviving corporation of the Merger. As a result of the Merger, we acquired the business of Coeptis
Therapeutics, Inc., which we now continue to operate as our wholly owned subsidiary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration: underline">About the Company&#8217;s
Subsidiaries</span>.</i> We are now a holding company that currently operates through our direct and indirect subsidiaries SNAP Biosciences,
Inc. and GEAR Therapeutics, Inc., which are majority owned, and Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc. and Coeptis
Pharmaceuticals, LLC, which are wholly owned.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Coeptis is a biopharmaceutical
and technology company. The biopharmaceutical division focuses on developing innovative cell therapy platforms for cancer, autoimmune,
and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its cutting-edge research and
development efforts. The technology division&#160;focuses on enhancing operational capabilities through advanced technologies. This division
features AI-powered marketing software and robotic process automation tools designed to optimize business processes and improve overall
efficiency.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Biopharmaceutical Division</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Collaborations for Product Development&#160;&#8212;&#160;Research
and Development</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that there is significant
market opportunity related to each of the assets we are currently pursuing. Set forth below is a brief summary of our current target assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i><span style="text-decoration: underline">Product Pipeline</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="3" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border: black 1pt solid; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Program</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Target Indication</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 42%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pre-Clinical</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 14%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Phase I</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Phase II</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Phase III</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CD38-GEAR-NK</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Protect
CD38+ NK Cells from destruction by anti-CD38 monoclonal antibodies</span></p></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="image_001.jpg" alt="" style="height: 42px; width: 88px"/></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CD38-Diagnostic</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diagnostic tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAB therapy</span></p>
                                                                              <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="image_001.jpg" alt="" style="height: 42px; width: 88px"/></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SNAP-CAR Platform</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SNAP-CAR
cells co-administered with one or more antibody adaptors</span></p></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="image_001.jpg" alt="" style="height: 42px; width: 88px"/></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Unmodified Natural Killer Cells</b></p></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acute Myeloid Leukemia</span></td>
    <td colspan="2" style="border-right: black 1pt solid; border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="image_002.jpg" alt="" style="height: 45px; width: 308px"/></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Unmodified Natural Killer Cells</b></p></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acute Respiratory Diseases</span></td>
    <td colspan="2" style="border-right: black 1pt solid; border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="image_002.jpg" alt="" style="height: 45px; width: 308px"/></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><i></i></p>

<!-- Field: Page; Sequence: 5 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Value: 1; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration: underline">License of Stem Cell
Expansion Platform &amp; Acquisition of Phase 1 Studies</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
August 16, 2023, we entered into an exclusive licensing arrangement (the &#8220;License Agreement&#8221;) with Deverra Therapeutics
Inc. (&#8220;Deverra&#8221;), pursuant to which we completed the exclusive license of key patent families and related intellectual
property related to a proprietary allogeneic stem cell expansion and directed differentiation platform for the generation of
multiple distinct immune effector cell types, including natural killer (NK) and monocyte/macrophages. The License Agreement provides
us with exclusive rights to use the license patents and related intellectual property in connection with development and
commercialization efforts in the defined field of use (the &#8220;Field&#8221;) of (a) use of unmodified NK cells as anti-viral
therapeutic for viral infections, and/or as a therapeutic approach for treatment of relapsed/refractory AML and high-risk MDS; (b)
use of Deverra&#8217;s cell therapy platform to generate NK cells for the purpose of engineering with Coeptis SNAP-CARs and/or
Coeptis GEAR Technology; and (c) use of Deverra&#8217;s cell therapy platform to generate myeloid cells for the purpose of
engineering with the Company&#8217;s current SNAP-CAR and GEAR technologies. In support of the exclusive license, the Company also
entered into with Deverra (i) an asset purchase agreement (the &#8220;APA&#8221;) pursuant to which we purchased certain assets from
Deverra, including but not limited to two Investigational New Drug (IND) applications and two Phase 1 clinical trial stage programs
(NCT04901416, NCT04900454) investigating infusion of DVX201, an unmodified natural killer (NK) cell therapy generated from pooled
donor CD34+ cells, in hematologic malignancies and viral infections and (ii) a non-exclusive sublicense agreement (the
&#8220;Sublicense Agreement&#8221;), in support of the assets obtained by the exclusive license, pursuant to which the Company
sublicensed from Deverra certain assets which Deverra has rights pursuant to a license agreement (&#8220;FHCRC Agreement&#8221;) by
and between Deverra and The Fred Hutchinson Cancer Research Center (&#8220;FHCRC&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As consideration for the Deverra
transaction described above, we paid Deverra approximately $570,000 in cash, issued to Deverra 200,000 shares of the Company&#8217;s common
stock and assumed certain liabilities related to the ongoing clinical trials. In addition, in accordance with the terms of the Sublicense
Agreement, the Company agreed to pay FHCRC certain specified contingent running royalty payments and milestone payments under the FHCRC
Agreement, in each case to the extent such payments are triggered by the Company&#8217;s development activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Until December 2024 we operated
under a Shared Services Agreement (&#8220;SSA&#8221;) with Deverra, which provided Coeptis and Deverra to share resources and collaborate
on the development of Coeptis&#8217; GEAR and SNAP-CAR platforms. The Company is continuing its development focus on both GEAR and SNAP-CAR
and is considering prospective strategic partners for such development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration: underline">CD38 Therapeutic and
Diagnostic; Vy-Gen Bio, Inc.</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2021, we entered into
two exclusive option agreements (the &#8220;CD38 Agreements&#8221;) relating to separate technologies (described below) designed to improve
the treatment of CD38-related cancers (e.g., multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia) with Vy-Gen-Bio,
Inc. (&#8220;Vy-Gen&#8221;), a majority-owned subsidiary of Vycellix, Inc., a Tampa, Florida-based private, immune-centric discovery life
science company focused on the development of transformational platform technologies to enhance and optimize next-generation cell and
gene-based therapies, including T-cell and Natural Killer (NK) cell-based cancer therapies. In August 2021, we exercised those two options
and acquired a 50% ownership interest in such technologies. In December 2021, we completed our purchase of the 50% ownership interest
in the CD38-Diagnostic, and subsequently in December 2022 we completed our purchase of the 50% ownership interest for the CD38-GEAR-NK
product candidate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The CD38 Agreements relate
to two separate Vy-Gen drug product candidates, as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt">&#160;</td>
    <td style="width: 2%; font-size: 10pt"><span style="font-size: 10pt">&#8211;</span></td>
    <td style="width: 93%; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">CD38-GEAR-NK. This Vy-Gen drug product candidate is designed to protect CD38+ NK cells from destruction by anti-CD38 monoclonal antibodies, or mAbs. CD38-GEAR-NK is an autologous, NK cell-based therapeutic that is derived from a patient&#8217;s own cells and gene-edited to enable combination therapy with anti-CD38 mAbs. We believe CD38-GEAR-NK possesses the potential to minimize the risks and side effects from CD38-positive NK cell fratricide. While third party license or collaboration agreements are not required in order for Vy-Gen to develop the product to commercial use, potential strategic relationships will be considered on an ongoing basis as a potential strategy. No licenses or collaborations are currently being actively pursued.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>

<!-- Field: Page; Sequence: 6 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><i>Market Opportunity<b>.&#160;</b></i>We
believe CD38-GEAR-NK could potentially revolutionize how CD38-related cancers are treated, by protecting CD38+ NK cells from destruction
by anti-CD38 mAbs, thereby promoting the opportunity to improve the treatment of CD38-related cancers, including multiple myeloma, chronic
lymphocytic leukemia, and acute myeloid leukemia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Multiple myeloma is the first cancer
indication targeted with CD38-GEAR-NK. The global multiple myeloma market was $28.42B in 2024 and is expected to reach $47.04B by 2031
[Source: Data Bridge Market Research].</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><i>GEAR-NK Product Plan Overview.</i>
GEAR-NK is an autologous, gene-edited, natural killer cell-based therapeutic development platform that allows for modified NK cells to
be co-administered with targeted mAbs, which, in the absence of the GEAR-NK, would otherwise be neutralized by mAb therapy. GEAR-NK is
a pre-clinical in vitro proof-of-concept product.. Vy-Gen is actively engaged in the research and development of GEAR-NK, and through
the joint steering committee, we are assessing market opportunities, intellectual property protection and potential regulatory strategy.
No human clinical trials have been conducted for GEAR-NK but are planned for 2027 or later.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%">&#160;</td>
    <td style="width: 2%"><span style="font-size: 10pt">&#8211;</span></td>
    <td style="width: 93%; text-align: justify"><span style="font-size: 10pt">CD38-Diagnostic<b>. </b>This Vy-Gen drug product candidate is an in vitro diagnostic tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. CD38-Diagnostic is an in vitro screening tool that is intended to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 mAb therapies, either as monotherapy or in combination with CD38-GEAR-NK.&#160;Our management believes that CD38-Diagnostic also has the potential to develop as a platform technology beyond CD38, including to identify patients likely to benefit for broad range of mAb therapies across myriad indications. CD38-Diagnostic is a discovery-stage product that is advancing towards pre-clinical activities. Vy-Gen is actively engaged in the research and development of CD38-Diagnostic, and through the joint steering committee, and we are assessing market opportunities, intellectual property protection and potential regulatory strategy are all areas of focus. No human clinical trials have been conducted for CD38-Diagnostic as the clinical study requirements are not yet defined.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><i>Market Opportunity</i>. We believe
CD38-Diagnostic provides opportunity to make more cost-effective medical decisions for the treatment of B cell malignancies with high
CD38 expression, including multiple myeloma, which may help to avoid unnecessary administration of anti-CD38 therapies. CD38-Diagnostic
is anticipated to reduce the number of patients that are subjected to ineffective therapy and to potentially result in significant savings
to healthcare systems.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">CD38-Diagnostic is viewed as a potential
in-vitro diagnostic for determining patient suitability and likelihood of positive treatment outcomes for CD38-GEAR-NK and/or CD38 monoclonal
antibody therapies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 28, 2023, we
received FDA&#8217;s response to our 513(g) request for information submission pertaining to the classification of the CD38-Diagnostic.
The CD38-Diagnostic has been designated a Class II type device. The confirmation of this classification is beneficial as we&#8217;re now
better able to plan for and execute future development activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2021, we made initial
payments totaling $750,000 under the CD38 Agreements, to acquire the exclusive options to acquire co-development rights with respect to
CD38-GEAR-NK and CD38-Diagnostic. On August&#160;15, 2021, we entered into amendments to each of the CD38 Agreements. In connection with
the two amendments, we delivered to Vy-Gen promissory notes aggregating $3,250,000 with maturity dates of December&#160;31, 2021, and
made a cash payment of $1,000,000, upon which cash payment we exercised the two definitive option purchase agreements. In December 2021,
we completed our payment obligations to secure our rights to 50% of the net revenue stream related to the CD38-Diagnostic, and in November
2022 we completed our purchase of the 50% ownership interest for the CD38-GEAR-NK product candidate. Details of the two August amendments
and the December amendment are summarized in the amendments attached at Exhibits 4.1 and 4.2 to our Current Report on Form&#160;8-K dated
August&#160;19, 2021, and Exhibit 4.2 to our Current Report on Form&#160;8-K dated December 27, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 7 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the Vy-Gen
relationship and the Company&#8217;s rights in respect of the two product candidates described above, in December 2021 we entered
into a co-development and steering committee agreement with Vy-Gen. The co-development and steering committee agreement provides for the
governance and economic agreements between the Company and Vy-Gen related of the development of the two Vy-Gen drug product candidates
and the revenue sharing related thereto, including each company having a 50% representation on the steering committee and each company
receiving 50% of the net revenues related to the Vy-Gen product candidates. Related to the joint development, under the direction of the
joint steering committee, we are currently assessing market opportunities, intellectual property protection and potential regulatory strategies
for the CD38 Assets, and Vy-Gen is overseeing the development activities being conducted through the scientists at Karolinska Institute.
Details of the co-development and steering committee agreement are summarized in the agreement attached as Exhibit 4.1 to our Current
Report on Form&#160;8-K dated December&#160;27, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2025, the Company
reached an agreement with Vy-Gen-Bio, Inc. (&#8220;Vy-Gen&#8221;) to successfully license the exclusive worldwide development and commercialization
rights to the GEAR&#8482; (Gene Edited Antibody Resistant) Cell Therapy Platform, representing a first-in-class approach to modifying
potent cancer-targeting immune cells to optimize the likelihood of deep remission in patients with hematologic malignancies and other
cancers. Coeptis had previously held limited co-development rights to GEAR.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration: underline">SNAP-CAR Technologies;
University of Pittsburgh</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration: underline">The SNAP-CAR License</span></i>:
On August 31, 2022, we entered into an exclusive license agreement with the University of Pittsburgh for certain intellectual property
rights related to the universal self-labeling SynNotch and CARs for programable antigen-targeting technology platform. We paid the University
of Pittsburgh a non-refundable fee in the amount of $75,000 for the exclusive patent rights to the licensed technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2023, we executed
the first amendment to the SNAP-CAR License in which we expanded the field of use to include natural killer cells. We believe this is
a valuable addition as we continue to develop the SNAP-CAR platform as a universal therapeutic.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A key potential benefit that
we see in the licensed technology is its potential application in therapeutic treatments that involve solid tumors. While there are currently
a number of FDA-approved CAR-T therapies for hematologic malignancies, there are currently no CAR-T therapies marketed that are indicated
for the treatment of solid tumors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the terms of the agreement,
we have been assigned the worldwide development and commercialization rights to the licensed technology in the field of human treatment
of cancer with antibody or antibody fragments using SNAP-CAR T-cell technology, along with (i) an intellectual property portfolio consisting
of issued and pending patents and (ii) options regarding future add-on technologies and developments. In consideration of these rights,
we paid an initial license fee of $75,000, and will have annual maintenance fees ranging between $15,000 and $25,000, as well as developmental
milestone payments (as defined in the agreement and royalties equal to 3.5% of net sales. Additionally, the agreement contemplates that
we will enter into a Sponsored Research Agreement with the University of Pittsburgh within ninety days of the execution of the agreement,
with the goal of further researching and optimizing the SNAP-CAR platform.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>The Sponsored Research
Agreement</i>: In January 2023 we entered into a sponsored research agreement (&#8220;SRA&#8221;) with the University of Pittsburgh, the
focus of which is to perform pre-clinical research as it relates to our SNAP-CAR program. Our target objectives have been to: (i) test
and validate CRO antibody conjugation chemistry and improve the activity of adaptors by investigating alternative chemical composition,
(ii) investigate HER2 and other solid-tumor model in mice for both breast and ovarian cancers, (iii) identify and test other non-HER2
targets, (iv) further investigate multi-antigen targeting by dosing multiple adaptors simultaneously to address tumor heterogeneity/resistance
in hematological and/or solid tumors and (v) expand the potential impact of SNAP-CAR by performing in vitro screening of many additional
antigen-antibody combinations in hematological and/or solid tumors. The term of the SRA expired by its terms at the end of January 2025.
The data generated during the term of the SRA will be instrumental in determining target indications, development plans, and clinical
study designs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>

<!-- Field: Page; Sequence: 8 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>The SNAP-CAR Platform</i>:
Chimeric antigen receptor (CAR) therapy is a treatment for cancer in which a patient&#8217;s T-cells (a type of immune cell) are genetically
engineered to recognize cancer cells to target and destroy them. Cells are extracted from the patient and then genetically engineered
to make the CAR and are re-introduced back into the patient. This therapy is revolutionizing the treatment of many blood cancers including
B cell leukemias and lymphomas by targeting specific proteins found on these cancers, and there is hope in treating additional cancers
including solid tumors by having them recognize new targets. The &#8220;SNAP-CAR&#8221; CAR cell therapy platform is being developed to
be a universal therapeutic. The SNAP-CAR technology is in the preclinical stage of development at the University of Pittsburgh. Instead
of directly binding to a target on the tumor cell, the CAR T-cells are co-administered with one or more antibody adaptors that bind to
the tumor cells and are fitted with a chemical group that irreversibly connects them to the SNAP-CAR on the therapeutic cells via a covalent
bond. A covalent bond is the highest affinity bond possible, and we believe this binding could translate into highly potent therapeutic
activity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pre-clinical studies in mice
have demonstrated a potential benefit that by targeting solid tumors via antibody adaptor molecules, the SNAP-CAR therapy may be able
to provide a highly programmable therapeutic platform, one that we envision could deliver several potential advantages over standard CAR-T
treatments, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#8211;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Reduction of Potential Toxicity: The therapeutic activity of the SNAP-CAR T-cells is being developed to allow controls by way of the antibody dose, which we envision would allow clinicians to mitigate toxicity from over-activity. We also envision that the immune response against cancer may also be boosted in patients administered with additional doses of the tagged tumor-specific antibody; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#8211;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Reduction in Cancer Relapse: Relapse from CAR T-cell therapy often results from the loss or down-regulation of the targeted protein on the cancer. Our research and development will continue the pre-clinical development efforts to date, which focuses in part on the potential avoidance of or reduction in relapses by combining SNAP-CAR T-cells with antibodies targeting multiple antigens at once.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Market Opportunity</i>:
Due to its unique targeting and binding properties, we believe the SNAP-CAR platform could help accelerate the utilization and effectiveness
of CAR T-cell therapies for the treatment of solid tumors. By way of market size, according to Polaris Market Research, the CAR T-cell
therapy market size is expected to reach $20.56 billion by 2029 (from $1.96 billion in 2021), representing a compound annual growth rate
(CAGR) of 31.6% during the forecast period from 2022 to 2029. However, based on the anticipated application of the licensed technology
(i.e. initially focusing on solid tumor treatment) we cannot at this time project the market size of our target market until we further
develop the licensed technology and settle on the initial target indications and follow-up indications. Additional research and analysis
are being conducted which will aid us in the proper identification and selection of the cancer indication(s) we intend to further study.
Once the optimal indication(s) are selected and the overall development strategy is fully identified, the market opportunity can be further
defined.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration: underline">CPT60621; Vici Health
Sciences, LLC</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2019, we entered into a
co-development agreement with Vici Health Sciences, LLC (&#8220;Vici&#8221;). Through this partnership, we would co-develop, seek FDA
approval and share ownership rights with Vici to CPT60621, a novel, ready to use, easy to swallow, oral liquid version of an already approved
drug used for the treatment of Parkinson&#8217;s Disease (PD). As we continue to direct its operational and financial focus towards the
other assets and opportunities previously described, we have stopped allocating resources to the development of CPT60621. We are currently
in negotiations in which Vici intends to buy-out most or all of the remaining ownership rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Technology Division</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration: underline">NexGenAI Affiliates
Network</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 19, 2024, the
Company acquired the assets of NexGenAI Affiliates Network Platform (&#8220;NexGenAI&#8221;), from the seller NexGenAI Solutions Group,
Inc., which contains AI-powered marketing software and robotic process automation capabilities. The acquired assets include intellectual
property, a domain name and associated website, and the technology stack as defined in the agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 9 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The acquired assets include
technology-enabled AI driven marketing automation platform, along with associated tools and infrastructure that enable the Company to
offer managed digital marketing services under its own brand. Originally launched in the third quarter of 2023, the platform was developed
to support client efforts in enhancing brand visibility, generating qualified leads, and advancing strategic growth initiatives. The Company&#8217;s
managed service offerings now include lead generation, content marketing, social media marketing, email marketing, account-based marketing,
marketing analytics, event marketing, and branding support.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is utilizing a proprietary suite of automation and virtual assistant technologies to streamline client outreach, engagement
workflows, and digital marketing operations across our operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Growth Strategy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To achieve our goals, we intend
to deploy an aggressive, three-pronged, growth strategy listed below that we believe will help us maximize our success and deleverage
some of the risk of finding, solely developing and funding our own products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration: underline">Portfolio
Optimization</span></i> &#8212; We will continue to evaluate, prioritize, optimize, and make appropriate changes in our pipeline
portfolio as market development dynamics and/or product opportunities change. For example, it may be a strategic business decision
for us to divest certain products and/or agreements to other companies so we can best focus on its core assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration: underline">Strategic
Partnerships</span></i> &#8212; We will focus on expanding our existing pipeline through establishing strategic partnerships with
companies that have interesting products and technologies. We intend to focus on novel, preclinical and clinical assets in a variety
of therapeutic areas, including oncology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration: underline">Business Development</span></i>&#160;&#8212;
We are actively seeking partnerships and/or strategic collaborations with companies that share in our vision and therapeutic focus. Our
platform technologies have expansive capabilities and thus we believe they are conducive to partnerships beyond our current focus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Sales and Marketing</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently do not have in-house
commercial capabilities required to market and distribute FDA-approved products. Therefore, we will be required to partner with firms
who are capable of conducting all sales, marketing, distribution, contracting and pricing for our future products. There is no assurance
that we will be able to secure the services of such a firm or that any such firm will be able to achieve sales expectations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Employees</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Currently, we have six employees,
of which four are full-time employees and two are part-time employees. Our employees are not represented by any labor union or any collective
bargaining arrangement with respect to their employment with the Company. We have never experienced any work stoppages or strikes as a
result of labor disputes. We believe that our employee relations are good.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain of our employees have
been reporting to work remotely and may continue to do so moving forward.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Recent Developments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Pending Merger Transaction</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 25, 2025, the Company
(&#8220;Coeptis&#8221; or the &#8220;Purchaser&#8221;), entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;)
with CP Merger Sub Inc., a Wyoming corporation and wholly-owned subsidiary of Coeptis (&#8220;Merger Sub&#8221;), and Z Squared, Inc.,
a Wyoming corporation (&#8220;Z Squared&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 10 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Merger Agreement,
subject to the terms and conditions set forth therein, upon the consummation of the transactions contemplated by the Merger Agreement
(the &#8220;Closing&#8221;), (i) Merger Sub will merge with and into Z Squared (the &#8220;Merger&#8221;) and (ii) Coeptis will immediately
prior to the Merger effect a spin out of its biotechnology operations (the &#8220;Spin Out&#8221; and, together with Merger and the other
transactions contemplated by the Merger Agreement, the &#8220;Transactions&#8221;), with Z squared continuing as the surviving corporation
in the Merger and becoming a wholly-owned subsidiary of Coeptis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the Merger, all shares
of Z Squared common stock issued and outstanding immediately prior to the effective time of the Merger (other than those properly exercising
any applicable dissenters rights under Wyoming law), will be converted into the right to receive a portion of the Merger Consideration
(as defined below) and (ii) any other outstanding securities with the right to convert into or acquire equity securities of Z Squared
will be terminated. At the Closing, Coeptis will change its name as mutually agreed upon by the Purchaser and Z Squared. The Merger is
expected to close in the second quarter 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the Spin
Out, all of Coeptis&#8217; assets comprising its biotechnology business will be assigned and contributed prior to Closing to one or more
Spin Out Subsidiaries, which will then spin out to Coeptis&#8217; stockholders of record on the record date established for the Coeptis
Special Meeting (as defined below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The aggregate Merger Consideration
received by Z Squared security holders from Coeptis at the Closing will be a number of shares of Purchaser Common Stock that represents
at Closing the Applicable Percentage of Purchaser&#8217;s issued and outstanding shares of Purchaser Common Stock as calculated on a Fully-Diluted
Basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Associated with our Business</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are a number of risks
related to us and our operations. You should carefully review the risks described in &#8220;<i>Risk Factors and Special Considerations</i>&#8221;
beginning on page 9. If any of these risks actually occur, our business, financial condition, results of operations and prospects would
likely be materially, adversely affected. In that event, the trading price of our Common Stock could be adversely impacted, and you could
lose part or all of your investment. Below is a summary of some of the principal risks we face:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We may not be able to successfully implement our growth strategy on a timely basis or at all;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We may have difficulties managing our anticipated growth, or we may not grow at all;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We have a history of losses, we expect to incur losses in the future and we may not be able to achieve or maintain profitability;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We may not be able to initiate and complete preclinical studies and clinical trials for our product candidates which could adversely affect our business;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We may not be able to obtain and maintain the third-party relationships that are necessary to develop, commercialize and manufacture some or all of our product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We may encounter difficulties in managing our growth, which could adversely affect our operations;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We need to obtain financing in order to continue our operations;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The drug development and approval process is uncertain, time-consuming and expensive;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Competition in the biotechnology, pharmaceutical, and technology industries may result in competing products, superior marketing of other products and lower revenues or profits for us;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Federal laws or regulations on drug importation could make lower cost versions of our future products available, which could adversely affect our revenues, if any;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The regulatory approval process is costly and lengthy, and we may not be able to successfully obtain all required regulatory approvals;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Healthcare reform measures could adversely affect our business;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Protecting and defending against intellectual property claims may have a material adverse effect on our business;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">If we are not able to retain our current senior management team and our scientific advisors or continue to attract and retain qualified scientific, technical and business personnel, our business will suffer; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We may not be able to maintain our listing on the Nasdaq Capital Market; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">There is a substantial doubt about our ability to continue as a going concern.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>

<!-- Field: Page; Sequence: 11 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Emerging Growth Company</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a company with less than
$1.07 billion in revenue during our last fiscal year, we qualify as an emerging growth company, as defined in the JOBS Act. As an emerging
growth company, we have elected to take advantage of specified reduced disclosure and other requirements that are otherwise applicable
generally to public companies. These provisions include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Only two years of audited consolidated financial statements in addition to any required unaudited interim financial statements with correspondingly reduced Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations disclosure.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Reduced disclosure about our executive compensation arrangements.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Not having to obtain non-binding advisory votes on executive compensation or golden parachute arrangements.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may take advantage of these
exemptions for up to five years or such an earlier time that we are no longer an emerging growth company. We would cease to be an emerging
growth company if we have more than $1.07 billion in annual revenue, we have more than $700 million in market value of our stock held
by non-affiliates, or we issue more than $1&#160;billion of non-convertible debt over a three-year period. We may choose to take advantage
of some but not all of these reduced burdens. We have taken advantage of these reduced reporting burdens herein, and the information that
we provide may be different than what you might get from other public companies in which you hold stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Available Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We file annual, quarterly
and current reports and other information with the United States Securities and Exchange Commission (&#8220;SEC&#8221;) that are publicly
available through the SEC&#8217;s website at&#160;<i>www.sec.gov</i>.&#160;Our SEC filings will also be available free of charge through
the home page of our website https://coeptistx.com as soon as reasonably practicable after they are filed with or furnished to the SEC.
Our website and the information contained on or connected to that site are not incorporated into this Annual Report on Form 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%"><span id="a_006"></span><span style="font-size: 10pt"><b>ITEM 1A.</b></span></td>
    <td style="width: 90%"><span style="font-size: 10pt"><b>RISK FACTORS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>As a smaller reporting
company, we are not required to provide a statement of risk factors. Nonetheless, we are voluntarily providing risk factors herein. You
should consider carefully the following risk factors, together with all the other information in this Annual Report on Form 10-K, including
our consolidated financial statements and notes thereto, and in our other public filings with the SEC. The risk factors discussed below
cover not only our current products, product candidates and relationships, but also the risks we expect to encounter when and if we add
new product candidates and approved products to our proprietary portfolio, which new products, if added, we expect to be at various stages
of pre-clinical and perhaps clinical development</i>.&#160;<i>The occurrence of any of the following risks could harm our business, financial
condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking
statements we have made in this report and those we may make from time to time. You should consider all of the risk factors described
when evaluating our business.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>We operate in a highly
competitive and highly regulated business environment. Our business can be expected to be affected by government regulation, economic,
political and social conditions, business&#8217; response to new and existing products and services, technological developments and the
ability to obtain and maintain patent and/or other intellectual property protection for our products and intellectual property. Our actual
results could differ materially from management&#8217;s expectations because of changes both within and outside of our control. Reviewers
of this Annual Report on Form 10-K are cautioned not to place undue reliance upon such forward-looking statements. Such forward-looking
statements may include projections with respect to market size and acceptance, revenues and earnings, marketing and sales strategies and
business operations, as well as efficacy of our products. The risk factors discussed below cover not only our current products, product
candidates and relationships, but also the risks we expect to encounter when and if we add new product candidates and approved products
to our proprietary portfolio, which new products, if added, we expect to be at various stages of pre-clinical and perhaps clinical development.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 12 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Throughout this section,
references to &#8220;Company,&#8221; &#8220;Coeptis,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar terms refer
collectively to Coeptis Therapeutics Holdings, Inc., a Delaware corporation, and its operating subsidiaries, as the context so requires.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to the Development and Regulatory
Approval of Our Product Candidates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Clinical trials are expensive, time consuming,
difficult to design and implement, and involve uncertain outcomes. Results of previous pre-clinical studies and clinical trials may not
be predictive of future results, and the results of our current and planned clinical trials may not satisfy the requirements of the FDA
or other regulatory authorities.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Positive or timely results
from pre-clinical or early-stage trials do not ensure positive or timely results in late-stage clinical trials or product approval by
the FDA or comparable foreign regulatory authorities. We will be required to demonstrate with substantial evidence through well-controlled
clinical trials that our product candidates are safe and effective for use in a diverse population before we can seek regulatory approvals
for their commercialization. Our planned clinical trials may produce negative or inconclusive results, and we or any of our current and
future strategic partners may decide, or regulators may require us, to conduct additional clinical or pre-clinical testing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Success in pre-clinical studies
or early-stage clinical trials does not mean that future clinical trials or registration clinical trials will be successful because product
candidates in later-stage clinical trials may fail to demonstrate sufficient safety and efficacy to the satisfaction of the FDA and foreign
regulatory authorities, despite having progressed through pre-clinical studies and initial clinical trials. Product candidates that have
shown promising results in early clinical trials may still suffer significant setbacks in subsequent clinical trials or registration clinical
trials. For example, a number of companies in the biopharmaceutical industry, including those with greater resources and experience than
us, have suffered significant setbacks in advanced clinical trials, even after obtaining promising results in earlier clinical trials.
Similarly, pre-clinical interim results of a clinical trial are not necessarily predictive of final results.&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If clinical trials for our product candidates
are prolonged, delayed or stopped, we may be unable to obtain regulatory approval and commercialize our product candidates on a timely
basis, or at all, which would require us to incur additional costs and delay our receipt of any product revenue.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.8pt; text-align: justify; text-indent: 31.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may experience delays in
our ongoing or future pre-clinical studies or clinical trials, and we do not know whether future pre-clinical studies or clinical trials
will begin on time, need to be redesigned, enroll an adequate number of patients or be completed on schedule, if at all. The commencement
or completion of these planned clinical trials could be substantially delayed or prevented by many factors, including, but not limited
to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">discussions with the FDA or other regulatory agencies regarding the scope or design of our clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the limited number of, and competition for, suitable sites to conduct our clinical trials, many of which may already be engaged in other clinical trial programs, including some that may be for the same indication as our product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">any delay or failure to obtain approval or agreement to commence a clinical trial in any of the countries where enrollment is planned;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">inability to obtain sufficient funds required for a clinical trial;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">clinical holds on, or other regulatory objections to, a new or ongoing clinical trial;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">delay or failure to manufacture sufficient supplies of product candidates for our clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">delay or failure to reach agreement on acceptable clinical trial agreement terms or clinical trial protocols with prospective sites or clinical research organizations (&#8220;CROs&#8221;), the terms of which can be subject to extensive negotiation and may vary significantly among different sites or CROs;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">delay or failure to obtain institutional review board (&#8220;IRB&#8221;) approval to conduct a clinical trial at a prospective site;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">slower than expected rates of patient recruitment and enrollment;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">failure of patients to complete the clinical trial;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the inability to enroll a sufficient number of patients in studies to ensure adequate statistical power to detect statistically significant treatment effects;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">unforeseen safety issues, including severe or unexpected drug-related adverse effects experienced by patients, including possible deaths;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 13 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">lack of efficacy during clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">termination of our clinical trials by one or more clinical trial sites;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">inability or unwillingness of patients or clinical investigators to follow our clinical trial protocols;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">inability to monitor patients adequately during or after treatment;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">clinical study sites failing to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, deviating from the protocol or dropping out of a study;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">inability to address any non-compliance with regulatory requirements or safety concerns that arise during the course of a clinical trial;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the need to repeat or terminate clinical trials as a result of inconclusive or negative results or unforeseen complications in testing; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our clinical trials may be suspended or terminated upon a breach or pursuant to the terms of any agreement with, or for any other reason by, current or future strategic partners that have responsibility for the clinical development of any of our product candidates.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Changes in regulatory requirements,
policies and guidelines may also occur and we may need to significantly amend clinical trial protocols to reflect these changes with appropriate
regulatory authorities. These changes may require us to renegotiate terms with CROs or resubmit clinical trial protocols to IRBs for re-examination,
which may impact the costs, timing or successful completion of a clinical trial. Our clinical trials may be suspended or terminated at
any time by the FDA, other regulatory authorities, the IRB overseeing the clinical trial at issue, any of our clinical trial sites with
respect to that site, or us. Any failure or significant delay in commencing or completing clinical trials for our product candidates may
adversely affect our ability to obtain regulatory approval and our commercial prospects and our ability to generate product revenue will
be diminished.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The design or our execution of clinical
trials may not support regulatory approval.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The design or execution of
a clinical trial can determine whether its results will support regulatory approval and flaws in the design or execution of a clinical
trial may not become apparent until the clinical trial is well advanced. In some instances, there can be significant variability in safety
or efficacy results between different trials of the same product candidate due to numerous factors, including changes in trial protocols,
differences in size and type of the patient populations, adherence to the dosing regimen and other trial protocols and the rate of dropout
among clinical trial participants. We do not know whether any clinical trials we may conduct will demonstrate consistent or adequate efficacy
and safety to obtain regulatory approval to market our product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, the FDA and comparable
foreign regulatory authorities have substantial discretion in the approval process and in determining when or whether regulatory approval
will be obtained for any of our product candidates. Our product candidates may not be approved even if they achieve their primary endpoints
in future clinical trials. The FDA or foreign regulatory authorities may disagree with our trial design and our interpretation of data
from pre-clinical studies and clinical trials. In addition, any of these regulatory authorities may change requirements for the approval
of a product candidate even after reviewing and providing comments or advice on a protocol for clinical trial that has the potential to
result in FDA or other agencies&#8217; approval. In addition, such regulatory authorities may also approve a product candidate for fewer
or more limited indications than we request or may grant approval contingent on the performance of costly post-marketing clinical trials.
The FDA or foreign regulatory authorities may not approve the labeling claims that we believe would be necessary or desirable for the
successful commercialization of our product candidates which may have a material adverse effect on our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may find it difficult to enroll patients
in our clinical trials given the limited number of patients who have the diseases for which our product candidates are being studied which
could delay or prevent the start of clinical trials for our product candidates.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Identifying and qualifying
patients to participate in clinical trials of our product candidate is essential to our success. The timing of our clinical trials depends
in part on the rate at which we can recruit patients to participate in clinical trials of our product candidates, and we may experience
delays in our clinical trials if we encounter difficulties in enrollment. If we experience delays in our clinical trials, the timeline
for obtaining regulatory approval of our product candidates will most likely be delayed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>

<!-- Field: Page; Sequence: 14 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many factors may affect our
ability to identify, enroll and maintain qualified patients, including the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">eligibility criteria of our ongoing and planned clinical trials with specific characteristics appropriate for inclusion in our clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">design of the clinical trial;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">size and nature of the patient population;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">patients&#8217; perceptions as to risks and benefits of the product candidate under study and the participation in a clinical trial generally in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the availability and efficacy of competing therapies and clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">pendency of other trials underway in the same patient population;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">willingness of physicians to participate in our planned clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">severity of the disease under investigation;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">proximity of patients to clinical sites;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">patients who do not complete the trials for personal reasons; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">issues with CROs and/or with other vendors that handle our clinical trials.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>General Risks</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>There is a substantial doubt about our ability
to continue as a going concern.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The report of our independent
registered public accounting firm that accompanies our consolidated financial statements includes an explanatory paragraph indicating
there is a substantial doubt about our ability to continue as a going concern, citing our need for additional capital for the future planned
expansion of our activities and to service our ordinary course activities (which may include servicing of indebtedness). The inclusion
of a going concern explanatory paragraph in the report of our independent registered public accounting firm will make it more difficult
for us to secure additional financing or enter into strategic relationships on terms acceptable to us, if at all, and likely will materially
and adversely affect the terms of any financing that we might obtain. Our consolidated financial statements do not include any adjustments
that may result from the outcome of this uncertainty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have incurred significant losses in prior
periods, and losses in the future could cause the quoted price of our Common Stock to decline or have a material adverse effect on our
financial condition, our ability to pay its debts as they become due, and on its cash flows.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the year ended December
31, 2025, we incurred a net loss of $12,277,192 and, as of that date, we had an accumulated deficit of $109,953,728. For the year ended
December 31, 2024, we incurred a net loss of $10,877,412 and, as of that date, had an accumulated deficit of $98,036,713. Any losses in
the future could cause the quoted price of our Common Stock to decline or have a material adverse effect on our financial condition, its
ability to pay its debts as they become due, and on its cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, we have generated
only minimal product revenue. We expect that our planned product development and strategic expansion pursuits will increase losses significantly
over the next five years. In order to achieve profitability, we will be required to generate significant revenue. We cannot be certain
that we will generate sufficient revenue to achieve profitability. We anticipate that we will continue to generate operating losses and
experience negative cash flow from operations at least through the end of 2025. We cannot be certain that we will ever achieve profitability
or that, if profitability is achieved, that it will be maintained. If our revenue grows at a slower rate than we anticipate or if our
product development, marketing and operating expenses exceed our expectations or cannot be adjusted accordingly, our business, results
of operation and financial condition will be materially adversely affected, and we may be unable to continue operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>

<!-- Field: Page; Sequence: 15 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will not be able to generate
meaningful product revenue unless and until one of our product candidates or co-development products successfully completes clinical trials
and receives regulatory approval. As some of our current and projected future product candidates or co-development products are, and we
expect will be, at an early proof-of-concept stage, we do not expect to receive revenue from any of these products for several years,
if at all. We intend to seek to obtain revenue from collaboration or licensing agreements with third parties. We expect that we will need
to rely on key third-party agreements, in order to be in a position to realize material revenues in the future, and we may never enter
into any such agreements or realize material, ongoing future revenue. Even if we eventually generate revenues, we may never be profitable,
and, if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are unable to manage future expansion
effectively, our business may be adversely impacted.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the future, we may experience
rapid growth in our business, which could place a significant strain on our operations, in general, and our internal controls and other
managerial, operating and financial resources, in particular. If we are unable to manage future expansion effectively, our business would
be harmed. There is, of course, no assurance that we will enjoy rapid development in our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Company&#8217;s ability to be successful
will depend upon the efforts of the Company&#8217;s Board and our key personnel and the loss of such persons could negatively impact the
operations and profitability of the Company&#8217;s business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s ability
to be successful is dependent upon the efforts of the Company&#8217;s board members and key personnel, in particular our President and
Chief Executive Officer David Mehalick. We cannot assure you that the Company&#8217;s board members and key personnel will be effective
or successful or remain with the Company. In addition to the other challenges they will face, such individuals may be unfamiliar with
the requirements of operating a public company, which could cause the Company&#8217;s management to expend time and resources becoming
familiar with such requirements. We have employment agreements in place with Mr. Mehalick and Daniel Yerace, but no other persons. The
loss of service of Mr. Mehalick, in particular, for any reason, could seriously impair our ability to effectuate our business plan, which
could have a materially adverse effect on our business and future results of operations. We also have not purchased any key-man life insurance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are unable to recruit and retain key
personnel, our business may be harmed.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are unable to attract
and retain key personnel, our business may be harmed. Our failure to enable the effective transfer of knowledge and facilitate smooth
transitions with regard to our key employees could adversely affect our long-term strategic planning and execution.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our business plan is not based on independent
market studies.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not commissioned any
independent market studies concerning our business plans. Rather, our plans for implementing our business strategy and achieving profitability
are based on the experience, judgment and assumptions of our management. If these assumptions prove to be incorrect, we may not be successful
in our business operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our Board of Directors may change our policies
without shareholder approval.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our policies, including any
policies with respect to investments, leverage, financing, growth, debt and capitalization, will be determined by our Board of Directors
or officers to whom our Board of Directors delegate such authority. Our Board of Directors will also establish the amount of any dividends
or other distributions that we may pay to our shareholders. Our Board of Directors or officers to which such decisions are delegated will
have the ability to amend or revise these and our other policies at any time without shareholder vote. Accordingly, our shareholders will
not be entitled to approve changes in our policies, which policy changes may have a material adverse effect on our financial condition
and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>

<!-- Field: Page; Sequence: 16 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We need to obtain financing in order to
continue our operations and pursue strategic transactions.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On a prospective basis, we
will require both short-term financing for operations and long-term capital to fund our expected growth. We currently have no existing
bank lines of credit and have not established any definitive sources for additional financing. We believe that cash on hand will be sufficient
to meet our short-term financial requirements through at least the 2<sup>nd</sup> quarter of 2026 assuming that we elect not to pursue
and consummate strategic transactions prior to that time. However, we will require additional funds if we want to fully implement our
business plan and growth strategy, including strategic transactions, which funds could come in the form of equity, debt (including secured
debt) or a combination of the two. Additional financing may not be available to us, or if available, then it may not be available upon
terms and conditions acceptable to us. If adequate funds are not available, then we may be required to delay, reduce or eliminate product
development or clinical programs. Our inability to take advantage of opportunities in the industry because of capital constraints may
have a material adverse effect on our business and our prospects. If we fail to obtain the capital necessary to fund our operations, we
will be unable to advance our development programs and complete our clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our research
and development expenses could exceed our current expectations. This could occur for many reasons, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">some or all of our product candidates and co-development candidates fail in clinical or preclinical studies and we are forced to seek additional product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our product candidates and co-development candidates require more extensive clinical or preclinical testing than we currently expect;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">we advance more of our product candidates and co-development candidates than expected into costly later stage clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">we advance more preclinical product candidates and co-development candidates than expected into early-stage clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">we are required, or consider it advisable, to acquire or license rights from one or more third parties; or</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">we determine to acquire or license rights to additional product candidates and co-development candidates or new technologies.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While we expect to seek additional
funding through public or private financings, we may not be able to obtain financing on acceptable terms, or at all. In addition, the
terms of our financings may be dilutive to, or otherwise adversely affect, holders of our common stock and other capital securities. We
may also seek additional funds through arrangements with collaborators or other third parties. These arrangements would generally require
us to relinquish rights to some of our technologies, product candidates or products, and we may not be able to enter into such agreements,
on acceptable terms, if at all. If we are unable to obtain additional funding on a timely basis, we may be required to curtail or terminate
some or all of our development programs, including some or all of our product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We currently do not have sufficient cash
to fully implement our business plan.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have experienced a lack
of adequate capital resources causing us to be unable to fully implement our full business plan. We believe that we need to raise or otherwise
obtain additional financing beyond our current cash position in order to satisfy our existing obligations or fully implement our business
plan. We do not expect to have positive cash flow for the foreseeable future. If we are not successful in obtaining additional financing
we will not be able to fully implement our business plan and we may not be able to continue our operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have a limited operating history and
a history of operating losses, and expect to incur significant additional operating losses.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We began our business in 2017
and have a limited operating history. Although we have enlisted the assistance of pharmaceutical experts, our lack of experience may cause
us to encounter unforeseen problems that could have a material adverse effect on our business and financial condition. Further, there
is limited historical financial information upon which to base an evaluation of our performance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The drug development and approval process
is uncertain, time-consuming and expensive.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The process of obtaining
and maintaining regulatory approvals for new therapeutic products is lengthy, expensive and uncertain. It also can vary
substantially based on the type, complexity, and novelty of the product. We, or our co-development partners, must provide the FDA
and foreign regulatory authorities with preclinical and clinical data demonstrating that our products are safe and effective before
they can be approved for commercial sale. Clinical development, including preclinical testing, is a long, expensive and uncertain
process. It may take us several&#160;years to complete our testing, and failure can occur at any stage of testing. Any preclinical
or clinical test may fail to produce results satisfactory to the FDA. Preclinical and clinical data can be interpreted in different
ways, which could delay, limit or prevent regulatory approval. Negative or inconclusive results from a preclinical study or clinical
trial, adverse medical events during a clinical trial or safety issues resulting from products of the same class of drug could cause
a preclinical study or clinical trial to be repeated or a program to be terminated, even if other studies or trials relating to the
program are successful.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>

<!-- Field: Page; Sequence: 17 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We will be required to sustain and further
build our intellectual property rights.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not currently have any
intellectual property rights in our name in respect of our current assets, and instead have rights in respect of our current assets through
agreements with third parties. We intend to fully protect any product, formulation and process that we develop with appropriate intellectual
property registrations. If we fail to sustain and further build our direct and indirect intellectual property rights, competitors will
be able to take advantage of our research and development efforts to develop competing products. If we are not able to protect our proprietary
technology, trade secrets, and know-how, our competitors may use our inventions to develop competing products. Our future patents and
patent applications, even if granted, may not protect us against our competitors. Patent positions generally, including those of other
pharmaceutical and biotechnology companies, are or will be generally uncertain and involve complex legal, scientific and factual questions.
The standards which the United&#160;States Patent and Trademark Office uses to grant patents, and the standards which courts use to interpret
patents, are not always applied predictably or uniformly and can change, particularly as new technologies develop. Consequently, the level
of protection, if any, that will be provided by our direct or indirect patent rights from time to time if we attempt to enforce them,
and they are challenged, is uncertain. In addition, the type and extent of patent claims that will be issued to us in the future is uncertain.
Any patents that are issued may not contain claims that permit us to stop competitors from using similar technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we may also rely
on unpatented technology, trade secrets, and confidential information. We may not be able to effectively protect our rights to this technology
or information. Other parties may independently develop substantially equivalent information and techniques or otherwise gain access to
or disclose our technology. We will generally require each of our employees, consultants, collaborators, and certain contractors to execute
a confidentiality agreement at the commencement of an employment, consulting, collaborative, or contractual relationship with us. However,
these agreements may not provide effective protection of our technology or information or, in the event of unauthorized use or disclosure,
they may not provide adequate remedies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Patent positions are often
uncertain and involve complex legal and factual questions. In addition, the laws of some foreign countries do not protect proprietary
rights to the same extent as the laws of the United&#160;States. Whether filed in the United&#160;States or abroad, our patent applications
may be challenged or may fail to result in issued patents. In addition, any future patents we obtain may not be sufficiently broad to
prevent others from practicing our technologies or from developing or commercializing competing products. Furthermore, others may independently
develop or commercialize similar or alternative technologies or drugs, or design around our patents. Our patents may be challenged, invalidated
or fail to provide us with any competitive advantages. We may not have the funds available to protect our patents or other technology;
such protection is costly and can result in further litigation expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we do not obtain or we
are unable to maintain adequate patent or trade secret protection for our products in the United&#160;States, competitors could duplicate
them without repeating the extensive testing that we will be required to undertake to obtain approval of the products by the FDA.&#160;Regardless
of any patent protection, under the current statutory framework the FDA is prohibited by law from approving any generic version of any
of our products for a period of&#160;years that would be determined based on the nature of the product (i.e. an orphan drugs would get
7&#160;years, a new chemical entity would get 5&#160;years and a new clinical investigation would get 3&#160;years). Upon the expiration
of that period, or if that time period is altered, the FDA could approve a generic version of our product unless we have patent protection
sufficient for us to block that generic version. Without sufficient patent protection, the applicant for a generic version of our product
would be required only to conduct a relatively inexpensive study to show that its product is bioequivalent to our product and may not
have to repeat the studies that we will need to conduct to demonstrate that the product is safe and effective. In the absence of adequate
patent protection in other countries, competitors may similarly be able to obtain regulatory approval in those countries of products that
duplicate our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>

<!-- Field: Page; Sequence: 18 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We will be required to comply with our obligations
in our intellectual property licenses and other agreements with third parties.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we fail to comply with
our obligations in our intellectual property licenses and other agreements with third parties, we could lose license rights that are important
to our business. We are not currently party to any intellectual property license agreement with any third parties, but we anticipate that
in-licensing and co-development will be strategies that we utilize as we continue to pursue our growth strategy. We expect to enter into
licenses and co-development and other agreements in the future, and we expect these agreements to impose, various diligences, milestone
payment, royalty, insurance and other obligations on us. If we fail to comply with these obligations, the licensor may have the right
to terminate the license, in which event we might not be able to market any product that is covered by the licensed patents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may need to resort to litigation
to enforce or defend our intellectual property rights, including any patents issued to us. If a competitor or collaborator files a patent
application claiming technology also invented by us, in order to protect our rights, we may have to participate in an expensive and time-consuming
interference proceeding before the United&#160;States Patent and Trademark Office. We cannot guarantee that our product candidates will
be free of claims by third parties alleging that we have infringed their intellectual property rights. Third parties may assert that we
are employing their proprietary technologies without authorization and they may resort to litigation to attempt to enforce their rights.
Third parties may have or obtain patents in the future and claim that the use of our technology or any of our product candidates infringes
their patents. We may not be able to develop or commercialize combination product candidates because of patent protection others have.
Our business will be harmed if we cannot obtain a necessary or desirable license, can obtain such a license only on terms we consider
to be unattractive or unacceptable, or if we are unable to redesign our product candidates or processes to avoid actual or potential patent
or other intellectual property infringement. Obtaining, protecting and defending patent and other intellectual property rights can be
expensive and may require us to incur substantial costs, including the diversion of management and technical personnel. An unfavorable
ruling in patent or intellectual property litigation could subject us to significant liabilities to third parties, require us to cease
developing, manufacturing or selling the affected products or using the affected processes, require us to license the disputed rights
from third parties, or result in awards of substantial damages against us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There can be no assurance
that we would prevail in any intellectual property infringement action, will be able to obtain a license to any third-party intellectual
property on commercially reasonable terms, successfully develop non-infringing alternatives on a timely basis, or license non-infringing
alternatives, if any exist, on commercially reasonable terms. Any significant intellectual property impediment to our ability to develop
and commercialize our products could seriously harm our business and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Patent litigation or other litigation in
connection with our intellectual property rights may lead to publicity that may harm our reputation and the value of our common stock
may decline.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the course of any patent
litigation, there may be public announcements of the results of hearings, motions, and other interim proceedings or developments in the
litigation. If securities analysts or investors regard these announcements as negative, the value of our common stock may decline. General
proclamations or statements by key public figures may also have a negative impact on the perceived value of our intellectual property.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Protecting and defending against intellectual
property claims may have a material adverse effect on our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
receive notice that others have infringed on our proprietary rights or that we have infringed on the intellectual property rights of others.
There can be no assurance that infringement or invalidity claims will not materially adversely affect our business, financial condition
or results of operations. Regardless of the validity or the success of the assertion of claims, we could incur significant costs and diversion
of resources in protecting or defending against claims, which could have a material adverse effect on our business, financial condition
or results of operations. We may not have the funds or resources available to protect our intellectual property.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>

<!-- Field: Page; Sequence: 19 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our competitors and potential competitors
may develop products and technologies that make ours less attractive or obsolete.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many companies, universities,
and research organizations developing competing product candidates have greater resources and significantly greater experience in financial,
research and development, manufacturing, marketing, sales, distribution, and technical regulatory matters than we have. In addition, many
competitors have greater name recognition and more extensive collaborative relationships. Our competitors could commence and complete
clinical testing of their product candidates, obtain regulatory approvals, and begin commercial-scale manufacturing of their products
faster than we or our co-development partners are able to for our products. They could develop products that would render our product
candidates and co-development candidates, and those of our collaborators, obsolete and noncompetitive. If we are unable to compete effectively
against these companies, then we may not be able to commercialize our product candidates or achieve a competitive position in the market.
This would adversely affect our ability to generate revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Competition in the biotechnology and pharmaceutical
industries may result in competing products, superior marketing of other products and lower revenues or profits for us.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are many companies that
are seeking to develop products and therapies for the treatment of the same diseases that we are currently targeting. Many of our competitors
have substantially greater financial, technical, human and other resources than we do and may be better equipped to develop, manufacture
and market technologically superior products. In addition, many of these competitors have significantly greater experience than we do
in undertaking preclinical testing and human clinical studies of new pharmaceutical products and in obtaining regulatory approvals of
human therapeutic products. Accordingly, our competitors may succeed in obtaining FDA approval for superior products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other risks and uncertainties
include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to successfully complete preclinical and clinical development of our products and services.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to manufacture sufficient amounts of products for development and commercialization activities.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to obtain, maintain and successfully enforce adequate patent and other proprietary rights protection of our products and services.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the scope, validity and enforceability of patents and other proprietary rights held by third parties and their impact on our ability to commercialize our products and services.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the accuracy of our estimates of the size and characteristics of the markets to be addressed by our products and services, including growth projections.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">market acceptance of our products and services.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to identify new patients for our products and services.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the accuracy of our information regarding the products and resources of our competitors and potential competitors.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the content and timing of submissions to and decisions made by the US Food and Drug Administration (FDA) and other regulatory agencies.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to obtain reimbursement for our products and services from third-party payors, and the extent of such coverage.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to establish and maintain strategic license, collaboration and distribution arrangements.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the continued funding of our collaborations and joint ventures, if any are ultimately established.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the possible disruption of our operations due to terrorist activities and armed conflict, including as a result of the disruption of operation of our subsidiaries and our customers, suppliers, distributors, couriers, collaborative partners, licensees and clinical trial sites.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Positive or timely results
from preclinical studies and early clinical trials do not ensure positive or timely results in late-stage clinical trials or product approval
by the FDA or any other regulatory authority. Product candidates that show positive preclinical or early clinical results often fail in
later stage clinical trials. Data obtained from preclinical and clinical activities is susceptible to varying interpretations, which could
delay, limit, or prevent regulatory approvals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>

<!-- Field: Page; Sequence: 20 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have limited experience
in conducting the clinical trials required to obtain regulatory approval. We may not be able to conduct clinical trials at preferred sites,
enlist clinical investigators, enroll sufficient numbers of participants, or begin or successfully complete clinical trials in a timely
fashion, if at all. Any failure to perform may delay or terminate the trials. Once Phase 1 human trials are initiated, the pre-defined
clinical outcome(s) may not be achieved. As a result, additional clinical trials may be required if clinical trial results are negative
or inconclusive, which will require us to incur additional costs and significant delays. If we do not receive the necessary regulatory
approvals, we will not be able to generate product revenues and may not become profitable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Company&#8217;s business and operations
could be negatively affected if it becomes subject to any securities litigation or shareholder activism, which could cause the Company
to incur significant expense, hinder execution of business and growth strategy and impact its stock price.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the past, following periods
of volatility in the market price of a company&#8217;s securities, securities class action litigation has often been brought against that
company. Shareholder activism, which could take many forms or arise in a variety of situations, has been increasing recently. Volatility
in the stock price of the common stock or other reasons may in the future cause it to become the target of securities litigation or shareholder
activism. Securities litigation and shareholder activism, including potential proxy contests, could result in substantial costs and divert
management&#8217;s and board of directors&#8217; attention and resources from the Company&#8217;s business. Additionally, such securities
litigation and shareholder activism could give rise to perceived uncertainties as to the Company&#8217;s future, adversely affect its
relationships with service providers and make it more difficult to attract and retain qualified personnel. Also, the Company may be required
to incur significant legal fees and other expenses related to any securities litigation and activist shareholder matters. Further, its
stock price could be subject to significant fluctuation or otherwise be adversely affected by the events, risks and uncertainties of any
securities litigation and shareholder activism.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risk Related to Regulation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The regulatory approval process is costly
and lengthy, and we may not be able to successfully obtain all required regulatory approvals.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preclinical development,
clinical trials, manufacturing, marketing and labeling of pharmaceuticals are all subject to extensive regulation by numerous governmental
authorities and agencies in the United&#160;States and other countries. We must obtain regulatory approval for each of our product candidates
before marketing or selling any of them. It is not possible to predict how long the approval processes of the FDA or any other applicable
federal or foreign regulatory authority or agency for any of our products will take or whether any such approvals ultimately will be granted.
The FDA and foreign regulatory agencies have substantial discretion in the drug approval process, and positive results in preclinical
testing or early phases of clinical studies offer no assurance of success in later phases of the approval process. Generally, preclinical
and clinical testing of products can take many&#160;years and require the expenditure of substantial resources, and the data obtained
from these tests and trials can be susceptible to varying interpretations that could delay, limit or prevent regulatory approval. If we
encounter significant delays in the regulatory process that result in excessive costs, this may prevent us from continuing to develop
our product candidates. Any delay in obtaining, or failure to obtain, approvals could adversely affect the marketing of our products and
our ability to generate product revenue. The risks associated with the approval process include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">failure of our product candidates to meet a regulatory agency&#8217;s requirements for safety, efficacy and quality;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">limitation on the indicated uses for which a product may be marketed;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">unforeseen safety issues or side effects; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">governmental or regulatory delays and changes in regulatory requirements and guidelines.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 21 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if we receive regulatory approvals
for marketing our product candidates, if we fail to comply with continuing regulatory requirements, we could lose our regulatory approvals,
and our business would be adversely affected.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA continues to review
products even after they receive initial approval. If we receive approval to commercialize any product candidates, the manufacturing,
marketing and sale of these drugs will be subject to continuing regulation, including compliance with quality systems regulations, good
manufacturing practices, adverse event requirements, and prohibitions on promoting a product for unapproved uses. Enforcement actions
resulting from our failure to comply with government and regulatory requirements could result in fines, suspension of approvals, withdrawal
of approvals, product recalls, product seizures, mandatory operating restrictions, criminal prosecution, civil penalties and other actions
that could impair the manufacturing, marketing and sale of our potential products and our ability to conduct our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if we are able to obtain regulatory
approvals for any of our product candidates, if they exhibit harmful side effects after approval, our regulatory approvals could be revoked
or otherwise negatively impacted, and we could be subject to costly and damaging product liability claims.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we receive regulatory
approval for our product candidates, we will have tested them in only a small number of patients during our clinical trials. If our applications
for marketing are approved and more patients begin to use our product, new risks and side effects associated with our products may be
discovered. As a result, regulatory authorities may revoke their approvals; we may be required to conduct additional clinical trials,
make changes in labeling of our product, reformulate our product or make changes and obtain new approvals for our and our suppliers&#8217;
manufacturing facilities. We might have to withdraw or recall our products from the marketplace. We may also experience a significant
drop in the potential sales of our product if and when regulatory approvals for such product are obtained, experience harm to our reputation
in the marketplace or become subject to lawsuits, including class actions. Any of these results could decrease or prevent any sales of
our approved product or substantially increase the costs and expenses of commercializing and marketing our product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Healthcare reform measures could adversely
affect our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The efforts of governmental
and third-party payers to contain or reduce the costs of healthcare may adversely affect the business and financial condition of pharmaceutical
companies. In the United&#160;States and in foreign jurisdictions there have been, and we expect that there will continue to be, a number
of legislative and regulatory proposals aimed at changing the healthcare system. For example, in some countries other than the United&#160;States,
pricing of prescription drugs is subject to government control, and we expect proposals to implement similar controls in the United&#160;States
to continue. The pendency or approval of such proposals could result in a decrease in our common stock value or limit our ability to raise
capital or to enter into collaborations or license rights to our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Federal legislation may increase the pressure
to reduce prices of pharmaceutical products paid for by Medicare, which could adversely affect our revenues, if any.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Medicare Prescription
Drug Improvement and Modernization Act&#160;of&#160;2003, or MMA, expanded Medicare coverage for drug purchases by the elderly and disabled
beginning in 2006. The legislation uses formularies, preferred drug lists and similar mechanisms that may limit the number of drugs that
will be covered in any therapeutic class or reduce the reimbursement for some of the drugs in a class. More recently, the Patient Protection
and Affordable Care Act&#160;of&#160;2010 also contained certain provisions with the potential to affect pricing of pharmaceutical products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the expansion
of legislation, including recent healthcare insurance legislation, and the expansion of federal coverage of drug products, we expect that
there will be additional pressure to contain and reduce costs. These cost reduction initiatives could decrease the coverage and price
that we receive for our products in the future and could seriously harm our business. While the MMA applies only to drug benefits for
Medicare beneficiaries, private payers often follow Medicare coverage policy and payment limitations in setting their own reimbursement
systems, and any limits on or reductions in reimbursement that occur in the Medicare program may result in similar limits on or reductions
in payments from private payers.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>

<!-- Field: Page; Sequence: 22 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Federal laws or regulations on drug importation
could make lower cost versions of our future products available, which could adversely affect our revenues, if any.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The prices of some drugs are
lower in other countries than in the United&#160;States because of government regulation and market conditions. Various proposals have
been advanced to permit the importation of drugs from other countries to provide lower cost alternatives to the products available in
the United States. In addition, the MMA requires the Secretary of Health and Human Services to promulgate regulations for drug reimportation
from Canada into the United States under some circumstances, including when the drugs are sold at a lower price than in the United&#160;States.
A prime example of the effort to provide safe, lower cost drugs to consumers is Safe Importation Action Plan that was released by the
Department of Health and Human Services (HHS) and the Food and Drug Administration (FDA), which plan is describes steps the HHS and FDA
will take to allow the safe importation of certain drugs originally intended for non-US markets. If the laws or regulations are changed
to permit or more easily permit the importation of drugs into the United&#160;States in circumstances that are currently not permitted,
such a change could have an adverse effect on our business by making available lower priced alternatives to our future products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Failure to obtain regulatory and pricing
approvals in foreign jurisdictions could delay or prevent commercialization of our products abroad.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we succeed in developing
any products, we intend to market them in the European Union and other foreign jurisdictions. In order to do so, we must obtain separate
regulatory approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can
involve additional testing. The time required to obtain approval abroad may differ from that required to obtain FDA approval. The foreign
regulatory approval process may include all of the risks associated with obtaining FDA approval and additional risks associated with requirements
particular to those foreign jurisdictions where we will seek regulatory approval of our products. We may not obtain foreign regulatory
approvals on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries, and
approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA.
We and our collaborators may not be able to file for regulatory approvals and may not receive necessary approvals to commercialize our
products in any market outside the United&#160;States. The failure to obtain these approvals could materially adversely affect our business,
financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Organization and Structure</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our holding company structure makes us dependent
on our subsidiaries for our cash flow and could serve to subordinate the rights of our shareholders to the rights of creditors of our
subsidiaries, in the event of an insolvency or liquidation of any such subsidiary.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Company acts as a holding
company and, accordingly, substantially all of our operations are conducted through our subsidiaries. Such subsidiaries will be separate
and distinct legal entities. As a result, substantially all of our cash flow will depend upon the earnings of our subsidiaries. In addition,
we will depend on the distribution of earnings, loans or other payments by our subsidiaries. No subsidiary will have any obligation to
provide our company with funds for our payment obligations. If there is an insolvency, liquidation or other reorganization of any of our
subsidiaries, our shareholders will have no right to proceed against their assets. Creditors of those subsidiaries will be entitled to
payment in full from the sale or other disposal of the assets of those subsidiaries before our company, as a shareholder, would be entitled
to receive any distribution from that sale or disposal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>

<!-- Field: Page; Sequence: 23 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Delaware law and the Amended and Restated
Certificate of Incorporation and Bylaws contain certain provisions, including anti-takeover provisions that limit the ability of stockholders
to take certain actions and could delay or discourage takeover attempts that stockholders may consider favorable.</i></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s Amended
and Restated Certificate of Incorporation and Bylaws, and the DGCL, contain provisions that could have the effect of rendering more difficult,
delaying, or preventing an acquisition deemed undesirable by the Company Board and therefore depress the trading price of the common stock.
These provisions could also make it difficult for stockholders to take certain actions, including electing directors who are not nominated
by the current members of the Company Board or taking other corporate actions, including effecting changes in management. Among other
things, the Amended and Restated Certificate of Incorporation and Bylaws include provisions regarding:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the ability of the Company Board to issue shares of preferred stock, including &#8220;blank check&#8221; preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the limitation of the liability of, and the indemnification of, the Company&#8217;s directors and officers;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the right of the Company Board to elect a director to fill a vacancy created by the expansion of the Company Board or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on the Company Board;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a prohibition on stockholder action by written consent (except as required for holders of future series of preferred stock), which forces stockholder action to be taken at an annual or special meeting of stockholders and could delay the ability of stockholders to force consideration of a stockholder proposal or to take action, including the removal of directors;</span></td></tr>

<tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the requirement that a special meeting of stockholders may be called only by the Company Board, the chairman of the Company Board, which could delay the ability of stockholders to force consideration of a proposal or to take action, including the removal of directors;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">controlling the procedures for the conduct and scheduling of the Company Board and stockholder meetings;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the requirement for the affirmative vote of holders of at least a majority of the voting power of all of the voting power of the then outstanding shares of the voting stock, voting as a single class, to amend, alter, change or repeal any provision of the Company&#8217;s Bylaws and certain provisions in the Amended and Restated Certificate of Incorporation, respectively, which could preclude stockholders from bringing matters before annual or special meetings of stockholders and delay changes in the Company Board and also may inhibit the ability of an acquirer to effect such amendments to facilitate an unsolicited takeover attempt;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the ability of the Company Board to amend the Bylaws by an affirmative vote of a majority of the Board, which may allow the Company Board to take additional actions to prevent an unsolicited takeover and inhibit the ability of an acquirer to amend the Bylaws to facilitate an unsolicited takeover attempt; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">advance notice procedures with which stockholders must comply to nominate candidates to the Company Board or to propose matters to be acted upon at a stockholders&#8217; meeting, which could preclude stockholders from bringing matters before annual or special meetings of stockholders and delay changes in the Company Board and also may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to obtain control of Company.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These provisions, alone or
together, could delay or prevent hostile takeovers and changes in control or changes in the Company Board or management.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, as a Delaware
corporation, the Company will generally be subject to provisions of Delaware law, including Section 203 of the DGCL.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any provision of the Amended
and Restated Certificate of Incorporation, Bylaws or Delaware law that has the effect of delaying or preventing a change in control could
limit the opportunity for stockholders to receive a premium for their shares of the Company&#8217;s capital stock and could also affect
the price that some investors are willing to pay for the common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Amended and Restated Certificate of
Incorporation designates a state or federal court located within the State of Delaware as the exclusive forum for substantially all disputes
between the Company and its stockholders, which could limit the Company&#8217;s stockholders&#8217; ability to choose the judicial forum
for disputes with the Company or its directors, officers, or employees.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Amended and Restated Certificate
of Incorporation will provide that, unless the Company consents in writing to the selection of an alternative forum, the Court of Chancery
of the State of Delaware, or if such court does not have subject matter jurisdiction, any other court located in the State of Delaware
with subject matter jurisdiction, will be the sole and exclusive forum for (i)&#160;any derivative action or proceeding brought on behalf
of the Company, (ii)&#160;any action asserting a claim of breach of a fiduciary duty owed by any current or former director, officer,
other employee or stockholder of the Company to the Company or the Company&#8217;s stockholders, (iii)&#160;any action asserting a claim
against the Company or its officers or directors arising pursuant to any provision of the DGCL or the Amended and Restated Certificate
of Incorporation or Bylaws or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware, or (iv)&#160;any
action asserting a claim against the Company or any director or officer of the Company governed by the internal affairs doctrine of the
law of the State of Delaware; provided, that, if and only if the Court of Chancery of the State of Delaware dismisses any such action
for lack of subject matter jurisdiction, such action may be brought in another state court sitting in the State of Delaware. Additionally,
the Amended and Restated Certificate of Incorporation will provide that, unless the Company consents to the selection of an alternative
forum, the federal district courts of the United&#160;States of America shall, to the fullest extent permitted by law, be the sole and
exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act; provided, however, that
such provision will not apply to suits brought to enforce any liability or duty created by the Exchange&#160;Act, or any other claim for
which the federal courts have exclusive jurisdiction. However, there is uncertainty as to whether a court would enforce this provision
and investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Section 22 of the Securities
Act creates concurrent jurisdiction for state and federal courts over all suits brought to enforce any duty or liability created by the
Securities Act or the rules and regulations thereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any person or entity purchasing
or otherwise acquiring any interest in any of the securities of the Company will be deemed to have notice of and consented to these provisions.
These exclusive-forum provisions may limit or make more costly a stockholder&#8217;s ability to bring a claim in a judicial forum of its
choosing for disputes with the Company or its directors, officers, or other employees, which may discourage lawsuits against the Company
and its directors, officers, and other employees. If a court were to find these exclusive-forum provisions to be inapplicable or unenforceable
in an action, the Company may incur additional costs associated with resolving the dispute in other jurisdictions, which could harm its
results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Capital Requirements and
Capital Structure</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Nasdaq may delist the Company&#8217;s securities
from trading on its exchange, which could limit investors&#8217; ability to make transactions in the Company&#8217;s securities and subject
the Company to additional trading restrictions.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s securities
are currently listed on The Nasdaq Capital Market (&#8220;Nasdaq&#8221;) effective as of the opening of business on June 13, 2023, and
it is anticipated that the Company&#8217;s securities will continue to be listed on The Nasdaq Capital Market. However, there can be no
assurance that the Company&#8217;s securities will maintain such listing at all times. To maintain the listing of the Company&#8217;s
securities on Nasdaq, the Company must maintain certain financial, distribution, liquidity and stock price levels to satisfy Nasdaq&#8217;s
continued listing requirements. The Company must, among other things, maintain a minimum bid price of $1.00 per share, a minimum market
value of listed securities of $35 million and a minimum of 300 public shareholders. The foregoing is a brief description of The Nasdaq
Capital Market continued listing requirements applicable to the Company&#8217;s securities, and more detailed information about such requirements
is set forth in Nasdaq Rules 5550 and 5560. If the Company is unable to maintain a minimum bid price for its shares of $1.00 per share,
or to satisfy any other continued listing requirement, Nasdaq may delist the Company&#8217;s securities from trading on its exchange.
Such a delisting would likely have a negative effect on the price of the Company&#8217;s securities and may impair your ability to sell
or purchase the Company&#8217;s securities when you wish to do so.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>

<!-- Field: Page; Sequence: 25 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 29, 2024, we received
notice from the Listing Qualifications Staff of Nasdaq indicating that, based upon the closing bid price of our common stock for the prior
30 consecutive business days, we were not in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued
listing on Nasdaq as set forth In Nasdaq Listing Rule 5550(a)(2). At that time, the Company was provided a compliance period of 180 calendar
days, or until July 29, 2024, to regain compliance with the Minimum Bid Price Requirement, pursuant to Nasdaq Listing Rule 5810(c)(3)(A).
As previously disclosed, on July 30, 2024, Coeptis received a letter from the Listing Qualifications Staff of Nasdaq indicating that the
Company did not regain compliance with the Minimum Bid Price Requirement by July 29, 2024, and it was determined that the Company was
not eligible for another 180 calendar-day extension because it did not meet the minimum stockholders&#8217; equity initial listing requirements
of $5,000,000 for Nasdaq, as set forth under Nasdaq Listing Rule 5505(b). The Company appealed the decision, as previously disclosed.
On September 17, 2024, the Company received a letter from Nasdaq advising the Company that the Company was granted an extension through
January 15, 2025, to regain listing compliance. On January 21, 2025, the Company was notified by Nasdaq that the Company has regained
compliance with the minimum bid price of $1.00, and that Nasdaq has determined to continue the listing of the Company&#8217;s securities.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If Nasdaq delists the Company&#8217;s
securities from trading on its exchange and the Company is not able to list its securities on another Nasdaq trading tier or on another
national securities exchange, the Company&#8217;s securities may be quoted on an over-the-counter market. However, if this were to occur,
the Company could face significant material adverse consequences, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a limited availability of market quotations for its securities;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">reduced liquidity for its securities;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a determination that the Common Stock is a &#8220;penny stock&#8221; which will require brokers trading in the common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for the Company&#8217;s securities;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a limited amount of news and analyst coverage; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a decreased ability to issue additional securities or obtain additional financing in the future.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If securities or industry analysts do not
publish research or reports about our business or publish negative reports about our business or our industry, the trading price and volume
of our securities could decline.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trading market for our
securities will depend in part on the research and reports that securities or industry analysts publish about us or our business, our
market and our competitors. We do not have any control over these analysts. If one or more of the analysts who cover us downgrade our
shares or change their opinion of our shares, the trading price for our securities would likely decline. If one or more of these analysts
cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could
cause the trading price or volume of our securities to decline.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are an &#8220;emerging growth company&#8221;
and the reduced disclosure requirements applicable to emerging growth companies may make our securities less attractive to investors.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an &#8220;emerging
growth company,&#8221; as defined in the JOBS Act. For so long as we remain an emerging growth company, we are permitted and plan to rely
on exemptions from certain disclosure requirements that are applicable to public companies that are not emerging growth companies. These
provisions include, but are not limited to: an exemption from compliance with the auditor attestation requirement in the assessment of
our internal control over financial reporting pursuant to Section&#160;404 of the Sarbanes-Oxley Act; reduced disclosure obligations regarding
executive compensation arrangements in our periodic reports, registration statements and proxy statements; and exemptions from the requirements
of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously
approved. In addition, the JOBS Act permits emerging growth companies to take advantage of an extended transition period to comply with
new or revised accounting standards applicable to public companies. We intend to take advantage of the exemptions discussed above. As
a result, the information we provide will be different than the information that is available with respect to other public companies that
are not emerging growth companies or that are not taking advantage of such exemptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will remain an emerging
growth company until the earliest of (i)&#160;December&#160;31, 2027, (ii)&#160;the first fiscal&#160;year after our annual gross revenue
exceed $1.07 billion, (iii)&#160;the date on which we have, during the immediately preceding three-year period, issued more than $1.00
billion in non-convertible debt securities, or (iv)&#160;the end of any fiscal&#160;year in which the market value of our common stock
held by non-affiliates exceeds $700.0 million as of the end of the second quarter of that fiscal&#160;year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot predict whether
investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive
as a result, there may be a less active trading market for our securities, and the market price of our securities may be more volatile.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 26 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span id="a_007"></span><i></i></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%; font-size: 10pt"><span style="font-size: 10pt"><b>ITEM 1B.</b></span></td>
    <td style="width: 90%; font-size: 10pt"><span style="font-size: 10pt"><b>UNRESOLVED STAFF COMMENTS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%; font-size: 10pt"><span id="a_008"></span><span style="font-size: 10pt"><b>ITEM 1C.</b></span></td>
    <td style="width: 90%; font-size: 10pt"><span style="font-size: 10pt"><b>CYBERSECURITY</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p id="xdx_984_ecyd--CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_iB_c20250101__20251231_gBFCRMPFAIAMT-JMFNBHV_zGz8xmYkBpN4" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" continuedAt="ConU000055-01" escape="true" id="Fact000055" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"><b>Cybersecurity Risk Management and Strategy</b></ix:nonNumeric></p>

<div id="xdx_C06_gBFCRMPFAIAMT-JMFNBHV_zK8R66t6A6tl"><ix:continuation continuedAt="ConU000055-02" id="ConU000055-01"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></div>

<div id="xdx_C0C_gBFCRMPFAIAMT-JMFNBHV_z3YZ3DSrAJ67"><ix:continuation continuedAt="ConU000055-03" id="ConU000055-02"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_900_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20250101__20251231_zhkbzupmLsk4" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000056" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock">The Company <span id="xdx_901_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20250101__20251231_zx4SGCcPUjGk" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000057" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag">recognizes</ix:nonNumeric></span> the
importance of cybersecurity in safeguarding its information systems and data.</ix:nonNumeric></span> Our cybersecurity measures primarily rely on standard security
protocols provided by Microsoft Outlook and OneDrive, which include encryption, multi-factor authentication, and access controls to protect
against unauthorized access and data breaches.</p></ix:continuation></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>

<div id="xdx_C00_gBFCRMPFAIAMT-JMFNBHV_zZkH4Ek0VYti"><ix:continuation continuedAt="ConU000055-04" id="ConU000055-03"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p></ix:continuation></div>

<div id="xdx_C01_gBFCRMPFAIAMT-JMFNBHV_zZ16Ygxho8Y"><ix:continuation continuedAt="ConU000055-05" id="ConU000055-04"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Given the evolving nature
of cybersecurity threats, the Company monitors its systems for potential vulnerabilities and relies on <span id="xdx_905_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20250101__20251231_zoNQFsm9lYoi" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000058" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag">third-party</ix:nonNumeric></span> security updates and
patches to mitigate risks. While we believe our current measures are appropriate for our operations, we acknowledge that no security system
is entirely immune from potential threats, including phishing attacks, malware, ransomware, and unauthorized access.</p></ix:continuation></div>

<div id="xdx_C09_gBFCRMPFAIAMT-JMFNBHV_za8GgfXwWX1k"><ix:continuation id="ConU000055-05"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p></ix:continuation></div>

<p id="xdx_984_ecyd--CybersecurityRiskBoardOfDirectorsOversightTextBlock_c20250101__20251231_gBFCRBODOTB-PDI_z8uz5wHGHLxc" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" continuedAt="ConU000065-01" escape="true" id="Fact000065" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock"><b>Governance and Oversight</b></ix:nonNumeric></p>

<div id="xdx_C0D_gBFCRBODOTB-PDI_z80XDX9HTXac"><ix:continuation continuedAt="ConU000065-02" id="ConU000065-01"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:continuation></div>

<div id="xdx_C07_gBFCRBODOTB-PDI_zwbiB7wJ80qi"><ix:continuation continuedAt="ConU000065-03" id="ConU000065-02"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_903_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20250101__20251231_zaAysTbebyl9" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000066" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">The Company&#8217;s executive
management is responsible for overseeing cybersecurity risks and ensuring compliance with our security practices. At this time, the Company
does not have a dedicated cybersecurity team but relies on its IT service providers and Microsoft&#8217;s security framework for system
protection and incident response.</ix:nonNumeric></span></p></ix:continuation></div>

<div id="xdx_C03_gBFCRBODOTB-PDI_zaXykv1hLqx7"><ix:continuation continuedAt="ConU000065-04" id="ConU000065-03"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></div>

<div id="xdx_C08_gBFCRBODOTB-PDI_zyrRBJLn8SM9"><ix:continuation continuedAt="ConU000065-05" id="ConU000065-04"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Potential Risks and Impact</b></p></ix:continuation></div>

<div id="xdx_C06_gBFCRBODOTB-PDI_zmU5MPaGzXHi"><ix:continuation continuedAt="ConU000065-06" id="ConU000065-05"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></div>

<div id="xdx_C0A_gBFCRBODOTB-PDI_z1T1JQtBW7Y3"><ix:continuation id="ConU000065-06"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_903_ecyd--CybersecurityRiskRoleOfManagementTextBlock_c20250101__20251231_zgpzdqv5fpu6" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000067" name="cyd:CybersecurityRiskRoleOfManagementTextBlock">Despite these measures, the
Company may be vulnerable to cybersecurity incidents that could disrupt operations, compromise sensitive data, or result in financial
or reputational harm. Any material cybersecurity incident would be assessed and disclosed as necessary.</ix:nonNumeric></span></p></ix:continuation></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%; font-size: 10pt"><span id="a_009"></span><span style="font-size: 10pt"><b>ITEM 2.</b></span></td>
    <td style="width: 90%; font-size: 10pt"><span style="font-size: 10pt"><b>PROPERTIES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our principal place of business
is located at 105 Bradford Street, Suite 420, Wexford, Pennsylvania 15090, which we lease. The lease is scheduled to expire on May 31,
2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We do not own any properties or land.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe our facilities
are adequate and suitable for our current needs and that, should it be needed, suitable additional or alternative space will be available.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%; font-size: 10pt"><span id="a_010"></span><span style="font-size: 10pt"><b>ITEM 3.</b></span></td>
    <td style="width: 90%; font-size: 10pt"><span style="font-size: 10pt"><b>LEGAL PROCEEDINGS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are from time to time subject
to litigation and other proceedings that arise in the ordinary course of our business. Subject to the inherent uncertainties of litigation
and although no assurances are possible, we believe that there are no pending lawsuits or claims that, individually or in the aggregate,
will have a material adverse effect on our business, financial condition or our yearly results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%; font-size: 10pt"><span id="a_011"></span><span style="font-size: 10pt"><b>ITEM 4.</b></span></td>
    <td style="width: 90%; font-size: 10pt"><span style="font-size: 10pt"><b>MINE SAFETY DISCLOSURES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 27 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="a_012"></span><b>PART II</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%; font-size: 10pt"><span id="a_013"></span><span style="font-size: 10pt"><b>ITEM 5.</b></span></td>
    <td style="width: 90%; font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b>MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Market Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock is listed
on the Nasdaq Global Market under the symbol &#8220;COEP.&#8221; The closing price of our common stock on Nasdaq on December 31, 2025
was $14.25 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Holders of Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 18, 2026, we had
6,223,221 shares of our common stock issued and outstanding, and there were 128 record holders of our common stock. Certain shares are
held in &#8220;street&#8221; name and accordingly, the number of beneficial owners of such shares is not known or included in the foregoing
number. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Dividend Policy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared or
paid dividends. We do not intend to pay cash dividends on our Common Stock for the foreseeable future, but currently intend to retain
any future earnings to fund the development and growth of our business. The payment of dividends if any, on our common stock will rest
solely within the discretion of our board of directors and will depend, among other things, upon our earnings, capital requirements, financial
condition, and other relevant factors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Securities Authorized for Issuance under Equity Compensation Plans</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of the principal features of the 2022 Equity Incentive Plan (the &#8220;Plan&#8221;). This summary does not purport to be a complete description
of all of the provisions of the 2022 Equity Incentive Plan and it is qualified in its entirety by reference to the full text of the 2022
Equity Incentive Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i><span style="text-decoration: underline">Eligibility and Administration</span>.&#160;&#160;&#160;&#160;</i></b>Employees,
consultants and directors of the Company and its subsidiaries may be eligible to receive awards under the 2022 Equity Incentive Plan.
Currently, we have seven employees and five non-employee directors. All seven employees, and all five non-employee directors and two consultants
have received awards under the 2022 Equity Incentive Plan.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i><span style="text-decoration: underline">Awards</span>.&#160;&#160;&#160;&#160;</i></b>The
2022 Equity Incentive Plan provides for the grant of ISOs within the meaning of Section&#160;422 of the Internal Revenue Code (the &#8220;Code&#8221;)
to employees, including employees of any parent or subsidiary, and for the grant of nonstatutory stock options (&#8220;NSOs&#8221;), stock
appreciation rights (&#8220;SARs&#8221;), Restricted Stock Awards, Restricted Stock Unit (&#8220;RSU&#8221;) awards, Performance Awards
and other forms of awards to employees, directors and consultants, including employees and consultants of our affiliates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i><span style="text-decoration: underline">Authorized Shares</span>.&#160;&#160;&#160;&#160;</i></b>The
initial maximum number of shares of our Common Stock that may be issued under the 2022 Equity Incentive Plan was 117,000. As approved
by the Company&#8217;s shareholders in December 2023, the maximum number of shares under the Plan was increased to 367,000. As of December
31, 2025, a total of 339,500 stock options to purchase shares of common stock were granted under the Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Shares subject to stock awards
granted under the Plan that expire or terminate without being exercised in full or that are paid out in cash rather than in shares do
not reduce the number of shares available for issuance under our Plan. Shares withheld under a stock award to satisfy the exercise, strike
or purchase price of a stock award or to satisfy a tax withholding obligation do not reduce the number of shares available for issuance
under our Plan. If any shares of our Common Stock issued pursuant to a stock award are forfeited back to or repurchased or reacquired
by us (i)&#160;because of a failure to meet a contingency or condition required for the vesting of such shares, (ii)&#160;to satisfy the
exercise, strike or purchase price of an award or (iii)&#160;to a tax withholding obligation in connection with an award, the shares that
are forfeited or repurchased or satisfy reacquired will revert to and again become available for issuance under the Plan. Any shares previously
issued which are reacquired in satisfaction of tax withholding obligations or as consideration for the exercise or purchase price of a
stock award will again become available for issuance under the Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>

<!-- Field: Page; Sequence: 28 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i><span style="text-decoration: underline">Plan Administration</span>.&#160;&#160;&#160;&#160;</i></b>Our
Board, or, if assigned authority by the Board, the Compensation Committee of the Board (the &#8220;Committee&#8221;), will have the authority
to administer the Plan, unless and until the Board delegates some or all of the administration of the Plan to a different Committee or
Committees of the Board. The Committee may delegate to one or more of our officers the authority to (i)&#160;designate employees (other
than officers) to receive specified stock awards and (ii)&#160;determine the number of shares subject to such stock awards. The Committee
will have the power, subject to, and within the limitations of, the express provisions of the Plan to determine from time to time (1)&#160;which
of the persons eligible under the Plan will be granted Awards; (2)&#160;when and how each Award will be granted; (3)&#160;what type or
combination of types of Award will be granted; (4)&#160;the provisions of each Award granted (which need not be identical), including
the time or times when a person will be permitted to receive an issuance of Common Stock or other payment pursuant to an Award; (5)&#160;the
number of shares of Common Stock or cash equivalent with respect to which an Award will be granted to each such person; and (6)&#160;the
Fair Market Value applicable to an Award. The Committee will also be granted with the power to construe and interpret the Plan and Awards
granted under it, correct any deficiencies or omissions in the Plan to make the Plan or Award fully effective, to settle all controversies
regarding the Plan and any Award, to accelerate the time at which an Award may first be exercised or the time during which an Award will
vest, to prohibit the exercise of any Option, SAR or exercisable award for administrative convenience, to approve forms of Award Agreements
under the Plan, and to exercise such powers and to perform such acts as the Committee deems necessary or expedient to promote the best
interests of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i><span style="text-decoration: underline">Stock Options</span>.&#160;&#160;&#160;&#160;</i></b>ISOs
and NSOs are granted under stock option agreements in a form approved by the Committee. The Committee determines the exercise price for
stock options, within the terms and conditions of the Plan, provided that the exercise price of a stock option generally cannot be less
than 100% of the fair market value of our Common Stock on the date of grant. Options granted under the Plan vest at the rate specified
in the stock option agreement as determined by the Committee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Committee determines the
term of stock options granted under the Plan, up to a maximum of 10&#160;years. Unless the terms of an option holder&#8217;s stock option
agreement, or other written agreement between us and the recipient approved by the Committee, provide otherwise, if an option holder&#8217;s
service relationship with us or any of our affiliates ceases for any reason other than disability, death or Cause (as defined in the Plan),
the option holder may generally exercise any vested options for a period of three&#160;months following the cessation of service. If an
option holder&#8217;s service relationship with us or any of our affiliates ceases due to death, or an option holder dies within a certain
period following cessation of service, the option holder or a beneficiary may generally exercise any vested options for a period of 18&#160;months
following the date of death. If an option holder&#8217;s service relationship with us or any of our affiliates ceases due to disability,
the option holder may generally exercise any vested options for a period of 12&#160;months following the cessation of service. In the
event of a termination for cause, options generally terminate upon the termination date. In no event may an option be exercised beyond
the expiration of its term.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Acceptable consideration for
the purchase of Common Stock issued upon the exercise of a stock option will be determined by the Committee and may include (i)&#160;cash,
check, bank draft or money order, (ii)&#160;a broker-assisted cashless exercise, (iii)&#160;the tender of shares of our Common Stock previously
owned by the option holder, (iv)&#160;a net exercise of the option if it is an NSO or (v)&#160;other legal consideration approved by the
Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless the Committee provides
otherwise, options or stock appreciation rights generally are not transferable except by will or the laws of descent and distribution.
Subject to approval of the Committee or a duly authorized officer, an option may be transferred pursuant to a domestic relations order,
official marital settlement agreement or other divorce or separation instrument.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i><span style="text-decoration: underline">Tax Limitations on
ISOs</span>.&#160;&#160;&#160;&#160;</i></b>The aggregate fair market value, determined at the time of grant, of our Common Stock with respect
to ISOs that are exercisable for the first time by an award holder during any calendar year under all of our stock plans may not exceed
$100,000. Options or portions thereof that exceed such limit will generally be treated as NSOs. No ISO may be granted to any person who,
at the time of the grant, owns or is deemed to own stock possessing more than 10% of our total combined voting power or that of any of
our parent or subsidiary corporations unless (i)&#160;the option exercise price is at least 110% of the fair market value of the stock
subject to the option on the date of grant and (ii)&#160;the term of the ISO does not exceed five&#160;years from the date of grant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>

<!-- Field: Page; Sequence: 29 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i><span style="text-decoration: underline">Restricted Stock
Unit Awards</span>.&#160;&#160;&#160;&#160;</i></b>Restricted stock unit awards are granted under restricted stock unit award agreements
in a form approved by the Committee. Restricted stock unit awards may be granted in consideration for any form of legal consideration
that may be acceptable to our board of directors and permissible under applicable law. A restricted stock unit award may be settled by
cash, delivery of stock, a combination of cash and stock as deemed appropriate by the Committee or in any other form of consideration
set forth in the restricted stock unit award agreement. Additionally, dividend equivalents may be credited in respect of shares covered
by a restricted stock unit award. Except as otherwise provided in the applicable award agreement, or other written agreement between us
and the recipient approved by the Committee, restricted stock unit awards that have not vested will be forfeited once the participant&#8217;s
continuous service ends for any reason.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i><span style="text-decoration: underline">Restricted Stock
Awards</span>.&#160;&#160;&#160;&#160;</i></b>Restricted stock awards are granted under restricted stock award agreements in a form approved
by the Committee. A restricted stock award may be awarded in consideration for cash, check, bank draft or money order, past or future
services to us or any other form of legal consideration that may be acceptable to our board of directors and permissible under applicable
law. The Committee determines the terms and conditions of restricted stock awards, including vesting and forfeiture terms. If a participant&#8217;s
service relationship with us ends for any reason, we may receive any or all of the shares of Common Stock held by the participant that
have not vested as of the date the participant terminates service with us through a forfeiture condition or a repurchase right.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i><span style="text-decoration: underline">Stock Appreciation
Rights</span>.&#160;&#160;&#160;&#160;</i></b>Stock appreciation rights are granted under stock appreciation right agreements in a form approved
by the Committee. The Committee determines the strike price for a stock appreciation right, which generally cannot be less than 100% of
the fair market value of our Common Stock on the date of grant. A stock appreciation right granted under the Plan vests at the rate specified
in the stock appreciation right agreement as determined by the Committee. Stock appreciation rights may be settled in cash or shares of
Common Stock or in any other form of payment as determined by the Board and specified in the stock appreciation right agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Committee determines the
term of stock appreciation rights granted under the Plan, up to a maximum of 10&#160;years. If a participant&#8217;s service relationship
with us or any of our affiliates ceases for any reason other than cause, disability or death, the participant may generally exercise any
vested stock appreciation right for a period of three&#160;months following the cessation of service. This period may be further extended
in the event that exercise of the stock appreciation right following such a termination of service is prohibited by applicable securities
laws. If a participant&#8217;s service relationship with us, or any of our affiliates, ceases due to disability or death, or a participant
dies within a certain period following cessation of service, the participant or a beneficiary may generally exercise any vested stock
appreciation right for a period of 12&#160;months in the event of disability and 18&#160;months in the event of death. In the event of
a termination for cause, stock appreciation rights generally terminate immediately upon the occurrence of the event giving rise to the
termination of the individual for cause. In no event may a stock appreciation right be exercised beyond the expiration of its term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i><span style="text-decoration: underline">Performance Awards</span>.&#160;&#160;&#160;&#160;</i></b>The
Plan permits the grant of performance awards that may be settled in stock, cash or other property. Performance awards may be structured
so that the stock or cash will be issued or paid only following the achievement of certain pre-established performance goals during a
designated performance period. Performance awards that are settled in cash or other property are not required to be valued in whole or
in part by reference to, or otherwise based on, the Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The performance goals may
be based on any measure of performance selected by the board of directors or the Committee. The performance goals may be based on company-wide
performance or performance of one or more business units, divisions, affiliates or business segments, and may be either absolute or relative
to the performance of one or more comparable companies or the performance of one or more relevant indices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i><span style="text-decoration: underline">Other Stock Awards</span>.&#160;&#160;&#160;&#160;</i></b>The
Committee may grant other awards based in whole or in part by reference to our Common Stock. The Compensation Committee will set the number
of shares under the stock award (or cash equivalent) and all other terms and conditions of such awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>

<!-- Field: Page; Sequence: 30 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i><span style="text-decoration: underline">Non-Employee Director
Compensation Limit</span>.&#160;&#160;&#160;&#160;</i></b>The aggregate value of all compensation granted or paid to any non-employee director
with respect to any calendar year, including awards granted and cash fees paid by us to such non-employee director, will not exceed $200,000
in total value; provided that such amount will increase to $400,000 for the first year for newly appointed or elected non-employee directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i><span style="text-decoration: underline">Changes to Capital
Structure</span>.&#160;&#160;&#160;&#160;</i></b>In the event there is a specified type of change in our capital structure, such as a stock
split, reverse stock split or recapitalization, appropriate adjustments will be made to (i)&#160;the class and maximum number of shares
reserved for issuance under the Plan, (ii)&#160;the class and maximum number of shares by which the share reserve may increase automatically
each year, (iii)&#160;the class and maximum number of shares that may be issued on the exercise of ISOs and (iv)&#160;the class and number
of shares and exercise price, strike price or purchase price, if applicable, of all outstanding stock awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i><span style="text-decoration: underline">Corporate Transactions</span>.&#160;&#160;&#160;&#160;</i></b>The
following applies to stock awards under the Plan in the event of a corporate transaction (as defined in the Plan), unless otherwise provided
in a participant&#8217;s stock award agreement or other written agreement with us or one of our affiliates or unless otherwise expressly
provided by the Committee at the time of grant.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of a corporate
transaction, any stock awards outstanding under the Plan may be assumed, continued or substituted for by any surviving or acquiring corporation
(or its parent company), and any reacquisition or repurchase rights held by us with respect to the stock award may be assigned to the
successor (or its parent company). If the surviving or acquiring corporation (or its parent company) does not assume, continue or substitute
for such stock awards, then (i)&#160;with respect to any such stock awards that are held by participants whose continuous service has
not terminated prior to the effective time of the corporate transaction, or current participants, the vesting (and exercisability, if
applicable) of such stock awards will be accelerated in full to a date prior to the effective time of the corporate transaction (contingent
upon the effectiveness of the corporate transaction), and such stock awards will terminate if not exercised (if applicable) at or prior
to the effective time of the corporate transaction, and any reacquisition or repurchase rights held by us with respect to such stock awards
will lapse (contingent upon the effectiveness of the corporate transaction), and (ii)&#160;any such stock awards that are held by persons
other than current participants will terminate if not exercised (if applicable) prior to the effective time of the corporate transaction,
except that any reacquisition or repurchase rights held by us with respect to such stock awards will not terminate and may continue to
be exercised notwithstanding the corporate transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event a stock award
will terminate if not exercised prior to the effective time of a corporate transaction, the board of directors may provide, in its sole
discretion, that the holder of such stock award may not exercise such stock award but instead will receive a payment equal in value to
the excess (if any) of (i)&#160;the per share amount payable to holders of Common Stock in connection with the corporate transaction over
(ii)&#160;any per share exercise price payable by such holder, if applicable. In addition, any escrow, holdback, earn out or similar provisions
in the definitive agreement for the corporate transaction may apply to such payment to the same extent and in the same manner as such
provisions apply to the holders of Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i><span style="text-decoration: underline">Plan Amendment or
Termination</span>.&#160;&#160;&#160;&#160;</i></b>Our board of directors has the authority to amend, suspend or terminate our Plan, provided
that such action does not materially impair the existing rights of any participant without such participant&#8217;s written consent. Certain
material amendments also require the approval of our stockholders. No ISOs may be granted after the tenth anniversary of the date our
board of directors adopts our Plan. No stock awards may be granted under our Plan while it is suspended or after it is terminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Summary of Material United&#160;States Federal
Income Tax Consequences of the 2022 Equity Incentive Plan</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of the principal federal income tax consequences of option grants and other awards under the 2022 Equity Incentive Plan. Optionees and
recipients of other rights and awards granted under the 2022 Equity Incentive Plan are advised to consult their personal tax advisors
before exercising an option or stock appreciation right or disposing of any stock received pursuant to the exercise of an option or stock
appreciation right or following vesting of a restricted stock award or restricted stock unit or upon grant of an unrestricted stock award.
In addition, the following summary is based upon an analysis of the Code as currently in effect, existing laws, judicial decisions, administrative
rulings, regulations and proposed regulations, all of which are subject to change and does not address state, local or other tax laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>

<!-- Field: Page; Sequence: 31 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Nonstatutory Stock Options.&#160;&#160;&#160;&#160;</i></b>Generally,
there is no taxation upon the grant of a NSO.&#160;Upon exercise, a participant will recognize ordinary income equal to the excess, if
any, of the fair market value of the underlying stock on the date of exercise of the stock option over the exercise price. If the participant
is employed by the Company or one of its affiliates, that income will be subject to withholding taxes. The participant&#8217;s tax basis
in those shares will be equal to their fair market value on the date of exercise of the stock option, and the participant&#8217;s capital
gain holding period for those shares will begin on the day after they are transferred to the participant. Subject to the requirement of
reasonableness, the deduction limits under Section&#160;162(m)&#160;of the Code and the satisfaction of a tax reporting obligation, the
Company will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the participant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Incentive Stock Options.&#160;&#160;&#160;&#160;</i></b>The
2022 Equity Incentive Plan provides for the grant of stock options that are intended to qualify as &#8220;incentive stock options,&#8221;
as defined in Section 422 of the Code. Under the Code, a participant generally is not subject to ordinary income tax upon the grant or
exercise of an ISO.&#160;If the participant holds a share received upon exercise of an ISO for more than two&#160;years from the date
the stock option was granted and more than one year from the date the stock option was exercised, which is referred to as the required
holding period, the difference, if any, between the amount realized on a sale or other taxable disposition of that share and the participant&#8217;s
tax basis in that share will be long-term capital gain or loss. If, however, a participant disposes of a share acquired upon exercise
of an ISO before the end of the required holding period, which is referred to as a disqualifying disposition, the participant generally
will recognize ordinary income in the year of the disqualifying disposition equal to the excess, if any, of the fair market value of the
share on the date of exercise of the stock option over the exercise price. However, if the sales proceeds are less than the fair market
value of the share on the date of exercise of the stock option, the amount of ordinary income recognized by the participant will not exceed
the gain, if any, realized on the sale. If the amount realized on a disqualifying disposition exceeds the fair market value of the share
on the date of exercise of the stock option, that excess will be short-term or long-term capital gain, depending on whether the holding
period for the share exceeds one year. For purposes of the alternative minimum tax, the amount by which the fair market value of a share
of stock acquired upon exercise of an ISO exceeds the exercise price of the stock option generally will be an adjustment included in the
participant&#8217;s alternative minimum taxable income for the year in which the stock option is exercised. If, however, there is a disqualifying
disposition of the share in the year in which the stock option is exercised, there will be no adjustment for alternative minimum tax purposes
with respect to that share. In computing alternative minimum taxable income, the tax basis of a share acquired upon exercise of an ISO
is increased by the amount of the adjustment taken into account with respect to that share for alternative minimum tax purposes in the
year the stock option is exercised. The Company is not allowed a tax deduction with respect to the grant or exercise of an ISO or the
disposition of a share acquired upon exercise of an ISO after the required holding period. If there is a disqualifying disposition of
a share, however, the Company will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the participant,
subject to the requirement of reasonableness, the deduction limits under Section&#160;162(m)&#160;of the Code and provided that either
the employee includes that amount in income or the Company timely satisfies its reporting requirements with respect to that amount.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Restricted Stock Awards.&#160;&#160;&#160;&#160;</i></b>Generally,
the recipient of a restricted stock award will recognize ordinary income at the time the stock is received equal to the excess, if any,
of the fair market value of the stock received over any amount paid by the recipient in exchange for the stock. If, however, the stock
is subject to restrictions constituting a substantial risk of forfeiture when it is received (for example, if the employee is required
to work for a period of time in order to have the right to transfer or sell the stock), the recipient generally will not recognize income
until the restrictions constituting a substantial risk of forfeiture lapse, at which time the recipient will recognize ordinary income
equal to the excess, if any, of the fair market value of the stock on the date it becomes vested over any amount paid by the recipient
in exchange for the stock. A recipient may, however, file an election with the Internal Revenue Service, within 30 days following the
date of grant, to recognize ordinary income, as of the date of grant, equal to the excess, if any, of the fair market value of the stock
on the date the award is granted over any amount paid by the recipient for the stock. The recipient&#8217;s basis for the determination
of gain or loss upon the subsequent disposition of shares acquired from a restricted stock award will be the amount paid for such shares
plus any ordinary income recognized either when the stock is received or when the restrictions constituting a substantial risk of forfeiture
lapse. Subject to the requirement of reasonableness, the deduction limits under Section 162(m) of the Code and the satisfaction of a tax
reporting obligation, the Company will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the recipient
of the restricted stock award.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Restricted Stock Unit
Awards.&#160;&#160;&#160;&#160;</i></b>Generally, the recipient of a restricted stock unit award will generally recognize ordinary income
at the time the stock is delivered equal to the excess, if any, of (i)&#160;the fair market value of the stock received over any amount
paid by the recipient in exchange for the stock or (ii)&#160;the amount of cash paid to the participant. The recipient&#8217;s basis for
the determination of gain or loss upon the subsequent disposition of shares acquired from a restricted stock unit award will be the amount
paid for such shares plus any ordinary income recognized when the stock is delivered, and the participant&#8217;s capital gain holding
period for those shares will begin on the&#160;day after they are transferred to the participant. Subject to the requirement of reasonableness,
the deduction limits under Section 162(m) of the Code and the satisfaction of a tax reporting obligation, the Company will generally be
entitled to a tax deduction equal to the taxable ordinary income realized by the recipient of the restricted stock unit award.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Stock Appreciation Rights.&#160;&#160;&#160;&#160;</i></b>Generally,
the recipient of a stock appreciation right will recognize ordinary income equal to the fair market value of the stock or cash received
upon such exercise. Subject to the requirement of reasonableness, the deduction limits under Section&#160;162(m)&#160;of the Code and
the satisfaction of a tax reporting obligation, the Company will generally be entitled to a tax deduction equal to the taxable ordinary
income realized by the recipient of the stock appreciation right.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>THE FOREGOING IS ONLY A SUMMARY OF THE EFFECT
OF THE U.S. FEDERAL INCOME TAXATION UPON PARTICIPANTS AND THE COMPANY UNDER THE 2022 EQUITY INCENTIVE PLAN. IT DOES NOT PURPORT TO BE
COMPLETE AND DOES NOT DISCUSS THE TAX CONSEQUENCES OF A PARTICIPANT&#8217;S DEATH OR THE PROVISIONS OF THE INCOME TAX LAWS OF ANY MUNICIPALITY,
STATE, OR FOREIGN COUNTRY IN WHICH THE PARTICIPANT MAY RESIDE.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Recent Sales of Unregistered Securities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Set forth below is information
regarding shares of capital stock issued by us within the past three&#160;years. All shares are presented on a post reverse stock split
basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2023 the Company
issued an aggregate of 43,709 shares of its common stock to service providers as compensation for services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2023 the Company
granted options to purchase an aggregate of 67,875 shares of its common stock under the 2022 Equity Incentive Plan, to various officers,
directors, employees and consultants, at an average exercise price of $32.60 per share. In October 2023 the Company granted options to
purchase an aggregate of 15,000 shares of its common stock under the 2022 Equity Incentive Plan, to two officers/employees and consultants,
at an exercise price of $21.40 per share The Company has also granted a stand-alone option to a former employee to purchase up to 5,000
shares of our common stock at an exercise price of $200 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April 2023 the Company
issued an aggregate of 50,000 shares of common stock in connection with the termination of several investment banking agreements and all
future rights and obligations under such agreements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2023, in connection
with the June 2023 Offering, the Company issued warrants to the underwriter of such offering to acquire up to 10,500 shares of the Company&#8217;s
common stock at an exercise price of $25.00.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 16, 2023, Coeptis
Therapeutics Holdings, Inc. (the &#8220;Company&#8221;) entered into an exclusive licensing arrangement (with Deverra Therapeutics Inc.,
and, issued to Deverra 200,000 shares of the Company&#8217;s common stock and assumed certain liabilities related to the ongoing clinical
trials.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 29, 2023, the
Company issued 120,000 shares of common stock of the Company to a private investor in exchange for $2,400,000, $400,000 of which was paid
in cash and the balance of which was paid with a promissory note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 29, 2023, the
Company issued 30,000 shares of common stock of the Company to a private investor in exchange for $600,000, $100,000 of which was paid
in cash and the balance of which was paid with a promissory note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>

<!-- Field: Page; Sequence: 33 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 26, 2023, in connection
with the private placement described elsewhere in the Annual Report on Form 10-K, the Company issued to an institutional investor (i)
38,850 Shares of the Company&#8217;s common stock, (ii) Pre-Funded Warrants to purchase up to 61,150 shares of Common Stock, (iii) Series
A Warrants to purchase up to 100,000 shares of Common Stock with an exercise price of $27.20 per share, and (iv) Series B Warrants (the
&#8220;Series B Warrants&#8221; and together with the Pre-Funded Warrants and the Series A Warrants , the &#8220;Warrants&#8221;) to purchase
up to 100,000 shares of Common Stock with an exercise price of $27.20 per share, for gross proceeds to the Company of $2,000,000. In connection
with the October 2023 private placement, the Company also issued placement agent warrants (the &#8220;Placement Agent Warrants&#8221;)
to purchase 6,000 shares of our common stock at an exercise price of $28.00 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2023, the Company
sold a pre-funded warrant to AMLS Holdings, LLC that are currently exercisable to acquire up to 150,000 of the shares of Common Stock
being registered hereunder for the benefit of such shareholder, for gross proceeds to the Company of $1,200,000 comprised of $100,000
in cash and a $1,100,000 promissory note. The promissory note accrues interest at the rate of six (6%) percent per annum (increasing to
eighteen percent (18%) per annum from and after the occurrence of a default) and matured on November 29, 2024, and has provision for mandatory
prepayment. In February 2024 the Company sold a pre-funded warrant to Alamo Board Marketing, LLC that are currently exercisable to acquire
up to 300,000 of the shares being registered hereunder for the benefit of such shareholder, for gross proceeds to the Company of $2,400,000
comprised of $500,000 in cash and a $1,900,000 promissory note. The promissory note accrues interest at the rate of six (6%) percent per
annum (increasing to eighteen percent (18%) per annum from and after the occurrence of a default) and matured on December 31, 2024, and
has provision for mandatory prepayment. Between June 14, 2024 and February 6, 2025, the Company sold 10,000 shares of its Series A Preferred
Stock for aggregate gross proceeds of $10 million. Christopher Calise, a current member of our Board of Directors, participated in the
offering personally and through an entity controlled by him.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2024 the Company
granted options to purchase an aggregate of 76,750 shares of its common stock under the 2022 Equity Incentive Plan, to various officers,
directors, employees and consultants, at an average exercise price of $12.92 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2024 the Company granted
options to purchase an aggregate of 120,000 shares of its common stock under the 2022 Equity Incentive Plan, to our CEO, at an exercise
price of $6.20 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2024, we issued
20,000 shares of Common Stock (&#8220;Commitment Shares&#8221;), to Yorkville as consideration for Yorkville&#8217;s commitment to purchase
shares of Common Stock at the Company&#8217;s direction upon the terms and subject to the conditions set forth in the SEPA, upon execution
of the SEPA. In the SEPA, Yorkville represented to the Company among other things, that it is an &#8220;accredited investor&#8221; (as
such term is defined in Rule 501(a) of Regulation D under the Securities Act). The Commitment Shares are being issued and sold by the
Company to Yorkville in reliance upon the exemptions from the registration requirements of the Securities Act afforded by Section 4(a)(2)
of the Securities Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2024, we also
issued a convertible promissory note in the principal amount of $1,304,758 to Yorkville pursuant to the SEPA (the &#8220;Yorkville Promissory
Note&#8221;). The Yorkville Promissory Note and the shares of Common Stock issuable upon conversion of the Yorkville Promissory Note have
not been registered under the Securities Act in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities
Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2025, we also issued
a convertible promissory note in the principal amount of $1,100,000 to Yorkville pursuant to the SEPA (the &#8220;Yorkville 2025 Promissory
Note&#8221;). The Yorkville 2025 Promissory Note and the shares of Common Stock issuable upon conversion of the Yorkville 2025 Promissory
Note have not been registered under the Securities Act in reliance on the exemption from registration provided by Section 4(a)(2) of the
Securities Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2025 we issued
warrants to a service provider to acquire up to 100,000 shares of the Company&#8217;s common stock at an exercise price of $12.00 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>

<!-- Field: Page; Sequence: 34 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2025 we issued
a stand-alone option to a service provider to acquire up to 100,000 shares of the Company&#8217;s common stock at an exercise price of
$5.72 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2025 the Company
granted options to purchase an aggregate of 87,375 shares of its common stock under the 2022 Equity Incentive Plan, to various officers,
directors, employees and consultants, at an average exercise price of $10.52 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From July 2025 to September
2025 the Company sold 436,467 shares of common stock through a private placement for $2,500,000 in cash and $2,500,000 in promissory notes.
The Company collected $2,000,000 of the $2,500,000 in promissory notes as of December 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2025 the Company
sold 260,000 shares of common stock to two private investors for $3,120,000 in promissory notes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These foregoing securities
were issued pursuant to exemptions from registration under the Securities Act in transactions not involving an underwriter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Description of our Capital Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The following description summarizes
the most important terms of our capital stock. Because it is only a summary of the provisions of our certificate of incorporation, as
amended (the &#8220;Certificate of Incorporation&#8221;), and bylaws, as amended (the &#8220;Bylaws&#8221;), it does not contain all of
the information that may be important to you. For a complete description of the matters set forth in this &#8220;Description of Capital
Stock,&#8221; you should refer to our Certificate of Incorporation and Bylaws, each of which are included as exhibits to the registration
statement of which this prospectus is a part, and to the applicable provisions of Delaware law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Authorized and Outstanding Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s authorized
capital stock consists of:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">150,000,000 shares of common stock, par value $0.0001 per share; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">10,000,000 shares of preferred stock, par value $0.0001 per share.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Common Stock</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Voting.&#160;</i>The holders
of common stock will be entitled to one vote for each share held of record on all matters on which the holders are entitled to vote (or
consent pursuant to written consent). Directors will be elected by a plurality of the votes present in person or represented by proxy
and entitled to vote.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dividends.&#160;</i>The
holders of common stock will be entitled to receive, ratably, dividends only if, when and as declared by the Company Board out of funds
legally available therefor and after provision is made for each class of capital stock having preference over the Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Liquidation Rights.&#160;</i>In
the event of the Company&#8217;s liquidation, dissolution or winding-up, the holders of common stock will be entitled to share, ratably,
in all assets remaining available for distribution after payment of all liabilities and after provision is made for each class of capital
stock having preference over the common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Conversion Right.&#160;</i>The
holders of common stock will have no conversion rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Preemptive and Similar
Rights.&#160;</i>The holders of common stock will have no preemptive or similar rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Redemption/Put Rights.&#160;</i>There
will be no redemption or sinking fund provisions applicable to the Common Stock. All of the outstanding shares of common stock are fully-paid
and nonassessable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>

<!-- Field: Page; Sequence: 35 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Options/Stock Awards. </i>There
were 279,625 stock options outstanding at December 31, 2024. The Company subsequently granted in 2025 options to purchase an
aggregate of 87,375 shares of our common stock under the 2022 Equity Incentive Plan, to various officers, directors, employees and
consultants, at an average exercise price of $10.52 per share. There were 437,000 stock options outstanding at December 31,
2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Preferred Stock</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There were no shares of series
A preferred stock outstanding at December 31, 2025. The Company Board has the authority to issue shares of preferred stock from time to
time on terms it may determine, to divide shares of preferred stock into one or more series and to fix the designations, preferences,
privileges, and restrictions of preferred stock, including dividend rights, conversion rights, voting rights, terms of redemption, liquidation
preference, sinking fund terms, and the number of shares constituting any series or the designation of any series to the fullest extent
permitted by the DGCL.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Warrants</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has warrants outstanding
to purchase (i) 570,105 shares of our common stock at an average exercise price of approximately $31.71 per share which were assumed from
Coeptis Therapeutics, Inc. as part of the Merger, and (ii) 375,000 shares of our common stock at an exercise price of $230.00 per share,
which were issued prior to the Merger.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%"><span id="a_014"></span><span style="font-size: 10pt"><b>ITEM 6.</b></span></td>
    <td style="width: 90%"><span style="font-size: 10pt"><b>SELECTED FINANCIAL DATA</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is a smaller reporting
company as defined by Rule 12b-2 of the Exchange Act and is not required to provide the information under this Item.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%"><span id="a_015"></span><span style="font-size: 10pt"><b>ITEM 7.</b></span></td>
    <td style="width: 90%; text-align: justify"><span style="font-size: 10pt"><b>MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>As discussed elsewhere
in this Annual Report on Form 10-K, pursuant to the Merger, we acquired our primary operating subsidiary Coeptis Therapeutics, Inc. The
Merger was accounted for as a &#8220;reverse merger,&#8221; and Coeptis Therapeutics, Inc. was deemed to be the accounting acquirer in
the Merger. Consequently, the financial condition, results of operations and cash flows discussed in this Management&#8217;s Discussion
and Analysis of Financial Condition and Results of Operations discussed below are those of Coeptis Therapeutics, Inc. and its consolidated
subsidiaries. When we use words in this section like &#8220;we,&#8221; &#8220;us&#8221;, &#8220;our,&#8221; the &#8220;Company&#8221;
and words of the like, unless otherwise indicated, we are referring to the operations of our wholly-owned subsidiaries, including Coeptis
Therapeutics, Inc.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>These statements represent
projections, beliefs, and expectations based on current circumstances and conditions and in light of recent events and trends, and you
should not construe these statements either as assurances of performance or as promises of a given course of action. Instead, various
known and unknown factors are likely to cause our actual performance and management&#8217;s actions to vary, and the results of these
variances may be both material and adverse. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements,
which reflect management&#8217;s analysis only as of the date hereof. We undertake no obligation to publicly release the results of any
revision to these forward-looking statements which may be made to reflect events or circumstances after the date hereof or to reflect
the occurrence of unanticipated events.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cautionary Statement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following discussion and
analysis should be read in conjunction with our consolidated financial statements and related notes included beginning at page F-1 of
this Annual Report on Form 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our actual results may differ
materially from those anticipated in the following discussion, as a result of a variety of risks and uncertainties, including those described
under &#8220;<i>Risk Factors&#160;and Special Considerations</i>&#8221; beginning on page 9 of this Annual Report on Form 10-K. We assume
no obligation to update any of the forward-looking statements included herein except as expressly required by law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 36 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Implications of Being an Emerging Growth Company</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a company with less than
$1.07&#160;billion in revenue during our last fiscal year, we qualify as an emerging growth company, as defined in the JOBS Act. As an
emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally
to public companies. These provisions include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Only two years of audited consolidated financial statements in addition to any required unaudited interim financial statements with correspondingly reduced Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations disclosure.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Reduced disclosure about our executive compensation arrangements.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Not having to obtain non-binding advisory votes on executive compensation or golden parachute arrangements.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may take advantage of these
exemptions for up to five years or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging
growth company if we have more than $1.07 billion in annual revenue, we have more than $700&#160;million in market value of our stock
held by non-affiliates, or we issue more than $1&#160;billion of non-convertible debt over a three-year period. We may choose to take
advantage of some but not all of these reduced burdens. We have taken advantage of these reduced reporting burdens herein, and the information
that we provide may be different than what you might get from other public companies in which you hold stock.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Company History</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration: underline">General</span>.&#160;</i>The
Company was originally incorporated in the British Virgin Islands on November 27, 2018 under the name Bull Horn Holdings Corp. On October
27, 2022, Bull Horn Holdings Corp. domesticated from the British Virgin Islands to the State of Delaware. On October 28, 2022, in connection
with the closing of the Merger, the Company changed its corporate name from Bull Horn Holdings Corp. to &#8220;Coeptis Therapeutics Holdings,
Inc.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration: underline">The Merger Transaction</span>.&#160;</i>On
October 28, 2022, a wholly-owned subsidiary of Bull Horn Holdings Corp., merged with and into Coeptis Therapeutics, Inc., with Coeptis
Therapeutics, Inc. as the surviving corporation of the Merger. As a result of the Merger, the Company acquired the business of Coeptis
Therapeutics, Inc., which now continues its existing business operations as the Company&#8217;s wholly-owned subsidiary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration: underline">About the Company&#8217;s
Subsidiaries</span>.</i>&#160;The Company now operates through its direct and indirect subsidiaries SNAP Biosciences, Inc. and GEAR Therapeutics,
Inc., which are majority owned, and Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc. and Coeptis Pharmaceuticals, LLC, which
are wholly owned.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Company History of Coeptis Therapeutics, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Coeptis Pharmaceuticals, LLC
was formed in July 12, 2017 as a Pennsylvania multi-member limited liability company. On December 1, 2018, the members of LLC contributed
their interest to a newly formed corporation, Coeptis Pharmaceuticals, Inc. As of December 1, 2018, the LLC became a disregarded single-member
limited liability company which is wholly owned by the newly formed corporation. On February 12, 2021, Vinings Holdings, Inc., a Delaware
corporation (&#8220;Vinings&#8221;), merged (the &#8220;Merger&#8221;) with and into Coeptis Pharmaceuticals, Inc. On July 12, 2021, Vinings
has legally changed its name from Vinings Holdings, Inc. to Coeptis Therapeutics, Inc. Coeptis was the surviving corporation of that Merger.
As a result of the Merger, Vinings acquired the business of Coeptis and will continue the existing business operations of Coeptis as a
wholly owned subsidiary. The Merger was treated as a recapitalization of the Company for financial accounting purposes. The historical
financial statements of Vinings before the Merger were replaced with the historical financial statements of Coeptis before the Merger
in all future filings with the Securities and Exchange Commission (the &#8220;SEC&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>

<!-- Field: Page; Sequence: 37 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Overview and Outlook</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a biopharmaceutical
and technology company which owns, acquires, and develops cell therapy technologies for cancer and other diseases. Our products and technologies
are intended to be commercialized in the US and other major markets throughout the world. Since our inception in 2017, we have acquired
and commercialized two drug products for the US market, which were approved as 505b2 applications. These anti-hypertension products were
launched into the US market during 2020 through a marketing partner. At launch, the sales and promotional efforts were significantly impeded
by the limitation of the global pandemic and as such, we have since abandoned all activities and ownership pertaining to both products.
We also began the development of several ANDA products which we divested in 2019 to a larger generic pharmaceutical drug manufacturer
and have moved away from focusing on the commercialization of generic products. In early 2021, we entered into strategic partnerships
to co-develop improved therapies for the auto-immune and oncology markets. Following the reverse merger transaction, we continue to focus
on identifying and investing resources into innovative products and technologies which we believe will significantly transform our current
products and therapies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During 2020 and continuing
through 2021, we faced several operational challenges related to the COVID-19 global pandemic, which we continue to work to overcome.
The launch of both 505b2 products was impacted because of various COVID-19 limitations, most notably field sales personnel were not able
to make healthcare provider visits in person; thereby limiting the awareness of the availability of these products. We explored and implemented
several non-personal promotion efforts, but given the global limitations and dynamics, it was challenging to achieve expected sales. We
have since abandoned all activities and ownership pertaining to both products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Vy-Gen-Bio, Inc</i>.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2021, we entered into
two exclusive option agreements (the &#8220;CD38 Agreements&#8221;) relating to separate technologies designed to improve the treatment
of CD38-related cancers (e.g., multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia) with Vy-Gen-Bio, Inc. (&#8220;Vy-Gen&#8221;),
a majority-owned subsidiary of Vycellix, Inc., a Tampa, Florida-based private, immuno-centric discovery life science company focused on
the development of transformational platform technologies to enhance and optimize next-generation cell and gene-based therapies, including
T-cell and Natural Killer (NK) cell-based cancer therapies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The CD38 Agreements relate to two separate Vy-Gen
drug product candidates, as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration: underline">CD38-GEAR-NK</span></i>.
This Vy-Gen drug product candidate is designed to protect CD38+ NK cells from destruction by anti-CD38 monoclonal antibodies, or mAbs.
CD38-GEAR-NK is an autologous, NK cell-based therapeutic that is derived from a patient&#8217;s own cells and gene-edited to enable combination
therapy with anti-CD38 mAbs. We believe CD38-GEAR-NK possesses the potential to minimize the risks and side effects from CD38-positive
NK cell fratricide.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Market Opportunity</i>.
We believe CD38-GEAR-NK could potentially revolutionize how CD38-related cancers are treated, by protecting CD38+ NK cells from destruction
by anti-CD38 mAbs, thereby promoting the opportunity to improve the treatment of CD38-related cancers, including multiple myeloma, chronic
lymphocytic leukemia, and acute myeloid leukemia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Multiple myeloma is the first
cancer indication targeted with CD38-GEAR-NK. The global multiple myeloma market was $19.48B in 2018 and is expected to reach $31B by
2026 [Source: Fortune Business Reports].</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration: underline">CD38-Diagnostic</span></i>.
This Vy-Gen product candidate is an in vitro diagnostic tool to analyze if cancer patients might be appropriate candidates for anti-CD38
mAb therapy. CD38-Diagnostic is an in vitro screening tool that provides the ability to pre-determine which cancer patients are most likely
to benefit from targeted anti-CD38 mAb therapies, either as monotherapy or in combination with CD38-GEAR-NK. CD38-Diagnostic also has
the potential to develop as a platform technology beyond CD38, to identify patients likely to benefit for broad range of mAb therapies
across myriad indications.&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 38 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Market Opportunity</i>.
We believe CD38-Diagnostic provides opportunity to make more cost-effective medical decisions for the treatment of B cell malignancies
with high CD38 expression, including multiple myeloma, which may help to avoid unnecessary administration of anti-CD38 therapies. CD38-Diagnostic
could prevent patients from being subjected to ineffective therapy and enable significant savings to healthcare systems.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">CD38-Diagnostic could be offered
as an in-vitro diagnostic for determining patient suitability and likelihood of positive treatment outcomes for CD38-GEAR-NK and/or CD38
monoclonal antibody therapies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 28, 2023, we
received FDA&#8217;s response to our 513(g) request for information submission pertaining to the classification of the CD38-Diagnostic.
The CD38-Diagnostic has been designated a Class II type device. The confirmation of this classification is beneficial as we&#8217;re now
better able to plan for and execute future development activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration: underline">GEAR-NK Product Overview</span></i>.
GEAR-NK is an autologous, gene-edited, natural killer cell-based therapeutic development platform that allows for modified NK cells to
be co-administered with targeted mAbs, which, in the absence of the GEAR-NK, would otherwise be neutralized by mAb therapy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2021, we made initial
payments totaling $750,000 under the CD38 Agreements, to acquire the exclusive options to acquire co-development rights with respect to
CD38-GEAR-NK and CD38-Diagnostic. On August 15, 2021, we entered into amendments to each of the CD38 Agreements. In connection with the
two amendments, we delivered to Vy-Gen promissory notes aggregating $3,250,000 with maturity dates of December 31, 2021, and made a cash
payment of $1,000,000, upon which cash payment we exercised the two definitive option purchase agreements. In December 2021, we completed
our payment obligations to secure the 50% ownership interest in the CD38-Diagnostic, and subsequently in November 2022 we completed our
purchase of the 50% ownership interest for the CD38-GEAR-NK product candidate. Details of the two August amendments and the December amendment
are summarized in the amendments attached at Exhibits 4.1 and 4.2 to our Current Report on Form 8-K dated August 19, 2021 and Exhibits
4.2 to the our Current Report on Form 8-K dated December 27, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the Vy-Gen
relationship and the Company&#8217;s ownership in the two product candidates described above, in December 2021 the Company and Vy-Gen
entered into a co-development and steering committee agreement. The co-development and steering committee agreement provides for the governance
and economic agreements between the Company and Vy-Gen related of the development of the two Vy-Gen drug product candidates and the revenue
sharing related thereto, including each company having a 50% representation on the steering committee and each company receiving 50% of
the net revenues related to the Vy-Gen product candidates. Details of the co-development and steering committee agreement are summarized
in our Current Report on Form 8-K dated December 27, 2021, including Exhibits 4.1 and 4.2 thereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2025, the Company
reached an agreement with Vy-Gen-Bio, Inc. (&#8220;Vy-Gen&#8221;) to successfully license the exclusive worldwide development and commercialization
rights to the GEAR&#8482; (Gene Edited Antibody Resistant) Cell Therapy Platform, representing a first-in-class approach to modifying
potent cancer-targeting immune cells to optimize the likelihood of deep remission in patients with hematologic malignancies and other
cancers. Coeptis had previously held limited co-development rights to GEAR.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Deverra Therapeutics, Inc</i>.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 16, 2023, the Company
entered into an exclusive licensing arrangement (the &#8220;License Agreement&#8221;) with Deverra Therapeutics Inc. (&#8220;Deverra&#8221;),
pursuant to which the Company completed the exclusive license of key patent families and related intellectual property related to a proprietary
allogeneic stem cell expansion and directed differentiation platform for the generation of multiple distinct immune effector cell types,
including natural killer (NK) and monocyte/macrophages. The License Agreement provides the Company with exclusive rights to use the license
patents and related intellectual property in connection with development and commercialization efforts in the defined field of use (the
&#8220;Field&#8221;) of (a) use of unmodified NK cells as anti-viral therapeutic for viral infections, and/or as a therapeutic approach
for treatment of relapsed/refractory AML and high-risk MDS; (b) use of Deverra&#8217;s cell therapy platform to generate NK cells for
the purpose of engineering with Coeptis SNAP-CARs and/or Coeptis GEAR Technology; and (c) use of Deverra&#8217;s cell therapy platform
to generate myeloid cells for the purpose of engineering with the Company&#8217;s current SNAP-CAR and GEAR technologies. In support of
the exclusive license, the Company also entered into with Deverra (i) an asset purchase agreement (the &#8220;APA&#8221;) pursuant to
which the Company purchased certain assets from Deverra, including but not limited to two Investigational New Drug (IND) applications
and two Phase 1 clinical trial stage programs (NCT04901416, NCT04900454) investigating infusion of DVX201, an unmodified natural killer
(NK) cell therapy generated from pooled donor CD34+ cells, in hematologic malignancies and viral infections and (ii) a non-exclusive sublicense
agreement (the &#8220;Sublicense Agreement&#8221;), in support of the assets obtained by the exclusive license, pursuant to which the
Company sublicensed from Deverra certain assets which Deverra has rights to pursuant a license agreement (&#8220;FHCRC Agreement&#8221;)
by and between Deverra and The Fred Hutchinson Cancer Research Center (&#8220;FHCRC&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>

<!-- Field: Page; Sequence: 39 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As consideration for the transactions
described above, the Company paid Deverra approximately $570,000 in cash, issued to Deverra 4,000,000 shares of the Company&#8217;s common
stock and assumed certain liabilities related to the ongoing clinical trials. Total consideration paid was $4,937,609, which was fully
expensed in accordance with ASC 730, and is reflected within research and development in the accompanying consolidated statements of operations
for the year ended December 31, 2023. In addition, in accordance with the terms of the Sublicense Agreement, the Company agreed to pay
FHCRC certain specified contingent running royalty payments and milestone payments under the FHCRC Agreement, in each case to the extent
such payments are triggered by the Company&#8217;s development activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 26, 2023, the Company
entered into a Shared Services Agreement (&#8220;SSA&#8221;) with Deverra, in accordance with requirements set forth in the APA. Under
the terms of the SSA, Coeptis and Deverra will share resources and collaborate to further the development of Coeptis&#8217; GEAR and SNAP-CAR
platforms, as well as the purchased and licensed assets under the License Agreement and APA. The SSA expired on December 31, 2024. The
Company is continuing its development focus on both GEAR and SNAP-CAR, and is considering prospective strategic partners for such development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Vici Health Sciences, LLC</i>.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2019, we entered into a
co-development agreement with Vici Health Sciences, LLC (&#8220;Vici&#8221;). Through this partnership, we would co-develop, seek FDA
approval and share ownership rights with Vici to CPT60621, a novel, ready to use, easy to swallow, oral liquid version of an already approved
drug used for the treatment of Parkinson&#8217;s Disease (PD). As we continue to direct its operational and financial focus towards the
other assets and opportunities previously described, we have stopped allocating resources to the development of CPT60621. We are currently
in negotiations in which Vici intends to buy-out most or all of the remaining ownership rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Results of Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration: underline">In General</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Revenue</i></b>. In
fiscal year 2025, we generated sales of $1,363,045 from lead generation and webinar services offered through our NexGenAI platform. This
represents a meaningful transition from prior periods when we generated minimal revenue. However, we have not yet achieved profitability,
and there remains uncertainty regarding our ability to generate sufficient revenue to cover operating expenses and fund our business plan
without additional capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Operating Expenses.&#160;</i></b>Operating
expenses consist primarily of salaries and related costs for personnel and professional fees for consulting services related to regulatory,
pharmacovigilance, quality, legal, and business development. We expect that our general and administrative expenses will increase in the
future as we increase our headcount to support the business growth. We also anticipate that we will incur increased accounting, audit,
legal, regulatory, compliance, insurance, and investor relation expenses associated with operating as a public company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Research and Development
Costs</i></b><i>.&#160;</i>Research and developments costs will continue to be dependent on the strategic business collaborations and
agreements we are anticipating in the future. We expect development costs to increase to support our new strategic initiatives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration: underline">Comparison of the years ended December
31, 2025 and December 31, 2024</span></i>.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Revenues</i></b>. Sales
of $1,363,045 resulted from lead generation and webinar services offered through our technology segment&#8217;s NexGenAI platform in the
year ended December 31, 2025. The Company had no sales recorded during year ended December 31, 2024. The Company&#8217;s activities in
its Biotechnology segment primarily include product development, raising capital, and building infrastructure. Management does not expect
the Company to generate any significant revenue in the Biotechnology segment for at least the next year, during which time drug development
will continue toward the goal of commercializing, through a partnership or otherwise, one or more of the Company&#8217;s target products
or technologies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>

<!-- Field: Page; Sequence: 40 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Operating Expenses</i></b>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt; text-align: justify; text-indent: 0.5in"><b><i>Overview</i></b>.
Operating expenses increased from $10,054,488 during the year ended December&#160;31, 2024 to $14,225,918 during the year ended December
31, 2025. The significant increase in 2025 is primarily a result of increased professional services expenses, including consulting and
legal fees in connection with the Merger Agreement, and higher stock based compensation expense resulting from 2025 stock option grants.
The year-over-year decrease in research and development expense is primarily a result of the SSA termination with Deverra Therapeutics
in December, 2024, as well as lower total salary expense in fiscal year 2025 as compared to 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt; text-align: justify; text-indent: 0.5in"><b><i>General and
Administrative Expenses</i></b>. General and administrative expenses increased from $945,641 during the year ended December 31, 2024 to
$1,148,004 during the year ended December&#160;31, 2025. The increase was primarily due to fees incurred in connection with the resolution
of an arbitration matter that has been concluded.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt; text-align: justify; text-indent: 0.5in"><b><i>Interest Expense</i></b>.
Interest expense was $246,116 for the year ended December&#160;31, 2024 and was $96,744 for the year ended December&#160;31, 2025. The
decrease was primarily a result of the satisfaction of the Purple Biotech convertible note and the Yorkville convertible notes. Interest
expense related to notes payable, which are discussed in detail in the notes to the consolidated financial statements, incorporated by
reference herein.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt; text-align: justify; text-indent: 0.5in"><b><i>Change in Fair
Value of Derivative Liabilities.</i></b> The change in fair value for the year ended December 31, 2024 was recorded as a loss of $341,660
and was recorded as a gain of $1,098,055 for the year ended December 31, 2025. The year over year change is a result of a gain on the
change in fair value of the SEPA derivative liability in the amount of $906,430, and a gain on the change in fair value of the derivative
liability warrants in the amount of $191,625.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unrealized gain on marketable securities. The Company recognized an
unrealized gain on its portfolio of marketable securities of $76,596 for the year ended December 31, 2025. The unrealized gain was attributable
to an increase in the market value of the securities during the period. The unrealized gain is non-cash in nature and reflects a temporary
change in fair value as of the consolidated balance sheet date. Management does not expect the unrealized gain to have a material impact
on the Company&#8217;s liquidity or ongoing operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Financial Resources
and Liquidity.&#160;</i></b>The Company had limited financial resources during the year ended December 31, 2024 with cash of $532,885.
For the year ended December 31, 2025, cash increased to $5,674,302. The increase in cash resulted primarily from the 2025 private placement
common stock offering and draws under the SEPA. During both of these time periods, the Company continues to operate a minimal infrastructure
in order to maintain its ability to fund operations, keep full focus on all product development targets and to stay current with all of
the Company&#8217;s scientist consultants, legal counsel, and accountants. Moving into 2026, the Company believes that the ability to
raise capital through equity transactions will increase liquidity and enable the execution of management&#8217;s operating strategy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%"><span id="a_016"></span><span style="font-size: 10pt"><b>ITEM 7A.</b></span></td>
    <td style="width: 90%"><span style="font-size: 10pt"><b>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is a smaller reporting
company as defined by Rule 12b-2 of the Exchange Act and is not required to provide the information under this Item.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%"><span id="a_017"></span><span style="font-size: 10pt"><b>ITEM 8.</b></span></td>
    <td style="width: 90%"><span style="font-size: 10pt"><b>FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The financial statements required
to be filed pursuant to this Item 8 are appended to this report and are incorporated herein by reference. An index of those consolidated
financial statements is found in Item 15 of Part IV of this Annual Report on Form 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 41 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%"><span id="a_018"></span><span style="font-size: 10pt"><b>ITEM 9.</b></span></td>
    <td style="width: 90%"><span style="font-size: 10pt"><b>CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As previously disclosed, in
connection with the Merger and the Company&#8217;s adoption of Coeptis&#8217; historical business, Turner, Stone and Company, L.L.P.,
the independent registered public accounting firm of Coeptis Therapeutics, Inc., became the Company&#8217;s auditors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As previously disclosed in
a Current Report on Form 8-K filed on September 30, 2024, the Company, with the approval of the Audit Committee of the Company and the
approval of the Board of Directors of the Company, the Company engaged Astra Audit &amp; Advisory, LLC (&#8220;Astra&#8221;) as the Company&#8217;s
independent registered public accounting firm for the Company&#8217;s fiscal year ending December 31, 2024. The Company dismissed Turner,
Stone &amp; Company, LLP (&#8220;Turner&#8221;) as the Company&#8217;s independent registered public accounting firm.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%"><span id="a_019"></span><span style="font-size: 10pt"><b>ITEM 9A.</b></span></td>
    <td style="width: 90%"><span style="font-size: 10pt"><b>CONTROLS AND PROCEDURES&#160;</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-indent: -45pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Evaluation of Disclosure Controls and Procedures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Disclosure controls and procedures
as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act are controls and other procedures that are designed to ensure that
information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported,
within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms. Disclosure controls and procedures
include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed
or submitted under the Exchange Act is accumulated and communicated to management, including our principal executive and principal financial
officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management, with the participation
of our chief executive officer (our principal executive officer) and our chief financial officer (our principal financial officer) evaluated
the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Annual Report on Form 10-K. Based
upon that evaluation, and as a result of the remediation efforts following the 2023 self-diagnosed material weaknesses described below,
our principal executive officer and principal financial officer concluded that, as of December 31, 2025, our disclosure controls and procedures
were effective.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Management&#8217;s Annual Report on Internal Control Over Financial
Reporting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Management is responsible
for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) and 15d-15(f) under the
Exchange Act. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.
Also, projection of any evaluation of effectiveness to future periods is subject to the risk that controls may become inadequate because
of changes in conditions, or that the degree of compliance with policies or procedures may deteriorate. In making this assessment, management
used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control &#8211;
Integrated Framework (2013 Framework). Based on this assessment, management concluded that, as of December 31, 2025, the Company&#8217;s
internal control over financial reporting was effective. In 2023, the Company self-diagnosed two material weaknesses. These weaknesses
were not issued by our independent auditors, Turner, Stone &amp; Company, LLP. A material weakness is a deficiency or combination of deficiencies,
in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or
interim consolidated financial statements will not be prevented or detected on a timely basis. The Company self-identified the following
material weaknesses as of December 31, 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>

<!-- Field: Page; Sequence: 42 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Company&#8217;s system of internal controls, as designed and implemented, is not operating effectively. The Company continues to improve and implement (i) segregation of duties and evidence of fiduciary oversight related to the financial statement close process, cash disbursements process, contract approval process and time and expense reimbursement process; (ii) formally documented accounting policies and procedures that are effective and consistently applied in accordance with GAAP; and (iii) effective controls and resources to address the accounting requirements for new accounting pronouncements.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Company&#8217;s financial statement close process and disclosure controls and procedures, including the secondary review and approval of financial information generated to prepare the consolidated financial statements, are ineffective.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Over the course of the year
ended December 31, 2024, the Company worked toward remediation of these self-diagnosed material weaknesses by (i) hiring additional resources
to effectively allow for segregation of duties and highly technical accounting expertise, formally documenting accounting policies, and
ensuring compliance with accounting requirements and (ii) adopting processes and procedures that support a timely financial statement
close, and secondary reviews. During 2025, the Company continued to strengthen its processes and procedures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Changes in Internal Control Over Financial Reporting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company continued to strengthen
its processes and procedures following the 2024 remediation of the self-diagnosed material weaknesses as described above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Attestation Report of Independent Registered Public Accounting Firm</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Annual Report on Form
10-K does not include an attestation report of the Company&#8217;s registered public accounting firm, as non-accelerated filers are exempt
from the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%"><span id="a_020"></span><span style="font-size: 10pt"><b>ITEM 9B.</b></span></td>
    <td style="width: 90%"><span style="font-size: 10pt"><b>OTHER INFORMATION</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>10b5-1 Plans</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Our directors
and executive officers may from time to time enter into plans or other arrangements for the purchase or sale of our common stock that
are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or may represent a &#8220;non-Rule
10b5-1 trading arrangement&#8221; (as defined in Item 408(c) of Regulation S-K).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On <span id="xdx_904_eecd--TrdArrAdoptionDate_c20250101__20251231_zFXpwK2JjJAj" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000068" name="ecd:TrdArrAdoptionDate">May 21, 2025</ix:nonNumeric></span>, <span id="xdx_90E_eecd--TrdArrIndName_c20250101__20251231_z2eQkXWmW92k" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000069" name="ecd:TrdArrIndName">Daniel Yerace</ix:nonNumeric></span>,
our <span id="xdx_909_eecd--TrdArrIndTitle_c20250101__20251231_zAiFWWaZrxra" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000070" name="ecd:TrdArrIndTitle">Vice President of Operations and a member of our Board of Directors</ix:nonNumeric></span>, <span id="xdx_907_eecd--Rule10b51ArrAdoptedFlag_dbT_c20250101__20251231_zy0eS0g1eZw8" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_905_eecd--NonRule10b51ArrAdoptedFlag_dbF_c20250101__20251231_ztFTbYXZhI74" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_90C_eecd--Rule10b51ArrTrmntdFlag_dbF_c20250101__20251231_zdphgb1rETX7" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_90F_eecd--NonRule10b51ArrTrmntdFlag_dbF_c20250101__20251231_zzRbHL1KBnf8" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000071" name="ecd:Rule10b51ArrAdoptedFlag"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000072" name="ecd:NonRule10b51ArrAdoptedFlag"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000073" name="ecd:Rule10b51ArrTrmntdFlag"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000074" name="ecd:NonRule10b51ArrTrmntdFlag">adopted</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span></span></span></span> a Rule 10b5-1 trading plan. Mr. Yerace&#8217;s Rule 10b5-1
trading plan provides for an active term commencing on August 31, 2025, and ending no later than <span id="xdx_902_eecd--TrdArrExpirationDate_c20250101__20251231_z4UEnfit84Ba" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000075" name="ecd:TrdArrExpirationDate">February 11, 2027</ix:nonNumeric></span>, for the sale of up
to <span id="xdx_907_eecd--TrdArrSecuritiesAggAvailAmt_iI_c20251231_zOkWVNWyBcu8" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonFraction name="ecd:TrdArrSecuritiesAggAvailAmt" contextRef="AsOf2025-12-31" id="Fact000076" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></span> shares of common stock of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Insider Trading Policy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has adopted insider
trading policies and procedures governing the purchase, sale, and other disposition of its securities, which has been included as an exhibit
to this report and has been posted to the investors and media/corporate governance section of the Company&#8217;s corporate website (www.coeptistx.com).</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 43 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="a_021"></span>PART III</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span id="a_022"></span><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%"><span style="font-size: 10pt"><b>ITEM 10.</b></span></td>
    <td style="width: 90%"><span style="font-size: 10pt"><b>DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 48.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 48.95pt">The following persons are our executive officers
and directors and hold the positions set forth opposite their name.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 23%"><span style="font-size: 10pt"><b>Executive Officers and Directors</b></span></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 6%"><span style="font-size: 10pt"><b>Age</b></span></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 69%"><span style="font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">David Mehalick</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-size: 10pt">57</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-size: 10pt">Chairman, Chief Executive Officer and President</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Daniel Yerace</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-size: 10pt">43</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-size: 10pt">Director and Vice President of Operations</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">Brian Cogley</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-size: 10pt">39</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-size: 10pt">Chief Financial Officer</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Christine Sheehy</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-size: 10pt">58</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-size: 10pt">Vice President of Compliance and Secretary</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">Christopher Calise</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-size: 10pt">52</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Tara Maria DeSilva</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-size: 10pt">57</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">Philippe Deschamps</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-size: 10pt">63</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Christopher Cochran</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-size: 10pt">56</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">Gene Salkind</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-size: 10pt">72</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-size: 10pt">Director</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>David Mehalick&#160;</i></b>&#8212;&#160;<b><i>Chairman,
Chief Executive Officer and President:</i></b>&#160;Mr. Mehalick has over 30 years of experience across a variety of industries including
life sciences, technology, financial services, military contracting, entertainment, and consumer products. He has served as our Chief
Executive Officer since October 2016. Since March 2004, Mr. Mehalick has served as the Managing Director of Steeltown Consulting Group,
a business consulting company through which he advises clients on business organizational and management strategies and solutions. Mr.
Mehalick was the Chief Financial Officer of Information Technology Procurement Sourcing, Inc. (&#8220;ITPS&#8221;), a computer hardware
and software company, from March 2017 to September 2017. In January 2019, ITPS filed a petition for voluntary reorganization under Chapter
11 of the U.S. Bankruptcy Code. Mr. Mehalick was the First Vice President at Gruntal and Co. from March 1992 to April 1995 and Senior
Vice President at First Union Capital Markets from May 1995 to June 1998 and Senior Vice President at Ferris, Baker Watts, Inc., an investment
banking firm from June 1998 to January 2001. Mr. Mehalick attended the University of Pittsburgh. We believe that Mr. Mehalick&#8217;s
three decades in business management and more than a decade in life sciences qualifies him to serve as a director of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Daniel Yerace &#8212; Director and Vice
President of Operations:</i></b>&#160;Dan Yerace is a co-founder of Coeptis Pharmaceuticals and serves as the Vice President of Operations.
Mr. Yerace has over ten years of experience in the pharmaceutical industry and is a key strategist responsible for supply chain management,
business development, portfolio management, and corporate strategy. Mr. Yerace has broad operational experience and has held leadership
positions in procurement, global supply chain management, operations, and business development for small private firms and fortune 500
multi-national corporations. Prior to joining Coeptis, Mr. Yerace served as Senior Director of Global Supply Chain and Commercial Business
Development for Kadmon Pharmaceuticals. Mr. Yerace holds a bachelor&#8217;s degree in economics, and a masters of business administration
from Waynesburg University.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Brian Cogley &#8212; Chief Financial Officer:</i></b>&#160;Mr.
Cogley has over 17 years of accounting and finance experience, having previously held positions of increasing authority at two &#8220;Big
4&#8221; accounting firms and served on the management teams of multiple companies in diverse industries. An accountant by training, Mr.
Cogley arrives at Coeptis with a career in corporate finance and accounting during which he advised and led the financial operations for
companies spanning multiple industries including life sciences, pharmaceuticals, financial services, and manufacturing. From February
2022 until joining Coeptis, Mr. Cogley was a Senior Manager, Accounting Advisory at CFGI, LLC where he served pharmaceutical and financial
services clients in technical accounting implementations and execution, interim Controller roles, interim SEC Reporting Manager roles,
segment reporting and carve-out engagements. From 2017-2022 Mr. Cogley held the position of Vice President of Finance &amp; Accounting
at NexTier Bank where he was a member of the Company&#8217;s senior management team and led its accounting and finance operations, including
the general ledger, financial planning and analysis, internal and external financial reporting, and human resources. From 2015-2017 Mr.
Cogley held the position of Global Cash Manager for Calgon Carbon Corporation, where he was responsible for all daily cash decisions across
the global enterprise. From 2012-2015 Mr. Cogley was a Financial Analyst at TriState Capital Bank where he was responsible for building
its Sarbanes-Oxley control environment, SEC/regulatory reporting and new system implementation, while also working on various process
improvement projects. Mr. Cogley began his career at KPMG, LLP, providing audit and assurance services to a variety of clients in the
financial services industry. Mr. Cogley earned a B.A. with a concentration in accounting and a Master of Business Administration with
a concentration in finance from Duquesne University.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 44 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Colleen Delaney -&#160;Chief Scientific
and Medical Officer:</i></b>&#160;Colleen Delaney, M.D., M.Sc. recently joined Coeptis, and brings more than two decades of experience
to the Company. Dr. Delaney, is a trained oncologist and stem cell transplant physician scientist. A highly accomplished and greatly respected
leader, Dr. Delaney is pioneering methods to make umbilical cord blood transplants more available and successful worldwide. As a trained
oncologist and stem cell transplant physician scientist with expertise in the translation of scientific discovery to clinical practice,
she is proficient in all aspects of cell therapy product development, from initial discovery to pre-clinical and Investigational New Drug
(IND)-enabling studies, manufacturing, global regulatory experience, and clinical trial design. She has served on federal advisory committees
focused on multiple cell and gene therapy and acted as a director for several nonprofit associations. In addition to her industry experience,
Dr. Delaney is a clinical professor at the University of Washington, Division of Pediatric Hematology/Oncology, and is an affiliate and
former professor at the Fred Hutchinson Cancer Research Center, where she also held the Madeline Dabney Adams Endowed Chair in Acute Myeloid
Leukemia research. She earned her B.A in Molecular Biology and Biochemistry from Wesleyan University, her MSc in Social Research and Social
Policy from Oxford University and her M.D. from Harvard Medical School.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 21, 2025, Colleen Delaney submitted her
resignation from her role as Chief Medical and Scientific Officer at the Company, effective March 24, 2025. Ms. Delaney, who has been
employed by the Company since August 2023, resigned to pursue another business opportunity. She continued on a consulting basis to provide
transition services to the Company for six months following her resignation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Christine Sheehy&#160;</i></b>&#8212;&#160;<b><i>Vice
President of Compliance and Secretary:</i></b>&#160;Ms. Sheehy has over 25 years of experience in the pharmaceutical business, including
globally commercializing drug products and working in development of targeted therapeutics including cell and gene therapies. Since 2017,
she has served as our Director, Chief Financial Officer and Secretary. From 2010 to 2016, Ms. Sheehy served as the Senior Vice-President
of Operations for Kadmon Pharmaceuticals, a clinical and commercial phase pharmaceutical company. From 2001 to 2010, she served as the
Vice-President of Operations of Three Rivers Pharmaceuticals, a start-up pharmaceutical company which was acquired by Kadmon Pharmaceuticals
in 2010. During that time, she launched branded and generic products in the U.S., leading the operational business. Ms. Sheehy earned
a bachelor&#8217;s degree in accounting from Penn State University.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Christopher Calise &#8211; Director:</i></b>&#160;Mr.
Calise has served as a director since our inception, and has remained a member of the Company&#8217;s board of directors following the
Merger. He has over 15 years of experience in the finance and insurance industries and has been responsible for setting the strategic
vision for Crown Global, a domestic and international private placement insurance holding company, as well as overseeing its day-to-day
management, including finance, operations and sales, since 2010. He also works closely with both internal and external sales and marketing
in the development of new product initiatives, as well as evaluating new markets. Prior to joining Crown Global, Mr. Calise was a principal
at LSC Investors, LLC, from 2001 to 2009, where he advised The Second City, Inc. and Narciso Rodriguez and restructured Phillips de Pury
&amp; Luxembourg, a large global auction house. From 1999 to 2001, he was an associate with Crown Capital Group, Inc., a private equity
investment firm focused on assisting middle-market companies build value over the long term and was one of the founding members of Fresh
Direct, LLC. Mr. Calise was also a consultant with the Industrial Products Group at PriceWaterhouse in its Chicago office, from 1997 to
1999. Mr. Calise is a member of the board of Song4Life and Student Finance League Inc. Mr. Calise received a Bachelor of Arts in Economics
from the University of Chicago, as well as certifications in insurance and finance. We believe Mr. Calise is qualified to serve as our
director due to his operational and executive experience.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Tara Maria DeSilva, Ph.D</i></b>.&#160;<b><i>&#8211;
Director:</i></b>&#160;Dr. DeSilva has been an Associate Professor at the Cleveland Clinic and Case Western Reserve University School
of Medicine since March 2016. She serves as Vice Chair for the Department of Neurosciences, Lerner Research Institute, Cleveland Clinic.
She was an Assistant Professor at University of Alabama at Birmingham from January 2010 to February 2016. Dr. DeSilva receives funding
from the National Institutes of Health, National Science Foundation, and the National Multiple Sclerosis Society. She serves on many government
and foundation scientific grant review panels including the National Institutes of Health and National Multiple Sclerosis Society. Dr.&#160;DeSilva
received her B.S. in Biochemistry from Albright College, her M.S. and Ph.D. in Biological Chemistry from the University of Pennsylvania
and completed her postdoctoral training at Children&#8217;s Hospital Boston, Harvard Medical School. We believe Dr. DeSilva is well qualified
to serve on the board due to her expertise in neuroscience and research.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 45 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Philippe Deschamps &#8211; Director:&#160;</i></b>Mr.
Deschamps is an experienced healthcare executive who has served as CEO of four companies over the last 20 years. Since March 2022, Mr.
Deschamps has served as the President and CEO of ChitogenX Inc. (formerly Ortho Regenerative Technologies), where he is focused primarily
on expansion of commercial uses for the company&#8217;s proprietary bio-polymer drug combination products. From 2012 to 2020, he co-founded
and served as CEO of Helius Medical Technologies (Nasdaq: HSDT), a neurotech company. From 2002 to 2011, he served as President and CEO
of GSW Worldwide, a leading healthcare commercialization company, and from 2011 to 2012 served as CEO of MediMedia Health, a private equity
owned company. Prior to his CEO experience he spent 13 years at Bristol-Myers Squibb (NYSE: BMY) from 1986 to 1998, including serving
as director of neuroscience marketing from where he oversaw the company&#8217;s neuroscience products including BuSpar and Serzone and
Stadol NS. Mr. Deschamps also holds the position as President of Deschamps Global Commercialization LLC, a healthcare commercialization
consulting company he founded where he has served clients as a consultant in the pharmaceutical and medical tech industries from 2020
to 2022. Mr. Deschamps received a BSc. from the University of Ottawa in Canada. We believe Mr. Deschamps is well qualified to serve on
the board due to his extensive experience in the healthcare industry and his public company experience.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Christopher Cochran &#8211; Director:&#160;</i></b>Mr.
Cochran is currently the President of BluChip Solutions, a provider of IT solutions for complex problems, an entity that he founded in
2008. From March 2012 to May 2013, Mr. Cochran held leadership positions within different companies, including serving as the EVP of Sales
&amp; Marketing for Velocity World Media, a private experiential television network. Additionally, from March 2010 to February 2012, Mr.
Cochran worked as an Enterprise Cloud Sales Executive for Hewlett Packard Enterprise. From April 2008 to January 2010, Mr. Cochran served
as the Executive Director of Sales and Operations for ASGN Inc. (NYSE: ASGN), formerly Apex Systems, a leading provider of IT services.
From 2008 to 2010, Mr. Cochran worked at Mastech Digital (Nasdaq: MHH), a publicly-traded company, where he held various roles, including
Senior Vice President of Global Sales and Operations from February 2004 to April 2008, where he reported directly to the CEO. From May
2014 to May 2016, Mr. Cochran served on the Board of Trustees for the Pine-Richland Opportunities Fund, a non-profit educational foundation
providing staff grants and student scholarships, and he currently serves as Director of the Christian Cochran Legacy Fund through the
Pittsburgh Foundation. Mr. Cochran received his Bachelor of Science in Public Administration and International Law from the University
of Tennessee in 1993. We believe Mr. Cochran is well qualified to serve on the board due to his public company experience and expertise
in business operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Gene Salkind, M.D</i></b>.&#160;<b><i>&#8211;
Director:</i></b>&#160;Mr. Salkind has been a practicing neurosurgeon within the Philadelphia area for more than 35 years. He graduated
from the University of Pennsylvania in 1974 with a B.A., Cum Laude, and received his medical degree from the Lewis Katz School of Medicine
in 1979. He returned to the University of Pennsylvania for his neurosurgical residency, and in 1985 was selected as the Chief Resident
in Neurosurgery at the Hospital of the University of Pennsylvania. Since 1985, Dr. Salkind has served in a university affiliated practice
of general neurological surgery. Since 2005, Dr. Salkind has served as the Chief of Neurosurgery at Holy Redeemer Hospital. He previously
served as the Chief of Neurosurgery at Albert Einstein Medical Center and Jeanes Hospital in Philadelphia in the late 1990s. He has authored
numerous peer reviewed journal articles and has given lectures throughout the country on various neurosurgical topics. He has also held
professorships at the University of Pennsylvania, the Allegheny Health Education and Research Foundation, and is currently at the Lewis
Katz School of Medicine. Since 2019, Dr. Salkind has also been on the board of directors of Cure Pharmaceutical Corporation (OTCMKTS:
CURR), a biopharmaceutical company focusing on the development and manufacturing of drug formulation and drug delivery technologies in
novel dosage forms, and has been the Chairman of Mobiquity Technologies Inc. (Nasdaq: MOBQ), a leading provider of next-generation advertising
technology. Dr. Salkind is also a member of the Strategic Advisory Board of BioSymetrics Inc., a company that has built data servicing
tools to benefit health and health and hospital systems, biopharma, drug discovery, and the precision medicine field. In addition, from
2004 to 2019, Dr. Salkind served as a board member of Derm Tech International, a global leader in non-invasive dermatological molecular
diagnostics. We believe Dr. Salkind is well qualified to serve on the board due to his expertise in life science industry.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Independence of the Board</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Common Stock is listed
on Nasdaq. Under the rules of Nasdaq, independent directors must comprise a majority of a listed company&#8217;s board of directors. In
addition, the rules of Nasdaq require that, subject to specified exceptions, each member of a listed company&#8217;s audit, compensation
and nominating and corporate governance committees be independent. Under the rules of Nasdaq, a director will only qualify as an &#8220;independent
director&#8221; if, in the opinion of that company&#8217;s board of directors, that person does not have a relationship that would interfere
with the exercise of independent judgment in carrying out the responsibilities of a director. Audit committee members must also satisfy
the additional independence criteria set forth in Rule&#160;10A-3 of the Exchange&#160;Act and the rules of Nasdaq. Compensation committee
members must also satisfy the additional independence criteria set forth in Rule&#160;10C-1 under the Exchange&#160;Act and the rules
of Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 46 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to be considered
independent for purposes of Rule10A-3 under the Exchange Act and under the rules of Nasdaq, a member of an audit committee
of a listed company may not, other than in his or her capacity as a member of the committee, the board of directors, or any other board
committee: (1)&#160;accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any
of its subsidiaries; or (2)&#160;be an affiliated person of the listed company or any of its subsidiaries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To be considered independent
for purposes of Rule&#160;10C-1 under the Exchange&#160;Act and under the rules of Nasdaq, the board of directors must affirmatively determine
that the member of the compensation committee is independent, including a consideration of all factors specifically relevant to determining
whether the director has a relationship to the company which is material to that director&#8217;s ability to be independent from management
in connection with the duties of a compensation committee member, including, but not limited to: (i)&#160;the source of compensation of
such director, including any consulting, advisory or other compensatory fee paid by the company to such director; and (ii)&#160;whether
such director is affiliated with the company, a subsidiary of the company or an affiliate of a subsidiary of the company.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has undertaken
a review of the independence of each director and considered whether each director of the Company has a material relationship with the
Company that could compromise his or her ability to exercise independent judgment in carrying out his or her responsibilities. As a result
of this review, Tara Maria DeSilva, Philippe Deschamps, Christopher Cochran and Gene Salkind are considered &#8220;independent directors&#8221;
as defined under the listing requirements and rules of Nasdaq and the applicable rules of the Exchange&#160;Act and Christopher Calise
is considered an &#8220;independent director&#8221; as defined under the listing requirements and rules of Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Committees of the Company Board</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company Board has an audit
committee, compensation committee and nominating and corporate governance committee. All of the committees will comply with all applicable
requirements of the Sarbanes-Oxley Act, Nasdaq and SEC rules and regulations as further described below. The responsibilities of each
of the committees of the Company Board is described below. Members will serve on these committees until their resignation or until as
otherwise determined by the Company Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Audit Committee</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company Board has an audit
committee. The audit committee currently consists of Philippe Deschamps, Christopher Cochran and Gene Salkind, with Mr. Deschamps serving
as the chair of the committee. Each of the members of the Company&#8217;s audit committee satisfy the requirements for independence and
financial literacy under the applicable rules and regulations of the SEC and rules of Nasdaq. The Company also determines that Mr. Deschamps
qualifies as an &#8220;audit committee financial expert&#8221; as defined in the SEC rules and will satisfy the financial sophistication
requirements of Nasdaq. The Company&#8217;s audit committee will be responsible for, among other things:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">appointing (and recommending that the Company Board submit for stockholder ratification, if applicable) compensate, retain and oversee the work performed by the independent auditor retained for the purpose of preparing or issuing an audit report or performing other audit or audit-related services;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">reviewing the performance and independence of the independent auditor;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">pre-approving all audit, review, and non-audit services (including any internal control-related services) to be provided to the Company or its subsidiaries by the independent auditor;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">discussing the scope and results of the audit with the independent registered public accounting firm and reviewing, with management and the independent registered public accounting firm, the Company&#8217;s interim and year-end financial statements;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">developing procedures for employees to submit concerns anonymously about questionable accounting or audit matters;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">reviewing the Company&#8217;s policies on and overseeing risk assessment and risk management, including enterprise risk management; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">reviewing the adequacy and effectiveness of internal control policies and procedures and the Company&#8217;s disclosure controls and procedures.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company Board has adopted
a written charter for the audit committee, which is available on the Company&#8217;s website.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>

<!-- Field: Page; Sequence: 47 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Compensation Committee</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company Board has a compensation
committee. The compensation committee currently consists of Tara Maria DeSilva, Christopher Cochran and Gene Salkind, with Mr. Cochran
serving as the chair of the committee. Each of the members of the Company&#8217;s compensation committee meet the requirements for independence
under the under the applicable rules and regulations of the SEC and rules of Nasdaq. The Company&#8217;s compensation committee will be
responsible for, among other things:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">developing and reviewing compensation policies and practices applicable to executive officers;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">reviewing, approving or recommending for approval by the Board, compensation for executive officers, including without limitation salary, bonus, incentive compensation, perquisites and equity compensation;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">reviewing, approving and determining compensation and benefits, including equity awards, to directors for service on the Company Board or any committee thereof;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">supervising, administering and evaluating incentive, equity-based and other compensatory plans of the Company in which executive officers and key employees participate; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">reviewing, approving and making recommendations to the Company Board regarding incentive compensation and equity compensation plans</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company Board has adopted
a written charter for the compensation committee, which is available on its website.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Nominating and Corporate Governance Committee</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company Board has a nominating
and corporate governance committee. The nominating and corporate governance committee currently consists of Tara Maria DeSilva, Philippe
Deschamps and Christopher Cochran, with Mr. Cochran serving as the chair of the committee. Each of the members of the nominating and corporate
governance committee meets the requirements for independence under the applicable rules and regulations of the SEC and rules of Nasdaq.
The nominating and corporate governance committee is responsible for, among other things:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">identifying individuals qualified to become Board members, consistent with criteria approved by the Board;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">recommending to the Board the persons to be nominated for election as directors by stockholders and the persons (if any) to be elected by the Board to fill any vacancies on the Board;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">recommending to the Board the directors to be appointed to each committee of the Board;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">developing and recommending to the Board corporate governance guidelines; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">overseeing the evaluation of the Board.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company Board has adopted
a written charter for the nominating and corporate governance committee, which is available on its website.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Code of Business Conduct and Ethics</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company Board has adopted
a Code of Business Conduct and Ethics that applies to all of its employees, officers and directors, including its Chief Executive Officer,
Chief Financial Officer and other executive and senior financial officers. The full text of the Company&#8217;s Code of Business Conduct
and Ethics is posted on the Corporate Governance portion of the Company&#8217;s website. The Company will post amendments to its Code
of Business Conduct and Ethics or waivers of its Code of Business Conduct and Ethics for directors and officers on the same website or
in a current report on Form 8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Family Relationships</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Christopher Calise and Tara
Maria DeSilva are first cousins. Other than that, there are no family relationships among any of our executive officers or directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 48 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Compensation Committee Interlocks and Insider
Participation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None of the Company&#8217;s
officers currently serves, and in the past year has not served, (i)&#160;as a member of the compensation committee or the board of directors
of another entity, one of whose officers served on the Company&#8217;s compensation committee, or (ii)&#160;as a member of the compensation
committee of another entity, one of whose officers served on the Company Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Consultants and Advisors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has several fee-for-service
consultancy arrangements with highly qualified firms and individuals who provide consulting services in the areas of regulatory affairs,
quality assurance, chemistry, manufacturing and control (CMC), and clinical/medical affairs. We don&#8217;t anticipate the expenses related
to these agreements to be material to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Involvement in Certain Legal Proceedings</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To our knowledge, during the
past ten years, none of our directors, executive officers, promoters, control persons, or nominees has:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">been convicted in a criminal proceeding or been subject to a pending criminal proceeding (excluding traffic violations and other minor offenses);</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">had any bankruptcy petition filed by or against the business or property of the person, or of any partnership, corporation or business association of which he was a general partner or executive officer, either at the time of the bankruptcy filing or within two years prior to that time; except that in 2019, a private limited liability company with which Mr. Mehalick had previously held an executive officer position, but from which he had previously resigned and then returned as interim CEO, filed for bankruptcy protection;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">been subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction or federal or state authority, permanently or temporarily enjoining, barring, suspending or otherwise limiting, his involvement in any type of business, securities, futures, commodities, investment, banking, savings and loan, or insurance activities, or to be associated with persons engaged in any such activity;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">been found by a court of competent jurisdiction in a civil action or by the SEC or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">been the subject of, or a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated (not including any settlement of a civil proceeding among private litigants), relating to an alleged violation of any federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order, or any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">been the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section&#160;3(a)(26) of the Exchange Act), any registered entity (as defined in Section&#160;1(a)(29) of the Commodity Exchange Act), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Indemnification under Certificate of Incorporation
and Bylaws; Indemnification Agreements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 48.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our bylaws provide that we
will indemnify our directors and officers to the fullest extent permitted by the DGCL, subject to certain exceptions contained in our
bylaws. In addition, our certificate of incorporation provides that our directors will not be liable for monetary damages for breach of
fiduciary duty.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>

<!-- Field: Page; Sequence: 49 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to enter into indemnification
agreements with each of our directors and executive officers. We expect the indemnification agreement to provide, among other things,
that we will indemnify and hold harmless each person subject to an indemnification agreement (each, an &#8220;Indemnified Party&#8221;)
to the fullest extent permitted by applicable law from and against all losses, costs, liabilities, judgments, penalties, fines, expenses
and other matters that may result or arise in connection with such Indemnified Party serving in his or her capacity as a director of ours
or serving at our direction as a director, officer, employee, fiduciary or agent of another entity. We expect the indemnification agreement
to further provide that, upon an Indemnified Party&#8217;s request, we will advance expenses to the Indemnified Party to the fullest extent
permitted by applicable law. Pursuant to the indemnification agreement, we will intend that an Indemnified Party is presumed to be entitled
to indemnification and we have the burden of proving otherwise. We also intend to secure and maintain in full force and effect directors&#8217;
liability insurance. If indemnification under an indemnification agreement is unavailable to an Indemnified Party for any reason, we,
in lieu of indemnifying the Indemnified Party, will contribute to any amounts incurred by the Indemnified Party in connection with any
claim relating to an indemnifiable event in such proportion as is deemed fair and reasonable in light of all of the circumstances to reflect
the relative benefits received or relative fault of the parties in connection with such event.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling persons pursuant to the
foregoing provisions, or otherwise, we have been advised that in the opinion of the Securities and Exchange Commission such indemnification
is against public policy as expressed in the Securities Act and is, therefore, unenforceable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Scientific and Clinical Advisory Board</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2022 we formed a Scientific
Advisory Board, which contributes key guidance on the advancement of our product portfolio. The Scientific Advisory Board is comprised
of three renowned scientific researchers from the Karolinska Institutet, Stockholm, Sweden; Evren Alici, M.D., Ph.D.; Hans-Gustaf Ljunggren,
M.D., Ph.D; and Arnika Kathleen Wagner, Ph.D.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%"><span id="a_023"></span><span style="font-size: 10pt"><b>ITEM 11.</b></span></td>
    <td style="width: 90%"><span style="font-size: 10pt"><b>EXECUTIVE COMPENSATION</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
information regarding each element of compensation that we paid or awarded to our named executive officers and for years ended December
31, 2025 and 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Summary Compensation Table</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Name and</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Principal</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Position</b></p></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Year</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Salary<br/>
($)</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Bonus<br/>
($)</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Stock<br/>
Awards<br/>
($)</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Option<br/>
Awards<br/>
($)</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Non-Equity<br/>
Incentive<br/>
Plan<br/>
Compensation ($)</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Non-qualified<br/>
Deferred<br/>
Compensation<br/>
Earnings<br/>
($)</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>All<br/>
Other<br/>
Compensation<br/>
($)</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Total<br/>
($)</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">David Mehalick</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">2025</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">360,000</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">237,000</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">597,000</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 18%"><span style="font-size: 10pt"><i>Chairman, CEO and President</i></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 5%; text-align: center"><span style="font-size: 10pt">2024</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 11%; text-align: right"><span style="font-size: 10pt">360,000</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 5%; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 5%; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 5%; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 10%; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 10%; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 10%; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 11%; text-align: right"><span style="font-size: 10pt">360,000</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Daniel Yerace</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">2025</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">360,000</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">92,000</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">452,000</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt"><i>Vice President of Operations</i></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2024</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-size: 10pt">360,000</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-size: 10pt">360,000</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #F2F2F2">
    <td><span style="font-size: 10pt">Brian Cogley</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">2025</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">215,385</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">95,000</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">310,385</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt"><i>Chief Financial Officer</i></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2024</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-size: 10pt">200,000</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-size: 10pt">200,000</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Colleen Delaney</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">2025</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">96,385</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">96,385</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt"><i>Chief Scientific and Medical Officer</i></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2024</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-size: 10pt">360,000</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-size: 10pt">360,000</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Christine Sheehy</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">2025</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">75,000</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">75,000</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt"><i>Former Chief Financial Officer</i></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2024</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-size: 10pt">83,769</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-size: 10pt">83,769</span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 2pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0pt"/><td style="width: 20pt; text-align: left">*</td><td style="text-align: justify">Dr. Delaney stepped down as Chief Scientific and Medical Officer
in March 2025.</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="width: 0pt"/><td style="width: 20pt; text-align: left">**</td><td style="text-align: justify">Ms. Sheehy stepped down as Chief Financial Officer in 2023 and
remains with the Company as Vice President of Compliance and Secretary.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 50 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Employment Agreements with Directors and Officers</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is party to employment
agreements with David Mehalick, Colleen Delaney and Daniel Yerace, each of which are described below. The Company does not currently have
employment agreements with any of its other officers and directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>David Mehalick:&#160;&#160;&#160;&#160;</i></b>David
Mehalick, our President and Chief Executive Officer, entered into an employment agreement with Coeptis Therapeutics, Inc. on February
21, 2022 (the &#8220;Effective Date&#8221;) covering Coeptis and its subsidiary, Coeptis Pharmaceuticals. The employment agreement is
in effect immediately and will remain in effect until the termination of the employment agreement by either party in accordance with Section&#160;5
of the employment agreement. Mr. Mehalick shall report to the Board of Directors and shall have the duties, responsibilities and authority
as may from time to time be assigned to him by the Board of Directors. Under the employment agreement, Coeptis currently pays to Mr. Mehalick
an annualized salary at the rate of $360,000. Mr. Mehalick will also receive a guaranteed bonus equal to twenty (20%) of his base salary
for each calendar year, and will be eligible to receive merit bonuses, certain milestone bonuses and awards of stock options, restricted
stock units or other equity awards pursuant to any plans or arrangements that Coeptis may have in effect from time to time. The foregoing
summary does not purport to be complete and is qualified in its entirety by reference. Mr. Mehalick&#8217;s employment agreement, which
is filed as Exhibit 4.1 to Coeptis&#8217; Current Report on Form&#160;8-K filed on February 21, 2022. This employment agreement was assumed
by the Company in connection with the Merger.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Daniel Yerace:&#160;&#160;&#160;&#160;</i></b>Daniel
A. Yerace, our Vice President of Operations, entered into an employment agreement with Coeptis on the Effective Date covering Coeptis
and its subsidiary, Coeptis Pharmaceuticals. The employment agreement is in effect immediately and will be effective from the Effective
Date until the termination of the employment agreement by either party in accordance with Section&#160;5 of the employment agreement.
Mr. Yerace reports to the President of Coeptis and has the duties, responsibilities and authority as may from time to time be assigned
to him by Coeptis&#8217; President. Under the employment agreement, Coeptis currently pays to Mr. Yerace an annualized salary at the rate
of $360,000. Mr.&#160;Yerace will also receive a guaranteed bonus equal to twenty (20%) of his base salary for each calendar year, and
will be eligible to receive merit bonuses, certain milestone bonuses and awards of stock options, restricted stock units or other equity
awards pursuant to any plans or arrangements that Coeptis may have in effect from time to time. The foregoing summary does not purport
to be complete and is qualified in its entirety by reference Mr. Yerace&#8217;s employment agreement, which is filed as Exhibit 4.1 to
Coeptis&#8217; Current Report on Form&#160;8-K filed on February&#160;21, 2022. This employment agreement was assumed by the Company in
connection with the Merger.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Brian Cogley:</i></b>&#160;&#160;&#160;&#160;Mr.
Cogley joined the Company in 2023. For 2024, Mr. Cogley received, (i) an initial base salary of $200,000 per year, (ii) eligibility for
annual discretionary bonus, (iii) participation in the Company&#8217;s stock incentive plan with the number of stock options to be determined
and (iv) additional benefits generally available to other salaried employees of the Company. For 2025, Mr. Cogley received a salary of
$215,385. Mr. Cogley&#8217;s employment is &#8220;at will&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Collen Delaney</i>:</b>
Dr. Delaney joined the Company in 2023. For 2023, Dr. Delaney is currently to receive, (i) an initial base salary of $360,000 per year,
(ii) an annual bonus of 20% of base salary plus eligibility for additional annual discretionary bonus, (iii) participation in the Company&#8217;s
stock incentive plan with the number of stock options to be determined and (iv) additional benefits generally available to other salaried
employees of the Company. On March 21, 2025, Dr. Delaney submitted her resignation from her role as Chief Medical and Scientific Officer
at the Company, effective March 24, 2025. Dr. Delaney resigned to pursue another business opportunity. She continued on a consulting basis
to provide transition services to the Company for six months following her resignation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Outstanding Equity Awards at Fiscal Year
End&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 48.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company had unexercised
options (including stock options that have not vested) to purchase an aggregate of 437,000 shares of Common Stock outstanding for executive
officers, directors, and consultants as of December 31, 2025. The Company had unexercised options to purchase an aggregate of 279,625
shares of Common Stock outstanding for executive officers, directors, and consultants as of December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 51 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Employee, Director and Consultant Stock Plan</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>General</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 48.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;ITEM 5. MARKET
FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES - Securities Authorized for
Issuance under Equity Compensation Plans&#8221; for a full description of the Company&#8217;s 2022 Equity Incentive Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Option Grants and Stock Awards (each presented
on a post reverse stock split basis)</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 27, 2023, the Company
granted options to purchase an aggregate of 67,875 shares of our common stock under the 2022 Equity Incentive Plan, to various officers,
directors, employees and consultants, at an average exercise price of $32.60 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 1, 2023, the Company
also granted a stand-alone option to a former employee to purchase up to 5,000 shares of our common stock at an exercise price of $200.00
per share. The stand-alone option expired on January 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 2, 2023, the Company
granted additional options to purchase an aggregate of 15,000 shares of our common stock to two employees at an average price of $21.40
per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2024, the Company
granted options to purchase an aggregate of 76,750 shares of our common stock under the 2022 Equity Incentive Plan, to various officers,
directors, employees and consultants, at an average exercise price of $13.00 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2024, the Company
granted additional options to purchase an aggregate of 120,000 shares of our common stock to our CEO at an exercise price of $6.20 per
share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2025, the Company
granted options to purchase an aggregate of 87,375 shares of our common stock under the 2025 Equity Incentive Plan, to various officers,
directors, employees and consultants, at an average exercise price of $10.52 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 52 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table provides
certain information regarding unexercised options to purchase Common Stock, stock options that have not vested and equity-incentive plan
awards outstanding as of December 31, 2025, for each named executive officer and director.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="12" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt"><b>Option Awards&#160;<sup>(1)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock Awards</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Name</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/> Securities<br/> Underlying<br/> Unexercised<br/> Options<br/> (#) Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/> Securities<br/> Underlying<br/> Unexercised<br/> Options<br/> (#) Unexercisable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Grant Date</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Option<br/> Exercise<br/> Price<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Option<br/> Expiration<br/> Date</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number&#160;of<br/> Shares&#160;or<br/> Units&#160;of<br/> Stock<br/> That<br/> Have&#160;Not<br/> Vested<br/> (#)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Market<br/> Value&#160;of<br/> Shares&#160;or<br/> Units&#160;of<br/> Stock<br/> That<br/> Have&#160;Not<br/> Vested<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Equity<br/> Incentive<br/> Plan<br/> Awards:<br/> Number&#160;of<br/> Unearned<br/> Shares,<br/> Units&#160;or<br/> Other<br/> Rights<br/> That<br/> Have Not<br/> Vested<br/> (#)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Equity<br/> Incentive<br/> Plan<br/> Awards:<br/> Market&#160;or Payout<br/> Value of<br/> Unearned<br/> Shares,<br/> Units&#160;or<br/> Other<br/> Rights<br/> That<br/> Have Not<br/> Vested<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 19%; text-align: left">David Mehalick<sup>(2)</sup></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">9,375</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">3,125</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 8%; text-align: right">1/27/2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">35.20</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 8%; text-align: right">1/27/2028</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">David Mehalick<sup>(2)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,062</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,688</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/27/2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/27/2033</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">David Mehalick</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/10/2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12.92</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/10/2034</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">David Mehalick</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">120,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">6/13/2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">6/12/2034</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">David Mehalick</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,219</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,656</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">3/4/2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.65</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">3/4/2035</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Daniel Yerace</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/27/2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/27/2033</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Daniel Yerace</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,375</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,625</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/10/2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12.92</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/10/2034</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Daniel Yerace</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">3/4/2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.56</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">3/4/2035</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Daniel Yerace</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">3/7/2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">3/4/2035</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Christine Sheehy</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/27/2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/27/2033</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Christine Sheehy</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,094</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,406</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/10/2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12.92</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/10/2034</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Christine Sheehy</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">3/4/2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.56</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">3/4/2035</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Christopher Calise</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/27/2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/27/2033</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Christopher Calise</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/10/2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12.92</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/10/2034</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Christopher Calise</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">3/4/2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.56</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">3/4/2035</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Tara DeSilva</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/27/2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/27/2033</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Tara DeSilva</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/10/2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12.92</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/10/2034</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Tara DeSilva</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">3/4/2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.56</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">3/4/2035</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Gene Salkind</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/27/2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/27/2033</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Gene Salkind</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/10/2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12.92</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/10/2034</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Gene Salkind</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">3/4/2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.56</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">3/4/2035</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Philippe Deschamps</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/27/2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/27/2033</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Philippe Deschamps</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/10/2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12.92</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/10/2034</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Philippe Deschamps</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">3/4/2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.56</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">3/4/2035</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Christopher Cochran</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/27/2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/27/2033</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Christopher Cochran</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/10/2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12.92</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/10/2034</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Christopher Cochran</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">3/4/2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.56</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">3/4/2035</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Brian Cogley</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,498</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,502</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">10/02/2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21.40</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">10/2/2033</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Brian Cogley</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,281</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,219</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/10/2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12.92</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/10/2034</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Brian Cogley</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">3/4/2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.56</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">3/4/2035</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 53 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1) All options were issued
(a) to Mr. Cogley on October 2, 2023 and (b) to the officers and directors on January 27, 2023 (as applicable, the &#8220;Grant Date&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2) Includes (i) 12,500 incentive
stock options with an exercise price of $35.20 and an expiration date of January 27, 2028 and (ii) 18,750 nonqualified stock options with
an exercise price of $32.00 and an expiration date of January 27, 2033.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>2025 and 2024 Director Compensation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Non-employee directors were
each paid a total of $20,000 and $20,000 for service as a director during 2025 and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Granting of Certain Equity Awards Close
in Time to the Release of Material Nonpublic Information</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_909_eecd--AwardTmgMnpiDiscTextBlock_c20250101__20251231_zzyjurElmvb8"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000077" name="ecd:AwardTmgMnpiDiscTextBlock">We <span id="xdx_90A_eecd--AwardTmgMnpiCnsdrdFlag_dbT_c20250101__20251231_zHHWEzS4pidc"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000078" name="ecd:AwardTmgMnpiCnsdrdFlag">do
not grant equity awards in anticipation of the release of material nonpublic information</ix:nonNumeric></span>&#160;that is likely to result in
changes to the price of our common stock, and do not time the public release of such information based on award grant dates. During
the last completed fiscal year, we have not made awards to any named executive officer or director during the period beginning four
business days before and ending one business day after the filing of a period report on Form 10-Q or Form 10-K or the filing or
furnishing of a current report on Form 8-K, and we have not timed the disclosure of material nonpublic information for the purpose
of affecting the value of executive compensation.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%"><span id="a_024"></span><span style="font-size: 10pt"><b>ITEM 12.</b></span></td>
    <td style="width: 90%"><span style="font-size: 10pt"><b>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 48.95pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
certain information regarding our Common Stock beneficially owned on March 18, 2026 for (i) each stockholder known to be the beneficial
owner of more than 5% of our outstanding common stock; (ii) all directors; (iii) all named executive officers; and (iv) all directors
and executive officers as a group. Beneficial ownership is determined in accordance with the rules of the SEC that deem shares to be beneficially
owned by any person who has voting or investment power with respect to such shares. Shares of common stock subject to options or warrants
that are exercisable as of the date of this Annual Report on Form 10-K or are exercisable within 60 days of such date are deemed to be
outstanding and to be beneficially owned by the person holding such options for the purpose of calculating the percentage ownership of
such person but are not treated as outstanding for the purpose of calculating the percentage ownership of any other person. Applicable
percentage ownership is based on an assumed 6,223,221 shares of common stock outstanding as the date of March 18, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise indicated
and subject to applicable community property and similar laws, we believe that all persons named in the table below have sole voting and
investment power with respect to the voting securities beneficially owned by them.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 48.95pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt"><b>Name of Beneficial Ownership<sup>(1)</sup></b></span></td>
    <td>&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Shares
    Owned</b></span></td>
    <td>&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Percentage</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt"><i><span style="text-decoration: underline">Executive Officers and Directors</span></i></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 68%"><span style="font-size: 10pt">David Mehalick</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt">330,192</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt">5.31%</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">Daniel Yerace</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">70,531</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1.13%</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Christopher Calise</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">368,741</span></td>
    <td><span style="font-size: 10pt">(2)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">5.88%</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">Tara DeSilva</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">8,950</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Philippe Deschamps</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">8,950</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">Christopher Cochran</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">8,950</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Gene Salkind</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">13,161</span></td>
    <td><span style="font-size: 10pt">(3)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">Brian Cogley</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">22,500</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Christine Sheehy</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">64,031</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1.03%</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt"><i>Officer and Directors as a Group (9 persons)</i></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">896,006</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">15.64%</span></td>
    <td>&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">_______________________</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 2%; font-size: 10pt"><span style="font-size: 9pt">*</span></td>
    <td style="width: 98%; font-size: 10pt; text-align: justify"><span style="font-size: 9pt">Less than 1.0%.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-size: 9pt">(1)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 9pt">Unless otherwise indicated, the business address of
    each of the individuals is c/o Coeptis Therapeutics, Inc., 105 Bradford Rd, Suite 420, Wexford, PA 15090.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-size: 9pt">(2)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 9pt">Includes (i) 49,500 shares of common stock that are
    owned by CJC Investment Trust (a trust in which Mr. Calise is a control person), and (ii) 47,106 shares of common stock that are
    issuable under currently exercisable warrants..</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 9pt">(3)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 9pt">Includes 4,211 shares of common stock that are held
    as JTWROS with Catherine Salkind..</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 54 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Changes in Control</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 48.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not aware of any arrangements
or a party to arrangements, including any pledge by any person of our securities, the operation of which may at a subsequent date result
in a change of control.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%"><span id="a_025"></span><span style="font-size: 10pt"><b>ITEM 13.</b></span></td>
    <td style="width: 90%"><span style="font-size: 10pt"><b>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS, AND DIRECTOR INDEPENDENCE</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of this section
of this Annual Report on Form 10-K, &#8220;Predecessor&#8221; refers to the Company before giving effect to the Merger, and the term &#8220;Coeptis&#8221;
refers to Coeptis Therapeutics, Inc., before giving effect to the Merger.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Predecessor Related Person Transactions Prior
to the Merger</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the Merger,
Predecessor&#8217;s sponsor, officers and directors and/or their affiliates were reimbursed for certain out-of-pocket expenses incurred
in connection with activities on Predecessor&#8217;s behalf.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Predecessor has entered into
a registration and shareholder rights agreement with respect to the Private Placement Warrants, the warrants issuable upon conversion
of working capital loans (if any) and the shares issuable upon exercise of the foregoing and upon conversion of the founder shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Coeptis Related Person Transactions Prior to
the Merger</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the closing of the
merger in 2021 involving Coeptis and an entity named Vinings Holdings, Inc. (which is now Coeptis Therapeutics, Inc.), Vinings had a 100%
ownership interest in an entity named NDYN Delaware, Inc. In December 2020, prior to the closing of the 2021 merger, Vinings divested
its 100% ownership interest NDYN Delaware, LLC to Sterling Acquisition I, LLC, an entity controlled by Vinings&#8217; then control person
Erik Nelson. The divestiture was accomplished through the sale of all of Vinings&#8217; share ownership of NDYN Delaware, Inc. pursuant
to a Divestiture Agreement, a copy of which is attached as Exhibit 10.1 to Vinings Holdings Inc.&#8217;s Current Report on Form 8-K that
was filed on December 31, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 12, 2021, David
Mehalick purchased 8,000 shares of Series B Preferred Stock from Coral Investment Partners, LP for an aggregate purchase price of $1,000.
These shares of Series B Preferred Stock were exchanged for our Common Stock in connection with the closing of the Merger.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Director Independence and Committees</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Common Stock is listed
on Nasdaq. Under the rules of Nasdaq, independent directors must comprise a majority of a listed company&#8217;s board of directors. In
addition, the rules of Nasdaq require that, subject to specified exceptions, each member of a listed company&#8217;s audit, compensation
and nominating and corporate governance committees be independent. Under the rules of Nasdaq, a director will only qualify as an &#8220;independent
director&#8221; if, in the opinion of that company&#8217;s board of directors, that person does not have a relationship that would interfere
with the exercise of independent judgment in carrying out the responsibilities of a director. Audit committee members must also satisfy
the additional independence criteria set forth in Rule&#160;10A-3 of the Exchange&#160;Act and the rules of Nasdaq. Compensation committee
members must also satisfy the additional independence criteria set forth in Rule&#160;10C-1 under the Exchange&#160;Act and the rules
of Nasdaq.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to be considered
independent for purposes of Rule&#160;10A-3 under the Exchange&#160;Act and under the rules of Nasdaq, a member of an audit committee
of a listed company may not, other than in his or her capacity as a member of the committee, the board of directors, or any other board
committee: (1)&#160;accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any
of its subsidiaries; or (2)&#160;be an affiliated person of the listed company or any of its subsidiaries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To be considered independent
for purposes of Rule&#160;10C-1 under the Exchange&#160;Act and under the rules of Nasdaq, the board of directors must affirmatively determine
that the member of the compensation committee is independent, including a consideration of all factors specifically relevant to determining
whether the director has a relationship to the company which is material to that director&#8217;s ability to be independent from management
in connection with the duties of a compensation committee member, including, but not limited to: (i)&#160;the source of compensation of
such director, including any consulting, advisory or other compensatory fee paid by the company to such director; and (ii)&#160;whether
such director is affiliated with the company, a subsidiary of the company or an affiliate of a subsidiary of the company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has undertaken
a review of the independence of each director and considered whether each director of the Company has a material relationship with the
Company that could compromise his or her ability to exercise independent judgment in carrying out his or her responsibilities. As a result
of this review, Tara Maria DeSilva, Philippe Deschamps, Christopher Cochran and Gene Salkind are considered &#8220;independent directors&#8221;
as defined under the listing requirements and rules of Nasdaq and the applicable rules of the Exchange&#160;Act and Christopher Calise
is considered an &#8220;independent director&#8221; as defined under the listing requirements and rules of Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>

<!-- Field: Page; Sequence: 55 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Code of Business Conduct and Ethics</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company Board has adopted
a Code of Business Conduct and Ethics that applies to all of its employees, officers and directors, including its Chief Executive Officer,
Chief Financial Officer and other executive and senior financial officers. The full text of the Company&#8217;s Code of Business Conduct
and Ethics is posted on the Corporate Governance portion of the Company&#8217;s website. The Company will post amendments to its Code
of Business Conduct and Ethics or waivers of its Code of Business Conduct and Ethics for directors and officers on the same website or
in a current report on Form&#160;8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Family Relationships</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Christopher Calise and Tara
Maria DeSilva are first cousins. Other than that, there are no family relationships among any of our executive officers or directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Compensation Committee Interlocks and Insider
Participation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None of the Company&#8217;s
officers currently serves, or has served in the past year, (i)&#160;as a member of the compensation committee or the board of directors
of another entity, one of whose officers served on the Company&#8217;s compensation committee, or (ii)&#160;as a member of the compensation
committee of another entity, one of whose officers served on the Company Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Consultants and Advisors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has several fee-for-service
consultancy arrangements with highly qualified firms and individuals who provide consulting services in the areas of regulatory affairs,
quality assurance, chemistry, manufacturing and control (CMC), and clinical/medical affairs. We don&#8217;t anticipate the expenses related
to these agreements to be material to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Involvement in Certain Legal Proceedings</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To our knowledge, during the
past ten years, none of our directors, executive officers, promoters, control persons, or nominees has:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">been convicted in a criminal proceeding or been subject to a pending criminal proceeding (excluding traffic violations and other minor offenses);</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">had any bankruptcy petition filed by or against the business or property of the person, or of any partnership, corporation or business association of which he was a general partner or executive officer, either at the time of the bankruptcy filing or within two years prior to that time; except that in 2019, a private limited liability company with which Mr. Mehalick had previously held an executive officer position, but from which he had previously resigned and then returned as interim CEO, filed for bankruptcy protection;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">been subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction or federal or state authority, permanently or temporarily enjoining, barring, suspending or otherwise limiting, his involvement in any type of business, securities, futures, commodities, investment, banking, savings and loan, or insurance activities, or to be associated with persons engaged in any such activity;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">been found by a court of competent jurisdiction in a civil action or by the SEC or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">been the subject of, or a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated (not including any settlement of a civil proceeding among private litigants), relating to an alleged violation of any federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order, or any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">been the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section&#160;3(a)(26) of the Exchange Act), any registered entity (as defined in Section&#160;1(a)(29) of the Commodity Exchange Act), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 56 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Indemnification under Certificate of Incorporation
and Bylaws; Indemnification Agreements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 48.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our bylaws provide that we
will indemnify our directors and officers to the fullest extent permitted by the DGCL, subject to certain exceptions contained in our
bylaws. In addition, our certificate of incorporation provides that our directors will not be liable for monetary damages for breach of
fiduciary duty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 48.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to enter into indemnification
agreements with each of our directors and executive officers. We expect the indemnification agreement to provide, among other things,
that we will indemnify and hold harmless each person subject to an indemnification agreement (each, an &#8220;Indemnified Party&#8221;)
to the fullest extent permitted by applicable law from and against all losses, costs, liabilities, judgments, penalties, fines, expenses
and other matters that may result or arise in connection with such Indemnified Party serving in his or her capacity as a director of ours
or serving at our direction as a director, officer, employee, fiduciary or agent of another entity. We expect the indemnification agreement
to further provide that, upon an Indemnified Party&#8217;s request, we will advance expenses to the Indemnified Party to the fullest extent
permitted by applicable law. Pursuant to the indemnification agreement, we will intend that an Indemnified Party is presumed to be entitled
to indemnification and we have the burden of proving otherwise. We also intend to secure and maintain in full force and effect directors&#8217;
liability insurance. If indemnification under an indemnification agreement is unavailable to an Indemnified Party for any reason, we,
in lieu of indemnifying the Indemnified Party, will contribute to any amounts incurred by the Indemnified Party in connection with any
claim relating to an indemnifiable event in such proportion as is deemed fair and reasonable in light of all of the circumstances to reflect
the relative benefits received or relative fault of the parties in connection with such event.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling persons pursuant to the
foregoing provisions, or otherwise, we have been advised that in the opinion of the Securities and Exchange Commission such indemnification
is against public policy as expressed in the Securities Act and is, therefore, unenforceable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Scientific and Clinical Advisory Board</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2022 we formed a Scientific
Advisory Board, which contributes key guidance on the advancement of our product portfolio. The Scientific Advisory Board is comprised
of three renowned scientific researchers from the Karolinska Institutet, Stockholm, Sweden; Evren Alici, M.D., Ph.D.; Hans-Gustaf Ljunggren,
M.D., Ph.D; and Arnika Kathleen Wagner, Ph.D.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="a_026"></span><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 11%"><span style="font-size: 10pt"><b>ITEM 14.</b></span></td>
    <td style="width: 89%"><span style="font-size: 10pt"><b>PRINCIPAL ACCOUNTANT FEES AND SERVICES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table shows
the fees paid or accrued for the audit and other services provided by Astra Audit &amp; Advisory, LLC and Tuner, Stone &amp; Company,
LLP, our independent registered public accounting firms for the years ended December 31, 2025 and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>12-31-2025</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>12-31-2024</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 68%"><span style="font-size: 10pt">Audit fees</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt">91,820</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt">159,335</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Other service fees</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">94,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">22,949</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Total</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">185,820</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">182,284</span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Audit fees consist of fees
billed for services rendered for the audit of our consolidated financial statements included in this Annual Report on Form 10&#8211;K,
and reviews of our quarterly condensed consolidated financial statements included in the Company&#8217;s quarterly filings on Form 10-Q.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other service fees consist
of fees reasonably related to the performance of the audit or review of the Company&#8217;s consolidated financial statements that are
not reported as &#8220;Audit fees&#8221;, and other miscellaneous items.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 57 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="a_027"></span><b>PART IV</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%"><span id="a_028"></span><span style="font-size: 10pt"><b>ITEM 15.</b></span></td>
    <td style="width: 90%"><span style="font-size: 10pt"><b>EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</b>&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%"><span style="font-size: 10pt">(a)</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">The following documents are filed as part of this report:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-size: 10pt">(1)</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-size: 10pt">Financial Statements&#8212;See Index to Consolidated Financial Statements at Item 8 of this Annual Report on Form 10-K, beginning on page F-1.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Financial Statement Schedules&#8212;Financial statement schedules have been omitted in this Annual Report on Form 10-K because they are not applicable, not required under the instructions, or the information requested is set forth in the consolidated financial statements or related notes thereto.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Exhibits&#8212;The exhibits listed in the accompanying index to exhibits are filed as part of, or incorporated by reference into, this Annual Report on Form 10-K.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%"><span id="a_029"></span><span style="font-size: 10pt"><b>ITEM 16.</b></span></td>
    <td style="width: 90%"><span style="font-size: 10pt"><b>FORM 10-K SUMMARY</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 58 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="a_030"></span><b>EXHIBIT INDEX</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 7%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Exhibit</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>No.</b></p></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 92%; text-align: justify"><span style="font-size: 10pt"><b>Description</b></span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap"><span style="font-size: 10pt">2.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1759186/000121390022020473/ea158593ex2-1_bullhorn.htm"><span style="font-size: 10pt">Agreement and Plan of Merger and Reorganization, dated as of April 18, 2022, by and among Bull Horn Holdings Corp., a British Virgin Island corporation, BH Acquisition Sub, a Delaware corporation and Coeptis Therapeutics, Inc., a Delaware corporation</span></a> <span style="font-size: 10pt">(incorporated by reference from Exhibit 2.1 to Bull Horn Holdings Corp.&#8217;s Current Report on Form 8-K, as filed with the SEC on April 19, 2022)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap"><span style="font-size: 10pt">2.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1759186/000168316822007257/coeptis_ex0202.htm"><span style="font-size: 10pt">Certificate of Merger as filed with the Delaware Secretary of State effective October 28, 2022</span></a> <span style="font-size: 10pt">(incorporated by reference to Exhibit 2.2 of Coeptis Therapeutics Holdings, Inc.&#8217;s Form 8-K, filed with the SEC on November 3, 2022)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap"><span style="font-size: 10pt">3.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1759186/000168316822007257/coeptis_ex0301.htm"><span style="font-size: 10pt">Amended and Restated Certificate of Incorporation of Coeptis Therapeutics Holdings, Inc.</span></a> <span style="font-size: 10pt">(incorporated by reference to Exhibit 3.1 of Coeptis Therapeutics Holdings, Inc.&#8217;s Form 8-K, filed with the SEC on November 3, 2022)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap"><span style="font-size: 10pt">3.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1759186/000168316822007257/coeptis_ex0202.htm"><span style="font-size: 10pt">Certificate of Incorporation of Coeptis Therapeutics, Inc</span></a><span style="font-size: 10pt">. (incorporated by reference from the Certificate of Merger included at Exhibit 2.2 to the Current Report on Form 8-K)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap"><span style="font-size: 10pt">3.3</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1759186/000168316822007257/coeptis_ex0303.htm"><span style="font-size: 10pt">Amended and Restated Bylaws of Coeptis Therapeutics Holdings, Inc.</span></a> <span style="font-size: 10pt">(incorporated by reference to Exhibit 3.3 of Coeptis Therapeutics Holdings, Inc.&#8217;s Form 8-K, filed with the SEC on November 3, 2022)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap"><span style="font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1759186/000121390020034843/ea129293ex10-3_bullhorn.htm"><span style="font-size: 10pt">Registration Rights Agreement, dated October 29, 2020, by and among Bull Horn and certain security holders</span></a> <span style="font-size: 10pt">(incorporated by reference to Exhibit 10.3 of Bull Horn&#8217;s Form 8-K, filed with the SEC on November 3, 2020).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap"><span style="font-size: 10pt">10.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1759186/000121390020034843/ea129293ex10-4_bullhorn.htm"><span style="font-size: 10pt">Private Placement Warrants Purchase Agreement, dated October 29, 2020, by and between Bull Horn and Imperial Capital LLC, I-Bankers Securities, Inc. and Northland Securities, Inc.</span></a> <span style="font-size: 10pt">(incorporated by reference to Exhibit 10.4 of Bull Horn&#8217;s Form 8-K, filed with the SEC on November 3, 2020).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap"><span style="font-size: 10pt">10.3</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1759186/000121390020034843/ea129293ex10-5_bullhorn.htm"><span style="font-size: 10pt">Private Placements Warrants Purchase Agreement, dated October 29, 2020, by and between Bull Horn and Sponsor</span></a> <span style="font-size: 10pt">(incorporated by reference to Exhibit 10.5 of Bull Horn&#8217;s Form 8-K, filed with the SEC on November 3, 2020).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap"><span style="font-size: 10pt">10.4</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1819663/000168316821001877/vinings_ex0401.htm"><span style="font-size: 10pt">Co-Development Option Purchase Agreement (SNP) between Coeptis and Vy-Gen Bio, Inc.</span></a> <span style="font-size: 10pt">(incorporated by reference to Exhibit 4.1 to Coeptis Therapeutics, Inc.&#8217;s Form 8-K, filed with the SEC on May 11, 2021).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap"><span style="font-size: 10pt">10.5</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1819663/000168316821001877/vinings_ex0402.htm"><span style="font-size: 10pt">Co-Development Option Purchase Agreement (GEAR) between Coeptis and Vy-Gen Bio, Inc.</span></a> <span style="font-size: 10pt">(incorporated by reference to Exhibit 4.2 to Coeptis&#8217; Form 8-K, filed with the SEC on May 11, 2021).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap"><span style="font-size: 10pt">10.6</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1819663/000168316821003778/coeptis_ex0401.htm"><span style="font-size: 10pt">Amendment No. 1 to Co-Development Option Purchase Agreement (SNP) between Coeptis and VyGen-Bio, Inc.</span></a> <span style="font-size: 10pt">(incorporated by reference to Exhibit 4.1 to Coeptis Therapeutics, Inc.&#8217;s Form 8-K, filed with the SEC on August 19, 2021).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap"><span style="font-size: 10pt">10.7</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1819663/000168316821006609/coeptis_ex0401.htm"><span style="font-size: 10pt">Co-development and Steering Committee Agreement with VyGen-Bio, Inc.</span></a> <span style="font-size: 10pt">(incorporated by reference to Exhibit 4.1 to Coeptis&#8217; Therapeutics, Inc.&#8217;s Form 8-K, filed with the SEC on December 27, 2021).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap"><span style="font-size: 10pt">10.8</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1819663/000168316822001274/coeptis_8k-ex0401.htm"><span style="font-size: 10pt">Employment Agreement between Coeptis and David Mehalick</span></a> <span style="font-size: 10pt">(incorporated by reference to Exhibit 4.1 to Coeptis Therapeutics, Inc.&#8217;s Form 8-K filed with the SEC on February 25, 2022).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap"><span style="font-size: 10pt">10.9</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1819663/000168316822001274/coeptis_8k-ex0402.htm"><span style="font-size: 10pt">Employment Agreement between Coeptis and Daniel Yerace</span></a> <span style="font-size: 10pt">(incorporated by reference to Exhibit 4.2 to Coeptis Therapeutics, Inc.&#8217;s Form 8-K filed with the SEC on February 25, 2022).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap"><span style="font-size: 10pt">10.10</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1759186/000168316822007257/coeptis_ex0401.htm"><span style="font-size: 10pt">2022 Equity Incentive Plan</span></a> <span style="font-size: 10pt">(incorporated by reference to Exhibit 4.1 of Coeptis Therapeutics Holdings, Inc.&#8217;s Form 8-K, filed with the SEC on November 3, 2022)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap"><span style="font-size: 10pt">10.11</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1759186/000168316823007466/coeptis_ex1001.htm"><span style="font-size: 10pt; background-color: white">Securities Purchase Agreement</span></a> <span style="font-size: 10pt; background-color: white">(incorporated by reference to Exhibit 10.1 of Coeptis Therapeutics Holdings, Inc.&#8217;s Form 8-K, filed with the SEC on October 27, 2023)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap"><span style="font-size: 10pt">10.12</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1759186/000168316823007466/coeptis_ex1002.htm"><span style="font-size: 10pt">Registration Rights Agreement</span></a> <span style="font-size: 10pt">(incorporated by reference to Exhibit 10.2 of Coeptis Therapeutics Holdings, Inc.&#8217;s Form 8-K, filed with the SEC on October 27, 2023)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap"><span style="font-size: 10pt">10.13</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1759186/000168316823007466/coeptis_ex1004.htm"><span style="font-size: 10pt">Form of Placement Agency Agreement</span></a> <span style="font-size: 10pt">(incorporated by reference to Exhibit 10.4 of Coeptis Therapeutics Holdings, Inc.&#8217;s Form 8-K, filed with the SEC on October 27, 2023)</span></td></tr>

<tr style="vertical-align: top">
    <td style="white-space: nowrap"><span style="font-size: 10pt">10.14</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1759186/000168316823007466/coeptis_ex1005.htm"><span style="font-size: 10pt">Form of Warrant Amendment Agreement</span></a> <span style="font-size: 10pt">(incorporated by reference to Exhibit 10.5 of Coeptis Therapeutics Holdings, Inc.&#8217;s Form 8-K, filed with the SEC on October 27, 2023)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap"><span style="font-size: 10pt">10.15</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1759186/000168316823005994/coeptis_ex1001.htm"><span style="font-size: 10pt; background-color: white">License Agreement, dated as of August 16, 2023, by and between Coeptis Therapeutics Holdings, Inc. and Deverra Therapeutics, Inc.</span></a> <span style="font-size: 10pt">(incorporated by reference to Exhibit 10.1 of Coeptis Therapeutics Holdings, Inc.&#8217;s Form 8-K, filed with the SEC on August 22, 2023)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap"><span style="font-size: 10pt">10.16</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1759186/000168316823005994/coeptis_ex1002.htm"><span style="font-size: 10pt; background-color: white">Sublicense Agreement, dated as of August 16, 2023, by and between Coeptis Therapeutics Holdings, Inc. and Deverra Therapeutics, Inc.</span></a> <span style="font-size: 10pt">(incorporated by reference to Exhibit 10.2 of Coeptis Therapeutics Holdings, Inc.&#8217;s Form 8-K, filed with the SEC on August 22, 2023)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 7%"><span style="font-size: 10pt">10.17</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 92%; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1759186/000168316823005994/coeptis_ex1003.htm"><span style="font-size: 10pt; background-color: white">Asset Purchase Agreement, dated as of August 16, 2023, by and between Coeptis Therapeutics Holdings, Inc. and Deverra Therapeutics, Inc.</span></a> <span style="font-size: 10pt">(incorporated by reference to Exhibit 10.3 of Coeptis Therapeutics Holdings, Inc.&#8217;s Form 8-K, filed with the SEC on August 22, 2023)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap"><span style="font-size: 10pt">19.1</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="coeptis_ex1901.htm"><span id="xdx_90D_eecd--InsiderTrdPoliciesProcAdoptedFlag_dbT_c20250101__20251231_z0JC6wQ8qpP7" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBQb2xpY2llcyBhbmQgUHJvY2VkdXJlcwA_"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000079" name="ecd:InsiderTrdPoliciesProcAdoptedFlag">Insider Trading Policies and Procedures</ix:nonNumeric></span></a> *</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">21.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="coeptis_ex2101.htm">Subsidiaries of Coeptis Therapeutics Holdings, Inc.</a></span> <span style="font-size: 10pt">*</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">31.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="coeptis_ex3101.htm">Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a>.</span><span style="font-size: 10pt">*</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">31.2</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="coeptis_ex3102.htm">Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a>.</span><span style="font-size: 10pt">*</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">32.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="coeptis_ex3201.htm">Certification of the Principal Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a>.</span><span style="font-size: 10pt">*</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">32.2</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="coeptis_ex3201.htm">Certification of the Principal Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a>.</span><span style="font-size: 10pt">*</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">101.INS</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">XBRL Instance Document*</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">101.SCH</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">XBRL Taxonomy Extension Schema*</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">101.CAL</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">XBRL Taxonomy Calculation Linkbase*</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">101.LAB</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">XBRL Taxonomy Label Linkbase*</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">101.PRE</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">XBRL Definition Linkbase Document*</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">101.DEF</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">XBRL Definition Linkbase Document*</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 33px"><span style="font-size: 10pt">*</span></td>
    <td><span style="font-size: 10pt">Filed herewith</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>

<!-- Field: Page; Sequence: 59 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="a_031"></span><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: top"><span style="font-size: 10pt">COEPTIS THERAPEUTICS HOLDINGS, INC.</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; width: 54%"><span style="font-size: 10pt">Date: March 19, 2026</span></td>
    <td style="vertical-align: top; width: 1%"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 45%"><span style="font-size: 10pt">/s/ David Mehalick</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">David Mehalick</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><i>Chief Executive Officer</i><br/>
<i>(Principal Executive Officer)</i></span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">Date: March 19, 2026</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-size: 10pt">/s/ Brian Cogley</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Brian Cogley</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><i>Chief Financial Officer</i><br/>
<i>(Principal Financial and Accounting Officer)</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant
in the capacities and on the dates indicated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 31%; text-align: center"><span style="font-size: 10pt"><b>Signature</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: center"><span style="font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 18%; text-align: center"><span style="font-size: 10pt"><b>Date</b></span></td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">/s/ David Mehalick</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Chief Executive Officer</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">March 19, 2026</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">David Mehalick</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">(Principal Executive Officer) and Director</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">/s/ Brian Cogley</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td><span style="font-size: 10pt">Chief Financial Officer</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">March 19, 2026</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">Brian Cogley</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">(Principal Financial and Accounting Officer) and Director</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">/s/ Daniel Yerace</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td><span style="font-size: 10pt">Director</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">March 19, 2026</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">Daniel Yerace</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">/s/ Christopher Calise</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td><span style="font-size: 10pt">Director</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">March 19, 2026</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">Christopher Calise</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">/s/ Christopher Cochran</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Director</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">March 19, 2026</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">Christopher Cochran</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">/s/ Philippe Deschamps</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td><span style="font-size: 10pt">Director</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">March 19, 2026</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">Philippe Deschamps</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">/s/ Tara DeSilva</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td><span style="font-size: 10pt">Director</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">March 19, 2026</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">Tara DeSilva</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">/s/ Gene Salkind</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td><span style="font-size: 10pt">Director</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">March 19, 2026</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">Gene Salkind</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 60 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Coeptis Therapeutics Holdings, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Consolidated Financial Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration: underline">Years Ended December 31, 2025 and 2024</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 95%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 5%; text-align: center"><span style="font-size: 10pt"><b>Pages</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#fs_001">Report of Independent Registered Public Accounting
    Firm</a> PCAOB Firm ID <span id="xdx_900_edei--AuditorFirmId_c20250101__20251231_zRxFdfdQ6wc6"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000080" name="dei:AuditorFirmId">6920</ix:nonNumeric></span></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-2</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#fs_007">Consolidated Balance Sheets as of December 31, 2025 and 2024</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-3</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#fs_is">Consolidated Statements of Operations for the years ended December 31, 2025 and 2024</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-4</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#fs-se">Consolidated Statements of Stockholders&#8217; Equity for the years ended December 31, 2025 and 2024</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-5</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#fs-cs">Consolidated Statements of Cash Flows for the years ended December 31, 2025 and 2024</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-6</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#fs_005">Notes to Consolidated Financial Statements</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-7</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 61; Options: NewSection; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;<img src="astralogo.jpg" alt="" style="height: 84px; width: 250px"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="fs_001"></span>REPORT OF INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the Board of Directors and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stockholders of Coeptis Therapeutics Holdings, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Opinion on the Financial Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><p style="margin-top: 0; text-align: justify; margin-bottom: 0">We have audited the accompanying consolidated balance sheets of Coeptis Therapeutics Holdings, Inc. (the Company) as of December 31,
2025 and 2024, and the related consolidated statements of operations, stockholders&#8217; equity, and cash flows for each of the years
in the two-year period ended December 31, 2025, and the related notes (collectively referred to as the financial statements). In our opinion,
the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024,
and the results of its operations and its cash flows for each of the years in the two-year period ended December 31 , 2025, in conformity
with accounting principles generally accepted in the United States of America.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Substantial Doubt about the Company&#8217;s
Ability to Continue as a Going Concern</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><p style="margin-top: 0; text-align: justify; margin-bottom: 0">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in
Note 2 to the financial statements, the Company has incurred net losses, negative operating cash flows, and working capital deficits.
These conditions raise substantial doubt about its ability to continue as a going concern. Management&#8217;s plans regarding these matters
are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Basis for Opinion</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><p style="text-align: justify; margin-top: 0; margin-bottom: 0">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on
the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting
Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">We conducted our audits
in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance
about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to
have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required
to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness
of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">Our audits included performing
procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the
financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management,
as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for
our opinion</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;<img src="image_003.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have served as the Company&#8217;s auditor
since 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;<span id="xdx_905_edei--AuditorName_c20250101__20251231_zm2yI6KIrZT3" style="display: none"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000081" name="dei:AuditorName">Astra Audit and Advisory LLC</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_90B_edei--AuditorLocation_c20250101__20251231_zA2laJLZqezl"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000082" name="dei:AuditorLocation">Tampa, Florida</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">March 19, 2026</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;<img src="astrafooter.jpg" alt="" style="height: 25px; width: 650px"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">COEPTIS THERAPEUTICS HOLDINGS, INC.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span id="fs_007"></span>CONSOLIDATED BALANCE SHEETS</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>



<p style="margin: 0"></p>

<table cellpadding="0" cellspacing="0" id="xdx_307_111_zsjsIvtOcnI" summary="xdx: Statement - CONSOLIDATED BALANCE SHEETS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_49A_20251231_zcpKqbKrchAk" style="text-align: center"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_497_20241231_zkWAqLgTTZk9" style="text-align: center"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">As of</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">December
    31, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">December
    31, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AssetsAbstract_iB_zfSFastWWd2j" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-size: 9pt"><b>ASSETS</b></span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AssetsCurrentAbstract_iB_zami9CKpMrIh" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 9pt">CURRENT ASSETS</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_i01I_maCzeJN_zwrQmnRFnJql" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; padding-left: 10pt"><span style="font-size: 9pt">Cash</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 13%; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2025-12-31" id="Fact000090" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,674,302</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 13%; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-12-31" id="Fact000091" format="ixt:numdotdecimal" decimals="0" unitRef="USD">532,885</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--MarketableSecuritiesCurrent_i01I_d0_maCzeJN_zEAx86rTWCkl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-size: 9pt">Marketable securities</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2025-12-31" id="Fact000093" format="ixt:numdotdecimal" decimals="0" unitRef="USD">676,596</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2024-12-31" id="Fact000094" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--InterestReceivableCurrent_i01I_d0_maCzeJN_zOZBpphvEgrb" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-size: 9pt">Interest receivable</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:InterestReceivableCurrent" contextRef="AsOf2025-12-31" id="Fact000096" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,348</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:InterestReceivableCurrent" contextRef="AsOf2024-12-31" id="Fact000097" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--PrepaidExpenseCurrent_i01I_maCzeJN_zft8zXU5SjE3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-size: 9pt">Prepaid assets</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2025-12-31" id="Fact000099" format="ixt:numdotdecimal" decimals="0" unitRef="USD">991,903</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2024-12-31" id="Fact000100" format="ixt:numdotdecimal" decimals="0" unitRef="USD">518,407</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AssetsCurrent_i01TI_mtCzeJN_maCzuUO_zcogVMAYuga9" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt; text-align: left; padding-left: 30pt"><span style="font-size: 9pt">TOTAL CURRENT ASSETS</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2025-12-31" id="Fact000102" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,350,149</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000103" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,051,292</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentAbstract_i01B_zhORrq3v5Rre" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 9pt">PROPERTY AND EQUIPMENT</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentNet_i02TI_maCzuUO_z87zv9qU0jZ2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-size: 9pt">Furniture and fixtures, net</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2025-12-31" id="Fact000108" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,873</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact000109" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,460</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--OtherAssetsAbstract_i01B_z1nlu93qMON6" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 9pt">OTHER ASSETS</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--Investments_i02I_maCzHCN_zBH9UdGfvmI3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt"><span style="font-size: 9pt">Investments</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><ix:nonFraction name="us-gaap:Investments" contextRef="AsOf2025-12-31" id="Fact000114" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,860,083</ix:nonFraction></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:Investments" contextRef="AsOf2024-12-31" id="Fact000115" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,691,084</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--IntangibleAssetsNetExcludingGoodwill_i02I_maCzHCN_zHDCgu0E0yb4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-size: 9pt">Intangible assets, net</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2025-12-31" id="Fact000117" format="ixt:numdotdecimal" decimals="0" unitRef="USD">361,250</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2024-12-31" id="Fact000118" format="ixt:numdotdecimal" decimals="0" unitRef="USD">541,875</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_405_ecustom--CodevelopmentRightsNet_i02I_maCzHCN_z8ly8JaHB4h7" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-size: 9pt">Co-development rights, net</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="coep:CodevelopmentRightsNet" contextRef="AsOf2025-12-31" id="Fact000120" format="ixt:numdotdecimal" decimals="0" unitRef="USD">554,167</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="coep:CodevelopmentRightsNet" contextRef="AsOf2024-12-31" id="Fact000121" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,554,166</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_maCzHCN_zPiOwf7YAAxk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-size: 9pt">Right of use asset, net of accumulated
    amortization</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2025-12-31" id="Fact000123" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,399</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-12-31" id="Fact000124" format="ixt:numdotdecimal" decimals="0" unitRef="USD">59,783</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--OtherAssets_i02TI_mtCzHCN_maCzuUO_zXHeoRONIMk9" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-size: 9pt">Total other assets</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:OtherAssets" contextRef="AsOf2025-12-31" id="Fact000126" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,793,899</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:OtherAssets" contextRef="AsOf2024-12-31" id="Fact000127" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,846,908</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--Assets_i01TI_mtCzuUO_zUKNKsEvijye" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 30pt"><span style="font-size: 9pt">TOTAL ASSETS</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-12-31" id="Fact000129" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,153,921</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31" id="Fact000130" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,908,660</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_znAFf2UXmMZe" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: center"><span style="font-size: 9pt">LIABILITIES AND STOCKHOLDERS' EQUITY</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesCurrentAbstract_i01B_zsvtFQzZzMN5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 9pt">CURRENT LIABILITIES</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AccountsPayableCurrent_i02I_maCzKQi_zN7Q4cRhuTJ3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-size: 9pt">Accounts payable</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2025-12-31" id="Fact000138" format="ixt:numdotdecimal" decimals="0" unitRef="USD">888,755</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-12-31" id="Fact000139" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,269,763</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--AccruedLiabilitiesCurrent_i02I_maCzKQi_zOqj71jBaWEi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-size: 9pt">Accrued expenses</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2025-12-31" id="Fact000141" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,054</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000142" format="ixt:numdotdecimal" decimals="0" unitRef="USD">736,884</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--ConvertibleNotesPayableCurrent_i02I_d0_maCzKQi_zwPbluIeY521" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-size: 9pt">Convertible notes payable, net of debt discount of
    $<span id="xdx_900_eus-gaap--DebtInstrumentUnamortizedDiscount_pp0p0_c20251231__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zJlPW9Ly7XJb"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2025-12-31_us-gaap_ConvertibleNotesPayableMember" id="Fact000146" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span></span>
    <span style="font-size: 9pt">and $<span id="xdx_903_eus-gaap--DebtInstrumentUnamortizedDiscount_c20241231__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2024-12-31_us-gaap_ConvertibleNotesPayableMember" id="Fact000147" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">435,635</ix:nonFraction></span></span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2025-12-31" id="Fact000144" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2024-12-31" id="Fact000145" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,087,873</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--OtherNotesPayableCurrent_i02I_maCzKQi_zltYXBHGmRZ6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-size: 9pt">Convertible notes payable, in
    default</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:OtherNotesPayableCurrent" contextRef="AsOf2025-12-31" id="Fact000149" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:OtherNotesPayableCurrent" contextRef="AsOf2024-12-31" id="Fact000150" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maCzKQi_zvtXIpTORFY4" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-size: 9pt">Right of use liability, current portion</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2025-12-31" id="Fact000152" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,875</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact000153" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,305</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredRevenueCurrent_i02I_d0_maCzKQi_zUVqHhpHK87h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-size: 9pt">Customer deposit</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:DeferredRevenueCurrent" contextRef="AsOf2025-12-31" id="Fact000155" format="ixt:numdotdecimal" decimals="0" unitRef="USD">599,455</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:DeferredRevenueCurrent" contextRef="AsOf2024-12-31" id="Fact000156" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--DerivativeLiabilitiesCurrent_i02I_d0_maCzKQi_zwc6zSXynzMf" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-size: 9pt">Derivative liability</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2025-12-31" id="Fact000158" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000159" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,041,484</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--OtherLiabilitiesCurrent_i02I_maCzKQi_zEVJ8NSbNJk8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-size: 9pt">Other current liabilities</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2025-12-31" id="Fact000161" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000162" format="ixt:numdotdecimal" decimals="0" unitRef="USD">235,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--LiabilitiesCurrent_i01TI_mtCzKQi_maCziRW_znOLJpeFgiYb" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 30pt"><span style="font-size: 9pt">TOTAL CURRENT LIABILITIES</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2025-12-31" id="Fact000164" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,768,139</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000165" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,513,309</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesNoncurrentAbstract_i01B_zoh5bAKha6e" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 9pt">LONG TERM LIABILITIES</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--LongTermDebtNoncurrent_i02I_maCzP2D_zLr4U6pyAdz2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-size: 9pt">SBA loan payable</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2025-12-31" id="Fact000170" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2024-12-31" id="Fact000171" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--DerivativeLiabilitiesNoncurrent_i02I_maCzP2D_z3njXg6a83Kf" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-size: 9pt">Derivative liability warrants</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2025-12-31" id="Fact000173" format="ixt:numdotdecimal" decimals="0" unitRef="USD">167,625</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2024-12-31" id="Fact000174" format="ixt:numdotdecimal" decimals="0" unitRef="USD">359,250</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_d0_maCzP2D_z0RBnNJqz0Rc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-size: 9pt">Right of use liability, non-current
    portion</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2025-12-31" id="Fact000176" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-12-31" id="Fact000177" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,875</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--LiabilitiesNoncurrent_i02TI_mtCzP2D_maCziRW_zjfFGWzcAiFi" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 30pt"><span style="font-size: 9pt">TOTAL LONG TERM LIABILITIES</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2025-12-31" id="Fact000179" format="ixt:numdotdecimal" decimals="0" unitRef="USD">317,625</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2024-12-31" id="Fact000180" format="ixt:numdotdecimal" decimals="0" unitRef="USD">528,125</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--Liabilities_i02TI_mtCziRW_maCzctZ_z2Z0PVRxW9Jd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 30pt"><span style="font-size: 9pt">TOTAL LIABILITIES</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2025-12-31" id="Fact000182" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,085,764</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-12-31" id="Fact000183" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,041,434</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--CommitmentsAndContingencies_i01I_maCzctZ_zrR8uuuhV153" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 9pt">COMMITMENTS AND CONTINGENCIES (NOTE 10)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><b>&#160;</b></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><b>&#160;</b></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_iB_z6V9skhkG416" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 9pt">STOCKHOLDERS' EQUITY</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--PreferredStockValue_i01I_d0_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_maCzBrj_z29jPyOKLmO8" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -10pt; padding-left: 20pt"><span style="font-size: 9pt">Preferred stock, $<span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_c20241231_pdd"><span id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20251231_zsVZLVW5A3G4"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000193" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2025-12-31" id="Fact000194" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span></span> <span style="font-size: 9pt">par
    value, <span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_c20241231_pdd"><span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_c20251231_z1t5Y2c90aP9"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000195" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-12-31" id="Fact000196" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span></span></span> <span style="font-size: 9pt">shares
    authorized, <span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zd6NDz7QqDAc"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact000197" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></span> designated as Series A, <span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_c20251231_z3VkUAd2sKX8"><span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_c20251231_zHHRlKQJZNfl"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-12-31" id="Fact000198" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2025-12-31" id="Fact000199" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></ix:nonFraction></span></span></span> <span style="font-size: 9pt">and <span id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_c20241231_z1PYsdwHprV5"><span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_c20241231_pdd"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000200" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000201" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,520</ix:nonFraction></ix:nonFraction></span></span></span> <span style="font-size: 9pt">shares
    issued and outstanding at December 31, 2025 and December 31, 2024, respectively</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2025-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact000191" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact000192" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--CommonStockValue_i01I_maCzBrj_z4ZqKuLTKiod" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt"><span style="font-size: 9pt">Common stock, $<span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_c20241231_pdd"><span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20251231_zpNILKH1Xyqd"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000205" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-12-31" id="Fact000206" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span></span>
    <span style="font-size: 9pt">par value, <span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_c20241231_pdd"><span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_c20251231_z9Y43epxHeIk"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000207" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-12-31" id="Fact000208" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000,000</ix:nonFraction></ix:nonFraction></span></span></span>
    <span style="font-size: 9pt">shares authorized, <span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_c20251231_zYnu5ogksWE4"><span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_c20251231_zVwOxJK2oQQ8"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-12-31" id="Fact000209" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-12-31" id="Fact000210" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,746,948</ix:nonFraction></ix:nonFraction></span></span></span>
    <span style="font-size: 9pt">and <span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_c20241231_pdd"><span id="xdx_90E_eus-gaap--CommonStockSharesIssued_iI_c20241231_zvXLQ1Dq3QN7"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000211" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000212" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,116,191</ix:nonFraction></ix:nonFraction></span></span></span>
    <span style="font-size: 9pt">shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2025-12-31" id="Fact000203" format="ixt:numdotdecimal" decimals="0" unitRef="USD">575</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-12-31" id="Fact000204" format="ixt:numdotdecimal" decimals="0" unitRef="USD">212</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--AdditionalPaidInCapital_i01I_maCzBrj_zgPStWL2iOB7" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-size: 9pt">Additional paid-in capital</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2025-12-31" id="Fact000214" format="ixt:numdotdecimal" decimals="0" unitRef="USD">127,201,691</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-12-31" id="Fact000215" format="ixt:numdotdecimal" decimals="0" unitRef="USD">102,976,748</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_403_ecustom--CommonStockSubscribed_i01I_d0_maCzBrj_z4jEqgAEG63g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-size: 9pt">Common stock subscribed</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="coep:CommonStockSubscribed" contextRef="AsOf2025-12-31" id="Fact000217" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="coep:CommonStockSubscribed" contextRef="AsOf2024-12-31" id="Fact000218" format="ixt:numdotdecimal" decimals="0" unitRef="USD">541,875</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--StockholdersEquityNoteSubscriptionsReceivable_i01NI_di_msCzBrj_ze20RiN0bjAh" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-size: 9pt">Subscription receivable</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquityNoteSubscriptionsReceivable" contextRef="AsOf2025-12-31" id="Fact000220" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,686,544</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquityNoteSubscriptionsReceivable" contextRef="AsOf2024-12-31" id="Fact000221" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,100,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr id="xdx_401_eus-gaap--RetainedEarningsAccumulatedDeficit_i01I_maCzBrj_zgwOABpTLJIa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-size: 9pt">Accumulated deficit</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-12-31" id="Fact000223" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">109,953,728</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact000224" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">98,036,713</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr id="xdx_408_eus-gaap--StockholdersEquity_i01TI_mtCzBrj_maCzEhF_zxug6zjW6xqa" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-left: 30pt"><span style="font-size: 9pt">TOTAL STOCKHOLDERS' EQUITY - CONTROLLING INTERESTS</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31" id="Fact000226" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,561,994</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000227" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,382,124</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--MinorityInterest_i01I_maCzEhF_zuDi8YFreNCc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 30pt"><span style="font-size: 9pt">TOTAL STOCKHOLDERS' EQUITY - NONCONTROLLING
    INTERESTS</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2025-12-31" id="Fact000229" format="ixt:numdotdecimal" decimals="0" unitRef="USD">506,163</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2024-12-31" id="Fact000230" format="ixt:numdotdecimal" decimals="0" unitRef="USD">485,102</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_i01TI_mtCzEhF_maCzctZ_z7O2p2zsxabc" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 30pt"><span style="font-size: 9pt">TOTAL STOCKHOLDERS' EQUITY</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-12-31" id="Fact000232" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,068,157</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31" id="Fact000233" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,867,226</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_mtCzctZ_zrEMyyhnrc4e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 30pt"><span style="font-size: 9pt">TOTAL LIABILITIES AND STOCKHOLDERS'
    EQUITY</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2025-12-31" id="Fact000235" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,153,921</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000236" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,908,660</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  </table>


<p style="margin: 0">&#160;</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">The accompanying
notes are an integral part of the consolidated financial statements.</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Value: 3; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">COEPTIS THERAPEUTICS HOLDINGS, INC.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span id="fs_is"></span>CONSOLIDATED STATEMENTS
OF OPERATIONS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_113_zyFKbFAIsh5e" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF OPERATIONS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_495_20250101__20251231_zgiJBpjZ7Rck" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_498_20240101__20241231_zg3s3mzPBt3g" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--RevenuesAbstract_iB_zMEuySpZ2jf9" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td colspan="1" style="font-weight: bold">SALES</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; padding-bottom: 1pt; padding-left: 10pt">Sales</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--Revenues_pp0p0_c20250101__20251231__srt--ProductOrServiceAxis__custom--SaleMember_zhmW9AxxxZA7" title="Total sales" style="border-bottom: Black 1pt solid; width: 13%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-01-012025-12-31_custom_SaleMember" id="Fact000241" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,363,045</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--Revenues_pp0p0_d0_c20240101__20241231__srt--ProductOrServiceAxis__custom--SaleMember_zwhu0x2s6ey7" title="Total sales" style="border-bottom: Black 1pt solid; width: 13%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-01-012024-12-31_custom_SaleMember" id="Fact000243" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--Revenues_d0_maCzxPz_zfLmBOtU8PH4" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-left: 20pt">Total sales</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-01-01to2025-12-31" id="Fact000245" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,363,045</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-01-012024-12-31" id="Fact000246" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CostOfRevenue_d0_msCzxPz_zKeRC0hmIeLc" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 10pt">Cost of goods</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2025-01-01to2025-12-31" id="Fact000248" format="ixt:numdotdecimal" decimals="0" unitRef="USD">180,625</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2024-01-012024-12-31" id="Fact000249" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--GrossProfit_iT_d0_mtCzxPz_maCzWL2_zf6g39GbWA0c" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt; text-align: left; padding-left: 10pt">Gross profit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2025-01-01to2025-12-31" id="Fact000251" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,182,420</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2024-01-012024-12-31" id="Fact000252" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingExpensesAbstract_iB_znJF385FuOm" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold">COST OF OPERATIONS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ResearchAndDevelopmentExpense_i01_maCz1Ly_zDhdrT4YR7Xi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Research and development expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-01to2025-12-31" id="Fact000257" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,277,150</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31" id="Fact000258" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,331,548</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--SalariesAndWages_i01_maCz1Ly_zZ7SQLH1YVLj" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-left: 10pt">Salary expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2025-01-01to2025-12-31" id="Fact000260" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,687,972</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2024-01-012024-12-31" id="Fact000261" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,722,050</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AmortizationOfIntangibleAssets_i01_maCz1Ly_zKRpUGV2ISud" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Amortization expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2025-01-01to2025-12-31" id="Fact000263" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2024-01-012024-12-31" id="Fact000264" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ProfessionalAndContractServicesExpense_i01_maCz1Ly_z3abUF9WalU6" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-left: 10pt">Professional services expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProfessionalAndContractServicesExpense" contextRef="From2025-01-01to2025-12-31" id="Fact000266" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,792,100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProfessionalAndContractServicesExpense" contextRef="From2024-01-012024-12-31" id="Fact000267" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,950,271</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_i01_maCz1Ly_zlowG42hHmNd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Stock based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2025-01-01to2025-12-31" id="Fact000269" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,215,692</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2024-01-012024-12-31" id="Fact000270" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,104,978</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OtherGeneralAndAdministrativeExpense_i01_maCz1Ly_znYhIPttSdM" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-left: 10pt">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="From2025-01-01to2025-12-31" id="Fact000272" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,148,004</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="From2024-01-012024-12-31" id="Fact000273" format="ixt:numdotdecimal" decimals="0" unitRef="USD">945,641</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--SellingAndMarketingExpense_i01_d0_maCz1Ly_zuuUY34YJeg3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Selling and marketing expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="From2025-01-01to2025-12-31" id="Fact000275" format="ixt:numdotdecimal" decimals="0" unitRef="USD">105,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="From2024-01-012024-12-31" id="Fact000276" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingExpenses_iT_mtCz1Ly_msCzWL2_zG5CGdrymVPj" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total cost of operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2025-01-01to2025-12-31" id="Fact000278" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,225,918</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-012024-12-31" id="Fact000279" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,054,488</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingIncomeLoss_iT_mtCzWL2_maCzLTR_zKwJetRPAbIh" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 30pt">LOSS FROM OPERATIONS</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-01-01to2025-12-31" id="Fact000281" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,043,498</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact000282" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,054,488</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_z6nZVbkqT93" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left">OTHER INCOME (EXPENSE)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--InterestExpenseNonoperating_i01N_di_msCziuZ_z02GWTvsxN9f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2025-01-01to2025-12-31" id="Fact000287" format="ixt:numdotdecimal" decimals="0" unitRef="USD">96,744</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2024-01-012024-12-31" id="Fact000288" format="ixt:numdotdecimal" decimals="0" unitRef="USD">246,116</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--InterestAndOtherIncome_i01_maCziuZ_zN0zXIIva0Fh" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-left: 10pt">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestAndOtherIncome" contextRef="From2025-01-01to2025-12-31" id="Fact000290" format="ixt:numdotdecimal" decimals="0" unitRef="USD">116,495</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestAndOtherIncome" contextRef="From2024-01-012024-12-31" id="Fact000291" format="ixt:numdotdecimal" decimals="0" unitRef="USD">234,742</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AmortizationOfDebtDiscountPremium_i01N_di_msCziuZ_zUEd6K84br3g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Amortization of debt discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2025-01-01to2025-12-31" id="Fact000293" format="ixt:numdotdecimal" decimals="0" unitRef="USD">545,635</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2024-01-012024-12-31" id="Fact000294" format="ixt:numdotdecimal" decimals="0" unitRef="USD">216,189</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_ecustom--GainOnForfeitureOfCustomerDeposit_i01_d0_maCziuZ_zqf8cBOUcoZ2" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-left: 10pt">Gain on forfeiture of customer deposit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:GainOnForfeitureOfCustomerDeposit" contextRef="From2025-01-01to2025-12-31" id="Fact000296" format="ixt:numdotdecimal" decimals="0" unitRef="USD">115,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:GainOnForfeitureOfCustomerDeposit" contextRef="From2024-01-012024-12-31" id="Fact000297" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OtherNonoperatingIncomeExpense_i01_maCziuZ_z6yiBtqCYkPb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Other income (expense), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2025-01-01to2025-12-31" id="Fact000299" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,004</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-01-012024-12-31" id="Fact000300" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">16,444</ix:nonFraction></td><td style="text-align: left">)&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_i01_d0_maCziuZ_zq4EN6rk9QU9" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-left: 10pt">Unrealized gain on marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2025-01-01to2025-12-31" id="Fact000302" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,596</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2024-01-012024-12-31" id="Fact000303" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--GainLossOnInvestments_i01_d0_maCziuZ_zQwtMUYKpX51" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Unrealized loss on investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="From2025-01-01to2025-12-31" id="Fact000305" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">163,500</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="From2024-01-012024-12-31" id="Fact000306" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_i01N_di0_msCziuZ_zmA9kesggzb1" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-left: 10pt">Loss on write down of assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" contextRef="From2025-01-01to2025-12-31" id="Fact000308" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" contextRef="From2024-01-012024-12-31" id="Fact000309" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,257</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_ecustom--GainsLossesOnExtinguishmentOfDebt1_i01_d0_maCziuZ_zDtUP32HieM1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Gain (loss) on extinguishment of debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:GainsLossesOnExtinguishmentOfDebt1" contextRef="From2025-01-01to2025-12-31" id="Fact000311" format="ixt:numdotdecimal" decimals="0" unitRef="USD">159,035</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="coep:GainsLossesOnExtinguishmentOfDebt1" contextRef="From2024-01-012024-12-31" id="Fact000312" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">200,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--DerivativeGainLossOnDerivativeNet_i01_maCziuZ_z5EwbdOe6sVj" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Change in fair value of derivative liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2025-01-01to2025-12-31" id="Fact000314" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,098,055</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2024-01-012024-12-31" id="Fact000315" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">341,660</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--NonoperatingIncomeExpense_i01T_mtCziuZ_maCzLTR_zWmdvRuPZF7c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 30pt">TOTAL OTHER INCOME (EXPENSE), net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2025-01-01to2025-12-31" id="Fact000317" format="ixt:numdotdecimal" decimals="0" unitRef="USD">766,306</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-01-012024-12-31" id="Fact000318" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">822,924</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtCzLTR_maPLzv3f_zbOEvkz2C8Ul" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 30pt">LOSS BEFORE INCOME TAXES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2025-01-01to2025-12-31" id="Fact000320" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,277,192</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2024-01-012024-12-31" id="Fact000321" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,877,412</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxExpenseBenefit_d0_msPLzv3f_zkVzhubaDIn3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">PROVISION FOR INCOME TAXES (BENEFIT)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2025-01-01to2025-12-31" id="Fact000323" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="Fact000324" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ProfitLoss_mtPLzv3f_maNILzjmm_zxCKjxxMaKSc" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">NET LOSS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-01-01to2025-12-31" id="Fact000326" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,277,192</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31" id="Fact000327" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,877,412</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_msNILzjmm_zo6wPXT8kqa4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">NET LOSS ATTRIBUTABLE TO NON-CONTROLLING INTERESTS</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2025-01-01to2025-12-31" id="Fact000329" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">360,177</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2024-01-012024-12-31" id="Fact000330" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">196,960</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_iT_mtNILzjmm_zMg94Xc953w7" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-12-31" id="Fact000332" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,917,015</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact000333" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,680,452</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--EarningsPerShareAbstract_iB_zwbUycpkpYOe" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold">LOSS PER SHARE</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-left: 10pt">Loss per share, basic and fully diluted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--EarningsPerShareBasic_c20250101__20251231_zgxRIgY1jf6d" title="Loss per share, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUwA_"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_c20250101__20251231_zjlFWiE3pHz7" title="Loss per share, fully diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUwA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-01-01to2025-12-31" id="Fact000338" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-01-01to2025-12-31" id="Fact000340" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.81</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_907_eus-gaap--EarningsPerShareBasic_c20240101__20241231_zmNYknbV8Iob" title="Loss per share, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUwA_"><span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_c20240101__20241231_z4rMPVH3bVI8" title="Loss per share, fully diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUwA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-012024-12-31" id="Fact000342" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-012024-12-31" id="Fact000344" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">5.56</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt">Weighted average number of common shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20251231_zr2IaDAQnqcl" title="Weighted average number of common shares outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUwA_"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250101__20251231_zh8LKMrufsOe" title="Weighted average number of common shares outstanding, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUwA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-01-01to2025-12-31" id="Fact000346" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-01-01to2025-12-31" id="Fact000348" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,234,787</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231_zqJccVHgCIN1" title="Weighted average number of common shares outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUwA_"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20241231_z81IktpejInk" title="Weighted average number of common shares outstanding, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUwA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-012024-12-31" id="Fact000350" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-012024-12-31" id="Fact000352" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,924,639</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="margin: 0">&#160;</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">The accompanying notes are an integral part of the consolidated financial statements.</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">COEPTIS THERAPEUTICS HOLDINGS, INC.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span id="fs-se"></span>CONSOLIDATED STATEMENTS
OF STOCKHOLDERS' EQUITY</p>



<p style="margin: 0">&#160;</p>


<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_309_114_zKo5bb0gql5e" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_zCzqaphOKoM7" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4B1_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zq9JNFEGqhTi" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zPnSAa61Ynb7" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_custom--CommonStockSubscribedMember_zWGS0XxAYwZ" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_custom--SubscriptionReceivableMember_zut1XSywiceb" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zFO9JUIHfLmi" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--ParentMember_zF9nVAFuaoi2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--NoncontrollingInterestMember_zCdwbFVq52m8" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B2_zyt9TRV6jTN6" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">PREFERRED
    STOCK</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">COMMON
    STOCK</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">ADDITIONAL<br/>
    PAID-IN</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">COMMON<br/>
    STOCK</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">SUBSCRIPTION</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">ACCUMULATED</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">TOTAL<br/>
    CONTROLLING</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">NON-<br/>
    CONTROLLING</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">TOTAL</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">SHARES</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">AMOUNT</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">SHARES</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">AMOUNT</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">CAPITAL</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">SUBSCRIBED</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">RECEIVABLE</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">DEFICIT</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">INTEREST</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">INTEREST</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">EQUITY</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_43B_c20240101__20241231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_d0_z6Zggg8cL88" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -5pt; padding-left: 5pt; width: 13%">BALANCE AT DECEMBER 31, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iS_d0_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zACjjlsoNYW9" title="Beginning balance, shares" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember" id="Fact000364" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember" id="Fact000354" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHt4xbuM4Di9" title="Beginning balance, shares" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000366" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,766,552</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000355" format="ixt:numdotdecimal" decimals="0" unitRef="USD">179</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000356" format="ixt:numdotdecimal" decimals="0" unitRef="USD">91,670,045</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_custom_CommonStockSubscribedMember" id="Fact000357" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_custom_SubscriptionReceivableMember" id="Fact000358" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,500,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000359" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">87,356,261</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_ParentMember" id="Fact000360" format="ixt:numdotdecimal" decimals="0" unitRef="USD">813,963</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000361" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31" id="Fact000362" format="ixt:numdotdecimal" decimals="0" unitRef="USD">813,963</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zkUkJmioN0pe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -5pt; padding-left: 10pt">Shares issued for cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0368">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5IhUwqlPBe5" title="Shares issued for cash, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000378" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000369" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000370" format="ixt:numdotdecimal" decimals="0" unitRef="USD">99,995</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0371">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0372">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0373">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_ParentMember" id="Fact000374" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0375">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31" id="Fact000376" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--SharesIssuedInConnectionWithSEPAValue_zm45xzpgqEh4" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -5pt; padding-left: 10pt">Shares issued for SEPA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0380">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--SharesIssuedInConnectionWithSEPAShares_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6J5ursbgZq1" title="Shares issued for SEPA, shares" style="text-align: right"><ix:nonFraction name="coep:SharesIssuedInConnectionWithSEPAShares" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000390" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:SharesIssuedInConnectionWithSEPAValue" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000381" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:SharesIssuedInConnectionWithSEPAValue" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000382" format="ixt:numdotdecimal" decimals="0" unitRef="USD">79,998</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0383">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0384">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0385">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:SharesIssuedInConnectionWithSEPAValue" contextRef="From2024-01-012024-12-31_us-gaap_ParentMember" id="Fact000386" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0387">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:SharesIssuedInConnectionWithSEPAValue" contextRef="From2024-01-012024-12-31" id="Fact000388" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zpbx6RcH02Of" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -5pt; padding-left: 10pt">Shares issued for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0392">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkct09W9fXfd" title="Shares issued for services, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000402" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">207,319</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000393" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000394" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,329,255</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0395">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0396">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0397">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-012024-12-31_us-gaap_ParentMember" id="Fact000398" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,329,275</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0399">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-012024-12-31" id="Fact000400" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,329,275</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--StockIssuedDuringPeriodValueWarrantsIssuedForCash_zyYg75M4MzN1" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -5pt; padding-left: 10pt">Warrants issued for cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0404">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0405">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:StockIssuedDuringPeriodValueWarrantsIssuedForCash" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000406" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0407">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0408">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0409">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:StockIssuedDuringPeriodValueWarrantsIssuedForCash" contextRef="From2024-01-012024-12-31_us-gaap_ParentMember" id="Fact000410" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0411">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:StockIssuedDuringPeriodValueWarrantsIssuedForCash" contextRef="From2024-01-012024-12-31" id="Fact000412" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_zrdqFGF9u50f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -5pt; padding-left: 10pt">Warrants issued for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0414">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0415">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000416" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,150</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0417">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0418">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0419">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-01-012024-12-31_us-gaap_ParentMember" id="Fact000420" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,150</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0421">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-01-012024-12-31" id="Fact000422" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,150</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--WarrantsIssuedInExchangeForSubscriptionsReceivable_zshnLrCcbtR6" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -5pt; padding-left: 10pt">Warrants issued in exchange for subscriptions receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0424">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0425">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:WarrantsIssuedInExchangeForSubscriptionsReceivable" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000426" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,900,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0427">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="coep:WarrantsIssuedInExchangeForSubscriptionsReceivable" contextRef="From2024-01-012024-12-31_custom_SubscriptionReceivableMember" id="Fact000428" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,000,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0429">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="coep:WarrantsIssuedInExchangeForSubscriptionsReceivable" contextRef="From2024-01-012024-12-31_us-gaap_ParentMember" id="Fact000430" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">100,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0431">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="coep:WarrantsIssuedInExchangeForSubscriptionsReceivable" contextRef="From2024-01-012024-12-31" id="Fact000432" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">100,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_ecustom--SharesIssuedForConversionOfDebtValue_zCp6TmInUPN7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -5pt; padding-left: 10pt">Shares issued for the conversion of debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--SharesIssuedForConversionOfDebtShares_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zgKAEh5DBHqf" title="Shares issued for the conversion of debt, shares" style="text-align: right"><ix:nonFraction name="coep:SharesIssuedForConversionOfDebtShares" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="Fact000444" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">506</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:SharesIssuedForConversionOfDebtValue" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="Fact000434" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--SharesIssuedForConversionOfDebtShares_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztKT5a0cZX86" title="Shares issued for the conversion of debt, shares" style="text-align: right"><ix:nonFraction name="coep:SharesIssuedForConversionOfDebtShares" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000446" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">72,059</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:SharesIssuedForConversionOfDebtValue" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000435" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:SharesIssuedForConversionOfDebtValue" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000436" format="ixt:numdotdecimal" decimals="0" unitRef="USD">951,856</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0437">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0438">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0439">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:SharesIssuedForConversionOfDebtValue" contextRef="From2024-01-012024-12-31_us-gaap_ParentMember" id="Fact000440" format="ixt:numdotdecimal" decimals="0" unitRef="USD">951,863</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0441">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:SharesIssuedForConversionOfDebtValue" contextRef="From2024-01-012024-12-31" id="Fact000442" format="ixt:numdotdecimal" decimals="0" unitRef="USD">951,863</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--StockIssuedDuringPeriodValueOfPreferredShareOffering_zmwUZY7OZnMc" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -5pt; padding-left: 10pt">Preferred share offering</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--StockIssuedDuringPeriodSharesOfPreferredShareOffering_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zpN34bKfbF66" title="Preferred share offering, shares" style="text-align: right"><ix:nonFraction name="coep:StockIssuedDuringPeriodSharesOfPreferredShareOffering" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="Fact000458" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,014</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:StockIssuedDuringPeriodValueOfPreferredShareOffering" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="Fact000448" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0449">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:StockIssuedDuringPeriodValueOfPreferredShareOffering" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000450" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,331,938</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0451">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="coep:StockIssuedDuringPeriodValueOfPreferredShareOffering" contextRef="From2024-01-012024-12-31_custom_SubscriptionReceivableMember" id="Fact000452" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,100,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0453">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:StockIssuedDuringPeriodValueOfPreferredShareOffering" contextRef="From2024-01-012024-12-31_us-gaap_ParentMember" id="Fact000454" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,231,939</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:StockIssuedDuringPeriodValueOfPreferredShareOffering" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000455" format="ixt:numdotdecimal" decimals="0" unitRef="USD">682,062</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:StockIssuedDuringPeriodValueOfPreferredShareOffering" contextRef="From2024-01-012024-12-31" id="Fact000456" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,914,001</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--StockIssuedDuringPeriodValueOfInvestmentsAssignmentAgreements_zqigutd0v8xi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -5pt; padding-left: 10pt">Investments in private companies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0460">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0461">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0462">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0463">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:StockIssuedDuringPeriodValueOfInvestmentsAssignmentAgreements" contextRef="From2024-01-012024-12-31_custom_SubscriptionReceivableMember" id="Fact000464" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0465">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:StockIssuedDuringPeriodValueOfInvestmentsAssignmentAgreements" contextRef="From2024-01-012024-12-31_us-gaap_ParentMember" id="Fact000466" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0467">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:StockIssuedDuringPeriodValueOfInvestmentsAssignmentAgreements" contextRef="From2024-01-012024-12-31" id="Fact000468" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--StockIssuedDuringPeriodValuePurchaseOfAssets1_z5tSLwq1Bdp3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -5pt; padding-left: 10pt">Common stock issued for intangible asset purchase</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0470">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0471">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0472">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:StockIssuedDuringPeriodValuePurchaseOfAssets1" contextRef="From2024-01-012024-12-31_custom_CommonStockSubscribedMember" id="Fact000473" format="ixt:numdotdecimal" decimals="0" unitRef="USD">541,875</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0474">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0475">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:StockIssuedDuringPeriodValuePurchaseOfAssets1" contextRef="From2024-01-012024-12-31_us-gaap_ParentMember" id="Fact000476" format="ixt:numdotdecimal" decimals="0" unitRef="USD">541,875</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0477">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:StockIssuedDuringPeriodValuePurchaseOfAssets1" contextRef="From2024-01-012024-12-31" id="Fact000478" format="ixt:numdotdecimal" decimals="0" unitRef="USD">541,875</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zOt4WKV1KtZh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -5pt; padding-left: 10pt">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0480">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0481">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000482" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,104,978</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0483">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0484">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0485">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_ParentMember" id="Fact000486" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,104,978</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0487">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31" id="Fact000488" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,104,978</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueOther_zbnZw3g2btd3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -5pt; padding-left: 10pt">Stock split adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0490">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesOther_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjrf0rWY4HXg" title="Stock split adjustment, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000500" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">261</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0491">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000492" format="ixt:numdotdecimal" decimals="0" unitRef="USD">533</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0493">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0494">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0495">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31_us-gaap_ParentMember" id="Fact000496" format="ixt:numdotdecimal" decimals="0" unitRef="USD">533</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0497">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31" id="Fact000498" format="ixt:numdotdecimal" decimals="0" unitRef="USD">533</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ProfitLoss_zY1iJSvSEgK3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -5pt; padding-left: 10pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0502">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0503">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0504">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0505">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0506">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="Fact000507" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,680,452</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31_us-gaap_ParentMember" id="Fact000508" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,680,452</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000509" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">196,960</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31" id="Fact000510" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,877,412</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_434_c20250101__20251231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_d0_zXvdAvrqrM72" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-indent: -5pt; padding-left: 5pt">BALANCE AT DECEMBER 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_d0_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zFkt48gX0h3a" title="Beginning balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember" id="Fact000522" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,520</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember" id="Fact000512" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSmvlYGJVWrf" title="Beginning balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000524" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,116,191</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000513" format="ixt:numdotdecimal" decimals="0" unitRef="USD">212</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000514" format="ixt:numdotdecimal" decimals="0" unitRef="USD">102,976,748</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_custom_CommonStockSubscribedMember" id="Fact000515" format="ixt:numdotdecimal" decimals="0" unitRef="USD">541,875</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_custom_SubscriptionReceivableMember" id="Fact000516" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,100,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000517" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">98,036,713</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_ParentMember" id="Fact000518" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,382,124</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000519" format="ixt:numdotdecimal" decimals="0" unitRef="USD">485,102</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31" id="Fact000520" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,867,226</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zoyNUzQzgKk7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -5pt; padding-left: 10pt">Shares issued for cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0526">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDlG012sUpui" title="Shares issued for cash, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000536" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">696,467</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000527" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000528" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,119,930</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0529">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-12-31_custom_SubscriptionReceivableMember" id="Fact000530" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,561,544</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0531">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-12-31_us-gaap_ParentMember" id="Fact000532" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,558,456</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0533">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-01to2025-12-31" id="Fact000534" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,558,456</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--SharesIssuedInConnectionWithSEPAValue_z3TqFsvf8xxg" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -5pt; padding-left: 10pt">Shares issued for SEPA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0538">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--SharesIssuedInConnectionWithSEPAShares_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zS6JA94M1zI9" title="Shares issued for SEPA, shares" style="text-align: right"><ix:nonFraction name="coep:SharesIssuedInConnectionWithSEPAShares" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000548" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">225,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:SharesIssuedInConnectionWithSEPAValue" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000539" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:SharesIssuedInConnectionWithSEPAValue" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000540" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,958,825</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0541">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0542">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0543">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:SharesIssuedInConnectionWithSEPAValue" contextRef="From2025-01-012025-12-31_us-gaap_ParentMember" id="Fact000544" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,958,848</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0545">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:SharesIssuedInConnectionWithSEPAValue" contextRef="From2025-01-01to2025-12-31" id="Fact000546" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,958,848</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zhBkz5pOQ73" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -5pt; padding-left: 10pt">Shares issued for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0550">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYkIR0zIuEQ3" title="Shares issued for services, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000560" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">362,871</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000551" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000552" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,829,184</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0553">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0554">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0555">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-012025-12-31_us-gaap_ParentMember" id="Fact000556" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,829,220</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0557">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-01to2025-12-31" id="Fact000558" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,829,220</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--SharesIssuedForInvestmentValue_iP3us-gaap--StockIssuedDuringPeriodSharesIssuedForServices_zP2Mkow41fy7" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -5pt; padding-left: 10pt">Shares issued for investment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0562">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--SharesIssuedForInvestmentShares_iP3custom--SharesIssuedForInvestmentValue_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgH89Olue50g" title="Shares issued for investment, shares" style="text-align: right"><ix:nonFraction name="coep:SharesIssuedForInvestmentShares" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000572" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">66,837</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:SharesIssuedForInvestmentValue" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000563" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:SharesIssuedForInvestmentValue" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000564" format="ixt:numdotdecimal" decimals="0" unitRef="USD">999,994</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0565">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0566">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0567">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:SharesIssuedForInvestmentValue" contextRef="From2025-01-012025-12-31_us-gaap_ParentMember" id="Fact000568" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0569">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:SharesIssuedForInvestmentValue" contextRef="From2025-01-01to2025-12-31" id="Fact000570" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_iP3custom--SharesIssuedForInvestmentShares_d0_z9pOtAY0GDX6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -5pt; padding-left: 10pt">Asset purchase agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember" id="Fact000574" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_iP3us-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z83rIGL50psa" title="Asset purchase agreement, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000584" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">187,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000575" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000576" format="ixt:numdotdecimal" decimals="0" unitRef="USD">541,856</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="From2025-01-012025-12-31_custom_CommonStockSubscribedMember" id="Fact000577" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">541,875</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="From2025-01-012025-12-31_custom_SubscriptionReceivableMember" id="Fact000578" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="Fact000579" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="From2025-01-012025-12-31_us-gaap_ParentMember" id="Fact000580" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000581" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="From2025-01-01to2025-12-31" id="Fact000582" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_ztkYRbEKODvk" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -5pt; padding-left: 10pt">Warrants issued for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0586">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0587">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000588" format="ixt:numdotdecimal" decimals="0" unitRef="USD">824,295</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0589">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0590">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0591">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2025-01-012025-12-31_us-gaap_ParentMember" id="Fact000592" format="ixt:numdotdecimal" decimals="0" unitRef="USD">824,295</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0593">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2025-01-01to2025-12-31" id="Fact000594" format="ixt:numdotdecimal" decimals="0" unitRef="USD">824,295</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--StockIssuedDuringPeriodValuePrefundedWarrantsExercise_iP3us-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_zMq8GfTYAnqa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -5pt; padding-left: 10pt">Pre-funded warrants exercise</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0596">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--StockIssuedDuringPeriodSharesPrefundedWarrantsExercise_iP3custom--StockIssuedDuringPeriodValuePrefundedWarrantsExercise_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zk6nSiBQCFB5" title="Pre-funded warrants exercise, shares" style="text-align: right"><ix:nonFraction name="coep:StockIssuedDuringPeriodSharesPrefundedWarrantsExercise" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000606" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">450,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:StockIssuedDuringPeriodValuePrefundedWarrantsExercise" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000597" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:StockIssuedDuringPeriodValuePrefundedWarrantsExercise" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000598" format="ixt:numdotdecimal" decimals="0" unitRef="USD">855</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0599">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0600">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0601">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:StockIssuedDuringPeriodValuePrefundedWarrantsExercise" contextRef="From2025-01-012025-12-31_us-gaap_ParentMember" id="Fact000602" format="ixt:numdotdecimal" decimals="0" unitRef="USD">900</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0603">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:StockIssuedDuringPeriodValuePrefundedWarrantsExercise" contextRef="From2025-01-01to2025-12-31" id="Fact000604" format="ixt:numdotdecimal" decimals="0" unitRef="USD">900</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--StockIssuedDuringPeriodValueOfPreferredShareOffering_zyMcuB4PNP54" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -5pt; padding-left: 10pt">Preferred stock offering</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--StockIssuedDuringPeriodSharesOfPreferredShareOffering_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zsYiU4uVthJh" title="Preferred share offering, shares" style="text-align: right"><ix:nonFraction name="coep:StockIssuedDuringPeriodSharesOfPreferredShareOffering" contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember" id="Fact000618" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,480</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="coep:StockIssuedDuringPeriodValueOfPreferredShareOffering" contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember" id="Fact000608" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0609">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:StockIssuedDuringPeriodValueOfPreferredShareOffering" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000610" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,098,763</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0611">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:StockIssuedDuringPeriodValueOfPreferredShareOffering" contextRef="From2025-01-012025-12-31_custom_SubscriptionReceivableMember" id="Fact000612" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,975,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0613">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:StockIssuedDuringPeriodValueOfPreferredShareOffering" contextRef="From2025-01-012025-12-31_us-gaap_ParentMember" id="Fact000614" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,073,762</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:StockIssuedDuringPeriodValueOfPreferredShareOffering" contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000615" format="ixt:numdotdecimal" decimals="0" unitRef="USD">381,238</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:StockIssuedDuringPeriodValueOfPreferredShareOffering" contextRef="From2025-01-01to2025-12-31" id="Fact000616" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,455,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--StockIssuedDuringPeriodValuePreferredShareConversion_iP3custom--StockIssuedDuringPeriodSharesOfPreferredShareOffering_zxF9CeNPOdqk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -5pt; padding-left: 10pt">Preferred share conversion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--StockIssuedDuringPeriodSharePreferredShareConversion_iP3custom--StockIssuedDuringPeriodValuePreferredShareConversion_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zztTonBwvRBa" title="Preferred share conversion, shares" style="text-align: right">(<ix:nonFraction name="coep:StockIssuedDuringPeriodSharePreferredShareConversion" contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember" id="Fact000630" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">10,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="coep:StockIssuedDuringPeriodValuePreferredShareConversion" contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember" id="Fact000620" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--StockIssuedDuringPeriodSharePreferredShareConversion_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zd1hkR519NRb" title="Preferred share conversion, shares" style="text-align: right"><ix:nonFraction name="coep:StockIssuedDuringPeriodSharePreferredShareConversion" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000632" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:StockIssuedDuringPeriodValuePreferredShareConversion" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000621" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="coep:StockIssuedDuringPeriodValuePreferredShareConversion" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000622" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">124</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0623">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0624">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0625">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0626">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0627">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0628">&#8211;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_iP3us-gaap--ConversionOfStockSharesConverted1_zjTELnd7ixXc" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -5pt; padding-left: 10pt">Debt converted to equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0634">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_iP3us-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zeERIfWEHvY9" title="Debt converted to equity, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000644" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">392,082</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000635" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000636" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,635,673</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0637">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0638">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0639">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-01-012025-12-31_us-gaap_ParentMember" id="Fact000640" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,635,712</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0641">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-01-01to2025-12-31" id="Fact000642" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,635,712</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zcXOzn7qsWEb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -5pt; padding-left: 10pt">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0646">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0647">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000648" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,215,692</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0649">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0650">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0651">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-012025-12-31_us-gaap_ParentMember" id="Fact000652" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,215,692</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0653">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-01to2025-12-31" id="Fact000654" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,215,692</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ProfitLoss_zayBMNvh9m5f" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -5pt; padding-left: 10pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0656">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0657">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0658">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0659">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0660">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="Fact000661" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,917,015</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-01-012025-12-31_us-gaap_ParentMember" id="Fact000662" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,917,015</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000663" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">360,177</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-01-01to2025-12-31" id="Fact000664" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,277,192</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_432_c20250101__20251231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_d0_zQsUH5zBMkm3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt; text-indent: -5pt; padding-left: 5pt">BALANCE AT DECEMBER 31, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iE_d0_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zCdXhxwBjfp7" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-12-31_us-gaap_PreferredStockMember" id="Fact000676" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-12-31_us-gaap_PreferredStockMember" id="Fact000666" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iE_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zt1jUSP61z13" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-12-31_us-gaap_CommonStockMember" id="Fact000678" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,746,948</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-12-31_us-gaap_CommonStockMember" id="Fact000667" format="ixt:numdotdecimal" decimals="0" unitRef="USD">575</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000668" format="ixt:numdotdecimal" decimals="0" unitRef="USD">127,201,691</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-12-31_custom_CommonStockSubscribedMember" id="Fact000669" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-12-31_custom_SubscriptionReceivableMember" id="Fact000670" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,686,544</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember" id="Fact000671" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">109,953,728</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-12-31_us-gaap_ParentMember" id="Fact000672" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,561,994</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000673" format="ixt:numdotdecimal" decimals="0" unitRef="USD">506,163</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-12-31" id="Fact000674" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,068,157</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">The accompanying notes are an integral part of the consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">COEPTIS THERAPEUTICS HOLDINGS, INC.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span id="fs-cs"></span>CONSOLIDATED STATEMENTS
OF CASH FLOWS</p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30C_112_zXrM5Okuz2Jf" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20250101__20251231_zMBD7hIJmxmh" style="text-align: center; font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49E_20240101__20241231_z7pH9KIMIDGh" style="text-align: center; font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_z4o2zxrICwjc" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left">OPERATING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ProfitLoss_i01_maCzuW4_zCbEr3g2Deuk" style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: left; padding-left: 10pt">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-01-01to2025-12-31" id="Fact000683" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,277,192</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31" id="Fact000684" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,877,412</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zkN0hi68mrc9" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-left: 10pt">Adjustments to reconcile net loss to net cash used in operating activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DepreciationDepletionAndAmortization_i02_maCzuW4_zDgX8HfDEIXk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 30pt">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2025-01-01to2025-12-31" id="Fact000689" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,181,212</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2024-01-012024-12-31" id="Fact000690" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,845</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_i02_maCzuW4_zZ6uvmtg53kk" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-left: 30pt">Right of use asset amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2025-01-01to2025-12-31" id="Fact000692" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,385</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2024-01-012024-12-31" id="Fact000693" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,788</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AmortizationOfDebtDiscountPremium_i02_maCzuW4_z4HyLGWfSVch" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 30pt">Amortization of debt discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2025-01-01to2025-12-31" id="Fact000695" format="ixt:numdotdecimal" decimals="0" unitRef="USD">545,635</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2024-01-012024-12-31" id="Fact000696" format="ixt:numdotdecimal" decimals="0" unitRef="USD">216,189</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OtherNoncashIncome_i02N_di0_msCzuW4_zLm5rLbsX5k6" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-left: 30pt">Non-cash revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherNoncashIncome" contextRef="From2025-01-01to2025-12-31" id="Fact000698" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,333,045</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNoncashIncome" contextRef="From2024-01-012024-12-31" id="Fact000699" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--EmployeeBenefitsAndShareBasedCompensationNoncash_i02_maCzuW4_z3PEhN0vdmx6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 30pt">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash" contextRef="From2025-01-01to2025-12-31" id="Fact000701" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,215,692</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash" contextRef="From2024-01-012024-12-31" id="Fact000702" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,104,978</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_i02_maCzuW4_zvte9dQJrKei" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-left: 30pt">Shares issued for non-employee services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2025-01-01to2025-12-31" id="Fact000704" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,829,220</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2024-01-012024-12-31" id="Fact000705" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,329,276</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--WarrantsIssuedForServices_i02_maCzuW4_zFNPLD5pzxK5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 30pt">Warrants issued for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:WarrantsIssuedForServices" contextRef="From2025-01-01to2025-12-31" id="Fact000707" format="ixt:numdotdecimal" decimals="0" unitRef="USD">824,295</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:WarrantsIssuedForServices" contextRef="From2024-01-012024-12-31" id="Fact000708" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,150</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--UnrealizedGainLossOnDerivatives_i02N_di_msCzuW4_zHaSRKQOLLF7" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-left: 30pt">Change in fair value of derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:UnrealizedGainLossOnDerivatives" contextRef="From2025-01-01to2025-12-31" id="Fact000710" format="ixt:numdotdecimal" decimals="0" unitRef="USD">906,430</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:UnrealizedGainLossOnDerivatives" contextRef="From2024-01-012024-12-31" id="Fact000711" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">539,660</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FairValueAdjustmentOfWarrants_i02_maCzuW4_zysThyeuVs4b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 30pt">Change in fair value of derivative liability warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2025-01-01to2025-12-31" id="Fact000713" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">191,625</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-012024-12-31" id="Fact000714" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">198,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--LossOnSharesIssuedForConversionOfDebt_i02_d0_maCzuW4_zA8ykdaEbkPl" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-left: 30pt">Loss on shares issued for conversion of debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:LossOnSharesIssuedForConversionOfDebt" contextRef="From2025-01-01to2025-12-31" id="Fact000716" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:LossOnSharesIssuedForConversionOfDebt" contextRef="From2024-01-012024-12-31" id="Fact000717" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,250</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i02N_di0_msCzuW4_zh7MFwazJlxc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 30pt">(Gain) loss on extinguishment of debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2025-01-01to2025-12-31" id="Fact000719" format="ixt:numdotdecimal" decimals="0" unitRef="USD">159,035</ix:nonFraction></td><td style="text-align: left">)&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2024-01-012024-12-31" id="Fact000720" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">200,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInInterestPayableNet_i02_d0_maCzuW4_zF9BvARixbif" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 30pt">Forgiveness of interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInterestPayableNet" contextRef="From2025-01-01to2025-12-31" id="Fact000722" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInterestPayableNet" contextRef="From2024-01-012024-12-31" id="Fact000723" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,257</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--GainLossOnInvestments_i02N_di0_msCzuW4_zw5wW9nsOfWj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt">Unrealized loss on investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="From2025-01-01to2025-12-31" id="Fact000725" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">163,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="From2024-01-012024-12-31" id="Fact000726" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_i02N_di0_msCzuW4_zZJBDHuXHLt7" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-left: 30pt">Unrealized gain on marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2025-01-01to2025-12-31" id="Fact000728" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,596</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2024-01-012024-12-31" id="Fact000729" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInOperatingLiabilitiesAbstract_i01B_z4FwmV7g6AY8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 30pt"><b>(Increase) decrease in:</b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInInterestAndDividendsReceivable_i02N_di0_msCzuW4_znf4jDoTNjGd" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-left: 40pt">Interest receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInterestAndDividendsReceivable" contextRef="From2025-01-01to2025-12-31" id="Fact000734" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,348</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInterestAndDividendsReceivable" contextRef="From2024-01-012024-12-31" id="Fact000735" format="ixt:numdotdecimal" decimals="0" unitRef="USD">234,742</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInPrepaidExpense_i02N_di_msCzuW4_zrEeSaHxZx25" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 40pt">Prepaid assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2025-01-01to2025-12-31" id="Fact000737" format="ixt:numdotdecimal" decimals="0" unitRef="USD">473,497</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2024-01-012024-12-31" id="Fact000738" format="ixt:numdotdecimal" decimals="0" unitRef="USD">118,472</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInOtherOperatingAssetsAbstract_i01B_zfVqWDsV6Iph" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-left: 30pt"><b>Increase (decrease) in:</b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInOtherAccountsPayable_i02_maCzuW4_z8M2SQm9HYuh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 40pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" contextRef="From2025-01-01to2025-12-31" id="Fact000743" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">381,012</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" contextRef="From2024-01-012024-12-31" id="Fact000744" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">149,935</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i02_maCzuW4_zfKk6VshK794" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-left: 40pt">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2025-01-01to2025-12-31" id="Fact000746" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">440,889</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2024-01-012024-12-31" id="Fact000747" format="ixt:numdotdecimal" decimals="0" unitRef="USD">180,934</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i02_maCzuW4_z10Nc7ryaRw5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 40pt">Right of use liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2025-01-01to2025-12-31" id="Fact000749" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">42,306</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2024-01-012024-12-31" id="Fact000750" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">38,047</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--IncreaseDecreaseInOtherCurrentLiabilities_i02_d0_maCzuW4_z05hiwfdL0Y" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 40pt">Other current liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="From2025-01-01to2025-12-31" id="Fact000752" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">115,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="From2024-01-012024-12-31" id="Fact000753" format="ixt:numdotdecimal" decimals="0" unitRef="USD">235,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iT_mtCzuW4_maCzL9M_zGQBkJIZzyBj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">NET CASH USED IN OPERATING ACTIVITIES</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2025-01-01to2025-12-31" id="Fact000755" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,603,036</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-012024-12-31" id="Fact000756" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,649,281</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zCusRCubKTob" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">INVESTING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetCashProvidedByUsedInInvestingActivities_iT_d0_mtCzl7g_maCzL9M_z1NbhArstA5d" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">NET CASH USED IN INVESTING ACTIVITIES</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2025-01-01to2025-12-31" id="Fact000761" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-01-012024-12-31" id="Fact000762" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zBv6IgPaWpud" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left">FINANCING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ProceedsFromNotesPayable_i01_maCzuuE_zUPLDNVmEQ54" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Proceeds from notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2025-01-01to2025-12-31" id="Fact000767" format="ixt:numdotdecimal" decimals="0" unitRef="USD">990,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2024-01-012024-12-31" id="Fact000768" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,850,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_i01_maCzuuE_zMMFBGKRA342" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-left: 10pt">Repayment of notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProceedsFromRepaymentsOfNotesPayable" contextRef="From2025-01-01to2025-12-31" id="Fact000770" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">218,750</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProceedsFromRepaymentsOfNotesPayable" contextRef="From2024-01-012024-12-31" id="Fact000771" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">650,969</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_ecustom--SharesIssuedForSepa_i01_d0_maCzuuE_z9NPfOCVoT1g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Shares issued for SEPA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:SharesIssuedForSepa" contextRef="From2025-01-01to2025-12-31" id="Fact000773" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,958,848</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="coep:SharesIssuedForSepa" contextRef="From2024-01-012024-12-31" id="Fact000774" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maCzuuE_z2akFITF7KKe" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-left: 10pt">Shares issued for cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-01-01to2025-12-31" id="Fact000776" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,558,455</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-01-012024-12-31" id="Fact000777" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ProceedsFromIssuanceOfWarrants_i01_d0_maCzuuE_zmb8ZShSt9Ng" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Warrants issued for cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2025-01-01to2025-12-31" id="Fact000779" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2024-01-012024-12-31" id="Fact000780" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ProceedsFromWarrantExercises_i01_d0_maCzuuE_zLEiygwm8qWj" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt">Pre-funded warrants exercise</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2025-01-01to2025-12-31" id="Fact000782" format="ixt:numdotdecimal" decimals="0" unitRef="USD">900</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2024-01-012024-12-31" id="Fact000783" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_i01_maCzuuE_zj80RdK2oRf6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Preferred stock offering</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="From2025-01-01to2025-12-31" id="Fact000785" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,455,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="From2024-01-012024-12-31" id="Fact000786" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,914,001</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_mtCzuuE_maCzL9M_zwoPYuioxQy1" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">NET CASH PROVIDED BY FINANCING ACTIVITIES</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2025-01-01to2025-12-31" id="Fact000788" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,744,453</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-012024-12-31" id="Fact000789" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,713,032</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_mtCzL9M_z8ugV5QIPeAk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">NET INCREASE (DECREASE) IN CASH</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2025-01-01to2025-12-31" id="Fact000791" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,141,417</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2024-01-012024-12-31" id="Fact000792" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">936,249</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_ztaFbCkqTs37" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt">CASH AT BEGINNING OF PERIOD</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-12-31" id="Fact000794" format="ixt:numdotdecimal" decimals="0" unitRef="USD">532,885</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-12-31" id="Fact000795" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,469,134</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_zESfrUVFDRhk" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">CASH AT END OF PERIOD</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2025-12-31" id="Fact000797" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,674,302</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-12-31" id="Fact000798" format="ixt:numdotdecimal" decimals="0" unitRef="USD">532,885</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">&#160;</td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">&#160;</td><td style="font-style: italic; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zHIAuXYeEpQk" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">SUPPLEMENTAL CASH FLOW DISCLOSURES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--InterestPaidNet_i01_zMpzDAjdiAFe" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-left: 10pt">Interest paid</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2025-01-01to2025-12-31" id="Fact000803" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,772</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2024-01-012024-12-31" id="Fact000804" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,772</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxesPaidNet_i01_d0_zQY87vG8mHjh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Taxes paid</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2025-01-01to2025-12-31" id="Fact000806" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2024-01-012024-12-31" id="Fact000807" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_zMWSPxGjSKm5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">SUPPLEMENTAL NON-CASH DISCLOSURES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--SubscriptionsReceivable_i01_zKhaBqGwfRi6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Subscriptions receivable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="coep:SubscriptionsReceivable" contextRef="From2025-01-01to2025-12-31" id="Fact000812" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,686,544</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="coep:SubscriptionsReceivable" contextRef="From2024-01-012024-12-31" id="Fact000813" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,100,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--SharesIssuedForConversionOfDebt_i01_zUGUzbMAHWKc" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-left: 10pt">Shares issued for the conversion of debt</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="coep:SharesIssuedForConversionOfDebt" contextRef="From2025-01-01to2025-12-31" id="Fact000815" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,635,712</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="coep:SharesIssuedForConversionOfDebt" contextRef="From2024-01-012024-12-31" id="Fact000816" format="ixt:numdotdecimal" decimals="0" unitRef="USD">951,684</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--SharesIssuedForInvestment_i01_d0_zNxo0AWrwg8h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Shares issued for investment</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="coep:SharesIssuedForInvestment" contextRef="From2025-01-01to2025-12-31" id="Fact000818" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="coep:SharesIssuedForInvestment" contextRef="From2024-01-012024-12-31" id="Fact000819" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="margin: 0">&#160;</p>

<p style="text-align: center; margin-top: 0; margin-bottom: 0"><i>The accompanying notes are an integral part of the consolidated financial
statements.</i></p>

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="text-align: center; margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="text-align: left; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="background-color: white"><b>COEPTIS
THERAPEUTICS HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="background-color: white"><b><span id="fs_005"></span>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000821" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock"><p id="xdx_803_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zLNR17dqahnh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 1 &#8211; <span id="xdx_829_ziS0hz4nzVB6">DESCRIPTION OF BUSINESS
AND BASIS OF PRESENTATION</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Nature of Business</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>General</i>. Coeptis Therapeutics Holdings,
Inc. (&#8220;Coeptis&#8221;, the &#8220;Company&#8221; or &#8220;we&#8221; or &#8220;our&#8221;) was originally incorporated in the British
Virgin Islands on November 27, 2018, under the name Bull Horn Holdings Corp. On October 27, 2022, Bull Horn Holdings Corp. domesticated
from the British Virgin Islands to the State of Delaware. On October 28, 2022, in connection with the closing of the Merger, we changed
our corporate name from Bull Horn Holdings Corp. to &#8220;Coeptis Therapeutics Holdings, Inc.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>The Merger Transaction</i>. On October 28,
2022, a wholly owned subsidiary of Bull Horn Holdings Corp., merged with and into Coeptis Therapeutics, Inc., with Coeptis Therapeutics,
Inc. as the surviving corporation of the Merger. As a result of the Merger, we acquired the business of Coeptis Therapeutics, Inc., which
now continues to operate as a wholly owned subsidiary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>About the Company&#8217;s Subsidiaries</i>.
We are now a holding company that currently operates through our direct and indirect subsidiaries SNAP Biosciences, Inc. and GEAR Therapeutics,
Inc., which are majority owned, and Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc. and Coeptis Pharmaceuticals, LLC, which
are wholly owned.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Coeptis is a biopharmaceutical and technology
company. The biopharmaceutical division focuses on developing innovative cell therapy platforms for cancer, autoimmune, and infectious
diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its cutting-edge research and development efforts.
The technology division&#160;focuses on enhancing operational capabilities through advanced technologies. This division features AI-powered
marketing software and robotic process automation tools designed to optimize business processes and improve overall efficiency.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis of Presentation &#8211; </b>The
accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the
United States of America (&#8220;GAAP&#8221;) for financial information and with the instructions to Form 10-K and Rule 8-03 of
Regulation S-X. Accordingly, they include all of the information and notes required by GAAP for complete financial statements. In
the opinion of the Company&#8217;s management, any adjustments contained in the accompanying consolidated financial statements are
of a normal recurring nature, and are necessary to fairly present the financial position and operating results of the Company as of
December 31, 2025 and 2024 and for the years then ended.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Principles of Consolidation </b>&#8211;
The accompanying consolidated financial statements include the accounts of Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals,
Inc., Coeptis Pharmaceuticals, LLC, SNAP Biosciences, Inc., and GEAR Therapeutics, Inc. All material intercompany accounts, balances
and transactions have been eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Reverse Stock Split </b>&#8211; On
December 31, 2024, the Company completed a <span id="xdx_907_eus-gaap--StockholdersEquityReverseStockSplit_c20241201__20241231_zTgKS5QXmvQ5" title="Reverse stock split"><ix:nonNumeric contextRef="From2024-12-012024-12-31" id="Fact000823" name="us-gaap:StockholdersEquityReverseStockSplit">20-1 reverse stock split</ix:nonNumeric></span> of its issued and outstanding common stock. As a result of the
reverse stock split, every 20 shares of issued and outstanding common stock were automatically combined into one share, with no
change in the par value per share. Fractional shares resulting from the reverse stock split were rounded to the nearest whole share.
The reverse stock split has been retrospectively applied to all share and per-share amounts presented in these consolidated
financial statements and accompanying notes for all periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_234_zdqHWDeYa5R6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23F_zrJR7diaWFPl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23B_zfQGlEloYzFi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 67; Value: 1 -->
    <div id="xdx_23C_zTFF2TQcQ8nd" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_236_za4QIWOtXH3c" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23F_zxcFxtwaDYU9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000829" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_809_eus-gaap--SignificantAccountingPoliciesTextBlock_zYg7jG2CuTT" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2 &#8211; <span id="xdx_820_zHeiZMHAMR31">SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000831" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zGm6yV3zsErd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86F_zyoHTINo5VH3">Cash</span></b> &#8211; For purposes of the consolidated
statements of cash flows, the Company considers all highly liquid investments purchased with maturities of three months or less to be
cash equivalents. At times, balances of cash and cash equivalents at financial banking institutions exceeded the federally insured limit
of $250,000. Uninsured balances were $<span id="xdx_903_eus-gaap--CashUninsuredAmount_iI_c20251231_zN2x1dAe3aXg" title="Cash uninsured amount"><ix:nonFraction name="us-gaap:CashUninsuredAmount" contextRef="AsOf2025-12-31" id="Fact000833" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,424,302</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--CashUninsuredAmount_iI_c20241231_zoFGPqjfmOD4" title="Cash uninsured amount"><ix:nonFraction name="us-gaap:CashUninsuredAmount" contextRef="AsOf2024-12-31" id="Fact000835" format="ixt:numdotdecimal" decimals="0" unitRef="USD">282,885</ix:nonFraction></span> at December 31, 2025 and 2024, respectively. The Company regularly monitors
the financial condition of the institution in which it has depository accounts and believes the risk of loss is minimal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000837" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zbI43jjYfaok" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_862_zTI2mm429brg">Property and Equipment</span></b> &#8211; Fixed assets
are stated at cost and depreciation is computed using the straight-line method for financial statement purposes. For the years ended December
31, 2025 and 2024, depreciation expense totaled $<span id="xdx_902_eus-gaap--Depreciation_pp0p0_c20250101__20251231_z1tZWfPnEmg2" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2025-01-01to2025-12-31" id="Fact000839" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">587</ix:nonFraction></span>&#160;and $<span id="xdx_900_eus-gaap--Depreciation_pp0p0_c20240101__20241231_zToUtw0uIgXc" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-012024-12-31" id="Fact000841" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">845</ix:nonFraction></span> respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000843" name="us-gaap:IntangibleAssetsFiniteLivedPolicy"><p id="xdx_84B_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zPZuzK2istNa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86D_zhEsujK9A1Q6">Intangible Assets</span></b> &#8211; The Company records
intangible assets at cost and evaluates them for impairment in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;)
Accounting Standards Codification (&#8220;ASC&#8221;) 350, <i>Intangibles &#8211; Goodwill and Other. </i>Intangibles are being amortized
using the straight-line method over estimated useful lives of between two and forty years. The Company recorded intangible assets of $<span id="xdx_905_eus-gaap--FinitelivedIntangibleAssetsAcquired1_c20250101__20251231__us-gaap--AssetAcquisitionAxis__custom--NexGenAIMember_zx0iJDtPiIvc" title="Intangible assets acquired"><ix:nonFraction name="us-gaap:FinitelivedIntangibleAssetsAcquired1" contextRef="From2025-01-012025-12-31_custom_NexGenAIMember" id="Fact000845" format="ixt:numdotdecimal" decimals="0" unitRef="USD">361,250</ix:nonFraction></span>
and $<span id="xdx_90F_eus-gaap--FinitelivedIntangibleAssetsAcquired1_c20240101__20241231__us-gaap--AssetAcquisitionAxis__custom--NexGenAIMember_zr7CYzFlfrek" title="Intangible assets acquired"><ix:nonFraction name="us-gaap:FinitelivedIntangibleAssetsAcquired1" contextRef="From2024-01-012024-12-31_custom_NexGenAIMember" id="Fact000847" format="ixt:numdotdecimal" decimals="0" unitRef="USD">541,875</ix:nonFraction></span> as of December 31, 2025 and December 31, 2024, respectively, related to the acquired assets of NexGenAI Affiliates Network
Platform (&#8220;NexGenAI&#8221;), which contains AI-powered marketing software and robotic process automation capabilities. See Note
14, Intangible Assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000849" name="us-gaap:MarketableSecuritiesPolicy"><p id="xdx_840_eus-gaap--MarketableSecuritiesPolicy_zYcevolqQtzf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_862_zgGq4RzAIRql">Investments
and Marketable Securities</span> </b>&#8211; The Company classifies its investments and marketable securities in accordance with ASC 320, <i>Investments
&#8211; Debt and Equity Securities</i>, and ASC 321, <i>Investments &#8211; Equity Securities</i>, as applicable. Investments in
equity securities with readily determinable fair values are measured at fair value, with unrealized gains and losses recognized in
net income. For equity securities without readily determinable fair values, the Company applies the measurement alternative,
recording these investments at cost, adjusted for impairments or observable price changes from transactions involving similar
securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Marketable securities are categorized as trading
securities and are thus marked to market and stated at fair value. Fair value is determined using the quoted closing bid prices and is
recorded as a Level&#160;1 asset. Realized gains and losses on marketable securities are recognized as incurred in the consolidated statements
of operations. Net changes in unrealized gains and losses are reported in the consolidated statements of operations in the current period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000851" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_841_eus-gaap--LesseeLeasesPolicyTextBlock_zZd5E69YaC1l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_861_z0y9vDd2f1ad">Leases</span> </b>&#8211; The Company accounts for
leases in accordance with ASC 842, <i>Leases</i>. At lease commencement, the Company recognizes a right-of-use (&#8220;ROU&#8221;) asset
and a corresponding lease liability based on the present value of future lease payments. Lease liabilities are measured using the Company&#8217;s
incremental borrowing rate if the implicit rate is not readily determinable. ROU assets include initial direct costs and prepaid lease
payments and are reduced for lease incentives received.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000853" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_zGhipFppvmqj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_862_zTqBTUr2ay9b">Research
and Development</span> &#8211; </b>Research and development costs are expensed when incurred. During the years ended December 31,
2025 and 2024, research and development expenses totaled $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20250101__20251231_zBA2qHuPDBA1" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-01to2025-12-31" id="Fact000855" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,277,150</ix:nonFraction></span>
and $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240101__20241231_zkmiNA8JRxJb" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31" id="Fact000857" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,331,548</ix:nonFraction></span>,
respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000859" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_84A_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zXWVvjClM0Hk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_865_zugKK9EiCuYd">Impairment
of Long-Lived Assets</span> &#8211; </b>The Company&#8217;s property and equipment and other non-current assets are reviewed
annually for possible impairment when events or changes in circumstances indicate that the carrying amount may not be recoverable.
An impairment loss would be recognized if and when the estimated future cash flows expected to result from the use of the asset and
its eventual disposition is less than its carrying amount. There was&#160;<span id="xdx_90C_eus-gaap--AssetImpairmentCharges_do_c20250101__20251231_zKtzAEblcpXd" title="Asset impairment charges"><span id="xdx_901_eus-gaap--AssetImpairmentCharges_do_c20240101__20241231_zEZpMcINsYf4"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="From2025-01-01to2025-12-31" id="Fact000861" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="From2024-01-012024-12-31" id="Fact000862" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span>
impairment recognized for the years ended December 31, 2025 and 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000864" name="us-gaap:DerivativesPolicyTextBlock"><p id="xdx_84C_eus-gaap--DerivativesPolicyTextBlock_zuMnkgjuA1yc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_864_znIkXgOSEJe2">Derivative Liability Warrants</span> &#8211; </b>The
Company accounts for the Public Warrants and Private Placement Warrants (the &#8220;Warrants&#8221;) in accordance with the guidance contained
in ASC 815-40, <i>Derivatives and Hedging</i>, under which the Warrants do not meet the criteria for equity treatment and must be recorded
as liabilities. Accordingly, the Company classifies the Warrants as liabilities at their fair value and adjusts the Warrants to fair value
in each respective reporting period. This liability is subject to re-measurement at each consolidated balance sheet date until the Warrants
are exercised, and any change in fair value is recognized in the consolidated statements of operations. The Private Placement Warrants
and the Public Warrants for periods where no observable traded price was available are valued using a binomial lattice simulation model.
For periods subsequent to the detachment of the Public Warrants from the Units, the Public Warrant quoted market price was used as the
fair value as of each relevant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000866" name="us-gaap:DebtPolicyTextBlock"><p id="xdx_844_eus-gaap--DebtPolicyTextBlock_zPHbxdJkHdZj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_866_z9JMzbYp8Og5">Convertible Debt</span></b> &#8211; The Company accounts
for convertible debt in accordance with ASC 470-20, <i>Debt &#8211; Debt with Conversion and Other Options</i>. Convertible debt instruments
are evaluated at issuance to determine whether they contain embedded features that require bifurcation as derivatives or equity components.
If the embedded conversion feature meets the criteria for derivative accounting under ASC 815, <i>Derivatives and Hedging</i>, it is bifurcated
and recorded separately at fair value, with subsequent changes in fair value recognized in earnings. Upon conversion or repurchase of
convertible debt, the Company recognizes a gain or loss in accordance with ASC 470-20 and ASC 470-50, <i>Debt Modifications and Extinguishments</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23C_zvtYWZH0KUC7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_236_z8afeVP7mOOh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_237_zeUjP0xfBzWb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 68; Value: 1 -->
    <div id="xdx_239_zvqgEK9d2pug" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_234_zWMSQppfKhu1" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_239_zDG2pLYVUUx7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000872" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zHAAha3GsZn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_865_z3u6TYbMNYnj">Income Taxes</span> </b>&#8211; Income taxes are provided
for the tax effects of transactions reported in the consolidated financial statements and consist of taxes currently due plus deferred
taxes related primarily to temporary differences between reporting of income and expenses for financial reporting purposes and income
tax purposes. The deferred tax assets and liabilities represent the future tax return consequences of those differences, which will either
be taxable or deductible when the assets and liabilities are recovered or settled. Deferred taxes also are recognized for operating losses
that are available to offset future federal income taxes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Income Taxes Topic of FASB ASC clarifies the
accounting and reporting for uncertainties in income tax law within subtopic FASB ASC 740-10-25-5. The guidance prescribes a comprehensive
model for the financial statement recognition, measurement, presentation, and disclosure of uncertain tax positions taken or expected
to be taken in income tax returns. Management believes that there is&#160;<span id="xdx_90C_eus-gaap--UnrecognizedTaxBenefits_iI_pp0p0_do_c20251231_zzgyalr1YRb1" title="Uncertain tax positions"><span id="xdx_90C_eus-gaap--UnrecognizedTaxBenefits_iI_pp0p0_do_c20241231_z9pJ5W7wdqmi" title="Uncertain tax positions"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2025-12-31" id="Fact000874" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2024-12-31" id="Fact000876" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span>&#160;liability related to uncertain tax positions during
the years ended December 31, 2025 and 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000878" name="us-gaap:UseOfEstimates"><p id="xdx_84D_eus-gaap--UseOfEstimates_zGhCno2pOdh6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86C_zicXUShi27md">Use of Estimates</span> &#8211; </b>The preparation
of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements
and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000880" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription"><p id="xdx_842_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zkXNemGlANOk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86B_zWfWKjGsO9M">Reclassification</span> </b>&#8211; The Company reclassified
certain amounts of total stockholders&#8217; equity &#8211; noncontrolling interests, net loss attributable to non-controlling interests,
and accumulated deficit from prior periods. These presentation changes did not affect total stockholders&#8217; equity or net loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000882" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p id="xdx_84C_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zRj8znYSaTXd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86D_zOCJE3Hv5If3">Employee and Non-Employee Share-Based Compensation</span>
</b>&#8211; The Company applies ASC 718-10,&#160;<i>Share-Based Payment</i>, which requires the measurement and recognition of compensation
expenses for all share-based payment awards made to employees and directors including employee stock option equity awards issued to employees
and non-employees based on estimated fair values.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 718-10 requires companies to estimate the
fair value of equity-based option awards on the date of grant using an option-pricing model. The fair value of the award is recognized
as an expense on a straight-line basis over the requisite service periods in the Company&#8217;s consolidated statements of operations.
The Company recognizes share-based award forfeitures as they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company estimates the fair value of granted
option equity awards using a Black-Scholes option pricing model. The option-pricing model requires a number of assumptions, of which the
most significant are share price, expected volatility and the expected option term (the time from the grant date until the options are
exercised or expire). Expected volatility is estimated based on volatility of the Company. The Company has historically not paid dividends
and has no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds
with an equivalent term. The expected option term is calculated for options granted to employees and directors using the &#8220;simplified&#8221;
method. Changes in the determination of each of the inputs can affect the fair value of the options granted and the results of operations
of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000884" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zOOWsmECMEZ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_860_zNI8i6I7Rtza"><b>Recent
Accounting Pronouncements</b></span><b>&#160;</b>&#8211; During the years ended December 31, 2025 and 2024, there were new accounting
pronouncements issued by the FASB. Each of these pronouncements, as applicable, including Accounting Standards Update (&#8220;ASU&#8221;)
2023-07, <i>Segment Reporting</i>, has been or will be adopted by the Company. Please see Note 15, Segment Reporting. Management does
not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company&#8217;s consolidated
financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000886" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p id="xdx_84E_eus-gaap--RevenueRecognitionPolicyTextBlock_z4z3tzepn6Fd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86A_zwA8j2PfPnfk">Revenue Recognition</span></b>&#160;&#8211; The Company
recognizes revenue in accordance with ASC Topic 606, <i>Revenue from Contracts with Customers</i> (&#8220;ASC 606&#8221;) to depict the
transfer of control to the Company&#8217;s customers in an amount reflecting the consideration to which the Company expects to be entitled.
The Company determines revenue recognition through the following steps:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 6%"><span style="font-size: 10pt">i.</span></td>
    <td style="width: 91%; text-align: justify"><span style="font-size: 10pt">Identification of the contract, or contracts, with a customer</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">ii.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Identification of the performance obligations in the contract</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">iii.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Determination of the transaction price</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">iv.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Allocation of the transaction price to the performance obligations in the contract</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">v.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Recognition of revenue, when, or as, the company satisfies the performance obligations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under ASC 606, revenue is recognized when control
of promised goods and services is transferred to customers. A performance obligation is a contractual promise to transfer a distinct good
or service to the customer and is the unit of account under ASC 606. The transaction price of a contract is allocated to distinct performance
obligations and recognized as revenue when or as the performance obligations are satisfied.</p>

<ix:exclude><p id="xdx_23A_zUbYZOpCANG1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23F_zR7hwNrzc0ri" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 69 -->
    <div id="xdx_23B_zHBMKna6Lgjj" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_237_zoRe6mCiFYJ" style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company generates revenue from its customers
by 1) performing data research for its customers and delivering advertising campaigns via cold emails and social media sites, and 2) providing
webinars for its customers to a targeted business-to-business audience. The fee for these services is based on observable prices explicitly
negotiated between the Company and the customer. The Company recognizes revenue at the point in time when the good or service is delivered
to the customer, which occurs upon delivery of the advertising campaign or webinar and there is a transfer of control to the customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2025, revenues
from delivering advertising campaigns via cold emails and social media sites were recognized from six customers who accounted for <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20251231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SixCustomersMember__srt--ProductOrServiceAxis__custom--AdvertisingCampaignsMember_zLX4oEOfVmxh" title="Concentration risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-01-012025-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_SixCustomersMember_custom_AdvertisingCampaignsMember" id="Fact000890" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>%
of this revenue. Revenue was recognized at the point of delivery to the customers in the amount of $<span id="xdx_90D_eus-gaap--Revenues_c20250101__20251231__srt--ProductOrServiceAxis__custom--AdvertisingCampaignsMember_zT74wjk0aKHa" title="Revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-01-012025-12-31_custom_AdvertisingCampaignsMember" id="Fact000892" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,250,545</ix:nonFraction></span>. As of December 31, 2025,
the Company has recorded customer deposits in the amount of $<span id="xdx_902_eus-gaap--DeferredRevenueCurrent_iI_c20251231__srt--ProductOrServiceAxis__custom--AdvertisingCampaignsMember_z60oqDcquob1" title="Customer deposits"><ix:nonFraction name="us-gaap:DeferredRevenueCurrent" contextRef="AsOf2025-12-31_custom_AdvertisingCampaignsMember" id="Fact000894" format="ixt:numdotdecimal" decimals="0" unitRef="USD">599,455</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2025, revenues
from delivering webinar services were recognized from three customers who accounted for <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20251231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThreeCustomersMember__srt--ProductOrServiceAxis__custom--WebinarServicesMember_zjRu100sQNS4" title="Concentration risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-01-012025-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_ThreeCustomersMember_custom_WebinarServicesMember" id="Fact000896" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% of this revenue. Revenue was recognized at
the point of delivery to the customers in the amount of $<span id="xdx_90E_eus-gaap--Revenues_c20250101__20251231__srt--ProductOrServiceAxis__custom--WebinarServicesMember_zsA6a78dhLyf" title="Revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-01-012025-12-31_custom_WebinarServicesMember" id="Fact000898" format="ixt:numdotdecimal" decimals="0" unitRef="USD">112,500</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000900" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zAsU6WAQ4KI8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_865_z2FQOuGhQvN9">Earnings Per Share</span></b> &#8211; Basic earnings
per share (or loss per share), is computed by dividing the earnings (loss) for the period by the weighted average number of common stock
shares outstanding for the period. Diluted earnings per share reflects potential dilution of securities by including other potentially
issuable shares of common stock, including shares issuable upon conversion of convertible securities or exercise of outstanding stock
options and warrants, in the weighted average number of common shares outstanding for the period. Therefore, because including shares
issuable upon conversion of convertible securities and/or exercise of outstanding options and warrants would have an anti-dilutive effect
on the loss per share, only the basic earnings (loss) per share is reported in the accompanying consolidated financial statements. The
Company does not have other potentially issuable shares of stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following potential common shares would have
an antidilutive effect on loss per share:</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000902" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><table cellspacing="0" cellpadding="0" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)" id="xdx_882_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zGWihs13k28a" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt; color: White"><b><span id="xdx_8BB_zFQw89wo8x2c" style="display: none">Schedule of antidilutive shares</span></b></span></td>
    <td>&#160;</td>
    <td colspan="6" style="text-align: center"><span style="font-size: 10pt"><b>Years ended December 31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2025</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2024</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 68%"><span style="font-size: 10pt">Warrants</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zxPQLg8XFKHf" title="Antidilutive shares" style="width: 13%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-12-31_custom_WarrantsMember" id="Fact000904" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">945,105</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_ziMaBdHFS59l" title="Antidilutive shares" style="width: 13%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_custom_WarrantsMember" id="Fact000906" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,399,316</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Stock options</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zwFiS2Xbflk5" title="Antidilutive shares" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-12-31_custom_StockOptionsMember" id="Fact000908" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">437,000</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zLzpYEY8VEh9" title="Antidilutive shares" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_custom_StockOptionsMember" id="Fact000910" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">279,625</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Convertible notes payable</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleNotesPayableMember_zpAXF3MhJOB7" title="Antidilutive shares" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-12-31_us-gaap_ConvertibleNotesPayableMember" id="Fact000912" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleNotesPayableMember_zdFZzQI3BU8e" title="Antidilutive shares" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_ConvertibleNotesPayableMember" id="Fact000914" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">406,629</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Preferred stock</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--PreferredStockMember_zHdONONx2RV8" title="Antidilutive shares" style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember206520625" id="Fact000916" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--PreferredStockMember_zKW6pQqwpZ0h" title="Antidilutive shares" style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember206520625" id="Fact000918" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">815,000</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Total</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231_z2Df7bPawez9" title="Antidilutive shares" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-01to2025-12-31" id="Fact000920" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,382,105</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231_ziJtf4fsJ3G" title="Antidilutive shares" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31" id="Fact000922" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,900,570</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000924" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock"><p id="xdx_84B_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_z2gYXYVgQI29" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86D_zRxnqmvvUvna">Going Concern</span> &#8211;</b> The accompanying
consolidated financial statements have been prepared in conformity with GAAP which contemplate continuation of the Company as a going
concern, which is dependent upon the Company&#8217;s ability to obtain sufficient financing or establish itself as a profitable business.
As of December 31, 2025, the Company had an accumulated deficit of $<span id="xdx_90C_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20251231_zNeMP0RaPasd" title="Accumulated deficit"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-12-31" id="Fact000926" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">109,953,728</ix:nonFraction></span>, and for the year ended December 31, 2025, the Company
had a net loss of $<span id="xdx_90F_eus-gaap--ProfitLoss_iN_di_c20250101__20251231_zwJw9pkfv7x" title="Net loss"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-01-01to2025-12-31" id="Fact000928" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,277,192</ix:nonFraction></span>. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern.
Management&#8217;s plans with respect to operations include raising additional capital through sales of equity or debt securities as may
be necessary to pursue its business plans and sustain operations until such time as the Company can achieve profitability. Management
believes that additional financing as necessary will result in improved operations and cash flow. However, there can be no assurance that
management will be successful in obtaining additional funding or in attaining profitable operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000930" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zHgRczn8lra3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_863_zGDiDX0QL2Ag">Fair Value of Financial Instruments and Measurements</span></b>
&#8211; The Company measures certain financial instruments at fair value in accordance with ASC 820, <i>Fair Value Measurement</i>, for
its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets
and liabilities that are re-measured and reported at fair value at least annually. The fair value of the Company&#8217;s financial assets
and liabilities reflects management&#8217;s estimate of amounts that the Company would have received in connection with the sale of the
assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement
date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs
(market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market
participants would price assets and liabilities).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 820 establishes a three-level fair value hierarchy
that prioritizes inputs used to measure fair value:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 1 &#8211; Quoted prices in active markets
for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability
occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 2 &#8211; Observable inputs other than Level
1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical
assets or liabilities in markets that are not active.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 3 &#8211; Unobservable inputs based on our
assessment of the assumptions that market participants would use in pricing the asset or liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The estimated fair value of cash, interest receivable,
subscription receivable, and notes payable approximate their carrying amounts due to the short-term nature of these instruments.</p>

<ix:exclude><p id="xdx_237_z0eq58QlAWUc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zQYJB0umFOF4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_230_zucnIB1JHR17" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 70 -->
    <div id="xdx_234_z6MiWbySJEz8" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_238_zcd78HhdvgJk" style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000935" name="us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock"><p id="xdx_80B_eus-gaap--MergersAcquisitionsAndDispositionsDisclosuresTextBlock_zUmKiiSvazI6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 3 &#8211; <span id="xdx_82C_zdWP03Gd12j9">CO-DEVELOPMENT
OPTIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2021, the
Company and Vy-Gen-Bio, Inc. (&#8220;Vy-Gen&#8221;) entered into agreements to jointly develop and commercialize two Vy-Gen product candidates,
CD38-GEAR-NK and CD38-Diagnostic (the &#8220;CD38 Assets&#8221;). The Company paid $<span id="xdx_909_eus-gaap--PaymentsToAcquireProductiveAssets_pp0p0_c20210101__20211231__srt--ProductOrServiceAxis__custom--CD38AssetsMember__srt--CounterpartyNameAxis__custom--VyGenMember_zhn892gwZbNe"><ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="From2021-01-012021-12-31_custom_CD38AssetsMember_custom_VyGenMember" id="Fact000936" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,750,000</ix:nonFraction></span>
and issued promissory notes totaling $<span id="xdx_90A_eus-gaap--OtherLongTermNotesPayable_iI_pp0p0_c20211231__srt--ProductOrServiceAxis__custom--CD38AssetsMember__srt--CounterpartyNameAxis__custom--VyGenMember_zla4R5JVRN5f"><ix:nonFraction name="us-gaap:OtherLongTermNotesPayable" contextRef="AsOf2021-12-31_custom_CD38AssetsMember_custom_VyGenMember" id="Fact000937" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,250,000</ix:nonFraction></span>
to Vy-Gen in accordance with the agreements. The Company paid a total of $<span id="xdx_90B_eus-gaap--RepaymentsOfLongTermDebt_pp0p0_c20210101__20211231__srt--ProductOrServiceAxis__custom--CD38AssetsMember__srt--CounterpartyNameAxis__custom--VyGenMember_ziN8x23sl6q2"><ix:nonFraction name="us-gaap:RepaymentsOfLongTermDebt" contextRef="From2021-01-012021-12-31_custom_CD38AssetsMember_custom_VyGenMember" id="Fact000938" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,500,000</ix:nonFraction></span>
toward the promissory notes, leaving $<span id="xdx_90A_eus-gaap--OtherLongTermNotesPayable_iI_pp0p0_c20211231__srt--ProductOrServiceAxis__custom--CD38AssetsMember_zQK3Ld9vjc6i"><ix:nonFraction name="us-gaap:OtherLongTermNotesPayable" contextRef="AsOf2021-12-31_custom_CD38AssetsMember" id="Fact000939" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,750,000</ix:nonFraction></span>
outstanding at December 31, 2021. The collaboration arrangement provides the right for the Company to participate, under the direction
of a joint steering committee, in the development and commercialization of the CD38 Assets and a 50/50 profit share, with the profit
share subject to contingent automatic downward adjustment up to 25% upon an event of default in connection with the promissory notes.
The Company capitalized $<span id="xdx_90D_eus-gaap--CapitalizedContractCostGross_iI_pp0p0_c20211231__srt--ProductOrServiceAxis__custom--CD38AssetsMember__srt--CounterpartyNameAxis__custom--VyGenMember_zGhW3EsItZhh"><ix:nonFraction name="us-gaap:CapitalizedContractCostGross" contextRef="AsOf2021-12-31_custom_CD38AssetsMember_custom_VyGenMember" id="Fact000940" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,000,000</ix:nonFraction></span>
to be amortized over a five-year period in which the CD38 Assets are expected to contribute to future cash flows. The promissory notes
were paid in full in 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company made certain judgements as the basis
in determining the accounting treatment of these options. The CD38 Assets represent a platform technology and a diagnostic tool which
have multiple applications and uses. Both projects are intended to be used in more than one therapy or diagnostic option. For example,
GEAR-NK is a technology which allows for the gene editing of human natural killer cells, so that these cells can no longer bind and be
destroyed by targeted monoclonal antibody treatments. The GEAR-NK technology can be modified to work concomitantly with many different
monoclonal antibody treatments in which there are currently over 100 approved by the FDA. Anti- CD38 is only the first class of monoclonal
antibody treatments being developed under the GEAR-NK platform. Therefore, the pursuit of FDA approval for the use of CD38 assets for
at least one indication or medical device approval is at least reasonably expected. Further, as the diagnostic asset may be used as an
in vitro technology, it could be classified as a medical device, and therefore toxicity studies would not be a contingency to be resolved
before reasonably establishing future value assumptions. In addition, there is perceived value in the CD38 assets, based on publicly disclosed
current business deals in cell therapies, the developing market for these innovative technologies, and current interest from third parties
in these technologies. The Company may sell or license its right to another party, with the written consent of Vy-Gen, which cannot be
unreasonably withheld. Furthermore, the Company believes that any negative results from ongoing development of a single therapy or use,
would not result in abandoning the project. Given these considerations, The Company has determined that these options have alternative
future use and should be recorded as assets pursuant to ASC 730-10-25-2,&#160;<i>Research and Development</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Related to the joint development, the Company,
under the direction of the joint steering committee, is assessing market opportunities, intellectual property protection, and potential
regulatory strategies for the CD38 Assets. Vy-Gen is responsible for development activities conducted and overseen by the scientists at
Karolinska Institute. The agreement does not currently require additional payments for research and development costs by the Company and
no additional payments are required upon development or regulatory milestones.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2025, the Company reached an
agreement with Vy-Gen-Bio, Inc. (&#8220;Vy-Gen&#8221;) to successfully license the exclusive worldwide development and
commercialization rights to the GEAR&#8482; (Gene Edited Antibody Resistant) Cell Therapy Platform, representing a first-in-class
approach to modifying potent cancer-targeting immune cells to optimize the likelihood of deep remission in patients with hematologic
malignancies and other cancers. Coeptis had previously held limited co-development rights to GEAR. As part of this exclusive GEAR
license agreement with VyGen-Bio, Inc., the Company paid a total of $<span id="xdx_90B_eus-gaap--ProceedsFromLicenseFeesReceived_c20250101__20251231_zq5qHCbTx006" title="License fees"><ix:nonFraction name="us-gaap:ProceedsFromLicenseFeesReceived" contextRef="From2025-01-01to2025-12-31" id="Fact000942" format="ixt:numdotdecimal" decimals="0" unitRef="USD">400,000</ix:nonFraction></span>
for license fees during the year ended December 31, 2025, which the company recorded as research and development expense, and
committed to pay other performance-based fees, milestone and royalty payments in 2026 and beyond.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The total gross capitalized Co-Development options
recorded was $<span id="xdx_905_eus-gaap--CapitalizedContractCostGross_iI_c20251231__us-gaap--TransactionTypeAxis__custom--CoDevelopmentRightsMember_zvWmd5FhTOhe"><ix:nonFraction name="us-gaap:CapitalizedContractCostGross" contextRef="AsOf2025-12-31_custom_CoDevelopmentRightsMember" id="Fact000943" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,291,667</ix:nonFraction></span>,
with accumulated amortization of $<span id="xdx_905_eus-gaap--CapitalizedContractCostAccumulatedAmortization_iI_c20251231__us-gaap--TransactionTypeAxis__custom--CoDevelopmentRightsMember_z10CcT42P5x4"><ix:nonFraction name="us-gaap:CapitalizedContractCostAccumulatedAmortization" contextRef="AsOf2025-12-31_custom_CoDevelopmentRightsMember" id="Fact000944" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,737,500</ix:nonFraction></span>,
resulting in a net carrying amount of $<span id="xdx_901_eus-gaap--CapitalizedContractCostNet_iI_c20251231__us-gaap--TransactionTypeAxis__custom--CoDevelopmentRightsMember_z1RtaPabMlsj"><ix:nonFraction name="us-gaap:CapitalizedContractCostNet" contextRef="AsOf2025-12-31_custom_CoDevelopmentRightsMember" id="Fact000945" format="ixt:numdotdecimal" decimals="0" unitRef="USD">554,167</ix:nonFraction></span>
at December 31, 2025. Amortization expense related to the Co-Development options was $<span id="xdx_90D_eus-gaap--AdjustmentForAmortization_c20250101__20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CoDevelopmentOptionsMember_zzlSEuG7woY8"><ix:nonFraction name="us-gaap:AdjustmentForAmortization" contextRef="From2025-01-012025-12-31_custom_CoDevelopmentOptionsMember" id="Fact000946" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></span>
and $<span id="xdx_901_eus-gaap--AdjustmentForAmortization_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CoDevelopmentOptionsMember_zF7JOQGp9bQi"><ix:nonFraction name="us-gaap:AdjustmentForAmortization" contextRef="From2024-01-012024-12-31_custom_CoDevelopmentOptionsMember" id="Fact000947" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></span>
for the years ended December 31, 2025 and December 31, 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000949" name="us-gaap:LongTermDebtTextBlock"><p id="xdx_80A_eus-gaap--LongTermDebtTextBlock_zw14nuNjyzWl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4 &#8211; <span id="xdx_82F_zMTTPpOvNtjf">CONVERTIBLE NOTES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2021, as part of a termination
of a license agreement with Purple, the Company issued a convertible note in the principal amount of $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20210930__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PurpleBioTechMember_zSy2DrcwK6tg" title="Debt face amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-09-30_custom_LicenseAgreementMember_custom_PurpleBioTechMember" id="Fact000951" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,500,000</ix:nonFraction></span>
that was payable on or before the maturity date in February 2023, bearing interest of&#160;<span id="xdx_903_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210902__20210930__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PurpleBioTechMember_zwiC7IXy0cij" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2021-09-022021-09-30_custom_LicenseAgreementMember_custom_PurpleBioTechMember" id="Fact000953" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>%
per annum and convertible in whole or in part at any time by Purple into shares of common stock of the Company. The conversion price
is $5 per share of common stock, subject to certain adjustments under such terms and conditions as agreed between the parties. The
Company may prepay the principal amount of the note plus accrued and unpaid interest at any time prior to the maturity date. On July
14, 2023, the Company and Purple executed an amendment to revise the note&#8217;s payment schedule, extending the maturity date to
March 31, 2024. On June 19, 2024, the Company and Purple executed another amendment to extend the maturity date to August 31, 2024.
The outstanding principal balance due under the convertible note at December 31, 2024 was $<span id="xdx_901_eus-gaap--ConvertibleNotesPayable_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PurpleBioTechMember_zWmLvOesANK9" title="Convertible notes outstanding"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2024-12-31_custom_LicenseAgreementMember_custom_PurpleBioTechMember" id="Fact000955" format="ixt:numdotdecimal" decimals="0" unitRef="USD">218,750</ix:nonFraction></span>.
The Company paid the outstanding $<span id="xdx_907_eus-gaap--RepaymentsOfConvertibleDebt_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PurpleBioTechMember_zXFwlVwIH0tk" title="Repayment of convertible debt"><ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="From2025-01-012025-03-31_custom_LicenseAgreementMember_custom_PurpleBioTechMember" id="Fact000957" format="ixt:numdotdecimal" decimals="0" unitRef="USD">218,750</ix:nonFraction></span>
principal balance in full during the quarter ended March 31, 2025, and the convertible note is considered satisfied.</p>

<ix:exclude><p id="xdx_230_zDVNMR3kT7v5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_232_z6EJh59FV3ng" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23E_zcbTK75x03w3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 71 -->
    <div id="xdx_23C_zer4bitrDQG1" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_231_zVL9JX0SvBhi" style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2022, as a result of the Merger, the
Company entered into a convertible promissory note agreement with an unrelated third party in the principal amount of $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20221031__us-gaap--LongtermDebtTypeAxis__custom--Oct2022ConvertiblePromissoryNoteMember_zSkRzyUu5rlk"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2022-10-31_custom_Oct2022ConvertiblePromissoryNoteMember" id="Fact000961" format="ixt:numdotdecimal" decimals="0" unitRef="USD">350,000</ix:nonFraction></span> with no
accruing interest and was due on October 28, 2023 for legal services rendered to the Company. The noteholder may elect, in its sole discretion
upon written notice to the Company, at any time prior to, as of or following the maturity date, to require that all or any portion of
the principal amount not then repaid be converted, without any further action on the part of the noteholder, into shares of common stock,
par value $0.0001 per share. Upon full conversion of the remaining principal amount due, the note will, for all purposes be deemed cancelled
and all obligations shall be deemed paid in full. On October 27, 2023, a $<span id="xdx_907_eus-gaap--RepaymentsOfConvertibleDebt_c20231026__20231027__us-gaap--LongtermDebtTypeAxis__custom--Oct2022ConvertiblePromissoryNoteMember_zrDdEsRiJq41"><ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="From2023-10-262023-10-27_custom_Oct2022ConvertiblePromissoryNoteMember" id="Fact000962" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></span> payment was made, and on December 15, 2023, another
$<span id="xdx_906_eus-gaap--RepaymentsOfConvertibleDebt_c20231214__20231215__us-gaap--LongtermDebtTypeAxis__custom--Oct2022ConvertiblePromissoryNoteMember_zaW6IW60rs5d"><ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="From2023-12-142023-12-15_custom_Oct2022ConvertiblePromissoryNoteMember" id="Fact000963" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span> payment was made. On June 25, 2024, the Company and the unrelated third party signed an amendment to the note that extended
the maturity date to July 31, 2024. The outstanding balance due under the convertible note at December 31, 2025 and December 31, 2024
was $<span id="xdx_907_eus-gaap--DebtDefaultLongtermDebtAmount_iI_c20251231__us-gaap--LongtermDebtTypeAxis__custom--Oct2022ConvertiblePromissoryNoteMember_zI4DwDX9lqal" title="Debt in default"><ix:nonFraction name="us-gaap:DebtDefaultLongtermDebtAmount" contextRef="AsOf2025-12-31_custom_Oct2022ConvertiblePromissoryNoteMember" id="Fact000965" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span>. The note was in default as of December 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2023, the Company entered into an
unsecured convertible promissory note with an unrelated party in the principal amount of $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_c20241231__us-gaap--LongtermDebtTypeAxis__custom--Dec2023ConvertiblePromissoryNoteMember_z284HxJybYad" title="Principal amount"><span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20240423__20240424__us-gaap--LongtermDebtTypeAxis__custom--Dec2023ConvertiblePromissoryNoteMember_ziyG4OGqt0f7" title="Debt converted, amount converted"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-12-31_custom_Dec2023ConvertiblePromissoryNoteMember" id="Fact000967" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="From2024-04-232024-04-24_custom_Dec2023ConvertiblePromissoryNoteMember" id="Fact000969" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></ix:nonFraction></span></span> together with interest at <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20241231__us-gaap--LongtermDebtTypeAxis__custom--Dec2023ConvertiblePromissoryNoteMember_zywuMQyRyy1i" title="Debt instrument stated percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-12-31_custom_Dec2023ConvertiblePromissoryNoteMember" id="Fact000971" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% and a maturity
date of <span id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_dd_c20240101__20241231__us-gaap--LongtermDebtTypeAxis__custom--Dec2023ConvertiblePromissoryNoteMember_zK50dl7BDZ48" title="Maturity period"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_Dec2023ConvertiblePromissoryNoteMember" format="ixt:datemonthdayyearen" id="Fact000973" name="us-gaap:DebtInstrumentMaturityDate">June 30, 2024</ix:nonNumeric></span>. On April 24, 2024, the Company converted the note into shares of common stock, which satisfied the note in full.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 17, 2024, the Company entered into an
unsecured note agreement with a related party in the principal amount of $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20240417__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--ShortTermDebtTypeAxis__custom--April2024UnsecuredNoteMember_zqBWfPoPXTB7"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-04-17_us-gaap_RelatedPartyMember_custom_April2024UnsecuredNoteMember" id="Fact000974" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></span> together with interest at <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20240417__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--ShortTermDebtTypeAxis__custom--April2024UnsecuredNoteMember_z16q6mGGrKKa" title="Debt stated interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-04-17_us-gaap_RelatedPartyMember_custom_April2024UnsecuredNoteMember" id="Fact000976" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>%, with a maturity date
of <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_c20240416__20240417__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--ShortTermDebtTypeAxis__custom--April2024UnsecuredNoteMember_zsakMq0g5cU9" title="Debt maturity date"><ix:nonNumeric contextRef="From2024-04-162024-04-17_us-gaap_RelatedPartyMember_custom_April2024UnsecuredNoteMember" format="ixt:datemonthdayyearen" id="Fact000978" name="us-gaap:DebtInstrumentMaturityDate">September 30, 2024</ix:nonNumeric></span>. The agreement is between the Company and an investment fund where the manager is a member of the Company&#8217;s
board of directors. On June 3, 2024, the Company and the related party agreed to convert the note agreement in full, both principal and
interest, to equity in connection with the Company&#8217;s Series A Preferred Stock offering. See Note 7, Capital Structure, for more
information on the Series A Preferred Stock offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Yorkville Convertible Notes</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 3, 2024, the Company entered into
an unsecured note agreement with an unrelated third party, YA II PN, LTD, a Cayman Islands exempt limited partnership
(&#8220;Yorkville&#8221;) in the principal amount of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20240103__us-gaap--ShortTermDebtTypeAxis__custom--YANote1Member_znxyJQMW0mR2" title="Debt face amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-01-03_custom_YANote1Member" id="Fact000980" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,500,000</ix:nonFraction></span>
(the &#8220;YA Note-1&#8221;). YA Note-1 was issued with a 10% original issue discount. The original principal amount, together with
interest of&#160;<span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20240103__us-gaap--ShortTermDebtTypeAxis__custom--YANote1Member_z68lUeJn1Ty" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-01-03_custom_YANote1Member" id="Fact000982" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>%,
was payable by the Company on March 15, 2024, and was extended to July 31, 2024. The note had an outstanding principal balance of
$<span id="xdx_901_eus-gaap--ShortTermBorrowings_iI_c20241031__us-gaap--ShortTermDebtTypeAxis__custom--YANote1Member_z7htkhwSippa" title="Short-term debt"><ix:nonFraction name="us-gaap:ShortTermBorrowings" contextRef="AsOf2024-10-31_custom_YANote1Member" id="Fact000984" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,235,178</ix:nonFraction></span>
with $<span id="xdx_905_eus-gaap--AmortizationOfDebtDiscountPremium_c20241001__20241031__us-gaap--ShortTermDebtTypeAxis__custom--YANote1Member_z8brDcKVzqDi" title="Amortization of debt discount"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2024-10-012024-10-31_custom_YANote1Member" id="Fact000986" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span>
of the debt discount fully amortized as of October 31, 2024. On November 1, 2024, the Company entered into an agreement with
Yorkville that completely terminates and replaces YA Note-1 (see the Yorkville Transaction defined below). See Note 7, Capital
Structure - Standby Equity Purchase Agreement, for further details.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 1, 2024, the Company entered into
a Standby Equity Purchase Agreement (&#8220;SEPA&#8221;) pursuant to which the Company has the right to sell Yorkville up to $20,000,000
of its shares of Company Common Stock, subject to certain limitations and conditions set forth in the SEPA, from time to time during the
term of the SEPA (such transaction, the &#8220;Yorkville Transaction&#8221;). In connection with the SEPA, Yorkville has agreed to advance
to the Company in the form of a convertible promissory note (the &#8220;Convertible Note&#8221;) an aggregate principal amount of up to
$<span id="xdx_90D_eus-gaap--ConvertibleDebt_iI_c20241102__us-gaap--DebtInstrumentAxis__custom--YorkvilleConvertibleNoteMember_zaTB9HL1AFv1" title="Convertible promissory note"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="AsOf2024-11-02_custom_YorkvilleConvertibleNoteMember" id="Fact000988" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,304,758</ix:nonFraction></span> (the &#8220;Pre-Paid Advance&#8221;), which terminated and replaced the $<span id="xdx_901_eus-gaap--DebtInstrumentDecreaseForgiveness_c20241101__20241102__us-gaap--ShortTermDebtTypeAxis__custom--YANote1Member_zv8w4VFa6kG" title="Short-term debt replaced"><ix:nonFraction name="us-gaap:DebtInstrumentDecreaseForgiveness" contextRef="From2024-11-012024-11-02_custom_YANote1Member" id="Fact000990" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,235,178</ix:nonFraction></span> YA Note-1 outstanding balance discussed
above. The Convertible Note bears an interest rate of&#160;<span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20241102__us-gaap--DebtInstrumentAxis__custom--YorkvilleConvertibleNoteMember_zQboPUZ40V4l" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-11-02_custom_YorkvilleConvertibleNoteMember" id="Fact000992" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>% per annum and is convertible in whole or in part at any time by Yorkville
into shares of common stock of the Company at a conversion price determined based on the lower of the lower of (i) $1.00 per common share
(the &#8220;Fixed Price&#8221;), or (ii) 95% of the lowest daily volume weighted average price during the five consecutive trading days
immediately preceding the conversion date (the &#8220;Variable Price&#8221;), but which Variable Price shall not be lower than the floor
price of $0.80 (the &#8220;Floor Price&#8221;). During the year ended December 31, 2025, the Company recorded amortization of debt discount
in the amount of $<span id="xdx_90D_eus-gaap--AmortizationOfDebtDiscountPremium_c20250101__20251231__us-gaap--DebtInstrumentAxis__custom--YorkvilleConvertibleNoteMember_zYw7bxgELBCc" title="Amortization of debt discount"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2025-01-012025-12-31_custom_YorkvilleConvertibleNoteMember" id="Fact000994" format="ixt:numdotdecimal" decimals="0" unitRef="USD">435,635</ix:nonFraction></span> for the Convertible Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the six months ended June 30, 2025, Yorkville
elected to convert the entire outstanding principal balance on YA Note-1, the convertible promissory note with an outstanding principal
balance of $1,304,758. Yorkville converted $<span id="xdx_90F_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20250101__20250630__us-gaap--DebtInstrumentAxis__custom--YorkvilleConvertibleNoteMember_zLAKmV9AegS1"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="From2025-01-012025-06-30_custom_YorkvilleConvertibleNoteMember" id="Fact000995" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,304,758</ix:nonFraction></span>
of the principal balance and $<span id="xdx_901_ecustom--DebtConversionConvertedInterestAmount1_c20250101__20250630__us-gaap--DebtInstrumentAxis__custom--YorkvilleConvertibleNoteMember_zQieGVHslAij"><ix:nonFraction name="coep:DebtConversionConvertedInterestAmount1" contextRef="From2025-01-012025-06-30_custom_YorkvilleConvertibleNoteMember" id="Fact000996" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,505</ix:nonFraction></span>
of accrued interest into <span id="xdx_908_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20250101__20250630__us-gaap--DebtInstrumentAxis__custom--YorkvilleConvertibleNoteMember_zrnsAa0UihBl"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2025-01-012025-06-30_custom_YorkvilleConvertibleNoteMember" id="Fact000997" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">233,500</ix:nonFraction></span>
shares of common stock at a weighted-average conversion price of $<span id="xdx_90C_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20250630__us-gaap--DebtInstrumentAxis__custom--YorkvilleConvertibleNoteMember_z3uPBBxB6DGe"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2025-06-30_custom_YorkvilleConvertibleNoteMember" id="Fact000998" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.81</ix:nonFraction></span>&#160;per
share. After conversion, the principal balance of the note had a remaining balance of $<span id="xdx_90C_eus-gaap--ConvertibleNotesPayable_iI_c20250630__us-gaap--DebtInstrumentAxis__custom--YorkvilleConvertibleNoteMember_zCCFcdB3qZHh"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2025-06-30_custom_YorkvilleConvertibleNoteMember" id="Fact000999" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The SEPA is an equity-linked contract that does
not qualify for equity classification and is accounted for as a derivative liability recognized at fair value. Any changes in fair value
between the carrying amount of the forward issuance contracts and the settlement amounts will be recognized in other (expense) income
in the consolidated statements of operations. As of December 31, 2025 and December 31, 2024, the fair value of the SEPA was $<span id="xdx_908_eus-gaap--DerivativeAssetFairValueGrossLiability_iI_c20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--StandbyEquityPurchaseAgreementMember_zTuDt0fiiKre" title="Fair value derivative liability"><ix:nonFraction name="us-gaap:DerivativeAssetFairValueGrossLiability" contextRef="AsOf2025-12-31_custom_StandbyEquityPurchaseAgreementMember" id="Fact001001" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_905_eus-gaap--DerivativeAssetFairValueGrossLiability_iI_c20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--StandbyEquityPurchaseAgreementMember_zzs5DwnKbgS" title="Fair value derivative liability"><ix:nonFraction name="us-gaap:DerivativeAssetFairValueGrossLiability" contextRef="AsOf2024-12-31_custom_StandbyEquityPurchaseAgreementMember" id="Fact001003" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,041,484</ix:nonFraction></span>,
respectively. For the year ended December 31, 2025, the Company recognized a gain on the change in fair value of derivative liability
in the amount of $<span id="xdx_90F_eus-gaap--UnrealizedGainLossOnDerivatives_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--StandbyEquityPurchaseAgreementMember_zU9OfV3NBFF1" title="Change in fair value of derivative liability"><ix:nonFraction name="us-gaap:UnrealizedGainLossOnDerivatives" contextRef="From2025-01-012025-12-31_custom_StandbyEquityPurchaseAgreementMember" id="Fact001005" format="ixt:numdotdecimal" decimals="0" unitRef="USD">906,430</ix:nonFraction></span>, in the Company&#8217;s consolidated statements of operations.</p>

<ix:exclude><p id="xdx_231_z6wUxURZpjX7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_235_zIcdwLGJYfii" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23D_zAN61S0FY6C8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<ix:exclude><!-- Field: Page; Sequence: 72 -->
    <div id="xdx_236_zRED5ZX1VG0j" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_235_zaFUC6jKhvcl" style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The following table presents
information about the Company&#8217;s derivative liability that is measured at fair value on a recurring basis at December 31, 2025 and
December 31, 2024 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001010" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zbvuEYR8TaQ4" summary="xdx: Disclosure - CONVERTIBLE NOTES (Details - Derivative liability)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span id="xdx_8B2_z5y8mFoKfK11" style="display: none">Schedule of derivative liability</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2025</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 49%; text-align: justify; padding-bottom: 1pt">Derivative liability</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1pt; width: 13%; text-align: center">3</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_d0_c20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zSScGOpRdWF6" title="Fair value of derivative liability" style="border-bottom: Black 1pt solid; width: 13%; text-align: right"><ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="AsOf2025-12-31_custom_DerivativeLiabilityMember" id="Fact001012" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_c20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zvkEJ2i5QsY5" title="Fair value of derivative liability" style="border-bottom: Black 1pt solid; width: 13%; text-align: right"><ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="AsOf2024-12-31_custom_DerivativeLiabilityMember" id="Fact001014" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,041,484</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_d0_c20251231_zl0cuXFGtsy6" title="Fair value of derivative liability" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="AsOf2025-12-31" id="Fact001016" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_c20241231_z59nuI9P6qT5" title="Fair value of derivative liability" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="AsOf2024-12-31" id="Fact001018" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,041,484</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zTlA5EXadzLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The derivative liability
is accounted for as a liability in accordance with ASC 480 and is presented within derivative liability in the accompanying consolidated
balance sheets. The derivative liability is measured at fair value at inception and on a recurring basis, with changes in fair value presented
in the consolidated statements of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The derivative liability
was valued using a binomial lattice model, which is considered to be a Level 3 fair value measurement. The binomial lattice model&#8217;s
primary unobservable input utilized in determining the fair value of the derivative liability is the step factors input, assumed price
movement, and probabilities assigned to them.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The following table provides
quantitative information regarding Level 3 fair value measurements for the derivative liability:</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001020" name="us-gaap:ScheduleOfServicingLiabilitiesAtFairValueTextBlock"><table cellspacing="0" cellpadding="0" id="xdx_89D_eus-gaap--ScheduleOfServicingLiabilitiesAtFairValueTextBlock_zMk5Fussqd7g" summary="xdx: Disclosure - CONVERTIBLE NOTES (Details - Assumptions)" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt; color: White"><span id="xdx_8B3_zmClAVoHovK3" style="display: none">Schedule of assumptions used for valuation</span></span></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024</b></p></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 83%; text-align: justify"><span style="font-size: 10pt">Risk-free interest rate</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 14%; text-align: right"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zMgiIIKRIoQ2" title="Derivative assumption valuation"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_FairValueInputsLevel3Member" id="Fact001022" name="us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue">4.16</ix:nonNumeric></span>%</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Expected volatility</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zjYxVkzv3sCe" title="Derivative assumption valuation"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_FairValueInputsLevel3Member" id="Fact001024" name="us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue">114.61</ix:nonNumeric></span>%</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Conversion price</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90B_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputConversionPriceMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zEIsIqZ4XoHj" title="Derivative assumption valuation"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputConversionPriceMember_us-gaap_FairValueInputsLevel3Member" id="Fact001026" name="us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue">3.71</ix:nonNumeric></span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Stock price</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_909_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zRqhRfZJsqc7" title="Derivative assumption valuation"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputSharePriceMember_us-gaap_FairValueInputsLevel3Member" id="Fact001028" name="us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue">5.50</ix:nonNumeric></span></span></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A1_zb9m86qB5vNa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The following table presents
the changes in the fair value of derivative liability:</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001030" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"><table cellspacing="0" cellpadding="0" id="xdx_893_eus-gaap--ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_zENQuhqRVCGi" summary="xdx: Disclosure - CONVERTIBLE NOTES (Details - Change in deriviative)" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt; color: White"><span id="xdx_8BC_zfOdvmHY7J5" style="display: none">Schedule of changes in fair value of derivative liability</span></span></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Warrant</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Liabilities</b></p></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 83%"><span style="font-size: 10pt"><b>Fair value as of November 1, 2024 (inception)</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98D_eus-gaap--DerivativeFairValueOfDerivativeLiability_iS_c20241101__20241231_zcBT4BGwXfHi" title="Fair value of derivative liability, beginning balance" style="width: 14%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="AsOf2024-10-31" id="Fact001032" format="ixt:numdotdecimal" decimals="0" unitRef="USD">501,824</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Change in fair value</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_988_eus-gaap--UnrealizedGainLossOnDerivatives_iN_di_c20241101__20241231_zuAywLAZNE3f" title="Change in fair value" style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:UnrealizedGainLossOnDerivatives" contextRef="From2024-11-012024-12-31" id="Fact001034" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">539,660</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt"><b>Fair value as of December 31, 2024</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--DerivativeFairValueOfDerivativeLiability_iS_c20250101__20251231_zrf3ufaAH9Rd" title="Fair value of derivative liability, beginning balance" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="AsOf2024-12-31" id="Fact001036" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,041,484</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Change in fair value</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_982_eus-gaap--UnrealizedGainLossOnDerivatives_iN_di_c20250101__20251231_z9QuDUjAjMub" title="Change in fair value" style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:UnrealizedGainLossOnDerivatives" contextRef="From2025-01-01to2025-12-31" id="Fact001038" format="ixt:numdotdecimal" decimals="0" unitRef="USD">906,430</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Extinguishment of fair value of liability</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_983_eus-gaap--ExtinguishmentOfDebtGainLossNetOfTax_iN_di_c20250101__20251231_zLopX0wn9puc" title="Extinguishment of fair value of liability" style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:ExtinguishmentOfDebtGainLossNetOfTax" contextRef="From2025-01-01to2025-12-31" id="Fact001040" format="ixt:numdotdecimal" decimals="0" unitRef="USD">135,054</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"><b>Fair value as of December 31, 2025</b></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98C_eus-gaap--DerivativeFairValueOfDerivativeLiability_iE_d0_c20250101__20251231_z0cgjM0ajdj" title="Fair value of derivative liability, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="AsOf2025-12-31" id="Fact001042" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A6_zk9Emh2IYbu7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">There were <span id="xdx_90C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_do_c20250101__20251231_zrkwDadYkk5" title="Transfers in or out of Level 3"><span id="xdx_904_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_do_c20240101__20241231_zRMP0WQQ7FA8" title="Transfers in or out of Level 3"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" contextRef="From2025-01-01to2025-12-31" id="Fact001044" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" contextRef="From2024-01-012024-12-31" id="Fact001046" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span>
transfers in or out of Level 3 from other levels in the fair value hierarchy during the years ended December 31, 2025 and 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 16, 2025, the Company entered into
a convertible promissory note with YA II PN, LTD, a Cayman Islands exempt limited partnership (&#8220;Yorkville&#8221;), in the original
principal amount of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20250116__us-gaap--DebtInstrumentAxis__custom--YorkvilleConvertibleNoteMember_zmHDMC4cMMkc"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2025-01-16_custom_YorkvilleConvertibleNoteMember" id="Fact001047" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,100,000</ix:nonFraction></span>.
Interest shall accrue on the outstanding balance of the note at an annual rate equal to&#160;<span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20250115__20250116__us-gaap--DebtInstrumentAxis__custom--YorkvilleConvertibleNoteMember_zv4zNx224Wm6"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2025-01-152025-01-16_custom_YorkvilleConvertibleNoteMember" id="Fact001048" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>%,
subject to an increase to 18% upon an event of default as described in the note. The maturity date of the note is&#160;<span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_pp0p0_dd_c20250115__20250116__us-gaap--DebtInstrumentAxis__custom--YorkvilleConvertibleNoteMember_zBC995Bxtq5i"><ix:nonNumeric contextRef="From2025-01-152025-01-16_custom_YorkvilleConvertibleNoteMember" format="ixt:datemonthdayyearen" id="Fact001049" name="us-gaap:DebtInstrumentMaturityDate">December
31, 2025</ix:nonNumeric></span>. Yorkville may convert the note into shares of Common Stock at any time at a conversion price equal to the lower of (i)
$20.00 (the &#8220;Fixed Price&#8221;) or (ii) a price per share equal to 95% of the lowest daily VWAP during the 5 consecutive trading
days immediately prior to the conversion date of the note (the &#8220;Variable Price&#8221;), but which Variable Price shall not be lower
than a floor price of $1.00 per share (the &#8220;Floor Price&#8221;). The Company internally refers to this note as YA Note-2.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, the Company, at its option, shall
have the right, but not the obligation, to redeem early a portion or all amounts outstanding under the note at a redemption amount equal
to the outstanding principal balance being repaid or redeemed, plus a 5% prepayment premium, plus all accrued and unpaid interest; provided
that (i) the Company provides Yorkville with no less than ten trading days&#8217; prior written notice thereof and (ii) on the date such
notice is issued, the VWAP of the Common Stock is less than the Fixed Price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An &#8220;Amortization Event&#8221; will occur
under the terms of the Promissory Note if (i) the daily VWAP is less than the Floor Price for five trading days during a period of seven
consecutive trading days, or (ii) the Company has issued has issued to Yorkville, pursuant to the transactions contemplated in the note
and any integrated transactions, in excess of 99% of the Common Shares available under the Exchange Cap.</p>

<ix:exclude><p id="xdx_231_zrOKX9YlK4Ag" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_234_zx8uft8YGYNi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23D_ziWnyGJvaXZc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 73 -->
    <div id="xdx_232_zAOAFprZX4Mj" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_235_z5KfFHmwzCgl" style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2025,
Yorkville elected to convert the entire outstanding principal balance on YA Note-2, the convertible promissory note with an
outstanding principal balance of $1,100,000. Yorkville converted $<span id="xdx_90D_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20250101__20251231__us-gaap--DebtInstrumentAxis__custom--YANote2Member_z1EBZZTr1Eq1" title="Debt converted, amount converted"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="From2025-01-012025-12-31_custom_YANote2Member" id="Fact001054" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,100,000</ix:nonFraction></span>
of the principal balance and $<span id="xdx_908_ecustom--DebtConversionConvertedInterestAmount1_c20250101__20251231__us-gaap--DebtInstrumentAxis__custom--YANote2Member_zVGUnH9FDP67"><ix:nonFraction name="coep:DebtConversionConvertedInterestAmount1" contextRef="From2025-01-012025-12-31_custom_YANote2Member" id="Fact001055" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,397</ix:nonFraction></span>
of accrued interest into <span id="xdx_903_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20250101__20251231__us-gaap--DebtInstrumentAxis__custom--YorkvilleConvertibleNoteMember_zKEonhpHtrh8"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2025-01-012025-12-31_custom_YorkvilleConvertibleNoteMember" id="Fact001056" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">158,582</ix:nonFraction></span>
shares of common stock at a weighted-average conversion price of $7.21&#160;per share. After conversion, the principal balance of
the note had a remaining balance of $<span id="xdx_90F_eus-gaap--ConvertibleNotesPayable_iI_c20251231__us-gaap--DebtInstrumentAxis__custom--YorkvilleConvertibleNoteMember_zKAToBSfEWnk" title="Convertible notes outstanding"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2025-12-31_custom_YorkvilleConvertibleNoteMember" id="Fact001058" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>. During the year ended December 31, 2025, the Company recorded amortization
of debt discount in the amount of $<span id="xdx_908_eus-gaap--AmortizationOfDebtDiscountPremium_c20250101__20251231__us-gaap--DebtInstrumentAxis__custom--YANote2Member_zUKKvfcWZyqi" title="Amortization of debt discount"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2025-01-012025-12-31_custom_YANote2Member" id="Fact001060" format="ixt:numdotdecimal" decimals="0" unitRef="USD">110,000</ix:nonFraction></span> for the Convertible Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001062" name="coep:SbaLoanPayableDisclosureTextBlock"><p id="xdx_80B_ecustom--SbaLoanPayableDisclosureTextBlock_zVcdQ3jGyrJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 5 &#8211; <span id="xdx_823_zXZJGo6BmgV2">SBA LOAN PAYABLE </span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Loans under the CARES Act&#160;</b>-- On July
8, 2020, the Company received a loan of $<span id="xdx_90A_eus-gaap--ProceedsFromLoans_c20200707__20200708__us-gaap--LongtermDebtTypeAxis__custom--EidlLoanMember_zm1ZqjPvaDM4" title="Proceeds from loans"><ix:nonFraction name="us-gaap:ProceedsFromLoans" contextRef="From2020-07-072020-07-08_custom_EidlLoanMember" id="Fact001064" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span> from the United States Small Business Administration (the &#8220;SBA&#8221;) under its
Economic Injury Disaster Loan (&#8220;EIDL&#8221;) assistance program in light of the impact of the COVID-19 pandemic on the Company&#8217;s
business. Proceeds are intended to be used for working capital purposes. Interest on the EIDL loan accrues at the rate of <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20200708__us-gaap--LongtermDebtTypeAxis__custom--EidlLoanMember_zHwXOVcN3JU7" title="Accrued interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2020-07-08_custom_EidlLoanMember" id="Fact001066" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.75</ix:nonFraction></span>% per annum
and interest payments are due monthly in the amount of $731. Each payment will be applied first to interest accrued to the date of receipt
of each payment, and the balance, if any, will be applied to principal. The Company began making interest payments in January 2023. The
balance of principal and interest is payable thirty years from the date of the promissory note. The balance of the loan is $<span id="xdx_904_eus-gaap--NotesPayable_iI_c20251231__us-gaap--LongtermDebtTypeAxis__custom--EidlLoanMember_zhJBNfy7y3O6" title="Notes payable"><span id="xdx_902_eus-gaap--NotesPayable_iI_c20241231__us-gaap--LongtermDebtTypeAxis__custom--EidlLoanMember_zBRlLfdt4HGc" title="Notes payable"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2025-12-31_custom_EidlLoanMember" id="Fact001068" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2024-12-31_custom_EidlLoanMember" id="Fact001070" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></ix:nonFraction></span></span>, as
of December 31, 2025 and December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001072" name="us-gaap:DerivativesAndFairValueTextBlock"><p id="xdx_803_eus-gaap--DerivativesAndFairValueTextBlock_zFxj60qJwxl4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 6 &#8211; <span id="xdx_824_zbWk0j08R41h">DERIVATIVE LIABILITY
WARRANTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At December 31, 2025 and December 31, 2024, there
were (i)&#160; <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--PublicWarrantsMember_z9cJ2RVLXbO2" title="Warrants outstanding"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--AwardTypeAxis__custom--PublicWarrantsMember_z9dU1pQt3e62" title="Warrants outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_PublicWarrantsMember" id="Fact001074" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_PublicWarrantsMember" id="Fact001076" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">375,000</ix:nonFraction></ix:nonFraction></span></span> public warrants (the &#8220;Public Warrants&#8221;) outstanding that were issued as part of Bull Horn&#8217;s November
2020 initial public offering, which warrants are exercisable in the aggregate to acquire 187,500 shares of our common stock at an exercise
price of $230.00 per share, (ii)&#160;<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantsMember_zudo6F3ZOPc9" title="Warrants outstanding"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantsMember_zA531p6bBIV8" title="Warrants outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_PrivatePlacementWarrantsMember" id="Fact001078" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_PrivatePlacementWarrantsMember" id="Fact001080" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">187,500</ix:nonFraction></ix:nonFraction></span></span>&#160;private warrants (the &#8220;Private Placement Warrants&#8221;) outstanding that were
issued to our sponsor Bull Horn Holdings Sponsor LC and the underwriters in Bull Horn&#8217;s initial public offering in November 2020,
which warrants are exercisable in the aggregate to 187,500 shares of our common stock at an exercise price of $230.00 per share. The amount
of warrants and related exercise price were adjusted for the Company&#8217;s 20-1 reverse stock split effective December 31, 2024. The
Private Placement Warrants became exercisable on the consummation of our Business Combination in October 2022. No Public Warrants will
be exercisable for cash unless the Company has an effective and current registration statement covering the ordinary shares issuable upon
exercise of the Public Warrants and a current prospectus relating to such shares of common stock. With respect to the shares of common
stock issuable upon the exercise of the Public Warrants, the class A warrants and the class B warrants during any period when the Company
shall have failed to maintain an effective registration statement related to the issuance of such shares underlying the applicable warrants,
the holder of any applicable warrants may exercise its warrant on a cashless basis pursuant to an available exemption from registration
under the Securities Act. If an exemption from registration is not available, holders will not be able to exercise their Public Warrants
on a cashless basis. The Public Warrants will expire five years from the consummation of a Business Combination or earlier upon redemption
or liquidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company may call the Public Warrants for redemption,
in whole and not in part, at a price of $0.01 per warrant:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 93%; text-align: justify"><span style="font-size: 10pt">at any time while the Public Warrants are exercisable,</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">upon not less than 30 days&#8217; prior written notice of redemption to each Public Warrant holder,</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">if, and only if, the reported last sale price of the ordinary shares equals or exceeds $16.50 per share, for any 20 trading days within a 30-trading day period ending on the third trading day prior to the notice of redemption to Public Warrant holders, and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">if, and only if, there is a current registration statement in effect with respect to the ordinary shares underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Company calls the Public Warrants for redemption,
management will have the option to require all holders that wish to exercise the Public Warrants to do so on a &#8220;cashless basis,&#8221;
as described in the warrant agreement. The exercise price and number of ordinary shares issuable upon exercise of the warrants may be
adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or recapitalization, reorganization,
merger or consolidation. However, except as described above, the warrants will not be adjusted for issuances of ordinary shares at a price
below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants. If the Company is unable
to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders
of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company&#8217;s
assets held outside of the Trust Account with respect to such warrants. Accordingly, the warrants may expire worthless.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Private Placement Warrants are identical to
the Public Warrants, except that the Private Placement Warrants only allow the holder thereof to one ordinary share. Additionally, the
Private Placement Warrants will be exercisable on a cashless basis and be non-redeemable so long as they are held by the initial purchasers
or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted
transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the
Public Warrants.</p>

<ix:exclude><p id="xdx_23C_zqGyR2ELAMP3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_238_zqUsyagPeHjd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23F_zD7Ew8EEMwQj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 74 -->
    <div id="xdx_234_zLpJLatZszUh" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23E_zlMD4C5BSCZ6" style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Within ASC 815,&#160;<i>Derivative and Hedging</i>,
Section 815-40-15 addresses equity versus liability treatment and classification of equity-linked financial instruments, including warrants,
and states that a warrant may be classified as a component of equity only if, among other things, the warrant is indexed to the issuer&#8217;s
ordinary share. Under ASC Section 815-40-15, a warrant is not indexed to the issuer&#8217;s ordinary share if the terms of the warrant
require an adjustment to the exercise price upon a specified event and that event is not an input to the fair value of the warrant. Based
on management&#8217;s evaluation, the Company&#8217;s audit committee, in consultation with management, concluded that the Company&#8217;s
Private Placement Warrants and Public Warrants are not indexed to the Company&#8217;s ordinary share in the manner contemplated by ASC
Section 815-40-15 because the holder of the instrument is not an input into the pricing of a fixed-for-fixed option on equity shares.
In addition, based on management&#8217;s evaluation, the Company&#8217;s audit committee, in consultation with management, concluded that
certain warrant provisions preclude equity treatment as by ASC Section 815-10-15.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for its Public Warrants and
Private Placement Warrants as liabilities as set forth in ASC 815-40-15-7D and 7F. See below for details about the methodology and valuation
of the Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table presents information about
the Company&#8217;s derivative liability warrant that are measured at fair value on a recurring basis at December 31, 2025 and December
31, 2024, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001085" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><table cellspacing="0" cellpadding="0" summary="xdx: Disclosure - DERIVATIVE LIABILITY WARRANTS (Details - Fair value)" id="xdx_89D_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zYZYqpWiEQSb" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BE_zgqKjRFwZ6u7" style="display: none">Schedule of fair value hierarchy</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt"><b>Description</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Level</b></span></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2025</b></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.2pt; text-align: center"><b>December 31,</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.2pt; text-align: center"><b>2024</b></p></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 52%; text-align: justify"><span style="font-size: 10pt">Warrant Liability &#8211; Public Warrants</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: center"><span style="font-size: 10pt">1</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_982_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pp0p0_c20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--PublicWarrantsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zykD5wfi9tOi" title="Financial liabilities fair value disclosure" style="width: 13%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2025-12-31_custom_PublicWarrantsMember_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member" id="Fact001087" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">81,000</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98D_eus-gaap--FinancialLiabilitiesFairValueDisclosure_pp0p0_c20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--PublicWarrantsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z17ss78aDgnf" title="Financial liabilities fair value disclosure" style="width: 13%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_custom_PublicWarrantsMember_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member" id="Fact001089" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">165,000</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; text-align: justify"><span style="font-size: 10pt">Warrant Liability &#8211; Private Placement Warrants</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt">3</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td id="xdx_98B_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pp0p0_c20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--PrivatePlacementWarrantsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z441SQZ8Og" title="Financial liabilities fair value disclosure" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2025-12-31_custom_PrivatePlacementWarrantsMember_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member" id="Fact001091" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">86,625</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td id="xdx_98D_eus-gaap--FinancialLiabilitiesFairValueDisclosure_pp0p0_c20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--PrivatePlacementWarrantsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwr7twPOickb" title="Financial liabilities fair value disclosure" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_custom_PrivatePlacementWarrantsMember_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member" id="Fact001093" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">194,250</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 2.5pt; text-align: justify"><span style="font-size: 10pt">Total</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98C_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_c20251231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zyUSDWg5YsK9" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2025-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001094" format="ixt:numdotdecimal" decimals="0" unitRef="USD">167,625</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_980_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zpMRnNeWEKw6" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001095" format="ixt:numdotdecimal" decimals="0" unitRef="USD">359,250</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AE_zjhDZPp78675" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants are accounted for as liabilities
in accordance with ASC 815-40 and are presented within derivative liability warrants in the accompanying consolidated balance sheets.
The derivative liability warrants are measured at fair value at inception and on a recurring basis, with changes in fair value presented
in the consolidated statements of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants were valued using a binomial lattice
model, which is considered to be a Level 3 fair value measurement. The binomial lattice model&#8217;s primary unobservable input utilized
in determining the fair value of the Warrants is the expected volatility of the ordinary shares. The expected volatility as of the Initial
Public Offering date was derived from observable public warrant pricing on comparable &#8216;blank-check&#8217; companies without an identified
target. For periods subsequent to the detachment of the Public Warrants from the Units, the close price of the Public Warrant price will
be used as the fair value as of each relevant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table provides quantitative information
regarding Level 3 fair value measurements:</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001097" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"><table cellspacing="0" cellpadding="0" id="xdx_89E_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_zWvyTg8a35Bd" summary="xdx: Disclosure - DERIVATIVE LIABILITY WARRANTS (Details - Fair value assumption)" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BE_zsam605Oqrhb" style="display: none">Schedule of fair value assumptions</span></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2025</b></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024</b></p></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 68%; text-align: justify"><span style="font-size: 10pt">Risk-free interest rate</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt"><span id="xdx_907_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250101__20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsMember_z9sjKqBiU8E9" title="Derivatives, determination of fair value"><ix:nonNumeric contextRef="From2025-01-012025-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WarrantsMember" id="Fact001099" name="us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue">3.41</ix:nonNumeric></span>%</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90B_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsMember_zGomT0glwFSe" title="Derivatives, determination of fair value"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WarrantsMember" id="Fact001101" name="us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue">4.10</ix:nonNumeric></span>%</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Expected volatility</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_907_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250101__20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsMember_zTxp77nNiJi7" title="Derivatives, determination of fair value"><ix:nonNumeric contextRef="From2025-01-012025-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_WarrantsMember" id="Fact001103" name="us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue">68.58</ix:nonNumeric></span>%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsMember_ziAlQrcigcR5" title="Derivatives, determination of fair value"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_WarrantsMember" id="Fact001105" name="us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue">82.01</ix:nonNumeric></span>%</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Exercise price</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250101__20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsMember_z4Ljn5EkmDn5" title="Derivatives, determination of fair value"><ix:nonNumeric contextRef="From2025-01-012025-12-31_us-gaap_MeasurementInputExercisePriceMember_custom_WarrantsMember" id="Fact001107" name="us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue">230.00</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsMember_zuWNHWHhasb5" title="Derivatives, determination of fair value"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputExercisePriceMember_custom_WarrantsMember" id="Fact001109" name="us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue">230.00</ix:nonNumeric></span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Stock price</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_901_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250101__20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsMember_z36e5rJitRxk" title="Derivatives, determination of fair value"><ix:nonNumeric contextRef="From2025-01-012025-12-31_us-gaap_MeasurementInputSharePriceMember_custom_WarrantsMember" id="Fact001111" name="us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue">14.25</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_909_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsMember_ziKSXBpIE0Fa" title="Derivatives, determination of fair value"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputSharePriceMember_custom_WarrantsMember" id="Fact001113" name="us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue">5.50</ix:nonNumeric></span></span></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A3_zAIjs6K6nKvg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table presents the changes in the
fair value of warrant liabilities:</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001115" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"><table cellspacing="0" cellpadding="0" summary="xdx: Disclosure - DERIVATIVE LIABILITY WARRANTS (Details - Changes in fair value of warrant liabilities)" id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zu3NHvWjouG" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B4_zrOQM567XcY5" style="display: none">Schedule of changes in fair value of warrant liabilities</span></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Private</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Placement</b></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Public</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Warrant</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Liabilities</b></p></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 52%; text-align: justify"><span style="font-size: 10pt"><b>Fair value as of December 31, 2024</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98B_eus-gaap--LiabilitiesFairValueDisclosure_iS_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--PrivatePlacementWarrantsMember_zJRNHSESjNC8" title="Fair value of liabilities, beginning" style="width: 13%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_custom_PrivatePlacementWarrantsMember206522015" id="Fact001117" format="ixt:numdotdecimal" decimals="0" unitRef="USD">194,250</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iS_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--PublicWarrantsMember_zcGUan0W4qAl" title="Fair value of liabilities, beginning" style="width: 13%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_custom_PublicWarrantsMember206522015" id="Fact001119" format="ixt:numdotdecimal" decimals="0" unitRef="USD">165,000</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98E_eus-gaap--LiabilitiesFairValueDisclosure_iS_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantLiabilitiesMember_zEhzUI30ezMd" title="Fair value of liabilities, beginning" style="width: 13%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_custom_WarrantLiabilitiesMember" id="Fact001121" format="ixt:numdotdecimal" decimals="0" unitRef="USD">359,250</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Change in valuation inputs</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98A_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--PrivatePlacementWarrantsMember_zvfSBXANTCUc" title="Change in valuation inputs" style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect" contextRef="From2025-01-012025-12-31_custom_PrivatePlacementWarrantsMember" id="Fact001123" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">107,625</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_988_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--PublicWarrantsMember_zxL0wuHoJy5k" title="Change in valuation inputs" style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect" contextRef="From2025-01-012025-12-31_custom_PublicWarrantsMember" id="Fact001125" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">84,000</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)&#160;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_982_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantLiabilitiesMember_zDZhStIRKTI" title="Change in valuation inputs" style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect" contextRef="From2025-01-012025-12-31_custom_WarrantLiabilitiesMember" id="Fact001127" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">191,625</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Fair value as of December 31, 2025</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_iE_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--PrivatePlacementWarrantsMember_z8KxeUcCjQy8" title="Fair value of liabilities, ending" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-12-31_custom_PrivatePlacementWarrantsMember206522046" id="Fact001129" format="ixt:numdotdecimal" decimals="0" unitRef="USD">86,625</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_982_eus-gaap--LiabilitiesFairValueDisclosure_iE_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--PublicWarrantsMember_zGuxjbu8LBY7" title="Fair value of liabilities, ending" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-12-31_custom_PublicWarrantsMember206522046" id="Fact001131" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81,000</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98E_eus-gaap--LiabilitiesFairValueDisclosure_iE_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantLiabilitiesMember_zYC5pEXwPSK6" title="Fair value of liabilities, ending" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-12-31_custom_WarrantLiabilitiesMember" id="Fact001133" format="ixt:numdotdecimal" decimals="0" unitRef="USD">167,625</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AF_zSy0QNSUdsH4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There were no transfers in or out of Level 3 from
other levels in the fair value hierarchy during the years ended December 31, 2025 and December 31, 2024.</p>

<ix:exclude><p id="xdx_239_zkjpbHBqvq6i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_237_zwScJKAK0ZNi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_231_zUbK7Cmb8ROe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 75 -->
    <div id="xdx_234_zT855gOX4P9k" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_236_zBL7Yn5DOM25" style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001138" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_800_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z2tDlxJAz5Q2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 7 &#8211; <span id="xdx_82C_zznjSspxVHYk">CAPITAL STRUCTURE</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The total number of shares of stock which the
corporation shall have authority to issue is 160,000,000 shares, of which 150,000,000 shares of $<span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zihYz2WUvUcl" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-12-31_us-gaap_CommonStockMember206522296" id="Fact001140" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> par value shall be designated
as Common Stock and <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_c20251231_zUXp70O0Nxlb" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-12-31" id="Fact001142" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></span> shares of $<span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20251231_zRa5Pb82Yspk" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2025-12-31" id="Fact001144" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> shall be designated as Preferred Stock. The Preferred Stock authorized by the Company&#8217;s
Articles of Incorporation may be issued in one or more series. The Board of Directors of the Corporation is authorized to determine or
alter the rights, preferences, privileges, and restrictions granted or imposed upon any wholly unissued series of Preferred Stock, and
within the limitations or restrictions stated in any resolution or resolutions of the Board of Directors originally fixing the number
of shares constituting any series, to increase or decrease (but not below the number of shares of any such series then outstanding) the
number of shares of any such series subsequent to the issue of shares of that series, to determine the designation and par value of any
series and to fix the numbers of shares of any series.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Common Stock</b>&#160;&#8211; As of December
31, 2025, the Company had <span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_c20251231_zTaADzJ56wLg" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-12-31" id="Fact001146" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,746,948</ix:nonFraction></span> shares of its common stock issued and outstanding, and on December 31, 2024, the Company had <span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_c20241231_zYQUpCj2EcA" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact001148" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,116,191</ix:nonFraction></span>
shares of its common stock issued and outstanding. All share amounts have been adjusted for the Company&#8217;s <span id="xdx_908_eus-gaap--StockholdersEquityReverseStockSplit_c20241201__20241231_zd1ui15ClQw4" title="Reverse stock split"><ix:nonNumeric contextRef="From2024-12-012024-12-31" id="Fact001150" name="us-gaap:StockholdersEquityReverseStockSplit">20-1 reverse stock split</ix:nonNumeric></span>
effective December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2025 and 2024,
there were no capital distributions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 16, 2023, the Company completed a
public offering issuing <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230615__20230616__us-gaap--SubsidiarySaleOfStockAxis__custom--PublicOfferingMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zQ7oEMdfSnD" title="Stock issued new, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-06-152023-06-16_custom_PublicOfferingMember_us-gaap_CommonStockMember" id="Fact001152" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">107,500</ix:nonFraction></span> shares of our common stock, <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230615__20230616__us-gaap--SubsidiarySaleOfStockAxis__custom--PublicOfferingMember__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_znQN47rLUtVc" title="Stock issued new, shares"><span id="xdx_909_eus-gaap--ConversionOfStockSharesConverted1_c20230615__20230616__us-gaap--SubsidiarySaleOfStockAxis__custom--PublicOfferingMember__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_zo4yfacSzyIh" title="Stock converted, shares converted"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-06-152023-06-16_custom_PublicOfferingMember_custom_PreFundedWarrantsMember" id="Fact001154" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2023-06-152023-06-16_custom_PublicOfferingMember_custom_PreFundedWarrantsMember" id="Fact001156" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">67,500</ix:nonFraction></ix:nonFraction></span></span> pre-funded warrants, <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230615__20230616__us-gaap--SubsidiarySaleOfStockAxis__custom--PublicOfferingMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsMember_zBybdNuxZzU1" title="Stock issued new, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-06-152023-06-16_custom_PublicOfferingMember_custom_SeriesAWarrantsMember" id="Fact001158" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">153,125</ix:nonFraction></span> Series A Warrants and <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230615__20230616__us-gaap--SubsidiarySaleOfStockAxis__custom--PublicOfferingMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_z3NX9iWOI5X6" title="Stock issued new, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-06-152023-06-16_custom_PublicOfferingMember_custom_SeriesBWarrantsMember" id="Fact001160" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">153,125</ix:nonFraction></span> Series
B Warrants, for net proceeds of approximately $3.0 million, after offering costs. The pre- funded warrants are immediately
exercisable, at a price of $0.0001 per share, with no expiration date. The Series A Warrants and the Series B Warrants are referred
to herein together as the &#8220;Series Warrants.&#8221; The shares of common stock and Series Warrants were purchased together and
then immediately separable and were issued separately. Each Series Warrant to purchase one share of common stock has an exercise
price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230616__us-gaap--SubsidiarySaleOfStockAxis__custom--PublicOfferingMember__us-gaap--StatementClassOfStockAxis__custom--SeriesWarrantsMember_zZPUnDeTYth" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-06-16_custom_PublicOfferingMember_custom_SeriesWarrantsMember" id="Fact001162" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">33.00</ix:nonFraction></span>&#160;per share, and is initially exercisable commencing six months from the date of the offering. The Series
Warrants are exercisable for a term of five years following the initial exercise date. As of December 31, 2024, all of the
pre-funded warrants had been exercised for a total of <span id="xdx_905_eus-gaap--ConversionOfStockSharesIssued1_c20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--PublicOfferingMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zoUJYij30JIc" title="Stock converted, shares issued"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2024-01-012024-12-31_custom_PublicOfferingMember_us-gaap_CommonStockMember" id="Fact001164" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">175,000</ix:nonFraction></span> shares of common stock issued as a result of the public offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 28, 2023, the Company granted pre-funded
warrants exercisable to acquire up to 60,000 shares of our common stock for net proceeds of $1,200,000. The pre-funded common stock purchase
warrants can be exercised at a price of $0.0001 per share, with no expiration date. During the first quarter of 2024, the Company and
the third-party borrower agreed to amend the note as a result of the decline in the publicly traded common stock price. The amount of
pre-funded warrants exercisable to acquire up to 60,000 shares of common stock was amended to 100,000 shares of common stock, and the
total principal balance of the note agreement was increased from $1,000,000 to $1,100,000. The aggregate exercise price of this Warrant
was partially pre-funded in connection with $100,000 and a $<span id="xdx_90C_eus-gaap--ProceedsFromWarrantExercises_pp0p0_c20231227__20231228__us-gaap--StatementClassOfStockAxis__custom--WarrantNoteSubscriptionReceivablesMember_zdVhXXwfpD93" title="Aggregate exercise price of warrant"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2023-12-272023-12-28_custom_WarrantNoteSubscriptionReceivablesMember" id="Fact001166" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,100,000</ix:nonFraction></span>&#160;subscription receivable at a 6% per annum interest rate due
on November 29, 2024. On August 12, 2024, the third-party assigned shares of common stock in a privately held company for the equivalent
amount of principal and accrued interest owed, which satisfied the subscription receivable in full. See Note 9, Investments, for additional
information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 8, 2024, the Company granted pre-funded
warrants exercisable to acquire up to 200,000 shares of our common stock for net proceeds of $2,400,000. The pre-funded common stock purchase
warrants can be exercised at a price of $0.0001 per share, with no expiration date. The aggregate exercise price of this Warrant was partially
pre-funded in connection with $500,000&#160;and a $1,900,000 subscription receivable at a 6% per annum interest rate due on December 31,
2024. On August 12, 2024, the third-party assigned shares of common stock in a privately held company for the equivalent amount of principal
and accrued interest owed, which satisfied the subscription receivable in full. See Note 9, Investments, for additional information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2025, the Company
completed a private placement offering issuing 436,467 shares of common stock for total proceeds of $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250701__20250930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zVVtSEBCxyB7" title="Proceeds from common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-07-012025-09-30_us-gaap_PrivatePlacementMember" id="Fact001168" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000,000</ix:nonFraction></span>. <span id="xdx_90B_eus-gaap--SaleOfStockDescriptionOfTransaction_c20250701__20250930__dei--LegalEntityAxis__custom--SNAPBiosciencesIncMember_zpuzYRJKsjFh" title="Investors description"><ix:nonNumeric contextRef="From2025-07-012025-09-30_custom_SNAPBiosciencesIncMember" id="Fact001170" name="us-gaap:SaleOfStockDescriptionOfTransaction">In addition to the shares
of common stock of the Company, investors also received 10% aggregate non-voting ownership in the Company&#8217;s subsidiary, SNAP Biosciences,
Inc. Of this $5,000,000 raised, $4,500,000 was collected as of December 31, 2025. $500,000 of the subscription receivable is tied to a
promissory note bearing 1% interest annum, with a maturity date of January 18, 2026.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the fourth quarter of 2025, the Company
completed subscription agreements with two investors, resulting in gross proceeds of $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20251001__20251231__us-gaap--TypeOfArrangementAxis__custom--TwoInvestorMember_z9pQAbn9MDYk" title="Gross proceeds"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-10-012025-12-31_custom_TwoInvestorMember" id="Fact001172" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,120,000</ix:nonFraction></span> for a total of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251001__20251231__us-gaap--TypeOfArrangementAxis__custom--TwoInvestorMember_ziVdYwbcBJk1" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-10-012025-12-31_custom_TwoInvestorMember" id="Fact001174" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">260,000</ix:nonFraction></span> shares of common
stock. The balance of $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--TwoInvestorMember_zceAYeQBD5F6" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2025-12-31_custom_TwoInvestorMember" id="Fact001176" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,120,000</ix:nonFraction></span> is tied to promissory notes bearing <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20241231__us-gaap--TypeOfArrangementAxis__custom--TwoInvestorMember_zvvhiUq1MPa3" title="Debt instrument stated percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-12-31_custom_TwoInvestorMember" id="Fact001178" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1</ix:nonFraction></span>% interest annum, with a maturity date of <span id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_dd_c20251001__20251231__us-gaap--TypeOfArrangementAxis__custom--TwoInvestorMember_zrOBfduIM777" title="Maturity period"><ix:nonNumeric contextRef="From2025-10-012025-12-31_custom_TwoInvestorMember" format="ixt:datemonthdayyearen" id="Fact001180" name="us-gaap:DebtInstrumentMaturityDate">December 18, 2026</ix:nonNumeric></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Treasury Stock&#160;</b>&#8211; There was&#160;<span id="xdx_90E_eus-gaap--TreasuryStockValue_iI_pp0p0_do_c20251231_zxpvoGdLxeN6" title="Treasury stock"><span id="xdx_90F_eus-gaap--TreasuryStockValue_iI_pp0p0_do_c20241231_zuDRLCsZd4rb" title="Treasury stock"><ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="AsOf2025-12-31" id="Fact001182" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="AsOf2024-12-31" id="Fact001184" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span>&#160;treasury
stock at December 31, 2025 and December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Preferred Stock&#160;</b>&#8211; The
Company has <span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_c20251231_zFv7nLTc7mW2" title="Preferred stock authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-12-31" id="Fact001186" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></span>
shares of preferred stock authorized, of which <span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zQ5v6fsq9yy" title="Preferred stock authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact001188" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></span>
have been designated as Series A preferred stock. As of December 31, 2024, the Company had <span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zie3EbC1YyT9" title="Preferred stock, shares issued"><span id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z3nJmcL3dvgf" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact001190" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact001192" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,520</ix:nonFraction></ix:nonFraction></span></span>
shares of Series A preferred stock issued and outstanding, and at December 31, 2025, the Company had <span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zxOBDmClRzik" title="Preferred stock, shares issued"><span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zyDeYNDsnkVb" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2025-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact001194" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact001196" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></ix:nonFraction></span></span>
shares of Series A preferred stock issued and outstanding.</p>

<ix:exclude><p id="xdx_232_zCxePhFqxP4i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_237_zVVaGC00j1ol" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23B_zHdurxu3mObf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 76 -->
    <div id="xdx_237_zUNWOcXDNCt3" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_235_z9kobzZm7rF2" style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 13, 2024, the Company performed an initial
Series A preferred stock closing and raised $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_dm_c20240612__20240613__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zcyXU3ZfJZwj" title="Proceeds from sale of preferred stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="From2024-06-122024-06-13_us-gaap_SeriesAPreferredStockMember" id="Fact001201" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">4.3</ix:nonFraction> million</span> in a sale to accredited investors (collectively, the &#8220;Series A Investors&#8221;)
of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240612__20240613__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zW2EOEk0MTQe" title="Stock issued new, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-06-122024-06-13_us-gaap_SeriesAPreferredStockMember" id="Fact001203" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,300</ix:nonFraction></span> shares of the Company&#8217;s series A preferred stock (the &#8220;Series A Preferred Stock&#8221;), at a purchase price of $1,000
per share, in a financing led by CJC Investment Trust, an entity controlled by board member Christopher Calise, in a combination of cash
and short- term collateralized promissory notes. The Series A Investors also received non-voting equity ownership interest in the Company&#8217;s
two newly formed subsidiaries, SNAP Biosciences Inc. and GEAR Therapeutics Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 31, 2024, the Company performed a second
closing as part of its series A preferred stock offering and raised $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_dm_c20240730__20240731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zivOXpFKQVF4" title="Proceeds from sale of preferred stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="From2024-07-302024-07-31_us-gaap_SeriesAPreferredStockMember" id="Fact001205" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">1.3</ix:nonFraction> million</span>, at a purchase price of $1,000 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 4, 2024, the Company performed a
third closing as part of its series A preferred stock offering and raised $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pp0p0_c20240903__20240904__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zLBMFtj9oSwj" title="Proceeds from sale of preferred stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="From2024-09-032024-09-04_us-gaap_SeriesAPreferredStockMember" id="Fact001207" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">225,000</ix:nonFraction></span>, at a purchase price of $1,000 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 23, 2024, the Company performed a
fourth closing as part of its series A preferred stock offering and raised $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pp0p0_c20241222__20241223__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zAgBsFtooT79" title="Proceeds from sale of preferred stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="From2024-12-222024-12-23_us-gaap_SeriesAPreferredStockMember" id="Fact001209" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">695,000</ix:nonFraction></span> at a purchase price of $1,000 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 6, 2025, the Company completed its
successful closure of the remaining $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_dm_c20250205__20250206__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z7CagD9Tdb2" title="Proceeds from sale of preferred stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="From2025-02-052025-02-06_us-gaap_SeriesAPreferredStockMember" id="Fact001211" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">3.48</ix:nonFraction> million</span>&#160;of its Series A preferred stock offering, completing the total $10.0 million financing
round.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 25, 2025, the Company and a holder of
its preferred stock, who is also a party to an existing consulting agreement with the Company, entered into an addendum to amend the terms
of the consulting arrangement. Under the amendment, the Company agreed to prepay the final six months of the consulting agreement by offsetting
the outstanding $<span id="xdx_90B_eus-gaap--StockholdersEquityNoteSubscriptionsReceivable_iI_c20250725__us-gaap--TransactionTypeAxis__custom--ConsultingAgreementMember_zWsV6rCeMNm3" title="Subscription receivable"><ix:nonFraction name="us-gaap:StockholdersEquityNoteSubscriptionsReceivable" contextRef="AsOf2025-07-25_custom_ConsultingAgreementMember" id="Fact001213" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></span> subscription receivable previously recorded from the shareholder. The prepayment will be amortized over the remaining
term of the consulting agreement as services are rendered, thereby reducing the subscription receivable balance over time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Throughout the year ended December 31, 2025, all
<span id="xdx_900_eus-gaap--ConversionOfStockSharesConverted1_c20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zYeEmoJaK3Rh" title="Conversion of stock, shares converted"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2025-01-012025-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact001215" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></span> series A preferred shares were converted to common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The series A investors currently have an aggregate
15% non-voting equity ownership interest in the Company&#8217;s two newly formed subsidiaries, SNAP Biosciences Inc. and GEAR Therapeutics
Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The key terms of the Series A Preferred Stock
are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Conversion.&#160;</i>Each share of Series A
Preferred Stock is convertible at the option of the holder, subject to the beneficial ownership and, if applicable, the primary market
limitations described below, into such number of shares of the Company&#8217;s common stock as is equal to the number of shares of Series
A Preferred Stock to be converted, multiplied by the stated value of $1,000 (the &#8220;Stated Value&#8221;), divided by the then conversion
price. The initial conversion price is $0.40 per share of common stock, subject to adjustment in the event of stock splits, stock dividends,
and similar transactions. In addition, the Series A Preferred Stock will automatically convert into shares of the Company&#8217;s common
stock, subject to the beneficial ownership and, if applicable, the primary market limitations described below upon the consummation of
a fundraising transaction in which the Company raises gross proceeds of at least $20&#160;million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Rank</i>. The Series A Preferred Stock will
be senior to the Company&#8217;s common stock and any other class of the Company&#8217;s capital stock that is not by its terms senior
to or pari passu with the Series A Preferred Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Dividends.&#160;</i>The holders of Series A
Preferred Stock will be entitled to dividends equal, on an as-if-converted to shares of the Company&#8217;s common stock basis (in each
case after applying the beneficial ownership and, if applicable, the primary market limitations described below), to and in the same form
as dividends actually paid on shares of the Company&#8217;s common stock when, as, and if such dividends are declared on shares of the
Company&#8217;s common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Liquidation.</i>&#160;In the event of any voluntary
or involuntary liquidation, dissolution or winding up of the Company, the holders of shares of Series A Preferred Stock then outstanding
will be entitled to be paid out of the assets of the Company available for distribution to its stockholders, before any payment shall
be made to the holders of the Company&#8217;s common stock by reason of their ownership thereof, an amount per share equal to the greater
of (i) the Stated Value, plus any dividends accrued but unpaid thereon, or (ii) such amount per share as would have been payable had all
shares of Series A Preferred Stock been converted (in each case after applying the beneficial ownership and, if applicable, the primary
market limitations described below) into the Company&#8217;s common stock immediately prior to such event.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Voting.&#160;</i>On any matter to be acted
upon or considered by the stockholders of the Company, each holder of Series A Preferred Stock shall be entitled to vote on an &#8220;as
converted&#8221; basis (after applying the beneficial ownership and primary market limitations described below).</p>

<ix:exclude><p id="xdx_238_zwxOPUovyG8g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_237_zCA81mL2zEZ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_236_zK10CpkJujk2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23C_z9dCC3miNij9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 77 -->
    <div id="xdx_23E_zcAlXBEbw5S8" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23F_zRj0UqzRCEmj" style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Beneficial Ownership Limitation.&#160;</i>The
Company will not affect any conversion of the Series A Preferred Stock, and a holder will not have the right to receive dividends or convert
any portion of its Series A Preferred Stock, to the extent that prior to the conversion such holder (together with such holder&#8217;s
affiliates, and any persons acting as a group together with such holder or any of the holder&#8217;s affiliates) beneficially owns less
than 20% of the Company&#8217;s outstanding common stock and, after giving effect to the receipt of dividends or the conversion, the holder
(together with such holder&#8217;s affiliates, and any persons acting as a group together with such holder or any of the holder&#8217;s
affiliates) would beneficially own 20% or more of the Company&#8217;s outstanding common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Exchange Limitation.</i>&#160;Unless the approval
of the Company&#8217;s stockholders is not required by the applicable rules of Nasdaq for issuances of the Company&#8217;s common stock
in excess of 19.99% of the outstanding common stock as of June 14, 2024 (the &#8220;Market Limit&#8221;), or unless the Company has obtained
such approval, the Company shall not affect any conversion of the Series A Preferred Stock, including, without limitation, any automatic
conversion, and a holder shall not have the right to receive dividends on or convert any portion of the Series A Preferred Stock, to the
extent that, after giving effect to the receipt of the Company&#8217;s common stock in connection with such dividends or conversion, the
holder would have received in excess of its pro rata share of the Market Limit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock Based Compensation &#8211;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A summary of the Company&#8217;s stock option activity is as follows:</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001221" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellspacing="0" cellpadding="0" summary="xdx: Disclosure - CAPITAL STRUCTURE (Details - Option activity)" id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zeakXLF5vY5j" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="display: none">Schedule of stock option activity</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td>
    <td><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Shares Underlying Options</b></span></td>
    <td><b>&#160;</b></td>
    <td><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted Average Exercise
    Price</b></span></td>
    <td><b>&#160;</b></td>
    <td><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted Average Contractual
    Life (Years)</b></span></td>
    <td><b>&#160;</b></td>
    <td><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Intrinsic Value</b></span></td>
    <td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Outstanding at December 31, 2023</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zAdqo9AwD0ml" title="Options outstanding, beginning" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31_custom_StockOptionsMember" id="Fact001223" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">87,875</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zdJHc0yuikK5" title="Weighted average exercise price, beginning balance outstanding" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_custom_StockOptionsMember" id="Fact001225" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">40.20</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zSCdNBLfZqn6" title="Weighted average contractual life (years), options outstanding"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_StockOptionsMember" format="ixt-sec:duryear" id="Fact001227" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.97</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 36%"><span style="font-size: 10pt">Granted</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zpzNcAhWG1Jk" title="Options granted" style="width: 13%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2024-01-012024-12-31_custom_StockOptionsMember206522468" id="Fact001229" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">196,750</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z46h2cts0dne" title="Weighted average exercise price, granted" style="width: 13%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31_custom_StockOptionsMember206522468" id="Fact001231" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.85</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2OptionsGranted_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zRou3ZT1jn8a" title="Weighted average contractual life (years), granted"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_StockOptionsMember206522468" format="ixt-sec:duryear" id="Fact001233" name="coep:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2OptionsGranted">10.00</ix:nonNumeric></span></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Forfeited</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zVU7qc8rEWfg" title="Options forfeited/expired" style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2024-01-012024-12-31_custom_StockOptionsMember206522468" id="Fact001235" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000</ix:nonFraction>)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zBrjwVoZ8iOh" title="Weighted average exercise price, forfeited/expired" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31_custom_StockOptionsMember206522468" id="Fact001237" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">200.00</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Exercised</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_d0_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zfXANZ7rjiO9" title="Options exercised" style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2024-01-012024-12-31_custom_StockOptionsMember206522468" id="Fact001239" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zzHQw19UCua6" title="Weighted average exercise price, exercised" style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31_custom_StockOptionsMember206522468" id="Fact001241" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8211;</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Outstanding at December 31, 2024</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zWYijifwwHj3" title="Options outstanding, beginning" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31_custom_StockOptionsMember" id="Fact001243" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">279,625</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zLUum3gcAUHg" title="Weighted average exercise price, beginning balance outstanding" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_custom_StockOptionsMember" id="Fact001245" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">15.29</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zdcJXeKn0NU8" title="Weighted average contractual life (years), options outstanding"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_StockOptionsMember206522468" format="ixt-sec:duryear" id="Fact001247" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.74</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_ztyMmW7ZFEb8" title="Options granted" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2025-01-012025-12-31_custom_StockOptionsMember206522468" id="Fact001249" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">187,375</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zIh031phyXP1" title="Weighted average exercise price, granted" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-012025-12-31_custom_StockOptionsMember206522468" id="Fact001251" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.96</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2OptionsGranted_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zUKJ0SCZtgD2" title="Weighted average contractual life (years), granted"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_StockOptionsMember206522468" format="ixt-sec:duryear" id="Fact001253" name="coep:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2OptionsGranted">5.20</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Forfeited</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z2gIUm4mfyJa" title="Options forfeited/expired" style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2025-01-012025-12-31_custom_StockOptionsMember206522468" id="Fact001255" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,000</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zRZ1TTo3Wyi1" title="Weighted average exercise price, forfeited/expired" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-012025-12-31_custom_StockOptionsMember206522468" id="Fact001257" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8211;</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Exercised</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_d0_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zuv8YlhRYPA2" title="Options exercised" style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2025-01-012025-12-31_custom_StockOptionsMember206522468" id="Fact001259" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zjJT6tT8gbql" title="Weighted average exercise price, exercised" style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-012025-12-31_custom_StockOptionsMember206522468" id="Fact001261" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8211;</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Outstanding at December 31, 2025</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z9ZXtWtL9N8f" title="Options outstanding, ending" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-12-31_custom_StockOptionsMember" id="Fact001263" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">437,000</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z9Dprg9sKBWk" title="Weighted average exercise price, ending balance outstanding" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-12-31_custom_StockOptionsMember" id="Fact001265" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.11</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zau0aOCg5xVf" title="Weighted average contractual life (years), options outstanding"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_StockOptionsMember206522468" format="ixt-sec:duryear" id="Fact001267" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.26</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zQA7SpV3vjH3" title="Intrinsic value, options outstanding" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2025-12-31_custom_StockOptionsMember" id="Fact001269" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,215,451</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A2_z77NwnJUTCla" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the years ended December 31, 2025 and 2024,
the Company recorded $<span id="xdx_907_eus-gaap--ShareBasedCompensation_pp0p0_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zZvNmgSsDP96" title="Share based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-012025-12-31_custom_StockOptionsMember206522468" id="Fact001271" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,215,692</ix:nonFraction> </span>and $<span id="xdx_903_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zOoW91DrAqOb" title="Share based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-12-31_custom_StockOptionsMember206522468" id="Fact001273" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,104,978</ix:nonFraction></span>, respectively, for stock based compensation expense related to stock options. As of December
31, 2025, unamortized stock based compensation for stock options was $<span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pp0p0_c20251231_zumQMdiNNPB9" title="Unamortized stock-based compensation"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2025-12-31" id="Fact001275" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">918,681</ix:nonFraction></span> to be recognized through December 31, 2027.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The options granted during the years ended December
31, 2025 and 2024 were valued using the Black-Scholes option pricing model using the following weighted average assumptions:</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001277" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><table cellspacing="0" cellpadding="0" summary="xdx: Disclosure - CAPITAL STRUCTURE (Details - Weighted average assumptions)" id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zuN6cUYSbiP7" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BC_zoaWrx1wddF1" style="display: none">Schedule of weighted average assumptions</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td>
    <td><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>For the years ended December
    31,</b></span></td>
    <td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td>
    <td><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2025</b></span></td>
    <td><b>&#160;</b></td>
    <td><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2024</b></span></td>
    <td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 60%"><span style="font-size: 10pt">Expected term, in years</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 16%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zb44d3yrl74g" title="Expected term, in years"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_StockOptionsMember206522468" format="ixt-sec:duryear" id="Fact001279" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">2.75</ix:nonNumeric></span></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 16%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zZNgltc1r60k" title="Expected term, in years"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_StockOptionsMember206522468" format="ixt-sec:duryear" id="Fact001281" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.25</ix:nonNumeric></span></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Expected volatility</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zATDT3E1qOxg" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2025-01-012025-12-31_custom_StockOptionsMember206522468" id="Fact001283" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">75.58</ix:nonFraction></span>%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zrS3qLfbf3pa" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-01-012024-12-31_custom_StockOptionsMember206522468" id="Fact001285" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">84.70</ix:nonFraction></span>%</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Risk-free interest rate</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zb3GaOUmKtDf" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2025-01-012025-12-31_custom_StockOptionsMember206522468" id="Fact001287" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.89</ix:nonFraction></span>%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zCZ2RKkQVEIk" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-012024-12-31_custom_StockOptionsMember206522468" id="Fact001289" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.18</ix:nonFraction></span>%</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Dividend yield</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zte09OWFCb2c" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2025-01-012025-12-31_custom_StockOptionsMember206522468" id="Fact001291" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8211;</ix:nonFraction></span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z2QN4EoyzZ71" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2024-01-012024-12-31_custom_StockOptionsMember206522468" id="Fact001293" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8211;</ix:nonFraction></span></span></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A2_zctNFre0IfR1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Options/Stock Awards Forfeited &#8211; </b>On
March 24, 2025, Colleen Delaney, Chief Scientific and Medical Officer, resigned her position for a reason other than cause. Per the Plan,
her unvested stock options (<span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_c20250323__20250324__srt--CounterpartyNameAxis__custom--ColleenDelaneyMember_z2YDHtKmADQ" title="Number of shares forfeited"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" contextRef="From2025-03-232025-03-24_custom_ColleenDelaneyMember" id="Fact001295" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">27,500</ix:nonFraction></span>) were immediately forfeited and go back into the Plan. Her vested stock options (<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20250324__srt--CounterpartyNameAxis__custom--ColleenDelaneyMember_zui5gilCeOfd" title="Number of shares exercised"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="AsOf2025-03-24_custom_ColleenDelaneyMember" id="Fact001297" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,500</ix:nonFraction></span>) were eligible
to be exercised for three months following her resignation (by June 24, 2025). As of December 31, 2025, all of her stock options are forfeited,
and the <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20250101__20251231__srt--CounterpartyNameAxis__custom--ColleenDelaneyMember_zZhWqKK4VJb5" title="Number of shares expired"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2025-01-012025-12-31_custom_ColleenDelaneyMember" id="Fact001299" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,500</ix:nonFraction></span> vested options are expired.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Modification of Options &#8211; </b>On December
31, 2025 the Company and the holder of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20251201__20251231__us-gaap--PlanNameAxis__custom--ModificationOfOptionsMember_zW3LA3KWVXU8" title="Options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2025-12-012025-12-31_custom_ModificationOfOptionsMember" id="Fact001301" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span> of the Company&#8217;s options (the &#8220;Modified Options&#8221;) agreed to amend the
terms of the holder&#8217;s options extending the maturity date to January 20, 2026, from the original maturity date of January 5, 2026.
There were no other changes to the terms of the Modified Options. The amendment qualified as a &#8220;Type I&#8221; modification as the
Modified Options were vested immediately prior to the amendment and immediately after the amendment. As a result of the amendment, the
Company recognized additional stock compensation expense of $<span id="xdx_908_eus-gaap--ShareBasedCompensation_c20251201__20251231__us-gaap--PlanNameAxis__custom--ModificationOfOptionsMember_z2Jhgq4f67Tg" title="Stock compensation expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-12-012025-12-31_custom_ModificationOfOptionsMember" id="Fact001303" format="ixt:numdotdecimal" decimals="0" unitRef="USD">870</ix:nonFraction></span> for the incremental change in fair value immediately before the modification
and immediately after the modification.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_234_zUUSK5CZPQKj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23B_zFLjwhjzmKxb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23F_z2GDNdhua8k7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 78; Value: 1 -->
    <div id="xdx_237_zNhUj5qam3uf" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23F_zCEY3fI3YIx3" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23E_zdfhFWnZnFca" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Common Stock Warrants&#160;</b>&#8211; On November
23, 2020, Coeptis Therapeutics, Inc. (under its prior name Vinings Holdings Inc.) issued a class A and a class B warrant to Coral Investment
Partners, LP (&#8220;CIP&#8221;), with each warrant granting CIP the right to purchase <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20201123__srt--CounterpartyNameAxis__custom--CoralInvestmentPartnersMember_zYZicBAPV7gh" title="Warrants outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2020-11-23_custom_CoralInvestmentPartnersMember" id="Fact001309" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span> shares of common stock at a price of
$<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201123__srt--CounterpartyNameAxis__custom--CoralInvestmentPartnersMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_pdd" title="Exercise price of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-11-23_custom_CoralInvestmentPartnersMember_us-gaap_CommonClassAMember" id="Fact001311" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">40.00</ix:nonFraction></span> for Class A or $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201123__srt--CounterpartyNameAxis__custom--CoralInvestmentPartnersMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_pdd" title="Exercise price of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-11-23_custom_CoralInvestmentPartnersMember_us-gaap_CommonClassBMember" id="Fact001313" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">100.00</ix:nonFraction></span> for Class B. The warrants expired on November 30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All common stock warrants outstanding, are listed
in the table below:</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001315" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><table cellspacing="0" cellpadding="0" summary="xdx: Disclosure - CAPITAL STRUCTURE (Details - Warrants outstanding)" id="xdx_89B_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zvnvizl0Zhh7" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt; color: White"><span id="xdx_8B7_zOdJkpwSXipd" style="display: none">Schedule of warrants outstanding</span></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt"><b>Reference</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Date</b></span><br/>
<span style="font-size: 10pt"><b>Issued</b></span></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Exercise</b></span><br/>
<span style="font-size: 10pt"><b>Price</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Expiration</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Outstanding at December 31,</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.75pt; text-align: center"><b>2025</b></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Outstanding at<br/>
    December 31,</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024</b></p></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 36%; text-align: justify"><span style="font-size: 10pt">Warrant Holder 1</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center"><span style="font-size: 10pt"><span id="xdx_909_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice59.40Member_zhPQKk5yNNMk" title="Date Issued"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantHolder1ExercisePrice59.40Member" format="ixt:datemonthdayyear" id="Fact001317" name="coep:WarrantsAndRightsOutstandingDateIssued">5/28/2021</ix:nonNumeric></span></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice59.40Member_zXRPOT9rhVG2" title="Warrants exercise price" style="width: 10%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_WarrantHolder1ExercisePrice59.40Member" id="Fact001319" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">59.40</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice59.40Member_zItdhyrT2Pk5" title="Expiration"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_WarrantHolder1ExercisePrice59.40Member" format="ixt:datemonthdayyear" id="Fact001321" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">5/13/2026</ix:nonNumeric></span></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice59.40Member_zqqHvnVaQLHh" title="Warrants outstanding" style="width: 10%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_WarrantHolder1ExercisePrice59.40Member" id="Fact001323" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,380</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice59.40Member_zMeNZng40tdb" title="Warrants outstanding" style="width: 10%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_WarrantHolder1ExercisePrice59.40Member" id="Fact001325" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,380</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Warrant Holder 1</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90C_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice118.80Member_zwQ5pwjwGMSf" title="Date Issued"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantHolder1ExercisePrice118.80Member" format="ixt:datemonthdayyear" id="Fact001327" name="coep:WarrantsAndRightsOutstandingDateIssued">5/28/2021</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice118.80Member_z4JELrJ017Xg" title="Warrants exercise price" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_WarrantHolder1ExercisePrice118.80Member" id="Fact001329" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">118.80</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice118.80Member_zv54vjEcUlni" title="Expiration"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_WarrantHolder1ExercisePrice118.80Member" format="ixt:datemonthdayyear" id="Fact001331" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">5/13/2026</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice118.80Member_zuIBsbFjCHNb" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_WarrantHolder1ExercisePrice118.80Member" id="Fact001332" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,422</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice118.80Member_zLlnDfHxGkke" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_WarrantHolder1ExercisePrice118.80Member" id="Fact001333" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,422</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Warrant Holder 1</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_900_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice296.80Member_zbAD3QgR0aE4" title="Date Issued"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantHolder1ExercisePrice296.80Member" format="ixt:datemonthdayyear" id="Fact001335" name="coep:WarrantsAndRightsOutstandingDateIssued">5/28/2021</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice296.80Member_zdOUYST0KBDk" title="Warrants exercise price" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_WarrantHolder1ExercisePrice296.80Member" id="Fact001337" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">296.80</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice296.80Member_zNWSeKS6l3J7" title="Expiration"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_WarrantHolder1ExercisePrice296.80Member" format="ixt:datemonthdayyear" id="Fact001339" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">5/13/2026</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice296.80Member_zicjK4torz8d" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_WarrantHolder1ExercisePrice296.80Member" id="Fact001340" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,422</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice296.80Member_ze7554J93sG3" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_WarrantHolder1ExercisePrice296.80Member" id="Fact001341" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,422</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Warrant Holder 2</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_902_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice59.40Member_z6Pz0tB8cFb1" title="Date Issued"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantHolder2ExercisePrice59.40Member" format="ixt:datemonthdayyear" id="Fact001343" name="coep:WarrantsAndRightsOutstandingDateIssued">7/30/2021</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice59.40Member_zXxLcYdy4V6g" title="Warrants exercise price" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_WarrantHolder2ExercisePrice59.40Member" id="Fact001345" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">59.40</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice59.40Member_zwxyj4u9O5Hk" title="Expiration"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_WarrantHolder2ExercisePrice59.40Member" format="ixt:datemonthdayyear" id="Fact001347" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">7/30/2026</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice59.40Member_zv1MnhCveYy2" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_WarrantHolder2ExercisePrice59.40Member" id="Fact001348" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">421</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice59.40Member_zTaTaGqLB7d7" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_WarrantHolder2ExercisePrice59.40Member" id="Fact001349" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">421</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Warrant Holder 2</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_905_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice296.80Member_z690toHMvrid" title="Date Issued"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantHolder2ExercisePrice296.80Member" format="ixt:datemonthdayyear" id="Fact001351" name="coep:WarrantsAndRightsOutstandingDateIssued">7/30/2021</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice296.80Member_zDVj61xqGm38" title="Warrants exercise price" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_WarrantHolder2ExercisePrice296.80Member" id="Fact001353" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">296.80</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice296.80Member_zuFNtTWa4Zk6" title="Expiration"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_WarrantHolder2ExercisePrice296.80Member" format="ixt:datemonthdayyear" id="Fact001355" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">6/1/2026</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice296.80Member_z7qV2GpL182j" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_WarrantHolder2ExercisePrice296.80Member" id="Fact001356" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,263</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice296.80Member_znkkujrqPZG" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_WarrantHolder2ExercisePrice296.80Member" id="Fact001357" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,263</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Warrant Holder 5</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90C_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder5ExercisePrice59.40Member_zT6nUYfMeP8k" title="Date Issued"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantHolder5ExercisePrice59.40Member" format="ixt:datemonthdayyear" id="Fact001359" name="coep:WarrantsAndRightsOutstandingDateIssued">12/20/2021</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder5ExercisePrice59.40Member_zEtq2QA2hzde" title="Warrants exercise price" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_WarrantHolder5ExercisePrice59.40Member" id="Fact001361" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">59.40</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder5ExercisePrice59.40Member_zHVEKXVm7j4d" title="Expiration"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_WarrantHolder5ExercisePrice59.40Member" format="ixt:datemonthdayyear" id="Fact001363" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">12/20/2026</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder5ExercisePrice59.40Member_zMO86NMJ8vVj" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_WarrantHolder5ExercisePrice59.40Member" id="Fact001364" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,948</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder5ExercisePrice59.40Member_zThs8fw5UFB4" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_WarrantHolder5ExercisePrice59.40Member" id="Fact001365" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,948</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Warrant Holder 18</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_909_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder18ExercisePrice178.20Member_zdbqLVXtpkh5" title="Date Issued"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantHolder18ExercisePrice178.20Member" format="ixt:datemonthdayyear" id="Fact001367" name="coep:WarrantsAndRightsOutstandingDateIssued">3/30/2022</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder18ExercisePrice178.20Member_zMNZCepjwXD5" title="Warrants exercise price" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_WarrantHolder18ExercisePrice178.20Member" id="Fact001369" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">178.20</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder18ExercisePrice178.20Member_zsyqR9n0P2te" title="Expiration"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_WarrantHolder18ExercisePrice178.20Member" format="ixt:datemonthdayyear" id="Fact001371" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">3/30/2025</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_d0_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder18ExercisePrice178.20Member_zDIvnpeWio7k" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_WarrantHolder18ExercisePrice178.20Member" id="Fact001372" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction> </span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder18ExercisePrice178.20Member_zJHbtgaG073a" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_WarrantHolder18ExercisePrice178.20Member" id="Fact001373" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,211</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Warrant Holder 20</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_906_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder20ExercisePrice50.00Member_z4C62Tx4YpMa" title="Date Issued"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantHolder20ExercisePrice50.00Member" format="ixt:datemonthdayyear" id="Fact001375" name="coep:WarrantsAndRightsOutstandingDateIssued">1/3/2023</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder20ExercisePrice50.00Member_z4lymClWNjb" title="Warrants exercise price" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_WarrantHolder20ExercisePrice50.00Member" id="Fact001377" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">50.00</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder20ExercisePrice50.00Member_zREA6mmTF107" title="Expiration"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_WarrantHolder20ExercisePrice50.00Member" format="ixt:datemonthdayyear" id="Fact001379" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">1/2/2027</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder20ExercisePrice50.00Member_zkNNxOL1MChg" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_WarrantHolder20ExercisePrice50.00Member" id="Fact001380" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder20ExercisePrice50.00Member_zQvBo3JQxaJk" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_WarrantHolder20ExercisePrice50.00Member" id="Fact001381" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Warrant Holder 21</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_902_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder21ExercisePrice38.00Member_zsy504HlvDYj" title="Date Issued"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantHolder21ExercisePrice38.00Member" format="ixt:datemonthdayyear" id="Fact001383" name="coep:WarrantsAndRightsOutstandingDateIssued">1/20/2023</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder21ExercisePrice38.00Member_zJFT8AGk3jGi" title="Warrants exercise price" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_WarrantHolder21ExercisePrice38.00Member" id="Fact001385" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">38.00</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder21ExercisePrice38.00Member_zBpFYBBVNXfb" title="Expiration"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_WarrantHolder21ExercisePrice38.00Member" format="ixt:datemonthdayyear" id="Fact001387" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">1/19/2027</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder21ExercisePrice38.00Member_zgcVAlGQV2m" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_WarrantHolder21ExercisePrice38.00Member" id="Fact001388" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,500</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder21ExercisePrice38.00Member_zw9jDPiB7KIc" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_WarrantHolder21ExercisePrice38.00Member" id="Fact001389" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,500</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Series A &amp; B Warrants</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_902_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesWarrantsAAndBExercisePrice27.20Member_zMLfl9kgCStk" title="Date Issued"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_SeriesWarrantsAAndBExercisePrice27.20Member" format="ixt:datemonthdayyear" id="Fact001391" name="coep:WarrantsAndRightsOutstandingDateIssued">6/16/2023</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesWarrantsAAndBExercisePrice27.20Member_zLGVuKEypFSe" title="Warrants exercise price" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_SeriesWarrantsAAndBExercisePrice27.20Member" id="Fact001393" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">27.20</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesWarrantsAAndBExercisePrice27.20Member_zWiQfQC8nAFk" title="Expiration"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_SeriesWarrantsAAndBExercisePrice27.20Member" format="ixt:datemonthdayyear" id="Fact001395" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">12/16/2028</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesWarrantsAAndBExercisePrice27.20Member_zGX16nfpzMfl" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_SeriesWarrantsAAndBExercisePrice27.20Member" id="Fact001396" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">306,250</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesWarrantsAAndBExercisePrice27.20Member_zMcpzrvKYNle" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_SeriesWarrantsAAndBExercisePrice27.20Member" id="Fact001397" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">306,250</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Series A Warrants</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_900_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsExercisePrice27.20Member_zUBMb8E7p44l" title="Date Issued"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_SeriesAWarrantsExercisePrice27.20Member" format="ixt:datemonthdayyear" id="Fact001399" name="coep:WarrantsAndRightsOutstandingDateIssued">10/23/2023</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsExercisePrice27.20Member_zaQRKQLtGKXi" title="Warrants exercise price" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_SeriesAWarrantsExercisePrice27.20Member" id="Fact001401" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">27.20</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsExercisePrice27.20Member_zJXfhF99xYw1" title="Expiration"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_SeriesAWarrantsExercisePrice27.20Member" format="ixt:datemonthdayyear" id="Fact001403" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">4/26/2025</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_d0_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsExercisePrice27.20Member_zGRBcCqmET71" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_SeriesAWarrantsExercisePrice27.20Member" id="Fact001404" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsExercisePrice27.20Member_zpQbIWGokML1" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_SeriesAWarrantsExercisePrice27.20Member" id="Fact001405" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Series B Warrants</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_907_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsExercisePrice27.20Member_z8vzypLgPvNg" title="Date Issued"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_SeriesBWarrantsExercisePrice27.20Member" format="ixt:datemonthdayyear" id="Fact001407" name="coep:WarrantsAndRightsOutstandingDateIssued">10/23/2023</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsExercisePrice27.20Member_zrXhgXeYRGTb" title="Warrants exercise price" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_SeriesBWarrantsExercisePrice27.20Member" id="Fact001409" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">27.20</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsExercisePrice27.20Member_zB1dVGnt8dP" title="Expiration"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_SeriesBWarrantsExercisePrice27.20Member" format="ixt:datemonthdayyear" id="Fact001411" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">4/26/2029</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsExercisePrice27.20Member_zrOAXCQY9kde" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_SeriesBWarrantsExercisePrice27.20Member" id="Fact001412" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsExercisePrice27.20Member_z4HshTcVMa75" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_SeriesBWarrantsExercisePrice27.20Member" id="Fact001413" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Warrant Holder 22</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_908_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice25.00Member_zDAEgsAil3ci" title="Date Issued"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantHolder22ExercisePrice25.00Member" format="ixt:datemonthdayyear" id="Fact001415" name="coep:WarrantsAndRightsOutstandingDateIssued">6/16/2023</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice25.00Member_zapMylA94m4f" title="Warrants exercise price" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_WarrantHolder22ExercisePrice25.00Member" id="Fact001417" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">25.00</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice25.00Member_z6Y6AUE9a7ue" title="Expiration"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_WarrantHolder22ExercisePrice25.00Member" format="ixt:datemonthdayyear" id="Fact001419" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">12/16/2028</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice25.00Member_zb9yirJ8v3Vc" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_WarrantHolder22ExercisePrice25.00Member" id="Fact001420" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,300</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice25.00Member_zA7gNTIgnKT8" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_WarrantHolder22ExercisePrice25.00Member" id="Fact001421" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,300</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Warrant Holder 22</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_902_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice28.00Member_zcptOzx2hAb3" title="Date Issued"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantHolder22ExercisePrice28.00Member" format="ixt:datemonthdayyear" id="Fact001423" name="coep:WarrantsAndRightsOutstandingDateIssued">10/23/2023</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice28.00Member_z4ubQZlsp0D7" title="Warrants exercise price" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_WarrantHolder22ExercisePrice28.00Member" id="Fact001425" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">28.00</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice28.00Member_zCFwpGSZBYI" title="Expiration"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_WarrantHolder22ExercisePrice28.00Member" format="ixt:datemonthdayyear" id="Fact001427" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">4/26/2029</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice28.00Member_zpzv0wMqgij7" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_WarrantHolder22ExercisePrice28.00Member" id="Fact001428" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,300</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice28.00Member_zD9mQorT6WC5" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_WarrantHolder22ExercisePrice28.00Member" id="Fact001429" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,300</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Warrant Holder 23</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_903_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice25.00Member_zdmKFPOfEsUk" title="Date Issued"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantHolder23ExercisePrice25.00Member" format="ixt:datemonthdayyear" id="Fact001431" name="coep:WarrantsAndRightsOutstandingDateIssued">6/16/2023</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice25.00Member_zsMDcc2OfNCf" title="Warrants exercise price" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_WarrantHolder23ExercisePrice25.00Member" id="Fact001433" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">25.00</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice25.00Member_zLuijdsruMf3" title="Expiration"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_WarrantHolder23ExercisePrice25.00Member" format="ixt:datemonthdayyear" id="Fact001435" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">12/16/2028</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice25.00Member_zCv7ZcFGFdl7" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_WarrantHolder23ExercisePrice25.00Member" id="Fact001436" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,200</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice25.00Member_zpw43IQxFYHe" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_WarrantHolder23ExercisePrice25.00Member" id="Fact001437" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,200</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Warrant Holder 23</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90A_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice28.00Member_z1fPzyMwcz27" title="Date issued"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantHolder23ExercisePrice28.00Member" format="ixt:datemonthdayyear" id="Fact001439" name="coep:WarrantsAndRightsOutstandingDateIssued">10/23/2023</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice28.00Member_z8FMtTy84jFb" title="Warrants exercise price" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_WarrantHolder23ExercisePrice28.00Member" id="Fact001441" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">28.00</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice28.00Member_zuWoZMkqoZ86" title="Expiration"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_WarrantHolder23ExercisePrice28.00Member" format="ixt:datemonthdayyear" id="Fact001443" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">4/26/2029</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice28.00Member_zkTrqhzVQeMk" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_WarrantHolder23ExercisePrice28.00Member" id="Fact001444" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,400</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice28.00Member_zlqY2DWKR1xi" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_WarrantHolder23ExercisePrice28.00Member" id="Fact001445" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,400</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Warrant Holder 24</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_903_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder24ExercisePrice28.00Member_zbZ5N7Nh6Cij" title="Date Issued"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantHolder24ExercisePrice28.00Member" format="ixt:datemonthdayyear" id="Fact001447" name="coep:WarrantsAndRightsOutstandingDateIssued">10/23/2023</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder24ExercisePrice28.00Member_zZzUb33gVac4" title="Warrants exercise price" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_WarrantHolder24ExercisePrice28.00Member" id="Fact001449" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">28.00</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder24ExercisePrice28.00Member_z1Up8he4rQi" title="Expiration"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_WarrantHolder24ExercisePrice28.00Member" format="ixt:datemonthdayyear" id="Fact001451" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">4/26/2029</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder24ExercisePrice28.00Member_z8anOUPcCnY6" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_WarrantHolder24ExercisePrice28.00Member" id="Fact001452" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">300</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder24ExercisePrice28.00Member_z4NcvcfmZ9H9" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_WarrantHolder24ExercisePrice28.00Member" id="Fact001453" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">300</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-Funded Warrants 2</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_905_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants2ExercisePrice0.002Member_zhbhDan1TPKg" title="Date Issued"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_PreFundedWarrants2ExercisePrice0.002Member" format="ixt:datemonthdayyear" id="Fact001455" name="coep:WarrantsAndRightsOutstandingDateIssued">12/28/2023</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants2ExercisePrice0.002Member_zH4g4amW63P5" title="Warrants exercise price" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_PreFundedWarrants2ExercisePrice0.002Member" id="Fact001457" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.002</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_d0_c20251231__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants2ExercisePrice0.002Member_zyPGcOuPPzge" title="Warrants outstanding" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_PreFundedWarrants2ExercisePrice0.002Member" id="Fact001459" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants2ExercisePrice0.002Member_zlgnxgIcCyKk" title="Warrants outstanding" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_PreFundedWarrants2ExercisePrice0.002Member" id="Fact001461" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-Funded Warrants 3</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_909_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants3ExercisePrice0.002Member_zbmqhDS6Sn67" title="Date issued"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_PreFundedWarrants3ExercisePrice0.002Member" format="ixt:datemonthdayyear" id="Fact001463" name="coep:WarrantsAndRightsOutstandingDateIssued">2/8/2024</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants3ExercisePrice0.002Member_z3kTd4B1x6h3" title="Warrants exercise price" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_PreFundedWarrants3ExercisePrice0.002Member" id="Fact001465" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.002</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_d0_c20251231__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants3ExercisePrice0.002Member_z1cKT9UR11l8" title="Warrants outstanding" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_PreFundedWarrants3ExercisePrice0.002Member" id="Fact001467" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants3ExercisePrice0.002Member_z2Qivc5Euhae" title="Warrants outstanding" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_PreFundedWarrants3ExercisePrice0.002Member" id="Fact001469" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">300,000</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Warrant Holder 25</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_903_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder25ExercisePrice12.00Member_z3hcmuuDwXi9" title="Date Issued"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantHolder25ExercisePrice12.00Member" format="ixt:datemonthdayyear" id="Fact001471" name="coep:WarrantsAndRightsOutstandingDateIssued">1/20/2025</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder25ExercisePrice12.00Member_zuQsgwAp9Ea1" title="Warrants exercise price" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_WarrantHolder25ExercisePrice12.00Member" id="Fact001473" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.00</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder25ExercisePrice12.00Member_z8bA0x6c1Lti" title="Expiration"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_WarrantHolder25ExercisePrice12.00Member" format="ixt:datemonthdayyear" id="Fact001475" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">1/20/2030</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder25ExercisePrice12.00Member_zGElVEDbXJt5" style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_WarrantHolder25ExercisePrice12.00Member" id="Fact001476" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_d0_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder25ExercisePrice12.00Member_z3UtJJ43UWI2" style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_WarrantHolder25ExercisePrice12.00Member" id="Fact001477" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td colspan="10" style="text-align: center"><span style="font-size: 10pt"><b>Total Warrants outstanding</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231_zqQPGJsI8HJ5" title="Total warrants outstanding" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><b><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31" id="Fact001479" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">570,105</ix:nonFraction></b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231_zhrYnAzD8ZSl" title="Total warrants outstanding" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><b><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31" id="Fact001481" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,024,316</ix:nonFraction></b></span></td>
    <td>&#160;</td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; padding-left: 10pt; text-indent: -0.01pt; width: 3%">*</td>
  <td style="text-align: justify; padding-left: 10pt; text-indent: -0.01pt; width: 97%">Pre-funded warrants, do not expire.</td></tr>
</table>


</ix:nonNumeric><p id="xdx_8AE_zp7T0FRyrNx" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Subscription receivable </b>&#8211; In
September 2023, the Company agreed to issue <span id="xdx_909_ecustom--StockIssuedForDebtShares_c20230901__20230930__us-gaap--FinancialInstrumentAxis__custom--SubscriptionReceivableSept2023Member_z4pE76mXRUO8" title="Stock issued for debt, shares"><ix:nonFraction name="coep:StockIssuedForDebtShares" contextRef="From2023-09-012023-09-30_custom_SubscriptionReceivableSept2023Member" id="Fact001483" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span>
shares of common stock to the borrower for a principal sum amount of $<span id="xdx_906_ecustom--StockIssuedForDebtValue_pp0p0_c20230901__20230930__us-gaap--FinancialInstrumentAxis__custom--SubscriptionReceivableSept2023Member_zPr72zVmmrNk" title="Stock issued for debt, value"><ix:nonFraction name="coep:StockIssuedForDebtValue" contextRef="From2023-09-012023-09-30_custom_SubscriptionReceivableSept2023Member" id="Fact001485" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">500,000</ix:nonFraction></span>.
On August 12, 2024, the Company was transferred and assigned $522,667, the sum of principal and accrued interest owed as of June 30,
2024, of shares of common stock in a privately held company by the third-party borrower. As a result of this assignment agreement,
the subscription receivable is paid in full, and $<span id="xdx_908_eus-gaap--Investments_iI_pp0p0_c20251231__us-gaap--FinancialInstrumentAxis__custom--SubscriptionReceivableSept2023Member_zL23KwfnqPm1" title="Investments"><span id="xdx_901_eus-gaap--Investments_iI_pp0p0_c20241231__us-gaap--FinancialInstrumentAxis__custom--SubscriptionReceivableSept2023Member_zor73S13jMJh"><ix:nonFraction name="us-gaap:Investments" contextRef="AsOf2025-12-31_custom_SubscriptionReceivableSept2023Member" id="Fact001487" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:Investments" contextRef="AsOf2024-12-31_custom_SubscriptionReceivableSept2023Member" id="Fact001488" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">522,667</ix:nonFraction></ix:nonFraction></span></span>
is recorded as an investment at December 31, 2025 and December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2023, the Company agreed to issue&#160;<span id="xdx_90F_ecustom--StockIssuedForDebtShares_c20230901__20230930__us-gaap--FinancialInstrumentAxis__custom--SubscriptionReceivableSept20232ndMember_zvOdA2fkQLLg" title="Stock issued for debt, shares"><ix:nonFraction name="coep:StockIssuedForDebtShares" contextRef="From2023-09-012023-09-30_custom_SubscriptionReceivableSept20232ndMember" id="Fact001490" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span>
shares of common stock to the borrower for a principal sum amount of $<span id="xdx_90C_ecustom--StockIssuedForDebtValue_pp0p0_c20230901__20230930__us-gaap--FinancialInstrumentAxis__custom--SubscriptionReceivableSept20232ndMember_zsqPKzBRNZt2" title="Stock issued for debt, value"><ix:nonFraction name="coep:StockIssuedForDebtValue" contextRef="From2023-09-012023-09-30_custom_SubscriptionReceivableSept20232ndMember" id="Fact001492" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,000,000</ix:nonFraction></span>. On August 12, 2024, the Company was transferred and assigned
$2,090,667, the sum of principal and accrued interest owed, of shares of common stock in a privately held company by the third-party borrower.
As a result of this assignment agreement, the subscription receivable is paid in full, and $<span id="xdx_901_eus-gaap--Investments_iI_pp0p0_c20251231__us-gaap--FinancialInstrumentAxis__custom--SubscriptionReceivableSept20232ndMember_zyXvPYeo3lG4" title="Investments"><span id="xdx_90B_eus-gaap--Investments_iI_pp0p0_c20241231__us-gaap--FinancialInstrumentAxis__custom--SubscriptionReceivableSept20232ndMember_zmBVyg52wbFi" title="Investments"><ix:nonFraction name="us-gaap:Investments" contextRef="AsOf2025-12-31_custom_SubscriptionReceivableSept20232ndMember" id="Fact001494" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:Investments" contextRef="AsOf2024-12-31_custom_SubscriptionReceivableSept20232ndMember" id="Fact001496" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,090,667</ix:nonFraction></ix:nonFraction></span></span> is recorded as an investment at
December 31, 2025 and December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2023, the Company agreed to
grant pre-funded warrants exercisable to acquire up to 60,000 shares of common stock to the borrower for a principal sum amount of
$1,000,000. During the first quarter of 2024, the Company and the third-party borrower agreed to amend the note as a result of the
decline in the publicly traded common stock price. The amount of pre-funded warrants exercisable to acquire up to 60,000 shares of
common stock was amended to <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240331__us-gaap--FinancialInstrumentAxis__custom--December2023FinancingMember_zty7svcEEie" title="Warrants issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-03-31_custom_December2023FinancingMember" id="Fact001498" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span>
shares of common stock, and the total principal balance of the note agreement was increased from $1,000,000 to $1,100,000. On August
12, 2024, the Company was transferred and assigned $1,132,869, the sum of principal and accrued interest owed, of shares of common
stock in a privately held company by the third-party borrower. As a result of this assignment agreement, the subscription receivable
is paid in full, and $<span id="xdx_905_eus-gaap--Investments_iI_pp0p0_c20251231__us-gaap--FinancialInstrumentAxis__custom--December2023FinancingMember_zfD2aBz9sb8d" title="Investments"><span id="xdx_900_eus-gaap--Investments_iI_pp0p0_c20241231__us-gaap--FinancialInstrumentAxis__custom--December2023FinancingMember_z6VMIe1QQZzf"><ix:nonFraction name="us-gaap:Investments" contextRef="AsOf2025-12-31_custom_December2023FinancingMember" id="Fact001500" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:Investments" contextRef="AsOf2024-12-31_custom_December2023FinancingMember" id="Fact001501" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,132,869</ix:nonFraction></ix:nonFraction></span></span>
is recorded as an investment at December 31, 2025 and December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23E_zbr5DzI7KNqk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23E_zuKLkJstbGx7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23B_zUp2lt0LNJ52" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 79; Value: 1 -->
    <div id="xdx_23D_z25clTC4pL6e" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_239_zEjeMCA11Ip6" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_zLMam2kj9Pe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2024, the Company agreed to grant
pre-funded warrants exercisable to acquire up to <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240228__us-gaap--FinancialInstrumentAxis__custom--February2024FinancingMember_zTNKfJN6quX9"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-02-28_custom_February2024FinancingMember" id="Fact001506" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000</ix:nonFraction></span> shares of common stock to the borrower for a principal sum amount of $1,900,000.
On August 12, 2024, the Company was transferred and assigned $1,944,879, the sum of principal and accrued interest owed, of shares of
common stock in a privately held company by the third-party borrower. As a result of this assignment agreement, the subscription receivable
is paid in full, and $<span id="xdx_90A_eus-gaap--Investments_iI_pp0p0_c20251231__us-gaap--FinancialInstrumentAxis__custom--February2024FinancingMember_zknFlblVQSf6" title="Investments"><span id="xdx_90E_eus-gaap--Investments_iI_pp0p0_c20241231__us-gaap--FinancialInstrumentAxis__custom--February2024FinancingMember_z2rrE8IEsIpl"><ix:nonFraction name="us-gaap:Investments" contextRef="AsOf2025-12-31_custom_February2024FinancingMember" id="Fact001508" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:Investments" contextRef="AsOf2024-12-31_custom_February2024FinancingMember" id="Fact001509" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,944,879</ix:nonFraction></ix:nonFraction></span></span> is recorded as an investment at December 31, 2025 and December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2024, in connection with the Company&#8217;s
series A preferred stock offering, the Company closed on subscription agreements totaling $2,100,000 due to the Company on February 28,
2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the second quarter of 2025, the Company
collected $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_c20250101__20250630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zxGUCspp6Czj" title="Proceeds from issuance of preferred stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" contextRef="From2025-01-012025-06-30_us-gaap_SeriesAPreferredStockMember" id="Fact001511" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></span> of outstanding subscription receivable resulting from one Series A preferred stock subscription agreement. At June
30, 2025, the Company had recorded subscription receivable of $<span id="xdx_903_eus-gaap--PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable_iI_pp0p0_c20250630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zFGsyJxR8NBf" title="Subscription receivable"><ix:nonFraction name="us-gaap:PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable" contextRef="AsOf2025-06-30_us-gaap_SeriesAPreferredStockMember" id="Fact001513" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">125,000</ix:nonFraction></span> resulting from the final Series A preferred stock subscription
agreement where preferred shares have been issued as part of the February 6, 2025 closing. In connection with this subscription receivable,
the Company and the investor agreed to satisfy the subscription as prepayment of the final six months of the consulting contract between
both parties. The subscription receivable is being amortized through the end of June 2026 as professional services expense.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the third quarter of 2025, in connection
with the Company&#8217;s private placement offering, the Company recorded $<span id="xdx_904_ecustom--SubscriptionsReceivable_c20250701__20250930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zbbUViUJCPR9" title="Subscriptions receivable"><ix:nonFraction name="coep:SubscriptionsReceivable" contextRef="From2025-07-012025-09-30_us-gaap_PrivatePlacementMember" id="Fact001515" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000,000</ix:nonFraction></span> in subscriptions receivable. As of December 31, 2025,
the Company collected $<span id="xdx_90A_ecustom--ProceedsFromSubscriptionsReceivable_iI_c20250930_zqWez86yW8cf" title="Proceeds subscriptions receivable"><ix:nonFraction name="coep:ProceedsFromSubscriptionsReceivable" contextRef="AsOf2025-09-30" id="Fact001517" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,500,000</ix:nonFraction></span> of the proceeds, resulting in a net $<span id="xdx_900_ecustom--SubscriptionsReceivableNet_iI_c20250930_z534i5DWF8E" title="Subscriptions receivable net"><ix:nonFraction name="coep:SubscriptionsReceivableNet" contextRef="AsOf2025-09-30" id="Fact001519" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></span> in subscriptions receivable still to be collected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the fourth quarter of 2025, the Company
issued a total of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251001__20251231__us-gaap--TypeOfArrangementAxis__custom--TwoInvestorMember_z1il3Cfioqo2" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-10-012025-12-31_custom_TwoInvestorMember" id="Fact001521" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">260,000</ix:nonFraction></span> shares to two investors, recording subscription receivables in the amount of $<span id="xdx_90F_ecustom--SubscriptionsReceivableNet_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--TwoInvestorMember_zfDo2IT5E2S6" title="Subscriptions receivable net"><ix:nonFraction name="coep:SubscriptionsReceivableNet" contextRef="AsOf2025-12-31_custom_TwoInvestorMember" id="Fact001523" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,120,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Standby Equity Purchase Agreement </b>&#8211;
On November 1, 2024, the Company entered into the SEPA with Yorkville pursuant to which the Company has the right to sell to Yorkville
up to $20,000,000 of common stock, subject to certain limitations and conditions set forth in the SEPA, from time to time during the term
of the SEPA. The Company also entered into a Registration Rights Agreement with Yorkville pursuant to which it will register the resale
of shares of common stock issued to Yorkville pursuant to the SEPA. Sales of common stock to Yorkville under the SEPA, and the timing
of any such sales, are at the Company&#8217;s option, and the Company is under no obligation to sell common stock to Yorkville under the
SEPA, except in connection with notices that may be submitted by Yorkville in certain circumstances as described below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each advance (each, an &#8220;Advance&#8221;)
the Company requests in writing to Yorkville under the SEPA (notice of such request, an &#8220;Advance Notice&#8221;) may be for a number
of shares of common stock up to such amount as is equal to 100% of the average daily volume traded of the common stock during the five
trading days immediately prior to the date the Company requests each Advance. The shares of common stock purchased pursuant to an Advance
delivered by the Company will be purchased at a price equal to 95% of the lowest daily VWAP of the shares of common stock during the three
consecutive trading days commencing on the date of the delivery of the Advance Notice, other than the daily VWAP on a day in which the
daily VWAP is less than a minimum acceptable price as stated by the Company in the Advance Notice or there is no VWAP on the subject trading
day. The Company may establish a minimum acceptable price in each Advance Notice below which the Company will not be obligated to make
any sales to Yorkville. &#8220;VWAP&#8221; is defined as the daily volume weighted average price of the shares of Common Stock for such
trading day on the Nasdaq Stock Market (&#8220;Nasdaq&#8221;) during regular trading hours as reported by Bloomberg L.P.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The SEPA will automatically terminate on the earliest
to occur of (i) December 1, 2027, provided that the Convertible Note (defined in Note 5) has been fully repaid or (ii) the date on which
the Company shall have made full payment of Advances pursuant to the SEPA. The Company has the right to terminate the SEPA at no cost
or penalty upon five trading days&#8217; prior written notice to Yorkville, provided that there are no outstanding Advance Notices for
which shares of common stock need to be issued and the Company has paid all amounts owed to Yorkville pursuant to the Convertible Note.
The Company and Yorkville may also agree to terminate the SEPA by mutual written consent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any purchase under an Advance would be subject
to certain limitations, including that Yorkville shall not purchase or acquire any shares that would result in it and its affiliates beneficially
owning more than 4.99% of the then outstanding voting power or number of shares of common stock or any shares that, aggregated with shares
issued under all other earlier Advances, would exceed 19.99% of all shares of common stock outstanding on the date of the SEPA (the &#8220;Exchange
Cap&#8221;), unless the Company obtains stockholder approval to issue shares of common stock in excess of the Exchange Cap in accordance
with applicable Nasdaq rules.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23C_zQMg5hAYLSh2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23D_zvtHfL02GcD3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_234_zDZD4cEjrcTa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 80; Value: 1 -->
    <div id="xdx_23B_zpPmzSqqtYD9" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23B_zuWhpV8CY8Ce" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_zQOn6WYfnMJg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the execution of the SEPA,
the Company agreed to pay a commitment fee of $<span id="xdx_90D_eus-gaap--PaymentsForBrokerageFees_pp0p0_c20241029__20241102__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--YorkvilleMember_zY8Q229W4apd" title="Payment of commitment fee"><ix:nonFraction name="us-gaap:PaymentsForBrokerageFees" contextRef="From2024-10-292024-11-02_custom_StandbyEquityPurchaseAgreementMember_custom_YorkvilleMember" id="Fact001529" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">200,000</ix:nonFraction></span> to Yorkville, payable as follows: (i) $<span id="xdx_909_eus-gaap--PaymentsForBrokerageFees_pp0p0_c20241029__20241102__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--TransactionTypeAxis__custom--StockIssuedForServicesMember_zrdNAZSMmWNh" title="Payment of commitment fee"><ix:nonFraction name="us-gaap:PaymentsForBrokerageFees" contextRef="From2024-10-292024-11-02_custom_StandbyEquityPurchaseAgreementMember_custom_YorkvilleMember_custom_StockIssuedForServicesMember" id="Fact001531" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">80,000</ix:nonFraction></span> payable when the SEPA was entered
into, in the form of the issuance of 20,000 shares of common stock, representing $80,000 divided by the closing price as of the trading
day immediately prior to the date of the SEPA, and (ii) $120,000 payable in cash or by way of an Advance on the date upon which the Company
has first received Advances in the aggregate amount of $5,000,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, Yorkville agreed to advance to
the Company, in exchange for the Convertible Note, an aggregate principal amount of $<span id="xdx_907_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_c20241102__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zXkuC2B3UUMd" title="Convertible notes outstanding"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2024-11-02_custom_StandbyEquityPurchaseAgreementMember_custom_YorkvilleMember_custom_ConvertibleNoteMember" id="Fact001533" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,304,758</ix:nonFraction></span>
(see Note 4 for a description of the Convertible Note). At any time while the SEPA is in place that there is a balance outstanding
under the Convertible Note, Yorkville may deliver a notice (an &#8220;Investor Notice&#8221;) to the Company to cause an Advance
Notice to be deemed delivered to Yorkville and the issuance and sale of shares of Common Stock to Yorkville pursuant to an Advance.
Yorkville may select the amount of the Advance in an amount not to exceed the balance owed under the Convertible Note outstanding on
the date of delivery of such Investor Notice. The shares will be issued and sold to Yorkville pursuant to an Investor Notice at a
per share price equal to the conversion price that would be applicable to the amount of the Advance selected by Yorkville if such
amount were to be converted as of the date of delivery of the Investor Notice. Yorkville will pay the purchase price for such shares
to be issued pursuant to the Investor Notice by offsetting the amount of the purchase price to be paid by Yorkville against an
amount outstanding under the Yorkville Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, the Company, at its option, shall
have the right, but not the obligation, to redeem early a portion or all amounts outstanding under the Convertible Note at a redemption
amount equal to the outstanding principal balance being repaid or redeemed, plus a 5% prepayment premium, plus all accrued and unpaid
interest; provided that (i) the Company provides Yorkville with no less than ten trading days&#8217; prior written notice thereof and
(ii) on the date such notice is issued, the VWAP of the common stock is less than the Fixed Price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Throughout the year ended December 31,
2025, in connection with the SEPA, the Company issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zB8hYyF9EKjf" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-01-012025-12-31_custom_StandbyEquityPurchaseAgreementMember206522812" id="Fact001535" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">225,000</ix:nonFraction></span> shares of common stock, resulting in gross proceeds of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zKs51zi7Bgrh" title="Gross proceeds"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-12-31_custom_StandbyEquityPurchaseAgreementMember206522812" id="Fact001537" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,958,848</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001539" name="us-gaap:MinorityInterestDisclosureTextBlock"><p id="xdx_809_eus-gaap--MinorityInterestDisclosureTextBlock_zizifLs4YmKa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 8 &#8211; <span id="xdx_827_z2UxdB84e2e9">NON-CONTROLLING INTEREST</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the series A preferred stock offering
discussed in Note 7, Capital Structure, the Company has consolidated the two newly formed subsidiaries, SNAP Biosciences, Inc. and GEAR
Therapeutics, Inc., because we have a controlling interest in both. Therefore, the entities&#8217; financial statements are consolidated
in our consolidated financial statements and the portion of the entities&#8217; equity attributable to external ownership is recorded
as a non-controlling interest. As part of the initial closings, the Series A Investors received in the aggregate a 15% non-voting equity
ownership in both of the newly formed subsidiaries. In addition, investors who participated in the 2025 private placement common stock
offering received an additional 10% aggregate non-voting ownership in SNAP Biosciences, Inc., resulting in an extra $79,000 in equity attributable
to non-controlling interests. The Company contributed the co-development rights to GEAR Therapeutics, Inc. and contributed both the exclusive
license and corporate research agreements with the University of Pittsburgh to SNAP Biosciences, Inc. The Company recorded $<span id="xdx_904_eus-gaap--MinorityInterest_iI_c20251231__dei--LegalEntityAxis__custom--GearTherapeuticsMember_zcwdUpTOBaog" title="Noncontrolling interest"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2025-12-31_custom_GearTherapeuticsMember" id="Fact001541" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,063,300</ix:nonFraction></span>
of non-controlling interest at December 31, 2025. Net of accumulated losses of $<span id="xdx_90E_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iI_c20251231__dei--LegalEntityAxis__custom--GearTherapeuticsMember_zGJerPrrLk9i" title="Net of accumulated losses"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2025-12-31_custom_GearTherapeuticsMember" id="Fact001543" format="ixt:numdotdecimal" decimals="0" unitRef="USD">557,137</ix:nonFraction></span>, the Company recorded $<span id="xdx_905_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iI_c20251231__dei--LegalEntityAxis__custom--GearTherapeuticsMember_z2uTqu2lYDL7" title="Equity attributable to non-controlling interests"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-12-31_custom_GearTherapeuticsMember" id="Fact001545" format="ixt:numdotdecimal" decimals="0" unitRef="USD">506,163</ix:nonFraction></span> in equity attributable
to non-controlling interests at December 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001547" name="us-gaap:InvestmentTextBlock"><p id="xdx_805_eus-gaap--InvestmentTextBlock_zoTzwyMRtk2k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 9 &#8211;&#160;<span id="xdx_827_zHmsjDFWeM9a">INVESTMENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2024, the Company satisfied $<span id="xdx_904_ecustom--SubscriptionReceivable_iI_dm_c20240831__srt--CounterpartyNameAxis__custom--TwoPrivatelyHeldCompaniesMember_z7mAbw8Itzjj"><ix:nonFraction name="coep:SubscriptionReceivable" contextRef="AsOf2024-08-31_custom_TwoPrivatelyHeldCompaniesMember" id="Fact001548" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">5.7</ix:nonFraction>
million</span> of subscription receivables and related interest receivable in the form of shares of common stock in two privately
held companies. During the year ended December 31, 2025, the Company received <span id="xdx_909_eus-gaap--InvestmentOwnedBalanceShares_iI_dm_c20251231__us-gaap--TransactionTypeAxis__custom--NexGenAIAffiliatesNetworkPlatformMember__srt--CounterpartyNameAxis__custom--FivePrivatelyHeldCompaniesMember_zygfI3UvOgDd"><ix:nonFraction name="us-gaap:InvestmentOwnedBalanceShares" contextRef="AsOf2025-12-31_custom_NexGenAIAffiliatesNetworkPlatformMember_custom_FivePrivatelyHeldCompaniesMember" id="Fact001549" format="ixt:numdotdecimal" decimals="INF" scale="6" unitRef="Shares">1.25</ix:nonFraction>
million</span> shares of common stock in five privately held companies in connection with master services agreements for access to
the NexGenAI Affiliates Network platform. Additionally, to satisfy outstanding accounts receivables related to webinar services
rendered in the master services agreements, the Company received <span id="xdx_904_eus-gaap--InvestmentOwnedBalanceShares_iI_dm_c20251231__us-gaap--TransactionTypeAxis__custom--NexGenAIAffiliatesNetworkPlatformMember__srt--CounterpartyNameAxis__custom--ThreePrivatelyHeldCompaniesMember_zWC2YVqGoTuk"><ix:nonFraction name="us-gaap:InvestmentOwnedBalanceShares" contextRef="AsOf2025-12-31_custom_NexGenAIAffiliatesNetworkPlatformMember_custom_ThreePrivatelyHeldCompaniesMember" id="Fact001550" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">82,500</ix:nonFraction></span>
shares of common stock in three of these privately held companies. The shares of common stock are carried as investments on the
Company&#8217;s consolidated balance sheets at its initial cost basis of $1.00 per share. As the investments are in privately held
companies, the Company will assess the investments for impairment on an annual basis. As of December 31, 2025, the Company
recognized a $<span id="xdx_906_eus-gaap--GainLossOnInvestments_iN_di_c20251101__20251231__us-gaap--TransactionTypeAxis__custom--NexGenAIAffiliatesNetworkPlatformMember_zTufr3C19kxa" title="Loss on investment"><ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="From2025-11-012025-12-31_custom_NexGenAIAffiliatesNetworkPlatformMember" id="Fact001552" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">163,500</ix:nonFraction></span> unrealized loss due to impairment of one of these investments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2025, the Company issued <span id="xdx_906_ecustom--StockIssuedDuringPeriodSharesIssuedForInvestment_c20251101__20251130__srt--CounterpartyNameAxis__custom--PrivatelyHeldCompanyMember_zgMu2FyQdV0b"><ix:nonFraction name="coep:StockIssuedDuringPeriodSharesIssuedForInvestment" contextRef="From2025-11-012025-11-30_custom_PrivatelyHeldCompanyMember" id="Fact001553" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">66,837</ix:nonFraction></span>
shares of common stock valued at $<span id="xdx_90C_ecustom--StockIssuedDuringPeriodValueIssuedForInvestment_c20251101__20251130__srt--CounterpartyNameAxis__custom--PrivatelyHeldCompanyMember_zbJt0MC6xAQc"><ix:nonFraction name="coep:StockIssuedDuringPeriodValueIssuedForInvestment" contextRef="From2025-11-012025-11-30_custom_PrivatelyHeldCompanyMember" id="Fact001554" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></span>,
in exchange for <span id="xdx_90F_eus-gaap--InvestmentOwnedBalanceShares_iI_c20251130__srt--CounterpartyNameAxis__custom--PrivatelyHeldCompanyMember_zB2jpaoTdOW5"><ix:nonFraction name="us-gaap:InvestmentOwnedBalanceShares" contextRef="AsOf2025-11-30_custom_PrivatelyHeldCompanyMember" id="Fact001555" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">667,000</ix:nonFraction></span>
shares of a privately held company. The shares of common stock are carried as investments on the Company&#8217;s consolidated
balance sheets at its initial cost basis of $1.50 per share. As the investments are in privately held companies, the Company
will assess the investments for impairment on an annual basis. As of December 31, 2025, <span id="xdx_90C_eus-gaap--GainLossOnInvestments_iN_dio_c20251101__20251231__srt--CounterpartyNameAxis__custom--PrivatelyHeldCompanyMember_zsN8lh9OnHo1" title="Loss on investment"><ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="From2025-11-012025-12-31_custom_PrivatelyHeldCompanyMember" id="Fact001557" format="ixt-sec:numwordsen" decimals="0" sign="-" unitRef="USD">no</ix:nonFraction></span> impairment has been recorded
related to this investment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2025, the
Company entered into a one-year agreement with a customer to provide access to the NexGenAI Affiliates Network platform. The
contract fee paid by the customer consisted of <span id="xdx_90C_ecustom--InvestmentCompanyFeePaidSharesIndirectly_c20250101__20251231_z4g8if05Rh8" title="Investment company fee paid shares indirectly"><ix:nonFraction name="coep:InvestmentCompanyFeePaidSharesIndirectly" contextRef="From2025-01-01to2025-12-31" id="Fact001559" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,830,189</ix:nonFraction></span>
shares in the customer&#8217;s publicly traded stock, or $<span id="xdx_90D_eus-gaap--InvestmentCompanyFeePaidIndirectly_c20250101__20251231_zngxbOqC2Y3h" title="Investment company fee paid indirectly"><ix:nonFraction name="us-gaap:InvestmentCompanyFeePaidIndirectly" contextRef="From2025-01-01to2025-12-31" id="Fact001561" format="ixt:numdotdecimal" decimals="0" unitRef="USD">600,000</ix:nonFraction></span>,
which the Company recorded as marketable securities on the consolidated balance sheets. The Company classified this marketable
security as a short-term asset as it is expected to be converted into cash within one year. During the year ended December 31, 2025,
the Company recorded an unrealized gain on marketable securities in the amount of $<span id="xdx_90B_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20250101__20251231_zT5ZCztWTXj3" title="Unrealized gain on marketable securities"><ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2025-01-01to2025-12-31" id="Fact001563" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,596</ix:nonFraction></span>.</p>

<ix:exclude><p id="xdx_238_z5JxMATqijFj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_235_zqHb3FLbSqi5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 81 -->
    <div id="xdx_23C_zoa46H11kqIl" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_238_zBKd9A19Cjca" style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001567" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_802_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z63rIQ88SQK6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 10 &#8211; <span id="xdx_82D_zK60r8rxyoR5">COMMITMENTS AND
CONTINGENCIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Leases &#8211;</b> The Company leases
office space under an operating lease that commenced December 1, 2017 and was extended through multiple lease extensions. The third lease
extension extended the lease for twenty-four months, beginning on June 1, 2022 and ended on May 31, 2024. The fourth lease extension,
signed on January 30, 2024, extended the lease for twenty-four months, beginning June 1, 2024 and ending on May 31, 2026. The monthly
rent is $<span id="xdx_90C_ecustom--MonthlyRent_uUSD_c20250101__20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FirstYearExtensionMember_zP97kLHgFb25" title="Monthly rent"><ix:nonFraction name="coep:MonthlyRent" contextRef="From2025-01-012025-12-31_custom_FirstYearExtensionMember" id="Fact001569" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,805</ix:nonFraction></span>&#160;for the first year of the extension and increasing to $<span id="xdx_907_ecustom--MonthlyRent_uUSD_c20250101__20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--SecondYearExtensionMember_zCbR59IAEgZd" title="Monthly rent"><ix:nonFraction name="coep:MonthlyRent" contextRef="From2025-01-012025-12-31_custom_SecondYearExtensionMember" id="Fact001571" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,860</ix:nonFraction></span>&#160;for the second year of the extension.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company records rent expense associated with
this lease on the straight-line basis in conjunction with the terms of the underlying lease. During the year ended December 31, 2025,
rents paid totaled $<span id="xdx_900_eus-gaap--OperatingLeaseExpense_c20250101__20251231_zSb7uE0KklXk" title="Operating lease expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2025-01-01to2025-12-31" id="Fact001573" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,101</ix:nonFraction></span>. During the year ended December 31, 2024, rents paid totaled $<span id="xdx_906_eus-gaap--OperatingLeaseExpense_c20240101__20241231_zwnXA6YZY4U" title="Operating lease expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2024-01-012024-12-31" id="Fact001575" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,440</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Right of use asset is summarized below:</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001577" name="us-gaap:LeaseCostTableTextBlock"><table cellspacing="0" cellpadding="0" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details - Lease cost)" id="xdx_89E_eus-gaap--LeaseCostTableTextBlock_zNurRGb4gJA9" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span id="xdx_8B9_zfBMVeVu1fG1" style="display: none">Schedule of lease information</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>December 31, 2025</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>December 31, 2024</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 68%; text-align: justify"><span style="font-size: 10pt">Office lease</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98C_ecustom--OperatingLeaseRightOfUseAssetGross_iI_c20251231_zTI5yKVpn9L7" title="Operating lease right of use asset, gross" style="width: 13%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="coep:OperatingLeaseRightOfUseAssetGross" contextRef="AsOf2025-12-31" id="Fact001579" format="ixt:numdotdecimal" decimals="0" unitRef="USD">243,550</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_988_ecustom--OperatingLeaseRightOfUseAssetGross_iI_c20241231_zCNmIOx5AEda" title="Operating lease right of use asset, gross" style="width: 13%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="coep:OperatingLeaseRightOfUseAssetGross" contextRef="AsOf2024-12-31" id="Fact001581" format="ixt:numdotdecimal" decimals="0" unitRef="USD">243,550</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; text-align: justify"><span style="font-size: 10pt">Less: accumulated depreciation</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td id="xdx_982_ecustom--OperatingLeaseRightOfUseAssetAccumulatedDepreciation_iNI_di_c20251231_zfjJ2CGRwWsd" title="Operating lease right of use asset, accumulated depreciation" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="coep:OperatingLeaseRightOfUseAssetAccumulatedDepreciation" contextRef="AsOf2025-12-31" id="Fact001583" format="ixt:numdotdecimal" decimals="0" unitRef="USD">225,151</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td id="xdx_98C_ecustom--OperatingLeaseRightOfUseAssetAccumulatedDepreciation_iNI_di_c20241231_zeEO5zVDrf14" title="Operating lease right of use asset, accumulated depreciation" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="coep:OperatingLeaseRightOfUseAssetAccumulatedDepreciation" contextRef="AsOf2024-12-31" id="Fact001585" format="ixt:numdotdecimal" decimals="0" unitRef="USD">183,767</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Right of use asset, net</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98D_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20251231_z3MqBXwIerud" title="Operating lease right of use asset" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2025-12-31" id="Fact001587" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,399</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98C_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20241231_z29q7WIDxG68" title="Operating lease right of use asset" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-12-31" id="Fact001589" format="ixt:numdotdecimal" decimals="0" unitRef="USD">59,783</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Operating lease liability is summarized below:</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>December 31, 2025</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>December 31, 2024</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 68%; text-align: justify"><span style="font-size: 10pt">Office lease</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98A_eus-gaap--OperatingLeaseLiability_iI_c20251231_z52hvCDNi538" title="Operating lease liability" style="width: 13%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2025-12-31" id="Fact001591" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,875</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98B_eus-gaap--OperatingLeaseLiability_iI_c20241231_z3X3UlzHpbR9" title="Operating lease liability" style="width: 13%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-12-31" id="Fact001593" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61,180</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; text-align: justify"><span style="font-size: 10pt">Less: current portion</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td id="xdx_988_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_c20251231_zbwMKcGw5RS1" title="Operating lease liability, current" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2025-12-31" id="Fact001595" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,875</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td id="xdx_989_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_c20241231_zaYiadVVq5g1" title="Operating lease liability, current" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact001597" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,305</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Long term portion</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_984_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_d0_c20251231_z5wk0aoUsIM" title="Operating lease liability, noncurrent" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2025-12-31" id="Fact001599" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_987_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20241231_zrViZofdPv1h" title="Operating lease liability, noncurrent" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-12-31" id="Fact001601" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,875</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A2_zqyctCikfcb8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Future minimum rental payments required under
the lease are as follows:</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001603" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><table cellspacing="0" cellpadding="0" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details - Future minimum payments)" id="xdx_890_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zhfD5xWoCW72" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 84%"><span id="xdx_8B8_zj1SoMqSanta" style="display: none">Schedule of future minimum rental payments</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_49E_20251231_zvweQfOVXaz9" style="text-align: center; width: 13%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzRwJ_zcNnpXsH026b" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">2026</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">$</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2025-12-31" id="Fact001605" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">19,301</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzRwJ_zf9cpLG5IKMj" style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Total minimum lease payments:</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2025-12-31" id="Fact001607" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">19,301</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zvJXonsH07G8" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Less amount representing interest</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2025-12-31" id="Fact001609" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">426</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Present value of minimum lease payments:</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2025-12-31" id="Fact001611" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,875</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AF_zHQkVCaIL2m2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Legal Matters&#160;</b>&#8211; The Company
is currently not a defendant in any litigation or threatened litigation that could have a material effect on the Company&#8217;s consolidated
financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Employment Agreements with Directors and
Officers &#8211;</b> David Mehalick, our President and Chief Executive Officer, and Daniel Yerace, our Vice President of Operations, entered
into employment agreements with Coeptis Therapeutics, Inc. on February 21, 2022 (the &#8220;Effective Date&#8221;) covering Coeptis and
its subsidiary, Coeptis Pharmaceuticals. The employment agreements will remain in effect until the termination of the employment agreement
by either party in accordance with Section&#160;5 of the employment agreement. Under the employment agreements, the Company currently
pays both Mr. Mehalick and Mr. Yerace an annualized salary at the rate of $<span id="xdx_904_ecustom--AnnualSalary_c20250101__20251231__srt--CounterpartyNameAxis__custom--MehalickMember_zvwLKWdDLC09" title="Annual salary"><span id="xdx_90E_ecustom--AnnualSalary_c20250101__20251231__srt--CounterpartyNameAxis__custom--YeraceMember_zJfoP6lmzqT2" title="Annual salary"><ix:nonFraction name="coep:AnnualSalary" contextRef="From2025-01-012025-12-31_custom_MehalickMember" id="Fact001613" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="coep:AnnualSalary" contextRef="From2025-01-012025-12-31_custom_YeraceMember" id="Fact001615" format="ixt:numdotdecimal" decimals="0" unitRef="USD">360,000</ix:nonFraction></ix:nonFraction></span></span>. Mr. Mehalick and Mr. Yerace will also receive a guaranteed
bonus equal to twenty (20%) of the base salary for each calendar year, and will be eligible to receive merit bonuses, certain milestone
bonuses and awards of stock options, restricted stock units or other equity awards pursuant to any plans or arrangements that the Company
may have in effect from time to time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CAR T License </b>&#8211; On August 31,
2022, the Company entered into an exclusive license agreement with the University of Pittsburgh for certain intellectual property
rights related to the universal self-labeling SynNotch and CARs for programable antigen-targeting technology platform. The Company
paid the University of Pittsburgh a non-refundable fee in the amount of $75,000 for the exclusive patent rights to the licensed
technology. Under the terms of the agreement, the Company has been assigned the worldwide development and commercialization rights
to the licensed technology in the field of human treatment of cancer with antibody or antibody fragments using SNAP-CAR T-cell
technology, along with (i) an intellectual property portfolio consisting of issued and pending patents and (ii) options regarding
future add-on technologies and developments. In consideration of these rights, the Company paid an initial license fee of $<span id="xdx_900_ecustom--InitialLicenseFee_iI_c20220831__us-gaap--TransactionTypeAxis__custom--CarTLicenseMember_z7ogeCkrL0E2" title="Initial license fee"><ix:nonFraction name="coep:InitialLicenseFee" contextRef="AsOf2022-08-31_custom_CarTLicenseMember" id="Fact001617" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,000</ix:nonFraction></span>,
and will have <span id="xdx_909_ecustom--AnnualMaintenanceFeeDescription_c20220829__20220831__us-gaap--TransactionTypeAxis__custom--CarTLicenseMember_z6zdmMaazNBh" title="Annual maintenance fee description"><ix:nonNumeric contextRef="From2022-08-292022-08-31_custom_CarTLicenseMember" id="Fact001619" name="coep:AnnualMaintenanceFeeDescription">annual
maintenance fees ranging between $15,000 and $25,000</ix:nonNumeric></span>, as well as developmental milestone payments (as defined in the
agreement) and royalties equal to 3.5% of net sales. On January 25, 2023, the Company entered into a Sponsored Research Agreement
(&#8220;SRA&#8221;) with the University of Pittsburgh for the pre- clinical development of SNAP-CAR T-cells targeting HER2. The
Company agreed to pay $<span id="xdx_90A_eus-gaap--ContractualObligation_iI_c20251231__us-gaap--TransactionTypeAxis__custom--CarTLicenseMember_z2RYCefqhTW3" title="Contractual obligation"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2025-12-31_custom_CarTLicenseMember" id="Fact001621" format="ixt:numdotdecimal" decimals="0" unitRef="USD">716,714</ix:nonFraction></span>
for performance-based milestones over a two-year term, all of which has been paid as of December 31, 2025. The Company&#8217;s
liability was $<span id="xdx_90F_eus-gaap--ContractualObligation_iI_c20251231_zKayGZDufN3d" title="Contractual obligation"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2025-12-31" id="Fact001623" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>
and $<span id="xdx_90C_eus-gaap--ContractualObligation_iI_c20241231_z1SCzeTXlzDl" title="Contractual obligation"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2024-12-31" id="Fact001625" format="ixt:numdotdecimal" decimals="0" unitRef="USD">507,535</ix:nonFraction></span> at
December 31, 2025 and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To supplement the development work conducted under
the SRA, the Company&#8217;s subsidiary SNAP Biosciences, in May 2025, entered into a grant agreement with the Alici Lab at the Karolinska
Institutet (&#8220;KI&#8221;). Under the terms of the grant agreement, KI will continue the pre-clinical and clinical development initially
started by Deverra under the terms of the Shared Services Agreement (&#8220;SSA&#8221;) described below. The grant agreement has an 18-month
term which the Company agreed to pay to KI quarterly payments equal to $105,000.</p>

<ix:exclude><p id="xdx_234_zLXlXAW05Am7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_239_zkEZSgjCfkGc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23D_zG1LLegY1OXi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 82 -->
    <div id="xdx_235_zj7bgCmqamgl" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_233_zNDnocBvsZni" style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Also in May 2025, the Company&#8217;s subsidiary,
SNAP Biosciences, entered into a License Agreement with Monarch Therapeutics. The agreement grants SNAP Biosciences access to Monarch&#8217;s
small-molecule adaptor-based technology platform for use with SNAP-CAR. Under the terms of the agreement, SNAP Biosciences agreed to pay
to Monarch a $50,000 upfront payment, a $10,000 annual license fee, and future success-based milestone payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2023, the Company expanded its exclusive
license agreement with the University of Pittsburgh to include SNAP-CAR technology platform in natural killer (NK) cells. The Company
paid $<span id="xdx_903_ecustom--AgreementAmendmentFee_iI_c20230930_z7Ccz973ONKc" title="Agreement amendment fee"><ix:nonFraction name="coep:AgreementAmendmentFee" contextRef="AsOf2023-09-30" id="Fact001630" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000</ix:nonFraction></span> to amend the agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Deverra Therapeutics, Inc.&#160;</b>&#8211;
On August 16, 2023, the Company entered into an exclusive licensing arrangement (the &#8220;License Agreement&#8221;) with Deverra Therapeutics
Inc. (&#8220;Deverra&#8221;), pursuant to which the Company completed the exclusive license of key patent families and related intellectual
property related to a proprietary allogeneic stem cell expansion and directed differentiation platform for the generation of multiple
distinct immune effector cell types, including natural killer (NK) and monocyte/macrophages. The License Agreement provides the Company
with exclusive rights to use the license patents and related intellectual property in connection with development and commercialization
efforts in the defined field of use (the &#8220;Field&#8221;) of (a) use of unmodified NK cells as anti-viral therapeutic for viral infections,
and/or as a therapeutic approach for treatment of relapsed/refractory AML and high-risk MDS; (b) use of Deverra&#8217;s cell therapy platform
to generate NK cells for the purpose of engineering with Coeptis SNAP-CARs and/or Coeptis GEAR Technology; and (c) use of Deverra&#8217;s
cell therapy platform to generate myeloid cells for the purpose of engineering with the Company&#8217;s current SNAP-CAR and GEAR technologies.
In support of the exclusive license, the Company also entered into with Deverra (i) an asset purchase agreement (the &#8220;APA&#8221;)
pursuant to which the Company purchased certain assets from Deverra, including but not limited to two Investigational New Drug (IND) applications
and two Phase 1 clinical trial stage programs (NCT04901416, NCT04900454) investigating infusion of DVX201, an unmodified natural killer
(NK) cell therapy generated from pooled donor CD34+ cells, in hematologic malignancies and viral infections and (ii) a non-exclusive sublicense
agreement (the &#8220;Sublicense Agreement&#8221;), in support of the assets obtained by the exclusive license, pursuant to which the
Company sublicensed from Deverra certain assets which Deverra has rights to pursuant a license agreement (&#8220;FHCRC Agreement&#8221;)
by and between Deverra and The Fred Hutchinson Cancer Research Center (&#8220;FHCRC&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, in accordance with the terms of
the Sublicense Agreement, the Company agreed to pay FHCRC certain specified contingent running royalty payments and milestone payments
under the FHCRC Agreement, in each case to the extent such payments are triggered by the Company&#8217;s development activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Until December 2024, we operated under a SSA with Deverra, which provided Coeptis and Deverra to share resources and collaborate on the development
of Coeptis&#8217; GEAR and SNAP-CAR platforms. The Company is continuing its development focus on both GEAR and SNAP-CAR, and will be
considering prospective strategic partners for such development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Registration Rights</b> &#8211; Pursuant to
a registration rights agreement entered into on October 29, 2020, the holders of the founder shares, the Private Placement Warrants and
underlying securities, and any securities issued upon conversion of Working Capital Loans (and underlying securities) would be entitled
to registration rights pursuant to a registration rights agreement. The holders of at least a majority in interest of the then-outstanding
number of these securities were entitled to make up to three demands, excluding short form demands, that the Company register such securities.
In addition, the holders have certain &#8220;piggy-back&#8221; registration rights with respect to registration statements filed subsequent
to the consummation of a Business Combination. Notwithstanding the foregoing, Imperial, I-Bankers and Northland did not exercise their
demand and &#8220;piggyback&#8221; registration rights after five (5) and seven (7) years after the effective date of the registration
statement and did not exercise its demand rights on more than one occasion. The registration rights agreement did not contain liquidating
damages or other cash settlement provisions resulting from delays in registering the Company&#8217;s securities. The Company would bear
the expenses incurred in connection with the filing of any such registration statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Finder&#8217;s Fee and Indemnity Agreement
</b>&#8211; The Company entered into a finder&#8217;s fee and indemnity agreement with a third party, pursuant to which the Company has
agreed to pay a fee in connection with the successful introduction and executive of the SEPA. Under the terms of the agreement, the Company
was obligated to pay a 4% fee upon the closing of the net funding amount of $1,350,000, equaling $54,000, and then 6% of the total cash
consideration received by the Company or the Company&#8217;s creditors in connection with any follow on financing, and 0.5% on the amount
of any drawdown made by the Company on the SEPA. The Company also agreed to indemnify and hold harmless the third party from and against
any and all losses, claims, damages, obligations, penalties, judgments, any and all legal and other actions caused by or related to the
third party&#8217;s engagement with the Company. As of December 31, 2025, the Company paid a total of $<span id="xdx_90D_eus-gaap--PaymentsForFees_c20250101__20251231__us-gaap--TransactionTypeAxis__custom--FindersFeeAndIndemnityAgreementMember_z3ks7zv6MO9l" title="Payment for fees"><ix:nonFraction name="us-gaap:PaymentsForFees" contextRef="From2025-01-012025-12-31_custom_FindersFeeAndIndemnityAgreementMember" id="Fact001632" format="ixt:numdotdecimal" decimals="0" unitRef="USD">103,500</ix:nonFraction></span> to the third party in connection
with this finder&#8217;s fee and indemnity agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Master Services Agreements</b>&#160;&#8211;
On December 31,2024 and during the year ended December 31, 2025, the Company entered into one-year agreements with six customers to provide
access to the NexGenAI Affiliates Network platform. Under the terms of these agreements, the Company is obligated to deliver platform
access and related services over the contract period beginning in 2025. Revenue recognition will commence upon the start of services
in accordance with ASC 606,&#160;<i>Revenue from Contracts with Customers</i>. As these agreements represent future contractual obligations,
there was no impact on the Company&#8217;s financial position, results of operations, or cash flows as of December 31, 2024. As of December
31, 2025, the Company has recognized $<span id="xdx_904_eus-gaap--Revenues_c20250101__20251231__us-gaap--TransactionTypeAxis__custom--MasterServicesAgreementsMember_zPrrhccubqge"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-01-012025-12-31_custom_MasterServicesAgreementsMember" id="Fact001633" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,363,045</ix:nonFraction></span>
in revenue in connection with these contracts, with $<span id="xdx_901_eus-gaap--ContractWithCustomerAssetNet_iI_c20251231__us-gaap--TransactionTypeAxis__custom--MasterServicesAgreementsMember_zR9QP5t796H4" title="Customer deposit receivable"><ix:nonFraction name="us-gaap:ContractWithCustomerAssetNet" contextRef="AsOf2025-12-31_custom_MasterServicesAgreementsMember" id="Fact001635" format="ixt:numdotdecimal" decimals="0" unitRef="USD">599,455</ix:nonFraction></span>
remaining in customer deposits expected to be recognized in 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 83 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>GEAR&#8482; Cell Therapy Platform &#8211;</b>
In March 2025, the Company reached an agreement with Vy-Gen-Bio, Inc. (&#8220;Vy-Gen&#8221;) to successfully license the exclusive worldwide
development and commercialization rights to the GEAR&#8482; Cell Therapy Platform, representing a first-in-class approach to modifying
potent cancer-targeting immune cells to optimize the likelihood of deep remission in patients with hematologic malignancies and other
cancers. Coeptis had previously held limited co-development rights to GEAR. As part of this exclusive GEAR license agreement with VyGen-Bio,
Inc., the Company paid a total of $<span id="xdx_908_eus-gaap--PaymentsForFees_c20250101__20251231__us-gaap--TransactionTypeAxis__custom--GearCellTherapyPlatformMember_zUy4rbi2jFEe" title="Payment for fees"><ix:nonFraction name="us-gaap:PaymentsForFees" contextRef="From2025-01-012025-12-31_custom_GearCellTherapyPlatformMember" id="Fact001637" format="ixt:numdotdecimal" decimals="0" unitRef="USD">400,000</ix:nonFraction></span> for license fees during the year ended December 31, 2025, which the company recorded as research
and development expense, and committed to pay other performance-based fees, milestone and royalty payments in 2026 and beyond.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001639" name="us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock"><p id="xdx_806_eus-gaap--CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_zMQNysjO24Da" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 11 - <span id="xdx_825_zJCTDhq7YJi8">401(k) PROFIT-SHARING
PLAN</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company sponsors a qualified profit-sharing
plan with a 401(k) feature that covers all eligible employees. Participation in the 401(k) feature of the plan is voluntary. Participating
employees may defer up to 100% of their compensation up to the maximum prescribed by the Internal Revenue Code. The plan permits for employee
elective deferrals but has no contribution requirements for the Company. During the years ended December 31, 2025 and 2024,&#160;<span id="xdx_904_eus-gaap--DefinedBenefitPlanContributionsByEmployer_pp0p0_do_c20250101__20251231_zIWhRsvwKX3" title="Employer contributions"><span id="xdx_90A_eus-gaap--DefinedBenefitPlanContributionsByEmployer_pp0p0_do_c20240101__20241231_zed3SSxxssji" title="Employer contributions"><ix:nonFraction name="us-gaap:DefinedBenefitPlanContributionsByEmployer" contextRef="From2025-01-01to2025-12-31" id="Fact001641" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:DefinedBenefitPlanContributionsByEmployer" contextRef="From2024-01-012024-12-31" id="Fact001643" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span>&#160;employer
contributions were made.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001645" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_805_eus-gaap--IncomeTaxDisclosureTextBlock_zhwx7qezIYae" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>NOTE
12 &#8211; <span id="xdx_820_zivfYEtOwphb">INCOME TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company
has established deferred tax assets and liabilities for the recognition of future deductions or taxable amounts and operating loss carry
forward. Deferred federal and state income tax expense or benefit is recognized as a result of the change in the deferred tax asset or
liability during the year using the currently enacted tax laws and rates that apply to the period in which they are expected to affect
taxable income. Valuation allowances are established, if necessary, to reduce deferred tax assets to the amount that will more likely
than not be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>During
the years ended December 31, 2025 and 2024, a reconciliation of income tax benefit at the statutory rate of 35% and 35%, respectively
to income tax benefit at the Company&#8217;s effective tax rate is as follows:</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001647" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><table cellspacing="0" cellpadding="0" summary="xdx: Disclosure - INCOME TAXES (Details - Reconcilation of income tax)" id="xdx_880_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zQRlzwnj8iTg" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-size: 10pt"><span id="xdx_8BB_zz5fIkO2LeJe" style="display: none">Schedule of effective income
    tax reconciliation</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_49F_20250101__20251231_zEZKqKHR0Vr4" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_49E_20240101__20241231_zw7wqMsWN7r" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2025</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2024</b></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_iN_di_zRJCLbPmId39" style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 68%; text-align: justify"><span style="font-size: 10pt">Income tax benefit at statutory rate</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2025-01-01to2025-12-31" id="Fact001649" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,983,800</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2024-01-012024-12-31" id="Fact001650" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,455,499</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_pp0p0_di_z7QukHZQwO7d" style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Change in valuation allowance</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2025-01-01to2025-12-31" id="Fact001652" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,983,800</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2024-01-012024-12-31" id="Fact001653" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,455,499</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The income
tax provision differs from the expense that would result from applying federal statutory rates to income taxes as follows:</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001655" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><table cellspacing="0" cellpadding="0" summary="xdx: Disclosure - INCOME TAXES (Details - Reconcilation of provision)" id="xdx_88E_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zuKJKVl0AiLb" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-size: 10pt"><span id="xdx_8B7_zVCL0npBJ3ee" style="display: none">Schedule of income tax provision</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2025</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2024</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 44%"><span style="font-size: 10pt">Excepted federal statutory income tax provision/rate</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98B_ecustom--ExpectedIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_iN_di_c20250101__20251231_zgJaatUK6x9c" title="Expected federal statutory income tax provision" style="width: 11%; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="coep:ExpectedIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2025-01-01to2025-12-31" id="Fact001657" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,521,826</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-size: 10pt">)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><span id="xdx_90A_ecustom--ExpectedEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pip0_dp_c20250101__20251231_zg0CG6XMikJi" style="font-size: 10pt">(<ix:nonFraction name="coep:ExpectedEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2025-01-01to2025-12-31" id="Fact001658" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">21.0</ix:nonFraction></span><span style="font-size: 10pt">%</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98D_ecustom--ExpectedIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_iN_di_c20240101__20241231_zpLeMPaNqmn6" title="Expected federal statutory income tax provision/rate" style="width: 11%; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="coep:ExpectedIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2024-01-012024-12-31" id="Fact001660" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,284,257</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-size: 10pt">)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><span id="xdx_904_ecustom--ExpectedEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_c20240101__20241231_zBq80To0LlB4" style="font-size: 10pt">(<ix:nonFraction name="coep:ExpectedEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2024-01-012024-12-31" id="Fact001661" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">21.0</ix:nonFraction></span><span style="font-size: 10pt">%</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">State income taxes, net of federal benefit</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_iN_di_c20250101__20251231_zv8bhZNz8msi" title="State income taxes, net of federal benefit" style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2025-01-01to2025-12-31" id="Fact001663" format="ixt:numdotdecimal" decimals="0" unitRef="USD">367,582</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pip0_dp_c20250101__20251231_zvrJZoK5FiEf" style="font-size: 10pt">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2025-01-01to2025-12-31" id="Fact001664" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">3.1</ix:nonFraction></span><span style="font-size: 10pt">%</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_iN_di_c20240101__20241231_zQub2Ex3zNI1" title="State income taxes, net of federal benefit" style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2024-01-012024-12-31" id="Fact001666" format="ixt:numdotdecimal" decimals="0" unitRef="USD">58,863</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_c20240101__20241231_zdkbDi8RN0lh" style="font-size: 10pt">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2024-01-012024-12-31" id="Fact001667" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.5</ix:nonFraction></span><span style="font-size: 10pt">%</span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Other</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_989_eus-gaap--IncomeTaxReconciliationOtherAdjustments_d0_c20250101__20251231_zmxjFEVCrXpb" title="Other" style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="From2025-01-01to2025-12-31" id="Fact001669" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">94,392</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)&#160;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_iN_pip0_dpi0_c20250101__20251231_zYh3smvTRDvl" style="font-size: 10pt">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="From2025-01-01to2025-12-31" id="Fact001670" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.8</ix:nonFraction></span><span style="font-size: 10pt">%</span></td>
    <td><span style="font-size: 10pt">)&#160;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_984_eus-gaap--IncomeTaxReconciliationOtherAdjustments_d0_c20240101__20241231_zw8VxXHZ5Shd" title="Other" style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="From2024-01-012024-12-31" id="Fact001672" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">112,379</ix:nonFraction>)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_iN_pip0_dpi0_c20240101__20241231_zEBzGddw97je" style="font-size: 10pt">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="From2024-01-012024-12-31" id="Fact001673" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.0</ix:nonFraction></span><span style="font-size: 10pt">%)</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Income tax benefit at statutory rate</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98A_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maprovision2025_c20250101__20251231_zwemTfow8Awi" title="Income tax benefit at statutory rate" style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2025-01-01to2025-12-31" id="Fact001675" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,983,800</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_pip0_dpi_marate2025_c20250101__20251231_zDODJ5rM56Qc" style="font-size: 10pt">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2025-01-01to2025-12-31" id="Fact001676" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">24.9</ix:nonFraction></span><span style="font-size: 10pt">%</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_981_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c20240101__20241231_zMr9ZKcuNona" title="Income tax benefit at statutory rate" style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2024-01-012024-12-31" id="Fact001678" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,455,499</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_dpi_c20240101__20241231_z4GVmULZyP7f" style="font-size: 10pt">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2024-01-012024-12-31" id="Fact001679" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">22.6</ix:nonFraction></span><span style="font-size: 10pt">%</span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Change in valuation allowance</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_989_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maprovision2025_c20250101__20251231_zMUIjVGTqpLc" title="Change in valuation allowance" style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2025-01-01to2025-12-31" id="Fact001681" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,983,800</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_pip0_dpi_marate2025_c20250101__20251231_zHvwiCenaScl" style="font-size: 10pt"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2025-01-01to2025-12-31" id="Fact001682" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">22.6</ix:nonFraction></span><span style="font-size: 10pt">%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_987_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c20240101__20241231_zdyr5v627Cmf" title="Change in valuation allowance" style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2024-01-012024-12-31" id="Fact001684" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,455,499</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_dpi_c20240101__20241231_z1TeO8BKFuMi" style="font-size: 10pt"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2024-01-012024-12-31" id="Fact001685" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">22.6</ix:nonFraction></span><span style="font-size: 10pt">%</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_988_eus-gaap--IncomeTaxExpenseBenefit_d0_mtprovision2025_c20250101__20251231_z1RqDGAfPcNf" title="Effective income tax rate reconciliation" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2025-01-01to2025-12-31" id="Fact001687" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pip0_dp0_mtrate2025_c20250101__20251231_zhmLjvr2ewz7" style="font-size: 10pt"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2025-01-01to2025-12-31" id="Fact001688" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8211;</ix:nonFraction></span><span style="font-size: 10pt">%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_980_eus-gaap--IncomeTaxExpenseBenefit_d0_c20240101__20241231_zAUFj5ujmvPi" title="Effective income tax rate reconciliation" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="Fact001690" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pip0_dp0_c20240101__20241231_zstWZS4RSFbh" style="font-size: 10pt"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2024-01-012024-12-31" id="Fact001691" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8211;</ix:nonFraction></span><span style="font-size: 10pt">%</span></td>
    <td>&#160;</td></tr>
  </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company&#8217;s
calculation of net operating loss carryforwards:</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001693" name="us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock"><table cellspacing="0" cellpadding="0" summary="xdx: Disclosure - INCOME TAXES (Details - Operating loss carryforwards)" id="xdx_88C_eus-gaap--SummaryOfOperatingLossCarryforwardsTextBlock_z9tlH1zytSh1" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt"><span id="xdx_8BB_zd0nrNFVfkUb" style="display: none">Schedule of net operating loss carryforwards</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_49F_20251231_zzT8UvYvcx4f" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_499_20241231_zk929KRLf6K8" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2025</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2024</b></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0" style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Deferred tax assets</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0" style="vertical-align: bottom; background-color: white">
    <td style="width: 68%"><span style="font-size: 10pt">Net operating loss carryforwards</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2025-12-31" id="Fact001698" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">28,184,213</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2024-12-31" id="Fact001699" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">24,971,010</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pp0p0" style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Section 174 R&amp;D</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2025-12-31" id="Fact001701" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,084,044</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2024-12-31" id="Fact001702" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,275,054</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_pp0p0" style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">PPE and intangible assets</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="AsOf2025-12-31" id="Fact001704" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">974,646</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="AsOf2024-12-31" id="Fact001705" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">915,327</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsStateTaxes_iNI_pp0p0_di_zxtLMq6E5fo9" style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">State taxes</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsStateTaxes" contextRef="AsOf2025-12-31" id="Fact001707" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,667,634</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsStateTaxes" contextRef="AsOf2024-12-31" id="Fact001708" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,569,922</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsGross_iI_pp0p0_zDPigNQka0d5" style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Subtotal</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2025-12-31" id="Fact001710" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">28,575,269</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2024-12-31" id="Fact001711" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,591,469</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_zxpC5d1kvps6" style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Valuation Allowance</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2025-12-31" id="Fact001713" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">28,575,269</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-12-31" id="Fact001714" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,591,469</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iI_pp0p0_d0_zNgvx6e3tjdf" style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Net deferred tax assets (liabilities)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2025-12-31" id="Fact001716" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2024-12-31" id="Fact001717" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>At December
31, 2025, the Company had approximately $<span id="xdx_90F_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20251231_zRiquT0WSzX" title="Net operating loss carry forwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2025-12-31" id="Fact001719" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">99,000,000</ix:nonFraction></span> of unused net operating loss carryforwards. Unused net operating loss carryforwards
may provide future benefits although there can be no assurance that these net operating losses will be realized in the future. The tax
benefits of these loss carryforwards have been fully offset by valuation allowance. These losses may be used to offset future taxable
income and will carryforward indefinitely.</span></p>

<ix:exclude><p id="xdx_237_zBaBzWmsF884" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_239_zFdTndSlAlma" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>&#160;</span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span></span></p>

<ix:exclude><!-- Field: Page; Sequence: 84 -->
    <div id="xdx_237_zOZWXDgzD94a" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23B_zZlTXijQY1m2" style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001723" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_807_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zW3f44dxS5Bh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 13 &#8211; <span id="xdx_82B_zxTHs3KSiwRl">RELATED PARTY
TRANSACTIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2023, the Company entered into a
transaction with AG Bio Life Capital I LP (&#8220;AG&#8221;), a Delaware limited partnership, where an employee of the Company is the
general partner. The Company agreed to issue <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesOther_c20230929__20230930__dei--LegalEntityAxis__custom--AGBioLifeCapitalILPMember_zR1n5s9xhjB" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2023-09-292023-09-30_custom_AGBioLifeCapitalILPMember" id="Fact001725" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">600,000</ix:nonFraction></span> shares (pre-reverse stock split) of common stock of the Company (&#8220;AG Shares&#8221;)
to AG, in exchange for $600,000, consisting of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230929__20230930__dei--LegalEntityAxis__custom--AGBioLifeCapitalILPMember_zzoClMlBNOr2" title="Proceeds from common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-09-292023-09-30_custom_AGBioLifeCapitalILPMember" id="Fact001727" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span>&#160;payable in cash and the balance payable under a promissory note (&#8220;AG
Note&#8221;). The principal amount including all interest under the AG Note is due and payable by AG no later than August 30, 2024 (the
&#8220;AG Maturity Date&#8221;). The outstanding unpaid principal balance of the AG Note bears interest commencing as of the Company&#8217;s
next registration statement at the rate of six (6%) percent per annum, which interest rate will increase to eighteen (18%) percent per
annum in the event an event of default occurs under the AG Note, computed on the basis of the actual number of days elapsed and a year
of 365 days. On August
12, 2024, AG transferred and assigned $<span id="xdx_90D_eus-gaap--AccountsAndNotesReceivableNet_iI_c20240812__dei--LegalEntityAxis__custom--AGBioLifeCapitalILPMember_zt4MEzfZ3Vm5" title="Note receivable"><ix:nonFraction name="us-gaap:AccountsAndNotesReceivableNet" contextRef="AsOf2024-08-12_custom_AGBioLifeCapitalILPMember" id="Fact001729" format="ixt:numdotdecimal" decimals="0" unitRef="USD">522,667</ix:nonFraction></span> to the Company, the sum of principal and accrued interest owed, of shares of common stock
in a privately held company. As a result of this assignment agreement, the AG Note is considered paid in full, and $<span id="xdx_901_eus-gaap--Investments_iI_pp0p0_c20241231__dei--LegalEntityAxis__custom--AGBioLifeCapitalILPMember_zJj2u1A5LDCj" title="Investment"><span id="xdx_908_eus-gaap--Investments_iI_pp0p0_c20251231__dei--LegalEntityAxis__custom--AGBioLifeCapitalILPMember_zvYnXx4HlYfa" title="Investment"><ix:nonFraction name="us-gaap:Investments" contextRef="AsOf2024-12-31_custom_AGBioLifeCapitalILPMember" id="Fact001731" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:Investments" contextRef="AsOf2025-12-31_custom_AGBioLifeCapitalILPMember" id="Fact001733" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">522,667</ix:nonFraction></ix:nonFraction></span></span> is recorded
as an investment at December 31, 2025 and December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2025, the Company accrued $<span id="xdx_901_eus-gaap--AccruedProfessionalFeesCurrent_iI_c20251231__srt--CounterpartyNameAxis__custom--BoardOfDirectorsMember_zj2iVD9VrIYc" title="Accrued professional fees"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2025-12-31_custom_BoardOfDirectorsMember" id="Fact001735" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,500</ix:nonFraction></span>
of professional services expenses related to Board of Directors and Scientific Advisory Board compensation. These payments were completed
in the first quarter of 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2025, the Company holds investments
in certain privately held companies, recorded as investments on the Company&#8217;s consolidated balance sheets. The Company&#8217;s Chief
Executive Officer and Chief Financial Officer each hold ownership interests in these privately held companies. The investments were made
in the ordinary course of business and on terms management believes are consistent with those that would be negotiated on an arm&#8217;s
length basis. As of December 31, 2025 and December 31, 2024, the Company&#8217;s carrying value of these investments was $<span id="xdx_900_eus-gaap--OtherInvestments_iI_c20251231_zd0uOhaLl93a" title="Other investments"><ix:nonFraction name="us-gaap:OtherInvestments" contextRef="AsOf2025-12-31" id="Fact001737" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,023,583</ix:nonFraction></span> and
$<span id="xdx_904_eus-gaap--OtherInvestments_iI_c20241231_zzZ8i5BALxYf" title="Other investments"><ix:nonFraction name="us-gaap:OtherInvestments" contextRef="AsOf2024-12-31" id="Fact001739" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,691,084</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001741" name="us-gaap:IntangibleAssetsDisclosureTextBlock"><p id="xdx_80B_eus-gaap--IntangibleAssetsDisclosureTextBlock_znCU8q6tmIEc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 14 &#8211; <span id="xdx_82F_zGxZBhbJiuUi">INTANGIBLE ASSETS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 19, 2024, the Company acquired the
assets of NexGenAI Affiliates Network Platform (&#8220;NexGenAI&#8221;), from the seller NexGenAI Solutions Group, Inc., which contains
AI-powered marketing software and robotic process automation capabilities. The acquired assets include intellectual property, a domain
name and associated website, and the technology stack as defined in the agreement. As consideration for the purchase, the Company paid
the seller <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20241218__20241219__srt--CounterpartyNameAxis__custom--NexGenAISolutionsGroupIncMember_zxxpMjYJ7uMc" title="Stock issued for purchase of assets, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" contextRef="From2024-12-182024-12-19_custom_NexGenAISolutionsGroupIncMember" id="Fact001743" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">187,500</ix:nonFraction></span> shares of common stock, or $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_c20241218__20241219__srt--CounterpartyNameAxis__custom--NexGenAISolutionsGroupIncMember_zPXxYWvYHTBf" title="Stock issued for purchase of assets, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="From2024-12-182024-12-19_custom_NexGenAISolutionsGroupIncMember" id="Fact001745" format="ixt:numdotdecimal" decimals="0" unitRef="USD">541,875</ix:nonFraction></span>. In connection with the purchase, the Company entered into a Master Services Agreement
with the seller, for website development services and for services to enhance the existing technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounted for the NexGenAI
transaction as an asset acquisition in accordance with ASC 805-50, <i>Business Combinations &#8211; Asset Acquisitions</i>, and
recorded as intangible assets on the consolidated balance sheet, net of amortization, in the amount of $<span id="xdx_907_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NexGenAIMember_zEZSlZrsouye"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2025-12-31_custom_NexGenAIMember" id="Fact001746" format="ixt:numdotdecimal" decimals="0" unitRef="USD">361,250</ix:nonFraction></span>
and $<span id="xdx_907_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NexGenAIMember_zRwZr0OfhrS2"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2024-12-31_custom_NexGenAIMember" id="Fact001747" format="ixt:numdotdecimal" decimals="0" unitRef="USD">541,875</ix:nonFraction></span> as of December 31,
2025 and December 31, 2024, respectively. The Company recorded amortization expense of $<span id="xdx_902_eus-gaap--AmortizationOfIntangibleAssets_c20250101__20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NexGenAIMember_zzOPVyxdJ9Xa" title="Amortization of intangible assets"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2025-01-012025-12-31_custom_NexGenAIMember206525843" id="Fact001749" format="ixt:numdotdecimal" decimals="0" unitRef="USD">180,625</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NexGenAIMember_zmayEPTz88A8" title="Amortization of intangible assets"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2024-01-012024-12-31_custom_NexGenAIMember206525843" id="Fact001751" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> during the years ended
December 31, 2025 and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001753" name="us-gaap:SegmentReportingDisclosureTextBlock"><p id="xdx_80A_eus-gaap--SegmentReportingDisclosureTextBlock_zY5Niu9LSMA7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 15 &#8211;&#160;<span id="xdx_82A_zw6rAoezTV4k">SEGMENT REPORTING</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Operating segments are components of an enterprise
about which separate financial information is available and is evaluated regularly by management, namely the Chief Operating Decision
Maker (&#8220;CODM&#8221;) of an organization, in order to determine operating and resource allocation decisions. By this definition,
the Company has identified its Chief Executive Officer as the CODM. Effective in 2024, the Company began operating in <span id="xdx_90B_eus-gaap--NumberOfReportableSegments_dxL_uInteger_c20250101__20251231_zb3RIjcYUnDb" title="Number of reportable segments::XDX::2"><span style="-sec-ix-hidden: xdx2ixbrl1755">two</span></span> segments: Biotechnology
and Technology. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Biotechnology Segment: This segment is non-revenue
generating and incurs expenses by developing its biotechnology product pipeline. The Biotechnology Segment had total assets of $<span id="xdx_904_eus-gaap--Assets_iI_c20251231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologySegmentMember_zoqgt0yQYyVf" title="Total assets"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-12-31_custom_BiotechnologySegmentMember" id="Fact001757" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,783,575</ix:nonFraction></span>
and $<span id="xdx_90B_eus-gaap--Assets_iI_c20241231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologySegmentMember_zXVZlhuEh8Rf" title="Total assets"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31_custom_BiotechnologySegmentMember" id="Fact001759" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,366,785</ix:nonFraction></span> as of December 31, 2025 and December 31, 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Technology Segment: This segment is revenue
generating and incurs expenses by acquiring technology assets to support and enhance operational capabilities through advanced technologies.
The Technology Segment had total assets of $<span id="xdx_901_eus-gaap--Assets_iI_c20251231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologySegmentMember_zxE2wSUQ1rq3" title="Total assets"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-12-31_custom_TechnologySegmentMember" id="Fact001761" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,370,346</ix:nonFraction></span> and $<span id="xdx_908_eus-gaap--Assets_iI_c20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologySegmentMember_zPVZQ3Gu47Z9" title="Total assets"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31_custom_TechnologySegmentMember" id="Fact001763" format="ixt:numdotdecimal" decimals="0" unitRef="USD">541,875</ix:nonFraction></span> as of December 31, 2025 and December 31, 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company believes that this structure reflects
its current operational and financial management, and that it provides the best structure for the Company to focus on growth opportunities
while maintaining financial discipline. The factors used to identify the Biotechnology and Technology operating segments were the difference
in future potential revenue streams and customer base for each segment, the reporting structure for operational and performance information
within the Company, and management&#8217;s decision to organize the Company around the different future potential revenue generating activities
of the segments.</p>

<ix:exclude><p id="xdx_233_z9eedzdcFpL8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_236_zEmmAKaXbBUf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_230_z5seE5fJ4zz9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 85 -->
    <div id="xdx_233_zZLDJz0CRjNj" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_239_zNXbEYhVFzof" style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Segment information relating the Company's two operating segments
for the years ended December 31, 2025 and December 31, 2024 are as follows:</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001768" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock"><table cellspacing="0" cellpadding="0" summary="xdx: Disclosure - SEGMENT REPORTING (Details)" id="xdx_89D_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zjX9HX3W2cJ8" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: White">
    <td><span id="xdx_8B3_zhFTKBU63z7i" style="display: none">Schedule of segment information</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="10" style="text-align: center"><span style="font-size: 10pt"><b>Year Ended December 31, 2025</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Biotechnology Segment</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Technology <br/>
Segment</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Consolidated</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 58%"><span style="font-size: 10pt">Sales</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98D_eus-gaap--Revenues_d0_c20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_zjOPg0dyozD" title="Sales" style="width: 11%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-01-012025-12-31_custom_BiotechnologyMember" id="Fact001770" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98C_eus-gaap--Revenues_c20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyMember_zuSi0ncYYfZ4" title="Sales" style="width: 11%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-01-012025-12-31_custom_TechnologyMember" id="Fact001772" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,363,045</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98C_eus-gaap--Revenues_c20250101__20251231_zt2l2Yxxzvah" title="Sales" style="width: 11%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-01-01to2025-12-31" id="Fact001774" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,363,045</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Cost of goods sold</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--CostOfRevenue_d0_c20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_z1mQVpjjabw5" title="Cost of goods sold" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2025-01-012025-12-31_custom_BiotechnologyMember" id="Fact001776" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--CostOfRevenue_c20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyMember_zQ2UtSYCMW95" title="Cost of goods sold" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2025-01-012025-12-31_custom_TechnologyMember" id="Fact001778" format="ixt:numdotdecimal" decimals="0" unitRef="USD">180,625</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98A_eus-gaap--CostOfRevenue_c20250101__20251231_zdGumLwZcbV9" title="Cost of goods sold" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2025-01-01to2025-12-31" id="Fact001780" format="ixt:numdotdecimal" decimals="0" unitRef="USD">180,625</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">Total operating expenses</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_982_eus-gaap--OperatingExpenses_c20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_zRhfiiVMtsQj" title="Total operating expenses" style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2025-01-012025-12-31_custom_BiotechnologyMember" id="Fact001782" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,540,971</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_983_eus-gaap--OperatingExpenses_c20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyMember_zFIuUn47BtQg" title="Total operating expenses" style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2025-01-012025-12-31_custom_TechnologyMember" id="Fact001784" format="ixt:numdotdecimal" decimals="0" unitRef="USD">684,947</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98C_eus-gaap--OperatingExpenses_c20250101__20251231_zizQaAuvHgX8" title="Total operating expenses" style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2025-01-01to2025-12-31" id="Fact001786" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,225,918</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Net (loss) gain from operations</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_988_eus-gaap--OperatingIncomeLoss_c20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_zvvYDj8S3lU" title="Net loss from operations" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-01-012025-12-31_custom_BiotechnologyMember" id="Fact001788" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,540,971</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_980_eus-gaap--OperatingIncomeLoss_c20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyMember_zHMKDyZHlpV5" title="Net loss from operations" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-01-012025-12-31_custom_TechnologyMember" id="Fact001790" format="ixt:numdotdecimal" decimals="0" unitRef="USD">497,473</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_988_eus-gaap--OperatingIncomeLoss_c20250101__20251231_ziLj9kCiPnkj" title="Net loss from operations" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-01-01to2025-12-31" id="Fact001792" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,043,498</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" summary="xdx: Disclosure - SEGMENT REPORTING (Details)" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="10" style="text-align: center"><span style="font-size: 10pt"><b>Year Ended December 31, 2024</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Biotechnology Segment</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Technology </b></span><br/>
<span style="font-size: 10pt"><b>Segment</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Consolidated</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 61%"><span style="font-size: 10pt">Sales</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_982_eus-gaap--Revenues_d0_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_zRch71FsyVI1" title="Sales" style="width: 10%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-01-012024-12-31_custom_BiotechnologyMember" id="Fact001794" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_984_eus-gaap--Revenues_d0_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyMember_zUGb5ZvWrtNk" title="Sales" style="width: 10%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-01-012024-12-31_custom_TechnologyMember" id="Fact001796" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98C_eus-gaap--Revenues_d0_c20240101__20241231_zPccjbODzKA5" title="Sales" style="width: 10%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-01-012024-12-31" id="Fact001798" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Cost of goods sold</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_985_eus-gaap--CostOfRevenue_d0_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_zIWFmPX2DPKj" title="Cost of goods sold" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2024-01-012024-12-31_custom_BiotechnologyMember" id="Fact001800" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_981_eus-gaap--CostOfRevenue_d0_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyMember_zLUfAV0Y7P9a" title="Cost of goods sold" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2024-01-012024-12-31_custom_TechnologyMember" id="Fact001802" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--CostOfRevenue_d0_c20240101__20241231_zZD7MCnt0iKf" title="Cost of goods sold" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2024-01-012024-12-31" id="Fact001804" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">Total operating expenses</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98C_eus-gaap--OperatingExpenses_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_zO2St6XwO9Wa" title="Total operating expenses" style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-012024-12-31_custom_BiotechnologyMember" id="Fact001806" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,054,488</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98F_eus-gaap--OperatingExpenses_d0_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyMember_znnmn6cYX5D3" title="Total operating expenses" style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-012024-12-31_custom_TechnologyMember" id="Fact001808" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_982_eus-gaap--OperatingExpenses_c20240101__20241231_zOWjJnUP578e" title="Total operating expenses" style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-012024-12-31" id="Fact001810" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,054,488</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Net loss from operations</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98B_eus-gaap--OperatingIncomeLoss_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_zxUQWwHKpD9k" title="Net loss from operations" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-012024-12-31_custom_BiotechnologyMember" id="Fact001812" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,054,488</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98E_eus-gaap--OperatingIncomeLoss_d0_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyMember_zYzKkFg1aHWd" title="Net loss from operations" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-012024-12-31_custom_TechnologyMember" id="Fact001814" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98E_eus-gaap--OperatingIncomeLoss_c20240101__20241231_z1Se8kIKBQFh" title="Net (loss) gain from operations" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact001816" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,054,488</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">)</span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A9_zz9cU8sRXl2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001818" name="coep:PendingMergerTransactionDisclosureTextBlock"><p id="xdx_808_ecustom--PendingMergerTransactionDisclosureTextBlock_zLg0tYgYaVR8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 16 &#8211; <span id="xdx_823_zbJIHfzTMJCg">PENDING MERGER
TRANSACTION</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 25, 2025, the Company (&#8220;Coeptis&#8221;
or the &#8220;Purchaser&#8221;), entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) with CP Merger Sub
Inc., a Wyoming corporation and wholly-owned subsidiary of Coeptis (&#8220;Merger Sub&#8221;), and Z Squared, Inc., a Wyoming corporation
(&#8220;Z Squared&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Merger Agreement, subject to the
terms and conditions set forth therein, upon the consummation of the transactions contemplated by the Merger Agreement (the &#8220;Closing&#8221;),
(i) Merger Sub will merge with and into Z Squared (the &#8220;Merger&#8221;) and (ii) Coeptis will immediately prior to the Merger effect
a spin out of its biotechnology operations (the &#8220;Spin Out&#8221; and, together with Merger and the other transactions contemplated
by the Merger Agreement, the &#8220;Transactions&#8221;), with Z squared continuing as the surviving corporation in the Merger and becoming
a wholly-owned subsidiary of Coeptis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the Merger, all shares of Z Squared common
stock issued and outstanding immediately prior to the effective time of the Merger (other than those properly exercising any applicable
dissenters rights under Wyoming law), will be converted into the right to receive a portion of the Merger Consideration (as defined below)
and (ii) any other outstanding securities with the right to convert into or acquire equity securities of Z Squared will be terminated.
At the Closing, Coeptis will change its name as mutually agreed upon by the Purchaser and Z Squared. <span>The
Merger is expected to close in the second quarter 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Spin Out, all of Coeptis&#8217;
assets comprising its biotechnology business will be assigned and contributed prior to Closing to one or more Spin Out Subsidiaries, which
will then spin out to Coeptis&#8217; stockholders of record on the record date established for the Coeptis Special Meeting (as defined
below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate Merger Consideration received by
Z Squared security holders from Coeptis at the Closing will be a number of shares of Purchaser Common Stock that represents at Closing
the Applicable Percentage of Purchaser&#8217;s issued and outstanding shares of Purchaser Common Stock as calculated on a Fully-Diluted
Basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001820" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_zf7swnmyJLMh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE
17 &#8211; <span id="xdx_820_zrwqph3Huiol">SUBSEQUENT EVENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management has performed a review of all events
and transactions occurring after December 31, 2025 for items that would require adjustment to or disclosure in the accompanying consolidated
financial statements, noting no such items or transactions other than the following.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 12, 2026, the Company received a written
notice from The Nasdaq Stock Market (&#8220;Nasdaq&#8221;), indicating that the Company was not in compliance with Nasdaq Listing Rules
5620(a) and 5810(c)(2)G) due to the Company&#8217;s failure to hold an annual meeting of shareholders within twelve months of the end
of the Company&#8217;s fiscal year end of December 31, 2024. On February 9, 2026, the Company was notified by The Nasdaq Stock Market
that the Company has regained compliance with the annual meeting requirement for continued listing on The Nasdaq Capital Market. Accordingly,
the Company has regained compliance with Nasdaq Listing Rules and the matter is now closed.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 12, 2026, 1,464 shares of common stock
were issued in connection the SEPA, resulting in net cash proceeds of $20,862.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 28, 2026, 13,809 shares of common stock
were issued in connection the SEPA, resulting in net cash proceeds of $180,942.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 5, 2026, 24,000 shares of common stock
were issued in connection the SEPA, resulting in net cash proceeds of $302,450.</p>

<ix:exclude><p id="xdx_23B_z3Ek2NEFBvql" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_230_zekXwlBiqKL4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_231_zvRhEY4x2lYb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_234_zQYRwVakFar9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 86 -->
    <div id="xdx_230_zvfBFISnfQth" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_235_zwlefww53Nd2" style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 11, 2026, the Company implemented
an option repricing/exchange program pursuant to Option Repricing and Exchange Election Agreements (the Option/Exchange Agreements) with
its then current holders of options previously granted under the Company&#8217;s 2022 Equity Incentive Plan, including each of the Company&#8217;s
current officers and directors. These Option/Exchange Agreements provided a one-time opportunity for the option holders to elect to either
(i) have a one-time option repricing be applied to their respective options with exercise prices greater than the current fair market
value of the Company&#8217;s common stock or (ii) surrender their outstanding options with exercise prices greater than the current fair
market value of the Company&#8217;s common stock in exchange for restricted stock. In connection with the Option/Exchange Program, the
Company also accelerated vesting of all options including those with exercise prices greater than the current fair market value of the
Company&#8217;s common stock, such that all options became fully vested.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s Board of Directors approved
the Option/Exchange program, including the accelerated vesting and the optionality of electing to reprice certain options or replace such
options with restricted stock. The Company&#8217;s stockholders approved this one-time repricing or exchange event at its recent stockholders
meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to these Option/Exchange Agreements,
officers and directors surrendered options to purchase a total of 112,500 shares of common stock, and received in exchange thereof 112,500
shares of restricted stock. Other option holders surrendered a total of 17,125 options to purchase shares of common stock and received
in exchange thereof 17,125 shares of restricted stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, certain officers and directors of
the Company exercised their respective retained options in full, pursuant to which officers and directors exercised options to purchase
a total of 198,375 shares of restricted common stock. Other option holders exercised options to purchase a total of 9,000 shares of restricted
common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Option/Exchange Agreements include customary
representations and warranties and acknowledgements by the participants. The foregoing description of the Option/Exchange Agreements does
not purport to be complete and is qualified in its entirety by reference to the full text of the Option/Exchange Agreements, a form of
which will be filed as an exhibit to a subsequent filing with the Securities and Exchange Commission.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 2, 2026, the holder of a standalone option exercised the option
to purchase 100,000 shares of the Company&#8217;s common stock. Upon exercise of the option, the Company issued 100,000 shares of restricted
common stock in accordance with the terms of the option agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</ix:nonNumeric><p id="xdx_817_zXZG0MSgrrw" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 87; Options: Last -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>2
<FILENAME>coeptis_ex1901.htm
<DESCRIPTION>COEPTIS THERAPEUTICS HOLDINGS, INC. INSIDER TRADING COMPLIANCE POLICY
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 19.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>COEPTIS THERAPEUTICS HOLDINGS, INC. INSIDER
TRADING COMPLIANCE POLICY</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 81.7pt 0pt 127.4pt; text-indent: -2.9pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt">This Insider Trading Compliance Policy (this &ldquo;<B><I>Policy</I></B>&rdquo;)
consists of seven sections:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Section I provides an overview;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Section II sets forth the policies of the Company prohibiting insider trading;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Section III explains insider trading;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Section IV consists of procedures that have been put in place by the Company to prevent insider trading;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Section V sets forth additional transactions that are prohibited by this Policy;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Section VI explains Rule 10b5-1 trading plans and provides information about Section 16 and Rule 144; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Section VII refers to the execution and return of a certificate of compliance.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt"><B>I.</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><B>SUMMARY</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Preventing insider trading
is necessary to comply with securities laws and to preserve the reputation and integrity of COEPTIS THERAPEUTICS HOLDINGS, INC. (the &ldquo;<B><I>Company</I></B>&rdquo;)
as well as that of all persons affiliated with the Company. &ldquo;Insider trading&rdquo; occurs when any person purchases or sells a
security while in possession of inside information relating to the security. As explained in Section III below, &ldquo;inside information&rdquo;
is information that is both &ldquo;material&rdquo; and &ldquo;non-public.&rdquo; Insider trading is a crime. The penalties for violating
insider trading laws include imprisonment, disgorgement of profits, civil fines, and significant criminal fines. Insider trading is also
prohibited by this Policy, and violation of this Policy may result in Company-imposed sanctions, including termination of employment for
cause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.7pt 0pt 5.95pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Policy applies to all
officers, directors and employees of the Company. Individuals subject to this Policy are responsible for ensuring that members of their
households also comply with this Policy. This Policy also applies to any entities controlled by individuals subject to the Policy and
over which such individual influences or controls such entity&rsquo;s investment decisions, including any corporations, partnerships or
trusts, and transactions by these entities should be treated for the purposes of this Policy and applicable securities laws as if they
were for the individual&rsquo;s own account. This Policy extends to all activities within and outside an individual&rsquo;s Company duties.
Every officer, director and employee must review this Policy. Questions regarding the Policy should be directed to any person(s) serving
as the Company&rsquo;s principal financial officer or his or her designee (each and, collectively, the &ldquo;<B><I>Policy Designee</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.65pt 0pt 5.95pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt"><B>II.</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><B>STATEMENT OF POLICIES PROHIBITING INSIDER TRADING</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No officer, director or employee
shall purchase or sell any type of security while in possession of material, non-public information relating to the security, whether
the issuer of such security is the Company or any other company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.7pt 0pt 5.95pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Additionally, no officer,
director or other employee designated from time to time by the Board of Directors or the Policy Designee as being subject to quarterly
blackout periods, including, in each case, such person&rsquo;s household members and entities over which such person influences or controls
such entity&rsquo;s investment decisions (collectively, &ldquo;<I>Covered Persons</I>,&rdquo; and, individually, a &ldquo;<I>Covered Person</I>&rdquo;),
shall purchase or sell any security of the Company during the period beginning at 11:59 p.m., Eastern time, on the fourteenth calendar
day before the end of any fiscal quarter of the Company and ending upon the completion of the second full trading day after the public
release of earnings data for such fiscal quarter or during any other trading suspension period declared by the Company. For example, if
the Company&rsquo;s fourth fiscal quarter ends at 11:59 p.m., Eastern time, on December 31, the corresponding blackout period would begin
at 11:59 p.m., Eastern time, on December 17. For the purposes of this Policy, a &ldquo;trading day&rdquo; is a day on which national stock
exchanges are open for trading.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.95pt">These prohibitions do not apply to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.95pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">purchases of the Company&rsquo;s securities by a Covered Person from the Company or sales of the Company&rsquo;s securities by a Covered Person to the Company;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">exercises of stock options or other equity awards or the surrender of shares to the Company in payment of the exercise price or in satisfaction of any tax withholding obligations in a manner permitted by the applicable equity award agreement, or vesting of equity-based awards, that in each case do not involve a market sale of the Company&rsquo;s securities (the &ldquo;cashless exercise&rdquo; of a Company stock option through a broker does involve a market sale of the Company&rsquo;s securities, and therefore would not qualify under this exception);</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">bona fide gifts of the Company&rsquo;s securities; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">purchases or sales of the Company&rsquo;s securities made pursuant to any binding contract, specific instruction or written plan entered into outside of a black-out period and while the purchaser or seller, as applicable, was unaware of any material, non-public information and which contract, instruction or plan (i) meets all of the requirements of the affirmative defense provided by Rule 10b5-1 (&ldquo;<B><I>Rule 10b5-1</I></B>&rdquo;) promulgated under the Securities Exchange Act of 1934, as amended (the &ldquo;<B><I>1934 Act</I></B>&rdquo;), (ii) was pre-cleared in advance pursuant to this Policy and (iii) has not been amended or modified in any respect after such initial pre-clearance without such amendment or modification being pre-cleared in advance pursuant to this Policy. For more information about Rule 10b5-1 trading plans, see Section VI below.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No officer, director or employee
shall directly or indirectly communicate (or &ldquo;<B><I>tip</I></B>&rdquo;) material, non- public information to anyone outside of the
Company (except in accordance with the Company&rsquo;s policies regarding the protection or authorized external disclosure of Company
information) or to anyone within the Company other than on a need-to-know basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.7pt 0pt 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt"><B>III.</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><B>EXPLANATION OF INSIDER TRADING</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Insider trading</I></B>&rdquo;
refers to the purchase or sale of a security while in possession of &ldquo;material,&rdquo; &ldquo;non-public&rdquo; information relating
to the security or its issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.7pt 0pt 6pt; text-align: justify; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Securities</I></B>&rdquo;
include stocks, bonds, notes, debentures, options, warrants and other convertible securities, as well as derivative instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt 0pt 6pt; text-align: justify; text-indent: 38.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Purchase</I></B>&rdquo;
and &ldquo;<B><I>sale</I></B>&rdquo; are defined broadly under the federal securities law. &ldquo;Purchase&rdquo; includes not only the
actual purchase of a security, but any contract to purchase or otherwise acquire a security. &ldquo;Sale&rdquo; includes not only the
actual sale of a security, but any contract to sell or otherwise dispose of a security. These definitions extend to a broad range of transactions,
including conventional cash-for-stock transactions, conversions, the exercise of stock options, and acquisitions and exercises of warrants
or puts, calls or other derivative securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.6pt 0pt 6pt; text-align: justify; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is generally understood
that insider trading includes the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">trading by insiders while in possession of material, non-public information;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">trading by persons other than insiders while in possession of material, non-public information, if the information either was given in breach of an insider&rsquo;s fiduciary duty to keep it confidential or was misappropriated; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">communicating or tipping material, non-public information to others, including recommending the purchase or sale of a security while in possession of such information.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">A.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">What Facts are Material?</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The materiality of a fact
depends upon the circumstances. A fact is considered &ldquo;material&rdquo; if there is a substantial likelihood that a reasonable investor
would consider it important in making a decision to buy, sell or hold a security, or if the fact is likely to have a significant effect
on the market price of the security. Material information can be positive or negative and can relate to virtually any aspect of a company&rsquo;s
business or to any type of security, debt or equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.65pt 0pt 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt">Examples of material information include (but are not limited
to) information about:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">corporate earnings or earnings forecasts;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">possible mergers, acquisitions, tender offers or dispositions;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">major new products or product developments;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">incidents involving cybersecurity or data protection;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">important business developments;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">management or control changes;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">significant financing developments including pending public sales or offerings of debt or equity securities;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">defaults on borrowings;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">bankruptcies; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">significant litigation or regulatory actions.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, material information
does not have to be related to a company&rsquo;s business. For example, the contents of a forthcoming newspaper column that is expected
to affect the market price of a security can be material.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt 0pt 5.95pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A good general rule of thumb:
<B>When in doubt, do not trade</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt 0pt 5.95pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">B.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">What is Non-Public?</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Information is &ldquo;non-public&rdquo;
if it is not available to the general public. In order for information to be considered public, it must be widely disseminated in a manner
making it generally available to investors through such media as <U>Dow Jones</U>, <U>Business Wire</U>, <U>Reuters</U>, <U>The Wall Street
Journal</U>, <U>Associated Press</U>, or <U>United Press International</U>, a broadcast on widely available radio or television programs,
publication in a widely available newspaper, magazine or news web site, a Regulation FD-compliant conference call, or public disclosure
documents filed with the Securities and Exchange Commission (&ldquo;<B><I>SEC</I></B>&rdquo;) that are available on the SEC&rsquo;s web
site.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.7pt 0pt 5.95pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The circulation of rumors,
even if accurate and reported in the media, does not constitute effective public dissemination. In addition, even after a public announcement,
a reasonable period of time must lapse in order for the market to react to the information. Generally, one should allow two full trading
days following publication as a reasonable waiting period before such information is deemed to be public.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">C.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Who is an Insider?</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Insiders</I></B>&rdquo;
include officers, directors and employees of a company and anyone else who has material inside information about a company. Insiders have
independent fiduciary duties to their company and its stockholders not to trade on material, non-public information relating to the company&rsquo;s
securities. All officers, directors and employees should consider themselves insiders with respect to material, non- public information
about the Company&rsquo;s business, activities and securities. Officers, directors and employees may not trade in the Company&rsquo;s
securities while in possession of material, non-public information relating to the Company, nor may they tip such information to anyone
outside the Company (except in accordance with the Company&rsquo;s policies regarding the protection or authorized external disclosure
of Company information) or to anyone within the Company other than on a need-to-know basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Individuals subject to this
Policy are responsible for ensuring that members of their households also comply with this Policy. This Policy also applies to any entities
controlled by individuals subject to the Policy and over which such individual influences or controls such entity&rsquo;s investment decisions,
including any corporations, partnerships or trusts, and transactions by these entities should be treated for the purposes of this Policy
and applicable securities laws as if they were for the individual&rsquo;s own account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.7pt 0pt 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">D.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Trading by Persons Other than Insiders.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Insiders may be liable for
communicating or tipping material, non-public information to a third party (&ldquo;<B>tippee</B>&rdquo;), and insider trading violations
are not limited to trading or tipping by insiders. Persons other than insiders also can be liable for insider trading, including tippees
who trade on material, non-public information tipped to them or individuals who trade on material, non-public information that has been
misappropriated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt 0pt 6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Tippees inherit an insider&rsquo;s
duties and are liable for trading on material, non-public information illegally tipped to them by an insider. Similarly, just as insiders
are liable for the insider trading of their tippees, so are tippees who pass the information along to others who trade.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt 0pt 6pt; text-align: justify; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In other words, a tippee&rsquo;s
liability for insider trading is no different from that of an insider. Tippees can obtain material, non-public information by receiving
overt tips from others or through, among other things, conversations at social, business, or other gatherings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 5.95pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">E.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Penalties for Engaging in Insider Trading.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Penalties for trading on or
tipping material, non-public information can extend significantly beyond any profits made or losses avoided, both for individuals engaging
in such unlawful conduct and their employers. The SEC and Department of Justice have made the civil and criminal prosecution of insider
trading violations a top priority. Enforcement remedies available to the government or private plaintiffs under the federal securities
laws include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt 0pt 5.95pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">SEC administrative sanctions;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">securities industry self-regulatory organization sanctions;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">civil injunctions;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">damage awards to private plaintiffs;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">disgorgement of all profits;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">civil fines for the violator of up to three times the amount of profit gained or loss avoided;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">civil fines for the employer or other controlling person of a violator (i.e., where the violator is an employee or other controlled person) of up to the greater of $1,000,000 (subject to adjustment for inflation) or three times the amount of profit gained or loss avoided by the violator;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">criminal fines for individual violators of up to $5,000,000 ($25,000,000 for an entity); and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">jail sentences of up to 20 years.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, insider trading
could result in serious sanctions by the Company, including dismissal. Insider trading violations are not limited to violations of the
federal securities laws. Other federal and state civil or criminal laws, such as the laws prohibiting mail and wire fraud and the Racketeer
Influenced and Corrupt Organizations Act (&ldquo;<B><I>RICO</I></B>&rdquo;), also may be violated in connection with insider trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.7pt 0pt 5.95pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">F.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Size of Transaction and Reason for Transaction Do Not <U>Matter.</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The size of the transaction
or the amount of profit received does not have to be significant to result in prosecution. The SEC has the ability to monitor even the
smallest trades, and the SEC performs routine market surveillance. Brokers and dealers are required by law to inform the SEC of any possible
violations by people who may have material, non-public information. The SEC aggressively investigates even small insider trading violations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.65pt 0pt 5.95pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">G.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Examples of Insider Trading.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Examples of insider trading
cases include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.95pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">actions brought against corporate officers, directors, and employees who traded in a company&rsquo;s securities after learning of significant confidential corporate developments;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">friends, business associates, family members and other tippees of such officers, directors, and employees who traded in the securities after receiving such information;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">government employees who learned of such information in the course of their employment; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">other persons who misappropriated, and took advantage of, confidential information from their employers.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following are illustrations
of insider trading violations. These illustrations are hypothetical and, consequently, not intended to reflect on the actual activities
or business of the Company or any other entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.6pt 0pt 5.95pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><U>Trading by Insider</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">An officer of X Corporation learns that
earnings to be reported by X Corporation will increase dramatically. Prior to the public announcement of such earnings, the officer purchases
X Corporation&rsquo;s stock. The officer, an insider, is liable for all profits as well as penalties of up to three times the amount of
all profits. The officer also is subject to, among other things, criminal prosecution, including up to $5,000,000 in additional fines
and 20 years in jail. Depending upon the circumstances, X Corporation and the individual to whom the officer reports also could be liable
as controlling persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><U>Trading by Tippee</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">An officer of X Corporation tells a
friend that X Corporation is about to publicly announce that it has concluded an agreement for a major acquisition. This tip causes the
friend to purchase X Corporation&rsquo;s stock in advance of the announcement. The officer is jointly liable with his friend for all of
the friend&rsquo;s profits, and each is liable for all civil penalties of up to three times the amount of the friend&rsquo;s profits.
The officer and his friend are also subject to criminal prosecution and other remedies and sanctions, as described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.65pt 0pt 41.95pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">H.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Prohibition of Records Falsification and False Statements</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 13(b)(2) of the 1934
Act requires companies subject to the Act to maintain proper internal books and records and to devise and maintain an adequate system
of internal accounting controls. The SEC has supplemented the statutory requirements by adopting rules that prohibit (1) any person from
falsifying records or accounts subject to the above requirements and (2) officers or directors from making any materially false, misleading,
or incomplete statement to any accountant in connection with any audit or filing with the SEC. These provisions reflect the SEC&rsquo;s
intent to discourage officers, directors and other persons with access to the Company&rsquo;s books and records from taking action that
might result in the communication of materially misleading financial information to the investing public.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.7pt 0pt 5.95pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt"><B>IV.</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><B>STATEMENT OF PROCEDURES PREVENTING INSIDER TRADING</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following procedures have
been established, and will be maintained and enforced, by the Company to prevent insider trading. Every officer, director and employee
is required to follow these procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.65pt 0pt 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">A.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Pre-Clearance of All Trades by All Officers, Directors and Certain Employees</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To provide assistance in preventing
inadvertent violations of applicable securities laws and to avoid the appearance of impropriety in connection with the purchase and sale
of the Company&rsquo;s securities, <B>all transactions in the Company&rsquo;s securities (including without limitation, acquisitions and
dispositions of Company stock, the exercise of stock options and the sale of Company stock issued upon exercise of stock options) by Covered
Persons and such other employees as are designated from time to time by the Board of Directors or the Policy Designee as being subject
to this pre-clearance process (each, a &ldquo;<I>Pre-Clearance Person</I>&rdquo;) must be pre- cleared</B> by the Company&rsquo;s Policy
Designee. Pre-clearance does not relieve anyone of his or her responsibility under SEC rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A request for pre-clearance
may be oral or in writing (including without limitation by e- mail), should be made at least two business days in advance of the proposed
transaction and should include the identity of the Pre-Clearance Person, the type of proposed transaction (for example, an open market
purchase, a privately negotiated sale, an option exercise, etc.), the proposed date of the transaction and the number of shares or options
to be involved. In addition, unless otherwise determined by the Policy Designee, the Pre-Clearance Person must execute a certification
(in the form approved by the Policy Designee) that he, she or it is not aware of material, nonpublic information about the Company. The
Policy Designee shall have sole discretion to decide whether to clear any contemplated transaction, provided that a Policy Designee shall
have sole discretion to decide whether to clear transactions by another Policy Designee or persons or entities subject to this policy
as a result of their relationship with such other Policy Designee. All trades that are pre- cleared must be effected within five business
days of receipt of the pre- clearance unless a specific exception has been granted by the Policy Designee. A pre-cleared trade (or any
portion of a pre- cleared trade) that has not been effected during the five business day period must be pre- cleared again prior to execution.
Notwithstanding receipt of pre-clearance, if the Pre-Clearance Person becomes aware of material, non-public information or becomes subject
to a black-out period before the transaction is effected, the transaction may not be completed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">B.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Black-Out Periods</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Additionally, no Covered
Person shall purchase or sell any security of the Company during the period beginning at 11:59 p.m., Eastern time, on the fourteenth calendar
day before the end of any fiscal quarter of the Company and ending upon the completion of the second full trading day after the public
release of earnings data for such fiscal quarter or during any other trading suspension period declared by the Company, </B>except for
purchases and sales made pursuant to the permitted transactions described in Section II. For example, if the Company&rsquo;s fourth fiscal
quarter ends at 11:59 p.m., Eastern time, on December 31, the corresponding blackout period would begin at 11:59 p.m., Eastern time, on
December 17.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.7pt 0pt 6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Exceptions to the black-out
period policy may be approved only the Policy Designee (or, in the case of an exception for a Policy Designee or persons or entities subject
to this policy as a result of their relationship with such Policy Designee, another Policy Designee or, in the case of exceptions for
directors or persons or entities subject to this policy as a result of their relationship with a director, the Board of Directors).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt 0pt 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, the Company,
through the Board of Directors, the Company&rsquo;s disclosure committee or the Policy Designee, may recommend that officers, directors,
employees or others suspend trading in the Company&rsquo;s securities because of developments that have not yet been disclosed to the
public. Subject to the exceptions noted above, all of those affected should not trade in the Company&rsquo;s securities while the suspension
is in effect, and should not disclose to others that the Company has suspended trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.65pt 0pt 5.95pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Company is required
to impose a &ldquo;pension fund black-out period&rdquo; under Regulation BTR, each director and executive officer shall not, directly
or indirectly sell, purchase or otherwise transfer during such black-out period any equity securities of the Company acquired in connection
with his or her service as a director or officer of the Company, except as permitted by Regulation BTR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt 0pt 5.95pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">C.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Post-Termination Transactions</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If an individual is in possession
of material, non-public information when his or her service terminates, that individual may not trade in the Company&rsquo;s securities
until that information has become public or is no longer material.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.65pt 0pt 5.95pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">D.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Information Relating to the Company</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><I>Access to Information</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Access to material,
non-public information about the Company, including the Company&rsquo;s business, earnings or prospects, should be limited to officers,
directors and employees of the Company on a need-to-know basis. In addition, such information should not be communicated to anyone outside
the Company under any circumstances (except in accordance with the Company&rsquo;s policies regarding the protection or authorized external
disclosure of Company information) or to anyone within the Company on an other than need-to-know basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt 0pt 41.95pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">In communicating
material, non-public information to employees of the Company, all officers, directors and employees must take care to emphasize the need
for confidential treatment of such information and adherence to the Company&rsquo;s policies with regard to confidential information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt 0pt 41.95pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><I>Inquiries From Third Parties</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Inquiries from third
parties, such as industry analysts or members of the media, about the Company should be directed to the Policy Designee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 41.95pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">E.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Limitations on Access to Company Information</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following procedures are
designed to maintain confidentiality with respect to the Company&rsquo;s business operations and activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 5.95pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All officers, directors and
employees should take all steps and precautions necessary to restrict access to, and secure, material, non-public information by, among
other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 5.95pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">maintaining the confidentiality of Company-related transactions;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">conducting their business and social activities so as not to risk inadvertent disclosure of confidential information. Review of confidential documents in public places should be conducted so as to prevent access by unauthorized persons;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">restricting access to documents and files (including computer files) containing material, non-public information to individuals on a need-to-know basis (including maintaining control over the distribution of documents and drafts of documents);</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">promptly removing and cleaning up all confidential documents and other materials from conference rooms following the conclusion of any meetings;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">disposing of all confidential documents and other papers, after there is no longer any business or other legally required need, through shredders when appropriate;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">restricting access to areas likely to contain confidential documents or material, non- public information;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">safeguarding laptop computers, mobile devices, tablets, memory sticks, CDs and other items that contain confidential information; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">avoiding the discussion of material, non-public information in places where the information could be overheard by others such as in elevators, restrooms, hallways, restaurants, airplanes or taxicabs.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Personnel involved with material,
non-public information, to the extent feasible, should conduct their business and activities in areas separate from other Company activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 5.95pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt"><B>V.</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><B>ADDITIONAL PROHIBITED TRANSACTIONS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has determined
that there is a heightened legal risk and/or the appearance of improper or inappropriate conduct if the persons subject to this Policy
engage in certain types of transactions. Therefore, officers, directors and employees shall comply with the following policies with respect
to certain transactions in the Company securities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt 0pt 5.95pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">A.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Short Sales</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Short sales of the Company&rsquo;s
securities evidence an expectation on the part of the seller that the securities will decline in value, and therefore signal to the market
that the seller has no confidence in the Company or its short-term prospects. In addition, short sales may reduce the seller&rsquo;s incentive
to improve the Company&rsquo;s performance. For these reasons, short sales of the Company&rsquo;s securities are prohibited by this Policy.
In addition, as noted below, Section 16(c) of the 1934 Act absolutely prohibits Section 16 reporting persons from making short sales of
the Company&rsquo;s equity securities, i.e., sales of shares that the insider does not own at the time of sale, or sales of shares against
which the insider does not deliver the shares within 20 days after the sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">B.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Publicly Traded Options</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A transaction in options is,
in effect, a bet on the short-term movement of the Company&rsquo;s stock and therefore creates the appearance that an officer, director
or employee is trading based on inside information. Transactions in options also may focus an officer&rsquo;s, director&rsquo;s or employee&rsquo;s
attention on short-term performance at the expense of the Company&rsquo;s long-term objectives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt 0pt 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Accordingly, transactions
in puts, calls or other derivative securities involving the Company&rsquo;s equity securities, on an exchange or in any other organized
market, are prohibited by this Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt 0pt 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">C.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Hedging Transactions</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain forms of hedging or
monetization transactions, such as zero-cost collars and forward sale contracts, allow an officer, director or employee to lock in much
of the value of his or her stock holdings, often in exchange for all or part of the potential for upside appreciation in the stock. These
transactions allow the officer, director or employee to continue to own the covered securities, but without the full risks and rewards
of ownership. When that occurs, the officer, director or employee may no longer have the same objectives as the Company&rsquo;s other
stockholders. Therefore, all hedging transactions involving the Company&rsquo;s equity securities are prohibited by this Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.6pt 0pt 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">D.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Purchases of the Company&rsquo;s Securities on Margin; Pledging the Company&rsquo;s Securities to Secure Margin or Other Loans</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Purchasing on margin means
borrowing from a brokerage firm, bank or other entity in order to purchase the Company&rsquo;s securities (other than in connection with
a cashless exercise of stock options through a broker under the Company&rsquo;s equity plans). Margin purchases of the Company&rsquo;s
securities are prohibited by this Policy. Pledging the Company&rsquo;s securities as collateral to secure loans is prohibited. This prohibition
means, among other things, that you cannot hold the Company&rsquo;s securities in a &ldquo;margin account&rdquo; (which would allow you
to borrow against your holdings to buy securities).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.7pt 0pt 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">E.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Director and Executive Officer Cashless Exercises</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company will not arrange
with brokers to administer cashless exercises on behalf of directors and executive officers of the Company. Directors and executive officers
of the Company may use the cashless exercise feature of their equity awards only if (i) the director or officer retains a broker independently
of the Company, (ii) the Company&rsquo;s involvement is limited to confirming that it will deliver the stock promptly upon payment of
the exercise price, (iii) the director or officer uses a &ldquo;T+2&rdquo; cashless exercise arrangement, in which the Company agrees
to deliver stock against the payment of the purchase price on the same day the sale of the stock underlying the equity award settles and
(iv) the director or officer otherwise complies with this Policy. Under a T+2 cashless exercise, a broker, the issuer, and the issuer&rsquo;s
transfer agent work together to make all transactions settle simultaneously. This approach is to avoid any inference that the Company
has &ldquo;extended credit&rdquo; in the form of a personal loan to the director or executive officer. Questions about cashless exercises
should be directed to the Policy Designee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 6pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">F.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Partnership Distributions</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nothing in this Policy is
intended to limit the ability of a venture capital partnership or other similar entity with which a director is affiliated to distribute
Company securities to its partners, members or other similar persons. It is the responsibility of each affected director and the affiliated
entity, in consultation with their own counsel (as appropriate), to determine the timing of any distributions, based on all relevant facts
and circumstances and applicable securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt"><B>VI.</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><B>RULE 10B5-1 TRADING PLANS, SECTION 16 AND RULE 144</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">A.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Rule 10b5-1 Trading Plans</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><I>Overview</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Rule 10b5-1 will
protect directors, officers and employees from insider trading liability under Rule 10b5-1 for transactions under a previously established
contract, plan or instruction to trade in the Company&rsquo;s stock (a &ldquo;Trading Plan&rdquo;) entered into in good faith and in accordance
with the terms of Rule 10b5-1 and all applicable state laws and will be exempt from the trading restrictions set forth in this Policy.
The initiation of, and any modification to, any such Trading Plan will be deemed to be a transaction in the Company&rsquo;s securities,
and such initiation or modification is subject to all limitations and prohibitions relating to transactions in the Company&rsquo;s securities.
Each such Trading Plan, and any modification thereof, must be submitted to and pre- approved by the Company&rsquo;s Policy Designee, or
such other person as the Board of Directors may designate from time to time (the &ldquo;Authorizing Officer&rdquo;), who may impose such
conditions on the implementation and operation of the Trading Plan as the Authorizing Officer deems necessary or advisable. However, compliance
of the Trading Plan to the terms of Rule 10b5-1 and the execution of transactions pursuant to the Trading Plan are the sole responsibility
of the person initiating the Trading Plan, not the Company or the Authorizing Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.55pt 0pt 41.95pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>Trading Plans
do not exempt individuals from complying with Section 16 short- swing profit rules or liability.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 41.95pt; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Rule 10b5-1 presents
an opportunity for insiders to establish arrangements to sell (or purchase) Company stock without the restrictions of trading windows
and black-out periods, even when there is undisclosed material information. A Trading Plan may also help reduce negative publicity that
may result when key executives sell the Company&rsquo;s stock. Rule 10b5-1 only provides an &ldquo;affirmative defense&rdquo; in the event
there is an insider trading lawsuit. It does not prevent someone from bringing a lawsuit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt 0pt 41.95pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">A director, officer
or employee may enter into a Trading Plan only when he or she is not in possession of material, non-public information, and only during
a trading window period outside of the trading black-out period. Although transactions effected under a Trading Plan will not require
further pre-clearance at the time of the trade, any transaction (including the quantity and price) made pursuant to a Trading Plan of
a Section 16 reporting person must be reported to the Company promptly on the day of each trade to permit the Company&rsquo;s filing coordinator
to assist in the preparation and filing of a required Form 4. Such reporting may be oral or in writing (including by e-mail) and should
include the identity of the reporting person, the type of transaction, the date of the transaction, the number of shares involved and
the purchase or sale price. However, the ultimate responsibility, and liability, for timely filing remains with the Section 16 reporting
person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt 0pt 42pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">The Company reserves
the right from time to time to suspend, discontinue or otherwise prohibit any transaction in the Company&rsquo;s securities, even pursuant
to a previously approved Trading Plan, if the Authorizing Officer or the Board of Directors, in its discretion, determines that such suspension,
discontinuation or other prohibition is in the best interests of the Company. Any Trading Plan submitted for approval hereunder should
explicitly acknowledge the Company&rsquo;s right to prohibit transactions in the Company&rsquo;s securities. Failure to discontinue purchases
and sales as directed shall constitute a violation of the terms of this Section VI and result in a loss of the exemption set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.6pt 0pt 42pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Officers, directors
and employees may adopt Trading Plans with brokers that outline a pre- set plan for trading of the Company&rsquo;s stock, including the
exercise of options. Trades pursuant to a Trading Plan generally may occur at any time. However, the Company requires a cooling-off period
of 30 days between the establishment of a Trading Plan and commencement of any transactions under such plan. An individual may adopt more
than one Trading Plan. Please review the following description of how a Trading Plan works.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Pursuant to Rule
10b5-1, an individual&rsquo;s purchase or sale of securities will not be &ldquo;on the basis of&rdquo; material, non-public information
if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.7pt 0pt 42pt; text-align: justify; text-indent: 35.95pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">First, before becoming aware of the information, the individual enters into a binding contract to purchase or sell the securities, provides instructions to another person to sell the securities or adopts a written plan for trading the securities (i.e., the Trading Plan).</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Second, the Trading Plan must either:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">specify the amount of securities to be purchased or sold, the price at which the securities are to be purchased or sold and the date on which the securities are to be purchased or sold;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">include a written formula or computer program for determining the amount, price and date of the transactions; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">prohibit the individual from exercising any subsequent influence over the purchase or sale of the Company&rsquo;s stock under the Trading Plan in question.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Third, the purchase or sale must occur pursuant to the Trading Plan and the individual must not enter into a corresponding hedging transaction or alter or deviate from the Trading Plan.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><I>Revocation of and Amendments to Trading Plans</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Revocation of Trading
Plans should occur only in unusual circumstances. Effectiveness of any revocation or amendment of a Trading Plan will be subject to the
prior review and approval of the Authorizing Officer. Revocation is effected upon written notice to the broker. Once a Trading Plan has
been revoked, the participant should wait at least 30 days before trading outside of a Trading Plan and 180 days before establishing a
new Trading Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.7pt 0pt 42pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">A person acting
in good faith may amend a prior Trading Plan so long as such amendments are made outside of a quarterly trading black-out period and at
a time when the Trading Plan participant does not possess material, non-public information. Plan amendments must not take effect for at
least 30 days after the plan amendments are made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt 0pt 42pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Under certain circumstances,
a Trading Plan must be revoked. This may include circumstances such as the announcement of a merger or the occurrence of an event that
would cause the transaction either to violate the law or to have an adverse effect on the Company. The Authorizing Officer or administrator
of the Company&rsquo;s stock plans is authorized to notify the broker in such circumstances, thereby insulating the insider in the event
of revocation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.65pt 0pt 42pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><I>Discretionary Plans</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Although non-discretionary
Trading Plans are preferred, discretionary Trading Plans, where the discretion or control over trading is transferred to a broker, are
permitted if pre-approved by the Authorizing Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.6pt 0pt 42pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">The Authorizing
Officer of the Company must pre-approve any Trading Plan, arrangement or trading instructions, etc., involving potential sales or purchases
of the Company&rsquo;s stock or option exercises, including but not limited to, blind trusts, discretionary accounts with banks or brokers,
or limit orders. The actual transactions effected pursuant to a pre-approved Trading Plan will not be subject to further pre-clearance
for transactions in the Company&rsquo;s stock once the Trading Plan or other arrangement has been pre-approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><I>Reporting (if Required)</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">If required, an
SEC Form 144 will be filled out and filed by the individual/brokerage firm in accordance with the existing rules regarding Form 144 filings.
A footnote at the bottom of the Form 144 should indicate that the trades &ldquo;are in accordance with a Trading Plan that complies with
Rule 10b5-1 and expires .&rdquo; For Section 16 reporting persons, Form 4s should be filed before the end of the second business day following
the date that the broker, dealer or plan administrator informs the individual that a transaction was executed, provided that the date
of such notification is not later than the third business day following the trade date. A similar footnote should be placed at the bottom
of the Form 4 as outlined above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.7pt 0pt 42pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><I>Options</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Exercises of options
for cash may be executed at any time. &ldquo;Cashless exercise&rdquo; option exercises through a broker are subject to trading windows.
However, the Company will permit same day sales under Trading Plans. If a broker is required to execute a cashless exercise in accordance
with a Trading Plan, then the Company must have exercise forms attached to the Trading Plan that are signed, undated and with the number
of shares to be exercised left blank. Once a broker determines that the time is right to exercise the option and dispose of the shares
in accordance with the Trading Plan, the broker will notify the Company in writing and the administrator of the Company&rsquo;s stock
plans will fill in the number of shares and the date of exercise on the previously signed exercise form. The insider should not be involved
with this part of the exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">6.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><I>Trades Outside of a Trading Plan</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">During an open trading
window, trades differing from Trading Plan instructions that are already in place are allowed as long as the Trading Plan continues to
be followed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.65pt 0pt 42pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">7.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><I>Public Announcements</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">The Company may
make a public announcement that Trading Plans are being implemented in accordance with Rule 10b5-1. It will consider in each case whether
a public announcement of a particular Trading Plan should be made. It may also make public announcements or respond to inquiries from
the media as transactions are made under a Trading Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.55pt 0pt 42pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">8.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><I>Prohibited Transactions</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">The transactions
prohibited under Section V of this Policy, including among others short sales and hedging transactions, may not be carried out through
a Trading Plan or other arrangement or trading instruction involving potential sales or purchases of the Company&rsquo;s securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 42pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">9.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><I>Limitation on Liability</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">None of the Company,
the Policy Designee, the Authorizing Officer, the Company&rsquo;s other employees or any other person will have any liability for any
delay in reviewing, or refusal of, a Trading Plan submitted pursuant to this Section VI or a request for pre-clearance submitted pursuant
to Section IV of this Policy. Notwithstanding any review of a Trading Plan pursuant to this Section VI or pre-clearance of a transaction
pursuant to Section IV of this Policy, none of the Company, the Policy Designee, the Authorizing Officer, the Company&rsquo;s other employees
or any other person assumes any liability for the legality or consequences of such Trading Plan or transaction to the person engaging
in or adopting such Trading Plan or transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">B.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Section 16: Insider Reporting Requirements, Short-Swing Profits and Short Sales</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><I>Reporting Obligations Under Section 16(a): SEC Forms 3, 4 and 5</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Section 16(a) of
the 1934 Act generally requires all officers, directors and 10% stockholders (&ldquo;Section 16 insiders&rdquo;), within 10 days after
the insider becomes an officer, director or 10% stockholder, to file with the SEC an &ldquo;Initial Statement of Beneficial Ownership
of Securities&rdquo; on SEC Form 3 listing the amount of the Company&rsquo;s stock, options and warrants which the Section 16 insider
beneficially owns. Following the initial filing on SEC Form 3, changes in beneficial ownership of the Company&rsquo;s stock, options and
warrants must be reported on SEC Form 4, generally within two business days after the date on which such change occurs, or in certain
cases on Form 5, within 45 days after fiscal year end. A Form 4 must be filed even if, as a result of balancing transactions, there has
been no net change in holdings. In certain situations, purchases or sales of Company stock made within six months prior to the filing
of a Form 3 must be reported on Form 4. Similarly, certain purchases or sales of Company stock made within six months after an officer
or director ceases to be a Section 16 insider must be reported on Form 4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.6pt 0pt 42pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><I>Recovery of Profits Under Section 16(b)</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">For the purpose
of preventing the unfair use of information which may have been obtained by a Section 16 insider, any profits realized by any officer,
director or 10% stockholder from any &ldquo;purchase&rdquo; and &ldquo;sale&rdquo; of Company stock during a six-month period, so called
&ldquo;short-swing profits,&rdquo; may be recovered by the Company. When such a purchase and sale occurs, good faith is no defense. The
Section 16 insider is liable even if compelled to sell for personal reasons, and even if the sale takes place after full disclosure and
without the use of any inside information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.65pt 0pt 41.95pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">The liability of
a Section 16 insider under Section 16(b) of the 1934 Act is only to the Company itself. The Company, however, cannot waive its right to
short swing profits, and any Company stockholder can bring suit in the name of the Company. Reports of ownership filed with the SEC on
Form 3, Form 4 or Form 5 pursuant to Section 16(a) (discussed above) are readily available to the public, and certain attorneys carefully
monitor these reports for potential Section 16(b) violations. In addition, liabilities under Section 16(b) may require separate disclosure
in the Company&rsquo;s annual report to the SEC on Form 10-K or its proxy statement for its annual meeting of stockholders. No suit may
be brought more than two years after the date the profit was realized. However, if the Section 16 insider fails to file a report of the
transaction under Section 16(a), as required, the two-year limitation period does not begin to run until after the transactions giving
rise to the profit have been disclosed. Failure to report transactions and late filing of reports require separate disclosure in the Company&rsquo;s
proxy statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.7pt 0pt 41.95pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Officers and directors
should consult the attached &ldquo;Short-Swing Profit Rule Section 16(b) Checklist&rdquo; attached hereto as &ldquo;Attachment A&rdquo;
in addition to consulting the Policy Designee prior to engaging in any transactions involving the Company&rsquo;s securities, including
without limitation, the Company&rsquo;s stock, options or warrants. The Company&rsquo;s employees who are not Section 16 insiders may
disregard Attachment A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 41.95pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><I>Short Sales Prohibited Under Section 16(c)</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Section 16(c) of
the 1934 Act prohibits Section 16 insiders absolutely from making short sales of the Company&rsquo;s equity securities. Short sales include
sales of stock which the Section 16 insider does not own at the time of sale, or sales of stock against which the Section 16 insider does
not deliver the shares within 20 days after the sale. Under certain circumstances, the purchase or sale of put or call options, or the
writing of such options, can result in a violation of Section 16(c). Section 16 insiders violating Section 16(c) face criminal liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.65pt 0pt 41.95pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">The Policy Designee
should be consulted if you have any questions regarding reporting obligations, short-swing profits or short sales under Section 16.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">C.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Rule 144</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Rule 144 provides a safe harbor
exemption to the registration requirements of the Securities Act of 1933, as amended, for certain resales of &ldquo;restricted securities&rdquo;
and &ldquo;control securities.&rdquo; &ldquo;Restricted securities&rdquo; are securities acquired from an issuer, or an affiliate of an
issuer, in a transaction or chain of transactions not involving a public offering. &ldquo;Control securities&rdquo; are any securities
owned by directors, executive officers or other &ldquo;affiliates&rdquo; of the issuer, including stock purchased in the open market and
stock received upon exercise of stock options. Sales of Company restricted and control securities must comply with the requirements of
Rule 144, which are summarized below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 6pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Holding Period</I></B>. Restricted securities must be held for at least six months before they may be sold in the market.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Current Public Information</I></B>. The Company must have filed all SEC-required reports during the last 12 months or such shorter period that the Company was required to file such reports.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Volume Limitations. For affiliates</I></B>, total sales of Company common stock for any three-month period may not exceed the greater of: (i) 1% of the total number of outstanding shares of Company common stock, as reflected in the most recent report or statement published by the Company, or (ii) the average weekly reported volume of such shares traded during the four calendar weeks preceding the filing of the requisite Form 144.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Method of Sale</I></B>. For affiliates, the shares must be sold either in a &ldquo;broker&rsquo;s transaction&rdquo; or in a transaction directly with a &ldquo;market maker.&rdquo; A &ldquo;broker&rsquo;s transaction&rdquo; is one in which the broker does no more than execute the sale order and receive the usual and customary commission. Neither the broker nor the selling person can solicit or arrange for the sale order. In addition, the selling person or Board member must not pay any fee or commission other than to the broker. A &ldquo;market maker&rdquo; includes a specialist permitted to act as a dealer, a dealer acting in the position of a block positioner, and a dealer who holds himself out as being willing to buy and sell Company common stock for his own account on a regular and continuous basis.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Notice of Proposed Sale</I></B>. For affiliates, a notice of the sale (a Form 144) may be required to be filed with the SEC at the time of the sale. Brokers generally have internal procedures for executing sales under Rule 144 and will assist you in completing the Form 144 and in complying with the other requirements of Rule 144.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you are subject to Rule
144, you must instruct your broker who handles trades in Company securities to follow the brokerage firm&rsquo;s Rule 144 compliance procedures
in connection with all trades.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt"><B>VII.</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><B>EXECUTION AND RETURN OF CERTIFICATION OF COMPLIANCE</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After reading this Policy,
all officers, directors and employees should execute and return to the Policy Designee the Certification of Compliance form attached hereto
as &ldquo;<U>Attachment B</U>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">* * * *</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 130.8pt 0pt 130.9pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>coeptis_ex2101.htm
<DESCRIPTION>SUBSIDIARIES OF COEPTIS THERAPEUTICS HOLDINGS, INC.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 21.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Subsidiaries of Coeptis Therapeutics Holdings,
Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">Coeptis Therapeutics, Inc.</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">Delaware</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Coeptis Pharmaceuticals, Inc.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Delaware</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Coeptis Pharmaceuticals LLC</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Pennsylvania</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">GEAR Therapeutics, Inc.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Florida</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">SNAP Biosciences, Inc.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Florida</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>coeptis_ex3101.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF THE </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PRINCIPAL EXECUTIVE OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RULE 13a-14(a) AND RULE 15d-14(a)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER THE </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934, </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, David Mehalick, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">I have reviewed this Annual Report on Form 10-K of Coeptis Therapeutics Holdings, Inc.;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Designed such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; and;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 65%; text-align: justify"><FONT STYLE="font-size: 10pt">Date: March 19, 2026</FONT></TD>
    <TD STYLE="width: 2%; text-align: justify"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 33%; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">/s/ David Mehalick</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">David Mehalick</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(Principal Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>coeptis_ex3102.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF THE </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PRINCIPAL FINANCIAL OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RULE 13a-14(a) AND RULE 15d-14(a)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER THE </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934, </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Brian Cogley, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">I have reviewed this Annual Report on Form 10-K of Coeptis Therapeutics Holdings, Inc.;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Designed such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; and;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 65%; text-align: justify"><FONT STYLE="font-size: 10pt">Date: March 19, 2026</FONT></TD>
    <TD STYLE="width: 2%; text-align: justify"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 33%; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">/s/ Brian Cogley</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Brian Cogley</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>coeptis_ex3201.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In connection with the Annual
Report on Form 10-K of Coeptis Therapeutics Holdings, Inc. (the &ldquo;Company&rdquo;) for the year ended December&nbsp;31, 2025, as filed
with the Securities and Exchange Commission (the &ldquo;Report&rdquo;), I, David Mehalick, Chief Executive Officer of the Company, certify,
pursuant to 18 U.S.C. &sect;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Report fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">To my knowledge, the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 65%; text-align: justify"><FONT STYLE="font-size: 10pt">Date: March 19, 2026</FONT></TD>
    <TD STYLE="width: 2%; text-align: justify"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 33%; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">/s/ David Mehalick</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">David Mehalick</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(Principal Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>coeptis_ex3202.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In connection with the Annual
Report on Form 10-K of Coeptis Therapeutics Holdings, Inc. (the &ldquo;Company&rdquo;) for the year ended December&nbsp;31, 2025, as filed
with the Securities and Exchange Commission (the &ldquo;Report&rdquo;), I, Brian Cogley, Chief Financial Officer of the Company, certify,
pursuant to 18 U.S.C. &sect;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Report fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">To my knowledge, the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the report.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 65%; text-align: justify"><FONT STYLE="font-size: 10pt">Date: March 19, 2026</FONT></TD>
    <TD STYLE="width: 2%; text-align: justify"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 33%; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">/s/ Brian Cogley</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Brian Cogley</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Chief Financial and Accounting Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>(Principal Financial Officer)</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>coep-20251231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +Kopo7xRiXgen8uEbXpMOaOGeaPty552mYkxvmR7fekajyUssTBC7SQUStKm0eEI -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:coep="http://coeptistx.com/20251231" elementFormDefault="qualified" targetNamespace="http://coeptistx.com/20251231">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://coeptistx.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
          <link:definition>00000002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/ConsolidatedStatementsOfOperations" id="ConsolidatedStatementsOfOperations">
          <link:definition>00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity" id="ConsolidatedStatementsOfStockholdersEquity">
          <link:definition>00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
          <link:definition>00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/DescriptionOfBusinessAndBasisOfPresentation" id="DescriptionOfBusinessAndBasisOfPresentation">
          <link:definition>999014 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>999015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/Co-developmentOptions" id="Co-developmentOptions">
          <link:definition>999016 - Disclosure - CO-DEVELOPMENT OPTIONS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/ConvertibleNotes" id="ConvertibleNotes">
          <link:definition>999017 - Disclosure - CONVERTIBLE NOTES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/SbaLoanPayable" id="SbaLoanPayable">
          <link:definition>999018 - Disclosure - SBA LOAN PAYABLE</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/DerivativeLiabilityWarrants" id="DerivativeLiabilityWarrants">
          <link:definition>999019 - Disclosure - DERIVATIVE LIABILITY WARRANTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/CapitalStructure" id="CapitalStructure">
          <link:definition>999020 - Disclosure - CAPITAL STRUCTURE</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/Non-controllingInterest" id="Non-controllingInterest">
          <link:definition>999021 - Disclosure - NON-CONTROLLING INTEREST</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/Investments" id="Investments">
          <link:definition>999022 - Disclosure - INVESTMENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>999023 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/KProfit-sharingPlan" id="KProfit-sharingPlan">
          <link:definition>999024 - Disclosure - 401(k) PROFIT-SHARING PLAN</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>999025 - Disclosure - INCOME TAXES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
          <link:definition>999026 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/IntangibleAssets" id="IntangibleAssets">
          <link:definition>999027 - Disclosure - INTANGIBLE ASSETS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/SegmentReporting" id="SegmentReporting">
          <link:definition>999028 - Disclosure - SEGMENT REPORTING</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/PendingMergerTransaction" id="PendingMergerTransaction">
          <link:definition>999029 - Disclosure - PENDING MERGER TRANSACTION</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>999030 - Disclosure - SUBSEQUENT EVENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>999031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
          <link:definition>999032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/ConvertibleNotesTables" id="ConvertibleNotesTables">
          <link:definition>999033 - Disclosure - CONVERTIBLE NOTES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/DerivativeLiabilityWarrantsTables" id="DerivativeLiabilityWarrantsTables">
          <link:definition>999034 - Disclosure - DERIVATIVE LIABILITY WARRANTS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/CapitalStructureTables" id="CapitalStructureTables">
          <link:definition>999035 - Disclosure - CAPITAL STRUCTURE (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
          <link:definition>999036 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>999037 - Disclosure - INCOME TAXES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/SegmentReportingTables" id="SegmentReportingTables">
          <link:definition>999038 - Disclosure - SEGMENT REPORTING (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative" id="DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative">
          <link:definition>999039 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetails" id="SummaryOfSignificantAccountingPoliciesDetails">
          <link:definition>999040 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>999041 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/Co-developmentOptionsDetailsNarrative" id="Co-developmentOptionsDetailsNarrative">
          <link:definition>999042 - Disclosure - CO-DEVELOPMENT OPTIONS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/ConvertibleNotesDetails-DerivativeLiability" id="ConvertibleNotesDetails-DerivativeLiability">
          <link:definition>999043 - Disclosure - CONVERTIBLE NOTES (Details - Derivative liability)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/ConvertibleNotesDetails-Assumptions" id="ConvertibleNotesDetails-Assumptions">
          <link:definition>999044 - Disclosure - CONVERTIBLE NOTES (Details - Assumptions)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/ConvertibleNotesDetails-ChangeInDeriviative" id="ConvertibleNotesDetails-ChangeInDeriviative">
          <link:definition>999045 - Disclosure - CONVERTIBLE NOTES (Details - Change in deriviative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/ConvertibleNotesDetailsNarrative" id="ConvertibleNotesDetailsNarrative">
          <link:definition>999046 - Disclosure - CONVERTIBLE NOTES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/SbaLoanPayableDetailsNarrative" id="SbaLoanPayableDetailsNarrative">
          <link:definition>999047 - Disclosure - SBA LOAN PAYABLE (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-FairValue" id="DerivativeLiabilityWarrantsDetails-FairValue">
          <link:definition>999048 - Disclosure - DERIVATIVE LIABILITY WARRANTS (Details - Fair value)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-FairValueAssumption" id="DerivativeLiabilityWarrantsDetails-FairValueAssumption">
          <link:definition>999049 - Disclosure - DERIVATIVE LIABILITY WARRANTS (Details - Fair value assumption)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-ChangesInFairValueOfWarrantLiabilities" id="DerivativeLiabilityWarrantsDetails-ChangesInFairValueOfWarrantLiabilities">
          <link:definition>999050 - Disclosure - DERIVATIVE LIABILITY WARRANTS (Details - Changes in fair value of warrant liabilities)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/DerivativeLiabilityWarrantsDetailsNarrative" id="DerivativeLiabilityWarrantsDetailsNarrative">
          <link:definition>999051 - Disclosure - DERIVATIVE LIABILITY WARRANTS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/CapitalStructureDetails-OptionActivity" id="CapitalStructureDetails-OptionActivity">
          <link:definition>999052 - Disclosure - CAPITAL STRUCTURE (Details - Option activity)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/CapitalStructureDetails-WeightedAverageAssumptions" id="CapitalStructureDetails-WeightedAverageAssumptions">
          <link:definition>999053 - Disclosure - CAPITAL STRUCTURE (Details - Weighted average assumptions)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/CapitalStructureDetails-WarrantsOutstanding" id="CapitalStructureDetails-WarrantsOutstanding">
          <link:definition>999054 - Disclosure - CAPITAL STRUCTURE (Details - Warrants outstanding)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/CapitalStructureDetailsNarrative" id="CapitalStructureDetailsNarrative">
          <link:definition>999055 - Disclosure - CAPITAL STRUCTURE (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/Non-controllingInterestDetailsNarrative" id="Non-controllingInterestDetailsNarrative">
          <link:definition>999056 - Disclosure - NON-CONTROLLING INTEREST (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/InvestmentsDetailsNarrative" id="InvestmentsDetailsNarrative">
          <link:definition>999057 - Disclosure - INVESTMENTS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/CommitmentsAndContingenciesDetails-LeaseCost" id="CommitmentsAndContingenciesDetails-LeaseCost">
          <link:definition>999058 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details - Lease cost)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/CommitmentsAndContingenciesDetails-FutureMinimumPayments" id="CommitmentsAndContingenciesDetails-FutureMinimumPayments">
          <link:definition>999059 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details - Future minimum payments)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>999060 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/KProfit-sharingPlanDetailsNarrative" id="KProfit-sharingPlanDetailsNarrative">
          <link:definition>999061 - Disclosure - 401(k) PROFIT-SHARING PLAN (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/IncomeTaxesDetails-ReconcilationOfIncomeTax" id="IncomeTaxesDetails-ReconcilationOfIncomeTax">
          <link:definition>999062 - Disclosure - INCOME TAXES (Details - Reconcilation of income tax)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/IncomeTaxesDetails-ReconcilationOfProvision" id="IncomeTaxesDetails-ReconcilationOfProvision">
          <link:definition>999063 - Disclosure - INCOME TAXES (Details - Reconcilation of provision)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/IncomeTaxesDetails-OperatingLossCarryforwards" id="IncomeTaxesDetails-OperatingLossCarryforwards">
          <link:definition>999064 - Disclosure - INCOME TAXES (Details - Operating loss carryforwards)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>999065 - Disclosure - INCOME TAXES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
          <link:definition>999066 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/IntangibleAssetsDetailsNarrative" id="IntangibleAssetsDetailsNarrative">
          <link:definition>999067 - Disclosure - INTANGIBLE ASSETS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/SegmentReportingDetails" id="SegmentReportingDetails">
          <link:definition>999068 - Disclosure - SEGMENT REPORTING (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://coeptistx.com/role/SegmentReportingDetailsNarrative" id="SegmentReportingDetailsNarrative">
          <link:definition>999069 - Disclosure - SEGMENT REPORTING (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="coep-20251231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="coep-20251231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="coep-20251231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="coep-20251231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://xbrl.sec.gov/cyd/2025" schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd" />
    <element id="coep_CommonStockParValue0.0001PerShareMember" name="CommonStockParValue0.0001PerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_WarrantsEachWholeWarrantExercisableForOnehalfOfOneShareOfCommonStockFor230.00PerWholeShareMember" name="WarrantsEachWholeWarrantExercisableForOnehalfOfOneShareOfCommonStockFor230.00PerWholeShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_SaleMember" name="SaleMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_CommonStockSubscribedMember" name="CommonStockSubscribedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_SubscriptionReceivableMember" name="SubscriptionReceivableMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_NexGenAIMember" name="NexGenAIMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_SixCustomersMember" name="SixCustomersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_AdvertisingCampaignsMember" name="AdvertisingCampaignsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_ThreeCustomersMember" name="ThreeCustomersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_WebinarServicesMember" name="WebinarServicesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_WarrantsMember" name="WarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_StockOptionsMember" name="StockOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_CD38AssetsMember" name="CD38AssetsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_VyGenMember" name="VyGenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_CoDevelopmentRightsMember" name="CoDevelopmentRightsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_CoDevelopmentOptionsMember" name="CoDevelopmentOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_LicenseAgreementMember" name="LicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_PurpleBioTechMember" name="PurpleBioTechMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_Oct2022ConvertiblePromissoryNoteMember" name="Oct2022ConvertiblePromissoryNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_Dec2023ConvertiblePromissoryNoteMember" name="Dec2023ConvertiblePromissoryNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_April2024UnsecuredNoteMember" name="April2024UnsecuredNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_YANote1Member" name="YANote1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_YorkvilleConvertibleNoteMember" name="YorkvilleConvertibleNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_StandbyEquityPurchaseAgreementMember" name="StandbyEquityPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_YANote2Member" name="YANote2Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_DerivativeLiabilityMember" name="DerivativeLiabilityMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_EidlLoanMember" name="EidlLoanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_PublicWarrantsMember" name="PublicWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_PrivatePlacementWarrantsMember" name="PrivatePlacementWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_WarrantLiabilitiesMember" name="WarrantLiabilitiesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_PublicOfferingMember" name="PublicOfferingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_PreFundedWarrantsMember" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_SeriesAWarrantsMember" name="SeriesAWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_SeriesBWarrantsMember" name="SeriesBWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_SeriesWarrantsMember" name="SeriesWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_WarrantNoteSubscriptionReceivablesMember" name="WarrantNoteSubscriptionReceivablesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_SNAPBiosciencesIncMember" name="SNAPBiosciencesIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_TwoInvestorMember" name="TwoInvestorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_ConsultingAgreementMember" name="ConsultingAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_ColleenDelaneyMember" name="ColleenDelaneyMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_ModificationOfOptionsMember" name="ModificationOfOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_CoralInvestmentPartnersMember" name="CoralInvestmentPartnersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_SubscriptionReceivableSept2023Member" name="SubscriptionReceivableSept2023Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_SubscriptionReceivableSept20232ndMember" name="SubscriptionReceivableSept20232ndMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_December2023FinancingMember" name="December2023FinancingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_February2024FinancingMember" name="February2024FinancingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_YorkvilleMember" name="YorkvilleMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_StockIssuedForServicesMember" name="StockIssuedForServicesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_ConvertibleNoteMember" name="ConvertibleNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_WarrantHolder1ExercisePrice59.40Member" name="WarrantHolder1ExercisePrice59.40Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_WarrantHolder1ExercisePrice118.80Member" name="WarrantHolder1ExercisePrice118.80Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_WarrantHolder1ExercisePrice296.80Member" name="WarrantHolder1ExercisePrice296.80Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_WarrantHolder2ExercisePrice59.40Member" name="WarrantHolder2ExercisePrice59.40Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_WarrantHolder2ExercisePrice296.80Member" name="WarrantHolder2ExercisePrice296.80Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_WarrantHolder5ExercisePrice59.40Member" name="WarrantHolder5ExercisePrice59.40Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_WarrantHolder18ExercisePrice178.20Member" name="WarrantHolder18ExercisePrice178.20Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_WarrantHolder20ExercisePrice50.00Member" name="WarrantHolder20ExercisePrice50.00Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_WarrantHolder21ExercisePrice38.00Member" name="WarrantHolder21ExercisePrice38.00Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_SeriesWarrantsAAndBExercisePrice27.20Member" name="SeriesWarrantsAAndBExercisePrice27.20Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_SeriesAWarrantsExercisePrice27.20Member" name="SeriesAWarrantsExercisePrice27.20Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_SeriesBWarrantsExercisePrice27.20Member" name="SeriesBWarrantsExercisePrice27.20Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_WarrantHolder22ExercisePrice25.00Member" name="WarrantHolder22ExercisePrice25.00Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_WarrantHolder22ExercisePrice28.00Member" name="WarrantHolder22ExercisePrice28.00Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_WarrantHolder23ExercisePrice25.00Member" name="WarrantHolder23ExercisePrice25.00Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_WarrantHolder23ExercisePrice28.00Member" name="WarrantHolder23ExercisePrice28.00Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_WarrantHolder24ExercisePrice28.00Member" name="WarrantHolder24ExercisePrice28.00Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_PreFundedWarrants2ExercisePrice0.002Member" name="PreFundedWarrants2ExercisePrice0.002Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_PreFundedWarrants3ExercisePrice0.002Member" name="PreFundedWarrants3ExercisePrice0.002Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_WarrantHolder25ExercisePrice12.00Member" name="WarrantHolder25ExercisePrice12.00Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_GearTherapeuticsMember" name="GearTherapeuticsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_TwoPrivatelyHeldCompaniesMember" name="TwoPrivatelyHeldCompaniesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_NexGenAIAffiliatesNetworkPlatformMember" name="NexGenAIAffiliatesNetworkPlatformMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_FivePrivatelyHeldCompaniesMember" name="FivePrivatelyHeldCompaniesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_ThreePrivatelyHeldCompaniesMember" name="ThreePrivatelyHeldCompaniesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_PrivatelyHeldCompanyMember" name="PrivatelyHeldCompanyMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_FirstYearExtensionMember" name="FirstYearExtensionMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_SecondYearExtensionMember" name="SecondYearExtensionMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_MehalickMember" name="MehalickMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_YeraceMember" name="YeraceMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_CarTLicenseMember" name="CarTLicenseMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_FindersFeeAndIndemnityAgreementMember" name="FindersFeeAndIndemnityAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_MasterServicesAgreementsMember" name="MasterServicesAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_GearCellTherapyPlatformMember" name="GearCellTherapyPlatformMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_AGBioLifeCapitalILPMember" name="AGBioLifeCapitalILPMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_BoardOfDirectorsMember" name="BoardOfDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_NexGenAISolutionsGroupIncMember" name="NexGenAISolutionsGroupIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_BiotechnologySegmentMember" name="BiotechnologySegmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_TechnologySegmentMember" name="TechnologySegmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_BiotechnologyMember" name="BiotechnologyMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_TechnologyMember" name="TechnologyMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="coep_CodevelopmentRightsNet" name="CodevelopmentRightsNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="coep_CommonStockSubscribed" name="CommonStockSubscribed" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="coep_GainOnForfeitureOfCustomerDeposit" name="GainOnForfeitureOfCustomerDeposit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="coep_GainsLossesOnExtinguishmentOfDebt1" name="GainsLossesOnExtinguishmentOfDebt1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="coep_SharesIssuedInConnectionWithSEPAValue" name="SharesIssuedInConnectionWithSEPAValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="coep_SharesIssuedInConnectionWithSEPAShares" name="SharesIssuedInConnectionWithSEPAShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="coep_SharesIssuedForInvestmentValue" name="SharesIssuedForInvestmentValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="coep_SharesIssuedForInvestmentShares" name="SharesIssuedForInvestmentShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="coep_StockIssuedDuringPeriodValueWarrantsIssuedForCash" name="StockIssuedDuringPeriodValueWarrantsIssuedForCash" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="coep_StockIssuedDuringPeriodValuePrefundedWarrantsExercise" name="StockIssuedDuringPeriodValuePrefundedWarrantsExercise" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="coep_StockIssuedDuringPeriodSharesPrefundedWarrantsExercise" name="StockIssuedDuringPeriodSharesPrefundedWarrantsExercise" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="coep_WarrantsIssuedInExchangeForSubscriptionsReceivable" name="WarrantsIssuedInExchangeForSubscriptionsReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="coep_SharesIssuedForConversionOfDebtValue" name="SharesIssuedForConversionOfDebtValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="coep_SharesIssuedForConversionOfDebtShares" name="SharesIssuedForConversionOfDebtShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="coep_StockIssuedDuringPeriodValueOfPreferredShareOffering" name="StockIssuedDuringPeriodValueOfPreferredShareOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="coep_StockIssuedDuringPeriodSharesOfPreferredShareOffering" name="StockIssuedDuringPeriodSharesOfPreferredShareOffering" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="coep_StockIssuedDuringPeriodValuePreferredShareConversion" name="StockIssuedDuringPeriodValuePreferredShareConversion" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="coep_StockIssuedDuringPeriodSharePreferredShareConversion" name="StockIssuedDuringPeriodSharePreferredShareConversion" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="coep_StockIssuedDuringPeriodValueOfInvestmentsAssignmentAgreements" name="StockIssuedDuringPeriodValueOfInvestmentsAssignmentAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="coep_StockIssuedDuringPeriodValuePurchaseOfAssets1" name="StockIssuedDuringPeriodValuePurchaseOfAssets1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="coep_WarrantsIssuedForServices" name="WarrantsIssuedForServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="coep_LossOnSharesIssuedForConversionOfDebt" name="LossOnSharesIssuedForConversionOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="coep_SharesIssuedForSepa" name="SharesIssuedForSepa" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="coep_SubscriptionsReceivable" name="SubscriptionsReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="coep_SharesIssuedForConversionOfDebt" name="SharesIssuedForConversionOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="coep_SharesIssuedForInvestment" name="SharesIssuedForInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="coep_SbaLoanPayableAbstract" name="SbaLoanPayableAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="coep_SbaLoanPayableDisclosureTextBlock" name="SbaLoanPayableDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="coep_DisclosurePendingMergerTransactionAbstract" name="DisclosurePendingMergerTransactionAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="coep_PendingMergerTransactionDisclosureTextBlock" name="PendingMergerTransactionDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="coep_DebtConversionConvertedInterestAmount1" name="DebtConversionConvertedInterestAmount1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="coep_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2OptionsGranted" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2OptionsGranted" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="coep_WarrantsAndRightsOutstandingDateIssued" name="WarrantsAndRightsOutstandingDateIssued" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="coep_StockIssuedForDebtShares" name="StockIssuedForDebtShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="coep_StockIssuedForDebtValue" name="StockIssuedForDebtValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="coep_ProceedsFromSubscriptionsReceivable" name="ProceedsFromSubscriptionsReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="coep_SubscriptionsReceivableNet" name="SubscriptionsReceivableNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="coep_SubscriptionReceivable" name="SubscriptionReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="coep_StockIssuedDuringPeriodSharesIssuedForInvestment" name="StockIssuedDuringPeriodSharesIssuedForInvestment" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="coep_StockIssuedDuringPeriodValueIssuedForInvestment" name="StockIssuedDuringPeriodValueIssuedForInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="coep_InvestmentCompanyFeePaidSharesIndirectly" name="InvestmentCompanyFeePaidSharesIndirectly" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="coep_OperatingLeaseRightOfUseAssetGross" name="OperatingLeaseRightOfUseAssetGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="coep_OperatingLeaseRightOfUseAssetAccumulatedDepreciation" name="OperatingLeaseRightOfUseAssetAccumulatedDepreciation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="coep_MonthlyRent" name="MonthlyRent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="coep_AnnualSalary" name="AnnualSalary" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="coep_InitialLicenseFee" name="InitialLicenseFee" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="coep_AnnualMaintenanceFeeDescription" name="AnnualMaintenanceFeeDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="coep_AgreementAmendmentFee" name="AgreementAmendmentFee" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="coep_ExpectedIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" name="ExpectedIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="coep_ExpectedEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" name="ExpectedEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="coep_DisclosureTable" name="DisclosureTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="coep_DisclosureLineElements" name="DisclosureLineElements" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>coep-20251231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#Cover" roleURI="http://coeptistx.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#ConsolidatedBalanceSheets" roleURI="http://coeptistx.com/role/ConsolidatedBalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://coeptistx.com/role/ConsolidatedBalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#ConsolidatedStatementsOfOperations" roleURI="http://coeptistx.com/role/ConsolidatedStatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#ConsolidatedStatementsOfStockholdersEquity" roleURI="http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#MaterialCybersecurityIncidentDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#DescriptionOfBusinessAndBasisOfPresentation" roleURI="http://coeptistx.com/role/DescriptionOfBusinessAndBasisOfPresentation" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://coeptistx.com/role/SummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#Co-developmentOptions" roleURI="http://coeptistx.com/role/Co-developmentOptions" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#ConvertibleNotes" roleURI="http://coeptistx.com/role/ConvertibleNotes" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#SbaLoanPayable" roleURI="http://coeptistx.com/role/SbaLoanPayable" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#DerivativeLiabilityWarrants" roleURI="http://coeptistx.com/role/DerivativeLiabilityWarrants" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#CapitalStructure" roleURI="http://coeptistx.com/role/CapitalStructure" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#Non-controllingInterest" roleURI="http://coeptistx.com/role/Non-controllingInterest" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#Investments" roleURI="http://coeptistx.com/role/Investments" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#CommitmentsAndContingencies" roleURI="http://coeptistx.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#KProfit-sharingPlan" roleURI="http://coeptistx.com/role/KProfit-sharingPlan" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#IncomeTaxes" roleURI="http://coeptistx.com/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#RelatedPartyTransactions" roleURI="http://coeptistx.com/role/RelatedPartyTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#IntangibleAssets" roleURI="http://coeptistx.com/role/IntangibleAssets" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#SegmentReporting" roleURI="http://coeptistx.com/role/SegmentReporting" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#PendingMergerTransaction" roleURI="http://coeptistx.com/role/PendingMergerTransaction" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#SubsequentEvents" roleURI="http://coeptistx.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#ConvertibleNotesTables" roleURI="http://coeptistx.com/role/ConvertibleNotesTables" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#DerivativeLiabilityWarrantsTables" roleURI="http://coeptistx.com/role/DerivativeLiabilityWarrantsTables" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#CapitalStructureTables" roleURI="http://coeptistx.com/role/CapitalStructureTables" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#CommitmentsAndContingenciesTables" roleURI="http://coeptistx.com/role/CommitmentsAndContingenciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#IncomeTaxesTables" roleURI="http://coeptistx.com/role/IncomeTaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#SegmentReportingTables" roleURI="http://coeptistx.com/role/SegmentReportingTables" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative" roleURI="http://coeptistx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#Co-developmentOptionsDetailsNarrative" roleURI="http://coeptistx.com/role/Co-developmentOptionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#ConvertibleNotesDetails-DerivativeLiability" roleURI="http://coeptistx.com/role/ConvertibleNotesDetails-DerivativeLiability" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#ConvertibleNotesDetails-Assumptions" roleURI="http://coeptistx.com/role/ConvertibleNotesDetails-Assumptions" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#ConvertibleNotesDetails-ChangeInDeriviative" roleURI="http://coeptistx.com/role/ConvertibleNotesDetails-ChangeInDeriviative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#ConvertibleNotesDetailsNarrative" roleURI="http://coeptistx.com/role/ConvertibleNotesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#SbaLoanPayableDetailsNarrative" roleURI="http://coeptistx.com/role/SbaLoanPayableDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#DerivativeLiabilityWarrantsDetails-FairValue" roleURI="http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-FairValue" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#DerivativeLiabilityWarrantsDetails-FairValueAssumption" roleURI="http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-FairValueAssumption" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#DerivativeLiabilityWarrantsDetails-ChangesInFairValueOfWarrantLiabilities" roleURI="http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-ChangesInFairValueOfWarrantLiabilities" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#DerivativeLiabilityWarrantsDetailsNarrative" roleURI="http://coeptistx.com/role/DerivativeLiabilityWarrantsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#CapitalStructureDetails-OptionActivity" roleURI="http://coeptistx.com/role/CapitalStructureDetails-OptionActivity" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#CapitalStructureDetails-WeightedAverageAssumptions" roleURI="http://coeptistx.com/role/CapitalStructureDetails-WeightedAverageAssumptions" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#CapitalStructureDetails-WarrantsOutstanding" roleURI="http://coeptistx.com/role/CapitalStructureDetails-WarrantsOutstanding" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#CapitalStructureDetailsNarrative" roleURI="http://coeptistx.com/role/CapitalStructureDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#Non-controllingInterestDetailsNarrative" roleURI="http://coeptistx.com/role/Non-controllingInterestDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#InvestmentsDetailsNarrative" roleURI="http://coeptistx.com/role/InvestmentsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#CommitmentsAndContingenciesDetails-LeaseCost" roleURI="http://coeptistx.com/role/CommitmentsAndContingenciesDetails-LeaseCost" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#CommitmentsAndContingenciesDetails-FutureMinimumPayments" roleURI="http://coeptistx.com/role/CommitmentsAndContingenciesDetails-FutureMinimumPayments" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://coeptistx.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#KProfit-sharingPlanDetailsNarrative" roleURI="http://coeptistx.com/role/KProfit-sharingPlanDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#IncomeTaxesDetails-ReconcilationOfIncomeTax" roleURI="http://coeptistx.com/role/IncomeTaxesDetails-ReconcilationOfIncomeTax" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#IncomeTaxesDetails-ReconcilationOfProvision" roleURI="http://coeptistx.com/role/IncomeTaxesDetails-ReconcilationOfProvision" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#IncomeTaxesDetails-OperatingLossCarryforwards" roleURI="http://coeptistx.com/role/IncomeTaxesDetails-OperatingLossCarryforwards" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#IncomeTaxesDetailsNarrative" roleURI="http://coeptistx.com/role/IncomeTaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#RelatedPartyTransactionsDetailsNarrative" roleURI="http://coeptistx.com/role/RelatedPartyTransactionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#IntangibleAssetsDetailsNarrative" roleURI="http://coeptistx.com/role/IntangibleAssetsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#SegmentReportingDetails" roleURI="http://coeptistx.com/role/SegmentReportingDetails" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#SegmentReportingDetailsNarrative" roleURI="http://coeptistx.com/role/SegmentReportingDetailsNarrative" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestReceivableCurrent" xlink:label="loc_us-gaapInterestReceivableCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInterestReceivableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaapOtherAssets" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Investments" xlink:label="loc_us-gaapInvestments" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssets" xlink:to="loc_us-gaapInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssets" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_CodevelopmentRightsNet" xlink:label="loc_coepCodevelopmentRightsNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssets" xlink:to="loc_coepCodevelopmentRightsNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNotesPayableCurrent" xlink:label="loc_us-gaapOtherNotesPayableCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaapDeferredRevenueCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDeferredRevenueCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapLongTermDebtNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_CommonStockSubscribed" xlink:label="loc_coepCommonStockSubscribed" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_coepCommonStockSubscribed" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:label="loc_us-gaapStockholdersEquityNoteSubscriptionsReceivable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquityNoteSubscriptionsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapMinorityInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSalariesAndWages" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="loc_us-gaapProfessionalAndContractServicesExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapProfessionalAndContractServicesExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapOtherGeneralAndAdministrativeExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapOtherGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaapSellingAndMarketingExpense" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingAndMarketingExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpenseNonoperating" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestAndOtherIncome" xlink:label="loc_us-gaapInterestAndOtherIncome" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestAndOtherIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_GainOnForfeitureOfCustomerDeposit" xlink:label="loc_coepGainOnForfeitureOfCustomerDeposit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_coepGainOnForfeitureOfCustomerDeposit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaapGainLossOnInvestments" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainLossOnInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="loc_us-gaapDisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapDisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_GainsLossesOnExtinguishmentOfDebt1" xlink:label="loc_coepGainsLossesOnExtinguishmentOfDebt1" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_coepGainsLossesOnExtinguishmentOfDebt1" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncome" xlink:label="loc_us-gaapOtherNoncashIncome" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOtherNoncashIncome" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensationNoncash" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensationNoncash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantsIssuedForServices" xlink:label="loc_coepWarrantsIssuedForServices" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_coepWarrantsIssuedForServices" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="loc_us-gaapUnrealizedGainLossOnDerivatives" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapUnrealizedGainLossOnDerivatives" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_LossOnSharesIssuedForConversionOfDebt" xlink:label="loc_coepLossOnSharesIssuedForConversionOfDebt" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_coepLossOnSharesIssuedForConversionOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaapIncreaseDecreaseInInterestPayableNet" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInterestPayableNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaapGainLossOnInvestments" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInInterestAndDividendsReceivable" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInterestAndDividendsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" />
      <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
      <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="loc_us-gaapProceedsFromRepaymentsOfNotesPayable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromRepaymentsOfNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SharesIssuedForSepa" xlink:label="loc_coepSharesIssuedForSepa" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_coepSharesIssuedForSepa" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:title="999014 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/Co-developmentOptions" xlink:title="999016 - Disclosure - CO-DEVELOPMENT OPTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/ConvertibleNotes" xlink:title="999017 - Disclosure - CONVERTIBLE NOTES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/SbaLoanPayable" xlink:title="999018 - Disclosure - SBA LOAN PAYABLE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/DerivativeLiabilityWarrants" xlink:title="999019 - Disclosure - DERIVATIVE LIABILITY WARRANTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/CapitalStructure" xlink:title="999020 - Disclosure - CAPITAL STRUCTURE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/Non-controllingInterest" xlink:title="999021 - Disclosure - NON-CONTROLLING INTEREST" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/Investments" xlink:title="999022 - Disclosure - INVESTMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/CommitmentsAndContingencies" xlink:title="999023 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/KProfit-sharingPlan" xlink:title="999024 - Disclosure - 401(k) PROFIT-SHARING PLAN" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/IncomeTaxes" xlink:title="999025 - Disclosure - INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/RelatedPartyTransactions" xlink:title="999026 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/IntangibleAssets" xlink:title="999027 - Disclosure - INTANGIBLE ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/SegmentReporting" xlink:title="999028 - Disclosure - SEGMENT REPORTING" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/PendingMergerTransaction" xlink:title="999029 - Disclosure - PENDING MERGER TRANSACTION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/SubsequentEvents" xlink:title="999030 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/ConvertibleNotesTables" xlink:title="999033 - Disclosure - CONVERTIBLE NOTES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/DerivativeLiabilityWarrantsTables" xlink:title="999034 - Disclosure - DERIVATIVE LIABILITY WARRANTS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/CapitalStructureTables" xlink:title="999035 - Disclosure - CAPITAL STRUCTURE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/CommitmentsAndContingenciesTables" xlink:title="999036 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/IncomeTaxesTables" xlink:title="999037 - Disclosure - INCOME TAXES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/SegmentReportingTables" xlink:title="999038 - Disclosure - SEGMENT REPORTING (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:title="999039 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="999040 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999041 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/Co-developmentOptionsDetailsNarrative" xlink:title="999042 - Disclosure - CO-DEVELOPMENT OPTIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/ConvertibleNotesDetails-DerivativeLiability" xlink:title="999043 - Disclosure - CONVERTIBLE NOTES (Details - Derivative liability)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/ConvertibleNotesDetails-Assumptions" xlink:title="999044 - Disclosure - CONVERTIBLE NOTES (Details - Assumptions)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/ConvertibleNotesDetails-ChangeInDeriviative" xlink:title="999045 - Disclosure - CONVERTIBLE NOTES (Details - Change in deriviative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/ConvertibleNotesDetailsNarrative" xlink:title="999046 - Disclosure - CONVERTIBLE NOTES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/SbaLoanPayableDetailsNarrative" xlink:title="999047 - Disclosure - SBA LOAN PAYABLE (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-FairValue" xlink:title="999048 - Disclosure - DERIVATIVE LIABILITY WARRANTS (Details - Fair value)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-FairValueAssumption" xlink:title="999049 - Disclosure - DERIVATIVE LIABILITY WARRANTS (Details - Fair value assumption)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-ChangesInFairValueOfWarrantLiabilities" xlink:title="999050 - Disclosure - DERIVATIVE LIABILITY WARRANTS (Details - Changes in fair value of warrant liabilities)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/DerivativeLiabilityWarrantsDetailsNarrative" xlink:title="999051 - Disclosure - DERIVATIVE LIABILITY WARRANTS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/CapitalStructureDetails-OptionActivity" xlink:title="999052 - Disclosure - CAPITAL STRUCTURE (Details - Option activity)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/CapitalStructureDetails-WeightedAverageAssumptions" xlink:title="999053 - Disclosure - CAPITAL STRUCTURE (Details - Weighted average assumptions)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/CapitalStructureDetails-WarrantsOutstanding" xlink:title="999054 - Disclosure - CAPITAL STRUCTURE (Details - Warrants outstanding)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/CapitalStructureDetailsNarrative" xlink:title="999055 - Disclosure - CAPITAL STRUCTURE (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/Non-controllingInterestDetailsNarrative" xlink:title="999056 - Disclosure - NON-CONTROLLING INTEREST (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/InvestmentsDetailsNarrative" xlink:title="999057 - Disclosure - INVESTMENTS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/CommitmentsAndContingenciesDetails-LeaseCost" xlink:title="999058 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details - Lease cost)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/CommitmentsAndContingenciesDetails-FutureMinimumPayments" xlink:title="999059 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details - Future minimum payments)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999060 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/KProfit-sharingPlanDetailsNarrative" xlink:title="999061 - Disclosure - 401(k) PROFIT-SHARING PLAN (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/IncomeTaxesDetails-ReconcilationOfIncomeTax" xlink:title="999062 - Disclosure - INCOME TAXES (Details - Reconcilation of income tax)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/IncomeTaxesDetails-ReconcilationOfProvision" xlink:title="999063 - Disclosure - INCOME TAXES (Details - Reconcilation of provision)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/IncomeTaxesDetails-OperatingLossCarryforwards" xlink:title="999064 - Disclosure - INCOME TAXES (Details - Operating loss carryforwards)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/IncomeTaxesDetailsNarrative" xlink:title="999065 - Disclosure - INCOME TAXES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999066 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/IntangibleAssetsDetailsNarrative" xlink:title="999067 - Disclosure - INTANGIBLE ASSETS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/SegmentReportingDetails" xlink:title="999068 - Disclosure - SEGMENT REPORTING (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/SegmentReportingDetailsNarrative" xlink:title="999069 - Disclosure - SEGMENT REPORTING (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>coep-20251231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#Cover" roleURI="http://coeptistx.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#ConsolidatedBalanceSheets" roleURI="http://coeptistx.com/role/ConsolidatedBalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://coeptistx.com/role/ConsolidatedBalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#ConsolidatedStatementsOfOperations" roleURI="http://coeptistx.com/role/ConsolidatedStatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#ConsolidatedStatementsOfStockholdersEquity" roleURI="http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#MaterialCybersecurityIncidentDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#DescriptionOfBusinessAndBasisOfPresentation" roleURI="http://coeptistx.com/role/DescriptionOfBusinessAndBasisOfPresentation" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://coeptistx.com/role/SummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#Co-developmentOptions" roleURI="http://coeptistx.com/role/Co-developmentOptions" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#ConvertibleNotes" roleURI="http://coeptistx.com/role/ConvertibleNotes" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#SbaLoanPayable" roleURI="http://coeptistx.com/role/SbaLoanPayable" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#DerivativeLiabilityWarrants" roleURI="http://coeptistx.com/role/DerivativeLiabilityWarrants" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#CapitalStructure" roleURI="http://coeptistx.com/role/CapitalStructure" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#Non-controllingInterest" roleURI="http://coeptistx.com/role/Non-controllingInterest" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#Investments" roleURI="http://coeptistx.com/role/Investments" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#CommitmentsAndContingencies" roleURI="http://coeptistx.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#KProfit-sharingPlan" roleURI="http://coeptistx.com/role/KProfit-sharingPlan" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#IncomeTaxes" roleURI="http://coeptistx.com/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#RelatedPartyTransactions" roleURI="http://coeptistx.com/role/RelatedPartyTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#IntangibleAssets" roleURI="http://coeptistx.com/role/IntangibleAssets" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#SegmentReporting" roleURI="http://coeptistx.com/role/SegmentReporting" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#PendingMergerTransaction" roleURI="http://coeptistx.com/role/PendingMergerTransaction" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#SubsequentEvents" roleURI="http://coeptistx.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#ConvertibleNotesTables" roleURI="http://coeptistx.com/role/ConvertibleNotesTables" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#DerivativeLiabilityWarrantsTables" roleURI="http://coeptistx.com/role/DerivativeLiabilityWarrantsTables" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#CapitalStructureTables" roleURI="http://coeptistx.com/role/CapitalStructureTables" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#CommitmentsAndContingenciesTables" roleURI="http://coeptistx.com/role/CommitmentsAndContingenciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#IncomeTaxesTables" roleURI="http://coeptistx.com/role/IncomeTaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#SegmentReportingTables" roleURI="http://coeptistx.com/role/SegmentReportingTables" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative" roleURI="http://coeptistx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#Co-developmentOptionsDetailsNarrative" roleURI="http://coeptistx.com/role/Co-developmentOptionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#ConvertibleNotesDetails-DerivativeLiability" roleURI="http://coeptistx.com/role/ConvertibleNotesDetails-DerivativeLiability" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#ConvertibleNotesDetails-Assumptions" roleURI="http://coeptistx.com/role/ConvertibleNotesDetails-Assumptions" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#ConvertibleNotesDetails-ChangeInDeriviative" roleURI="http://coeptistx.com/role/ConvertibleNotesDetails-ChangeInDeriviative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#ConvertibleNotesDetailsNarrative" roleURI="http://coeptistx.com/role/ConvertibleNotesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#SbaLoanPayableDetailsNarrative" roleURI="http://coeptistx.com/role/SbaLoanPayableDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#DerivativeLiabilityWarrantsDetails-FairValue" roleURI="http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-FairValue" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#DerivativeLiabilityWarrantsDetails-FairValueAssumption" roleURI="http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-FairValueAssumption" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#DerivativeLiabilityWarrantsDetails-ChangesInFairValueOfWarrantLiabilities" roleURI="http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-ChangesInFairValueOfWarrantLiabilities" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#DerivativeLiabilityWarrantsDetailsNarrative" roleURI="http://coeptistx.com/role/DerivativeLiabilityWarrantsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#CapitalStructureDetails-OptionActivity" roleURI="http://coeptistx.com/role/CapitalStructureDetails-OptionActivity" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#CapitalStructureDetails-WeightedAverageAssumptions" roleURI="http://coeptistx.com/role/CapitalStructureDetails-WeightedAverageAssumptions" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#CapitalStructureDetails-WarrantsOutstanding" roleURI="http://coeptistx.com/role/CapitalStructureDetails-WarrantsOutstanding" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#CapitalStructureDetailsNarrative" roleURI="http://coeptistx.com/role/CapitalStructureDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#Non-controllingInterestDetailsNarrative" roleURI="http://coeptistx.com/role/Non-controllingInterestDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#InvestmentsDetailsNarrative" roleURI="http://coeptistx.com/role/InvestmentsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#CommitmentsAndContingenciesDetails-LeaseCost" roleURI="http://coeptistx.com/role/CommitmentsAndContingenciesDetails-LeaseCost" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#CommitmentsAndContingenciesDetails-FutureMinimumPayments" roleURI="http://coeptistx.com/role/CommitmentsAndContingenciesDetails-FutureMinimumPayments" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://coeptistx.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#KProfit-sharingPlanDetailsNarrative" roleURI="http://coeptistx.com/role/KProfit-sharingPlanDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#IncomeTaxesDetails-ReconcilationOfIncomeTax" roleURI="http://coeptistx.com/role/IncomeTaxesDetails-ReconcilationOfIncomeTax" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#IncomeTaxesDetails-ReconcilationOfProvision" roleURI="http://coeptistx.com/role/IncomeTaxesDetails-ReconcilationOfProvision" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#IncomeTaxesDetails-OperatingLossCarryforwards" roleURI="http://coeptistx.com/role/IncomeTaxesDetails-OperatingLossCarryforwards" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#IncomeTaxesDetailsNarrative" roleURI="http://coeptistx.com/role/IncomeTaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#RelatedPartyTransactionsDetailsNarrative" roleURI="http://coeptistx.com/role/RelatedPartyTransactionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#IntangibleAssetsDetailsNarrative" roleURI="http://coeptistx.com/role/IntangibleAssetsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#SegmentReportingDetails" roleURI="http://coeptistx.com/role/SegmentReportingDetails" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#SegmentReportingDetailsNarrative" roleURI="http://coeptistx.com/role/SegmentReportingDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpExecutiveCategoriesOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpAdjustmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#IndividualsOnly" roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTypeOnly" roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TradingArrangmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_CommonStockParValue0.0001PerShareMember" xlink:label="loc_coepCommonStockParValue0.0001PerShareMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepCommonStockParValue0.0001PerShareMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantsEachWholeWarrantExercisableForOnehalfOfOneShareOfCommonStockFor230.00PerWholeShareMember" xlink:label="loc_coepWarrantsEachWholeWarrantExercisableForOnehalfOfOneShareOfCommonStockFor230.00PerWholeShareMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepWarrantsEachWholeWarrantExercisableForOnehalfOfOneShareOfCommonStockFor230.00PerWholeShareMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber_60" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_60" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_60" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1_60" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2_60" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3_60" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown_60" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_60" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry_60" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_60" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion_60" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode_60" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber_60" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension_60" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications_60" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial_60" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer_60" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_60" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle_60" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag_60" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol_60" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName_60" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle_60" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation_60" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm_60" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_60" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_60" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers_60" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_60" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_60" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory_60" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness_60" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_60" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod_60" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard_60" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_60" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany_60" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat_60" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_60" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_60" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_60" xlink:type="arc" order="57" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiIcfrAuditorAttestationFlag_60" xlink:type="arc" order="58" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag_60" xlink:type="arc" order="59" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorFirmId_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorName_60" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorLocation_60" xlink:type="arc" order="64" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsCurrentAbstract_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapMarketableSecuritiesCurrent_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestReceivableCurrent" xlink:label="loc_us-gaapInterestReceivableCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapInterestReceivableCurrent_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapPrepaidExpenseCurrent_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapAssetsCurrent_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapPropertyPlantAndEquipmentAbstract_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_50" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaapOtherAssetsAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapOtherAssetsAbstract_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Investments" xlink:label="loc_us-gaapInvestments_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherAssetsAbstract_50" xlink:to="loc_us-gaapInvestments_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherAssetsAbstract_50" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_CodevelopmentRightsNet" xlink:label="loc_coepCodevelopmentRightsNet_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherAssetsAbstract_50" xlink:to="loc_coepCodevelopmentRightsNet_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherAssetsAbstract_50" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaapOtherAssets_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherAssetsAbstract_50" xlink:to="loc_us-gaapOtherAssets_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapAssets_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_50" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_us-gaapAccountsPayableCurrent_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_50" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent_50" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNotesPayableCurrent" xlink:label="loc_us-gaapOtherNotesPayableCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_us-gaapOtherNotesPayableCurrent_50" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_50" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaapDeferredRevenueCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_us-gaapDeferredRevenueCurrent_50" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent_50" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_us-gaapOtherLiabilitiesCurrent_50" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_50" xlink:to="loc_us-gaapLiabilitiesCurrent_50" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_50" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract_50" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_50" xlink:to="loc_us-gaapLongTermDebtNoncurrent_50" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_50" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent_50" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_50" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_50" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_50" xlink:to="loc_us-gaapLiabilitiesNoncurrent_50" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_50" xlink:to="loc_us-gaapLiabilities_50" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_50" xlink:to="loc_us-gaapCommitmentsAndContingencies_50" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityAbstract_50" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_us-gaapPreferredStockValue_50" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_us-gaapCommonStockValue_50" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_us-gaapAdditionalPaidInCapital_50" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_CommonStockSubscribed" xlink:label="loc_coepCommonStockSubscribed_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_coepCommonStockSubscribed_50" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:label="loc_us-gaapStockholdersEquityNoteSubscriptionsReceivable_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_us-gaapStockholdersEquityNoteSubscriptionsReceivable_50" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_50" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_us-gaapMinorityInterest_50" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_50" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_50" xlink:type="arc" order="44" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaapConvertibleNotesPayableMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_us-gaapConvertibleNotesPayableMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_60" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SaleMember" xlink:label="loc_coepSaleMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_coepSaleMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaapRevenuesAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenuesAbstract_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostOfRevenue_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGrossProfit_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_50" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_50" xlink:to="loc_us-gaapSalariesAndWages_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_50" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="loc_us-gaapProfessionalAndContractServicesExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_50" xlink:to="loc_us-gaapProfessionalAndContractServicesExpense_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_50" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapOtherGeneralAndAdministrativeExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_50" xlink:to="loc_us-gaapOtherGeneralAndAdministrativeExpense_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaapSellingAndMarketingExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_50" xlink:to="loc_us-gaapSellingAndMarketingExpense_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingExpenses_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_50" xlink:to="loc_us-gaapInterestExpenseNonoperating_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestAndOtherIncome" xlink:label="loc_us-gaapInterestAndOtherIncome_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_50" xlink:to="loc_us-gaapInterestAndOtherIncome_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_50" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_GainOnForfeitureOfCustomerDeposit" xlink:label="loc_coepGainOnForfeitureOfCustomerDeposit_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_50" xlink:to="loc_coepGainOnForfeitureOfCustomerDeposit_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_50" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense_50" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_50" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss_50" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaapGainLossOnInvestments_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_50" xlink:to="loc_us-gaapGainLossOnInvestments_50" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="loc_us-gaapDisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_50" xlink:to="loc_us-gaapDisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_50" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_GainsLossesOnExtinguishmentOfDebt1" xlink:label="loc_coepGainsLossesOnExtinguishmentOfDebt1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_50" xlink:to="loc_coepGainsLossesOnExtinguishmentOfDebt1_50" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_50" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet_50" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_50" xlink:to="loc_us-gaapNonoperatingIncomeExpense_50" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_50" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_50" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss_50" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest_50" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareAbstract_50" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic_50" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted_50" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_50" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_50" xlink:type="arc" order="35" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_CommonStockSubscribedMember" xlink:label="loc_coepCommonStockSubscribedMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_coepCommonStockSubscribedMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SubscriptionReceivableMember" xlink:label="loc_coepSubscriptionReceivableMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_coepSubscriptionReceivableMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaapParentMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapParentMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaapNoncontrollingInterestMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapNoncontrollingInterestMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SharesIssuedInConnectionWithSEPAValue" xlink:label="loc_coepSharesIssuedInConnectionWithSEPAValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_coepSharesIssuedInConnectionWithSEPAValue_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SharesIssuedInConnectionWithSEPAShares" xlink:label="loc_coepSharesIssuedInConnectionWithSEPAShares_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_coepSharesIssuedInConnectionWithSEPAShares_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SharesIssuedForInvestmentValue" xlink:label="loc_coepSharesIssuedForInvestmentValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_coepSharesIssuedForInvestmentValue_100" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SharesIssuedForInvestmentShares" xlink:label="loc_coepSharesIssuedForInvestmentShares_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_coepSharesIssuedForInvestmentShares_100" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodValuePurchaseOfAssets_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValuePurchaseOfAssets_100" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets_100" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockIssuedDuringPeriodValueWarrantsIssuedForCash" xlink:label="loc_coepStockIssuedDuringPeriodValueWarrantsIssuedForCash_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_coepStockIssuedDuringPeriodValueWarrantsIssuedForCash_100" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_100" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockIssuedDuringPeriodValuePrefundedWarrantsExercise" xlink:label="loc_coepStockIssuedDuringPeriodValuePrefundedWarrantsExercise_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_coepStockIssuedDuringPeriodValuePrefundedWarrantsExercise_100" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockIssuedDuringPeriodSharesPrefundedWarrantsExercise" xlink:label="loc_coepStockIssuedDuringPeriodSharesPrefundedWarrantsExercise_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_coepStockIssuedDuringPeriodSharesPrefundedWarrantsExercise_100" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantsIssuedInExchangeForSubscriptionsReceivable" xlink:label="loc_coepWarrantsIssuedInExchangeForSubscriptionsReceivable_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_coepWarrantsIssuedInExchangeForSubscriptionsReceivable_100" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SharesIssuedForConversionOfDebtValue" xlink:label="loc_coepSharesIssuedForConversionOfDebtValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_coepSharesIssuedForConversionOfDebtValue_100" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SharesIssuedForConversionOfDebtShares" xlink:label="loc_coepSharesIssuedForConversionOfDebtShares_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_coepSharesIssuedForConversionOfDebtShares_100" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockIssuedDuringPeriodValueOfPreferredShareOffering" xlink:label="loc_coepStockIssuedDuringPeriodValueOfPreferredShareOffering_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_coepStockIssuedDuringPeriodValueOfPreferredShareOffering_100" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockIssuedDuringPeriodSharesOfPreferredShareOffering" xlink:label="loc_coepStockIssuedDuringPeriodSharesOfPreferredShareOffering_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_coepStockIssuedDuringPeriodSharesOfPreferredShareOffering_100" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockIssuedDuringPeriodValuePreferredShareConversion" xlink:label="loc_coepStockIssuedDuringPeriodValuePreferredShareConversion_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_coepStockIssuedDuringPeriodValuePreferredShareConversion_100" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockIssuedDuringPeriodSharePreferredShareConversion" xlink:label="loc_coepStockIssuedDuringPeriodSharePreferredShareConversion_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_coepStockIssuedDuringPeriodSharePreferredShareConversion_100" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockIssuedDuringPeriodValueOfInvestmentsAssignmentAgreements" xlink:label="loc_coepStockIssuedDuringPeriodValueOfInvestmentsAssignmentAgreements_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_coepStockIssuedDuringPeriodValueOfInvestmentsAssignmentAgreements_100" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockIssuedDuringPeriodValuePurchaseOfAssets1" xlink:label="loc_coepStockIssuedDuringPeriodValuePurchaseOfAssets1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_coepStockIssuedDuringPeriodValuePurchaseOfAssets1_100" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_100" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_100" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_100" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss_100" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_100" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_100" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_100" xlink:type="arc" order="32" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:title="999014 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/Co-developmentOptions" xlink:title="999016 - Disclosure - CO-DEVELOPMENT OPTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/ConvertibleNotes" xlink:title="999017 - Disclosure - CONVERTIBLE NOTES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/SbaLoanPayable" xlink:title="999018 - Disclosure - SBA LOAN PAYABLE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/DerivativeLiabilityWarrants" xlink:title="999019 - Disclosure - DERIVATIVE LIABILITY WARRANTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/CapitalStructure" xlink:title="999020 - Disclosure - CAPITAL STRUCTURE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/Non-controllingInterest" xlink:title="999021 - Disclosure - NON-CONTROLLING INTEREST" />
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/Investments" xlink:title="999022 - Disclosure - INVESTMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/CommitmentsAndContingencies" xlink:title="999023 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/KProfit-sharingPlan" xlink:title="999024 - Disclosure - 401(k) PROFIT-SHARING PLAN" />
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/IncomeTaxes" xlink:title="999025 - Disclosure - INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/RelatedPartyTransactions" xlink:title="999026 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/IntangibleAssets" xlink:title="999027 - Disclosure - INTANGIBLE ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/SegmentReporting" xlink:title="999028 - Disclosure - SEGMENT REPORTING" />
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/PendingMergerTransaction" xlink:title="999029 - Disclosure - PENDING MERGER TRANSACTION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/SubsequentEvents" xlink:title="999030 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/ConvertibleNotesTables" xlink:title="999033 - Disclosure - CONVERTIBLE NOTES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/DerivativeLiabilityWarrantsTables" xlink:title="999034 - Disclosure - DERIVATIVE LIABILITY WARRANTS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/CapitalStructureTables" xlink:title="999035 - Disclosure - CAPITAL STRUCTURE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/CommitmentsAndContingenciesTables" xlink:title="999036 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/IncomeTaxesTables" xlink:title="999037 - Disclosure - INCOME TAXES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/SegmentReportingTables" xlink:title="999038 - Disclosure - SEGMENT REPORTING (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:title="999039 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="999040 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantsMember" xlink:label="loc_coepWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_coepWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockOptionsMember" xlink:label="loc_coepStockOptionsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_coepStockOptionsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaapConvertibleNotesPayableMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapConvertibleNotesPayableMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapPreferredStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapProfitLoss_120" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999041 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapScheduleOfProductInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaapAssetAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapAssetAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaapAssetAcquisitionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAssetAcquisitionAxis" xlink:to="loc_us-gaapAssetAcquisitionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaapAssetAcquisitionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAssetAcquisitionAxis" xlink:to="loc_us-gaapAssetAcquisitionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_NexGenAIMember" xlink:label="loc_coepNexGenAIMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetAcquisitionDomain" xlink:to="loc_coepNexGenAIMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtMajorCustomersAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SixCustomersMember" xlink:label="loc_coepSixCustomersMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_coepSixCustomersMember_60" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_ThreeCustomersMember" xlink:label="loc_coepThreeCustomersMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_coepThreeCustomersMember_90" xlink:type="arc" order="93" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_AdvertisingCampaignsMember" xlink:label="loc_coepAdvertisingCampaignsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_coepAdvertisingCampaignsMember_60" xlink:type="arc" order="64" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WebinarServicesMember" xlink:label="loc_coepWebinarServicesMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_coepWebinarServicesMember_90" xlink:type="arc" order="94" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaapCashUninsuredAmount_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapCashUninsuredAmount_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapDepreciation_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaapFinitelivedIntangibleAssetsAcquired1_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapFinitelivedIntangibleAssetsAcquired1_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAssetImpairmentCharges_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapUnrecognizedTaxBenefits_120" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_120" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenues_120" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaapDeferredRevenueCurrent_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapDeferredRevenueCurrent_120" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/Co-developmentOptionsDetailsNarrative" xlink:title="999042 - Disclosure - CO-DEVELOPMENT OPTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_CD38AssetsMember" xlink:label="loc_coepCD38AssetsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_coepCD38AssetsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:to="loc_srtCounterpartyNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_VyGenMember" xlink:label="loc_coepVyGenMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_coepVyGenMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaapTransactionTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:to="loc_us-gaapTransactionTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_CoDevelopmentRightsMember" xlink:label="loc_coepCoDevelopmentRightsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_coepCoDevelopmentRightsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_CoDevelopmentOptionsMember" xlink:label="loc_coepCoDevelopmentOptionsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_coepCoDevelopmentOptionsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaapPaymentsToAcquireProductiveAssets_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapPaymentsToAcquireProductiveAssets_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLongTermNotesPayable" xlink:label="loc_us-gaapOtherLongTermNotesPayable_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapOtherLongTermNotesPayable_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaapRepaymentsOfLongTermDebt_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapRepaymentsOfLongTermDebt_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostGross" xlink:label="loc_us-gaapCapitalizedContractCostGross_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapCapitalizedContractCostGross_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="loc_us-gaapProceedsFromLicenseFeesReceived_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapProceedsFromLicenseFeesReceived_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostAccumulatedAmortization" xlink:label="loc_us-gaapCapitalizedContractCostAccumulatedAmortization_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapCapitalizedContractCostAccumulatedAmortization_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="loc_us-gaapCapitalizedContractCostNet_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapCapitalizedContractCostNet_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaapAdjustmentForAmortization_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAdjustmentForAmortization_80" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/ConvertibleNotesDetails-DerivativeLiability" xlink:title="999043 - Disclosure - CONVERTIBLE NOTES (Details - Derivative liability)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapOffsettingAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_DerivativeLiabilityMember" xlink:label="loc_coepDerivativeLiabilityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_coepDerivativeLiabilityMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaapDerivativeFairValueOfDerivativeLiability_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapDerivativeFairValueOfDerivativeLiability_50" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/ConvertibleNotesDetails-Assumptions" xlink:title="999044 - Disclosure - CONVERTIBLE NOTES (Details - Assumptions)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputConversionPriceMember" xlink:label="loc_us-gaapMeasurementInputConversionPriceMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputConversionPriceMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue" xlink:label="loc_us-gaapDerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapDerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_50" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/ConvertibleNotesDetails-ChangeInDeriviative" xlink:title="999045 - Disclosure - CONVERTIBLE NOTES (Details - Change in deriviative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/ConvertibleNotesDetailsNarrative" xlink:title="999046 - Disclosure - CONVERTIBLE NOTES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_LicenseAgreementMember" xlink:label="loc_coepLicenseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_coepLicenseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_PurpleBioTechMember" xlink:label="loc_coepPurpleBioTechMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_coepPurpleBioTechMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_Oct2022ConvertiblePromissoryNoteMember" xlink:label="loc_coepOct2022ConvertiblePromissoryNoteMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_coepOct2022ConvertiblePromissoryNoteMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_Dec2023ConvertiblePromissoryNoteMember" xlink:label="loc_coepDec2023ConvertiblePromissoryNoteMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_coepDec2023ConvertiblePromissoryNoteMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_April2024UnsecuredNoteMember" xlink:label="loc_coepApril2024UnsecuredNoteMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_coepApril2024UnsecuredNoteMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_YANote1Member" xlink:label="loc_coepYANote1Member_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_coepYANote1Member_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_YorkvilleConvertibleNoteMember" xlink:label="loc_coepYorkvilleConvertibleNoteMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_coepYorkvilleConvertibleNoteMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_YANote2Member" xlink:label="loc_coepYANote2Member_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_coepYANote2Member_280" xlink:type="arc" order="281" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StandbyEquityPurchaseAgreementMember" xlink:label="loc_coepStandbyEquityPurchaseAgreementMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_coepStandbyEquityPurchaseAgreementMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_310" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_310" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable_310" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaapRepaymentsOfConvertibleDebt_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapRepaymentsOfConvertibleDebt_310" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDefaultLongtermDebtAmount" xlink:label="loc_us-gaapDebtDefaultLongtermDebtAmount_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtDefaultLongtermDebtAmount_310" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1_310" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_310" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_310" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaapShortTermBorrowings_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShortTermBorrowings_310" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium_310" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleDebt_310" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="loc_us-gaapDebtInstrumentDecreaseForgiveness_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentDecreaseForgiveness_310" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_DebtConversionConvertedInterestAmount1" xlink:label="loc_coepDebtConversionConvertedInterestAmount1_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_coepDebtConversionConvertedInterestAmount1_310" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_310" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_310" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeAssetFairValueGrossLiability" xlink:label="loc_us-gaapDerivativeAssetFairValueGrossLiability_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDerivativeAssetFairValueGrossLiability_310" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="loc_us-gaapUnrealizedGainLossOnDerivatives_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapUnrealizedGainLossOnDerivatives_310" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_310" xlink:type="arc" order="17" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/SbaLoanPayableDetailsNarrative" xlink:title="999047 - Disclosure - SBA LOAN PAYABLE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_EidlLoanMember" xlink:label="loc_coepEidlLoanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_coepEidlLoanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLoans" xlink:label="loc_us-gaapProceedsFromLoans_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromLoans_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapNotesPayable_50" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-FairValue" xlink:title="999048 - Disclosure - DERIVATIVE LIABILITY WARRANTS (Details - Fair value)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="loc_us-gaapDerivativeInstrumentsGainLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="loc_us-gaapDerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentsGainLossLineItems" xlink:to="loc_us-gaapDerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_PublicWarrantsMember" xlink:label="loc_coepPublicWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_coepPublicWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_PrivatePlacementWarrantsMember" xlink:label="loc_coepPrivatePlacementWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_coepPrivatePlacementWarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapFinancialLiabilitiesFairValueDisclosure_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeInstrumentsGainLossLineItems" xlink:to="loc_us-gaapFinancialLiabilitiesFairValueDisclosure_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-FairValueAssumption" xlink:title="999049 - Disclosure - DERIVATIVE LIABILITY WARRANTS (Details - Fair value assumption)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="loc_us-gaapDerivativeInstrumentsGainLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="loc_us-gaapDerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentsGainLossLineItems" xlink:to="loc_us-gaapDerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaapMeasurementInputExercisePriceMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExercisePriceMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantsMember" xlink:label="loc_coepWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_coepWarrantsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue" xlink:label="loc_us-gaapDerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeInstrumentsGainLossLineItems" xlink:to="loc_us-gaapDerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-ChangesInFairValueOfWarrantLiabilities" xlink:title="999050 - Disclosure - DERIVATIVE LIABILITY WARRANTS (Details - Changes in fair value of warrant liabilities)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="loc_us-gaapDerivativeInstrumentsGainLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="loc_us-gaapDerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentsGainLossLineItems" xlink:to="loc_us-gaapDerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_PrivatePlacementWarrantsMember" xlink:label="loc_coepPrivatePlacementWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_coepPrivatePlacementWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_PublicWarrantsMember" xlink:label="loc_coepPublicWarrantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_coepPublicWarrantsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantLiabilitiesMember" xlink:label="loc_coepWarrantLiabilitiesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_coepWarrantLiabilitiesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeInstrumentsGainLossLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosure_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeInstrumentsGainLossLineItems" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect_100" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/DerivativeLiabilityWarrantsDetailsNarrative" xlink:title="999051 - Disclosure - DERIVATIVE LIABILITY WARRANTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_PublicWarrantsMember" xlink:label="loc_coepPublicWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_coepPublicWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_PrivatePlacementWarrantsMember" xlink:label="loc_coepPrivatePlacementWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_coepPrivatePlacementWarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_50" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/CapitalStructureDetails-OptionActivity" xlink:title="999052 - Disclosure - CAPITAL STRUCTURE (Details - Option activity)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockOptionsMember" xlink:label="loc_coepStockOptionsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_coepStockOptionsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2OptionsGranted" xlink:label="loc_coepSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2OptionsGranted_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_coepSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2OptionsGranted_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_70" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/CapitalStructureDetails-WeightedAverageAssumptions" xlink:title="999053 - Disclosure - CAPITAL STRUCTURE (Details - Weighted average assumptions)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockOptionsMember" xlink:label="loc_coepStockOptionsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_coepStockOptionsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_30" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/CapitalStructureDetails-WarrantsOutstanding" xlink:title="999054 - Disclosure - CAPITAL STRUCTURE (Details - Warrants outstanding)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder1ExercisePrice59.40Member" xlink:label="loc_coepWarrantHolder1ExercisePrice59.40Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepWarrantHolder1ExercisePrice59.40Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder1ExercisePrice118.80Member" xlink:label="loc_coepWarrantHolder1ExercisePrice118.80Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepWarrantHolder1ExercisePrice118.80Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder1ExercisePrice296.80Member" xlink:label="loc_coepWarrantHolder1ExercisePrice296.80Member_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepWarrantHolder1ExercisePrice296.80Member_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder2ExercisePrice59.40Member" xlink:label="loc_coepWarrantHolder2ExercisePrice59.40Member_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepWarrantHolder2ExercisePrice59.40Member_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder2ExercisePrice296.80Member" xlink:label="loc_coepWarrantHolder2ExercisePrice296.80Member_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepWarrantHolder2ExercisePrice296.80Member_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder5ExercisePrice59.40Member" xlink:label="loc_coepWarrantHolder5ExercisePrice59.40Member_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepWarrantHolder5ExercisePrice59.40Member_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder18ExercisePrice178.20Member" xlink:label="loc_coepWarrantHolder18ExercisePrice178.20Member_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepWarrantHolder18ExercisePrice178.20Member_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder20ExercisePrice50.00Member" xlink:label="loc_coepWarrantHolder20ExercisePrice50.00Member_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepWarrantHolder20ExercisePrice50.00Member_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder21ExercisePrice38.00Member" xlink:label="loc_coepWarrantHolder21ExercisePrice38.00Member_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepWarrantHolder21ExercisePrice38.00Member_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SeriesWarrantsAAndBExercisePrice27.20Member" xlink:label="loc_coepSeriesWarrantsAAndBExercisePrice27.20Member_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepSeriesWarrantsAAndBExercisePrice27.20Member_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SeriesAWarrantsExercisePrice27.20Member" xlink:label="loc_coepSeriesAWarrantsExercisePrice27.20Member_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepSeriesAWarrantsExercisePrice27.20Member_300" xlink:type="arc" order="301" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SeriesBWarrantsExercisePrice27.20Member" xlink:label="loc_coepSeriesBWarrantsExercisePrice27.20Member_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepSeriesBWarrantsExercisePrice27.20Member_330" xlink:type="arc" order="331" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder22ExercisePrice25.00Member" xlink:label="loc_coepWarrantHolder22ExercisePrice25.00Member_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepWarrantHolder22ExercisePrice25.00Member_360" xlink:type="arc" order="361" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder22ExercisePrice28.00Member" xlink:label="loc_coepWarrantHolder22ExercisePrice28.00Member_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepWarrantHolder22ExercisePrice28.00Member_390" xlink:type="arc" order="391" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder23ExercisePrice25.00Member" xlink:label="loc_coepWarrantHolder23ExercisePrice25.00Member_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepWarrantHolder23ExercisePrice25.00Member_420" xlink:type="arc" order="421" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder23ExercisePrice28.00Member" xlink:label="loc_coepWarrantHolder23ExercisePrice28.00Member_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepWarrantHolder23ExercisePrice28.00Member_450" xlink:type="arc" order="451" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder24ExercisePrice28.00Member" xlink:label="loc_coepWarrantHolder24ExercisePrice28.00Member_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepWarrantHolder24ExercisePrice28.00Member_480" xlink:type="arc" order="481" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_PreFundedWarrants2ExercisePrice0.002Member" xlink:label="loc_coepPreFundedWarrants2ExercisePrice0.002Member_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepPreFundedWarrants2ExercisePrice0.002Member_510" xlink:type="arc" order="511" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_PreFundedWarrants3ExercisePrice0.002Member" xlink:label="loc_coepPreFundedWarrants3ExercisePrice0.002Member_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepPreFundedWarrants3ExercisePrice0.002Member_540" xlink:type="arc" order="541" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder25ExercisePrice12.00Member" xlink:label="loc_coepWarrantHolder25ExercisePrice12.00Member_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepWarrantHolder25ExercisePrice12.00Member_570" xlink:type="arc" order="571" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantsAndRightsOutstandingDateIssued" xlink:label="loc_coepWarrantsAndRightsOutstandingDateIssued_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_coepWarrantsAndRightsOutstandingDateIssued_630" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_630" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_630" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_630" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/CapitalStructureDetailsNarrative" xlink:title="999055 - Disclosure - CAPITAL STRUCTURE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_PreFundedWarrantsMember" xlink:label="loc_coepPreFundedWarrantsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepPreFundedWarrantsMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SeriesAWarrantsMember" xlink:label="loc_coepSeriesAWarrantsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepSeriesAWarrantsMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SeriesBWarrantsMember" xlink:label="loc_coepSeriesBWarrantsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepSeriesBWarrantsMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SeriesWarrantsMember" xlink:label="loc_coepSeriesWarrantsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepSeriesWarrantsMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantNoteSubscriptionReceivablesMember" xlink:label="loc_coepWarrantNoteSubscriptionReceivablesMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepWarrantNoteSubscriptionReceivablesMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember_320" xlink:type="arc" order="322" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassBMember_330" xlink:type="arc" order="332" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_PublicOfferingMember" xlink:label="loc_coepPublicOfferingMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_coepPublicOfferingMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SNAPBiosciencesIncMember" xlink:label="loc_coepSNAPBiosciencesIncMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_coepSNAPBiosciencesIncMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_TwoInvestorMember" xlink:label="loc_coepTwoInvestorMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_coepTwoInvestorMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StandbyEquityPurchaseAgreementMember" xlink:label="loc_coepStandbyEquityPurchaseAgreementMember_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_coepStandbyEquityPurchaseAgreementMember_490" xlink:type="arc" order="491" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaapTransactionTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTransactionTypeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_ConsultingAgreementMember" xlink:label="loc_coepConsultingAgreementMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_coepConsultingAgreementMember_230" xlink:type="arc" order="231" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockIssuedForServicesMember" xlink:label="loc_coepStockIssuedForServicesMember_500" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_coepStockIssuedForServicesMember_500" xlink:type="arc" order="503" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockOptionsMember" xlink:label="loc_coepStockOptionsMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_coepStockOptionsMember_250" xlink:type="arc" order="251" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtCounterpartyNameAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_ColleenDelaneyMember" xlink:label="loc_coepColleenDelaneyMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_coepColleenDelaneyMember_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_CoralInvestmentPartnersMember" xlink:label="loc_coepCoralInvestmentPartnersMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_coepCoralInvestmentPartnersMember_310" xlink:type="arc" order="311" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_YorkvilleMember" xlink:label="loc_coepYorkvilleMember_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_coepYorkvilleMember_490" xlink:type="arc" order="492" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_ModificationOfOptionsMember" xlink:label="loc_coepModificationOfOptionsMember_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_coepModificationOfOptionsMember_300" xlink:type="arc" order="301" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SubscriptionReceivableSept2023Member" xlink:label="loc_coepSubscriptionReceivableSept2023Member_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_coepSubscriptionReceivableSept2023Member_340" xlink:type="arc" order="341" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SubscriptionReceivableSept20232ndMember" xlink:label="loc_coepSubscriptionReceivableSept20232ndMember_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_coepSubscriptionReceivableSept20232ndMember_370" xlink:type="arc" order="371" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_December2023FinancingMember" xlink:label="loc_coepDecember2023FinancingMember_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_coepDecember2023FinancingMember_400" xlink:type="arc" order="401" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_February2024FinancingMember" xlink:label="loc_coepFebruary2024FinancingMember_430" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_coepFebruary2024FinancingMember_430" xlink:type="arc" order="431" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_ConvertibleNoteMember" xlink:label="loc_coepConvertibleNoteMember_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_coepConvertibleNoteMember_510" xlink:type="arc" order="513" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_540" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_540" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_540" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_540" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_540" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_540" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_540" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_540" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1_540" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises_540" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_540" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaapSaleOfStockDescriptionOfTransaction_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockDescriptionOfTransaction_540" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_540" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_540" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_540" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_540" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaapTreasuryStockValue_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapTreasuryStockValue_540" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_540" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_540" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock_540" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:label="loc_us-gaapStockholdersEquityNoteSubscriptionsReceivable_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockholdersEquityNoteSubscriptionsReceivable_540" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensation_540" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_540" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_540" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_540" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_540" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_540" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_540" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockIssuedForDebtShares" xlink:label="loc_coepStockIssuedForDebtShares_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_coepStockIssuedForDebtShares_540" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockIssuedForDebtValue" xlink:label="loc_coepStockIssuedForDebtValue_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_coepStockIssuedForDebtValue_540" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Investments" xlink:label="loc_us-gaapInvestments_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapInvestments_540" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_540" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable" xlink:label="loc_us-gaapPreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable_540" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SubscriptionsReceivable" xlink:label="loc_coepSubscriptionsReceivable_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_coepSubscriptionsReceivable_540" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_ProceedsFromSubscriptionsReceivable" xlink:label="loc_coepProceedsFromSubscriptionsReceivable_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_coepProceedsFromSubscriptionsReceivable_540" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SubscriptionsReceivableNet" xlink:label="loc_coepSubscriptionsReceivableNet_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_coepSubscriptionsReceivableNet_540" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForBrokerageFees" xlink:label="loc_us-gaapPaymentsForBrokerageFees_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPaymentsForBrokerageFees_540" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable_540" xlink:type="arc" order="37" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/Non-controllingInterestDetailsNarrative" xlink:title="999056 - Disclosure - NON-CONTROLLING INTEREST (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestLineItems" xlink:label="loc_us-gaapMinorityInterestLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestTable" xlink:label="loc_us-gaapMinorityInterestTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMinorityInterestLineItems" xlink:to="loc_us-gaapMinorityInterestTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapMinorityInterestTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_GearTherapeuticsMember" xlink:label="loc_coepGearTherapeuticsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_coepGearTherapeuticsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMinorityInterestLineItems" xlink:to="loc_us-gaapMinorityInterest_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMinorityInterestLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMinorityInterestLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_20" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/InvestmentsDetailsNarrative" xlink:title="999057 - Disclosure - INVESTMENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtCounterpartyNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_TwoPrivatelyHeldCompaniesMember" xlink:label="loc_coepTwoPrivatelyHeldCompaniesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_coepTwoPrivatelyHeldCompaniesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_FivePrivatelyHeldCompaniesMember" xlink:label="loc_coepFivePrivatelyHeldCompaniesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_coepFivePrivatelyHeldCompaniesMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_ThreePrivatelyHeldCompaniesMember" xlink:label="loc_coepThreePrivatelyHeldCompaniesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_coepThreePrivatelyHeldCompaniesMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_PrivatelyHeldCompanyMember" xlink:label="loc_coepPrivatelyHeldCompanyMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_coepPrivatelyHeldCompanyMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaapTransactionTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTransactionTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_NexGenAIAffiliatesNetworkPlatformMember" xlink:label="loc_coepNexGenAIAffiliatesNetworkPlatformMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_coepNexGenAIAffiliatesNetworkPlatformMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SubscriptionReceivable" xlink:label="loc_coepSubscriptionReceivable_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_coepSubscriptionReceivable_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaapInvestmentOwnedBalanceShares_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapInvestmentOwnedBalanceShares_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaapGainLossOnInvestments_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapGainLossOnInvestments_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockIssuedDuringPeriodSharesIssuedForInvestment" xlink:label="loc_coepStockIssuedDuringPeriodSharesIssuedForInvestment_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_coepStockIssuedDuringPeriodSharesIssuedForInvestment_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockIssuedDuringPeriodValueIssuedForInvestment" xlink:label="loc_coepStockIssuedDuringPeriodValueIssuedForInvestment_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_coepStockIssuedDuringPeriodValueIssuedForInvestment_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_InvestmentCompanyFeePaidSharesIndirectly" xlink:label="loc_coepInvestmentCompanyFeePaidSharesIndirectly_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_coepInvestmentCompanyFeePaidSharesIndirectly_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentCompanyFeePaidIndirectly" xlink:label="loc_us-gaapInvestmentCompanyFeePaidIndirectly_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapInvestmentCompanyFeePaidIndirectly_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss_90" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/CommitmentsAndContingenciesDetails-LeaseCost" xlink:title="999058 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details - Lease cost)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/CommitmentsAndContingenciesDetails-FutureMinimumPayments" xlink:title="999059 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details - Future minimum payments)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999060 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_FirstYearExtensionMember" xlink:label="loc_coepFirstYearExtensionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_coepFirstYearExtensionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SecondYearExtensionMember" xlink:label="loc_coepSecondYearExtensionMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_coepSecondYearExtensionMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtCounterpartyNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_MehalickMember" xlink:label="loc_coepMehalickMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_coepMehalickMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_YeraceMember" xlink:label="loc_coepYeraceMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_coepYeraceMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaapTransactionTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapTransactionTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_CarTLicenseMember" xlink:label="loc_coepCarTLicenseMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_coepCarTLicenseMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_FindersFeeAndIndemnityAgreementMember" xlink:label="loc_coepFindersFeeAndIndemnityAgreementMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_coepFindersFeeAndIndemnityAgreementMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_MasterServicesAgreementsMember" xlink:label="loc_coepMasterServicesAgreementsMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_coepMasterServicesAgreementsMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_GearCellTherapyPlatformMember" xlink:label="loc_coepGearCellTherapyPlatformMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_coepGearCellTherapyPlatformMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_MonthlyRent" xlink:label="loc_coepMonthlyRent_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_coepMonthlyRent_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_AnnualSalary" xlink:label="loc_coepAnnualSalary_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_coepAnnualSalary_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_InitialLicenseFee" xlink:label="loc_coepInitialLicenseFee_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_coepInitialLicenseFee_170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_AnnualMaintenanceFeeDescription" xlink:label="loc_coepAnnualMaintenanceFeeDescription_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_coepAnnualMaintenanceFeeDescription_170" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaapContractualObligation_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapContractualObligation_170" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_AgreementAmendmentFee" xlink:label="loc_coepAgreementAmendmentFee_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_coepAgreementAmendmentFee_170" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaapPaymentsForFees_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPaymentsForFees_170" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapRevenues_170" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="loc_us-gaapContractWithCustomerAssetNet_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapContractWithCustomerAssetNet_170" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/KProfit-sharingPlanDetailsNarrative" xlink:title="999061 - Disclosure - 401(k) PROFIT-SHARING PLAN (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/IncomeTaxesDetails-ReconcilationOfIncomeTax" xlink:title="999062 - Disclosure - INCOME TAXES (Details - Reconcilation of income tax)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/IncomeTaxesDetails-ReconcilationOfProvision" xlink:title="999063 - Disclosure - INCOME TAXES (Details - Reconcilation of provision)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/IncomeTaxesDetails-OperatingLossCarryforwards" xlink:title="999064 - Disclosure - INCOME TAXES (Details - Operating loss carryforwards)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/IncomeTaxesDetailsNarrative" xlink:title="999065 - Disclosure - INCOME TAXES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999066 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_DisclosureLineElements" xlink:label="loc_coepDisclosureLineElements" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_DisclosureTable" xlink:label="loc_coepDisclosureTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_coepDisclosureLineElements" xlink:to="loc_coepDisclosureTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_coepDisclosureTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_AGBioLifeCapitalILPMember" xlink:label="loc_coepAGBioLifeCapitalILPMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_coepAGBioLifeCapitalILPMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_coepDisclosureTable" xlink:to="loc_srtCounterpartyNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_BoardOfDirectorsMember" xlink:label="loc_coepBoardOfDirectorsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_coepBoardOfDirectorsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_coepDisclosureLineElements" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_coepDisclosureLineElements" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsAndNotesReceivableNet" xlink:label="loc_us-gaapAccountsAndNotesReceivableNet_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_coepDisclosureLineElements" xlink:to="loc_us-gaapAccountsAndNotesReceivableNet_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Investments" xlink:label="loc_us-gaapInvestments_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_coepDisclosureLineElements" xlink:to="loc_us-gaapInvestments_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_coepDisclosureLineElements" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherInvestments" xlink:label="loc_us-gaapOtherInvestments_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_coepDisclosureLineElements" xlink:to="loc_us-gaapOtherInvestments_80" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/IntangibleAssetsDetailsNarrative" xlink:title="999067 - Disclosure - INTANGIBLE ASSETS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_srtCounterpartyNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_NexGenAISolutionsGroupIncMember" xlink:label="loc_coepNexGenAISolutionsGroupIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_coepNexGenAISolutionsGroupIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_NexGenAIMember" xlink:label="loc_coepNexGenAIMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_coepNexGenAIMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodValuePurchaseOfAssets_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValuePurchaseOfAssets_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_60" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/SegmentReportingDetails" xlink:title="999068 - Disclosure - SEGMENT REPORTING (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_BiotechnologyMember" xlink:label="loc_coepBiotechnologyMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_coepBiotechnologyMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_TechnologyMember" xlink:label="loc_coepTechnologyMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_coepTechnologyMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapRevenues_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapCostOfRevenue_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOperatingExpenses_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_70" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://coeptistx.com/role/SegmentReportingDetailsNarrative" xlink:title="999069 - Disclosure - SEGMENT REPORTING (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_BiotechnologySegmentMember" xlink:label="loc_coepBiotechnologySegmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_coepBiotechnologySegmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_TechnologySegmentMember" xlink:label="loc_coepTechnologySegmentMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_coepTechnologySegmentMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaapNumberOfReportableSegments_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNumberOfReportableSegments_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapAssets_60" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_PublicWarrantsMember" xlink:label="loc_coepPublicWarrantsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_coepPublicWarrantsMember" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockOptionsMember" xlink:label="loc_coepStockOptionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_coepStockOptionsMember" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>coep-20251231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_CommonStockParValue0.0001PerShareMember" xlink:label="coep_CommonStockParValue0.0001PerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_CommonStockParValue0.0001PerShareMember" xlink:to="coep_CommonStockParValue0.0001PerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_CommonStockParValue0.0001PerShareMember_lbl" xml:lang="en-US">Common Stock, par value $0.0001 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantsEachWholeWarrantExercisableForOnehalfOfOneShareOfCommonStockFor230.00PerWholeShareMember" xlink:label="coep_WarrantsEachWholeWarrantExercisableForOnehalfOfOneShareOfCommonStockFor230.00PerWholeShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_WarrantsEachWholeWarrantExercisableForOnehalfOfOneShareOfCommonStockFor230.00PerWholeShareMember" xlink:to="coep_WarrantsEachWholeWarrantExercisableForOnehalfOfOneShareOfCommonStockFor230.00PerWholeShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_WarrantsEachWholeWarrantExercisableForOnehalfOfOneShareOfCommonStockFor230.00PerWholeShareMember_lbl" xml:lang="en-US">Warrants, each whole warrant exercisable for one-half of one share of Common Stock for $230.00 per whole share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xml:lang="en-US">Convertible Notes Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SaleMember" xlink:label="coep_SaleMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_SaleMember" xlink:to="coep_SaleMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_SaleMember_lbl" xml:lang="en-US">Sale [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_CommonStockSubscribedMember" xlink:label="coep_CommonStockSubscribedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_CommonStockSubscribedMember" xlink:to="coep_CommonStockSubscribedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_CommonStockSubscribedMember_lbl" xml:lang="en-US">Common Stock Subscribed [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SubscriptionReceivableMember" xlink:label="coep_SubscriptionReceivableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_SubscriptionReceivableMember" xlink:to="coep_SubscriptionReceivableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_SubscriptionReceivableMember_lbl" xml:lang="en-US">Subscription Receivable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ParentMember" xlink:label="us-gaap_ParentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParentMember" xlink:to="us-gaap_ParentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ParentMember_lbl" xml:lang="en-US">Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionAxis_lbl" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_NexGenAIMember" xlink:label="coep_NexGenAIMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_NexGenAIMember" xlink:to="coep_NexGenAIMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_NexGenAIMember_lbl" xml:lang="en-US">NexGenAI [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SixCustomersMember" xlink:label="coep_SixCustomersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_SixCustomersMember" xlink:to="coep_SixCustomersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_SixCustomersMember_lbl" xml:lang="en-US">Six Customers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_AdvertisingCampaignsMember" xlink:label="coep_AdvertisingCampaignsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_AdvertisingCampaignsMember" xlink:to="coep_AdvertisingCampaignsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_AdvertisingCampaignsMember_lbl" xml:lang="en-US">Advertising Campaigns [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_ThreeCustomersMember" xlink:label="coep_ThreeCustomersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_ThreeCustomersMember" xlink:to="coep_ThreeCustomersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_ThreeCustomersMember_lbl" xml:lang="en-US">Three Customers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WebinarServicesMember" xlink:label="coep_WebinarServicesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_WebinarServicesMember" xlink:to="coep_WebinarServicesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_WebinarServicesMember_lbl" xml:lang="en-US">Webinar Services [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantsMember" xlink:label="coep_WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_WarrantsMember" xlink:to="coep_WarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_WarrantsMember_lbl" xml:lang="en-US">Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockOptionsMember" xlink:label="coep_StockOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_StockOptionsMember" xlink:to="coep_StockOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_StockOptionsMember_lbl" xml:lang="en-US">Stock Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_CD38AssetsMember" xlink:label="coep_CD38AssetsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_CD38AssetsMember" xlink:to="coep_CD38AssetsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_CD38AssetsMember_lbl" xml:lang="en-US">CD38 Assets [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_VyGenMember" xlink:label="coep_VyGenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_VyGenMember" xlink:to="coep_VyGenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_VyGenMember_lbl" xml:lang="en-US">Vy Gen [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransactionTypeAxis_lbl" xml:lang="en-US">Transaction Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_CoDevelopmentRightsMember" xlink:label="coep_CoDevelopmentRightsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_CoDevelopmentRightsMember" xlink:to="coep_CoDevelopmentRightsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_CoDevelopmentRightsMember_lbl" xml:lang="en-US">Co Development Rights [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_CoDevelopmentOptionsMember" xlink:label="coep_CoDevelopmentOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_CoDevelopmentOptionsMember" xlink:to="coep_CoDevelopmentOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_CoDevelopmentOptionsMember_lbl" xml:lang="en-US">Co Development Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_LicenseAgreementMember" xlink:label="coep_LicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_LicenseAgreementMember" xlink:to="coep_LicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_LicenseAgreementMember_lbl" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_PurpleBioTechMember" xlink:label="coep_PurpleBioTechMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_PurpleBioTechMember" xlink:to="coep_PurpleBioTechMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_PurpleBioTechMember_lbl" xml:lang="en-US">Purple Bio Tech [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_Oct2022ConvertiblePromissoryNoteMember" xlink:label="coep_Oct2022ConvertiblePromissoryNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_Oct2022ConvertiblePromissoryNoteMember" xlink:to="coep_Oct2022ConvertiblePromissoryNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_Oct2022ConvertiblePromissoryNoteMember_lbl" xml:lang="en-US">Oct 2022 Convertible Promissory Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_Dec2023ConvertiblePromissoryNoteMember" xlink:label="coep_Dec2023ConvertiblePromissoryNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_Dec2023ConvertiblePromissoryNoteMember" xlink:to="coep_Dec2023ConvertiblePromissoryNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_Dec2023ConvertiblePromissoryNoteMember_lbl" xml:lang="en-US">Dec 2023 Convertible Promissory Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_April2024UnsecuredNoteMember" xlink:label="coep_April2024UnsecuredNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_April2024UnsecuredNoteMember" xlink:to="coep_April2024UnsecuredNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_April2024UnsecuredNoteMember_lbl" xml:lang="en-US">April 2024 Unsecured Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_YANote1Member" xlink:label="coep_YANote1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_YANote1Member" xlink:to="coep_YANote1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_YANote1Member_lbl" xml:lang="en-US">YA Note-1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_YorkvilleConvertibleNoteMember" xlink:label="coep_YorkvilleConvertibleNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_YorkvilleConvertibleNoteMember" xlink:to="coep_YorkvilleConvertibleNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_YorkvilleConvertibleNoteMember_lbl" xml:lang="en-US">Yorkville Convertible Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StandbyEquityPurchaseAgreementMember" xlink:label="coep_StandbyEquityPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_StandbyEquityPurchaseAgreementMember" xlink:to="coep_StandbyEquityPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_StandbyEquityPurchaseAgreementMember_lbl" xml:lang="en-US">Standby Equity Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_YANote2Member" xlink:label="coep_YANote2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_YANote2Member" xlink:to="coep_YANote2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_YANote2Member_lbl" xml:lang="en-US">Y A Note 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_DerivativeLiabilityMember" xlink:label="coep_DerivativeLiabilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_DerivativeLiabilityMember" xlink:to="coep_DerivativeLiabilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_DerivativeLiabilityMember_lbl" xml:lang="en-US">Derivative Liability [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputConversionPriceMember" xlink:label="us-gaap_MeasurementInputConversionPriceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputConversionPriceMember" xlink:to="us-gaap_MeasurementInputConversionPriceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputConversionPriceMember_lbl" xml:lang="en-US">Measurement Input, Conversion Price [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US">Measurement Input, Share Price [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_EidlLoanMember" xlink:label="coep_EidlLoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_EidlLoanMember" xlink:to="coep_EidlLoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_EidlLoanMember_lbl" xml:lang="en-US">Eidl Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_PublicWarrantsMember" xlink:label="coep_PublicWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_PublicWarrantsMember" xlink:to="coep_PublicWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_PublicWarrantsMember_lbl" xml:lang="en-US">Public Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_PrivatePlacementWarrantsMember" xlink:label="coep_PrivatePlacementWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_PrivatePlacementWarrantsMember" xlink:to="coep_PrivatePlacementWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_PrivatePlacementWarrantsMember_lbl" xml:lang="en-US">Private Placement Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExercisePriceMember" xlink:to="us-gaap_MeasurementInputExercisePriceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl" xml:lang="en-US">Measurement Input, Exercise Price [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantLiabilitiesMember" xlink:label="coep_WarrantLiabilitiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_WarrantLiabilitiesMember" xlink:to="coep_WarrantLiabilitiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_WarrantLiabilitiesMember_lbl" xml:lang="en-US">Warrant Liabilities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_PublicOfferingMember" xlink:label="coep_PublicOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_PublicOfferingMember" xlink:to="coep_PublicOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_PublicOfferingMember_lbl" xml:lang="en-US">Public Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_PreFundedWarrantsMember" xlink:label="coep_PreFundedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_PreFundedWarrantsMember" xlink:to="coep_PreFundedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_PreFundedWarrantsMember_lbl" xml:lang="en-US">Pre Funded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SeriesAWarrantsMember" xlink:label="coep_SeriesAWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_SeriesAWarrantsMember" xlink:to="coep_SeriesAWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_SeriesAWarrantsMember_lbl" xml:lang="en-US">Series A Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SeriesBWarrantsMember" xlink:label="coep_SeriesBWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_SeriesBWarrantsMember" xlink:to="coep_SeriesBWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_SeriesBWarrantsMember_lbl" xml:lang="en-US">Series B Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SeriesWarrantsMember" xlink:label="coep_SeriesWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_SeriesWarrantsMember" xlink:to="coep_SeriesWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_SeriesWarrantsMember_lbl" xml:lang="en-US">Series Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantNoteSubscriptionReceivablesMember" xlink:label="coep_WarrantNoteSubscriptionReceivablesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_WarrantNoteSubscriptionReceivablesMember" xlink:to="coep_WarrantNoteSubscriptionReceivablesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_WarrantNoteSubscriptionReceivablesMember_lbl" xml:lang="en-US">Warrant Note Subscription Receivables [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SNAPBiosciencesIncMember" xlink:label="coep_SNAPBiosciencesIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_SNAPBiosciencesIncMember" xlink:to="coep_SNAPBiosciencesIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_SNAPBiosciencesIncMember_lbl" xml:lang="en-US">SNAP Biosciences Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_TwoInvestorMember" xlink:label="coep_TwoInvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_TwoInvestorMember" xlink:to="coep_TwoInvestorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_TwoInvestorMember_lbl" xml:lang="en-US">Two Investor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_ConsultingAgreementMember" xlink:label="coep_ConsultingAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_ConsultingAgreementMember" xlink:to="coep_ConsultingAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_ConsultingAgreementMember_lbl" xml:lang="en-US">Consulting Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_ColleenDelaneyMember" xlink:label="coep_ColleenDelaneyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_ColleenDelaneyMember" xlink:to="coep_ColleenDelaneyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_ColleenDelaneyMember_lbl" xml:lang="en-US">Colleen Delaney [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_ModificationOfOptionsMember" xlink:label="coep_ModificationOfOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_ModificationOfOptionsMember" xlink:to="coep_ModificationOfOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_ModificationOfOptionsMember_lbl" xml:lang="en-US">Modification Of Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_CoralInvestmentPartnersMember" xlink:label="coep_CoralInvestmentPartnersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_CoralInvestmentPartnersMember" xlink:to="coep_CoralInvestmentPartnersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_CoralInvestmentPartnersMember_lbl" xml:lang="en-US">Coral Investment Partners [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonClassAMember_lbl" xml:lang="en-US">Common Class A [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassBMember" xlink:to="us-gaap_CommonClassBMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonClassBMember_lbl" xml:lang="en-US">Common Class B [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SubscriptionReceivableSept2023Member" xlink:label="coep_SubscriptionReceivableSept2023Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_SubscriptionReceivableSept2023Member" xlink:to="coep_SubscriptionReceivableSept2023Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_SubscriptionReceivableSept2023Member_lbl" xml:lang="en-US">Subscription Receivable Sept 2023 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SubscriptionReceivableSept20232ndMember" xlink:label="coep_SubscriptionReceivableSept20232ndMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_SubscriptionReceivableSept20232ndMember" xlink:to="coep_SubscriptionReceivableSept20232ndMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_SubscriptionReceivableSept20232ndMember_lbl" xml:lang="en-US">Subscription Receivable Sept 2023 One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_December2023FinancingMember" xlink:label="coep_December2023FinancingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_December2023FinancingMember" xlink:to="coep_December2023FinancingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_December2023FinancingMember_lbl" xml:lang="en-US">December 2023 Financing [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_February2024FinancingMember" xlink:label="coep_February2024FinancingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_February2024FinancingMember" xlink:to="coep_February2024FinancingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_February2024FinancingMember_lbl" xml:lang="en-US">February 2024 Financing [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_YorkvilleMember" xlink:label="coep_YorkvilleMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_YorkvilleMember" xlink:to="coep_YorkvilleMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_YorkvilleMember_lbl" xml:lang="en-US">Yorkville [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockIssuedForServicesMember" xlink:label="coep_StockIssuedForServicesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_StockIssuedForServicesMember" xlink:to="coep_StockIssuedForServicesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_StockIssuedForServicesMember_lbl" xml:lang="en-US">Stock Issued For Services [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_ConvertibleNoteMember" xlink:label="coep_ConvertibleNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_ConvertibleNoteMember" xlink:to="coep_ConvertibleNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_ConvertibleNoteMember_lbl" xml:lang="en-US">Convertible Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder1ExercisePrice59.40Member" xlink:label="coep_WarrantHolder1ExercisePrice59.40Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_WarrantHolder1ExercisePrice59.40Member" xlink:to="coep_WarrantHolder1ExercisePrice59.40Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_WarrantHolder1ExercisePrice59.40Member_lbl" xml:lang="en-US">Warrant Holder 1 Exercise Price 59. 40 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder1ExercisePrice118.80Member" xlink:label="coep_WarrantHolder1ExercisePrice118.80Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_WarrantHolder1ExercisePrice118.80Member" xlink:to="coep_WarrantHolder1ExercisePrice118.80Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_WarrantHolder1ExercisePrice118.80Member_lbl" xml:lang="en-US">Warrant Holder 1 Exercise Price 118. 80 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder1ExercisePrice296.80Member" xlink:label="coep_WarrantHolder1ExercisePrice296.80Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_WarrantHolder1ExercisePrice296.80Member" xlink:to="coep_WarrantHolder1ExercisePrice296.80Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_WarrantHolder1ExercisePrice296.80Member_lbl" xml:lang="en-US">Warrant Holder 1 Exercise Price 296. 80 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder2ExercisePrice59.40Member" xlink:label="coep_WarrantHolder2ExercisePrice59.40Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_WarrantHolder2ExercisePrice59.40Member" xlink:to="coep_WarrantHolder2ExercisePrice59.40Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_WarrantHolder2ExercisePrice59.40Member_lbl" xml:lang="en-US">Warrant Holder 2 Exercise Price 59. 40 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder2ExercisePrice296.80Member" xlink:label="coep_WarrantHolder2ExercisePrice296.80Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_WarrantHolder2ExercisePrice296.80Member" xlink:to="coep_WarrantHolder2ExercisePrice296.80Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_WarrantHolder2ExercisePrice296.80Member_lbl" xml:lang="en-US">Warrant Holder 2 Exercise Price 296. 80 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder5ExercisePrice59.40Member" xlink:label="coep_WarrantHolder5ExercisePrice59.40Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_WarrantHolder5ExercisePrice59.40Member" xlink:to="coep_WarrantHolder5ExercisePrice59.40Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_WarrantHolder5ExercisePrice59.40Member_lbl" xml:lang="en-US">Warrant Holder 5 Exercise Price 59. 40 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder18ExercisePrice178.20Member" xlink:label="coep_WarrantHolder18ExercisePrice178.20Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_WarrantHolder18ExercisePrice178.20Member" xlink:to="coep_WarrantHolder18ExercisePrice178.20Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_WarrantHolder18ExercisePrice178.20Member_lbl" xml:lang="en-US">Warrant Holder 18 Exercise Price 178. 20 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder20ExercisePrice50.00Member" xlink:label="coep_WarrantHolder20ExercisePrice50.00Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_WarrantHolder20ExercisePrice50.00Member" xlink:to="coep_WarrantHolder20ExercisePrice50.00Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_WarrantHolder20ExercisePrice50.00Member_lbl" xml:lang="en-US">Warrant Holder 20 Exercise Price 50. 00 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder21ExercisePrice38.00Member" xlink:label="coep_WarrantHolder21ExercisePrice38.00Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_WarrantHolder21ExercisePrice38.00Member" xlink:to="coep_WarrantHolder21ExercisePrice38.00Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_WarrantHolder21ExercisePrice38.00Member_lbl" xml:lang="en-US">Warrant Holder 21 Exercise Price 38. 00 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SeriesWarrantsAAndBExercisePrice27.20Member" xlink:label="coep_SeriesWarrantsAAndBExercisePrice27.20Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_SeriesWarrantsAAndBExercisePrice27.20Member" xlink:to="coep_SeriesWarrantsAAndBExercisePrice27.20Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_SeriesWarrantsAAndBExercisePrice27.20Member_lbl" xml:lang="en-US">Series Warrants A And B Exercise Price 27. 20 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SeriesAWarrantsExercisePrice27.20Member" xlink:label="coep_SeriesAWarrantsExercisePrice27.20Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_SeriesAWarrantsExercisePrice27.20Member" xlink:to="coep_SeriesAWarrantsExercisePrice27.20Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_SeriesAWarrantsExercisePrice27.20Member_lbl" xml:lang="en-US">Series A Warrants Exercise Price 27. 20 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SeriesBWarrantsExercisePrice27.20Member" xlink:label="coep_SeriesBWarrantsExercisePrice27.20Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_SeriesBWarrantsExercisePrice27.20Member" xlink:to="coep_SeriesBWarrantsExercisePrice27.20Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_SeriesBWarrantsExercisePrice27.20Member_lbl" xml:lang="en-US">Series B Warrants Exercise Price 27. 20 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder22ExercisePrice25.00Member" xlink:label="coep_WarrantHolder22ExercisePrice25.00Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_WarrantHolder22ExercisePrice25.00Member" xlink:to="coep_WarrantHolder22ExercisePrice25.00Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_WarrantHolder22ExercisePrice25.00Member_lbl" xml:lang="en-US">Warrant Holder 22 Exercise Price 25. 00 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder22ExercisePrice28.00Member" xlink:label="coep_WarrantHolder22ExercisePrice28.00Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_WarrantHolder22ExercisePrice28.00Member" xlink:to="coep_WarrantHolder22ExercisePrice28.00Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_WarrantHolder22ExercisePrice28.00Member_lbl" xml:lang="en-US">Warrant Holder 22 Exercise Price 28. 00 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder23ExercisePrice25.00Member" xlink:label="coep_WarrantHolder23ExercisePrice25.00Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_WarrantHolder23ExercisePrice25.00Member" xlink:to="coep_WarrantHolder23ExercisePrice25.00Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_WarrantHolder23ExercisePrice25.00Member_lbl" xml:lang="en-US">Warrant Holder 23 Exercise Price 25. 00 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder23ExercisePrice28.00Member" xlink:label="coep_WarrantHolder23ExercisePrice28.00Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_WarrantHolder23ExercisePrice28.00Member" xlink:to="coep_WarrantHolder23ExercisePrice28.00Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_WarrantHolder23ExercisePrice28.00Member_lbl" xml:lang="en-US">Warrant Holder 23 Exercise Price 28. 00 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder24ExercisePrice28.00Member" xlink:label="coep_WarrantHolder24ExercisePrice28.00Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_WarrantHolder24ExercisePrice28.00Member" xlink:to="coep_WarrantHolder24ExercisePrice28.00Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_WarrantHolder24ExercisePrice28.00Member_lbl" xml:lang="en-US">Warrant Holder 24 Exercise Price 28. 00 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_PreFundedWarrants2ExercisePrice0.002Member" xlink:label="coep_PreFundedWarrants2ExercisePrice0.002Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_PreFundedWarrants2ExercisePrice0.002Member" xlink:to="coep_PreFundedWarrants2ExercisePrice0.002Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_PreFundedWarrants2ExercisePrice0.002Member_lbl" xml:lang="en-US">Pre Funded Warrants 2 Exercise Price 0. 002 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_PreFundedWarrants3ExercisePrice0.002Member" xlink:label="coep_PreFundedWarrants3ExercisePrice0.002Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_PreFundedWarrants3ExercisePrice0.002Member" xlink:to="coep_PreFundedWarrants3ExercisePrice0.002Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_PreFundedWarrants3ExercisePrice0.002Member_lbl" xml:lang="en-US">Pre Funded Warrants 3 Exercise Price 0. 002 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder25ExercisePrice12.00Member" xlink:label="coep_WarrantHolder25ExercisePrice12.00Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_WarrantHolder25ExercisePrice12.00Member" xlink:to="coep_WarrantHolder25ExercisePrice12.00Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_WarrantHolder25ExercisePrice12.00Member_lbl" xml:lang="en-US">Warrant Holder 25 Exercise Price 12. 00 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_GearTherapeuticsMember" xlink:label="coep_GearTherapeuticsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_GearTherapeuticsMember" xlink:to="coep_GearTherapeuticsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_GearTherapeuticsMember_lbl" xml:lang="en-US">Gear Therapeutics [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_TwoPrivatelyHeldCompaniesMember" xlink:label="coep_TwoPrivatelyHeldCompaniesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_TwoPrivatelyHeldCompaniesMember" xlink:to="coep_TwoPrivatelyHeldCompaniesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_TwoPrivatelyHeldCompaniesMember_lbl" xml:lang="en-US">Two Privately Held Companies [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_NexGenAIAffiliatesNetworkPlatformMember" xlink:label="coep_NexGenAIAffiliatesNetworkPlatformMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_NexGenAIAffiliatesNetworkPlatformMember" xlink:to="coep_NexGenAIAffiliatesNetworkPlatformMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_NexGenAIAffiliatesNetworkPlatformMember_lbl" xml:lang="en-US">Nex Gen A I Affiliates Network Platform [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_FivePrivatelyHeldCompaniesMember" xlink:label="coep_FivePrivatelyHeldCompaniesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_FivePrivatelyHeldCompaniesMember" xlink:to="coep_FivePrivatelyHeldCompaniesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_FivePrivatelyHeldCompaniesMember_lbl" xml:lang="en-US">Five Privately Held Companies [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_ThreePrivatelyHeldCompaniesMember" xlink:label="coep_ThreePrivatelyHeldCompaniesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_ThreePrivatelyHeldCompaniesMember" xlink:to="coep_ThreePrivatelyHeldCompaniesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_ThreePrivatelyHeldCompaniesMember_lbl" xml:lang="en-US">Three Privately Held Companies [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_PrivatelyHeldCompanyMember" xlink:label="coep_PrivatelyHeldCompanyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_PrivatelyHeldCompanyMember" xlink:to="coep_PrivatelyHeldCompanyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_PrivatelyHeldCompanyMember_lbl" xml:lang="en-US">Privately Held Company [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_FirstYearExtensionMember" xlink:label="coep_FirstYearExtensionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_FirstYearExtensionMember" xlink:to="coep_FirstYearExtensionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_FirstYearExtensionMember_lbl" xml:lang="en-US">First Year Extension [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SecondYearExtensionMember" xlink:label="coep_SecondYearExtensionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_SecondYearExtensionMember" xlink:to="coep_SecondYearExtensionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_SecondYearExtensionMember_lbl" xml:lang="en-US">Second Year Extension [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_MehalickMember" xlink:label="coep_MehalickMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_MehalickMember" xlink:to="coep_MehalickMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_MehalickMember_lbl" xml:lang="en-US">Mehalick [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_YeraceMember" xlink:label="coep_YeraceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_YeraceMember" xlink:to="coep_YeraceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_YeraceMember_lbl" xml:lang="en-US">Yerace [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_CarTLicenseMember" xlink:label="coep_CarTLicenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_CarTLicenseMember" xlink:to="coep_CarTLicenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_CarTLicenseMember_lbl" xml:lang="en-US">Car T License [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_FindersFeeAndIndemnityAgreementMember" xlink:label="coep_FindersFeeAndIndemnityAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_FindersFeeAndIndemnityAgreementMember" xlink:to="coep_FindersFeeAndIndemnityAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_FindersFeeAndIndemnityAgreementMember_lbl" xml:lang="en-US">Finders Fee And Indemnity Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_MasterServicesAgreementsMember" xlink:label="coep_MasterServicesAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_MasterServicesAgreementsMember" xlink:to="coep_MasterServicesAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_MasterServicesAgreementsMember_lbl" xml:lang="en-US">Master Services Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_GearCellTherapyPlatformMember" xlink:label="coep_GearCellTherapyPlatformMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_GearCellTherapyPlatformMember" xlink:to="coep_GearCellTherapyPlatformMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_GearCellTherapyPlatformMember_lbl" xml:lang="en-US">Gear Cell Therapy Platform [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_AGBioLifeCapitalILPMember" xlink:label="coep_AGBioLifeCapitalILPMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_AGBioLifeCapitalILPMember" xlink:to="coep_AGBioLifeCapitalILPMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_AGBioLifeCapitalILPMember_lbl" xml:lang="en-US">AG Bio Life Capital I LP [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_BoardOfDirectorsMember" xlink:label="coep_BoardOfDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_BoardOfDirectorsMember" xlink:to="coep_BoardOfDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_BoardOfDirectorsMember_lbl" xml:lang="en-US">Board Of Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_NexGenAISolutionsGroupIncMember" xlink:label="coep_NexGenAISolutionsGroupIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_NexGenAISolutionsGroupIncMember" xlink:to="coep_NexGenAISolutionsGroupIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_NexGenAISolutionsGroupIncMember_lbl" xml:lang="en-US">Nex Gen A I Solutions Group Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_BiotechnologySegmentMember" xlink:label="coep_BiotechnologySegmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_BiotechnologySegmentMember" xlink:to="coep_BiotechnologySegmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_BiotechnologySegmentMember_lbl" xml:lang="en-US">Biotechnology Segment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_TechnologySegmentMember" xlink:label="coep_TechnologySegmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_TechnologySegmentMember" xlink:to="coep_TechnologySegmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_TechnologySegmentMember_lbl" xml:lang="en-US">Technology Segment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_BiotechnologyMember" xlink:label="coep_BiotechnologyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_BiotechnologyMember" xlink:to="coep_BiotechnologyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="coep_BiotechnologyMember_lbl" xml:lang="en-US">Biotechnology Segment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_TechnologyMember" xlink:label="coep_TechnologyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_TechnologyMember" xlink:to="coep_TechnologyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="coep_TechnologyMember_lbl" xml:lang="en-US">Technology Segment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US">Marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableCurrent" xlink:to="us-gaap_InterestReceivableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xml:lang="en-US">Interest receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">TOTAL CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Furniture and fixtures, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsAbstract" xlink:label="us-gaap_OtherAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsAbstract_lbl" xml:lang="en-US">OTHER ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Investments" xlink:label="us-gaap_Investments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Investments" xlink:to="us-gaap_Investments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Investments_lbl" xml:lang="en-US">Investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_CodevelopmentRightsNet" xlink:label="coep_CodevelopmentRightsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_CodevelopmentRightsNet" xlink:to="coep_CodevelopmentRightsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_CodevelopmentRightsNet_lbl" xml:lang="en-US">Co-development rights, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right of use asset, net of accumulated amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherAssets_lbl" xml:lang="en-US">Total other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US">Convertible notes payable, net of debt discount of $0 and $435,635</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNotesPayableCurrent" xlink:label="us-gaap_OtherNotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNotesPayableCurrent" xlink:to="us-gaap_OtherNotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNotesPayableCurrent_lbl" xml:lang="en-US">Convertible notes payable, in default</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Right of use liability, current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Customer deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xml:lang="en-US">Derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">TOTAL CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">LONG TERM LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US">SBA loan payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US">Derivative liability warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Right of use liability, non-current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">TOTAL LONG TERM LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES (NOTE 10)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.0001 par value, 10,000,000 shares authorized, 10,000 designated as Series A, 0 and 6,520 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.0001 par value, 150,000,000 shares authorized, 5,746,948 and 2,116,191 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_CommonStockSubscribed" xlink:label="coep_CommonStockSubscribed" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_CommonStockSubscribed" xlink:to="coep_CommonStockSubscribed_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_CommonStockSubscribed_lbl" xml:lang="en-US">Common stock subscribed</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_lbl" xml:lang="en-US">Subscription receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">TOTAL STOCKHOLDERS' EQUITY - CONTROLLING INTERESTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterest_lbl" xml:lang="en-US">TOTAL STOCKHOLDERS' EQUITY - NONCONTROLLING INTERESTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">TOTAL STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">SALES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Total sales</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of goods</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">COST OF OPERATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesAndWages" xlink:label="us-gaap_SalariesAndWages" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesAndWages" xlink:to="us-gaap_SalariesAndWages_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesAndWages_lbl" xml:lang="en-US">Salary expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="us-gaap_ProfessionalAndContractServicesExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalAndContractServicesExpense" xlink:to="us-gaap_ProfessionalAndContractServicesExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_lbl" xml:lang="en-US">Professional services expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xml:lang="en-US">Stock based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xml:lang="en-US">Selling and marketing expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total cost of operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">LOSS FROM OPERATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">OTHER INCOME (EXPENSE)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_GainOnForfeitureOfCustomerDeposit" xlink:label="coep_GainOnForfeitureOfCustomerDeposit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_GainOnForfeitureOfCustomerDeposit" xlink:to="coep_GainOnForfeitureOfCustomerDeposit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_GainOnForfeitureOfCustomerDeposit_lbl" xml:lang="en-US">Gain on forfeiture of customer deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income (expense), net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xml:lang="en-US">Unrealized gain on marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestments" xlink:label="us-gaap_GainLossOnInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnInvestments_lbl" xml:lang="en-US">Unrealized loss on investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:to="us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_lbl" xml:lang="en-US">Loss on write down of assets</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_GainsLossesOnExtinguishmentOfDebt1" xlink:label="coep_GainsLossesOnExtinguishmentOfDebt1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_GainsLossesOnExtinguishmentOfDebt1" xlink:to="coep_GainsLossesOnExtinguishmentOfDebt1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_GainsLossesOnExtinguishmentOfDebt1_lbl" xml:lang="en-US">Gain (loss) on extinguishment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US">Change in fair value of derivative liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">TOTAL OTHER INCOME (EXPENSE), net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">LOSS BEFORE INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">PROVISION FOR INCOME TAXES (BENEFIT)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">NET LOSS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">NET LOSS ATTRIBUTABLE TO NON-CONTROLLING INTERESTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">LOSS PER SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Loss per share, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Loss per share, fully diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average number of common shares outstanding, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average number of common shares outstanding, diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Shares issued for cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Shares issued for cash, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SharesIssuedInConnectionWithSEPAValue" xlink:label="coep_SharesIssuedInConnectionWithSEPAValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_SharesIssuedInConnectionWithSEPAValue" xlink:to="coep_SharesIssuedInConnectionWithSEPAValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_SharesIssuedInConnectionWithSEPAValue_lbl" xml:lang="en-US">Shares issued for SEPA</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SharesIssuedInConnectionWithSEPAShares" xlink:label="coep_SharesIssuedInConnectionWithSEPAShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_SharesIssuedInConnectionWithSEPAShares" xlink:to="coep_SharesIssuedInConnectionWithSEPAShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_SharesIssuedInConnectionWithSEPAShares_lbl" xml:lang="en-US">Shares issued for SEPA, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Shares issued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Shares issued for services, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SharesIssuedForInvestmentValue" xlink:label="coep_SharesIssuedForInvestmentValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_SharesIssuedForInvestmentValue" xlink:to="coep_SharesIssuedForInvestmentValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_SharesIssuedForInvestmentValue_lbl" xml:lang="en-US">Shares issued for investment</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SharesIssuedForInvestmentShares" xlink:label="coep_SharesIssuedForInvestmentShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_SharesIssuedForInvestmentShares" xlink:to="coep_SharesIssuedForInvestmentShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_SharesIssuedForInvestmentShares_lbl" xml:lang="en-US">Shares issued for investment, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl" xml:lang="en-US">Asset purchase agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xml:lang="en-US">Asset purchase agreement, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockIssuedDuringPeriodValueWarrantsIssuedForCash" xlink:label="coep_StockIssuedDuringPeriodValueWarrantsIssuedForCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_StockIssuedDuringPeriodValueWarrantsIssuedForCash" xlink:to="coep_StockIssuedDuringPeriodValueWarrantsIssuedForCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_StockIssuedDuringPeriodValueWarrantsIssuedForCash_lbl" xml:lang="en-US">Warrants issued for cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Warrants issued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockIssuedDuringPeriodValuePrefundedWarrantsExercise" xlink:label="coep_StockIssuedDuringPeriodValuePrefundedWarrantsExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_StockIssuedDuringPeriodValuePrefundedWarrantsExercise" xlink:to="coep_StockIssuedDuringPeriodValuePrefundedWarrantsExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_StockIssuedDuringPeriodValuePrefundedWarrantsExercise_lbl" xml:lang="en-US">Pre-funded warrants exercise</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockIssuedDuringPeriodSharesPrefundedWarrantsExercise" xlink:label="coep_StockIssuedDuringPeriodSharesPrefundedWarrantsExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_StockIssuedDuringPeriodSharesPrefundedWarrantsExercise" xlink:to="coep_StockIssuedDuringPeriodSharesPrefundedWarrantsExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_StockIssuedDuringPeriodSharesPrefundedWarrantsExercise_lbl" xml:lang="en-US">Pre-funded warrants exercise, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantsIssuedInExchangeForSubscriptionsReceivable" xlink:label="coep_WarrantsIssuedInExchangeForSubscriptionsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_WarrantsIssuedInExchangeForSubscriptionsReceivable" xlink:to="coep_WarrantsIssuedInExchangeForSubscriptionsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_WarrantsIssuedInExchangeForSubscriptionsReceivable_lbl" xml:lang="en-US">Warrants issued in exchange for subscriptions receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SharesIssuedForConversionOfDebtValue" xlink:label="coep_SharesIssuedForConversionOfDebtValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_SharesIssuedForConversionOfDebtValue" xlink:to="coep_SharesIssuedForConversionOfDebtValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_SharesIssuedForConversionOfDebtValue_lbl" xml:lang="en-US">Shares issued for the conversion of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SharesIssuedForConversionOfDebtShares" xlink:label="coep_SharesIssuedForConversionOfDebtShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_SharesIssuedForConversionOfDebtShares" xlink:to="coep_SharesIssuedForConversionOfDebtShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_SharesIssuedForConversionOfDebtShares_lbl" xml:lang="en-US">Shares issued for the conversion of debt, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockIssuedDuringPeriodValueOfPreferredShareOffering" xlink:label="coep_StockIssuedDuringPeriodValueOfPreferredShareOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_StockIssuedDuringPeriodValueOfPreferredShareOffering" xlink:to="coep_StockIssuedDuringPeriodValueOfPreferredShareOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_StockIssuedDuringPeriodValueOfPreferredShareOffering_lbl" xml:lang="en-US">Preferred stock offering</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockIssuedDuringPeriodSharesOfPreferredShareOffering" xlink:label="coep_StockIssuedDuringPeriodSharesOfPreferredShareOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_StockIssuedDuringPeriodSharesOfPreferredShareOffering" xlink:to="coep_StockIssuedDuringPeriodSharesOfPreferredShareOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_StockIssuedDuringPeriodSharesOfPreferredShareOffering_lbl" xml:lang="en-US">Preferred share offering, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockIssuedDuringPeriodValuePreferredShareConversion" xlink:label="coep_StockIssuedDuringPeriodValuePreferredShareConversion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_StockIssuedDuringPeriodValuePreferredShareConversion" xlink:to="coep_StockIssuedDuringPeriodValuePreferredShareConversion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_StockIssuedDuringPeriodValuePreferredShareConversion_lbl" xml:lang="en-US">Preferred share conversion</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockIssuedDuringPeriodSharePreferredShareConversion" xlink:label="coep_StockIssuedDuringPeriodSharePreferredShareConversion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_StockIssuedDuringPeriodSharePreferredShareConversion" xlink:to="coep_StockIssuedDuringPeriodSharePreferredShareConversion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_StockIssuedDuringPeriodSharePreferredShareConversion_lbl" xml:lang="en-US">Preferred share conversion, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockIssuedDuringPeriodValueOfInvestmentsAssignmentAgreements" xlink:label="coep_StockIssuedDuringPeriodValueOfInvestmentsAssignmentAgreements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_StockIssuedDuringPeriodValueOfInvestmentsAssignmentAgreements" xlink:to="coep_StockIssuedDuringPeriodValueOfInvestmentsAssignmentAgreements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_StockIssuedDuringPeriodValueOfInvestmentsAssignmentAgreements_lbl" xml:lang="en-US">Investments in private companies</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockIssuedDuringPeriodValuePurchaseOfAssets1" xlink:label="coep_StockIssuedDuringPeriodValuePurchaseOfAssets1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_StockIssuedDuringPeriodValuePurchaseOfAssets1" xlink:to="coep_StockIssuedDuringPeriodValuePurchaseOfAssets1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_StockIssuedDuringPeriodValuePurchaseOfAssets1_lbl" xml:lang="en-US">Common stock issued for intangible asset purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Stock split adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Stock split adjustment, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfitLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Conversion of Stock, Shares Converted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Debt converted to equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Debt converted to equity, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">OPERATING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Right of use asset amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_2_lbl" xml:lang="en-US">Amortization of debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncome" xlink:label="us-gaap_OtherNoncashIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncome" xlink:to="us-gaap_OtherNoncashIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNoncashIncome_lbl" xml:lang="en-US">Non-cash revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Shares issued for non-employee services</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantsIssuedForServices" xlink:label="coep_WarrantsIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_WarrantsIssuedForServices" xlink:to="coep_WarrantsIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="coep_WarrantsIssuedForServices_lbl" xml:lang="en-US">Warrants issued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xml:lang="en-US">Change in fair value of derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Change in fair value of derivative liability warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_LossOnSharesIssuedForConversionOfDebt" xlink:label="coep_LossOnSharesIssuedForConversionOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_LossOnSharesIssuedForConversionOfDebt" xlink:to="coep_LossOnSharesIssuedForConversionOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_LossOnSharesIssuedForConversionOfDebt_lbl" xml:lang="en-US">Loss on shares issued for conversion of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">(Gain) loss on extinguishment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xml:lang="en-US">Forgiveness of interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnInvestments_2_lbl" xml:lang="en-US">Unrealized loss on investments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_2_lbl" xml:lang="en-US">Unrealized gain on marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" xml:lang="en-US">(Increase) decrease in:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable" xlink:label="us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable" xlink:to="us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable_lbl" xml:lang="en-US">Interest receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAbstract_lbl" xml:lang="en-US">Increase (decrease) in:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Right of use liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">NET CASH USED IN OPERATING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">NET CASH USED IN INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:to="us-gaap_ProceedsFromRepaymentsOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayment of notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SharesIssuedForSepa" xlink:label="coep_SharesIssuedForSepa" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_SharesIssuedForSepa" xlink:to="coep_SharesIssuedForSepa_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="coep_SharesIssuedForSepa_lbl" xml:lang="en-US">Shares issued for SEPA</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Shares issued for cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Warrants issued for cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Pre-funded warrants exercise</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US">Preferred stock offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">NET CASH PROVIDED BY FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">NET INCREASE (DECREASE) IN CASH</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">CASH AT BEGINNING OF PERIOD</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">CASH AT END OF PERIOD</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL CASH FLOW DISCLOSURES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Taxes paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL NON-CASH DISCLOSURES</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SubscriptionsReceivable" xlink:label="coep_SubscriptionsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_SubscriptionsReceivable" xlink:to="coep_SubscriptionsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_SubscriptionsReceivable_lbl" xml:lang="en-US">Subscriptions receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SharesIssuedForConversionOfDebt" xlink:label="coep_SharesIssuedForConversionOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_SharesIssuedForConversionOfDebt" xlink:to="coep_SharesIssuedForConversionOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="coep_SharesIssuedForConversionOfDebt_lbl" xml:lang="en-US">Shares issued for the conversion of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SharesIssuedForInvestment" xlink:label="coep_SharesIssuedForInvestment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_SharesIssuedForInvestment" xlink:to="coep_SharesIssuedForInvestment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="coep_SharesIssuedForInvestment_lbl" xml:lang="en-US">Shares issued for investment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock" xlink:label="ecd_EqtyAwrdsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="ecd_EqtyAwrdsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EqtyAwrdsAdjFnTextBlock_lbl" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_2_lbl" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_2_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingArrLineItems_lbl" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xml:lang="en-US">Aggregate Available</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xml:lang="en-US">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Role of Management [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="cyd_MaterialCybersecurityIncidentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentAbstract" xlink:to="cyd_MaterialCybersecurityIncidentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentAbstract_lbl" xml:lang="en-US">Material Cybersecurity Incident [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Nature [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Scope [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Timing [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xml:lang="en-US">Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl" xml:lang="en-US">CO-DEVELOPMENT OPTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US">CONVERTIBLE NOTES</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SbaLoanPayableAbstract" xlink:label="coep_SbaLoanPayableAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_SbaLoanPayableAbstract" xlink:to="coep_SbaLoanPayableAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_SbaLoanPayableAbstract_lbl" xml:lang="en-US">Sba Loan Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SbaLoanPayableDisclosureTextBlock" xlink:label="coep_SbaLoanPayableDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_SbaLoanPayableDisclosureTextBlock" xlink:to="coep_SbaLoanPayableDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_SbaLoanPayableDisclosureTextBlock_lbl" xml:lang="en-US">SBA LOAN PAYABLE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesAndFairValueTextBlock" xlink:label="us-gaap_DerivativesAndFairValueTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesAndFairValueTextBlock" xlink:to="us-gaap_DerivativesAndFairValueTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesAndFairValueTextBlock_lbl" xml:lang="en-US">DERIVATIVE LIABILITY WARRANTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">CAPITAL STRUCTURE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="us-gaap_NoncontrollingInterestAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestAbstract" xlink:to="us-gaap_NoncontrollingInterestAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestAbstract_lbl" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestDisclosureTextBlock" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestDisclosureTextBlock" xlink:to="us-gaap_MinorityInterestDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock_lbl" xml:lang="en-US">NON-CONTROLLING INTEREST</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTextBlock" xlink:label="us-gaap_InvestmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTextBlock" xlink:to="us-gaap_InvestmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTextBlock_lbl" xml:lang="en-US">INVESTMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_lbl" xml:lang="en-US">401(k) PROFIT-SHARING PLAN</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INTANGIBLE ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">SEGMENT REPORTING</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_DisclosurePendingMergerTransactionAbstract" xlink:label="coep_DisclosurePendingMergerTransactionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_DisclosurePendingMergerTransactionAbstract" xlink:to="coep_DisclosurePendingMergerTransactionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_DisclosurePendingMergerTransactionAbstract_lbl" xml:lang="en-US">Pending Merger Transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_PendingMergerTransactionDisclosureTextBlock" xlink:label="coep_PendingMergerTransactionDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_PendingMergerTransactionDisclosureTextBlock" xlink:to="coep_PendingMergerTransactionDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_PendingMergerTransactionDisclosureTextBlock_lbl" xml:lang="en-US">PENDING MERGER TRANSACTION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US">Investments and Marketable Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US">Derivative Liability Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US">Convertible Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US">Reclassification</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Employee and Non-Employee Share-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">Going Concern</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments and Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of antidilutive shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US">Schedule of derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfServicingLiabilitiesAtFairValueTextBlock" xlink:label="us-gaap_ScheduleOfServicingLiabilitiesAtFairValueTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfServicingLiabilitiesAtFairValueTextBlock" xlink:to="us-gaap_ScheduleOfServicingLiabilitiesAtFairValueTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfServicingLiabilitiesAtFairValueTextBlock_lbl" xml:lang="en-US">Schedule of assumptions used for valuation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_lbl" xml:lang="en-US">Schedule of changes in fair value of derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of fair value hierarchy</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US">Schedule of fair value assumptions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of changes in fair value of warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of weighted average assumptions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of lease information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of future minimum rental payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of effective income tax reconciliation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of income tax provision</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl" xml:lang="en-US">Schedule of net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">Schedule of segment information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ProfitLoss_3_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ScheduleOfProductInformationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfProductInformationTable_lbl" xml:lang="en-US">Nature of Operation, Product Information, Concentration of Risk [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductInformationLineItems" xlink:label="us-gaap_ProductInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ProductInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductInformationLineItems_lbl" xml:lang="en-US">Product Information [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US">Cash uninsured amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="us-gaap_FinitelivedIntangibleAssetsAcquired1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1_lbl" xml:lang="en-US">Intangible assets acquired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US">Asset impairment charges</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Uncertain tax positions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration risk percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_2_lbl" xml:lang="en-US">Revenues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_2_lbl" xml:lang="en-US">Customer deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_lbl" xml:lang="en-US">Business Combination, Intangible Asset, Acquired, Finite-Lived [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Intangible Asset, Acquired, Finite-Lived [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLongTermNotesPayable" xlink:label="us-gaap_OtherLongTermNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLongTermNotesPayable" xlink:to="us-gaap_OtherLongTermNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLongTermNotesPayable_lbl" xml:lang="en-US">Other Notes Payable, Noncurrent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostGross" xlink:label="us-gaap_CapitalizedContractCostGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostGross" xlink:to="us-gaap_CapitalizedContractCostGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedContractCostGross_lbl" xml:lang="en-US">Capitalized Contract Cost, Gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived_lbl" xml:lang="en-US">License fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostAccumulatedAmortization" xlink:label="us-gaap_CapitalizedContractCostAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostAccumulatedAmortization" xlink:to="us-gaap_CapitalizedContractCostAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedContractCostAccumulatedAmortization_lbl" xml:lang="en-US">Capitalized Contract Cost, Accumulated Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostNet" xlink:to="us-gaap_CapitalizedContractCostNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedContractCostNet_lbl" xml:lang="en-US">Capitalized Contract Cost, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentForAmortization" xlink:label="us-gaap_AdjustmentForAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentForAmortization" xlink:to="us-gaap_AdjustmentForAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentForAmortization_lbl" xml:lang="en-US">Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OffsettingAssetsTable" xlink:label="us-gaap_OffsettingAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsTable" xlink:to="us-gaap_OffsettingAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsTable_lbl" xml:lang="en-US">Offsetting Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="us-gaap_OffsettingAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsLineItems" xlink:to="us-gaap_OffsettingAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsLineItems_lbl" xml:lang="en-US">Offsetting Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xml:lang="en-US">Fair value of derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US">Business Combination [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US">Business Combination [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue" xlink:label="us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue" xlink:to="us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_lbl" xml:lang="en-US">Derivative assumption valuation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_2_lbl" xml:lang="en-US">Fair value of derivative liability, beginning balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_2_lbl" xml:lang="en-US">Change in fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ExtinguishmentOfDebtGainLossNetOfTax" xlink:label="us-gaap_ExtinguishmentOfDebtGainLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtGainLossNetOfTax" xlink:to="us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_lbl" xml:lang="en-US">Extinguishment of fair value of liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_3_lbl" xml:lang="en-US">Fair value of derivative liability, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Short-Term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Debt face amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US">Convertible notes outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US">Repayment of convertible debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDefaultLongtermDebtAmount" xlink:label="us-gaap_DebtDefaultLongtermDebtAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDefaultLongtermDebtAmount" xlink:to="us-gaap_DebtDefaultLongtermDebtAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDefaultLongtermDebtAmount_lbl" xml:lang="en-US">Debt in default</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Debt converted, amount converted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Debt maturity date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US">Short-term debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebt_lbl" xml:lang="en-US">Convertible promissory note</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDecreaseForgiveness" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" xml:lang="en-US">Short-term debt replaced</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_DebtConversionConvertedInterestAmount1" xlink:label="coep_DebtConversionConvertedInterestAmount1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_DebtConversionConvertedInterestAmount1" xlink:to="coep_DebtConversionConvertedInterestAmount1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_DebtConversionConvertedInterestAmount1_lbl" xml:lang="en-US">[custom:DebtConversionConvertedInterestAmount1]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeAssetFairValueGrossLiability" xlink:label="us-gaap_DerivativeAssetFairValueGrossLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeAssetFairValueGrossLiability" xlink:to="us-gaap_DerivativeAssetFairValueGrossLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeAssetFairValueGrossLiability_lbl" xml:lang="en-US">Fair value derivative liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_3_lbl" xml:lang="en-US">Change in fair value of derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_lbl" xml:lang="en-US">Transfers in or out of Level 3</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLoans" xlink:label="us-gaap_ProceedsFromLoans" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLoans" xlink:to="us-gaap_ProceedsFromLoans_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLoans_lbl" xml:lang="en-US">Proceeds from loans</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_2_lbl" xml:lang="en-US">Accrued interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_lbl" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="us-gaap_DerivativeInstrumentsGainLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="us-gaap_DerivativeInstrumentsGainLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsGainLossLineItems_lbl" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Financial liabilities fair value disclosure</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue" xlink:to="us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_2_lbl" xml:lang="en-US">Derivatives, determination of fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Fair value of liabilities, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect_lbl" xml:lang="en-US">Change in valuation inputs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_2_lbl" xml:lang="en-US">Fair value of liabilities, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, beginning balance outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average contractual life (years), options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2OptionsGranted" xlink:label="coep_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2OptionsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2OptionsGranted" xlink:to="coep_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2OptionsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2OptionsGranted_lbl" xml:lang="en-US">Weighted average contractual life (years), granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Options forfeited/expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, forfeited/expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Options outstanding, ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, ending balance outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Intrinsic value, options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term, in years</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantsAndRightsOutstandingDateIssued" xlink:label="coep_WarrantsAndRightsOutstandingDateIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_WarrantsAndRightsOutstandingDateIssued" xlink:to="coep_WarrantsAndRightsOutstandingDateIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_WarrantsAndRightsOutstandingDateIssued_lbl" xml:lang="en-US">Date Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrants exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US">Expiration</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xml:lang="en-US">Total warrants outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_2_lbl" xml:lang="en-US">Preferred stock authorized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_2_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_2_lbl" xml:lang="en-US">Conversion of stock, shares converted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Exercise price of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Stock converted, shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_2_lbl" xml:lang="en-US">Aggregate exercise price of warrant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Proceeds from common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockDescriptionOfTransaction" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction_lbl" xml:lang="en-US">Investors description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Gross proceeds</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_2_lbl" xml:lang="en-US">Principal amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_3_lbl" xml:lang="en-US">Debt instrument stated percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_2_lbl" xml:lang="en-US">Maturity period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US">Treasury stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_2_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_2_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_2_lbl" xml:lang="en-US">Proceeds from sale of preferred stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_2_lbl" xml:lang="en-US">Subscription receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Unamortized stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xml:lang="en-US">Number of shares forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xml:lang="en-US">Number of shares exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Number of shares expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockIssuedForDebtShares" xlink:label="coep_StockIssuedForDebtShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_StockIssuedForDebtShares" xlink:to="coep_StockIssuedForDebtShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_StockIssuedForDebtShares_lbl" xml:lang="en-US">Stock issued for debt, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockIssuedForDebtValue" xlink:label="coep_StockIssuedForDebtValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_StockIssuedForDebtValue" xlink:to="coep_StockIssuedForDebtValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_StockIssuedForDebtValue_lbl" xml:lang="en-US">Stock issued for debt, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_lbl" xml:lang="en-US">Proceeds from issuance of preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable" xlink:label="us-gaap_PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable" xlink:to="us-gaap_PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable_lbl" xml:lang="en-US">Subscription receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_ProceedsFromSubscriptionsReceivable" xlink:label="coep_ProceedsFromSubscriptionsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_ProceedsFromSubscriptionsReceivable" xlink:to="coep_ProceedsFromSubscriptionsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_ProceedsFromSubscriptionsReceivable_lbl" xml:lang="en-US">Proceeds subscriptions receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SubscriptionsReceivableNet" xlink:label="coep_SubscriptionsReceivableNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_SubscriptionsReceivableNet" xlink:to="coep_SubscriptionsReceivableNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_SubscriptionsReceivableNet_lbl" xml:lang="en-US">Subscriptions receivable net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForBrokerageFees" xlink:label="us-gaap_PaymentsForBrokerageFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForBrokerageFees" xlink:to="us-gaap_PaymentsForBrokerageFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForBrokerageFees_lbl" xml:lang="en-US">Payment of commitment fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestTable" xlink:label="us-gaap_MinorityInterestTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestTable" xlink:to="us-gaap_MinorityInterestTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestTable_lbl" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestLineItems" xlink:label="us-gaap_MinorityInterestLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestLineItems" xlink:to="us-gaap_MinorityInterestLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestLineItems_lbl" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MinorityInterest_2_lbl" xml:lang="en-US">Noncontrolling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Net of accumulated losses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4_lbl" xml:lang="en-US">Equity attributable to non-controlling interests</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SubscriptionReceivable" xlink:label="coep_SubscriptionReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_SubscriptionReceivable" xlink:to="coep_SubscriptionReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_SubscriptionReceivable_lbl" xml:lang="en-US">[custom:SubscriptionReceivable-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="us-gaap_InvestmentOwnedBalanceShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedBalanceShares" xlink:to="us-gaap_InvestmentOwnedBalanceShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentOwnedBalanceShares_lbl" xml:lang="en-US">Investment Owned, Balance, Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_GainLossOnInvestments_3_lbl" xml:lang="en-US">Loss on investment</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockIssuedDuringPeriodSharesIssuedForInvestment" xlink:label="coep_StockIssuedDuringPeriodSharesIssuedForInvestment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_StockIssuedDuringPeriodSharesIssuedForInvestment" xlink:to="coep_StockIssuedDuringPeriodSharesIssuedForInvestment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_StockIssuedDuringPeriodSharesIssuedForInvestment_lbl" xml:lang="en-US">[custom:StockIssuedDuringPeriodSharesIssuedForInvestment]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockIssuedDuringPeriodValueIssuedForInvestment" xlink:label="coep_StockIssuedDuringPeriodValueIssuedForInvestment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_StockIssuedDuringPeriodValueIssuedForInvestment" xlink:to="coep_StockIssuedDuringPeriodValueIssuedForInvestment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_StockIssuedDuringPeriodValueIssuedForInvestment_lbl" xml:lang="en-US">[custom:StockIssuedDuringPeriodValueIssuedForInvestment]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_InvestmentCompanyFeePaidSharesIndirectly" xlink:label="coep_InvestmentCompanyFeePaidSharesIndirectly" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_InvestmentCompanyFeePaidSharesIndirectly" xlink:to="coep_InvestmentCompanyFeePaidSharesIndirectly_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_InvestmentCompanyFeePaidSharesIndirectly_lbl" xml:lang="en-US">Investment company fee paid shares indirectly</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentCompanyFeePaidIndirectly" xlink:label="us-gaap_InvestmentCompanyFeePaidIndirectly" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentCompanyFeePaidIndirectly" xlink:to="us-gaap_InvestmentCompanyFeePaidIndirectly_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentCompanyFeePaidIndirectly_lbl" xml:lang="en-US">Investment company fee paid indirectly</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_OperatingLeaseRightOfUseAssetGross" xlink:label="coep_OperatingLeaseRightOfUseAssetGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_OperatingLeaseRightOfUseAssetGross" xlink:to="coep_OperatingLeaseRightOfUseAssetGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_OperatingLeaseRightOfUseAssetGross_lbl" xml:lang="en-US">Operating lease right of use asset, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_OperatingLeaseRightOfUseAssetAccumulatedDepreciation" xlink:label="coep_OperatingLeaseRightOfUseAssetAccumulatedDepreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_OperatingLeaseRightOfUseAssetAccumulatedDepreciation" xlink:to="coep_OperatingLeaseRightOfUseAssetAccumulatedDepreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="coep_OperatingLeaseRightOfUseAssetAccumulatedDepreciation_lbl" xml:lang="en-US">Operating lease right of use asset, accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Operating lease right of use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Operating lease liability, current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Operating lease liability, noncurrent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total minimum lease payments:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less amount representing interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Present value of minimum lease payments:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_MonthlyRent" xlink:label="coep_MonthlyRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_MonthlyRent" xlink:to="coep_MonthlyRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_MonthlyRent_lbl" xml:lang="en-US">Monthly rent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_AnnualSalary" xlink:label="coep_AnnualSalary" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_AnnualSalary" xlink:to="coep_AnnualSalary_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_AnnualSalary_lbl" xml:lang="en-US">Annual salary</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_InitialLicenseFee" xlink:label="coep_InitialLicenseFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_InitialLicenseFee" xlink:to="coep_InitialLicenseFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_InitialLicenseFee_lbl" xml:lang="en-US">Initial license fee</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_AnnualMaintenanceFeeDescription" xlink:label="coep_AnnualMaintenanceFeeDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_AnnualMaintenanceFeeDescription" xlink:to="coep_AnnualMaintenanceFeeDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_AnnualMaintenanceFeeDescription_lbl" xml:lang="en-US">Annual maintenance fee description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US">Contractual obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_AgreementAmendmentFee" xlink:label="coep_AgreementAmendmentFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_AgreementAmendmentFee" xlink:to="coep_AgreementAmendmentFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_AgreementAmendmentFee_lbl" xml:lang="en-US">Agreement amendment fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForFees" xlink:label="us-gaap_PaymentsForFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForFees_lbl" xml:lang="en-US">Payment for fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNet" xlink:to="us-gaap_ContractWithCustomerAssetNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xml:lang="en-US">Customer deposit receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" xml:lang="en-US">Employer contributions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Income tax benefit at statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_ExpectedIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="coep_ExpectedIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_ExpectedIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="coep_ExpectedIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="coep_ExpectedIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Expected federal statutory income tax provision/rate</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_ExpectedEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="coep_ExpectedEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_ExpectedEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="coep_ExpectedEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_ExpectedEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">[custom:ExpectedEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income taxes, net of federal benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_2_lbl" xml:lang="en-US">Income tax benefit at statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Effective income tax rate reconciliation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Section 174 R&amp;D</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US">PPE and intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsStateTaxes" xlink:label="us-gaap_DeferredTaxAssetsStateTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsStateTaxes" xlink:to="us-gaap_DeferredTaxAssetsStateTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsStateTaxes_lbl" xml:lang="en-US">State taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Subtotal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation Allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred tax assets (liabilities)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carry forwards</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_DisclosureTable" xlink:label="coep_DisclosureTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_DisclosureTable" xlink:to="coep_DisclosureTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_DisclosureTable_lbl" xml:lang="en-US">DisclosureTable [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_DisclosureLineElements" xlink:label="coep_DisclosureLineElements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_DisclosureLineElements" xlink:to="coep_DisclosureLineElements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_DisclosureLineElements_lbl" xml:lang="en-US">DisclosureLineElements [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_2_lbl" xml:lang="en-US">Shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsAndNotesReceivableNet" xlink:label="us-gaap_AccountsAndNotesReceivableNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndNotesReceivableNet" xlink:to="us-gaap_AccountsAndNotesReceivableNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsAndNotesReceivableNet_lbl" xml:lang="en-US">Note receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Investments" xlink:to="us-gaap_Investments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Investments_2_lbl" xml:lang="en-US">Investment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued professional fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherInvestments" xlink:label="us-gaap_OtherInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherInvestments" xlink:to="us-gaap_OtherInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherInvestments_lbl" xml:lang="en-US">Other investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_2_lbl" xml:lang="en-US">Stock issued for purchase of assets, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_2_lbl" xml:lang="en-US">Stock issued for purchase of assets, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_2_lbl" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xml:lang="en-US">Amortization of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_3_lbl" xml:lang="en-US">Sales</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CostOfRevenue_2_lbl" xml:lang="en-US">Cost of goods sold</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Net (loss) gain from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Number of reportable segments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Total assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_BiotechnologyMember" xlink:to="coep_BiotechnologyMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_BiotechnologyMember_2_lbl" xml:lang="en-US">Biotechnology Segment [Member] [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_TechnologyMember" xlink:to="coep_TechnologyMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_TechnologyMember_2_lbl" xml:lang="en-US">Technology Segment [Member] [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssets_2_lbl" xml:lang="en-US">Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_2_lbl" xml:lang="en-US">Liabilities, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseNonoperating_2_lbl" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:to="us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_2_lbl" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncome" xlink:to="us-gaap_OtherNoncashIncome_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashIncome_2_lbl" xml:lang="en-US">Other Noncash Income</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_2_lbl" xml:lang="en-US">Employee Benefit and Share-Based Payment Arrangement, Noncash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_WarrantsIssuedForServices" xlink:to="coep_WarrantsIssuedForServices_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_WarrantsIssuedForServices_2_lbl" xml:lang="en-US">WarrantsIssuedForServices</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable" xlink:to="us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Interest and Dividends Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_SharesIssuedForSepa" xlink:to="coep_SharesIssuedForSepa_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_SharesIssuedForSepa_2_lbl" xml:lang="en-US">SharesIssuedForSepa</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_2_lbl" xml:lang="en-US">Proceeds from Issuance of Warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_SharesIssuedForConversionOfDebt" xlink:to="coep_SharesIssuedForConversionOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_SharesIssuedForConversionOfDebt_2_lbl" xml:lang="en-US">SharesIssuedForConversionOfDebt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_SharesIssuedForInvestment" xlink:to="coep_SharesIssuedForInvestment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_SharesIssuedForInvestment_2_lbl" xml:lang="en-US">SharesIssuedForInvestment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtGainLossNetOfTax" xlink:to="us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_2_lbl" xml:lang="en-US">Extinguishment of Debt, Gain (Loss), Net of Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_3_lbl" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable" xlink:to="us-gaap_PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable_2_lbl" xml:lang="en-US">Preferred Stock, Shares Subscribed but Unissued, Subscriptions Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_OperatingLeaseRightOfUseAssetAccumulatedDepreciation" xlink:to="coep_OperatingLeaseRightOfUseAssetAccumulatedDepreciation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_OperatingLeaseRightOfUseAssetAccumulatedDepreciation_2_lbl" xml:lang="en-US">OperatingLeaseRightOfUseAssetAccumulatedDepreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="coep_ExpectedIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="coep_ExpectedIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="coep_ExpectedIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_2_lbl" xml:lang="en-US">ExpectedIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsStateTaxes" xlink:to="us-gaap_DeferredTaxAssetsStateTaxes_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsStateTaxes_2_lbl" xml:lang="en-US">Deferred Tax Assets, State Taxes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>coep-20251231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#Cover" roleURI="http://coeptistx.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#ConsolidatedBalanceSheets" roleURI="http://coeptistx.com/role/ConsolidatedBalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://coeptistx.com/role/ConsolidatedBalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#ConsolidatedStatementsOfOperations" roleURI="http://coeptistx.com/role/ConsolidatedStatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#ConsolidatedStatementsOfStockholdersEquity" roleURI="http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#MaterialCybersecurityIncidentDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#DescriptionOfBusinessAndBasisOfPresentation" roleURI="http://coeptistx.com/role/DescriptionOfBusinessAndBasisOfPresentation" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://coeptistx.com/role/SummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#Co-developmentOptions" roleURI="http://coeptistx.com/role/Co-developmentOptions" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#ConvertibleNotes" roleURI="http://coeptistx.com/role/ConvertibleNotes" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#SbaLoanPayable" roleURI="http://coeptistx.com/role/SbaLoanPayable" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#DerivativeLiabilityWarrants" roleURI="http://coeptistx.com/role/DerivativeLiabilityWarrants" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#CapitalStructure" roleURI="http://coeptistx.com/role/CapitalStructure" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#Non-controllingInterest" roleURI="http://coeptistx.com/role/Non-controllingInterest" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#Investments" roleURI="http://coeptistx.com/role/Investments" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#CommitmentsAndContingencies" roleURI="http://coeptistx.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#KProfit-sharingPlan" roleURI="http://coeptistx.com/role/KProfit-sharingPlan" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#IncomeTaxes" roleURI="http://coeptistx.com/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#RelatedPartyTransactions" roleURI="http://coeptistx.com/role/RelatedPartyTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#IntangibleAssets" roleURI="http://coeptistx.com/role/IntangibleAssets" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#SegmentReporting" roleURI="http://coeptistx.com/role/SegmentReporting" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#PendingMergerTransaction" roleURI="http://coeptistx.com/role/PendingMergerTransaction" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#SubsequentEvents" roleURI="http://coeptistx.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#ConvertibleNotesTables" roleURI="http://coeptistx.com/role/ConvertibleNotesTables" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#DerivativeLiabilityWarrantsTables" roleURI="http://coeptistx.com/role/DerivativeLiabilityWarrantsTables" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#CapitalStructureTables" roleURI="http://coeptistx.com/role/CapitalStructureTables" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#CommitmentsAndContingenciesTables" roleURI="http://coeptistx.com/role/CommitmentsAndContingenciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#IncomeTaxesTables" roleURI="http://coeptistx.com/role/IncomeTaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#SegmentReportingTables" roleURI="http://coeptistx.com/role/SegmentReportingTables" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative" roleURI="http://coeptistx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#Co-developmentOptionsDetailsNarrative" roleURI="http://coeptistx.com/role/Co-developmentOptionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#ConvertibleNotesDetails-DerivativeLiability" roleURI="http://coeptistx.com/role/ConvertibleNotesDetails-DerivativeLiability" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#ConvertibleNotesDetails-Assumptions" roleURI="http://coeptistx.com/role/ConvertibleNotesDetails-Assumptions" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#ConvertibleNotesDetails-ChangeInDeriviative" roleURI="http://coeptistx.com/role/ConvertibleNotesDetails-ChangeInDeriviative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#ConvertibleNotesDetailsNarrative" roleURI="http://coeptistx.com/role/ConvertibleNotesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#SbaLoanPayableDetailsNarrative" roleURI="http://coeptistx.com/role/SbaLoanPayableDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#DerivativeLiabilityWarrantsDetails-FairValue" roleURI="http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-FairValue" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#DerivativeLiabilityWarrantsDetails-FairValueAssumption" roleURI="http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-FairValueAssumption" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#DerivativeLiabilityWarrantsDetails-ChangesInFairValueOfWarrantLiabilities" roleURI="http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-ChangesInFairValueOfWarrantLiabilities" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#DerivativeLiabilityWarrantsDetailsNarrative" roleURI="http://coeptistx.com/role/DerivativeLiabilityWarrantsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#CapitalStructureDetails-OptionActivity" roleURI="http://coeptistx.com/role/CapitalStructureDetails-OptionActivity" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#CapitalStructureDetails-WeightedAverageAssumptions" roleURI="http://coeptistx.com/role/CapitalStructureDetails-WeightedAverageAssumptions" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#CapitalStructureDetails-WarrantsOutstanding" roleURI="http://coeptistx.com/role/CapitalStructureDetails-WarrantsOutstanding" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#CapitalStructureDetailsNarrative" roleURI="http://coeptistx.com/role/CapitalStructureDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#Non-controllingInterestDetailsNarrative" roleURI="http://coeptistx.com/role/Non-controllingInterestDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#InvestmentsDetailsNarrative" roleURI="http://coeptistx.com/role/InvestmentsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#CommitmentsAndContingenciesDetails-LeaseCost" roleURI="http://coeptistx.com/role/CommitmentsAndContingenciesDetails-LeaseCost" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#CommitmentsAndContingenciesDetails-FutureMinimumPayments" roleURI="http://coeptistx.com/role/CommitmentsAndContingenciesDetails-FutureMinimumPayments" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://coeptistx.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#KProfit-sharingPlanDetailsNarrative" roleURI="http://coeptistx.com/role/KProfit-sharingPlanDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#IncomeTaxesDetails-ReconcilationOfIncomeTax" roleURI="http://coeptistx.com/role/IncomeTaxesDetails-ReconcilationOfIncomeTax" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#IncomeTaxesDetails-ReconcilationOfProvision" roleURI="http://coeptistx.com/role/IncomeTaxesDetails-ReconcilationOfProvision" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#IncomeTaxesDetails-OperatingLossCarryforwards" roleURI="http://coeptistx.com/role/IncomeTaxesDetails-OperatingLossCarryforwards" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#IncomeTaxesDetailsNarrative" roleURI="http://coeptistx.com/role/IncomeTaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#RelatedPartyTransactionsDetailsNarrative" roleURI="http://coeptistx.com/role/RelatedPartyTransactionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#IntangibleAssetsDetailsNarrative" roleURI="http://coeptistx.com/role/IntangibleAssetsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#SegmentReportingDetails" roleURI="http://coeptistx.com/role/SegmentReportingDetails" />
    <link:roleRef xlink:type="simple" xlink:href="coep-20251231.xsd#SegmentReportingDetailsNarrative" roleURI="http://coeptistx.com/role/SegmentReportingDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosureWithAdditionalMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpTable" roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpAdjustmentsToCompensation" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TabularListsByExecutiveCategory" roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TabularListMeasures" roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpPensionBenefitsAdjustments" roleURI="http://xbrl.sec.gov/ecd/role/PvpPensionBenefitsAdjustments" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ForgoneRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#OutstandingRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardsCloseToMnpiDisc" roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangemenstByInd" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#Defaults" roleURI="http://xbrl.sec.gov/ecd/role/Defaults" />
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_CommonStockParValue0.0001PerShareMember" xlink:label="loc_coepCommonStockParValue0.0001PerShareMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepCommonStockParValue0.0001PerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantsEachWholeWarrantExercisableForOnehalfOfOneShareOfCommonStockFor230.00PerWholeShareMember" xlink:label="loc_coepWarrantsEachWholeWarrantExercisableForOnehalfOfOneShareOfCommonStockFor230.00PerWholeShareMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepWarrantsEachWholeWarrantExercisableForOnehalfOfOneShareOfCommonStockFor230.00PerWholeShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="630" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="640" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestReceivableCurrent" xlink:label="loc_us-gaapInterestReceivableCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInterestReceivableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaapOtherAssetsAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Investments" xlink:label="loc_us-gaapInvestments" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_CodevelopmentRightsNet" xlink:label="loc_coepCodevelopmentRightsNet" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_coepCodevelopmentRightsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaapOtherAssets" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNotesPayableCurrent" xlink:label="loc_us-gaapOtherNotesPayableCurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaapDeferredRevenueCurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeferredRevenueCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLongTermDebtNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_CommonStockSubscribed" xlink:label="loc_coepCommonStockSubscribed" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_coepCommonStockSubscribed" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:label="loc_us-gaapStockholdersEquityNoteSubscriptionsReceivable" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteSubscriptionsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapMinorityInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaapConvertibleNotesPayableMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_us-gaapConvertibleNotesPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SaleMember" xlink:label="loc_coepSaleMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_coepSaleMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaapRevenuesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenuesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSalariesAndWages" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="loc_us-gaapProfessionalAndContractServicesExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapProfessionalAndContractServicesExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapOtherGeneralAndAdministrativeExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOtherGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaapSellingAndMarketingExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingAndMarketingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpenseNonoperating" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestAndOtherIncome" xlink:label="loc_us-gaapInterestAndOtherIncome" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestAndOtherIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_GainOnForfeitureOfCustomerDeposit" xlink:label="loc_coepGainOnForfeitureOfCustomerDeposit" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_coepGainOnForfeitureOfCustomerDeposit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaapGainLossOnInvestments" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainLossOnInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="loc_us-gaapDisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapDisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_GainsLossesOnExtinguishmentOfDebt1" xlink:label="loc_coepGainsLossesOnExtinguishmentOfDebt1" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_coepGainsLossesOnExtinguishmentOfDebt1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="90" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_CommonStockSubscribedMember" xlink:label="loc_coepCommonStockSubscribedMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_coepCommonStockSubscribedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SubscriptionReceivableMember" xlink:label="loc_coepSubscriptionReceivableMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_coepSubscriptionReceivableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaapParentMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapParentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaapNoncontrollingInterestMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapNoncontrollingInterestMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SharesIssuedInConnectionWithSEPAValue" xlink:label="loc_coepSharesIssuedInConnectionWithSEPAValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_coepSharesIssuedInConnectionWithSEPAValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SharesIssuedInConnectionWithSEPAShares" xlink:label="loc_coepSharesIssuedInConnectionWithSEPAShares" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_coepSharesIssuedInConnectionWithSEPAShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SharesIssuedForInvestmentValue" xlink:label="loc_coepSharesIssuedForInvestmentValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_coepSharesIssuedForInvestmentValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SharesIssuedForInvestmentShares" xlink:label="loc_coepSharesIssuedForInvestmentShares" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_coepSharesIssuedForInvestmentShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodValuePurchaseOfAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValuePurchaseOfAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockIssuedDuringPeriodValueWarrantsIssuedForCash" xlink:label="loc_coepStockIssuedDuringPeriodValueWarrantsIssuedForCash" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_coepStockIssuedDuringPeriodValueWarrantsIssuedForCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockIssuedDuringPeriodValuePrefundedWarrantsExercise" xlink:label="loc_coepStockIssuedDuringPeriodValuePrefundedWarrantsExercise" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_coepStockIssuedDuringPeriodValuePrefundedWarrantsExercise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockIssuedDuringPeriodSharesPrefundedWarrantsExercise" xlink:label="loc_coepStockIssuedDuringPeriodSharesPrefundedWarrantsExercise" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_coepStockIssuedDuringPeriodSharesPrefundedWarrantsExercise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantsIssuedInExchangeForSubscriptionsReceivable" xlink:label="loc_coepWarrantsIssuedInExchangeForSubscriptionsReceivable" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_coepWarrantsIssuedInExchangeForSubscriptionsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SharesIssuedForConversionOfDebtValue" xlink:label="loc_coepSharesIssuedForConversionOfDebtValue" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_coepSharesIssuedForConversionOfDebtValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SharesIssuedForConversionOfDebtShares" xlink:label="loc_coepSharesIssuedForConversionOfDebtShares" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_coepSharesIssuedForConversionOfDebtShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockIssuedDuringPeriodValueOfPreferredShareOffering" xlink:label="loc_coepStockIssuedDuringPeriodValueOfPreferredShareOffering" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_coepStockIssuedDuringPeriodValueOfPreferredShareOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockIssuedDuringPeriodSharesOfPreferredShareOffering" xlink:label="loc_coepStockIssuedDuringPeriodSharesOfPreferredShareOffering" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_coepStockIssuedDuringPeriodSharesOfPreferredShareOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockIssuedDuringPeriodValuePreferredShareConversion" xlink:label="loc_coepStockIssuedDuringPeriodValuePreferredShareConversion" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_coepStockIssuedDuringPeriodValuePreferredShareConversion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockIssuedDuringPeriodSharePreferredShareConversion" xlink:label="loc_coepStockIssuedDuringPeriodSharePreferredShareConversion" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_coepStockIssuedDuringPeriodSharePreferredShareConversion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockIssuedDuringPeriodValueOfInvestmentsAssignmentAgreements" xlink:label="loc_coepStockIssuedDuringPeriodValueOfInvestmentsAssignmentAgreements" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_coepStockIssuedDuringPeriodValueOfInvestmentsAssignmentAgreements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockIssuedDuringPeriodValuePurchaseOfAssets1" xlink:label="loc_coepStockIssuedDuringPeriodValuePurchaseOfAssets1" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_coepStockIssuedDuringPeriodValuePurchaseOfAssets1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncome" xlink:label="loc_us-gaapOtherNoncashIncome" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOtherNoncashIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensationNoncash" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensationNoncash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantsIssuedForServices" xlink:label="loc_coepWarrantsIssuedForServices" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_coepWarrantsIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="loc_us-gaapUnrealizedGainLossOnDerivatives" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapUnrealizedGainLossOnDerivatives" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_LossOnSharesIssuedForConversionOfDebt" xlink:label="loc_coepLossOnSharesIssuedForConversionOfDebt" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_coepLossOnSharesIssuedForConversionOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaapIncreaseDecreaseInInterestPayableNet" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInterestPayableNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaapGainLossOnInvestments" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainLossOnInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInInterestAndDividendsReceivable" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInterestAndDividendsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="loc_us-gaapProceedsFromRepaymentsOfNotesPayable" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromRepaymentsOfNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SharesIssuedForSepa" xlink:label="loc_coepSharesIssuedForSepa" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_coepSharesIssuedForSepa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SubscriptionsReceivable" xlink:label="loc_coepSubscriptionsReceivable" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_coepSubscriptionsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SharesIssuedForConversionOfDebt" xlink:label="loc_coepSharesIssuedForConversionOfDebt" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_coepSharesIssuedForConversionOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SharesIssuedForInvestment" xlink:label="loc_coepSharesIssuedForInvestment" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_coepSharesIssuedForInvestment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock" xlink:label="loc_ecdEqtyAwrdsAdjFnTextBlock" />
      <link:presentationArc order="2290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdEqtyAwrdsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="loc_ecdTrdArrSecuritiesAggAvailAmt" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrSecuritiesAggAvailAmt" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="loc_cydCybersecurityRiskRoleOfManagementTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskRoleOfManagementTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="loc_cydMaterialCybersecurityIncidentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentNatureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentNatureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentScopeTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentScopeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentTimingTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentTimingTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:title="999014 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/Co-developmentOptions" xlink:title="999016 - Disclosure - CO-DEVELOPMENT OPTIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:label="loc_us-gaapMergersAcquisitionsAndDispositionsDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapMergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/ConvertibleNotes" xlink:title="999017 - Disclosure - CONVERTIBLE NOTES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="loc_us-gaapLongTermDebtTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/SbaLoanPayable" xlink:title="999018 - Disclosure - SBA LOAN PAYABLE">
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SbaLoanPayableAbstract" xlink:label="loc_coepSbaLoanPayableAbstract" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SbaLoanPayableDisclosureTextBlock" xlink:label="loc_coepSbaLoanPayableDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_coepSbaLoanPayableAbstract" xlink:to="loc_coepSbaLoanPayableDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/DerivativeLiabilityWarrants" xlink:title="999019 - Disclosure - DERIVATIVE LIABILITY WARRANTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesAndFairValueTextBlock" xlink:label="loc_us-gaapDerivativesAndFairValueTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapDerivativesAndFairValueTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/CapitalStructure" xlink:title="999020 - Disclosure - CAPITAL STRUCTURE">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/Non-controllingInterest" xlink:title="999021 - Disclosure - NON-CONTROLLING INTEREST">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="loc_us-gaapNoncontrollingInterestAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestDisclosureTextBlock" xlink:label="loc_us-gaapMinorityInterestDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncontrollingInterestAbstract" xlink:to="loc_us-gaapMinorityInterestDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/Investments" xlink:title="999022 - Disclosure - INVESTMENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTextBlock" xlink:label="loc_us-gaapInvestmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_us-gaapInvestmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/CommitmentsAndContingencies" xlink:title="999023 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/KProfit-sharingPlan" xlink:title="999024 - Disclosure - 401(k) PROFIT-SHARING PLAN">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:label="loc_us-gaapCompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapCompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/IncomeTaxes" xlink:title="999025 - Disclosure - INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/RelatedPartyTransactions" xlink:title="999026 - Disclosure - RELATED PARTY TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/IntangibleAssets" xlink:title="999027 - Disclosure - INTANGIBLE ASSETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/SegmentReporting" xlink:title="999028 - Disclosure - SEGMENT REPORTING">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/PendingMergerTransaction" xlink:title="999029 - Disclosure - PENDING MERGER TRANSACTION">
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_DisclosurePendingMergerTransactionAbstract" xlink:label="loc_coepDisclosurePendingMergerTransactionAbstract" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_PendingMergerTransactionDisclosureTextBlock" xlink:label="loc_coepPendingMergerTransactionDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_coepDisclosurePendingMergerTransactionAbstract" xlink:to="loc_coepPendingMergerTransactionDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/SubsequentEvents" xlink:title="999030 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaapMarketableSecuritiesPolicy" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaapDerivativesPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDerivativesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaapDebtPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDebtPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/ConvertibleNotesTables" xlink:title="999033 - Disclosure - CONVERTIBLE NOTES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfServicingLiabilitiesAtFairValueTextBlock" xlink:label="loc_us-gaapScheduleOfServicingLiabilitiesAtFairValueTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfServicingLiabilitiesAtFairValueTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:label="loc_us-gaapScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/DerivativeLiabilityWarrantsTables" xlink:title="999034 - Disclosure - DERIVATIVE LIABILITY WARRANTS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/CapitalStructureTables" xlink:title="999035 - Disclosure - CAPITAL STRUCTURE (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/CommitmentsAndContingenciesTables" xlink:title="999036 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/IncomeTaxesTables" xlink:title="999037 - Disclosure - INCOME TAXES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="loc_us-gaapSummaryOfOperatingLossCarryforwardsTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapSummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/SegmentReportingTables" xlink:title="999038 - Disclosure - SEGMENT REPORTING (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:title="999039 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="999040 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantsMember" xlink:label="loc_coepWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_coepWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockOptionsMember" xlink:label="loc_coepStockOptionsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_coepStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaapConvertibleNotesPayableMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapConvertibleNotesPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999041 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfProductInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapProductInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaapAssetAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapAssetAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaapAssetAcquisitionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionAxis" xlink:to="loc_us-gaapAssetAcquisitionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_NexGenAIMember" xlink:label="loc_coepNexGenAIMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionDomain" xlink:to="loc_coepNexGenAIMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtMajorCustomersAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SixCustomersMember" xlink:label="loc_coepSixCustomersMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_coepSixCustomersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_ThreeCustomersMember" xlink:label="loc_coepThreeCustomersMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_coepThreeCustomersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_AdvertisingCampaignsMember" xlink:label="loc_coepAdvertisingCampaignsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_coepAdvertisingCampaignsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WebinarServicesMember" xlink:label="loc_coepWebinarServicesMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_coepWebinarServicesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaapCashUninsuredAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapCashUninsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaapFinitelivedIntangibleAssetsAcquired1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapFinitelivedIntangibleAssetsAcquired1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAssetImpairmentCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapUnrecognizedTaxBenefits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaapDeferredRevenueCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapDeferredRevenueCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/Co-developmentOptionsDetailsNarrative" xlink:title="999042 - Disclosure - CO-DEVELOPMENT OPTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:to="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_CD38AssetsMember" xlink:label="loc_coepCD38AssetsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_coepCD38AssetsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:to="loc_srtCounterpartyNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_VyGenMember" xlink:label="loc_coepVyGenMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_coepVyGenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaapTransactionTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:to="loc_us-gaapTransactionTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_CoDevelopmentRightsMember" xlink:label="loc_coepCoDevelopmentRightsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_coepCoDevelopmentRightsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_CoDevelopmentOptionsMember" xlink:label="loc_coepCoDevelopmentOptionsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_coepCoDevelopmentOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaapPaymentsToAcquireProductiveAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapPaymentsToAcquireProductiveAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLongTermNotesPayable" xlink:label="loc_us-gaapOtherLongTermNotesPayable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapOtherLongTermNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaapRepaymentsOfLongTermDebt" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapRepaymentsOfLongTermDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostGross" xlink:label="loc_us-gaapCapitalizedContractCostGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapCapitalizedContractCostGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="loc_us-gaapProceedsFromLicenseFeesReceived" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapProceedsFromLicenseFeesReceived" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostAccumulatedAmortization" xlink:label="loc_us-gaapCapitalizedContractCostAccumulatedAmortization" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapCapitalizedContractCostAccumulatedAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="loc_us-gaapCapitalizedContractCostNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapCapitalizedContractCostNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaapAdjustmentForAmortization" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAdjustmentForAmortization" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/ConvertibleNotesDetails-DerivativeLiability" xlink:title="999043 - Disclosure - CONVERTIBLE NOTES (Details - Derivative liability)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapOffsettingAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapOffsettingAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_DerivativeLiabilityMember" xlink:label="loc_coepDerivativeLiabilityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_coepDerivativeLiabilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaapDerivativeFairValueOfDerivativeLiability" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapDerivativeFairValueOfDerivativeLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/ConvertibleNotesDetails-Assumptions" xlink:title="999044 - Disclosure - CONVERTIBLE NOTES (Details - Assumptions)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputConversionPriceMember" xlink:label="loc_us-gaapMeasurementInputConversionPriceMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputConversionPriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue" xlink:label="loc_us-gaapDerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapDerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/ConvertibleNotesDetails-ChangeInDeriviative" xlink:title="999045 - Disclosure - CONVERTIBLE NOTES (Details - Change in deriviative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaapDerivativeFairValueOfDerivativeLiability" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDerivativeFairValueOfDerivativeLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="loc_us-gaapUnrealizedGainLossOnDerivatives" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapUnrealizedGainLossOnDerivatives" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ExtinguishmentOfDebtGainLossNetOfTax" xlink:label="loc_us-gaapExtinguishmentOfDebtGainLossNetOfTax" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapExtinguishmentOfDebtGainLossNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaapDerivativeFairValueOfDerivativeLiability_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDerivativeFairValueOfDerivativeLiability_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/ConvertibleNotesDetailsNarrative" xlink:title="999046 - Disclosure - CONVERTIBLE NOTES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_LicenseAgreementMember" xlink:label="loc_coepLicenseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_coepLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_PurpleBioTechMember" xlink:label="loc_coepPurpleBioTechMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_coepPurpleBioTechMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_Oct2022ConvertiblePromissoryNoteMember" xlink:label="loc_coepOct2022ConvertiblePromissoryNoteMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_coepOct2022ConvertiblePromissoryNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_Dec2023ConvertiblePromissoryNoteMember" xlink:label="loc_coepDec2023ConvertiblePromissoryNoteMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_coepDec2023ConvertiblePromissoryNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_April2024UnsecuredNoteMember" xlink:label="loc_coepApril2024UnsecuredNoteMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_coepApril2024UnsecuredNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_YANote1Member" xlink:label="loc_coepYANote1Member" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_coepYANote1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_YorkvilleConvertibleNoteMember" xlink:label="loc_coepYorkvilleConvertibleNoteMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_coepYorkvilleConvertibleNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_YANote2Member" xlink:label="loc_coepYANote2Member" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_coepYANote2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StandbyEquityPurchaseAgreementMember" xlink:label="loc_coepStandbyEquityPurchaseAgreementMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_coepStandbyEquityPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaapRepaymentsOfConvertibleDebt" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapRepaymentsOfConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDefaultLongtermDebtAmount" xlink:label="loc_us-gaapDebtDefaultLongtermDebtAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtDefaultLongtermDebtAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaapShortTermBorrowings" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShortTermBorrowings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="loc_us-gaapDebtInstrumentDecreaseForgiveness" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentDecreaseForgiveness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_DebtConversionConvertedInterestAmount1" xlink:label="loc_coepDebtConversionConvertedInterestAmount1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_coepDebtConversionConvertedInterestAmount1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeAssetFairValueGrossLiability" xlink:label="loc_us-gaapDerivativeAssetFairValueGrossLiability" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDerivativeAssetFairValueGrossLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="loc_us-gaapUnrealizedGainLossOnDerivatives" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapUnrealizedGainLossOnDerivatives" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/SbaLoanPayableDetailsNarrative" xlink:title="999047 - Disclosure - SBA LOAN PAYABLE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SbaLoanPayableAbstract" xlink:label="loc_coepSbaLoanPayableAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_coepSbaLoanPayableAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_EidlLoanMember" xlink:label="loc_coepEidlLoanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_coepEidlLoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLoans" xlink:label="loc_us-gaapProceedsFromLoans" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromLoans" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-FairValue" xlink:title="999048 - Disclosure - DERIVATIVE LIABILITY WARRANTS (Details - Fair value)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="loc_us-gaapDerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapDerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="loc_us-gaapDerivativeInstrumentsGainLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="loc_us-gaapDerivativeInstrumentsGainLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_PublicWarrantsMember" xlink:label="loc_coepPublicWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_coepPublicWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_PrivatePlacementWarrantsMember" xlink:label="loc_coepPrivatePlacementWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_coepPrivatePlacementWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapFinancialLiabilitiesFairValueDisclosure" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsGainLossLineItems" xlink:to="loc_us-gaapFinancialLiabilitiesFairValueDisclosure" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-FairValueAssumption" xlink:title="999049 - Disclosure - DERIVATIVE LIABILITY WARRANTS (Details - Fair value assumption)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="loc_us-gaapDerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapDerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="loc_us-gaapDerivativeInstrumentsGainLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="loc_us-gaapDerivativeInstrumentsGainLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaapMeasurementInputExercisePriceMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExercisePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantsMember" xlink:label="loc_coepWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_coepWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue" xlink:label="loc_us-gaapDerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsGainLossLineItems" xlink:to="loc_us-gaapDerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-ChangesInFairValueOfWarrantLiabilities" xlink:title="999050 - Disclosure - DERIVATIVE LIABILITY WARRANTS (Details - Changes in fair value of warrant liabilities)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="loc_us-gaapDerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapDerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="loc_us-gaapDerivativeInstrumentsGainLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="loc_us-gaapDerivativeInstrumentsGainLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_PrivatePlacementWarrantsMember" xlink:label="loc_coepPrivatePlacementWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_coepPrivatePlacementWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_PublicWarrantsMember" xlink:label="loc_coepPublicWarrantsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_coepPublicWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantLiabilitiesMember" xlink:label="loc_coepWarrantLiabilitiesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_coepWarrantLiabilitiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsGainLossLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosure" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsGainLossLineItems" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsGainLossLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosure_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/DerivativeLiabilityWarrantsDetailsNarrative" xlink:title="999051 - Disclosure - DERIVATIVE LIABILITY WARRANTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_PublicWarrantsMember" xlink:label="loc_coepPublicWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_coepPublicWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_PrivatePlacementWarrantsMember" xlink:label="loc_coepPrivatePlacementWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_coepPrivatePlacementWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/CapitalStructureDetails-OptionActivity" xlink:title="999052 - Disclosure - CAPITAL STRUCTURE (Details - Option activity)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockOptionsMember" xlink:label="loc_coepStockOptionsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_coepStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2OptionsGranted" xlink:label="loc_coepSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2OptionsGranted" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_coepSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2OptionsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/CapitalStructureDetails-WeightedAverageAssumptions" xlink:title="999053 - Disclosure - CAPITAL STRUCTURE (Details - Weighted average assumptions)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockOptionsMember" xlink:label="loc_coepStockOptionsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_coepStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/CapitalStructureDetails-WarrantsOutstanding" xlink:title="999054 - Disclosure - CAPITAL STRUCTURE (Details - Warrants outstanding)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder1ExercisePrice59.40Member" xlink:label="loc_coepWarrantHolder1ExercisePrice59.40Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepWarrantHolder1ExercisePrice59.40Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder1ExercisePrice118.80Member" xlink:label="loc_coepWarrantHolder1ExercisePrice118.80Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepWarrantHolder1ExercisePrice118.80Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder1ExercisePrice296.80Member" xlink:label="loc_coepWarrantHolder1ExercisePrice296.80Member" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepWarrantHolder1ExercisePrice296.80Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder2ExercisePrice59.40Member" xlink:label="loc_coepWarrantHolder2ExercisePrice59.40Member" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepWarrantHolder2ExercisePrice59.40Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder2ExercisePrice296.80Member" xlink:label="loc_coepWarrantHolder2ExercisePrice296.80Member" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepWarrantHolder2ExercisePrice296.80Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder5ExercisePrice59.40Member" xlink:label="loc_coepWarrantHolder5ExercisePrice59.40Member" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepWarrantHolder5ExercisePrice59.40Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder18ExercisePrice178.20Member" xlink:label="loc_coepWarrantHolder18ExercisePrice178.20Member" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepWarrantHolder18ExercisePrice178.20Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder20ExercisePrice50.00Member" xlink:label="loc_coepWarrantHolder20ExercisePrice50.00Member" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepWarrantHolder20ExercisePrice50.00Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder21ExercisePrice38.00Member" xlink:label="loc_coepWarrantHolder21ExercisePrice38.00Member" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepWarrantHolder21ExercisePrice38.00Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SeriesWarrantsAAndBExercisePrice27.20Member" xlink:label="loc_coepSeriesWarrantsAAndBExercisePrice27.20Member" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepSeriesWarrantsAAndBExercisePrice27.20Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SeriesAWarrantsExercisePrice27.20Member" xlink:label="loc_coepSeriesAWarrantsExercisePrice27.20Member" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepSeriesAWarrantsExercisePrice27.20Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SeriesBWarrantsExercisePrice27.20Member" xlink:label="loc_coepSeriesBWarrantsExercisePrice27.20Member" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepSeriesBWarrantsExercisePrice27.20Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder22ExercisePrice25.00Member" xlink:label="loc_coepWarrantHolder22ExercisePrice25.00Member" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepWarrantHolder22ExercisePrice25.00Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder22ExercisePrice28.00Member" xlink:label="loc_coepWarrantHolder22ExercisePrice28.00Member" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepWarrantHolder22ExercisePrice28.00Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder23ExercisePrice25.00Member" xlink:label="loc_coepWarrantHolder23ExercisePrice25.00Member" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepWarrantHolder23ExercisePrice25.00Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder23ExercisePrice28.00Member" xlink:label="loc_coepWarrantHolder23ExercisePrice28.00Member" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepWarrantHolder23ExercisePrice28.00Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder24ExercisePrice28.00Member" xlink:label="loc_coepWarrantHolder24ExercisePrice28.00Member" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepWarrantHolder24ExercisePrice28.00Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_PreFundedWarrants2ExercisePrice0.002Member" xlink:label="loc_coepPreFundedWarrants2ExercisePrice0.002Member" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepPreFundedWarrants2ExercisePrice0.002Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_PreFundedWarrants3ExercisePrice0.002Member" xlink:label="loc_coepPreFundedWarrants3ExercisePrice0.002Member" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepPreFundedWarrants3ExercisePrice0.002Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantHolder25ExercisePrice12.00Member" xlink:label="loc_coepWarrantHolder25ExercisePrice12.00Member" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepWarrantHolder25ExercisePrice12.00Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantsAndRightsOutstandingDateIssued" xlink:label="loc_coepWarrantsAndRightsOutstandingDateIssued" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_coepWarrantsAndRightsOutstandingDateIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/CapitalStructureDetailsNarrative" xlink:title="999055 - Disclosure - CAPITAL STRUCTURE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_PreFundedWarrantsMember" xlink:label="loc_coepPreFundedWarrantsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepPreFundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SeriesAWarrantsMember" xlink:label="loc_coepSeriesAWarrantsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepSeriesAWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SeriesBWarrantsMember" xlink:label="loc_coepSeriesBWarrantsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepSeriesBWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SeriesWarrantsMember" xlink:label="loc_coepSeriesWarrantsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepSeriesWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_WarrantNoteSubscriptionReceivablesMember" xlink:label="loc_coepWarrantNoteSubscriptionReceivablesMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_coepWarrantNoteSubscriptionReceivablesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_PublicOfferingMember" xlink:label="loc_coepPublicOfferingMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_coepPublicOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_deiLegalEntityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SNAPBiosciencesIncMember" xlink:label="loc_coepSNAPBiosciencesIncMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_coepSNAPBiosciencesIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_TwoInvestorMember" xlink:label="loc_coepTwoInvestorMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_coepTwoInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StandbyEquityPurchaseAgreementMember" xlink:label="loc_coepStandbyEquityPurchaseAgreementMember" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_coepStandbyEquityPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaapTransactionTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTransactionTypeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_ConsultingAgreementMember" xlink:label="loc_coepConsultingAgreementMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_coepConsultingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockIssuedForServicesMember" xlink:label="loc_coepStockIssuedForServicesMember" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_coepStockIssuedForServicesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapAwardTypeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockOptionsMember" xlink:label="loc_coepStockOptionsMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_coepStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtCounterpartyNameAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_ColleenDelaneyMember" xlink:label="loc_coepColleenDelaneyMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_coepColleenDelaneyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_CoralInvestmentPartnersMember" xlink:label="loc_coepCoralInvestmentPartnersMember" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_coepCoralInvestmentPartnersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_YorkvilleMember" xlink:label="loc_coepYorkvilleMember" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_coepYorkvilleMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapPlanNameAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_ModificationOfOptionsMember" xlink:label="loc_coepModificationOfOptionsMember" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_coepModificationOfOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="90" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SubscriptionReceivableSept2023Member" xlink:label="loc_coepSubscriptionReceivableSept2023Member" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_coepSubscriptionReceivableSept2023Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SubscriptionReceivableSept20232ndMember" xlink:label="loc_coepSubscriptionReceivableSept20232ndMember" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_coepSubscriptionReceivableSept20232ndMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_December2023FinancingMember" xlink:label="loc_coepDecember2023FinancingMember" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_coepDecember2023FinancingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_February2024FinancingMember" xlink:label="loc_coepFebruary2024FinancingMember" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_coepFebruary2024FinancingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_ConvertibleNoteMember" xlink:label="loc_coepConvertibleNoteMember" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_coepConvertibleNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaapSaleOfStockDescriptionOfTransaction" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockDescriptionOfTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaapTreasuryStockValue" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapTreasuryStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:label="loc_us-gaapStockholdersEquityNoteSubscriptionsReceivable" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockholdersEquityNoteSubscriptionsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockIssuedForDebtShares" xlink:label="loc_coepStockIssuedForDebtShares" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_coepStockIssuedForDebtShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockIssuedForDebtValue" xlink:label="loc_coepStockIssuedForDebtValue" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_coepStockIssuedForDebtValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Investments" xlink:label="loc_us-gaapInvestments" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable" xlink:label="loc_us-gaapPreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SubscriptionsReceivable" xlink:label="loc_coepSubscriptionsReceivable" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_coepSubscriptionsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_ProceedsFromSubscriptionsReceivable" xlink:label="loc_coepProceedsFromSubscriptionsReceivable" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_coepProceedsFromSubscriptionsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SubscriptionsReceivableNet" xlink:label="loc_coepSubscriptionsReceivableNet" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_coepSubscriptionsReceivableNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForBrokerageFees" xlink:label="loc_us-gaapPaymentsForBrokerageFees" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPaymentsForBrokerageFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/Non-controllingInterestDetailsNarrative" xlink:title="999056 - Disclosure - NON-CONTROLLING INTEREST (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="loc_us-gaapNoncontrollingInterestAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestTable" xlink:label="loc_us-gaapMinorityInterestTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncontrollingInterestAbstract" xlink:to="loc_us-gaapMinorityInterestTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestLineItems" xlink:label="loc_us-gaapMinorityInterestLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMinorityInterestTable" xlink:to="loc_us-gaapMinorityInterestLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMinorityInterestTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_GearTherapeuticsMember" xlink:label="loc_coepGearTherapeuticsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_coepGearTherapeuticsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMinorityInterestLineItems" xlink:to="loc_us-gaapMinorityInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMinorityInterestLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMinorityInterestLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/InvestmentsDetailsNarrative" xlink:title="999057 - Disclosure - INVESTMENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtCounterpartyNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_TwoPrivatelyHeldCompaniesMember" xlink:label="loc_coepTwoPrivatelyHeldCompaniesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_coepTwoPrivatelyHeldCompaniesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_FivePrivatelyHeldCompaniesMember" xlink:label="loc_coepFivePrivatelyHeldCompaniesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_coepFivePrivatelyHeldCompaniesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_ThreePrivatelyHeldCompaniesMember" xlink:label="loc_coepThreePrivatelyHeldCompaniesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_coepThreePrivatelyHeldCompaniesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_PrivatelyHeldCompanyMember" xlink:label="loc_coepPrivatelyHeldCompanyMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_coepPrivatelyHeldCompanyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaapTransactionTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTransactionTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_NexGenAIAffiliatesNetworkPlatformMember" xlink:label="loc_coepNexGenAIAffiliatesNetworkPlatformMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_coepNexGenAIAffiliatesNetworkPlatformMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SubscriptionReceivable" xlink:label="loc_coepSubscriptionReceivable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_coepSubscriptionReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaapInvestmentOwnedBalanceShares" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapInvestmentOwnedBalanceShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaapGainLossOnInvestments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapGainLossOnInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockIssuedDuringPeriodSharesIssuedForInvestment" xlink:label="loc_coepStockIssuedDuringPeriodSharesIssuedForInvestment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_coepStockIssuedDuringPeriodSharesIssuedForInvestment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_StockIssuedDuringPeriodValueIssuedForInvestment" xlink:label="loc_coepStockIssuedDuringPeriodValueIssuedForInvestment" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_coepStockIssuedDuringPeriodValueIssuedForInvestment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_InvestmentCompanyFeePaidSharesIndirectly" xlink:label="loc_coepInvestmentCompanyFeePaidSharesIndirectly" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_coepInvestmentCompanyFeePaidSharesIndirectly" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentCompanyFeePaidIndirectly" xlink:label="loc_us-gaapInvestmentCompanyFeePaidIndirectly" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapInvestmentCompanyFeePaidIndirectly" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/CommitmentsAndContingenciesDetails-LeaseCost" xlink:title="999058 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details - Lease cost)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_OperatingLeaseRightOfUseAssetGross" xlink:label="loc_coepOperatingLeaseRightOfUseAssetGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_coepOperatingLeaseRightOfUseAssetGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_OperatingLeaseRightOfUseAssetAccumulatedDepreciation" xlink:label="loc_coepOperatingLeaseRightOfUseAssetAccumulatedDepreciation" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_coepOperatingLeaseRightOfUseAssetAccumulatedDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/CommitmentsAndContingenciesDetails-FutureMinimumPayments" xlink:title="999059 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details - Future minimum payments)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999060 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_FirstYearExtensionMember" xlink:label="loc_coepFirstYearExtensionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_coepFirstYearExtensionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_SecondYearExtensionMember" xlink:label="loc_coepSecondYearExtensionMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_coepSecondYearExtensionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtCounterpartyNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_MehalickMember" xlink:label="loc_coepMehalickMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_coepMehalickMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_YeraceMember" xlink:label="loc_coepYeraceMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_coepYeraceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaapTransactionTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapTransactionTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_CarTLicenseMember" xlink:label="loc_coepCarTLicenseMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_coepCarTLicenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_FindersFeeAndIndemnityAgreementMember" xlink:label="loc_coepFindersFeeAndIndemnityAgreementMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_coepFindersFeeAndIndemnityAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_MasterServicesAgreementsMember" xlink:label="loc_coepMasterServicesAgreementsMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_coepMasterServicesAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_GearCellTherapyPlatformMember" xlink:label="loc_coepGearCellTherapyPlatformMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_coepGearCellTherapyPlatformMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_MonthlyRent" xlink:label="loc_coepMonthlyRent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_coepMonthlyRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_AnnualSalary" xlink:label="loc_coepAnnualSalary" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_coepAnnualSalary" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_InitialLicenseFee" xlink:label="loc_coepInitialLicenseFee" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_coepInitialLicenseFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_AnnualMaintenanceFeeDescription" xlink:label="loc_coepAnnualMaintenanceFeeDescription" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_coepAnnualMaintenanceFeeDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaapContractualObligation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapContractualObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_AgreementAmendmentFee" xlink:label="loc_coepAgreementAmendmentFee" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_coepAgreementAmendmentFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaapPaymentsForFees" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPaymentsForFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="loc_us-gaapContractWithCustomerAssetNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapContractWithCustomerAssetNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/KProfit-sharingPlanDetailsNarrative" xlink:title="999061 - Disclosure - 401(k) PROFIT-SHARING PLAN (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="loc_us-gaapDefinedBenefitPlanContributionsByEmployer" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapDefinedBenefitPlanContributionsByEmployer" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/IncomeTaxesDetails-ReconcilationOfIncomeTax" xlink:title="999062 - Disclosure - INCOME TAXES (Details - Reconcilation of income tax)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/IncomeTaxesDetails-ReconcilationOfProvision" xlink:title="999063 - Disclosure - INCOME TAXES (Details - Reconcilation of provision)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_ExpectedIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_coepExpectedIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_coepExpectedIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_ExpectedEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_coepExpectedEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_coepExpectedEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/IncomeTaxesDetails-OperatingLossCarryforwards" xlink:title="999064 - Disclosure - INCOME TAXES (Details - Operating loss carryforwards)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsStateTaxes" xlink:label="loc_us-gaapDeferredTaxAssetsStateTaxes" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsStateTaxes" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/IncomeTaxesDetailsNarrative" xlink:title="999065 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999066 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_DisclosureTable" xlink:label="loc_coepDisclosureTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_coepDisclosureTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_DisclosureLineElements" xlink:label="loc_coepDisclosureLineElements" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_coepDisclosureTable" xlink:to="loc_coepDisclosureLineElements" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_coepDisclosureTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_AGBioLifeCapitalILPMember" xlink:label="loc_coepAGBioLifeCapitalILPMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_coepAGBioLifeCapitalILPMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_coepDisclosureTable" xlink:to="loc_srtCounterpartyNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_BoardOfDirectorsMember" xlink:label="loc_coepBoardOfDirectorsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_coepBoardOfDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_coepDisclosureLineElements" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_coepDisclosureLineElements" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsAndNotesReceivableNet" xlink:label="loc_us-gaapAccountsAndNotesReceivableNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_coepDisclosureLineElements" xlink:to="loc_us-gaapAccountsAndNotesReceivableNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Investments" xlink:label="loc_us-gaapInvestments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_coepDisclosureLineElements" xlink:to="loc_us-gaapInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_coepDisclosureLineElements" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherInvestments" xlink:label="loc_us-gaapOtherInvestments" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_coepDisclosureLineElements" xlink:to="loc_us-gaapOtherInvestments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/IntangibleAssetsDetailsNarrative" xlink:title="999067 - Disclosure - INTANGIBLE ASSETS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_srtCounterpartyNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_NexGenAISolutionsGroupIncMember" xlink:label="loc_coepNexGenAISolutionsGroupIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_coepNexGenAISolutionsGroupIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_NexGenAIMember" xlink:label="loc_coepNexGenAIMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_coepNexGenAIMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodValuePurchaseOfAssets" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValuePurchaseOfAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/SegmentReportingDetails" xlink:title="999068 - Disclosure - SEGMENT REPORTING (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapSegmentReportingInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_BiotechnologyMember" xlink:label="loc_coepBiotechnologyMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_coepBiotechnologyMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_TechnologyMember" xlink:label="loc_coepTechnologyMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_coepTechnologyMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://coeptistx.com/role/SegmentReportingDetailsNarrative" xlink:title="999069 - Disclosure - SEGMENT REPORTING (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapSegmentReportingInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_BiotechnologySegmentMember" xlink:label="loc_coepBiotechnologySegmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_coepBiotechnologySegmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="coep-20251231.xsd#coep_TechnologySegmentMember" xlink:label="loc_coepTechnologySegmentMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_coepTechnologySegmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaapNumberOfReportableSegments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNumberOfReportableSegments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapAssets" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ? $(# 2(  A$! Q$!_\0
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;]V&D?Q9K1PL8:RU8@ 4    < "BEHKRSL/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  B .<# 2(  A$! Q$!_\0
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MH?\ @7)_C1_;&J_]!;4/_ N3_&C^R*O\R_$/KL.Q]445\K_VQJO_ $%M0_\
M N3_ !H_MC5?^@MJ'_@7)_C1_9%7^9?B'UV'8^J**^5_[8U7_H+:A_X%R?XT
M?VQJO_06U#_P+D_QH_LBK_,OQ#Z[#L?5%%?*_P#;&J_]!;4/_ N3_&C^V-5_
MZ"VH?^!<G^-']D5?YE^(?78=CZHHKY7_ +8U7_H+:A_X%R?XT?VQJO\ T%M0
M_P# N3_&C^R*O\R_$/KL.Q]445\K_P!L:K_T%M0_\"Y/\:/[8U7_ *"VH?\
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MK_T+^G_]^!1_P@OA7_H7]/\ ^_ H_ME?R?B'U%_S'S717TI_P@OA7_H7]/\
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MSPOX(T;PD)&TU)S-*NV2664L7'NHPOX@"BNCHKS6VW=G4DDK(****0PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH K2Z?93W<5W-9
AV\ES",1S/$I=![,1D?A5FBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !2 3$# 2(  A$! Q$!_\0
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M0 44A(4$GH*Y'1?%=WX@\87-K901KH=O9"87#?ZR=W?$;*.R$)(1W88;H5)
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M!!X8\/W.ISHTK1@+# GWIY6.$C7W+$#VY/:G>&[?5+;0+1=:N?M&INIDN6
M578EBBX_A7.T>P% %R_U&STR!9KVX2&-Y$B4M_$[L%51ZDDBK5>?6C2>-OB)
M)>,&.@^&Y&BMP?NW-]@AW]Q&#M'N<@UZ#0 44U)$DW;&#;3M.#G!]*=0 444
M4 5K^^MM,L+B^O)EAMK>,R2R-T50,D\=:\\O;"ZUO5],BU.%X[S6I?.FMV /
MV/3H&63R3SPSN8@^.I<CD(*Z.;/B;Q+]F!SI&D2JTV#Q<W8PRI[K%PQ]7*C^
M BH_#0_M;Q3K_B!OFB60:79DC_EG"3YC#ZRLX_[9B@#J+B>&TMI;FXE6*&)#
M))(YPJ*!DDGT %5M'U(:QI-MJ"V\UO'<)YD<<P ?83\I('3(P<=1G!YK UYD
M\2Z[%X60A[.%4N]7P>/+SF* _P"^PW$?W$(/WQ70ZGJ=GHVFSZAJ$PAM8%W2
M/M+8&<<  DG) P!DT 7** <BB@ HHJ&YN[>SB$MS/'#&75 TC!068A5&3W)(
M 'J: )JQY_$EC!XAM]%Q+)<S':61<I$VQG"N<\$JC' S@ $XR,S:[JR:+I,M
MV8S-+E8X(%.#-*QVH@],L0,]N2>!7,:!H[^'QJ'B+Q'.BRP+*3*3D!<AIISC
MH7*+M7G;&D:]=U '<9&<9YJEJFM:;HELMQJE]!:0L^Q7F<+N;K@>O )^@)[5
MQ>G6LMC?WGQ%\37#6RFP816C AK2$MN"$=WPJ<#G>[CGY<5+O1=7UZ6%M1MI
M8]3UI'C=\$QZ1I_&^)6Z>>X(4GKEC_"@H ]+1TDC5XV#(P!5E.01ZBG57D>U
MTS3FD<QV]I:Q%B?NK'&H_0 #]*AT>_;5=&LM0>VDMFNH$F\B0Y:/<,X/OS0!
M>HHHH P&\5VTTSPZ39WFKR(Q1S9Q@1*1P097*QD@\$!B1Z4X2>*+OI;:5IR9
MZR2/=/CW51& ?^!&I%T2YMXTBL=8N[:!.$A,<<BJ.P!9=V![GM2#2-6+9?Q+
M> >D=M /YH: &II6LR$&Y\1S*W\0M+.*-?PWAR/S-2#1KX'_ )&753]8[7_X
MS4?_  CCR8%SKFL3C.2/M AS_P!^E3'X4O\ PB6C-GS[:6Z#=1=W,LX/X.QH
M 9=27FE_/+K]GM)R%U"-4R/0,I7';G:?I7.:[\0K/RX])MM2L;;4;MO+^UPW
M*3Q6T?\ ')D<[APJJP&YV7@@-CJQHN@:1!+=)I>G6D<2%Y)5MT7:H&220*S/
M#FEC4M,N]4U6V'G:RH+6[C_46W/E0X[$!BQ_VW;VH DTW6M#TO3K>PT^#43;
M0H%C\K3;F0$>I81G))Y))R2237!WWBJ36/&%SXDCT6_O-(\-[K2V4[(E^VN0
MLCR%V!54! R5.T$MQ6W>^+[S2_ -Q'#(UUKJZA+HED7(W3SB0I&Y]3LPY]P:
MTX-)U#P;X)T_1?#^DIJMRJ^7*TLRQQ[F!+RON.6!8GY1SSC('- %K3O$&J65
MOJ<_BNWM+"&VE1(98"["8LH.Q%(W.02%! !=L@*,<\U'XF6;Q"GB'7K.6&VB
MOAI&C6<:^9(LKC]]*^/X@!M.,[=KJ,DG-VUT6?PGX62_U*2+4/$,0-O8+EC!
M;R2MLBBA4_=4%E4M][:.3M  U=/\'FSUG1IGG26ST>R>. -GS)+J0_O9F[9(
M!]>9'Z=P"Y?>,]%TZV^T74MW%$6"*6L)QN<\!1\G+'L.IK2TC5K37-,BU"R9
MV@EW ;T*,K*Q5E*G!!# @CVKD]6\*:[KWC62[NKZ"WTF"-4LGA8F>/('F%01
MA)&.1YF257 4 DL-C2?"BZ D=KI&H3V>F)*919+'&R_,VYAN92V"2>^1G@]*
M .A9@JEB0 !DD]!7.Z K:Q?2^)9P1',AATY#GY+;(._'8RD!O]T1C@@UA:_X
M;.M^(UT@ZQJDT<^;J^C>13%;VY)"QJNW&78$ D$[4DR>E<_XUMU\+:E;6.BW
M5U'>:C9300P0RBW#3O+#' V(PH^7?(WT4CI0!J:;KR3>+KO7PD<JWMPVFV32
MN$2&QMLM<W&[^Z9"1[G8..M=3-XTTMO#UKK&GF34([Z3R;&*)"KW,F2, /C
M&UB6. %!/2L^R^&7A^T73EQ=2QV5NL'D27#M%, P<;D)/&\;MHPI.,@X&-"Z
M\!^&;V]6[GTF)I06)VNZJP8Y964'#*3R5(P23D<F@#F(O$&F^)KA_%FJ,+7P
M[X=9O),K!DFN\8:4$$AU4$*A&=S.2.0*?XIUDS:38Z-M34-:UF<&S2:S ^P1
MR[BLDBY(!C0-U.6*'C .-32? Y>Q2W\1207T<8D"6T8(BWR;C),W3=(Q=L=
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M;%].L/3"M^_D'^](NSZ1 CK0!SL7B2]\+>!K^*'16%QHRF"8RW*DR7#!65L
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M[T 9Y\WQQ/%^[:/PPC"0F12K:DP.5 4\B$$ \_?X_A^]U]%% !1110 4444
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M%>I[1NW8&>F:\^^"NEMI_P -;*XE4+<:C+)>R\8SN;"G_OE5/XUZ%0 4444
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>astralogo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 astralogo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" $6 T # 2(  A$! Q$!_\0
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M%% !1110 4444 %%%% !17@O_!0+]LBU_8V^$<.LXCGU*]NDM[>!LDL"?F;
MYP /UKU3X/?$_3_C+\-=(\2Z7(LMGJULDZ$-G;N .#[\T =-1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !117(?'OXL6/P0^$6N^*-0E6*
MWTFU>;D_>8 D >] 'YQ?\%VOVKCK?B#3OA?I=P##9@7FI%&ZL6^5#]"GZUP?
M_!$G]J9/A!\;+KP7J4_EZ5XK(,)=L+%.!_4*!^-?(OQ=^)>H?&3XG:UXHU25
MI;W6+EYF);.T$\ >W^-97AGQ+=^#/$VGZQ82-%>:7<)<Q,IP058'^E ']*]%
M>4?L5_M#VO[37[/.@>)89%>YEMTAO%SDK,JA7S_P(&O5Z "BBB@ HHHH ***
M1F"*23@ 9)H CO+R+3[5YYY$AAB&YW=MJJ/4FOS;_P""B'_!9-_#^I7W@SX7
MR1RSQAH;O60 RH3P5CSW]\=ZH?\ !8'_ (*2W,6HW7PO\#WQB"@IK%]"Y5E/
M3RE(_P"!9^@K\T@.22223DD]2: -#Q3XKU3QSK<VI:UJ%WJ=]<,7>6XD+G)]
M,]/PJA110 4444 %%%% !1110 4444 %?1__  2W_:@;]F?]IW3C<RE-%\1L
M+&\!.%4G[K'_ (%M%?.%.BF>VFCEC8K)"PD0CJ&!R#^= ']+UK<QWMM'-$P>
M.50Z,.0P/0U)7S+_ ,$I_P!J,?M*_LP:<;N4/K/AU5TZ\!.2=@VHWOD+FOIJ
M@ ILL2SQ,C %7!4@]P:=10!^)/\ P5\_9;?]GS]IBXU:QMRFA>+=UW$RC"1R
MY!=?S;]*^4:_=+_@J1^R_%^TI^S!JT5O KZYHB_;+!\?-E0<IGT.1^5?A=)"
M]M*\4BE9(F*,#U!!Q0 E%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5V/[/OQCOO@!\9-"\66$C1OI=RCR@'&^/(W*?;%<=00&&#TH _I#^%/Q!L
MOBI\.M'\0:?,D]KJELDRLIR,D<C\P:Z&OSK_ ."$_P"U3_PDG@S4?AOJMUNN
M]()GT\.V2T1QE1GT)8U^BE !1110!^8'_!>#]EI=/N=)^)FE6Y D/V74]B]?
M[KG_ ,=%?FT#D9%?T7?M%?!S3_CU\&]>\,:C"LL.I6K*F1DJX^92/3Y@*_GM
M^)WP]O?A/\0]9\.:A&\5UI%U);D,,%@K$!OQ S0!AT444 %%%% !1110 444
M4 %%%% !1110 4444 3:;J-SHE_'=6-S/9W41W)+#(8W4_45]Y_L!_\ !9#6
MOAQJ-AX5^)$SZIHDC+#%JC8\VU[#?TR.G/)KX&I&4.I!Y!H _I4\*>+-.\;Z
M#;:GI5Y!?6-V@DBEA<,K UHU^-O_  2F_P""B]]^SSXUM?!7B>[DN/".KS+'
M!+*Q8V$C' QG^$G'YU^QME>Q:C9Q7$#K+#.@D1U.0RD9!'X4 2T444 %%%%
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MOP:_OZY_W^7_  H _'"BOV/_ .'$OP:_OZY_W^7_  H_X<2_!K^_KG_?Y?\
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MIX7L-5LI%EM=0@2>-E.00P!_K0!I4444 %%%% !1110 4444 %%%% !1110
M4444 %%%8WQ"\:V?PY\$:KKE_(L5KI=K)<N6.,A%+8_'% 'Y_P#_  7;_:I/
MA[PIIOPUTJXQ=:L?M&H[&Y2(<A3]3M-?EFJA5 '05Z#^U+\=+[]H[X[>(/%5
M]*T@O+EDM@3PD*G:@'_ 0*\_H ****  C(K]$?\ @A-^U6/#OBW4?AEJD^VW
MU(_:M,WMP).=R#ZY7\J_.ZN@^%'Q,U#X,?$K1O%6E.R7^B7*W$9!P3@YQ^.*
M /Z1**XO]GGXOV/QW^#NA>*=/E66#5+99,@YPW0C\Q7:4 %%%%  3@5^"/\
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M9!:7Z9^38Q'S'Z8_6OWITZ_BU2PAN8'62*= Z,IR"#0!-1110 4444 %%%%
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MA_C7\Z/.3^\OYU^XNO\ _!'_ .".M7'F)X;-IDY(CG?!_P#'JS_^',GP4_Z
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MJ?3[&YU>Y2&TMKF[FD.%2&)I&;Z "OVXTC_@CK\$=-N"\GAZ2Y4_PO<28_\
M0J];^&O['?PU^$R1C1/"&BP-%]R22U25U^C,": /QT_9J_X)<?%+]HV_A?\
MLF;P]H[D%[N_0Q$+[(?F_2OU0_8O_P""<?@C]C_1TFM+5-5\0R*//U&X&Y\X
MY"CH!U[9KZ%AA2WC"1HJ(O15& *=0 =**** "BBB@ HHHH *_,G_ (+P_M1E
MCI7PSTNZ&&Q=ZGL;D<_*A].5!_&OT1^+WQ+L/A!\.-7\1ZE*D-KI5L\[%CC.
MU2<?CBOY[OCS\6;[XX_&#7_%&H3232ZI=,Z%FSM0?*H_("@#D0,# Z"BBB@
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M5DR@)^H7/XU^#U?7W_!&_P#:A/P-_:-C\/7]SY6B>*_W!#-A(YARI]N ?SH
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M!H]#\2#[;:D#Y5))#+_X[G\:^9J "FR)YB$9(SW%.HH _9+_ ((O?M8#XV?
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M,_\  ./_  H _;FD=UC4LQ"J.22< 5^(_P#P^>^.8_YBNF?^ <?^%<O\0O\
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MT^!YY&8X "C-?S]_MB_M 7G[3/[0>O\ B>YE9[>2X:&R4MD)"IPN/P H \Q
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MOQT_X(G_ +4O_"I?CL_@O49]FD^*L+!N/"7&< ?CN/Y5^Q8(8 CD&@ HHHH
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M  5M_9<'[17[,=[<V4!DUOPR&O[5E7+%5&YU_%5/YU^(95HW9'4K)&Q1U/\
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M^"1_P9^'GB_3]<TG1;NVU+2YA/;R"Y/RL#D=J^FD78@'7 Q0 M%%% !1110
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MXTMN/G#(T8 _\?-<]3$TX35.6[/>R_AO'8W!5<PH13IT[\SNELK[>A^J-%?
M_P#P60_X*E^+_P#@GCJWAF'PWI6G:E'K0;S?M(Y7&.GYUZW_ ,$GOVT]=_;M
M_9AB\;>(+*TL+Z2Z>#RK<?( I(_I0L3!U716Z)J\.XVGEL<UE%>RD[)WUOKT
M^1].T445T'AA117CG[>O[0>I_LN?LM^*/'&D6\%U?Z';K-%%,,HY,B+S_P!]
M5,Y**<GT-L-AYUZL:%/XI-)>KT1['17X2Q?\'/\ \5GA1CX7\/C< ?NUZC^R
M]_P<Z3ZOX_M-/^)GABWL]'O)%B-_8R?\>Q)QN9=O('U%<,<TP[=KGW%?PSS^
ME3=1TD[=%)-_)'[$T5G>$O%5CXX\,V.L:9.EU8:C"L\$J'(=6&0:T:] ^"DF
MG9A1110(**^&_P#@M_\ \%"/'?\ P3\^%O@_6/ J:2]WK>IM9W'VZW,R[!$[
M<#(P<J*\M_X(G_\ !6;XH_M\_'7Q)X=\<1:"EAI6F&[A-C:F)]^Y!R=QR/F-
M<LL9357V+W/J*/"./JY5+.(\OLE?KKH[;6/TVHHHKJ/EPHHKR3]NCX]ZA^S%
M^ROXO\<Z5!!<W_A^R:YBBE^XY'8U,I**<GT-L-AYUZL:-/XI-)>KT1ZW17X3
M1?\ !S_\595!'ACP_P ^U./_  <^?%5>OACP_P#]\UY_]JX?O^!][_Q"[B#_
M )]Q_P# D?NO17R__P $E_VV=<_;T_9<B\;^(+*TL+Z2]FMS%;_<PDCH#^2B
MOJ"N^G44XJ<=F?#X_ UL'B9X6NK3@[/KJ@HHHJSD"BBB@ HHHH **** "BOS
MJ_X*J_\ !='3OV,/&$O@7P580Z]XQ@3-Y)*W[BP)&0",'<<$'&1UKX1\'?\
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MS(=0TR>)E]?D)'ZBOYS?^"9&N']GS_@JMX9M79K.UT_6YM,D1_ER@D  .?\
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M9^W#HWA?QEI,.M:'=0R/):RE@K$,H'0@]Z_H>_:^_P"38_&__8*E_E7\XO\
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M_(^T?^#I?_D/_#[Z2?\ LM?2O_!MS_RCYMO^PC+_ .A-7P'_ ,%^?V\/A_\
MM@>/?"]KX$U%]6MM#A9[FZV%$#'^$9Z].N>]?HO_ ,&]/P_U+P+_ ,$\-#?4
MK=[=M4N);J(,,;D\QP#^E.A)2QTI1U5O\B,\P]3"\#X>AB(N,^?9Z/>3V]#[
MHHHHKVC\9"OEW_@LG_RCN^(G_7DG_HZ.OJ*OEW_@LG_RCN^(G_7DG_HZ.L<1
M_"EZ,];(?^1EA_\ ''_TI'Y9_P#!L7_R=WKO_8(_JE=/_P '27_)PW@7_L&2
M5X1_P0V_;"\"_L8?M!ZIXA\?:C/INF7>G>1%)% TQ+Y7C"\]C5__ (+I_MV>
M!OVX?C;H&J> [FYO-+T2Q:%[B:%HC(Q[!2,]OUKY[VL/J/)?6^Q_04\MQ;XW
M6,5-^S4+<UM+\MM]C]6?^"!7_*/#PU_OR?\ H35]K5\D_P#!$?P!=> O^">?
M@E+N.6&2_@>Y"2#! ,C@<?A7UM7T&%5J,?1'X%Q+-2S7$RCMSR_-A1116YXA
M^5'_  =0_P#) OAO_P!AY_\ T1)7@G_!KM_R=AXW_P"P&?\ T..O>_\ @ZA_
MY(%\-_\ L//_ .B)*\$_X-=O^3L/&_\ V S_ .AQUX%7_D8KY?D?O&6_\F_J
M^DO_ $L_=*BBBO?/P<**** /ST_X.3_^3"D_["D7_H25XC_P:I_\B9\3O^P@
MG_HJ"O;O^#D__DPI/^PI%_Z$E>(_\&J?_(F?$[_L()_Z*@KQJG_(PCZ'Z]@?
M^2"K_P#7S]8GZ\T445[)^0A1110 4444 %%%% !7R]_P5_\ VKKW]D+]B;Q'
MXBTF9K?6;T#3K&5?O122@J''N"0:^H:^.O\ @NA^S[J/[0G[ /B2TTJ.2:^T
M1UU58XU+-(L.790!ZA:PQ+DJ4G#>Q[/#L,//-,/'%? YQOZ7/Q;_ .";G[ /
MB3_@IQ^T)?K=ZA/'IEM)]MU_4Y"7E?<?N@]R3@<G@&O=O^"I'_!"O6OV1M*;
MQG\.'O=?\)6B*U[$P)N;(@<R<9RN1ZCJ*X'_ ((G_P#!1_1?^"?WQDUN#Q=#
M./#GB9%M[F6-"7LY%(^8@ D\J!BOU$_:O_X+C_ ;PC\"]1FTS68?%M_JMJT5
MMIL29\PLI_UF,[1]:\+#4<-/#MS=I'[CQ'F_$F#SZ$<%2<J%DE%+W9+K=]&O
MP/RH_9E_X+A_&+]F7X'+X.TN]BUA+>=)+.ZU!C*]M$.L0SGY2,?3%?M'_P $
MK?V^=2_X* ? @^)M2\-3:#/9R?9I),EHKIP 2R' XYK^:7QIXA'C+Q9JFIK:
MPV/]H7#SBWA&(X QSM'L*_HM_P""$7QHT3XM_L">'(=*LK?3[CP^6L+R*(8W
MR##;R/<,/RK3*J]253DE+1(X?%#(\#A\N6,HX=1J2G[TETNNO1W_ *W/LZBB
MBOH#\#"BBB@ HHHH ****  G K^<_P#X. ?B9)\3?^"C.MZ8TXELM!@BL8QG
MA&RP?^0K^B3Q!J"Z3H-[=.P5;>!Y"3VPI-?RU?'N36/VR/VZ/$__  C5O+J>
MJ^,=?D6QB!Y<O)A1GL,GK7CYQ/\ =Q@NK/UOPBPL7F%;&3TC3AOVN_\ ),^X
M/^"TOA7PGIW_  3L^"D&AZEI]_?^'4CM)(H'#/$C!2<CZN:^FO\ @V:^*[>+
M_P!C[5O#\]P9KGP_J+*%)SL1BS#_ -"%?F!\7?\ @D;^T'\(?A]?>(O$GAUH
M]%TN/S9W^W"78OKMKZH_X-=_BM'H/QR\=^$Y&(.L62WL8)X+*T:_G@&N7#U9
M?6XN4>6ZL?3Y_EF&?"=:CAJZK^SGS\RMI>5VM&^C9^WU%%%?1'\^A4&J_P#(
M+N?^N3?R-3U!JO\ R"[G_KDW\C0-'\T'Q,_Y2\W/_8Z_^U6K]E_^"W?_ "BX
M\5?]>UM_2OQ5^/WBVQ\ _P#!4W6M;U.1HM.TGQ<US<NJ[BJ+(V3CO7WU_P %
M6O\ @LI\&OVAOV(=0\">"-3OM8UO5EAB97M'@6 +C+$L,'O^5?.8:K"%.JI.
MU[G]!Y_E>+Q.-RFKAZ;E&"A=I:+6+U?30X'_ (-8/^2P?$#_ *\(_P"<=?M[
M7XJ_\&KWA"^;Q]\1M6\B5=/BMHX!,4.QWS&< ],XK]JJ]/*_]W7S/SKQ.DGQ
M#6MVC_Z2@HHHKT#X *_!O_@YO^$J>%_VNO#?B=,A/$6FF,KCC,/E G_QZOWD
MK\O/^#GOX2)X@_9O\+^+DM3+<:%J(M3*JY,:2@EL^@_=BN#,Z?-AY>6I]WX;
MX[ZMG]&^T[Q^]:?C8_*/]IKXVG]L7XM^"8U:1&6QLO#X)'*G>R\?]]U_3/\
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MZ)NWY(^[:***]L_%@KP[_@H;^R[JW[8O[,NL^ M)U:+1I=:VI+<2 E=@(..
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M_!N1X4N_V7]-\&>$M7CL_$T%XEU>:[>*6EN0/O)PN #]!7MO_!([_@F?K_\
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M^"M/_!)36/\ @HQXJ\/W^G>);70DT:-D994+&3.WT4^E>T_\$S?V-;W]A/\
M9AL? 5_JL6LW%I<O,;F-2JL&51CD#^[Z5]!T5@L/!5'52U9[-;/\;5P$,LG+
M]U%W2LM]>N_4****W/&"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
<H **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>astrafooter.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 astrafooter.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !3"(,# 2(  A$! Q$!_\0
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M (W7T3_PK7PY_P! #1/_  !B_P#B:/\ A6OAS_H :)_X Q?_ !-'+BOYH_\
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M=O\ A]9^RO\ ]%K\(_G/_P#&Z/\ A]9^RO\ ]%K\(_G/_P#&Z^B?^%:^'/\
MH :)_P" ,7_Q-'_"M?#G_0 T3_P!B_\ B:.7%?S1_P# 7_\ )![?(?\ GQ6_
M\&P_^4GSM_P^L_97_P"BU^$?SG_^-T?\/K/V5_\ HM?A'\Y__C=?1/\ PK7P
MY_T -$_\ 8O_ (FC_A6OAS_H :)_X Q?_$T<N*_FC_X"_P#Y(/;Y#_SXK?\
M@V'_ ,I/G;_A]9^RO_T6OPC^<_\ \;H_X?6?LK_]%K\(_G/_ /&Z^B?^%:^'
M/^@!HG_@#%_\31_PK7PY_P! #1/_  !B_P#B:.7%?S1_\!?_ ,D'M\A_Y\5O
M_!L/_E)\[?\ #ZS]E?\ Z+7X1_.?_P"-T?\ #ZS]E?\ Z+7X1_.?_P"-U]$_
M\*U\.?\ 0 T3_P  8O\ XFC_ (5KX<_Z &B?^ ,7_P 31RXK^:/_ ("__D@]
MOD/_ #XK?^#8?_*3YV_X?6?LK_\ 1:_"/YS_ /QNC_A]9^RO_P!%K\(_G/\
M_&Z^B?\ A6OAS_H :)_X Q?_ !-'_"M?#G_0 T3_ , 8O_B:.7%?S1_\!?\
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M_P /K/V5_P#HM?A'\Y__ (W7T3_PK7PY_P! #1/_  !B_P#B:/\ A6OAS_H
M:)_X Q?_ !-'+BOYH_\ @+_^2#V^0_\ /BM_X-A_\I/G;_A]9^RO_P!%K\(_
MG/\ _&Z/^'UG[*__ $6OPC^<_P#\;KZ)_P"%:^'/^@!HG_@#%_\ $T?\*U\.
M?] #1/\ P!B_^)HY<5_-'_P%_P#R0>WR'_GQ6_\ !L/_ )2?.W_#ZS]E?_HM
M?A'\Y_\ XW1_P^L_97_Z+7X1_.?_ .-U]$_\*U\.?] #1/\ P!B_^)H_X5KX
M<_Z &B?^ ,7_ ,31RXK^:/\ X"__ )(/;Y#_ ,^*W_@V'_RD^=O^'UG[*_\
MT6OPC^<__P ;H_X?6?LK_P#1:_"/YS__ !NOHG_A6OAS_H :)_X Q?\ Q-'_
M  K7PY_T -$_\ 8O_B:.7%?S1_\  7_\D'M\A_Y\5O\ P;#_ .4GSM_P^L_9
M7_Z+7X1_.?\ ^-T?\/K/V5_^BU^$?SG_ /C=?1/_  K7PY_T -$_\ 8O_B:/
M^%:^'/\ H :)_P" ,7_Q-'+BOYH_^ O_ .2#V^0_\^*W_@V'_P I/G;_ (?6
M?LK_ /1:_"/YS_\ QNC_ (?6?LK_ /1:_"/YS_\ QNOHG_A6OAS_ * &B?\
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MD/\ SXK?^#8?_*3YV_X?6?LK_P#1:_"/YS__ !NC_A]9^RO_ -%K\(_G/_\
M&Z^B?^%:^'/^@!HG_@#%_P#$T?\ "M?#G_0 T3_P!B_^)HY<5_-'_P !?_R0
M>WR'_GQ6_P#!L/\ Y2?.W_#ZS]E?_HM?A'\Y_P#XW1_P^L_97_Z+7X1_.?\
M^-U]$_\ "M?#G_0 T3_P!B_^)H_X5KX<_P"@!HG_ ( Q?_$T<N*_FC_X"_\
MY(/;Y#_SXK?^#8?_ "D^=O\ A]9^RO\ ]%K\(_G/_P#&Z/\ A]9^RO\ ]%K\
M(_G/_P#&Z^B?^%:^'/\ H :)_P" ,7_Q-'_"M?#G_0 T3_P!B_\ B:.7%?S1
M_P# 7_\ )![?(?\ GQ6_\&P_^4GSM_P^L_97_P"BU^$?SG_^-T?\/K/V5_\
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M]E?_ *+7X1_.?_XW1_P^L_97_P"BU^$?SG_^-U]$_P#"M?#G_0 T3_P!B_\
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M^@!HG_@#%_\ $T?\*U\.?] #1/\ P!B_^)HY<5_-'_P%_P#R0>WR'_GQ6_\
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M\^*W_@V'_P I/G;_ (?6?LK_ /1:_"/YS_\ QNC_ (?6?LK_ /1:_"/YS_\
MQNOHG_A6OAS_ * &B?\ @#%_\31_PK7PY_T -$_\ 8O_ (FCEQ7\T?\ P%__
M "0>WR'_ )\5O_!L/_E)\[?\/K/V5_\ HM?A'\Y__C='_#ZS]E?_ *+7X1_.
M?_XW7T3_ ,*U\.?] #1/_ &+_P")H_X5KX<_Z &B?^ ,7_Q-'+BOYH_^ O\
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MZS]E?_HM?A'\Y_\ XW7T3_PK7PY_T -$_P# &+_XFC_A6OAS_H :)_X Q?\
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M_P! #1/_  !B_P#B:.7%?S1_\!?_ ,D'M\A_Y\5O_!L/_E)\[?\ #ZS]E?\
MZ+7X1_.?_P"-T?\ #ZS]E?\ Z+7X1_.?_P"-U]$_\*U\.?\ 0 T3_P  8O\
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MI/G;_A]9^RO_ -%K\(_G/_\ &Z/^'UG[*_\ T6OPC^<__P ;KZ)_X5KX<_Z
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M (W7T3_PK7PY_P! #1/_  !B_P#B:/\ A6OAS_H :)_X Q?_ !-'+BOYH_\
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M=O\ A]9^RO\ ]%K\(_G/_P#&Z/\ A]9^RO\ ]%K\(_G/_P#&Z^B?^%:^'/\
MH :)_P" ,7_Q-'_"M?#G_0 T3_P!B_\ B:.7%?S1_P# 7_\ )![?(?\ GQ6_
M\&P_^4GSM_P^L_97_P"BU^$?SG_^-T?\/K/V5_\ HM?A'\Y__C=?1/\ PK7P
MY_T -$_\ 8O_ (FC_A6OAS_H :)_X Q?_$T<N*_FC_X"_P#Y(/;Y#_SXK?\
M@V'_ ,I/G;_A]9^RO_T6OPC^<_\ \;H_X?6?LK_]%K\(_G/_ /&Z^B?^%:^'
M/^@!HG_@#%_\31_PK7PY_P! #1/_  !B_P#B:.7%?S1_\!?_ ,D'M\A_Y\5O
M_!L/_E)\[?\ #ZS]E?\ Z+7X1_.?_P"-T?\ #ZS]E?\ Z+7X1_.?_P"-U]$_
M\*U\.?\ 0 T3_P  8O\ XFC_ (5KX<_Z &B?^ ,7_P 31RXK^:/_ ("__D@]
MOD/_ #XK?^#8?_*3YV_X?6?LK_\ 1:_"/YS_ /QNC_A]9^RO_P!%K\(_G/\
M_&Z^B?\ A6OAS_H :)_X Q?_ !-'_"M?#G_0 T3_ , 8O_B:.7%?S1_\!?\
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M_P /K/V5_P#HM?A'\Y__ (W7T3_PK7PY_P! #1/_  !B_P#B:/\ A6OAS_H
M:)_X Q?_ !-'+BOYH_\ @+_^2#V^0_\ /BM_X-A_\I/G;_A]9^RO_P!%K\(_
MG/\ _&Z/^'UG[*__ $6OPC^<_P#\;KZ)_P"%:^'/^@!HG_@#%_\ $T?\*U\.
M?] #1/\ P!B_^)HY<5_-'_P%_P#R0>WR'_GQ6_\ !L/_ )2?.W_#ZS]E?_HM
M?A'\Y_\ XW1_P^L_97_Z+7X1_.?_ .-U]$_\*U\.?] #1/\ P!B_^)H_X5KX
M<_Z &B?^ ,7_ ,31RXK^:/\ X"__ )(/;Y#_ ,^*W_@V'_RD^=O^'UG[*_\
MT6OPC^<__P ;H_X?6?LK_P#1:_"/YS__ !NOHG_A6OAS_H :)_X Q?\ Q-'_
M  K7PY_T -$_\ 8O_B:.7%?S1_\  7_\D'M\A_Y\5O\ P;#_ .4GSM_P^L_9
M7_Z+7X1_.?\ ^-T?\/K/V5_^BU^$?SG_ /C=?1/_  K7PY_T -$_\ 8O_B:/
M^%:^'/\ H :)_P" ,7_Q-'+BOYH_^ O_ .2#V^0_\^*W_@V'_P I/G;_ (?6
M?LK_ /1:_"/YS_\ QNC_ (?6?LK_ /1:_"/YS_\ QNOHG_A6OAS_ * &B?\
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MD/\ SXK?^#8?_*3YV_X?6?LK_P#1:_"/YS__ !NC_A]9^RO_ -%K\(_G/_\
M&Z^B?^%:^'/^@!HG_@#%_P#$T?\ "M?#G_0 T3_P!B_^)HY<5_-'_P !?_R0
M>WR'_GQ6_P#!L/\ Y2?.W_#ZS]E?_HM?A'\Y_P#XW1_P^L_97_Z+7X1_.?\
M^-U]$_\ "M?#G_0 T3_P!B_^)H_X5KX<_P"@!HG_ ( Q?_$T<N*_FC_X"_\
MY(/;Y#_SXK?^#8?_ "D^=O\ A]9^RO\ ]%K\(_G/_P#&Z/\ A]9^RO\ ]%K\
M(_G/_P#&Z^B?^%:^'/\ H :)_P" ,7_Q-'_"M?#G_0 T3_P!B_\ B:.7%?S1
M_P# 7_\ )![?(?\ GQ6_\&P_^4GSM_P^L_97_P"BU^$?SG_^-T?\/K/V5_\
MHM?A'\Y__C=?1/\ PK7PY_T -$_\ 8O_ (FC_A6OAS_H :)_X Q?_$T<N*_F
MC_X"_P#Y(/;Y#_SXK?\ @V'_ ,I/G;_A]9^RO_T6OPC^<_\ \;H_X?6?LK_]
M%K\(_G/_ /&Z^B?^%:^'/^@!HG_@#%_\31_PK7PY_P! #1/_  !B_P#B:.7%
M?S1_\!?_ ,D'M\A_Y\5O_!L/_E)\[?\ #ZS]E?\ Z+7X1_.?_P"-T?\ #ZS]
ME?\ Z+7X1_.?_P"-U]$_\*U\.?\ 0 T3_P  8O\ XFC_ (5KX<_Z &B?^ ,7
M_P 31RXK^:/_ ("__D@]OD/_ #XK?^#8?_*3YV_X?6?LK_\ 1:_"/YS_ /QN
MC_A]9^RO_P!%K\(_G/\ _&Z^B?\ A6OAS_H :)_X Q?_ !-'_"M?#G_0 T3_
M , 8O_B:.7%?S1_\!?\ \D'M\A_Y\5O_  ;#_P"4GSM_P^L_97_Z+7X1_.?_
M .-T?\/K/V5_^BU^$?SG_P#C=?1/_"M?#G_0 T3_ , 8O_B:/^%:^'/^@!HG
M_@#%_P#$T<N*_FC_ . O_P"2#V^0_P#/BM_X-A_\I/G;_A]9^RO_ -%K\(_G
M/_\ &Z/^'UG[*_\ T6OPC^<__P ;KZ)_X5KX<_Z &B?^ ,7_ ,31_P *U\.?
M] #1/_ &+_XFCEQ7\T?_  %__)![?(?^?%;_ ,&P_P#E)\[?\/K/V5_^BU^$
M?SG_ /C='_#ZS]E?_HM?A'\Y_P#XW7T3_P *U\.?] #1/_ &+_XFC_A6OAS_
M * &B?\ @#%_\31RXK^:/_@+_P#D@]OD/_/BM_X-A_\ *3YV_P"'UG[*_P#T
M6OPC^<__ ,;H_P"'UG[*_P#T6OPC^<__ ,;KZ)_X5KX<_P"@!HG_ ( Q?_$T
M?\*U\.?] #1/_ &+_P")HY<5_-'_ ,!?_P D'M\A_P"?%;_P;#_Y2?.W_#ZS
M]E?_ *+7X1_.?_XW1_P^L_97_P"BU^$?SG_^-U]$_P#"M?#G_0 T3_P!B_\
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M^@!HG_@#%_\ $T?\*U\.?] #1/\ P!B_^)HY<5_-'_P%_P#R0>WR'_GQ6_\
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M\^*W_@V'_P I/G;_ (?6?LK_ /1:_"/YS_\ QNC_ (?6?LK_ /1:_"/YS_\
MQNOHG_A6OAS_ * &B?\ @#%_\31_PK7PY_T -$_\ 8O_ (FCEQ7\T?\ P%__
M "0>WR'_ )\5O_!L/_E)\[?\/K/V5_\ HM?A'\Y__C='_#ZS]E?_ *+7X1_.
M?_XW7T3_ ,*U\.?] #1/_ &+_P")H_X5KX<_Z &B?^ ,7_Q-'+BOYH_^ O\
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MZS]E?_HM?A'\Y_\ XW7T3_PK7PY_T -$_P# &+_XFC_A6OAS_H :)_X Q?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBO*?VB_P!K/1OV>;FVL;BQO-4U6\A^T16\3".-4W%07<YQD@XPK=#TI-I;
MC2;V/5J*^7/#?_!3C3;W5HX]5\*7>GV;'#SV]^+ET]]AC3(_X%GV-?1-WX^T
MZ'X?S>)H)&OM*BL6U%7MP"TT2H7^4,0,D#H2.>N*;TCS/82UERK<VJ*^>O\
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MM2E))78TFW9'445\\_"[Q7\6OVD]/.OV>N:5X#\/2NZ6BQ:<E]/<!3C)$O!
M.1N!7)!PM1>/O&GQ=_9VU33[S4]7T3QKH.HWL=CODLTLYHW<\ K&!M)P<'+C
MCD=*I1?,HO1O]26U9M:V/HNBHKR^ATVREN;F6*WMX$,DLLCA$C4#)9B>  .2
M37$>!_VD?"?Q*^($_AS0;Z35+JVMGNI;B&(_9D"NJE0YQN.6!!4%<=Z2U=D-
MZ*[.\HHHH **** "BBB@ HHHH **\^U']J#P;9_$"P\,6^I_VIK-_<BU\JQ3
MSDMV.<EW^Z,$8(!+#TKT&A:KF6P/1V>X445@_%#QW%\,OA]J^ORP_:4TNW:8
M0[]GFMT5=V#C)(&<'KTI-V5V.*;=D;U%<?XM^*DGA/3O"C2:9YE[XGO[>Q-M
M]HV_9?,0L[9VG<$ /&!GVKH]>\1Z=X6L&N]3O[+3K53@S74ZPQC_ ($Q JFK
M7OT=OGI_FB8N]FNJO\B[17BOQ!_;V\ >"UDCL[RZ\07:97R["(^6&'3,C[5(
M/JN[Z5Z3\*/'9^)WP[TG7S9FP_M6 3BW,GF&,$G W8&>.>G>A*Z<EL-Z.S.A
MHHKPSXW?MW^'OA'XGN]$M=.O-=U.Q(2?RY5AMXWQRF_YCN'<!< \9R#4N23L
M-)O4]SHJEX:U<^(/#EA?M%]G:]MXYS%OW^7N4-MS@9QG&<5\[_$#_@I)HWAK
M7Y[+1_#MYK$=L[1//-="T5R"1E!L<E?<X/M3E[LN1[BC[T>9;'TK17A_P$_;
MET'XS^(XM%N]/GT#5KDD6R23">&X(&=HDPI#=>"H!QUSQ7LGB'Q#9>$]#NM2
MU&YBM+&RC,L\TAPL:CJ?_K#DTY+E5WL*+N[(N45X7!^V#K7BW2=0UCPE\.-7
MU_P]IQ8/?2WT=JTFW[VR+:[.!_LY/J!74_L^?M1:#^T':SQV4<^G:M9H'N+&
M<@L%/&]&'WUSQG (.,@9&1)L&['I=%%%(844$@#)X KY:^.?_!1)O#'B:;2_
M!VGV&H+92&.:^O=[PS,,@B-$920#_$6Y],8)ER2=AJ+:N?4M%?+7P+_X*(MX
MH\40Z7XQT^PT]+V01P7UEO2*%C@ 2([,0"?XPW'&1C)'U*#D9'(-:.+2N2I)
MNP4445(PHKYP_P"%_P#QE\5^-/$MEX4\*>&=5T_0-3FT_P ^3=$248@ E[A
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M?2)9VUM$9IWE8 0J!DDD<<5XQ:_M?:MXWCU&\\$_#[5O$^BZ82LM\]ZEGYC
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MVQ?$/@#3K'5?$WPRU72=!OV 6[34HYY%!&1NCV#:Q'\+LIZUZ[X4^(^E>./
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MM(87C*L,CEI5.?PHE[MK]0CK>W0];HKYZ_X>5>!?^@3XM_\  6W_ /C]=/\
M"']M+PQ\:?&L.A:3IOB**[FC>7S+FWB6)%49)8K*Q'ITZD4TF]$)M+<]>HHH
MI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *XB'X)6<_QMO?&NH31:A<-9Q6=A;R6P
MQIP7)9E8DY9B3R N 2.<UV]8?Q*\+W_C3P/J&EZ9K$^@7MZ@2._A0O);?,"2
MH#*<D C(88SFDVU[RW0TK^Z]F?/7_!2;1M%FT#P])'!"WBBYO/*A$2 SSP;3
MN!QRP#[ ,]R<=37H?P_^'NJ^#?V,I-!NX)Y=6&A78-LBEY \JR.L04<EAO"X
M'>O /VA?V9?&WP/">-X?%]]X@>R=%FU%GDBO;;)VJ<EW)3)"_>_BZ8S7O/[%
M?QYU'XX?#N[.LE)=5T:=8)9T0(+A&7*N0. W# XXX![T0@I4IP3]?+I^MPE)
MQJ0D^FWYF+\'_P!A[P-/\,=$F\0^'KB?6KBTCFO#/=W,#I(PW%"BNH7;G&,9
MXYKA_P!H;]F_P3:>./"_@CP?H:V?B'7;@3W-S]LN)OL5HN=S%7D*\X8]/X#Z
MBOJ#QUXSL?AWX0U#6]2D\JRTV$S2'NV.BC_:)P .Y(KQ;]C'0KWX@:QXA^*&
MN)_Q,/$<[6]@IY$%LAP0OME0H_ZY^]5?FJ7Z+5_HOF_PN1;EIVZO1?J_DOQL
M<]_P4"U"+X<?!7POX0TI?LMA<3;=BGK%;HN%/KEG5C[K7L'[*^B1Z%^SOX2@
M10HDT]+@X[F7,A/YM7A7_!3Y9/M/@UB?W16[ &>^8<_TKW_]FVZ6\^ /@YUZ
M#2;=.O=4"G^5*DW*G.3ZR_S7Z!45IPBME%_FCY&^$,Q^%G[=1L;7,5M_;5SI
MVP' ,4C.JCZ#*G\!7U1X>^!21?'_ ,1^-=5BTZ[:\CMX=)&#)):*D861CN4!
M6) P5)XSSR:^6]0L_M/_  4+"(,8\2I)P/1@Q_D:^ZI)%B1F9@JJ,DDX 'K1
M2TH0GVNOP7_!^\NJOWTX]_\ -_Y?@?-?_!27P;I;_#?2]=^S01ZO%J"6HG50
MLDL31N2K'JP!4$9Z<XZFN@_X)X6]W#^SV&N-XAEU*=K7</\ EGA <>V\/^.:
MX;XE+??MS_&*WT70WDA\#^%Y"+O4@/DGD/WF3L6(&U!Z98\'%?3_ (6\,6/@
MOPY9:3IMNEK86$2PPQ+_  J/YD]23R22:*/NPDW]K;TTU^=OQ%5UDHK[._KK
MI^)?KY^_X*->$O[:^"=IJ:(6DT;4$9F_NQR HW_CVROH&N+_ &B?"G_";? [
MQ1IV-SRZ?))&,9R\8\Q?_'E%95O@;[:_=J:4OC2[Z??H>+_\$S/%'VOP1XCT
M9FYLKR.Z4>TJ;3^L?ZUR_P"UO8:E^T%\0/%9TLL^E_#/3AO &1+.SJ9@/<('
M_P"_/O7G/[(OQKA^"?BCQ#?7#+Y=QHTPA1CQ)<(0T2_B<C\:^L?V2/AHWAOX
M(1RZM'YVI>+&DU/43(,F7SAPK?\  ,9'JS5O6BY^^NB_'5+\$V_D8TI<ON]W
M^&C?XM(\=_X)J?$S[/J>M^$[B3"W*C4;12?XEPL@'N1L/_ 37<?%N#_A:7[:
MW@O0!F2S\*VK:M<@<A'SN7/XK#_WU7S5&US^RS^T_P ^8$\/ZG@^LUJW_P 5
M$WYFOIG]E"5/B3\:OB1XZ#":VN+Q=,L)1T:)/3ZJL)_&G&2FX5%T3?W*R_-?
M<*4>13IOK9?>]?P3^\]_HHHJ"PKX<_X*)3W%M^T%8R2!FBCTR!H0WW2!)(3C
M\<U]QUY_\>_V<=!_:"T>"'5//M;VRW?9;VWP)(L]5((PRDX.#Z<$5$K\T91Z
M.Y<6K.+ZHA^'7[5/@7X@Z%;7,7B+2M/N9$7S+2]N%MIHG(Y3#D;L'C*Y'O76
MS>$]&\1^)-,\1&&*YU#3HI([.Z29B$20 .  =K X'4'';%?)7BO_ ()G^([%
MW;1O$&D:E&JY NHY+61CZ #>/S(_"O,/ 'C+Q5^RO\7UMYS=Z=/9W*)J5@9,
MQ7,9QD$ E6RIRK#.,@@UK'EE-):-_P##?K]QDTXQ[K^OZ]3[5^,/[5G@_P""
M&J'3]8N;V34_*686EM:L[E&S@[CA.<'^*N&TS_@H;X6O/"^LZI/87=I]BF6&
MPM&E5KK42RDYVCB-5P,G<P&>YP#TO[<4$=W^S#XA=D5S']FDC)'W3]HC&1^!
M/YUY?_P30\*Z;=Z1XAU:6RMI=2M[F."&Y= TD*%"2%)^[D]<=>/2HI)SY[_9
M_P"!_G;\?(J<DN5KK_E_7Y>9<\+?\%-=+U#68H=7\+7>F63G#7$%\+IH_<H8
MTX]<$GT!KW3QY\;O#7PX\$6OB+5-1"Z3?E%M9H8GF%P70NH7:#U4$Y.![U\\
M?\%)/A?INFV.B^*+.U@M;VYN6L[QHT"_:<J71FQU8;6&>I!'H*]8_8GEDU#]
ME[P^MUF0;;B(!QG*">0 ?3'%+FO3DUO$)>[.-]F8?A3]O[PKXP\:#3X+*^LM
M+AMIKFYU&^=(A$(U+86-2Q;=C Y!R0,&J_@/_@H'X=\4W^LR:EIUQH>BZ8JF
M*]>1KA[@LV$4Q)'\A(!/WB!CK7SA^R=X!TKX@?M&V.F:M:I>:>IN)FMWSLD*
M*Q4,.XR <=#C!XK[J\*?"#PQX%UR[U'1=$T_2KJ]A6"?[)'Y4;HIR!Y:X0<G
MJ!D]ZT2LHR?5/]=?Z]=1-ZRBNC_R_K_(\S\$?MSZ#\3?BEI'AG0=(U.?^TI'
M1[NZ9(%B"HS[E4%BW"]#MK=^+?[8G@OX-Z]<:3J,^H76JVFWSK6TM2S)N4,O
MS.50Y5@>&-?+G[.5M'9?MPVL,2+'%%JM^B*O 4".< "O>_\ @HQ DGP!A=E4
MO'JL&TD<KE) :RYKTH377];%\O[Z=-]%_G_D>@?L^?'&+X_^$+O6K?39=-MH
M+Y[2)99A(\H54;>< !3\V,<].IJW\8?CIX=^!^AB\UR[VRS _9K.$![FZ([(
MOIZL< >O(KS+_@G%_P D#NO^PQ/_ .BXJ\;^'/B)OC!^WQ!=ZH3=0QZE<_9H
MW)*Q) DAA ';:54_7)[UK./[R--:75_P5_S(B[4Y5'K;_@_Y'I>N?\% =7\*
MB"?5OAAK>F6%TV(;BZNGB\T=<KN@ )QS@-^->_:[XZTWPIX/;7-8N4TK3XH5
MFE>X.#'D A<#.6R<8&23P,U5^*?PQT[XO>#IM$U1KB.TFDCE+P%5D5D<,,%E
M8=L'CH37S9_P4T\43QR^%]#C=DM"DMY(@X#L"$3/T&__ +ZK*4[1MU;T]+?\
M.7&%W?HEJ>A:E^U_K-]X5N_$GAWX=:OK/A6SW%M1GOH[1G"G#.L.UW9!S\PZ
M8.<8..O_ &?OVE-#_:$TF>33TFLM1L@INK*<@O&#T96'#)G(SP?4#(SY[\*?
MV@[?1_@IH>C)\.OB5?01Z5';M+:Z%YEM<YC 9D;?\RL23G'(->=_L-?"/QGX
M,^-@U*^\/ZOI6DO:30W$EY 8 0<%1A\$_,J] :VC%>TE![):/[_Z^9DY-P4^
MO;U/LJOF/_@IM]H_X0CPQLW_ &7[=+YN/N[_ "QLS[XWX_&OIRN?^)WPQTCX
MO>#[G1-;@,UG<88,AVR0N/NNC=F'Y<D$$$BL:D6UIY?F;0E9Z^?Y'C/['O[3
M?@^/X0Z1H&IZQ8Z)JFD1M \=[(((Y5#$AU=L*<@],YR#QC!/LVK:-X=^+VC6
MPF>SUJQM;J.[A:WN=R)-&<HP:-NQ[9P>XKYB\8_\$R;Z*1G\/^)[2=&8[8M0
MMVB*+VRZ;MQ_X *\6\;_  ^\9_LK^.[5KB6;2M0 ,EI>V<^8[A0<':PQD>JL
M!P>1@UK*HI2YI:-_GN9J#4;1V_0^\_VA/$EAX9^"_B674+RWLTN--N+>(RN%
M\V5XF"HOJQ/0"OCC]AWXK>'/A!\1M4U+Q)J TZVGTXV\+_9Y9BSF1&QB-6(X
M4]:^G=5U.P^./[);>(=7TO3[R[?0;BZ0SVR2?9[A87#/'N!VG<I((YZ5\\_\
M$]/!FC^-?B+KD&LZ3INK0PZ<'CCO;5+A4;S5&0'! ..]%.$HUYQZI?H_^"$Y
M)T8RZ-_Y'TAX[_;*\"> =+T^ZGO[R[_M6U6]M(K:SDWS0LS*&^<*HR5;AB#Q
MTKE=,_X*!>'+_P %Z[K<NFW5K'ITZ6]A;23J;C4G96/W0"(P,<G+  ^N >A_
M;$T.RTK]E7Q#:6MI;6UK9Q0""&&)4CA GC "J!A<>U>*?\$\?A+X=\>0>(]0
MUO2;'5YK)X8($O(A-%&&#%CL;*DG Y(R,<8R:F*YG-+I_FOQZ?CY#?NJ+?7_
M "_K\CZ$^!_[0-M\6OA1-XLO[2+P[9V\TL<HFNQ*B*F,N7*KQSZ=JYA_VMM1
M\6VVH7O@;P)JWBW1]+++/?M=I9([ 9(B1E9Y.,'  ;D<=*X/]O#2[#X1?!71
M_#7AVT72],U?4Y+F>&)V*MM&XCDG +,IP.!M&!5K]E?X_1>!/@9HNFQ>!?B%
MJIA\YGN],T;S[:=C*Y)5]XW8S@\<$$=J+J7,UI:R^=E=^@-.*C?6]_NN_P 3
MT;]G?]K70_V@)IK&*VGTC6K:/S7LIG$@=,X+1N -V,C((!YZ$<UUGQ;^-'A_
MX)^'AJ.O7GDK(2L$$8WSW3#JJ+W[9)P!D9(S7R?^S[\*?&-K^U':^(;?PKKV
MCZ,=1GF9KZU-MY-O)O&TAL D*P&!GFLW]L;Q>^L?M;B&\CN+NQT66TMTMHEW
M.Z821U5>[,7;'KQ1\7(MG+?R_JZ^=Q?"Y]5';S\CW'QI^V/XB\ :/::SJOPQ
MU2R\/7[A8;R74X_-VGD;X@A,;$=%9A]:]1^'_P 9_#WQ'^'R^)[&_CATI58S
MO=,(3:%?O+)DX4CZXP002"#7CO[0/QDN?B[\(-7\/67PW^)T=Y?I&(7N=!*1
M(RR*^20S$?=["JO["7P>UK1/!OB?3?&'AUXM(U*6"2&TU.W5DF9=VXF)\],1
M]1U QTIQNU)=MO\ @A)VY7]__ / ?AAX[T7P]^U;%XAU&]2#18M6N;HW/E/(
M-A\PH0J@L<DKT'>OO/X;?%30?B[H4FI>'K[^T+**8V[2>1)#AP 2,2*IZ,.<
M8YKX?^!WAC3-6_;-BTN[TZQNM,.J7L9M)8$> JJ3;5V$;<# P,<8%?>/AOPG
MI7@ZP-II&FZ?I5JSF0PV=ND$98X!;:H SP.?:E2:]A!=+:?AN.M?ZQ/OU^][
M&A7SE^V3H?Q$UK5K33M.UO1[?PMXDO;72[>P9 9GG)W[W;R20@9,G:YX XY(
MKZ-KP_XI?%KPIKOQV\!6Y\3>'S8:/)>7]Y*=1A\J&58Q'$K-NP&W,W!YXI6O
M**\_RU?X;>=AWM&3\OQZ?B><^(O WQMU?XNZ!H]YXP\-W.MZ=:S:M92K HAM
M%XA9F MAECNP,JV.3Q7N_C7]G[2?B_I7AM?&7FZM=Z%'F0QOY,=U*R*)"P4
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M?;OP]TJ?0_ 6B65U'Y5S:6$$,J;@VQUC4$9&0>1VKXB_9A_Y/5M?^O\ OO\
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MW&,\Y)SA+EIU''??Y%S7-*%]MOG_ $SSO7/%4O[8_P"UG8:3-+(?"^G7#B*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "O!_!7[6]IX8^+GBOPCXWU&.SDLM3D_LR^EC6.$P$@I$Y4 *0I!#-P03DY
MS[Q7">/_ -F7P+\4-:;4=;\/6UU?. 'GCEEMWDQP"QC9=QQ@9.3@"DKJ5^G_
M  W^0W9QMU/,OVPOVB_#&L_"F]\+Z#J=IXBUGQ 8[>&'3I!<A!YBL263(S\N
M H.XEAQBNH_8M^!]Y\%?A8RZJGDZOK,WVJXBSDVZ@82,^X&2?0L1VKL/AY\
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MR< "NUTS3+?1=.@L[2&.WM;6-8H8HUVK&BC 4#L *BFN6DH/=%5/>JNHNO\
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M%76M<LO#>ES7VHW=M8V=N-TL]Q*L<<8SCEB0!R0/QKXL_P""@OQ4T'XC>)M
MAT+5+754T^"7SI+9]\:LS# W#@G"]J^T]9T2R\1Z9+9:A:6M_9S@"2"XB66*
M0 Y *L"#R >?2N=_X4'X%_Z$OPE_X*+?_P"(J)1NTWT+C*R:[GG_ .Q[\8?#
M-Q\%O#.C/KVD0ZQ%$;8V4ETD<Y?>< (Q!)(QT!K:^,W[7OA/X'>*(M'U5=4N
MKYXUED2R@5Q IZ%BSKU'.!DXKK=,^"_@[1=0AN[/PGX9M+JW8/%-#I<$<D;#
MH58+D'W%4?B-^SUX-^+6JP7WB#0X-0O+=0B3>;)$Q4'(#%&7</9LUK4DY2YN
M[U,Z<5&/+Y:'CW[?&F2?$SX':!XET3?>Z7;2BZ=D4_ZF5!MD(Z@# '/3=7K7
MP&^+&B_$7X4:;J-G>VJBUM$6\C,BAK-U7#!Q_"!@\G@CGI78VVD6EGI26$5M
M!'91Q>0L 0>6(\8V[>F,<8KSG5?V,OAEK.I27<WA6V665MS"&YG@CS[(CA0/
M8"DG;F2V;O\ H#U46]TK?J>"Z7X;C_:%_;HNM7T-?.T+2+N&ZN+R,9B8PJH&
M&'!WNG'J,GM7U;XQ^)?A[X>)&=<UK3-)\X%HUNKA8VE Z[5)RV/858\(>"=(
M\ Z.FGZ+IUIIEFG(BMXP@)Z;CW8^YR33/$_P^T#QL\3:UH>D:NUN"(C>V<=P
M8P>NW>#C/M2^&$:<=D/>3G+J?GUKOCS3;[]JQ_$4=RK:2?$2W@N"#CR1.&WX
MQG&WGI7W%XG^*NG^*OAAXCN_!WB+2KS4M-T^2XC>TGBN6MV5&92R<XSM(^85
M>_X4'X%_Z$OPE_X*+?\ ^(K2\/\ PW\.^$H[E-*T#1=,6\79<"TL8H1.O/#[
M5&X<G@^II6_=>S73J._[SVGI^9YK\#?VR_"GQ#\(VYUK6=.T/6X(PMY#>S+;
MH[CJZ,Q"D'K@'(]*\A_:J\51_M9?$[0/"O@@?VQ_9?F-<7L0/D1ERH9BW38H
M4?-T).!GC/N.H_L7?#'5+^2YE\*VZRR-N817=Q$F?9$D"@>P&*[GP9\/]$^'
M>E_8]#TJRTNVX++;Q!"Y'=CU8^Y)-5)1E)2DMM;$J\4XQ^\Y7Q!XRT#]E'X-
M:6-3DN7LM,BBL(E@C#37+A>P) R=I)R0/>H? 7Q,\'_M=_#[4[6*WNY].9A!
M>V5V#!*O(9<F-SP2,@JW:NP\=?#_ $;XF>'I-*UVPAU&PE(8Q2$C##HRLI#*
M>O((/)]:K?#GX5>'_A)HSZ?X=TR+3;61S(ZJ[R-(W3+,Y+'\31?F<G/6^W]?
M>%N514.AY7XO_9F^!?@#8-<L]*TEI5+QI=:Y<1/(!U*J9LG\!7RC\,+#P;JG
M[0<%OK(A3P=->3K^^GDB18L/Y6YPP8#.WDGZU^A?B?X=^'_&TT4FLZ%HVKR0
M*5C:]LH[@Q@]0"ZG ^E9?_"@_ O_ $)?A+_P46__ ,14QNI<S*EK%Q7WG-1?
MLV?"_P"(WA'2([?3+/5M&TQ)(["2UU2>2-%9RS@.DOS?-GJ3CI7BG[3OPS^"
M_@'X;:NF@?V4OBF)TA@A@U>:YFB<2#>&0RL!A0P.X<?6OK'0_#]AX7TR.RTR
MRM-.LXL[(+:%88DR<G"J !DDFL.^^"7@S5+V6YN?"/ABXN)W,DLLNE0.\C$Y
M+$E<DD]S2FFWI_7]=0B[;GR1^P[X;^'6N/<S>*Y-.AU^QOX9=--UJ#VI;H5"
M*'57.\="#VK["\8?$OP]\/8XVUS6],TKSE+1+=7*QM*!UV@G+?A5*U^!O@FR
MN8YH?!_A:&:%@Z.FDP*R,#D$$)D$'O6CXG^'N@>-GA;6=#T?5VMP1$;VSCN#
M&#U"[P<9]JTG*Z5B(12;N?GYK_CS3;[]JR3Q%'<J^DGQ$MV+@@X\D3AM^,9Q
MMYZ5]^^&?BCX;\96=Q/I.NZ3J4=G'YEP;:Z24P+SRX4DKT/7T-4?^%!^!?\
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MZ#J/_E7_ .5'UO17R1_PH']LC_HX;X8?^&X/_P E4?\ "@?VR/\ HX;X8?\
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M5?\ Y4?6]%?)'_"@?VR/^CAOAA_X;@__ "51_P *!_;(_P"CAOAA_P"&X/\
M\E4?69_\^I?^2_\ R0?V'AO^@ZC_ .5?_E1];T5\D?\ "@?VR/\ HX;X8?\
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MG_SZE_Y+_P#)!_8>&_Z#J/\ Y5_^5'UO17R1_P *!_;(_P"CAOAA_P"&X/\
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M?VR/^CAOAA_X;@__ "51_P *!_;(_P"CAOAA_P"&X/\ \E4?69_\^I?^2_\
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M#_\ )5'_  H']LC_ *.&^&'_ (;@_P#R51]9G_SZE_Y+_P#)!_8>&_Z#J/\
MY5_^5'UO17R1_P *!_;(_P"CAOAA_P"&X/\ \E4?\*!_;(_Z.&^&'_AN#_\
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M17R1_P *!_;(_P"CAOAA_P"&X/\ \E4?\*!_;(_Z.&^&'_AN#_\ )5'UF?\
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M*H^LS_Y]2_\ )?\ Y(/[#PW_ $'4?_*O_P J/K>BODC_ (4#^V1_T<-\,/\
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MY(_X4#^V1_T<-\,/_#<'_P"2J/\ A0/[9'_1PWPP_P##<'_Y*H^LS_Y]2_\
M)?\ Y(/[#PW_ $'4?_*O_P J/K>BODC_ (4#^V1_T<-\,/\ PW!_^2J/^% _
MMD?]'#?##_PW!_\ DJCZS/\ Y]2_\E_^2#^P\-_T'4?_ "K_ /*CZWHKY(_X
M4#^V1_T<-\,/_#<'_P"2J/\ A0/[9'_1PWPP_P##<'_Y*H^LS_Y]2_\ )?\
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M?_*O_P J/K>BODC_ (4#^V1_T<-\,/\ PW!_^2J/^% _MD?]'#?##_PW!_\
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M/K>BODC_ (4#^V1_T<-\,/\ PW!_^2J/^% _MD?]'#?##_PW!_\ DJCZS/\
MY]2_\E_^2#^P\-_T'4?_ "K_ /*CZWHKY(_X4#^V1_T<-\,/_#<'_P"2J/\
MA0/[9'_1PWPP_P##<'_Y*H^LS_Y]2_\ )?\ Y(/[#PW_ $'4?_*O_P J/K>B
MODC_ (4#^V1_T<-\,/\ PW!_^2J/^% _MD?]'#?##_PW!_\ DJCZS/\ Y]2_
M\E_^2#^P\-_T'4?_ "K_ /*CZWHKY(_X4#^V1_T<-\,/_#<'_P"2J/\ A0/[
M9'_1PWPP_P##<'_Y*H^LS_Y]2_\ )?\ Y(/[#PW_ $'4?_*O_P J/K>BODC_
M (4#^V1_T<-\,/\ PW!_^2J/^% _MD?]'#?##_PW!_\ DJCZS/\ Y]2_\E_^
M2#^P\-_T'4?_ "K_ /*CZWHKY(_X4#^V1_T<-\,/_#<'_P"2J/\ A0/[9'_1
MPWPP_P##<'_Y*H^LS_Y]2_\ )?\ Y(/[#PW_ $'4?_*O_P J/K>BODC_ (4#
M^V1_T<-\,/\ PW!_^2J/^% _MD?]'#?##_PW!_\ DJCZS/\ Y]2_\E_^2#^P
M\-_T'4?_ "K_ /*CZWHKY(_X4#^V1_T<-\,/_#<'_P"2J/\ A0/[9'_1PWPP
M_P##<'_Y*H^LS_Y]2_\ )?\ Y(/[#PW_ $'4?_*O_P J/K>BODC_ (4#^V1_
MT<-\,/\ PW!_^2J/^% _MD?]'#?##_PW!_\ DJCZS/\ Y]2_\E_^2#^P\-_T
M'4?_ "K_ /*CZWHKY(_X4#^V1_T<-\,/_#<'_P"2J/\ A0/[9'_1PWPP_P##
M<'_Y*H^LS_Y]2_\ )?\ Y(/[#PW_ $'4?_*O_P J/K>BODC_ (4#^V1_T<-\
M,/\ PW!_^2J/^% _MD?]'#?##_PW!_\ DJCZS/\ Y]2_\E_^2#^P\-_T'4?_
M "K_ /*CZWHKY(_X4#^V1_T<-\,/_#<'_P"2J/\ A0/[9'_1PWPP_P##<'_Y
M*H^LS_Y]2_\ )?\ Y(/[#PW_ $'4?_*O_P J/K>BODC_ (4#^V1_T<-\,/\
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MY(_X4#^V1_T<-\,/_#<'_P"2J/\ A0/[9'_1PWPP_P##<'_Y*H^LS_Y]2_\
M)?\ Y(/[#PW_ $'4?_*O_P J/K>BODC_ (4#^V1_T<-\,/\ PW!_^2J/^% _
MMD?]'#?##_PW!_\ DJCZS/\ Y]2_\E_^2#^P\-_T'4?_ "K_ /*CZWHKY(_X
M4#^V1_T<-\,/_#<'_P"2J/\ A0/[9'_1PWPP_P##<'_Y*H^LS_Y]2_\ )?\
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M?_*O_P J/K>BODC_ (4#^V1_T<-\,/\ PW!_^2J/^% _MD?]'#?##_PW!_\
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M/K>BODC_ (4#^V1_T<-\,/\ PW!_^2J/^% _MD?]'#?##_PW!_\ DJCZS/\
MY]2_\E_^2#^P\-_T'4?_ "K_ /*CZWHKY(_X4#^V1_T<-\,/_#<'_P"2J/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
4B@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 18, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Coeptis Therapeutics Holdings, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001759186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1465952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">105 Bradford Rd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Wexford<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">15090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">934-6467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,225,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,223,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMnpiDiscTextBlock', window );">Award Timing MNPI Disclosure [Text Block]</a></td>
<td class="text">We <span id="xdx_90A_eecd--AwardTmgMnpiCnsdrdFlag_dbT_c20250101__20251231_zHHWEzS4pidc">do
not grant equity awards in anticipation of the release of material nonpublic information</span>&#160;that is likely to result in
changes to the price of our common stock, and do not time the public release of such information based on award grant dates. During
the last completed fiscal year, we have not made awards to any named executive officer or director during the period beginning four
business days before and ending one business day after the filing of a period report on Form 10-Q or Form 10-K or the filing or
furnishing of a current report on Form 8-K, and we have not timed the disclosure of material nonpublic information for the purpose
of affecting the value of executive compensation.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMnpiCnsdrdFlag', window );">Award Timing MNPI Considered [Flag]</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">6920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Astra Audit and Advisory LLC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tampa, Florida<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=coep_CommonStockParValue0.0001PerShareMember', window );">Common Stock, par value $0.0001 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">COEP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=coep_WarrantsEachWholeWarrantExercisableForOnehalfOfOneShareOfCommonStockFor230.00PerWholeShareMember', window );">Warrants, each whole warrant exercisable for one-half of one share of Common Stock for $230.00 per whole share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants, each whole warrant exercisable for one-half of one share of Common Stock for $230.00 per whole share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">COEPW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMnpiCnsdrdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMnpiCnsdrdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMnpiDiscTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMnpiDiscTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=coep_CommonStockParValue0.0001PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=coep_CommonStockParValue0.0001PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=coep_WarrantsEachWholeWarrantExercisableForOnehalfOfOneShareOfCommonStockFor230.00PerWholeShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=coep_WarrantsEachWholeWarrantExercisableForOnehalfOfOneShareOfCommonStockFor230.00PerWholeShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash</a></td>
<td class="nump">$ 5,674,302<span></span>
</td>
<td class="nump">$ 532,885<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">676,596<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable</a></td>
<td class="nump">7,348<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid assets</a></td>
<td class="nump">991,903<span></span>
</td>
<td class="nump">518,407<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">TOTAL CURRENT ASSETS</a></td>
<td class="nump">7,350,149<span></span>
</td>
<td class="nump">1,051,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Furniture and fixtures, net</a></td>
<td class="nump">9,873<span></span>
</td>
<td class="nump">10,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>OTHER ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Investments</a></td>
<td class="nump">7,860,083<span></span>
</td>
<td class="nump">5,691,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">361,250<span></span>
</td>
<td class="nump">541,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_CodevelopmentRightsNet', window );">Co-development rights, net</a></td>
<td class="nump">554,167<span></span>
</td>
<td class="nump">1,554,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset, net of accumulated amortization</a></td>
<td class="nump">18,399<span></span>
</td>
<td class="nump">59,783<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Total other assets</a></td>
<td class="nump">8,793,899<span></span>
</td>
<td class="nump">7,846,908<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">16,153,921<span></span>
</td>
<td class="nump">8,908,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">888,755<span></span>
</td>
<td class="nump">1,269,763<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">41,054<span></span>
</td>
<td class="nump">736,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable, net of debt discount of $0 and $435,635</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,087,873<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNotesPayableCurrent', window );">Convertible notes payable, in default</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Right of use liability, current portion</a></td>
<td class="nump">18,875<span></span>
</td>
<td class="nump">42,305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Customer deposit</a></td>
<td class="nump">599,455<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,041,484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">235,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">TOTAL CURRENT LIABILITIES</a></td>
<td class="nump">1,768,139<span></span>
</td>
<td class="nump">4,513,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">SBA loan payable</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liability warrants</a></td>
<td class="nump">167,625<span></span>
</td>
<td class="nump">359,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Right of use liability, non-current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,875<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">TOTAL LONG TERM LIABILITIES</a></td>
<td class="nump">317,625<span></span>
</td>
<td class="nump">528,125<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">2,085,764<span></span>
</td>
<td class="nump">5,041,434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 150,000,000 shares authorized, 5,746,948 and 2,116,191 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively</a></td>
<td class="nump">575<span></span>
</td>
<td class="nump">212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">127,201,691<span></span>
</td>
<td class="nump">102,976,748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_CommonStockSubscribed', window );">Common stock subscribed</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">541,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSubscriptionsReceivable', window );">Subscription receivable</a></td>
<td class="num">(3,686,544)<span></span>
</td>
<td class="num">(2,100,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(109,953,728)<span></span>
</td>
<td class="num">(98,036,713)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS' EQUITY - CONTROLLING INTERESTS</a></td>
<td class="nump">13,561,994<span></span>
</td>
<td class="nump">3,382,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">TOTAL STOCKHOLDERS' EQUITY - NONCONTROLLING INTERESTS</a></td>
<td class="nump">506,163<span></span>
</td>
<td class="nump">485,102<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">TOTAL STOCKHOLDERS' EQUITY</a></td>
<td class="nump">14,068,157<span></span>
</td>
<td class="nump">3,867,226<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</a></td>
<td class="nump">16,153,921<span></span>
</td>
<td class="nump">8,908,660<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value, 10,000,000 shares authorized, 10,000 designated as Series A, 0 and 6,520 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_CodevelopmentRightsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_CodevelopmentRightsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_CommonStockSubscribed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_CommonStockSubscribed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(h))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term notes classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 42: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 47: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 51: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 52: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 54: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 55: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteSubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Note received instead of cash as contribution to equity. The transaction may be a sale of capital stock or a contribution to paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481142/505-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteSubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">5,746,948<span></span>
</td>
<td class="nump">2,116,191<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">5,746,948<span></span>
</td>
<td class="nump">2,116,191<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,520<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt Instrument, Unamortized Discount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 435,635<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>SALES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total sales</a></td>
<td class="nump">$ 1,363,045<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of goods</a></td>
<td class="nump">180,625<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">1,182,420<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>COST OF OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">1,277,150<span></span>
</td>
<td class="nump">2,331,548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Salary expense</a></td>
<td class="nump">1,687,972<span></span>
</td>
<td class="nump">1,722,050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalAndContractServicesExpense', window );">Professional services expense</a></td>
<td class="nump">7,792,100<span></span>
</td>
<td class="nump">2,950,271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Stock based compensation expense</a></td>
<td class="nump">1,215,692<span></span>
</td>
<td class="nump">1,104,978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">1,148,004<span></span>
</td>
<td class="nump">945,641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and marketing expense</a></td>
<td class="nump">105,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total cost of operations</a></td>
<td class="nump">14,225,918<span></span>
</td>
<td class="nump">10,054,488<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">LOSS FROM OPERATIONS</a></td>
<td class="num">(13,043,498)<span></span>
</td>
<td class="num">(10,054,488)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER INCOME (EXPENSE)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(96,744)<span></span>
</td>
<td class="num">(246,116)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest income</a></td>
<td class="nump">116,495<span></span>
</td>
<td class="nump">234,742<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="num">(545,635)<span></span>
</td>
<td class="num">(216,189)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_GainOnForfeitureOfCustomerDeposit', window );">Gain on forfeiture of customer deposit</a></td>
<td class="nump">115,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">7,004<span></span>
</td>
<td class="num">(16,444)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized gain on marketable securities</a></td>
<td class="nump">76,596<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Unrealized loss on investments</a></td>
<td class="num">(163,500)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown', window );">Loss on write down of assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(37,257)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_GainsLossesOnExtinguishmentOfDebt1', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="nump">159,035<span></span>
</td>
<td class="num">(200,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liabilities</a></td>
<td class="nump">1,098,055<span></span>
</td>
<td class="num">(341,660)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">TOTAL OTHER INCOME (EXPENSE), net</a></td>
<td class="nump">766,306<span></span>
</td>
<td class="num">(822,924)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">LOSS BEFORE INCOME TAXES</a></td>
<td class="num">(12,277,192)<span></span>
</td>
<td class="num">(10,877,412)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">PROVISION FOR INCOME TAXES (BENEFIT)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">NET LOSS</a></td>
<td class="num">(12,277,192)<span></span>
</td>
<td class="num">(10,877,412)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">NET LOSS ATTRIBUTABLE TO NON-CONTROLLING INTERESTS</a></td>
<td class="num">(360,177)<span></span>
</td>
<td class="num">(196,960)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS</a></td>
<td class="num">$ (11,917,015)<span></span>
</td>
<td class="num">$ (10,680,452)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>LOSS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per share, basic</a></td>
<td class="num">$ (2.81)<span></span>
</td>
<td class="num">$ (5.56)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Loss per share, fully diluted</a></td>
<td class="num">$ (2.81)<span></span>
</td>
<td class="num">$ (5.56)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding, basic</a></td>
<td class="nump">4,234,787<span></span>
</td>
<td class="nump">1,924,639<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares outstanding, diluted</a></td>
<td class="nump">4,234,787<span></span>
</td>
<td class="nump">1,924,639<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=coep_SaleMember', window );">Sale [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>SALES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total sales</a></td>
<td class="nump">$ 1,363,045<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_GainOnForfeitureOfCustomerDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_GainOnForfeitureOfCustomerDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_GainsLossesOnExtinguishmentOfDebt1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_GainsLossesOnExtinguishmentOfDebt1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalAndContractServicesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalAndContractServicesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesAndWages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesAndWages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=coep_SaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=coep_SaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br></strong></div></th>
<th class="th"><div>Preferred Stock [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Common Stock Subscribed [Member]</div></th>
<th class="th"><div>Subscription Receivable [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Parent [Member]</div></th>
<th class="th"><div>Noncontrolling Interest [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance, value at Dec. 31, 2023</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 179<span></span>
</td>
<td class="nump">$ 91,670,045<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (3,500,000)<span></span>
</td>
<td class="num">$ (87,356,261)<span></span>
</td>
<td class="nump">$ 813,963<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 813,963<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,766,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued for cash</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">99,995<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued for cash, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_SharesIssuedInConnectionWithSEPAValue', window );">Shares issued for SEPA</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">79,998<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">80,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_SharesIssuedInConnectionWithSEPAShares', window );">Shares issued for SEPA, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issued for services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">1,329,255<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,329,275<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,329,275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued for services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_StockIssuedDuringPeriodValueWarrantsIssuedForCash', window );">Warrants issued for cash</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrants issued for services</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,150<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,150<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_WarrantsIssuedInExchangeForSubscriptionsReceivable', window );">Warrants issued in exchange for subscriptions receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,000,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_SharesIssuedForConversionOfDebtValue', window );">Shares issued for the conversion of debt</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">951,856<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">951,863<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">951,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_SharesIssuedForConversionOfDebtShares', window );">Shares issued for the conversion of debt, shares</a></td>
<td class="nump">506<span></span>
</td>
<td class="nump">72,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_StockIssuedDuringPeriodValueOfPreferredShareOffering', window );">Preferred stock offering</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,331,938<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,100,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,231,939<span></span>
</td>
<td class="nump">682,062<span></span>
</td>
<td class="nump">3,914,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_StockIssuedDuringPeriodSharesOfPreferredShareOffering', window );">Preferred share offering, shares</a></td>
<td class="nump">6,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_StockIssuedDuringPeriodValueOfInvestmentsAssignmentAgreements', window );">Investments in private companies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_StockIssuedDuringPeriodValuePurchaseOfAssets1', window );">Common stock issued for intangible asset purchase</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">541,875<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">541,875<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">541,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,104,978<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,104,978<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,104,978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Stock split adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">533<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">533<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Stock split adjustment, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,680,452)<span></span>
</td>
<td class="num">(10,680,452)<span></span>
</td>
<td class="num">(196,960)<span></span>
</td>
<td class="num">(10,877,412)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance, value at Dec. 31, 2024</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 212<span></span>
</td>
<td class="nump">102,976,748<span></span>
</td>
<td class="nump">541,875<span></span>
</td>
<td class="num">(2,100,000)<span></span>
</td>
<td class="num">(98,036,713)<span></span>
</td>
<td class="nump">3,382,124<span></span>
</td>
<td class="nump">485,102<span></span>
</td>
<td class="nump">3,867,226<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2024</a></td>
<td class="nump">6,520<span></span>
</td>
<td class="nump">2,116,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued for cash</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
<td class="nump">8,119,930<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,561,544)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,558,456<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,558,456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued for cash, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">696,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_SharesIssuedInConnectionWithSEPAValue', window );">Shares issued for SEPA</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">2,958,825<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,958,848<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,958,848<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_SharesIssuedInConnectionWithSEPAShares', window );">Shares issued for SEPA, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issued for services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">3,829,184<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,829,220<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,829,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued for services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">362,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_SharesIssuedForInvestmentValue', window );">Shares issued for investment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">999,994<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_SharesIssuedForInvestmentShares', window );">Shares issued for investment, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Asset purchase agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">541,856<span></span>
</td>
<td class="num">(541,875)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Asset purchase agreement, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrants issued for services</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">824,295<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">824,295<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">824,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_StockIssuedDuringPeriodValuePrefundedWarrantsExercise', window );">Pre-funded warrants exercise</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">855<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_StockIssuedDuringPeriodSharesPrefundedWarrantsExercise', window );">Pre-funded warrants exercise, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_StockIssuedDuringPeriodValueOfPreferredShareOffering', window );">Preferred stock offering</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,098,763<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,975,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,073,762<span></span>
</td>
<td class="nump">381,238<span></span>
</td>
<td class="nump">5,455,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_StockIssuedDuringPeriodSharesOfPreferredShareOffering', window );">Preferred share offering, shares</a></td>
<td class="nump">3,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_StockIssuedDuringPeriodValuePreferredShareConversion', window );">Preferred share conversion</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
<td class="num">(124)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_StockIssuedDuringPeriodSharePreferredShareConversion', window );">Preferred share conversion, shares</a></td>
<td class="num">(10,000)<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,215,692<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,215,692<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,215,692<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(11,917,015)<span></span>
</td>
<td class="num">(11,917,015)<span></span>
</td>
<td class="num">(360,177)<span></span>
</td>
<td class="num">(12,277,192)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Debt converted to equity</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">2,635,673<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,635,712<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,635,712<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Debt converted to equity, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">392,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance, value at Dec. 31, 2025</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 575<span></span>
</td>
<td class="nump">$ 127,201,691<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (3,686,544)<span></span>
</td>
<td class="num">$ (109,953,728)<span></span>
</td>
<td class="nump">$ 13,561,994<span></span>
</td>
<td class="nump">$ 506,163<span></span>
</td>
<td class="nump">$ 14,068,157<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2025</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,746,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_SharesIssuedForConversionOfDebtShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_SharesIssuedForConversionOfDebtShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_SharesIssuedForConversionOfDebtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_SharesIssuedForConversionOfDebtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_SharesIssuedForInvestmentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_SharesIssuedForInvestmentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_SharesIssuedForInvestmentValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_SharesIssuedForInvestmentValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_SharesIssuedInConnectionWithSEPAShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_SharesIssuedInConnectionWithSEPAShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_SharesIssuedInConnectionWithSEPAValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_SharesIssuedInConnectionWithSEPAValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_StockIssuedDuringPeriodSharePreferredShareConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_StockIssuedDuringPeriodSharePreferredShareConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_StockIssuedDuringPeriodSharesOfPreferredShareOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_StockIssuedDuringPeriodSharesOfPreferredShareOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_StockIssuedDuringPeriodSharesPrefundedWarrantsExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_StockIssuedDuringPeriodSharesPrefundedWarrantsExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_StockIssuedDuringPeriodValueOfInvestmentsAssignmentAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_StockIssuedDuringPeriodValueOfInvestmentsAssignmentAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_StockIssuedDuringPeriodValueOfPreferredShareOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_StockIssuedDuringPeriodValueOfPreferredShareOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_StockIssuedDuringPeriodValuePreferredShareConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_StockIssuedDuringPeriodValuePreferredShareConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_StockIssuedDuringPeriodValuePrefundedWarrantsExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_StockIssuedDuringPeriodValuePrefundedWarrantsExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_StockIssuedDuringPeriodValuePurchaseOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_StockIssuedDuringPeriodValuePurchaseOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_StockIssuedDuringPeriodValueWarrantsIssuedForCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_StockIssuedDuringPeriodValueWarrantsIssuedForCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_WarrantsIssuedInExchangeForSubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_WarrantsIssuedInExchangeForSubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 42: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 47: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 51: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 52: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 54: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 55: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (12,277,192)<span></span>
</td>
<td class="num">$ (10,877,412)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,181,212<span></span>
</td>
<td class="nump">1,000,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Right of use asset amortization</a></td>
<td class="nump">41,385<span></span>
</td>
<td class="nump">37,788<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">545,635<span></span>
</td>
<td class="nump">216,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncome', window );">Non-cash revenue</a></td>
<td class="num">(1,333,045)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash', window );">Stock based compensation</a></td>
<td class="nump">1,215,692<span></span>
</td>
<td class="nump">1,104,978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Shares issued for non-employee services</a></td>
<td class="nump">3,829,220<span></span>
</td>
<td class="nump">1,329,276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_WarrantsIssuedForServices', window );">Warrants issued for services</a></td>
<td class="nump">824,295<span></span>
</td>
<td class="nump">8,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Change in fair value of derivative liability</a></td>
<td class="num">(906,430)<span></span>
</td>
<td class="nump">539,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of derivative liability warrants</a></td>
<td class="num">(191,625)<span></span>
</td>
<td class="num">(198,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_LossOnSharesIssuedForConversionOfDebt', window );">Loss on shares issued for conversion of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">77,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">(Gain) loss on extinguishment of debt</a></td>
<td class="num">(159,035)<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Forgiveness of interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">37,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Unrealized loss on investments</a></td>
<td class="nump">163,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized gain on marketable securities</a></td>
<td class="num">(76,596)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>(Increase) decrease in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable', window );">Interest receivable</a></td>
<td class="num">(7,348)<span></span>
</td>
<td class="num">(234,742)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid assets</a></td>
<td class="num">(473,497)<span></span>
</td>
<td class="num">(118,472)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAbstract', window );"><strong>Increase (decrease) in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(381,012)<span></span>
</td>
<td class="num">(149,935)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(440,889)<span></span>
</td>
<td class="nump">180,934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Right of use liability</a></td>
<td class="num">(42,306)<span></span>
</td>
<td class="num">(38,047)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="num">(115,000)<span></span>
</td>
<td class="nump">235,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">NET CASH USED IN OPERATING ACTIVITIES</a></td>
<td class="num">(8,603,036)<span></span>
</td>
<td class="num">(6,649,281)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">NET CASH USED IN INVESTING ACTIVITIES</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from notes payable</a></td>
<td class="nump">990,000<span></span>
</td>
<td class="nump">1,850,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfNotesPayable', window );">Repayment of notes payable</a></td>
<td class="num">(218,750)<span></span>
</td>
<td class="num">(650,969)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_SharesIssuedForSepa', window );">Shares issued for SEPA</a></td>
<td class="nump">2,958,848<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Shares issued for cash</a></td>
<td class="nump">4,558,455<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Warrants issued for cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Pre-funded warrants exercise</a></td>
<td class="nump">900<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Preferred stock offering</a></td>
<td class="nump">5,455,000<span></span>
</td>
<td class="nump">3,914,001<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">NET CASH PROVIDED BY FINANCING ACTIVITIES</a></td>
<td class="nump">13,744,453<span></span>
</td>
<td class="nump">5,713,032<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">NET INCREASE (DECREASE) IN CASH</a></td>
<td class="nump">5,141,417<span></span>
</td>
<td class="num">(936,249)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AT BEGINNING OF PERIOD</a></td>
<td class="nump">532,885<span></span>
</td>
<td class="nump">1,469,134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AT END OF PERIOD</a></td>
<td class="nump">5,674,302<span></span>
</td>
<td class="nump">532,885<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL CASH FLOW DISCLOSURES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">8,772<span></span>
</td>
<td class="nump">8,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Taxes paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>SUPPLEMENTAL NON-CASH DISCLOSURES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_SubscriptionsReceivable', window );">Subscriptions receivable</a></td>
<td class="nump">3,686,544<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_SharesIssuedForConversionOfDebt', window );">Shares issued for the conversion of debt</a></td>
<td class="nump">2,635,712<span></span>
</td>
<td class="nump">951,684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_SharesIssuedForInvestment', window );">Shares issued for investment</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_LossOnSharesIssuedForConversionOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_LossOnSharesIssuedForConversionOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_SharesIssuedForConversionOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_SharesIssuedForConversionOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_SharesIssuedForInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_SharesIssuedForInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_SharesIssuedForSepa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_SharesIssuedForSepa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_SubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_SubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_WarrantsIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_WarrantsIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense (reversal of expense) for employee benefits and share-based payment arrangement. Includes, but is not limited to, pension, other postretirement, postemployment and termination benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount due to the entity in the form of unpaid interest and dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income or gain included in net income that result in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (11,917,015)<span></span>
</td>
<td class="num">$ (10,680,452)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Award Timing Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardsCloseToMnpiDiscTable', window );"><strong>Awards Close in Time to MNPI Disclosures [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMnpiDiscTextBlock', window );">Award Timing MNPI Disclosure</a></td>
<td class="text">We <span id="xdx_90A_eecd--AwardTmgMnpiCnsdrdFlag_dbT_c20250101__20251231_zHHWEzS4pidc">do
not grant equity awards in anticipation of the release of material nonpublic information</span>&#160;that is likely to result in
changes to the price of our common stock, and do not time the public release of such information based on award grant dates. During
the last completed fiscal year, we have not made awards to any named executive officer or director during the period beginning four
business days before and ending one business day after the filing of a period report on Form 10-Q or Form 10-K or the filing or
furnishing of a current report on Form 8-K, and we have not timed the disclosure of material nonpublic information for the purpose
of affecting the value of executive compensation.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMnpiCnsdrdFlag', window );">Award Timing MNPI Considered</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMnpiCnsdrdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMnpiCnsdrdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMnpiDiscTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMnpiDiscTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardsCloseToMnpiDiscTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardsCloseToMnpiDiscTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Daniel Yerace<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Vice President of Operations and a member of our Board of Directors<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">May 21, 2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">February 11, 2027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">20,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><b>Cybersecurity Risk Management and Strategy</b><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_900_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20250101__20251231_zhkbzupmLsk4">The Company <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_901_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20250101__20251231_zx4SGCcPUjGk">recognizes</span> the
importance of cybersecurity in safeguarding its information systems and data.</span> Our cybersecurity measures primarily rely on standard security
protocols provided by Microsoft Outlook and OneDrive, which include encryption, multi-factor authentication, and access controls to protect
against unauthorized access and data breaches.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Given the evolving nature
of cybersecurity threats, the Company monitors its systems for potential vulnerabilities and relies on <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_905_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20250101__20251231_zoNQFsm9lYoi">third-party</span> security updates and
patches to mitigate risks. While we believe our current measures are appropriate for our operations, we acknowledge that no security system
is entirely immune from potential threats, including phishing attacks, malware, ransomware, and unauthorized access.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">The Company <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_901_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20250101__20251231_zx4SGCcPUjGk">recognizes</span> the
importance of cybersecurity in safeguarding its information systems and data.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><b>Governance and Oversight</b><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_903_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20250101__20251231_zaAysTbebyl9">The Company&#8217;s executive
management is responsible for overseeing cybersecurity risks and ensuring compliance with our security practices. At this time, the Company
does not have a dedicated cybersecurity team but relies on its IT service providers and Microsoft&#8217;s security framework for system
protection and incident response.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Potential Risks and Impact</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_903_ecyd--CybersecurityRiskRoleOfManagementTextBlock_c20250101__20251231_zgpzdqv5fpu6">Despite these measures, the
Company may be vulnerable to cybersecurity incidents that could disrupt operations, compromise sensitive data, or result in financial
or reputational harm. Any material cybersecurity incident would be assessed and disclosed as necessary.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">The Company&#8217;s executive
management is responsible for overseeing cybersecurity risks and ensuring compliance with our security practices. At this time, the Company
does not have a dedicated cybersecurity team but relies on its IT service providers and Microsoft&#8217;s security framework for system
protection and incident response.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text">Despite these measures, the
Company may be vulnerable to cybersecurity incidents that could disrupt operations, compromise sensitive data, or result in financial
or reputational harm. Any material cybersecurity incident would be assessed and disclosed as necessary.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION</a></td>
<td class="text"><p id="xdx_803_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zLNR17dqahnh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 1 &#8211; <span id="xdx_829_ziS0hz4nzVB6">DESCRIPTION OF BUSINESS
AND BASIS OF PRESENTATION</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Nature of Business</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>General</i>. Coeptis Therapeutics Holdings,
Inc. (&#8220;Coeptis&#8221;, the &#8220;Company&#8221; or &#8220;we&#8221; or &#8220;our&#8221;) was originally incorporated in the British
Virgin Islands on November 27, 2018, under the name Bull Horn Holdings Corp. On October 27, 2022, Bull Horn Holdings Corp. domesticated
from the British Virgin Islands to the State of Delaware. On October 28, 2022, in connection with the closing of the Merger, we changed
our corporate name from Bull Horn Holdings Corp. to &#8220;Coeptis Therapeutics Holdings, Inc.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>The Merger Transaction</i>. On October 28,
2022, a wholly owned subsidiary of Bull Horn Holdings Corp., merged with and into Coeptis Therapeutics, Inc., with Coeptis Therapeutics,
Inc. as the surviving corporation of the Merger. As a result of the Merger, we acquired the business of Coeptis Therapeutics, Inc., which
now continues to operate as a wholly owned subsidiary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>About the Company&#8217;s Subsidiaries</i>.
We are now a holding company that currently operates through our direct and indirect subsidiaries SNAP Biosciences, Inc. and GEAR Therapeutics,
Inc., which are majority owned, and Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc. and Coeptis Pharmaceuticals, LLC, which
are wholly owned.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Coeptis is a biopharmaceutical and technology
company. The biopharmaceutical division focuses on developing innovative cell therapy platforms for cancer, autoimmune, and infectious
diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its cutting-edge research and development efforts.
The technology division&#160;focuses on enhancing operational capabilities through advanced technologies. This division features AI-powered
marketing software and robotic process automation tools designed to optimize business processes and improve overall efficiency.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis of Presentation &#8211; </b>The
accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the
United States of America (&#8220;GAAP&#8221;) for financial information and with the instructions to Form 10-K and Rule 8-03 of
Regulation S-X. Accordingly, they include all of the information and notes required by GAAP for complete financial statements. In
the opinion of the Company&#8217;s management, any adjustments contained in the accompanying consolidated financial statements are
of a normal recurring nature, and are necessary to fairly present the financial position and operating results of the Company as of
December 31, 2025 and 2024 and for the years then ended.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Principles of Consolidation </b>&#8211;
The accompanying consolidated financial statements include the accounts of Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals,
Inc., Coeptis Pharmaceuticals, LLC, SNAP Biosciences, Inc., and GEAR Therapeutics, Inc. All material intercompany accounts, balances
and transactions have been eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Reverse Stock Split </b>&#8211; On
December 31, 2024, the Company completed a <span id="xdx_907_eus-gaap--StockholdersEquityReverseStockSplit_c20241201__20241231_zTgKS5QXmvQ5" title="Reverse stock split">20-1 reverse stock split</span> of its issued and outstanding common stock. As a result of the
reverse stock split, every 20 shares of issued and outstanding common stock were automatically combined into one share, with no
change in the par value per share. Fractional shares resulting from the reverse stock split were rounded to the nearest whole share.
The reverse stock split has been retrospectively applied to all share and per-share amounts presented in these consolidated
financial statements and accompanying notes for all periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_809_eus-gaap--SignificantAccountingPoliciesTextBlock_zYg7jG2CuTT" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2 &#8211; <span id="xdx_820_zHeiZMHAMR31">SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zGm6yV3zsErd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86F_zyoHTINo5VH3">Cash</span></b> &#8211; For purposes of the consolidated
statements of cash flows, the Company considers all highly liquid investments purchased with maturities of three months or less to be
cash equivalents. At times, balances of cash and cash equivalents at financial banking institutions exceeded the federally insured limit
of $250,000. Uninsured balances were $<span id="xdx_903_eus-gaap--CashUninsuredAmount_iI_c20251231_zN2x1dAe3aXg" title="Cash uninsured amount">5,424,302</span> and $<span id="xdx_90B_eus-gaap--CashUninsuredAmount_iI_c20241231_zoFGPqjfmOD4" title="Cash uninsured amount">282,885</span> at December 31, 2025 and 2024, respectively. The Company regularly monitors
the financial condition of the institution in which it has depository accounts and believes the risk of loss is minimal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zbI43jjYfaok" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_862_zTI2mm429brg">Property and Equipment</span></b> &#8211; Fixed assets
are stated at cost and depreciation is computed using the straight-line method for financial statement purposes. For the years ended December
31, 2025 and 2024, depreciation expense totaled $<span id="xdx_902_eus-gaap--Depreciation_pp0p0_c20250101__20251231_z1tZWfPnEmg2" title="Depreciation expense">587</span>&#160;and $<span id="xdx_900_eus-gaap--Depreciation_pp0p0_c20240101__20241231_zToUtw0uIgXc" title="Depreciation expense">845</span> respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_84B_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zPZuzK2istNa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86D_zhEsujK9A1Q6">Intangible Assets</span></b> &#8211; The Company records
intangible assets at cost and evaluates them for impairment in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;)
Accounting Standards Codification (&#8220;ASC&#8221;) 350, <i>Intangibles &#8211; Goodwill and Other. </i>Intangibles are being amortized
using the straight-line method over estimated useful lives of between two and forty years. The Company recorded intangible assets of $<span id="xdx_905_eus-gaap--FinitelivedIntangibleAssetsAcquired1_c20250101__20251231__us-gaap--AssetAcquisitionAxis__custom--NexGenAIMember_zx0iJDtPiIvc" title="Intangible assets acquired">361,250</span>
and $<span id="xdx_90F_eus-gaap--FinitelivedIntangibleAssetsAcquired1_c20240101__20241231__us-gaap--AssetAcquisitionAxis__custom--NexGenAIMember_zr7CYzFlfrek" title="Intangible assets acquired">541,875</span> as of December 31, 2025 and December 31, 2024, respectively, related to the acquired assets of NexGenAI Affiliates Network
Platform (&#8220;NexGenAI&#8221;), which contains AI-powered marketing software and robotic process automation capabilities. See Note
14, Intangible Assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_840_eus-gaap--MarketableSecuritiesPolicy_zYcevolqQtzf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_862_zgGq4RzAIRql">Investments
and Marketable Securities</span> </b>&#8211; The Company classifies its investments and marketable securities in accordance with ASC 320, <i>Investments
&#8211; Debt and Equity Securities</i>, and ASC 321, <i>Investments &#8211; Equity Securities</i>, as applicable. Investments in
equity securities with readily determinable fair values are measured at fair value, with unrealized gains and losses recognized in
net income. For equity securities without readily determinable fair values, the Company applies the measurement alternative,
recording these investments at cost, adjusted for impairments or observable price changes from transactions involving similar
securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Marketable securities are categorized as trading
securities and are thus marked to market and stated at fair value. Fair value is determined using the quoted closing bid prices and is
recorded as a Level&#160;1 asset. Realized gains and losses on marketable securities are recognized as incurred in the consolidated statements
of operations. Net changes in unrealized gains and losses are reported in the consolidated statements of operations in the current period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_841_eus-gaap--LesseeLeasesPolicyTextBlock_zZd5E69YaC1l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_861_z0y9vDd2f1ad">Leases</span> </b>&#8211; The Company accounts for
leases in accordance with ASC 842, <i>Leases</i>. At lease commencement, the Company recognizes a right-of-use (&#8220;ROU&#8221;) asset
and a corresponding lease liability based on the present value of future lease payments. Lease liabilities are measured using the Company&#8217;s
incremental borrowing rate if the implicit rate is not readily determinable. ROU assets include initial direct costs and prepaid lease
payments and are reduced for lease incentives received.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_zGhipFppvmqj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_862_zTqBTUr2ay9b">Research
and Development</span> &#8211; </b>Research and development costs are expensed when incurred. During the years ended December 31,
2025 and 2024, research and development expenses totaled $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20250101__20251231_zBA2qHuPDBA1" title="Research and development expenses">1,277,150</span>
and $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240101__20241231_zkmiNA8JRxJb" title="Research and development expenses">2,331,548</span>,
respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_84A_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zXWVvjClM0Hk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_865_zugKK9EiCuYd">Impairment
of Long-Lived Assets</span> &#8211; </b>The Company&#8217;s property and equipment and other non-current assets are reviewed
annually for possible impairment when events or changes in circumstances indicate that the carrying amount may not be recoverable.
An impairment loss would be recognized if and when the estimated future cash flows expected to result from the use of the asset and
its eventual disposition is less than its carrying amount. There was&#160;<span id="xdx_90C_eus-gaap--AssetImpairmentCharges_do_c20250101__20251231_zKtzAEblcpXd" title="Asset impairment charges"><span id="xdx_901_eus-gaap--AssetImpairmentCharges_do_c20240101__20241231_zEZpMcINsYf4">no</span></span>
impairment recognized for the years ended December 31, 2025 and 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_84C_eus-gaap--DerivativesPolicyTextBlock_zuMnkgjuA1yc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_864_znIkXgOSEJe2">Derivative Liability Warrants</span> &#8211; </b>The
Company accounts for the Public Warrants and Private Placement Warrants (the &#8220;Warrants&#8221;) in accordance with the guidance contained
in ASC 815-40, <i>Derivatives and Hedging</i>, under which the Warrants do not meet the criteria for equity treatment and must be recorded
as liabilities. Accordingly, the Company classifies the Warrants as liabilities at their fair value and adjusts the Warrants to fair value
in each respective reporting period. This liability is subject to re-measurement at each consolidated balance sheet date until the Warrants
are exercised, and any change in fair value is recognized in the consolidated statements of operations. The Private Placement Warrants
and the Public Warrants for periods where no observable traded price was available are valued using a binomial lattice simulation model.
For periods subsequent to the detachment of the Public Warrants from the Units, the Public Warrant quoted market price was used as the
fair value as of each relevant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_844_eus-gaap--DebtPolicyTextBlock_zPHbxdJkHdZj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_866_z9JMzbYp8Og5">Convertible Debt</span></b> &#8211; The Company accounts
for convertible debt in accordance with ASC 470-20, <i>Debt &#8211; Debt with Conversion and Other Options</i>. Convertible debt instruments
are evaluated at issuance to determine whether they contain embedded features that require bifurcation as derivatives or equity components.
If the embedded conversion feature meets the criteria for derivative accounting under ASC 815, <i>Derivatives and Hedging</i>, it is bifurcated
and recorded separately at fair value, with subsequent changes in fair value recognized in earnings. Upon conversion or repurchase of
convertible debt, the Company recognizes a gain or loss in accordance with ASC 470-20 and ASC 470-50, <i>Debt Modifications and Extinguishments</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zHAAha3GsZn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_865_z3u6TYbMNYnj">Income Taxes</span> </b>&#8211; Income taxes are provided
for the tax effects of transactions reported in the consolidated financial statements and consist of taxes currently due plus deferred
taxes related primarily to temporary differences between reporting of income and expenses for financial reporting purposes and income
tax purposes. The deferred tax assets and liabilities represent the future tax return consequences of those differences, which will either
be taxable or deductible when the assets and liabilities are recovered or settled. Deferred taxes also are recognized for operating losses
that are available to offset future federal income taxes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Income Taxes Topic of FASB ASC clarifies the
accounting and reporting for uncertainties in income tax law within subtopic FASB ASC 740-10-25-5. The guidance prescribes a comprehensive
model for the financial statement recognition, measurement, presentation, and disclosure of uncertain tax positions taken or expected
to be taken in income tax returns. Management believes that there is&#160;<span id="xdx_90C_eus-gaap--UnrecognizedTaxBenefits_iI_pp0p0_do_c20251231_zzgyalr1YRb1" title="Uncertain tax positions"><span id="xdx_90C_eus-gaap--UnrecognizedTaxBenefits_iI_pp0p0_do_c20241231_z9pJ5W7wdqmi" title="Uncertain tax positions">no</span></span>&#160;liability related to uncertain tax positions during
the years ended December 31, 2025 and 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_84D_eus-gaap--UseOfEstimates_zGhCno2pOdh6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86C_zicXUShi27md">Use of Estimates</span> &#8211; </b>The preparation
of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements
and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_842_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zkXNemGlANOk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86B_zWfWKjGsO9M">Reclassification</span> </b>&#8211; The Company reclassified
certain amounts of total stockholders&#8217; equity &#8211; noncontrolling interests, net loss attributable to non-controlling interests,
and accumulated deficit from prior periods. These presentation changes did not affect total stockholders&#8217; equity or net loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_84C_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zRj8znYSaTXd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86D_zOCJE3Hv5If3">Employee and Non-Employee Share-Based Compensation</span>
</b>&#8211; The Company applies ASC 718-10,&#160;<i>Share-Based Payment</i>, which requires the measurement and recognition of compensation
expenses for all share-based payment awards made to employees and directors including employee stock option equity awards issued to employees
and non-employees based on estimated fair values.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 718-10 requires companies to estimate the
fair value of equity-based option awards on the date of grant using an option-pricing model. The fair value of the award is recognized
as an expense on a straight-line basis over the requisite service periods in the Company&#8217;s consolidated statements of operations.
The Company recognizes share-based award forfeitures as they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company estimates the fair value of granted
option equity awards using a Black-Scholes option pricing model. The option-pricing model requires a number of assumptions, of which the
most significant are share price, expected volatility and the expected option term (the time from the grant date until the options are
exercised or expire). Expected volatility is estimated based on volatility of the Company. The Company has historically not paid dividends
and has no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds
with an equivalent term. The expected option term is calculated for options granted to employees and directors using the &#8220;simplified&#8221;
method. Changes in the determination of each of the inputs can affect the fair value of the options granted and the results of operations
of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zOOWsmECMEZ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_860_zNI8i6I7Rtza"><b>Recent
Accounting Pronouncements</b></span><b>&#160;</b>&#8211; During the years ended December 31, 2025 and 2024, there were new accounting
pronouncements issued by the FASB. Each of these pronouncements, as applicable, including Accounting Standards Update (&#8220;ASU&#8221;)
2023-07, <i>Segment Reporting</i>, has been or will be adopted by the Company. Please see Note 15, Segment Reporting. Management does
not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company&#8217;s consolidated
financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_84E_eus-gaap--RevenueRecognitionPolicyTextBlock_z4z3tzepn6Fd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86A_zwA8j2PfPnfk">Revenue Recognition</span></b>&#160;&#8211; The Company
recognizes revenue in accordance with ASC Topic 606, <i>Revenue from Contracts with Customers</i> (&#8220;ASC 606&#8221;) to depict the
transfer of control to the Company&#8217;s customers in an amount reflecting the consideration to which the Company expects to be entitled.
The Company determines revenue recognition through the following steps:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 6%"><span style="font-size: 10pt">i.</span></td>
    <td style="width: 91%; text-align: justify"><span style="font-size: 10pt">Identification of the contract, or contracts, with a customer</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">ii.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Identification of the performance obligations in the contract</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">iii.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Determination of the transaction price</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">iv.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Allocation of the transaction price to the performance obligations in the contract</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">v.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Recognition of revenue, when, or as, the company satisfies the performance obligations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under ASC 606, revenue is recognized when control
of promised goods and services is transferred to customers. A performance obligation is a contractual promise to transfer a distinct good
or service to the customer and is the unit of account under ASC 606. The transaction price of a contract is allocated to distinct performance
obligations and recognized as revenue when or as the performance obligations are satisfied.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company generates revenue from its customers
by 1) performing data research for its customers and delivering advertising campaigns via cold emails and social media sites, and 2) providing
webinars for its customers to a targeted business-to-business audience. The fee for these services is based on observable prices explicitly
negotiated between the Company and the customer. The Company recognizes revenue at the point in time when the good or service is delivered
to the customer, which occurs upon delivery of the advertising campaign or webinar and there is a transfer of control to the customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2025, revenues
from delivering advertising campaigns via cold emails and social media sites were recognized from six customers who accounted for <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20251231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SixCustomersMember__srt--ProductOrServiceAxis__custom--AdvertisingCampaignsMember_zLX4oEOfVmxh" title="Concentration risk percentage">100</span>%
of this revenue. Revenue was recognized at the point of delivery to the customers in the amount of $<span id="xdx_90D_eus-gaap--Revenues_c20250101__20251231__srt--ProductOrServiceAxis__custom--AdvertisingCampaignsMember_zT74wjk0aKHa" title="Revenues">1,250,545</span>. As of December 31, 2025,
the Company has recorded customer deposits in the amount of $<span id="xdx_902_eus-gaap--DeferredRevenueCurrent_iI_c20251231__srt--ProductOrServiceAxis__custom--AdvertisingCampaignsMember_z60oqDcquob1" title="Customer deposits">599,455</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2025, revenues
from delivering webinar services were recognized from three customers who accounted for <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20251231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThreeCustomersMember__srt--ProductOrServiceAxis__custom--WebinarServicesMember_zjRu100sQNS4" title="Concentration risk percentage">100</span>% of this revenue. Revenue was recognized at
the point of delivery to the customers in the amount of $<span id="xdx_90E_eus-gaap--Revenues_c20250101__20251231__srt--ProductOrServiceAxis__custom--WebinarServicesMember_zsA6a78dhLyf" title="Revenues">112,500</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zAsU6WAQ4KI8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_865_z2FQOuGhQvN9">Earnings Per Share</span></b> &#8211; Basic earnings
per share (or loss per share), is computed by dividing the earnings (loss) for the period by the weighted average number of common stock
shares outstanding for the period. Diluted earnings per share reflects potential dilution of securities by including other potentially
issuable shares of common stock, including shares issuable upon conversion of convertible securities or exercise of outstanding stock
options and warrants, in the weighted average number of common shares outstanding for the period. Therefore, because including shares
issuable upon conversion of convertible securities and/or exercise of outstanding options and warrants would have an anti-dilutive effect
on the loss per share, only the basic earnings (loss) per share is reported in the accompanying consolidated financial statements. The
Company does not have other potentially issuable shares of stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following potential common shares would have
an antidilutive effect on loss per share:</p>

<table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zGWihs13k28a" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt; color: White"><b><span id="xdx_8BB_zFQw89wo8x2c" style="display: none">Schedule of antidilutive shares</span></b></span></td>
    <td>&#160;</td>
    <td colspan="6" style="text-align: center"><span style="font-size: 10pt"><b>Years ended December 31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2025</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2024</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 68%"><span style="font-size: 10pt">Warrants</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zxPQLg8XFKHf" style="width: 13%; text-align: right" title="Antidilutive shares"><span style="font-size: 10pt">945,105</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_ziMaBdHFS59l" style="width: 13%; text-align: right" title="Antidilutive shares"><span style="font-size: 10pt">1,399,316</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Stock options</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zwFiS2Xbflk5" style="text-align: right" title="Antidilutive shares"><span style="font-size: 10pt">437,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zLzpYEY8VEh9" style="text-align: right" title="Antidilutive shares"><span style="font-size: 10pt">279,625</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Convertible notes payable</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleNotesPayableMember_zpAXF3MhJOB7" style="text-align: right" title="Antidilutive shares"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleNotesPayableMember_zdFZzQI3BU8e" style="text-align: right" title="Antidilutive shares"><span style="font-size: 10pt">406,629</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Preferred stock</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--PreferredStockMember_zHdONONx2RV8" style="border-bottom: black 1pt solid; text-align: right" title="Antidilutive shares"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--PreferredStockMember_zKW6pQqwpZ0h" style="border-bottom: black 1pt solid; text-align: right" title="Antidilutive shares"><span style="font-size: 10pt">815,000</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Total</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231_z2Df7bPawez9" style="border-bottom: black 2.25pt double; text-align: right" title="Antidilutive shares"><span style="font-size: 10pt">1,382,105</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231_ziJtf4fsJ3G" style="border-bottom: black 2.25pt double; text-align: right" title="Antidilutive shares"><span style="font-size: 10pt">2,900,570</span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p id="xdx_84B_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_z2gYXYVgQI29" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86D_zRxnqmvvUvna">Going Concern</span> &#8211;</b> The accompanying
consolidated financial statements have been prepared in conformity with GAAP which contemplate continuation of the Company as a going
concern, which is dependent upon the Company&#8217;s ability to obtain sufficient financing or establish itself as a profitable business.
As of December 31, 2025, the Company had an accumulated deficit of $<span id="xdx_90C_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20251231_zNeMP0RaPasd" title="Accumulated deficit">109,953,728</span>, and for the year ended December 31, 2025, the Company
had a net loss of $<span id="xdx_90F_eus-gaap--ProfitLoss_iN_di_c20250101__20251231_zwJw9pkfv7x" title="Net loss">12,277,192</span>. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern.
Management&#8217;s plans with respect to operations include raising additional capital through sales of equity or debt securities as may
be necessary to pursue its business plans and sustain operations until such time as the Company can achieve profitability. Management
believes that additional financing as necessary will result in improved operations and cash flow. However, there can be no assurance that
management will be successful in obtaining additional funding or in attaining profitable operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zHgRczn8lra3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_863_zGDiDX0QL2Ag">Fair Value of Financial Instruments and Measurements</span></b>
&#8211; The Company measures certain financial instruments at fair value in accordance with ASC 820, <i>Fair Value Measurement</i>, for
its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets
and liabilities that are re-measured and reported at fair value at least annually. The fair value of the Company&#8217;s financial assets
and liabilities reflects management&#8217;s estimate of amounts that the Company would have received in connection with the sale of the
assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement
date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs
(market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market
participants would price assets and liabilities).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 820 establishes a three-level fair value hierarchy
that prioritizes inputs used to measure fair value:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 1 &#8211; Quoted prices in active markets
for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability
occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 2 &#8211; Observable inputs other than Level
1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical
assets or liabilities in markets that are not active.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 3 &#8211; Unobservable inputs based on our
assessment of the assumptions that market participants would use in pricing the asset or liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The estimated fair value of cash, interest receivable,
subscription receivable, and notes payable approximate their carrying amounts due to the short-term nature of these instruments.</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CO-DEVELOPMENT OPTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">CO-DEVELOPMENT OPTIONS</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--MergersAcquisitionsAndDispositionsDisclosuresTextBlock_zUmKiiSvazI6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 3 &#8211; <span id="xdx_82C_zdWP03Gd12j9">CO-DEVELOPMENT
OPTIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2021, the
Company and Vy-Gen-Bio, Inc. (&#8220;Vy-Gen&#8221;) entered into agreements to jointly develop and commercialize two Vy-Gen product candidates,
CD38-GEAR-NK and CD38-Diagnostic (the &#8220;CD38 Assets&#8221;). The Company paid $<span id="xdx_909_eus-gaap--PaymentsToAcquireProductiveAssets_pp0p0_c20210101__20211231__srt--ProductOrServiceAxis__custom--CD38AssetsMember__srt--CounterpartyNameAxis__custom--VyGenMember_zhn892gwZbNe">1,750,000</span>
and issued promissory notes totaling $<span id="xdx_90A_eus-gaap--OtherLongTermNotesPayable_iI_pp0p0_c20211231__srt--ProductOrServiceAxis__custom--CD38AssetsMember__srt--CounterpartyNameAxis__custom--VyGenMember_zla4R5JVRN5f">3,250,000</span>
to Vy-Gen in accordance with the agreements. The Company paid a total of $<span id="xdx_90B_eus-gaap--RepaymentsOfLongTermDebt_pp0p0_c20210101__20211231__srt--ProductOrServiceAxis__custom--CD38AssetsMember__srt--CounterpartyNameAxis__custom--VyGenMember_ziN8x23sl6q2">1,500,000</span>
toward the promissory notes, leaving $<span id="xdx_90A_eus-gaap--OtherLongTermNotesPayable_iI_pp0p0_c20211231__srt--ProductOrServiceAxis__custom--CD38AssetsMember_zQK3Ld9vjc6i">1,750,000</span>
outstanding at December 31, 2021. The collaboration arrangement provides the right for the Company to participate, under the direction
of a joint steering committee, in the development and commercialization of the CD38 Assets and a 50/50 profit share, with the profit
share subject to contingent automatic downward adjustment up to 25% upon an event of default in connection with the promissory notes.
The Company capitalized $<span id="xdx_90D_eus-gaap--CapitalizedContractCostGross_iI_pp0p0_c20211231__srt--ProductOrServiceAxis__custom--CD38AssetsMember__srt--CounterpartyNameAxis__custom--VyGenMember_zGhW3EsItZhh">5,000,000</span>
to be amortized over a five-year period in which the CD38 Assets are expected to contribute to future cash flows. The promissory notes
were paid in full in 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company made certain judgements as the basis
in determining the accounting treatment of these options. The CD38 Assets represent a platform technology and a diagnostic tool which
have multiple applications and uses. Both projects are intended to be used in more than one therapy or diagnostic option. For example,
GEAR-NK is a technology which allows for the gene editing of human natural killer cells, so that these cells can no longer bind and be
destroyed by targeted monoclonal antibody treatments. The GEAR-NK technology can be modified to work concomitantly with many different
monoclonal antibody treatments in which there are currently over 100 approved by the FDA. Anti- CD38 is only the first class of monoclonal
antibody treatments being developed under the GEAR-NK platform. Therefore, the pursuit of FDA approval for the use of CD38 assets for
at least one indication or medical device approval is at least reasonably expected. Further, as the diagnostic asset may be used as an
in vitro technology, it could be classified as a medical device, and therefore toxicity studies would not be a contingency to be resolved
before reasonably establishing future value assumptions. In addition, there is perceived value in the CD38 assets, based on publicly disclosed
current business deals in cell therapies, the developing market for these innovative technologies, and current interest from third parties
in these technologies. The Company may sell or license its right to another party, with the written consent of Vy-Gen, which cannot be
unreasonably withheld. Furthermore, the Company believes that any negative results from ongoing development of a single therapy or use,
would not result in abandoning the project. Given these considerations, The Company has determined that these options have alternative
future use and should be recorded as assets pursuant to ASC 730-10-25-2,&#160;<i>Research and Development</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Related to the joint development, the Company,
under the direction of the joint steering committee, is assessing market opportunities, intellectual property protection, and potential
regulatory strategies for the CD38 Assets. Vy-Gen is responsible for development activities conducted and overseen by the scientists at
Karolinska Institute. The agreement does not currently require additional payments for research and development costs by the Company and
no additional payments are required upon development or regulatory milestones.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2025, the Company reached an
agreement with Vy-Gen-Bio, Inc. (&#8220;Vy-Gen&#8221;) to successfully license the exclusive worldwide development and
commercialization rights to the GEAR&#8482; (Gene Edited Antibody Resistant) Cell Therapy Platform, representing a first-in-class
approach to modifying potent cancer-targeting immune cells to optimize the likelihood of deep remission in patients with hematologic
malignancies and other cancers. Coeptis had previously held limited co-development rights to GEAR. As part of this exclusive GEAR
license agreement with VyGen-Bio, Inc., the Company paid a total of $<span id="xdx_90B_eus-gaap--ProceedsFromLicenseFeesReceived_c20250101__20251231_zq5qHCbTx006" title="License fees">400,000</span>
for license fees during the year ended December 31, 2025, which the company recorded as research and development expense, and
committed to pay other performance-based fees, milestone and royalty payments in 2026 and beyond.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The total gross capitalized Co-Development options
recorded was $<span id="xdx_905_eus-gaap--CapitalizedContractCostGross_iI_c20251231__us-gaap--TransactionTypeAxis__custom--CoDevelopmentRightsMember_zvWmd5FhTOhe">5,291,667</span>,
with accumulated amortization of $<span id="xdx_905_eus-gaap--CapitalizedContractCostAccumulatedAmortization_iI_c20251231__us-gaap--TransactionTypeAxis__custom--CoDevelopmentRightsMember_z10CcT42P5x4">4,737,500</span>,
resulting in a net carrying amount of $<span id="xdx_901_eus-gaap--CapitalizedContractCostNet_iI_c20251231__us-gaap--TransactionTypeAxis__custom--CoDevelopmentRightsMember_z1RtaPabMlsj">554,167</span>
at December 31, 2025. Amortization expense related to the Co-Development options was $<span id="xdx_90D_eus-gaap--AdjustmentForAmortization_c20250101__20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CoDevelopmentOptionsMember_zzlSEuG7woY8">1,000,000</span>
and $<span id="xdx_901_eus-gaap--AdjustmentForAmortization_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CoDevelopmentOptionsMember_zF7JOQGp9bQi">1,000,000</span>
for the years ended December 31, 2025 and December 31, 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-20/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE NOTES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">CONVERTIBLE NOTES</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--LongTermDebtTextBlock_zw14nuNjyzWl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4 &#8211; <span id="xdx_82F_zMTTPpOvNtjf">CONVERTIBLE NOTES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2021, as part of a termination
of a license agreement with Purple, the Company issued a convertible note in the principal amount of $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20210930__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PurpleBioTechMember_zSy2DrcwK6tg" title="Debt face amount">1,500,000</span>
that was payable on or before the maturity date in February 2023, bearing interest of&#160;<span id="xdx_903_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210902__20210930__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PurpleBioTechMember_zwiC7IXy0cij" title="Interest rate">5</span>%
per annum and convertible in whole or in part at any time by Purple into shares of common stock of the Company. The conversion price
is $5 per share of common stock, subject to certain adjustments under such terms and conditions as agreed between the parties. The
Company may prepay the principal amount of the note plus accrued and unpaid interest at any time prior to the maturity date. On July
14, 2023, the Company and Purple executed an amendment to revise the note&#8217;s payment schedule, extending the maturity date to
March 31, 2024. On June 19, 2024, the Company and Purple executed another amendment to extend the maturity date to August 31, 2024.
The outstanding principal balance due under the convertible note at December 31, 2024 was $<span id="xdx_901_eus-gaap--ConvertibleNotesPayable_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PurpleBioTechMember_zWmLvOesANK9" title="Convertible notes outstanding">218,750</span>.
The Company paid the outstanding $<span id="xdx_907_eus-gaap--RepaymentsOfConvertibleDebt_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PurpleBioTechMember_zXFwlVwIH0tk" title="Repayment of convertible debt">218,750</span>
principal balance in full during the quarter ended March 31, 2025, and the convertible note is considered satisfied.</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2022, as a result of the Merger, the
Company entered into a convertible promissory note agreement with an unrelated third party in the principal amount of $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20221031__us-gaap--LongtermDebtTypeAxis__custom--Oct2022ConvertiblePromissoryNoteMember_zSkRzyUu5rlk">350,000</span> with no
accruing interest and was due on October 28, 2023 for legal services rendered to the Company. The noteholder may elect, in its sole discretion
upon written notice to the Company, at any time prior to, as of or following the maturity date, to require that all or any portion of
the principal amount not then repaid be converted, without any further action on the part of the noteholder, into shares of common stock,
par value $0.0001 per share. Upon full conversion of the remaining principal amount due, the note will, for all purposes be deemed cancelled
and all obligations shall be deemed paid in full. On October 27, 2023, a $<span id="xdx_907_eus-gaap--RepaymentsOfConvertibleDebt_c20231026__20231027__us-gaap--LongtermDebtTypeAxis__custom--Oct2022ConvertiblePromissoryNoteMember_zrDdEsRiJq41">200,000</span> payment was made, and on December 15, 2023, another
$<span id="xdx_906_eus-gaap--RepaymentsOfConvertibleDebt_c20231214__20231215__us-gaap--LongtermDebtTypeAxis__custom--Oct2022ConvertiblePromissoryNoteMember_zaW6IW60rs5d">50,000</span> payment was made. On June 25, 2024, the Company and the unrelated third party signed an amendment to the note that extended
the maturity date to July 31, 2024. The outstanding balance due under the convertible note at December 31, 2025 and December 31, 2024
was $<span id="xdx_907_eus-gaap--DebtDefaultLongtermDebtAmount_iI_c20251231__us-gaap--LongtermDebtTypeAxis__custom--Oct2022ConvertiblePromissoryNoteMember_zI4DwDX9lqal" title="Debt in default">100,000</span>. The note was in default as of December 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2023, the Company entered into an
unsecured convertible promissory note with an unrelated party in the principal amount of $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_c20241231__us-gaap--LongtermDebtTypeAxis__custom--Dec2023ConvertiblePromissoryNoteMember_z284HxJybYad" title="Principal amount"><span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20240423__20240424__us-gaap--LongtermDebtTypeAxis__custom--Dec2023ConvertiblePromissoryNoteMember_ziyG4OGqt0f7" title="Debt converted, amount converted">150,000</span></span> together with interest at <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20241231__us-gaap--LongtermDebtTypeAxis__custom--Dec2023ConvertiblePromissoryNoteMember_zywuMQyRyy1i" title="Debt instrument stated percentage">5</span>% and a maturity
date of <span id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_dd_c20240101__20241231__us-gaap--LongtermDebtTypeAxis__custom--Dec2023ConvertiblePromissoryNoteMember_zK50dl7BDZ48" title="Maturity period">June 30, 2024</span>. On April 24, 2024, the Company converted the note into shares of common stock, which satisfied the note in full.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 17, 2024, the Company entered into an
unsecured note agreement with a related party in the principal amount of $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20240417__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--ShortTermDebtTypeAxis__custom--April2024UnsecuredNoteMember_zqBWfPoPXTB7">500,000</span> together with interest at <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20240417__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--ShortTermDebtTypeAxis__custom--April2024UnsecuredNoteMember_z16q6mGGrKKa" title="Debt stated interest rate">10</span>%, with a maturity date
of <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_c20240416__20240417__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--ShortTermDebtTypeAxis__custom--April2024UnsecuredNoteMember_zsakMq0g5cU9" title="Debt maturity date">September 30, 2024</span>. The agreement is between the Company and an investment fund where the manager is a member of the Company&#8217;s
board of directors. On June 3, 2024, the Company and the related party agreed to convert the note agreement in full, both principal and
interest, to equity in connection with the Company&#8217;s Series A Preferred Stock offering. See Note 7, Capital Structure, for more
information on the Series A Preferred Stock offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Yorkville Convertible Notes</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 3, 2024, the Company entered into
an unsecured note agreement with an unrelated third party, YA II PN, LTD, a Cayman Islands exempt limited partnership
(&#8220;Yorkville&#8221;) in the principal amount of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20240103__us-gaap--ShortTermDebtTypeAxis__custom--YANote1Member_znxyJQMW0mR2" title="Debt face amount">1,500,000</span>
(the &#8220;YA Note-1&#8221;). YA Note-1 was issued with a 10% original issue discount. The original principal amount, together with
interest of&#160;<span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20240103__us-gaap--ShortTermDebtTypeAxis__custom--YANote1Member_z68lUeJn1Ty" title="Interest rate">8</span>%,
was payable by the Company on March 15, 2024, and was extended to July 31, 2024. The note had an outstanding principal balance of
$<span id="xdx_901_eus-gaap--ShortTermBorrowings_iI_c20241031__us-gaap--ShortTermDebtTypeAxis__custom--YANote1Member_z7htkhwSippa" title="Short-term debt">1,235,178</span>
with $<span id="xdx_905_eus-gaap--AmortizationOfDebtDiscountPremium_c20241001__20241031__us-gaap--ShortTermDebtTypeAxis__custom--YANote1Member_z8brDcKVzqDi" title="Amortization of debt discount">150,000</span>
of the debt discount fully amortized as of October 31, 2024. On November 1, 2024, the Company entered into an agreement with
Yorkville that completely terminates and replaces YA Note-1 (see the Yorkville Transaction defined below). See Note 7, Capital
Structure - Standby Equity Purchase Agreement, for further details.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 1, 2024, the Company entered into
a Standby Equity Purchase Agreement (&#8220;SEPA&#8221;) pursuant to which the Company has the right to sell Yorkville up to $20,000,000
of its shares of Company Common Stock, subject to certain limitations and conditions set forth in the SEPA, from time to time during the
term of the SEPA (such transaction, the &#8220;Yorkville Transaction&#8221;). In connection with the SEPA, Yorkville has agreed to advance
to the Company in the form of a convertible promissory note (the &#8220;Convertible Note&#8221;) an aggregate principal amount of up to
$<span id="xdx_90D_eus-gaap--ConvertibleDebt_iI_c20241102__us-gaap--DebtInstrumentAxis__custom--YorkvilleConvertibleNoteMember_zaTB9HL1AFv1" title="Convertible promissory note">1,304,758</span> (the &#8220;Pre-Paid Advance&#8221;), which terminated and replaced the $<span id="xdx_901_eus-gaap--DebtInstrumentDecreaseForgiveness_c20241101__20241102__us-gaap--ShortTermDebtTypeAxis__custom--YANote1Member_zv8w4VFa6kG" title="Short-term debt replaced">1,235,178</span> YA Note-1 outstanding balance discussed
above. The Convertible Note bears an interest rate of&#160;<span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20241102__us-gaap--DebtInstrumentAxis__custom--YorkvilleConvertibleNoteMember_zQboPUZ40V4l" title="Interest rate">8</span>% per annum and is convertible in whole or in part at any time by Yorkville
into shares of common stock of the Company at a conversion price determined based on the lower of the lower of (i) $1.00 per common share
(the &#8220;Fixed Price&#8221;), or (ii) 95% of the lowest daily volume weighted average price during the five consecutive trading days
immediately preceding the conversion date (the &#8220;Variable Price&#8221;), but which Variable Price shall not be lower than the floor
price of $0.80 (the &#8220;Floor Price&#8221;). During the year ended December 31, 2025, the Company recorded amortization of debt discount
in the amount of $<span id="xdx_90D_eus-gaap--AmortizationOfDebtDiscountPremium_c20250101__20251231__us-gaap--DebtInstrumentAxis__custom--YorkvilleConvertibleNoteMember_zYw7bxgELBCc" title="Amortization of debt discount">435,635</span> for the Convertible Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the six months ended June 30, 2025, Yorkville
elected to convert the entire outstanding principal balance on YA Note-1, the convertible promissory note with an outstanding principal
balance of $1,304,758. Yorkville converted $<span id="xdx_90F_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20250101__20250630__us-gaap--DebtInstrumentAxis__custom--YorkvilleConvertibleNoteMember_zLAKmV9AegS1">1,304,758</span>
of the principal balance and $<span id="xdx_901_ecustom--DebtConversionConvertedInterestAmount1_c20250101__20250630__us-gaap--DebtInstrumentAxis__custom--YorkvilleConvertibleNoteMember_zQieGVHslAij">52,505</span>
of accrued interest into <span id="xdx_908_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20250101__20250630__us-gaap--DebtInstrumentAxis__custom--YorkvilleConvertibleNoteMember_zrnsAa0UihBl">233,500</span>
shares of common stock at a weighted-average conversion price of $<span id="xdx_90C_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20250630__us-gaap--DebtInstrumentAxis__custom--YorkvilleConvertibleNoteMember_z3uPBBxB6DGe">5.81</span>&#160;per
share. After conversion, the principal balance of the note had a remaining balance of $<span id="xdx_90C_eus-gaap--ConvertibleNotesPayable_iI_c20250630__us-gaap--DebtInstrumentAxis__custom--YorkvilleConvertibleNoteMember_zCCFcdB3qZHh">0</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The SEPA is an equity-linked contract that does
not qualify for equity classification and is accounted for as a derivative liability recognized at fair value. Any changes in fair value
between the carrying amount of the forward issuance contracts and the settlement amounts will be recognized in other (expense) income
in the consolidated statements of operations. As of December 31, 2025 and December 31, 2024, the fair value of the SEPA was $<span id="xdx_908_eus-gaap--DerivativeAssetFairValueGrossLiability_iI_c20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--StandbyEquityPurchaseAgreementMember_zTuDt0fiiKre" title="Fair value derivative liability">0</span> and $<span id="xdx_905_eus-gaap--DerivativeAssetFairValueGrossLiability_iI_c20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--StandbyEquityPurchaseAgreementMember_zzs5DwnKbgS" title="Fair value derivative liability">1,041,484</span>,
respectively. For the year ended December 31, 2025, the Company recognized a gain on the change in fair value of derivative liability
in the amount of $<span id="xdx_90F_eus-gaap--UnrealizedGainLossOnDerivatives_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--StandbyEquityPurchaseAgreementMember_zU9OfV3NBFF1" title="Change in fair value of derivative liability">906,430</span>, in the Company&#8217;s consolidated statements of operations.</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The following table presents
information about the Company&#8217;s derivative liability that is measured at fair value on a recurring basis at December 31, 2025 and
December 31, 2024 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:</p>

<table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zbvuEYR8TaQ4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CONVERTIBLE NOTES (Details - Derivative liability)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span id="xdx_8B2_z5y8mFoKfK11" style="display: none">Schedule of derivative liability</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2025</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 49%; text-align: justify; padding-bottom: 1pt">Derivative liability</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1pt; width: 13%; text-align: center">3</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_d0_c20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zSScGOpRdWF6" style="border-bottom: Black 1pt solid; width: 13%; text-align: right" title="Fair value of derivative liability">&#8211;</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_c20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zvkEJ2i5QsY5" style="border-bottom: Black 1pt solid; width: 13%; text-align: right" title="Fair value of derivative liability">1,041,484</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_d0_c20251231_zl0cuXFGtsy6" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of derivative liability">&#8211;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_c20241231_z59nuI9P6qT5" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of derivative liability">1,041,484</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zTlA5EXadzLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The derivative liability
is accounted for as a liability in accordance with ASC 480 and is presented within derivative liability in the accompanying consolidated
balance sheets. The derivative liability is measured at fair value at inception and on a recurring basis, with changes in fair value presented
in the consolidated statements of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The derivative liability
was valued using a binomial lattice model, which is considered to be a Level 3 fair value measurement. The binomial lattice model&#8217;s
primary unobservable input utilized in determining the fair value of the derivative liability is the step factors input, assumed price
movement, and probabilities assigned to them.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The following table provides
quantitative information regarding Level 3 fair value measurements for the derivative liability:</p>

<table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfServicingLiabilitiesAtFairValueTextBlock_zMk5Fussqd7g" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - CONVERTIBLE NOTES (Details - Assumptions)">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt; color: White"><span id="xdx_8B3_zmClAVoHovK3" style="display: none">Schedule of assumptions used for valuation</span></span></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024</b></p></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 83%; text-align: justify"><span style="font-size: 10pt">Risk-free interest rate</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 14%; text-align: right"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zMgiIIKRIoQ2" title="Derivative assumption valuation">4.16</span>%</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Expected volatility</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zjYxVkzv3sCe" title="Derivative assumption valuation">114.61</span>%</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Conversion price</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90B_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputConversionPriceMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zEIsIqZ4XoHj" title="Derivative assumption valuation">3.71</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Stock price</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_909_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zRqhRfZJsqc7" title="Derivative assumption valuation">5.50</span></span></td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8A1_zb9m86qB5vNa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The following table presents
the changes in the fair value of derivative liability:</p>

<table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_zENQuhqRVCGi" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - CONVERTIBLE NOTES (Details - Change in deriviative)">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt; color: White"><span id="xdx_8BC_zfOdvmHY7J5" style="display: none">Schedule of changes in fair value of derivative liability</span></span></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Warrant</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Liabilities</b></p></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 83%"><span style="font-size: 10pt"><b>Fair value as of November 1, 2024 (inception)</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98D_eus-gaap--DerivativeFairValueOfDerivativeLiability_iS_c20241101__20241231_zcBT4BGwXfHi" style="width: 14%; text-align: right" title="Fair value of derivative liability, beginning balance"><span style="font-size: 10pt">501,824</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Change in fair value</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_988_eus-gaap--UnrealizedGainLossOnDerivatives_iN_di_c20241101__20241231_zuAywLAZNE3f" style="border-bottom: black 1pt solid; text-align: right" title="Change in fair value"><span style="font-size: 10pt">539,660</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt"><b>Fair value as of December 31, 2024</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--DerivativeFairValueOfDerivativeLiability_iS_c20250101__20251231_zrf3ufaAH9Rd" style="text-align: right" title="Fair value of derivative liability, beginning balance"><span style="font-size: 10pt">1,041,484</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Change in fair value</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_982_eus-gaap--UnrealizedGainLossOnDerivatives_iN_di_c20250101__20251231_z9QuDUjAjMub" style="text-align: right" title="Change in fair value"><span style="font-size: 10pt">(906,430</span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Extinguishment of fair value of liability</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_983_eus-gaap--ExtinguishmentOfDebtGainLossNetOfTax_iN_di_c20250101__20251231_zLopX0wn9puc" style="border-bottom: black 1pt solid; text-align: right" title="Extinguishment of fair value of liability"><span style="font-size: 10pt">(135,054</span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"><b>Fair value as of December 31, 2025</b></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98C_eus-gaap--DerivativeFairValueOfDerivativeLiability_iE_d0_c20250101__20251231_z0cgjM0ajdj" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of derivative liability, ending balance"><span style="font-size: 10pt">&#8211;</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>
<p id="xdx_8A6_zk9Emh2IYbu7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">There were <span id="xdx_90C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_do_c20250101__20251231_zrkwDadYkk5" title="Transfers in or out of Level 3"><span id="xdx_904_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_do_c20240101__20241231_zRMP0WQQ7FA8" title="Transfers in or out of Level 3">no</span></span>
transfers in or out of Level 3 from other levels in the fair value hierarchy during the years ended December 31, 2025 and 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 16, 2025, the Company entered into
a convertible promissory note with YA II PN, LTD, a Cayman Islands exempt limited partnership (&#8220;Yorkville&#8221;), in the original
principal amount of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20250116__us-gaap--DebtInstrumentAxis__custom--YorkvilleConvertibleNoteMember_zmHDMC4cMMkc">1,100,000</span>.
Interest shall accrue on the outstanding balance of the note at an annual rate equal to&#160;<span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20250115__20250116__us-gaap--DebtInstrumentAxis__custom--YorkvilleConvertibleNoteMember_zv4zNx224Wm6">8</span>%,
subject to an increase to 18% upon an event of default as described in the note. The maturity date of the note is&#160;<span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_pp0p0_dd_c20250115__20250116__us-gaap--DebtInstrumentAxis__custom--YorkvilleConvertibleNoteMember_zBC995Bxtq5i">December
31, 2025</span>. Yorkville may convert the note into shares of Common Stock at any time at a conversion price equal to the lower of (i)
$20.00 (the &#8220;Fixed Price&#8221;) or (ii) a price per share equal to 95% of the lowest daily VWAP during the 5 consecutive trading
days immediately prior to the conversion date of the note (the &#8220;Variable Price&#8221;), but which Variable Price shall not be lower
than a floor price of $1.00 per share (the &#8220;Floor Price&#8221;). The Company internally refers to this note as YA Note-2.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, the Company, at its option, shall
have the right, but not the obligation, to redeem early a portion or all amounts outstanding under the note at a redemption amount equal
to the outstanding principal balance being repaid or redeemed, plus a 5% prepayment premium, plus all accrued and unpaid interest; provided
that (i) the Company provides Yorkville with no less than ten trading days&#8217; prior written notice thereof and (ii) on the date such
notice is issued, the VWAP of the Common Stock is less than the Fixed Price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An &#8220;Amortization Event&#8221; will occur
under the terms of the Promissory Note if (i) the daily VWAP is less than the Floor Price for five trading days during a period of seven
consecutive trading days, or (ii) the Company has issued has issued to Yorkville, pursuant to the transactions contemplated in the note
and any integrated transactions, in excess of 99% of the Common Shares available under the Exchange Cap.</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2025,
Yorkville elected to convert the entire outstanding principal balance on YA Note-2, the convertible promissory note with an
outstanding principal balance of $1,100,000. Yorkville converted $<span id="xdx_90D_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20250101__20251231__us-gaap--DebtInstrumentAxis__custom--YANote2Member_z1EBZZTr1Eq1" title="Debt converted, amount converted">1,100,000</span>
of the principal balance and $<span id="xdx_908_ecustom--DebtConversionConvertedInterestAmount1_c20250101__20251231__us-gaap--DebtInstrumentAxis__custom--YANote2Member_zVGUnH9FDP67">43,397</span>
of accrued interest into <span id="xdx_903_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20250101__20251231__us-gaap--DebtInstrumentAxis__custom--YorkvilleConvertibleNoteMember_zKEonhpHtrh8">158,582</span>
shares of common stock at a weighted-average conversion price of $7.21&#160;per share. After conversion, the principal balance of
the note had a remaining balance of $<span id="xdx_90F_eus-gaap--ConvertibleNotesPayable_iI_c20251231__us-gaap--DebtInstrumentAxis__custom--YorkvilleConvertibleNoteMember_zKAToBSfEWnk" title="Convertible notes outstanding">0</span>. During the year ended December 31, 2025, the Company recorded amortization
of debt discount in the amount of $<span id="xdx_908_eus-gaap--AmortizationOfDebtDiscountPremium_c20250101__20251231__us-gaap--DebtInstrumentAxis__custom--YANote2Member_zUKKvfcWZyqi" title="Amortization of debt discount">110,000</span> for the Convertible Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SBA LOAN PAYABLE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_SbaLoanPayableAbstract', window );"><strong>Sba Loan Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_SbaLoanPayableDisclosureTextBlock', window );">SBA LOAN PAYABLE</a></td>
<td class="text"><p id="xdx_80B_ecustom--SbaLoanPayableDisclosureTextBlock_zVcdQ3jGyrJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 5 &#8211; <span id="xdx_823_zXZJGo6BmgV2">SBA LOAN PAYABLE </span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Loans under the CARES Act&#160;</b>-- On July
8, 2020, the Company received a loan of $<span id="xdx_90A_eus-gaap--ProceedsFromLoans_c20200707__20200708__us-gaap--LongtermDebtTypeAxis__custom--EidlLoanMember_zm1ZqjPvaDM4" title="Proceeds from loans">150,000</span> from the United States Small Business Administration (the &#8220;SBA&#8221;) under its
Economic Injury Disaster Loan (&#8220;EIDL&#8221;) assistance program in light of the impact of the COVID-19 pandemic on the Company&#8217;s
business. Proceeds are intended to be used for working capital purposes. Interest on the EIDL loan accrues at the rate of <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20200708__us-gaap--LongtermDebtTypeAxis__custom--EidlLoanMember_zHwXOVcN3JU7" title="Accrued interest rate">3.75</span>% per annum
and interest payments are due monthly in the amount of $731. Each payment will be applied first to interest accrued to the date of receipt
of each payment, and the balance, if any, will be applied to principal. The Company began making interest payments in January 2023. The
balance of principal and interest is payable thirty years from the date of the promissory note. The balance of the loan is $<span id="xdx_904_eus-gaap--NotesPayable_iI_c20251231__us-gaap--LongtermDebtTypeAxis__custom--EidlLoanMember_zhJBNfy7y3O6" title="Notes payable"><span id="xdx_902_eus-gaap--NotesPayable_iI_c20241231__us-gaap--LongtermDebtTypeAxis__custom--EidlLoanMember_zBRlLfdt4HGc" title="Notes payable">150,000</span></span>, as
of December 31, 2025 and December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_SbaLoanPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_SbaLoanPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_SbaLoanPayableDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_SbaLoanPayableDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE LIABILITY WARRANTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesAndFairValueTextBlock', window );">DERIVATIVE LIABILITY WARRANTS</a></td>
<td class="text"><p id="xdx_803_eus-gaap--DerivativesAndFairValueTextBlock_zFxj60qJwxl4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 6 &#8211; <span id="xdx_824_zbWk0j08R41h">DERIVATIVE LIABILITY
WARRANTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At December 31, 2025 and December 31, 2024, there
were (i)&#160; <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--PublicWarrantsMember_z9cJ2RVLXbO2" title="Warrants outstanding"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--AwardTypeAxis__custom--PublicWarrantsMember_z9dU1pQt3e62" title="Warrants outstanding">375,000</span></span> public warrants (the &#8220;Public Warrants&#8221;) outstanding that were issued as part of Bull Horn&#8217;s November
2020 initial public offering, which warrants are exercisable in the aggregate to acquire 187,500 shares of our common stock at an exercise
price of $230.00 per share, (ii)&#160;<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantsMember_zudo6F3ZOPc9" title="Warrants outstanding"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantsMember_zA531p6bBIV8" title="Warrants outstanding">187,500</span></span>&#160;private warrants (the &#8220;Private Placement Warrants&#8221;) outstanding that were
issued to our sponsor Bull Horn Holdings Sponsor LC and the underwriters in Bull Horn&#8217;s initial public offering in November 2020,
which warrants are exercisable in the aggregate to 187,500 shares of our common stock at an exercise price of $230.00 per share. The amount
of warrants and related exercise price were adjusted for the Company&#8217;s 20-1 reverse stock split effective December 31, 2024. The
Private Placement Warrants became exercisable on the consummation of our Business Combination in October 2022. No Public Warrants will
be exercisable for cash unless the Company has an effective and current registration statement covering the ordinary shares issuable upon
exercise of the Public Warrants and a current prospectus relating to such shares of common stock. With respect to the shares of common
stock issuable upon the exercise of the Public Warrants, the class A warrants and the class B warrants during any period when the Company
shall have failed to maintain an effective registration statement related to the issuance of such shares underlying the applicable warrants,
the holder of any applicable warrants may exercise its warrant on a cashless basis pursuant to an available exemption from registration
under the Securities Act. If an exemption from registration is not available, holders will not be able to exercise their Public Warrants
on a cashless basis. The Public Warrants will expire five years from the consummation of a Business Combination or earlier upon redemption
or liquidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company may call the Public Warrants for redemption,
in whole and not in part, at a price of $0.01 per warrant:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 93%; text-align: justify"><span style="font-size: 10pt">at any time while the Public Warrants are exercisable,</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">upon not less than 30 days&#8217; prior written notice of redemption to each Public Warrant holder,</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">if, and only if, the reported last sale price of the ordinary shares equals or exceeds $16.50 per share, for any 20 trading days within a 30-trading day period ending on the third trading day prior to the notice of redemption to Public Warrant holders, and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">if, and only if, there is a current registration statement in effect with respect to the ordinary shares underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Company calls the Public Warrants for redemption,
management will have the option to require all holders that wish to exercise the Public Warrants to do so on a &#8220;cashless basis,&#8221;
as described in the warrant agreement. The exercise price and number of ordinary shares issuable upon exercise of the warrants may be
adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or recapitalization, reorganization,
merger or consolidation. However, except as described above, the warrants will not be adjusted for issuances of ordinary shares at a price
below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants. If the Company is unable
to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders
of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company&#8217;s
assets held outside of the Trust Account with respect to such warrants. Accordingly, the warrants may expire worthless.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Private Placement Warrants are identical to
the Public Warrants, except that the Private Placement Warrants only allow the holder thereof to one ordinary share. Additionally, the
Private Placement Warrants will be exercisable on a cashless basis and be non-redeemable so long as they are held by the initial purchasers
or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted
transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the
Public Warrants.</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Within ASC 815,&#160;<i>Derivative and Hedging</i>,
Section 815-40-15 addresses equity versus liability treatment and classification of equity-linked financial instruments, including warrants,
and states that a warrant may be classified as a component of equity only if, among other things, the warrant is indexed to the issuer&#8217;s
ordinary share. Under ASC Section 815-40-15, a warrant is not indexed to the issuer&#8217;s ordinary share if the terms of the warrant
require an adjustment to the exercise price upon a specified event and that event is not an input to the fair value of the warrant. Based
on management&#8217;s evaluation, the Company&#8217;s audit committee, in consultation with management, concluded that the Company&#8217;s
Private Placement Warrants and Public Warrants are not indexed to the Company&#8217;s ordinary share in the manner contemplated by ASC
Section 815-40-15 because the holder of the instrument is not an input into the pricing of a fixed-for-fixed option on equity shares.
In addition, based on management&#8217;s evaluation, the Company&#8217;s audit committee, in consultation with management, concluded that
certain warrant provisions preclude equity treatment as by ASC Section 815-10-15.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for its Public Warrants and
Private Placement Warrants as liabilities as set forth in ASC 815-40-15-7D and 7F. See below for details about the methodology and valuation
of the Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table presents information about
the Company&#8217;s derivative liability warrant that are measured at fair value on a recurring basis at December 31, 2025 and December
31, 2024, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:</p>

<table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zYZYqpWiEQSb" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - DERIVATIVE LIABILITY WARRANTS (Details - Fair value)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BE_zgqKjRFwZ6u7" style="display: none">Schedule of fair value hierarchy</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt"><b>Description</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Level</b></span></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2025</b></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.2pt; text-align: center"><b>December 31,</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.2pt; text-align: center"><b>2024</b></p></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 52%; text-align: justify"><span style="font-size: 10pt">Warrant Liability &#8211; Public Warrants</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: center"><span style="font-size: 10pt">1</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_982_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pp0p0_c20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--PublicWarrantsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zykD5wfi9tOi" style="width: 13%; text-align: right" title="Financial liabilities fair value disclosure"><span style="font-size: 10pt">81,000</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98D_eus-gaap--FinancialLiabilitiesFairValueDisclosure_pp0p0_c20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--PublicWarrantsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z17ss78aDgnf" style="width: 13%; text-align: right" title="Financial liabilities fair value disclosure"><span style="font-size: 10pt">165,000</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; text-align: justify"><span style="font-size: 10pt">Warrant Liability &#8211; Private Placement Warrants</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt">3</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td id="xdx_98B_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pp0p0_c20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--PrivatePlacementWarrantsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z441SQZ8Og" style="border-bottom: Black 1pt solid; text-align: right" title="Financial liabilities fair value disclosure"><span style="font-size: 10pt">86,625</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td id="xdx_98D_eus-gaap--FinancialLiabilitiesFairValueDisclosure_pp0p0_c20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--PrivatePlacementWarrantsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwr7twPOickb" style="border-bottom: Black 1pt solid; text-align: right" title="Financial liabilities fair value disclosure"><span style="font-size: 10pt">194,250</span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 2.5pt; text-align: justify"><span style="font-size: 10pt">Total</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98C_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_c20251231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zyUSDWg5YsK9" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">167,625</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_980_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zpMRnNeWEKw6" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">359,250</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>
<p id="xdx_8AE_zjhDZPp78675" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants are accounted for as liabilities
in accordance with ASC 815-40 and are presented within derivative liability warrants in the accompanying consolidated balance sheets.
The derivative liability warrants are measured at fair value at inception and on a recurring basis, with changes in fair value presented
in the consolidated statements of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants were valued using a binomial lattice
model, which is considered to be a Level 3 fair value measurement. The binomial lattice model&#8217;s primary unobservable input utilized
in determining the fair value of the Warrants is the expected volatility of the ordinary shares. The expected volatility as of the Initial
Public Offering date was derived from observable public warrant pricing on comparable &#8216;blank-check&#8217; companies without an identified
target. For periods subsequent to the detachment of the Public Warrants from the Units, the close price of the Public Warrant price will
be used as the fair value as of each relevant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table provides quantitative information
regarding Level 3 fair value measurements:</p>

<table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_zWvyTg8a35Bd" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - DERIVATIVE LIABILITY WARRANTS (Details - Fair value assumption)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BE_zsam605Oqrhb" style="display: none">Schedule of fair value assumptions</span></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2025</b></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024</b></p></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 68%; text-align: justify"><span style="font-size: 10pt">Risk-free interest rate</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt"><span id="xdx_907_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250101__20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsMember_z9sjKqBiU8E9" title="Derivatives, determination of fair value">3.41</span>%</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90B_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsMember_zGomT0glwFSe" title="Derivatives, determination of fair value">4.10</span>%</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Expected volatility</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_907_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250101__20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsMember_zTxp77nNiJi7" title="Derivatives, determination of fair value">68.58</span>%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsMember_ziAlQrcigcR5" title="Derivatives, determination of fair value">82.01</span>%</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Exercise price</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250101__20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsMember_z4Ljn5EkmDn5" title="Derivatives, determination of fair value">230.00</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsMember_zuWNHWHhasb5" title="Derivatives, determination of fair value">230.00</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Stock price</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_901_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250101__20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsMember_z36e5rJitRxk" title="Derivatives, determination of fair value">14.25</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_909_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsMember_ziKSXBpIE0Fa" title="Derivatives, determination of fair value">5.50</span></span></td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8A3_zAIjs6K6nKvg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table presents the changes in the
fair value of warrant liabilities:</p>

<table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zu3NHvWjouG" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - DERIVATIVE LIABILITY WARRANTS (Details - Changes in fair value of warrant liabilities)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B4_zrOQM567XcY5" style="display: none">Schedule of changes in fair value of warrant liabilities</span></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Private</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Placement</b></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Public</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Warrant</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Liabilities</b></p></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 52%; text-align: justify"><span style="font-size: 10pt"><b>Fair value as of December 31, 2024</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98B_eus-gaap--LiabilitiesFairValueDisclosure_iS_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--PrivatePlacementWarrantsMember_zJRNHSESjNC8" style="width: 13%; text-align: right" title="Fair value of liabilities, beginning"><span style="font-size: 10pt">194,250</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iS_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--PublicWarrantsMember_zcGUan0W4qAl" style="width: 13%; text-align: right" title="Fair value of liabilities, beginning"><span style="font-size: 10pt">165,000</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98E_eus-gaap--LiabilitiesFairValueDisclosure_iS_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantLiabilitiesMember_zEhzUI30ezMd" style="width: 13%; text-align: right" title="Fair value of liabilities, beginning"><span style="font-size: 10pt">359,250</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Change in valuation inputs</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98A_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--PrivatePlacementWarrantsMember_zvfSBXANTCUc" style="border-bottom: black 1pt solid; text-align: right" title="Change in valuation inputs"><span style="font-size: 10pt">(107,625</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_988_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--PublicWarrantsMember_zxL0wuHoJy5k" style="border-bottom: black 1pt solid; text-align: right" title="Change in valuation inputs"><span style="font-size: 10pt">(84,000</span></td>
    <td><span style="font-size: 10pt">)&#160;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_982_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantLiabilitiesMember_zDZhStIRKTI" style="border-bottom: black 1pt solid; text-align: right" title="Change in valuation inputs"><span style="font-size: 10pt">(191,625</span></td>
    <td><span style="font-size: 10pt">)&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Fair value as of December 31, 2025</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_iE_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--PrivatePlacementWarrantsMember_z8KxeUcCjQy8" style="border-bottom: black 2.25pt double; text-align: right" title="Fair value of liabilities, ending"><span style="font-size: 10pt">86,625</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_982_eus-gaap--LiabilitiesFairValueDisclosure_iE_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--PublicWarrantsMember_zGuxjbu8LBY7" style="border-bottom: black 2.25pt double; text-align: right" title="Fair value of liabilities, ending"><span style="font-size: 10pt">81,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98E_eus-gaap--LiabilitiesFairValueDisclosure_iE_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantLiabilitiesMember_zYC5pEXwPSK6" style="border-bottom: black 2.25pt double; text-align: right" title="Fair value of liabilities, ending"><span style="font-size: 10pt">167,625</span></td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8AF_zSy0QNSUdsH4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There were no transfers in or out of Level 3 from
other levels in the fair value hierarchy during the years ended December 31, 2025 and December 31, 2024.</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesAndFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivatives and fair value of assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/820/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/815/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesAndFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STRUCTURE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">CAPITAL STRUCTURE</a></td>
<td class="text"><p id="xdx_800_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z2tDlxJAz5Q2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 7 &#8211; <span id="xdx_82C_zznjSspxVHYk">CAPITAL STRUCTURE</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The total number of shares of stock which the
corporation shall have authority to issue is 160,000,000 shares, of which 150,000,000 shares of $<span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zihYz2WUvUcl" title="Common stock, par value">0.0001</span> par value shall be designated
as Common Stock and <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_c20251231_zUXp70O0Nxlb" title="Preferred stock, shares authorized">10,000,000</span> shares of $<span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20251231_zRa5Pb82Yspk" title="Preferred stock, par value">0.0001</span> shall be designated as Preferred Stock. The Preferred Stock authorized by the Company&#8217;s
Articles of Incorporation may be issued in one or more series. The Board of Directors of the Corporation is authorized to determine or
alter the rights, preferences, privileges, and restrictions granted or imposed upon any wholly unissued series of Preferred Stock, and
within the limitations or restrictions stated in any resolution or resolutions of the Board of Directors originally fixing the number
of shares constituting any series, to increase or decrease (but not below the number of shares of any such series then outstanding) the
number of shares of any such series subsequent to the issue of shares of that series, to determine the designation and par value of any
series and to fix the numbers of shares of any series.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Common Stock</b>&#160;&#8211; As of December
31, 2025, the Company had <span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_c20251231_zTaADzJ56wLg" title="Common stock, shares outstanding">5,746,948</span> shares of its common stock issued and outstanding, and on December 31, 2024, the Company had <span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_c20241231_zYQUpCj2EcA" title="Common stock, shares outstanding">2,116,191</span>
shares of its common stock issued and outstanding. All share amounts have been adjusted for the Company&#8217;s <span id="xdx_908_eus-gaap--StockholdersEquityReverseStockSplit_c20241201__20241231_zd1ui15ClQw4" title="Reverse stock split">20-1 reverse stock split</span>
effective December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2025 and 2024,
there were no capital distributions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 16, 2023, the Company completed a
public offering issuing <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230615__20230616__us-gaap--SubsidiarySaleOfStockAxis__custom--PublicOfferingMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zQ7oEMdfSnD" title="Stock issued new, shares">107,500</span> shares of our common stock, <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230615__20230616__us-gaap--SubsidiarySaleOfStockAxis__custom--PublicOfferingMember__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_znQN47rLUtVc" title="Stock issued new, shares"><span id="xdx_909_eus-gaap--ConversionOfStockSharesConverted1_c20230615__20230616__us-gaap--SubsidiarySaleOfStockAxis__custom--PublicOfferingMember__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_zo4yfacSzyIh" title="Stock converted, shares converted">67,500</span></span> pre-funded warrants, <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230615__20230616__us-gaap--SubsidiarySaleOfStockAxis__custom--PublicOfferingMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsMember_zBybdNuxZzU1" title="Stock issued new, shares">153,125</span> Series A Warrants and <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230615__20230616__us-gaap--SubsidiarySaleOfStockAxis__custom--PublicOfferingMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_z3NX9iWOI5X6" title="Stock issued new, shares">153,125</span> Series
B Warrants, for net proceeds of approximately $3.0 million, after offering costs. The pre- funded warrants are immediately
exercisable, at a price of $0.0001 per share, with no expiration date. The Series A Warrants and the Series B Warrants are referred
to herein together as the &#8220;Series Warrants.&#8221; The shares of common stock and Series Warrants were purchased together and
then immediately separable and were issued separately. Each Series Warrant to purchase one share of common stock has an exercise
price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230616__us-gaap--SubsidiarySaleOfStockAxis__custom--PublicOfferingMember__us-gaap--StatementClassOfStockAxis__custom--SeriesWarrantsMember_zZPUnDeTYth" title="Warrants exercise price">33.00</span>&#160;per share, and is initially exercisable commencing six months from the date of the offering. The Series
Warrants are exercisable for a term of five years following the initial exercise date. As of December 31, 2024, all of the
pre-funded warrants had been exercised for a total of <span id="xdx_905_eus-gaap--ConversionOfStockSharesIssued1_c20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--PublicOfferingMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zoUJYij30JIc" title="Stock converted, shares issued">175,000</span> shares of common stock issued as a result of the public offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 28, 2023, the Company granted pre-funded
warrants exercisable to acquire up to 60,000 shares of our common stock for net proceeds of $1,200,000. The pre-funded common stock purchase
warrants can be exercised at a price of $0.0001 per share, with no expiration date. During the first quarter of 2024, the Company and
the third-party borrower agreed to amend the note as a result of the decline in the publicly traded common stock price. The amount of
pre-funded warrants exercisable to acquire up to 60,000 shares of common stock was amended to 100,000 shares of common stock, and the
total principal balance of the note agreement was increased from $1,000,000 to $1,100,000. The aggregate exercise price of this Warrant
was partially pre-funded in connection with $100,000 and a $<span id="xdx_90C_eus-gaap--ProceedsFromWarrantExercises_pp0p0_c20231227__20231228__us-gaap--StatementClassOfStockAxis__custom--WarrantNoteSubscriptionReceivablesMember_zdVhXXwfpD93" title="Aggregate exercise price of warrant">1,100,000</span>&#160;subscription receivable at a 6% per annum interest rate due
on November 29, 2024. On August 12, 2024, the third-party assigned shares of common stock in a privately held company for the equivalent
amount of principal and accrued interest owed, which satisfied the subscription receivable in full. See Note 9, Investments, for additional
information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 8, 2024, the Company granted pre-funded
warrants exercisable to acquire up to 200,000 shares of our common stock for net proceeds of $2,400,000. The pre-funded common stock purchase
warrants can be exercised at a price of $0.0001 per share, with no expiration date. The aggregate exercise price of this Warrant was partially
pre-funded in connection with $500,000&#160;and a $1,900,000 subscription receivable at a 6% per annum interest rate due on December 31,
2024. On August 12, 2024, the third-party assigned shares of common stock in a privately held company for the equivalent amount of principal
and accrued interest owed, which satisfied the subscription receivable in full. See Note 9, Investments, for additional information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2025, the Company
completed a private placement offering issuing 436,467 shares of common stock for total proceeds of $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250701__20250930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zVVtSEBCxyB7" title="Proceeds from common stock">5,000,000</span>. <span id="xdx_90B_eus-gaap--SaleOfStockDescriptionOfTransaction_c20250701__20250930__dei--LegalEntityAxis__custom--SNAPBiosciencesIncMember_zpuzYRJKsjFh" title="Investors description">In addition to the shares
of common stock of the Company, investors also received 10% aggregate non-voting ownership in the Company&#8217;s subsidiary, SNAP Biosciences,
Inc. Of this $5,000,000 raised, $4,500,000 was collected as of December 31, 2025. $500,000 of the subscription receivable is tied to a
promissory note bearing 1% interest annum, with a maturity date of January 18, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the fourth quarter of 2025, the Company
completed subscription agreements with two investors, resulting in gross proceeds of $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20251001__20251231__us-gaap--TypeOfArrangementAxis__custom--TwoInvestorMember_z9pQAbn9MDYk" title="Gross proceeds">3,120,000</span> for a total of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251001__20251231__us-gaap--TypeOfArrangementAxis__custom--TwoInvestorMember_ziVdYwbcBJk1" title="Number of shares issued">260,000</span> shares of common
stock. The balance of $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--TwoInvestorMember_zceAYeQBD5F6" title="Principal amount">3,120,000</span> is tied to promissory notes bearing <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20241231__us-gaap--TypeOfArrangementAxis__custom--TwoInvestorMember_zvvhiUq1MPa3" title="Debt instrument stated percentage">1</span>% interest annum, with a maturity date of <span id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_dd_c20251001__20251231__us-gaap--TypeOfArrangementAxis__custom--TwoInvestorMember_zrOBfduIM777" title="Maturity period">December 18, 2026</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Treasury Stock&#160;</b>&#8211; There was&#160;<span id="xdx_90E_eus-gaap--TreasuryStockValue_iI_pp0p0_do_c20251231_zxpvoGdLxeN6" title="Treasury stock"><span id="xdx_90F_eus-gaap--TreasuryStockValue_iI_pp0p0_do_c20241231_zuDRLCsZd4rb" title="Treasury stock">no</span></span>&#160;treasury
stock at December 31, 2025 and December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Preferred Stock&#160;</b>&#8211; The
Company has <span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_c20251231_zFv7nLTc7mW2" title="Preferred stock authorized">10,000,000</span>
shares of preferred stock authorized, of which <span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zQ5v6fsq9yy" title="Preferred stock authorized">10,000</span>
have been designated as Series A preferred stock. As of December 31, 2024, the Company had <span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zie3EbC1YyT9" title="Preferred stock, shares issued"><span id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z3nJmcL3dvgf" title="Preferred stock, shares outstanding">6,520</span></span>
shares of Series A preferred stock issued and outstanding, and at December 31, 2025, the Company had <span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zxOBDmClRzik" title="Preferred stock, shares issued"><span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zyDeYNDsnkVb" title="Preferred stock, shares outstanding">0</span></span>
shares of Series A preferred stock issued and outstanding.</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 13, 2024, the Company performed an initial
Series A preferred stock closing and raised $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_dm_c20240612__20240613__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zcyXU3ZfJZwj" title="Proceeds from sale of preferred stock">4.3 million</span> in a sale to accredited investors (collectively, the &#8220;Series A Investors&#8221;)
of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240612__20240613__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zW2EOEk0MTQe" title="Stock issued new, shares">4,300</span> shares of the Company&#8217;s series A preferred stock (the &#8220;Series A Preferred Stock&#8221;), at a purchase price of $1,000
per share, in a financing led by CJC Investment Trust, an entity controlled by board member Christopher Calise, in a combination of cash
and short- term collateralized promissory notes. The Series A Investors also received non-voting equity ownership interest in the Company&#8217;s
two newly formed subsidiaries, SNAP Biosciences Inc. and GEAR Therapeutics Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 31, 2024, the Company performed a second
closing as part of its series A preferred stock offering and raised $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_dm_c20240730__20240731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zivOXpFKQVF4" title="Proceeds from sale of preferred stock">1.3 million</span>, at a purchase price of $1,000 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 4, 2024, the Company performed a
third closing as part of its series A preferred stock offering and raised $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pp0p0_c20240903__20240904__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zLBMFtj9oSwj" title="Proceeds from sale of preferred stock">225,000</span>, at a purchase price of $1,000 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 23, 2024, the Company performed a
fourth closing as part of its series A preferred stock offering and raised $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pp0p0_c20241222__20241223__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zAgBsFtooT79" title="Proceeds from sale of preferred stock">695,000</span> at a purchase price of $1,000 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 6, 2025, the Company completed its
successful closure of the remaining $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_dm_c20250205__20250206__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z7CagD9Tdb2" title="Proceeds from sale of preferred stock">3.48 million</span>&#160;of its Series A preferred stock offering, completing the total $10.0 million financing
round.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 25, 2025, the Company and a holder of
its preferred stock, who is also a party to an existing consulting agreement with the Company, entered into an addendum to amend the terms
of the consulting arrangement. Under the amendment, the Company agreed to prepay the final six months of the consulting agreement by offsetting
the outstanding $<span id="xdx_90B_eus-gaap--StockholdersEquityNoteSubscriptionsReceivable_iI_c20250725__us-gaap--TransactionTypeAxis__custom--ConsultingAgreementMember_zWsV6rCeMNm3" title="Subscription receivable">125,000</span> subscription receivable previously recorded from the shareholder. The prepayment will be amortized over the remaining
term of the consulting agreement as services are rendered, thereby reducing the subscription receivable balance over time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Throughout the year ended December 31, 2025, all
<span id="xdx_900_eus-gaap--ConversionOfStockSharesConverted1_c20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zYeEmoJaK3Rh" title="Conversion of stock, shares converted">10,000</span> series A preferred shares were converted to common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The series A investors currently have an aggregate
15% non-voting equity ownership interest in the Company&#8217;s two newly formed subsidiaries, SNAP Biosciences Inc. and GEAR Therapeutics
Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The key terms of the Series A Preferred Stock
are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Conversion.&#160;</i>Each share of Series A
Preferred Stock is convertible at the option of the holder, subject to the beneficial ownership and, if applicable, the primary market
limitations described below, into such number of shares of the Company&#8217;s common stock as is equal to the number of shares of Series
A Preferred Stock to be converted, multiplied by the stated value of $1,000 (the &#8220;Stated Value&#8221;), divided by the then conversion
price. The initial conversion price is $0.40 per share of common stock, subject to adjustment in the event of stock splits, stock dividends,
and similar transactions. In addition, the Series A Preferred Stock will automatically convert into shares of the Company&#8217;s common
stock, subject to the beneficial ownership and, if applicable, the primary market limitations described below upon the consummation of
a fundraising transaction in which the Company raises gross proceeds of at least $20&#160;million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Rank</i>. The Series A Preferred Stock will
be senior to the Company&#8217;s common stock and any other class of the Company&#8217;s capital stock that is not by its terms senior
to or pari passu with the Series A Preferred Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Dividends.&#160;</i>The holders of Series A
Preferred Stock will be entitled to dividends equal, on an as-if-converted to shares of the Company&#8217;s common stock basis (in each
case after applying the beneficial ownership and, if applicable, the primary market limitations described below), to and in the same form
as dividends actually paid on shares of the Company&#8217;s common stock when, as, and if such dividends are declared on shares of the
Company&#8217;s common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Liquidation.</i>&#160;In the event of any voluntary
or involuntary liquidation, dissolution or winding up of the Company, the holders of shares of Series A Preferred Stock then outstanding
will be entitled to be paid out of the assets of the Company available for distribution to its stockholders, before any payment shall
be made to the holders of the Company&#8217;s common stock by reason of their ownership thereof, an amount per share equal to the greater
of (i) the Stated Value, plus any dividends accrued but unpaid thereon, or (ii) such amount per share as would have been payable had all
shares of Series A Preferred Stock been converted (in each case after applying the beneficial ownership and, if applicable, the primary
market limitations described below) into the Company&#8217;s common stock immediately prior to such event.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Voting.&#160;</i>On any matter to be acted
upon or considered by the stockholders of the Company, each holder of Series A Preferred Stock shall be entitled to vote on an &#8220;as
converted&#8221; basis (after applying the beneficial ownership and primary market limitations described below).</p>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Beneficial Ownership Limitation.&#160;</i>The
Company will not affect any conversion of the Series A Preferred Stock, and a holder will not have the right to receive dividends or convert
any portion of its Series A Preferred Stock, to the extent that prior to the conversion such holder (together with such holder&#8217;s
affiliates, and any persons acting as a group together with such holder or any of the holder&#8217;s affiliates) beneficially owns less
than 20% of the Company&#8217;s outstanding common stock and, after giving effect to the receipt of dividends or the conversion, the holder
(together with such holder&#8217;s affiliates, and any persons acting as a group together with such holder or any of the holder&#8217;s
affiliates) would beneficially own 20% or more of the Company&#8217;s outstanding common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Exchange Limitation.</i>&#160;Unless the approval
of the Company&#8217;s stockholders is not required by the applicable rules of Nasdaq for issuances of the Company&#8217;s common stock
in excess of 19.99% of the outstanding common stock as of June 14, 2024 (the &#8220;Market Limit&#8221;), or unless the Company has obtained
such approval, the Company shall not affect any conversion of the Series A Preferred Stock, including, without limitation, any automatic
conversion, and a holder shall not have the right to receive dividends on or convert any portion of the Series A Preferred Stock, to the
extent that, after giving effect to the receipt of the Company&#8217;s common stock in connection with such dividends or conversion, the
holder would have received in excess of its pro rata share of the Market Limit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock Based Compensation &#8211;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A summary of the Company&#8217;s stock option activity is as follows:</p>

<table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zeakXLF5vY5j" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - CAPITAL STRUCTURE (Details - Option activity)">
  <tr style="vertical-align: bottom">
    <td style="display: none">Schedule of stock option activity</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td>
    <td><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Shares Underlying Options</b></span></td>
    <td><b>&#160;</b></td>
    <td><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted Average Exercise
    Price</b></span></td>
    <td><b>&#160;</b></td>
    <td><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted Average Contractual
    Life (Years)</b></span></td>
    <td><b>&#160;</b></td>
    <td><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Intrinsic Value</b></span></td>
    <td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Outstanding at December 31, 2023</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zAdqo9AwD0ml" style="text-align: right" title="Options outstanding, beginning"><span style="font-size: 10pt">87,875</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zdJHc0yuikK5" style="text-align: right" title="Weighted average exercise price, beginning balance outstanding"><span style="font-size: 10pt">40.20</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zSCdNBLfZqn6" title="Weighted average contractual life (years), options outstanding">7.97</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 36%"><span style="font-size: 10pt">Granted</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zpzNcAhWG1Jk" style="width: 13%; text-align: right" title="Options granted"><span style="font-size: 10pt">196,750</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z46h2cts0dne" style="width: 13%; text-align: right" title="Weighted average exercise price, granted"><span style="font-size: 10pt">8.85</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2OptionsGranted_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zRou3ZT1jn8a" title="Weighted average contractual life (years), granted">10.00</span></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Forfeited</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zVU7qc8rEWfg" style="text-align: right" title="Options forfeited/expired"><span style="font-size: 10pt">(5,000)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zBrjwVoZ8iOh" style="text-align: right" title="Weighted average exercise price, forfeited/expired"><span style="font-size: 10pt">200.00</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Exercised</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_d0_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zfXANZ7rjiO9" style="border-bottom: black 1pt solid; text-align: right" title="Options exercised"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zzHQw19UCua6" style="border-bottom: black 1pt solid; text-align: right" title="Weighted average exercise price, exercised"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Outstanding at December 31, 2024</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zWYijifwwHj3" style="text-align: right" title="Options outstanding, beginning"><span style="font-size: 10pt">279,625</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zLUum3gcAUHg" style="text-align: right" title="Weighted average exercise price, beginning balance outstanding"><span style="font-size: 10pt">15.29</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zdcJXeKn0NU8" title="Weighted average contractual life (years), options outstanding">8.74</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_ztyMmW7ZFEb8" style="text-align: right" title="Options granted"><span style="font-size: 10pt">187,375</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zIh031phyXP1" style="text-align: right" title="Weighted average exercise price, granted"><span style="font-size: 10pt">7.96</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2OptionsGranted_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zUKJ0SCZtgD2" title="Weighted average contractual life (years), granted">5.20</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Forfeited</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z2gIUm4mfyJa" style="text-align: right" title="Options forfeited/expired"><span style="font-size: 10pt">(30,000</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zRZ1TTo3Wyi1" style="text-align: right" title="Weighted average exercise price, forfeited/expired"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Exercised</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_d0_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zuv8YlhRYPA2" style="border-bottom: black 1pt solid; text-align: right" title="Options exercised"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zjJT6tT8gbql" style="border-bottom: black 1pt solid; text-align: right" title="Weighted average exercise price, exercised"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Outstanding at December 31, 2025</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z9ZXtWtL9N8f" style="border-bottom: black 2.25pt double; text-align: right" title="Options outstanding, ending"><span style="font-size: 10pt">437,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z9Dprg9sKBWk" style="border-bottom: black 2.25pt double; text-align: right" title="Weighted average exercise price, ending balance outstanding"><span style="font-size: 10pt">12.11</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zau0aOCg5xVf" title="Weighted average contractual life (years), options outstanding">6.26</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zQA7SpV3vjH3" style="border-bottom: black 2.25pt double; text-align: right" title="Intrinsic value, options outstanding"><span style="font-size: 10pt">2,215,451</span></td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8A2_z77NwnJUTCla" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the years ended December 31, 2025 and 2024,
the Company recorded $<span id="xdx_907_eus-gaap--ShareBasedCompensation_pp0p0_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zZvNmgSsDP96" title="Share based compensation">1,215,692 </span>and $<span id="xdx_903_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zOoW91DrAqOb" title="Share based compensation">1,104,978</span>, respectively, for stock based compensation expense related to stock options. As of December
31, 2025, unamortized stock based compensation for stock options was $<span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pp0p0_c20251231_zumQMdiNNPB9" title="Unamortized stock-based compensation">918,681</span> to be recognized through December 31, 2027.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The options granted during the years ended December
31, 2025 and 2024 were valued using the Black-Scholes option pricing model using the following weighted average assumptions:</p>

<table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zuN6cUYSbiP7" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - CAPITAL STRUCTURE (Details - Weighted average assumptions)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BC_zoaWrx1wddF1" style="display: none">Schedule of weighted average assumptions</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td>
    <td><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>For the years ended December
    31,</b></span></td>
    <td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td>
    <td><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2025</b></span></td>
    <td><b>&#160;</b></td>
    <td><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2024</b></span></td>
    <td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 60%"><span style="font-size: 10pt">Expected term, in years</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 16%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zb44d3yrl74g" title="Expected term, in years">2.75</span></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 16%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zZNgltc1r60k" title="Expected term, in years">5.25</span></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Expected volatility</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zATDT3E1qOxg" title="Expected volatility">75.58</span>%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zrS3qLfbf3pa" title="Expected volatility">84.70</span>%</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Risk-free interest rate</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zb3GaOUmKtDf" title="Risk-free interest rate">3.89</span>%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zCZ2RKkQVEIk" title="Risk-free interest rate">4.18</span>%</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Dividend yield</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zte09OWFCb2c" title="Dividend yield">&#8211;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z2QN4EoyzZ71" title="Dividend yield">&#8211;</span></span></td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8A2_zctNFre0IfR1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Options/Stock Awards Forfeited &#8211; </b>On
March 24, 2025, Colleen Delaney, Chief Scientific and Medical Officer, resigned her position for a reason other than cause. Per the Plan,
her unvested stock options (<span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_c20250323__20250324__srt--CounterpartyNameAxis__custom--ColleenDelaneyMember_z2YDHtKmADQ" title="Number of shares forfeited">27,500</span>) were immediately forfeited and go back into the Plan. Her vested stock options (<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20250324__srt--CounterpartyNameAxis__custom--ColleenDelaneyMember_zui5gilCeOfd" title="Number of shares exercised">2,500</span>) were eligible
to be exercised for three months following her resignation (by June 24, 2025). As of December 31, 2025, all of her stock options are forfeited,
and the <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20250101__20251231__srt--CounterpartyNameAxis__custom--ColleenDelaneyMember_zZhWqKK4VJb5" title="Number of shares expired">2,500</span> vested options are expired.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Modification of Options &#8211; </b>On December
31, 2025 the Company and the holder of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20251201__20251231__us-gaap--PlanNameAxis__custom--ModificationOfOptionsMember_zW3LA3KWVXU8" title="Options granted">100,000</span> of the Company&#8217;s options (the &#8220;Modified Options&#8221;) agreed to amend the
terms of the holder&#8217;s options extending the maturity date to January 20, 2026, from the original maturity date of January 5, 2026.
There were no other changes to the terms of the Modified Options. The amendment qualified as a &#8220;Type I&#8221; modification as the
Modified Options were vested immediately prior to the amendment and immediately after the amendment. As a result of the amendment, the
Company recognized additional stock compensation expense of $<span id="xdx_908_eus-gaap--ShareBasedCompensation_c20251201__20251231__us-gaap--PlanNameAxis__custom--ModificationOfOptionsMember_z2Jhgq4f67Tg" title="Stock compensation expense">870</span> for the incremental change in fair value immediately before the modification
and immediately after the modification.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Common Stock Warrants&#160;</b>&#8211; On November
23, 2020, Coeptis Therapeutics, Inc. (under its prior name Vinings Holdings Inc.) issued a class A and a class B warrant to Coral Investment
Partners, LP (&#8220;CIP&#8221;), with each warrant granting CIP the right to purchase <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20201123__srt--CounterpartyNameAxis__custom--CoralInvestmentPartnersMember_zYZicBAPV7gh" title="Warrants outstanding">25,000</span> shares of common stock at a price of
$<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201123__srt--CounterpartyNameAxis__custom--CoralInvestmentPartnersMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_pdd" title="Exercise price of warrants">40.00</span> for Class A or $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201123__srt--CounterpartyNameAxis__custom--CoralInvestmentPartnersMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_pdd" title="Exercise price of warrants">100.00</span> for Class B. The warrants expired on November 30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All common stock warrants outstanding, are listed
in the table below:</p>

<table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zvnvizl0Zhh7" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - CAPITAL STRUCTURE (Details - Warrants outstanding)">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt; color: White"><span id="xdx_8B7_zOdJkpwSXipd" style="display: none">Schedule of warrants outstanding</span></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt"><b>Reference</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Date</b></span><br/>
<span style="font-size: 10pt"><b>Issued</b></span></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Exercise</b></span><br/>
<span style="font-size: 10pt"><b>Price</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Expiration</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Outstanding at December 31,</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.75pt; text-align: center"><b>2025</b></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Outstanding at<br/>
    December 31,</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024</b></p></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 36%; text-align: justify"><span style="font-size: 10pt">Warrant Holder 1</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center"><span style="font-size: 10pt"><span id="xdx_909_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice59.40Member_zhPQKk5yNNMk" title="Date Issued">5/28/2021</span></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice59.40Member_zXRPOT9rhVG2" style="width: 10%; text-align: right" title="Warrants exercise price"><span style="font-size: 10pt">59.40</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice59.40Member_zItdhyrT2Pk5" title="Expiration">5/13/2026</span></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice59.40Member_zqqHvnVaQLHh" style="width: 10%; text-align: right" title="Warrants outstanding"><span style="font-size: 10pt">8,380</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice59.40Member_zMeNZng40tdb" style="width: 10%; text-align: right" title="Warrants outstanding"><span style="font-size: 10pt">8,380</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Warrant Holder 1</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90C_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice118.80Member_zwQ5pwjwGMSf" title="Date Issued">5/28/2021</span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice118.80Member_z4JELrJ017Xg" style="text-align: right" title="Warrants exercise price"><span style="font-size: 10pt">118.80</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice118.80Member_zv54vjEcUlni" title="Expiration">5/13/2026</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice118.80Member_zuIBsbFjCHNb" style="text-align: right"><span style="font-size: 10pt">8,422</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice118.80Member_zLlnDfHxGkke" style="text-align: right"><span style="font-size: 10pt">8,422</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Warrant Holder 1</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_900_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice296.80Member_zbAD3QgR0aE4" title="Date Issued">5/28/2021</span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice296.80Member_zdOUYST0KBDk" style="text-align: right" title="Warrants exercise price"><span style="font-size: 10pt">296.80</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice296.80Member_zNWSeKS6l3J7" title="Expiration">5/13/2026</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice296.80Member_zicjK4torz8d" style="text-align: right"><span style="font-size: 10pt">8,422</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice296.80Member_ze7554J93sG3" style="text-align: right"><span style="font-size: 10pt">8,422</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Warrant Holder 2</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_902_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice59.40Member_z6Pz0tB8cFb1" title="Date Issued">7/30/2021</span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice59.40Member_zXxLcYdy4V6g" style="text-align: right" title="Warrants exercise price"><span style="font-size: 10pt">59.40</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice59.40Member_zwxyj4u9O5Hk" title="Expiration">7/30/2026</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice59.40Member_zv1MnhCveYy2" style="text-align: right"><span style="font-size: 10pt">421</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice59.40Member_zTaTaGqLB7d7" style="text-align: right"><span style="font-size: 10pt">421</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Warrant Holder 2</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_905_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice296.80Member_z690toHMvrid" title="Date Issued">7/30/2021</span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice296.80Member_zDVj61xqGm38" style="text-align: right" title="Warrants exercise price"><span style="font-size: 10pt">296.80</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice296.80Member_zuFNtTWa4Zk6" title="Expiration">6/1/2026</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice296.80Member_z7qV2GpL182j" style="text-align: right"><span style="font-size: 10pt">1,263</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice296.80Member_znkkujrqPZG" style="text-align: right"><span style="font-size: 10pt">1,263</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Warrant Holder 5</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90C_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder5ExercisePrice59.40Member_zT6nUYfMeP8k" title="Date Issued">12/20/2021</span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder5ExercisePrice59.40Member_zEtq2QA2hzde" style="text-align: right" title="Warrants exercise price"><span style="font-size: 10pt">59.40</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder5ExercisePrice59.40Member_zHVEKXVm7j4d" title="Expiration">12/20/2026</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder5ExercisePrice59.40Member_zMO86NMJ8vVj" style="text-align: right"><span style="font-size: 10pt">2,948</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder5ExercisePrice59.40Member_zThs8fw5UFB4" style="text-align: right"><span style="font-size: 10pt">2,948</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Warrant Holder 18</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_909_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder18ExercisePrice178.20Member_zdbqLVXtpkh5" title="Date Issued">3/30/2022</span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder18ExercisePrice178.20Member_zMNZCepjwXD5" style="text-align: right" title="Warrants exercise price"><span style="font-size: 10pt">178.20</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder18ExercisePrice178.20Member_zsyqR9n0P2te" title="Expiration">3/30/2025</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_d0_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder18ExercisePrice178.20Member_zDIvnpeWio7k" style="text-align: right"><span style="font-size: 10pt">&#8211; </span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder18ExercisePrice178.20Member_zJHbtgaG073a" style="text-align: right"><span style="font-size: 10pt">4,211</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Warrant Holder 20</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_906_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder20ExercisePrice50.00Member_z4C62Tx4YpMa" title="Date Issued">1/3/2023</span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder20ExercisePrice50.00Member_z4lymClWNjb" style="text-align: right" title="Warrants exercise price"><span style="font-size: 10pt">50.00</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder20ExercisePrice50.00Member_zREA6mmTF107" title="Expiration">1/2/2027</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder20ExercisePrice50.00Member_zkNNxOL1MChg" style="text-align: right"><span style="font-size: 10pt">5,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder20ExercisePrice50.00Member_zQvBo3JQxaJk" style="text-align: right"><span style="font-size: 10pt">5,000</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Warrant Holder 21</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_902_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder21ExercisePrice38.00Member_zsy504HlvDYj" title="Date Issued">1/20/2023</span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder21ExercisePrice38.00Member_zJFT8AGk3jGi" style="text-align: right" title="Warrants exercise price"><span style="font-size: 10pt">38.00</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder21ExercisePrice38.00Member_zBpFYBBVNXfb" title="Expiration">1/19/2027</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder21ExercisePrice38.00Member_zgcVAlGQV2m" style="text-align: right"><span style="font-size: 10pt">12,500</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder21ExercisePrice38.00Member_zw9jDPiB7KIc" style="text-align: right"><span style="font-size: 10pt">12,500</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Series A &amp; B Warrants</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_902_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesWarrantsAAndBExercisePrice27.20Member_zMLfl9kgCStk" title="Date Issued">6/16/2023</span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesWarrantsAAndBExercisePrice27.20Member_zLGVuKEypFSe" style="text-align: right" title="Warrants exercise price"><span style="font-size: 10pt">27.20</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesWarrantsAAndBExercisePrice27.20Member_zWiQfQC8nAFk" title="Expiration">12/16/2028</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesWarrantsAAndBExercisePrice27.20Member_zGX16nfpzMfl" style="text-align: right"><span style="font-size: 10pt">306,250</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesWarrantsAAndBExercisePrice27.20Member_zMcpzrvKYNle" style="text-align: right"><span style="font-size: 10pt">306,250</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Series A Warrants</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_900_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsExercisePrice27.20Member_zUBMb8E7p44l" title="Date Issued">10/23/2023</span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsExercisePrice27.20Member_zaQRKQLtGKXi" style="text-align: right" title="Warrants exercise price"><span style="font-size: 10pt">27.20</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsExercisePrice27.20Member_zJXfhF99xYw1" title="Expiration">4/26/2025</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_d0_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsExercisePrice27.20Member_zGRBcCqmET71" style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsExercisePrice27.20Member_zpQbIWGokML1" style="text-align: right"><span style="font-size: 10pt">100,000</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Series B Warrants</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_907_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsExercisePrice27.20Member_z8vzypLgPvNg" title="Date Issued">10/23/2023</span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsExercisePrice27.20Member_zrXhgXeYRGTb" style="text-align: right" title="Warrants exercise price"><span style="font-size: 10pt">27.20</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsExercisePrice27.20Member_zB1dVGnt8dP" title="Expiration">4/26/2029</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsExercisePrice27.20Member_zrOAXCQY9kde" style="text-align: right"><span style="font-size: 10pt">100,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsExercisePrice27.20Member_z4HshTcVMa75" style="text-align: right"><span style="font-size: 10pt">100,000</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Warrant Holder 22</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_908_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice25.00Member_zDAEgsAil3ci" title="Date Issued">6/16/2023</span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice25.00Member_zapMylA94m4f" style="text-align: right" title="Warrants exercise price"><span style="font-size: 10pt">25.00</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice25.00Member_z6Y6AUE9a7ue" title="Expiration">12/16/2028</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice25.00Member_zb9yirJ8v3Vc" style="text-align: right"><span style="font-size: 10pt">6,300</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice25.00Member_zA7gNTIgnKT8" style="text-align: right"><span style="font-size: 10pt">6,300</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Warrant Holder 22</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_902_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice28.00Member_zcptOzx2hAb3" title="Date Issued">10/23/2023</span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice28.00Member_z4ubQZlsp0D7" style="text-align: right" title="Warrants exercise price"><span style="font-size: 10pt">28.00</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice28.00Member_zCFwpGSZBYI" title="Expiration">4/26/2029</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice28.00Member_zpzv0wMqgij7" style="text-align: right"><span style="font-size: 10pt">3,300</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice28.00Member_zD9mQorT6WC5" style="text-align: right"><span style="font-size: 10pt">3,300</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Warrant Holder 23</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_903_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice25.00Member_zdmKFPOfEsUk" title="Date Issued">6/16/2023</span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice25.00Member_zsMDcc2OfNCf" style="text-align: right" title="Warrants exercise price"><span style="font-size: 10pt">25.00</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice25.00Member_zLuijdsruMf3" title="Expiration">12/16/2028</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice25.00Member_zCv7ZcFGFdl7" style="text-align: right"><span style="font-size: 10pt">4,200</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice25.00Member_zpw43IQxFYHe" style="text-align: right"><span style="font-size: 10pt">4,200</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Warrant Holder 23</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90A_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice28.00Member_z1fPzyMwcz27" title="Date issued">10/23/2023</span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice28.00Member_z8FMtTy84jFb" style="text-align: right" title="Warrants exercise price"><span style="font-size: 10pt">28.00</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice28.00Member_zuWoZMkqoZ86" title="Expiration">4/26/2029</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice28.00Member_zkTrqhzVQeMk" style="text-align: right"><span style="font-size: 10pt">2,400</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice28.00Member_zlqY2DWKR1xi" style="text-align: right"><span style="font-size: 10pt">2,400</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Warrant Holder 24</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_903_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder24ExercisePrice28.00Member_zbZ5N7Nh6Cij" title="Date Issued">10/23/2023</span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder24ExercisePrice28.00Member_zZzUb33gVac4" style="text-align: right" title="Warrants exercise price"><span style="font-size: 10pt">28.00</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder24ExercisePrice28.00Member_z1Up8he4rQi" title="Expiration">4/26/2029</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder24ExercisePrice28.00Member_z8anOUPcCnY6" style="text-align: right"><span style="font-size: 10pt">300</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder24ExercisePrice28.00Member_z4NcvcfmZ9H9" style="text-align: right"><span style="font-size: 10pt">300</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-Funded Warrants 2</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_905_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants2ExercisePrice0.002Member_zhbhDan1TPKg" title="Date Issued">12/28/2023</span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants2ExercisePrice0.002Member_zH4g4amW63P5" style="text-align: right" title="Warrants exercise price"><span style="font-size: 10pt">0.002</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_d0_c20251231__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants2ExercisePrice0.002Member_zyPGcOuPPzge" style="text-align: right" title="Warrants outstanding"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants2ExercisePrice0.002Member_zlgnxgIcCyKk" style="text-align: right" title="Warrants outstanding"><span style="font-size: 10pt">150,000</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-Funded Warrants 3</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_909_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants3ExercisePrice0.002Member_zbmqhDS6Sn67" title="Date issued">2/8/2024</span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants3ExercisePrice0.002Member_z3kTd4B1x6h3" style="text-align: right" title="Warrants exercise price"><span style="font-size: 10pt">0.002</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_d0_c20251231__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants3ExercisePrice0.002Member_z1cKT9UR11l8" style="text-align: right" title="Warrants outstanding"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants3ExercisePrice0.002Member_z2Qivc5Euhae" style="text-align: right" title="Warrants outstanding"><span style="font-size: 10pt">300,000</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Warrant Holder 25</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_903_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder25ExercisePrice12.00Member_z3hcmuuDwXi9" title="Date Issued">1/20/2025</span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder25ExercisePrice12.00Member_zuQsgwAp9Ea1" style="text-align: right" title="Warrants exercise price"><span style="font-size: 10pt">12.00</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder25ExercisePrice12.00Member_z8bA0x6c1Lti" title="Expiration">1/20/2030</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder25ExercisePrice12.00Member_zGElVEDbXJt5" style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">100,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_d0_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder25ExercisePrice12.00Member_z3UtJJ43UWI2" style="border-bottom: black 1pt solid; text-align: right">&#8211;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td colspan="10" style="text-align: center"><span style="font-size: 10pt"><b>Total Warrants outstanding</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231_zqQPGJsI8HJ5" style="border-bottom: black 2.25pt double; text-align: right" title="Total warrants outstanding"><span style="font-size: 10pt"><b>570,105</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231_zhrYnAzD8ZSl" style="border-bottom: black 2.25pt double; text-align: right" title="Total warrants outstanding"><span style="font-size: 10pt"><b>1,024,316</b></span></td>
    <td>&#160;</td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; padding-left: 10pt; text-indent: -0.01pt; width: 3%">*</td>
  <td style="text-align: justify; padding-left: 10pt; text-indent: -0.01pt; width: 97%">Pre-funded warrants, do not expire.</td></tr>
</table>


<p id="xdx_8AE_zp7T0FRyrNx" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Subscription receivable </b>&#8211; In
September 2023, the Company agreed to issue <span id="xdx_909_ecustom--StockIssuedForDebtShares_c20230901__20230930__us-gaap--FinancialInstrumentAxis__custom--SubscriptionReceivableSept2023Member_z4pE76mXRUO8" title="Stock issued for debt, shares">25,000</span>
shares of common stock to the borrower for a principal sum amount of $<span id="xdx_906_ecustom--StockIssuedForDebtValue_pp0p0_c20230901__20230930__us-gaap--FinancialInstrumentAxis__custom--SubscriptionReceivableSept2023Member_zPr72zVmmrNk" title="Stock issued for debt, value">500,000</span>.
On August 12, 2024, the Company was transferred and assigned $522,667, the sum of principal and accrued interest owed as of June 30,
2024, of shares of common stock in a privately held company by the third-party borrower. As a result of this assignment agreement,
the subscription receivable is paid in full, and $<span id="xdx_908_eus-gaap--Investments_iI_pp0p0_c20251231__us-gaap--FinancialInstrumentAxis__custom--SubscriptionReceivableSept2023Member_zL23KwfnqPm1" title="Investments"><span id="xdx_901_eus-gaap--Investments_iI_pp0p0_c20241231__us-gaap--FinancialInstrumentAxis__custom--SubscriptionReceivableSept2023Member_zor73S13jMJh">522,667</span></span>
is recorded as an investment at December 31, 2025 and December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2023, the Company agreed to issue&#160;<span id="xdx_90F_ecustom--StockIssuedForDebtShares_c20230901__20230930__us-gaap--FinancialInstrumentAxis__custom--SubscriptionReceivableSept20232ndMember_zvOdA2fkQLLg" title="Stock issued for debt, shares">100,000</span>
shares of common stock to the borrower for a principal sum amount of $<span id="xdx_90C_ecustom--StockIssuedForDebtValue_pp0p0_c20230901__20230930__us-gaap--FinancialInstrumentAxis__custom--SubscriptionReceivableSept20232ndMember_zsqPKzBRNZt2" title="Stock issued for debt, value">2,000,000</span>. On August 12, 2024, the Company was transferred and assigned
$2,090,667, the sum of principal and accrued interest owed, of shares of common stock in a privately held company by the third-party borrower.
As a result of this assignment agreement, the subscription receivable is paid in full, and $<span id="xdx_901_eus-gaap--Investments_iI_pp0p0_c20251231__us-gaap--FinancialInstrumentAxis__custom--SubscriptionReceivableSept20232ndMember_zyXvPYeo3lG4" title="Investments"><span id="xdx_90B_eus-gaap--Investments_iI_pp0p0_c20241231__us-gaap--FinancialInstrumentAxis__custom--SubscriptionReceivableSept20232ndMember_zmBVyg52wbFi" title="Investments">2,090,667</span></span> is recorded as an investment at
December 31, 2025 and December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2023, the Company agreed to
grant pre-funded warrants exercisable to acquire up to 60,000 shares of common stock to the borrower for a principal sum amount of
$1,000,000. During the first quarter of 2024, the Company and the third-party borrower agreed to amend the note as a result of the
decline in the publicly traded common stock price. The amount of pre-funded warrants exercisable to acquire up to 60,000 shares of
common stock was amended to <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240331__us-gaap--FinancialInstrumentAxis__custom--December2023FinancingMember_zty7svcEEie" title="Warrants issued">100,000</span>
shares of common stock, and the total principal balance of the note agreement was increased from $1,000,000 to $1,100,000. On August
12, 2024, the Company was transferred and assigned $1,132,869, the sum of principal and accrued interest owed, of shares of common
stock in a privately held company by the third-party borrower. As a result of this assignment agreement, the subscription receivable
is paid in full, and $<span id="xdx_905_eus-gaap--Investments_iI_pp0p0_c20251231__us-gaap--FinancialInstrumentAxis__custom--December2023FinancingMember_zfD2aBz9sb8d" title="Investments"><span id="xdx_900_eus-gaap--Investments_iI_pp0p0_c20241231__us-gaap--FinancialInstrumentAxis__custom--December2023FinancingMember_z6VMIe1QQZzf">1,132,869</span></span>
is recorded as an investment at December 31, 2025 and December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2024, the Company agreed to grant
pre-funded warrants exercisable to acquire up to <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240228__us-gaap--FinancialInstrumentAxis__custom--February2024FinancingMember_zTNKfJN6quX9">200,000</span> shares of common stock to the borrower for a principal sum amount of $1,900,000.
On August 12, 2024, the Company was transferred and assigned $1,944,879, the sum of principal and accrued interest owed, of shares of
common stock in a privately held company by the third-party borrower. As a result of this assignment agreement, the subscription receivable
is paid in full, and $<span id="xdx_90A_eus-gaap--Investments_iI_pp0p0_c20251231__us-gaap--FinancialInstrumentAxis__custom--February2024FinancingMember_zknFlblVQSf6" title="Investments"><span id="xdx_90E_eus-gaap--Investments_iI_pp0p0_c20241231__us-gaap--FinancialInstrumentAxis__custom--February2024FinancingMember_z2rrE8IEsIpl">1,944,879</span></span> is recorded as an investment at December 31, 2025 and December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2024, in connection with the Company&#8217;s
series A preferred stock offering, the Company closed on subscription agreements totaling $2,100,000 due to the Company on February 28,
2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the second quarter of 2025, the Company
collected $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_c20250101__20250630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zxGUCspp6Czj" title="Proceeds from issuance of preferred stock">125,000</span> of outstanding subscription receivable resulting from one Series A preferred stock subscription agreement. At June
30, 2025, the Company had recorded subscription receivable of $<span id="xdx_903_eus-gaap--PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable_iI_pp0p0_c20250630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zFGsyJxR8NBf" title="Subscription receivable">125,000</span> resulting from the final Series A preferred stock subscription
agreement where preferred shares have been issued as part of the February 6, 2025 closing. In connection with this subscription receivable,
the Company and the investor agreed to satisfy the subscription as prepayment of the final six months of the consulting contract between
both parties. The subscription receivable is being amortized through the end of June 2026 as professional services expense.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the third quarter of 2025, in connection
with the Company&#8217;s private placement offering, the Company recorded $<span id="xdx_904_ecustom--SubscriptionsReceivable_c20250701__20250930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zbbUViUJCPR9" title="Subscriptions receivable">5,000,000</span> in subscriptions receivable. As of December 31, 2025,
the Company collected $<span id="xdx_90A_ecustom--ProceedsFromSubscriptionsReceivable_iI_c20250930_zqWez86yW8cf" title="Proceeds subscriptions receivable">4,500,000</span> of the proceeds, resulting in a net $<span id="xdx_900_ecustom--SubscriptionsReceivableNet_iI_c20250930_z534i5DWF8E" title="Subscriptions receivable net">500,000</span> in subscriptions receivable still to be collected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the fourth quarter of 2025, the Company
issued a total of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251001__20251231__us-gaap--TypeOfArrangementAxis__custom--TwoInvestorMember_z1il3Cfioqo2" title="Number of shares issued">260,000</span> shares to two investors, recording subscription receivables in the amount of $<span id="xdx_90F_ecustom--SubscriptionsReceivableNet_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--TwoInvestorMember_zfDo2IT5E2S6" title="Subscriptions receivable net">3,120,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Standby Equity Purchase Agreement </b>&#8211;
On November 1, 2024, the Company entered into the SEPA with Yorkville pursuant to which the Company has the right to sell to Yorkville
up to $20,000,000 of common stock, subject to certain limitations and conditions set forth in the SEPA, from time to time during the term
of the SEPA. The Company also entered into a Registration Rights Agreement with Yorkville pursuant to which it will register the resale
of shares of common stock issued to Yorkville pursuant to the SEPA. Sales of common stock to Yorkville under the SEPA, and the timing
of any such sales, are at the Company&#8217;s option, and the Company is under no obligation to sell common stock to Yorkville under the
SEPA, except in connection with notices that may be submitted by Yorkville in certain circumstances as described below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each advance (each, an &#8220;Advance&#8221;)
the Company requests in writing to Yorkville under the SEPA (notice of such request, an &#8220;Advance Notice&#8221;) may be for a number
of shares of common stock up to such amount as is equal to 100% of the average daily volume traded of the common stock during the five
trading days immediately prior to the date the Company requests each Advance. The shares of common stock purchased pursuant to an Advance
delivered by the Company will be purchased at a price equal to 95% of the lowest daily VWAP of the shares of common stock during the three
consecutive trading days commencing on the date of the delivery of the Advance Notice, other than the daily VWAP on a day in which the
daily VWAP is less than a minimum acceptable price as stated by the Company in the Advance Notice or there is no VWAP on the subject trading
day. The Company may establish a minimum acceptable price in each Advance Notice below which the Company will not be obligated to make
any sales to Yorkville. &#8220;VWAP&#8221; is defined as the daily volume weighted average price of the shares of Common Stock for such
trading day on the Nasdaq Stock Market (&#8220;Nasdaq&#8221;) during regular trading hours as reported by Bloomberg L.P.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The SEPA will automatically terminate on the earliest
to occur of (i) December 1, 2027, provided that the Convertible Note (defined in Note 5) has been fully repaid or (ii) the date on which
the Company shall have made full payment of Advances pursuant to the SEPA. The Company has the right to terminate the SEPA at no cost
or penalty upon five trading days&#8217; prior written notice to Yorkville, provided that there are no outstanding Advance Notices for
which shares of common stock need to be issued and the Company has paid all amounts owed to Yorkville pursuant to the Convertible Note.
The Company and Yorkville may also agree to terminate the SEPA by mutual written consent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any purchase under an Advance would be subject
to certain limitations, including that Yorkville shall not purchase or acquire any shares that would result in it and its affiliates beneficially
owning more than 4.99% of the then outstanding voting power or number of shares of common stock or any shares that, aggregated with shares
issued under all other earlier Advances, would exceed 19.99% of all shares of common stock outstanding on the date of the SEPA (the &#8220;Exchange
Cap&#8221;), unless the Company obtains stockholder approval to issue shares of common stock in excess of the Exchange Cap in accordance
with applicable Nasdaq rules.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the execution of the SEPA,
the Company agreed to pay a commitment fee of $<span id="xdx_90D_eus-gaap--PaymentsForBrokerageFees_pp0p0_c20241029__20241102__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--YorkvilleMember_zY8Q229W4apd" title="Payment of commitment fee">200,000</span> to Yorkville, payable as follows: (i) $<span id="xdx_909_eus-gaap--PaymentsForBrokerageFees_pp0p0_c20241029__20241102__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--TransactionTypeAxis__custom--StockIssuedForServicesMember_zrdNAZSMmWNh" title="Payment of commitment fee">80,000</span> payable when the SEPA was entered
into, in the form of the issuance of 20,000 shares of common stock, representing $80,000 divided by the closing price as of the trading
day immediately prior to the date of the SEPA, and (ii) $120,000 payable in cash or by way of an Advance on the date upon which the Company
has first received Advances in the aggregate amount of $5,000,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, Yorkville agreed to advance to
the Company, in exchange for the Convertible Note, an aggregate principal amount of $<span id="xdx_907_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_c20241102__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zXkuC2B3UUMd" title="Convertible notes outstanding">1,304,758</span>
(see Note 4 for a description of the Convertible Note). At any time while the SEPA is in place that there is a balance outstanding
under the Convertible Note, Yorkville may deliver a notice (an &#8220;Investor Notice&#8221;) to the Company to cause an Advance
Notice to be deemed delivered to Yorkville and the issuance and sale of shares of Common Stock to Yorkville pursuant to an Advance.
Yorkville may select the amount of the Advance in an amount not to exceed the balance owed under the Convertible Note outstanding on
the date of delivery of such Investor Notice. The shares will be issued and sold to Yorkville pursuant to an Investor Notice at a
per share price equal to the conversion price that would be applicable to the amount of the Advance selected by Yorkville if such
amount were to be converted as of the date of delivery of the Investor Notice. Yorkville will pay the purchase price for such shares
to be issued pursuant to the Investor Notice by offsetting the amount of the purchase price to be paid by Yorkville against an
amount outstanding under the Yorkville Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, the Company, at its option, shall
have the right, but not the obligation, to redeem early a portion or all amounts outstanding under the Convertible Note at a redemption
amount equal to the outstanding principal balance being repaid or redeemed, plus a 5% prepayment premium, plus all accrued and unpaid
interest; provided that (i) the Company provides Yorkville with no less than ten trading days&#8217; prior written notice thereof and
(ii) on the date such notice is issued, the VWAP of the common stock is less than the Fixed Price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Throughout the year ended December 31,
2025, in connection with the SEPA, the Company issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zB8hYyF9EKjf" title="Number of shares issued">225,000</span> shares of common stock, resulting in gross proceeds of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zKs51zi7Bgrh" title="Gross proceeds">2,958,848</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NON-CONTROLLING INTEREST<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDisclosureTextBlock', window );">NON-CONTROLLING INTEREST</a></td>
<td class="text"><p id="xdx_809_eus-gaap--MinorityInterestDisclosureTextBlock_zizifLs4YmKa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 8 &#8211; <span id="xdx_827_z2UxdB84e2e9">NON-CONTROLLING INTEREST</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the series A preferred stock offering
discussed in Note 7, Capital Structure, the Company has consolidated the two newly formed subsidiaries, SNAP Biosciences, Inc. and GEAR
Therapeutics, Inc., because we have a controlling interest in both. Therefore, the entities&#8217; financial statements are consolidated
in our consolidated financial statements and the portion of the entities&#8217; equity attributable to external ownership is recorded
as a non-controlling interest. As part of the initial closings, the Series A Investors received in the aggregate a 15% non-voting equity
ownership in both of the newly formed subsidiaries. In addition, investors who participated in the 2025 private placement common stock
offering received an additional 10% aggregate non-voting ownership in SNAP Biosciences, Inc., resulting in an extra $79,000 in equity attributable
to non-controlling interests. The Company contributed the co-development rights to GEAR Therapeutics, Inc. and contributed both the exclusive
license and corporate research agreements with the University of Pittsburgh to SNAP Biosciences, Inc. The Company recorded $<span id="xdx_904_eus-gaap--MinorityInterest_iI_c20251231__dei--LegalEntityAxis__custom--GearTherapeuticsMember_zcwdUpTOBaog" title="Noncontrolling interest">1,063,300</span>
of non-controlling interest at December 31, 2025. Net of accumulated losses of $<span id="xdx_90E_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iI_c20251231__dei--LegalEntityAxis__custom--GearTherapeuticsMember_zGJerPrrLk9i" title="Net of accumulated losses">557,137</span>, the Company recorded $<span id="xdx_905_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iI_c20251231__dei--LegalEntityAxis__custom--GearTherapeuticsMember_z2uTqu2lYDL7" title="Equity attributable to non-controlling interests">506,163</span> in equity attributable
to non-controlling interests at December 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTextBlock', window );">INVESTMENTS</a></td>
<td class="text"><p id="xdx_805_eus-gaap--InvestmentTextBlock_zoTzwyMRtk2k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 9 &#8211;&#160;<span id="xdx_827_zHmsjDFWeM9a">INVESTMENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2024, the Company satisfied $<span id="xdx_904_ecustom--SubscriptionReceivable_iI_dm_c20240831__srt--CounterpartyNameAxis__custom--TwoPrivatelyHeldCompaniesMember_z7mAbw8Itzjj">5.7
million</span> of subscription receivables and related interest receivable in the form of shares of common stock in two privately
held companies. During the year ended December 31, 2025, the Company received <span id="xdx_909_eus-gaap--InvestmentOwnedBalanceShares_iI_dm_c20251231__us-gaap--TransactionTypeAxis__custom--NexGenAIAffiliatesNetworkPlatformMember__srt--CounterpartyNameAxis__custom--FivePrivatelyHeldCompaniesMember_zygfI3UvOgDd">1.25
million</span> shares of common stock in five privately held companies in connection with master services agreements for access to
the NexGenAI Affiliates Network platform. Additionally, to satisfy outstanding accounts receivables related to webinar services
rendered in the master services agreements, the Company received <span id="xdx_904_eus-gaap--InvestmentOwnedBalanceShares_iI_dm_c20251231__us-gaap--TransactionTypeAxis__custom--NexGenAIAffiliatesNetworkPlatformMember__srt--CounterpartyNameAxis__custom--ThreePrivatelyHeldCompaniesMember_zWC2YVqGoTuk">82,500</span>
shares of common stock in three of these privately held companies. The shares of common stock are carried as investments on the
Company&#8217;s consolidated balance sheets at its initial cost basis of $1.00 per share. As the investments are in privately held
companies, the Company will assess the investments for impairment on an annual basis. As of December 31, 2025, the Company
recognized a $<span id="xdx_906_eus-gaap--GainLossOnInvestments_iN_di_c20251101__20251231__us-gaap--TransactionTypeAxis__custom--NexGenAIAffiliatesNetworkPlatformMember_zTufr3C19kxa" title="Loss on investment">163,500</span> unrealized loss due to impairment of one of these investments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2025, the Company issued <span id="xdx_906_ecustom--StockIssuedDuringPeriodSharesIssuedForInvestment_c20251101__20251130__srt--CounterpartyNameAxis__custom--PrivatelyHeldCompanyMember_zgMu2FyQdV0b">66,837</span>
shares of common stock valued at $<span id="xdx_90C_ecustom--StockIssuedDuringPeriodValueIssuedForInvestment_c20251101__20251130__srt--CounterpartyNameAxis__custom--PrivatelyHeldCompanyMember_zbJt0MC6xAQc">1,000,000</span>,
in exchange for <span id="xdx_90F_eus-gaap--InvestmentOwnedBalanceShares_iI_c20251130__srt--CounterpartyNameAxis__custom--PrivatelyHeldCompanyMember_zB2jpaoTdOW5">667,000</span>
shares of a privately held company. The shares of common stock are carried as investments on the Company&#8217;s consolidated
balance sheets at its initial cost basis of $1.50 per share. As the investments are in privately held companies, the Company
will assess the investments for impairment on an annual basis. As of December 31, 2025, <span id="xdx_90C_eus-gaap--GainLossOnInvestments_iN_dio_c20251101__20251231__srt--CounterpartyNameAxis__custom--PrivatelyHeldCompanyMember_zsN8lh9OnHo1" title="Loss on investment">no</span> impairment has been recorded
related to this investment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2025, the
Company entered into a one-year agreement with a customer to provide access to the NexGenAI Affiliates Network platform. The
contract fee paid by the customer consisted of <span id="xdx_90C_ecustom--InvestmentCompanyFeePaidSharesIndirectly_c20250101__20251231_z4g8if05Rh8" title="Investment company fee paid shares indirectly">2,830,189</span>
shares in the customer&#8217;s publicly traded stock, or $<span id="xdx_90D_eus-gaap--InvestmentCompanyFeePaidIndirectly_c20250101__20251231_zngxbOqC2Y3h" title="Investment company fee paid indirectly">600,000</span>,
which the Company recorded as marketable securities on the consolidated balance sheets. The Company classified this marketable
security as a short-term asset as it is expected to be converted into cash within one year. During the year ended December 31, 2025,
the Company recorded an unrealized gain on marketable securities in the amount of $<span id="xdx_90B_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20250101__20251231_zT5ZCztWTXj3" title="Unrealized gain on marketable securities">76,596</span>.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 321<br> -Publisher FASB<br> -URI https://asc.fasb.org/321/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 325<br> -Publisher FASB<br> -URI https://asc.fasb.org/325/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_802_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z63rIQ88SQK6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 10 &#8211; <span id="xdx_82D_zK60r8rxyoR5">COMMITMENTS AND
CONTINGENCIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Leases &#8211;</b> The Company leases
office space under an operating lease that commenced December 1, 2017 and was extended through multiple lease extensions. The third lease
extension extended the lease for twenty-four months, beginning on June 1, 2022 and ended on May 31, 2024. The fourth lease extension,
signed on January 30, 2024, extended the lease for twenty-four months, beginning June 1, 2024 and ending on May 31, 2026. The monthly
rent is $<span id="xdx_90C_ecustom--MonthlyRent_uUSD_c20250101__20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FirstYearExtensionMember_zP97kLHgFb25" title="Monthly rent">3,805</span>&#160;for the first year of the extension and increasing to $<span id="xdx_907_ecustom--MonthlyRent_uUSD_c20250101__20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--SecondYearExtensionMember_zCbR59IAEgZd" title="Monthly rent">3,860</span>&#160;for the second year of the extension.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company records rent expense associated with
this lease on the straight-line basis in conjunction with the terms of the underlying lease. During the year ended December 31, 2025,
rents paid totaled $<span id="xdx_900_eus-gaap--OperatingLeaseExpense_c20250101__20251231_zSb7uE0KklXk" title="Operating lease expense">46,101</span>. During the year ended December 31, 2024, rents paid totaled $<span id="xdx_906_eus-gaap--OperatingLeaseExpense_c20240101__20241231_zwnXA6YZY4U" title="Operating lease expense">45,440</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Right of use asset is summarized below:</p>

<table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--LeaseCostTableTextBlock_zNurRGb4gJA9" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details - Lease cost)">
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span id="xdx_8B9_zfBMVeVu1fG1" style="display: none">Schedule of lease information</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>December 31, 2025</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>December 31, 2024</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 68%; text-align: justify"><span style="font-size: 10pt">Office lease</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98C_ecustom--OperatingLeaseRightOfUseAssetGross_iI_c20251231_zTI5yKVpn9L7" style="width: 13%; text-align: right" title="Operating lease right of use asset, gross"><span style="font-size: 10pt">243,550</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_988_ecustom--OperatingLeaseRightOfUseAssetGross_iI_c20241231_zCNmIOx5AEda" style="width: 13%; text-align: right" title="Operating lease right of use asset, gross"><span style="font-size: 10pt">243,550</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; text-align: justify"><span style="font-size: 10pt">Less: accumulated depreciation</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td id="xdx_982_ecustom--OperatingLeaseRightOfUseAssetAccumulatedDepreciation_iNI_di_c20251231_zfjJ2CGRwWsd" style="border-bottom: Black 1pt solid; text-align: right" title="Operating lease right of use asset, accumulated depreciation"><span style="font-size: 10pt">(225,151</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td id="xdx_98C_ecustom--OperatingLeaseRightOfUseAssetAccumulatedDepreciation_iNI_di_c20241231_zeEO5zVDrf14" style="border-bottom: Black 1pt solid; text-align: right" title="Operating lease right of use asset, accumulated depreciation"><span style="font-size: 10pt">(183,767</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Right of use asset, net</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98D_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20251231_z3MqBXwIerud" style="border-bottom: black 2.25pt double; text-align: right" title="Operating lease right of use asset"><span style="font-size: 10pt">18,399</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98C_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20241231_z29q7WIDxG68" style="border-bottom: black 2.25pt double; text-align: right" title="Operating lease right of use asset"><span style="font-size: 10pt">59,783</span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Operating lease liability is summarized below:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>December 31, 2025</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>December 31, 2024</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 68%; text-align: justify"><span style="font-size: 10pt">Office lease</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98A_eus-gaap--OperatingLeaseLiability_iI_c20251231_z52hvCDNi538" style="width: 13%; text-align: right" title="Operating lease liability"><span style="font-size: 10pt">18,875</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98B_eus-gaap--OperatingLeaseLiability_iI_c20241231_z3X3UlzHpbR9" style="width: 13%; text-align: right" title="Operating lease liability"><span style="font-size: 10pt">61,180</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; text-align: justify"><span style="font-size: 10pt">Less: current portion</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td id="xdx_988_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_c20251231_zbwMKcGw5RS1" style="border-bottom: Black 1pt solid; text-align: right" title="Operating lease liability, current"><span style="font-size: 10pt">(18,875</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td id="xdx_989_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_c20241231_zaYiadVVq5g1" style="border-bottom: Black 1pt solid; text-align: right" title="Operating lease liability, current"><span style="font-size: 10pt">(42,305</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Long term portion</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_984_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_d0_c20251231_z5wk0aoUsIM" style="border-bottom: black 2.25pt double; text-align: right" title="Operating lease liability, noncurrent"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_987_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20241231_zrViZofdPv1h" style="border-bottom: black 2.25pt double; text-align: right" title="Operating lease liability, noncurrent"><span style="font-size: 10pt">18,875</span></td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8A2_zqyctCikfcb8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Future minimum rental payments required under
the lease are as follows:</p>

<table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zhfD5xWoCW72" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details - Future minimum payments)">
  <tr style="vertical-align: bottom">
    <td style="width: 84%"><span id="xdx_8B8_zj1SoMqSanta" style="display: none">Schedule of future minimum rental payments</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_49E_20251231_zvweQfOVXaz9" style="text-align: center; width: 13%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzRwJ_zcNnpXsH026b" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">2026</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">$</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">19,301</span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzRwJ_zf9cpLG5IKMj" style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Total minimum lease payments:</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">19,301</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zvJXonsH07G8" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Less amount representing interest</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(426</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Present value of minimum lease payments:</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">18,875</span></td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8AF_zHQkVCaIL2m2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Legal Matters&#160;</b>&#8211; The Company
is currently not a defendant in any litigation or threatened litigation that could have a material effect on the Company&#8217;s consolidated
financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Employment Agreements with Directors and
Officers &#8211;</b> David Mehalick, our President and Chief Executive Officer, and Daniel Yerace, our Vice President of Operations, entered
into employment agreements with Coeptis Therapeutics, Inc. on February 21, 2022 (the &#8220;Effective Date&#8221;) covering Coeptis and
its subsidiary, Coeptis Pharmaceuticals. The employment agreements will remain in effect until the termination of the employment agreement
by either party in accordance with Section&#160;5 of the employment agreement. Under the employment agreements, the Company currently
pays both Mr. Mehalick and Mr. Yerace an annualized salary at the rate of $<span id="xdx_904_ecustom--AnnualSalary_c20250101__20251231__srt--CounterpartyNameAxis__custom--MehalickMember_zvwLKWdDLC09" title="Annual salary"><span id="xdx_90E_ecustom--AnnualSalary_c20250101__20251231__srt--CounterpartyNameAxis__custom--YeraceMember_zJfoP6lmzqT2" title="Annual salary">360,000</span></span>. Mr. Mehalick and Mr. Yerace will also receive a guaranteed
bonus equal to twenty (20%) of the base salary for each calendar year, and will be eligible to receive merit bonuses, certain milestone
bonuses and awards of stock options, restricted stock units or other equity awards pursuant to any plans or arrangements that the Company
may have in effect from time to time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CAR T License </b>&#8211; On August 31,
2022, the Company entered into an exclusive license agreement with the University of Pittsburgh for certain intellectual property
rights related to the universal self-labeling SynNotch and CARs for programable antigen-targeting technology platform. The Company
paid the University of Pittsburgh a non-refundable fee in the amount of $75,000 for the exclusive patent rights to the licensed
technology. Under the terms of the agreement, the Company has been assigned the worldwide development and commercialization rights
to the licensed technology in the field of human treatment of cancer with antibody or antibody fragments using SNAP-CAR T-cell
technology, along with (i) an intellectual property portfolio consisting of issued and pending patents and (ii) options regarding
future add-on technologies and developments. In consideration of these rights, the Company paid an initial license fee of $<span id="xdx_900_ecustom--InitialLicenseFee_iI_c20220831__us-gaap--TransactionTypeAxis__custom--CarTLicenseMember_z7ogeCkrL0E2" title="Initial license fee">75,000</span>,
and will have <span id="xdx_909_ecustom--AnnualMaintenanceFeeDescription_c20220829__20220831__us-gaap--TransactionTypeAxis__custom--CarTLicenseMember_z6zdmMaazNBh" title="Annual maintenance fee description">annual
maintenance fees ranging between $15,000 and $25,000</span>, as well as developmental milestone payments (as defined in the
agreement) and royalties equal to 3.5% of net sales. On January 25, 2023, the Company entered into a Sponsored Research Agreement
(&#8220;SRA&#8221;) with the University of Pittsburgh for the pre- clinical development of SNAP-CAR T-cells targeting HER2. The
Company agreed to pay $<span id="xdx_90A_eus-gaap--ContractualObligation_iI_c20251231__us-gaap--TransactionTypeAxis__custom--CarTLicenseMember_z2RYCefqhTW3" title="Contractual obligation">716,714</span>
for performance-based milestones over a two-year term, all of which has been paid as of December 31, 2025. The Company&#8217;s
liability was $<span id="xdx_90F_eus-gaap--ContractualObligation_iI_c20251231_zKayGZDufN3d" title="Contractual obligation">0</span>
and $<span id="xdx_90C_eus-gaap--ContractualObligation_iI_c20241231_z1SCzeTXlzDl" title="Contractual obligation">507,535</span> at
December 31, 2025 and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To supplement the development work conducted under
the SRA, the Company&#8217;s subsidiary SNAP Biosciences, in May 2025, entered into a grant agreement with the Alici Lab at the Karolinska
Institutet (&#8220;KI&#8221;). Under the terms of the grant agreement, KI will continue the pre-clinical and clinical development initially
started by Deverra under the terms of the Shared Services Agreement (&#8220;SSA&#8221;) described below. The grant agreement has an 18-month
term which the Company agreed to pay to KI quarterly payments equal to $105,000.</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Also in May 2025, the Company&#8217;s subsidiary,
SNAP Biosciences, entered into a License Agreement with Monarch Therapeutics. The agreement grants SNAP Biosciences access to Monarch&#8217;s
small-molecule adaptor-based technology platform for use with SNAP-CAR. Under the terms of the agreement, SNAP Biosciences agreed to pay
to Monarch a $50,000 upfront payment, a $10,000 annual license fee, and future success-based milestone payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2023, the Company expanded its exclusive
license agreement with the University of Pittsburgh to include SNAP-CAR technology platform in natural killer (NK) cells. The Company
paid $<span id="xdx_903_ecustom--AgreementAmendmentFee_iI_c20230930_z7Ccz973ONKc" title="Agreement amendment fee">2,000</span> to amend the agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Deverra Therapeutics, Inc.&#160;</b>&#8211;
On August 16, 2023, the Company entered into an exclusive licensing arrangement (the &#8220;License Agreement&#8221;) with Deverra Therapeutics
Inc. (&#8220;Deverra&#8221;), pursuant to which the Company completed the exclusive license of key patent families and related intellectual
property related to a proprietary allogeneic stem cell expansion and directed differentiation platform for the generation of multiple
distinct immune effector cell types, including natural killer (NK) and monocyte/macrophages. The License Agreement provides the Company
with exclusive rights to use the license patents and related intellectual property in connection with development and commercialization
efforts in the defined field of use (the &#8220;Field&#8221;) of (a) use of unmodified NK cells as anti-viral therapeutic for viral infections,
and/or as a therapeutic approach for treatment of relapsed/refractory AML and high-risk MDS; (b) use of Deverra&#8217;s cell therapy platform
to generate NK cells for the purpose of engineering with Coeptis SNAP-CARs and/or Coeptis GEAR Technology; and (c) use of Deverra&#8217;s
cell therapy platform to generate myeloid cells for the purpose of engineering with the Company&#8217;s current SNAP-CAR and GEAR technologies.
In support of the exclusive license, the Company also entered into with Deverra (i) an asset purchase agreement (the &#8220;APA&#8221;)
pursuant to which the Company purchased certain assets from Deverra, including but not limited to two Investigational New Drug (IND) applications
and two Phase 1 clinical trial stage programs (NCT04901416, NCT04900454) investigating infusion of DVX201, an unmodified natural killer
(NK) cell therapy generated from pooled donor CD34+ cells, in hematologic malignancies and viral infections and (ii) a non-exclusive sublicense
agreement (the &#8220;Sublicense Agreement&#8221;), in support of the assets obtained by the exclusive license, pursuant to which the
Company sublicensed from Deverra certain assets which Deverra has rights to pursuant a license agreement (&#8220;FHCRC Agreement&#8221;)
by and between Deverra and The Fred Hutchinson Cancer Research Center (&#8220;FHCRC&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, in accordance with the terms of
the Sublicense Agreement, the Company agreed to pay FHCRC certain specified contingent running royalty payments and milestone payments
under the FHCRC Agreement, in each case to the extent such payments are triggered by the Company&#8217;s development activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Until December 2024, we operated under a SSA with Deverra, which provided Coeptis and Deverra to share resources and collaborate on the development
of Coeptis&#8217; GEAR and SNAP-CAR platforms. The Company is continuing its development focus on both GEAR and SNAP-CAR, and will be
considering prospective strategic partners for such development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Registration Rights</b> &#8211; Pursuant to
a registration rights agreement entered into on October 29, 2020, the holders of the founder shares, the Private Placement Warrants and
underlying securities, and any securities issued upon conversion of Working Capital Loans (and underlying securities) would be entitled
to registration rights pursuant to a registration rights agreement. The holders of at least a majority in interest of the then-outstanding
number of these securities were entitled to make up to three demands, excluding short form demands, that the Company register such securities.
In addition, the holders have certain &#8220;piggy-back&#8221; registration rights with respect to registration statements filed subsequent
to the consummation of a Business Combination. Notwithstanding the foregoing, Imperial, I-Bankers and Northland did not exercise their
demand and &#8220;piggyback&#8221; registration rights after five (5) and seven (7) years after the effective date of the registration
statement and did not exercise its demand rights on more than one occasion. The registration rights agreement did not contain liquidating
damages or other cash settlement provisions resulting from delays in registering the Company&#8217;s securities. The Company would bear
the expenses incurred in connection with the filing of any such registration statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Finder&#8217;s Fee and Indemnity Agreement
</b>&#8211; The Company entered into a finder&#8217;s fee and indemnity agreement with a third party, pursuant to which the Company has
agreed to pay a fee in connection with the successful introduction and executive of the SEPA. Under the terms of the agreement, the Company
was obligated to pay a 4% fee upon the closing of the net funding amount of $1,350,000, equaling $54,000, and then 6% of the total cash
consideration received by the Company or the Company&#8217;s creditors in connection with any follow on financing, and 0.5% on the amount
of any drawdown made by the Company on the SEPA. The Company also agreed to indemnify and hold harmless the third party from and against
any and all losses, claims, damages, obligations, penalties, judgments, any and all legal and other actions caused by or related to the
third party&#8217;s engagement with the Company. As of December 31, 2025, the Company paid a total of $<span id="xdx_90D_eus-gaap--PaymentsForFees_c20250101__20251231__us-gaap--TransactionTypeAxis__custom--FindersFeeAndIndemnityAgreementMember_z3ks7zv6MO9l" title="Payment for fees">103,500</span> to the third party in connection
with this finder&#8217;s fee and indemnity agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Master Services Agreements</b>&#160;&#8211;
On December 31,2024 and during the year ended December 31, 2025, the Company entered into one-year agreements with six customers to provide
access to the NexGenAI Affiliates Network platform. Under the terms of these agreements, the Company is obligated to deliver platform
access and related services over the contract period beginning in 2025. Revenue recognition will commence upon the start of services
in accordance with ASC 606,&#160;<i>Revenue from Contracts with Customers</i>. As these agreements represent future contractual obligations,
there was no impact on the Company&#8217;s financial position, results of operations, or cash flows as of December 31, 2024. As of December
31, 2025, the Company has recognized $<span id="xdx_904_eus-gaap--Revenues_c20250101__20251231__us-gaap--TransactionTypeAxis__custom--MasterServicesAgreementsMember_zPrrhccubqge">1,363,045</span>
in revenue in connection with these contracts, with $<span id="xdx_901_eus-gaap--ContractWithCustomerAssetNet_iI_c20251231__us-gaap--TransactionTypeAxis__custom--MasterServicesAgreementsMember_zR9QP5t796H4" title="Customer deposit receivable">599,455</span>
remaining in customer deposits expected to be recognized in 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>GEAR&#8482; Cell Therapy Platform &#8211;</b>
In March 2025, the Company reached an agreement with Vy-Gen-Bio, Inc. (&#8220;Vy-Gen&#8221;) to successfully license the exclusive worldwide
development and commercialization rights to the GEAR&#8482; Cell Therapy Platform, representing a first-in-class approach to modifying
potent cancer-targeting immune cells to optimize the likelihood of deep remission in patients with hematologic malignancies and other
cancers. Coeptis had previously held limited co-development rights to GEAR. As part of this exclusive GEAR license agreement with VyGen-Bio,
Inc., the Company paid a total of $<span id="xdx_908_eus-gaap--PaymentsForFees_c20250101__20251231__us-gaap--TransactionTypeAxis__custom--GearCellTherapyPlatformMember_zUy4rbi2jFEe" title="Payment for fees">400,000</span> for license fees during the year ended December 31, 2025, which the company recorded as research
and development expense, and committed to pay other performance-based fees, milestone and royalty payments in 2026 and beyond.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) PROFIT-SHARING PLAN<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock', window );">401(k) PROFIT-SHARING PLAN</a></td>
<td class="text"><p id="xdx_806_eus-gaap--CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_zMQNysjO24Da" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 11 - <span id="xdx_825_zJCTDhq7YJi8">401(k) PROFIT-SHARING
PLAN</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company sponsors a qualified profit-sharing
plan with a 401(k) feature that covers all eligible employees. Participation in the 401(k) feature of the plan is voluntary. Participating
employees may defer up to 100% of their compensation up to the maximum prescribed by the Internal Revenue Code. The plan permits for employee
elective deferrals but has no contribution requirements for the Company. During the years ended December 31, 2025 and 2024,&#160;<span id="xdx_904_eus-gaap--DefinedBenefitPlanContributionsByEmployer_pp0p0_do_c20250101__20251231_zIWhRsvwKX3" title="Employer contributions"><span id="xdx_90A_eus-gaap--DefinedBenefitPlanContributionsByEmployer_pp0p0_do_c20240101__20241231_zed3SSxxssji" title="Employer contributions">no</span></span>&#160;employer
contributions were made.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of an entity's employee compensation and benefit plans, excluding share-based compensation and including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p id="xdx_805_eus-gaap--IncomeTaxDisclosureTextBlock_zhwx7qezIYae" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>NOTE
12 &#8211; <span id="xdx_820_zivfYEtOwphb">INCOME TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company
has established deferred tax assets and liabilities for the recognition of future deductions or taxable amounts and operating loss carry
forward. Deferred federal and state income tax expense or benefit is recognized as a result of the change in the deferred tax asset or
liability during the year using the currently enacted tax laws and rates that apply to the period in which they are expected to affect
taxable income. Valuation allowances are established, if necessary, to reduce deferred tax assets to the amount that will more likely
than not be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>During
the years ended December 31, 2025 and 2024, a reconciliation of income tax benefit at the statutory rate of 35% and 35%, respectively
to income tax benefit at the Company&#8217;s effective tax rate is as follows:</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zQRlzwnj8iTg" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - INCOME TAXES (Details - Reconcilation of income tax)">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-size: 10pt"><span id="xdx_8BB_zz5fIkO2LeJe" style="display: none">Schedule of effective income
    tax reconciliation</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_49F_20250101__20251231_zEZKqKHR0Vr4" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_49E_20240101__20241231_zw7wqMsWN7r" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2025</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2024</b></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_iN_di_zRJCLbPmId39" style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 68%; text-align: justify"><span style="font-size: 10pt">Income tax benefit at statutory rate</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt">2,983,800</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt">2,455,499</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_pp0p0_di_z7QukHZQwO7d" style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Change in valuation allowance</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">(2,983,800</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">(2,455,499</span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The income
tax provision differs from the expense that would result from applying federal statutory rates to income taxes as follows:</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zuKJKVl0AiLb" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - INCOME TAXES (Details - Reconcilation of provision)">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-size: 10pt"><span id="xdx_8B7_zVCL0npBJ3ee" style="display: none">Schedule of income tax provision</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2025</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2024</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 44%"><span style="font-size: 10pt">Excepted federal statutory income tax provision/rate</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98B_ecustom--ExpectedIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_iN_di_c20250101__20251231_zgJaatUK6x9c" style="width: 11%; text-align: right" title="Expected federal statutory income tax provision"><span style="font-size: 10pt">(2,521,826</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><span id="xdx_90A_ecustom--ExpectedEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pip0_dp_c20250101__20251231_zg0CG6XMikJi" style="font-size: 10pt">(21.0</span><span style="font-size: 10pt">%</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98D_ecustom--ExpectedIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_iN_di_c20240101__20241231_zpLeMPaNqmn6" style="width: 11%; text-align: right" title="Expected federal statutory income tax provision/rate"><span style="font-size: 10pt">(2,284,257</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><span id="xdx_904_ecustom--ExpectedEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_c20240101__20241231_zBq80To0LlB4" style="font-size: 10pt">(21.0</span><span style="font-size: 10pt">%</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">State income taxes, net of federal benefit</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_iN_di_c20250101__20251231_zv8bhZNz8msi" style="text-align: right" title="State income taxes, net of federal benefit"><span style="font-size: 10pt">(367,582</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pip0_dp_c20250101__20251231_zvrJZoK5FiEf" style="font-size: 10pt">(3.1</span><span style="font-size: 10pt">%</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_iN_di_c20240101__20241231_zQub2Ex3zNI1" style="text-align: right" title="State income taxes, net of federal benefit"><span style="font-size: 10pt">(58,863</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_c20240101__20241231_zdkbDi8RN0lh" style="font-size: 10pt">(0.5</span><span style="font-size: 10pt">%</span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Other</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_989_eus-gaap--IncomeTaxReconciliationOtherAdjustments_d0_c20250101__20251231_zmxjFEVCrXpb" style="border-bottom: black 1pt solid; text-align: right" title="Other"><span style="font-size: 10pt">(94,392</span></td>
    <td><span style="font-size: 10pt">)&#160;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_iN_pip0_dpi0_c20250101__20251231_zYh3smvTRDvl" style="font-size: 10pt">(0.8</span><span style="font-size: 10pt">%</span></td>
    <td><span style="font-size: 10pt">)&#160;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_984_eus-gaap--IncomeTaxReconciliationOtherAdjustments_d0_c20240101__20241231_zw8VxXHZ5Shd" style="border-bottom: black 1pt solid; text-align: right" title="Other"><span style="font-size: 10pt">(112,379)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_iN_pip0_dpi0_c20240101__20241231_zEBzGddw97je" style="font-size: 10pt">(1.0</span><span style="font-size: 10pt">%)</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Income tax benefit at statutory rate</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98A_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maprovision2025_c20250101__20251231_zwemTfow8Awi" style="text-align: right" title="Income tax benefit at statutory rate"><span style="font-size: 10pt">(2,983,800</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_pip0_dpi_marate2025_c20250101__20251231_zDODJ5rM56Qc" style="font-size: 10pt">(24.9</span><span style="font-size: 10pt">%</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_981_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c20240101__20241231_zMr9ZKcuNona" style="text-align: right" title="Income tax benefit at statutory rate"><span style="font-size: 10pt">(2,455,499</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_dpi_c20240101__20241231_z4GVmULZyP7f" style="font-size: 10pt">(22.6</span><span style="font-size: 10pt">%</span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Change in valuation allowance</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_989_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maprovision2025_c20250101__20251231_zMUIjVGTqpLc" style="border-bottom: black 1pt solid; text-align: right" title="Change in valuation allowance"><span style="font-size: 10pt">2,983,800</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_pip0_dpi_marate2025_c20250101__20251231_zHvwiCenaScl" style="font-size: 10pt">22.6</span><span style="font-size: 10pt">%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_987_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c20240101__20241231_zdyr5v627Cmf" style="border-bottom: black 1pt solid; text-align: right" title="Change in valuation allowance"><span style="font-size: 10pt">2,455,499</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_dpi_c20240101__20241231_z1TeO8BKFuMi" style="font-size: 10pt">22.6</span><span style="font-size: 10pt">%</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_988_eus-gaap--IncomeTaxExpenseBenefit_d0_mtprovision2025_c20250101__20251231_z1RqDGAfPcNf" style="border-bottom: black 2.25pt double; text-align: right" title="Effective income tax rate reconciliation"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pip0_dp0_mtrate2025_c20250101__20251231_zhmLjvr2ewz7" style="font-size: 10pt">&#8211;</span><span style="font-size: 10pt">%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_980_eus-gaap--IncomeTaxExpenseBenefit_d0_c20240101__20241231_zAUFj5ujmvPi" style="border-bottom: black 2.25pt double; text-align: right" title="Effective income tax rate reconciliation"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pip0_dp0_c20240101__20241231_zstWZS4RSFbh" style="font-size: 10pt">&#8211;</span><span style="font-size: 10pt">%</span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company&#8217;s
calculation of net operating loss carryforwards:</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--SummaryOfOperatingLossCarryforwardsTextBlock_z9tlH1zytSh1" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - INCOME TAXES (Details - Operating loss carryforwards)">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt"><span id="xdx_8BB_zd0nrNFVfkUb" style="display: none">Schedule of net operating loss carryforwards</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_49F_20251231_zzT8UvYvcx4f" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_499_20241231_zk929KRLf6K8" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2025</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2024</b></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0" style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Deferred tax assets</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0" style="vertical-align: bottom; background-color: white">
    <td style="width: 68%"><span style="font-size: 10pt">Net operating loss carryforwards</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt">28,184,213</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt">24,971,010</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pp0p0" style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Section 174 R&amp;D</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,084,044</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,275,054</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_pp0p0" style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">PPE and intangible assets</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">974,646</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">915,327</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsStateTaxes_iNI_pp0p0_di_zxtLMq6E5fo9" style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">State taxes</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(1,667,634</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(1,569,922</span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsGross_iI_pp0p0_zDPigNQka0d5" style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Subtotal</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">28,575,269</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">25,591,469</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_zxpC5d1kvps6" style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Valuation Allowance</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(28,575,269</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(25,591,469</span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iI_pp0p0_d0_zNgvx6e3tjdf" style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Net deferred tax assets (liabilities)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>At December
31, 2025, the Company had approximately $<span id="xdx_90F_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20251231_zRiquT0WSzX" title="Net operating loss carry forwards">99,000,000</span> of unused net operating loss carryforwards. Unused net operating loss carryforwards
may provide future benefits although there can be no assurance that these net operating losses will be realized in the future. The tax
benefits of these loss carryforwards have been fully offset by valuation allowance. These losses may be used to offset future taxable
income and will carryforward indefinitely.</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p id="xdx_807_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zW3f44dxS5Bh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 13 &#8211; <span id="xdx_82B_zxTHs3KSiwRl">RELATED PARTY
TRANSACTIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2023, the Company entered into a
transaction with AG Bio Life Capital I LP (&#8220;AG&#8221;), a Delaware limited partnership, where an employee of the Company is the
general partner. The Company agreed to issue <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesOther_c20230929__20230930__dei--LegalEntityAxis__custom--AGBioLifeCapitalILPMember_zR1n5s9xhjB" title="Shares issued">600,000</span> shares (pre-reverse stock split) of common stock of the Company (&#8220;AG Shares&#8221;)
to AG, in exchange for $600,000, consisting of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230929__20230930__dei--LegalEntityAxis__custom--AGBioLifeCapitalILPMember_zzoClMlBNOr2" title="Proceeds from common stock">100,000</span>&#160;payable in cash and the balance payable under a promissory note (&#8220;AG
Note&#8221;). The principal amount including all interest under the AG Note is due and payable by AG no later than August 30, 2024 (the
&#8220;AG Maturity Date&#8221;). The outstanding unpaid principal balance of the AG Note bears interest commencing as of the Company&#8217;s
next registration statement at the rate of six (6%) percent per annum, which interest rate will increase to eighteen (18%) percent per
annum in the event an event of default occurs under the AG Note, computed on the basis of the actual number of days elapsed and a year
of 365 days. On August
12, 2024, AG transferred and assigned $<span id="xdx_90D_eus-gaap--AccountsAndNotesReceivableNet_iI_c20240812__dei--LegalEntityAxis__custom--AGBioLifeCapitalILPMember_zt4MEzfZ3Vm5" title="Note receivable">522,667</span> to the Company, the sum of principal and accrued interest owed, of shares of common stock
in a privately held company. As a result of this assignment agreement, the AG Note is considered paid in full, and $<span id="xdx_901_eus-gaap--Investments_iI_pp0p0_c20241231__dei--LegalEntityAxis__custom--AGBioLifeCapitalILPMember_zJj2u1A5LDCj" title="Investment"><span id="xdx_908_eus-gaap--Investments_iI_pp0p0_c20251231__dei--LegalEntityAxis__custom--AGBioLifeCapitalILPMember_zvYnXx4HlYfa" title="Investment">522,667</span></span> is recorded
as an investment at December 31, 2025 and December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2025, the Company accrued $<span id="xdx_901_eus-gaap--AccruedProfessionalFeesCurrent_iI_c20251231__srt--CounterpartyNameAxis__custom--BoardOfDirectorsMember_zj2iVD9VrIYc" title="Accrued professional fees">32,500</span>
of professional services expenses related to Board of Directors and Scientific Advisory Board compensation. These payments were completed
in the first quarter of 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2025, the Company holds investments
in certain privately held companies, recorded as investments on the Company&#8217;s consolidated balance sheets. The Company&#8217;s Chief
Executive Officer and Chief Financial Officer each hold ownership interests in these privately held companies. The investments were made
in the ordinary course of business and on terms management believes are consistent with those that would be negotiated on an arm&#8217;s
length basis. As of December 31, 2025 and December 31, 2024, the Company&#8217;s carrying value of these investments was $<span id="xdx_900_eus-gaap--OtherInvestments_iI_c20251231_zd0uOhaLl93a" title="Other investments">7,023,583</span> and
$<span id="xdx_904_eus-gaap--OtherInvestments_iI_c20241231_zzZ8i5BALxYf" title="Other investments">5,691,084</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--IntangibleAssetsDisclosureTextBlock_znCU8q6tmIEc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 14 &#8211; <span id="xdx_82F_zGxZBhbJiuUi">INTANGIBLE ASSETS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 19, 2024, the Company acquired the
assets of NexGenAI Affiliates Network Platform (&#8220;NexGenAI&#8221;), from the seller NexGenAI Solutions Group, Inc., which contains
AI-powered marketing software and robotic process automation capabilities. The acquired assets include intellectual property, a domain
name and associated website, and the technology stack as defined in the agreement. As consideration for the purchase, the Company paid
the seller <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20241218__20241219__srt--CounterpartyNameAxis__custom--NexGenAISolutionsGroupIncMember_zxxpMjYJ7uMc" title="Stock issued for purchase of assets, shares">187,500</span> shares of common stock, or $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_c20241218__20241219__srt--CounterpartyNameAxis__custom--NexGenAISolutionsGroupIncMember_zPXxYWvYHTBf" title="Stock issued for purchase of assets, value">541,875</span>. In connection with the purchase, the Company entered into a Master Services Agreement
with the seller, for website development services and for services to enhance the existing technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounted for the NexGenAI
transaction as an asset acquisition in accordance with ASC 805-50, <i>Business Combinations &#8211; Asset Acquisitions</i>, and
recorded as intangible assets on the consolidated balance sheet, net of amortization, in the amount of $<span id="xdx_907_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NexGenAIMember_zEZSlZrsouye">361,250</span>
and $<span id="xdx_907_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NexGenAIMember_zRwZr0OfhrS2">541,875</span> as of December 31,
2025 and December 31, 2024, respectively. The Company recorded amortization expense of $<span id="xdx_902_eus-gaap--AmortizationOfIntangibleAssets_c20250101__20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NexGenAIMember_zzOPVyxdJ9Xa" title="Amortization of intangible assets">180,625</span> and $<span id="xdx_90A_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NexGenAIMember_zmayEPTz88A8" title="Amortization of intangible assets">0</span> during the years ended
December 31, 2025 and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT REPORTING</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--SegmentReportingDisclosureTextBlock_zY5Niu9LSMA7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 15 &#8211;&#160;<span id="xdx_82A_zw6rAoezTV4k">SEGMENT REPORTING</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Operating segments are components of an enterprise
about which separate financial information is available and is evaluated regularly by management, namely the Chief Operating Decision
Maker (&#8220;CODM&#8221;) of an organization, in order to determine operating and resource allocation decisions. By this definition,
the Company has identified its Chief Executive Officer as the CODM. Effective in 2024, the Company began operating in <span id="xdx_90B_eus-gaap--NumberOfReportableSegments_dxL_uInteger_c20250101__20251231_zb3RIjcYUnDb" title="Number of reportable segments::XDX::2"><span style="-sec-ix-hidden: xdx2ixbrl1755">two</span></span> segments: Biotechnology
and Technology. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Biotechnology Segment: This segment is non-revenue
generating and incurs expenses by developing its biotechnology product pipeline. The Biotechnology Segment had total assets of $<span id="xdx_904_eus-gaap--Assets_iI_c20251231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologySegmentMember_zoqgt0yQYyVf" title="Total assets">13,783,575</span>
and $<span id="xdx_90B_eus-gaap--Assets_iI_c20241231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologySegmentMember_zXVZlhuEh8Rf" title="Total assets">8,366,785</span> as of December 31, 2025 and December 31, 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Technology Segment: This segment is revenue
generating and incurs expenses by acquiring technology assets to support and enhance operational capabilities through advanced technologies.
The Technology Segment had total assets of $<span id="xdx_901_eus-gaap--Assets_iI_c20251231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologySegmentMember_zxE2wSUQ1rq3" title="Total assets">2,370,346</span> and $<span id="xdx_908_eus-gaap--Assets_iI_c20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologySegmentMember_zPVZQ3Gu47Z9" title="Total assets">541,875</span> as of December 31, 2025 and December 31, 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company believes that this structure reflects
its current operational and financial management, and that it provides the best structure for the Company to focus on growth opportunities
while maintaining financial discipline. The factors used to identify the Biotechnology and Technology operating segments were the difference
in future potential revenue streams and customer base for each segment, the reporting structure for operational and performance information
within the Company, and management&#8217;s decision to organize the Company around the different future potential revenue generating activities
of the segments.</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Segment information relating the Company's two operating segments
for the years ended December 31, 2025 and December 31, 2024 are as follows:</p>

<table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zjX9HX3W2cJ8" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - SEGMENT REPORTING (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td><span id="xdx_8B3_zhFTKBU63z7i" style="display: none">Schedule of segment information</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="10" style="text-align: center"><span style="font-size: 10pt"><b>Year Ended December 31, 2025</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Biotechnology Segment</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Technology <br/>
Segment</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Consolidated</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 58%"><span style="font-size: 10pt">Sales</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98D_eus-gaap--Revenues_d0_c20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_zjOPg0dyozD" style="width: 11%; text-align: right" title="Sales"><span style="font-size: 10pt">&#8211;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98C_eus-gaap--Revenues_c20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyMember_zuSi0ncYYfZ4" style="width: 11%; text-align: right" title="Sales"><span style="font-size: 10pt">1,363,045</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98C_eus-gaap--Revenues_c20250101__20251231_zt2l2Yxxzvah" style="width: 11%; text-align: right" title="Sales"><span style="font-size: 10pt">1,363,045</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Cost of goods sold</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--CostOfRevenue_d0_c20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_z1mQVpjjabw5" style="text-align: right" title="Cost of goods sold"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--CostOfRevenue_c20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyMember_zQ2UtSYCMW95" style="text-align: right" title="Cost of goods sold"><span style="font-size: 10pt">180,625</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98A_eus-gaap--CostOfRevenue_c20250101__20251231_zdGumLwZcbV9" style="text-align: right" title="Cost of goods sold"><span style="font-size: 10pt">180,625</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">Total operating expenses</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_982_eus-gaap--OperatingExpenses_c20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_zRhfiiVMtsQj" style="border-bottom: black 1pt solid; text-align: right" title="Total operating expenses"><span style="font-size: 10pt">13,540,971</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_983_eus-gaap--OperatingExpenses_c20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyMember_zFIuUn47BtQg" style="border-bottom: black 1pt solid; text-align: right" title="Total operating expenses"><span style="font-size: 10pt">684,947</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98C_eus-gaap--OperatingExpenses_c20250101__20251231_zizQaAuvHgX8" style="border-bottom: black 1pt solid; text-align: right" title="Total operating expenses"><span style="font-size: 10pt">14,225,918</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Net (loss) gain from operations</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_988_eus-gaap--OperatingIncomeLoss_c20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_zvvYDj8S3lU" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss from operations"><span style="font-size: 10pt">(13,540,971</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_980_eus-gaap--OperatingIncomeLoss_c20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyMember_zHMKDyZHlpV5" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss from operations"><span style="font-size: 10pt">497,473</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_988_eus-gaap--OperatingIncomeLoss_c20250101__20251231_ziLj9kCiPnkj" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss from operations"><span style="font-size: 10pt">(13,043,498</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - SEGMENT REPORTING (Details)">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="10" style="text-align: center"><span style="font-size: 10pt"><b>Year Ended December 31, 2024</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Biotechnology Segment</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Technology </b></span><br/>
<span style="font-size: 10pt"><b>Segment</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Consolidated</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 61%"><span style="font-size: 10pt">Sales</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_982_eus-gaap--Revenues_d0_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_zRch71FsyVI1" style="width: 10%; text-align: right" title="Sales"><span style="font-size: 10pt">&#8211;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_984_eus-gaap--Revenues_d0_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyMember_zUGb5ZvWrtNk" style="width: 10%; text-align: right" title="Sales"><span style="font-size: 10pt">&#8211;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98C_eus-gaap--Revenues_d0_c20240101__20241231_zPccjbODzKA5" style="width: 10%; text-align: right" title="Sales"><span style="font-size: 10pt">&#8211;</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Cost of goods sold</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_985_eus-gaap--CostOfRevenue_d0_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_zIWFmPX2DPKj" style="text-align: right" title="Cost of goods sold"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_981_eus-gaap--CostOfRevenue_d0_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyMember_zLUfAV0Y7P9a" style="text-align: right" title="Cost of goods sold"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--CostOfRevenue_d0_c20240101__20241231_zZD7MCnt0iKf" style="text-align: right" title="Cost of goods sold"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">Total operating expenses</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98C_eus-gaap--OperatingExpenses_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_zO2St6XwO9Wa" style="border-bottom: black 1pt solid; text-align: right" title="Total operating expenses"><span style="font-size: 10pt">10,054,488</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98F_eus-gaap--OperatingExpenses_d0_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyMember_znnmn6cYX5D3" style="border-bottom: black 1pt solid; text-align: right" title="Total operating expenses"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_982_eus-gaap--OperatingExpenses_c20240101__20241231_zOWjJnUP578e" style="border-bottom: black 1pt solid; text-align: right" title="Total operating expenses"><span style="font-size: 10pt">10,054,488</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Net loss from operations</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98B_eus-gaap--OperatingIncomeLoss_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_zxUQWwHKpD9k" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss from operations"><span style="font-size: 10pt">(10,054,488</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98E_eus-gaap--OperatingIncomeLoss_d0_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyMember_zYzKkFg1aHWd" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss from operations"><span style="font-size: 10pt">&#8211;</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98E_eus-gaap--OperatingIncomeLoss_c20240101__20241231_z1Se8kIKBQFh" style="border-bottom: Black 2.5pt double; text-align: right" title="Net (loss) gain from operations"><span style="font-size: 10pt">(10,054,488</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">)</span></td></tr>
  </table>
<p id="xdx_8A9_zz9cU8sRXl2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PENDING MERGER TRANSACTION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_DisclosurePendingMergerTransactionAbstract', window );"><strong>Pending Merger Transaction</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_PendingMergerTransactionDisclosureTextBlock', window );">PENDING MERGER TRANSACTION</a></td>
<td class="text"><p id="xdx_808_ecustom--PendingMergerTransactionDisclosureTextBlock_zLg0tYgYaVR8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 16 &#8211; <span id="xdx_823_zbJIHfzTMJCg">PENDING MERGER
TRANSACTION</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 25, 2025, the Company (&#8220;Coeptis&#8221;
or the &#8220;Purchaser&#8221;), entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) with CP Merger Sub
Inc., a Wyoming corporation and wholly-owned subsidiary of Coeptis (&#8220;Merger Sub&#8221;), and Z Squared, Inc., a Wyoming corporation
(&#8220;Z Squared&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Merger Agreement, subject to the
terms and conditions set forth therein, upon the consummation of the transactions contemplated by the Merger Agreement (the &#8220;Closing&#8221;),
(i) Merger Sub will merge with and into Z Squared (the &#8220;Merger&#8221;) and (ii) Coeptis will immediately prior to the Merger effect
a spin out of its biotechnology operations (the &#8220;Spin Out&#8221; and, together with Merger and the other transactions contemplated
by the Merger Agreement, the &#8220;Transactions&#8221;), with Z squared continuing as the surviving corporation in the Merger and becoming
a wholly-owned subsidiary of Coeptis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the Merger, all shares of Z Squared common
stock issued and outstanding immediately prior to the effective time of the Merger (other than those properly exercising any applicable
dissenters rights under Wyoming law), will be converted into the right to receive a portion of the Merger Consideration (as defined below)
and (ii) any other outstanding securities with the right to convert into or acquire equity securities of Z Squared will be terminated.
At the Closing, Coeptis will change its name as mutually agreed upon by the Purchaser and Z Squared. <span>The
Merger is expected to close in the second quarter 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Spin Out, all of Coeptis&#8217;
assets comprising its biotechnology business will be assigned and contributed prior to Closing to one or more Spin Out Subsidiaries, which
will then spin out to Coeptis&#8217; stockholders of record on the record date established for the Coeptis Special Meeting (as defined
below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate Merger Consideration received by
Z Squared security holders from Coeptis at the Closing will be a number of shares of Purchaser Common Stock that represents at Closing
the Applicable Percentage of Purchaser&#8217;s issued and outstanding shares of Purchaser Common Stock as calculated on a Fully-Diluted
Basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_DisclosurePendingMergerTransactionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_DisclosurePendingMergerTransactionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_PendingMergerTransactionDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_PendingMergerTransactionDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_zf7swnmyJLMh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE
17 &#8211; <span id="xdx_820_zrwqph3Huiol">SUBSEQUENT EVENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management has performed a review of all events
and transactions occurring after December 31, 2025 for items that would require adjustment to or disclosure in the accompanying consolidated
financial statements, noting no such items or transactions other than the following.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 12, 2026, the Company received a written
notice from The Nasdaq Stock Market (&#8220;Nasdaq&#8221;), indicating that the Company was not in compliance with Nasdaq Listing Rules
5620(a) and 5810(c)(2)G) due to the Company&#8217;s failure to hold an annual meeting of shareholders within twelve months of the end
of the Company&#8217;s fiscal year end of December 31, 2024. On February 9, 2026, the Company was notified by The Nasdaq Stock Market
that the Company has regained compliance with the annual meeting requirement for continued listing on The Nasdaq Capital Market. Accordingly,
the Company has regained compliance with Nasdaq Listing Rules and the matter is now closed.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 12, 2026, 1,464 shares of common stock
were issued in connection the SEPA, resulting in net cash proceeds of $20,862.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 28, 2026, 13,809 shares of common stock
were issued in connection the SEPA, resulting in net cash proceeds of $180,942.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 5, 2026, 24,000 shares of common stock
were issued in connection the SEPA, resulting in net cash proceeds of $302,450.</p>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 11, 2026, the Company implemented
an option repricing/exchange program pursuant to Option Repricing and Exchange Election Agreements (the Option/Exchange Agreements) with
its then current holders of options previously granted under the Company&#8217;s 2022 Equity Incentive Plan, including each of the Company&#8217;s
current officers and directors. These Option/Exchange Agreements provided a one-time opportunity for the option holders to elect to either
(i) have a one-time option repricing be applied to their respective options with exercise prices greater than the current fair market
value of the Company&#8217;s common stock or (ii) surrender their outstanding options with exercise prices greater than the current fair
market value of the Company&#8217;s common stock in exchange for restricted stock. In connection with the Option/Exchange Program, the
Company also accelerated vesting of all options including those with exercise prices greater than the current fair market value of the
Company&#8217;s common stock, such that all options became fully vested.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s Board of Directors approved
the Option/Exchange program, including the accelerated vesting and the optionality of electing to reprice certain options or replace such
options with restricted stock. The Company&#8217;s stockholders approved this one-time repricing or exchange event at its recent stockholders
meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to these Option/Exchange Agreements,
officers and directors surrendered options to purchase a total of 112,500 shares of common stock, and received in exchange thereof 112,500
shares of restricted stock. Other option holders surrendered a total of 17,125 options to purchase shares of common stock and received
in exchange thereof 17,125 shares of restricted stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, certain officers and directors of
the Company exercised their respective retained options in full, pursuant to which officers and directors exercised options to purchase
a total of 198,375 shares of restricted common stock. Other option holders exercised options to purchase a total of 9,000 shares of restricted
common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Option/Exchange Agreements include customary
representations and warranties and acknowledgements by the participants. The foregoing description of the Option/Exchange Agreements does
not purport to be complete and is qualified in its entirety by reference to the full text of the Option/Exchange Agreements, a form of
which will be filed as an exhibit to a subsequent filing with the Securities and Exchange Commission.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 2, 2026, the holder of a standalone option exercised the option
to purchase 100,000 shares of the Company&#8217;s common stock. Upon exercise of the option, the Company issued 100,000 shares of restricted
common stock in accordance with the terms of the option agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zGm6yV3zsErd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86F_zyoHTINo5VH3">Cash</span></b> &#8211; For purposes of the consolidated
statements of cash flows, the Company considers all highly liquid investments purchased with maturities of three months or less to be
cash equivalents. At times, balances of cash and cash equivalents at financial banking institutions exceeded the federally insured limit
of $250,000. Uninsured balances were $<span id="xdx_903_eus-gaap--CashUninsuredAmount_iI_c20251231_zN2x1dAe3aXg" title="Cash uninsured amount">5,424,302</span> and $<span id="xdx_90B_eus-gaap--CashUninsuredAmount_iI_c20241231_zoFGPqjfmOD4" title="Cash uninsured amount">282,885</span> at December 31, 2025 and 2024, respectively. The Company regularly monitors
the financial condition of the institution in which it has depository accounts and believes the risk of loss is minimal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zbI43jjYfaok" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_862_zTI2mm429brg">Property and Equipment</span></b> &#8211; Fixed assets
are stated at cost and depreciation is computed using the straight-line method for financial statement purposes. For the years ended December
31, 2025 and 2024, depreciation expense totaled $<span id="xdx_902_eus-gaap--Depreciation_pp0p0_c20250101__20251231_z1tZWfPnEmg2" title="Depreciation expense">587</span>&#160;and $<span id="xdx_900_eus-gaap--Depreciation_pp0p0_c20240101__20241231_zToUtw0uIgXc" title="Depreciation expense">845</span> respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zPZuzK2istNa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86D_zhEsujK9A1Q6">Intangible Assets</span></b> &#8211; The Company records
intangible assets at cost and evaluates them for impairment in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;)
Accounting Standards Codification (&#8220;ASC&#8221;) 350, <i>Intangibles &#8211; Goodwill and Other. </i>Intangibles are being amortized
using the straight-line method over estimated useful lives of between two and forty years. The Company recorded intangible assets of $<span id="xdx_905_eus-gaap--FinitelivedIntangibleAssetsAcquired1_c20250101__20251231__us-gaap--AssetAcquisitionAxis__custom--NexGenAIMember_zx0iJDtPiIvc" title="Intangible assets acquired">361,250</span>
and $<span id="xdx_90F_eus-gaap--FinitelivedIntangibleAssetsAcquired1_c20240101__20241231__us-gaap--AssetAcquisitionAxis__custom--NexGenAIMember_zr7CYzFlfrek" title="Intangible assets acquired">541,875</span> as of December 31, 2025 and December 31, 2024, respectively, related to the acquired assets of NexGenAI Affiliates Network
Platform (&#8220;NexGenAI&#8221;), which contains AI-powered marketing software and robotic process automation capabilities. See Note
14, Intangible Assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Investments and Marketable Securities</a></td>
<td class="text"><p id="xdx_840_eus-gaap--MarketableSecuritiesPolicy_zYcevolqQtzf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_862_zgGq4RzAIRql">Investments
and Marketable Securities</span> </b>&#8211; The Company classifies its investments and marketable securities in accordance with ASC 320, <i>Investments
&#8211; Debt and Equity Securities</i>, and ASC 321, <i>Investments &#8211; Equity Securities</i>, as applicable. Investments in
equity securities with readily determinable fair values are measured at fair value, with unrealized gains and losses recognized in
net income. For equity securities without readily determinable fair values, the Company applies the measurement alternative,
recording these investments at cost, adjusted for impairments or observable price changes from transactions involving similar
securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Marketable securities are categorized as trading
securities and are thus marked to market and stated at fair value. Fair value is determined using the quoted closing bid prices and is
recorded as a Level&#160;1 asset. Realized gains and losses on marketable securities are recognized as incurred in the consolidated statements
of operations. Net changes in unrealized gains and losses are reported in the consolidated statements of operations in the current period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_841_eus-gaap--LesseeLeasesPolicyTextBlock_zZd5E69YaC1l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_861_z0y9vDd2f1ad">Leases</span> </b>&#8211; The Company accounts for
leases in accordance with ASC 842, <i>Leases</i>. At lease commencement, the Company recognizes a right-of-use (&#8220;ROU&#8221;) asset
and a corresponding lease liability based on the present value of future lease payments. Lease liabilities are measured using the Company&#8217;s
incremental borrowing rate if the implicit rate is not readily determinable. ROU assets include initial direct costs and prepaid lease
payments and are reduced for lease incentives received.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_zGhipFppvmqj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_862_zTqBTUr2ay9b">Research
and Development</span> &#8211; </b>Research and development costs are expensed when incurred. During the years ended December 31,
2025 and 2024, research and development expenses totaled $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20250101__20251231_zBA2qHuPDBA1" title="Research and development expenses">1,277,150</span>
and $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240101__20241231_zkmiNA8JRxJb" title="Research and development expenses">2,331,548</span>,
respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zXWVvjClM0Hk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_865_zugKK9EiCuYd">Impairment
of Long-Lived Assets</span> &#8211; </b>The Company&#8217;s property and equipment and other non-current assets are reviewed
annually for possible impairment when events or changes in circumstances indicate that the carrying amount may not be recoverable.
An impairment loss would be recognized if and when the estimated future cash flows expected to result from the use of the asset and
its eventual disposition is less than its carrying amount. There was&#160;<span id="xdx_90C_eus-gaap--AssetImpairmentCharges_do_c20250101__20251231_zKtzAEblcpXd" title="Asset impairment charges"><span id="xdx_901_eus-gaap--AssetImpairmentCharges_do_c20240101__20241231_zEZpMcINsYf4">no</span></span>
impairment recognized for the years ended December 31, 2025 and 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Liability Warrants</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--DerivativesPolicyTextBlock_zuMnkgjuA1yc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_864_znIkXgOSEJe2">Derivative Liability Warrants</span> &#8211; </b>The
Company accounts for the Public Warrants and Private Placement Warrants (the &#8220;Warrants&#8221;) in accordance with the guidance contained
in ASC 815-40, <i>Derivatives and Hedging</i>, under which the Warrants do not meet the criteria for equity treatment and must be recorded
as liabilities. Accordingly, the Company classifies the Warrants as liabilities at their fair value and adjusts the Warrants to fair value
in each respective reporting period. This liability is subject to re-measurement at each consolidated balance sheet date until the Warrants
are exercised, and any change in fair value is recognized in the consolidated statements of operations. The Private Placement Warrants
and the Public Warrants for periods where no observable traded price was available are valued using a binomial lattice simulation model.
For periods subsequent to the detachment of the Public Warrants from the Units, the Public Warrant quoted market price was used as the
fair value as of each relevant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Convertible Debt</a></td>
<td class="text"><p id="xdx_844_eus-gaap--DebtPolicyTextBlock_zPHbxdJkHdZj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_866_z9JMzbYp8Og5">Convertible Debt</span></b> &#8211; The Company accounts
for convertible debt in accordance with ASC 470-20, <i>Debt &#8211; Debt with Conversion and Other Options</i>. Convertible debt instruments
are evaluated at issuance to determine whether they contain embedded features that require bifurcation as derivatives or equity components.
If the embedded conversion feature meets the criteria for derivative accounting under ASC 815, <i>Derivatives and Hedging</i>, it is bifurcated
and recorded separately at fair value, with subsequent changes in fair value recognized in earnings. Upon conversion or repurchase of
convertible debt, the Company recognizes a gain or loss in accordance with ASC 470-20 and ASC 470-50, <i>Debt Modifications and Extinguishments</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zHAAha3GsZn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_865_z3u6TYbMNYnj">Income Taxes</span> </b>&#8211; Income taxes are provided
for the tax effects of transactions reported in the consolidated financial statements and consist of taxes currently due plus deferred
taxes related primarily to temporary differences between reporting of income and expenses for financial reporting purposes and income
tax purposes. The deferred tax assets and liabilities represent the future tax return consequences of those differences, which will either
be taxable or deductible when the assets and liabilities are recovered or settled. Deferred taxes also are recognized for operating losses
that are available to offset future federal income taxes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Income Taxes Topic of FASB ASC clarifies the
accounting and reporting for uncertainties in income tax law within subtopic FASB ASC 740-10-25-5. The guidance prescribes a comprehensive
model for the financial statement recognition, measurement, presentation, and disclosure of uncertain tax positions taken or expected
to be taken in income tax returns. Management believes that there is&#160;<span id="xdx_90C_eus-gaap--UnrecognizedTaxBenefits_iI_pp0p0_do_c20251231_zzgyalr1YRb1" title="Uncertain tax positions"><span id="xdx_90C_eus-gaap--UnrecognizedTaxBenefits_iI_pp0p0_do_c20241231_z9pJ5W7wdqmi" title="Uncertain tax positions">no</span></span>&#160;liability related to uncertain tax positions during
the years ended December 31, 2025 and 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--UseOfEstimates_zGhCno2pOdh6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86C_zicXUShi27md">Use of Estimates</span> &#8211; </b>The preparation
of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements
and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
<td class="text"><p id="xdx_842_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zkXNemGlANOk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86B_zWfWKjGsO9M">Reclassification</span> </b>&#8211; The Company reclassified
certain amounts of total stockholders&#8217; equity &#8211; noncontrolling interests, net loss attributable to non-controlling interests,
and accumulated deficit from prior periods. These presentation changes did not affect total stockholders&#8217; equity or net loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Employee and Non-Employee Share-Based Compensation</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zRj8znYSaTXd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86D_zOCJE3Hv5If3">Employee and Non-Employee Share-Based Compensation</span>
</b>&#8211; The Company applies ASC 718-10,&#160;<i>Share-Based Payment</i>, which requires the measurement and recognition of compensation
expenses for all share-based payment awards made to employees and directors including employee stock option equity awards issued to employees
and non-employees based on estimated fair values.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 718-10 requires companies to estimate the
fair value of equity-based option awards on the date of grant using an option-pricing model. The fair value of the award is recognized
as an expense on a straight-line basis over the requisite service periods in the Company&#8217;s consolidated statements of operations.
The Company recognizes share-based award forfeitures as they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company estimates the fair value of granted
option equity awards using a Black-Scholes option pricing model. The option-pricing model requires a number of assumptions, of which the
most significant are share price, expected volatility and the expected option term (the time from the grant date until the options are
exercised or expire). Expected volatility is estimated based on volatility of the Company. The Company has historically not paid dividends
and has no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds
with an equivalent term. The expected option term is calculated for options granted to employees and directors using the &#8220;simplified&#8221;
method. Changes in the determination of each of the inputs can affect the fair value of the options granted and the results of operations
of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zOOWsmECMEZ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_860_zNI8i6I7Rtza"><b>Recent
Accounting Pronouncements</b></span><b>&#160;</b>&#8211; During the years ended December 31, 2025 and 2024, there were new accounting
pronouncements issued by the FASB. Each of these pronouncements, as applicable, including Accounting Standards Update (&#8220;ASU&#8221;)
2023-07, <i>Segment Reporting</i>, has been or will be adopted by the Company. Please see Note 15, Segment Reporting. Management does
not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company&#8217;s consolidated
financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--RevenueRecognitionPolicyTextBlock_z4z3tzepn6Fd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86A_zwA8j2PfPnfk">Revenue Recognition</span></b>&#160;&#8211; The Company
recognizes revenue in accordance with ASC Topic 606, <i>Revenue from Contracts with Customers</i> (&#8220;ASC 606&#8221;) to depict the
transfer of control to the Company&#8217;s customers in an amount reflecting the consideration to which the Company expects to be entitled.
The Company determines revenue recognition through the following steps:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 6%"><span style="font-size: 10pt">i.</span></td>
    <td style="width: 91%; text-align: justify"><span style="font-size: 10pt">Identification of the contract, or contracts, with a customer</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">ii.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Identification of the performance obligations in the contract</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">iii.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Determination of the transaction price</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">iv.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Allocation of the transaction price to the performance obligations in the contract</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">v.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Recognition of revenue, when, or as, the company satisfies the performance obligations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under ASC 606, revenue is recognized when control
of promised goods and services is transferred to customers. A performance obligation is a contractual promise to transfer a distinct good
or service to the customer and is the unit of account under ASC 606. The transaction price of a contract is allocated to distinct performance
obligations and recognized as revenue when or as the performance obligations are satisfied.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company generates revenue from its customers
by 1) performing data research for its customers and delivering advertising campaigns via cold emails and social media sites, and 2) providing
webinars for its customers to a targeted business-to-business audience. The fee for these services is based on observable prices explicitly
negotiated between the Company and the customer. The Company recognizes revenue at the point in time when the good or service is delivered
to the customer, which occurs upon delivery of the advertising campaign or webinar and there is a transfer of control to the customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2025, revenues
from delivering advertising campaigns via cold emails and social media sites were recognized from six customers who accounted for <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20251231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SixCustomersMember__srt--ProductOrServiceAxis__custom--AdvertisingCampaignsMember_zLX4oEOfVmxh" title="Concentration risk percentage">100</span>%
of this revenue. Revenue was recognized at the point of delivery to the customers in the amount of $<span id="xdx_90D_eus-gaap--Revenues_c20250101__20251231__srt--ProductOrServiceAxis__custom--AdvertisingCampaignsMember_zT74wjk0aKHa" title="Revenues">1,250,545</span>. As of December 31, 2025,
the Company has recorded customer deposits in the amount of $<span id="xdx_902_eus-gaap--DeferredRevenueCurrent_iI_c20251231__srt--ProductOrServiceAxis__custom--AdvertisingCampaignsMember_z60oqDcquob1" title="Customer deposits">599,455</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2025, revenues
from delivering webinar services were recognized from three customers who accounted for <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20251231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThreeCustomersMember__srt--ProductOrServiceAxis__custom--WebinarServicesMember_zjRu100sQNS4" title="Concentration risk percentage">100</span>% of this revenue. Revenue was recognized at
the point of delivery to the customers in the amount of $<span id="xdx_90E_eus-gaap--Revenues_c20250101__20251231__srt--ProductOrServiceAxis__custom--WebinarServicesMember_zsA6a78dhLyf" title="Revenues">112,500</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share</a></td>
<td class="text"><p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zAsU6WAQ4KI8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_865_z2FQOuGhQvN9">Earnings Per Share</span></b> &#8211; Basic earnings
per share (or loss per share), is computed by dividing the earnings (loss) for the period by the weighted average number of common stock
shares outstanding for the period. Diluted earnings per share reflects potential dilution of securities by including other potentially
issuable shares of common stock, including shares issuable upon conversion of convertible securities or exercise of outstanding stock
options and warrants, in the weighted average number of common shares outstanding for the period. Therefore, because including shares
issuable upon conversion of convertible securities and/or exercise of outstanding options and warrants would have an anti-dilutive effect
on the loss per share, only the basic earnings (loss) per share is reported in the accompanying consolidated financial statements. The
Company does not have other potentially issuable shares of stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following potential common shares would have
an antidilutive effect on loss per share:</p>

<table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zGWihs13k28a" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt; color: White"><b><span id="xdx_8BB_zFQw89wo8x2c" style="display: none">Schedule of antidilutive shares</span></b></span></td>
    <td>&#160;</td>
    <td colspan="6" style="text-align: center"><span style="font-size: 10pt"><b>Years ended December 31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2025</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2024</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 68%"><span style="font-size: 10pt">Warrants</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zxPQLg8XFKHf" style="width: 13%; text-align: right" title="Antidilutive shares"><span style="font-size: 10pt">945,105</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_ziMaBdHFS59l" style="width: 13%; text-align: right" title="Antidilutive shares"><span style="font-size: 10pt">1,399,316</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Stock options</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zwFiS2Xbflk5" style="text-align: right" title="Antidilutive shares"><span style="font-size: 10pt">437,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zLzpYEY8VEh9" style="text-align: right" title="Antidilutive shares"><span style="font-size: 10pt">279,625</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Convertible notes payable</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleNotesPayableMember_zpAXF3MhJOB7" style="text-align: right" title="Antidilutive shares"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleNotesPayableMember_zdFZzQI3BU8e" style="text-align: right" title="Antidilutive shares"><span style="font-size: 10pt">406,629</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Preferred stock</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--PreferredStockMember_zHdONONx2RV8" style="border-bottom: black 1pt solid; text-align: right" title="Antidilutive shares"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--PreferredStockMember_zKW6pQqwpZ0h" style="border-bottom: black 1pt solid; text-align: right" title="Antidilutive shares"><span style="font-size: 10pt">815,000</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Total</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231_z2Df7bPawez9" style="border-bottom: black 2.25pt double; text-align: right" title="Antidilutive shares"><span style="font-size: 10pt">1,382,105</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231_ziJtf4fsJ3G" style="border-bottom: black 2.25pt double; text-align: right" title="Antidilutive shares"><span style="font-size: 10pt">2,900,570</span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Going Concern</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_z2gYXYVgQI29" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86D_zRxnqmvvUvna">Going Concern</span> &#8211;</b> The accompanying
consolidated financial statements have been prepared in conformity with GAAP which contemplate continuation of the Company as a going
concern, which is dependent upon the Company&#8217;s ability to obtain sufficient financing or establish itself as a profitable business.
As of December 31, 2025, the Company had an accumulated deficit of $<span id="xdx_90C_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20251231_zNeMP0RaPasd" title="Accumulated deficit">109,953,728</span>, and for the year ended December 31, 2025, the Company
had a net loss of $<span id="xdx_90F_eus-gaap--ProfitLoss_iN_di_c20250101__20251231_zwJw9pkfv7x" title="Net loss">12,277,192</span>. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern.
Management&#8217;s plans with respect to operations include raising additional capital through sales of equity or debt securities as may
be necessary to pursue its business plans and sustain operations until such time as the Company can achieve profitability. Management
believes that additional financing as necessary will result in improved operations and cash flow. However, there can be no assurance that
management will be successful in obtaining additional funding or in attaining profitable operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments and Measurements</a></td>
<td class="text"><p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zHgRczn8lra3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_863_zGDiDX0QL2Ag">Fair Value of Financial Instruments and Measurements</span></b>
&#8211; The Company measures certain financial instruments at fair value in accordance with ASC 820, <i>Fair Value Measurement</i>, for
its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets
and liabilities that are re-measured and reported at fair value at least annually. The fair value of the Company&#8217;s financial assets
and liabilities reflects management&#8217;s estimate of amounts that the Company would have received in connection with the sale of the
assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement
date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs
(market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market
participants would price assets and liabilities).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 820 establishes a three-level fair value hierarchy
that prioritizes inputs used to measure fair value:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 1 &#8211; Quoted prices in active markets
for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability
occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 2 &#8211; Observable inputs other than Level
1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical
assets or liabilities in markets that are not active.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 3 &#8211; Unobservable inputs based on our
assessment of the assumptions that market participants would use in pricing the asset or liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The estimated fair value of cash, interest receivable,
subscription receivable, and notes payable approximate their carrying amounts due to the short-term nature of these instruments.</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479693/815-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4F<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/815/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483504/205-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of antidilutive shares</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zGWihs13k28a" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt; color: White"><b><span id="xdx_8BB_zFQw89wo8x2c" style="display: none">Schedule of antidilutive shares</span></b></span></td>
    <td>&#160;</td>
    <td colspan="6" style="text-align: center"><span style="font-size: 10pt"><b>Years ended December 31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2025</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2024</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 68%"><span style="font-size: 10pt">Warrants</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zxPQLg8XFKHf" style="width: 13%; text-align: right" title="Antidilutive shares"><span style="font-size: 10pt">945,105</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_ziMaBdHFS59l" style="width: 13%; text-align: right" title="Antidilutive shares"><span style="font-size: 10pt">1,399,316</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Stock options</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zwFiS2Xbflk5" style="text-align: right" title="Antidilutive shares"><span style="font-size: 10pt">437,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zLzpYEY8VEh9" style="text-align: right" title="Antidilutive shares"><span style="font-size: 10pt">279,625</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Convertible notes payable</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleNotesPayableMember_zpAXF3MhJOB7" style="text-align: right" title="Antidilutive shares"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleNotesPayableMember_zdFZzQI3BU8e" style="text-align: right" title="Antidilutive shares"><span style="font-size: 10pt">406,629</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Preferred stock</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--PreferredStockMember_zHdONONx2RV8" style="border-bottom: black 1pt solid; text-align: right" title="Antidilutive shares"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--PreferredStockMember_zKW6pQqwpZ0h" style="border-bottom: black 1pt solid; text-align: right" title="Antidilutive shares"><span style="font-size: 10pt">815,000</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Total</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231_z2Df7bPawez9" style="border-bottom: black 2.25pt double; text-align: right" title="Antidilutive shares"><span style="font-size: 10pt">1,382,105</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231_ziJtf4fsJ3G" style="border-bottom: black 2.25pt double; text-align: right" title="Antidilutive shares"><span style="font-size: 10pt">2,900,570</span></td>
    <td>&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE NOTES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of derivative liability</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zbvuEYR8TaQ4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CONVERTIBLE NOTES (Details - Derivative liability)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span id="xdx_8B2_z5y8mFoKfK11" style="display: none">Schedule of derivative liability</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2025</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 49%; text-align: justify; padding-bottom: 1pt">Derivative liability</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1pt; width: 13%; text-align: center">3</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_d0_c20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zSScGOpRdWF6" style="border-bottom: Black 1pt solid; width: 13%; text-align: right" title="Fair value of derivative liability">&#8211;</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_c20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zvkEJ2i5QsY5" style="border-bottom: Black 1pt solid; width: 13%; text-align: right" title="Fair value of derivative liability">1,041,484</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_d0_c20251231_zl0cuXFGtsy6" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of derivative liability">&#8211;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_c20241231_z59nuI9P6qT5" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of derivative liability">1,041,484</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfServicingLiabilitiesAtFairValueTextBlock', window );">Schedule of assumptions used for valuation</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfServicingLiabilitiesAtFairValueTextBlock_zMk5Fussqd7g" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - CONVERTIBLE NOTES (Details - Assumptions)">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt; color: White"><span id="xdx_8B3_zmClAVoHovK3" style="display: none">Schedule of assumptions used for valuation</span></span></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024</b></p></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 83%; text-align: justify"><span style="font-size: 10pt">Risk-free interest rate</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 14%; text-align: right"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zMgiIIKRIoQ2" title="Derivative assumption valuation">4.16</span>%</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Expected volatility</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zjYxVkzv3sCe" title="Derivative assumption valuation">114.61</span>%</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Conversion price</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90B_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputConversionPriceMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zEIsIqZ4XoHj" title="Derivative assumption valuation">3.71</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Stock price</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_909_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zRqhRfZJsqc7" title="Derivative assumption valuation">5.50</span></span></td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Schedule of changes in fair value of derivative liability</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_zENQuhqRVCGi" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - CONVERTIBLE NOTES (Details - Change in deriviative)">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt; color: White"><span id="xdx_8BC_zfOdvmHY7J5" style="display: none">Schedule of changes in fair value of derivative liability</span></span></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Warrant</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Liabilities</b></p></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 83%"><span style="font-size: 10pt"><b>Fair value as of November 1, 2024 (inception)</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98D_eus-gaap--DerivativeFairValueOfDerivativeLiability_iS_c20241101__20241231_zcBT4BGwXfHi" style="width: 14%; text-align: right" title="Fair value of derivative liability, beginning balance"><span style="font-size: 10pt">501,824</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Change in fair value</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_988_eus-gaap--UnrealizedGainLossOnDerivatives_iN_di_c20241101__20241231_zuAywLAZNE3f" style="border-bottom: black 1pt solid; text-align: right" title="Change in fair value"><span style="font-size: 10pt">539,660</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt"><b>Fair value as of December 31, 2024</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--DerivativeFairValueOfDerivativeLiability_iS_c20250101__20251231_zrf3ufaAH9Rd" style="text-align: right" title="Fair value of derivative liability, beginning balance"><span style="font-size: 10pt">1,041,484</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Change in fair value</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_982_eus-gaap--UnrealizedGainLossOnDerivatives_iN_di_c20250101__20251231_z9QuDUjAjMub" style="text-align: right" title="Change in fair value"><span style="font-size: 10pt">(906,430</span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Extinguishment of fair value of liability</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_983_eus-gaap--ExtinguishmentOfDebtGainLossNetOfTax_iN_di_c20250101__20251231_zLopX0wn9puc" style="border-bottom: black 1pt solid; text-align: right" title="Extinguishment of fair value of liability"><span style="font-size: 10pt">(135,054</span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"><b>Fair value as of December 31, 2025</b></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98C_eus-gaap--DerivativeFairValueOfDerivativeLiability_iE_d0_c20250101__20251231_z0cgjM0ajdj" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of derivative liability, ending balance"><span style="font-size: 10pt">&#8211;</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4CC<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfServicingLiabilitiesAtFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the activity in the balance of servicing liabilities subsequently measured at fair value (including a description of where changes in fair value are reported in the statement of income for each period for which results of operations are presented), including but not limited to, the following: beginning and ending balances, additions (through assumptions of servicing obligations, and servicing obligations that result from transfers of financial assets), disposals, changes in fair value during the period resulting from changes in inputs or assumptions used in the valuation model, other changes in fair value and a description of those changes, and other changes that affect the balance and a description of those changes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 860<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481229/860-50-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfServicingLiabilitiesAtFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE LIABILITY WARRANTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of fair value hierarchy</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zYZYqpWiEQSb" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - DERIVATIVE LIABILITY WARRANTS (Details - Fair value)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BE_zgqKjRFwZ6u7" style="display: none">Schedule of fair value hierarchy</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt"><b>Description</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Level</b></span></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2025</b></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.2pt; text-align: center"><b>December 31,</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.2pt; text-align: center"><b>2024</b></p></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 52%; text-align: justify"><span style="font-size: 10pt">Warrant Liability &#8211; Public Warrants</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: center"><span style="font-size: 10pt">1</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_982_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pp0p0_c20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--PublicWarrantsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zykD5wfi9tOi" style="width: 13%; text-align: right" title="Financial liabilities fair value disclosure"><span style="font-size: 10pt">81,000</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98D_eus-gaap--FinancialLiabilitiesFairValueDisclosure_pp0p0_c20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--PublicWarrantsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z17ss78aDgnf" style="width: 13%; text-align: right" title="Financial liabilities fair value disclosure"><span style="font-size: 10pt">165,000</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; text-align: justify"><span style="font-size: 10pt">Warrant Liability &#8211; Private Placement Warrants</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt">3</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td id="xdx_98B_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pp0p0_c20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--PrivatePlacementWarrantsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z441SQZ8Og" style="border-bottom: Black 1pt solid; text-align: right" title="Financial liabilities fair value disclosure"><span style="font-size: 10pt">86,625</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td id="xdx_98D_eus-gaap--FinancialLiabilitiesFairValueDisclosure_pp0p0_c20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--PrivatePlacementWarrantsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwr7twPOickb" style="border-bottom: Black 1pt solid; text-align: right" title="Financial liabilities fair value disclosure"><span style="font-size: 10pt">194,250</span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 2.5pt; text-align: justify"><span style="font-size: 10pt">Total</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98C_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_c20251231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zyUSDWg5YsK9" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">167,625</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_980_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zpMRnNeWEKw6" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">359,250</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of fair value assumptions</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_zWvyTg8a35Bd" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - DERIVATIVE LIABILITY WARRANTS (Details - Fair value assumption)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BE_zsam605Oqrhb" style="display: none">Schedule of fair value assumptions</span></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2025</b></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024</b></p></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 68%; text-align: justify"><span style="font-size: 10pt">Risk-free interest rate</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt"><span id="xdx_907_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250101__20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsMember_z9sjKqBiU8E9" title="Derivatives, determination of fair value">3.41</span>%</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90B_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsMember_zGomT0glwFSe" title="Derivatives, determination of fair value">4.10</span>%</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Expected volatility</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_907_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250101__20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsMember_zTxp77nNiJi7" title="Derivatives, determination of fair value">68.58</span>%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsMember_ziAlQrcigcR5" title="Derivatives, determination of fair value">82.01</span>%</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Exercise price</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250101__20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsMember_z4Ljn5EkmDn5" title="Derivatives, determination of fair value">230.00</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsMember_zuWNHWHhasb5" title="Derivatives, determination of fair value">230.00</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Stock price</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_901_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250101__20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsMember_z36e5rJitRxk" title="Derivatives, determination of fair value">14.25</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_909_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsMember_ziKSXBpIE0Fa" title="Derivatives, determination of fair value">5.50</span></span></td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of changes in fair value of warrant liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zu3NHvWjouG" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - DERIVATIVE LIABILITY WARRANTS (Details - Changes in fair value of warrant liabilities)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B4_zrOQM567XcY5" style="display: none">Schedule of changes in fair value of warrant liabilities</span></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Private</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Placement</b></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Public</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Warrant</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Liabilities</b></p></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 52%; text-align: justify"><span style="font-size: 10pt"><b>Fair value as of December 31, 2024</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98B_eus-gaap--LiabilitiesFairValueDisclosure_iS_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--PrivatePlacementWarrantsMember_zJRNHSESjNC8" style="width: 13%; text-align: right" title="Fair value of liabilities, beginning"><span style="font-size: 10pt">194,250</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iS_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--PublicWarrantsMember_zcGUan0W4qAl" style="width: 13%; text-align: right" title="Fair value of liabilities, beginning"><span style="font-size: 10pt">165,000</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98E_eus-gaap--LiabilitiesFairValueDisclosure_iS_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantLiabilitiesMember_zEhzUI30ezMd" style="width: 13%; text-align: right" title="Fair value of liabilities, beginning"><span style="font-size: 10pt">359,250</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Change in valuation inputs</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98A_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--PrivatePlacementWarrantsMember_zvfSBXANTCUc" style="border-bottom: black 1pt solid; text-align: right" title="Change in valuation inputs"><span style="font-size: 10pt">(107,625</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_988_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--PublicWarrantsMember_zxL0wuHoJy5k" style="border-bottom: black 1pt solid; text-align: right" title="Change in valuation inputs"><span style="font-size: 10pt">(84,000</span></td>
    <td><span style="font-size: 10pt">)&#160;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_982_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantLiabilitiesMember_zDZhStIRKTI" style="border-bottom: black 1pt solid; text-align: right" title="Change in valuation inputs"><span style="font-size: 10pt">(191,625</span></td>
    <td><span style="font-size: 10pt">)&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Fair value as of December 31, 2025</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_iE_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--PrivatePlacementWarrantsMember_z8KxeUcCjQy8" style="border-bottom: black 2.25pt double; text-align: right" title="Fair value of liabilities, ending"><span style="font-size: 10pt">86,625</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_982_eus-gaap--LiabilitiesFairValueDisclosure_iE_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--PublicWarrantsMember_zGuxjbu8LBY7" style="border-bottom: black 2.25pt double; text-align: right" title="Fair value of liabilities, ending"><span style="font-size: 10pt">81,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98E_eus-gaap--LiabilitiesFairValueDisclosure_iE_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantLiabilitiesMember_zYC5pEXwPSK6" style="border-bottom: black 2.25pt double; text-align: right" title="Fair value of liabilities, ending"><span style="font-size: 10pt">167,625</span></td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STRUCTURE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zeakXLF5vY5j" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - CAPITAL STRUCTURE (Details - Option activity)">
  <tr style="vertical-align: bottom">
    <td style="display: none">Schedule of stock option activity</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td>
    <td><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Shares Underlying Options</b></span></td>
    <td><b>&#160;</b></td>
    <td><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted Average Exercise
    Price</b></span></td>
    <td><b>&#160;</b></td>
    <td><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted Average Contractual
    Life (Years)</b></span></td>
    <td><b>&#160;</b></td>
    <td><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Intrinsic Value</b></span></td>
    <td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Outstanding at December 31, 2023</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zAdqo9AwD0ml" style="text-align: right" title="Options outstanding, beginning"><span style="font-size: 10pt">87,875</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zdJHc0yuikK5" style="text-align: right" title="Weighted average exercise price, beginning balance outstanding"><span style="font-size: 10pt">40.20</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zSCdNBLfZqn6" title="Weighted average contractual life (years), options outstanding">7.97</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 36%"><span style="font-size: 10pt">Granted</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zpzNcAhWG1Jk" style="width: 13%; text-align: right" title="Options granted"><span style="font-size: 10pt">196,750</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z46h2cts0dne" style="width: 13%; text-align: right" title="Weighted average exercise price, granted"><span style="font-size: 10pt">8.85</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2OptionsGranted_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zRou3ZT1jn8a" title="Weighted average contractual life (years), granted">10.00</span></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Forfeited</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zVU7qc8rEWfg" style="text-align: right" title="Options forfeited/expired"><span style="font-size: 10pt">(5,000)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zBrjwVoZ8iOh" style="text-align: right" title="Weighted average exercise price, forfeited/expired"><span style="font-size: 10pt">200.00</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Exercised</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_d0_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zfXANZ7rjiO9" style="border-bottom: black 1pt solid; text-align: right" title="Options exercised"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zzHQw19UCua6" style="border-bottom: black 1pt solid; text-align: right" title="Weighted average exercise price, exercised"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Outstanding at December 31, 2024</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zWYijifwwHj3" style="text-align: right" title="Options outstanding, beginning"><span style="font-size: 10pt">279,625</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zLUum3gcAUHg" style="text-align: right" title="Weighted average exercise price, beginning balance outstanding"><span style="font-size: 10pt">15.29</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zdcJXeKn0NU8" title="Weighted average contractual life (years), options outstanding">8.74</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_ztyMmW7ZFEb8" style="text-align: right" title="Options granted"><span style="font-size: 10pt">187,375</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zIh031phyXP1" style="text-align: right" title="Weighted average exercise price, granted"><span style="font-size: 10pt">7.96</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2OptionsGranted_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zUKJ0SCZtgD2" title="Weighted average contractual life (years), granted">5.20</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Forfeited</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z2gIUm4mfyJa" style="text-align: right" title="Options forfeited/expired"><span style="font-size: 10pt">(30,000</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zRZ1TTo3Wyi1" style="text-align: right" title="Weighted average exercise price, forfeited/expired"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Exercised</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_d0_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zuv8YlhRYPA2" style="border-bottom: black 1pt solid; text-align: right" title="Options exercised"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zjJT6tT8gbql" style="border-bottom: black 1pt solid; text-align: right" title="Weighted average exercise price, exercised"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Outstanding at December 31, 2025</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z9ZXtWtL9N8f" style="border-bottom: black 2.25pt double; text-align: right" title="Options outstanding, ending"><span style="font-size: 10pt">437,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z9Dprg9sKBWk" style="border-bottom: black 2.25pt double; text-align: right" title="Weighted average exercise price, ending balance outstanding"><span style="font-size: 10pt">12.11</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zau0aOCg5xVf" title="Weighted average contractual life (years), options outstanding">6.26</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zQA7SpV3vjH3" style="border-bottom: black 2.25pt double; text-align: right" title="Intrinsic value, options outstanding"><span style="font-size: 10pt">2,215,451</span></td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted average assumptions</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zuN6cUYSbiP7" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - CAPITAL STRUCTURE (Details - Weighted average assumptions)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BC_zoaWrx1wddF1" style="display: none">Schedule of weighted average assumptions</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td>
    <td><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>For the years ended December
    31,</b></span></td>
    <td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td>
    <td><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2025</b></span></td>
    <td><b>&#160;</b></td>
    <td><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2024</b></span></td>
    <td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 60%"><span style="font-size: 10pt">Expected term, in years</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 16%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zb44d3yrl74g" title="Expected term, in years">2.75</span></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 16%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zZNgltc1r60k" title="Expected term, in years">5.25</span></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Expected volatility</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zATDT3E1qOxg" title="Expected volatility">75.58</span>%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zrS3qLfbf3pa" title="Expected volatility">84.70</span>%</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Risk-free interest rate</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zb3GaOUmKtDf" title="Risk-free interest rate">3.89</span>%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zCZ2RKkQVEIk" title="Risk-free interest rate">4.18</span>%</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Dividend yield</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zte09OWFCb2c" title="Dividend yield">&#8211;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z2QN4EoyzZ71" title="Dividend yield">&#8211;</span></span></td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrants outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zvnvizl0Zhh7" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - CAPITAL STRUCTURE (Details - Warrants outstanding)">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt; color: White"><span id="xdx_8B7_zOdJkpwSXipd" style="display: none">Schedule of warrants outstanding</span></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt"><b>Reference</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Date</b></span><br/>
<span style="font-size: 10pt"><b>Issued</b></span></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Exercise</b></span><br/>
<span style="font-size: 10pt"><b>Price</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Expiration</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Outstanding at December 31,</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.75pt; text-align: center"><b>2025</b></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Outstanding at<br/>
    December 31,</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024</b></p></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 36%; text-align: justify"><span style="font-size: 10pt">Warrant Holder 1</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center"><span style="font-size: 10pt"><span id="xdx_909_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice59.40Member_zhPQKk5yNNMk" title="Date Issued">5/28/2021</span></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice59.40Member_zXRPOT9rhVG2" style="width: 10%; text-align: right" title="Warrants exercise price"><span style="font-size: 10pt">59.40</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice59.40Member_zItdhyrT2Pk5" title="Expiration">5/13/2026</span></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice59.40Member_zqqHvnVaQLHh" style="width: 10%; text-align: right" title="Warrants outstanding"><span style="font-size: 10pt">8,380</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice59.40Member_zMeNZng40tdb" style="width: 10%; text-align: right" title="Warrants outstanding"><span style="font-size: 10pt">8,380</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Warrant Holder 1</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90C_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice118.80Member_zwQ5pwjwGMSf" title="Date Issued">5/28/2021</span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice118.80Member_z4JELrJ017Xg" style="text-align: right" title="Warrants exercise price"><span style="font-size: 10pt">118.80</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice118.80Member_zv54vjEcUlni" title="Expiration">5/13/2026</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice118.80Member_zuIBsbFjCHNb" style="text-align: right"><span style="font-size: 10pt">8,422</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice118.80Member_zLlnDfHxGkke" style="text-align: right"><span style="font-size: 10pt">8,422</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Warrant Holder 1</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_900_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice296.80Member_zbAD3QgR0aE4" title="Date Issued">5/28/2021</span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice296.80Member_zdOUYST0KBDk" style="text-align: right" title="Warrants exercise price"><span style="font-size: 10pt">296.80</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice296.80Member_zNWSeKS6l3J7" title="Expiration">5/13/2026</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice296.80Member_zicjK4torz8d" style="text-align: right"><span style="font-size: 10pt">8,422</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice296.80Member_ze7554J93sG3" style="text-align: right"><span style="font-size: 10pt">8,422</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Warrant Holder 2</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_902_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice59.40Member_z6Pz0tB8cFb1" title="Date Issued">7/30/2021</span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice59.40Member_zXxLcYdy4V6g" style="text-align: right" title="Warrants exercise price"><span style="font-size: 10pt">59.40</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice59.40Member_zwxyj4u9O5Hk" title="Expiration">7/30/2026</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice59.40Member_zv1MnhCveYy2" style="text-align: right"><span style="font-size: 10pt">421</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice59.40Member_zTaTaGqLB7d7" style="text-align: right"><span style="font-size: 10pt">421</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Warrant Holder 2</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_905_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice296.80Member_z690toHMvrid" title="Date Issued">7/30/2021</span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice296.80Member_zDVj61xqGm38" style="text-align: right" title="Warrants exercise price"><span style="font-size: 10pt">296.80</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice296.80Member_zuFNtTWa4Zk6" title="Expiration">6/1/2026</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice296.80Member_z7qV2GpL182j" style="text-align: right"><span style="font-size: 10pt">1,263</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice296.80Member_znkkujrqPZG" style="text-align: right"><span style="font-size: 10pt">1,263</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Warrant Holder 5</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90C_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder5ExercisePrice59.40Member_zT6nUYfMeP8k" title="Date Issued">12/20/2021</span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder5ExercisePrice59.40Member_zEtq2QA2hzde" style="text-align: right" title="Warrants exercise price"><span style="font-size: 10pt">59.40</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder5ExercisePrice59.40Member_zHVEKXVm7j4d" title="Expiration">12/20/2026</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder5ExercisePrice59.40Member_zMO86NMJ8vVj" style="text-align: right"><span style="font-size: 10pt">2,948</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder5ExercisePrice59.40Member_zThs8fw5UFB4" style="text-align: right"><span style="font-size: 10pt">2,948</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Warrant Holder 18</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_909_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder18ExercisePrice178.20Member_zdbqLVXtpkh5" title="Date Issued">3/30/2022</span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder18ExercisePrice178.20Member_zMNZCepjwXD5" style="text-align: right" title="Warrants exercise price"><span style="font-size: 10pt">178.20</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder18ExercisePrice178.20Member_zsyqR9n0P2te" title="Expiration">3/30/2025</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_d0_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder18ExercisePrice178.20Member_zDIvnpeWio7k" style="text-align: right"><span style="font-size: 10pt">&#8211; </span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder18ExercisePrice178.20Member_zJHbtgaG073a" style="text-align: right"><span style="font-size: 10pt">4,211</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Warrant Holder 20</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_906_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder20ExercisePrice50.00Member_z4C62Tx4YpMa" title="Date Issued">1/3/2023</span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder20ExercisePrice50.00Member_z4lymClWNjb" style="text-align: right" title="Warrants exercise price"><span style="font-size: 10pt">50.00</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder20ExercisePrice50.00Member_zREA6mmTF107" title="Expiration">1/2/2027</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder20ExercisePrice50.00Member_zkNNxOL1MChg" style="text-align: right"><span style="font-size: 10pt">5,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder20ExercisePrice50.00Member_zQvBo3JQxaJk" style="text-align: right"><span style="font-size: 10pt">5,000</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Warrant Holder 21</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_902_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder21ExercisePrice38.00Member_zsy504HlvDYj" title="Date Issued">1/20/2023</span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder21ExercisePrice38.00Member_zJFT8AGk3jGi" style="text-align: right" title="Warrants exercise price"><span style="font-size: 10pt">38.00</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder21ExercisePrice38.00Member_zBpFYBBVNXfb" title="Expiration">1/19/2027</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder21ExercisePrice38.00Member_zgcVAlGQV2m" style="text-align: right"><span style="font-size: 10pt">12,500</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder21ExercisePrice38.00Member_zw9jDPiB7KIc" style="text-align: right"><span style="font-size: 10pt">12,500</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Series A &amp; B Warrants</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_902_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesWarrantsAAndBExercisePrice27.20Member_zMLfl9kgCStk" title="Date Issued">6/16/2023</span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesWarrantsAAndBExercisePrice27.20Member_zLGVuKEypFSe" style="text-align: right" title="Warrants exercise price"><span style="font-size: 10pt">27.20</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesWarrantsAAndBExercisePrice27.20Member_zWiQfQC8nAFk" title="Expiration">12/16/2028</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesWarrantsAAndBExercisePrice27.20Member_zGX16nfpzMfl" style="text-align: right"><span style="font-size: 10pt">306,250</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesWarrantsAAndBExercisePrice27.20Member_zMcpzrvKYNle" style="text-align: right"><span style="font-size: 10pt">306,250</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Series A Warrants</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_900_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsExercisePrice27.20Member_zUBMb8E7p44l" title="Date Issued">10/23/2023</span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsExercisePrice27.20Member_zaQRKQLtGKXi" style="text-align: right" title="Warrants exercise price"><span style="font-size: 10pt">27.20</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsExercisePrice27.20Member_zJXfhF99xYw1" title="Expiration">4/26/2025</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_d0_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsExercisePrice27.20Member_zGRBcCqmET71" style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsExercisePrice27.20Member_zpQbIWGokML1" style="text-align: right"><span style="font-size: 10pt">100,000</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Series B Warrants</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_907_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsExercisePrice27.20Member_z8vzypLgPvNg" title="Date Issued">10/23/2023</span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsExercisePrice27.20Member_zrXhgXeYRGTb" style="text-align: right" title="Warrants exercise price"><span style="font-size: 10pt">27.20</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsExercisePrice27.20Member_zB1dVGnt8dP" title="Expiration">4/26/2029</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsExercisePrice27.20Member_zrOAXCQY9kde" style="text-align: right"><span style="font-size: 10pt">100,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsExercisePrice27.20Member_z4HshTcVMa75" style="text-align: right"><span style="font-size: 10pt">100,000</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Warrant Holder 22</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_908_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice25.00Member_zDAEgsAil3ci" title="Date Issued">6/16/2023</span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice25.00Member_zapMylA94m4f" style="text-align: right" title="Warrants exercise price"><span style="font-size: 10pt">25.00</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice25.00Member_z6Y6AUE9a7ue" title="Expiration">12/16/2028</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice25.00Member_zb9yirJ8v3Vc" style="text-align: right"><span style="font-size: 10pt">6,300</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice25.00Member_zA7gNTIgnKT8" style="text-align: right"><span style="font-size: 10pt">6,300</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Warrant Holder 22</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_902_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice28.00Member_zcptOzx2hAb3" title="Date Issued">10/23/2023</span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice28.00Member_z4ubQZlsp0D7" style="text-align: right" title="Warrants exercise price"><span style="font-size: 10pt">28.00</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice28.00Member_zCFwpGSZBYI" title="Expiration">4/26/2029</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice28.00Member_zpzv0wMqgij7" style="text-align: right"><span style="font-size: 10pt">3,300</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice28.00Member_zD9mQorT6WC5" style="text-align: right"><span style="font-size: 10pt">3,300</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Warrant Holder 23</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_903_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice25.00Member_zdmKFPOfEsUk" title="Date Issued">6/16/2023</span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice25.00Member_zsMDcc2OfNCf" style="text-align: right" title="Warrants exercise price"><span style="font-size: 10pt">25.00</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice25.00Member_zLuijdsruMf3" title="Expiration">12/16/2028</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice25.00Member_zCv7ZcFGFdl7" style="text-align: right"><span style="font-size: 10pt">4,200</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice25.00Member_zpw43IQxFYHe" style="text-align: right"><span style="font-size: 10pt">4,200</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Warrant Holder 23</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90A_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice28.00Member_z1fPzyMwcz27" title="Date issued">10/23/2023</span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice28.00Member_z8FMtTy84jFb" style="text-align: right" title="Warrants exercise price"><span style="font-size: 10pt">28.00</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice28.00Member_zuWoZMkqoZ86" title="Expiration">4/26/2029</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice28.00Member_zkTrqhzVQeMk" style="text-align: right"><span style="font-size: 10pt">2,400</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice28.00Member_zlqY2DWKR1xi" style="text-align: right"><span style="font-size: 10pt">2,400</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Warrant Holder 24</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_903_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder24ExercisePrice28.00Member_zbZ5N7Nh6Cij" title="Date Issued">10/23/2023</span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder24ExercisePrice28.00Member_zZzUb33gVac4" style="text-align: right" title="Warrants exercise price"><span style="font-size: 10pt">28.00</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder24ExercisePrice28.00Member_z1Up8he4rQi" title="Expiration">4/26/2029</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder24ExercisePrice28.00Member_z8anOUPcCnY6" style="text-align: right"><span style="font-size: 10pt">300</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder24ExercisePrice28.00Member_z4NcvcfmZ9H9" style="text-align: right"><span style="font-size: 10pt">300</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-Funded Warrants 2</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_905_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants2ExercisePrice0.002Member_zhbhDan1TPKg" title="Date Issued">12/28/2023</span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants2ExercisePrice0.002Member_zH4g4amW63P5" style="text-align: right" title="Warrants exercise price"><span style="font-size: 10pt">0.002</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_d0_c20251231__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants2ExercisePrice0.002Member_zyPGcOuPPzge" style="text-align: right" title="Warrants outstanding"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants2ExercisePrice0.002Member_zlgnxgIcCyKk" style="text-align: right" title="Warrants outstanding"><span style="font-size: 10pt">150,000</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-Funded Warrants 3</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_909_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants3ExercisePrice0.002Member_zbmqhDS6Sn67" title="Date issued">2/8/2024</span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants3ExercisePrice0.002Member_z3kTd4B1x6h3" style="text-align: right" title="Warrants exercise price"><span style="font-size: 10pt">0.002</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_d0_c20251231__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants3ExercisePrice0.002Member_z1cKT9UR11l8" style="text-align: right" title="Warrants outstanding"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants3ExercisePrice0.002Member_z2Qivc5Euhae" style="text-align: right" title="Warrants outstanding"><span style="font-size: 10pt">300,000</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Warrant Holder 25</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_903_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder25ExercisePrice12.00Member_z3hcmuuDwXi9" title="Date Issued">1/20/2025</span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder25ExercisePrice12.00Member_zuQsgwAp9Ea1" style="text-align: right" title="Warrants exercise price"><span style="font-size: 10pt">12.00</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder25ExercisePrice12.00Member_z8bA0x6c1Lti" title="Expiration">1/20/2030</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder25ExercisePrice12.00Member_zGElVEDbXJt5" style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">100,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_d0_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder25ExercisePrice12.00Member_z3UtJJ43UWI2" style="border-bottom: black 1pt solid; text-align: right">&#8211;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td colspan="10" style="text-align: center"><span style="font-size: 10pt"><b>Total Warrants outstanding</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231_zqQPGJsI8HJ5" style="border-bottom: black 2.25pt double; text-align: right" title="Total warrants outstanding"><span style="font-size: 10pt"><b>570,105</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231_zhrYnAzD8ZSl" style="border-bottom: black 2.25pt double; text-align: right" title="Total warrants outstanding"><span style="font-size: 10pt"><b>1,024,316</b></span></td>
    <td>&#160;</td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; padding-left: 10pt; text-indent: -0.01pt; width: 3%">*</td>
  <td style="text-align: justify; padding-left: 10pt; text-indent: -0.01pt; width: 97%">Pre-funded warrants, do not expire.</td></tr>
</table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of lease information</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--LeaseCostTableTextBlock_zNurRGb4gJA9" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details - Lease cost)">
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span id="xdx_8B9_zfBMVeVu1fG1" style="display: none">Schedule of lease information</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>December 31, 2025</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>December 31, 2024</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 68%; text-align: justify"><span style="font-size: 10pt">Office lease</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98C_ecustom--OperatingLeaseRightOfUseAssetGross_iI_c20251231_zTI5yKVpn9L7" style="width: 13%; text-align: right" title="Operating lease right of use asset, gross"><span style="font-size: 10pt">243,550</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_988_ecustom--OperatingLeaseRightOfUseAssetGross_iI_c20241231_zCNmIOx5AEda" style="width: 13%; text-align: right" title="Operating lease right of use asset, gross"><span style="font-size: 10pt">243,550</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; text-align: justify"><span style="font-size: 10pt">Less: accumulated depreciation</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td id="xdx_982_ecustom--OperatingLeaseRightOfUseAssetAccumulatedDepreciation_iNI_di_c20251231_zfjJ2CGRwWsd" style="border-bottom: Black 1pt solid; text-align: right" title="Operating lease right of use asset, accumulated depreciation"><span style="font-size: 10pt">(225,151</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td id="xdx_98C_ecustom--OperatingLeaseRightOfUseAssetAccumulatedDepreciation_iNI_di_c20241231_zeEO5zVDrf14" style="border-bottom: Black 1pt solid; text-align: right" title="Operating lease right of use asset, accumulated depreciation"><span style="font-size: 10pt">(183,767</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Right of use asset, net</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98D_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20251231_z3MqBXwIerud" style="border-bottom: black 2.25pt double; text-align: right" title="Operating lease right of use asset"><span style="font-size: 10pt">18,399</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98C_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20241231_z29q7WIDxG68" style="border-bottom: black 2.25pt double; text-align: right" title="Operating lease right of use asset"><span style="font-size: 10pt">59,783</span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Operating lease liability is summarized below:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>December 31, 2025</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>December 31, 2024</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 68%; text-align: justify"><span style="font-size: 10pt">Office lease</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98A_eus-gaap--OperatingLeaseLiability_iI_c20251231_z52hvCDNi538" style="width: 13%; text-align: right" title="Operating lease liability"><span style="font-size: 10pt">18,875</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98B_eus-gaap--OperatingLeaseLiability_iI_c20241231_z3X3UlzHpbR9" style="width: 13%; text-align: right" title="Operating lease liability"><span style="font-size: 10pt">61,180</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; text-align: justify"><span style="font-size: 10pt">Less: current portion</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td id="xdx_988_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_c20251231_zbwMKcGw5RS1" style="border-bottom: Black 1pt solid; text-align: right" title="Operating lease liability, current"><span style="font-size: 10pt">(18,875</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td id="xdx_989_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_c20241231_zaYiadVVq5g1" style="border-bottom: Black 1pt solid; text-align: right" title="Operating lease liability, current"><span style="font-size: 10pt">(42,305</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Long term portion</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_984_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_d0_c20251231_z5wk0aoUsIM" style="border-bottom: black 2.25pt double; text-align: right" title="Operating lease liability, noncurrent"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_987_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20241231_zrViZofdPv1h" style="border-bottom: black 2.25pt double; text-align: right" title="Operating lease liability, noncurrent"><span style="font-size: 10pt">18,875</span></td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of future minimum rental payments</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zhfD5xWoCW72" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details - Future minimum payments)">
  <tr style="vertical-align: bottom">
    <td style="width: 84%"><span id="xdx_8B8_zj1SoMqSanta" style="display: none">Schedule of future minimum rental payments</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_49E_20251231_zvweQfOVXaz9" style="text-align: center; width: 13%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzRwJ_zcNnpXsH026b" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">2026</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">$</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">19,301</span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzRwJ_zf9cpLG5IKMj" style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Total minimum lease payments:</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">19,301</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zvJXonsH07G8" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Less amount representing interest</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(426</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Present value of minimum lease payments:</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">18,875</span></td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of effective income tax reconciliation</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zQRlzwnj8iTg" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - INCOME TAXES (Details - Reconcilation of income tax)">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-size: 10pt"><span id="xdx_8BB_zz5fIkO2LeJe" style="display: none">Schedule of effective income
    tax reconciliation</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_49F_20250101__20251231_zEZKqKHR0Vr4" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_49E_20240101__20241231_zw7wqMsWN7r" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2025</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2024</b></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_iN_di_zRJCLbPmId39" style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 68%; text-align: justify"><span style="font-size: 10pt">Income tax benefit at statutory rate</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt">2,983,800</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt">2,455,499</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_pp0p0_di_z7QukHZQwO7d" style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Change in valuation allowance</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">(2,983,800</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">(2,455,499</span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of income tax provision</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zuKJKVl0AiLb" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - INCOME TAXES (Details - Reconcilation of provision)">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-size: 10pt"><span id="xdx_8B7_zVCL0npBJ3ee" style="display: none">Schedule of income tax provision</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2025</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2024</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 44%"><span style="font-size: 10pt">Excepted federal statutory income tax provision/rate</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98B_ecustom--ExpectedIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_iN_di_c20250101__20251231_zgJaatUK6x9c" style="width: 11%; text-align: right" title="Expected federal statutory income tax provision"><span style="font-size: 10pt">(2,521,826</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><span id="xdx_90A_ecustom--ExpectedEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pip0_dp_c20250101__20251231_zg0CG6XMikJi" style="font-size: 10pt">(21.0</span><span style="font-size: 10pt">%</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98D_ecustom--ExpectedIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_iN_di_c20240101__20241231_zpLeMPaNqmn6" style="width: 11%; text-align: right" title="Expected federal statutory income tax provision/rate"><span style="font-size: 10pt">(2,284,257</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><span id="xdx_904_ecustom--ExpectedEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_c20240101__20241231_zBq80To0LlB4" style="font-size: 10pt">(21.0</span><span style="font-size: 10pt">%</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">State income taxes, net of federal benefit</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_iN_di_c20250101__20251231_zv8bhZNz8msi" style="text-align: right" title="State income taxes, net of federal benefit"><span style="font-size: 10pt">(367,582</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pip0_dp_c20250101__20251231_zvrJZoK5FiEf" style="font-size: 10pt">(3.1</span><span style="font-size: 10pt">%</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_iN_di_c20240101__20241231_zQub2Ex3zNI1" style="text-align: right" title="State income taxes, net of federal benefit"><span style="font-size: 10pt">(58,863</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_c20240101__20241231_zdkbDi8RN0lh" style="font-size: 10pt">(0.5</span><span style="font-size: 10pt">%</span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Other</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_989_eus-gaap--IncomeTaxReconciliationOtherAdjustments_d0_c20250101__20251231_zmxjFEVCrXpb" style="border-bottom: black 1pt solid; text-align: right" title="Other"><span style="font-size: 10pt">(94,392</span></td>
    <td><span style="font-size: 10pt">)&#160;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_iN_pip0_dpi0_c20250101__20251231_zYh3smvTRDvl" style="font-size: 10pt">(0.8</span><span style="font-size: 10pt">%</span></td>
    <td><span style="font-size: 10pt">)&#160;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_984_eus-gaap--IncomeTaxReconciliationOtherAdjustments_d0_c20240101__20241231_zw8VxXHZ5Shd" style="border-bottom: black 1pt solid; text-align: right" title="Other"><span style="font-size: 10pt">(112,379)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_iN_pip0_dpi0_c20240101__20241231_zEBzGddw97je" style="font-size: 10pt">(1.0</span><span style="font-size: 10pt">%)</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify"><span style="font-size: 10pt">Income tax benefit at statutory rate</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98A_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maprovision2025_c20250101__20251231_zwemTfow8Awi" style="text-align: right" title="Income tax benefit at statutory rate"><span style="font-size: 10pt">(2,983,800</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_pip0_dpi_marate2025_c20250101__20251231_zDODJ5rM56Qc" style="font-size: 10pt">(24.9</span><span style="font-size: 10pt">%</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_981_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c20240101__20241231_zMr9ZKcuNona" style="text-align: right" title="Income tax benefit at statutory rate"><span style="font-size: 10pt">(2,455,499</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_dpi_c20240101__20241231_z4GVmULZyP7f" style="font-size: 10pt">(22.6</span><span style="font-size: 10pt">%</span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Change in valuation allowance</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_989_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maprovision2025_c20250101__20251231_zMUIjVGTqpLc" style="border-bottom: black 1pt solid; text-align: right" title="Change in valuation allowance"><span style="font-size: 10pt">2,983,800</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_pip0_dpi_marate2025_c20250101__20251231_zHvwiCenaScl" style="font-size: 10pt">22.6</span><span style="font-size: 10pt">%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_987_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c20240101__20241231_zdyr5v627Cmf" style="border-bottom: black 1pt solid; text-align: right" title="Change in valuation allowance"><span style="font-size: 10pt">2,455,499</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_dpi_c20240101__20241231_z1TeO8BKFuMi" style="font-size: 10pt">22.6</span><span style="font-size: 10pt">%</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_988_eus-gaap--IncomeTaxExpenseBenefit_d0_mtprovision2025_c20250101__20251231_z1RqDGAfPcNf" style="border-bottom: black 2.25pt double; text-align: right" title="Effective income tax rate reconciliation"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pip0_dp0_mtrate2025_c20250101__20251231_zhmLjvr2ewz7" style="font-size: 10pt">&#8211;</span><span style="font-size: 10pt">%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_980_eus-gaap--IncomeTaxExpenseBenefit_d0_c20240101__20241231_zAUFj5ujmvPi" style="border-bottom: black 2.25pt double; text-align: right" title="Effective income tax rate reconciliation"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pip0_dp0_c20240101__20241231_zstWZS4RSFbh" style="font-size: 10pt">&#8211;</span><span style="font-size: 10pt">%</span></td>
    <td>&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock', window );">Schedule of net operating loss carryforwards</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--SummaryOfOperatingLossCarryforwardsTextBlock_z9tlH1zytSh1" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - INCOME TAXES (Details - Operating loss carryforwards)">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt"><span id="xdx_8BB_zd0nrNFVfkUb" style="display: none">Schedule of net operating loss carryforwards</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_49F_20251231_zzT8UvYvcx4f" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_499_20241231_zk929KRLf6K8" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2025</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2024</b></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0" style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Deferred tax assets</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0" style="vertical-align: bottom; background-color: white">
    <td style="width: 68%"><span style="font-size: 10pt">Net operating loss carryforwards</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt">28,184,213</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt">24,971,010</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pp0p0" style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Section 174 R&amp;D</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,084,044</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,275,054</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_pp0p0" style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">PPE and intangible assets</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">974,646</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">915,327</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsStateTaxes_iNI_pp0p0_di_zxtLMq6E5fo9" style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">State taxes</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(1,667,634</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(1,569,922</span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsGross_iI_pp0p0_zDPigNQka0d5" style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Subtotal</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">28,575,269</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">25,591,469</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_zxpC5d1kvps6" style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Valuation Allowance</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(28,575,269</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(25,591,469</span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iI_pp0p0_d0_zNgvx6e3tjdf" style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Net deferred tax assets (liabilities)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of segment information</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zjX9HX3W2cJ8" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - SEGMENT REPORTING (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td><span id="xdx_8B3_zhFTKBU63z7i" style="display: none">Schedule of segment information</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="10" style="text-align: center"><span style="font-size: 10pt"><b>Year Ended December 31, 2025</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Biotechnology Segment</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Technology <br/>
Segment</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Consolidated</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 58%"><span style="font-size: 10pt">Sales</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98D_eus-gaap--Revenues_d0_c20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_zjOPg0dyozD" style="width: 11%; text-align: right" title="Sales"><span style="font-size: 10pt">&#8211;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98C_eus-gaap--Revenues_c20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyMember_zuSi0ncYYfZ4" style="width: 11%; text-align: right" title="Sales"><span style="font-size: 10pt">1,363,045</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98C_eus-gaap--Revenues_c20250101__20251231_zt2l2Yxxzvah" style="width: 11%; text-align: right" title="Sales"><span style="font-size: 10pt">1,363,045</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Cost of goods sold</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--CostOfRevenue_d0_c20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_z1mQVpjjabw5" style="text-align: right" title="Cost of goods sold"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--CostOfRevenue_c20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyMember_zQ2UtSYCMW95" style="text-align: right" title="Cost of goods sold"><span style="font-size: 10pt">180,625</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98A_eus-gaap--CostOfRevenue_c20250101__20251231_zdGumLwZcbV9" style="text-align: right" title="Cost of goods sold"><span style="font-size: 10pt">180,625</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">Total operating expenses</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_982_eus-gaap--OperatingExpenses_c20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_zRhfiiVMtsQj" style="border-bottom: black 1pt solid; text-align: right" title="Total operating expenses"><span style="font-size: 10pt">13,540,971</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_983_eus-gaap--OperatingExpenses_c20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyMember_zFIuUn47BtQg" style="border-bottom: black 1pt solid; text-align: right" title="Total operating expenses"><span style="font-size: 10pt">684,947</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98C_eus-gaap--OperatingExpenses_c20250101__20251231_zizQaAuvHgX8" style="border-bottom: black 1pt solid; text-align: right" title="Total operating expenses"><span style="font-size: 10pt">14,225,918</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Net (loss) gain from operations</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_988_eus-gaap--OperatingIncomeLoss_c20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_zvvYDj8S3lU" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss from operations"><span style="font-size: 10pt">(13,540,971</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_980_eus-gaap--OperatingIncomeLoss_c20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyMember_zHMKDyZHlpV5" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss from operations"><span style="font-size: 10pt">497,473</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_988_eus-gaap--OperatingIncomeLoss_c20250101__20251231_ziLj9kCiPnkj" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss from operations"><span style="font-size: 10pt">(13,043,498</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - SEGMENT REPORTING (Details)">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="10" style="text-align: center"><span style="font-size: 10pt"><b>Year Ended December 31, 2024</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Biotechnology Segment</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Technology </b></span><br/>
<span style="font-size: 10pt"><b>Segment</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Consolidated</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 61%"><span style="font-size: 10pt">Sales</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_982_eus-gaap--Revenues_d0_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_zRch71FsyVI1" style="width: 10%; text-align: right" title="Sales"><span style="font-size: 10pt">&#8211;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_984_eus-gaap--Revenues_d0_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyMember_zUGb5ZvWrtNk" style="width: 10%; text-align: right" title="Sales"><span style="font-size: 10pt">&#8211;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98C_eus-gaap--Revenues_d0_c20240101__20241231_zPccjbODzKA5" style="width: 10%; text-align: right" title="Sales"><span style="font-size: 10pt">&#8211;</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Cost of goods sold</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_985_eus-gaap--CostOfRevenue_d0_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_zIWFmPX2DPKj" style="text-align: right" title="Cost of goods sold"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_981_eus-gaap--CostOfRevenue_d0_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyMember_zLUfAV0Y7P9a" style="text-align: right" title="Cost of goods sold"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--CostOfRevenue_d0_c20240101__20241231_zZD7MCnt0iKf" style="text-align: right" title="Cost of goods sold"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">Total operating expenses</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98C_eus-gaap--OperatingExpenses_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_zO2St6XwO9Wa" style="border-bottom: black 1pt solid; text-align: right" title="Total operating expenses"><span style="font-size: 10pt">10,054,488</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98F_eus-gaap--OperatingExpenses_d0_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyMember_znnmn6cYX5D3" style="border-bottom: black 1pt solid; text-align: right" title="Total operating expenses"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_982_eus-gaap--OperatingExpenses_c20240101__20241231_zOWjJnUP578e" style="border-bottom: black 1pt solid; text-align: right" title="Total operating expenses"><span style="font-size: 10pt">10,054,488</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Net loss from operations</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98B_eus-gaap--OperatingIncomeLoss_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_zxUQWwHKpD9k" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss from operations"><span style="font-size: 10pt">(10,054,488</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98E_eus-gaap--OperatingIncomeLoss_d0_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyMember_zYzKkFg1aHWd" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss from operations"><span style="font-size: 10pt">&#8211;</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98E_eus-gaap--OperatingIncomeLoss_c20240101__20241231_z1Se8kIKBQFh" style="border-bottom: Black 2.5pt double; text-align: right" title="Net (loss) gain from operations"><span style="font-size: 10pt">(10,054,488</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">)</span></td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">20-1 reverse stock split<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares</a></td>
<td class="nump">1,382,105<span></span>
</td>
<td class="nump">2,900,570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 109,953,728<span></span>
</td>
<td class="nump">$ 98,036,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="nump">$ 12,277,192<span></span>
</td>
<td class="nump">$ 10,877,412<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=coep_WarrantsMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares</a></td>
<td class="nump">945,105<span></span>
</td>
<td class="nump">1,399,316<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=coep_StockOptionsMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares</a></td>
<td class="nump">437,000<span></span>
</td>
<td class="nump">279,625<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">406,629<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">815,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=coep_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=coep_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=coep_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=coep_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Cash uninsured amount</a></td>
<td class="nump">$ 5,424,302<span></span>
</td>
<td class="nump">$ 282,885<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">587<span></span>
</td>
<td class="nump">845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">1,277,150<span></span>
</td>
<td class="nump">2,331,548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,363,045<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Customer deposits</a></td>
<td class="nump">599,455<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=coep_AdvertisingCampaignsMember', window );">Advertising Campaigns [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,250,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Customer deposits</a></td>
<td class="nump">599,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=coep_WebinarServicesMember', window );">Webinar Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 112,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Six Customers [Member] | Advertising Campaigns [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Three Customers [Member] | Webinar Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=coep_NexGenAIMember', window );">NexGenAI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Intangible assets acquired</a></td>
<td class="nump">$ 361,250<span></span>
</td>
<td class="nump">$ 541,875<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480095/942-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480035/942-10-S99-6<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 805<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478072/944-805-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=coep_AdvertisingCampaignsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=coep_AdvertisingCampaignsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=coep_WebinarServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=coep_WebinarServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=coep_SixCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=coep_SixCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=coep_ThreeCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=coep_ThreeCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=coep_NexGenAIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=coep_NexGenAIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CO-DEVELOPMENT OPTIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Asset, Acquired, Finite-Lived [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">License fees</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=coep_CoDevelopmentOptionsMember', window );">Co Development Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Asset, Acquired, Finite-Lived [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=coep_CoDevelopmentRightsMember', window );">Co Development Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Asset, Acquired, Finite-Lived [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostGross', window );">Capitalized Contract Cost, Gross</a></td>
<td class="nump">5,291,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAccumulatedAmortization', window );">Capitalized Contract Cost, Accumulated Amortization</a></td>
<td class="nump">4,737,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Capitalized Contract Cost, Net</a></td>
<td class="nump">$ 554,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=coep_CD38AssetsMember', window );">CD38 Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Asset, Acquired, Finite-Lived [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermNotesPayable', window );">Other Notes Payable, Noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=coep_CD38AssetsMember', window );">CD38 Assets [Member] | Vy Gen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Asset, Acquired, Finite-Lived [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Payments to Acquire Productive Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermNotesPayable', window );">Other Notes Payable, Noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of Long-Term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostGross', window );">Capitalized Contract Cost, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 805<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478072/944-805-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term notes classified as other, payable after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=coep_CoDevelopmentOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=coep_CoDevelopmentOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=coep_CoDevelopmentRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=coep_CoDevelopmentRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=coep_CD38AssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=coep_CD38AssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=coep_VyGenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=coep_VyGenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONVERTIBLE NOTES (Details - Derivative liability) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair value of derivative liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,041,484<span></span>
</td>
<td class="nump">$ 501,824<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=coep_DerivativeLiabilityMember', window );">Derivative Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair value of derivative liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,041,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-20<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -SubTopic 20<br> -Topic 860<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-12<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-21<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-15<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=coep_DerivativeLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=coep_DerivativeLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE NOTES (Details - Assumptions) - Fair Value, Inputs, Level 3 [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue', window );">Derivative assumption valuation</a></td>
<td class="text">4.16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue', window );">Derivative assumption valuation</a></td>
<td class="text">114.61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputConversionPriceMember', window );">Measurement Input, Conversion Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue', window );">Derivative assumption valuation</a></td>
<td class="text">3.71<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue', window );">Derivative assumption valuation</a></td>
<td class="text">5.50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-47<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 37: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes how an entity determines the fair values of its derivatives, including its valuation methodology and significant assumptions used.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputConversionPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputConversionPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE NOTES (Details - Change in deriviative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair value of derivative liability, beginning balance</a></td>
<td class="nump">$ 501,824<span></span>
</td>
<td class="nump">$ 1,041,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Change in fair value</a></td>
<td class="nump">539,660<span></span>
</td>
<td class="num">(906,430)<span></span>
</td>
<td class="nump">$ 539,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax', window );">Extinguishment of fair value of liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(135,054)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair value of derivative liability, ending balance</a></td>
<td class="nump">$ 1,041,484<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,041,484<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-20<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -SubTopic 20<br> -Topic 860<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the reacquisition price and the net carrying amount of the extinguished debt recognized currently as a component of income in the period of extinguishment, net of tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtGainLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE NOTES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 16, 2025</div></th>
<th class="th"><div>Nov. 02, 2024</div></th>
<th class="th"><div>Apr. 24, 2024</div></th>
<th class="th"><div>Apr. 17, 2024</div></th>
<th class="th"><div>Dec. 15, 2023</div></th>
<th class="th"><div>Oct. 27, 2023</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jan. 03, 2024</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 545,635<span></span>
</td>
<td class="nump">$ 216,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Change in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (539,660)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">906,430<span></span>
</td>
<td class="num">(539,660)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet', window );">Transfers in or out of Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=coep_StandbyEquityPurchaseAgreementMember', window );">Standby Equity Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossLiability', window );">Fair value derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,041,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,041,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Change in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">906,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=coep_YorkvilleConvertibleNoteMember', window );">Yorkville Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt face amount</a></td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt converted, amount converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,304,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 435,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,304,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_DebtConversionConvertedInterestAmount1', window );">[custom:DebtConversionConvertedInterestAmount1]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233,500<span></span>
</td>
<td class="nump">158,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=coep_YANote2Member', window );">Y A Note 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt converted, amount converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_DebtConversionConvertedInterestAmount1', window );">[custom:DebtConversionConvertedInterestAmount1]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=coep_YANote1Member', window );">YA Note-1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,235,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDecreaseForgiveness', window );">Short-term debt replaced</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,235,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=coep_Oct2022ConvertiblePromissoryNoteMember', window );">Oct 2022 Convertible Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayment of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDefaultLongtermDebtAmount', window );">Debt in default</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=coep_Dec2023ConvertiblePromissoryNoteMember', window );">Dec 2023 Convertible Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt converted, amount converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member] | April 2024 Unsecured Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=coep_LicenseAgreementMember', window );">License Agreement [Member] | Purple Bio Tech [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 218,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 218,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayment of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 218,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_DebtConversionConvertedInterestAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_DebtConversionConvertedInterestAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDefaultLongtermDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of outstanding long-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDefaultLongtermDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDecreaseForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDecreaseForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueGrossLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueGrossLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=coep_StandbyEquityPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=coep_StandbyEquityPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=coep_YorkvilleConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=coep_YorkvilleConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=coep_YANote2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=coep_YANote2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=coep_YANote1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=coep_YANote1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=coep_Oct2022ConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=coep_Oct2022ConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=coep_Dec2023ConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=coep_Dec2023ConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=coep_April2024UnsecuredNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=coep_April2024UnsecuredNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=coep_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=coep_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=coep_PurpleBioTechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=coep_PurpleBioTechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SBA LOAN PAYABLE (Details Narrative) - Eidl Loan [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Jul. 08, 2020</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLoans', window );">Proceeds from loans</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Accrued interest rate</a></td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received from principal payments made on loans related to operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=coep_EidlLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=coep_EidlLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DERIVATIVE LIABILITY WARRANTS (Details - Fair value) - Fair Value, Recurring [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities fair value disclosure</a></td>
<td class="nump">$ 167,625<span></span>
</td>
<td class="nump">$ 359,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=coep_PublicWarrantsMember', window );">Public Warrants [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities fair value disclosure</a></td>
<td class="nump">81,000<span></span>
</td>
<td class="nump">165,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=coep_PrivatePlacementWarrantsMember', window );">Private Placement Warrants [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities fair value disclosure</a></td>
<td class="nump">$ 86,625<span></span>
</td>
<td class="nump">$ 194,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 182<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480401/815-10-55-182<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4CC<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CC<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=coep_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=coep_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=coep_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=coep_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE LIABILITY WARRANTS (Details - Fair value assumption) - Warrants [Member]<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue', window );">Derivatives, determination of fair value</a></td>
<td class="text">3.41<span></span>
</td>
<td class="text">4.10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue', window );">Derivatives, determination of fair value</a></td>
<td class="text">68.58<span></span>
</td>
<td class="text">82.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember', window );">Measurement Input, Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue', window );">Derivatives, determination of fair value</a></td>
<td class="text">230.00<span></span>
</td>
<td class="text">230.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue', window );">Derivatives, determination of fair value</a></td>
<td class="text">14.25<span></span>
</td>
<td class="text">5.50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 182<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480401/815-10-55-182<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4CC<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CC<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes how an entity determines the fair values of its derivatives, including its valuation methodology and significant assumptions used.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=coep_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=coep_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE LIABILITY WARRANTS (Details - Changes in fair value of warrant liabilities)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=coep_PrivatePlacementWarrantsMember', window );">Private Placement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of liabilities, beginning</a></td>
<td class="nump">$ 194,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect', window );">Change in valuation inputs</a></td>
<td class="num">(107,625)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of liabilities, ending</a></td>
<td class="nump">86,625<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=coep_PublicWarrantsMember', window );">Public Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of liabilities, beginning</a></td>
<td class="nump">165,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect', window );">Change in valuation inputs</a></td>
<td class="num">(84,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of liabilities, ending</a></td>
<td class="nump">81,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=coep_WarrantLiabilitiesMember', window );">Warrant Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of liabilities, beginning</a></td>
<td class="nump">359,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect', window );">Change in valuation inputs</a></td>
<td class="num">(191,625)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of liabilities, ending</a></td>
<td class="nump">$ 167,625<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 182<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480401/815-10-55-182<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4CC<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CC<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the quantification of the effect of changes in the valuation technique and related inputs, during the period, used to measure the liability at fair value as of the statement of financial position reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=coep_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=coep_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=coep_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=coep_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=coep_WarrantLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=coep_WarrantLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DERIVATIVE LIABILITY WARRANTS (Details Narrative) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">570,105<span></span>
</td>
<td class="nump">1,024,316<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=coep_PrivatePlacementWarrantsMember', window );">Private Placement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">187,500<span></span>
</td>
<td class="nump">187,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=coep_PublicWarrantsMember', window );">Public Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">375,000<span></span>
</td>
<td class="nump">375,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=coep_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=coep_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=coep_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=coep_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STRUCTURE (Details - Option activity) - Stock Options [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning</a></td>
<td class="nump">279,625<span></span>
</td>
<td class="nump">87,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning balance outstanding</a></td>
<td class="nump">$ 15.29<span></span>
</td>
<td class="nump">$ 40.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average contractual life (years), options outstanding</a></td>
<td class="text">6 years 3 months 3 days<span></span>
</td>
<td class="text">8 years 8 months 26 days<span></span>
</td>
<td class="text">7 years 11 months 19 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted</a></td>
<td class="nump">187,375<span></span>
</td>
<td class="nump">196,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted</a></td>
<td class="nump">$ 7.96<span></span>
</td>
<td class="nump">$ 8.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2OptionsGranted', window );">Weighted average contractual life (years), granted</a></td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited/expired</a></td>
<td class="num">(30,000)<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, forfeited/expired</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 200.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending</a></td>
<td class="nump">437,000<span></span>
</td>
<td class="nump">279,625<span></span>
</td>
<td class="nump">87,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, ending balance outstanding</a></td>
<td class="nump">$ 12.11<span></span>
</td>
<td class="nump">$ 15.29<span></span>
</td>
<td class="nump">$ 40.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic value, options outstanding</a></td>
<td class="nump">$ 2,215,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2OptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2OptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=coep_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=coep_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STRUCTURE (Details - Weighted average assumptions) - Stock Options [Member]<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term, in years</a></td>
<td class="text">2 years 9 months<span></span>
</td>
<td class="text">5 years 3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">75.58%<span></span>
</td>
<td class="nump">84.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.89%<span></span>
</td>
<td class="nump">4.18%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=coep_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=coep_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STRUCTURE (Details - Warrants outstanding) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Total warrants outstanding</a></td>
<td class="nump">570,105<span></span>
</td>
<td class="nump">1,024,316<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=coep_WarrantHolder1ExercisePrice59.40Member', window );">Warrant Holder 1 Exercise Price 59. 40 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_WarrantsAndRightsOutstandingDateIssued', window );">Date Issued</a></td>
<td class="text">May 28,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 59.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration</a></td>
<td class="text">May 13,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Total warrants outstanding</a></td>
<td class="nump">8,380<span></span>
</td>
<td class="nump">8,380<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=coep_WarrantHolder1ExercisePrice118.80Member', window );">Warrant Holder 1 Exercise Price 118. 80 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_WarrantsAndRightsOutstandingDateIssued', window );">Date Issued</a></td>
<td class="text">May 28,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 118.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration</a></td>
<td class="text">May 13,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Total warrants outstanding</a></td>
<td class="nump">8,422<span></span>
</td>
<td class="nump">8,422<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=coep_WarrantHolder1ExercisePrice296.80Member', window );">Warrant Holder 1 Exercise Price 296. 80 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_WarrantsAndRightsOutstandingDateIssued', window );">Date Issued</a></td>
<td class="text">May 28,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 296.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration</a></td>
<td class="text">May 13,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Total warrants outstanding</a></td>
<td class="nump">8,422<span></span>
</td>
<td class="nump">8,422<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=coep_WarrantHolder2ExercisePrice59.40Member', window );">Warrant Holder 2 Exercise Price 59. 40 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_WarrantsAndRightsOutstandingDateIssued', window );">Date Issued</a></td>
<td class="text">Jul. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 59.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration</a></td>
<td class="text">Jul. 30,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Total warrants outstanding</a></td>
<td class="nump">421<span></span>
</td>
<td class="nump">421<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=coep_WarrantHolder2ExercisePrice296.80Member', window );">Warrant Holder 2 Exercise Price 296. 80 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_WarrantsAndRightsOutstandingDateIssued', window );">Date Issued</a></td>
<td class="text">Jul. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 296.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration</a></td>
<td class="text">Jun.  01,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Total warrants outstanding</a></td>
<td class="nump">1,263<span></span>
</td>
<td class="nump">1,263<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=coep_WarrantHolder5ExercisePrice59.40Member', window );">Warrant Holder 5 Exercise Price 59. 40 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_WarrantsAndRightsOutstandingDateIssued', window );">Date Issued</a></td>
<td class="text">Dec. 20,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 59.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration</a></td>
<td class="text">Dec. 20,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Total warrants outstanding</a></td>
<td class="nump">2,948<span></span>
</td>
<td class="nump">2,948<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=coep_WarrantHolder18ExercisePrice178.20Member', window );">Warrant Holder 18 Exercise Price 178. 20 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_WarrantsAndRightsOutstandingDateIssued', window );">Date Issued</a></td>
<td class="text">Mar. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 178.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration</a></td>
<td class="text">Mar. 30,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Total warrants outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=coep_WarrantHolder20ExercisePrice50.00Member', window );">Warrant Holder 20 Exercise Price 50. 00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_WarrantsAndRightsOutstandingDateIssued', window );">Date Issued</a></td>
<td class="text">Jan.  03,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 50.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration</a></td>
<td class="text">Jan.  02,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Total warrants outstanding</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=coep_WarrantHolder21ExercisePrice38.00Member', window );">Warrant Holder 21 Exercise Price 38. 00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_WarrantsAndRightsOutstandingDateIssued', window );">Date Issued</a></td>
<td class="text">Jan. 20,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 38.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration</a></td>
<td class="text">Jan. 19,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Total warrants outstanding</a></td>
<td class="nump">12,500<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=coep_SeriesWarrantsAAndBExercisePrice27.20Member', window );">Series Warrants A And B Exercise Price 27. 20 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_WarrantsAndRightsOutstandingDateIssued', window );">Date Issued</a></td>
<td class="text">Jun. 16,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 27.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration</a></td>
<td class="text">Dec. 16,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Total warrants outstanding</a></td>
<td class="nump">306,250<span></span>
</td>
<td class="nump">306,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=coep_SeriesAWarrantsExercisePrice27.20Member', window );">Series A Warrants Exercise Price 27. 20 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_WarrantsAndRightsOutstandingDateIssued', window );">Date Issued</a></td>
<td class="text">Oct. 23,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 27.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration</a></td>
<td class="text">Apr. 26,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Total warrants outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=coep_SeriesBWarrantsExercisePrice27.20Member', window );">Series B Warrants Exercise Price 27. 20 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_WarrantsAndRightsOutstandingDateIssued', window );">Date Issued</a></td>
<td class="text">Oct. 23,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 27.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration</a></td>
<td class="text">Apr. 26,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Total warrants outstanding</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=coep_WarrantHolder22ExercisePrice25.00Member', window );">Warrant Holder 22 Exercise Price 25. 00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_WarrantsAndRightsOutstandingDateIssued', window );">Date Issued</a></td>
<td class="text">Jun. 16,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration</a></td>
<td class="text">Dec. 16,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Total warrants outstanding</a></td>
<td class="nump">6,300<span></span>
</td>
<td class="nump">6,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=coep_WarrantHolder22ExercisePrice28.00Member', window );">Warrant Holder 22 Exercise Price 28. 00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_WarrantsAndRightsOutstandingDateIssued', window );">Date Issued</a></td>
<td class="text">Oct. 23,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 28.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration</a></td>
<td class="text">Apr. 26,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Total warrants outstanding</a></td>
<td class="nump">3,300<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=coep_WarrantHolder23ExercisePrice25.00Member', window );">Warrant Holder 23 Exercise Price 25. 00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_WarrantsAndRightsOutstandingDateIssued', window );">Date Issued</a></td>
<td class="text">Jun. 16,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration</a></td>
<td class="text">Dec. 16,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Total warrants outstanding</a></td>
<td class="nump">4,200<span></span>
</td>
<td class="nump">4,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=coep_WarrantHolder23ExercisePrice28.00Member', window );">Warrant Holder 23 Exercise Price 28. 00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_WarrantsAndRightsOutstandingDateIssued', window );">Date Issued</a></td>
<td class="text">Oct. 23,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 28.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration</a></td>
<td class="text">Apr. 26,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Total warrants outstanding</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=coep_WarrantHolder24ExercisePrice28.00Member', window );">Warrant Holder 24 Exercise Price 28. 00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_WarrantsAndRightsOutstandingDateIssued', window );">Date Issued</a></td>
<td class="text">Oct. 23,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 28.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration</a></td>
<td class="text">Apr. 26,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Total warrants outstanding</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=coep_PreFundedWarrants2ExercisePrice0.002Member', window );">Pre Funded Warrants 2 Exercise Price 0. 002 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_WarrantsAndRightsOutstandingDateIssued', window );">Date Issued</a></td>
<td class="text">Dec. 28,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 0.002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Total warrants outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=coep_PreFundedWarrants3ExercisePrice0.002Member', window );">Pre Funded Warrants 3 Exercise Price 0. 002 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_WarrantsAndRightsOutstandingDateIssued', window );">Date Issued</a></td>
<td class="text">Feb.  08,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 0.002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Total warrants outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=coep_WarrantHolder25ExercisePrice12.00Member', window );">Warrant Holder 25 Exercise Price 12. 00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_WarrantsAndRightsOutstandingDateIssued', window );">Date Issued</a></td>
<td class="text">Jan. 20,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration</a></td>
<td class="text">Jan. 20,  2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Total warrants outstanding</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_WarrantsAndRightsOutstandingDateIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_WarrantsAndRightsOutstandingDateIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=coep_WarrantHolder1ExercisePrice59.40Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=coep_WarrantHolder1ExercisePrice59.40Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=coep_WarrantHolder1ExercisePrice118.80Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=coep_WarrantHolder1ExercisePrice118.80Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=coep_WarrantHolder1ExercisePrice296.80Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=coep_WarrantHolder1ExercisePrice296.80Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=coep_WarrantHolder2ExercisePrice59.40Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=coep_WarrantHolder2ExercisePrice59.40Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=coep_WarrantHolder2ExercisePrice296.80Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=coep_WarrantHolder2ExercisePrice296.80Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=coep_WarrantHolder5ExercisePrice59.40Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=coep_WarrantHolder5ExercisePrice59.40Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=coep_WarrantHolder18ExercisePrice178.20Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=coep_WarrantHolder18ExercisePrice178.20Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=coep_WarrantHolder20ExercisePrice50.00Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=coep_WarrantHolder20ExercisePrice50.00Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=coep_WarrantHolder21ExercisePrice38.00Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=coep_WarrantHolder21ExercisePrice38.00Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=coep_SeriesWarrantsAAndBExercisePrice27.20Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=coep_SeriesWarrantsAAndBExercisePrice27.20Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=coep_SeriesAWarrantsExercisePrice27.20Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=coep_SeriesAWarrantsExercisePrice27.20Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=coep_SeriesBWarrantsExercisePrice27.20Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=coep_SeriesBWarrantsExercisePrice27.20Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=coep_WarrantHolder22ExercisePrice25.00Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=coep_WarrantHolder22ExercisePrice25.00Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=coep_WarrantHolder22ExercisePrice28.00Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=coep_WarrantHolder22ExercisePrice28.00Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=coep_WarrantHolder23ExercisePrice25.00Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=coep_WarrantHolder23ExercisePrice25.00Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=coep_WarrantHolder23ExercisePrice28.00Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=coep_WarrantHolder23ExercisePrice28.00Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=coep_WarrantHolder24ExercisePrice28.00Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=coep_WarrantHolder24ExercisePrice28.00Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=coep_PreFundedWarrants2ExercisePrice0.002Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=coep_PreFundedWarrants2ExercisePrice0.002Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=coep_PreFundedWarrants3ExercisePrice0.002Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=coep_PreFundedWarrants3ExercisePrice0.002Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=coep_WarrantHolder25ExercisePrice12.00Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=coep_WarrantHolder25ExercisePrice12.00Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STRUCTURE (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 24, 2025</div></th>
<th class="th"><div>Feb. 06, 2025</div></th>
<th class="th"><div>Dec. 23, 2024</div></th>
<th class="th"><div>Nov. 02, 2024</div></th>
<th class="th"><div>Sep. 04, 2024</div></th>
<th class="th"><div>Jul. 31, 2024</div></th>
<th class="th"><div>Jun. 13, 2024</div></th>
<th class="th"><div>Dec. 28, 2023</div></th>
<th class="th"><div>Jun. 16, 2023</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jul. 25, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Feb. 28, 2024</div></th>
<th class="th"><div>Nov. 23, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,746,948<span></span>
</td>
<td class="nump">2,116,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,746,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,746,948<span></span>
</td>
<td class="nump">2,116,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20-1 reverse stock split<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Aggregate exercise price of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,558,455<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,558,456<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from sale of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,455,000<span></span>
</td>
<td class="nump">$ 3,914,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSubscriptionsReceivable', window );">Subscription receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,686,544<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,686,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,686,544<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unamortized stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">918,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">918,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">918,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,860,083<span></span>
</td>
<td class="nump">5,691,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,860,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,860,083<span></span>
</td>
<td class="nump">5,691,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_SubscriptionsReceivable', window );">Subscriptions receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,686,544<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_ProceedsFromSubscriptionsReceivable', window );">Proceeds subscriptions receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_SubscriptionsReceivableNet', window );">Subscriptions receivable net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=coep_SubscriptionReceivableSept2023Member', window );">Subscription Receivable Sept 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_StockIssuedForDebtShares', window );">Stock issued for debt, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_StockIssuedForDebtValue', window );">Stock issued for debt, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">522,667<span></span>
</td>
<td class="nump">522,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">522,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">522,667<span></span>
</td>
<td class="nump">522,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=coep_SubscriptionReceivableSept20232ndMember', window );">Subscription Receivable Sept 2023 One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_StockIssuedForDebtShares', window );">Stock issued for debt, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_StockIssuedForDebtValue', window );">Stock issued for debt, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,090,667<span></span>
</td>
<td class="nump">2,090,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,090,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,090,667<span></span>
</td>
<td class="nump">2,090,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=coep_December2023FinancingMember', window );">December 2023 Financing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,132,869<span></span>
</td>
<td class="nump">1,132,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,132,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,132,869<span></span>
</td>
<td class="nump">1,132,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=coep_February2024FinancingMember', window );">February 2024 Financing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,944,879<span></span>
</td>
<td class="nump">$ 1,944,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,944,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,944,879<span></span>
</td>
<td class="nump">1,944,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=coep_ModificationOfOptionsMember', window );">Modification Of Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=coep_ColleenDelaneyMember', window );">Colleen Delaney [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Number of shares forfeited</a></td>
<td class="nump">27,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Number of shares exercised</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of shares expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=coep_CoralInvestmentPartnersMember', window );">Coral Investment Partners [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=coep_StockOptionsMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,215,692<span></span>
</td>
<td class="nump">$ 1,104,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,375<span></span>
</td>
<td class="nump">196,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=coep_ConsultingAgreementMember', window );">Consulting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSubscriptionsReceivable', window );">Subscription receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=coep_TwoInvestorMember', window );">Two Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 18,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_SubscriptionsReceivableNet', window );">Subscriptions receivable net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=coep_StandbyEquityPurchaseAgreementMember', window );">Standby Equity Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,958,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=coep_StandbyEquityPurchaseAgreementMember', window );">Standby Equity Purchase Agreement [Member] | Yorkville [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForBrokerageFees', window );">Payment of commitment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=coep_StandbyEquityPurchaseAgreementMember', window );">Standby Equity Purchase Agreement [Member] | Yorkville [Member] | Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,304,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=coep_StandbyEquityPurchaseAgreementMember', window );">Standby Equity Purchase Agreement [Member] | Stock Issued For Services [Member] | Yorkville [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForBrokerageFees', window );">Payment of commitment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=coep_SNAPBiosciencesIncMember', window );">SNAP Biosciences Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockDescriptionOfTransaction', window );">Investors description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In addition to the shares
of common stock of the Company, investors also received 10% aggregate non-voting ownership in the Company&#8217;s subsidiary, SNAP Biosciences,
Inc. Of this $5,000,000 raised, $4,500,000 was collected as of December 31, 2025. $500,000 of the subscription receivable is tied to a
promissory note bearing 1% interest annum, with a maturity date of January 18, 2026.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_SubscriptionsReceivable', window );">Subscriptions receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Stock converted, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=coep_PreFundedWarrantsMember', window );">Pre Funded Warrants [Member] | Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock, shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=coep_SeriesAWarrantsMember', window );">Series A Warrants [Member] | Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=coep_SeriesBWarrantsMember', window );">Series B Warrants [Member] | Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=coep_SeriesWarrantsMember', window );">Series Warrants [Member] | Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=coep_WarrantNoteSubscriptionReceivablesMember', window );">Warrant Note Subscription Receivables [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Aggregate exercise price of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock, shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from sale of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,480,000<span></span>
</td>
<td class="nump">$ 695,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">$ 4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants', window );">Proceeds from issuance of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable', window );">Subscription receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Coral Investment Partners [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member] | Coral Investment Partners [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_ProceedsFromSubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_ProceedsFromSubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_StockIssuedForDebtShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_StockIssuedForDebtShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_StockIssuedForDebtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_StockIssuedForDebtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_SubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_SubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_SubscriptionsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_SubscriptionsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(h))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForBrokerageFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for brokerage fees during the current period. This element is intended to represent the brokerage fees paid by and between financial industry participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForBrokerageFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of subscription receivable from investors who have been allocated nonredeemable preferred stock or preferred stock redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481142/505-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-23<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteSubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Note received instead of cash as contribution to equity. The transaction may be a sale of capital stock or a contribution to paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481142/505-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteSubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=coep_SubscriptionReceivableSept2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=coep_SubscriptionReceivableSept2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=coep_SubscriptionReceivableSept20232ndMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=coep_SubscriptionReceivableSept20232ndMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=coep_December2023FinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=coep_December2023FinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=coep_February2024FinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=coep_February2024FinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=coep_ModificationOfOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=coep_ModificationOfOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=coep_ColleenDelaneyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=coep_ColleenDelaneyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=coep_CoralInvestmentPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=coep_CoralInvestmentPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=coep_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=coep_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=coep_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=coep_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=coep_TwoInvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=coep_TwoInvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=coep_StandbyEquityPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=coep_StandbyEquityPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=coep_YorkvilleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=coep_YorkvilleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=coep_ConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=coep_ConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=coep_StockIssuedForServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=coep_StockIssuedForServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=coep_SNAPBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=coep_SNAPBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=coep_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=coep_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=coep_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=coep_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=coep_SeriesAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=coep_SeriesAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=coep_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=coep_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=coep_SeriesWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=coep_SeriesWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=coep_WarrantNoteSubscriptionReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=coep_WarrantNoteSubscriptionReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>NON-CONTROLLING INTEREST (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="nump">$ 506,163<span></span>
</td>
<td class="nump">$ 485,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity attributable to non-controlling interests</a></td>
<td class="nump">14,068,157<span></span>
</td>
<td class="nump">$ 3,867,226<span></span>
</td>
<td class="nump">$ 813,963<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=coep_GearTherapeuticsMember', window );">Gear Therapeutics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="nump">1,063,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Net of accumulated losses</a></td>
<td class="nump">557,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity attributable to non-controlling interests</a></td>
<td class="nump">$ 506,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 42: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 47: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 51: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 52: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 54: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 55: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=coep_GearTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=coep_GearTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Aug. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Loss on investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 163,500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_InvestmentCompanyFeePaidSharesIndirectly', window );">Investment company fee paid shares indirectly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,830,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentCompanyFeePaidIndirectly', window );">Investment company fee paid indirectly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized gain on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,596<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=coep_NexGenAIAffiliatesNetworkPlatformMember', window );">Nex Gen A I Affiliates Network Platform [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Loss on investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 163,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=coep_TwoPrivatelyHeldCompaniesMember', window );">Two Privately Held Companies [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_SubscriptionReceivable', window );">[custom:SubscriptionReceivable-0]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=coep_FivePrivatelyHeldCompaniesMember', window );">Five Privately Held Companies [Member] | Nex Gen A I Affiliates Network Platform [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment Owned, Balance, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=coep_ThreePrivatelyHeldCompaniesMember', window );">Three Privately Held Companies [Member] | Nex Gen A I Affiliates Network Platform [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment Owned, Balance, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,500<span></span>
</td>
<td class="nump">82,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=coep_PrivatelyHeldCompanyMember', window );">Privately Held Company [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment Owned, Balance, Shares</a></td>
<td class="nump">667,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Loss on investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_StockIssuedDuringPeriodSharesIssuedForInvestment', window );">[custom:StockIssuedDuringPeriodSharesIssuedForInvestment]</a></td>
<td class="nump">66,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_StockIssuedDuringPeriodValueIssuedForInvestment', window );">[custom:StockIssuedDuringPeriodValueIssuedForInvestment]</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_InvestmentCompanyFeePaidSharesIndirectly">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_InvestmentCompanyFeePaidSharesIndirectly</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_StockIssuedDuringPeriodSharesIssuedForInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_StockIssuedDuringPeriodSharesIssuedForInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_StockIssuedDuringPeriodValueIssuedForInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_StockIssuedDuringPeriodValueIssuedForInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_SubscriptionReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_SubscriptionReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentCompanyFeePaidIndirectly">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount that would have been incurred for brokerage service had service been paid for directly in arm's-length transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481019/946-20-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentCompanyFeePaidIndirectly</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of investment owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=coep_NexGenAIAffiliatesNetworkPlatformMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=coep_NexGenAIAffiliatesNetworkPlatformMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=coep_TwoPrivatelyHeldCompaniesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=coep_TwoPrivatelyHeldCompaniesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=coep_FivePrivatelyHeldCompaniesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=coep_FivePrivatelyHeldCompaniesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=coep_ThreePrivatelyHeldCompaniesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=coep_ThreePrivatelyHeldCompaniesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=coep_PrivatelyHeldCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=coep_PrivatelyHeldCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details - Lease cost) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_OperatingLeaseRightOfUseAssetGross', window );">Operating lease right of use asset, gross</a></td>
<td class="nump">$ 243,550<span></span>
</td>
<td class="nump">$ 243,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_OperatingLeaseRightOfUseAssetAccumulatedDepreciation', window );">Operating lease right of use asset, accumulated depreciation</a></td>
<td class="num">(225,151)<span></span>
</td>
<td class="num">(183,767)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use asset</a></td>
<td class="nump">18,399<span></span>
</td>
<td class="nump">59,783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">18,875<span></span>
</td>
<td class="nump">61,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="num">(18,875)<span></span>
</td>
<td class="num">(42,305)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, noncurrent</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 18,875<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_OperatingLeaseRightOfUseAssetAccumulatedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_OperatingLeaseRightOfUseAssetAccumulatedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_OperatingLeaseRightOfUseAssetGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_OperatingLeaseRightOfUseAssetGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details - Future minimum payments) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">$ 19,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments:</a></td>
<td class="nump">19,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less amount representing interest</a></td>
<td class="num">(426)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of minimum lease payments:</a></td>
<td class="nump">$ 18,875<span></span>
</td>
<td class="nump">$ 61,180<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,101<span></span>
</td>
<td class="nump">$ 45,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">507,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_AgreementAmendmentFee', window );">Agreement amendment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,363,045<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=coep_CarTLicenseMember', window );">Car T License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_InitialLicenseFee', window );">Initial license fee</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_AnnualMaintenanceFeeDescription', window );">Annual maintenance fee description</a></td>
<td class="text">annual
maintenance fees ranging between $15,000 and $25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=coep_FindersFeeAndIndemnityAgreementMember', window );">Finders Fee And Indemnity Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payment for fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=coep_MasterServicesAgreementsMember', window );">Master Services Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,363,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Customer deposit receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">599,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=coep_GearCellTherapyPlatformMember', window );">Gear Cell Therapy Platform [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payment for fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=coep_MehalickMember', window );">Mehalick [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_AnnualSalary', window );">Annual salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=coep_YeraceMember', window );">Yerace [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_AnnualSalary', window );">Annual salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=coep_FirstYearExtensionMember', window );">First Year Extension [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_MonthlyRent', window );">Monthly rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=coep_SecondYearExtensionMember', window );">Second Year Extension [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_MonthlyRent', window );">Monthly rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_AgreementAmendmentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_AgreementAmendmentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_AnnualMaintenanceFeeDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_AnnualMaintenanceFeeDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_AnnualSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_AnnualSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_InitialLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_InitialLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_MonthlyRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_MonthlyRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=coep_CarTLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=coep_CarTLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=coep_FindersFeeAndIndemnityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=coep_FindersFeeAndIndemnityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=coep_MasterServicesAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=coep_MasterServicesAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=coep_GearCellTherapyPlatformMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=coep_GearCellTherapyPlatformMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=coep_MehalickMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=coep_MehalickMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=coep_YeraceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=coep_YeraceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=coep_FirstYearExtensionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=coep_FirstYearExtensionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=coep_SecondYearExtensionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=coep_SecondYearExtensionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) PROFIT-SHARING PLAN (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Employer contributions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details - Reconcilation of income tax) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax benefit at statutory rate</a></td>
<td class="nump">$ 2,983,800<span></span>
</td>
<td class="nump">$ 2,455,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">$ (2,983,800)<span></span>
</td>
<td class="num">$ (2,455,499)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details - Reconcilation of provision) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_ExpectedIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Expected federal statutory income tax provision/rate</a></td>
<td class="num">$ (2,521,826)<span></span>
</td>
<td class="num">$ (2,284,257)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_ExpectedEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">[custom:ExpectedEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate]</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="num">$ (367,582)<span></span>
</td>
<td class="num">$ (58,863)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</a></td>
<td class="num">(3.10%)<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">$ (94,392)<span></span>
</td>
<td class="num">$ (112,379)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</a></td>
<td class="num">(0.80%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax benefit at statutory rate</a></td>
<td class="num">$ (2,983,800)<span></span>
</td>
<td class="num">$ (2,455,499)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</a></td>
<td class="num">(24.90%)<span></span>
</td>
<td class="num">(22.60%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">$ 2,983,800<span></span>
</td>
<td class="nump">$ 2,455,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</a></td>
<td class="nump">22.60%<span></span>
</td>
<td class="nump">22.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Effective income tax rate reconciliation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective Income Tax Rate Reconciliation, Percent</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_ExpectedEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_ExpectedEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_ExpectedIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_ExpectedIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES (Details - Operating loss carryforwards) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 28,184,213<span></span>
</td>
<td class="nump">$ 24,971,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Section 174 R&amp;D</a></td>
<td class="nump">1,084,044<span></span>
</td>
<td class="nump">1,275,054<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">PPE and intangible assets</a></td>
<td class="nump">974,646<span></span>
</td>
<td class="nump">915,327<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsStateTaxes', window );">State taxes</a></td>
<td class="num">(1,667,634)<span></span>
</td>
<td class="num">(1,569,922)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Subtotal</a></td>
<td class="nump">28,575,269<span></span>
</td>
<td class="nump">25,591,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation Allowance</a></td>
<td class="num">(28,575,269)<span></span>
</td>
<td class="num">(25,591,469)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets (liabilities)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsStateTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from state taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsStateTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES (Details Narrative)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">$ 99,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Aug. 12, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_DisclosureLineElements', window );"><strong>DisclosureLineElements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,558,455<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,860,083<span></span>
</td>
<td class="nump">5,691,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInvestments', window );">Other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,023,583<span></span>
</td>
<td class="nump">5,691,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=coep_BoardOfDirectorsMember', window );">Board Of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_DisclosureLineElements', window );"><strong>DisclosureLineElements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=coep_AGBioLifeCapitalILPMember', window );">AG Bio Life Capital I LP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_coep_DisclosureLineElements', window );"><strong>DisclosureLineElements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from common stock</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsAndNotesReceivableNet', window );">Note receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 522,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 522,667<span></span>
</td>
<td class="nump">$ 522,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coep_DisclosureLineElements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coep_DisclosureLineElements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coep_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndNotesReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accounts and financing receivable. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndNotesReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(h))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=coep_BoardOfDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=coep_BoardOfDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=coep_AGBioLifeCapitalILPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=coep_AGBioLifeCapitalILPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 19, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Stock issued for purchase of assets, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, Net (Excluding Goodwill)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">361,250<span></span>
</td>
<td class="nump">$ 541,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=coep_NexGenAIMember', window );">NexGenAI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, Net (Excluding Goodwill)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">361,250<span></span>
</td>
<td class="nump">541,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,625<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=coep_NexGenAISolutionsGroupIncMember', window );">Nex Gen A I Solutions Group Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Stock issued for purchase of assets, shares</a></td>
<td class="nump">187,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Stock issued for purchase of assets, value</a></td>
<td class="nump">$ 541,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-29<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-29<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 24: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 26: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 27: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=coep_NexGenAIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=coep_NexGenAIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=coep_NexGenAISolutionsGroupIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=coep_NexGenAISolutionsGroupIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 1,363,045<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of goods sold</a></td>
<td class="nump">180,625<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">14,225,918<span></span>
</td>
<td class="nump">10,054,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Net (loss) gain from operations</a></td>
<td class="num">(13,043,498)<span></span>
</td>
<td class="num">(10,054,488)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=coep_BiotechnologyMember', window );">Biotechnology Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of goods sold</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">13,540,971<span></span>
</td>
<td class="nump">10,054,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Net (loss) gain from operations</a></td>
<td class="num">(13,540,971)<span></span>
</td>
<td class="num">(10,054,488)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=coep_TechnologyMember', window );">Technology Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,363,045<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of goods sold</a></td>
<td class="nump">180,625<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">684,947<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Net (loss) gain from operations</a></td>
<td class="nump">$ 497,473<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=coep_BiotechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=coep_BiotechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=coep_TechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=coep_TechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>Integer</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | Integer</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 16,153,921<span></span>
</td>
<td class="nump">$ 8,908,660<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=coep_BiotechnologySegmentMember', window );">Biotechnology Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">13,783,575<span></span>
</td>
<td class="nump">8,366,785<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=coep_TechnologySegmentMember', window );">Technology Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 2,370,346<span></span>
</td>
<td class="nump">$ 541,875<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=coep_BiotechnologySegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=coep_BiotechnologySegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=coep_TechnologySegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=coep_TechnologySegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>294</ContextCount>
  <ElementCount>370</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>121</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995443 - Disclosure - Award Timing Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure</Role>
      <ShortName>Award Timing Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>999014 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/DescriptionOfBusinessAndBasisOfPresentation</Role>
      <ShortName>DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999016 - Disclosure - CO-DEVELOPMENT OPTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/Co-developmentOptions</Role>
      <ShortName>CO-DEVELOPMENT OPTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999017 - Disclosure - CONVERTIBLE NOTES</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://coeptistx.com/role/ConvertibleNotes</Role>
      <ShortName>CONVERTIBLE NOTES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999018 - Disclosure - SBA LOAN PAYABLE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/SbaLoanPayable</Role>
      <ShortName>SBA LOAN PAYABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999019 - Disclosure - DERIVATIVE LIABILITY WARRANTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/DerivativeLiabilityWarrants</Role>
      <ShortName>DERIVATIVE LIABILITY WARRANTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999020 - Disclosure - CAPITAL STRUCTURE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/CapitalStructure</Role>
      <ShortName>CAPITAL STRUCTURE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999021 - Disclosure - NON-CONTROLLING INTEREST</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/Non-controllingInterest</Role>
      <ShortName>NON-CONTROLLING INTEREST</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999022 - Disclosure - INVESTMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/Investments</Role>
      <ShortName>INVESTMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999023 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999024 - Disclosure - 401(k) PROFIT-SHARING PLAN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/KProfit-sharingPlan</Role>
      <ShortName>401(k) PROFIT-SHARING PLAN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999025 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999026 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999027 - Disclosure - INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/IntangibleAssets</Role>
      <ShortName>INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999028 - Disclosure - SEGMENT REPORTING</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/SegmentReporting</Role>
      <ShortName>SEGMENT REPORTING</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999029 - Disclosure - PENDING MERGER TRANSACTION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/PendingMergerTransaction</Role>
      <ShortName>PENDING MERGER TRANSACTION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999030 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://coeptistx.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999033 - Disclosure - CONVERTIBLE NOTES (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://coeptistx.com/role/ConvertibleNotesTables</Role>
      <ShortName>CONVERTIBLE NOTES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://coeptistx.com/role/ConvertibleNotes</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999034 - Disclosure - DERIVATIVE LIABILITY WARRANTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/DerivativeLiabilityWarrantsTables</Role>
      <ShortName>DERIVATIVE LIABILITY WARRANTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://coeptistx.com/role/DerivativeLiabilityWarrants</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999035 - Disclosure - CAPITAL STRUCTURE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/CapitalStructureTables</Role>
      <ShortName>CAPITAL STRUCTURE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://coeptistx.com/role/CapitalStructure</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999036 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://coeptistx.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999037 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://coeptistx.com/role/IncomeTaxes</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999038 - Disclosure - SEGMENT REPORTING (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/SegmentReportingTables</Role>
      <ShortName>SEGMENT REPORTING (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://coeptistx.com/role/SegmentReporting</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999039 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative</Role>
      <ShortName>DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://coeptistx.com/role/DescriptionOfBusinessAndBasisOfPresentation</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999040 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>999041 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>999042 - Disclosure - CO-DEVELOPMENT OPTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/Co-developmentOptionsDetailsNarrative</Role>
      <ShortName>CO-DEVELOPMENT OPTIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://coeptistx.com/role/Co-developmentOptions</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>999043 - Disclosure - CONVERTIBLE NOTES (Details - Derivative liability)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://coeptistx.com/role/ConvertibleNotesDetails-DerivativeLiability</Role>
      <ShortName>CONVERTIBLE NOTES (Details - Derivative liability)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://coeptistx.com/role/ConvertibleNotesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>999044 - Disclosure - CONVERTIBLE NOTES (Details - Assumptions)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://coeptistx.com/role/ConvertibleNotesDetails-Assumptions</Role>
      <ShortName>CONVERTIBLE NOTES (Details - Assumptions)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://coeptistx.com/role/ConvertibleNotesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>999045 - Disclosure - CONVERTIBLE NOTES (Details - Change in deriviative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://coeptistx.com/role/ConvertibleNotesDetails-ChangeInDeriviative</Role>
      <ShortName>CONVERTIBLE NOTES (Details - Change in deriviative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://coeptistx.com/role/ConvertibleNotesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>999046 - Disclosure - CONVERTIBLE NOTES (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://coeptistx.com/role/ConvertibleNotesDetailsNarrative</Role>
      <ShortName>CONVERTIBLE NOTES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://coeptistx.com/role/ConvertibleNotesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>999047 - Disclosure - SBA LOAN PAYABLE (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/SbaLoanPayableDetailsNarrative</Role>
      <ShortName>SBA LOAN PAYABLE (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://coeptistx.com/role/SbaLoanPayable</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>999048 - Disclosure - DERIVATIVE LIABILITY WARRANTS (Details - Fair value)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-FairValue</Role>
      <ShortName>DERIVATIVE LIABILITY WARRANTS (Details - Fair value)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://coeptistx.com/role/DerivativeLiabilityWarrantsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>999049 - Disclosure - DERIVATIVE LIABILITY WARRANTS (Details - Fair value assumption)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-FairValueAssumption</Role>
      <ShortName>DERIVATIVE LIABILITY WARRANTS (Details - Fair value assumption)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://coeptistx.com/role/DerivativeLiabilityWarrantsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>999050 - Disclosure - DERIVATIVE LIABILITY WARRANTS (Details - Changes in fair value of warrant liabilities)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-ChangesInFairValueOfWarrantLiabilities</Role>
      <ShortName>DERIVATIVE LIABILITY WARRANTS (Details - Changes in fair value of warrant liabilities)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://coeptistx.com/role/DerivativeLiabilityWarrantsTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>999051 - Disclosure - DERIVATIVE LIABILITY WARRANTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/DerivativeLiabilityWarrantsDetailsNarrative</Role>
      <ShortName>DERIVATIVE LIABILITY WARRANTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://coeptistx.com/role/DerivativeLiabilityWarrantsTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>999052 - Disclosure - CAPITAL STRUCTURE (Details - Option activity)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/CapitalStructureDetails-OptionActivity</Role>
      <ShortName>CAPITAL STRUCTURE (Details - Option activity)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://coeptistx.com/role/CapitalStructureTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>999053 - Disclosure - CAPITAL STRUCTURE (Details - Weighted average assumptions)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/CapitalStructureDetails-WeightedAverageAssumptions</Role>
      <ShortName>CAPITAL STRUCTURE (Details - Weighted average assumptions)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://coeptistx.com/role/CapitalStructureTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>999054 - Disclosure - CAPITAL STRUCTURE (Details - Warrants outstanding)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/CapitalStructureDetails-WarrantsOutstanding</Role>
      <ShortName>CAPITAL STRUCTURE (Details - Warrants outstanding)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://coeptistx.com/role/CapitalStructureTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>999055 - Disclosure - CAPITAL STRUCTURE (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/CapitalStructureDetailsNarrative</Role>
      <ShortName>CAPITAL STRUCTURE (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://coeptistx.com/role/CapitalStructureTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>999056 - Disclosure - NON-CONTROLLING INTEREST (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/Non-controllingInterestDetailsNarrative</Role>
      <ShortName>NON-CONTROLLING INTEREST (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://coeptistx.com/role/Non-controllingInterest</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>999057 - Disclosure - INVESTMENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/InvestmentsDetailsNarrative</Role>
      <ShortName>INVESTMENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://coeptistx.com/role/Investments</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>999058 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details - Lease cost)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/CommitmentsAndContingenciesDetails-LeaseCost</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details - Lease cost)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://coeptistx.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>999059 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details - Future minimum payments)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/CommitmentsAndContingenciesDetails-FutureMinimumPayments</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details - Future minimum payments)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://coeptistx.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>999060 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://coeptistx.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>999061 - Disclosure - 401(k) PROFIT-SHARING PLAN (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/KProfit-sharingPlanDetailsNarrative</Role>
      <ShortName>401(k) PROFIT-SHARING PLAN (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://coeptistx.com/role/KProfit-sharingPlan</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>999062 - Disclosure - INCOME TAXES (Details - Reconcilation of income tax)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/IncomeTaxesDetails-ReconcilationOfIncomeTax</Role>
      <ShortName>INCOME TAXES (Details - Reconcilation of income tax)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://coeptistx.com/role/IncomeTaxesTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>999063 - Disclosure - INCOME TAXES (Details - Reconcilation of provision)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/IncomeTaxesDetails-ReconcilationOfProvision</Role>
      <ShortName>INCOME TAXES (Details - Reconcilation of provision)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://coeptistx.com/role/IncomeTaxesTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>999064 - Disclosure - INCOME TAXES (Details - Operating loss carryforwards)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/IncomeTaxesDetails-OperatingLossCarryforwards</Role>
      <ShortName>INCOME TAXES (Details - Operating loss carryforwards)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://coeptistx.com/role/IncomeTaxesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>999065 - Disclosure - INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://coeptistx.com/role/IncomeTaxesTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>999066 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://coeptistx.com/role/RelatedPartyTransactions</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>999067 - Disclosure - INTANGIBLE ASSETS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/IntangibleAssetsDetailsNarrative</Role>
      <ShortName>INTANGIBLE ASSETS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://coeptistx.com/role/IntangibleAssets</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>999068 - Disclosure - SEGMENT REPORTING (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/SegmentReportingDetails</Role>
      <ShortName>SEGMENT REPORTING (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://coeptistx.com/role/SegmentReportingTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="coeptis_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>999069 - Disclosure - SEGMENT REPORTING (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://coeptistx.com/role/SegmentReportingDetailsNarrative</Role>
      <ShortName>SEGMENT REPORTING (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://coeptistx.com/role/SegmentReportingTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>coep-20251231.xsd</File>
    <File>coep-20251231_cal.xml</File>
    <File>coep-20251231_def.xml</File>
    <File>coep-20251231_lab.xml</File>
    <File>coep-20251231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="coeptis_i10k-123125.htm">coeptis_i10k-123125.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>astrafooter.jpg</File>
    <File>astralogo.jpg</File>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="837">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="7">http://xbrl.sec.gov/cyd/2025</BaseTaxonomy>
    <BaseTaxonomy items="42">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="12">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>92
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "coeptis_i10k-123125.htm": {
   "nsprefix": "coep",
   "nsuri": "http://coeptistx.com/20251231",
   "dts": {
    "schema": {
     "local": [
      "coep-20251231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "coep-20251231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "coep-20251231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "coep-20251231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "coep-20251231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "coeptis_i10k-123125.htm"
     ]
    }
   },
   "keyStandard": 322,
   "keyCustom": 48,
   "axisStandard": 27,
   "axisCustom": 0,
   "memberStandard": 22,
   "memberCustom": 90,
   "hidden": {
    "total": 128,
    "http://fasb.org/us-gaap/2025": 65,
    "http://coeptistx.com/20251231": 59,
    "http://xbrl.sec.gov/dei/2025": 4
   },
   "contextCount": 294,
   "entityCount": 1,
   "segmentCount": 121,
   "elementCount": 726,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 837,
    "http://xbrl.sec.gov/dei/2025": 42,
    "http://xbrl.sec.gov/ecd/2025": 12,
    "http://xbrl.sec.gov/cyd/2025": 7
   },
   "report": {
    "R1": {
     "role": "http://coeptistx.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://coeptistx.com/role/ConsolidatedBalanceSheets",
     "longName": "00000002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://coeptistx.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://coeptistx.com/role/ConsolidatedStatementsOfOperations",
     "longName": "00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:GrossProfit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity",
     "longName": "00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_PreferredStockMember",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_PreferredStockMember",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows",
     "longName": "00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
     "longName": "995443 - Disclosure - Award Timing Disclosure",
     "shortName": "Award Timing Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "ecd:AwardTmgMnpiDiscTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "ecd:TrdArrIndName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "ecd:TrdArrIndName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "a",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "a",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://coeptistx.com/role/DescriptionOfBusinessAndBasisOfPresentation",
     "longName": "999014 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION",
     "shortName": "DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://coeptistx.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "999015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://coeptistx.com/role/Co-developmentOptions",
     "longName": "999016 - Disclosure - CO-DEVELOPMENT OPTIONS",
     "shortName": "CO-DEVELOPMENT OPTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://coeptistx.com/role/ConvertibleNotes",
     "longName": "999017 - Disclosure - CONVERTIBLE NOTES",
     "shortName": "CONVERTIBLE NOTES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://coeptistx.com/role/SbaLoanPayable",
     "longName": "999018 - Disclosure - SBA LOAN PAYABLE",
     "shortName": "SBA LOAN PAYABLE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "coep:SbaLoanPayableDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "coep:SbaLoanPayableDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://coeptistx.com/role/DerivativeLiabilityWarrants",
     "longName": "999019 - Disclosure - DERIVATIVE LIABILITY WARRANTS",
     "shortName": "DERIVATIVE LIABILITY WARRANTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:DerivativesAndFairValueTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:DerivativesAndFairValueTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://coeptistx.com/role/CapitalStructure",
     "longName": "999020 - Disclosure - CAPITAL STRUCTURE",
     "shortName": "CAPITAL STRUCTURE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://coeptistx.com/role/Non-controllingInterest",
     "longName": "999021 - Disclosure - NON-CONTROLLING INTEREST",
     "shortName": "NON-CONTROLLING INTEREST",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://coeptistx.com/role/Investments",
     "longName": "999022 - Disclosure - INVESTMENTS",
     "shortName": "INVESTMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:InvestmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:InvestmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://coeptistx.com/role/CommitmentsAndContingencies",
     "longName": "999023 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://coeptistx.com/role/KProfit-sharingPlan",
     "longName": "999024 - Disclosure - 401(k) PROFIT-SHARING PLAN",
     "shortName": "401(k) PROFIT-SHARING PLAN",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://coeptistx.com/role/IncomeTaxes",
     "longName": "999025 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://coeptistx.com/role/RelatedPartyTransactions",
     "longName": "999026 - Disclosure - RELATED PARTY TRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://coeptistx.com/role/IntangibleAssets",
     "longName": "999027 - Disclosure - INTANGIBLE ASSETS",
     "shortName": "INTANGIBLE ASSETS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://coeptistx.com/role/SegmentReporting",
     "longName": "999028 - Disclosure - SEGMENT REPORTING",
     "shortName": "SEGMENT REPORTING",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://coeptistx.com/role/PendingMergerTransaction",
     "longName": "999029 - Disclosure - PENDING MERGER TRANSACTION",
     "shortName": "PENDING MERGER TRANSACTION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "coep:PendingMergerTransactionDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "coep:PendingMergerTransactionDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://coeptistx.com/role/SubsequentEvents",
     "longName": "999030 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "999031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "999032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://coeptistx.com/role/ConvertibleNotesTables",
     "longName": "999033 - Disclosure - CONVERTIBLE NOTES (Tables)",
     "shortName": "CONVERTIBLE NOTES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://coeptistx.com/role/DerivativeLiabilityWarrantsTables",
     "longName": "999034 - Disclosure - DERIVATIVE LIABILITY WARRANTS (Tables)",
     "shortName": "DERIVATIVE LIABILITY WARRANTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DerivativesAndFairValueTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DerivativesAndFairValueTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://coeptistx.com/role/CapitalStructureTables",
     "longName": "999035 - Disclosure - CAPITAL STRUCTURE (Tables)",
     "shortName": "CAPITAL STRUCTURE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://coeptistx.com/role/CommitmentsAndContingenciesTables",
     "longName": "999036 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://coeptistx.com/role/IncomeTaxesTables",
     "longName": "999037 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://coeptistx.com/role/SegmentReportingTables",
     "longName": "999038 - Disclosure - SEGMENT REPORTING (Tables)",
     "shortName": "SEGMENT REPORTING (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://coeptistx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative",
     "longName": "999039 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative)",
     "shortName": "DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "From2024-12-012024-12-31",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R38": {
     "role": "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetails",
     "longName": "999040 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "999041 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:CashUninsuredAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:CashUninsuredAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://coeptistx.com/role/Co-developmentOptionsDetailsNarrative",
     "longName": "999042 - Disclosure - CO-DEVELOPMENT OPTIONS (Details Narrative)",
     "shortName": "CO-DEVELOPMENT OPTIONS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ProceedsFromLicenseFeesReceived",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ProceedsFromLicenseFeesReceived",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://coeptistx.com/role/ConvertibleNotesDetails-DerivativeLiability",
     "longName": "999043 - Disclosure - CONVERTIBLE NOTES (Details - Derivative liability)",
     "shortName": "CONVERTIBLE NOTES (Details - Derivative liability)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:DerivativeFairValueOfDerivativeLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31_custom_DerivativeLiabilityMember",
      "name": "us-gaap:DerivativeFairValueOfDerivativeLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://coeptistx.com/role/ConvertibleNotesDetails-Assumptions",
     "longName": "999044 - Disclosure - CONVERTIBLE NOTES (Details - Assumptions)",
     "shortName": "CONVERTIBLE NOTES (Details - Assumptions)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_FairValueInputsLevel3Member",
      "name": "us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfServicingLiabilitiesAtFairValueTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_FairValueInputsLevel3Member",
      "name": "us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfServicingLiabilitiesAtFairValueTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://coeptistx.com/role/ConvertibleNotesDetails-ChangeInDeriviative",
     "longName": "999045 - Disclosure - CONVERTIBLE NOTES (Details - Change in deriviative)",
     "shortName": "CONVERTIBLE NOTES (Details - Change in deriviative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2024-10-31",
      "name": "us-gaap:DerivativeFairValueOfDerivativeLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ExtinguishmentOfDebtGainLossNetOfTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://coeptistx.com/role/ConvertibleNotesDetailsNarrative",
     "longName": "999046 - Disclosure - CONVERTIBLE NOTES (Details Narrative)",
     "shortName": "CONVERTIBLE NOTES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:AmortizationOfDebtDiscountPremium",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://coeptistx.com/role/SbaLoanPayableDetailsNarrative",
     "longName": "999047 - Disclosure - SBA LOAN PAYABLE (Details Narrative)",
     "shortName": "SBA LOAN PAYABLE (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "From2020-07-072020-07-08_custom_EidlLoanMember",
      "name": "us-gaap:ProceedsFromLoans",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "coep:SbaLoanPayableDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2020-07-072020-07-08_custom_EidlLoanMember",
      "name": "us-gaap:ProceedsFromLoans",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "coep:SbaLoanPayableDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-FairValue",
     "longName": "999048 - Disclosure - DERIVATIVE LIABILITY WARRANTS (Details - Fair value)",
     "shortName": "DERIVATIVE LIABILITY WARRANTS (Details - Fair value)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31_us-gaap_FairValueMeasurementsRecurringMember",
      "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:DerivativesAndFairValueTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31_us-gaap_FairValueMeasurementsRecurringMember",
      "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:DerivativesAndFairValueTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-FairValueAssumption",
     "longName": "999049 - Disclosure - DERIVATIVE LIABILITY WARRANTS (Details - Fair value assumption)",
     "shortName": "DERIVATIVE LIABILITY WARRANTS (Details - Fair value assumption)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "From2025-01-012025-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WarrantsMember",
      "name": "us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "us-gaap:DerivativesAndFairValueTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WarrantsMember",
      "name": "us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "us-gaap:DerivativesAndFairValueTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-ChangesInFairValueOfWarrantLiabilities",
     "longName": "999050 - Disclosure - DERIVATIVE LIABILITY WARRANTS (Details - Changes in fair value of warrant liabilities)",
     "shortName": "DERIVATIVE LIABILITY WARRANTS (Details - Changes in fair value of warrant liabilities)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_custom_PrivatePlacementWarrantsMember206522015",
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:DerivativesAndFairValueTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_custom_PrivatePlacementWarrantsMember206522015",
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:DerivativesAndFairValueTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetailsNarrative",
     "longName": "999051 - Disclosure - DERIVATIVE LIABILITY WARRANTS (Details Narrative)",
     "shortName": "DERIVATIVE LIABILITY WARRANTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "b",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31_custom_PrivatePlacementWarrantsMember",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DerivativesAndFairValueTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://coeptistx.com/role/CapitalStructureDetails-OptionActivity",
     "longName": "999052 - Disclosure - CAPITAL STRUCTURE (Details - Option activity)",
     "shortName": "CAPITAL STRUCTURE (Details - Option activity)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_custom_StockOptionsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-12-31_custom_StockOptionsMember206522468",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://coeptistx.com/role/CapitalStructureDetails-WeightedAverageAssumptions",
     "longName": "999053 - Disclosure - CAPITAL STRUCTURE (Details - Weighted average assumptions)",
     "shortName": "CAPITAL STRUCTURE (Details - Weighted average assumptions)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "From2025-01-012025-12-31_custom_StockOptionsMember206522468",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-12-31_custom_StockOptionsMember206522468",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://coeptistx.com/role/CapitalStructureDetails-WarrantsOutstanding",
     "longName": "999054 - Disclosure - CAPITAL STRUCTURE (Details - Warrants outstanding)",
     "shortName": "CAPITAL STRUCTURE (Details - Warrants outstanding)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "b",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-12-31_custom_WarrantHolder1ExercisePrice59.40Member",
      "name": "coep:WarrantsAndRightsOutstandingDateIssued",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://coeptistx.com/role/CapitalStructureDetailsNarrative",
     "longName": "999055 - Disclosure - CAPITAL STRUCTURE (Details Narrative)",
     "shortName": "CAPITAL STRUCTURE (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "coep:ProceedsFromSubscriptionsReceivable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://coeptistx.com/role/Non-controllingInterestDetailsNarrative",
     "longName": "999056 - Disclosure - NON-CONTROLLING INTEREST (Details Narrative)",
     "shortName": "NON-CONTROLLING INTEREST (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:MinorityInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31_custom_GearTherapeuticsMember",
      "name": "us-gaap:MinorityInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:MinorityInterestDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://coeptistx.com/role/InvestmentsDetailsNarrative",
     "longName": "999057 - Disclosure - INVESTMENTS (Details Narrative)",
     "shortName": "INVESTMENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:GainLossOnInvestments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "coep:InvestmentCompanyFeePaidSharesIndirectly",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://coeptistx.com/role/CommitmentsAndContingenciesDetails-LeaseCost",
     "longName": "999058 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details - Lease cost)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details - Lease cost)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "coep:OperatingLeaseRightOfUseAssetGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "coep:OperatingLeaseRightOfUseAssetGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://coeptistx.com/role/CommitmentsAndContingenciesDetails-FutureMinimumPayments",
     "longName": "999059 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details - Future minimum payments)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details - Future minimum payments)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://coeptistx.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "999060 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://coeptistx.com/role/KProfit-sharingPlanDetailsNarrative",
     "longName": "999061 - Disclosure - 401(k) PROFIT-SHARING PLAN (Details Narrative)",
     "shortName": "401(k) PROFIT-SHARING PLAN (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://coeptistx.com/role/IncomeTaxesDetails-ReconcilationOfIncomeTax",
     "longName": "999062 - Disclosure - INCOME TAXES (Details - Reconcilation of income tax)",
     "shortName": "INCOME TAXES (Details - Reconcilation of income tax)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R61": {
     "role": "http://coeptistx.com/role/IncomeTaxesDetails-ReconcilationOfProvision",
     "longName": "999063 - Disclosure - INCOME TAXES (Details - Reconcilation of provision)",
     "shortName": "INCOME TAXES (Details - Reconcilation of provision)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "coep:ExpectedIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "coep:ExpectedIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://coeptistx.com/role/IncomeTaxesDetails-OperatingLossCarryforwards",
     "longName": "999064 - Disclosure - INCOME TAXES (Details - Operating loss carryforwards)",
     "shortName": "INCOME TAXES (Details - Operating loss carryforwards)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://coeptistx.com/role/IncomeTaxesDetailsNarrative",
     "longName": "999065 - Disclosure - INCOME TAXES (Details Narrative)",
     "shortName": "INCOME TAXES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://coeptistx.com/role/RelatedPartyTransactionsDetailsNarrative",
     "longName": "999066 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)",
     "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:OtherInvestments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://coeptistx.com/role/IntangibleAssetsDetailsNarrative",
     "longName": "999067 - Disclosure - INTANGIBLE ASSETS (Details Narrative)",
     "shortName": "INTANGIBLE ASSETS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31_custom_NexGenAIMember",
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://coeptistx.com/role/SegmentReportingDetails",
     "longName": "999068 - Disclosure - SEGMENT REPORTING (Details)",
     "shortName": "SEGMENT REPORTING (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-12-31_custom_BiotechnologyMember",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://coeptistx.com/role/SegmentReportingDetailsNarrative",
     "longName": "999069 - Disclosure - SEGMENT REPORTING (Details Narrative)",
     "shortName": "SEGMENT REPORTING (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:Assets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31_custom_BiotechnologySegmentMember",
      "name": "us-gaap:Assets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "coeptis_i10k-123125.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "coep_AGBioLifeCapitalILPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "AGBioLifeCapitalILPMember",
     "presentation": [
      "http://coeptistx.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AG Bio Life Capital I LP [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsAndNotesReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsAndNotesReceivableNet",
     "crdr": "debit",
     "presentation": [
      "http://coeptistx.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note receivable",
        "documentation": "Amount, after allowance for credit loss, of accounts and financing receivable. Includes, but is not limited to, notes and loan receivable."
       }
      }
     },
     "auth_ref": [
      "r1169",
      "r1288"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r922"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued professional fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/Non-controllingInterestDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net of accumulated losses",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r69",
      "r146",
      "r669",
      "r707",
      "r708",
      "r1247"
     ]
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://coeptistx.com/role/Co-developmentOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset, Acquired, Finite-Lived [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r313",
      "r314",
      "r316",
      "r710",
      "r825"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1011"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r922",
      "r1319"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r727",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1248",
      "r1322"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r1018"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1018"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r1018"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1018"
     ]
    },
    "us-gaap_AdjustmentForAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentForAmortization",
     "crdr": "debit",
     "presentation": [
      "http://coeptistx.com/role/Co-developmentOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization",
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants issued for services",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r32",
      "r97"
     ]
    },
    "coep_AdvertisingCampaignsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "AdvertisingCampaignsMember",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advertising Campaigns [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r978",
      "r989",
      "r1003",
      "r1030"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r981",
      "r992",
      "r1006",
      "r1033"
     ]
    },
    "coep_AgreementAmendmentFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "AgreementAmendmentFee",
     "crdr": "debit",
     "presentation": [
      "http://coeptistx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreement amendment fee"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r1018"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r1025"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r982",
      "r993",
      "r1007",
      "r1025",
      "r1034",
      "r1038",
      "r1046"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 3.0
      },
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows",
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations",
      "http://coeptistx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amortization of debt discount",
        "label": "Amortization of debt discount",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r78",
      "r354",
      "r1274"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations",
      "http://coeptistx.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization expense",
        "verboseLabel": "Amortization of intangible assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r163",
      "r311",
      "r318",
      "r828",
      "r835",
      "r836",
      "r838",
      "r840"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "coep_AnnualMaintenanceFeeDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "AnnualMaintenanceFeeDescription",
     "presentation": [
      "http://coeptistx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual maintenance fee description"
       }
      }
     },
     "auth_ref": []
    },
    "coep_AnnualSalary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "AnnualSalary",
     "crdr": "debit",
     "presentation": [
      "http://coeptistx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual salary"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive shares",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "coep_April2024UnsecuredNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "April2024UnsecuredNoteMember",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "April 2024 Unsecured Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative",
      "http://coeptistx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r710",
      "r1236"
     ]
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r710",
      "r1236"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset impairment charges",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r29",
      "r924",
      "r925"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheets",
      "http://coeptistx.com/role/SegmentReportingDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "label": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r122",
      "r140",
      "r174",
      "r176",
      "r177",
      "r212",
      "r225",
      "r243",
      "r247",
      "r285",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r515",
      "r519",
      "r587",
      "r654",
      "r655",
      "r664",
      "r765",
      "r851",
      "r852",
      "r863",
      "r922",
      "r933",
      "r934",
      "r948",
      "r1189",
      "r1190",
      "r1280"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL CURRENT ASSETS",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r148",
      "r174",
      "r176",
      "r177",
      "r285",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r515",
      "r519",
      "r587",
      "r922",
      "r1189",
      "r1190",
      "r1280"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r960",
      "r962",
      "r985"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r960",
      "r962",
      "r985"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r960",
      "r962",
      "r985"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1041"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r1042"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r1037"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://coeptistx.com/role/Cover",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "verboseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://coeptistx.com/role/Cover",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "verboseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-OptionActivity",
      "http://coeptistx.com/role/CapitalStructureDetails-WeightedAverageAssumptions",
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative",
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r1040"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1039"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "coep_BiotechnologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "BiotechnologyMember",
     "presentation": [
      "http://coeptistx.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Biotechnology Segment [Member]",
        "label": "Biotechnology Segment [Member] [Default Label]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_BiotechnologySegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "BiotechnologySegmentMember",
     "presentation": [
      "http://coeptistx.com/role/SegmentReportingDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Biotechnology Segment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_BoardOfDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "BoardOfDirectorsMember",
     "presentation": [
      "http://coeptistx.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board Of Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetails-Assumptions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r507",
      "r508",
      "r509",
      "r510",
      "r876",
      "r878",
      "r1231",
      "r1232",
      "r1234"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://coeptistx.com/role/DescriptionOfBusinessAndBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r1079",
      "r1144"
     ]
    },
    "coep_CD38AssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "CD38AssetsMember",
     "presentation": [
      "http://coeptistx.com/role/Co-developmentOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CD38 Assets [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalizedContractCostAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalizedContractCostAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/Co-developmentOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized Contract Cost, Accumulated Amortization",
        "documentation": "Amount of accumulated amortization of asset recognized from cost incurred to obtain or fulfill contract with customer."
       }
      }
     },
     "auth_ref": [
      "r1176"
     ]
    },
    "us-gaap_CapitalizedContractCostGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalizedContractCostGross",
     "crdr": "debit",
     "presentation": [
      "http://coeptistx.com/role/Co-developmentOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized Contract Cost, Gross",
        "documentation": "Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer."
       }
      }
     },
     "auth_ref": [
      "r1176"
     ]
    },
    "us-gaap_CapitalizedContractCostNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalizedContractCostNet",
     "crdr": "debit",
     "presentation": [
      "http://coeptistx.com/role/Co-developmentOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized Contract Cost, Net",
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer."
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "coep_CarTLicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "CarTLicenseMember",
     "presentation": [
      "http://coeptistx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Car T License [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheets",
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "periodStartLabel": "CASH AT BEGINNING OF PERIOD",
        "periodEndLabel": "CASH AT END OF PERIOD",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r82",
      "r171"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET INCREASE (DECREASE) IN CASH",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation",
        "documentation": "Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r82"
     ]
    },
    "us-gaap_CashUninsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashUninsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash uninsured amount",
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-WarrantsOutstanding",
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative",
      "http://coeptistx.com/role/ConsolidatedBalanceSheets",
      "http://coeptistx.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r143",
      "r144",
      "r145",
      "r174",
      "r177",
      "r203",
      "r204",
      "r206",
      "r208",
      "r214",
      "r215",
      "r285",
      "r330",
      "r332",
      "r333",
      "r334",
      "r337",
      "r338",
      "r358",
      "r359",
      "r361",
      "r362",
      "r364",
      "r367",
      "r370",
      "r371",
      "r374",
      "r377",
      "r384",
      "r587",
      "r715",
      "r716",
      "r717",
      "r718",
      "r727",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r752",
      "r773",
      "r796",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r1067",
      "r1147",
      "r1149",
      "r1157"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-WarrantsOutstanding",
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r214",
      "r361",
      "r370",
      "r371",
      "r372",
      "r374",
      "r377",
      "r382",
      "r384",
      "r557",
      "r715",
      "r716",
      "r717",
      "r718",
      "r864",
      "r1067",
      "r1145",
      "r1147"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-WarrantsOutstanding",
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercise price",
        "verboseLabel": "Exercise price of warrants",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r179",
      "r385"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants issued",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-WarrantsOutstanding",
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants outstanding",
        "verboseLabel": "Total warrants outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "coep_CoDevelopmentOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "CoDevelopmentOptionsMember",
     "presentation": [
      "http://coeptistx.com/role/Co-developmentOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Co Development Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_CoDevelopmentRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "CoDevelopmentRightsMember",
     "presentation": [
      "http://coeptistx.com/role/Co-developmentOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Co Development Rights [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "coep_CodevelopmentRightsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "CodevelopmentRightsNet",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_OtherAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Co-development rights, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://coeptistx.com/role/InvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "coep_ColleenDelaneyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "ColleenDelaneyMember",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Colleen Delaney [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES (NOTE 10)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r114",
      "r666",
      "r751"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://coeptistx.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r328",
      "r329",
      "r823",
      "r1182",
      "r1186"
     ]
    },
    "us-gaap_CommonClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonClassAMember",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class A [Member]",
        "documentation": "Classification of common stock representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r1322"
     ]
    },
    "us-gaap_CommonClassBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonClassBMember",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class B [Member]",
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r1322"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative",
      "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r938",
      "r939",
      "r940",
      "r942",
      "r943",
      "r944",
      "r945",
      "r1153",
      "r1154",
      "r1156",
      "r1248",
      "r1318",
      "r1322"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative",
      "http://coeptistx.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "coep_CommonStockParValue0.0001PerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "CommonStockParValue0.0001PerShareMember",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, par value $0.0001 per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r752"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative",
      "http://coeptistx.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "verboseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r63",
      "r752",
      "r771",
      "r1322",
      "r1323"
     ]
    },
    "coep_CommonStockSubscribed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "CommonStockSubscribed",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock subscribed"
       }
      }
     },
     "auth_ref": []
    },
    "coep_CommonStockSubscribedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "CommonStockSubscribedMember",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Subscribed [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.0001 par value, 150,000,000 shares authorized, 5,746,948 and 2,116,191 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r359",
      "r366",
      "r668",
      "r922"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r1022"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r1020"
     ]
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
     "presentation": [
      "http://coeptistx.com/role/KProfit-sharingPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "401(k) PROFIT-SHARING PLAN",
        "documentation": "The entire disclosure of an entity's employee compensation and benefit plans, excluding share-based compensation and including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r100",
      "r101"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee and Non-Employee Share-Based Compensation",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r104"
     ]
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r253",
      "r711",
      "r712",
      "r822",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r253",
      "r711",
      "r712",
      "r822",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r253",
      "r711",
      "r712",
      "r822",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration risk percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r253",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r253",
      "r711",
      "r712",
      "r822",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163"
     ]
    },
    "coep_ConsultingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "ConsultingAgreementMember",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerAssetNet",
     "crdr": "debit",
     "presentation": [
      "http://coeptistx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer deposit receivable",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r388",
      "r389",
      "r390"
     ]
    },
    "us-gaap_ContractualObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractualObligation",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual obligation",
        "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments."
       }
      }
     },
     "auth_ref": [
      "r1146",
      "r1152",
      "r1284"
     ]
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative",
      "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Shares Converted",
        "verboseLabel": "Conversion of stock, shares converted",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r23"
     ]
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock converted, shares issued",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r23"
     ]
    },
    "us-gaap_ConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleDebt",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible promissory note",
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r113",
      "r1286"
     ]
    },
    "coep_ConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "ConvertibleNoteMember",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative",
      "http://coeptistx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible notes outstanding",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r113",
      "r1286"
     ]
    },
    "us-gaap_ConvertibleNotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleNotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible notes payable, net of debt discount of $0 and $435,635",
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleNotesPayableMember",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes Payable [Member]",
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r112"
     ]
    },
    "coep_CoralInvestmentPartnersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "CoralInvestmentPartnersMember",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Coral Investment Partners [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations",
      "http://coeptistx.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of goods",
        "verboseLabel": "Cost of goods sold",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r174",
      "r176",
      "r177",
      "r285",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r587",
      "r851",
      "r1189"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative",
      "http://coeptistx.com/role/Co-developmentOptionsDetailsNarrative",
      "http://coeptistx.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://coeptistx.com/role/IntangibleAssetsDetailsNarrative",
      "http://coeptistx.com/role/InvestmentsDetailsNarrative",
      "http://coeptistx.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r174",
      "r182",
      "r183",
      "r342",
      "r372",
      "r612",
      "r631",
      "r661",
      "r831",
      "r833",
      "r834",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1242",
      "r1244",
      "r1245",
      "r1246"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r1160"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r970",
      "r1057"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r970",
      "r1057"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r972",
      "r1059"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r972",
      "r1059"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r974",
      "r1061"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r972",
      "r1059"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r965",
      "r1052"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r966",
      "r1053"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r966",
      "r1053"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r964",
      "r1051"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r967",
      "r1054"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r969",
      "r1056"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r969",
      "r1056"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r970",
      "r1057"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r973",
      "r1060"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r971",
      "r1058"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r968",
      "r1055"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt converted, amount converted",
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r23"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r23"
     ]
    },
    "coep_DebtConversionConvertedInterestAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "DebtConversionConvertedInterestAmount1",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:DebtConversionConvertedInterestAmount1]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDefaultLongtermDebtAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDefaultLongtermDebtAmount",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt in default",
        "documentation": "Amount of outstanding long-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r175"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative",
      "http://coeptistx.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://coeptistx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r54",
      "r55",
      "r112",
      "r113",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r921",
      "r1145",
      "r1146",
      "r1148",
      "r1152",
      "r1183",
      "r1184",
      "r1185",
      "r1273",
      "r1275",
      "r1284"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Convertible, Conversion Price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r341"
     ]
    },
    "us-gaap_DebtInstrumentDecreaseForgiveness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentDecreaseForgiveness",
     "crdr": "debit",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term debt replaced",
        "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r1145",
      "r1148"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative",
      "http://coeptistx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt face amount",
        "verboseLabel": "Principal amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r595",
      "r596",
      "r859",
      "r860",
      "r921"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest rate",
        "documentation": "The average effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r351",
      "r1273"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative",
      "http://coeptistx.com/role/ConvertibleNotesDetailsNarrative",
      "http://coeptistx.com/role/SbaLoanPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest rate",
        "label": "Accrued interest rate",
        "terseLabel": "Debt instrument stated percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r340"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://coeptistx.com/role/SbaLoanPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r557",
      "r657",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r921",
      "r1145",
      "r1146",
      "r1148",
      "r1152",
      "r1273",
      "r1275"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative",
      "http://coeptistx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt maturity date",
        "verboseLabel": "Maturity period",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r858",
      "r1254",
      "r1255"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative",
      "http://coeptistx.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://coeptistx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r921",
      "r1145",
      "r1146",
      "r1148",
      "r1152",
      "r1183",
      "r1184",
      "r1185",
      "r1273",
      "r1275",
      "r1284"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://coeptistx.com/role/SbaLoanPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r37",
      "r40",
      "r50",
      "r95",
      "r96",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r557",
      "r657",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r921",
      "r1145",
      "r1146",
      "r1148",
      "r1152",
      "r1273",
      "r1275"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Unamortized Discount",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r1191",
      "r1272",
      "r1273",
      "r1275"
     ]
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "coep_Dec2023ConvertiblePromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "Dec2023ConvertiblePromissoryNoteMember",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dec 2023 Convertible Promissory Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_December2023FinancingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "December2023FinancingMember",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "December 2023 Financing [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredRevenueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredRevenueCurrent",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheets",
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer deposit",
        "verboseLabel": "Customer deposits",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1083"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://coeptistx.com/role/IncomeTaxesDetails-OperatingLossCarryforwards"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subtotal",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://coeptistx.com/role/IncomeTaxesDetails-OperatingLossCarryforwards"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Section 174 R&amp;D",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r1228"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "presentation": [
      "http://coeptistx.com/role/IncomeTaxesDetails-OperatingLossCarryforwards"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net deferred tax assets (liabilities)",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1226"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://coeptistx.com/role/IncomeTaxesDetails-OperatingLossCarryforwards"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1226"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://coeptistx.com/role/IncomeTaxesDetails-OperatingLossCarryforwards"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1228"
     ]
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://coeptistx.com/role/IncomeTaxesDetails-OperatingLossCarryforwards"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PPE and intangible assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r1228"
     ]
    },
    "us-gaap_DeferredTaxAssetsStateTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsStateTaxes",
     "crdr": "debit",
     "presentation": [
      "http://coeptistx.com/role/IncomeTaxesDetails-OperatingLossCarryforwards"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "State taxes",
        "label": "Deferred Tax Assets, State Taxes",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from state taxes."
       }
      }
     },
     "auth_ref": [
      "r1228"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/IncomeTaxesDetails-OperatingLossCarryforwards"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation Allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "crdr": "debit",
     "presentation": [
      "http://coeptistx.com/role/KProfit-sharingPlanDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employer contributions",
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r392",
      "r399",
      "r400",
      "r403",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation expense",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r30",
      "r162",
      "r835",
      "r836",
      "r838",
      "r840"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r164",
      "r212",
      "r230",
      "r247",
      "r835",
      "r851",
      "r852"
     ]
    },
    "us-gaap_DerivativeAssetFairValueGrossLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeAssetFairValueGrossLiability",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value derivative liability",
        "documentation": "Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r553",
      "r811",
      "r812"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetails-DerivativeLiability",
      "http://coeptistx.com/role/ConvertibleNotesDetailsNarrative",
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-ChangesInFairValueOfWarrantLiabilities",
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-FairValue",
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-FairValueAssumption"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r522",
      "r524",
      "r525",
      "r527",
      "r528",
      "r529",
      "r530",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r741",
      "r743",
      "r757",
      "r758",
      "r759",
      "r761",
      "r762",
      "r763",
      "r764",
      "r766",
      "r767",
      "r768",
      "r769",
      "r784",
      "r785",
      "r786",
      "r787",
      "r790",
      "r791",
      "r792",
      "r793",
      "r807",
      "r808",
      "r810",
      "r813",
      "r830",
      "r831",
      "r834",
      "r909",
      "r910",
      "r938",
      "r940",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1242",
      "r1244",
      "r1245",
      "r1246",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1263",
      "r1264"
     ]
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetails-ChangeInDeriviative",
      "http://coeptistx.com/role/ConvertibleNotesDetails-DerivativeLiability"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of derivative liability",
        "periodStartLabel": "Fair value of derivative liability, beginning balance",
        "periodEndLabel": "Fair value of derivative liability, ending balance",
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r149",
      "r553",
      "r830",
      "r832",
      "r833",
      "r834"
     ]
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeGainLossOnDerivativeNet",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of derivative liabilities",
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r826",
      "r1241"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetails-DerivativeLiability",
      "http://coeptistx.com/role/ConvertibleNotesDetailsNarrative",
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-ChangesInFairValueOfWarrantLiabilities",
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-FairValue",
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-FairValueAssumption"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r522",
      "r524",
      "r525",
      "r527",
      "r528",
      "r529",
      "r530",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r741",
      "r743",
      "r757",
      "r758",
      "r759",
      "r761",
      "r762",
      "r763",
      "r764",
      "r766",
      "r767",
      "r768",
      "r769",
      "r784",
      "r785",
      "r786",
      "r787",
      "r790",
      "r791",
      "r792",
      "r793",
      "r807",
      "r808",
      "r810",
      "r813",
      "r830",
      "r831",
      "r834",
      "r909",
      "r910",
      "r938",
      "r940",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1242",
      "r1244",
      "r1245",
      "r1246",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1263",
      "r1264"
     ]
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "presentation": [
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-ChangesInFairValueOfWarrantLiabilities",
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-FairValue",
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-FairValueAssumption"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r524",
      "r525",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r910"
     ]
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "presentation": [
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-ChangesInFairValueOfWarrantLiabilities",
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-FairValue",
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-FairValueAssumption"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r524",
      "r525",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r910"
     ]
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative liability",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative liability warrants",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "coep_DerivativeLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "DerivativeLiabilityMember",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetails-DerivativeLiability"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativesAndFairValueTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativesAndFairValueTextBlock",
     "presentation": [
      "http://coeptistx.com/role/DerivativeLiabilityWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DERIVATIVE LIABILITY WARRANTS",
        "documentation": "The entire disclosure for derivatives and fair value of assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r1240",
      "r1249"
     ]
    },
    "us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetails-Assumptions",
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-FairValueAssumption"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative assumption valuation",
        "verboseLabel": "Derivatives, determination of fair value",
        "documentation": "Describes how an entity determines the fair values of its derivatives, including its valuation methodology and significant assumptions used."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability Warrants",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r184",
      "r200",
      "r521",
      "r551",
      "r552",
      "r554",
      "r555",
      "r556",
      "r558",
      "r559"
     ]
    },
    "coep_DisclosureLineElements": {
     "xbrltype": "stringItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "DisclosureLineElements",
     "presentation": [
      "http://coeptistx.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DisclosureLineElements [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_DisclosurePendingMergerTransactionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "DisclosurePendingMergerTransactionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pending Merger Transaction"
       }
      }
     },
     "auth_ref": []
    },
    "coep_DisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "DisclosureTable",
     "presentation": [
      "http://coeptistx.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DisclosureTable [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on write down of assets",
        "label": "Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down",
        "documentation": "Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r6",
      "r89",
      "r160"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r960",
      "r962",
      "r985"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r960",
      "r962",
      "r985",
      "r1026"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LOSS PER SHARE"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss per share, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r159",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r201",
      "r203",
      "r206",
      "r207",
      "r208",
      "r211",
      "r357",
      "r435",
      "r472",
      "r512",
      "r573",
      "r574",
      "r653",
      "r683",
      "r843"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss per share, fully diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r159",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r203",
      "r206",
      "r207",
      "r208",
      "r211",
      "r357",
      "r435",
      "r472",
      "r512",
      "r573",
      "r574",
      "r653",
      "r683",
      "r843"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r210"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://coeptistx.com/role/IncomeTaxesDetails-ReconcilationOfProvision": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://coeptistx.com/role/IncomeTaxesDetails-ReconcilationOfProvision"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r443",
      "r875"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://coeptistx.com/role/IncomeTaxesDetails-ReconcilationOfProvision": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/IncomeTaxesDetails-ReconcilationOfProvision"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r178",
      "r443",
      "r463",
      "r875"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://coeptistx.com/role/IncomeTaxesDetails-ReconcilationOfProvision": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/IncomeTaxesDetails-ReconcilationOfProvision"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r875",
      "r1145",
      "r1151",
      "r1224"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "presentation": [
      "http://coeptistx.com/role/IncomeTaxesDetails-ReconcilationOfProvision"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r875",
      "r1145",
      "r1151",
      "r1224",
      "r1225"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "presentation": [
      "http://coeptistx.com/role/IncomeTaxesDetails-ReconcilationOfProvision"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r875",
      "r1145",
      "r1151",
      "r1224"
     ]
    },
    "coep_EidlLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "EidlLoanMember",
     "presentation": [
      "http://coeptistx.com/role/SbaLoanPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Eidl Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock based compensation expense",
        "documentation": "Amount of expense for employee benefit and equity-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1097"
     ]
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeBenefitsAndShareBasedCompensationNoncash",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock based compensation",
        "label": "Employee Benefit and Share-Based Payment Arrangement, Noncash",
        "documentation": "Amount of noncash expense (reversal of expense) for employee benefits and share-based payment arrangement. Includes, but is not limited to, pension, other postretirement, postemployment and termination benefits."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unamortized stock-based compensation",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1222"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative",
      "http://coeptistx.com/role/Non-controllingInterestDetailsNarrative",
      "http://coeptistx.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r1065"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1063"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r131",
      "r133",
      "r134",
      "r155",
      "r156",
      "r157",
      "r185",
      "r186",
      "r187",
      "r189",
      "r196",
      "r198",
      "r200",
      "r213",
      "r286",
      "r287",
      "r324",
      "r356",
      "r386",
      "r435",
      "r461",
      "r462",
      "r469",
      "r470",
      "r471",
      "r473",
      "r511",
      "r512",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r572",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r597",
      "r599",
      "r605",
      "r681",
      "r703",
      "r704",
      "r705",
      "r727",
      "r796"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1019"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r978",
      "r989",
      "r1003",
      "r1030"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r975",
      "r986",
      "r1000",
      "r1027"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1025"
     ]
    },
    "coep_ExpectedEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "ExpectedEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://coeptistx.com/role/IncomeTaxesDetails-ReconcilationOfProvision"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:ExpectedEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_ExpectedIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "ExpectedIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "presentation": [
      "http://coeptistx.com/role/IncomeTaxesDetails-ReconcilationOfProvision"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expected federal statutory income tax provision/rate",
        "label": "ExpectedIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ExtinguishmentOfDebtGainLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ExtinguishmentOfDebtGainLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetails-ChangeInDeriviative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Extinguishment of fair value of liability",
        "label": "Extinguishment of Debt, Gain (Loss), Net of Tax",
        "documentation": "The difference between the reacquisition price and the net carrying amount of the extinguished debt recognized currently as a component of income in the period of extinguishment, net of tax."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of derivative liability warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of changes in fair value of warrant liabilities",
        "documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r911",
      "r1251",
      "r1252",
      "r1263"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of derivative liability",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1251",
      "r1252"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetails-Assumptions",
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-FairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r400",
      "r401",
      "r575",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r585",
      "r619",
      "r620",
      "r621",
      "r826",
      "r859",
      "r860",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r911",
      "r913",
      "r920"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-FairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r576",
      "r577",
      "r578",
      "r580",
      "r911",
      "r1254",
      "r1265"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-FairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r392",
      "r397",
      "r400",
      "r577",
      "r582",
      "r585",
      "r619",
      "r826",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r911",
      "r920"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetails-Assumptions",
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-FairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r400",
      "r401",
      "r577",
      "r578",
      "r579",
      "r580",
      "r582",
      "r585",
      "r621",
      "r826",
      "r859",
      "r860",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r911",
      "r913",
      "r920"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-ChangesInFairValueOfWarrantLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in valuation inputs",
        "documentation": "Represents the quantification of the effect of changes in the valuation technique and related inputs, during the period, used to measure the liability at fair value as of the statement of financial position reporting date."
       }
      }
     },
     "auth_ref": [
      "r1253"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of fair value assumptions",
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset."
       }
      }
     },
     "auth_ref": [
      "r1251",
      "r1252"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-FairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r576",
      "r577",
      "r578",
      "r580",
      "r911",
      "r1254",
      "r1265"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transfers in or out of Level 3",
        "documentation": "Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r1260",
      "r1264"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetails-Assumptions",
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-FairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r400",
      "r401",
      "r575",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r585",
      "r619",
      "r620",
      "r621",
      "r826",
      "r859",
      "r860",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r911",
      "r913",
      "r920"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-FairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r911",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1265"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments and Measurements",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r1266"
     ]
    },
    "coep_February2024FinancingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "February2024FinancingMember",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "February 2024 Financing [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r355",
      "r382",
      "r557",
      "r570",
      "r584",
      "r586",
      "r588",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r660",
      "r682",
      "r856",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r923",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1250",
      "r1253",
      "r1254",
      "r1255",
      "r1262",
      "r1265",
      "r1267",
      "r1268"
     ]
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-FairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial liabilities fair value disclosure",
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities."
       }
      }
     },
     "auth_ref": [
      "r1251",
      "r1252",
      "r1262",
      "r1267",
      "r1268",
      "r1269",
      "r1270"
     ]
    },
    "coep_FindersFeeAndIndemnityAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "FindersFeeAndIndemnityAgreementMember",
     "presentation": [
      "http://coeptistx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finders Fee And Indemnity Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable",
     "presentation": [
      "http://coeptistx.com/role/Co-developmentOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Intangible Asset, Acquired, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset acquired in business combination."
       }
      }
     },
     "auth_ref": [
      "r1178",
      "r1179",
      "r1233",
      "r1235"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://coeptistx.com/role/Co-developmentOptionsDetailsNarrative",
      "http://coeptistx.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r312",
      "r313",
      "r314",
      "r316",
      "r317",
      "r319",
      "r320",
      "r651",
      "r652",
      "r710",
      "r825",
      "r828",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://coeptistx.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r317",
      "r319",
      "r320",
      "r322",
      "r651",
      "r825",
      "r828",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://coeptistx.com/role/Co-developmentOptionsDetailsNarrative",
      "http://coeptistx.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r312",
      "r313",
      "r314",
      "r316",
      "r317",
      "r319",
      "r320",
      "r710",
      "r825",
      "r828",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905"
     ]
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "crdr": "debit",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets acquired",
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r710"
     ]
    },
    "coep_FirstYearExtensionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "FirstYearExtensionMember",
     "presentation": [
      "http://coeptistx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "First Year Extension [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_FivePrivatelyHeldCompaniesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "FivePrivatelyHeldCompaniesMember",
     "presentation": [
      "http://coeptistx.com/role/InvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Five Privately Held Companies [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r982",
      "r993",
      "r1007",
      "r1034"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r982",
      "r993",
      "r1007",
      "r1034"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r982",
      "r993",
      "r1007",
      "r1034"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r982",
      "r993",
      "r1007",
      "r1034"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r982",
      "r993",
      "r1007",
      "r1034"
     ]
    },
    "us-gaap_GainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainLossOnInvestments",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 7.0
      },
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows",
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations",
      "http://coeptistx.com/role/InvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized loss on investments",
        "negatedLabel": "Unrealized loss on investments",
        "negatedTerseLabel": "Loss on investment",
        "documentation": "Amount of realized and unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r79",
      "r1066"
     ]
    },
    "coep_GainOnForfeitureOfCustomerDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "GainOnForfeitureOfCustomerDeposit",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on forfeiture of customer deposit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "(Gain) loss on extinguishment of debt",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r33",
      "r34"
     ]
    },
    "coep_GainsLossesOnExtinguishmentOfDebt1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "GainsLossesOnExtinguishmentOfDebt1",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (loss) on extinguishment of debt"
       }
      }
     },
     "auth_ref": []
    },
    "coep_GearCellTherapyPlatformMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "GearCellTherapyPlatformMember",
     "presentation": [
      "http://coeptistx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gear Cell Therapy Platform [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_GearTherapeuticsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "GearTherapeuticsMember",
     "presentation": [
      "http://coeptistx.com/role/Non-controllingInterestDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gear Therapeutics [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r73",
      "r121",
      "r174",
      "r176",
      "r177",
      "r285",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r587",
      "r846",
      "r851",
      "r1158",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1189"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r960",
      "r962",
      "r985"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r90"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "LOSS BEFORE INCOME TAXES",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r117",
      "r121",
      "r654",
      "r656",
      "r677",
      "r837",
      "r839",
      "r841",
      "r846",
      "r851",
      "r1158",
      "r1165",
      "r1166",
      "r1167",
      "r1168"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://coeptistx.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r178",
      "r438",
      "r443",
      "r447",
      "r448",
      "r449",
      "r451",
      "r456",
      "r464",
      "r466",
      "r467",
      "r468",
      "r659",
      "r709",
      "r721",
      "r875"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://coeptistx.com/role/IncomeTaxesDetails-ReconcilationOfProvision": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations",
      "http://coeptistx.com/role/IncomeTaxesDetails-ReconcilationOfProvision"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PROVISION FOR INCOME TAXES (BENEFIT)",
        "verboseLabel": "Effective income tax rate reconciliation",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r129",
      "r174",
      "r199",
      "r200",
      "r212",
      "r233",
      "r247",
      "r442",
      "r443",
      "r465",
      "r684",
      "r837",
      "r839",
      "r841",
      "r875"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r440",
      "r441",
      "r451",
      "r452",
      "r455",
      "r460",
      "r714"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/IncomeTaxesDetails-ReconcilationOfProvision": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/IncomeTaxesDetails-ReconcilationOfIncomeTax",
      "http://coeptistx.com/role/IncomeTaxesDetails-ReconcilationOfProvision"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in valuation allowance",
        "label": "Change in valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r875",
      "r1224"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/IncomeTaxesDetails-ReconcilationOfProvision": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/IncomeTaxesDetails-ReconcilationOfIncomeTax",
      "http://coeptistx.com/role/IncomeTaxesDetails-ReconcilationOfProvision"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax benefit at statutory rate",
        "label": "Income tax benefit at statutory rate",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r443",
      "r875"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "presentation": [
      "http://coeptistx.com/role/IncomeTaxesDetails-ReconcilationOfProvision"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r875",
      "r1224",
      "r1225"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "presentation": [
      "http://coeptistx.com/role/IncomeTaxesDetails-ReconcilationOfProvision"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "State income taxes, net of federal benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r875",
      "r1224"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes paid",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r170",
      "r457",
      "r458"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInInterestAndDividendsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest receivable",
        "label": "Increase (Decrease) in Interest and Dividends Receivable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount due to the entity in the form of unpaid interest and dividends."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInInterestPayableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInInterestPayableNet",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgiveness of interest",
        "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right of use liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r1069",
      "r1142"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(Increase) decrease in:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Other Accounts Payable",
        "documentation": "Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other current liabilities",
        "label": "Increase (Decrease) in Other Current Liabilities",
        "documentation": "Amount of increase (decrease) in current liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r1142"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherOperatingAssetsAbstract",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) in:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid assets",
        "label": "Increase (Decrease) in Prepaid Expense",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r982",
      "r993",
      "r1007",
      "r1025",
      "r1034",
      "r1038",
      "r1046"
     ]
    },
    "coep_InitialLicenseFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "InitialLicenseFee",
     "crdr": "debit",
     "presentation": [
      "http://coeptistx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial license fee"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r963",
      "r1050"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r963",
      "r1050"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r963",
      "r1050"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://coeptistx.com/role/IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INTANGIBLE ASSETS",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r321",
      "r323",
      "r824",
      "r825"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r647",
      "r648",
      "r649",
      "r651",
      "r842",
      "r1177"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_OtherAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheets",
      "http://coeptistx.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets, net",
        "verboseLabel": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r1180",
      "r1181"
     ]
    },
    "us-gaap_InterestAndOtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestAndOtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r837",
      "r841",
      "r1099"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest paid",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r168",
      "r169"
     ]
    },
    "us-gaap_InterestReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest receivable",
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1086"
     ]
    },
    "us-gaap_InvestmentCompanyFeePaidIndirectly": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentCompanyFeePaidIndirectly",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/InvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment company fee paid indirectly",
        "documentation": "Amount that would have been incurred for brokerage service had service been paid for directly in arm's-length transaction."
       }
      }
     },
     "auth_ref": [
      "r719",
      "r775",
      "r776",
      "r777",
      "r778",
      "r781"
     ]
    },
    "coep_InvestmentCompanyFeePaidSharesIndirectly": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "InvestmentCompanyFeePaidSharesIndirectly",
     "presentation": [
      "http://coeptistx.com/role/InvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment company fee paid shares indirectly"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentOwnedBalanceShares",
     "presentation": [
      "http://coeptistx.com/role/InvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Owned, Balance, Shares",
        "documentation": "Number of shares of investment owned."
       }
      }
     },
     "auth_ref": [
      "r740",
      "r742",
      "r805",
      "r806",
      "r814",
      "r940"
     ]
    },
    "us-gaap_InvestmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentTextBlock",
     "presentation": [
      "http://coeptistx.com/role/Investments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INVESTMENTS",
        "documentation": "The entire disclosure for investment."
       }
      }
     },
     "auth_ref": [
      "r1070",
      "r1071",
      "r1170"
     ]
    },
    "us-gaap_Investments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Investments",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_OtherAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative",
      "http://coeptistx.com/role/ConsolidatedBalanceSheets",
      "http://coeptistx.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments",
        "verboseLabel": "Investment",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments."
       }
      }
     },
     "auth_ref": [
      "r661",
      "r662",
      "r933",
      "r934",
      "r935",
      "r937"
     ]
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued for non-employee services",
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://coeptistx.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of lease information",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1277"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative",
      "http://coeptistx.com/role/Non-controllingInterestDetailsNarrative",
      "http://coeptistx.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://coeptistx.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of future minimum rental payments",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1278"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/CommitmentsAndContingenciesDetails-FutureMinimumPayments": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://coeptistx.com/role/CommitmentsAndContingenciesDetails-FutureMinimumPayments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total minimum lease payments:",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r603",
      "r1146",
      "r1152",
      "r1284"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/CommitmentsAndContingenciesDetails-FutureMinimumPayments": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/CommitmentsAndContingenciesDetails-FutureMinimumPayments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r603",
      "r1146",
      "r1152",
      "r1284"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/CommitmentsAndContingenciesDetails-FutureMinimumPayments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less amount representing interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r54",
      "r55",
      "r56",
      "r58",
      "r59",
      "r60",
      "r61",
      "r174",
      "r176",
      "r177",
      "r285",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r516",
      "r519",
      "r520",
      "r587",
      "r750",
      "r845",
      "r863",
      "r948",
      "r1189",
      "r1280",
      "r1281"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r116",
      "r672",
      "r922",
      "r933",
      "r934",
      "r1145",
      "r1150",
      "r1175",
      "r1271"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL CURRENT LIABILITIES",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r138",
      "r174",
      "r176",
      "r177",
      "r285",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r516",
      "r519",
      "r520",
      "r587",
      "r922",
      "r1189",
      "r1280",
      "r1281"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT LIABILITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-ChangesInFairValueOfWarrantLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Fair value of liabilities, beginning",
        "periodEndLabel": "Fair value of liabilities, ending",
        "label": "Liabilities, Fair Value Disclosure",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r577",
      "r1251"
     ]
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LONG TERM LIABILITIES",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r58",
      "r59",
      "r60",
      "r61",
      "r174",
      "r176",
      "r177",
      "r285",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r516",
      "r519",
      "r520",
      "r587",
      "r1189",
      "r1280",
      "r1281"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LONG TERM LIABILITIES"
       }
      }
     },
     "auth_ref": []
    },
    "coep_LicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "LicenseAgreementMember",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SBA loan payable",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "us-gaap_LongTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtTextBlock",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONVERTIBLE NOTES",
        "documentation": "The entire disclosure for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetailsNarrative",
      "http://coeptistx.com/role/SbaLoanPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r1183",
      "r1184",
      "r1185"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetailsNarrative",
      "http://coeptistx.com/role/SbaLoanPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r31",
      "r1183",
      "r1184",
      "r1185"
     ]
    },
    "coep_LossOnSharesIssuedForConversionOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "LossOnSharesIssuedForConversionOfDebt",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on shares issued for conversion of debt"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r253",
      "r865",
      "r867",
      "r927",
      "r931",
      "r1289",
      "r1290",
      "r1291",
      "r1293",
      "r1294",
      "r1295",
      "r1296",
      "r1297",
      "r1298",
      "r1299",
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304",
      "r1305",
      "r1306",
      "r1307",
      "r1308",
      "r1309",
      "r1310",
      "r1311",
      "r1312",
      "r1313",
      "r1314",
      "r1315",
      "r1316",
      "r1317"
     ]
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable securities",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1082"
     ]
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments and Marketable Securities",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 6.0
      },
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows",
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations",
      "http://coeptistx.com/role/InvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized gain on marketable securities",
        "negatedLabel": "Unrealized gain on marketable securities",
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "coep_MasterServicesAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "MasterServicesAgreementsMember",
     "presentation": [
      "http://coeptistx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Master Services Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cyd_MaterialCybersecurityIncidentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r996",
      "r997"
     ]
    },
    "cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r996",
      "r998"
     ]
    },
    "cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r996",
      "r999"
     ]
    },
    "cyd_MaterialCybersecurityIncidentNatureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentNatureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Nature [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r996",
      "r999"
     ]
    },
    "cyd_MaterialCybersecurityIncidentScopeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentScopeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Scope [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r996",
      "r999"
     ]
    },
    "cyd_MaterialCybersecurityIncidentTimingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentTimingTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Timing [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r996",
      "r999"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "us-gaap_MeasurementInputConversionPriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputConversionPriceMember",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetails-Assumptions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Conversion Price [Member]",
        "documentation": "Measurement input using price per share at which convertible share can be converted into common stock."
       }
      }
     },
     "auth_ref": [
      "r1253",
      "r1254",
      "r1255"
     ]
    },
    "us-gaap_MeasurementInputExercisePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputExercisePriceMember",
     "presentation": [
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-FairValueAssumption"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Exercise Price [Member]",
        "documentation": "Measurement input using agreed upon price for exchange of underlying asset."
       }
      }
     },
     "auth_ref": [
      "r1216",
      "r1253",
      "r1254",
      "r1255"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetails-Assumptions",
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-FairValueAssumption"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r913",
      "r1253",
      "r1254",
      "r1255"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetails-Assumptions",
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-FairValueAssumption"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r432",
      "r1253",
      "r1254",
      "r1255"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetails-Assumptions",
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-FairValueAssumption"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Share Price [Member]",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r1253",
      "r1254",
      "r1255"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetails-Assumptions",
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-FairValueAssumption"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r578",
      "r579",
      "r580",
      "r876",
      "r877",
      "r878",
      "r913"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetails-Assumptions",
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-FairValueAssumption"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r578",
      "r579",
      "r580",
      "r876",
      "r877",
      "r878",
      "r913"
     ]
    },
    "coep_MehalickMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "MehalickMember",
     "presentation": [
      "http://coeptistx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mehalick [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
     "presentation": [
      "http://coeptistx.com/role/Co-developmentOptions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CO-DEVELOPMENT OPTIONS",
        "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r1230"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheets",
      "http://coeptistx.com/role/Non-controllingInterestDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "TOTAL STOCKHOLDERS' EQUITY - NONCONTROLLING INTERESTS",
        "verboseLabel": "Noncontrolling interest",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r115",
      "r174",
      "r176",
      "r177",
      "r285",
      "r330",
      "r332",
      "r333",
      "r334",
      "r337",
      "r338",
      "r671",
      "r754",
      "r1271"
     ]
    },
    "us-gaap_MinorityInterestDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MinorityInterestDisclosureTextBlock",
     "presentation": [
      "http://coeptistx.com/role/Non-controllingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NON-CONTROLLING INTEREST",
        "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_MinorityInterestLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MinorityInterestLineItems",
     "presentation": [
      "http://coeptistx.com/role/Non-controllingInterestDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MinorityInterestTable",
     "presentation": [
      "http://coeptistx.com/role/Non-controllingInterestDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Table]",
        "documentation": "Disclosure of information about noncontrolling interest, including, but not limited to, name of subsidiary, ownership percentage held by parent, ownership percentage held by noncontrolling owner, amount of noncontrolling interest and its location in statement of financial position, explanation of increase (decrease) in noncontrolling interest, noncontrolling interest share of net income (loss) of subsidiary and its location in statement of income, amount of noncontrolling interest represented by preferred stock, description and dividend requirement of preferred stock, and nature of noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r67",
      "r72"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "coep_ModificationOfOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "ModificationOfOptionsMember",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Modification Of Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_MonthlyRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "MonthlyRent",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Monthly rent"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r1045"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "auth_ref": [
      "r253",
      "r865",
      "r867",
      "r927",
      "r931",
      "r1289",
      "r1290",
      "r1291",
      "r1293",
      "r1294",
      "r1295",
      "r1296",
      "r1297",
      "r1298",
      "r1299",
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304",
      "r1305",
      "r1306",
      "r1307",
      "r1308",
      "r1309",
      "r1310",
      "r1311",
      "r1312",
      "r1313",
      "r1314",
      "r1315",
      "r1316",
      "r1317"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1018"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH PROVIDED BY FINANCING ACTIVITIES",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FINANCING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH USED IN INVESTING ACTIVITIES",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INVESTING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH USED IN OPERATING ACTIVITIES",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r83",
      "r86"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OPERATING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r86",
      "r118",
      "r134",
      "r136",
      "r152",
      "r153",
      "r157",
      "r174",
      "r176",
      "r177",
      "r181",
      "r188",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r199",
      "r200",
      "r205",
      "r285",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r357",
      "r360",
      "r363",
      "r368",
      "r435",
      "r472",
      "r512",
      "r574",
      "r587",
      "r680",
      "r772",
      "r794",
      "r795",
      "r837",
      "r839",
      "r841",
      "r946",
      "r1189"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NET LOSS ATTRIBUTABLE TO NON-CONTROLLING INTERESTS",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r109",
      "r152",
      "r153",
      "r196",
      "r199",
      "r200",
      "r679",
      "r1096"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "coep_NexGenAIAffiliatesNetworkPlatformMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "NexGenAIAffiliatesNetworkPlatformMember",
     "presentation": [
      "http://coeptistx.com/role/InvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nex Gen A I Affiliates Network Platform [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_NexGenAIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "NexGenAIMember",
     "presentation": [
      "http://coeptistx.com/role/IntangibleAssetsDetailsNarrative",
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NexGenAI [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_NexGenAISolutionsGroupIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "NexGenAISolutionsGroupIncMember",
     "presentation": [
      "http://coeptistx.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nex Gen A I Solutions Group Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1013"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1045"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1045"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL NON-CASH DISCLOSURES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncontrollingInterestAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r386",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1322"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL OTHER INCOME (EXPENSE), net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER INCOME (EXPENSE)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/SbaLoanPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes payable",
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r113",
      "r1286",
      "r1287"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://coeptistx.com/role/SegmentReportingDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of reportable segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r847",
      "r855",
      "r1164"
     ]
    },
    "coep_Oct2022ConvertiblePromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "Oct2022ConvertiblePromissoryNoteMember",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Oct 2022 Convertible Promissory Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OffsettingAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OffsettingAssetsLineItems",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetails-DerivativeLiability"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offsetting Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r830",
      "r831",
      "r833",
      "r834",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1242",
      "r1244",
      "r1245",
      "r1246"
     ]
    },
    "us-gaap_OffsettingAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OffsettingAssetsTable",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetails-DerivativeLiability"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offsetting Assets [Table]",
        "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements."
       }
      }
     },
     "auth_ref": [
      "r830",
      "r831",
      "r833",
      "r834",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1242",
      "r1244",
      "r1245",
      "r1246"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations",
      "http://coeptistx.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total cost of operations",
        "label": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COST OF OPERATIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations",
      "http://coeptistx.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "LOSS FROM OPERATIONS",
        "label": "Net (loss) gain from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r837",
      "r841",
      "r846",
      "r1158",
      "r1165",
      "r1166",
      "r1167",
      "r1168"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://coeptistx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r1276"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/CommitmentsAndContingenciesDetails-FutureMinimumPayments",
      "http://coeptistx.com/role/CommitmentsAndContingenciesDetails-LeaseCost"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability",
        "verboseLabel": "Present value of minimum lease payments:",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/CommitmentsAndContingenciesDetails-LeaseCost",
      "http://coeptistx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right of use liability, current portion",
        "negatedLabel": "Operating lease liability, current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/CommitmentsAndContingenciesDetails-LeaseCost",
      "http://coeptistx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right of use liability, non-current portion",
        "verboseLabel": "Operating lease liability, noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_OtherAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/CommitmentsAndContingenciesDetails-LeaseCost",
      "http://coeptistx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right of use asset, net of accumulated amortization",
        "verboseLabel": "Operating lease right of use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "coep_OperatingLeaseRightOfUseAssetAccumulatedDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "OperatingLeaseRightOfUseAssetAccumulatedDepreciation",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/CommitmentsAndContingenciesDetails-LeaseCost"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Operating lease right of use asset, accumulated depreciation",
        "label": "OperatingLeaseRightOfUseAssetAccumulatedDepreciation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right of use asset amortization",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r1143"
     ]
    },
    "coep_OperatingLeaseRightOfUseAssetGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "OperatingLeaseRightOfUseAssetGross",
     "crdr": "debit",
     "presentation": [
      "http://coeptistx.com/role/CommitmentsAndContingenciesDetails-LeaseCost"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right of use asset, gross"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://coeptistx.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carry forwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "us-gaap_OtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other assets",
        "label": "Other Assets",
        "documentation": "Amount of assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r139",
      "r663",
      "r852",
      "r933",
      "r934",
      "r948"
     ]
    },
    "us-gaap_OtherAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsAbstract",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative expenses",
        "documentation": "Amount of general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r1321"
     ]
    },
    "us-gaap_OtherInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherInvestments",
     "crdr": "debit",
     "presentation": [
      "http://coeptistx.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other investments",
        "documentation": "Amount of investments classified as other."
       }
      }
     },
     "auth_ref": [
      "r673",
      "r1081"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current liabilities",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r922"
     ]
    },
    "us-gaap_OtherLongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLongTermNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/Co-developmentOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Notes Payable, Noncurrent",
        "documentation": "Amount of long-term notes classified as other, payable after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_OtherNoncashIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNoncashIncome",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Non-cash revenue",
        "label": "Other Noncash Income",
        "documentation": "Amount of income or gain included in net income that result in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense), net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r908"
     ]
    },
    "us-gaap_OtherNotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible notes payable, in default",
        "documentation": "Amount of long-term notes classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r980",
      "r991",
      "r1005",
      "r1032"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r983",
      "r994",
      "r1008",
      "r1035"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r983",
      "r994",
      "r1008",
      "r1035"
     ]
    },
    "us-gaap_ParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ParentMember",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent [Member]",
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r1012"
     ]
    },
    "us-gaap_PaymentsForBrokerageFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForBrokerageFees",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment of commitment fee",
        "documentation": "The amount of cash paid for brokerage fees during the current period. This element is intended to represent the brokerage fees paid by and between financial industry participants."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PaymentsForFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForFees",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment for fees",
        "documentation": "Amount of cash outflow for fees classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireProductiveAssets",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/Co-developmentOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Productive Assets",
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r1237",
      "r1238",
      "r1239"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "coep_PendingMergerTransactionDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "PendingMergerTransactionDisclosureTextBlock",
     "presentation": [
      "http://coeptistx.com/role/PendingMergerTransaction"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PENDING MERGER TRANSACTION"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1018"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1013"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "coep_PreFundedWarrants2ExercisePrice0.002Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "PreFundedWarrants2ExercisePrice0.002Member",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-WarrantsOutstanding"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Funded Warrants 2 Exercise Price 0. 002 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_PreFundedWarrants3ExercisePrice0.002Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "PreFundedWarrants3ExercisePrice0.002Member",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-WarrantsOutstanding"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Funded Warrants 3 Exercise Price 0. 002 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Funded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r938",
      "r939",
      "r942",
      "r943",
      "r944",
      "r945",
      "r1318",
      "r1322"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative",
      "http://coeptistx.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r370"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative",
      "http://coeptistx.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Preferred stock authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r752"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative",
      "http://coeptistx.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "verboseLabel": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r370"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative",
      "http://coeptistx.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "verboseLabel": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r752",
      "r771",
      "r1322",
      "r1323"
     ]
    },
    "us-gaap_PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Subscription receivable",
        "label": "Preferred Stock, Shares Subscribed but Unissued, Subscriptions Receivable",
        "documentation": "Amount of subscription receivable from investors who have been allocated nonredeemable preferred stock or preferred stock redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r62",
      "r760",
      "r803"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, $0.0001 par value, 10,000,000 shares authorized, 10,000 designated as Series A, 0 and 6,520 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r359",
      "r365",
      "r667",
      "r922"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r296",
      "r297",
      "r829"
     ]
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification",
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error."
       }
      }
     },
     "auth_ref": [
      "r1080"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "coep_PrivatePlacementWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "PrivatePlacementWarrantsMember",
     "presentation": [
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-ChangesInFairValueOfWarrantLiabilities",
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-FairValue",
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_PrivatelyHeldCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "PrivatelyHeldCompanyMember",
     "presentation": [
      "http://coeptistx.com/role/InvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Privately Held Company [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative",
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows",
      "http://coeptistx.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares issued for cash",
        "label": "Proceeds from common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative",
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock offering",
        "label": "Proceeds from sale of preferred stock",
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants",
     "crdr": "debit",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of preferred stock",
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price."
       }
      }
     },
     "auth_ref": [
      "r1141"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrants issued for cash",
        "label": "Proceeds from Issuance of Warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromLicenseFeesReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromLicenseFeesReceived",
     "crdr": "debit",
     "presentation": [
      "http://coeptistx.com/role/Co-developmentOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License fees",
        "documentation": "Cash received from licensees for license fees during the current period."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_ProceedsFromLoans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromLoans",
     "crdr": "debit",
     "presentation": [
      "http://coeptistx.com/role/SbaLoanPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from loans",
        "documentation": "Cash received from principal payments made on loans related to operating activities."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromNotesPayable",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from notes payable",
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_ProceedsFromRepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromRepaymentsOfNotesPayable",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayment of notes payable",
        "documentation": "Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": []
    },
    "coep_ProceedsFromSubscriptionsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "ProceedsFromSubscriptionsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds subscriptions receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative",
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Pre-funded warrants exercise",
        "label": "Aggregate exercise price of warrant",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r1141"
     ]
    },
    "us-gaap_ProductInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProductInformationLineItems",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://coeptistx.com/role/Co-developmentOptionsDetailsNarrative",
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations",
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r250",
      "r650",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r827",
      "r836",
      "r839",
      "r841",
      "r865",
      "r866",
      "r926",
      "r928",
      "r929",
      "r932",
      "r936",
      "r1068",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1187",
      "r1188",
      "r1289",
      "r1290",
      "r1291",
      "r1292",
      "r1293",
      "r1294",
      "r1295",
      "r1296",
      "r1297",
      "r1298",
      "r1299",
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304",
      "r1305",
      "r1306",
      "r1307",
      "r1308",
      "r1309",
      "r1310",
      "r1311",
      "r1312",
      "r1313",
      "r1314",
      "r1315",
      "r1316",
      "r1317"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://coeptistx.com/role/Co-developmentOptionsDetailsNarrative",
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations",
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "auth_ref": [
      "r250",
      "r650",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r827",
      "r836",
      "r839",
      "r841",
      "r865",
      "r866",
      "r926",
      "r928",
      "r929",
      "r932",
      "r936",
      "r1068",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1187",
      "r1188",
      "r1289",
      "r1290",
      "r1291",
      "r1292",
      "r1293",
      "r1294",
      "r1295",
      "r1296",
      "r1297",
      "r1298",
      "r1299",
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304",
      "r1305",
      "r1306",
      "r1307",
      "r1308",
      "r1309",
      "r1310",
      "r1311",
      "r1312",
      "r1313",
      "r1314",
      "r1315",
      "r1316",
      "r1317"
     ]
    },
    "us-gaap_ProfessionalAndContractServicesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfessionalAndContractServicesExpense",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional services expense",
        "documentation": "Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows",
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations",
      "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NET LOSS",
        "verboseLabel": "Net loss",
        "negatedLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r136",
      "r152",
      "r153",
      "r166",
      "r174",
      "r176",
      "r177",
      "r181",
      "r188",
      "r196",
      "r199",
      "r200",
      "r285",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r357",
      "r435",
      "r472",
      "r512",
      "r514",
      "r517",
      "r518",
      "r574",
      "r587",
      "r654",
      "r656",
      "r678",
      "r726",
      "r772",
      "r794",
      "r795",
      "r906",
      "r907",
      "r947",
      "r1096",
      "r1189"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY AND EQUIPMENT"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://coeptistx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r604"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://coeptistx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r604"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Furniture and fixtures, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r604",
      "r658",
      "r676",
      "r922"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r127",
      "r128",
      "r675"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://coeptistx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r604"
     ]
    },
    "coep_PublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "PublicOfferingMember",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_PublicWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "PublicWarrantsMember",
     "presentation": [
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-ChangesInFairValueOfWarrantLiabilities",
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-FairValue",
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_PurpleBioTechMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "PurpleBioTechMember",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purple Bio Tech [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r1012"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r1012"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r975",
      "r986",
      "r1000",
      "r1027"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r180",
      "r181",
      "r254",
      "r398",
      "r402",
      "r609",
      "r610",
      "r665",
      "r674",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r770",
      "r804",
      "r1320"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r180",
      "r181",
      "r609",
      "r610",
      "r611",
      "r612",
      "r665",
      "r674",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r770",
      "r804"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r180",
      "r181",
      "r254",
      "r398",
      "r402",
      "r609",
      "r610",
      "r665",
      "r674",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r770",
      "r804",
      "r1279",
      "r1320"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://coeptistx.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r606",
      "r607",
      "r608",
      "r610",
      "r613",
      "r722",
      "r723",
      "r724",
      "r779",
      "r780",
      "r781",
      "r800",
      "r802"
     ]
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfConvertibleDebt",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayment of convertible debt",
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/Co-developmentOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Long-Term Debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r718"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative",
      "http://coeptistx.com/role/Co-developmentOptionsDetailsNarrative",
      "http://coeptistx.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://coeptistx.com/role/IntangibleAssetsDetailsNarrative",
      "http://coeptistx.com/role/InvestmentsDetailsNarrative",
      "http://coeptistx.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "auth_ref": [
      "r174",
      "r182",
      "r183",
      "r342",
      "r372",
      "r612",
      "r631",
      "r661",
      "r831",
      "r833",
      "r834",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1242",
      "r1244",
      "r1245",
      "r1246"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations",
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expense",
        "verboseLabel": "Research and development expenses",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r825",
      "r837",
      "r838",
      "r851",
      "r1283"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r976",
      "r987",
      "r1001",
      "r1028"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r977",
      "r988",
      "r1002",
      "r1029"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r984",
      "r995",
      "r1009",
      "r1036"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheets",
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r97",
      "r670",
      "r706",
      "r708",
      "r720",
      "r753",
      "r922"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r133",
      "r134",
      "r185",
      "r186",
      "r187",
      "r189",
      "r196",
      "r198",
      "r200",
      "r286",
      "r287",
      "r324",
      "r356",
      "r435",
      "r461",
      "r462",
      "r469",
      "r470",
      "r471",
      "r473",
      "r511",
      "r512",
      "r560",
      "r562",
      "r563",
      "r565",
      "r572",
      "r597",
      "r599",
      "r703",
      "r705",
      "r727",
      "r1322"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations",
      "http://coeptistx.com/role/SegmentReportingDetails",
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total sales",
        "verboseLabel": "Revenues",
        "terseLabel": "Sales",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r120",
      "r158",
      "r174",
      "r176",
      "r177",
      "r212",
      "r226",
      "r227",
      "r241",
      "r247",
      "r250",
      "r252",
      "r253",
      "r285",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r587",
      "r654",
      "r656",
      "r851",
      "r908",
      "r933",
      "r934",
      "r1189"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SALES"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1045"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1045"
     ]
    },
    "coep_SNAPBiosciencesIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "SNAPBiosciencesIncMember",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SNAP Biosciences Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalariesAndWages": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalariesAndWages",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Salary expense",
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": [
      "r1098"
     ]
    },
    "coep_SaleMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "SaleMember",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockDescriptionOfTransaction": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockDescriptionOfTransaction",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investors description",
        "documentation": "Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r46",
      "r108"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative",
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r1160",
      "r1161"
     ]
    },
    "coep_SbaLoanPayableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "SbaLoanPayableAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Sba Loan Payable"
       }
      }
     },
     "auth_ref": []
    },
    "coep_SbaLoanPayableDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "SbaLoanPayableDisclosureTextBlock",
     "presentation": [
      "http://coeptistx.com/role/SbaLoanPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SBA LOAN PAYABLE"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of antidilutive shares",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetails-Assumptions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r507",
      "r508",
      "r509",
      "r510",
      "r876",
      "r878",
      "r1231",
      "r1232",
      "r1234"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://coeptistx.com/role/InvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://coeptistx.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of effective income tax reconciliation",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1229"
     ]
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of changes in fair value of derivative liability",
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r523",
      "r526",
      "r531",
      "r539",
      "r550"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://coeptistx.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of income tax provision",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r875",
      "r1224"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of fair value hierarchy",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1251",
      "r1252"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://coeptistx.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r317",
      "r319",
      "r320",
      "r322",
      "r651",
      "r825",
      "r828",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905"
     ]
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfProductInformationTable",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operation, Product Information, Concentration of Risk [Table]",
        "documentation": "Disclosure of information about concentration risk of product within nature of operation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://coeptistx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r604"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://coeptistx.com/role/SegmentReportingDetails",
      "http://coeptistx.com/role/SegmentReportingDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://coeptistx.com/role/SegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of segment information",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28"
     ]
    },
    "us-gaap_ScheduleOfServicingLiabilitiesAtFairValueTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfServicingLiabilitiesAtFairValueTextBlock",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of assumptions used for valuation",
        "documentation": "Tabular disclosure of the activity in the balance of servicing liabilities subsequently measured at fair value (including a description of where changes in fair value are reported in the statement of income for each period for which results of operations are presented), including but not limited to, the following: beginning and ending balances, additions (through assumptions of servicing obligations, and servicing obligations that result from transfers of financial assets), disposals, changes in fair value during the period resulting from changes in inputs or assumptions used in the valuation model, other changes in fair value and a description of those changes, and other changes that affect the balance and a description of those changes."
       }
      }
     },
     "auth_ref": [
      "r1282"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-OptionActivity",
      "http://coeptistx.com/role/CapitalStructureDetails-WeightedAverageAssumptions",
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r103"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of weighted average assumptions",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShortTermDebtTable",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Table]",
        "documentation": "Disclosure of information about short-term debt arrangement. Includes, but is not limited to, description of arrangement, lender, repayment term, weighted-average interest rate, borrowed amount, and description and amount of refinancing of short-term obligation when obligation is excluded from current liability."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-WarrantsOutstanding",
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r95",
      "r96",
      "r97",
      "r143",
      "r144",
      "r145",
      "r214",
      "r370",
      "r371",
      "r372",
      "r374",
      "r377",
      "r382",
      "r384",
      "r557",
      "r715",
      "r716",
      "r717",
      "r718",
      "r864",
      "r1067",
      "r1145",
      "r1147"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of warrants outstanding",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r1194"
     ]
    },
    "coep_SecondYearExtensionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "SecondYearExtensionMember",
     "presentation": [
      "http://coeptistx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Second Year Extension [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentDomain",
     "presentation": [
      "http://coeptistx.com/role/SegmentReportingDetails",
      "http://coeptistx.com/role/SegmentReportingDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r122",
      "r212",
      "r222",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r247",
      "r248",
      "r249",
      "r253",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r322",
      "r326",
      "r327",
      "r506",
      "r509",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r848",
      "r851",
      "r852",
      "r857",
      "r930",
      "r1289",
      "r1290",
      "r1291",
      "r1292",
      "r1293",
      "r1294",
      "r1295",
      "r1296",
      "r1297",
      "r1298",
      "r1299",
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304",
      "r1305",
      "r1306",
      "r1307",
      "r1308",
      "r1309",
      "r1310",
      "r1311",
      "r1312",
      "r1313",
      "r1314",
      "r1315",
      "r1316",
      "r1317"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://coeptistx.com/role/SegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEGMENT REPORTING",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r212",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r237",
      "r239",
      "r240",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r253",
      "r847",
      "r849",
      "r850",
      "r851",
      "r853",
      "r854",
      "r855"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://coeptistx.com/role/SegmentReportingDetails",
      "http://coeptistx.com/role/SegmentReportingDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling and marketing expense",
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative",
      "http://coeptistx.com/role/ConsolidatedBalanceSheets",
      "http://coeptistx.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r1084",
      "r1085",
      "r1192",
      "r1193"
     ]
    },
    "coep_SeriesAWarrantsExercisePrice27.20Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "SeriesAWarrantsExercisePrice27.20Member",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-WarrantsOutstanding"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Warrants Exercise Price 27. 20 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_SeriesAWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "SeriesAWarrantsMember",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_SeriesBWarrantsExercisePrice27.20Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "SeriesBWarrantsExercisePrice27.20Member",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-WarrantsOutstanding"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Warrants Exercise Price 27. 20 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_SeriesBWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "SeriesBWarrantsMember",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_SeriesWarrantsAAndBExercisePrice27.20Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "SeriesWarrantsAAndBExercisePrice27.20Member",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-WarrantsOutstanding"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series Warrants A And B Exercise Price 27. 20 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_SeriesWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "SeriesWarrantsMember",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-WeightedAverageAssumptions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-WeightedAverageAssumptions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-WeightedAverageAssumptions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-OptionActivity",
      "http://coeptistx.com/role/CapitalStructureDetails-WeightedAverageAssumptions",
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares expired",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r1201"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-OptionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options forfeited/expired",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-OptionActivity",
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options granted",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r1202"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-OptionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intrinsic value, options outstanding",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-OptionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options outstanding, beginning",
        "periodEndLabel": "Options outstanding, ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r411"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-OptionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, beginning balance outstanding",
        "periodEndLabel": "Weighted average exercise price, ending balance outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r411"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares exercised",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-OptionActivity",
      "http://coeptistx.com/role/CapitalStructureDetails-WeightedAverageAssumptions",
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative",
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-OptionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-OptionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, forfeited/expired",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-OptionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-WeightedAverageAssumptions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected term, in years",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares forfeited",
        "documentation": "Number of non-vested options forfeited."
       }
      }
     },
     "auth_ref": [
      "r1223"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-OptionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average contractual life (years), options outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "coep_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2OptionsGranted": {
     "xbrltype": "durationItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2OptionsGranted",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-OptionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average contractual life (years), granted"
       }
      }
     },
     "auth_ref": []
    },
    "coep_SharesIssuedForConversionOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "SharesIssuedForConversionOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares issued for the conversion of debt",
        "label": "SharesIssuedForConversionOfDebt"
       }
      }
     },
     "auth_ref": []
    },
    "coep_SharesIssuedForConversionOfDebtShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "SharesIssuedForConversionOfDebtShares",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued for the conversion of debt, shares"
       }
      }
     },
     "auth_ref": []
    },
    "coep_SharesIssuedForConversionOfDebtValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "SharesIssuedForConversionOfDebtValue",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued for the conversion of debt"
       }
      }
     },
     "auth_ref": []
    },
    "coep_SharesIssuedForInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "SharesIssuedForInvestment",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares issued for investment",
        "label": "SharesIssuedForInvestment"
       }
      }
     },
     "auth_ref": []
    },
    "coep_SharesIssuedForInvestmentShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "SharesIssuedForInvestmentShares",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued for investment, shares"
       }
      }
     },
     "auth_ref": []
    },
    "coep_SharesIssuedForInvestmentValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "SharesIssuedForInvestmentValue",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued for investment"
       }
      }
     },
     "auth_ref": []
    },
    "coep_SharesIssuedForSepa": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "SharesIssuedForSepa",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares issued for SEPA",
        "label": "SharesIssuedForSepa"
       }
      }
     },
     "auth_ref": []
    },
    "coep_SharesIssuedInConnectionWithSEPAShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "SharesIssuedInConnectionWithSEPAShares",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued for SEPA, shares"
       }
      }
     },
     "auth_ref": []
    },
    "coep_SharesIssuedInConnectionWithSEPAValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "SharesIssuedInConnectionWithSEPAValue",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued for SEPA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, shares",
        "periodEndLabel": "Ending balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermBorrowings",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term debt",
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r112",
      "r922",
      "r1285"
     ]
    },
    "us-gaap_ShortTermDebtLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermDebtLineItems",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r1183",
      "r1184",
      "r1185"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r1183",
      "r1184",
      "r1185"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173"
     ]
    },
    "coep_SixCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "SixCustomersMember",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Six Customers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "coep_StandbyEquityPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "StandbyEquityPurchaseAgreementMember",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative",
      "http://coeptistx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Standby Equity Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://coeptistx.com/role/SegmentReportingDetails",
      "http://coeptistx.com/role/SegmentReportingDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r122",
      "r135",
      "r212",
      "r222",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r247",
      "r248",
      "r249",
      "r253",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r322",
      "r325",
      "r326",
      "r327",
      "r506",
      "r509",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r848",
      "r851",
      "r852",
      "r857",
      "r930",
      "r1289",
      "r1290",
      "r1291",
      "r1292",
      "r1293",
      "r1294",
      "r1295",
      "r1296",
      "r1297",
      "r1298",
      "r1299",
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304",
      "r1305",
      "r1306",
      "r1307",
      "r1308",
      "r1309",
      "r1310",
      "r1311",
      "r1312",
      "r1313",
      "r1314",
      "r1315",
      "r1316",
      "r1317"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-WarrantsOutstanding",
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative",
      "http://coeptistx.com/role/ConsolidatedBalanceSheets",
      "http://coeptistx.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r143",
      "r144",
      "r145",
      "r174",
      "r177",
      "r203",
      "r204",
      "r206",
      "r208",
      "r214",
      "r215",
      "r285",
      "r330",
      "r332",
      "r333",
      "r334",
      "r337",
      "r338",
      "r358",
      "r359",
      "r361",
      "r362",
      "r364",
      "r367",
      "r370",
      "r371",
      "r374",
      "r377",
      "r384",
      "r587",
      "r715",
      "r716",
      "r717",
      "r718",
      "r727",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r752",
      "r773",
      "r796",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r1067",
      "r1147",
      "r1149",
      "r1157"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r63",
      "r66",
      "r67",
      "r131",
      "r133",
      "r134",
      "r155",
      "r156",
      "r157",
      "r185",
      "r186",
      "r187",
      "r189",
      "r196",
      "r198",
      "r200",
      "r213",
      "r286",
      "r287",
      "r324",
      "r356",
      "r386",
      "r435",
      "r461",
      "r462",
      "r469",
      "r470",
      "r471",
      "r473",
      "r511",
      "r512",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r572",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r597",
      "r599",
      "r605",
      "r681",
      "r703",
      "r704",
      "r705",
      "r727",
      "r796"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheets",
      "http://coeptistx.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations",
      "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r213",
      "r358",
      "r359",
      "r361",
      "r364",
      "r599",
      "r650",
      "r713",
      "r728",
      "r739",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r752",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r761",
      "r762",
      "r763",
      "r764",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r774",
      "r775",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r796",
      "r839",
      "r841",
      "r941",
      "r1320"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheets",
      "http://coeptistx.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations",
      "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r213",
      "r254",
      "r358",
      "r359",
      "r361",
      "r364",
      "r599",
      "r650",
      "r713",
      "r728",
      "r739",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r752",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r761",
      "r762",
      "r763",
      "r764",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r774",
      "r775",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r796",
      "r839",
      "r841",
      "r941",
      "r1320"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r979",
      "r990",
      "r1004",
      "r1031"
     ]
    },
    "coep_StockIssuedDuringPeriodSharePreferredShareConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "StockIssuedDuringPeriodSharePreferredShareConversion",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred share conversion, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt converted to equity, shares",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r37",
      "r63",
      "r66",
      "r97",
      "r349"
     ]
    },
    "coep_StockIssuedDuringPeriodSharesIssuedForInvestment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesIssuedForInvestment",
     "presentation": [
      "http://coeptistx.com/role/InvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:StockIssuedDuringPeriodSharesIssuedForInvestment]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued for services, shares",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative",
      "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued for cash, shares",
        "verboseLabel": "Number of shares issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r62",
      "r63",
      "r97",
      "r715",
      "r796",
      "r816"
     ]
    },
    "coep_StockIssuedDuringPeriodSharesOfPreferredShareOffering": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesOfPreferredShareOffering",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred share offering, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://coeptistx.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock split adjustment, shares",
        "verboseLabel": "Shares issued",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "coep_StockIssuedDuringPeriodSharesPrefundedWarrantsExercise": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesPrefundedWarrantsExercise",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-funded warrants exercise, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://coeptistx.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset purchase agreement, shares",
        "verboseLabel": "Stock issued for purchase of assets, shares",
        "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-OptionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r62",
      "r63",
      "r97",
      "r415"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt converted to equity",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r63",
      "r66",
      "r67",
      "r97"
     ]
    },
    "coep_StockIssuedDuringPeriodValueIssuedForInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "StockIssuedDuringPeriodValueIssuedForInvestment",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/InvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:StockIssuedDuringPeriodValueIssuedForInvestment]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued for services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative",
      "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued for cash",
        "verboseLabel": "Gross proceeds",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r62",
      "r63",
      "r97",
      "r727",
      "r796",
      "r816",
      "r947"
     ]
    },
    "coep_StockIssuedDuringPeriodValueOfInvestmentsAssignmentAgreements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "StockIssuedDuringPeriodValueOfInvestmentsAssignmentAgreements",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in private companies"
       }
      }
     },
     "auth_ref": []
    },
    "coep_StockIssuedDuringPeriodValueOfPreferredShareOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "StockIssuedDuringPeriodValueOfPreferredShareOffering",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock split adjustment",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "coep_StockIssuedDuringPeriodValuePreferredShareConversion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "StockIssuedDuringPeriodValuePreferredShareConversion",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred share conversion"
       }
      }
     },
     "auth_ref": []
    },
    "coep_StockIssuedDuringPeriodValuePrefundedWarrantsExercise": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "StockIssuedDuringPeriodValuePrefundedWarrantsExercise",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-funded warrants exercise"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://coeptistx.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset purchase agreement",
        "verboseLabel": "Stock issued for purchase of assets, value",
        "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "coep_StockIssuedDuringPeriodValuePurchaseOfAssets1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets1",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for intangible asset purchase"
       }
      }
     },
     "auth_ref": []
    },
    "coep_StockIssuedDuringPeriodValueWarrantsIssuedForCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "StockIssuedDuringPeriodValueWarrantsIssuedForCash",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants issued for cash"
       }
      }
     },
     "auth_ref": []
    },
    "coep_StockIssuedForDebtShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "StockIssuedForDebtShares",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued for debt, shares"
       }
      }
     },
     "auth_ref": []
    },
    "coep_StockIssuedForDebtValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "StockIssuedForDebtValue",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued for debt, value"
       }
      }
     },
     "auth_ref": []
    },
    "coep_StockIssuedForServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "StockIssuedForServicesMember",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued For Services [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_StockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "StockOptionsMember",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-OptionActivity",
      "http://coeptistx.com/role/CapitalStructureDetails-WeightedAverageAssumptions",
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative",
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL STOCKHOLDERS' EQUITY - CONTROLLING INTERESTS",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r66",
      "r67",
      "r87",
      "r754",
      "r771",
      "r797",
      "r798",
      "r922",
      "r948",
      "r1145",
      "r1149",
      "r1150",
      "r1175",
      "r1271",
      "r1322"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedBalanceSheets",
      "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://coeptistx.com/role/Non-controllingInterestDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL STOCKHOLDERS' EQUITY",
        "periodStartLabel": "Beginning balance, value",
        "periodEndLabel": "Ending balance, value",
        "label": "Equity attributable to non-controlling interests",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r47",
      "r131",
      "r132",
      "r133",
      "r134",
      "r156",
      "r185",
      "r186",
      "r187",
      "r189",
      "r196",
      "r198",
      "r286",
      "r287",
      "r324",
      "r356",
      "r386",
      "r435",
      "r461",
      "r462",
      "r469",
      "r470",
      "r471",
      "r473",
      "r511",
      "r512",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r572",
      "r589",
      "r590",
      "r594",
      "r598",
      "r605",
      "r704",
      "r705",
      "r725",
      "r754",
      "r771",
      "r797",
      "r798",
      "r820",
      "r933",
      "r934",
      "r947",
      "r1145",
      "r1149",
      "r1150",
      "r1175",
      "r1271",
      "r1322"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CAPITAL STRUCTURE",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r369",
      "r371",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r386",
      "r557",
      "r571",
      "r799",
      "r801",
      "r821"
     ]
    },
    "us-gaap_StockholdersEquityNoteSubscriptionsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteSubscriptionsReceivable",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative",
      "http://coeptistx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Subscription receivable",
        "label": "Subscription receivable",
        "documentation": "Note received instead of cash as contribution to equity. The transaction may be a sale of capital stock or a contribution to paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r62",
      "r63",
      "r66",
      "r803"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative",
      "http://coeptistx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse stock split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "coep_SubscriptionReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "SubscriptionReceivable",
     "crdr": "debit",
     "presentation": [
      "http://coeptistx.com/role/InvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:SubscriptionReceivable-0]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_SubscriptionReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "SubscriptionReceivableMember",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subscription Receivable [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_SubscriptionReceivableSept20232ndMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "SubscriptionReceivableSept20232ndMember",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subscription Receivable Sept 2023 One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_SubscriptionReceivableSept2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "SubscriptionReceivableSept2023Member",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subscription Receivable Sept 2023 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_SubscriptionsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "SubscriptionsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative",
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subscriptions receivable"
       }
      }
     },
     "auth_ref": []
    },
    "coep_SubscriptionsReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "SubscriptionsReceivableNet",
     "crdr": "debit",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subscriptions receivable net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://coeptistx.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r614",
      "r615"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative",
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Going Concern",
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SummaryOfOperatingLossCarryforwardsTextBlock",
     "presentation": [
      "http://coeptistx.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of net operating loss carryforwards",
        "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r1227"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL CASH FLOW DISCLOSURES"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r1024"
     ]
    },
    "coep_TechnologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "TechnologyMember",
     "presentation": [
      "http://coeptistx.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Technology Segment [Member]",
        "label": "Technology Segment [Member] [Default Label]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_TechnologySegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "TechnologySegmentMember",
     "presentation": [
      "http://coeptistx.com/role/SegmentReportingDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Technology Segment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_ThreeCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "ThreeCustomersMember",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Three Customers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_ThreePrivatelyHeldCompaniesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "ThreePrivatelyHeldCompaniesMember",
     "presentation": [
      "http://coeptistx.com/role/InvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Three Privately Held Companies [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransactionDomain",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative",
      "http://coeptistx.com/role/Co-developmentOptionsDetailsNarrative",
      "http://coeptistx.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://coeptistx.com/role/InvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement between buyer and seller for the exchange of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r834",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1242",
      "r1244",
      "r1245",
      "r1246"
     ]
    },
    "us-gaap_TransactionTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransactionTypeAxis",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative",
      "http://coeptistx.com/role/Co-developmentOptionsDetailsNarrative",
      "http://coeptistx.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://coeptistx.com/role/InvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Type [Axis]",
        "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r834",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1243",
      "r1244",
      "r1245",
      "r1246"
     ]
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r355",
      "r382",
      "r557",
      "r570",
      "r584",
      "r586",
      "r588",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r660",
      "r682",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r923",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1250",
      "r1253",
      "r1254",
      "r1255",
      "r1262",
      "r1265",
      "r1267",
      "r1268"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1047"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1048"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1048"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1047"
     ]
    },
    "us-gaap_TreasuryStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockValue",
     "crdr": "debit",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury stock",
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r63",
      "r66"
     ]
    },
    "coep_TwoInvestorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "TwoInvestorMember",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Investor [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_TwoPrivatelyHeldCompaniesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "TwoPrivatelyHeldCompaniesMember",
     "presentation": [
      "http://coeptistx.com/role/InvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Privately Held Companies [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative",
      "http://coeptistx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "us-gaap_UnrealizedGainLossOnDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrealizedGainLossOnDerivatives",
     "crdr": "credit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows",
      "http://coeptistx.com/role/ConvertibleNotesDetails-ChangeInDeriviative",
      "http://coeptistx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of derivative liability",
        "negatedTerseLabel": "Change in fair value",
        "label": "Change in fair value of derivative liability",
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r790",
      "r791",
      "r792",
      "r793",
      "r809"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Uncertain tax positions",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r450",
      "r874"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r126",
      "r216",
      "r218",
      "r219",
      "r220",
      "r654",
      "r656",
      "r844"
     ]
    },
    "coep_VyGenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "VyGenMember",
     "presentation": [
      "http://coeptistx.com/role/Co-developmentOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vy Gen [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_WarrantHolder18ExercisePrice178.20Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "WarrantHolder18ExercisePrice178.20Member",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-WarrantsOutstanding"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Holder 18 Exercise Price 178. 20 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_WarrantHolder1ExercisePrice118.80Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "WarrantHolder1ExercisePrice118.80Member",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-WarrantsOutstanding"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Holder 1 Exercise Price 118. 80 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_WarrantHolder1ExercisePrice296.80Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "WarrantHolder1ExercisePrice296.80Member",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-WarrantsOutstanding"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Holder 1 Exercise Price 296. 80 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_WarrantHolder1ExercisePrice59.40Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "WarrantHolder1ExercisePrice59.40Member",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-WarrantsOutstanding"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Holder 1 Exercise Price 59. 40 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_WarrantHolder20ExercisePrice50.00Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "WarrantHolder20ExercisePrice50.00Member",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-WarrantsOutstanding"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Holder 20 Exercise Price 50. 00 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_WarrantHolder21ExercisePrice38.00Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "WarrantHolder21ExercisePrice38.00Member",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-WarrantsOutstanding"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Holder 21 Exercise Price 38. 00 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_WarrantHolder22ExercisePrice25.00Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "WarrantHolder22ExercisePrice25.00Member",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-WarrantsOutstanding"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Holder 22 Exercise Price 25. 00 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_WarrantHolder22ExercisePrice28.00Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "WarrantHolder22ExercisePrice28.00Member",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-WarrantsOutstanding"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Holder 22 Exercise Price 28. 00 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_WarrantHolder23ExercisePrice25.00Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "WarrantHolder23ExercisePrice25.00Member",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-WarrantsOutstanding"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Holder 23 Exercise Price 25. 00 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_WarrantHolder23ExercisePrice28.00Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "WarrantHolder23ExercisePrice28.00Member",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-WarrantsOutstanding"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Holder 23 Exercise Price 28. 00 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_WarrantHolder24ExercisePrice28.00Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "WarrantHolder24ExercisePrice28.00Member",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-WarrantsOutstanding"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Holder 24 Exercise Price 28. 00 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_WarrantHolder25ExercisePrice12.00Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "WarrantHolder25ExercisePrice12.00Member",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-WarrantsOutstanding"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Holder 25 Exercise Price 12. 00 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_WarrantHolder2ExercisePrice296.80Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "WarrantHolder2ExercisePrice296.80Member",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-WarrantsOutstanding"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Holder 2 Exercise Price 296. 80 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_WarrantHolder2ExercisePrice59.40Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "WarrantHolder2ExercisePrice59.40Member",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-WarrantsOutstanding"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Holder 2 Exercise Price 59. 40 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_WarrantHolder5ExercisePrice59.40Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "WarrantHolder5ExercisePrice59.40Member",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-WarrantsOutstanding"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Holder 5 Exercise Price 59. 40 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_WarrantLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "WarrantLiabilitiesMember",
     "presentation": [
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-ChangesInFairValueOfWarrantLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Liabilities [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_WarrantNoteSubscriptionReceivablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "WarrantNoteSubscriptionReceivablesMember",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Note Subscription Receivables [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_WarrantsAndRightsOutstandingDateIssued": {
     "xbrltype": "dateItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "WarrantsAndRightsOutstandingDateIssued",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-WarrantsOutstanding"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Date Issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetails-WarrantsOutstanding"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r1253",
      "r1254",
      "r1255"
     ]
    },
    "coep_WarrantsEachWholeWarrantExercisableForOnehalfOfOneShareOfCommonStockFor230.00PerWholeShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "WarrantsEachWholeWarrantExercisableForOnehalfOfOneShareOfCommonStockFor230.00PerWholeShareMember",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants, each whole warrant exercisable for one-half of one share of Common Stock for $230.00 per whole share"
       }
      }
     },
     "auth_ref": []
    },
    "coep_WarrantsIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "WarrantsIssuedForServices",
     "crdr": "debit",
     "calculation": {
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrants issued for services",
        "label": "WarrantsIssuedForServices"
       }
      }
     },
     "auth_ref": []
    },
    "coep_WarrantsIssuedInExchangeForSubscriptionsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "WarrantsIssuedInExchangeForSubscriptionsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants issued in exchange for subscriptions receivable"
       }
      }
     },
     "auth_ref": []
    },
    "coep_WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "WarrantsMember",
     "presentation": [
      "http://coeptistx.com/role/DerivativeLiabilityWarrantsDetails-FairValueAssumption",
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_WebinarServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "WebinarServicesMember",
     "presentation": [
      "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Webinar Services [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of common shares outstanding, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r208"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://coeptistx.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of common shares outstanding, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r208"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://coeptistx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r1064"
     ]
    },
    "coep_YANote1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "YANote1Member",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "YA Note-1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_YANote2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "YANote2Member",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Y A Note 2 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_YeraceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "YeraceMember",
     "presentation": [
      "http://coeptistx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Yerace [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_YorkvilleConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "YorkvilleConvertibleNoteMember",
     "presentation": [
      "http://coeptistx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Yorkville Convertible Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "coep_YorkvilleMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://coeptistx.com/20251231",
     "localname": "YorkvilleMember",
     "presentation": [
      "http://coeptistx.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Yorkville [Member]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(c)(2)",
   "SubTopic": "20",
   "Topic": "860",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4D"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-20/tableOfContent"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-40/tableOfContent"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/710/tableOfContent"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/712/tableOfContent"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-23"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479483/340-40-50-3"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-4"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-3"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-11"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/815/tableOfContent"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8C"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479693/815-10-S50-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(h))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "805",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481019/946-20-45-3"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-15"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-20"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-18"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "181",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-181"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "942",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480095/942-10-S50-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "942",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480035/942-10-S99-6"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 6-K",
   "Section": "General Instruction",
   "Subsection": "B"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "Instruction",
   "Paragraph": "2"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "a"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "321",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/321/tableOfContent"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "325",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/325/tableOfContent"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479483/340-40-50-3"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805/tableOfContent"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/815/tableOfContent"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1249": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/820/tableOfContent"
  },
  "r1250": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1251": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1252": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1253": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1254": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1255": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1256": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1257": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1258": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1259": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1260": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1261": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1262": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1263": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1264": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1265": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1266": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r1267": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1268": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1269": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1270": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1271": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1272": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r1273": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1274": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1275": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1276": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r1277": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1278": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1279": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1280": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1281": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1282": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r1283": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1284": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1285": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1286": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1287": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1288": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1289": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1290": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1291": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1292": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1293": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1294": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1295": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1296": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1297": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1298": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1299": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1300": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1301": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1302": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1303": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1304": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1305": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1306": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1307": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1308": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1309": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1310": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1311": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1312": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1313": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1314": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1315": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1316": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1317": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1318": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1319": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1320": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1321": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1322": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1323": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>93
<FILENAME>0001683168-26-002026-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001683168-26-002026-xbrl.zip
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M\&\R<&!&X#_I(P/M:_]E97,-\>_FX,T5F%4B(*-'H(@F ^]R4MD(9]XT0<B
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M4F-GK+)I]0LONI:P!BE#A7U6HQ,8&IQ;K$F58CFI@)D06$]>XO7>F"*FV>H
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MN9LX+_?VYCU7;C[#&*5RN HNE6BO#KZ RVF5'V-HM&R/O1W.@15L9AZ06/
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ME>$Y7V6M#3VS]@;<M;F&1WOFT?&T,*N%!5\I[5O_2WOG&=5DT^[[*"@"2D=
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M"%0"F*.ECKG+/WTM<E4A1U.N%5X0-16(V+:MZZ5N4""-MPOGX28G.S[6GQV
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M.ZJ/^16/]AO=YH:;WNEWO6]E<9-P_Q[%B@7R;1,SW WMEZJ,QE_KTC(&R:F
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MD[K:U$;QL=R[QN7XM=WC0F:/8M>^-F_SB:FHV<JH+S6S@L<,1:\[[T8_B:6
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M9F5F8F)A8F1D86=A864#+T;FPQSL;(</OC^XR<';#]X%?K$Q,3*Q_4]?U":
MDXF&ATZ+CD88H.6DH>.DH;8"$ "@8:#Y?0'_<='0TM$S' *GQ,(*#J@Z DZ?
MCHX6G"P#/3WXVW#P]P ])\/14W+:AXZ9.S(*^W')/TAZPR1RL:R9VV( *ZIP
MRS^2F86'EX]?X/09,7$)246E\\HJ%U0O7=;1U=,W,+QZS=+*VN:ZK9.SBZN;
MNX=GP-W >T'!(?>C'D;'Q#YZ')><\CPU+?W%RXR<W+=Y^07O"M^75U165=?4
MUGW\W-+:UM[1V=4].#0\,CKV;7QB9G9N?F%QZ>?R"N[7UO8.?I>PMW^@%PU
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MD(G%[\Y 6S7<6C(>^G*/)@6>KF,[9R-U1!!'IT@3^]]D$OV$3VY #JPCT"E
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MT!84.D0SG3K4*T</FEBUNOK]HB7#^EIWL1_D2FH7:74 .M.*/H1&ER(P"U2
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MQ^>0\ZLV.46?3CA;A*>;7@PHYQ:#?*WW_+T80WSITX,X6XXJ)G<WFW,YEVD
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MDMCS\U4S(SR\<:9?)K4DOVU/7+,>LB3$@F,2R 48_'UROLS=U<)N]RQ)X<%
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MMK8HK'E$F40!DOP'0E2^'<^PNN9EZRS; %'Z+-/^FF4M2,JPA=0A,[U+O3(
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M\Y;351<+O9W<6*<<'/2%8Q3YW6[= ;AZI"1VC'Z6>-_,6%F\QRQD?BKHGA@
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MJ;!>&YCC$&A-,@C,7JZX,2F*O&=@R2J)+.3*$TT=+V%1*+%0+-P\D[SCEC\
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M/>< =DD$O96-N@\V68*F^/IO,(-AWQ%P4'WJHSN:_<X C7&(-^A&3MP3^8-
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M"Z\4_O2M2N_)@@/C#G3NTY8%&M)%P@Q^5 ZL:VH_:*)<"E7Y=67BU\X)F-2
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M,Q7,Z*S/IGXX&XW8./X@P, @SX#.^F]S$4Y#NT*O'#]MMS@J8S9[9.,F/M$
M-YV2U $$2+DJCJKN[_6(E' RR9L(:Q[:M)MZU-#T^\PC*^SWZ 9Y?";HH-@/
M4!8@0$MAOO_FLO_;][^Q&;TQUA<]\[,Z#Z>$$[6;V%?;*_83%N@9#O8J_2#
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M).=NU-4*.Y@)2Z?@/Q'O^\Q!_HIXVZQ2XG 9E!OC1Q"A2@ G@SKAX1>AJB<
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MEO;O8 VB&) C" @<1(J[.\T(=BC&7<+&ZCT*T2I9T1Q)?7_H>.+=B=<TK6U
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M'V/Y)F^=/^1TT&VHBL@*135JQ9E&8)5MM(-FNHV+RS6G.N0 )H/,84^"T\[
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M^17S7E%\[LW8?QX!@?0G_P=02P,$%     @ "HAS7"68EH\Q2P  "?$$ !4
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MPEN--YZN+=?=UD;D*?R@H0$*+_(+*KS5B.+^&ODKL@Q^\?'/\"%]R,M3/)/
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M&-T'MN_<(U:BKR2BD]'6"(7SN0=UK<Q94!2.7DNF;#_&18CWSP'+V'A.-T8
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MW17!@"7$T,[VY=D4^MF ]HJ\JCPE\_'0V E:"R1:.SR/A:U5_^00/7]!7G?
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M]?R=0?X @100,N\:]0?DN2HY9T#J^3MS/ (B*4!D&G4)7+P["AF0>O[.'(>
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M_(=9I6?K4>;2&0&:C C@=D$/O,K/.#EZ _&K-N\49_++C#RYXBP<*B,P$PL
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MH/+;47/""IB4C#0Y;-%R;CB.QC# (>ARJ\7U4[=&M4SK5EKKK>9O^X(L?_9
M-FZ/* H=FU]'@=UXWO)6"!JD6(;11E>(.JRHO &=LR9A"WO08PUES#>$@S*7
M<M>VHW7DTM=;HY ,'7I+ZZ,'.ON?T, C^U1TBX. G#U'RYGU#,-4LB-34*PB
MEG:3K1A833AW(_HZ8HS]6-]AZ#OW44AW'#-,#B6,,PDGKJ&6_DT9$C5*"^XS
M%)U&,W=@,B?0C_D3Z&#XC9PW[_K#V52?0R<MG6C=XX2';''@KK>(L6'_.9,'
M() XI];[%47KQ"ZQ=0W2",[%37Q+FT-U$T,NOPHUAE6KA_B_4(WKVG&J6AJ[
MU>+DI]+8I]+8I]+8+;HV9C_QV'>>R(G%W?R.W#CNUO(<Q/=Q"*C:=G8<6S58
M0IRZ5T>H?@U9S2O@(2)K8.HTBXB40" F-8?2S,A?JZ BI&O]#'OT1)&2"#1+
M->/"8&3#!00FF+=]57TL$@)1( @JU[RKISIFLC&E-:OX!9R8C5_PIIPGMH37
M1QF24L5*#YNJ*?7$TRR(@;Y%GHZ!0,MM]/$PM;IK'J+G+\CK#KK+I>,Z9!VF
M+OV?V/\Q=JUPB?TUUPQ)4K>^:1/. %Q-!G"?UDH!5@ $=N/Y9T4A:PVZ  72
M:G?)N+]6&/WTT.+*<NGS"U&F"A[52T155FSMKA>_$,712]"1)_4PC-G\!0,*
MRUOW1E#\B+)8;67WZG#/'+2^ENSF)4):60_@/J85J./7I$<C#?7R%P.:JP;P
MF%XOSONOIIZ"&X3&EK,=A-["\9$=NAL 8%GREXIL*?DA2)6]MH&XY\)>V%U
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MK+*-_]J'^8%NCY$ G<3U)BMM8ATGJVTJ^,(5-Y&"<P8-0=GG52&*&EDHX<J
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M[N<XUKGP<S\=[><4FFY(IS5%S#FI&D#*Z;!J&/<3 #_W]N_=J/1?__[].^.
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M+VF; %:3L:WU(XQ/*D#$Y6IC(A=/N^6EJX?0)VY!E7*+%[*7;DL&L$FUU9>
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M@T+2.>WX+F7<]UQ[/C/W!FNE5XI/O. K6D%!UVRM;C%[>)A,/Z#)=#5>C)<
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M7!S4 !B&'H.ZS]NJ#>05C:"8M<)._96%D8OLP:WR[%#\H\3^LJ.:)A8>W H
M9NM,-."VK GH[-;@/@^_#?SV!3\Z^'*)[ZR2A(RJ81(L<R_-5=/.,]O6)](-
MWH0Q#0B(\R,_^&2,9YO SKV@J9]S[,F,?)5;;V1*-$/7(V!,X6O<4X9VE2*U
M]MT^I1V$6<ZJ4$SQ5_:+-%.<F:[U\K*FYG#N4*<(9D <@I9+ 5$,<B'3IK<[
MD.]E3U")6* ]DHF<,@ J2@PRX&)/$SH9Q7#-V'@N]R@Y'-JN03");Y,XQCZ-
M"GX+\Z?E>#YB_:AG[1!%:T=$!QE2GQ(UTG).K\%0]=2B&HXH5?Q^C(F5)AA2
M=4TQ9E7Q^^N@50>K&:]>1417_/D^2:OTC4?$%X(V  RK:O-,(SVN >=T/06U
MGKA52DZHI&WWTZ-9*VT$ &TU!AI'A:^.N&K8YLRU&"D2F,T-/Z,04:3A9!B7
M0Q<.W[RX<SJ98]1SI[ER:9LU9E&@4,4];PSB/H$\<.8,C/0:ZKR*>&].7N"3
ME^'96IG,?U@3 (9-I7&FP5Y?WSE33P#-I0"B/Z)=*8R\38KQ.1S>90.]T^@J
M:P, 7]7F&4=YKXVQ2M2FE+UTA*?H;+]Y:>K%>3-NW'K9DW!X&=Z(O?'\6 .;
M$7YH"\YY>1)L[MQ *0MNRV04_->^3!VR2D9!$.:LT,;<"^FBEK<+<R\JP2NK
M'1_1CM5D?\>:V4G^-[01YQP^%;D)C<^U_G.$;YT3Q7T<X*#"-7[!J1]RU])/
M:0B$C]4::N1GI:TXY^G)T/FB0?BZ4$!?*\[B4L4N4<OXY0Q,U;;DFJJ&INJX
MJFD&-%G-L ]AZX5#UVX0,XG'+SY+34+74_>/F9^&.W;??8%]'#[3HVZBMW%,
M*];8>KR)-5.'-P&#I4?CU@W\(<V;5+15! 'MUE!:-V=G<?0VB9]QFM4ICDT7
MUB5ZKI9)E6;(UDJ%2C#8-P"I?M4T?\+(KULX5YJNX_AEO 0O4X3",+/E>+'6
MJ^#8P*5Y,<D<KA[-UC26P&E:7E&8K<E_\(>R3VC'==!H9*;1]$;6"!"B'H]<
M$"X6PBAC=2>34MS%Q.8,!-4UY)JA9H::S6I>)4>-H"M(2J5KDCITIEW\S5!Q
MS&*$N!W75#4RTWBM2-0(:**:(-?QM!G^';C3,S!4TXYKAAJ9:>1+7R5#39";
M,]1I8-K*5#_*LG 3TW^.JAU7\>SHM 9=<W>8X88QJZ8UT&P>9 )?UJS6HLM)
M.Y;X&+/RZ5Y\AJ3'QP0(O5,&POSN QL 05JI86:Q0%\;/BEED+D\W.6E?3:/
MZIS1RXE82(NS>)TS):]BPYZ-*X\$;4#LHWE#6<[:!?YK'V9ACLN#TL7K6F _
MV<2L%=&RJ;W'0CL.<(Z7./3TP"G/=-XI+1O*K>:Q/LS:9(-(U:CS'JL</&FI
MLB..<)9Z (XE\F:8GIUE2F!8:XI43+ML%X4Y\FKF0R5=N90SG'4=10"T$QAB
M? 3V51"/AVK&/),YX04_EW$2;;M)?\B$^3')\(/B.PBP<6EF22!(ZP8Y[]WM
M;2Y&@X(MQ9]S'/0G+@/T;/9M8S/:'-(J@>G9IDCY24E[!Y)I7J%RL[)6=LY!
MU8#9MKQ$''8*9QXQ"!NT"6!<&F:^::BD;1 ,Y\]A1;\_T(W\<M63IM[+$X19
M0C:H7:#=S<_6!XP;!= )!KX X\#MU7>#86:8]@/'(1_X_)+O':3]&\?*XJAG
MMJS/E#%+)#@@M>0EZ5%,9(9F:G21%%3WT:0@=>\?S#5O+\=%@51Z5^T^2KYF
MFNH3:A6[8XT>?-=YR.4!C1-:D/RTOU2ADP.JA)@6^J/2^]_.>4;FR108F5$_
MAP$.;@Z?,GKZ?%;5K1SY>?C,1CH-^XYIR')=G2,-[17?&=@*&/X>#;W/ZME\
MO!BM:%&GT>UJ\GFRF@"H?=C:R: #,#&4%79<)71+(O;#"'>*$ZV2\[#^\H]U
MM-=VT9<HV6N[R#/!]#]+AG)Y%IK'TFE(6CV,UA-F*Z3TK_3?%!':9\6-H;IN
M,?+J!SGOXW=X1^"';*N0_#O"+/B.@]&6QN'_8'^7O'PS5;O5ULV-Z19<U^N!
MX?P L/P,NE%%)(9'7DO'.17K?OB O0PO:*6)V9IT47:$I6V=NOCZ\&9L4O18
M(]MT'=H&&.H>";Q/8Z9(P_]]5IU/,B7R)0?Z%H3B]M5=F/G)/L[G*=Z&^ZUP
MI-8I65X(4 ZVQEBY\;*E6=TJ0T&I[-[OT$WF*GQ@L8*,O@)!J[Y#"K3C'3@I
M.PSZN6!0C#=D@JY<2)(BY#:<D_B:A5 I?L8Q@.HPX^TN2@ZXJD.>D6&7K8K=
M](]RE=9)7L#P9JQ6'3S2R$XYPH%M0#L-<23^5W,HC^[-T+79<F>>F%>E.&AE
M$IZEMY$7;F4[=0/;L$GAH\QK\W=0 V!&Z&-0ZV^%Q\0+X[(_7#K=%9=43I*O
M7"?L*+N*)/^X6A**[S-":3,EVLE>[E.<8B\*_X&##UX8TQ6@&9DRLYLVX;/T
M!()6RZ8G,S2A[;LT*M"B03.XW"&Q(OE.&*.U%Z;%#F\QM:@T411ZCV$$X:#,
M/8'(C@ U"X>S==5S)*]%HV.3@T;PVPQ4*H 9+4U0GD*[.IG9A<;*HJMH,L"(
M?+RAHK4Q=) A]7AJI.6<;(.A"DNA-X5UVPETSYX.ZF1'1SUX1A&3,#,>O]"E
MOGV8/15=2T#' 7HV'9ZQ&6VGIU6"-O": NXS\ENJ^%VQSY701'AM33!4G,1^
M2E>9[W#QOY.X.C8V]P[T5-D4R]AHIFIU/CO F,XTUD#/N8L\ FR?DL2=;LC8
M&V-*R36]OLST'.T$-'%LZY*_S&5P@K96_(<Y"CG,_K=HXOG:130E7UP=TOWH
MI5\P.TS:'#/F)QZB;V2F">^C#<2M^(H;CQY>B-&V;I',\*LF ?KY9I>QC,3U
M1XZ&-N+6]YL8J!X%5"T '@\,8'/!2M7*=R0L*?Y%W-$O &E;#7:C.+@+Z0&E
M.)"GG3Z^&1AAB]I(LQ!&W 8T/WPD?CY=4*%TQN32%^#P/,4[+PS4!W3T:FXY
M*C9"S<FN#GP."O$*,J]1H>*(#<B1GAXD:(YO,IC#1WIE(XY'>@,#-2.]H@7(
M([T>-N\AR^']VVJ@_P[H2,^,&_GL]%-6SFV'O1E.&0!-)089T+.G"64_]"C4
MW-&W4@KM"C& ="00TST90)J8VOA%B%3=4E%NC)J(O!Y\&DHQ"TA(!1$NAGN0
M0WGG:'!ETN&(J6%/'\I476B6Z2R]HPQYV%8B5I[CAK-;+_'WM_LTQ7%^C)N4
MZ@,8MN5F&8S<O#)\KZD&SEW,I-+(+\1KDD)8^#2_>RIY-4,:@'FK6,14<VVK
M5,V3W(M41!V,FSLL/UZAV]'R5_1I.;Y#DRD">:=88F:QL72&N_'*A@"PV,!0
M S8K6@$3'1P-G9O83S^/EZ^7QR>_'JB\/8VOK\+[RG%KO>]K8NU]&'NQ?P;O
MJVP( (L-##5@LZ(5Z-Y7#YT[6C.9CJ:WP'A,S/(Q#K)[\M&G28XUJZAR<9N<
MU('N90H6RH+AEP8@OY54B"/Z2E!,%<"LB+9-66""BAU4FJT'$DNNZHID.F-D
MA)/I@22?!BRWYE2)TW6GL_+0K);NDCR_9Y5<S%6=W#9(655<*@-EL4>#3W_%
M<3F>CT#YH>8F9U&BA]WG-.@-$CU7'DAIALS]")6@4&TH8#WWZ/5QH-S37%'3
M*;EGG>J2FEKC=?!-<UM-=#D7'-U*D.,7G/IA)ETO4:NXHIH,O(QH?7G(-)-@
M%9P2NU[O8S+)K"\\(ESJ@"):TVV:"J1EFH3B#YC\.'R@U3?FW@^:&JSWC[J6
M(!-ZL!6V*L];7-<[>;D(ZCK>:>MWKV(U6HY;NAH]7\P^3^[&=^CF=P1R)8_:
M2?^/5@%X]B(ZCU_@+$]#/\<!_8%TSNX?6I)%58G^%O_XI2PE0/[!KNLOO!R/
M25>5KF;;!F&UR)23%]RI6&45 :R>[,1VD3>83&\7X]%RC+Z]&Q?_^H[N4E$G
MX>A*YDFOYNP\<U)P8YE[:7XQ^DCO=K*18;1"-^,/D^F4#@BS>S0?+R:SN_^?
M"_3% :R8<QZ#9$P83^_,.&"G3LM^MXM8C0\OJLJ"3.)UDFY9\D1=R193;:O5
M6X:9U"GD8J8*9G-F&%YN??33?/XP_CB>KD8/10A[_S#[#=U-EK</L^6G!8"0
MM<E*$0:J)"(]*;MG?840NR=Z.R)@Z"/&);T.2R\H F $36*\\E[H[J.:%+R@
MY3/@$J"]P]X]*4#LD$#K$X2)P&!'G>FZ.DL6!_5,GI4KT9VU,M>WNC0SU*S.
MRHRI,ACF#46L'-BFL^DU&]S..*[)SA_L'S,_#7=T[)7GDU"+VCN'H ;;G$40
MRSDGBP$XCA=MZ3-F=S [CF*2+A).HLBA*2(A)8<<>'S%,#LD?YP@?\(7R QI
MQJ8F/9B!A6UA5PSB <NXTTA"9@V'4L^7)C?;60.E#/O?;Y+G'[ ?E#&2'S2A
M$?F//^?/NY5@).K^9(,8(C"4!NV_.Q]9!&"XW4GO@)XS-,<IFVP3>Q$MT!,E
MV3[%Z ^F>M[BJ/J//'[!_IZF1;[U<KQ)TL/H)>SO02KD;'U^)<R*"T(A$,10
M(>-J,U>RJ!)&?U!QV\R8Q %-?K7W(@DE^@*VN" &5I&@^RN(KR^$Q"^85$)N
M/O<H^*]50@OG2+YV[W=;'UL(J_K6G1]!?&H1(GEQ4EJ%M%VKR,V7_X@].@!)
MOGOG5UM?70"I^N:MGT!\<1Y/_WN7$FX^;A62K/!+?A/Q1^<D,K;#.@Y>/[ZK
M!4!\=!FJ01'?%5J=_7J5GA"WR1)'F.Y!EKR<>EP]186<+6(H85;D$ J!((@*
M&;?'2T8 +SZ@2@-5#H/J6&8'?6101Z"S]3KT<9K=QRKW8:!CBS7&\"L&:15
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MG#.AJ-T7T7(L_;)^(_^O?4A(^U9BLIFJU0MJ XSI7#DST /#M %@%048/::
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M'&3T'.M#Z-,MH'N,,UI4DH:.\D,N:BW+AXA,3.@=)%*I@&&<&<X^Z4I)M,8
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M"48PA;M(C3>Y C$TM,M;EYVFOM<DCIWE\H *0AO!Y$I ;S8I2WO06WQL.04
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M=BA<%+;1\"GL;?J89Y![ZHD6E(W[^S*-5O2#)ME64S9F.AFOJNO82:O^#M#
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MTD#H?[$">I&P2-C/'XCOLQ,T)P#I/:\\$/^_68&_6& +&$BO_%]3:> D%*H
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M4O+'ZB O&(FKG(WW6RDV^@B:4>3HY]D#J=?'-T[R[LIF#&DU;(>W&O?R; )
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M!ZR$R&K^]9J(H4_AAC;+YM[EJP_UB]Y+%YRH;$5 (4KGFD7(O*&!Z_GDY)&
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M#W]5#9^*%K8[AJ"0G8Z<$PF*6<"Z0';X3-PM2\0UH N9=1CM^L^>0!L$12W
MO*0=!6 %?2X\5= %R'W?+W?$(_$=V=QS7Y&D5>0U\"&7JDT!?[D<Q^<\NF!A
M%"S9M>ZMXXMUO%P&'VF)<I<[6W@,H2.M/O9 I<V<DOC8\C7B5'TY'>]6;?O+
M?R]"EH17K+6E(OC 2I2VU-?"4PT=Z>RA PJ-K93#AY6K"J?J6NEUM\IZ1QRV
MUA&KZDD!?$0EBGK2T\*+$5VN=Q=T@W+E\\-^"KTO%(.G6&A]!]EX]5N1ME5O
MIAKU03@G/F''4CGW8X?[% $M*R@*1K]]?[\4QU#5<12\V:>/*\G):N6Y)(IO
M H76 ZJ!>6C?P:_$.-01!(67*2'1QRC<IEG;(8Q(*X"Y:-])K\$%0.:NK5$:
MMW/LF)(%:04P"^W[Z358 ,C<^5@(%RS>*5UU;7@>W51Y2H7 :+?OBM?2>:YL
MW2/<=Q.ZO_)W[#!3!32W+!CO]OWF>GA+).T8]G2C0'O$>J$T+<+"8.#;C[?4
M %XA:]?+GC"@?1E397A:JVV+N#08^_8##H&+396DB,"G/2D,1A#^W$I@&MJ/
MTJM!@T1N# -TZ!K<#(FKP+/.F6 "BG((%0>%%1:,F>S8ZQL9;'0UO$FC(ZZ]
M57YK1DF3;AM@WHSLFO5YJX=1Y\Z,4U$^QZD%3H_H'T*?(CI+E#L*S3; 1!K9
M=NL360\C="(/6=.UZ>/5!)-F9'_>!FEB/-"IJJQ0M2F3M0"FSLBFO@WJU/AT
M3"'' #"/=NZ/4+ 'K@PFSHA_0)\X3530AUV:C['NB!-4!G-FQ,?0QF"3HM+U
M.'/NM[X3W7IQ CGIDA0'\V+$!5%C+*DDQ[=XPLVPJ"R8 R.NB%;L&:8#=&]'
M-9A05@)38L0MH4\)$ 7\"R[%)XLXW!R3#12+P7.?HSB)^)U&FLQ+*T+A$."7
M!"-M,A$:!T7)$3R>Z4E7!"Q>0X4UMR 8:I-IQZ102^3#\'9*'?VG)<#8FDSE
M)<66)U'W1X?B$)W#'\%0FDR*)86R)$?'*"J#G6J%.!G(ST[J!IA9$.H4!A^I
M(N0=N2:'2X>J6"= /3 C1C:FBA GL-R=V^.EQ_KA^.]?OWTZJI'R!$I9#4R'
MD?UHO0$"1J-K Q_$P56P2F(ZV:BCT$2%P8R8.2BO%Q,KE[SS4\%DU_\6+4$\
M" N#>3!S4EZ+!X7D'!XP+J4.HXBMQ*074]]7+J:R9WB?2+3KA:L>;2$,2+B-
M_5VO_\VA3"Q[K$D2Q&DON[BGNN_/9%61IT+1J<K!:G8R4K+O[SLDN;7*+XE_
M)4*'A>) X8K3]756EEDJS\AQ3?\KOH?"+8@/ODQ]"F!S>]_QI=;SO$X)!/AR
MM?)[N%I9'$8D(='&"U*(V)A2FXUJ#=S+5S4--P2$KC=GZW62RR!VEY7*X%Z]
M H$8"CN/LZC/.T!W?;O8BU6K>F%IW,M6 B@K"Q.AF!VC/D^^3B-W$BWB:!@G
M7I;O[8XD#^%2P0"L)NYU*R4;.N)W?1BR3>@@#EC69(@!DA3'O6REY$ I*)ZY
M'X?)[^1@0HEJ2,!JXM[&4M*A(W['S-Q0<<. [%<6=,$F/B40E<6]FZ5$7RZB
M-8]":'-UO26+</C,'#B$K@A9;E$W79\(#9I6 [@7OW19A8"!.[32'G[V0C]%
M<++Z+=R00;@-DFAWZWS3XDS>"NZM,<UU<EV0+."2;K[^I#M;;^6Y>6\7SO,5
M"<C*2V(M/M4MX5Y!:X%3*%BXO%(#XCM!WL'1YI&EP:0=3E][WRE6*C6;PKW2
MUH@J(>-Z,.)M D"K'EEYW'MM+9&G!N2,UD@<8:![O$IYW,MNYMC%W0L6)Y.0
MQ'1#-"-_;KWH(*G"SNK4Q[WYUA*#^H!9<F:=GC(O/+I:6,O/K=^5SZW3FKVL
M:L>IE+-.;](>W\K/I 5%.W&HL$_' PH+U:F[X-%C?9 <1<O*XQ\E23$O^E$D
M4G1]#GV>AZ-JO5$?D7:84_ER1(IQ 28;CO0# LW.RY6*X<,-5VZ^!*V& -1Z
M4XS=B;IR8K(L!F;UV=/(ZW3^CZ]VQS)39Y<ZN)@01TF"Y93NO=CJ_3K<.%X@
MYL_,UY#5@,\LEWTS\G><.CJ?.0_:KCA-$1?'C6S06@'(Y#VCK>I!%LC1L+ P
M;E2$-F]6G /O>S.ERI%$FV!YXSMK.>ZEHL@1$9JH<^5$PIR-W$$0+R, Z.6R
MR)$/-6Q45=(S-%"_A=^.L@#ME*@.<N"$)H5RR;N^Q;>?\[Q-_G[:YO&SXXN'
MD;0"<L@$D B S!AVC+O)@(P,547D4(K&?ACL,<+MF?1X1UX#.0BB"1_G>X:3
MBO,I6$;^;CTG[C;R$H^(3]0EQ7%#(;3HD\F+,8B&SY$[C3Q7-FP*97 #%+20
MKDB& >_'R,EN]MPX7L02C<IPYA7&C1O0 EPL:\?(GXZQW=W7)-6#P4.PGG+?
MJZ:55'5P0P"@/, DM^3<<!3$'@5M$3EI '/!(<<[//RY?'B85^_E]7LG#71R
M,E3J?H68\BF1N'PG^XHD\A<DVL23U2):TN\K%K*R\L#18&(HJ&$O[BN4,G>=
MHR_MA72E6BH"A-J(V='"FBO:&2U'#_U?,*NCX"8O UX.64/.B7!=AP1M??+F
M]?W/;VA7^LOP,2$2YZ"P,!!S([Y!+<P5XG:?N$@+?UEY( 5&?'M:%*B%1K'_
M:3^DUY-YY8"H&W'DU3 V/"$1#<XBV@0)T-X4RP)1-^*HJVUNJL+B6AL5^)+B
M0/R-..::V!IT"O8+7D R!$%1(/1&G&HU#(Y 5!38A\^/7@1"O5P2"+H1_UH-
MT/F"HF!^O<TZ(D/[6 :\K[($Z+)T*! 7W-;K=?_)\7QQAGE9!2CXMNQJI7);
MZ4Z;AK[GTOY.H_ 0?%=TI_U-Y4[;-]!S@F6/M4*6M"""9ZTH284IF8M-4+&;
MJ/&\(\MB)Y1[+D U:SQO4EI.HLN!4'1LT/C]&H=)WC6%=U2CNCT>O&:<2;#!
M-8'N+C>!@]T]B>+\\&/FQ5_OG,#)C@3ZP7*>T!F4K'?"2TJOT_^]>5LVC2?-
M]EB[O6/#J7W<-VWD$A,3+]5A^H^C#M,?_I#(N^\1E?LCNST6L$RI_?LX89=T
M.2I-FZO?6GOCM9:LZ>P4QR2^":,^^V],=7VTI'_Q5CLVQ0?+M##]YX)^VTFD
M*;+D2#3Z%I;Q;D3NJ74PB([!::"96HT""@_#2#1U T$IMX,V,9@G44];^ !;
MK0DM6!!N8V@G2O;JA,4F8O'@T362$R6[8;"FOZMG( 2MH!UT6:(*4G"Q=>#8
MN0F=,F-O_<"6F#D,^:7_(U)PK:C1+MII'*J>U"8 6W/NJ$V+//:&7G^U2E\/
MFT0SXL1AX-S[NUOO*_%WB[!<:D;6'EN1!8F6B6GC4VCGCLAVJ#V:SEWE]!<[
MK7T/[?CUK)7/NB735>A$R\GJVHMH/\,H/MAL7=6"-(1V9(RJ,W"(K5"&0;C9
M>$E"R"2:;^_=_4\S$C^&0>S=^X3"U$Q-:G\"[> ;7X$:TH*M6CE$M(\CEAN6
M)9;J0-M:_RI:$ "J AHB#ULG9Q3VR:JPK]74+DE]O" &5$51(HI->0&),$X?
M9(PGT4&-XZ+FUO(H@QK%"[*PQ(&D@_WY:$P#SS.\9:CNO%P_M"X+]B@02X\?
M)5Y\8B);42"-EJ$*U+7WNL7#3FV<L56$L[XZ=KPE:]/P&U"UZ=J9W5AM6L$>
M6X'@YG%&'L,H683I^MW(&H?S!:CR=.VI;C/ HB[NED1H[5V6)R*. M=C4[@J
M,*N2/WK?6BE":]]>Q]%84MGDH5? JET,>FE7QD[">TQ>0YA*"X@Q45J$%<9G
M'8@Z-MW2+L[=\+$1B>4&, .9C)#(1\@F#K.D^4U(K+2 &7IDA$4!1C;1N/_C
M:/-(!:P>\IW^O0G=M;^$&89D1"T:8FZ3^F1[B90*%IW/+B:Q]'R3Z!-=ET&>
MWE1AI?L!S%@D(\I2#^'.5]MN2!X3+TZ>?W3#3;;4OB:Q&WF/V>LS5]N8=C2.
MZ1;DRHF]>+*:%KY56FY_^/#A]9OWY<7V]7 ^F(VFB]%DW)O<]*X^S4?CX7S>
MZX^O>U?]^6C.?CN=#>?#\:+/2C5?<]=ZU<!UV4."A=LNDJ7W/HV\I [.$P%[
MO@HD\JF3#>Z\L3IM8:W* 82<CM\&,MHS5.?;S<:)=I/5W%L':?0B-5@5"'BC
MM)(5;?[I[JX_^YV-Q?GHXWAT,QKTQXM>?S"8?!HO1N./O>GD=C08#>>7X=G@
M!0\93X A":U_;L-0#Q<;AMX@?+4D3\0/'U-';&HYN"/ME\JMP,FKZ^'GX>UD
M>D=GO-XDG1F11M7>_ W"S7V> H.:/W9 1GGX<^ME3D/U2--M!V?TW9%H35=J
MA1ZQ=0TEYW'O'3T2!1F-==M#'IWU2"^-V&98VC&"@R=V#D=7Y72%SI\F*]D.
M!I/QY^%L,;JZ'?;&DP76;'A-[@M>;_7X%)7'&8>W(?.N1!O6*\ P$Q1''D5R
M"DJC12JQ#8-A?N_<ADXP=78G[Z$5AL*OE17C5;]W.^F/>]/^[WTZ'FJ-!-:5
M5$'>O'WW)O-=T-_\<=H=V1D(+2TJ7$NY01TZXB#UD53ZQJV'=I A@:[DZX )
M8H\V7Y/(>Z)-/9%;+W]6_(O#TCQS4D13U?Y0=5G,1I_[B]'G8>]VU+\:W8X6
MO_>^]&<SNB5"L_A[D48!96F;IJNF,^YO9,F"EOHN_5.::$AO6FC0*,[<<>PR
MZ^@A8SQ@&E'71)]1&E-<FG:@8-DP9@?.HY<X_IP*[B:\AZ _O'[[NK(<ZT]'
MB_YM;[Z8?1HL/LWJ34*-E7)(%\')3CW>RN60G! )I?XA]*DRQUF/V/H7-J?M
M]^OP)I '%9^:LOM!%Q$;!LPX#%ZY89#0'WP6S!HDA#:?\,;-F_*X&4_&K^A6
M9C&;W-XRW]YHO!C.AO,%SO"ADG $40\G53TD+X,7A-E)4-8?K8$%JHP\I&!T
ME?T%<%1L&%RC@,Z9"?]1$3J@*JF^1N//=/@PAQ[2^K#0X;[O3Y('$A5_I1Q+
MT/HX8^K8%< 8XA9&'C-Z])3&CD1Z&\9*%E"Z7ZT.PM1Y3P+!T=/;2C3F8')W
M-\K&3GHHS"8F.BD-QWBG31*1=/97FLW@C"U0)P'#3K<=Y!%9B^+2P*P'G0UC
M]E_3*%QYR:OXP8G849OO\((YWE:".=Z_?O.7KW_M36>3F]'BU?RW_BP]&K[M
M(T5ML =?21#O#S%F)/&B-.!=<YC"&T$;I,4N#C>/?K@CY(H$A-+(Z(O3267Q
MX 1SRBFY<F*R+-:"C>#V/H(_O'45HSJXVX;<AI$_HHOW#5DXS_S9N?I<WIC.
MS\/>HO\_6)/QH<<Z8UI:"6L16^D2:#4KJX6^K%524UG+JD&P89C,B,]R2*:)
MXA81'>M4)$&(Q]M*B,=L>-M?#*][T_YL\7MO,>N/Y_T!8IB'2!CU,%+7Q!E+
MHGYI#2VM1I!'&I3"TG"K@9,-HV]$&PK6+#0C#4OACKKJ2Q3C17_\,0W-Z,_G
M0RQ/S,<P7'[S?)]EE2R)H3.!:3:#-:6)>@::V0"5D8==+3(K4QX8)!O&WIRL
MLX0$[$8PW1ORQEXU&&3X,8UFG VGDQGSWN",O7+?U<-,7 /I<*[4'[UC.4AE
MY!&EHJA\- ?'PX;!,Z6E68J&-#JR,.'R!E$E[&0Z'%\S=\K=</9Q."NN&]N,
MK3I^4M191;R53@-MQF")O@:/QM)J 3,N2Y^C8JQ6#:!L&#OS[7U,_MS2]H9/
M@H.W=Y4(D/FGJ_GPOS^QN6?X&>_XK=QWP,0CK($T\93Z YENQ%6P)QD%'>5)
M1B6['<,#<ME+<NGK724,!'[IJ_>7?<-_O=S_:N#&=^('=E)$_\/BC)X<GZE;
MVKL=Q$$/JWYNM[^T4"D,12K7BD016=YF2 F[G_;]B43W84S2LEC\3Z.0Y7[;
ML=,#]NP$$_<QR\\$5 %X"VC)5>JJ@2XXK294:,/[<>,%7D)NO2>2O7^X@_L^
M.%71TJK4Y0\,!SIQ=T[TE23L(L/Q@5X58[(Z:*E.ZE*E!@"=HUN6KI7<$B<F
M\ E26@DMQTA=E@ 0H-,THQC2S[/Y^_IX'YJE. UBHAI3H,IHSPC5I4T#$G3Z
M6*XB+\IRB6:7=QU_LF+7%5.[G1ER\/"KUQK:4SVU)[H&H*$S7K@3!.955@?M
MT9RZ[*D!L("C>_B.@%L8[26:^JP(14:GXQ"S C>$PAIH+[347]7+A4=GYQ-+
MI#Z,$V_C%+(X5#DIE\-[ Z4N%7Q)T0F81EX83:E5#9<SXOI.'!\>TNPO_[W-
M;BX4$FS)G!NZ+>&]55+?RU$/+72:BY&M>5C1((QUO)?0!O >$:GMP=3#!IW+
M,?E6D#$* _I/-PV/SKL,)E6_);P7/NJR6Q<M=)IG=/L9; FU,^$Z2+,R@7D%
M5,5[<Z/^SAR(!SIS0R<*J%PQG2C2NP5@WI05\1Z[J,L:$ MTSM@I<N)0R1S_
M.MS>)_W[<)M\#&G7!R&U%Q'D"HY.&U F[7&<Z".$3NHA:<ID=>.Q!UA8@N]C
M>A:5AQ-8'4JE/5X4+5S.)WQBP<Y$N,$3E2O_.L$36;.7T(DFUM5](,LM>[^S
M3_NU]/PM<^$=CZ^&SZZ_I?IP0U6;+<>WF=[0#7-I^H!880/?.K>@#'-XVV -
MRLD_Q>.>DZZ@E (4>7B?=R[0PSR2G9K<$8?U:CFAVVBJ:>QN>IJ,'3!H]5M"
MS_>FD4&T+D[H"ZBC'9F3Z(E:'G9*EB5E9$8HT4GA5Z<M[# H+9;K@V41S]P\
MAA\=+[@-XW@4S"GVV>N5QY4CG2O2YU+H)D!+#5K[%':P54TM:1EJ&V9F2>Y6
M\23->71&DL$5?<*^I'(]M1BER8UVNV#UA%.=HWAFN#):6OD,^J*A[22Q1FA
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M"%.,YFI.SLM^-QT$N>3%]#>7%].M?C'](W&BQ0-=KCV2;>*Y\FS\HL)H2<L
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MDU#O2_._L/]W[\2$_N;_!U!+ P04    "  *B'-<]%J+#QE)  !UV $ $@
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MI^#C, !8H-^+S(RQKC70-\['U;0HX00OAL$V_PYV#!-51!R:6Y*I*5H38B2
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M5S;1I)J.?@&Q_)M_G$I@,<JJ$8C')%\&T4X#-,Y]G+_[[M!8J<OY[<U=SG2
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MSF,V2L=@K""M*@\A!L#=,A\&A\ #UL4;%R@YW%5@>Q,Z,CM"5WVZWVOT6>N
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M!3E<BB1D?(5)C7E0AU/MYR0)OZQ%;R32C/#MB2RNSB 2L@BSI40"Q91"<&A
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M(!^U?+?5J!_-F@=_(OK!T[1GZSAG6"'[]X?;C_'C0?;S\:-O L]P_)[K#8T
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MX3 @TGG=DVX>V:_^PSA[@(Q.XR7 EC!YE0#;.H!MB>5,VKPP6..:?/8ER!8
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M[/B6:1G>^,ZPV76/FG^IASYSY2_E=I?'7Z3C+P+OGC1D*H8]_Q8K27B6TU_
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MH^P9MI_FE">90EYJEH);MHK#+>]OVU=WE\06=X)CKE?1$(PSB(Y9YX8BO0>
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M8!BN##,/]-]1Z/DA:L6!"V-Q^;/>>-5YK<%E10M:NQN\7>F\MD<KYG;=27U
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M\D/0T_R!BV&G,C8]&!A!FM\\&O[D?:0?BS6\!I;CF/JK!E]C!Z0 ^+[S%5:
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MA4_ P?4[H\>"L7YF^6C4#;TM1^AR8N-2S\]:YS/%NP6*+RR.IL3Q-A86<']
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M-Q T'(0-_:^X<GP7>4]</TXUN#M/ED3//T^Q6([V7[%'MPC,2<055#3T>_,
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M3N')$J,(431H<B?G(X;?<M!).4&D"'%'IRT%%#)B\8),>$ FU886F!3_4"4
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MF%3';672FN7K0PHWZS">$S;R*.M?2=A'A5ZA'>T/T@:G4 S:M?S^;R.[5A+
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M1.J@2 T41?$4S9(B]213YE%K,!;;[V.JN[0CD-HU-+#!H><"G];M\7 T0)L
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M]HFVH/X8;%%)C8*L@ V1WHNP-=P66BI)4D*.TN_08^VB8!55:FHO(4?A$[
M!U9"GK1Q=%DXSU1\U^KMD>/V75@;!DV%'L7KR9 PTKGB!'MID)A@8^OE51L7
MLDEVGCBPN"(1"=!X0?YI ) ]<C$W)X5GW8_&B&/P)@O,W*8*S,P" J%/$W5<
M>D+PL8BT <$@B2,1*1B_%WFHD+)]::.)SYD+T/LZQF.*YKHNQ2%9&(T9D^#
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M$R:WU;]W8V#$0G(#<A/@X6(&!W<><$5=H\S#D>V.>7V /A4\Q5HJP0#DY"H
MUNFC+4%0J\A&:5OD_J0NEU'H@71(\!0=]#R$F)SVQ+/G\?VBCH!P?-D4D]!G
MFN\.HP)DV *+DDRXTP/)ELW(L$%D6OI$,)F60(R0?8P*@KRDPH3+J.$W,@-,
MN^9).O2(HH%3[%F]\0X-/BDWI LD'C-84=,"\H4M0<FO(^LB</I"L8")RN4#
MK')-O),*S5DC3+YF6IR,9LC4Q83YR1R#K@><1<;PRU(O29,7'WT?RX'H[,G
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MDGQ-:2T0BARL9+2<_I<; F9X:IN!Y?YY4V7L&QQ%-JE=JX!F"6GX9XM.0K\
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M#J7\7M85-("7V!_"%P*%=K<1FX)$B=U%4$I(_8Y/9&R%,=(*P_TKJB>&M/-
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ML*T.,'7:C9Z<7E)(^$6P3Z58,-\BBS93WL(Y9BAN[YR255VXQ6J 76JT0XO
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M+27ZV-(OZ?[ .%T^SHTX%WBY\/M ,B1=*5,/@]<%7Y=S;M$%O8>K'RXH._'
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M=NVZ>P)D\<Q.3@PK<OGNB> XDEW9S9$_M_XXPW%\WVT1*]HCZ)*IT:%'L"'
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MH5>7Q50"9WWP_J1?A!6$,BLDQ2?O@?%33F#D'F]]=!^#$2QO*!+2:/RO9=M
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MJ;[)4P)T<Y3JZ]_>EV"A,X:)(W9DFP]<!CSB%^Z/YA)G^L0Y/CP!RNR<:(X
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MF(7B/%KM ?8SR#XS5Q\P2RUL#D03J*DQ+5I-E&HP9!LB4!^PJW&S/+IEH(7
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M:CM2;4# C]65!JQ-\4L;WD&T1=3$QZQ2C!NR# 626H@'4T"%J"=#'RBA>J'
M=>0J$FO]@W7NRND<U@)MJF3IA@WYZ7OE#C/"HKU3!PM$(<ZFU@W1P\1%:RS'
M15VL2(I)3C[+SCM+N)[K%4E*"#+^: [&BDL1<G*$GWM8AC>>!,Z+14^4S8O*
MEV__ZVQ=F[.7R[(.:., B#?4121=KX:/2JW:.+.HDXYG(_C?()C6D@1WW\L'
MUI&Z1=Q  ?U]X""#[1:$NQH>"GKVDF=0['V7 3@<9>E:,#]*AQI=;N18&W_M
MU #<R9=G;>O<>6H5I$"MB("S*D"!5VSJLC\2X15(&K*D6(@EM>576^ +)H2"
M7 *$ C!6\.MPL/H.Z'"_?E24!>/)LJ01!I+E(QJIY,9Q0Y,Y+]3,LU7!F>=(
M5;/? JM$>42<-%)'OY;\;F*(GC$2PZ]K-\2$)U5G#JPLL*.&)-?6B#(LF-)A
MBK+/!84(IP!TS M CF2-C=&THX2D IZ7-N2=,\LR5LEKM9\-4CD\7Z*KX%,,
M+VHW>4+)G!S..WK^>D'_>V=__RXB 5Z\.$2GR/W&V25_ ^$?(%(PN,%JW<P)
M,R*(1X J2FA6M!"+Y@8]]XJEX=Q-[M-.UTM(2H?@US8(U@YM-W@G:+D1_YZ,
MR]*"M2S:I>?JWO#NQMX,'YV094/DMN2A1+R5!<0T^R,Y:_&!->1T0+LK_=9D
M.<$$X8_WW# WUB.V*67VFJ*8Y+6G\,)C\Q".U!PC]L<PPB-3<K!/?C*?I= '
M3@A2 NX2H8>'201'&9"RM$NTR1_?>]?18(UO&!7?R?SA.A?)$;4FM0M/DZE/
MY*!G'/TD,'?P1>$N@E[S^X=7I6+_C9T+HYP+HKB2L%$LJ_:NR*W U8JN%>ZN
MEOY!'S#B#%NX4&JN%VZ05\8/1QG10JGN22IAP&8R(GQZD=R;"_Y.BY)NZ<P,
MY0/@8(#4 N"78%QFMK+":&R\^:&_S@MO((HS8L[;4',==I)CW\B(R5K5[LQF
MEF82ITX"E '?I+6=-!>ZF+X^[W&Y&$X\TQR#V<#?8\)8S(6_5FPQ2%\(V)!D
MQ/SSN:$\:;)ECQ]:3-S$'0PJ;&X8ID*-\'HL]G:K37NW;GN)6OF=FUKY9ZB5
M/[RIE7_YV^U*(4YVWBH8DE0'\81RL6[=<&Z0SCS,O1(W/QZ\K&/F<Y5\2(;R
ME<B"W<0XE^G=D.@1/6]RN=WY:6C BZK? D%)D.FN":5YKK(<JD5#<>3[7)-S
M7G[.T+-1B0C($AELUW13!PYASNU[$HFHI1+"$:H-]Y^YEF8\O9 BC6#N_1NN
M(J#/">^:T&OVR/O%Y^+2!.:YH%6S(>9;]W"4$<67_P$I (Z%JXZ>S85G)Z3X
M$;:$#P;!Z0F[ M_P<59E>499E,'3$?T_Y["*9KY>MDA#&B7/,:<?PBQ,AM4E
M)LLR'B7JX-L^X7OF$+ZWM)(^\]X_)C7UT ,X,]43P $D.MPMM.U@GNS8?0T"
M;#^WA^1FORXQ^P:><X9]B^!A2T>@>6(A1RHLY=/#?>N''XZ_]M'$Q02-8D16
M</<"U)8@%3"#1OC.KFBFW27Q(N[[)K3!0)R(/C,I72P&"U;"31J&VAU21<5E
MALYB@@!6 ,A3_W0LW+Q8[H,+CME0],NQ2(6MH+Q5H'R%PD=96T SRP4;J+>D
MHLT-9"%Z/=%TQ'H=V*R$]X!BLZ'N'WZL2#VRND U$F9V21(683.JA9D/-O#(
M:7 = W!_G/;;2J(2'0>;*&GNRW63B7G5E*-K9$-"^D$GRJRIL]T"CA'22TF4
M! 4VH]!=E'R@O4S: "0,PR5_V&)/UR!.ZG:"VVNU%J09G20\=-#QQWB^3J =
M_#QN2&S!#+J]:D:KM9FHEC%0RO=*P@?2M#4!EZ+48MPME,/R.V/&PV6-X#(Y
M<_%>&11XS^KR+,JU<"<;71$X=\8XAOR=:(41TTZ![79<^\ZZL=]IE1BZ P_F
MV)#XIB?.M$/C$S::BKKX:-O4A"0-IB_"6X[_5@^I(=(BR,R2_P%(SO']>4YY
M*TY=@?32:.]I;W=&I$P\/L.^2F4?ZL""E,S<>='&'$AR&T5KF->VU?2)F?K.
M!,QCZ%1BZL?HG]:5W=Z0^F?N*Q=6];U&O=.>^<4& D\M2C?6([Z I-NBGH!G
M:>(A+X[MV8W"]\;T#8Q.!Q+= UJ0>MTA%&?"(:,U/S@;"!;1!XY=6MG:C)6(
MF=%C1,/YNAZ[1[BI%:$"Z$2^4GJ<.";'7;-&$9AK2+( +PS$&0(E1AB-O"\&
MZRUTT.:6ZLV=8;<NHL>5A/<\:T^3!3C)48[[C-D79J@2)H1J2N%]'?'C^.@M
M?&,.+?*X9>GK1M\^E?.7G!PD"X&Z YQ37" O"V>F<^_R^#YV?YG=2A7 I OI
M3$;P/W=0\#(0WB:8PQ3$"8*V6PR?XH.UQ]%,U03$\2$B$IFA!DMF+SF.QA]6
MD4>_B],C%.3N)!?>&RC:$<0N0B!./EA8D7AU6L;)>L4]F39KX. /JS!Z1)T4
M,')8\R7X A%#NKN(7! "XXPP$"R=(W4(5E^)[_2R5DM1X4H1>SPKA>JFJXU$
MWR+X -] 3P3HR)7$!M=NPH]]K E%N3;>(FF\00(/EI8FEHTSN@,'6SB\0U73
M1N;< 7K92L<5<*%MB['P8[W+R7T:72"X"$HTV$9>%%RAM?O8 RD)%2^OXN8)
M\U">LP%O.7$?YO-00YS2#E%OF(;&&WD<0G%PPPC0!^BU$9Q<>3!YI!M2Y&MY
MVTO4G^[>U)\^0_WIVYOZTY>_W2[C13UQ;OLYN!ON?WP*^'!)N5;X]Q%(:S@O
MQ#R&M;E ]@4P^<\KY].LM-#)HPTF8 4I,D0.15H2SM[?AIPP%$0TN@C->X!6
M*2D]!%?RT0C'!&:4Y2Z,>%<^LT_<8<O%&H$9_H; T;=<B7*[OC*&II!\!YI"
M%S.>N5<D0EQR-#_=U'QN!_?-".\CKPRC5T9RR941 $M/OG_\8^H72G_R54*<
MBR88>2^<7P U'%@],6%D2@(*0BW$B5I:96YA.*>,Y>=S:Y=(<IG;ML!IE12'
M./*/D+.3G[,A%\8YJPV1)@&!=4;,H5,$J$C8U5K]4EQK!5R=$%X&KDL$^.GE
M-[&P]=ZQI25J<D\LFIR?UD1077?N_Q'C=BY2&UR(2);64X,/WQF R%19D$04
MS:$=?0*<$PQW0Q-1H$%U@05F/O%*ICLE9W[*LEQV_?ADI!I;+^UV0\UT0\TD
M4H#AR!@N<V@= "8<"D-8?MAS[L-&U.L<[-Z=_>]F95:]=4O=SM_B7PZ^Z_^(
M3 8PHA'AO4#3P4J$$@9\IN,E?(2(D!BO:K&.B/4'Z@RG' YU6]?KZ+Q2_; :
MV3$#^GG*QJDVMQ+BJ7+-N:/Z')243HL5D5F[1^H@;XL&L['-;A(G81U9T4YQ
M9;D(BRH<8V /EC2V_.6(BM@?FL%,XU( T^\&?G?'ES(94]L33S=HL>%1XX)"
MB1SF;A7/-Y#)S#3SL<8_CY]L"*R'G<#0Z=Q=X)2P DNI$H5;>H #>1)M?$)C
M%F)FT;\(!8^2GX[PQ</'V,WISC3?12).DB*9)H+:\P:@$2B[TH*G<@L8*=WI
MF"FI%?"49 H YTZ@!D!_CYIQCU)!UHQV[,:DZ0S>5H7U/' VJC4U9;4KBX4=
MH/$3E5.]"/IQQI98!1<("K!+6!%2@=%C"<Z+F\+0#:1'U6<$K66_:KUQ&5U@
MYL8K$*,3BLP,T;EPCKFY'AK-;4Y- V/A AE]YP@7#<"JQFQ0?#C_N17S$5;)
MM3=#W!M:*@UH0FI0LI^".*9-@*XOY^KE:R%$&(\/]<;E!;2C@]O?73*BF7-T
M4(+;!?+.D<783AEP2//8##"G;J/]ERFU:;39[5TAL V^&M G_8\P* ?8)B
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M%,+X9F/8LQDL79S"@JD+:<7[?C#1!D3'F<+EJ)<N54*(\6:9VBB&5'VW75*
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M'QJ(EJ8>^SNQ)EA.!'O"/--8=BP65QP%. 66!2J>!KU1H@*$+8>^(O*<;MG
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M7\:B0AILC7^R4'="'*#8$/DMC"E>OW*^%EX>7BR,:^16SNS&G8.& \DB1/2
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MU>'+?==K6J,#;5FO*\8("LT8W.]OW] U>BA'1"["GRI[7F+ZIBYD<,1WG2#
MO'&^QI?UX].L.J&RX&-B9S;'$HE>NJTR3MT!=QO1^_I,-?7,NS 4[P8.&))2
M,QVT#WU37A6MY$I,NRJA9QH9F%IQIO"/Y,3S)8H_,J:-5H")+(>!HHJ)!,[+
M++<1!0,F+4$XF^.%<5H\ P3?S1G38$V0(*4]B.7%ET60.A97?,4PX3M)6P5M
MB6SM+&B&QV6Y,=@ 3[NYUQ!QB5N.D!".]((@[IA0HV>CUQ]XO/#'&-?J";^X
M);7//D5=>SX%FXKY4X(+,3'%S1Z>V,,,.[;)&^@W(,:P*P51(7>$\T'V( )#
M](IN_91MYK'/W/3 M&63G9 "CQY"?0A$-IIY'\-<;(/]J#(+1N:#,DO=#)^#
MN4K</O,'UK#O:030OVL@G>?32\"H)9 2^:%>2WJ#]]:5($V<85J"V#'CHYB?
M;SUSS].M.[;#V._@KKUNSBA-#T4))-##HD@ XQL(O"&IRZA]SD9]G7H"#&;>
M:ST\H@^.:#UR8]T..$OZ<7YX"Z)4XLJ!.]R@4@,M8^//@U4GO-B%KS1UB0#D
MIS$,0QB/H%G@/WO</Y@^K<+I..9/#GX4\KXR1&KSBB#,"-#-#2[2A_K23 [G
M E%TXLH26I.HX6/4SF V6%2T]=TI'RRHH%OJD/*]V\7"A$/HZ\!KJ=_02VE[
M=I3 FTKM7/! [_OTR2U/O]F9T)HI%\"\YK;?\SJ>>&Q5^5JPGRZ5IEO1 ?PU
MF#4XI>$US/M,PH?938/W( HJS"_HH4K>?ZA4V^DE5S2131E=@1]9;E<>\?=>
M\(;;'.E)/_R8A[ NO(UDU+U%Z6H352[=U^'"WKA//O[NN'+1*1F1^IJ+ULH%
M:V/"Y4JG2C<P<^S1I*)( OH_)DC^I*'N*!P+0VNHN@,U1Y+^Q@R9H]O.9IY!
MEV&2'N1D01T%'H,R'VXE40@RIYXY[+5#8QQ%:EYK3S('[G*"1ST=E[,;HPB>
MML0 5C>Q=0CW[+7MR;UG;$&DDSS:X@@#R/(@:[1)0&>F/D_Q^T#EG*)"$M)M
MPYE<+(LR:Q1%G$!CT(\N< T$%U<2)..O@[ #]RP;O\=E_,5K :$YQ.!T3&86
M_NQV06615QA^:11GG;]D6"F#<=^=+?Y>K)UN$G(.7\R;@"BY G_GV!X_S4;H
M)K,E:G2UZQ;$NF)2>&$I#Y121F7G:!%YCW+I?M$4"*<IG+=9"+UT0=X5GS*U
M5_;PR".AGN<5.(SL)'0#[#EVG[!@HI%;TDM0+@?Y^1@X($TAOEW?MS+SLI3N
MXD%G4;80GE%8_-!^4T&?#M&U*="UNZ 9@[GG]0I>UK.\O^P%S+W;Q:3PD/5Q
MEH.8)'AB*,:AQZ(/@F/\5](\FY+\G?WSF+6X:M#FY'F%UC6;TP,<=QB4/[/0
M?5":YQ42D$.?_F-8%U1WN80&UT<3B]8O(V/V<6_U(:34<#0AEPBC"23R\]YH
M"D-<XW6NH@+ZI82=F!J )6F,[ZZB&^#E!/)>Y?W2PZ544/#4S\\*%B)AT1OX
M5=&P?^Y>$]X/O^4VJ:':F9S;U!?B^^2W0.T!D5FT*]((9GM&7_:B5YK-HY\\
M'=YD#$()O3E^#I6JPDB7G%=&&.]'@RS62B:0'V!=C5]EST3^2!>M)!'+*P0U
M@9=%GM"LW+2%8J?,+0H.*(5+=E'3<"  D#9U*SDG/A-W'GKP3D3;:9IU20*1
MC3U9"QT*-A(UM9L%]R#J@U2Z;()N@F)"X H#TKOX3$B>(_LPR$<YW[>LYUD9
MTH:P8A#RNRM @]VZ[25@%0<WL(K/ *MX< .K^/*WV_M&0R^U6%_$U7MA:/.]
M8/:1_I!JR54-9II.3Y_U"\<=\ CQ=7]:*7Z=-"XD^5Q$?5*YS9.@LCJ>=^0;
M44["'^B0BJ#T, HI7\#)0Q'>)A0M>_UMX]TLXB><V9Y6#Z88?#U ]X2XX6!\
M@RY,K;@#E>M<D-S1S2<8U/%K2C);G9I:5L@-M/7*TL-0#8Y+YQP4G)908N]R
M73V,;K!&1NSR(Y-Z9MBQ9^'JOT&](GE^WQW3C#[>2:$XDC8A#"1,NB9L$V1P
MN/%><AQS+BDA:^A0H38M,#X5KAW*VN1KBJ.1#TO<Z4AH\^#^G5M+(1'4'A:_
M>U\)BB2Q&HL<7)$2%-[3R'H8<F^!0XW0?"^L%9XO6OZPW6;E<(^X5RR1]&[8
MP[QK&9\0GUS-P+UY7]W6GHSB_\_>FS:W;67MHM_Q*U ^Z5MV'8@1-=A6TITJ
M6H.MQ!I>48X[?>M6"B0W1<0@P!>#9/:OOVO: P92E"-+MJ13Y^U8$@GL8>VU
MU_"L9^D<!3>7YSWEGM-SM,VE!4MDGEXE')>.+%XU02]BZ3NM7U$2D0M:NVCX
M<UVQ6AF+V.1V=$M=@E#HZCH\\VK^TZ%1Z$T-2">=?%X!S(A+5KJJWSZ'UM&R
MOA57Z4)>,Z^AF+'_I0N0L\]!1<MXM HS6NL33$Q?UU+#*A'R7-2,1.UT,8Q7
M566B1Z1?C<;-X)VD:4TH",8!<7,^T7$#Q<&(=^/IT)D6W]96L&' CZ/JBY6M
M9Q0_!XG-=[3:C]/D8HU*;#6NB]0RO#U.<RJHQ)#W%2*YZN+# ^)@A-Y6TPFO
MLJV>W59Q[NG63$9:6DU!47T-%RT\=@+*Y=C@YYW%:990&CGWKC$E)(Y. J*C
MB8M>L\CN\%>Q.SQ>K5LQ-M[IW8GD6R ]5#*+N$[F*K %_[5!>56"PIL.*G!E
M&"-&C6M'5KJ5/*,&0:5CC,)G5]$]%GIJQKIJ/3I+MNLSK\=2<Y!6P+OA"@B!
M9FYMJ7P"5SR?*CI(;4<,.:8P@$R6 (:6E22IE3X$7L4F4B:=Q?/0FJSC'S!&
MSYQ%6IR8.G_3#8)!&P05@BJH;%@%QMBZ)*%>$%-]WWJ\':WMKG*SN45#J.T-
M9+ :B8, U0S5.L/EM9F3"Z9*.E/D4*\@'6RJ*3+H37<TD:/S:YJOL/C8BHAY
M#:VL]\G5):N]4K]%+T62NDM!M=OM4S6[WT"26X5/&4V$&Y7,M'/MH@7:H)3K
MXUHE;Z7 B]SVTW+RK9:@G^S$BO"30F@BMS$29/FB::RT#%I::.VOV>5SQQ$3
M*RC$P"I:#C5+NPT_IBVAMK/ 0E>7D%47T4EU+;@=M29L%<R:N>#):ZLB[=^/
MRQ'427"K#IG_-1RR:AD#EY8R>$%7'8BNT28ZBRLB+G@^MH:65@SQ'+!2[.,A
M]!;'9'T[9T9MP$/S@L?F?=5)WZ1T](;A)8<&<%GJY1IKSX4#6RU!MJ;X)LM,
M/.\:$Z^>>B+[#27'8& B<S;L="(R5#@;8NY]KFJMWT>2HXHJ?2'U2I"O20WO
M$#=*&I]AI'#\,*N31?DG'*C#,T8="#F%;0;]?$RJ+80SHHR!:4],;IT?#$>E
MV:<F]4S$=C7%R GPHWM2<CX-%U>B-TR&'\=V<B^"VO+4[ 7F(M#[R]OJV7ZC
M?V,Q*'X?V!YZ1DCL6)9+E_=WW(.66&142&OOW'2,646@O"4"U7,F,PWGCG2-
M$>8 UQ!59U7P5X<)7;VQ?X;8.!AP7_/6"-_-YCH&Z&H$0UZ%+BR09I;M"Q?4
M^?/LU_[^DE9,>[)#2%%$-ERPVC&MK>2Y^T=CF++=I#^J6:T8VHZ3<OQL&UI!
MN:2D2E%W^'7%CK8;*(*Q7/<-E&MZT50L@)Q+I&8Q]?&:+_/=A(B!%$2[HDR=
MOW[YJ?/HU%T3KOT"Z\!GP\"OVP0+@[3>PB#M75I,]A";*$DK-N"QY(0?UVM7
MR(!O/&7 [R$#_OHI _[M'[=;\T\0Z>C=V$FIF0OM3HK#X%Z[319;E0M]%B&L
MO\9I:4#SO]![\6[HO5##M4K-LPT'$7N!)DFH10JN-:V\AFGE?T73JKYC%?O*
M:[.O_%7LJZ9A979SI4RZ[V;2O94SZ;P9MYU.K]MGWE>PSQ8GT1?;9][7L\_\
M1?:9TR?AD<5YFN3;/I-O_\U(ST+P[TU 0M>YW4+WI94?%W?2H=9AVMOW4:Z-
M8'JW>AJ^W%OQ5CT-B[;JX5;<D_"?O]OW#T[.]M^>'!Z_]0_[_LGQ^S_\GM__
M<'34._O#/SGP\2/[!P?[N^>>_/2AT^_X!_M[^V>]]_[A\>[)T;Y_WOMW[_SP
MY-C_< K_<]H[.S_</3SM'9_W_=[Q'GT-/@>_^,/_< S?I-\P0N5_/AR>_X'/
MV3\^/_Q]WS]]WSON^(?G_M[)?M\_/CGW3S^<G9Z<G?OG)_Z;?0^?\W[_?)\>
M;#ZS=]C?_=#OTW-A,/"VXSX\>A\>V\=I]-Q!R9W4]_?V>^?O_!,>SNG9R>^'
M?9A$7\_;3LY_W_O(SX$9''TXI@>]AX$'7O^\=[X?X$-P)0_?'L.[/QR?G^&<
M_(_O#G??\=/MZ_VCWA_^V7[_<&^_\_4+26Y5E$AJSA3U-^U3[AX.T(<D@YLZ
M+\BBZQN6Z_LI7+FOJZ1OFB -5)Q>^916).).BJ$A"5?&?#.F:X<E)W+Z)MOB
M:4G*4I<5AQ1=V.![R TIIF"&:6N%96T:6@ &8]%&:>21,7JW[,X;SK[<8XWT
MKV%2XB4+6F?3O6\\67A,YANR--B=K<W@U?J.LUUX#0ZY_)17% M>A6A",G98
MM9=7R=7(QI;..(^(57O9@IOPM889II:VJ;X++U\%KU]M+]N%52J[*(I_&6;8
MI-N77LI@[9M:R\#DB0PQ*E9^,;T'L1_X(9PE##$T@2(_;&YT7J[;(FY"+YS
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MYE?8SI=F,[O?[F9^+QGJQ_7:%?+QFT_Y^'O(Q^\\Y>.__>/V11>%<?B-V;?
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M?KV7A/$<>Q;"DP_,FW?UF^D59_;E)_;E]FW<!(<:]%%?/ZI_7FQ4H5XNV,'
M("6R)WEF#\&#Z/@?,>4,&X\(TRO07+F94*YTI[)/!M=YI<PFR6]*C?(,]&]
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MW]U4]:T<,?\;E6[Z.5\0FS]!CQOI'ZC--5FF)?/<7N]98%G!2&*4U G',=7
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M)R8<5*0>X6_6]+U"B1X&LFJ'BX-"=#D%IM9[D&OJ1/Q1IA)(1;$E2<&N=##
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M6SO/1KTLZPDL?P_NF3^':&BO=]>[?_Z)_^IN;';__._!OV=7OVW\^M>OO;]
M%\=AGO.39I.D^//L;?S?/S8^7PXW?Y__I]\K#O?C<K@1?_K/OP\O?G_WZ^0_
M;^/R/_,W;X;)KY/!=!0//OY>CMX=]> <1)]_@CT]!D<EHX8#"8[_3(W_]>P
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M^9MA^35TW4$F5*KUA6@=VK/*.O?RD_'"M7U9/8I).1VE!4+IIV'\S)=_P%3
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M8OQI6XSS)$HSK_DH?L6'!$>\*^VACJC+7JX?.^?'P$-_+4&YPP^OG6>V#.]
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M*S4R6-^?;]C0K")"RZ3EFQ8/]MIT>;2LF</STDS]M^S7XUPZI+*$$X#8()1
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MB)7N+V+*LMDBL  ?^M[C-&2K8*O4+H=&V^1B'0W,@1;0$[%6"?NK]2-@11U
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M*O6!<FZ9(JW#,"SXPD$547931RQF58V#HU 7J7 K(TF+AF>88Q\8_4#Q*.J
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M-RR;%[<"9W4Q'80G>V$-(7(NKX_H@0,"G$UHU8#WS"6Q>\1F5BY-,R.P#%^
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M:>L.F'P>0W2)1BD=9].Y=#3#R.W3Y$D160O4#EL1"94,D)5LC#T0\[=%\QN
M6L 6IC_PK7!J'_<>H31+G^C35(L)*XG>QCX.*>=XS"E.U.IV1YB"3M7\8&!I
M_--Q[WB14A;;@7)'<\R1++&<1F1Y1=Q*#I1%T3\P,]43!-Z5O]?*GI@]I<?5
M!.R1I@KP%SR^8JJE142TP'HI=3$%"P S!,6G-YZI@8-2>%2@PM'Z*)PS3&/U
MCL;J4< A=V@)DVNQO%"F5U'.S%)N8$2 90>I!0<7C.M%_:M[]/60L^BY0CA*
M#+#4*\8XC5US665U68J?7XW/4O5F4 $PYL-TX&$-,Z%8P1VJFVDYYPDY=N/
M<HM6%'C"&_S"9!J10US78&*&)3910@Q8;2Q@.E:LKM[#V,=;D0=6T9JS:%:/
M81"4!+Y-YXG7U2@0/^+>/-6R^(:9C_VAGSA=QK]_04-(=T?^])ZQ2&/:7V?U
MH/,SL]"$\,0WE>6^:(?O_1Z9*ML2RV>E 3JG9]D]#CZ:RN)M0.20!.@1--W
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MN+OV"_9<>8,AV3Y+*;U*P8<!>P.KJ9S<-<WF^#++YX\^B%1.K=H>]P"%8S_
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M#B?[FB[)NOWS\PDZ&3S$&-I$D>AV8N#L)N]9KWN&0R7&-H[H^+%Y4J3M\*=
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M-[7\;/E^G3^T@+5VZ";3#Z5,/&DZ%&X)23!Q\6R)%UB^?&2V9 (01E%:8O,
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MR(Q%!L@,>A0@5@FP)0FQ"&C:!+U4ADHX6! XHJE,E:6+L]+'9"\,T7](\YH
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M#5E.6: -Q>EKB3G8W$0$I5H6Q%13R7N"C+Q,P$HL Y\MT.TP!@EQPQK1[V=
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M\)$[1.]_AJPBT1[XL11!V[%NJY"NO4%W-]R W*.O24["UFI4HC+ P7&K"^@
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M\')S=&,BZ">2]J9B)!8ET,BF)&T)?L[G_R()3##)]U6V.EL.11JX#PIF^:G
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M,(-YF;N.D_KE;-=QDHMQU5567*_;]55QV>K@3N#;^7<AX56%;'27EY=X")W
M%G/%=1.)V RQHDBZ-2WW]*5$!MX@%WV#3=D_,W#[V^J88EOLWTZ,IX2WA3:U
MRYO))R:KO,!RX425"8@9Y9&:X28L*EZ0_/&85L&<,IA!>MIXV6&7"TWWD-SZ
MOEP7"CJ8? ,2OZ$B57$$=@\QBLX79% =J()K[MC7YG0YZ=;GE\4W[;$4V9 B
M;,^;]<0-WXWONC=(T_ '#*,B&B#)UU+9^OL);QNU\_NY*'YO_;B<E?L_(L.X
MF]U/:!O8V/>S0<K%IO?CKI\/&@F"*90Z;[R?"JQ5BHWN8'+0//U]IU(*97\J
MI3NS(BQ3TIUV$/C[WO*-$]1Y\VFQ?)CL.1%2"$V$O.@M;^_NVK/6:]-\&D(B
M9/-GO7/7.+^I,_#HI\R!;*CHUS.3(##)=A0=VQ9"6> D%9WD@A#3MCW7(0[F
ML6AI[IGH&6X&@53+/3]#]AAD,TS6:1[GGDG%?=,IDT98:358\H;FH<+<K7T@
ME:,UK#C9%E[>1TW9BG6@E4FNU)?9!F>Z2Y-![-3]C?>E!![(U+^3!V.+DW87
M?$T?O%T7S)%M@,.1F*$XL$9S1L] #@9!2' _6SY#L*!\->2D]-N +7NI/\\=
M)+4)O/%OHE/#0\)D-&"$ZXLA4 IA)TB%!5RZD/OZ'#H\H"/G8 "?J!,%ET99
MM"$E)Q]JY4)1JT$?[: 52)IP&R<86!.$.1B$1K+?THIL;TJUV/BUR Z4)QO9
M&G8YE6A&FJKQ(!*63E<^R_*[Q\"X9FW$[-W0SG-_X0&>T A@2C.C',Z%H]8:
M(*1._(^(1])0%^YATE]0+DCRO8,'7OIZ"5AI8?8H2%QTF5&0[IYWS5M<F9KI
M3JZB:1I.&I5! ]JDO0IBX(9U%JM%#<2JX HDNYP?LV,2@?3.9H18(^YAM0AE
MV? Y9NNSR=P QX ^IT&.N4J392C:N<&%"[LM(\9#TE^9ELI\GT\6&4Y@*4W[
MXA(6I.5W>3 G(16T(:2E88F$7@IN7>HYAZTY_7*(1PWA!AE"QZ)70":(Y1CT
M\A93RQ!OOZ7:T:VI,L.5+64O>FO$]>?9'UDU<$FF,A^AFW36Q*EL[@1#YQ+Z
MX@2G_T(1HQ-#6Y&W =:E$&PA>NS\X/;;EI'O-SQ2P_D>IC>O+=FH-*_+[@GF
MOJD*+H#&F& >!(A D>LS9;9E>(D=#CQ7@J35T+Y5GOQ(3*6F#\M6<*,8DB'N
M @].$O?Y#[*Y=*+)KXNWR<^WQE76?';-(K<8A&\F+S3"VB3CW >32/]$-K=#
MI$EL%D<@36:5\5AYD*[8R@M2Q1"_IS:SAW_F[0RB )O L',VH,<],CD,R$.*
MJK;.]I:UG\W;3N[YKOB:3TU9,]];%NK?Q_GRQ<\<8C!IV5:]MQST[ZZ+^?=L
M[FU?/;#27FW-A55;5WM+61?ZBJG7?EQRIVKK?55;<Q]7;<WUEC]ORM]_9;NO
MYV/E#ZBVWI_?J#4P->HUXEF2+DI3]*A-0*JBO>6SWI)8CQ3P9=O[/4Q(%8&<
M1!K[L%,F%QLYDX28SB1089!I[U%<P'5I6J[+E2@6@@8\XY+[;?L\H#3:/J#G
MSG)Q/\_KD^>=NGIX2#%T5(AXV_'J#84-_#N^NL7UU5'D E4M@VU#CVL&U $P
M1," T5PX52*&'\Y:F\@CZ*Y,:FL@_T(E.H(= '.9TH YR$@'2P@L5QER_W#=
M$^3'&F"]0]*O+F.')DY<LW)BT9.0?^U]*1MHLF)LAQ9S.MH?I/8'6H\LL4-)
M1A[)BB4INUCCAM@(CI9G I$7\OK0%]#?!BOG?5MCDB62T MMY>!-0Y*1RU 4
MTAQ;WFV;$YBPZUP3++2FH_G3_\I^1??).2Z(K\P]  OK>BYW!5U!EZ=V[U+?
M0=#%LHZ' +JCLJ3[&'K1#&FRFB%#0CXD>$TA[PJTRLE$EG" # .LCU@/K>A
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MBS[,Y? 2C+?!ZQT^AY;X@4:Z@A=8 @TMYX>(GJ\4OMO'5:$;NHC0I=Z5>2X
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M8$Q2( Z2UR=&<R3<SL(KT<VOO"U>@[EBAZO?,_/1J>"-?<8UB5MHF'L8!5?
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M&SX.^VG@4[HD 5U5?:X=D)X=-).:1$)0+5/%;IJX31=]6S"0_H=JB*H1PWM
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M$<P6[8"&WC.<6HB"E"R9>>]%OX$GC#7K_)-B:(0FY"J7#ZUZE^F9#.3<X9T
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MZ%I6.L6'^EZ[V>/11K+$U7BTL:=.=G;[@)W= \#.^ANK_.BL=779;ZIW&V[
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M&2[:.A3,C@VET^NN?WTC7Y^7.U>%4*EF;"'6: W:-J+*5:HY1ZD6O$(K',R
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M&!?(+AL6%G6CZHCN'X!9^/4%$C6@&5XN&^-U,,&KO51BOYL(H!!M2HX;NZ7
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MNX.Q)%JTJQ-E=EFEK.>6OY*(@0V#-XJP[F]AL*[&(79=];!O(E$0;N/);'D
MVX(+9XMH_=\OR:B863\8,PN+)M'S]I"L/]35_V=%=5-O]@U'^JL@3V\#.3W,
M/1GM_U;)_U9/FG%X-O]GE ._=C-MZK43S@K;0. UB3]#R2CD6^M?^T?HNQQ3
M(>_Q3OU*FZB7]O#:D(JH6TAO$/]%OV6OGEE<W$S5@N?*7M!@T%>T5(SV3/D2
MW$I$J'(#B43[/9NWLZ[@.J#M]G93D^E4+).)M$,.0P+O02CY?0B%&9;EUJ3>
MGF>*55'X/(02:J_F]W:&#T<H;Q)_$78&,]0<Z9[ 'O9[2,&&9!A_^2YKB]A
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MTM0$$@H9/0C'79/Z.NFWD;0[>'Q%"L"-)>-_5PE9(*P5.&KRQ\3?WX >7NG
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M.)2NS0&GIJ0L^#_671S8(F5)ZUEI)<*5_&+UXK?=Y9U3OAB57>2=G,P&"CM
M*BZ7.$ VIU"(Q>-Q_"^*R+ FQ5(M \3\IM*4'_SU=E_D)L*"MH<7)7YHF5AI
MQ*Z8&[R@F&/-&I&Y]?#W 1QC7^)5#36,I:/^I_/!X&-#"GD5$!T9,.^9)8\7
MBI!>Z*M^\%CW!3J+<]X)>Z3+K<(*Q/6*T$DJ/*X :6G#(8@$OK\(NZ-$UF;K
M ""X3X"#(,74[$?9C@$"Y$Z.5<!BV)H [GT]0 Y:5H8S ZK^L5)K)LT'BB4"
M@T\=4D^F<H_+DE!:WDZ,6CZ?WJ-R:GO6##0]FU))8T.U!L;"X[(F]E2QJQ25
MB?!K83RJ\(H^LO]S<L+79$D1_^([P@B46%=ZL22@H;_X?)H_.6&2791?_6?;
M?KB]JXR6E4):B*KD*06-= JO\WF6J$"W--!;"A@L%?2_8;6 +E!HMZIIHPNO
M3&WJQYTB#<D3P:QQ*A5(&Z]^(_UG>+U2[<2+:!O%?_.]Q11 +.J@UP=_\RT0
MSO086AJB/IGV/O73?@P_B@(@H@8@J)5=E0P'&WK$I<?E@]*[DY\N[Q,33[$6
M"+/GD[X$@@% G1**8<<*>+3/U*%E#X5Z=;7WM=X=XM;I[MZ%-WS&0\ X.70-
M;2ZY4D-[)2E@)H@=03<7/5 I!E5YAEOXZBVA=>56WA?RV6&5Q^5M:IA.B_-N
MIC0^EK3K_]-J]ZI\(L4SNY$/5*,F@;3FO3,C==&59U?*EW^NJHUBKUKA.\6K
MWCW7NRJVNL5RK]YN=1VQU?_GR"9>WR&&8[^JKL*WIR8Q)-&(3/F-2"(PB*T
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MRKGVHP(Y@+\X @ZA5[MX;'0F89D(3YU->CT1'C?D.?\U^^<W'MQ.-#/Q7\
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M@4B4\VR-5/HUP,06@\N4%DWA2=/+"FPF7/38DJ;ZT%4>=$.S%AO%QC:P;A.
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M   -    :6UA9V5?,# S+FIP9[68=U#379> ?Z$E-"&AA"8U=(CT+D4E-(6
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MSX'BVVC+FKT/=A#HCAR^./C#W. @X"+ Q/]?&_U_ #Z;^C=02P$"% ,4
M"  *B'-<X 9.VH5J   GOP  #P              @ $     87-T<F%F;V]T
M97(N:G!G4$L! A0#%     @ "HAS7&J0?1]69P  :78   T
M ( !LFH  &%S=')A;&]G;RYJ<&=02P$"% ,4    "  *B'-<G]5<MW44   &
M[P  $0              @ $ST@  8V]E<"TR,#(U,3(S,2YX<V102P$"% ,4
M    "  *B'-<,-%;\8$6  "E% $ %0              @ '7Y@  8V]E<"TR
M,#(U,3(S,5]C86PN>&UL4$L! A0#%     @ "HAS7"68EH\Q2P  "?$$ !4
M             ( !B_T  &-O97 M,C R-3$R,S%?9&5F+GAM;%!+ 0(4 Q0
M   (  J(<UR"E<( -(,  )M_!P 5              "  >]( 0!C;V5P+3(P
M,C4Q,C,Q7VQA8BYX;6Q02P$"% ,4    "  *B'-<DA#>46%F  !HK 8 %0
M            @ %6S $ 8V]E<"TR,#(U,3(S,5]P<F4N>&UL4$L! A0#%
M  @ "HAS7/1:BP\920  ==@! !(              ( !ZC(" &-O97!T:7-?
M97@Q.3 Q+FAT;5!+ 0(4 Q0    (  J(<UPF?N+EMP$  'X(   2
M      "  3-\ @!C;V5P=&ES7V5X,C$P,2YH=&U02P$"% ,4    "  *B'-<
M3F+V(V '  "3+   $@              @ $:?@( 8V]E<'1I<U]E>#,Q,#$N
M:'1M4$L! A0#%     @ "HAS7$_FO!M<!P  E2P  !(              ( !
MJH4" &-O97!T:7-?97@S,3 R+FAT;5!+ 0(4 Q0    (  J(<URI9:7PVP,
M '80   2              "  3:- @!C;V5P=&ES7V5X,S(P,2YH=&U02P$"
M% ,4    "  *B'-<XDCTE/SZ @!]^Q< %P              @ %!D0( 8V]E
M<'1I<U]I,3!K+3$R,S$R-2YH=&U02P$"% ,4    "  *B'-<Q2(V Q0$  "M
M!   #0              @ %RC 4 :6UA9V5?,# Q+FIP9U!+ 0(4 Q0    (
M  J(<UQ E>@S0@8  &0(   -              "  ;&0!0!I;6%G95\P,#(N
M:G!G4$L! A0#%     @ "HAS7-^6<YHY$P  DQ0   T              ( !
G'I<% &EM86=E7S P,RYJ<&=02P4&     !  $ #Y P  @JH%

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>coeptis_i10k-123125_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:coep="http://coeptistx.com/20251231"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="coep-20251231.xsd" xlink:type="simple"/>
    <context id="From2025-01-01to2025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_CommonStockParValue0.0001PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:CommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_WarrantsEachWholeWarrantExercisableForOnehalfOfOneShareOfCommonStockFor230.00PerWholeShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantsEachWholeWarrantExercisableForOnehalfOfOneShareOfCommonStockFor230.00PerWholeShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-03-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
        </entity>
        <period>
            <instant>2026-03-18</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_ConvertibleNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_ConvertibleNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_SaleMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">coep:SaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SaleMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">coep:SaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_CommonStockSubscribedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">coep:CommonStockSubscribedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubscriptionReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">coep:SubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_CommonStockSubscribedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">coep:CommonStockSubscribedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SubscriptionReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">coep:SubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_CommonStockSubscribedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">coep:CommonStockSubscribedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SubscriptionReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">coep:SubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_CommonStockSubscribedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">coep:CommonStockSubscribedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_SubscriptionReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">coep:SubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_CommonStockSubscribedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">coep:CommonStockSubscribedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SubscriptionReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">coep:SubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2024-12-012024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
        </entity>
        <period>
            <startDate>2024-12-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_NexGenAIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">coep:NexGenAIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_NexGenAIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">coep:NexGenAIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_SixCustomersMember_custom_AdvertisingCampaignsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">coep:SixCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">coep:AdvertisingCampaignsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_AdvertisingCampaignsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">coep:AdvertisingCampaignsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_AdvertisingCampaignsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">coep:AdvertisingCampaignsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_ThreeCustomersMember_custom_WebinarServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">coep:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">coep:WebinarServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_WebinarServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">coep:WebinarServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">coep:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">coep:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">coep:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">coep:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_ConvertibleNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_ConvertibleNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_PreferredStockMember206520625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember206520625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_CD38AssetsMember_custom_VyGenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">coep:VyGenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">coep:CD38AssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_CD38AssetsMember_custom_VyGenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">coep:VyGenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">coep:CD38AssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_CD38AssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">coep:CD38AssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_CoDevelopmentRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">coep:CoDevelopmentRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_CoDevelopmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">coep:CoDevelopmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_CoDevelopmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">coep:CoDevelopmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_LicenseAgreementMember_custom_PurpleBioTechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">coep:PurpleBioTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">coep:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2021-09-022021-09-30_custom_LicenseAgreementMember_custom_PurpleBioTechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">coep:PurpleBioTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">coep:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-02</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_LicenseAgreementMember_custom_PurpleBioTechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">coep:PurpleBioTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">coep:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_LicenseAgreementMember_custom_PurpleBioTechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">coep:PurpleBioTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">coep:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-10-31_custom_Oct2022ConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">coep:Oct2022ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="From2023-10-262023-10-27_custom_Oct2022ConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">coep:Oct2022ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-26</startDate>
            <endDate>2023-10-27</endDate>
        </period>
    </context>
    <context id="From2023-12-142023-12-15_custom_Oct2022ConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">coep:Oct2022ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-14</startDate>
            <endDate>2023-12-15</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_Oct2022ConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">coep:Oct2022ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_Dec2023ConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">coep:Dec2023ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-04-232024-04-24_custom_Dec2023ConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">coep:Dec2023ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-23</startDate>
            <endDate>2024-04-24</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_Dec2023ConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">coep:Dec2023ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-04-17_us-gaap_RelatedPartyMember_custom_April2024UnsecuredNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">coep:April2024UnsecuredNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-17</instant>
        </period>
    </context>
    <context id="From2024-04-162024-04-17_us-gaap_RelatedPartyMember_custom_April2024UnsecuredNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">coep:April2024UnsecuredNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-16</startDate>
            <endDate>2024-04-17</endDate>
        </period>
    </context>
    <context id="AsOf2024-01-03_custom_YANote1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">coep:YANote1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-03</instant>
        </period>
    </context>
    <context id="AsOf2024-10-31_custom_YANote1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">coep:YANote1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="From2024-10-012024-10-31_custom_YANote1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">coep:YANote1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-11-02_custom_YorkvilleConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">coep:YorkvilleConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-02</instant>
        </period>
    </context>
    <context id="From2024-11-012024-11-02_custom_YANote1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">coep:YANote1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-02</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_YorkvilleConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">coep:YorkvilleConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_YorkvilleConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">coep:YorkvilleConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_YorkvilleConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">coep:YorkvilleConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_StandbyEquityPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_StandbyEquityPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_StandbyEquityPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-01-16_custom_YorkvilleConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">coep:YorkvilleConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-16</instant>
        </period>
    </context>
    <context id="From2025-01-152025-01-16_custom_YorkvilleConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">coep:YorkvilleConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-15</startDate>
            <endDate>2025-01-16</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_YANote2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">coep:YANote2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_YorkvilleConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">coep:YorkvilleConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_DerivativeLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:DerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_DerivativeLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:DerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_MeasurementInputConversionPriceMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_MeasurementInputSharePriceMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-10-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="From2024-11-012024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2020-07-072020-07-08_custom_EidlLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">coep:EidlLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-07</startDate>
            <endDate>2020-07-08</endDate>
        </period>
    </context>
    <context id="AsOf2020-07-08_custom_EidlLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">coep:EidlLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-08</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_EidlLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">coep:EidlLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_EidlLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">coep:EidlLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_PublicWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">coep:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PublicWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">coep:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_PrivatePlacementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">coep:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PrivatePlacementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">coep:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_PublicWarrantsMember_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PublicWarrantsMember_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_PrivatePlacementWarrantsMember_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PrivatePlacementWarrantsMember_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_MeasurementInputExercisePriceMember_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_MeasurementInputExercisePriceMember_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_MeasurementInputSharePriceMember_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_MeasurementInputSharePriceMember_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PrivatePlacementWarrantsMember206522015">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PublicWarrantsMember206522015">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WarrantLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:WarrantLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_PrivatePlacementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_PublicWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_WarrantLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:WarrantLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_PrivatePlacementWarrantsMember206522046">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_PublicWarrantsMember206522046">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_WarrantLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">coep:WarrantLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_CommonStockMember206522296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2023-06-152023-06-16_custom_PublicOfferingMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">coep:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-15</startDate>
            <endDate>2023-06-16</endDate>
        </period>
    </context>
    <context id="From2023-06-152023-06-16_custom_PublicOfferingMember_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">coep:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-15</startDate>
            <endDate>2023-06-16</endDate>
        </period>
    </context>
    <context id="From2023-06-152023-06-16_custom_PublicOfferingMember_custom_SeriesAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:SeriesAWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">coep:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-15</startDate>
            <endDate>2023-06-16</endDate>
        </period>
    </context>
    <context id="From2023-06-152023-06-16_custom_PublicOfferingMember_custom_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:SeriesBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">coep:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-15</startDate>
            <endDate>2023-06-16</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-16_custom_PublicOfferingMember_custom_SeriesWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:SeriesWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">coep:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-16</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_PublicOfferingMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">coep:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-12-272023-12-28_custom_WarrantNoteSubscriptionReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantNoteSubscriptionReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-27</startDate>
            <endDate>2023-12-28</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_SNAPBiosciencesIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">coep:SNAPBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-10-012025-12-31_custom_TwoInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">coep:TwoInvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_TwoInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">coep:TwoInvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwoInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">coep:TwoInvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-06-122024-06-13_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-12</startDate>
            <endDate>2024-06-13</endDate>
        </period>
    </context>
    <context id="From2024-07-302024-07-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-30</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="From2024-09-032024-09-04_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-03</startDate>
            <endDate>2024-09-04</endDate>
        </period>
    </context>
    <context id="From2024-12-222024-12-23_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-22</startDate>
            <endDate>2024-12-23</endDate>
        </period>
    </context>
    <context id="From2025-02-052025-02-06_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-05</startDate>
            <endDate>2025-02-06</endDate>
        </period>
    </context>
    <context id="AsOf2025-07-25_custom_ConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">coep:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-25</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_StockOptionsMember206522468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">coep:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_StockOptionsMember206522468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">coep:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-03-232025-03-24_custom_ColleenDelaneyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">coep:ColleenDelaneyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-23</startDate>
            <endDate>2025-03-24</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-24_custom_ColleenDelaneyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">coep:ColleenDelaneyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-24</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_ColleenDelaneyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">coep:ColleenDelaneyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-12-012025-12-31_custom_ModificationOfOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">coep:ModificationOfOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-11-23_custom_CoralInvestmentPartnersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">coep:CoralInvestmentPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-23</instant>
        </period>
    </context>
    <context id="AsOf2020-11-23_custom_CoralInvestmentPartnersMember_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">coep:CoralInvestmentPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-23</instant>
        </period>
    </context>
    <context id="AsOf2020-11-23_custom_CoralInvestmentPartnersMember_us-gaap_CommonClassBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">coep:CoralInvestmentPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-23</instant>
        </period>
    </context>
    <context id="From2023-09-012023-09-30_custom_SubscriptionReceivableSept2023Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">coep:SubscriptionReceivableSept2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SubscriptionReceivableSept2023Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">coep:SubscriptionReceivableSept2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SubscriptionReceivableSept2023Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">coep:SubscriptionReceivableSept2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2023-09-012023-09-30_custom_SubscriptionReceivableSept20232ndMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">coep:SubscriptionReceivableSept20232ndMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SubscriptionReceivableSept20232ndMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">coep:SubscriptionReceivableSept20232ndMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SubscriptionReceivableSept20232ndMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">coep:SubscriptionReceivableSept20232ndMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_December2023FinancingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">coep:December2023FinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_December2023FinancingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">coep:December2023FinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_December2023FinancingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">coep:December2023FinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-02-28_custom_February2024FinancingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">coep:February2024FinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-28</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_February2024FinancingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">coep:February2024FinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_February2024FinancingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">coep:February2024FinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2024-10-292024-11-02_custom_StandbyEquityPurchaseAgreementMember_custom_YorkvilleMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">coep:YorkvilleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">coep:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-29</startDate>
            <endDate>2024-11-02</endDate>
        </period>
    </context>
    <context id="From2024-10-292024-11-02_custom_StandbyEquityPurchaseAgreementMember_custom_YorkvilleMember_custom_StockIssuedForServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">coep:YorkvilleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">coep:StockIssuedForServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">coep:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-29</startDate>
            <endDate>2024-11-02</endDate>
        </period>
    </context>
    <context id="AsOf2024-11-02_custom_StandbyEquityPurchaseAgreementMember_custom_YorkvilleMember_custom_ConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">coep:YorkvilleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">coep:ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">coep:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-02</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_StandbyEquityPurchaseAgreementMember206522812">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">coep:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">coep:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">coep:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">coep:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">coep:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_WarrantHolder1ExercisePrice59.40Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder1ExercisePrice59.40Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_WarrantHolder1ExercisePrice59.40Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder1ExercisePrice59.40Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WarrantHolder1ExercisePrice59.40Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder1ExercisePrice59.40Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_WarrantHolder1ExercisePrice118.80Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder1ExercisePrice118.80Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_WarrantHolder1ExercisePrice118.80Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder1ExercisePrice118.80Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WarrantHolder1ExercisePrice118.80Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder1ExercisePrice118.80Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_WarrantHolder1ExercisePrice296.80Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder1ExercisePrice296.80Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_WarrantHolder1ExercisePrice296.80Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder1ExercisePrice296.80Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WarrantHolder1ExercisePrice296.80Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder1ExercisePrice296.80Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_WarrantHolder2ExercisePrice59.40Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder2ExercisePrice59.40Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_WarrantHolder2ExercisePrice59.40Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder2ExercisePrice59.40Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WarrantHolder2ExercisePrice59.40Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder2ExercisePrice59.40Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_WarrantHolder2ExercisePrice296.80Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder2ExercisePrice296.80Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_WarrantHolder2ExercisePrice296.80Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder2ExercisePrice296.80Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WarrantHolder2ExercisePrice296.80Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder2ExercisePrice296.80Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_WarrantHolder5ExercisePrice59.40Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder5ExercisePrice59.40Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_WarrantHolder5ExercisePrice59.40Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder5ExercisePrice59.40Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WarrantHolder5ExercisePrice59.40Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder5ExercisePrice59.40Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_WarrantHolder18ExercisePrice178.20Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder18ExercisePrice178.20Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_WarrantHolder18ExercisePrice178.20Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder18ExercisePrice178.20Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WarrantHolder18ExercisePrice178.20Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder18ExercisePrice178.20Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_WarrantHolder20ExercisePrice50.00Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder20ExercisePrice50.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_WarrantHolder20ExercisePrice50.00Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder20ExercisePrice50.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WarrantHolder20ExercisePrice50.00Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder20ExercisePrice50.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_WarrantHolder21ExercisePrice38.00Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder21ExercisePrice38.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_WarrantHolder21ExercisePrice38.00Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder21ExercisePrice38.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WarrantHolder21ExercisePrice38.00Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder21ExercisePrice38.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_SeriesWarrantsAAndBExercisePrice27.20Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:SeriesWarrantsAAndBExercisePrice27.20Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SeriesWarrantsAAndBExercisePrice27.20Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:SeriesWarrantsAAndBExercisePrice27.20Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeriesWarrantsAAndBExercisePrice27.20Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:SeriesWarrantsAAndBExercisePrice27.20Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_SeriesAWarrantsExercisePrice27.20Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:SeriesAWarrantsExercisePrice27.20Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SeriesAWarrantsExercisePrice27.20Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:SeriesAWarrantsExercisePrice27.20Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeriesAWarrantsExercisePrice27.20Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:SeriesAWarrantsExercisePrice27.20Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_SeriesBWarrantsExercisePrice27.20Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:SeriesBWarrantsExercisePrice27.20Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SeriesBWarrantsExercisePrice27.20Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:SeriesBWarrantsExercisePrice27.20Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeriesBWarrantsExercisePrice27.20Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:SeriesBWarrantsExercisePrice27.20Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_WarrantHolder22ExercisePrice25.00Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder22ExercisePrice25.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_WarrantHolder22ExercisePrice25.00Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder22ExercisePrice25.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WarrantHolder22ExercisePrice25.00Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder22ExercisePrice25.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_WarrantHolder22ExercisePrice28.00Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder22ExercisePrice28.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_WarrantHolder22ExercisePrice28.00Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder22ExercisePrice28.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WarrantHolder22ExercisePrice28.00Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder22ExercisePrice28.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_WarrantHolder23ExercisePrice25.00Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder23ExercisePrice25.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_WarrantHolder23ExercisePrice25.00Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder23ExercisePrice25.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WarrantHolder23ExercisePrice25.00Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder23ExercisePrice25.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_WarrantHolder23ExercisePrice28.00Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder23ExercisePrice28.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_WarrantHolder23ExercisePrice28.00Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder23ExercisePrice28.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WarrantHolder23ExercisePrice28.00Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder23ExercisePrice28.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_WarrantHolder24ExercisePrice28.00Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder24ExercisePrice28.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_WarrantHolder24ExercisePrice28.00Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder24ExercisePrice28.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WarrantHolder24ExercisePrice28.00Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder24ExercisePrice28.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_PreFundedWarrants2ExercisePrice0.002Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:PreFundedWarrants2ExercisePrice0.002Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_PreFundedWarrants2ExercisePrice0.002Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:PreFundedWarrants2ExercisePrice0.002Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PreFundedWarrants2ExercisePrice0.002Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:PreFundedWarrants2ExercisePrice0.002Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_PreFundedWarrants3ExercisePrice0.002Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:PreFundedWarrants3ExercisePrice0.002Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_PreFundedWarrants3ExercisePrice0.002Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:PreFundedWarrants3ExercisePrice0.002Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PreFundedWarrants3ExercisePrice0.002Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:PreFundedWarrants3ExercisePrice0.002Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_WarrantHolder25ExercisePrice12.00Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder25ExercisePrice12.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_WarrantHolder25ExercisePrice12.00Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder25ExercisePrice12.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WarrantHolder25ExercisePrice12.00Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coep:WarrantHolder25ExercisePrice12.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_GearTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">coep:GearTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-08-31_custom_TwoPrivatelyHeldCompaniesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">coep:TwoPrivatelyHeldCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_NexGenAIAffiliatesNetworkPlatformMember_custom_FivePrivatelyHeldCompaniesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">coep:FivePrivatelyHeldCompaniesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">coep:NexGenAIAffiliatesNetworkPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_NexGenAIAffiliatesNetworkPlatformMember_custom_ThreePrivatelyHeldCompaniesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">coep:ThreePrivatelyHeldCompaniesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">coep:NexGenAIAffiliatesNetworkPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-11-012025-12-31_custom_NexGenAIAffiliatesNetworkPlatformMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">coep:NexGenAIAffiliatesNetworkPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-11-012025-11-30_custom_PrivatelyHeldCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">coep:PrivatelyHeldCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2025-11-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-11-30_custom_PrivatelyHeldCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">coep:PrivatelyHeldCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-30</instant>
        </period>
    </context>
    <context id="From2025-11-012025-12-31_custom_PrivatelyHeldCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">coep:PrivatelyHeldCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_FirstYearExtensionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">coep:FirstYearExtensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_SecondYearExtensionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">coep:SecondYearExtensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_MehalickMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">coep:MehalickMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_YeraceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">coep:YeraceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-08-31_custom_CarTLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">coep:CarTLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="From2022-08-292022-08-31_custom_CarTLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">coep:CarTLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-29</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_CarTLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">coep:CarTLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_FindersFeeAndIndemnityAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">coep:FindersFeeAndIndemnityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_MasterServicesAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">coep:MasterServicesAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_MasterServicesAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">coep:MasterServicesAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_GearCellTherapyPlatformMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">coep:GearCellTherapyPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2023-09-292023-09-30_custom_AGBioLifeCapitalILPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">coep:AGBioLifeCapitalILPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-29</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-08-12_custom_AGBioLifeCapitalILPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">coep:AGBioLifeCapitalILPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-12</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_AGBioLifeCapitalILPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">coep:AGBioLifeCapitalILPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_AGBioLifeCapitalILPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">coep:AGBioLifeCapitalILPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_BoardOfDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">coep:BoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2024-12-182024-12-19_custom_NexGenAISolutionsGroupIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">coep:NexGenAISolutionsGroupIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-18</startDate>
            <endDate>2024-12-19</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_NexGenAIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">coep:NexGenAIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_NexGenAIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">coep:NexGenAIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_NexGenAIMember206525843">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">coep:NexGenAIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_NexGenAIMember206525843">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">coep:NexGenAIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_BiotechnologySegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">coep:BiotechnologySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_BiotechnologySegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">coep:BiotechnologySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_TechnologySegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">coep:TechnologySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TechnologySegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">coep:TechnologySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_BiotechnologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">coep:BiotechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_TechnologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">coep:TechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_BiotechnologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">coep:BiotechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TechnologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759186</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">coep:TechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Integer">
        <measure>coep:Integer</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2025-01-01to2025-12-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="From2025-01-01to2025-12-31" id="Fact000004">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2025-01-01to2025-12-31" id="Fact000005">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2025-01-01to2025-12-31" id="Fact000006">0001759186</dei:EntityCentralIndexKey>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0368"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_custom_CommonStockSubscribedMember"
      id="xdx2ixbrl0371"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0372"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0373"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0375"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:SharesIssuedInConnectionWithSEPAValue
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0380"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:SharesIssuedInConnectionWithSEPAValue
      contextRef="From2024-01-012024-12-31_custom_CommonStockSubscribedMember"
      id="xdx2ixbrl0383"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:SharesIssuedInConnectionWithSEPAValue
      contextRef="From2024-01-012024-12-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0384"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:SharesIssuedInConnectionWithSEPAValue
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0385"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:SharesIssuedInConnectionWithSEPAValue
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0387"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0392"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-12-31_custom_CommonStockSubscribedMember"
      id="xdx2ixbrl0395"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-12-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0396"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0397"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0399"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:StockIssuedDuringPeriodValueWarrantsIssuedForCash
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0404"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:StockIssuedDuringPeriodValueWarrantsIssuedForCash
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0405"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:StockIssuedDuringPeriodValueWarrantsIssuedForCash
      contextRef="From2024-01-012024-12-31_custom_CommonStockSubscribedMember"
      id="xdx2ixbrl0407"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:StockIssuedDuringPeriodValueWarrantsIssuedForCash
      contextRef="From2024-01-012024-12-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0408"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:StockIssuedDuringPeriodValueWarrantsIssuedForCash
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0409"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:StockIssuedDuringPeriodValueWarrantsIssuedForCash
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0411"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0414"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0415"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-01-012024-12-31_custom_CommonStockSubscribedMember"
      id="xdx2ixbrl0417"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-01-012024-12-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0418"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0419"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0421"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:WarrantsIssuedInExchangeForSubscriptionsReceivable
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0424"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:WarrantsIssuedInExchangeForSubscriptionsReceivable
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0425"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:WarrantsIssuedInExchangeForSubscriptionsReceivable
      contextRef="From2024-01-012024-12-31_custom_CommonStockSubscribedMember"
      id="xdx2ixbrl0427"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:WarrantsIssuedInExchangeForSubscriptionsReceivable
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0429"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:WarrantsIssuedInExchangeForSubscriptionsReceivable
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0431"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:SharesIssuedForConversionOfDebtValue
      contextRef="From2024-01-012024-12-31_custom_CommonStockSubscribedMember"
      id="xdx2ixbrl0437"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:SharesIssuedForConversionOfDebtValue
      contextRef="From2024-01-012024-12-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0438"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:SharesIssuedForConversionOfDebtValue
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0439"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:SharesIssuedForConversionOfDebtValue
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0441"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:StockIssuedDuringPeriodValueOfPreferredShareOffering
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0449"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:StockIssuedDuringPeriodValueOfPreferredShareOffering
      contextRef="From2024-01-012024-12-31_custom_CommonStockSubscribedMember"
      id="xdx2ixbrl0451"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:StockIssuedDuringPeriodValueOfPreferredShareOffering
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0453"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:StockIssuedDuringPeriodValueOfInvestmentsAssignmentAgreements
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0460"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:StockIssuedDuringPeriodValueOfInvestmentsAssignmentAgreements
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0461"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:StockIssuedDuringPeriodValueOfInvestmentsAssignmentAgreements
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0462"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:StockIssuedDuringPeriodValueOfInvestmentsAssignmentAgreements
      contextRef="From2024-01-012024-12-31_custom_CommonStockSubscribedMember"
      id="xdx2ixbrl0463"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:StockIssuedDuringPeriodValueOfInvestmentsAssignmentAgreements
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0465"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:StockIssuedDuringPeriodValueOfInvestmentsAssignmentAgreements
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0467"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:StockIssuedDuringPeriodValuePurchaseOfAssets1
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0470"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:StockIssuedDuringPeriodValuePurchaseOfAssets1
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0471"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:StockIssuedDuringPeriodValuePurchaseOfAssets1
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0472"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:StockIssuedDuringPeriodValuePurchaseOfAssets1
      contextRef="From2024-01-012024-12-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0474"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:StockIssuedDuringPeriodValuePurchaseOfAssets1
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0475"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:StockIssuedDuringPeriodValuePurchaseOfAssets1
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0477"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0480"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0481"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_custom_CommonStockSubscribedMember"
      id="xdx2ixbrl0483"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0484"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0485"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0487"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0490"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0491"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_custom_CommonStockSubscribedMember"
      id="xdx2ixbrl0493"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0494"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0495"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0497"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0502"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0503"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0504"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31_custom_CommonStockSubscribedMember"
      id="xdx2ixbrl0505"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0506"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0526"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-12-31_custom_CommonStockSubscribedMember"
      id="xdx2ixbrl0529"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0531"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0533"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:SharesIssuedInConnectionWithSEPAValue
      contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0538"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:SharesIssuedInConnectionWithSEPAValue
      contextRef="From2025-01-012025-12-31_custom_CommonStockSubscribedMember"
      id="xdx2ixbrl0541"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:SharesIssuedInConnectionWithSEPAValue
      contextRef="From2025-01-012025-12-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0542"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:SharesIssuedInConnectionWithSEPAValue
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0543"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:SharesIssuedInConnectionWithSEPAValue
      contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0545"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0550"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-012025-12-31_custom_CommonStockSubscribedMember"
      id="xdx2ixbrl0553"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-012025-12-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0554"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0555"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0557"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:SharesIssuedForInvestmentValue
      contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0562"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:SharesIssuedForInvestmentValue
      contextRef="From2025-01-012025-12-31_custom_CommonStockSubscribedMember"
      id="xdx2ixbrl0565"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:SharesIssuedForInvestmentValue
      contextRef="From2025-01-012025-12-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0566"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:SharesIssuedForInvestmentValue
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0567"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:SharesIssuedForInvestmentValue
      contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0569"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0586"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0587"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2025-01-012025-12-31_custom_CommonStockSubscribedMember"
      id="xdx2ixbrl0589"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2025-01-012025-12-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0590"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0591"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0593"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:StockIssuedDuringPeriodValuePrefundedWarrantsExercise
      contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0596"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:StockIssuedDuringPeriodValuePrefundedWarrantsExercise
      contextRef="From2025-01-012025-12-31_custom_CommonStockSubscribedMember"
      id="xdx2ixbrl0599"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:StockIssuedDuringPeriodValuePrefundedWarrantsExercise
      contextRef="From2025-01-012025-12-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0600"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:StockIssuedDuringPeriodValuePrefundedWarrantsExercise
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0601"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:StockIssuedDuringPeriodValuePrefundedWarrantsExercise
      contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0603"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:StockIssuedDuringPeriodValueOfPreferredShareOffering
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0609"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:StockIssuedDuringPeriodValueOfPreferredShareOffering
      contextRef="From2025-01-012025-12-31_custom_CommonStockSubscribedMember"
      id="xdx2ixbrl0611"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:StockIssuedDuringPeriodValueOfPreferredShareOffering
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0613"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:StockIssuedDuringPeriodValuePreferredShareConversion
      contextRef="From2025-01-012025-12-31_custom_CommonStockSubscribedMember"
      id="xdx2ixbrl0623"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:StockIssuedDuringPeriodValuePreferredShareConversion
      contextRef="From2025-01-012025-12-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0624"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:StockIssuedDuringPeriodValuePreferredShareConversion
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0625"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:StockIssuedDuringPeriodValuePreferredShareConversion
      contextRef="From2025-01-012025-12-31_us-gaap_ParentMember"
      id="xdx2ixbrl0626"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:StockIssuedDuringPeriodValuePreferredShareConversion
      contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0627"
      unitRef="USD"
      xsi:nil="true"/>
    <coep:StockIssuedDuringPeriodValuePreferredShareConversion
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0628"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0634"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-01-012025-12-31_custom_CommonStockSubscribedMember"
      id="xdx2ixbrl0637"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-01-012025-12-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0638"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0639"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0641"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0646"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0647"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-12-31_custom_CommonStockSubscribedMember"
      id="xdx2ixbrl0649"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-12-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0650"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0651"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0653"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0656"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0657"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0658"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-12-31_custom_CommonStockSubscribedMember"
      id="xdx2ixbrl0659"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-12-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0660"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NumberOfReportableSegments
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="xdx2ixbrl1755"
      unitRef="Integer">2</us-gaap:NumberOfReportableSegments>
    <dei:DocumentType contextRef="From2025-01-01to2025-12-31" id="Fact000014">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2025-01-01to2025-12-31" id="Fact000015">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2025-01-01to2025-12-31" id="Fact000016">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2025-01-01to2025-12-31" id="Fact000018">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="From2025-01-01to2025-12-31" id="Fact000019">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2025-01-01to2025-12-31" id="Fact000020">001-39669</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2025-01-01to2025-12-31" id="Fact000021">Coeptis Therapeutics Holdings, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2025-01-01to2025-12-31" id="Fact000022">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2025-01-01to2025-12-31" id="Fact000023">98-1465952</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2025-01-01to2025-12-31" id="Fact000024">105 Bradford Rd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2025-01-01to2025-12-31" id="Fact000025">Suite 420</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2025-01-01to2025-12-31" id="Fact000026">Wexford</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2025-01-01to2025-12-31" id="Fact000027">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2025-01-01to2025-12-31" id="Fact000028">15090</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2025-01-01to2025-12-31" id="Fact000029">724</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2025-01-01to2025-12-31" id="Fact000030">934-6467</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="From2025-01-012025-12-31_custom_CommonStockParValue0.0001PerShareMember"
      id="Fact000031">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2025-01-012025-12-31_custom_CommonStockParValue0.0001PerShareMember"
      id="Fact000032">COEP</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2025-01-012025-12-31_custom_CommonStockParValue0.0001PerShareMember"
      id="Fact000033">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="From2025-01-012025-12-31_custom_WarrantsEachWholeWarrantExercisableForOnehalfOfOneShareOfCommonStockFor230.00PerWholeShareMember"
      id="Fact000034">Warrants, each whole warrant exercisable for one-half of one share of Common Stock for $230.00 per whole share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2025-01-012025-12-31_custom_WarrantsEachWholeWarrantExercisableForOnehalfOfOneShareOfCommonStockFor230.00PerWholeShareMember"
      id="Fact000035">COEPW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2025-01-012025-12-31_custom_WarrantsEachWholeWarrantExercisableForOnehalfOfOneShareOfCommonStockFor230.00PerWholeShareMember"
      id="Fact000036">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2025-01-01to2025-12-31" id="Fact000037">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2025-01-01to2025-12-31" id="Fact000038">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2025-01-01to2025-12-31" id="Fact000039">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2025-01-01to2025-12-31" id="Fact000040">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2025-01-01to2025-12-31" id="Fact000041">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2025-01-01to2025-12-31" id="Fact000042">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2025-01-01to2025-12-31" id="Fact000043">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2025-01-01to2025-12-31" id="Fact000044">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="From2025-01-01to2025-12-31" id="Fact000045">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2025-01-01to2025-12-31" id="Fact000046">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2025-01-01to2025-12-31" id="Fact000047">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000048"
      unitRef="USD">28225766</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2026-03-18"
      decimals="INF"
      id="Fact000049"
      unitRef="Shares">6223221</dei:EntityCommonStockSharesOutstanding>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000055">&lt;b&gt;Cybersecurity Risk Management and Strategy&lt;/b&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_900_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20250101__20251231_zhkbzupmLsk4"&gt;The Company &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_901_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20250101__20251231_zx4SGCcPUjGk"&gt;recognizes&lt;/span&gt; the
importance of cybersecurity in safeguarding its information systems and data.&lt;/span&gt; Our cybersecurity measures primarily rely on standard security
protocols provided by Microsoft Outlook and OneDrive, which include encryption, multi-factor authentication, and access controls to protect
against unauthorized access and data breaches.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Given the evolving nature
of cybersecurity threats, the Company monitors its systems for potential vulnerabilities and relies on &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_905_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20250101__20251231_zoNQFsm9lYoi"&gt;third-party&lt;/span&gt; security updates and
patches to mitigate risks. While we believe our current measures are appropriate for our operations, we acknowledge that no security system
is entirely immune from potential threats, including phishing attacks, malware, ransomware, and unauthorized access.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000056">The Company &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_901_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20250101__20251231_zx4SGCcPUjGk"&gt;recognizes&lt;/span&gt; the
importance of cybersecurity in safeguarding its information systems and data.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="From2025-01-01to2025-12-31" id="Fact000057">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="From2025-01-01to2025-12-31" id="Fact000058">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000065">&lt;b&gt;Governance and Oversight&lt;/b&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_903_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20250101__20251231_zaAysTbebyl9"&gt;The Company&#x2019;s executive
management is responsible for overseeing cybersecurity risks and ensuring compliance with our security practices. At this time, the Company
does not have a dedicated cybersecurity team but relies on its IT service providers and Microsoft&#x2019;s security framework for system
protection and incident response.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Potential Risks and Impact&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_903_ecyd--CybersecurityRiskRoleOfManagementTextBlock_c20250101__20251231_zgpzdqv5fpu6"&gt;Despite these measures, the
Company may be vulnerable to cybersecurity incidents that could disrupt operations, compromise sensitive data, or result in financial
or reputational harm. Any material cybersecurity incident would be assessed and disclosed as necessary.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000066">The Company&#x2019;s executive
management is responsible for overseeing cybersecurity risks and ensuring compliance with our security practices. At this time, the Company
does not have a dedicated cybersecurity team but relies on its IT service providers and Microsoft&#x2019;s security framework for system
protection and incident response.</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000067">Despite these measures, the
Company may be vulnerable to cybersecurity incidents that could disrupt operations, compromise sensitive data, or result in financial
or reputational harm. Any material cybersecurity incident would be assessed and disclosed as necessary.</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <ecd:TrdArrAdoptionDate contextRef="From2025-01-01to2025-12-31" id="Fact000068">May 21, 2025</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrIndName contextRef="From2025-01-01to2025-12-31" id="Fact000069">Daniel Yerace</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="From2025-01-01to2025-12-31" id="Fact000070">Vice President of Operations and a member of our Board of Directors</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="From2025-01-01to2025-12-31" id="Fact000071">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="From2025-01-01to2025-12-31" id="Fact000072">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="From2025-01-01to2025-12-31" id="Fact000073">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="From2025-01-01to2025-12-31" id="Fact000074">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:TrdArrExpirationDate contextRef="From2025-01-01to2025-12-31" id="Fact000075">February 11, 2027</ecd:TrdArrExpirationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000076"
      unitRef="Shares">20000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:AwardTmgMnpiDiscTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000077">We &lt;span id="xdx_90A_eecd--AwardTmgMnpiCnsdrdFlag_dbT_c20250101__20251231_zHHWEzS4pidc"&gt;do
not grant equity awards in anticipation of the release of material nonpublic information&lt;/span&gt;&#160;that is likely to result in
changes to the price of our common stock, and do not time the public release of such information based on award grant dates. During
the last completed fiscal year, we have not made awards to any named executive officer or director during the period beginning four
business days before and ending one business day after the filing of a period report on Form 10-Q or Form 10-K or the filing or
furnishing of a current report on Form 8-K, and we have not timed the disclosure of material nonpublic information for the purpose
of affecting the value of executive compensation.</ecd:AwardTmgMnpiDiscTextBlock>
    <ecd:AwardTmgMnpiCnsdrdFlag contextRef="From2025-01-01to2025-12-31" id="Fact000078">true</ecd:AwardTmgMnpiCnsdrdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="From2025-01-01to2025-12-31" id="Fact000079">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <dei:AuditorFirmId contextRef="From2025-01-01to2025-12-31" id="Fact000080">6920</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2025-01-01to2025-12-31" id="Fact000081">Astra Audit and Advisory LLC</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2025-01-01to2025-12-31" id="Fact000082">Tampa, Florida</dei:AuditorLocation>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000090"
      unitRef="USD">5674302</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000091"
      unitRef="USD">532885</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000093"
      unitRef="USD">676596</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000094"
      unitRef="USD">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000096"
      unitRef="USD">7348</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000097"
      unitRef="USD">0</us-gaap:InterestReceivableCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000099"
      unitRef="USD">991903</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000100"
      unitRef="USD">518407</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000102"
      unitRef="USD">7350149</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000103"
      unitRef="USD">1051292</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000108"
      unitRef="USD">9873</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000109"
      unitRef="USD">10460</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Investments
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000114"
      unitRef="USD">7860083</us-gaap:Investments>
    <us-gaap:Investments
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000115"
      unitRef="USD">5691084</us-gaap:Investments>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000117"
      unitRef="USD">361250</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000118"
      unitRef="USD">541875</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <coep:CodevelopmentRightsNet
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000120"
      unitRef="USD">554167</coep:CodevelopmentRightsNet>
    <coep:CodevelopmentRightsNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000121"
      unitRef="USD">1554166</coep:CodevelopmentRightsNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000123"
      unitRef="USD">18399</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000124"
      unitRef="USD">59783</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssets
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000126"
      unitRef="USD">8793899</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000127"
      unitRef="USD">7846908</us-gaap:OtherAssets>
    <us-gaap:Assets
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000129"
      unitRef="USD">16153921</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000130"
      unitRef="USD">8908660</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000138"
      unitRef="USD">888755</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000139"
      unitRef="USD">1269763</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000141"
      unitRef="USD">41054</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000142"
      unitRef="USD">736884</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2025-12-31_us-gaap_ConvertibleNotesPayableMember"
      decimals="0"
      id="Fact000146"
      unitRef="USD">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2024-12-31_us-gaap_ConvertibleNotesPayableMember"
      decimals="0"
      id="Fact000147"
      unitRef="USD">435635</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000144"
      unitRef="USD">0</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000145"
      unitRef="USD">1087873</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:OtherNotesPayableCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000149"
      unitRef="USD">100000</us-gaap:OtherNotesPayableCurrent>
    <us-gaap:OtherNotesPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000150"
      unitRef="USD">100000</us-gaap:OtherNotesPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000152"
      unitRef="USD">18875</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000153"
      unitRef="USD">42305</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000155"
      unitRef="USD">599455</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000156"
      unitRef="USD">0</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000158"
      unitRef="USD">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000159"
      unitRef="USD">1041484</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000161"
      unitRef="USD">120000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000162"
      unitRef="USD">235000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000164"
      unitRef="USD">1768139</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000165"
      unitRef="USD">4513309</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000170"
      unitRef="USD">150000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000171"
      unitRef="USD">150000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000173"
      unitRef="USD">167625</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000174"
      unitRef="USD">359250</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000176"
      unitRef="USD">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000177"
      unitRef="USD">18875</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000179"
      unitRef="USD">317625</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000180"
      unitRef="USD">528125</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000182"
      unitRef="USD">2085764</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000183"
      unitRef="USD">5041434</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000193"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000194"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000195"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000196"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000197"
      unitRef="Shares">10000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000198"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000199"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000200"
      unitRef="Shares">6520</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000201"
      unitRef="Shares">6520</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact000191"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact000192"
      unitRef="USD">2</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000205"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000206"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000207"
      unitRef="Shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000208"
      unitRef="Shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000209"
      unitRef="Shares">5746948</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000210"
      unitRef="Shares">5746948</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000211"
      unitRef="Shares">2116191</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000212"
      unitRef="Shares">2116191</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000203"
      unitRef="USD">575</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000204"
      unitRef="USD">212</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000214"
      unitRef="USD">127201691</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000215"
      unitRef="USD">102976748</us-gaap:AdditionalPaidInCapital>
    <coep:CommonStockSubscribed
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000217"
      unitRef="USD">0</coep:CommonStockSubscribed>
    <coep:CommonStockSubscribed
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000218"
      unitRef="USD">541875</coep:CommonStockSubscribed>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000220"
      unitRef="USD">3686544</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000221"
      unitRef="USD">2100000</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000223"
      unitRef="USD">-109953728</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000224"
      unitRef="USD">-98036713</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000226"
      unitRef="USD">13561994</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000227"
      unitRef="USD">3382124</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000229"
      unitRef="USD">506163</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000230"
      unitRef="USD">485102</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000232"
      unitRef="USD">14068157</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000233"
      unitRef="USD">3867226</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000235"
      unitRef="USD">16153921</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000236"
      unitRef="USD">8908660</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-12-31_custom_SaleMember"
      decimals="0"
      id="Fact000241"
      unitRef="USD">1363045</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-01-012024-12-31_custom_SaleMember"
      decimals="0"
      id="Fact000243"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000245"
      unitRef="USD">1363045</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000246"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000248"
      unitRef="USD">180625</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000249"
      unitRef="USD">0</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000251"
      unitRef="USD">1182420</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000252"
      unitRef="USD">0</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000257"
      unitRef="USD">1277150</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000258"
      unitRef="USD">2331548</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SalariesAndWages
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000260"
      unitRef="USD">1687972</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000261"
      unitRef="USD">1722050</us-gaap:SalariesAndWages>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000263"
      unitRef="USD">1000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000264"
      unitRef="USD">1000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000266"
      unitRef="USD">7792100</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000267"
      unitRef="USD">2950271</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000269"
      unitRef="USD">1215692</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000270"
      unitRef="USD">1104978</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000272"
      unitRef="USD">1148004</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000273"
      unitRef="USD">945641</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000275"
      unitRef="USD">105000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000276"
      unitRef="USD">0</us-gaap:SellingAndMarketingExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000278"
      unitRef="USD">14225918</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000279"
      unitRef="USD">10054488</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000281"
      unitRef="USD">-13043498</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000282"
      unitRef="USD">-10054488</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000287"
      unitRef="USD">96744</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000288"
      unitRef="USD">246116</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestAndOtherIncome
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000290"
      unitRef="USD">116495</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000291"
      unitRef="USD">234742</us-gaap:InterestAndOtherIncome>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000293"
      unitRef="USD">545635</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000294"
      unitRef="USD">216189</us-gaap:AmortizationOfDebtDiscountPremium>
    <coep:GainOnForfeitureOfCustomerDeposit
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000296"
      unitRef="USD">115000</coep:GainOnForfeitureOfCustomerDeposit>
    <coep:GainOnForfeitureOfCustomerDeposit
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000297"
      unitRef="USD">0</coep:GainOnForfeitureOfCustomerDeposit>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000299"
      unitRef="USD">7004</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000300"
      unitRef="USD">-16444</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000302"
      unitRef="USD">76596</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000303"
      unitRef="USD">0</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:GainLossOnInvestments
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000305"
      unitRef="USD">-163500</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000306"
      unitRef="USD">0</us-gaap:GainLossOnInvestments>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000308"
      unitRef="USD">-0</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000309"
      unitRef="USD">37257</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <coep:GainsLossesOnExtinguishmentOfDebt1
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000311"
      unitRef="USD">159035</coep:GainsLossesOnExtinguishmentOfDebt1>
    <coep:GainsLossesOnExtinguishmentOfDebt1
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000312"
      unitRef="USD">-200000</coep:GainsLossesOnExtinguishmentOfDebt1>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000314"
      unitRef="USD">1098055</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000315"
      unitRef="USD">-341660</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000317"
      unitRef="USD">766306</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000318"
      unitRef="USD">-822924</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000320"
      unitRef="USD">-12277192</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000321"
      unitRef="USD">-10877412</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000323"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000324"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000326"
      unitRef="USD">-12277192</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000327"
      unitRef="USD">-10877412</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000329"
      unitRef="USD">-360177</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000330"
      unitRef="USD">-196960</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000332"
      unitRef="USD">-11917015</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000333"
      unitRef="USD">-10680452</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000338"
      unitRef="USDPShares">-2.81</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000340"
      unitRef="USDPShares">-2.81</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000342"
      unitRef="USDPShares">-5.56</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000344"
      unitRef="USDPShares">-5.56</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000346"
      unitRef="Shares">4234787</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000348"
      unitRef="Shares">4234787</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000350"
      unitRef="Shares">1924639</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000352"
      unitRef="Shares">1924639</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000364"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact000354"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000366"
      unitRef="Shares">1766552</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000355"
      unitRef="USD">179</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000356"
      unitRef="USD">91670045</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_custom_CommonStockSubscribedMember"
      decimals="0"
      id="Fact000357"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_custom_SubscriptionReceivableMember"
      decimals="0"
      id="Fact000358"
      unitRef="USD">-3500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000359"
      unitRef="USD">-87356261</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000360"
      unitRef="USD">813963</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000361"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000362"
      unitRef="USD">813963</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000378"
      unitRef="Shares">50000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000369"
      unitRef="USD">5</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000370"
      unitRef="USD">99995</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000374"
      unitRef="USD">100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000376"
      unitRef="USD">100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <coep:SharesIssuedInConnectionWithSEPAShares
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000390"
      unitRef="Shares">20000</coep:SharesIssuedInConnectionWithSEPAShares>
    <coep:SharesIssuedInConnectionWithSEPAValue
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000381"
      unitRef="USD">2</coep:SharesIssuedInConnectionWithSEPAValue>
    <coep:SharesIssuedInConnectionWithSEPAValue
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000382"
      unitRef="USD">79998</coep:SharesIssuedInConnectionWithSEPAValue>
    <coep:SharesIssuedInConnectionWithSEPAValue
      contextRef="From2024-01-012024-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000386"
      unitRef="USD">80000</coep:SharesIssuedInConnectionWithSEPAValue>
    <coep:SharesIssuedInConnectionWithSEPAValue
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000388"
      unitRef="USD">80000</coep:SharesIssuedInConnectionWithSEPAValue>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000402"
      unitRef="Shares">207319</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000393"
      unitRef="USD">20</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000394"
      unitRef="USD">1329255</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000398"
      unitRef="USD">1329275</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000400"
      unitRef="USD">1329275</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <coep:StockIssuedDuringPeriodValueWarrantsIssuedForCash
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000406"
      unitRef="USD">500000</coep:StockIssuedDuringPeriodValueWarrantsIssuedForCash>
    <coep:StockIssuedDuringPeriodValueWarrantsIssuedForCash
      contextRef="From2024-01-012024-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000410"
      unitRef="USD">500000</coep:StockIssuedDuringPeriodValueWarrantsIssuedForCash>
    <coep:StockIssuedDuringPeriodValueWarrantsIssuedForCash
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000412"
      unitRef="USD">500000</coep:StockIssuedDuringPeriodValueWarrantsIssuedForCash>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000416"
      unitRef="USD">8150</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-01-012024-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000420"
      unitRef="USD">8150</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000422"
      unitRef="USD">8150</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <coep:WarrantsIssuedInExchangeForSubscriptionsReceivable
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000426"
      unitRef="USD">1900000</coep:WarrantsIssuedInExchangeForSubscriptionsReceivable>
    <coep:WarrantsIssuedInExchangeForSubscriptionsReceivable
      contextRef="From2024-01-012024-12-31_custom_SubscriptionReceivableMember"
      decimals="0"
      id="Fact000428"
      unitRef="USD">-2000000</coep:WarrantsIssuedInExchangeForSubscriptionsReceivable>
    <coep:WarrantsIssuedInExchangeForSubscriptionsReceivable
      contextRef="From2024-01-012024-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000430"
      unitRef="USD">-100000</coep:WarrantsIssuedInExchangeForSubscriptionsReceivable>
    <coep:WarrantsIssuedInExchangeForSubscriptionsReceivable
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000432"
      unitRef="USD">-100000</coep:WarrantsIssuedInExchangeForSubscriptionsReceivable>
    <coep:SharesIssuedForConversionOfDebtShares
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000444"
      unitRef="Shares">506</coep:SharesIssuedForConversionOfDebtShares>
    <coep:SharesIssuedForConversionOfDebtValue
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact000434"
      unitRef="USD">1</coep:SharesIssuedForConversionOfDebtValue>
    <coep:SharesIssuedForConversionOfDebtShares
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000446"
      unitRef="Shares">72059</coep:SharesIssuedForConversionOfDebtShares>
    <coep:SharesIssuedForConversionOfDebtValue
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000435"
      unitRef="USD">6</coep:SharesIssuedForConversionOfDebtValue>
    <coep:SharesIssuedForConversionOfDebtValue
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000436"
      unitRef="USD">951856</coep:SharesIssuedForConversionOfDebtValue>
    <coep:SharesIssuedForConversionOfDebtValue
      contextRef="From2024-01-012024-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000440"
      unitRef="USD">951863</coep:SharesIssuedForConversionOfDebtValue>
    <coep:SharesIssuedForConversionOfDebtValue
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000442"
      unitRef="USD">951863</coep:SharesIssuedForConversionOfDebtValue>
    <coep:StockIssuedDuringPeriodSharesOfPreferredShareOffering
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000458"
      unitRef="Shares">6014</coep:StockIssuedDuringPeriodSharesOfPreferredShareOffering>
    <coep:StockIssuedDuringPeriodValueOfPreferredShareOffering
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact000448"
      unitRef="USD">1</coep:StockIssuedDuringPeriodValueOfPreferredShareOffering>
    <coep:StockIssuedDuringPeriodValueOfPreferredShareOffering
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000450"
      unitRef="USD">5331938</coep:StockIssuedDuringPeriodValueOfPreferredShareOffering>
    <coep:StockIssuedDuringPeriodValueOfPreferredShareOffering
      contextRef="From2024-01-012024-12-31_custom_SubscriptionReceivableMember"
      decimals="0"
      id="Fact000452"
      unitRef="USD">-2100000</coep:StockIssuedDuringPeriodValueOfPreferredShareOffering>
    <coep:StockIssuedDuringPeriodValueOfPreferredShareOffering
      contextRef="From2024-01-012024-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000454"
      unitRef="USD">3231939</coep:StockIssuedDuringPeriodValueOfPreferredShareOffering>
    <coep:StockIssuedDuringPeriodValueOfPreferredShareOffering
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000455"
      unitRef="USD">682062</coep:StockIssuedDuringPeriodValueOfPreferredShareOffering>
    <coep:StockIssuedDuringPeriodValueOfPreferredShareOffering
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000456"
      unitRef="USD">3914001</coep:StockIssuedDuringPeriodValueOfPreferredShareOffering>
    <coep:StockIssuedDuringPeriodValueOfInvestmentsAssignmentAgreements
      contextRef="From2024-01-012024-12-31_custom_SubscriptionReceivableMember"
      decimals="0"
      id="Fact000464"
      unitRef="USD">5500000</coep:StockIssuedDuringPeriodValueOfInvestmentsAssignmentAgreements>
    <coep:StockIssuedDuringPeriodValueOfInvestmentsAssignmentAgreements
      contextRef="From2024-01-012024-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000466"
      unitRef="USD">5500000</coep:StockIssuedDuringPeriodValueOfInvestmentsAssignmentAgreements>
    <coep:StockIssuedDuringPeriodValueOfInvestmentsAssignmentAgreements
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000468"
      unitRef="USD">5500000</coep:StockIssuedDuringPeriodValueOfInvestmentsAssignmentAgreements>
    <coep:StockIssuedDuringPeriodValuePurchaseOfAssets1
      contextRef="From2024-01-012024-12-31_custom_CommonStockSubscribedMember"
      decimals="0"
      id="Fact000473"
      unitRef="USD">541875</coep:StockIssuedDuringPeriodValuePurchaseOfAssets1>
    <coep:StockIssuedDuringPeriodValuePurchaseOfAssets1
      contextRef="From2024-01-012024-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000476"
      unitRef="USD">541875</coep:StockIssuedDuringPeriodValuePurchaseOfAssets1>
    <coep:StockIssuedDuringPeriodValuePurchaseOfAssets1
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000478"
      unitRef="USD">541875</coep:StockIssuedDuringPeriodValuePurchaseOfAssets1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000482"
      unitRef="USD">1104978</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000486"
      unitRef="USD">1104978</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000488"
      unitRef="USD">1104978</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000500"
      unitRef="Shares">261</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000492"
      unitRef="USD">533</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000496"
      unitRef="USD">533</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000498"
      unitRef="USD">533</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000507"
      unitRef="USD">-10680452</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000508"
      unitRef="USD">-10680452</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000509"
      unitRef="USD">-196960</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000510"
      unitRef="USD">-10877412</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000522"
      unitRef="Shares">6520</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact000512"
      unitRef="USD">2</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000524"
      unitRef="Shares">2116191</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000513"
      unitRef="USD">212</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000514"
      unitRef="USD">102976748</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_custom_CommonStockSubscribedMember"
      decimals="0"
      id="Fact000515"
      unitRef="USD">541875</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_custom_SubscriptionReceivableMember"
      decimals="0"
      id="Fact000516"
      unitRef="USD">-2100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000517"
      unitRef="USD">-98036713</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000518"
      unitRef="USD">3382124</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000519"
      unitRef="USD">485102</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000520"
      unitRef="USD">3867226</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000536"
      unitRef="Shares">696467</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000527"
      unitRef="USD">70</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000528"
      unitRef="USD">8119930</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-12-31_custom_SubscriptionReceivableMember"
      decimals="0"
      id="Fact000530"
      unitRef="USD">-3561544</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000532"
      unitRef="USD">4558456</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000534"
      unitRef="USD">4558456</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <coep:SharesIssuedInConnectionWithSEPAShares
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000548"
      unitRef="Shares">225000</coep:SharesIssuedInConnectionWithSEPAShares>
    <coep:SharesIssuedInConnectionWithSEPAValue
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000539"
      unitRef="USD">23</coep:SharesIssuedInConnectionWithSEPAValue>
    <coep:SharesIssuedInConnectionWithSEPAValue
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000540"
      unitRef="USD">2958825</coep:SharesIssuedInConnectionWithSEPAValue>
    <coep:SharesIssuedInConnectionWithSEPAValue
      contextRef="From2025-01-012025-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000544"
      unitRef="USD">2958848</coep:SharesIssuedInConnectionWithSEPAValue>
    <coep:SharesIssuedInConnectionWithSEPAValue
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000546"
      unitRef="USD">2958848</coep:SharesIssuedInConnectionWithSEPAValue>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000560"
      unitRef="Shares">362871</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000551"
      unitRef="USD">36</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000552"
      unitRef="USD">3829184</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-012025-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000556"
      unitRef="USD">3829220</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000558"
      unitRef="USD">3829220</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <coep:SharesIssuedForInvestmentShares
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000572"
      unitRef="Shares">66837</coep:SharesIssuedForInvestmentShares>
    <coep:SharesIssuedForInvestmentValue
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000563"
      unitRef="USD">6</coep:SharesIssuedForInvestmentValue>
    <coep:SharesIssuedForInvestmentValue
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000564"
      unitRef="USD">999994</coep:SharesIssuedForInvestmentValue>
    <coep:SharesIssuedForInvestmentValue
      contextRef="From2025-01-012025-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000568"
      unitRef="USD">1000000</coep:SharesIssuedForInvestmentValue>
    <coep:SharesIssuedForInvestmentValue
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000570"
      unitRef="USD">1000000</coep:SharesIssuedForInvestmentValue>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact000574"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000584"
      unitRef="Shares">187500</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000575"
      unitRef="USD">19</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000576"
      unitRef="USD">541856</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2025-01-012025-12-31_custom_CommonStockSubscribedMember"
      decimals="0"
      id="Fact000577"
      unitRef="USD">-541875</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2025-01-012025-12-31_custom_SubscriptionReceivableMember"
      decimals="0"
      id="Fact000578"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000579"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2025-01-012025-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000580"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000581"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000582"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000588"
      unitRef="USD">824295</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2025-01-012025-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000592"
      unitRef="USD">824295</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000594"
      unitRef="USD">824295</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <coep:StockIssuedDuringPeriodSharesPrefundedWarrantsExercise
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000606"
      unitRef="Shares">450000</coep:StockIssuedDuringPeriodSharesPrefundedWarrantsExercise>
    <coep:StockIssuedDuringPeriodValuePrefundedWarrantsExercise
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000597"
      unitRef="USD">45</coep:StockIssuedDuringPeriodValuePrefundedWarrantsExercise>
    <coep:StockIssuedDuringPeriodValuePrefundedWarrantsExercise
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000598"
      unitRef="USD">855</coep:StockIssuedDuringPeriodValuePrefundedWarrantsExercise>
    <coep:StockIssuedDuringPeriodValuePrefundedWarrantsExercise
      contextRef="From2025-01-012025-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000602"
      unitRef="USD">900</coep:StockIssuedDuringPeriodValuePrefundedWarrantsExercise>
    <coep:StockIssuedDuringPeriodValuePrefundedWarrantsExercise
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000604"
      unitRef="USD">900</coep:StockIssuedDuringPeriodValuePrefundedWarrantsExercise>
    <coep:StockIssuedDuringPeriodSharesOfPreferredShareOffering
      contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000618"
      unitRef="Shares">3480</coep:StockIssuedDuringPeriodSharesOfPreferredShareOffering>
    <coep:StockIssuedDuringPeriodValueOfPreferredShareOffering
      contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact000608"
      unitRef="USD">-1</coep:StockIssuedDuringPeriodValueOfPreferredShareOffering>
    <coep:StockIssuedDuringPeriodValueOfPreferredShareOffering
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000610"
      unitRef="USD">3098763</coep:StockIssuedDuringPeriodValueOfPreferredShareOffering>
    <coep:StockIssuedDuringPeriodValueOfPreferredShareOffering
      contextRef="From2025-01-012025-12-31_custom_SubscriptionReceivableMember"
      decimals="0"
      id="Fact000612"
      unitRef="USD">1975000</coep:StockIssuedDuringPeriodValueOfPreferredShareOffering>
    <coep:StockIssuedDuringPeriodValueOfPreferredShareOffering
      contextRef="From2025-01-012025-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000614"
      unitRef="USD">5073762</coep:StockIssuedDuringPeriodValueOfPreferredShareOffering>
    <coep:StockIssuedDuringPeriodValueOfPreferredShareOffering
      contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000615"
      unitRef="USD">381238</coep:StockIssuedDuringPeriodValueOfPreferredShareOffering>
    <coep:StockIssuedDuringPeriodValueOfPreferredShareOffering
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000616"
      unitRef="USD">5455000</coep:StockIssuedDuringPeriodValueOfPreferredShareOffering>
    <coep:StockIssuedDuringPeriodSharePreferredShareConversion
      contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000630"
      unitRef="Shares">-10000</coep:StockIssuedDuringPeriodSharePreferredShareConversion>
    <coep:StockIssuedDuringPeriodValuePreferredShareConversion
      contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact000620"
      unitRef="USD">-1</coep:StockIssuedDuringPeriodValuePreferredShareConversion>
    <coep:StockIssuedDuringPeriodSharePreferredShareConversion
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000632"
      unitRef="Shares">1250000</coep:StockIssuedDuringPeriodSharePreferredShareConversion>
    <coep:StockIssuedDuringPeriodValuePreferredShareConversion
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000621"
      unitRef="USD">125</coep:StockIssuedDuringPeriodValuePreferredShareConversion>
    <coep:StockIssuedDuringPeriodValuePreferredShareConversion
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000622"
      unitRef="USD">-124</coep:StockIssuedDuringPeriodValuePreferredShareConversion>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000644"
      unitRef="Shares">392082</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000635"
      unitRef="USD">39</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000636"
      unitRef="USD">2635673</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-01-012025-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000640"
      unitRef="USD">2635712</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000642"
      unitRef="USD">2635712</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000648"
      unitRef="USD">1215692</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000652"
      unitRef="USD">1215692</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000654"
      unitRef="USD">1215692</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000661"
      unitRef="USD">-11917015</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000662"
      unitRef="USD">-11917015</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000663"
      unitRef="USD">-360177</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000664"
      unitRef="USD">-12277192</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000676"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-12-31_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact000666"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000678"
      unitRef="Shares">5746948</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000667"
      unitRef="USD">575</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000668"
      unitRef="USD">127201691</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-12-31_custom_CommonStockSubscribedMember"
      decimals="0"
      id="Fact000669"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-12-31_custom_SubscriptionReceivableMember"
      decimals="0"
      id="Fact000670"
      unitRef="USD">-3686544</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000671"
      unitRef="USD">-109953728</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000672"
      unitRef="USD">13561994</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000673"
      unitRef="USD">506163</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000674"
      unitRef="USD">14068157</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000683"
      unitRef="USD">-12277192</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000684"
      unitRef="USD">-10877412</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000689"
      unitRef="USD">1181212</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000690"
      unitRef="USD">1000845</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000692"
      unitRef="USD">41385</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000693"
      unitRef="USD">37788</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000695"
      unitRef="USD">545635</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000696"
      unitRef="USD">216189</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:OtherNoncashIncome
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000698"
      unitRef="USD">1333045</us-gaap:OtherNoncashIncome>
    <us-gaap:OtherNoncashIncome
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000699"
      unitRef="USD">-0</us-gaap:OtherNoncashIncome>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000701"
      unitRef="USD">1215692</us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000702"
      unitRef="USD">1104978</us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000704"
      unitRef="USD">3829220</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000705"
      unitRef="USD">1329276</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <coep:WarrantsIssuedForServices
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000707"
      unitRef="USD">824295</coep:WarrantsIssuedForServices>
    <coep:WarrantsIssuedForServices
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000708"
      unitRef="USD">8150</coep:WarrantsIssuedForServices>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000710"
      unitRef="USD">906430</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000711"
      unitRef="USD">-539660</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000713"
      unitRef="USD">-191625</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000714"
      unitRef="USD">-198000</us-gaap:FairValueAdjustmentOfWarrants>
    <coep:LossOnSharesIssuedForConversionOfDebt
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000716"
      unitRef="USD">0</coep:LossOnSharesIssuedForConversionOfDebt>
    <coep:LossOnSharesIssuedForConversionOfDebt
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000717"
      unitRef="USD">77250</coep:LossOnSharesIssuedForConversionOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000719"
      unitRef="USD">159035</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000720"
      unitRef="USD">-200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000722"
      unitRef="USD">0</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000723"
      unitRef="USD">37257</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:GainLossOnInvestments
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000725"
      unitRef="USD">-163500</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000726"
      unitRef="USD">-0</us-gaap:GainLossOnInvestments>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000728"
      unitRef="USD">76596</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000729"
      unitRef="USD">-0</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:IncreaseDecreaseInInterestAndDividendsReceivable
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000734"
      unitRef="USD">7348</us-gaap:IncreaseDecreaseInInterestAndDividendsReceivable>
    <us-gaap:IncreaseDecreaseInInterestAndDividendsReceivable
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000735"
      unitRef="USD">234742</us-gaap:IncreaseDecreaseInInterestAndDividendsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000737"
      unitRef="USD">473497</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000738"
      unitRef="USD">118472</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000743"
      unitRef="USD">-381012</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000744"
      unitRef="USD">-149935</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000746"
      unitRef="USD">-440889</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000747"
      unitRef="USD">180934</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000749"
      unitRef="USD">-42306</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000750"
      unitRef="USD">-38047</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000752"
      unitRef="USD">-115000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000753"
      unitRef="USD">235000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000755"
      unitRef="USD">-8603036</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000756"
      unitRef="USD">-6649281</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000761"
      unitRef="USD">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000762"
      unitRef="USD">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000767"
      unitRef="USD">990000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000768"
      unitRef="USD">1850000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromRepaymentsOfNotesPayable
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000770"
      unitRef="USD">-218750</us-gaap:ProceedsFromRepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromRepaymentsOfNotesPayable
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000771"
      unitRef="USD">-650969</us-gaap:ProceedsFromRepaymentsOfNotesPayable>
    <coep:SharesIssuedForSepa
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000773"
      unitRef="USD">2958848</coep:SharesIssuedForSepa>
    <coep:SharesIssuedForSepa
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000774"
      unitRef="USD">0</coep:SharesIssuedForSepa>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000776"
      unitRef="USD">4558455</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000777"
      unitRef="USD">100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000779"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000780"
      unitRef="USD">500000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000782"
      unitRef="USD">900</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000783"
      unitRef="USD">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000785"
      unitRef="USD">5455000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000786"
      unitRef="USD">3914001</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000788"
      unitRef="USD">13744453</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000789"
      unitRef="USD">5713032</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000791"
      unitRef="USD">5141417</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000792"
      unitRef="USD">-936249</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000794"
      unitRef="USD">532885</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000795"
      unitRef="USD">1469134</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000797"
      unitRef="USD">5674302</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000798"
      unitRef="USD">532885</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000803"
      unitRef="USD">8772</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000804"
      unitRef="USD">8772</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000806"
      unitRef="USD">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000807"
      unitRef="USD">0</us-gaap:IncomeTaxesPaidNet>
    <coep:SubscriptionsReceivable
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000812"
      unitRef="USD">3686544</coep:SubscriptionsReceivable>
    <coep:SubscriptionsReceivable
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000813"
      unitRef="USD">2100000</coep:SubscriptionsReceivable>
    <coep:SharesIssuedForConversionOfDebt
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000815"
      unitRef="USD">2635712</coep:SharesIssuedForConversionOfDebt>
    <coep:SharesIssuedForConversionOfDebt
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000816"
      unitRef="USD">951684</coep:SharesIssuedForConversionOfDebt>
    <coep:SharesIssuedForInvestment
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000818"
      unitRef="USD">1000000</coep:SharesIssuedForInvestment>
    <coep:SharesIssuedForInvestment
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000819"
      unitRef="USD">0</coep:SharesIssuedForInvestment>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000821">&lt;p id="xdx_803_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zLNR17dqahnh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 1 &#x2013; &lt;span id="xdx_829_ziS0hz4nzVB6"&gt;DESCRIPTION OF BUSINESS
AND BASIS OF PRESENTATION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Nature of Business&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;General&lt;/i&gt;. Coeptis Therapeutics Holdings,
Inc. (&#x201c;Coeptis&#x201d;, the &#x201c;Company&#x201d; or &#x201c;we&#x201d; or &#x201c;our&#x201d;) was originally incorporated in the British
Virgin Islands on November 27, 2018, under the name Bull Horn Holdings Corp. On October 27, 2022, Bull Horn Holdings Corp. domesticated
from the British Virgin Islands to the State of Delaware. On October 28, 2022, in connection with the closing of the Merger, we changed
our corporate name from Bull Horn Holdings Corp. to &#x201c;Coeptis Therapeutics Holdings, Inc.&#x201d;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;The Merger Transaction&lt;/i&gt;. On October 28,
2022, a wholly owned subsidiary of Bull Horn Holdings Corp., merged with and into Coeptis Therapeutics, Inc., with Coeptis Therapeutics,
Inc. as the surviving corporation of the Merger. As a result of the Merger, we acquired the business of Coeptis Therapeutics, Inc., which
now continues to operate as a wholly owned subsidiary.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;About the Company&#x2019;s Subsidiaries&lt;/i&gt;.
We are now a holding company that currently operates through our direct and indirect subsidiaries SNAP Biosciences, Inc. and GEAR Therapeutics,
Inc., which are majority owned, and Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc. and Coeptis Pharmaceuticals, LLC, which
are wholly owned.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Coeptis is a biopharmaceutical and technology
company. The biopharmaceutical division focuses on developing innovative cell therapy platforms for cancer, autoimmune, and infectious
diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its cutting-edge research and development efforts.
The technology division&#160;focuses on enhancing operational capabilities through advanced technologies. This division features AI-powered
marketing software and robotic process automation tools designed to optimize business processes and improve overall efficiency.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Basis of Presentation &#x2013; &lt;/b&gt;The
accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the
United States of America (&#x201c;GAAP&#x201d;) for financial information and with the instructions to Form 10-K and Rule 8-03 of
Regulation S-X. Accordingly, they include all of the information and notes required by GAAP for complete financial statements. In
the opinion of the Company&#x2019;s management, any adjustments contained in the accompanying consolidated financial statements are
of a normal recurring nature, and are necessary to fairly present the financial position and operating results of the Company as of
December 31, 2025 and 2024 and for the years then ended.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Principles of Consolidation &lt;/b&gt;&#x2013;
The accompanying consolidated financial statements include the accounts of Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals,
Inc., Coeptis Pharmaceuticals, LLC, SNAP Biosciences, Inc., and GEAR Therapeutics, Inc. All material intercompany accounts, balances
and transactions have been eliminated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Reverse Stock Split &lt;/b&gt;&#x2013; On
December 31, 2024, the Company completed a &lt;span id="xdx_907_eus-gaap--StockholdersEquityReverseStockSplit_c20241201__20241231_zTgKS5QXmvQ5" title="Reverse stock split"&gt;20-1 reverse stock split&lt;/span&gt; of its issued and outstanding common stock. As a result of the
reverse stock split, every 20 shares of issued and outstanding common stock were automatically combined into one share, with no
change in the par value per share. Fractional shares resulting from the reverse stock split were rounded to the nearest whole share.
The reverse stock split has been retrospectively applied to all share and per-share amounts presented in these consolidated
financial statements and accompanying notes for all periods presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2024-12-012024-12-31" id="Fact000823">20-1 reverse stock split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000829">&lt;p id="xdx_809_eus-gaap--SignificantAccountingPoliciesTextBlock_zYg7jG2CuTT" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 2 &#x2013; &lt;span id="xdx_820_zHeiZMHAMR31"&gt;SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zGm6yV3zsErd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86F_zyoHTINo5VH3"&gt;Cash&lt;/span&gt;&lt;/b&gt; &#x2013; For purposes of the consolidated
statements of cash flows, the Company considers all highly liquid investments purchased with maturities of three months or less to be
cash equivalents. At times, balances of cash and cash equivalents at financial banking institutions exceeded the federally insured limit
of $250,000. Uninsured balances were $&lt;span id="xdx_903_eus-gaap--CashUninsuredAmount_iI_c20251231_zN2x1dAe3aXg" title="Cash uninsured amount"&gt;5,424,302&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--CashUninsuredAmount_iI_c20241231_zoFGPqjfmOD4" title="Cash uninsured amount"&gt;282,885&lt;/span&gt; at December 31, 2025 and 2024, respectively. The Company regularly monitors
the financial condition of the institution in which it has depository accounts and believes the risk of loss is minimal.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zbI43jjYfaok" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_862_zTI2mm429brg"&gt;Property and Equipment&lt;/span&gt;&lt;/b&gt; &#x2013; Fixed assets
are stated at cost and depreciation is computed using the straight-line method for financial statement purposes. For the years ended December
31, 2025 and 2024, depreciation expense totaled $&lt;span id="xdx_902_eus-gaap--Depreciation_pp0p0_c20250101__20251231_z1tZWfPnEmg2" title="Depreciation expense"&gt;587&lt;/span&gt;&#160;and $&lt;span id="xdx_900_eus-gaap--Depreciation_pp0p0_c20240101__20241231_zToUtw0uIgXc" title="Depreciation expense"&gt;845&lt;/span&gt; respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zPZuzK2istNa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86D_zhEsujK9A1Q6"&gt;Intangible Assets&lt;/span&gt;&lt;/b&gt; &#x2013; The Company records
intangible assets at cost and evaluates them for impairment in accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;)
Accounting Standards Codification (&#x201c;ASC&#x201d;) 350, &lt;i&gt;Intangibles &#x2013; Goodwill and Other. &lt;/i&gt;Intangibles are being amortized
using the straight-line method over estimated useful lives of between two and forty years. The Company recorded intangible assets of $&lt;span id="xdx_905_eus-gaap--FinitelivedIntangibleAssetsAcquired1_c20250101__20251231__us-gaap--AssetAcquisitionAxis__custom--NexGenAIMember_zx0iJDtPiIvc" title="Intangible assets acquired"&gt;361,250&lt;/span&gt;
and $&lt;span id="xdx_90F_eus-gaap--FinitelivedIntangibleAssetsAcquired1_c20240101__20241231__us-gaap--AssetAcquisitionAxis__custom--NexGenAIMember_zr7CYzFlfrek" title="Intangible assets acquired"&gt;541,875&lt;/span&gt; as of December 31, 2025 and December 31, 2024, respectively, related to the acquired assets of NexGenAI Affiliates Network
Platform (&#x201c;NexGenAI&#x201d;), which contains AI-powered marketing software and robotic process automation capabilities. See Note
14, Intangible Assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--MarketableSecuritiesPolicy_zYcevolqQtzf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_862_zgGq4RzAIRql"&gt;Investments
and Marketable Securities&lt;/span&gt; &lt;/b&gt;&#x2013; The Company classifies its investments and marketable securities in accordance with ASC 320, &lt;i&gt;Investments
&#x2013; Debt and Equity Securities&lt;/i&gt;, and ASC 321, &lt;i&gt;Investments &#x2013; Equity Securities&lt;/i&gt;, as applicable. Investments in
equity securities with readily determinable fair values are measured at fair value, with unrealized gains and losses recognized in
net income. For equity securities without readily determinable fair values, the Company applies the measurement alternative,
recording these investments at cost, adjusted for impairments or observable price changes from transactions involving similar
securities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Marketable securities are categorized as trading
securities and are thus marked to market and stated at fair value. Fair value is determined using the quoted closing bid prices and is
recorded as a Level&#160;1 asset. Realized gains and losses on marketable securities are recognized as incurred in the consolidated statements
of operations. Net changes in unrealized gains and losses are reported in the consolidated statements of operations in the current period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--LesseeLeasesPolicyTextBlock_zZd5E69YaC1l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_861_z0y9vDd2f1ad"&gt;Leases&lt;/span&gt; &lt;/b&gt;&#x2013; The Company accounts for
leases in accordance with ASC 842, &lt;i&gt;Leases&lt;/i&gt;. At lease commencement, the Company recognizes a right-of-use (&#x201c;ROU&#x201d;) asset
and a corresponding lease liability based on the present value of future lease payments. Lease liabilities are measured using the Company&#x2019;s
incremental borrowing rate if the implicit rate is not readily determinable. ROU assets include initial direct costs and prepaid lease
payments and are reduced for lease incentives received.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_zGhipFppvmqj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_862_zTqBTUr2ay9b"&gt;Research
and Development&lt;/span&gt; &#x2013; &lt;/b&gt;Research and development costs are expensed when incurred. During the years ended December 31,
2025 and 2024, research and development expenses totaled $&lt;span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20250101__20251231_zBA2qHuPDBA1" title="Research and development expenses"&gt;1,277,150&lt;/span&gt;
and $&lt;span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240101__20241231_zkmiNA8JRxJb" title="Research and development expenses"&gt;2,331,548&lt;/span&gt;,
respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zXWVvjClM0Hk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_865_zugKK9EiCuYd"&gt;Impairment
of Long-Lived Assets&lt;/span&gt; &#x2013; &lt;/b&gt;The Company&#x2019;s property and equipment and other non-current assets are reviewed
annually for possible impairment when events or changes in circumstances indicate that the carrying amount may not be recoverable.
An impairment loss would be recognized if and when the estimated future cash flows expected to result from the use of the asset and
its eventual disposition is less than its carrying amount. There was&#160;&lt;span id="xdx_90C_eus-gaap--AssetImpairmentCharges_do_c20250101__20251231_zKtzAEblcpXd" title="Asset impairment charges"&gt;&lt;span id="xdx_901_eus-gaap--AssetImpairmentCharges_do_c20240101__20241231_zEZpMcINsYf4"&gt;no&lt;/span&gt;&lt;/span&gt;
impairment recognized for the years ended December 31, 2025 and 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--DerivativesPolicyTextBlock_zuMnkgjuA1yc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_864_znIkXgOSEJe2"&gt;Derivative Liability Warrants&lt;/span&gt; &#x2013; &lt;/b&gt;The
Company accounts for the Public Warrants and Private Placement Warrants (the &#x201c;Warrants&#x201d;) in accordance with the guidance contained
in ASC 815-40, &lt;i&gt;Derivatives and Hedging&lt;/i&gt;, under which the Warrants do not meet the criteria for equity treatment and must be recorded
as liabilities. Accordingly, the Company classifies the Warrants as liabilities at their fair value and adjusts the Warrants to fair value
in each respective reporting period. This liability is subject to re-measurement at each consolidated balance sheet date until the Warrants
are exercised, and any change in fair value is recognized in the consolidated statements of operations. The Private Placement Warrants
and the Public Warrants for periods where no observable traded price was available are valued using a binomial lattice simulation model.
For periods subsequent to the detachment of the Public Warrants from the Units, the Public Warrant quoted market price was used as the
fair value as of each relevant date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--DebtPolicyTextBlock_zPHbxdJkHdZj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_866_z9JMzbYp8Og5"&gt;Convertible Debt&lt;/span&gt;&lt;/b&gt; &#x2013; The Company accounts
for convertible debt in accordance with ASC 470-20, &lt;i&gt;Debt &#x2013; Debt with Conversion and Other Options&lt;/i&gt;. Convertible debt instruments
are evaluated at issuance to determine whether they contain embedded features that require bifurcation as derivatives or equity components.
If the embedded conversion feature meets the criteria for derivative accounting under ASC 815, &lt;i&gt;Derivatives and Hedging&lt;/i&gt;, it is bifurcated
and recorded separately at fair value, with subsequent changes in fair value recognized in earnings. Upon conversion or repurchase of
convertible debt, the Company recognizes a gain or loss in accordance with ASC 470-20 and ASC 470-50, &lt;i&gt;Debt Modifications and Extinguishments&lt;/i&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zHAAha3GsZn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_865_z3u6TYbMNYnj"&gt;Income Taxes&lt;/span&gt; &lt;/b&gt;&#x2013; Income taxes are provided
for the tax effects of transactions reported in the consolidated financial statements and consist of taxes currently due plus deferred
taxes related primarily to temporary differences between reporting of income and expenses for financial reporting purposes and income
tax purposes. The deferred tax assets and liabilities represent the future tax return consequences of those differences, which will either
be taxable or deductible when the assets and liabilities are recovered or settled. Deferred taxes also are recognized for operating losses
that are available to offset future federal income taxes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Income Taxes Topic of FASB ASC clarifies the
accounting and reporting for uncertainties in income tax law within subtopic FASB ASC 740-10-25-5. The guidance prescribes a comprehensive
model for the financial statement recognition, measurement, presentation, and disclosure of uncertain tax positions taken or expected
to be taken in income tax returns. Management believes that there is&#160;&lt;span id="xdx_90C_eus-gaap--UnrecognizedTaxBenefits_iI_pp0p0_do_c20251231_zzgyalr1YRb1" title="Uncertain tax positions"&gt;&lt;span id="xdx_90C_eus-gaap--UnrecognizedTaxBenefits_iI_pp0p0_do_c20241231_z9pJ5W7wdqmi" title="Uncertain tax positions"&gt;no&lt;/span&gt;&lt;/span&gt;&#160;liability related to uncertain tax positions during
the years ended December 31, 2025 and 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--UseOfEstimates_zGhCno2pOdh6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86C_zicXUShi27md"&gt;Use of Estimates&lt;/span&gt; &#x2013; &lt;/b&gt;The preparation
of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements
and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zkXNemGlANOk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86B_zWfWKjGsO9M"&gt;Reclassification&lt;/span&gt; &lt;/b&gt;&#x2013; The Company reclassified
certain amounts of total stockholders&#x2019; equity &#x2013; noncontrolling interests, net loss attributable to non-controlling interests,
and accumulated deficit from prior periods. These presentation changes did not affect total stockholders&#x2019; equity or net loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zRj8znYSaTXd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86D_zOCJE3Hv5If3"&gt;Employee and Non-Employee Share-Based Compensation&lt;/span&gt;
&lt;/b&gt;&#x2013; The Company applies ASC 718-10,&#160;&lt;i&gt;Share-Based Payment&lt;/i&gt;, which requires the measurement and recognition of compensation
expenses for all share-based payment awards made to employees and directors including employee stock option equity awards issued to employees
and non-employees based on estimated fair values.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;ASC 718-10 requires companies to estimate the
fair value of equity-based option awards on the date of grant using an option-pricing model. The fair value of the award is recognized
as an expense on a straight-line basis over the requisite service periods in the Company&#x2019;s consolidated statements of operations.
The Company recognizes share-based award forfeitures as they occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company estimates the fair value of granted
option equity awards using a Black-Scholes option pricing model. The option-pricing model requires a number of assumptions, of which the
most significant are share price, expected volatility and the expected option term (the time from the grant date until the options are
exercised or expire). Expected volatility is estimated based on volatility of the Company. The Company has historically not paid dividends
and has no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds
with an equivalent term. The expected option term is calculated for options granted to employees and directors using the &#x201c;simplified&#x201d;
method. Changes in the determination of each of the inputs can affect the fair value of the options granted and the results of operations
of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zOOWsmECMEZ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_860_zNI8i6I7Rtza"&gt;&lt;b&gt;Recent
Accounting Pronouncements&lt;/b&gt;&lt;/span&gt;&lt;b&gt;&#160;&lt;/b&gt;&#x2013; During the years ended December 31, 2025 and 2024, there were new accounting
pronouncements issued by the FASB. Each of these pronouncements, as applicable, including Accounting Standards Update (&#x201c;ASU&#x201d;)
2023-07, &lt;i&gt;Segment Reporting&lt;/i&gt;, has been or will be adopted by the Company. Please see Note 15, Segment Reporting. Management does
not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company&#x2019;s consolidated
financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--RevenueRecognitionPolicyTextBlock_z4z3tzepn6Fd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86A_zwA8j2PfPnfk"&gt;Revenue Recognition&lt;/span&gt;&lt;/b&gt;&#160;&#x2013; The Company
recognizes revenue in accordance with ASC Topic 606, &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt; (&#x201c;ASC 606&#x201d;) to depict the
transfer of control to the Company&#x2019;s customers in an amount reflecting the consideration to which the Company expects to be entitled.
The Company determines revenue recognition through the following steps:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 6%"&gt;&lt;span style="font-size: 10pt"&gt;i.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 91%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Identification of the contract, or contracts, with a customer&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;ii.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Identification of the performance obligations in the contract&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;iii.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Determination of the transaction price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;iv.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Allocation of the transaction price to the performance obligations in the contract&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;v.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Recognition of revenue, when, or as, the company satisfies the performance obligations.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Under ASC 606, revenue is recognized when control
of promised goods and services is transferred to customers. A performance obligation is a contractual promise to transfer a distinct good
or service to the customer and is the unit of account under ASC 606. The transaction price of a contract is allocated to distinct performance
obligations and recognized as revenue when or as the performance obligations are satisfied.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company generates revenue from its customers
by 1) performing data research for its customers and delivering advertising campaigns via cold emails and social media sites, and 2) providing
webinars for its customers to a targeted business-to-business audience. The fee for these services is based on observable prices explicitly
negotiated between the Company and the customer. The Company recognizes revenue at the point in time when the good or service is delivered
to the customer, which occurs upon delivery of the advertising campaign or webinar and there is a transfer of control to the customer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2025, revenues
from delivering advertising campaigns via cold emails and social media sites were recognized from six customers who accounted for &lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20251231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SixCustomersMember__srt--ProductOrServiceAxis__custom--AdvertisingCampaignsMember_zLX4oEOfVmxh" title="Concentration risk percentage"&gt;100&lt;/span&gt;%
of this revenue. Revenue was recognized at the point of delivery to the customers in the amount of $&lt;span id="xdx_90D_eus-gaap--Revenues_c20250101__20251231__srt--ProductOrServiceAxis__custom--AdvertisingCampaignsMember_zT74wjk0aKHa" title="Revenues"&gt;1,250,545&lt;/span&gt;. As of December 31, 2025,
the Company has recorded customer deposits in the amount of $&lt;span id="xdx_902_eus-gaap--DeferredRevenueCurrent_iI_c20251231__srt--ProductOrServiceAxis__custom--AdvertisingCampaignsMember_z60oqDcquob1" title="Customer deposits"&gt;599,455&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2025, revenues
from delivering webinar services were recognized from three customers who accounted for &lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20251231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThreeCustomersMember__srt--ProductOrServiceAxis__custom--WebinarServicesMember_zjRu100sQNS4" title="Concentration risk percentage"&gt;100&lt;/span&gt;% of this revenue. Revenue was recognized at
the point of delivery to the customers in the amount of $&lt;span id="xdx_90E_eus-gaap--Revenues_c20250101__20251231__srt--ProductOrServiceAxis__custom--WebinarServicesMember_zsA6a78dhLyf" title="Revenues"&gt;112,500&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zAsU6WAQ4KI8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_865_z2FQOuGhQvN9"&gt;Earnings Per Share&lt;/span&gt;&lt;/b&gt; &#x2013; Basic earnings
per share (or loss per share), is computed by dividing the earnings (loss) for the period by the weighted average number of common stock
shares outstanding for the period. Diluted earnings per share reflects potential dilution of securities by including other potentially
issuable shares of common stock, including shares issuable upon conversion of convertible securities or exercise of outstanding stock
options and warrants, in the weighted average number of common shares outstanding for the period. Therefore, because including shares
issuable upon conversion of convertible securities and/or exercise of outstanding options and warrants would have an anti-dilutive effect
on the loss per share, only the basic earnings (loss) per share is reported in the accompanying consolidated financial statements. The
Company does not have other potentially issuable shares of stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following potential common shares would have
an antidilutive effect on loss per share:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zGWihs13k28a" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt; color: White"&gt;&lt;b&gt;&lt;span id="xdx_8BB_zFQw89wo8x2c" style="display: none"&gt;Schedule of antidilutive shares&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Years ended December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 68%"&gt;&lt;span style="font-size: 10pt"&gt;Warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zxPQLg8XFKHf" style="width: 13%; text-align: right" title="Antidilutive shares"&gt;&lt;span style="font-size: 10pt"&gt;945,105&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_ziMaBdHFS59l" style="width: 13%; text-align: right" title="Antidilutive shares"&gt;&lt;span style="font-size: 10pt"&gt;1,399,316&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Stock options&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zwFiS2Xbflk5" style="text-align: right" title="Antidilutive shares"&gt;&lt;span style="font-size: 10pt"&gt;437,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zLzpYEY8VEh9" style="text-align: right" title="Antidilutive shares"&gt;&lt;span style="font-size: 10pt"&gt;279,625&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Convertible notes payable&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleNotesPayableMember_zpAXF3MhJOB7" style="text-align: right" title="Antidilutive shares"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleNotesPayableMember_zdFZzQI3BU8e" style="text-align: right" title="Antidilutive shares"&gt;&lt;span style="font-size: 10pt"&gt;406,629&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Preferred stock&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--PreferredStockMember_zHdONONx2RV8" style="border-bottom: black 1pt solid; text-align: right" title="Antidilutive shares"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--PreferredStockMember_zKW6pQqwpZ0h" style="border-bottom: black 1pt solid; text-align: right" title="Antidilutive shares"&gt;&lt;span style="font-size: 10pt"&gt;815,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231_z2Df7bPawez9" style="border-bottom: black 2.25pt double; text-align: right" title="Antidilutive shares"&gt;&lt;span style="font-size: 10pt"&gt;1,382,105&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231_ziJtf4fsJ3G" style="border-bottom: black 2.25pt double; text-align: right" title="Antidilutive shares"&gt;&lt;span style="font-size: 10pt"&gt;2,900,570&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_z2gYXYVgQI29" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86D_zRxnqmvvUvna"&gt;Going Concern&lt;/span&gt; &#x2013;&lt;/b&gt; The accompanying
consolidated financial statements have been prepared in conformity with GAAP which contemplate continuation of the Company as a going
concern, which is dependent upon the Company&#x2019;s ability to obtain sufficient financing or establish itself as a profitable business.
As of December 31, 2025, the Company had an accumulated deficit of $&lt;span id="xdx_90C_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20251231_zNeMP0RaPasd" title="Accumulated deficit"&gt;109,953,728&lt;/span&gt;, and for the year ended December 31, 2025, the Company
had a net loss of $&lt;span id="xdx_90F_eus-gaap--ProfitLoss_iN_di_c20250101__20251231_zwJw9pkfv7x" title="Net loss"&gt;12,277,192&lt;/span&gt;. These conditions raise substantial doubt about the Company&#x2019;s ability to continue as a going concern.
Management&#x2019;s plans with respect to operations include raising additional capital through sales of equity or debt securities as may
be necessary to pursue its business plans and sustain operations until such time as the Company can achieve profitability. Management
believes that additional financing as necessary will result in improved operations and cash flow. However, there can be no assurance that
management will be successful in obtaining additional funding or in attaining profitable operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zHgRczn8lra3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_863_zGDiDX0QL2Ag"&gt;Fair Value of Financial Instruments and Measurements&lt;/span&gt;&lt;/b&gt;
&#x2013; The Company measures certain financial instruments at fair value in accordance with ASC 820, &lt;i&gt;Fair Value Measurement&lt;/i&gt;, for
its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets
and liabilities that are re-measured and reported at fair value at least annually. The fair value of the Company&#x2019;s financial assets
and liabilities reflects management&#x2019;s estimate of amounts that the Company would have received in connection with the sale of the
assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement
date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs
(market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market
participants would price assets and liabilities).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;ASC 820 establishes a three-level fair value hierarchy
that prioritizes inputs used to measure fair value:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level 1 &#x2013; Quoted prices in active markets
for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability
occur with sufficient frequency and volume to provide pricing information on an ongoing basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level 2 &#x2013; Observable inputs other than Level
1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical
assets or liabilities in markets that are not active.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level 3 &#x2013; Unobservable inputs based on our
assessment of the assumptions that market participants would use in pricing the asset or liability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The estimated fair value of cash, interest receivable,
subscription receivable, and notes payable approximate their carrying amounts due to the short-term nature of these instruments.&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000831">&lt;p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zGm6yV3zsErd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86F_zyoHTINo5VH3"&gt;Cash&lt;/span&gt;&lt;/b&gt; &#x2013; For purposes of the consolidated
statements of cash flows, the Company considers all highly liquid investments purchased with maturities of three months or less to be
cash equivalents. At times, balances of cash and cash equivalents at financial banking institutions exceeded the federally insured limit
of $250,000. Uninsured balances were $&lt;span id="xdx_903_eus-gaap--CashUninsuredAmount_iI_c20251231_zN2x1dAe3aXg" title="Cash uninsured amount"&gt;5,424,302&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--CashUninsuredAmount_iI_c20241231_zoFGPqjfmOD4" title="Cash uninsured amount"&gt;282,885&lt;/span&gt; at December 31, 2025 and 2024, respectively. The Company regularly monitors
the financial condition of the institution in which it has depository accounts and believes the risk of loss is minimal.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashUninsuredAmount
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000833"
      unitRef="USD">5424302</us-gaap:CashUninsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000835"
      unitRef="USD">282885</us-gaap:CashUninsuredAmount>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000837">&lt;p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zbI43jjYfaok" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_862_zTI2mm429brg"&gt;Property and Equipment&lt;/span&gt;&lt;/b&gt; &#x2013; Fixed assets
are stated at cost and depreciation is computed using the straight-line method for financial statement purposes. For the years ended December
31, 2025 and 2024, depreciation expense totaled $&lt;span id="xdx_902_eus-gaap--Depreciation_pp0p0_c20250101__20251231_z1tZWfPnEmg2" title="Depreciation expense"&gt;587&lt;/span&gt;&#160;and $&lt;span id="xdx_900_eus-gaap--Depreciation_pp0p0_c20240101__20241231_zToUtw0uIgXc" title="Depreciation expense"&gt;845&lt;/span&gt; respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:Depreciation
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000839"
      unitRef="USD">587</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000841"
      unitRef="USD">845</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2025-01-01to2025-12-31" id="Fact000843">&lt;p id="xdx_84B_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zPZuzK2istNa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86D_zhEsujK9A1Q6"&gt;Intangible Assets&lt;/span&gt;&lt;/b&gt; &#x2013; The Company records
intangible assets at cost and evaluates them for impairment in accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;)
Accounting Standards Codification (&#x201c;ASC&#x201d;) 350, &lt;i&gt;Intangibles &#x2013; Goodwill and Other. &lt;/i&gt;Intangibles are being amortized
using the straight-line method over estimated useful lives of between two and forty years. The Company recorded intangible assets of $&lt;span id="xdx_905_eus-gaap--FinitelivedIntangibleAssetsAcquired1_c20250101__20251231__us-gaap--AssetAcquisitionAxis__custom--NexGenAIMember_zx0iJDtPiIvc" title="Intangible assets acquired"&gt;361,250&lt;/span&gt;
and $&lt;span id="xdx_90F_eus-gaap--FinitelivedIntangibleAssetsAcquired1_c20240101__20241231__us-gaap--AssetAcquisitionAxis__custom--NexGenAIMember_zr7CYzFlfrek" title="Intangible assets acquired"&gt;541,875&lt;/span&gt; as of December 31, 2025 and December 31, 2024, respectively, related to the acquired assets of NexGenAI Affiliates Network
Platform (&#x201c;NexGenAI&#x201d;), which contains AI-powered marketing software and robotic process automation capabilities. See Note
14, Intangible Assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="From2025-01-012025-12-31_custom_NexGenAIMember"
      decimals="0"
      id="Fact000845"
      unitRef="USD">361250</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="From2024-01-012024-12-31_custom_NexGenAIMember"
      decimals="0"
      id="Fact000847"
      unitRef="USD">541875</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:MarketableSecuritiesPolicy contextRef="From2025-01-01to2025-12-31" id="Fact000849">&lt;p id="xdx_840_eus-gaap--MarketableSecuritiesPolicy_zYcevolqQtzf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_862_zgGq4RzAIRql"&gt;Investments
and Marketable Securities&lt;/span&gt; &lt;/b&gt;&#x2013; The Company classifies its investments and marketable securities in accordance with ASC 320, &lt;i&gt;Investments
&#x2013; Debt and Equity Securities&lt;/i&gt;, and ASC 321, &lt;i&gt;Investments &#x2013; Equity Securities&lt;/i&gt;, as applicable. Investments in
equity securities with readily determinable fair values are measured at fair value, with unrealized gains and losses recognized in
net income. For equity securities without readily determinable fair values, the Company applies the measurement alternative,
recording these investments at cost, adjusted for impairments or observable price changes from transactions involving similar
securities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Marketable securities are categorized as trading
securities and are thus marked to market and stated at fair value. Fair value is determined using the quoted closing bid prices and is
recorded as a Level&#160;1 asset. Realized gains and losses on marketable securities are recognized as incurred in the consolidated statements
of operations. Net changes in unrealized gains and losses are reported in the consolidated statements of operations in the current period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000851">&lt;p id="xdx_841_eus-gaap--LesseeLeasesPolicyTextBlock_zZd5E69YaC1l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_861_z0y9vDd2f1ad"&gt;Leases&lt;/span&gt; &lt;/b&gt;&#x2013; The Company accounts for
leases in accordance with ASC 842, &lt;i&gt;Leases&lt;/i&gt;. At lease commencement, the Company recognizes a right-of-use (&#x201c;ROU&#x201d;) asset
and a corresponding lease liability based on the present value of future lease payments. Lease liabilities are measured using the Company&#x2019;s
incremental borrowing rate if the implicit rate is not readily determinable. ROU assets include initial direct costs and prepaid lease
payments and are reduced for lease incentives received.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2025-01-01to2025-12-31" id="Fact000853">&lt;p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_zGhipFppvmqj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_862_zTqBTUr2ay9b"&gt;Research
and Development&lt;/span&gt; &#x2013; &lt;/b&gt;Research and development costs are expensed when incurred. During the years ended December 31,
2025 and 2024, research and development expenses totaled $&lt;span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20250101__20251231_zBA2qHuPDBA1" title="Research and development expenses"&gt;1,277,150&lt;/span&gt;
and $&lt;span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240101__20241231_zkmiNA8JRxJb" title="Research and development expenses"&gt;2,331,548&lt;/span&gt;,
respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000855"
      unitRef="USD">1277150</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000857"
      unitRef="USD">2331548</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000859">&lt;p id="xdx_84A_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zXWVvjClM0Hk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_865_zugKK9EiCuYd"&gt;Impairment
of Long-Lived Assets&lt;/span&gt; &#x2013; &lt;/b&gt;The Company&#x2019;s property and equipment and other non-current assets are reviewed
annually for possible impairment when events or changes in circumstances indicate that the carrying amount may not be recoverable.
An impairment loss would be recognized if and when the estimated future cash flows expected to result from the use of the asset and
its eventual disposition is less than its carrying amount. There was&#160;&lt;span id="xdx_90C_eus-gaap--AssetImpairmentCharges_do_c20250101__20251231_zKtzAEblcpXd" title="Asset impairment charges"&gt;&lt;span id="xdx_901_eus-gaap--AssetImpairmentCharges_do_c20240101__20241231_zEZpMcINsYf4"&gt;no&lt;/span&gt;&lt;/span&gt;
impairment recognized for the years ended December 31, 2025 and 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:AssetImpairmentCharges
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000861"
      unitRef="USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000862"
      unitRef="USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:DerivativesPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000864">&lt;p id="xdx_84C_eus-gaap--DerivativesPolicyTextBlock_zuMnkgjuA1yc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_864_znIkXgOSEJe2"&gt;Derivative Liability Warrants&lt;/span&gt; &#x2013; &lt;/b&gt;The
Company accounts for the Public Warrants and Private Placement Warrants (the &#x201c;Warrants&#x201d;) in accordance with the guidance contained
in ASC 815-40, &lt;i&gt;Derivatives and Hedging&lt;/i&gt;, under which the Warrants do not meet the criteria for equity treatment and must be recorded
as liabilities. Accordingly, the Company classifies the Warrants as liabilities at their fair value and adjusts the Warrants to fair value
in each respective reporting period. This liability is subject to re-measurement at each consolidated balance sheet date until the Warrants
are exercised, and any change in fair value is recognized in the consolidated statements of operations. The Private Placement Warrants
and the Public Warrants for periods where no observable traded price was available are valued using a binomial lattice simulation model.
For periods subsequent to the detachment of the Public Warrants from the Units, the Public Warrant quoted market price was used as the
fair value as of each relevant date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000866">&lt;p id="xdx_844_eus-gaap--DebtPolicyTextBlock_zPHbxdJkHdZj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_866_z9JMzbYp8Og5"&gt;Convertible Debt&lt;/span&gt;&lt;/b&gt; &#x2013; The Company accounts
for convertible debt in accordance with ASC 470-20, &lt;i&gt;Debt &#x2013; Debt with Conversion and Other Options&lt;/i&gt;. Convertible debt instruments
are evaluated at issuance to determine whether they contain embedded features that require bifurcation as derivatives or equity components.
If the embedded conversion feature meets the criteria for derivative accounting under ASC 815, &lt;i&gt;Derivatives and Hedging&lt;/i&gt;, it is bifurcated
and recorded separately at fair value, with subsequent changes in fair value recognized in earnings. Upon conversion or repurchase of
convertible debt, the Company recognizes a gain or loss in accordance with ASC 470-20 and ASC 470-50, &lt;i&gt;Debt Modifications and Extinguishments&lt;/i&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











</us-gaap:DebtPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000872">&lt;p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zHAAha3GsZn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_865_z3u6TYbMNYnj"&gt;Income Taxes&lt;/span&gt; &lt;/b&gt;&#x2013; Income taxes are provided
for the tax effects of transactions reported in the consolidated financial statements and consist of taxes currently due plus deferred
taxes related primarily to temporary differences between reporting of income and expenses for financial reporting purposes and income
tax purposes. The deferred tax assets and liabilities represent the future tax return consequences of those differences, which will either
be taxable or deductible when the assets and liabilities are recovered or settled. Deferred taxes also are recognized for operating losses
that are available to offset future federal income taxes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Income Taxes Topic of FASB ASC clarifies the
accounting and reporting for uncertainties in income tax law within subtopic FASB ASC 740-10-25-5. The guidance prescribes a comprehensive
model for the financial statement recognition, measurement, presentation, and disclosure of uncertain tax positions taken or expected
to be taken in income tax returns. Management believes that there is&#160;&lt;span id="xdx_90C_eus-gaap--UnrecognizedTaxBenefits_iI_pp0p0_do_c20251231_zzgyalr1YRb1" title="Uncertain tax positions"&gt;&lt;span id="xdx_90C_eus-gaap--UnrecognizedTaxBenefits_iI_pp0p0_do_c20241231_z9pJ5W7wdqmi" title="Uncertain tax positions"&gt;no&lt;/span&gt;&lt;/span&gt;&#160;liability related to uncertain tax positions during
the years ended December 31, 2025 and 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000874"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000876"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UseOfEstimates contextRef="From2025-01-01to2025-12-31" id="Fact000878">&lt;p id="xdx_84D_eus-gaap--UseOfEstimates_zGhCno2pOdh6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86C_zicXUShi27md"&gt;Use of Estimates&lt;/span&gt; &#x2013; &lt;/b&gt;The preparation
of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements
and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="From2025-01-01to2025-12-31" id="Fact000880">&lt;p id="xdx_842_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zkXNemGlANOk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86B_zWfWKjGsO9M"&gt;Reclassification&lt;/span&gt; &lt;/b&gt;&#x2013; The Company reclassified
certain amounts of total stockholders&#x2019; equity &#x2013; noncontrolling interests, net loss attributable to non-controlling interests,
and accumulated deficit from prior periods. These presentation changes did not affect total stockholders&#x2019; equity or net loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000882">&lt;p id="xdx_84C_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zRj8znYSaTXd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86D_zOCJE3Hv5If3"&gt;Employee and Non-Employee Share-Based Compensation&lt;/span&gt;
&lt;/b&gt;&#x2013; The Company applies ASC 718-10,&#160;&lt;i&gt;Share-Based Payment&lt;/i&gt;, which requires the measurement and recognition of compensation
expenses for all share-based payment awards made to employees and directors including employee stock option equity awards issued to employees
and non-employees based on estimated fair values.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;ASC 718-10 requires companies to estimate the
fair value of equity-based option awards on the date of grant using an option-pricing model. The fair value of the award is recognized
as an expense on a straight-line basis over the requisite service periods in the Company&#x2019;s consolidated statements of operations.
The Company recognizes share-based award forfeitures as they occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company estimates the fair value of granted
option equity awards using a Black-Scholes option pricing model. The option-pricing model requires a number of assumptions, of which the
most significant are share price, expected volatility and the expected option term (the time from the grant date until the options are
exercised or expire). Expected volatility is estimated based on volatility of the Company. The Company has historically not paid dividends
and has no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds
with an equivalent term. The expected option term is calculated for options granted to employees and directors using the &#x201c;simplified&#x201d;
method. Changes in the determination of each of the inputs can affect the fair value of the options granted and the results of operations
of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000884">&lt;p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zOOWsmECMEZ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_860_zNI8i6I7Rtza"&gt;&lt;b&gt;Recent
Accounting Pronouncements&lt;/b&gt;&lt;/span&gt;&lt;b&gt;&#160;&lt;/b&gt;&#x2013; During the years ended December 31, 2025 and 2024, there were new accounting
pronouncements issued by the FASB. Each of these pronouncements, as applicable, including Accounting Standards Update (&#x201c;ASU&#x201d;)
2023-07, &lt;i&gt;Segment Reporting&lt;/i&gt;, has been or will be adopted by the Company. Please see Note 15, Segment Reporting. Management does
not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company&#x2019;s consolidated
financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000886">&lt;p id="xdx_84E_eus-gaap--RevenueRecognitionPolicyTextBlock_z4z3tzepn6Fd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86A_zwA8j2PfPnfk"&gt;Revenue Recognition&lt;/span&gt;&lt;/b&gt;&#160;&#x2013; The Company
recognizes revenue in accordance with ASC Topic 606, &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt; (&#x201c;ASC 606&#x201d;) to depict the
transfer of control to the Company&#x2019;s customers in an amount reflecting the consideration to which the Company expects to be entitled.
The Company determines revenue recognition through the following steps:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 6%"&gt;&lt;span style="font-size: 10pt"&gt;i.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 91%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Identification of the contract, or contracts, with a customer&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;ii.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Identification of the performance obligations in the contract&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;iii.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Determination of the transaction price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;iv.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Allocation of the transaction price to the performance obligations in the contract&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;v.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Recognition of revenue, when, or as, the company satisfies the performance obligations.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Under ASC 606, revenue is recognized when control
of promised goods and services is transferred to customers. A performance obligation is a contractual promise to transfer a distinct good
or service to the customer and is the unit of account under ASC 606. The transaction price of a contract is allocated to distinct performance
obligations and recognized as revenue when or as the performance obligations are satisfied.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company generates revenue from its customers
by 1) performing data research for its customers and delivering advertising campaigns via cold emails and social media sites, and 2) providing
webinars for its customers to a targeted business-to-business audience. The fee for these services is based on observable prices explicitly
negotiated between the Company and the customer. The Company recognizes revenue at the point in time when the good or service is delivered
to the customer, which occurs upon delivery of the advertising campaign or webinar and there is a transfer of control to the customer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2025, revenues
from delivering advertising campaigns via cold emails and social media sites were recognized from six customers who accounted for &lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20251231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SixCustomersMember__srt--ProductOrServiceAxis__custom--AdvertisingCampaignsMember_zLX4oEOfVmxh" title="Concentration risk percentage"&gt;100&lt;/span&gt;%
of this revenue. Revenue was recognized at the point of delivery to the customers in the amount of $&lt;span id="xdx_90D_eus-gaap--Revenues_c20250101__20251231__srt--ProductOrServiceAxis__custom--AdvertisingCampaignsMember_zT74wjk0aKHa" title="Revenues"&gt;1,250,545&lt;/span&gt;. As of December 31, 2025,
the Company has recorded customer deposits in the amount of $&lt;span id="xdx_902_eus-gaap--DeferredRevenueCurrent_iI_c20251231__srt--ProductOrServiceAxis__custom--AdvertisingCampaignsMember_z60oqDcquob1" title="Customer deposits"&gt;599,455&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2025, revenues
from delivering webinar services were recognized from three customers who accounted for &lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20251231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThreeCustomersMember__srt--ProductOrServiceAxis__custom--WebinarServicesMember_zjRu100sQNS4" title="Concentration risk percentage"&gt;100&lt;/span&gt;% of this revenue. Revenue was recognized at
the point of delivery to the customers in the amount of $&lt;span id="xdx_90E_eus-gaap--Revenues_c20250101__20251231__srt--ProductOrServiceAxis__custom--WebinarServicesMember_zsA6a78dhLyf" title="Revenues"&gt;112,500&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-01-012025-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_SixCustomersMember_custom_AdvertisingCampaignsMember"
      decimals="INF"
      id="Fact000890"
      unitRef="Pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-12-31_custom_AdvertisingCampaignsMember"
      decimals="0"
      id="Fact000892"
      unitRef="USD">1250545</us-gaap:Revenues>
    <us-gaap:DeferredRevenueCurrent
      contextRef="AsOf2025-12-31_custom_AdvertisingCampaignsMember"
      decimals="0"
      id="Fact000894"
      unitRef="USD">599455</us-gaap:DeferredRevenueCurrent>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-01-012025-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_ThreeCustomersMember_custom_WebinarServicesMember"
      decimals="INF"
      id="Fact000896"
      unitRef="Pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-12-31_custom_WebinarServicesMember"
      decimals="0"
      id="Fact000898"
      unitRef="USD">112500</us-gaap:Revenues>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000900">&lt;p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zAsU6WAQ4KI8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_865_z2FQOuGhQvN9"&gt;Earnings Per Share&lt;/span&gt;&lt;/b&gt; &#x2013; Basic earnings
per share (or loss per share), is computed by dividing the earnings (loss) for the period by the weighted average number of common stock
shares outstanding for the period. Diluted earnings per share reflects potential dilution of securities by including other potentially
issuable shares of common stock, including shares issuable upon conversion of convertible securities or exercise of outstanding stock
options and warrants, in the weighted average number of common shares outstanding for the period. Therefore, because including shares
issuable upon conversion of convertible securities and/or exercise of outstanding options and warrants would have an anti-dilutive effect
on the loss per share, only the basic earnings (loss) per share is reported in the accompanying consolidated financial statements. The
Company does not have other potentially issuable shares of stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following potential common shares would have
an antidilutive effect on loss per share:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zGWihs13k28a" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt; color: White"&gt;&lt;b&gt;&lt;span id="xdx_8BB_zFQw89wo8x2c" style="display: none"&gt;Schedule of antidilutive shares&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Years ended December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 68%"&gt;&lt;span style="font-size: 10pt"&gt;Warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zxPQLg8XFKHf" style="width: 13%; text-align: right" title="Antidilutive shares"&gt;&lt;span style="font-size: 10pt"&gt;945,105&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_ziMaBdHFS59l" style="width: 13%; text-align: right" title="Antidilutive shares"&gt;&lt;span style="font-size: 10pt"&gt;1,399,316&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Stock options&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zwFiS2Xbflk5" style="text-align: right" title="Antidilutive shares"&gt;&lt;span style="font-size: 10pt"&gt;437,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zLzpYEY8VEh9" style="text-align: right" title="Antidilutive shares"&gt;&lt;span style="font-size: 10pt"&gt;279,625&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Convertible notes payable&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleNotesPayableMember_zpAXF3MhJOB7" style="text-align: right" title="Antidilutive shares"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleNotesPayableMember_zdFZzQI3BU8e" style="text-align: right" title="Antidilutive shares"&gt;&lt;span style="font-size: 10pt"&gt;406,629&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Preferred stock&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--PreferredStockMember_zHdONONx2RV8" style="border-bottom: black 1pt solid; text-align: right" title="Antidilutive shares"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--PreferredStockMember_zKW6pQqwpZ0h" style="border-bottom: black 1pt solid; text-align: right" title="Antidilutive shares"&gt;&lt;span style="font-size: 10pt"&gt;815,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231_z2Df7bPawez9" style="border-bottom: black 2.25pt double; text-align: right" title="Antidilutive shares"&gt;&lt;span style="font-size: 10pt"&gt;1,382,105&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231_ziJtf4fsJ3G" style="border-bottom: black 2.25pt double; text-align: right" title="Antidilutive shares"&gt;&lt;span style="font-size: 10pt"&gt;2,900,570&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000902">&lt;table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zGWihs13k28a" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt; color: White"&gt;&lt;b&gt;&lt;span id="xdx_8BB_zFQw89wo8x2c" style="display: none"&gt;Schedule of antidilutive shares&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Years ended December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 68%"&gt;&lt;span style="font-size: 10pt"&gt;Warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zxPQLg8XFKHf" style="width: 13%; text-align: right" title="Antidilutive shares"&gt;&lt;span style="font-size: 10pt"&gt;945,105&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_ziMaBdHFS59l" style="width: 13%; text-align: right" title="Antidilutive shares"&gt;&lt;span style="font-size: 10pt"&gt;1,399,316&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Stock options&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zwFiS2Xbflk5" style="text-align: right" title="Antidilutive shares"&gt;&lt;span style="font-size: 10pt"&gt;437,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zLzpYEY8VEh9" style="text-align: right" title="Antidilutive shares"&gt;&lt;span style="font-size: 10pt"&gt;279,625&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Convertible notes payable&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleNotesPayableMember_zpAXF3MhJOB7" style="text-align: right" title="Antidilutive shares"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleNotesPayableMember_zdFZzQI3BU8e" style="text-align: right" title="Antidilutive shares"&gt;&lt;span style="font-size: 10pt"&gt;406,629&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Preferred stock&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--PreferredStockMember_zHdONONx2RV8" style="border-bottom: black 1pt solid; text-align: right" title="Antidilutive shares"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--PreferredStockMember_zKW6pQqwpZ0h" style="border-bottom: black 1pt solid; text-align: right" title="Antidilutive shares"&gt;&lt;span style="font-size: 10pt"&gt;815,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231_z2Df7bPawez9" style="border-bottom: black 2.25pt double; text-align: right" title="Antidilutive shares"&gt;&lt;span style="font-size: 10pt"&gt;1,382,105&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231_ziJtf4fsJ3G" style="border-bottom: black 2.25pt double; text-align: right" title="Antidilutive shares"&gt;&lt;span style="font-size: 10pt"&gt;2,900,570&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-12-31_custom_WarrantsMember"
      decimals="INF"
      id="Fact000904"
      unitRef="Shares">945105</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_custom_WarrantsMember"
      decimals="INF"
      id="Fact000906"
      unitRef="Shares">1399316</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-12-31_custom_StockOptionsMember"
      decimals="INF"
      id="Fact000908"
      unitRef="Shares">437000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_custom_StockOptionsMember"
      decimals="INF"
      id="Fact000910"
      unitRef="Shares">279625</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-12-31_us-gaap_ConvertibleNotesPayableMember"
      decimals="INF"
      id="Fact000912"
      unitRef="Shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_ConvertibleNotesPayableMember"
      decimals="INF"
      id="Fact000914"
      unitRef="Shares">406629</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember206520625"
      decimals="INF"
      id="Fact000916"
      unitRef="Shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember206520625"
      decimals="INF"
      id="Fact000918"
      unitRef="Shares">815000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000920"
      unitRef="Shares">1382105</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000922"
      unitRef="Shares">2900570</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000924">&lt;p id="xdx_84B_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_z2gYXYVgQI29" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86D_zRxnqmvvUvna"&gt;Going Concern&lt;/span&gt; &#x2013;&lt;/b&gt; The accompanying
consolidated financial statements have been prepared in conformity with GAAP which contemplate continuation of the Company as a going
concern, which is dependent upon the Company&#x2019;s ability to obtain sufficient financing or establish itself as a profitable business.
As of December 31, 2025, the Company had an accumulated deficit of $&lt;span id="xdx_90C_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20251231_zNeMP0RaPasd" title="Accumulated deficit"&gt;109,953,728&lt;/span&gt;, and for the year ended December 31, 2025, the Company
had a net loss of $&lt;span id="xdx_90F_eus-gaap--ProfitLoss_iN_di_c20250101__20251231_zwJw9pkfv7x" title="Net loss"&gt;12,277,192&lt;/span&gt;. These conditions raise substantial doubt about the Company&#x2019;s ability to continue as a going concern.
Management&#x2019;s plans with respect to operations include raising additional capital through sales of equity or debt securities as may
be necessary to pursue its business plans and sustain operations until such time as the Company can achieve profitability. Management
believes that additional financing as necessary will result in improved operations and cash flow. However, there can be no assurance that
management will be successful in obtaining additional funding or in attaining profitable operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000926"
      unitRef="USD">-109953728</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000928"
      unitRef="USD">-12277192</us-gaap:ProfitLoss>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2025-01-01to2025-12-31" id="Fact000930">&lt;p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zHgRczn8lra3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_863_zGDiDX0QL2Ag"&gt;Fair Value of Financial Instruments and Measurements&lt;/span&gt;&lt;/b&gt;
&#x2013; The Company measures certain financial instruments at fair value in accordance with ASC 820, &lt;i&gt;Fair Value Measurement&lt;/i&gt;, for
its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets
and liabilities that are re-measured and reported at fair value at least annually. The fair value of the Company&#x2019;s financial assets
and liabilities reflects management&#x2019;s estimate of amounts that the Company would have received in connection with the sale of the
assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement
date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs
(market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market
participants would price assets and liabilities).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;ASC 820 establishes a three-level fair value hierarchy
that prioritizes inputs used to measure fair value:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level 1 &#x2013; Quoted prices in active markets
for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability
occur with sufficient frequency and volume to provide pricing information on an ongoing basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level 2 &#x2013; Observable inputs other than Level
1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical
assets or liabilities in markets that are not active.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level 3 &#x2013; Unobservable inputs based on our
assessment of the assumptions that market participants would use in pricing the asset or liability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The estimated fair value of cash, interest receivable,
subscription receivable, and notes payable approximate their carrying amounts due to the short-term nature of these instruments.&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000935">&lt;p id="xdx_80B_eus-gaap--MergersAcquisitionsAndDispositionsDisclosuresTextBlock_zUmKiiSvazI6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 3 &#x2013; &lt;span id="xdx_82C_zdWP03Gd12j9"&gt;CO-DEVELOPMENT
OPTIONS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2021, the
Company and Vy-Gen-Bio, Inc. (&#x201c;Vy-Gen&#x201d;) entered into agreements to jointly develop and commercialize two Vy-Gen product candidates,
CD38-GEAR-NK and CD38-Diagnostic (the &#x201c;CD38 Assets&#x201d;). The Company paid $&lt;span id="xdx_909_eus-gaap--PaymentsToAcquireProductiveAssets_pp0p0_c20210101__20211231__srt--ProductOrServiceAxis__custom--CD38AssetsMember__srt--CounterpartyNameAxis__custom--VyGenMember_zhn892gwZbNe"&gt;1,750,000&lt;/span&gt;
and issued promissory notes totaling $&lt;span id="xdx_90A_eus-gaap--OtherLongTermNotesPayable_iI_pp0p0_c20211231__srt--ProductOrServiceAxis__custom--CD38AssetsMember__srt--CounterpartyNameAxis__custom--VyGenMember_zla4R5JVRN5f"&gt;3,250,000&lt;/span&gt;
to Vy-Gen in accordance with the agreements. The Company paid a total of $&lt;span id="xdx_90B_eus-gaap--RepaymentsOfLongTermDebt_pp0p0_c20210101__20211231__srt--ProductOrServiceAxis__custom--CD38AssetsMember__srt--CounterpartyNameAxis__custom--VyGenMember_ziN8x23sl6q2"&gt;1,500,000&lt;/span&gt;
toward the promissory notes, leaving $&lt;span id="xdx_90A_eus-gaap--OtherLongTermNotesPayable_iI_pp0p0_c20211231__srt--ProductOrServiceAxis__custom--CD38AssetsMember_zQK3Ld9vjc6i"&gt;1,750,000&lt;/span&gt;
outstanding at December 31, 2021. The collaboration arrangement provides the right for the Company to participate, under the direction
of a joint steering committee, in the development and commercialization of the CD38 Assets and a 50/50 profit share, with the profit
share subject to contingent automatic downward adjustment up to 25% upon an event of default in connection with the promissory notes.
The Company capitalized $&lt;span id="xdx_90D_eus-gaap--CapitalizedContractCostGross_iI_pp0p0_c20211231__srt--ProductOrServiceAxis__custom--CD38AssetsMember__srt--CounterpartyNameAxis__custom--VyGenMember_zGhW3EsItZhh"&gt;5,000,000&lt;/span&gt;
to be amortized over a five-year period in which the CD38 Assets are expected to contribute to future cash flows. The promissory notes
were paid in full in 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company made certain judgements as the basis
in determining the accounting treatment of these options. The CD38 Assets represent a platform technology and a diagnostic tool which
have multiple applications and uses. Both projects are intended to be used in more than one therapy or diagnostic option. For example,
GEAR-NK is a technology which allows for the gene editing of human natural killer cells, so that these cells can no longer bind and be
destroyed by targeted monoclonal antibody treatments. The GEAR-NK technology can be modified to work concomitantly with many different
monoclonal antibody treatments in which there are currently over 100 approved by the FDA. Anti- CD38 is only the first class of monoclonal
antibody treatments being developed under the GEAR-NK platform. Therefore, the pursuit of FDA approval for the use of CD38 assets for
at least one indication or medical device approval is at least reasonably expected. Further, as the diagnostic asset may be used as an
in vitro technology, it could be classified as a medical device, and therefore toxicity studies would not be a contingency to be resolved
before reasonably establishing future value assumptions. In addition, there is perceived value in the CD38 assets, based on publicly disclosed
current business deals in cell therapies, the developing market for these innovative technologies, and current interest from third parties
in these technologies. The Company may sell or license its right to another party, with the written consent of Vy-Gen, which cannot be
unreasonably withheld. Furthermore, the Company believes that any negative results from ongoing development of a single therapy or use,
would not result in abandoning the project. Given these considerations, The Company has determined that these options have alternative
future use and should be recorded as assets pursuant to ASC 730-10-25-2,&#160;&lt;i&gt;Research and Development&lt;/i&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Related to the joint development, the Company,
under the direction of the joint steering committee, is assessing market opportunities, intellectual property protection, and potential
regulatory strategies for the CD38 Assets. Vy-Gen is responsible for development activities conducted and overseen by the scientists at
Karolinska Institute. The agreement does not currently require additional payments for research and development costs by the Company and
no additional payments are required upon development or regulatory milestones.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In March 2025, the Company reached an
agreement with Vy-Gen-Bio, Inc. (&#x201c;Vy-Gen&#x201d;) to successfully license the exclusive worldwide development and
commercialization rights to the GEAR&#x2122; (Gene Edited Antibody Resistant) Cell Therapy Platform, representing a first-in-class
approach to modifying potent cancer-targeting immune cells to optimize the likelihood of deep remission in patients with hematologic
malignancies and other cancers. Coeptis had previously held limited co-development rights to GEAR. As part of this exclusive GEAR
license agreement with VyGen-Bio, Inc., the Company paid a total of $&lt;span id="xdx_90B_eus-gaap--ProceedsFromLicenseFeesReceived_c20250101__20251231_zq5qHCbTx006" title="License fees"&gt;400,000&lt;/span&gt;
for license fees during the year ended December 31, 2025, which the company recorded as research and development expense, and
committed to pay other performance-based fees, milestone and royalty payments in 2026 and beyond.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The total gross capitalized Co-Development options
recorded was $&lt;span id="xdx_905_eus-gaap--CapitalizedContractCostGross_iI_c20251231__us-gaap--TransactionTypeAxis__custom--CoDevelopmentRightsMember_zvWmd5FhTOhe"&gt;5,291,667&lt;/span&gt;,
with accumulated amortization of $&lt;span id="xdx_905_eus-gaap--CapitalizedContractCostAccumulatedAmortization_iI_c20251231__us-gaap--TransactionTypeAxis__custom--CoDevelopmentRightsMember_z10CcT42P5x4"&gt;4,737,500&lt;/span&gt;,
resulting in a net carrying amount of $&lt;span id="xdx_901_eus-gaap--CapitalizedContractCostNet_iI_c20251231__us-gaap--TransactionTypeAxis__custom--CoDevelopmentRightsMember_z1RtaPabMlsj"&gt;554,167&lt;/span&gt;
at December 31, 2025. Amortization expense related to the Co-Development options was $&lt;span id="xdx_90D_eus-gaap--AdjustmentForAmortization_c20250101__20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CoDevelopmentOptionsMember_zzlSEuG7woY8"&gt;1,000,000&lt;/span&gt;
and $&lt;span id="xdx_901_eus-gaap--AdjustmentForAmortization_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CoDevelopmentOptionsMember_zF7JOQGp9bQi"&gt;1,000,000&lt;/span&gt;
for the years ended December 31, 2025 and December 31, 2024, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="From2021-01-012021-12-31_custom_CD38AssetsMember_custom_VyGenMember"
      decimals="0"
      id="Fact000936"
      unitRef="USD">1750000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:OtherLongTermNotesPayable
      contextRef="AsOf2021-12-31_custom_CD38AssetsMember_custom_VyGenMember"
      decimals="0"
      id="Fact000937"
      unitRef="USD">3250000</us-gaap:OtherLongTermNotesPayable>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="From2021-01-012021-12-31_custom_CD38AssetsMember_custom_VyGenMember"
      decimals="0"
      id="Fact000938"
      unitRef="USD">1500000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:OtherLongTermNotesPayable
      contextRef="AsOf2021-12-31_custom_CD38AssetsMember"
      decimals="0"
      id="Fact000939"
      unitRef="USD">1750000</us-gaap:OtherLongTermNotesPayable>
    <us-gaap:CapitalizedContractCostGross
      contextRef="AsOf2021-12-31_custom_CD38AssetsMember_custom_VyGenMember"
      decimals="0"
      id="Fact000940"
      unitRef="USD">5000000</us-gaap:CapitalizedContractCostGross>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000942"
      unitRef="USD">400000</us-gaap:ProceedsFromLicenseFeesReceived>
    <us-gaap:CapitalizedContractCostGross
      contextRef="AsOf2025-12-31_custom_CoDevelopmentRightsMember"
      decimals="0"
      id="Fact000943"
      unitRef="USD">5291667</us-gaap:CapitalizedContractCostGross>
    <us-gaap:CapitalizedContractCostAccumulatedAmortization
      contextRef="AsOf2025-12-31_custom_CoDevelopmentRightsMember"
      decimals="0"
      id="Fact000944"
      unitRef="USD">4737500</us-gaap:CapitalizedContractCostAccumulatedAmortization>
    <us-gaap:CapitalizedContractCostNet
      contextRef="AsOf2025-12-31_custom_CoDevelopmentRightsMember"
      decimals="0"
      id="Fact000945"
      unitRef="USD">554167</us-gaap:CapitalizedContractCostNet>
    <us-gaap:AdjustmentForAmortization
      contextRef="From2025-01-012025-12-31_custom_CoDevelopmentOptionsMember"
      decimals="0"
      id="Fact000946"
      unitRef="USD">1000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="From2024-01-012024-12-31_custom_CoDevelopmentOptionsMember"
      decimals="0"
      id="Fact000947"
      unitRef="USD">1000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:LongTermDebtTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000949">&lt;p id="xdx_80A_eus-gaap--LongTermDebtTextBlock_zw14nuNjyzWl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 4 &#x2013; &lt;span id="xdx_82F_zMTTPpOvNtjf"&gt;CONVERTIBLE NOTES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In September 2021, as part of a termination
of a license agreement with Purple, the Company issued a convertible note in the principal amount of $&lt;span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20210930__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PurpleBioTechMember_zSy2DrcwK6tg" title="Debt face amount"&gt;1,500,000&lt;/span&gt;
that was payable on or before the maturity date in February 2023, bearing interest of&#160;&lt;span id="xdx_903_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210902__20210930__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PurpleBioTechMember_zwiC7IXy0cij" title="Interest rate"&gt;5&lt;/span&gt;%
per annum and convertible in whole or in part at any time by Purple into shares of common stock of the Company. The conversion price
is $5 per share of common stock, subject to certain adjustments under such terms and conditions as agreed between the parties. The
Company may prepay the principal amount of the note plus accrued and unpaid interest at any time prior to the maturity date. On July
14, 2023, the Company and Purple executed an amendment to revise the note&#x2019;s payment schedule, extending the maturity date to
March 31, 2024. On June 19, 2024, the Company and Purple executed another amendment to extend the maturity date to August 31, 2024.
The outstanding principal balance due under the convertible note at December 31, 2024 was $&lt;span id="xdx_901_eus-gaap--ConvertibleNotesPayable_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PurpleBioTechMember_zWmLvOesANK9" title="Convertible notes outstanding"&gt;218,750&lt;/span&gt;.
The Company paid the outstanding $&lt;span id="xdx_907_eus-gaap--RepaymentsOfConvertibleDebt_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PurpleBioTechMember_zXFwlVwIH0tk" title="Repayment of convertible debt"&gt;218,750&lt;/span&gt;
principal balance in full during the quarter ended March 31, 2025, and the convertible note is considered satisfied.&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In October 2022, as a result of the Merger, the
Company entered into a convertible promissory note agreement with an unrelated third party in the principal amount of $&lt;span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20221031__us-gaap--LongtermDebtTypeAxis__custom--Oct2022ConvertiblePromissoryNoteMember_zSkRzyUu5rlk"&gt;350,000&lt;/span&gt; with no
accruing interest and was due on October 28, 2023 for legal services rendered to the Company. The noteholder may elect, in its sole discretion
upon written notice to the Company, at any time prior to, as of or following the maturity date, to require that all or any portion of
the principal amount not then repaid be converted, without any further action on the part of the noteholder, into shares of common stock,
par value $0.0001 per share. Upon full conversion of the remaining principal amount due, the note will, for all purposes be deemed cancelled
and all obligations shall be deemed paid in full. On October 27, 2023, a $&lt;span id="xdx_907_eus-gaap--RepaymentsOfConvertibleDebt_c20231026__20231027__us-gaap--LongtermDebtTypeAxis__custom--Oct2022ConvertiblePromissoryNoteMember_zrDdEsRiJq41"&gt;200,000&lt;/span&gt; payment was made, and on December 15, 2023, another
$&lt;span id="xdx_906_eus-gaap--RepaymentsOfConvertibleDebt_c20231214__20231215__us-gaap--LongtermDebtTypeAxis__custom--Oct2022ConvertiblePromissoryNoteMember_zaW6IW60rs5d"&gt;50,000&lt;/span&gt; payment was made. On June 25, 2024, the Company and the unrelated third party signed an amendment to the note that extended
the maturity date to July 31, 2024. The outstanding balance due under the convertible note at December 31, 2025 and December 31, 2024
was $&lt;span id="xdx_907_eus-gaap--DebtDefaultLongtermDebtAmount_iI_c20251231__us-gaap--LongtermDebtTypeAxis__custom--Oct2022ConvertiblePromissoryNoteMember_zI4DwDX9lqal" title="Debt in default"&gt;100,000&lt;/span&gt;. The note was in default as of December 31, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In December 2023, the Company entered into an
unsecured convertible promissory note with an unrelated party in the principal amount of $&lt;span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_c20241231__us-gaap--LongtermDebtTypeAxis__custom--Dec2023ConvertiblePromissoryNoteMember_z284HxJybYad" title="Principal amount"&gt;&lt;span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20240423__20240424__us-gaap--LongtermDebtTypeAxis__custom--Dec2023ConvertiblePromissoryNoteMember_ziyG4OGqt0f7" title="Debt converted, amount converted"&gt;150,000&lt;/span&gt;&lt;/span&gt; together with interest at &lt;span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20241231__us-gaap--LongtermDebtTypeAxis__custom--Dec2023ConvertiblePromissoryNoteMember_zywuMQyRyy1i" title="Debt instrument stated percentage"&gt;5&lt;/span&gt;% and a maturity
date of &lt;span id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_dd_c20240101__20241231__us-gaap--LongtermDebtTypeAxis__custom--Dec2023ConvertiblePromissoryNoteMember_zK50dl7BDZ48" title="Maturity period"&gt;June 30, 2024&lt;/span&gt;. On April 24, 2024, the Company converted the note into shares of common stock, which satisfied the note in full.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 17, 2024, the Company entered into an
unsecured note agreement with a related party in the principal amount of $&lt;span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20240417__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--ShortTermDebtTypeAxis__custom--April2024UnsecuredNoteMember_zqBWfPoPXTB7"&gt;500,000&lt;/span&gt; together with interest at &lt;span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20240417__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--ShortTermDebtTypeAxis__custom--April2024UnsecuredNoteMember_z16q6mGGrKKa" title="Debt stated interest rate"&gt;10&lt;/span&gt;%, with a maturity date
of &lt;span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_c20240416__20240417__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--ShortTermDebtTypeAxis__custom--April2024UnsecuredNoteMember_zsakMq0g5cU9" title="Debt maturity date"&gt;September 30, 2024&lt;/span&gt;. The agreement is between the Company and an investment fund where the manager is a member of the Company&#x2019;s
board of directors. On June 3, 2024, the Company and the related party agreed to convert the note agreement in full, both principal and
interest, to equity in connection with the Company&#x2019;s Series A Preferred Stock offering. See Note 7, Capital Structure, for more
information on the Series A Preferred Stock offering.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Yorkville Convertible Notes&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 3, 2024, the Company entered into
an unsecured note agreement with an unrelated third party, YA II PN, LTD, a Cayman Islands exempt limited partnership
(&#x201c;Yorkville&#x201d;) in the principal amount of $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20240103__us-gaap--ShortTermDebtTypeAxis__custom--YANote1Member_znxyJQMW0mR2" title="Debt face amount"&gt;1,500,000&lt;/span&gt;
(the &#x201c;YA Note-1&#x201d;). YA Note-1 was issued with a 10% original issue discount. The original principal amount, together with
interest of&#160;&lt;span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20240103__us-gaap--ShortTermDebtTypeAxis__custom--YANote1Member_z68lUeJn1Ty" title="Interest rate"&gt;8&lt;/span&gt;%,
was payable by the Company on March 15, 2024, and was extended to July 31, 2024. The note had an outstanding principal balance of
$&lt;span id="xdx_901_eus-gaap--ShortTermBorrowings_iI_c20241031__us-gaap--ShortTermDebtTypeAxis__custom--YANote1Member_z7htkhwSippa" title="Short-term debt"&gt;1,235,178&lt;/span&gt;
with $&lt;span id="xdx_905_eus-gaap--AmortizationOfDebtDiscountPremium_c20241001__20241031__us-gaap--ShortTermDebtTypeAxis__custom--YANote1Member_z8brDcKVzqDi" title="Amortization of debt discount"&gt;150,000&lt;/span&gt;
of the debt discount fully amortized as of October 31, 2024. On November 1, 2024, the Company entered into an agreement with
Yorkville that completely terminates and replaces YA Note-1 (see the Yorkville Transaction defined below). See Note 7, Capital
Structure - Standby Equity Purchase Agreement, for further details.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On November 1, 2024, the Company entered into
a Standby Equity Purchase Agreement (&#x201c;SEPA&#x201d;) pursuant to which the Company has the right to sell Yorkville up to $20,000,000
of its shares of Company Common Stock, subject to certain limitations and conditions set forth in the SEPA, from time to time during the
term of the SEPA (such transaction, the &#x201c;Yorkville Transaction&#x201d;). In connection with the SEPA, Yorkville has agreed to advance
to the Company in the form of a convertible promissory note (the &#x201c;Convertible Note&#x201d;) an aggregate principal amount of up to
$&lt;span id="xdx_90D_eus-gaap--ConvertibleDebt_iI_c20241102__us-gaap--DebtInstrumentAxis__custom--YorkvilleConvertibleNoteMember_zaTB9HL1AFv1" title="Convertible promissory note"&gt;1,304,758&lt;/span&gt; (the &#x201c;Pre-Paid Advance&#x201d;), which terminated and replaced the $&lt;span id="xdx_901_eus-gaap--DebtInstrumentDecreaseForgiveness_c20241101__20241102__us-gaap--ShortTermDebtTypeAxis__custom--YANote1Member_zv8w4VFa6kG" title="Short-term debt replaced"&gt;1,235,178&lt;/span&gt; YA Note-1 outstanding balance discussed
above. The Convertible Note bears an interest rate of&#160;&lt;span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20241102__us-gaap--DebtInstrumentAxis__custom--YorkvilleConvertibleNoteMember_zQboPUZ40V4l" title="Interest rate"&gt;8&lt;/span&gt;% per annum and is convertible in whole or in part at any time by Yorkville
into shares of common stock of the Company at a conversion price determined based on the lower of the lower of (i) $1.00 per common share
(the &#x201c;Fixed Price&#x201d;), or (ii) 95% of the lowest daily volume weighted average price during the five consecutive trading days
immediately preceding the conversion date (the &#x201c;Variable Price&#x201d;), but which Variable Price shall not be lower than the floor
price of $0.80 (the &#x201c;Floor Price&#x201d;). During the year ended December 31, 2025, the Company recorded amortization of debt discount
in the amount of $&lt;span id="xdx_90D_eus-gaap--AmortizationOfDebtDiscountPremium_c20250101__20251231__us-gaap--DebtInstrumentAxis__custom--YorkvilleConvertibleNoteMember_zYw7bxgELBCc" title="Amortization of debt discount"&gt;435,635&lt;/span&gt; for the Convertible Note.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the six months ended June 30, 2025, Yorkville
elected to convert the entire outstanding principal balance on YA Note-1, the convertible promissory note with an outstanding principal
balance of $1,304,758. Yorkville converted $&lt;span id="xdx_90F_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20250101__20250630__us-gaap--DebtInstrumentAxis__custom--YorkvilleConvertibleNoteMember_zLAKmV9AegS1"&gt;1,304,758&lt;/span&gt;
of the principal balance and $&lt;span id="xdx_901_ecustom--DebtConversionConvertedInterestAmount1_c20250101__20250630__us-gaap--DebtInstrumentAxis__custom--YorkvilleConvertibleNoteMember_zQieGVHslAij"&gt;52,505&lt;/span&gt;
of accrued interest into &lt;span id="xdx_908_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20250101__20250630__us-gaap--DebtInstrumentAxis__custom--YorkvilleConvertibleNoteMember_zrnsAa0UihBl"&gt;233,500&lt;/span&gt;
shares of common stock at a weighted-average conversion price of $&lt;span id="xdx_90C_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20250630__us-gaap--DebtInstrumentAxis__custom--YorkvilleConvertibleNoteMember_z3uPBBxB6DGe"&gt;5.81&lt;/span&gt;&#160;per
share. After conversion, the principal balance of the note had a remaining balance of $&lt;span id="xdx_90C_eus-gaap--ConvertibleNotesPayable_iI_c20250630__us-gaap--DebtInstrumentAxis__custom--YorkvilleConvertibleNoteMember_zCCFcdB3qZHh"&gt;0&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The SEPA is an equity-linked contract that does
not qualify for equity classification and is accounted for as a derivative liability recognized at fair value. Any changes in fair value
between the carrying amount of the forward issuance contracts and the settlement amounts will be recognized in other (expense) income
in the consolidated statements of operations. As of December 31, 2025 and December 31, 2024, the fair value of the SEPA was $&lt;span id="xdx_908_eus-gaap--DerivativeAssetFairValueGrossLiability_iI_c20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--StandbyEquityPurchaseAgreementMember_zTuDt0fiiKre" title="Fair value derivative liability"&gt;0&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--DerivativeAssetFairValueGrossLiability_iI_c20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--StandbyEquityPurchaseAgreementMember_zzs5DwnKbgS" title="Fair value derivative liability"&gt;1,041,484&lt;/span&gt;,
respectively. For the year ended December 31, 2025, the Company recognized a gain on the change in fair value of derivative liability
in the amount of $&lt;span id="xdx_90F_eus-gaap--UnrealizedGainLossOnDerivatives_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--StandbyEquityPurchaseAgreementMember_zU9OfV3NBFF1" title="Change in fair value of derivative liability"&gt;906,430&lt;/span&gt;, in the Company&#x2019;s consolidated statements of operations.&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The following table presents
information about the Company&#x2019;s derivative liability that is measured at fair value on a recurring basis at December 31, 2025 and
December 31, 2024 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zbvuEYR8TaQ4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CONVERTIBLE NOTES (Details - Derivative liability)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_8B2_z5y8mFoKfK11" style="display: none"&gt;Schedule of derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 49%; text-align: justify; padding-bottom: 1pt"&gt;Derivative liability&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 13%; text-align: center"&gt;3&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_d0_c20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zSScGOpRdWF6" style="border-bottom: Black 1pt solid; width: 13%; text-align: right" title="Fair value of derivative liability"&gt;&#x2013;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_c20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zvkEJ2i5QsY5" style="border-bottom: Black 1pt solid; width: 13%; text-align: right" title="Fair value of derivative liability"&gt;1,041,484&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_d0_c20251231_zl0cuXFGtsy6" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of derivative liability"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_c20241231_z59nuI9P6qT5" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of derivative liability"&gt;1,041,484&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zTlA5EXadzLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The derivative liability
is accounted for as a liability in accordance with ASC 480 and is presented within derivative liability in the accompanying consolidated
balance sheets. The derivative liability is measured at fair value at inception and on a recurring basis, with changes in fair value presented
in the consolidated statements of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The derivative liability
was valued using a binomial lattice model, which is considered to be a Level 3 fair value measurement. The binomial lattice model&#x2019;s
primary unobservable input utilized in determining the fair value of the derivative liability is the step factors input, assumed price
movement, and probabilities assigned to them.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The following table provides
quantitative information regarding Level 3 fair value measurements for the derivative liability:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfServicingLiabilitiesAtFairValueTextBlock_zMk5Fussqd7g" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - CONVERTIBLE NOTES (Details - Assumptions)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt; color: White"&gt;&lt;span id="xdx_8B3_zmClAVoHovK3" style="display: none"&gt;Schedule of assumptions used for valuation&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 83%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; width: 14%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zMgiIIKRIoQ2" title="Derivative assumption valuation"&gt;4.16&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zjYxVkzv3sCe" title="Derivative assumption valuation"&gt;114.61&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Conversion price&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputConversionPriceMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zEIsIqZ4XoHj" title="Derivative assumption valuation"&gt;3.71&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Stock price&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zRqhRfZJsqc7" title="Derivative assumption valuation"&gt;5.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A1_zb9m86qB5vNa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The following table presents
the changes in the fair value of derivative liability:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_zENQuhqRVCGi" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - CONVERTIBLE NOTES (Details - Change in deriviative)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt; color: White"&gt;&lt;span id="xdx_8BC_zfOdvmHY7J5" style="display: none"&gt;Schedule of changes in fair value of derivative liability&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Warrant&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 83%"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Fair value as of November 1, 2024 (inception)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--DerivativeFairValueOfDerivativeLiability_iS_c20241101__20241231_zcBT4BGwXfHi" style="width: 14%; text-align: right" title="Fair value of derivative liability, beginning balance"&gt;&lt;span style="font-size: 10pt"&gt;501,824&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--UnrealizedGainLossOnDerivatives_iN_di_c20241101__20241231_zuAywLAZNE3f" style="border-bottom: black 1pt solid; text-align: right" title="Change in fair value"&gt;&lt;span style="font-size: 10pt"&gt;539,660&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Fair value as of December 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--DerivativeFairValueOfDerivativeLiability_iS_c20250101__20251231_zrf3ufaAH9Rd" style="text-align: right" title="Fair value of derivative liability, beginning balance"&gt;&lt;span style="font-size: 10pt"&gt;1,041,484&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--UnrealizedGainLossOnDerivatives_iN_di_c20250101__20251231_z9QuDUjAjMub" style="text-align: right" title="Change in fair value"&gt;&lt;span style="font-size: 10pt"&gt;(906,430&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Extinguishment of fair value of liability&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ExtinguishmentOfDebtGainLossNetOfTax_iN_di_c20250101__20251231_zLopX0wn9puc" style="border-bottom: black 1pt solid; text-align: right" title="Extinguishment of fair value of liability"&gt;&lt;span style="font-size: 10pt"&gt;(135,054&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Fair value as of December 31, 2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--DerivativeFairValueOfDerivativeLiability_iE_d0_c20250101__20251231_z0cgjM0ajdj" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of derivative liability, ending balance"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A6_zk9Emh2IYbu7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;There were &lt;span id="xdx_90C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_do_c20250101__20251231_zrkwDadYkk5" title="Transfers in or out of Level 3"&gt;&lt;span id="xdx_904_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_do_c20240101__20241231_zRMP0WQQ7FA8" title="Transfers in or out of Level 3"&gt;no&lt;/span&gt;&lt;/span&gt;
transfers in or out of Level 3 from other levels in the fair value hierarchy during the years ended December 31, 2025 and 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 16, 2025, the Company entered into
a convertible promissory note with YA II PN, LTD, a Cayman Islands exempt limited partnership (&#x201c;Yorkville&#x201d;), in the original
principal amount of $&lt;span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20250116__us-gaap--DebtInstrumentAxis__custom--YorkvilleConvertibleNoteMember_zmHDMC4cMMkc"&gt;1,100,000&lt;/span&gt;.
Interest shall accrue on the outstanding balance of the note at an annual rate equal to&#160;&lt;span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20250115__20250116__us-gaap--DebtInstrumentAxis__custom--YorkvilleConvertibleNoteMember_zv4zNx224Wm6"&gt;8&lt;/span&gt;%,
subject to an increase to 18% upon an event of default as described in the note. The maturity date of the note is&#160;&lt;span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_pp0p0_dd_c20250115__20250116__us-gaap--DebtInstrumentAxis__custom--YorkvilleConvertibleNoteMember_zBC995Bxtq5i"&gt;December
31, 2025&lt;/span&gt;. Yorkville may convert the note into shares of Common Stock at any time at a conversion price equal to the lower of (i)
$20.00 (the &#x201c;Fixed Price&#x201d;) or (ii) a price per share equal to 95% of the lowest daily VWAP during the 5 consecutive trading
days immediately prior to the conversion date of the note (the &#x201c;Variable Price&#x201d;), but which Variable Price shall not be lower
than a floor price of $1.00 per share (the &#x201c;Floor Price&#x201d;). The Company internally refers to this note as YA Note-2.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Additionally, the Company, at its option, shall
have the right, but not the obligation, to redeem early a portion or all amounts outstanding under the note at a redemption amount equal
to the outstanding principal balance being repaid or redeemed, plus a 5% prepayment premium, plus all accrued and unpaid interest; provided
that (i) the Company provides Yorkville with no less than ten trading days&#x2019; prior written notice thereof and (ii) on the date such
notice is issued, the VWAP of the Common Stock is less than the Fixed Price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;An &#x201c;Amortization Event&#x201d; will occur
under the terms of the Promissory Note if (i) the daily VWAP is less than the Floor Price for five trading days during a period of seven
consecutive trading days, or (ii) the Company has issued has issued to Yorkville, pursuant to the transactions contemplated in the note
and any integrated transactions, in excess of 99% of the Common Shares available under the Exchange Cap.&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2025,
Yorkville elected to convert the entire outstanding principal balance on YA Note-2, the convertible promissory note with an
outstanding principal balance of $1,100,000. Yorkville converted $&lt;span id="xdx_90D_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20250101__20251231__us-gaap--DebtInstrumentAxis__custom--YANote2Member_z1EBZZTr1Eq1" title="Debt converted, amount converted"&gt;1,100,000&lt;/span&gt;
of the principal balance and $&lt;span id="xdx_908_ecustom--DebtConversionConvertedInterestAmount1_c20250101__20251231__us-gaap--DebtInstrumentAxis__custom--YANote2Member_zVGUnH9FDP67"&gt;43,397&lt;/span&gt;
of accrued interest into &lt;span id="xdx_903_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20250101__20251231__us-gaap--DebtInstrumentAxis__custom--YorkvilleConvertibleNoteMember_zKEonhpHtrh8"&gt;158,582&lt;/span&gt;
shares of common stock at a weighted-average conversion price of $7.21&#160;per share. After conversion, the principal balance of
the note had a remaining balance of $&lt;span id="xdx_90F_eus-gaap--ConvertibleNotesPayable_iI_c20251231__us-gaap--DebtInstrumentAxis__custom--YorkvilleConvertibleNoteMember_zKAToBSfEWnk" title="Convertible notes outstanding"&gt;0&lt;/span&gt;. During the year ended December 31, 2025, the Company recorded amortization
of debt discount in the amount of $&lt;span id="xdx_908_eus-gaap--AmortizationOfDebtDiscountPremium_c20250101__20251231__us-gaap--DebtInstrumentAxis__custom--YANote2Member_zUKKvfcWZyqi" title="Amortization of debt discount"&gt;110,000&lt;/span&gt; for the Convertible Note.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:LongTermDebtTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2021-09-30_custom_LicenseAgreementMember_custom_PurpleBioTechMember"
      decimals="0"
      id="Fact000951"
      unitRef="USD">1500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2021-09-022021-09-30_custom_LicenseAgreementMember_custom_PurpleBioTechMember"
      decimals="INF"
      id="Fact000953"
      unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2024-12-31_custom_LicenseAgreementMember_custom_PurpleBioTechMember"
      decimals="0"
      id="Fact000955"
      unitRef="USD">218750</us-gaap:ConvertibleNotesPayable>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="From2025-01-012025-03-31_custom_LicenseAgreementMember_custom_PurpleBioTechMember"
      decimals="0"
      id="Fact000957"
      unitRef="USD">218750</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2022-10-31_custom_Oct2022ConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact000961"
      unitRef="USD">350000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="From2023-10-262023-10-27_custom_Oct2022ConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact000962"
      unitRef="USD">200000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="From2023-12-142023-12-15_custom_Oct2022ConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact000963"
      unitRef="USD">50000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:DebtDefaultLongtermDebtAmount
      contextRef="AsOf2025-12-31_custom_Oct2022ConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact000965"
      unitRef="USD">100000</us-gaap:DebtDefaultLongtermDebtAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-12-31_custom_Dec2023ConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact000967"
      unitRef="USD">150000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="From2024-04-232024-04-24_custom_Dec2023ConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact000969"
      unitRef="USD">150000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-12-31_custom_Dec2023ConvertiblePromissoryNoteMember"
      decimals="INF"
      id="Fact000971"
      unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2024-01-012024-12-31_custom_Dec2023ConvertiblePromissoryNoteMember"
      id="Fact000973">2024-06-30</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-04-17_us-gaap_RelatedPartyMember_custom_April2024UnsecuredNoteMember"
      decimals="0"
      id="Fact000974"
      unitRef="USD">500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-04-17_us-gaap_RelatedPartyMember_custom_April2024UnsecuredNoteMember"
      decimals="INF"
      id="Fact000976"
      unitRef="Pure">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2024-04-162024-04-17_us-gaap_RelatedPartyMember_custom_April2024UnsecuredNoteMember"
      id="Fact000978">2024-09-30</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-01-03_custom_YANote1Member"
      decimals="0"
      id="Fact000980"
      unitRef="USD">1500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-01-03_custom_YANote1Member"
      decimals="INF"
      id="Fact000982"
      unitRef="Pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ShortTermBorrowings
      contextRef="AsOf2024-10-31_custom_YANote1Member"
      decimals="0"
      id="Fact000984"
      unitRef="USD">1235178</us-gaap:ShortTermBorrowings>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2024-10-012024-10-31_custom_YANote1Member"
      decimals="0"
      id="Fact000986"
      unitRef="USD">150000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2024-11-02_custom_YorkvilleConvertibleNoteMember"
      decimals="0"
      id="Fact000988"
      unitRef="USD">1304758</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentDecreaseForgiveness
      contextRef="From2024-11-012024-11-02_custom_YANote1Member"
      decimals="0"
      id="Fact000990"
      unitRef="USD">1235178</us-gaap:DebtInstrumentDecreaseForgiveness>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-11-02_custom_YorkvilleConvertibleNoteMember"
      decimals="INF"
      id="Fact000992"
      unitRef="Pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2025-01-012025-12-31_custom_YorkvilleConvertibleNoteMember"
      decimals="0"
      id="Fact000994"
      unitRef="USD">435635</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="From2025-01-012025-06-30_custom_YorkvilleConvertibleNoteMember"
      decimals="0"
      id="Fact000995"
      unitRef="USD">1304758</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <coep:DebtConversionConvertedInterestAmount1
      contextRef="From2025-01-012025-06-30_custom_YorkvilleConvertibleNoteMember"
      decimals="0"
      id="Fact000996"
      unitRef="USD">52505</coep:DebtConversionConvertedInterestAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2025-01-012025-06-30_custom_YorkvilleConvertibleNoteMember"
      decimals="INF"
      id="Fact000997"
      unitRef="Shares">233500</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2025-06-30_custom_YorkvilleConvertibleNoteMember"
      decimals="INF"
      id="Fact000998"
      unitRef="USDPShares">5.81</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2025-06-30_custom_YorkvilleConvertibleNoteMember"
      decimals="0"
      id="Fact000999"
      unitRef="USD">0</us-gaap:ConvertibleNotesPayable>
    <us-gaap:DerivativeAssetFairValueGrossLiability
      contextRef="AsOf2025-12-31_custom_StandbyEquityPurchaseAgreementMember"
      decimals="0"
      id="Fact001001"
      unitRef="USD">0</us-gaap:DerivativeAssetFairValueGrossLiability>
    <us-gaap:DerivativeAssetFairValueGrossLiability
      contextRef="AsOf2024-12-31_custom_StandbyEquityPurchaseAgreementMember"
      decimals="0"
      id="Fact001003"
      unitRef="USD">1041484</us-gaap:DerivativeAssetFairValueGrossLiability>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="From2025-01-012025-12-31_custom_StandbyEquityPurchaseAgreementMember"
      decimals="0"
      id="Fact001005"
      unitRef="USD">906430</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001010">&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zbvuEYR8TaQ4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CONVERTIBLE NOTES (Details - Derivative liability)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_8B2_z5y8mFoKfK11" style="display: none"&gt;Schedule of derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 49%; text-align: justify; padding-bottom: 1pt"&gt;Derivative liability&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 13%; text-align: center"&gt;3&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_d0_c20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zSScGOpRdWF6" style="border-bottom: Black 1pt solid; width: 13%; text-align: right" title="Fair value of derivative liability"&gt;&#x2013;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_c20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zvkEJ2i5QsY5" style="border-bottom: Black 1pt solid; width: 13%; text-align: right" title="Fair value of derivative liability"&gt;1,041,484&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_d0_c20251231_zl0cuXFGtsy6" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of derivative liability"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_c20241231_z59nuI9P6qT5" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of derivative liability"&gt;1,041,484&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="AsOf2025-12-31_custom_DerivativeLiabilityMember"
      decimals="0"
      id="Fact001012"
      unitRef="USD">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="AsOf2024-12-31_custom_DerivativeLiabilityMember"
      decimals="0"
      id="Fact001014"
      unitRef="USD">1041484</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001016"
      unitRef="USD">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001018"
      unitRef="USD">1041484</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:ScheduleOfServicingLiabilitiesAtFairValueTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001020">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfServicingLiabilitiesAtFairValueTextBlock_zMk5Fussqd7g" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - CONVERTIBLE NOTES (Details - Assumptions)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt; color: White"&gt;&lt;span id="xdx_8B3_zmClAVoHovK3" style="display: none"&gt;Schedule of assumptions used for valuation&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 83%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; width: 14%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zMgiIIKRIoQ2" title="Derivative assumption valuation"&gt;4.16&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zjYxVkzv3sCe" title="Derivative assumption valuation"&gt;114.61&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Conversion price&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputConversionPriceMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zEIsIqZ4XoHj" title="Derivative assumption valuation"&gt;3.71&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Stock price&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zRqhRfZJsqc7" title="Derivative assumption valuation"&gt;5.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfServicingLiabilitiesAtFairValueTextBlock>
    <us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue
      contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_FairValueInputsLevel3Member"
      id="Fact001022">4.16</us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue>
    <us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue
      contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_FairValueInputsLevel3Member"
      id="Fact001024">114.61</us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue>
    <us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue
      contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputConversionPriceMember_us-gaap_FairValueInputsLevel3Member"
      id="Fact001026">3.71</us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue>
    <us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue
      contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputSharePriceMember_us-gaap_FairValueInputsLevel3Member"
      id="Fact001028">5.50</us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001030">&lt;table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_zENQuhqRVCGi" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - CONVERTIBLE NOTES (Details - Change in deriviative)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt; color: White"&gt;&lt;span id="xdx_8BC_zfOdvmHY7J5" style="display: none"&gt;Schedule of changes in fair value of derivative liability&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Warrant&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 83%"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Fair value as of November 1, 2024 (inception)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--DerivativeFairValueOfDerivativeLiability_iS_c20241101__20241231_zcBT4BGwXfHi" style="width: 14%; text-align: right" title="Fair value of derivative liability, beginning balance"&gt;&lt;span style="font-size: 10pt"&gt;501,824&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--UnrealizedGainLossOnDerivatives_iN_di_c20241101__20241231_zuAywLAZNE3f" style="border-bottom: black 1pt solid; text-align: right" title="Change in fair value"&gt;&lt;span style="font-size: 10pt"&gt;539,660&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Fair value as of December 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--DerivativeFairValueOfDerivativeLiability_iS_c20250101__20251231_zrf3ufaAH9Rd" style="text-align: right" title="Fair value of derivative liability, beginning balance"&gt;&lt;span style="font-size: 10pt"&gt;1,041,484&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--UnrealizedGainLossOnDerivatives_iN_di_c20250101__20251231_z9QuDUjAjMub" style="text-align: right" title="Change in fair value"&gt;&lt;span style="font-size: 10pt"&gt;(906,430&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Extinguishment of fair value of liability&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ExtinguishmentOfDebtGainLossNetOfTax_iN_di_c20250101__20251231_zLopX0wn9puc" style="border-bottom: black 1pt solid; text-align: right" title="Extinguishment of fair value of liability"&gt;&lt;span style="font-size: 10pt"&gt;(135,054&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Fair value as of December 31, 2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--DerivativeFairValueOfDerivativeLiability_iE_d0_c20250101__20251231_z0cgjM0ajdj" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of derivative liability, ending balance"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="AsOf2024-10-31"
      decimals="0"
      id="Fact001032"
      unitRef="USD">501824</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="From2024-11-012024-12-31"
      decimals="0"
      id="Fact001034"
      unitRef="USD">-539660</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001036"
      unitRef="USD">1041484</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001038"
      unitRef="USD">906430</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:ExtinguishmentOfDebtGainLossNetOfTax
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001040"
      unitRef="USD">135054</us-gaap:ExtinguishmentOfDebtGainLossNetOfTax>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001042"
      unitRef="USD">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001044"
      unitRef="USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001046"
      unitRef="USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-01-16_custom_YorkvilleConvertibleNoteMember"
      decimals="0"
      id="Fact001047"
      unitRef="USD">1100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2025-01-152025-01-16_custom_YorkvilleConvertibleNoteMember"
      decimals="INF"
      id="Fact001048"
      unitRef="Pure">0.08</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2025-01-152025-01-16_custom_YorkvilleConvertibleNoteMember"
      id="Fact001049">2025-12-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="From2025-01-012025-12-31_custom_YANote2Member"
      decimals="0"
      id="Fact001054"
      unitRef="USD">1100000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <coep:DebtConversionConvertedInterestAmount1
      contextRef="From2025-01-012025-12-31_custom_YANote2Member"
      decimals="0"
      id="Fact001055"
      unitRef="USD">43397</coep:DebtConversionConvertedInterestAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2025-01-012025-12-31_custom_YorkvilleConvertibleNoteMember"
      decimals="INF"
      id="Fact001056"
      unitRef="Shares">158582</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2025-12-31_custom_YorkvilleConvertibleNoteMember"
      decimals="0"
      id="Fact001058"
      unitRef="USD">0</us-gaap:ConvertibleNotesPayable>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2025-01-012025-12-31_custom_YANote2Member"
      decimals="0"
      id="Fact001060"
      unitRef="USD">110000</us-gaap:AmortizationOfDebtDiscountPremium>
    <coep:SbaLoanPayableDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001062">&lt;p id="xdx_80B_ecustom--SbaLoanPayableDisclosureTextBlock_zVcdQ3jGyrJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 5 &#x2013; &lt;span id="xdx_823_zXZJGo6BmgV2"&gt;SBA LOAN PAYABLE &lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Loans under the CARES Act&#160;&lt;/b&gt;-- On July
8, 2020, the Company received a loan of $&lt;span id="xdx_90A_eus-gaap--ProceedsFromLoans_c20200707__20200708__us-gaap--LongtermDebtTypeAxis__custom--EidlLoanMember_zm1ZqjPvaDM4" title="Proceeds from loans"&gt;150,000&lt;/span&gt; from the United States Small Business Administration (the &#x201c;SBA&#x201d;) under its
Economic Injury Disaster Loan (&#x201c;EIDL&#x201d;) assistance program in light of the impact of the COVID-19 pandemic on the Company&#x2019;s
business. Proceeds are intended to be used for working capital purposes. Interest on the EIDL loan accrues at the rate of &lt;span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20200708__us-gaap--LongtermDebtTypeAxis__custom--EidlLoanMember_zHwXOVcN3JU7" title="Accrued interest rate"&gt;3.75&lt;/span&gt;% per annum
and interest payments are due monthly in the amount of $731. Each payment will be applied first to interest accrued to the date of receipt
of each payment, and the balance, if any, will be applied to principal. The Company began making interest payments in January 2023. The
balance of principal and interest is payable thirty years from the date of the promissory note. The balance of the loan is $&lt;span id="xdx_904_eus-gaap--NotesPayable_iI_c20251231__us-gaap--LongtermDebtTypeAxis__custom--EidlLoanMember_zhJBNfy7y3O6" title="Notes payable"&gt;&lt;span id="xdx_902_eus-gaap--NotesPayable_iI_c20241231__us-gaap--LongtermDebtTypeAxis__custom--EidlLoanMember_zBRlLfdt4HGc" title="Notes payable"&gt;150,000&lt;/span&gt;&lt;/span&gt;, as
of December 31, 2025 and December 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</coep:SbaLoanPayableDisclosureTextBlock>
    <us-gaap:ProceedsFromLoans
      contextRef="From2020-07-072020-07-08_custom_EidlLoanMember"
      decimals="0"
      id="Fact001064"
      unitRef="USD">150000</us-gaap:ProceedsFromLoans>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2020-07-08_custom_EidlLoanMember"
      decimals="INF"
      id="Fact001066"
      unitRef="Pure">0.0375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:NotesPayable
      contextRef="AsOf2025-12-31_custom_EidlLoanMember"
      decimals="0"
      id="Fact001068"
      unitRef="USD">150000</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="AsOf2024-12-31_custom_EidlLoanMember"
      decimals="0"
      id="Fact001070"
      unitRef="USD">150000</us-gaap:NotesPayable>
    <us-gaap:DerivativesAndFairValueTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001072">&lt;p id="xdx_803_eus-gaap--DerivativesAndFairValueTextBlock_zFxj60qJwxl4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 6 &#x2013; &lt;span id="xdx_824_zbWk0j08R41h"&gt;DERIVATIVE LIABILITY
WARRANTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At December 31, 2025 and December 31, 2024, there
were (i)&#160; &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--PublicWarrantsMember_z9cJ2RVLXbO2" title="Warrants outstanding"&gt;&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--AwardTypeAxis__custom--PublicWarrantsMember_z9dU1pQt3e62" title="Warrants outstanding"&gt;375,000&lt;/span&gt;&lt;/span&gt; public warrants (the &#x201c;Public Warrants&#x201d;) outstanding that were issued as part of Bull Horn&#x2019;s November
2020 initial public offering, which warrants are exercisable in the aggregate to acquire 187,500 shares of our common stock at an exercise
price of $230.00 per share, (ii)&#160;&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantsMember_zudo6F3ZOPc9" title="Warrants outstanding"&gt;&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantsMember_zA531p6bBIV8" title="Warrants outstanding"&gt;187,500&lt;/span&gt;&lt;/span&gt;&#160;private warrants (the &#x201c;Private Placement Warrants&#x201d;) outstanding that were
issued to our sponsor Bull Horn Holdings Sponsor LC and the underwriters in Bull Horn&#x2019;s initial public offering in November 2020,
which warrants are exercisable in the aggregate to 187,500 shares of our common stock at an exercise price of $230.00 per share. The amount
of warrants and related exercise price were adjusted for the Company&#x2019;s 20-1 reverse stock split effective December 31, 2024. The
Private Placement Warrants became exercisable on the consummation of our Business Combination in October 2022. No Public Warrants will
be exercisable for cash unless the Company has an effective and current registration statement covering the ordinary shares issuable upon
exercise of the Public Warrants and a current prospectus relating to such shares of common stock. With respect to the shares of common
stock issuable upon the exercise of the Public Warrants, the class A warrants and the class B warrants during any period when the Company
shall have failed to maintain an effective registration statement related to the issuance of such shares underlying the applicable warrants,
the holder of any applicable warrants may exercise its warrant on a cashless basis pursuant to an available exemption from registration
under the Securities Act. If an exemption from registration is not available, holders will not be able to exercise their Public Warrants
on a cashless basis. The Public Warrants will expire five years from the consummation of a Business Combination or earlier upon redemption
or liquidation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company may call the Public Warrants for redemption,
in whole and not in part, at a price of $0.01 per warrant:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 93%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;at any time while the Public Warrants are exercisable,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;upon not less than 30 days&#x2019; prior written notice of redemption to each Public Warrant holder,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;if, and only if, the reported last sale price of the ordinary shares equals or exceeds $16.50 per share, for any 20 trading days within a 30-trading day period ending on the third trading day prior to the notice of redemption to Public Warrant holders, and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;if, and only if, there is a current registration statement in effect with respect to the ordinary shares underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;If the Company calls the Public Warrants for redemption,
management will have the option to require all holders that wish to exercise the Public Warrants to do so on a &#x201c;cashless basis,&#x201d;
as described in the warrant agreement. The exercise price and number of ordinary shares issuable upon exercise of the warrants may be
adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or recapitalization, reorganization,
merger or consolidation. However, except as described above, the warrants will not be adjusted for issuances of ordinary shares at a price
below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants. If the Company is unable
to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders
of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company&#x2019;s
assets held outside of the Trust Account with respect to such warrants. Accordingly, the warrants may expire worthless.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Private Placement Warrants are identical to
the Public Warrants, except that the Private Placement Warrants only allow the holder thereof to one ordinary share. Additionally, the
Private Placement Warrants will be exercisable on a cashless basis and be non-redeemable so long as they are held by the initial purchasers
or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted
transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the
Public Warrants.&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Within ASC 815,&#160;&lt;i&gt;Derivative and Hedging&lt;/i&gt;,
Section 815-40-15 addresses equity versus liability treatment and classification of equity-linked financial instruments, including warrants,
and states that a warrant may be classified as a component of equity only if, among other things, the warrant is indexed to the issuer&#x2019;s
ordinary share. Under ASC Section 815-40-15, a warrant is not indexed to the issuer&#x2019;s ordinary share if the terms of the warrant
require an adjustment to the exercise price upon a specified event and that event is not an input to the fair value of the warrant. Based
on management&#x2019;s evaluation, the Company&#x2019;s audit committee, in consultation with management, concluded that the Company&#x2019;s
Private Placement Warrants and Public Warrants are not indexed to the Company&#x2019;s ordinary share in the manner contemplated by ASC
Section 815-40-15 because the holder of the instrument is not an input into the pricing of a fixed-for-fixed option on equity shares.
In addition, based on management&#x2019;s evaluation, the Company&#x2019;s audit committee, in consultation with management, concluded that
certain warrant provisions preclude equity treatment as by ASC Section 815-10-15.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company accounts for its Public Warrants and
Private Placement Warrants as liabilities as set forth in ASC 815-40-15-7D and 7F. See below for details about the methodology and valuation
of the Warrants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table presents information about
the Company&#x2019;s derivative liability warrant that are measured at fair value on a recurring basis at December 31, 2025 and December
31, 2024, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zYZYqpWiEQSb" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - DERIVATIVE LIABILITY WARRANTS (Details - Fair value)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BE_zgqKjRFwZ6u7" style="display: none"&gt;Schedule of fair value hierarchy&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Description&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Level&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.2pt; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.2pt; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 52%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Warrant Liability &#x2013; Public Warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pp0p0_c20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--PublicWarrantsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zykD5wfi9tOi" style="width: 13%; text-align: right" title="Financial liabilities fair value disclosure"&gt;&lt;span style="font-size: 10pt"&gt;81,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--FinancialLiabilitiesFairValueDisclosure_pp0p0_c20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--PublicWarrantsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z17ss78aDgnf" style="width: 13%; text-align: right" title="Financial liabilities fair value disclosure"&gt;&lt;span style="font-size: 10pt"&gt;165,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Warrant Liability &#x2013; Private Placement Warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pp0p0_c20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--PrivatePlacementWarrantsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z441SQZ8Og" style="border-bottom: Black 1pt solid; text-align: right" title="Financial liabilities fair value disclosure"&gt;&lt;span style="font-size: 10pt"&gt;86,625&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--FinancialLiabilitiesFairValueDisclosure_pp0p0_c20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--PrivatePlacementWarrantsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwr7twPOickb" style="border-bottom: Black 1pt solid; text-align: right" title="Financial liabilities fair value disclosure"&gt;&lt;span style="font-size: 10pt"&gt;194,250&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_c20251231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zyUSDWg5YsK9" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;167,625&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zpMRnNeWEKw6" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;359,250&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AE_zjhDZPp78675" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Warrants are accounted for as liabilities
in accordance with ASC 815-40 and are presented within derivative liability warrants in the accompanying consolidated balance sheets.
The derivative liability warrants are measured at fair value at inception and on a recurring basis, with changes in fair value presented
in the consolidated statements of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Warrants were valued using a binomial lattice
model, which is considered to be a Level 3 fair value measurement. The binomial lattice model&#x2019;s primary unobservable input utilized
in determining the fair value of the Warrants is the expected volatility of the ordinary shares. The expected volatility as of the Initial
Public Offering date was derived from observable public warrant pricing on comparable &#x2018;blank-check&#x2019; companies without an identified
target. For periods subsequent to the detachment of the Public Warrants from the Units, the close price of the Public Warrant price will
be used as the fair value as of each relevant date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table provides quantitative information
regarding Level 3 fair value measurements:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_zWvyTg8a35Bd" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - DERIVATIVE LIABILITY WARRANTS (Details - Fair value assumption)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BE_zsam605Oqrhb" style="display: none"&gt;Schedule of fair value assumptions&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 68%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250101__20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsMember_z9sjKqBiU8E9" title="Derivatives, determination of fair value"&gt;3.41&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsMember_zGomT0glwFSe" title="Derivatives, determination of fair value"&gt;4.10&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250101__20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsMember_zTxp77nNiJi7" title="Derivatives, determination of fair value"&gt;68.58&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsMember_ziAlQrcigcR5" title="Derivatives, determination of fair value"&gt;82.01&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250101__20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsMember_z4Ljn5EkmDn5" title="Derivatives, determination of fair value"&gt;230.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsMember_zuWNHWHhasb5" title="Derivatives, determination of fair value"&gt;230.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Stock price&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250101__20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsMember_z36e5rJitRxk" title="Derivatives, determination of fair value"&gt;14.25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsMember_ziKSXBpIE0Fa" title="Derivatives, determination of fair value"&gt;5.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A3_zAIjs6K6nKvg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table presents the changes in the
fair value of warrant liabilities:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zu3NHvWjouG" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - DERIVATIVE LIABILITY WARRANTS (Details - Changes in fair value of warrant liabilities)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B4_zrOQM567XcY5" style="display: none"&gt;Schedule of changes in fair value of warrant liabilities&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Private&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Placement&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Public&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Warrant&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 52%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Fair value as of December 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--LiabilitiesFairValueDisclosure_iS_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--PrivatePlacementWarrantsMember_zJRNHSESjNC8" style="width: 13%; text-align: right" title="Fair value of liabilities, beginning"&gt;&lt;span style="font-size: 10pt"&gt;194,250&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iS_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--PublicWarrantsMember_zcGUan0W4qAl" style="width: 13%; text-align: right" title="Fair value of liabilities, beginning"&gt;&lt;span style="font-size: 10pt"&gt;165,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--LiabilitiesFairValueDisclosure_iS_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantLiabilitiesMember_zEhzUI30ezMd" style="width: 13%; text-align: right" title="Fair value of liabilities, beginning"&gt;&lt;span style="font-size: 10pt"&gt;359,250&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Change in valuation inputs&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--PrivatePlacementWarrantsMember_zvfSBXANTCUc" style="border-bottom: black 1pt solid; text-align: right" title="Change in valuation inputs"&gt;&lt;span style="font-size: 10pt"&gt;(107,625&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--PublicWarrantsMember_zxL0wuHoJy5k" style="border-bottom: black 1pt solid; text-align: right" title="Change in valuation inputs"&gt;&lt;span style="font-size: 10pt"&gt;(84,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantLiabilitiesMember_zDZhStIRKTI" style="border-bottom: black 1pt solid; text-align: right" title="Change in valuation inputs"&gt;&lt;span style="font-size: 10pt"&gt;(191,625&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Fair value as of December 31, 2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_iE_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--PrivatePlacementWarrantsMember_z8KxeUcCjQy8" style="border-bottom: black 2.25pt double; text-align: right" title="Fair value of liabilities, ending"&gt;&lt;span style="font-size: 10pt"&gt;86,625&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--LiabilitiesFairValueDisclosure_iE_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--PublicWarrantsMember_zGuxjbu8LBY7" style="border-bottom: black 2.25pt double; text-align: right" title="Fair value of liabilities, ending"&gt;&lt;span style="font-size: 10pt"&gt;81,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--LiabilitiesFairValueDisclosure_iE_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantLiabilitiesMember_zYC5pEXwPSK6" style="border-bottom: black 2.25pt double; text-align: right" title="Fair value of liabilities, ending"&gt;&lt;span style="font-size: 10pt"&gt;167,625&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AF_zSy0QNSUdsH4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;There were no transfers in or out of Level 3 from
other levels in the fair value hierarchy during the years ended December 31, 2025 and December 31, 2024.&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:DerivativesAndFairValueTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_PublicWarrantsMember"
      decimals="INF"
      id="Fact001074"
      unitRef="Shares">375000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_PublicWarrantsMember"
      decimals="INF"
      id="Fact001076"
      unitRef="Shares">375000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_PrivatePlacementWarrantsMember"
      decimals="INF"
      id="Fact001078"
      unitRef="Shares">187500</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_PrivatePlacementWarrantsMember"
      decimals="INF"
      id="Fact001080"
      unitRef="Shares">187500</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001085">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zYZYqpWiEQSb" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - DERIVATIVE LIABILITY WARRANTS (Details - Fair value)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BE_zgqKjRFwZ6u7" style="display: none"&gt;Schedule of fair value hierarchy&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Description&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Level&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.2pt; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.2pt; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 52%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Warrant Liability &#x2013; Public Warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pp0p0_c20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--PublicWarrantsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zykD5wfi9tOi" style="width: 13%; text-align: right" title="Financial liabilities fair value disclosure"&gt;&lt;span style="font-size: 10pt"&gt;81,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--FinancialLiabilitiesFairValueDisclosure_pp0p0_c20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--PublicWarrantsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z17ss78aDgnf" style="width: 13%; text-align: right" title="Financial liabilities fair value disclosure"&gt;&lt;span style="font-size: 10pt"&gt;165,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Warrant Liability &#x2013; Private Placement Warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pp0p0_c20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--PrivatePlacementWarrantsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z441SQZ8Og" style="border-bottom: Black 1pt solid; text-align: right" title="Financial liabilities fair value disclosure"&gt;&lt;span style="font-size: 10pt"&gt;86,625&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--FinancialLiabilitiesFairValueDisclosure_pp0p0_c20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--PrivatePlacementWarrantsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwr7twPOickb" style="border-bottom: Black 1pt solid; text-align: right" title="Financial liabilities fair value disclosure"&gt;&lt;span style="font-size: 10pt"&gt;194,250&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_c20251231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zyUSDWg5YsK9" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;167,625&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zpMRnNeWEKw6" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;359,250&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2025-12-31_custom_PublicWarrantsMember_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact001087"
      unitRef="USD">81000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_custom_PublicWarrantsMember_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact001089"
      unitRef="USD">165000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2025-12-31_custom_PrivatePlacementWarrantsMember_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001091"
      unitRef="USD">86625</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_custom_PrivatePlacementWarrantsMember_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001093"
      unitRef="USD">194250</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2025-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact001094"
      unitRef="USD">167625</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact001095"
      unitRef="USD">359250</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001097">&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_zWvyTg8a35Bd" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - DERIVATIVE LIABILITY WARRANTS (Details - Fair value assumption)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BE_zsam605Oqrhb" style="display: none"&gt;Schedule of fair value assumptions&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 68%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250101__20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsMember_z9sjKqBiU8E9" title="Derivatives, determination of fair value"&gt;3.41&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsMember_zGomT0glwFSe" title="Derivatives, determination of fair value"&gt;4.10&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250101__20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsMember_zTxp77nNiJi7" title="Derivatives, determination of fair value"&gt;68.58&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsMember_ziAlQrcigcR5" title="Derivatives, determination of fair value"&gt;82.01&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250101__20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsMember_z4Ljn5EkmDn5" title="Derivatives, determination of fair value"&gt;230.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsMember_zuWNHWHhasb5" title="Derivatives, determination of fair value"&gt;230.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Stock price&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250101__20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsMember_z36e5rJitRxk" title="Derivatives, determination of fair value"&gt;14.25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsMember_ziKSXBpIE0Fa" title="Derivatives, determination of fair value"&gt;5.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue
      contextRef="From2025-01-012025-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WarrantsMember"
      id="Fact001099">3.41</us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue>
    <us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue
      contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WarrantsMember"
      id="Fact001101">4.10</us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue>
    <us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue
      contextRef="From2025-01-012025-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_WarrantsMember"
      id="Fact001103">68.58</us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue>
    <us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue
      contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_WarrantsMember"
      id="Fact001105">82.01</us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue>
    <us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue
      contextRef="From2025-01-012025-12-31_us-gaap_MeasurementInputExercisePriceMember_custom_WarrantsMember"
      id="Fact001107">230.00</us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue>
    <us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue
      contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputExercisePriceMember_custom_WarrantsMember"
      id="Fact001109">230.00</us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue>
    <us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue
      contextRef="From2025-01-012025-12-31_us-gaap_MeasurementInputSharePriceMember_custom_WarrantsMember"
      id="Fact001111">14.25</us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue>
    <us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue
      contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputSharePriceMember_custom_WarrantsMember"
      id="Fact001113">5.50</us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001115">&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zu3NHvWjouG" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - DERIVATIVE LIABILITY WARRANTS (Details - Changes in fair value of warrant liabilities)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B4_zrOQM567XcY5" style="display: none"&gt;Schedule of changes in fair value of warrant liabilities&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Private&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Placement&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Public&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Warrant&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 52%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Fair value as of December 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--LiabilitiesFairValueDisclosure_iS_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--PrivatePlacementWarrantsMember_zJRNHSESjNC8" style="width: 13%; text-align: right" title="Fair value of liabilities, beginning"&gt;&lt;span style="font-size: 10pt"&gt;194,250&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iS_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--PublicWarrantsMember_zcGUan0W4qAl" style="width: 13%; text-align: right" title="Fair value of liabilities, beginning"&gt;&lt;span style="font-size: 10pt"&gt;165,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--LiabilitiesFairValueDisclosure_iS_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantLiabilitiesMember_zEhzUI30ezMd" style="width: 13%; text-align: right" title="Fair value of liabilities, beginning"&gt;&lt;span style="font-size: 10pt"&gt;359,250&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Change in valuation inputs&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--PrivatePlacementWarrantsMember_zvfSBXANTCUc" style="border-bottom: black 1pt solid; text-align: right" title="Change in valuation inputs"&gt;&lt;span style="font-size: 10pt"&gt;(107,625&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--PublicWarrantsMember_zxL0wuHoJy5k" style="border-bottom: black 1pt solid; text-align: right" title="Change in valuation inputs"&gt;&lt;span style="font-size: 10pt"&gt;(84,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantLiabilitiesMember_zDZhStIRKTI" style="border-bottom: black 1pt solid; text-align: right" title="Change in valuation inputs"&gt;&lt;span style="font-size: 10pt"&gt;(191,625&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Fair value as of December 31, 2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_iE_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--PrivatePlacementWarrantsMember_z8KxeUcCjQy8" style="border-bottom: black 2.25pt double; text-align: right" title="Fair value of liabilities, ending"&gt;&lt;span style="font-size: 10pt"&gt;86,625&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--LiabilitiesFairValueDisclosure_iE_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--PublicWarrantsMember_zGuxjbu8LBY7" style="border-bottom: black 2.25pt double; text-align: right" title="Fair value of liabilities, ending"&gt;&lt;span style="font-size: 10pt"&gt;81,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--LiabilitiesFairValueDisclosure_iE_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantLiabilitiesMember_zYC5pEXwPSK6" style="border-bottom: black 2.25pt double; text-align: right" title="Fair value of liabilities, ending"&gt;&lt;span style="font-size: 10pt"&gt;167,625&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_custom_PrivatePlacementWarrantsMember206522015"
      decimals="0"
      id="Fact001117"
      unitRef="USD">194250</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_custom_PublicWarrantsMember206522015"
      decimals="0"
      id="Fact001119"
      unitRef="USD">165000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_custom_WarrantLiabilitiesMember"
      decimals="0"
      id="Fact001121"
      unitRef="USD">359250</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect
      contextRef="From2025-01-012025-12-31_custom_PrivatePlacementWarrantsMember"
      decimals="0"
      id="Fact001123"
      unitRef="USD">-107625</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect
      contextRef="From2025-01-012025-12-31_custom_PublicWarrantsMember"
      decimals="0"
      id="Fact001125"
      unitRef="USD">-84000</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect
      contextRef="From2025-01-012025-12-31_custom_WarrantLiabilitiesMember"
      decimals="0"
      id="Fact001127"
      unitRef="USD">-191625</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-12-31_custom_PrivatePlacementWarrantsMember206522046"
      decimals="0"
      id="Fact001129"
      unitRef="USD">86625</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-12-31_custom_PublicWarrantsMember206522046"
      decimals="0"
      id="Fact001131"
      unitRef="USD">81000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-12-31_custom_WarrantLiabilitiesMember"
      decimals="0"
      id="Fact001133"
      unitRef="USD">167625</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001138">&lt;p id="xdx_800_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z2tDlxJAz5Q2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 7 &#x2013; &lt;span id="xdx_82C_zznjSspxVHYk"&gt;CAPITAL STRUCTURE&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The total number of shares of stock which the
corporation shall have authority to issue is 160,000,000 shares, of which 150,000,000 shares of $&lt;span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zihYz2WUvUcl" title="Common stock, par value"&gt;0.0001&lt;/span&gt; par value shall be designated
as Common Stock and &lt;span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_c20251231_zUXp70O0Nxlb" title="Preferred stock, shares authorized"&gt;10,000,000&lt;/span&gt; shares of $&lt;span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20251231_zRa5Pb82Yspk" title="Preferred stock, par value"&gt;0.0001&lt;/span&gt; shall be designated as Preferred Stock. The Preferred Stock authorized by the Company&#x2019;s
Articles of Incorporation may be issued in one or more series. The Board of Directors of the Corporation is authorized to determine or
alter the rights, preferences, privileges, and restrictions granted or imposed upon any wholly unissued series of Preferred Stock, and
within the limitations or restrictions stated in any resolution or resolutions of the Board of Directors originally fixing the number
of shares constituting any series, to increase or decrease (but not below the number of shares of any such series then outstanding) the
number of shares of any such series subsequent to the issue of shares of that series, to determine the designation and par value of any
series and to fix the numbers of shares of any series.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Common Stock&lt;/b&gt;&#160;&#x2013; As of December
31, 2025, the Company had &lt;span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_c20251231_zTaADzJ56wLg" title="Common stock, shares outstanding"&gt;5,746,948&lt;/span&gt; shares of its common stock issued and outstanding, and on December 31, 2024, the Company had &lt;span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_c20241231_zYQUpCj2EcA" title="Common stock, shares outstanding"&gt;2,116,191&lt;/span&gt;
shares of its common stock issued and outstanding. All share amounts have been adjusted for the Company&#x2019;s &lt;span id="xdx_908_eus-gaap--StockholdersEquityReverseStockSplit_c20241201__20241231_zd1ui15ClQw4" title="Reverse stock split"&gt;20-1 reverse stock split&lt;/span&gt;
effective December 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the years ended December 31, 2025 and 2024,
there were no capital distributions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 16, 2023, the Company completed a
public offering issuing &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230615__20230616__us-gaap--SubsidiarySaleOfStockAxis__custom--PublicOfferingMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zQ7oEMdfSnD" title="Stock issued new, shares"&gt;107,500&lt;/span&gt; shares of our common stock, &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230615__20230616__us-gaap--SubsidiarySaleOfStockAxis__custom--PublicOfferingMember__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_znQN47rLUtVc" title="Stock issued new, shares"&gt;&lt;span id="xdx_909_eus-gaap--ConversionOfStockSharesConverted1_c20230615__20230616__us-gaap--SubsidiarySaleOfStockAxis__custom--PublicOfferingMember__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_zo4yfacSzyIh" title="Stock converted, shares converted"&gt;67,500&lt;/span&gt;&lt;/span&gt; pre-funded warrants, &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230615__20230616__us-gaap--SubsidiarySaleOfStockAxis__custom--PublicOfferingMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsMember_zBybdNuxZzU1" title="Stock issued new, shares"&gt;153,125&lt;/span&gt; Series A Warrants and &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230615__20230616__us-gaap--SubsidiarySaleOfStockAxis__custom--PublicOfferingMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_z3NX9iWOI5X6" title="Stock issued new, shares"&gt;153,125&lt;/span&gt; Series
B Warrants, for net proceeds of approximately $3.0 million, after offering costs. The pre- funded warrants are immediately
exercisable, at a price of $0.0001 per share, with no expiration date. The Series A Warrants and the Series B Warrants are referred
to herein together as the &#x201c;Series Warrants.&#x201d; The shares of common stock and Series Warrants were purchased together and
then immediately separable and were issued separately. Each Series Warrant to purchase one share of common stock has an exercise
price of $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230616__us-gaap--SubsidiarySaleOfStockAxis__custom--PublicOfferingMember__us-gaap--StatementClassOfStockAxis__custom--SeriesWarrantsMember_zZPUnDeTYth" title="Warrants exercise price"&gt;33.00&lt;/span&gt;&#160;per share, and is initially exercisable commencing six months from the date of the offering. The Series
Warrants are exercisable for a term of five years following the initial exercise date. As of December 31, 2024, all of the
pre-funded warrants had been exercised for a total of &lt;span id="xdx_905_eus-gaap--ConversionOfStockSharesIssued1_c20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--PublicOfferingMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zoUJYij30JIc" title="Stock converted, shares issued"&gt;175,000&lt;/span&gt; shares of common stock issued as a result of the public offering.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 28, 2023, the Company granted pre-funded
warrants exercisable to acquire up to 60,000 shares of our common stock for net proceeds of $1,200,000. The pre-funded common stock purchase
warrants can be exercised at a price of $0.0001 per share, with no expiration date. During the first quarter of 2024, the Company and
the third-party borrower agreed to amend the note as a result of the decline in the publicly traded common stock price. The amount of
pre-funded warrants exercisable to acquire up to 60,000 shares of common stock was amended to 100,000 shares of common stock, and the
total principal balance of the note agreement was increased from $1,000,000 to $1,100,000. The aggregate exercise price of this Warrant
was partially pre-funded in connection with $100,000 and a $&lt;span id="xdx_90C_eus-gaap--ProceedsFromWarrantExercises_pp0p0_c20231227__20231228__us-gaap--StatementClassOfStockAxis__custom--WarrantNoteSubscriptionReceivablesMember_zdVhXXwfpD93" title="Aggregate exercise price of warrant"&gt;1,100,000&lt;/span&gt;&#160;subscription receivable at a 6% per annum interest rate due
on November 29, 2024. On August 12, 2024, the third-party assigned shares of common stock in a privately held company for the equivalent
amount of principal and accrued interest owed, which satisfied the subscription receivable in full. See Note 9, Investments, for additional
information.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 8, 2024, the Company granted pre-funded
warrants exercisable to acquire up to 200,000 shares of our common stock for net proceeds of $2,400,000. The pre-funded common stock purchase
warrants can be exercised at a price of $0.0001 per share, with no expiration date. The aggregate exercise price of this Warrant was partially
pre-funded in connection with $500,000&#160;and a $1,900,000 subscription receivable at a 6% per annum interest rate due on December 31,
2024. On August 12, 2024, the third-party assigned shares of common stock in a privately held company for the equivalent amount of principal
and accrued interest owed, which satisfied the subscription receivable in full. See Note 9, Investments, for additional information.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2025, the Company
completed a private placement offering issuing 436,467 shares of common stock for total proceeds of $&lt;span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250701__20250930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zVVtSEBCxyB7" title="Proceeds from common stock"&gt;5,000,000&lt;/span&gt;. &lt;span id="xdx_90B_eus-gaap--SaleOfStockDescriptionOfTransaction_c20250701__20250930__dei--LegalEntityAxis__custom--SNAPBiosciencesIncMember_zpuzYRJKsjFh" title="Investors description"&gt;In addition to the shares
of common stock of the Company, investors also received 10% aggregate non-voting ownership in the Company&#x2019;s subsidiary, SNAP Biosciences,
Inc. Of this $5,000,000 raised, $4,500,000 was collected as of December 31, 2025. $500,000 of the subscription receivable is tied to a
promissory note bearing 1% interest annum, with a maturity date of January 18, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the fourth quarter of 2025, the Company
completed subscription agreements with two investors, resulting in gross proceeds of $&lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20251001__20251231__us-gaap--TypeOfArrangementAxis__custom--TwoInvestorMember_z9pQAbn9MDYk" title="Gross proceeds"&gt;3,120,000&lt;/span&gt; for a total of &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251001__20251231__us-gaap--TypeOfArrangementAxis__custom--TwoInvestorMember_ziVdYwbcBJk1" title="Number of shares issued"&gt;260,000&lt;/span&gt; shares of common
stock. The balance of $&lt;span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--TwoInvestorMember_zceAYeQBD5F6" title="Principal amount"&gt;3,120,000&lt;/span&gt; is tied to promissory notes bearing &lt;span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20241231__us-gaap--TypeOfArrangementAxis__custom--TwoInvestorMember_zvvhiUq1MPa3" title="Debt instrument stated percentage"&gt;1&lt;/span&gt;% interest annum, with a maturity date of &lt;span id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_dd_c20251001__20251231__us-gaap--TypeOfArrangementAxis__custom--TwoInvestorMember_zrOBfduIM777" title="Maturity period"&gt;December 18, 2026&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Treasury Stock&#160;&lt;/b&gt;&#x2013; There was&#160;&lt;span id="xdx_90E_eus-gaap--TreasuryStockValue_iI_pp0p0_do_c20251231_zxpvoGdLxeN6" title="Treasury stock"&gt;&lt;span id="xdx_90F_eus-gaap--TreasuryStockValue_iI_pp0p0_do_c20241231_zuDRLCsZd4rb" title="Treasury stock"&gt;no&lt;/span&gt;&lt;/span&gt;&#160;treasury
stock at December 31, 2025 and December 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Preferred Stock&#160;&lt;/b&gt;&#x2013; The
Company has &lt;span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_c20251231_zFv7nLTc7mW2" title="Preferred stock authorized"&gt;10,000,000&lt;/span&gt;
shares of preferred stock authorized, of which &lt;span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zQ5v6fsq9yy" title="Preferred stock authorized"&gt;10,000&lt;/span&gt;
have been designated as Series A preferred stock. As of December 31, 2024, the Company had &lt;span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zie3EbC1YyT9" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z3nJmcL3dvgf" title="Preferred stock, shares outstanding"&gt;6,520&lt;/span&gt;&lt;/span&gt;
shares of Series A preferred stock issued and outstanding, and at December 31, 2025, the Company had &lt;span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zxOBDmClRzik" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zyDeYNDsnkVb" title="Preferred stock, shares outstanding"&gt;0&lt;/span&gt;&lt;/span&gt;
shares of Series A preferred stock issued and outstanding.&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 13, 2024, the Company performed an initial
Series A preferred stock closing and raised $&lt;span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_dm_c20240612__20240613__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zcyXU3ZfJZwj" title="Proceeds from sale of preferred stock"&gt;4.3 million&lt;/span&gt; in a sale to accredited investors (collectively, the &#x201c;Series A Investors&#x201d;)
of &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240612__20240613__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zW2EOEk0MTQe" title="Stock issued new, shares"&gt;4,300&lt;/span&gt; shares of the Company&#x2019;s series A preferred stock (the &#x201c;Series A Preferred Stock&#x201d;), at a purchase price of $1,000
per share, in a financing led by CJC Investment Trust, an entity controlled by board member Christopher Calise, in a combination of cash
and short- term collateralized promissory notes. The Series A Investors also received non-voting equity ownership interest in the Company&#x2019;s
two newly formed subsidiaries, SNAP Biosciences Inc. and GEAR Therapeutics Inc.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 31, 2024, the Company performed a second
closing as part of its series A preferred stock offering and raised $&lt;span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_dm_c20240730__20240731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zivOXpFKQVF4" title="Proceeds from sale of preferred stock"&gt;1.3 million&lt;/span&gt;, at a purchase price of $1,000 per share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 4, 2024, the Company performed a
third closing as part of its series A preferred stock offering and raised $&lt;span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pp0p0_c20240903__20240904__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zLBMFtj9oSwj" title="Proceeds from sale of preferred stock"&gt;225,000&lt;/span&gt;, at a purchase price of $1,000 per share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 23, 2024, the Company performed a
fourth closing as part of its series A preferred stock offering and raised $&lt;span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pp0p0_c20241222__20241223__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zAgBsFtooT79" title="Proceeds from sale of preferred stock"&gt;695,000&lt;/span&gt; at a purchase price of $1,000 per share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 6, 2025, the Company completed its
successful closure of the remaining $&lt;span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_dm_c20250205__20250206__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z7CagD9Tdb2" title="Proceeds from sale of preferred stock"&gt;3.48 million&lt;/span&gt;&#160;of its Series A preferred stock offering, completing the total $10.0 million financing
round.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 25, 2025, the Company and a holder of
its preferred stock, who is also a party to an existing consulting agreement with the Company, entered into an addendum to amend the terms
of the consulting arrangement. Under the amendment, the Company agreed to prepay the final six months of the consulting agreement by offsetting
the outstanding $&lt;span id="xdx_90B_eus-gaap--StockholdersEquityNoteSubscriptionsReceivable_iI_c20250725__us-gaap--TransactionTypeAxis__custom--ConsultingAgreementMember_zWsV6rCeMNm3" title="Subscription receivable"&gt;125,000&lt;/span&gt; subscription receivable previously recorded from the shareholder. The prepayment will be amortized over the remaining
term of the consulting agreement as services are rendered, thereby reducing the subscription receivable balance over time.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Throughout the year ended December 31, 2025, all
&lt;span id="xdx_900_eus-gaap--ConversionOfStockSharesConverted1_c20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zYeEmoJaK3Rh" title="Conversion of stock, shares converted"&gt;10,000&lt;/span&gt; series A preferred shares were converted to common stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The series A investors currently have an aggregate
15% non-voting equity ownership interest in the Company&#x2019;s two newly formed subsidiaries, SNAP Biosciences Inc. and GEAR Therapeutics
Inc.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The key terms of the Series A Preferred Stock
are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Conversion.&#160;&lt;/i&gt;Each share of Series A
Preferred Stock is convertible at the option of the holder, subject to the beneficial ownership and, if applicable, the primary market
limitations described below, into such number of shares of the Company&#x2019;s common stock as is equal to the number of shares of Series
A Preferred Stock to be converted, multiplied by the stated value of $1,000 (the &#x201c;Stated Value&#x201d;), divided by the then conversion
price. The initial conversion price is $0.40 per share of common stock, subject to adjustment in the event of stock splits, stock dividends,
and similar transactions. In addition, the Series A Preferred Stock will automatically convert into shares of the Company&#x2019;s common
stock, subject to the beneficial ownership and, if applicable, the primary market limitations described below upon the consummation of
a fundraising transaction in which the Company raises gross proceeds of at least $20&#160;million.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Rank&lt;/i&gt;. The Series A Preferred Stock will
be senior to the Company&#x2019;s common stock and any other class of the Company&#x2019;s capital stock that is not by its terms senior
to or pari passu with the Series A Preferred Stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Dividends.&#160;&lt;/i&gt;The holders of Series A
Preferred Stock will be entitled to dividends equal, on an as-if-converted to shares of the Company&#x2019;s common stock basis (in each
case after applying the beneficial ownership and, if applicable, the primary market limitations described below), to and in the same form
as dividends actually paid on shares of the Company&#x2019;s common stock when, as, and if such dividends are declared on shares of the
Company&#x2019;s common stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Liquidation.&lt;/i&gt;&#160;In the event of any voluntary
or involuntary liquidation, dissolution or winding up of the Company, the holders of shares of Series A Preferred Stock then outstanding
will be entitled to be paid out of the assets of the Company available for distribution to its stockholders, before any payment shall
be made to the holders of the Company&#x2019;s common stock by reason of their ownership thereof, an amount per share equal to the greater
of (i) the Stated Value, plus any dividends accrued but unpaid thereon, or (ii) such amount per share as would have been payable had all
shares of Series A Preferred Stock been converted (in each case after applying the beneficial ownership and, if applicable, the primary
market limitations described below) into the Company&#x2019;s common stock immediately prior to such event.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Voting.&#160;&lt;/i&gt;On any matter to be acted
upon or considered by the stockholders of the Company, each holder of Series A Preferred Stock shall be entitled to vote on an &#x201c;as
converted&#x201d; basis (after applying the beneficial ownership and primary market limitations described below).&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Beneficial Ownership Limitation.&#160;&lt;/i&gt;The
Company will not affect any conversion of the Series A Preferred Stock, and a holder will not have the right to receive dividends or convert
any portion of its Series A Preferred Stock, to the extent that prior to the conversion such holder (together with such holder&#x2019;s
affiliates, and any persons acting as a group together with such holder or any of the holder&#x2019;s affiliates) beneficially owns less
than 20% of the Company&#x2019;s outstanding common stock and, after giving effect to the receipt of dividends or the conversion, the holder
(together with such holder&#x2019;s affiliates, and any persons acting as a group together with such holder or any of the holder&#x2019;s
affiliates) would beneficially own 20% or more of the Company&#x2019;s outstanding common stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Exchange Limitation.&lt;/i&gt;&#160;Unless the approval
of the Company&#x2019;s stockholders is not required by the applicable rules of Nasdaq for issuances of the Company&#x2019;s common stock
in excess of 19.99% of the outstanding common stock as of June 14, 2024 (the &#x201c;Market Limit&#x201d;), or unless the Company has obtained
such approval, the Company shall not affect any conversion of the Series A Preferred Stock, including, without limitation, any automatic
conversion, and a holder shall not have the right to receive dividends on or convert any portion of the Series A Preferred Stock, to the
extent that, after giving effect to the receipt of the Company&#x2019;s common stock in connection with such dividends or conversion, the
holder would have received in excess of its pro rata share of the Market Limit.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Stock Based Compensation &#x2013;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;A summary of the Company&#x2019;s stock option activity is as follows:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zeakXLF5vY5j" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - CAPITAL STRUCTURE (Details - Option activity)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="display: none"&gt;Schedule of stock option activity&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Shares Underlying Options&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Weighted Average Exercise
    Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Weighted Average Contractual
    Life (Years)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Intrinsic Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zAdqo9AwD0ml" style="text-align: right" title="Options outstanding, beginning"&gt;&lt;span style="font-size: 10pt"&gt;87,875&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zdJHc0yuikK5" style="text-align: right" title="Weighted average exercise price, beginning balance outstanding"&gt;&lt;span style="font-size: 10pt"&gt;40.20&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zSCdNBLfZqn6" title="Weighted average contractual life (years), options outstanding"&gt;7.97&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 36%"&gt;&lt;span style="font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zpzNcAhWG1Jk" style="width: 13%; text-align: right" title="Options granted"&gt;&lt;span style="font-size: 10pt"&gt;196,750&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z46h2cts0dne" style="width: 13%; text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="font-size: 10pt"&gt;8.85&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2OptionsGranted_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zRou3ZT1jn8a" title="Weighted average contractual life (years), granted"&gt;10.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zVU7qc8rEWfg" style="text-align: right" title="Options forfeited/expired"&gt;&lt;span style="font-size: 10pt"&gt;(5,000)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zBrjwVoZ8iOh" style="text-align: right" title="Weighted average exercise price, forfeited/expired"&gt;&lt;span style="font-size: 10pt"&gt;200.00&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_d0_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zfXANZ7rjiO9" style="border-bottom: black 1pt solid; text-align: right" title="Options exercised"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zzHQw19UCua6" style="border-bottom: black 1pt solid; text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zWYijifwwHj3" style="text-align: right" title="Options outstanding, beginning"&gt;&lt;span style="font-size: 10pt"&gt;279,625&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zLUum3gcAUHg" style="text-align: right" title="Weighted average exercise price, beginning balance outstanding"&gt;&lt;span style="font-size: 10pt"&gt;15.29&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zdcJXeKn0NU8" title="Weighted average contractual life (years), options outstanding"&gt;8.74&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_ztyMmW7ZFEb8" style="text-align: right" title="Options granted"&gt;&lt;span style="font-size: 10pt"&gt;187,375&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zIh031phyXP1" style="text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="font-size: 10pt"&gt;7.96&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2OptionsGranted_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zUKJ0SCZtgD2" title="Weighted average contractual life (years), granted"&gt;5.20&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z2gIUm4mfyJa" style="text-align: right" title="Options forfeited/expired"&gt;&lt;span style="font-size: 10pt"&gt;(30,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zRZ1TTo3Wyi1" style="text-align: right" title="Weighted average exercise price, forfeited/expired"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_d0_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zuv8YlhRYPA2" style="border-bottom: black 1pt solid; text-align: right" title="Options exercised"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zjJT6tT8gbql" style="border-bottom: black 1pt solid; text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Outstanding at December 31, 2025&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z9ZXtWtL9N8f" style="border-bottom: black 2.25pt double; text-align: right" title="Options outstanding, ending"&gt;&lt;span style="font-size: 10pt"&gt;437,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z9Dprg9sKBWk" style="border-bottom: black 2.25pt double; text-align: right" title="Weighted average exercise price, ending balance outstanding"&gt;&lt;span style="font-size: 10pt"&gt;12.11&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zau0aOCg5xVf" title="Weighted average contractual life (years), options outstanding"&gt;6.26&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zQA7SpV3vjH3" style="border-bottom: black 2.25pt double; text-align: right" title="Intrinsic value, options outstanding"&gt;&lt;span style="font-size: 10pt"&gt;2,215,451&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A2_z77NwnJUTCla" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the years ended December 31, 2025 and 2024,
the Company recorded $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensation_pp0p0_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zZvNmgSsDP96" title="Share based compensation"&gt;1,215,692 &lt;/span&gt;and $&lt;span id="xdx_903_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zOoW91DrAqOb" title="Share based compensation"&gt;1,104,978&lt;/span&gt;, respectively, for stock based compensation expense related to stock options. As of December
31, 2025, unamortized stock based compensation for stock options was $&lt;span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pp0p0_c20251231_zumQMdiNNPB9" title="Unamortized stock-based compensation"&gt;918,681&lt;/span&gt; to be recognized through December 31, 2027.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The options granted during the years ended December
31, 2025 and 2024 were valued using the Black-Scholes option pricing model using the following weighted average assumptions:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zuN6cUYSbiP7" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - CAPITAL STRUCTURE (Details - Weighted average assumptions)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BC_zoaWrx1wddF1" style="display: none"&gt;Schedule of weighted average assumptions&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;For the years ended December
    31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 60%"&gt;&lt;span style="font-size: 10pt"&gt;Expected term, in years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zb44d3yrl74g" title="Expected term, in years"&gt;2.75&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zZNgltc1r60k" title="Expected term, in years"&gt;5.25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zATDT3E1qOxg" title="Expected volatility"&gt;75.58&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zrS3qLfbf3pa" title="Expected volatility"&gt;84.70&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zb3GaOUmKtDf" title="Risk-free interest rate"&gt;3.89&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zCZ2RKkQVEIk" title="Risk-free interest rate"&gt;4.18&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zte09OWFCb2c" title="Dividend yield"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z2QN4EoyzZ71" title="Dividend yield"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A2_zctNFre0IfR1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Options/Stock Awards Forfeited &#x2013; &lt;/b&gt;On
March 24, 2025, Colleen Delaney, Chief Scientific and Medical Officer, resigned her position for a reason other than cause. Per the Plan,
her unvested stock options (&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_c20250323__20250324__srt--CounterpartyNameAxis__custom--ColleenDelaneyMember_z2YDHtKmADQ" title="Number of shares forfeited"&gt;27,500&lt;/span&gt;) were immediately forfeited and go back into the Plan. Her vested stock options (&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20250324__srt--CounterpartyNameAxis__custom--ColleenDelaneyMember_zui5gilCeOfd" title="Number of shares exercised"&gt;2,500&lt;/span&gt;) were eligible
to be exercised for three months following her resignation (by June 24, 2025). As of December 31, 2025, all of her stock options are forfeited,
and the &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20250101__20251231__srt--CounterpartyNameAxis__custom--ColleenDelaneyMember_zZhWqKK4VJb5" title="Number of shares expired"&gt;2,500&lt;/span&gt; vested options are expired.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Modification of Options &#x2013; &lt;/b&gt;On December
31, 2025 the Company and the holder of &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20251201__20251231__us-gaap--PlanNameAxis__custom--ModificationOfOptionsMember_zW3LA3KWVXU8" title="Options granted"&gt;100,000&lt;/span&gt; of the Company&#x2019;s options (the &#x201c;Modified Options&#x201d;) agreed to amend the
terms of the holder&#x2019;s options extending the maturity date to January 20, 2026, from the original maturity date of January 5, 2026.
There were no other changes to the terms of the Modified Options. The amendment qualified as a &#x201c;Type I&#x201d; modification as the
Modified Options were vested immediately prior to the amendment and immediately after the amendment. As a result of the amendment, the
Company recognized additional stock compensation expense of $&lt;span id="xdx_908_eus-gaap--ShareBasedCompensation_c20251201__20251231__us-gaap--PlanNameAxis__custom--ModificationOfOptionsMember_z2Jhgq4f67Tg" title="Stock compensation expense"&gt;870&lt;/span&gt; for the incremental change in fair value immediately before the modification
and immediately after the modification.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Common Stock Warrants&#160;&lt;/b&gt;&#x2013; On November
23, 2020, Coeptis Therapeutics, Inc. (under its prior name Vinings Holdings Inc.) issued a class A and a class B warrant to Coral Investment
Partners, LP (&#x201c;CIP&#x201d;), with each warrant granting CIP the right to purchase &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20201123__srt--CounterpartyNameAxis__custom--CoralInvestmentPartnersMember_zYZicBAPV7gh" title="Warrants outstanding"&gt;25,000&lt;/span&gt; shares of common stock at a price of
$&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201123__srt--CounterpartyNameAxis__custom--CoralInvestmentPartnersMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_pdd" title="Exercise price of warrants"&gt;40.00&lt;/span&gt; for Class A or $&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201123__srt--CounterpartyNameAxis__custom--CoralInvestmentPartnersMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_pdd" title="Exercise price of warrants"&gt;100.00&lt;/span&gt; for Class B. The warrants expired on November 30, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;All common stock warrants outstanding, are listed
in the table below:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zvnvizl0Zhh7" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - CAPITAL STRUCTURE (Details - Warrants outstanding)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt; color: White"&gt;&lt;span id="xdx_8B7_zOdJkpwSXipd" style="display: none"&gt;Schedule of warrants outstanding&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Reference&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Date&lt;/b&gt;&lt;/span&gt;&lt;br/&gt;
&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Issued&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;br/&gt;
&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Expiration&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Outstanding at December 31,&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.75pt; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Outstanding at&lt;br/&gt;
    December 31,&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 36%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Warrant Holder 1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_909_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice59.40Member_zhPQKk5yNNMk" title="Date Issued"&gt;5/28/2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice59.40Member_zXRPOT9rhVG2" style="width: 10%; text-align: right" title="Warrants exercise price"&gt;&lt;span style="font-size: 10pt"&gt;59.40&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice59.40Member_zItdhyrT2Pk5" title="Expiration"&gt;5/13/2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice59.40Member_zqqHvnVaQLHh" style="width: 10%; text-align: right" title="Warrants outstanding"&gt;&lt;span style="font-size: 10pt"&gt;8,380&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice59.40Member_zMeNZng40tdb" style="width: 10%; text-align: right" title="Warrants outstanding"&gt;&lt;span style="font-size: 10pt"&gt;8,380&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Warrant Holder 1&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90C_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice118.80Member_zwQ5pwjwGMSf" title="Date Issued"&gt;5/28/2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice118.80Member_z4JELrJ017Xg" style="text-align: right" title="Warrants exercise price"&gt;&lt;span style="font-size: 10pt"&gt;118.80&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice118.80Member_zv54vjEcUlni" title="Expiration"&gt;5/13/2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice118.80Member_zuIBsbFjCHNb" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;8,422&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice118.80Member_zLlnDfHxGkke" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;8,422&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Warrant Holder 1&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice296.80Member_zbAD3QgR0aE4" title="Date Issued"&gt;5/28/2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice296.80Member_zdOUYST0KBDk" style="text-align: right" title="Warrants exercise price"&gt;&lt;span style="font-size: 10pt"&gt;296.80&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice296.80Member_zNWSeKS6l3J7" title="Expiration"&gt;5/13/2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice296.80Member_zicjK4torz8d" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;8,422&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice296.80Member_ze7554J93sG3" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;8,422&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Warrant Holder 2&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_902_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice59.40Member_z6Pz0tB8cFb1" title="Date Issued"&gt;7/30/2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice59.40Member_zXxLcYdy4V6g" style="text-align: right" title="Warrants exercise price"&gt;&lt;span style="font-size: 10pt"&gt;59.40&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice59.40Member_zwxyj4u9O5Hk" title="Expiration"&gt;7/30/2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice59.40Member_zv1MnhCveYy2" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;421&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice59.40Member_zTaTaGqLB7d7" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;421&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Warrant Holder 2&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice296.80Member_z690toHMvrid" title="Date Issued"&gt;7/30/2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice296.80Member_zDVj61xqGm38" style="text-align: right" title="Warrants exercise price"&gt;&lt;span style="font-size: 10pt"&gt;296.80&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice296.80Member_zuFNtTWa4Zk6" title="Expiration"&gt;6/1/2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice296.80Member_z7qV2GpL182j" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,263&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice296.80Member_znkkujrqPZG" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,263&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Warrant Holder 5&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90C_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder5ExercisePrice59.40Member_zT6nUYfMeP8k" title="Date Issued"&gt;12/20/2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder5ExercisePrice59.40Member_zEtq2QA2hzde" style="text-align: right" title="Warrants exercise price"&gt;&lt;span style="font-size: 10pt"&gt;59.40&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder5ExercisePrice59.40Member_zHVEKXVm7j4d" title="Expiration"&gt;12/20/2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder5ExercisePrice59.40Member_zMO86NMJ8vVj" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,948&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder5ExercisePrice59.40Member_zThs8fw5UFB4" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,948&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Warrant Holder 18&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_909_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder18ExercisePrice178.20Member_zdbqLVXtpkh5" title="Date Issued"&gt;3/30/2022&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder18ExercisePrice178.20Member_zMNZCepjwXD5" style="text-align: right" title="Warrants exercise price"&gt;&lt;span style="font-size: 10pt"&gt;178.20&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder18ExercisePrice178.20Member_zsyqR9n0P2te" title="Expiration"&gt;3/30/2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_d0_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder18ExercisePrice178.20Member_zDIvnpeWio7k" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013; &lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder18ExercisePrice178.20Member_zJHbtgaG073a" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,211&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Warrant Holder 20&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_906_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder20ExercisePrice50.00Member_z4C62Tx4YpMa" title="Date Issued"&gt;1/3/2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder20ExercisePrice50.00Member_z4lymClWNjb" style="text-align: right" title="Warrants exercise price"&gt;&lt;span style="font-size: 10pt"&gt;50.00&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder20ExercisePrice50.00Member_zREA6mmTF107" title="Expiration"&gt;1/2/2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder20ExercisePrice50.00Member_zkNNxOL1MChg" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder20ExercisePrice50.00Member_zQvBo3JQxaJk" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Warrant Holder 21&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_902_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder21ExercisePrice38.00Member_zsy504HlvDYj" title="Date Issued"&gt;1/20/2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder21ExercisePrice38.00Member_zJFT8AGk3jGi" style="text-align: right" title="Warrants exercise price"&gt;&lt;span style="font-size: 10pt"&gt;38.00&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder21ExercisePrice38.00Member_zBpFYBBVNXfb" title="Expiration"&gt;1/19/2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder21ExercisePrice38.00Member_zgcVAlGQV2m" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;12,500&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder21ExercisePrice38.00Member_zw9jDPiB7KIc" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;12,500&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Series A &amp;amp; B Warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_902_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesWarrantsAAndBExercisePrice27.20Member_zMLfl9kgCStk" title="Date Issued"&gt;6/16/2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesWarrantsAAndBExercisePrice27.20Member_zLGVuKEypFSe" style="text-align: right" title="Warrants exercise price"&gt;&lt;span style="font-size: 10pt"&gt;27.20&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesWarrantsAAndBExercisePrice27.20Member_zWiQfQC8nAFk" title="Expiration"&gt;12/16/2028&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesWarrantsAAndBExercisePrice27.20Member_zGX16nfpzMfl" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;306,250&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesWarrantsAAndBExercisePrice27.20Member_zMcpzrvKYNle" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;306,250&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Series A Warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsExercisePrice27.20Member_zUBMb8E7p44l" title="Date Issued"&gt;10/23/2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsExercisePrice27.20Member_zaQRKQLtGKXi" style="text-align: right" title="Warrants exercise price"&gt;&lt;span style="font-size: 10pt"&gt;27.20&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsExercisePrice27.20Member_zJXfhF99xYw1" title="Expiration"&gt;4/26/2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_d0_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsExercisePrice27.20Member_zGRBcCqmET71" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsExercisePrice27.20Member_zpQbIWGokML1" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;100,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Series B Warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_907_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsExercisePrice27.20Member_z8vzypLgPvNg" title="Date Issued"&gt;10/23/2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsExercisePrice27.20Member_zrXhgXeYRGTb" style="text-align: right" title="Warrants exercise price"&gt;&lt;span style="font-size: 10pt"&gt;27.20&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsExercisePrice27.20Member_zB1dVGnt8dP" title="Expiration"&gt;4/26/2029&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsExercisePrice27.20Member_zrOAXCQY9kde" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;100,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsExercisePrice27.20Member_z4HshTcVMa75" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;100,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Warrant Holder 22&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_908_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice25.00Member_zDAEgsAil3ci" title="Date Issued"&gt;6/16/2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice25.00Member_zapMylA94m4f" style="text-align: right" title="Warrants exercise price"&gt;&lt;span style="font-size: 10pt"&gt;25.00&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice25.00Member_z6Y6AUE9a7ue" title="Expiration"&gt;12/16/2028&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice25.00Member_zb9yirJ8v3Vc" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;6,300&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice25.00Member_zA7gNTIgnKT8" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;6,300&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Warrant Holder 22&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_902_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice28.00Member_zcptOzx2hAb3" title="Date Issued"&gt;10/23/2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice28.00Member_z4ubQZlsp0D7" style="text-align: right" title="Warrants exercise price"&gt;&lt;span style="font-size: 10pt"&gt;28.00&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice28.00Member_zCFwpGSZBYI" title="Expiration"&gt;4/26/2029&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice28.00Member_zpzv0wMqgij7" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3,300&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice28.00Member_zD9mQorT6WC5" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3,300&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Warrant Holder 23&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice25.00Member_zdmKFPOfEsUk" title="Date Issued"&gt;6/16/2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice25.00Member_zsMDcc2OfNCf" style="text-align: right" title="Warrants exercise price"&gt;&lt;span style="font-size: 10pt"&gt;25.00&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice25.00Member_zLuijdsruMf3" title="Expiration"&gt;12/16/2028&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice25.00Member_zCv7ZcFGFdl7" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,200&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice25.00Member_zpw43IQxFYHe" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,200&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Warrant Holder 23&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice28.00Member_z1fPzyMwcz27" title="Date issued"&gt;10/23/2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice28.00Member_z8FMtTy84jFb" style="text-align: right" title="Warrants exercise price"&gt;&lt;span style="font-size: 10pt"&gt;28.00&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice28.00Member_zuWoZMkqoZ86" title="Expiration"&gt;4/26/2029&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice28.00Member_zkTrqhzVQeMk" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,400&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice28.00Member_zlqY2DWKR1xi" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,400&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Warrant Holder 24&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder24ExercisePrice28.00Member_zbZ5N7Nh6Cij" title="Date Issued"&gt;10/23/2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder24ExercisePrice28.00Member_zZzUb33gVac4" style="text-align: right" title="Warrants exercise price"&gt;&lt;span style="font-size: 10pt"&gt;28.00&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder24ExercisePrice28.00Member_z1Up8he4rQi" title="Expiration"&gt;4/26/2029&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder24ExercisePrice28.00Member_z8anOUPcCnY6" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;300&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder24ExercisePrice28.00Member_z4NcvcfmZ9H9" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;300&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Pre-Funded Warrants 2&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants2ExercisePrice0.002Member_zhbhDan1TPKg" title="Date Issued"&gt;12/28/2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants2ExercisePrice0.002Member_zH4g4amW63P5" style="text-align: right" title="Warrants exercise price"&gt;&lt;span style="font-size: 10pt"&gt;0.002&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_d0_c20251231__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants2ExercisePrice0.002Member_zyPGcOuPPzge" style="text-align: right" title="Warrants outstanding"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants2ExercisePrice0.002Member_zlgnxgIcCyKk" style="text-align: right" title="Warrants outstanding"&gt;&lt;span style="font-size: 10pt"&gt;150,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Pre-Funded Warrants 3&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_909_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants3ExercisePrice0.002Member_zbmqhDS6Sn67" title="Date issued"&gt;2/8/2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants3ExercisePrice0.002Member_z3kTd4B1x6h3" style="text-align: right" title="Warrants exercise price"&gt;&lt;span style="font-size: 10pt"&gt;0.002&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_d0_c20251231__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants3ExercisePrice0.002Member_z1cKT9UR11l8" style="text-align: right" title="Warrants outstanding"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants3ExercisePrice0.002Member_z2Qivc5Euhae" style="text-align: right" title="Warrants outstanding"&gt;&lt;span style="font-size: 10pt"&gt;300,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Warrant Holder 25&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder25ExercisePrice12.00Member_z3hcmuuDwXi9" title="Date Issued"&gt;1/20/2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder25ExercisePrice12.00Member_zuQsgwAp9Ea1" style="text-align: right" title="Warrants exercise price"&gt;&lt;span style="font-size: 10pt"&gt;12.00&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder25ExercisePrice12.00Member_z8bA0x6c1Lti" title="Expiration"&gt;1/20/2030&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder25ExercisePrice12.00Member_zGElVEDbXJt5" style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;100,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_d0_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder25ExercisePrice12.00Member_z3UtJJ43UWI2" style="border-bottom: black 1pt solid; text-align: right"&gt;&#x2013;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td colspan="10" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Total Warrants outstanding&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231_zqQPGJsI8HJ5" style="border-bottom: black 2.25pt double; text-align: right" title="Total warrants outstanding"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;570,105&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231_zhrYnAzD8ZSl" style="border-bottom: black 2.25pt double; text-align: right" title="Total warrants outstanding"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;1,024,316&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;
&lt;tr style="vertical-align: top"&gt;
  &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -0.01pt; width: 3%"&gt;*&lt;/td&gt;
  &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -0.01pt; width: 97%"&gt;Pre-funded warrants, do not expire.&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8AE_zp7T0FRyrNx" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Subscription receivable &lt;/b&gt;&#x2013; In
September 2023, the Company agreed to issue &lt;span id="xdx_909_ecustom--StockIssuedForDebtShares_c20230901__20230930__us-gaap--FinancialInstrumentAxis__custom--SubscriptionReceivableSept2023Member_z4pE76mXRUO8" title="Stock issued for debt, shares"&gt;25,000&lt;/span&gt;
shares of common stock to the borrower for a principal sum amount of $&lt;span id="xdx_906_ecustom--StockIssuedForDebtValue_pp0p0_c20230901__20230930__us-gaap--FinancialInstrumentAxis__custom--SubscriptionReceivableSept2023Member_zPr72zVmmrNk" title="Stock issued for debt, value"&gt;500,000&lt;/span&gt;.
On August 12, 2024, the Company was transferred and assigned $522,667, the sum of principal and accrued interest owed as of June 30,
2024, of shares of common stock in a privately held company by the third-party borrower. As a result of this assignment agreement,
the subscription receivable is paid in full, and $&lt;span id="xdx_908_eus-gaap--Investments_iI_pp0p0_c20251231__us-gaap--FinancialInstrumentAxis__custom--SubscriptionReceivableSept2023Member_zL23KwfnqPm1" title="Investments"&gt;&lt;span id="xdx_901_eus-gaap--Investments_iI_pp0p0_c20241231__us-gaap--FinancialInstrumentAxis__custom--SubscriptionReceivableSept2023Member_zor73S13jMJh"&gt;522,667&lt;/span&gt;&lt;/span&gt;
is recorded as an investment at December 31, 2025 and December 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In September 2023, the Company agreed to issue&#160;&lt;span id="xdx_90F_ecustom--StockIssuedForDebtShares_c20230901__20230930__us-gaap--FinancialInstrumentAxis__custom--SubscriptionReceivableSept20232ndMember_zvOdA2fkQLLg" title="Stock issued for debt, shares"&gt;100,000&lt;/span&gt;
shares of common stock to the borrower for a principal sum amount of $&lt;span id="xdx_90C_ecustom--StockIssuedForDebtValue_pp0p0_c20230901__20230930__us-gaap--FinancialInstrumentAxis__custom--SubscriptionReceivableSept20232ndMember_zsqPKzBRNZt2" title="Stock issued for debt, value"&gt;2,000,000&lt;/span&gt;. On August 12, 2024, the Company was transferred and assigned
$2,090,667, the sum of principal and accrued interest owed, of shares of common stock in a privately held company by the third-party borrower.
As a result of this assignment agreement, the subscription receivable is paid in full, and $&lt;span id="xdx_901_eus-gaap--Investments_iI_pp0p0_c20251231__us-gaap--FinancialInstrumentAxis__custom--SubscriptionReceivableSept20232ndMember_zyXvPYeo3lG4" title="Investments"&gt;&lt;span id="xdx_90B_eus-gaap--Investments_iI_pp0p0_c20241231__us-gaap--FinancialInstrumentAxis__custom--SubscriptionReceivableSept20232ndMember_zmBVyg52wbFi" title="Investments"&gt;2,090,667&lt;/span&gt;&lt;/span&gt; is recorded as an investment at
December 31, 2025 and December 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In December 2023, the Company agreed to
grant pre-funded warrants exercisable to acquire up to 60,000 shares of common stock to the borrower for a principal sum amount of
$1,000,000. During the first quarter of 2024, the Company and the third-party borrower agreed to amend the note as a result of the
decline in the publicly traded common stock price. The amount of pre-funded warrants exercisable to acquire up to 60,000 shares of
common stock was amended to &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240331__us-gaap--FinancialInstrumentAxis__custom--December2023FinancingMember_zty7svcEEie" title="Warrants issued"&gt;100,000&lt;/span&gt;
shares of common stock, and the total principal balance of the note agreement was increased from $1,000,000 to $1,100,000. On August
12, 2024, the Company was transferred and assigned $1,132,869, the sum of principal and accrued interest owed, of shares of common
stock in a privately held company by the third-party borrower. As a result of this assignment agreement, the subscription receivable
is paid in full, and $&lt;span id="xdx_905_eus-gaap--Investments_iI_pp0p0_c20251231__us-gaap--FinancialInstrumentAxis__custom--December2023FinancingMember_zfD2aBz9sb8d" title="Investments"&gt;&lt;span id="xdx_900_eus-gaap--Investments_iI_pp0p0_c20241231__us-gaap--FinancialInstrumentAxis__custom--December2023FinancingMember_z6VMIe1QQZzf"&gt;1,132,869&lt;/span&gt;&lt;/span&gt;
is recorded as an investment at December 31, 2025 and December 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In February 2024, the Company agreed to grant
pre-funded warrants exercisable to acquire up to &lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240228__us-gaap--FinancialInstrumentAxis__custom--February2024FinancingMember_zTNKfJN6quX9"&gt;200,000&lt;/span&gt; shares of common stock to the borrower for a principal sum amount of $1,900,000.
On August 12, 2024, the Company was transferred and assigned $1,944,879, the sum of principal and accrued interest owed, of shares of
common stock in a privately held company by the third-party borrower. As a result of this assignment agreement, the subscription receivable
is paid in full, and $&lt;span id="xdx_90A_eus-gaap--Investments_iI_pp0p0_c20251231__us-gaap--FinancialInstrumentAxis__custom--February2024FinancingMember_zknFlblVQSf6" title="Investments"&gt;&lt;span id="xdx_90E_eus-gaap--Investments_iI_pp0p0_c20241231__us-gaap--FinancialInstrumentAxis__custom--February2024FinancingMember_z2rrE8IEsIpl"&gt;1,944,879&lt;/span&gt;&lt;/span&gt; is recorded as an investment at December 31, 2025 and December 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In June 2024, in connection with the Company&#x2019;s
series A preferred stock offering, the Company closed on subscription agreements totaling $2,100,000 due to the Company on February 28,
2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the second quarter of 2025, the Company
collected $&lt;span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_c20250101__20250630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zxGUCspp6Czj" title="Proceeds from issuance of preferred stock"&gt;125,000&lt;/span&gt; of outstanding subscription receivable resulting from one Series A preferred stock subscription agreement. At June
30, 2025, the Company had recorded subscription receivable of $&lt;span id="xdx_903_eus-gaap--PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable_iI_pp0p0_c20250630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zFGsyJxR8NBf" title="Subscription receivable"&gt;125,000&lt;/span&gt; resulting from the final Series A preferred stock subscription
agreement where preferred shares have been issued as part of the February 6, 2025 closing. In connection with this subscription receivable,
the Company and the investor agreed to satisfy the subscription as prepayment of the final six months of the consulting contract between
both parties. The subscription receivable is being amortized through the end of June 2026 as professional services expense.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the third quarter of 2025, in connection
with the Company&#x2019;s private placement offering, the Company recorded $&lt;span id="xdx_904_ecustom--SubscriptionsReceivable_c20250701__20250930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zbbUViUJCPR9" title="Subscriptions receivable"&gt;5,000,000&lt;/span&gt; in subscriptions receivable. As of December 31, 2025,
the Company collected $&lt;span id="xdx_90A_ecustom--ProceedsFromSubscriptionsReceivable_iI_c20250930_zqWez86yW8cf" title="Proceeds subscriptions receivable"&gt;4,500,000&lt;/span&gt; of the proceeds, resulting in a net $&lt;span id="xdx_900_ecustom--SubscriptionsReceivableNet_iI_c20250930_z534i5DWF8E" title="Subscriptions receivable net"&gt;500,000&lt;/span&gt; in subscriptions receivable still to be collected.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the fourth quarter of 2025, the Company
issued a total of &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251001__20251231__us-gaap--TypeOfArrangementAxis__custom--TwoInvestorMember_z1il3Cfioqo2" title="Number of shares issued"&gt;260,000&lt;/span&gt; shares to two investors, recording subscription receivables in the amount of $&lt;span id="xdx_90F_ecustom--SubscriptionsReceivableNet_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--TwoInvestorMember_zfDo2IT5E2S6" title="Subscriptions receivable net"&gt;3,120,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Standby Equity Purchase Agreement &lt;/b&gt;&#x2013;
On November 1, 2024, the Company entered into the SEPA with Yorkville pursuant to which the Company has the right to sell to Yorkville
up to $20,000,000 of common stock, subject to certain limitations and conditions set forth in the SEPA, from time to time during the term
of the SEPA. The Company also entered into a Registration Rights Agreement with Yorkville pursuant to which it will register the resale
of shares of common stock issued to Yorkville pursuant to the SEPA. Sales of common stock to Yorkville under the SEPA, and the timing
of any such sales, are at the Company&#x2019;s option, and the Company is under no obligation to sell common stock to Yorkville under the
SEPA, except in connection with notices that may be submitted by Yorkville in certain circumstances as described below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Each advance (each, an &#x201c;Advance&#x201d;)
the Company requests in writing to Yorkville under the SEPA (notice of such request, an &#x201c;Advance Notice&#x201d;) may be for a number
of shares of common stock up to such amount as is equal to 100% of the average daily volume traded of the common stock during the five
trading days immediately prior to the date the Company requests each Advance. The shares of common stock purchased pursuant to an Advance
delivered by the Company will be purchased at a price equal to 95% of the lowest daily VWAP of the shares of common stock during the three
consecutive trading days commencing on the date of the delivery of the Advance Notice, other than the daily VWAP on a day in which the
daily VWAP is less than a minimum acceptable price as stated by the Company in the Advance Notice or there is no VWAP on the subject trading
day. The Company may establish a minimum acceptable price in each Advance Notice below which the Company will not be obligated to make
any sales to Yorkville. &#x201c;VWAP&#x201d; is defined as the daily volume weighted average price of the shares of Common Stock for such
trading day on the Nasdaq Stock Market (&#x201c;Nasdaq&#x201d;) during regular trading hours as reported by Bloomberg L.P.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The SEPA will automatically terminate on the earliest
to occur of (i) December 1, 2027, provided that the Convertible Note (defined in Note 5) has been fully repaid or (ii) the date on which
the Company shall have made full payment of Advances pursuant to the SEPA. The Company has the right to terminate the SEPA at no cost
or penalty upon five trading days&#x2019; prior written notice to Yorkville, provided that there are no outstanding Advance Notices for
which shares of common stock need to be issued and the Company has paid all amounts owed to Yorkville pursuant to the Convertible Note.
The Company and Yorkville may also agree to terminate the SEPA by mutual written consent.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Any purchase under an Advance would be subject
to certain limitations, including that Yorkville shall not purchase or acquire any shares that would result in it and its affiliates beneficially
owning more than 4.99% of the then outstanding voting power or number of shares of common stock or any shares that, aggregated with shares
issued under all other earlier Advances, would exceed 19.99% of all shares of common stock outstanding on the date of the SEPA (the &#x201c;Exchange
Cap&#x201d;), unless the Company obtains stockholder approval to issue shares of common stock in excess of the Exchange Cap in accordance
with applicable Nasdaq rules.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In connection with the execution of the SEPA,
the Company agreed to pay a commitment fee of $&lt;span id="xdx_90D_eus-gaap--PaymentsForBrokerageFees_pp0p0_c20241029__20241102__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--YorkvilleMember_zY8Q229W4apd" title="Payment of commitment fee"&gt;200,000&lt;/span&gt; to Yorkville, payable as follows: (i) $&lt;span id="xdx_909_eus-gaap--PaymentsForBrokerageFees_pp0p0_c20241029__20241102__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--TransactionTypeAxis__custom--StockIssuedForServicesMember_zrdNAZSMmWNh" title="Payment of commitment fee"&gt;80,000&lt;/span&gt; payable when the SEPA was entered
into, in the form of the issuance of 20,000 shares of common stock, representing $80,000 divided by the closing price as of the trading
day immediately prior to the date of the SEPA, and (ii) $120,000 payable in cash or by way of an Advance on the date upon which the Company
has first received Advances in the aggregate amount of $5,000,000.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Additionally, Yorkville agreed to advance to
the Company, in exchange for the Convertible Note, an aggregate principal amount of $&lt;span id="xdx_907_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_c20241102__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zXkuC2B3UUMd" title="Convertible notes outstanding"&gt;1,304,758&lt;/span&gt;
(see Note 4 for a description of the Convertible Note). At any time while the SEPA is in place that there is a balance outstanding
under the Convertible Note, Yorkville may deliver a notice (an &#x201c;Investor Notice&#x201d;) to the Company to cause an Advance
Notice to be deemed delivered to Yorkville and the issuance and sale of shares of Common Stock to Yorkville pursuant to an Advance.
Yorkville may select the amount of the Advance in an amount not to exceed the balance owed under the Convertible Note outstanding on
the date of delivery of such Investor Notice. The shares will be issued and sold to Yorkville pursuant to an Investor Notice at a
per share price equal to the conversion price that would be applicable to the amount of the Advance selected by Yorkville if such
amount were to be converted as of the date of delivery of the Investor Notice. Yorkville will pay the purchase price for such shares
to be issued pursuant to the Investor Notice by offsetting the amount of the purchase price to be paid by Yorkville against an
amount outstanding under the Yorkville Note.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Additionally, the Company, at its option, shall
have the right, but not the obligation, to redeem early a portion or all amounts outstanding under the Convertible Note at a redemption
amount equal to the outstanding principal balance being repaid or redeemed, plus a 5% prepayment premium, plus all accrued and unpaid
interest; provided that (i) the Company provides Yorkville with no less than ten trading days&#x2019; prior written notice thereof and
(ii) on the date such notice is issued, the VWAP of the common stock is less than the Fixed Price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Throughout the year ended December 31,
2025, in connection with the SEPA, the Company issued &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zB8hYyF9EKjf" title="Number of shares issued"&gt;225,000&lt;/span&gt; shares of common stock, resulting in gross proceeds of $&lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zKs51zi7Bgrh" title="Gross proceeds"&gt;2,958,848&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember206522296"
      decimals="INF"
      id="Fact001140"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact001142"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact001144"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact001146"
      unitRef="Shares">5746948</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001148"
      unitRef="Shares">2116191</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2024-12-012024-12-31" id="Fact001150">20-1 reverse stock split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-06-152023-06-16_custom_PublicOfferingMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001152"
      unitRef="Shares">107500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-06-152023-06-16_custom_PublicOfferingMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact001154"
      unitRef="Shares">67500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2023-06-152023-06-16_custom_PublicOfferingMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact001156"
      unitRef="Shares">67500</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-06-152023-06-16_custom_PublicOfferingMember_custom_SeriesAWarrantsMember"
      decimals="INF"
      id="Fact001158"
      unitRef="Shares">153125</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-06-152023-06-16_custom_PublicOfferingMember_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact001160"
      unitRef="Shares">153125</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-06-16_custom_PublicOfferingMember_custom_SeriesWarrantsMember"
      decimals="INF"
      id="Fact001162"
      unitRef="USDPShares">33.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2024-01-012024-12-31_custom_PublicOfferingMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001164"
      unitRef="Shares">175000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2023-12-272023-12-28_custom_WarrantNoteSubscriptionReceivablesMember"
      decimals="0"
      id="Fact001166"
      unitRef="USD">1100000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-07-012025-09-30_us-gaap_PrivatePlacementMember"
      decimals="0"
      id="Fact001168"
      unitRef="USD">5000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockDescriptionOfTransaction
      contextRef="From2025-07-012025-09-30_custom_SNAPBiosciencesIncMember"
      id="Fact001170">In addition to the shares
of common stock of the Company, investors also received 10% aggregate non-voting ownership in the Company&#x2019;s subsidiary, SNAP Biosciences,
Inc. Of this $5,000,000 raised, $4,500,000 was collected as of December 31, 2025. $500,000 of the subscription receivable is tied to a
promissory note bearing 1% interest annum, with a maturity date of January 18, 2026.</us-gaap:SaleOfStockDescriptionOfTransaction>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-10-012025-12-31_custom_TwoInvestorMember"
      decimals="0"
      id="Fact001172"
      unitRef="USD">3120000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-10-012025-12-31_custom_TwoInvestorMember"
      decimals="INF"
      id="Fact001174"
      unitRef="Shares">260000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-12-31_custom_TwoInvestorMember"
      decimals="0"
      id="Fact001176"
      unitRef="USD">3120000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-12-31_custom_TwoInvestorMember"
      decimals="INF"
      id="Fact001178"
      unitRef="Pure">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2025-10-012025-12-31_custom_TwoInvestorMember"
      id="Fact001180">2026-12-18</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:TreasuryStockValue
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001182"
      unitRef="USD">0</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001184"
      unitRef="USD">0</us-gaap:TreasuryStockValue>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact001186"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001188"
      unitRef="Shares">10000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001190"
      unitRef="Shares">6520</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001192"
      unitRef="Shares">6520</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001194"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001196"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="From2024-06-122024-06-13_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact001201"
      unitRef="USD">4300000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-06-122024-06-13_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001203"
      unitRef="Shares">4300</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="From2024-07-302024-07-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact001205"
      unitRef="USD">1300000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="From2024-09-032024-09-04_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact001207"
      unitRef="USD">225000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="From2024-12-222024-12-23_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact001209"
      unitRef="USD">695000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="From2025-02-052025-02-06_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact001211"
      unitRef="USD">3480000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable
      contextRef="AsOf2025-07-25_custom_ConsultingAgreementMember"
      decimals="0"
      id="Fact001213"
      unitRef="USD">125000</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2025-01-012025-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001215"
      unitRef="Shares">10000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001221">&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zeakXLF5vY5j" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - CAPITAL STRUCTURE (Details - Option activity)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="display: none"&gt;Schedule of stock option activity&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Shares Underlying Options&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Weighted Average Exercise
    Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Weighted Average Contractual
    Life (Years)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Intrinsic Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zAdqo9AwD0ml" style="text-align: right" title="Options outstanding, beginning"&gt;&lt;span style="font-size: 10pt"&gt;87,875&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zdJHc0yuikK5" style="text-align: right" title="Weighted average exercise price, beginning balance outstanding"&gt;&lt;span style="font-size: 10pt"&gt;40.20&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zSCdNBLfZqn6" title="Weighted average contractual life (years), options outstanding"&gt;7.97&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 36%"&gt;&lt;span style="font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zpzNcAhWG1Jk" style="width: 13%; text-align: right" title="Options granted"&gt;&lt;span style="font-size: 10pt"&gt;196,750&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z46h2cts0dne" style="width: 13%; text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="font-size: 10pt"&gt;8.85&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2OptionsGranted_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zRou3ZT1jn8a" title="Weighted average contractual life (years), granted"&gt;10.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zVU7qc8rEWfg" style="text-align: right" title="Options forfeited/expired"&gt;&lt;span style="font-size: 10pt"&gt;(5,000)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zBrjwVoZ8iOh" style="text-align: right" title="Weighted average exercise price, forfeited/expired"&gt;&lt;span style="font-size: 10pt"&gt;200.00&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_d0_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zfXANZ7rjiO9" style="border-bottom: black 1pt solid; text-align: right" title="Options exercised"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zzHQw19UCua6" style="border-bottom: black 1pt solid; text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zWYijifwwHj3" style="text-align: right" title="Options outstanding, beginning"&gt;&lt;span style="font-size: 10pt"&gt;279,625&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zLUum3gcAUHg" style="text-align: right" title="Weighted average exercise price, beginning balance outstanding"&gt;&lt;span style="font-size: 10pt"&gt;15.29&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zdcJXeKn0NU8" title="Weighted average contractual life (years), options outstanding"&gt;8.74&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_ztyMmW7ZFEb8" style="text-align: right" title="Options granted"&gt;&lt;span style="font-size: 10pt"&gt;187,375&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zIh031phyXP1" style="text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="font-size: 10pt"&gt;7.96&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2OptionsGranted_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zUKJ0SCZtgD2" title="Weighted average contractual life (years), granted"&gt;5.20&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z2gIUm4mfyJa" style="text-align: right" title="Options forfeited/expired"&gt;&lt;span style="font-size: 10pt"&gt;(30,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zRZ1TTo3Wyi1" style="text-align: right" title="Weighted average exercise price, forfeited/expired"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_d0_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zuv8YlhRYPA2" style="border-bottom: black 1pt solid; text-align: right" title="Options exercised"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zjJT6tT8gbql" style="border-bottom: black 1pt solid; text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Outstanding at December 31, 2025&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z9ZXtWtL9N8f" style="border-bottom: black 2.25pt double; text-align: right" title="Options outstanding, ending"&gt;&lt;span style="font-size: 10pt"&gt;437,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z9Dprg9sKBWk" style="border-bottom: black 2.25pt double; text-align: right" title="Weighted average exercise price, ending balance outstanding"&gt;&lt;span style="font-size: 10pt"&gt;12.11&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zau0aOCg5xVf" title="Weighted average contractual life (years), options outstanding"&gt;6.26&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zQA7SpV3vjH3" style="border-bottom: black 2.25pt double; text-align: right" title="Intrinsic value, options outstanding"&gt;&lt;span style="font-size: 10pt"&gt;2,215,451&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31_custom_StockOptionsMember"
      decimals="INF"
      id="Fact001223"
      unitRef="Shares">87875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_custom_StockOptionsMember"
      decimals="INF"
      id="Fact001225"
      unitRef="USDPShares">40.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-01-012023-12-31_custom_StockOptionsMember"
      id="Fact001227">P7Y11M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2024-01-012024-12-31_custom_StockOptionsMember206522468"
      decimals="INF"
      id="Fact001229"
      unitRef="Shares">196750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_custom_StockOptionsMember206522468"
      decimals="INF"
      id="Fact001231"
      unitRef="USDPShares">8.85</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <coep:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2OptionsGranted
      contextRef="From2024-01-012024-12-31_custom_StockOptionsMember206522468"
      id="Fact001233">P10Y</coep:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2OptionsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2024-01-012024-12-31_custom_StockOptionsMember206522468"
      decimals="INF"
      id="Fact001235"
      unitRef="Shares">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_custom_StockOptionsMember206522468"
      decimals="INF"
      id="Fact001237"
      unitRef="USDPShares">200.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2024-01-012024-12-31_custom_StockOptionsMember206522468"
      decimals="INF"
      id="Fact001239"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_custom_StockOptionsMember206522468"
      decimals="INF"
      id="Fact001241"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_StockOptionsMember"
      decimals="INF"
      id="Fact001243"
      unitRef="Shares">279625</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_custom_StockOptionsMember"
      decimals="INF"
      id="Fact001245"
      unitRef="USDPShares">15.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_custom_StockOptionsMember206522468"
      id="Fact001247">P8Y8M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2025-01-012025-12-31_custom_StockOptionsMember206522468"
      decimals="INF"
      id="Fact001249"
      unitRef="Shares">187375</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-012025-12-31_custom_StockOptionsMember206522468"
      decimals="INF"
      id="Fact001251"
      unitRef="USDPShares">7.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <coep:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2OptionsGranted
      contextRef="From2025-01-012025-12-31_custom_StockOptionsMember206522468"
      id="Fact001253">P5Y2M12D</coep:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2OptionsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2025-01-012025-12-31_custom_StockOptionsMember206522468"
      decimals="INF"
      id="Fact001255"
      unitRef="Shares">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-012025-12-31_custom_StockOptionsMember206522468"
      decimals="INF"
      id="Fact001257"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2025-01-012025-12-31_custom_StockOptionsMember206522468"
      decimals="INF"
      id="Fact001259"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-012025-12-31_custom_StockOptionsMember206522468"
      decimals="INF"
      id="Fact001261"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-12-31_custom_StockOptionsMember"
      decimals="INF"
      id="Fact001263"
      unitRef="Shares">437000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-12-31_custom_StockOptionsMember"
      decimals="INF"
      id="Fact001265"
      unitRef="USDPShares">12.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_custom_StockOptionsMember206522468"
      id="Fact001267">P6Y3M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2025-12-31_custom_StockOptionsMember"
      decimals="0"
      id="Fact001269"
      unitRef="USD">2215451</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-12-31_custom_StockOptionsMember206522468"
      decimals="0"
      id="Fact001271"
      unitRef="USD">1215692</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-12-31_custom_StockOptionsMember206522468"
      decimals="0"
      id="Fact001273"
      unitRef="USD">1104978</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001275"
      unitRef="USD">918681</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001277">&lt;table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zuN6cUYSbiP7" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - CAPITAL STRUCTURE (Details - Weighted average assumptions)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BC_zoaWrx1wddF1" style="display: none"&gt;Schedule of weighted average assumptions&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;For the years ended December
    31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 60%"&gt;&lt;span style="font-size: 10pt"&gt;Expected term, in years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zb44d3yrl74g" title="Expected term, in years"&gt;2.75&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zZNgltc1r60k" title="Expected term, in years"&gt;5.25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zATDT3E1qOxg" title="Expected volatility"&gt;75.58&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zrS3qLfbf3pa" title="Expected volatility"&gt;84.70&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zb3GaOUmKtDf" title="Risk-free interest rate"&gt;3.89&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zCZ2RKkQVEIk" title="Risk-free interest rate"&gt;4.18&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20250101__20251231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zte09OWFCb2c" title="Dividend yield"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z2QN4EoyzZ71" title="Dividend yield"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2025-01-012025-12-31_custom_StockOptionsMember206522468"
      id="Fact001279">P2Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-12-31_custom_StockOptionsMember206522468"
      id="Fact001281">P5Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2025-01-012025-12-31_custom_StockOptionsMember206522468"
      decimals="INF"
      id="Fact001283"
      unitRef="Pure">0.7558</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-01-012024-12-31_custom_StockOptionsMember206522468"
      decimals="INF"
      id="Fact001285"
      unitRef="Pure">0.8470</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2025-01-012025-12-31_custom_StockOptionsMember206522468"
      decimals="INF"
      id="Fact001287"
      unitRef="Pure">0.0389</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-012024-12-31_custom_StockOptionsMember206522468"
      decimals="INF"
      id="Fact001289"
      unitRef="Pure">0.0418</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2025-01-012025-12-31_custom_StockOptionsMember206522468"
      decimals="INF"
      id="Fact001291"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-01-012024-12-31_custom_StockOptionsMember206522468"
      decimals="INF"
      id="Fact001293"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="From2025-03-232025-03-24_custom_ColleenDelaneyMember"
      decimals="INF"
      id="Fact001295"
      unitRef="Shares">27500</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="AsOf2025-03-24_custom_ColleenDelaneyMember"
      decimals="INF"
      id="Fact001297"
      unitRef="Shares">2500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2025-01-012025-12-31_custom_ColleenDelaneyMember"
      decimals="INF"
      id="Fact001299"
      unitRef="Shares">2500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2025-12-012025-12-31_custom_ModificationOfOptionsMember"
      decimals="INF"
      id="Fact001301"
      unitRef="Shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-12-012025-12-31_custom_ModificationOfOptionsMember"
      decimals="0"
      id="Fact001303"
      unitRef="USD">870</us-gaap:ShareBasedCompensation>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2020-11-23_custom_CoralInvestmentPartnersMember"
      decimals="INF"
      id="Fact001309"
      unitRef="Shares">25000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-11-23_custom_CoralInvestmentPartnersMember_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact001311"
      unitRef="USDPShares">40.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-11-23_custom_CoralInvestmentPartnersMember_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact001313"
      unitRef="USDPShares">100.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001315">&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zvnvizl0Zhh7" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - CAPITAL STRUCTURE (Details - Warrants outstanding)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt; color: White"&gt;&lt;span id="xdx_8B7_zOdJkpwSXipd" style="display: none"&gt;Schedule of warrants outstanding&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Reference&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Date&lt;/b&gt;&lt;/span&gt;&lt;br/&gt;
&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Issued&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;br/&gt;
&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Expiration&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Outstanding at December 31,&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.75pt; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Outstanding at&lt;br/&gt;
    December 31,&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 36%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Warrant Holder 1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_909_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice59.40Member_zhPQKk5yNNMk" title="Date Issued"&gt;5/28/2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice59.40Member_zXRPOT9rhVG2" style="width: 10%; text-align: right" title="Warrants exercise price"&gt;&lt;span style="font-size: 10pt"&gt;59.40&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice59.40Member_zItdhyrT2Pk5" title="Expiration"&gt;5/13/2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice59.40Member_zqqHvnVaQLHh" style="width: 10%; text-align: right" title="Warrants outstanding"&gt;&lt;span style="font-size: 10pt"&gt;8,380&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice59.40Member_zMeNZng40tdb" style="width: 10%; text-align: right" title="Warrants outstanding"&gt;&lt;span style="font-size: 10pt"&gt;8,380&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Warrant Holder 1&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90C_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice118.80Member_zwQ5pwjwGMSf" title="Date Issued"&gt;5/28/2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice118.80Member_z4JELrJ017Xg" style="text-align: right" title="Warrants exercise price"&gt;&lt;span style="font-size: 10pt"&gt;118.80&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice118.80Member_zv54vjEcUlni" title="Expiration"&gt;5/13/2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice118.80Member_zuIBsbFjCHNb" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;8,422&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice118.80Member_zLlnDfHxGkke" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;8,422&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Warrant Holder 1&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice296.80Member_zbAD3QgR0aE4" title="Date Issued"&gt;5/28/2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice296.80Member_zdOUYST0KBDk" style="text-align: right" title="Warrants exercise price"&gt;&lt;span style="font-size: 10pt"&gt;296.80&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice296.80Member_zNWSeKS6l3J7" title="Expiration"&gt;5/13/2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice296.80Member_zicjK4torz8d" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;8,422&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder1ExercisePrice296.80Member_ze7554J93sG3" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;8,422&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Warrant Holder 2&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_902_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice59.40Member_z6Pz0tB8cFb1" title="Date Issued"&gt;7/30/2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice59.40Member_zXxLcYdy4V6g" style="text-align: right" title="Warrants exercise price"&gt;&lt;span style="font-size: 10pt"&gt;59.40&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice59.40Member_zwxyj4u9O5Hk" title="Expiration"&gt;7/30/2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice59.40Member_zv1MnhCveYy2" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;421&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice59.40Member_zTaTaGqLB7d7" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;421&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Warrant Holder 2&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice296.80Member_z690toHMvrid" title="Date Issued"&gt;7/30/2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice296.80Member_zDVj61xqGm38" style="text-align: right" title="Warrants exercise price"&gt;&lt;span style="font-size: 10pt"&gt;296.80&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice296.80Member_zuFNtTWa4Zk6" title="Expiration"&gt;6/1/2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice296.80Member_z7qV2GpL182j" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,263&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder2ExercisePrice296.80Member_znkkujrqPZG" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,263&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Warrant Holder 5&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90C_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder5ExercisePrice59.40Member_zT6nUYfMeP8k" title="Date Issued"&gt;12/20/2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder5ExercisePrice59.40Member_zEtq2QA2hzde" style="text-align: right" title="Warrants exercise price"&gt;&lt;span style="font-size: 10pt"&gt;59.40&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder5ExercisePrice59.40Member_zHVEKXVm7j4d" title="Expiration"&gt;12/20/2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder5ExercisePrice59.40Member_zMO86NMJ8vVj" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,948&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder5ExercisePrice59.40Member_zThs8fw5UFB4" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,948&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Warrant Holder 18&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_909_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder18ExercisePrice178.20Member_zdbqLVXtpkh5" title="Date Issued"&gt;3/30/2022&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder18ExercisePrice178.20Member_zMNZCepjwXD5" style="text-align: right" title="Warrants exercise price"&gt;&lt;span style="font-size: 10pt"&gt;178.20&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder18ExercisePrice178.20Member_zsyqR9n0P2te" title="Expiration"&gt;3/30/2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_d0_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder18ExercisePrice178.20Member_zDIvnpeWio7k" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013; &lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder18ExercisePrice178.20Member_zJHbtgaG073a" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,211&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Warrant Holder 20&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_906_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder20ExercisePrice50.00Member_z4C62Tx4YpMa" title="Date Issued"&gt;1/3/2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder20ExercisePrice50.00Member_z4lymClWNjb" style="text-align: right" title="Warrants exercise price"&gt;&lt;span style="font-size: 10pt"&gt;50.00&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder20ExercisePrice50.00Member_zREA6mmTF107" title="Expiration"&gt;1/2/2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder20ExercisePrice50.00Member_zkNNxOL1MChg" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder20ExercisePrice50.00Member_zQvBo3JQxaJk" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Warrant Holder 21&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_902_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder21ExercisePrice38.00Member_zsy504HlvDYj" title="Date Issued"&gt;1/20/2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder21ExercisePrice38.00Member_zJFT8AGk3jGi" style="text-align: right" title="Warrants exercise price"&gt;&lt;span style="font-size: 10pt"&gt;38.00&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder21ExercisePrice38.00Member_zBpFYBBVNXfb" title="Expiration"&gt;1/19/2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder21ExercisePrice38.00Member_zgcVAlGQV2m" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;12,500&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder21ExercisePrice38.00Member_zw9jDPiB7KIc" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;12,500&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Series A &amp;amp; B Warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_902_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesWarrantsAAndBExercisePrice27.20Member_zMLfl9kgCStk" title="Date Issued"&gt;6/16/2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesWarrantsAAndBExercisePrice27.20Member_zLGVuKEypFSe" style="text-align: right" title="Warrants exercise price"&gt;&lt;span style="font-size: 10pt"&gt;27.20&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesWarrantsAAndBExercisePrice27.20Member_zWiQfQC8nAFk" title="Expiration"&gt;12/16/2028&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesWarrantsAAndBExercisePrice27.20Member_zGX16nfpzMfl" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;306,250&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesWarrantsAAndBExercisePrice27.20Member_zMcpzrvKYNle" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;306,250&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Series A Warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsExercisePrice27.20Member_zUBMb8E7p44l" title="Date Issued"&gt;10/23/2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsExercisePrice27.20Member_zaQRKQLtGKXi" style="text-align: right" title="Warrants exercise price"&gt;&lt;span style="font-size: 10pt"&gt;27.20&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsExercisePrice27.20Member_zJXfhF99xYw1" title="Expiration"&gt;4/26/2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_d0_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsExercisePrice27.20Member_zGRBcCqmET71" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsExercisePrice27.20Member_zpQbIWGokML1" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;100,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Series B Warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_907_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsExercisePrice27.20Member_z8vzypLgPvNg" title="Date Issued"&gt;10/23/2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsExercisePrice27.20Member_zrXhgXeYRGTb" style="text-align: right" title="Warrants exercise price"&gt;&lt;span style="font-size: 10pt"&gt;27.20&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsExercisePrice27.20Member_zB1dVGnt8dP" title="Expiration"&gt;4/26/2029&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsExercisePrice27.20Member_zrOAXCQY9kde" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;100,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsExercisePrice27.20Member_z4HshTcVMa75" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;100,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Warrant Holder 22&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_908_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice25.00Member_zDAEgsAil3ci" title="Date Issued"&gt;6/16/2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice25.00Member_zapMylA94m4f" style="text-align: right" title="Warrants exercise price"&gt;&lt;span style="font-size: 10pt"&gt;25.00&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice25.00Member_z6Y6AUE9a7ue" title="Expiration"&gt;12/16/2028&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice25.00Member_zb9yirJ8v3Vc" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;6,300&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice25.00Member_zA7gNTIgnKT8" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;6,300&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Warrant Holder 22&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_902_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice28.00Member_zcptOzx2hAb3" title="Date Issued"&gt;10/23/2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice28.00Member_z4ubQZlsp0D7" style="text-align: right" title="Warrants exercise price"&gt;&lt;span style="font-size: 10pt"&gt;28.00&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice28.00Member_zCFwpGSZBYI" title="Expiration"&gt;4/26/2029&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice28.00Member_zpzv0wMqgij7" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3,300&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder22ExercisePrice28.00Member_zD9mQorT6WC5" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3,300&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Warrant Holder 23&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice25.00Member_zdmKFPOfEsUk" title="Date Issued"&gt;6/16/2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice25.00Member_zsMDcc2OfNCf" style="text-align: right" title="Warrants exercise price"&gt;&lt;span style="font-size: 10pt"&gt;25.00&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice25.00Member_zLuijdsruMf3" title="Expiration"&gt;12/16/2028&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice25.00Member_zCv7ZcFGFdl7" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,200&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice25.00Member_zpw43IQxFYHe" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,200&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Warrant Holder 23&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice28.00Member_z1fPzyMwcz27" title="Date issued"&gt;10/23/2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice28.00Member_z8FMtTy84jFb" style="text-align: right" title="Warrants exercise price"&gt;&lt;span style="font-size: 10pt"&gt;28.00&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice28.00Member_zuWoZMkqoZ86" title="Expiration"&gt;4/26/2029&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice28.00Member_zkTrqhzVQeMk" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,400&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder23ExercisePrice28.00Member_zlqY2DWKR1xi" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,400&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Warrant Holder 24&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder24ExercisePrice28.00Member_zbZ5N7Nh6Cij" title="Date Issued"&gt;10/23/2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder24ExercisePrice28.00Member_zZzUb33gVac4" style="text-align: right" title="Warrants exercise price"&gt;&lt;span style="font-size: 10pt"&gt;28.00&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder24ExercisePrice28.00Member_z1Up8he4rQi" title="Expiration"&gt;4/26/2029&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder24ExercisePrice28.00Member_z8anOUPcCnY6" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;300&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder24ExercisePrice28.00Member_z4NcvcfmZ9H9" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;300&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Pre-Funded Warrants 2&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants2ExercisePrice0.002Member_zhbhDan1TPKg" title="Date Issued"&gt;12/28/2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants2ExercisePrice0.002Member_zH4g4amW63P5" style="text-align: right" title="Warrants exercise price"&gt;&lt;span style="font-size: 10pt"&gt;0.002&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_d0_c20251231__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants2ExercisePrice0.002Member_zyPGcOuPPzge" style="text-align: right" title="Warrants outstanding"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants2ExercisePrice0.002Member_zlgnxgIcCyKk" style="text-align: right" title="Warrants outstanding"&gt;&lt;span style="font-size: 10pt"&gt;150,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Pre-Funded Warrants 3&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_909_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants3ExercisePrice0.002Member_zbmqhDS6Sn67" title="Date issued"&gt;2/8/2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants3ExercisePrice0.002Member_z3kTd4B1x6h3" style="text-align: right" title="Warrants exercise price"&gt;&lt;span style="font-size: 10pt"&gt;0.002&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_d0_c20251231__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants3ExercisePrice0.002Member_z1cKT9UR11l8" style="text-align: right" title="Warrants outstanding"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants3ExercisePrice0.002Member_z2Qivc5Euhae" style="text-align: right" title="Warrants outstanding"&gt;&lt;span style="font-size: 10pt"&gt;300,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Warrant Holder 25&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--WarrantsAndRightsOutstandingDateIssued_dd_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder25ExercisePrice12.00Member_z3hcmuuDwXi9" title="Date Issued"&gt;1/20/2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder25ExercisePrice12.00Member_zuQsgwAp9Ea1" style="text-align: right" title="Warrants exercise price"&gt;&lt;span style="font-size: 10pt"&gt;12.00&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder25ExercisePrice12.00Member_z8bA0x6c1Lti" title="Expiration"&gt;1/20/2030&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder25ExercisePrice12.00Member_zGElVEDbXJt5" style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;100,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_d0_c20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantHolder25ExercisePrice12.00Member_z3UtJJ43UWI2" style="border-bottom: black 1pt solid; text-align: right"&gt;&#x2013;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td colspan="10" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Total Warrants outstanding&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231_zqQPGJsI8HJ5" style="border-bottom: black 2.25pt double; text-align: right" title="Total warrants outstanding"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;570,105&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231_zhrYnAzD8ZSl" style="border-bottom: black 2.25pt double; text-align: right" title="Total warrants outstanding"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;1,024,316&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;
&lt;tr style="vertical-align: top"&gt;
  &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -0.01pt; width: 3%"&gt;*&lt;/td&gt;
  &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -0.01pt; width: 97%"&gt;Pre-funded warrants, do not expire.&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <coep:WarrantsAndRightsOutstandingDateIssued
      contextRef="From2025-01-012025-12-31_custom_WarrantHolder1ExercisePrice59.40Member"
      id="Fact001317">2021-05-28</coep:WarrantsAndRightsOutstandingDateIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_WarrantHolder1ExercisePrice59.40Member"
      decimals="INF"
      id="Fact001319"
      unitRef="USDPShares">59.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_WarrantHolder1ExercisePrice59.40Member"
      id="Fact001321">2026-05-13</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_WarrantHolder1ExercisePrice59.40Member"
      decimals="INF"
      id="Fact001323"
      unitRef="Shares">8380</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_WarrantHolder1ExercisePrice59.40Member"
      decimals="INF"
      id="Fact001325"
      unitRef="Shares">8380</us-gaap:ClassOfWarrantOrRightOutstanding>
    <coep:WarrantsAndRightsOutstandingDateIssued
      contextRef="From2025-01-012025-12-31_custom_WarrantHolder1ExercisePrice118.80Member"
      id="Fact001327">2021-05-28</coep:WarrantsAndRightsOutstandingDateIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_WarrantHolder1ExercisePrice118.80Member"
      decimals="INF"
      id="Fact001329"
      unitRef="USDPShares">118.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_WarrantHolder1ExercisePrice118.80Member"
      id="Fact001331">2026-05-13</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_WarrantHolder1ExercisePrice118.80Member"
      decimals="INF"
      id="Fact001332"
      unitRef="Shares">8422</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_WarrantHolder1ExercisePrice118.80Member"
      decimals="INF"
      id="Fact001333"
      unitRef="Shares">8422</us-gaap:ClassOfWarrantOrRightOutstanding>
    <coep:WarrantsAndRightsOutstandingDateIssued
      contextRef="From2025-01-012025-12-31_custom_WarrantHolder1ExercisePrice296.80Member"
      id="Fact001335">2021-05-28</coep:WarrantsAndRightsOutstandingDateIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_WarrantHolder1ExercisePrice296.80Member"
      decimals="INF"
      id="Fact001337"
      unitRef="USDPShares">296.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_WarrantHolder1ExercisePrice296.80Member"
      id="Fact001339">2026-05-13</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_WarrantHolder1ExercisePrice296.80Member"
      decimals="INF"
      id="Fact001340"
      unitRef="Shares">8422</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_WarrantHolder1ExercisePrice296.80Member"
      decimals="INF"
      id="Fact001341"
      unitRef="Shares">8422</us-gaap:ClassOfWarrantOrRightOutstanding>
    <coep:WarrantsAndRightsOutstandingDateIssued
      contextRef="From2025-01-012025-12-31_custom_WarrantHolder2ExercisePrice59.40Member"
      id="Fact001343">2021-07-30</coep:WarrantsAndRightsOutstandingDateIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_WarrantHolder2ExercisePrice59.40Member"
      decimals="INF"
      id="Fact001345"
      unitRef="USDPShares">59.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_WarrantHolder2ExercisePrice59.40Member"
      id="Fact001347">2026-07-30</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_WarrantHolder2ExercisePrice59.40Member"
      decimals="INF"
      id="Fact001348"
      unitRef="Shares">421</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_WarrantHolder2ExercisePrice59.40Member"
      decimals="INF"
      id="Fact001349"
      unitRef="Shares">421</us-gaap:ClassOfWarrantOrRightOutstanding>
    <coep:WarrantsAndRightsOutstandingDateIssued
      contextRef="From2025-01-012025-12-31_custom_WarrantHolder2ExercisePrice296.80Member"
      id="Fact001351">2021-07-30</coep:WarrantsAndRightsOutstandingDateIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_WarrantHolder2ExercisePrice296.80Member"
      decimals="INF"
      id="Fact001353"
      unitRef="USDPShares">296.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_WarrantHolder2ExercisePrice296.80Member"
      id="Fact001355">2026-06-01</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_WarrantHolder2ExercisePrice296.80Member"
      decimals="INF"
      id="Fact001356"
      unitRef="Shares">1263</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_WarrantHolder2ExercisePrice296.80Member"
      decimals="INF"
      id="Fact001357"
      unitRef="Shares">1263</us-gaap:ClassOfWarrantOrRightOutstanding>
    <coep:WarrantsAndRightsOutstandingDateIssued
      contextRef="From2025-01-012025-12-31_custom_WarrantHolder5ExercisePrice59.40Member"
      id="Fact001359">2021-12-20</coep:WarrantsAndRightsOutstandingDateIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_WarrantHolder5ExercisePrice59.40Member"
      decimals="INF"
      id="Fact001361"
      unitRef="USDPShares">59.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_WarrantHolder5ExercisePrice59.40Member"
      id="Fact001363">2026-12-20</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_WarrantHolder5ExercisePrice59.40Member"
      decimals="INF"
      id="Fact001364"
      unitRef="Shares">2948</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_WarrantHolder5ExercisePrice59.40Member"
      decimals="INF"
      id="Fact001365"
      unitRef="Shares">2948</us-gaap:ClassOfWarrantOrRightOutstanding>
    <coep:WarrantsAndRightsOutstandingDateIssued
      contextRef="From2025-01-012025-12-31_custom_WarrantHolder18ExercisePrice178.20Member"
      id="Fact001367">2022-03-30</coep:WarrantsAndRightsOutstandingDateIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_WarrantHolder18ExercisePrice178.20Member"
      decimals="INF"
      id="Fact001369"
      unitRef="USDPShares">178.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_WarrantHolder18ExercisePrice178.20Member"
      id="Fact001371">2025-03-30</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_WarrantHolder18ExercisePrice178.20Member"
      decimals="INF"
      id="Fact001372"
      unitRef="Shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_WarrantHolder18ExercisePrice178.20Member"
      decimals="INF"
      id="Fact001373"
      unitRef="Shares">4211</us-gaap:ClassOfWarrantOrRightOutstanding>
    <coep:WarrantsAndRightsOutstandingDateIssued
      contextRef="From2025-01-012025-12-31_custom_WarrantHolder20ExercisePrice50.00Member"
      id="Fact001375">2023-01-03</coep:WarrantsAndRightsOutstandingDateIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_WarrantHolder20ExercisePrice50.00Member"
      decimals="INF"
      id="Fact001377"
      unitRef="USDPShares">50.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_WarrantHolder20ExercisePrice50.00Member"
      id="Fact001379">2027-01-02</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_WarrantHolder20ExercisePrice50.00Member"
      decimals="INF"
      id="Fact001380"
      unitRef="Shares">5000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_WarrantHolder20ExercisePrice50.00Member"
      decimals="INF"
      id="Fact001381"
      unitRef="Shares">5000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <coep:WarrantsAndRightsOutstandingDateIssued
      contextRef="From2025-01-012025-12-31_custom_WarrantHolder21ExercisePrice38.00Member"
      id="Fact001383">2023-01-20</coep:WarrantsAndRightsOutstandingDateIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_WarrantHolder21ExercisePrice38.00Member"
      decimals="INF"
      id="Fact001385"
      unitRef="USDPShares">38.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_WarrantHolder21ExercisePrice38.00Member"
      id="Fact001387">2027-01-19</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_WarrantHolder21ExercisePrice38.00Member"
      decimals="INF"
      id="Fact001388"
      unitRef="Shares">12500</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_WarrantHolder21ExercisePrice38.00Member"
      decimals="INF"
      id="Fact001389"
      unitRef="Shares">12500</us-gaap:ClassOfWarrantOrRightOutstanding>
    <coep:WarrantsAndRightsOutstandingDateIssued
      contextRef="From2025-01-012025-12-31_custom_SeriesWarrantsAAndBExercisePrice27.20Member"
      id="Fact001391">2023-06-16</coep:WarrantsAndRightsOutstandingDateIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_SeriesWarrantsAAndBExercisePrice27.20Member"
      decimals="INF"
      id="Fact001393"
      unitRef="USDPShares">27.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_SeriesWarrantsAAndBExercisePrice27.20Member"
      id="Fact001395">2028-12-16</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_SeriesWarrantsAAndBExercisePrice27.20Member"
      decimals="INF"
      id="Fact001396"
      unitRef="Shares">306250</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_SeriesWarrantsAAndBExercisePrice27.20Member"
      decimals="INF"
      id="Fact001397"
      unitRef="Shares">306250</us-gaap:ClassOfWarrantOrRightOutstanding>
    <coep:WarrantsAndRightsOutstandingDateIssued
      contextRef="From2025-01-012025-12-31_custom_SeriesAWarrantsExercisePrice27.20Member"
      id="Fact001399">2023-10-23</coep:WarrantsAndRightsOutstandingDateIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_SeriesAWarrantsExercisePrice27.20Member"
      decimals="INF"
      id="Fact001401"
      unitRef="USDPShares">27.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_SeriesAWarrantsExercisePrice27.20Member"
      id="Fact001403">2025-04-26</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_SeriesAWarrantsExercisePrice27.20Member"
      decimals="INF"
      id="Fact001404"
      unitRef="Shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_SeriesAWarrantsExercisePrice27.20Member"
      decimals="INF"
      id="Fact001405"
      unitRef="Shares">100000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <coep:WarrantsAndRightsOutstandingDateIssued
      contextRef="From2025-01-012025-12-31_custom_SeriesBWarrantsExercisePrice27.20Member"
      id="Fact001407">2023-10-23</coep:WarrantsAndRightsOutstandingDateIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_SeriesBWarrantsExercisePrice27.20Member"
      decimals="INF"
      id="Fact001409"
      unitRef="USDPShares">27.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_SeriesBWarrantsExercisePrice27.20Member"
      id="Fact001411">2029-04-26</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_SeriesBWarrantsExercisePrice27.20Member"
      decimals="INF"
      id="Fact001412"
      unitRef="Shares">100000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_SeriesBWarrantsExercisePrice27.20Member"
      decimals="INF"
      id="Fact001413"
      unitRef="Shares">100000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <coep:WarrantsAndRightsOutstandingDateIssued
      contextRef="From2025-01-012025-12-31_custom_WarrantHolder22ExercisePrice25.00Member"
      id="Fact001415">2023-06-16</coep:WarrantsAndRightsOutstandingDateIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_WarrantHolder22ExercisePrice25.00Member"
      decimals="INF"
      id="Fact001417"
      unitRef="USDPShares">25.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_WarrantHolder22ExercisePrice25.00Member"
      id="Fact001419">2028-12-16</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_WarrantHolder22ExercisePrice25.00Member"
      decimals="INF"
      id="Fact001420"
      unitRef="Shares">6300</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_WarrantHolder22ExercisePrice25.00Member"
      decimals="INF"
      id="Fact001421"
      unitRef="Shares">6300</us-gaap:ClassOfWarrantOrRightOutstanding>
    <coep:WarrantsAndRightsOutstandingDateIssued
      contextRef="From2025-01-012025-12-31_custom_WarrantHolder22ExercisePrice28.00Member"
      id="Fact001423">2023-10-23</coep:WarrantsAndRightsOutstandingDateIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_WarrantHolder22ExercisePrice28.00Member"
      decimals="INF"
      id="Fact001425"
      unitRef="USDPShares">28.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_WarrantHolder22ExercisePrice28.00Member"
      id="Fact001427">2029-04-26</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_WarrantHolder22ExercisePrice28.00Member"
      decimals="INF"
      id="Fact001428"
      unitRef="Shares">3300</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_WarrantHolder22ExercisePrice28.00Member"
      decimals="INF"
      id="Fact001429"
      unitRef="Shares">3300</us-gaap:ClassOfWarrantOrRightOutstanding>
    <coep:WarrantsAndRightsOutstandingDateIssued
      contextRef="From2025-01-012025-12-31_custom_WarrantHolder23ExercisePrice25.00Member"
      id="Fact001431">2023-06-16</coep:WarrantsAndRightsOutstandingDateIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_WarrantHolder23ExercisePrice25.00Member"
      decimals="INF"
      id="Fact001433"
      unitRef="USDPShares">25.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_WarrantHolder23ExercisePrice25.00Member"
      id="Fact001435">2028-12-16</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_WarrantHolder23ExercisePrice25.00Member"
      decimals="INF"
      id="Fact001436"
      unitRef="Shares">4200</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_WarrantHolder23ExercisePrice25.00Member"
      decimals="INF"
      id="Fact001437"
      unitRef="Shares">4200</us-gaap:ClassOfWarrantOrRightOutstanding>
    <coep:WarrantsAndRightsOutstandingDateIssued
      contextRef="From2025-01-012025-12-31_custom_WarrantHolder23ExercisePrice28.00Member"
      id="Fact001439">2023-10-23</coep:WarrantsAndRightsOutstandingDateIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_WarrantHolder23ExercisePrice28.00Member"
      decimals="INF"
      id="Fact001441"
      unitRef="USDPShares">28.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_WarrantHolder23ExercisePrice28.00Member"
      id="Fact001443">2029-04-26</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_WarrantHolder23ExercisePrice28.00Member"
      decimals="INF"
      id="Fact001444"
      unitRef="Shares">2400</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_WarrantHolder23ExercisePrice28.00Member"
      decimals="INF"
      id="Fact001445"
      unitRef="Shares">2400</us-gaap:ClassOfWarrantOrRightOutstanding>
    <coep:WarrantsAndRightsOutstandingDateIssued
      contextRef="From2025-01-012025-12-31_custom_WarrantHolder24ExercisePrice28.00Member"
      id="Fact001447">2023-10-23</coep:WarrantsAndRightsOutstandingDateIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_WarrantHolder24ExercisePrice28.00Member"
      decimals="INF"
      id="Fact001449"
      unitRef="USDPShares">28.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_WarrantHolder24ExercisePrice28.00Member"
      id="Fact001451">2029-04-26</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_WarrantHolder24ExercisePrice28.00Member"
      decimals="INF"
      id="Fact001452"
      unitRef="Shares">300</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_WarrantHolder24ExercisePrice28.00Member"
      decimals="INF"
      id="Fact001453"
      unitRef="Shares">300</us-gaap:ClassOfWarrantOrRightOutstanding>
    <coep:WarrantsAndRightsOutstandingDateIssued
      contextRef="From2025-01-012025-12-31_custom_PreFundedWarrants2ExercisePrice0.002Member"
      id="Fact001455">2023-12-28</coep:WarrantsAndRightsOutstandingDateIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_PreFundedWarrants2ExercisePrice0.002Member"
      decimals="INF"
      id="Fact001457"
      unitRef="USDPShares">0.002</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_PreFundedWarrants2ExercisePrice0.002Member"
      decimals="INF"
      id="Fact001459"
      unitRef="Shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_PreFundedWarrants2ExercisePrice0.002Member"
      decimals="INF"
      id="Fact001461"
      unitRef="Shares">150000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <coep:WarrantsAndRightsOutstandingDateIssued
      contextRef="From2025-01-012025-12-31_custom_PreFundedWarrants3ExercisePrice0.002Member"
      id="Fact001463">2024-02-08</coep:WarrantsAndRightsOutstandingDateIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_PreFundedWarrants3ExercisePrice0.002Member"
      decimals="INF"
      id="Fact001465"
      unitRef="USDPShares">0.002</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_PreFundedWarrants3ExercisePrice0.002Member"
      decimals="INF"
      id="Fact001467"
      unitRef="Shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_PreFundedWarrants3ExercisePrice0.002Member"
      decimals="INF"
      id="Fact001469"
      unitRef="Shares">300000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <coep:WarrantsAndRightsOutstandingDateIssued
      contextRef="From2025-01-012025-12-31_custom_WarrantHolder25ExercisePrice12.00Member"
      id="Fact001471">2025-01-20</coep:WarrantsAndRightsOutstandingDateIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_WarrantHolder25ExercisePrice12.00Member"
      decimals="INF"
      id="Fact001473"
      unitRef="USDPShares">12.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_WarrantHolder25ExercisePrice12.00Member"
      id="Fact001475">2030-01-20</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_WarrantHolder25ExercisePrice12.00Member"
      decimals="INF"
      id="Fact001476"
      unitRef="Shares">100000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_WarrantHolder25ExercisePrice12.00Member"
      decimals="INF"
      id="Fact001477"
      unitRef="Shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact001479"
      unitRef="Shares">570105</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001481"
      unitRef="Shares">1024316</us-gaap:ClassOfWarrantOrRightOutstanding>
    <coep:StockIssuedForDebtShares
      contextRef="From2023-09-012023-09-30_custom_SubscriptionReceivableSept2023Member"
      decimals="INF"
      id="Fact001483"
      unitRef="Shares">25000</coep:StockIssuedForDebtShares>
    <coep:StockIssuedForDebtValue
      contextRef="From2023-09-012023-09-30_custom_SubscriptionReceivableSept2023Member"
      decimals="0"
      id="Fact001485"
      unitRef="USD">500000</coep:StockIssuedForDebtValue>
    <us-gaap:Investments
      contextRef="AsOf2025-12-31_custom_SubscriptionReceivableSept2023Member"
      decimals="0"
      id="Fact001487"
      unitRef="USD">522667</us-gaap:Investments>
    <us-gaap:Investments
      contextRef="AsOf2024-12-31_custom_SubscriptionReceivableSept2023Member"
      decimals="0"
      id="Fact001488"
      unitRef="USD">522667</us-gaap:Investments>
    <coep:StockIssuedForDebtShares
      contextRef="From2023-09-012023-09-30_custom_SubscriptionReceivableSept20232ndMember"
      decimals="INF"
      id="Fact001490"
      unitRef="Shares">100000</coep:StockIssuedForDebtShares>
    <coep:StockIssuedForDebtValue
      contextRef="From2023-09-012023-09-30_custom_SubscriptionReceivableSept20232ndMember"
      decimals="0"
      id="Fact001492"
      unitRef="USD">2000000</coep:StockIssuedForDebtValue>
    <us-gaap:Investments
      contextRef="AsOf2025-12-31_custom_SubscriptionReceivableSept20232ndMember"
      decimals="0"
      id="Fact001494"
      unitRef="USD">2090667</us-gaap:Investments>
    <us-gaap:Investments
      contextRef="AsOf2024-12-31_custom_SubscriptionReceivableSept20232ndMember"
      decimals="0"
      id="Fact001496"
      unitRef="USD">2090667</us-gaap:Investments>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-03-31_custom_December2023FinancingMember"
      decimals="INF"
      id="Fact001498"
      unitRef="Shares">100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:Investments
      contextRef="AsOf2025-12-31_custom_December2023FinancingMember"
      decimals="0"
      id="Fact001500"
      unitRef="USD">1132869</us-gaap:Investments>
    <us-gaap:Investments
      contextRef="AsOf2024-12-31_custom_December2023FinancingMember"
      decimals="0"
      id="Fact001501"
      unitRef="USD">1132869</us-gaap:Investments>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-02-28_custom_February2024FinancingMember"
      decimals="INF"
      id="Fact001506"
      unitRef="Shares">200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:Investments
      contextRef="AsOf2025-12-31_custom_February2024FinancingMember"
      decimals="0"
      id="Fact001508"
      unitRef="USD">1944879</us-gaap:Investments>
    <us-gaap:Investments
      contextRef="AsOf2024-12-31_custom_February2024FinancingMember"
      decimals="0"
      id="Fact001509"
      unitRef="USD">1944879</us-gaap:Investments>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
      contextRef="From2025-01-012025-06-30_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact001511"
      unitRef="USD">125000</us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants>
    <us-gaap:PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable
      contextRef="AsOf2025-06-30_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact001513"
      unitRef="USD">125000</us-gaap:PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable>
    <coep:SubscriptionsReceivable
      contextRef="From2025-07-012025-09-30_us-gaap_PrivatePlacementMember"
      decimals="0"
      id="Fact001515"
      unitRef="USD">5000000</coep:SubscriptionsReceivable>
    <coep:ProceedsFromSubscriptionsReceivable
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001517"
      unitRef="USD">4500000</coep:ProceedsFromSubscriptionsReceivable>
    <coep:SubscriptionsReceivableNet
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001519"
      unitRef="USD">500000</coep:SubscriptionsReceivableNet>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-10-012025-12-31_custom_TwoInvestorMember"
      decimals="INF"
      id="Fact001521"
      unitRef="Shares">260000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <coep:SubscriptionsReceivableNet
      contextRef="AsOf2025-12-31_custom_TwoInvestorMember"
      decimals="0"
      id="Fact001523"
      unitRef="USD">3120000</coep:SubscriptionsReceivableNet>
    <us-gaap:PaymentsForBrokerageFees
      contextRef="From2024-10-292024-11-02_custom_StandbyEquityPurchaseAgreementMember_custom_YorkvilleMember"
      decimals="0"
      id="Fact001529"
      unitRef="USD">200000</us-gaap:PaymentsForBrokerageFees>
    <us-gaap:PaymentsForBrokerageFees
      contextRef="From2024-10-292024-11-02_custom_StandbyEquityPurchaseAgreementMember_custom_YorkvilleMember_custom_StockIssuedForServicesMember"
      decimals="0"
      id="Fact001531"
      unitRef="USD">80000</us-gaap:PaymentsForBrokerageFees>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2024-11-02_custom_StandbyEquityPurchaseAgreementMember_custom_YorkvilleMember_custom_ConvertibleNoteMember"
      decimals="0"
      id="Fact001533"
      unitRef="USD">1304758</us-gaap:ConvertibleNotesPayable>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-01-012025-12-31_custom_StandbyEquityPurchaseAgreementMember206522812"
      decimals="INF"
      id="Fact001535"
      unitRef="Shares">225000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-12-31_custom_StandbyEquityPurchaseAgreementMember206522812"
      decimals="0"
      id="Fact001537"
      unitRef="USD">2958848</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:MinorityInterestDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001539">&lt;p id="xdx_809_eus-gaap--MinorityInterestDisclosureTextBlock_zizifLs4YmKa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 8 &#x2013; &lt;span id="xdx_827_z2UxdB84e2e9"&gt;NON-CONTROLLING INTEREST&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As a result of the series A preferred stock offering
discussed in Note 7, Capital Structure, the Company has consolidated the two newly formed subsidiaries, SNAP Biosciences, Inc. and GEAR
Therapeutics, Inc., because we have a controlling interest in both. Therefore, the entities&#x2019; financial statements are consolidated
in our consolidated financial statements and the portion of the entities&#x2019; equity attributable to external ownership is recorded
as a non-controlling interest. As part of the initial closings, the Series A Investors received in the aggregate a 15% non-voting equity
ownership in both of the newly formed subsidiaries. In addition, investors who participated in the 2025 private placement common stock
offering received an additional 10% aggregate non-voting ownership in SNAP Biosciences, Inc., resulting in an extra $79,000 in equity attributable
to non-controlling interests. The Company contributed the co-development rights to GEAR Therapeutics, Inc. and contributed both the exclusive
license and corporate research agreements with the University of Pittsburgh to SNAP Biosciences, Inc. The Company recorded $&lt;span id="xdx_904_eus-gaap--MinorityInterest_iI_c20251231__dei--LegalEntityAxis__custom--GearTherapeuticsMember_zcwdUpTOBaog" title="Noncontrolling interest"&gt;1,063,300&lt;/span&gt;
of non-controlling interest at December 31, 2025. Net of accumulated losses of $&lt;span id="xdx_90E_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iI_c20251231__dei--LegalEntityAxis__custom--GearTherapeuticsMember_zGJerPrrLk9i" title="Net of accumulated losses"&gt;557,137&lt;/span&gt;, the Company recorded $&lt;span id="xdx_905_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iI_c20251231__dei--LegalEntityAxis__custom--GearTherapeuticsMember_z2uTqu2lYDL7" title="Equity attributable to non-controlling interests"&gt;506,163&lt;/span&gt; in equity attributable
to non-controlling interests at December 31, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:MinorityInterestDisclosureTextBlock>
    <us-gaap:MinorityInterest
      contextRef="AsOf2025-12-31_custom_GearTherapeuticsMember"
      decimals="0"
      id="Fact001541"
      unitRef="USD">1063300</us-gaap:MinorityInterest>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2025-12-31_custom_GearTherapeuticsMember"
      decimals="0"
      id="Fact001543"
      unitRef="USD">557137</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-12-31_custom_GearTherapeuticsMember"
      decimals="0"
      id="Fact001545"
      unitRef="USD">506163</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:InvestmentTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001547">&lt;p id="xdx_805_eus-gaap--InvestmentTextBlock_zoTzwyMRtk2k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 9 &#x2013;&#160;&lt;span id="xdx_827_zHmsjDFWeM9a"&gt;INVESTMENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In August 2024, the Company satisfied $&lt;span id="xdx_904_ecustom--SubscriptionReceivable_iI_dm_c20240831__srt--CounterpartyNameAxis__custom--TwoPrivatelyHeldCompaniesMember_z7mAbw8Itzjj"&gt;5.7
million&lt;/span&gt; of subscription receivables and related interest receivable in the form of shares of common stock in two privately
held companies. During the year ended December 31, 2025, the Company received &lt;span id="xdx_909_eus-gaap--InvestmentOwnedBalanceShares_iI_dm_c20251231__us-gaap--TransactionTypeAxis__custom--NexGenAIAffiliatesNetworkPlatformMember__srt--CounterpartyNameAxis__custom--FivePrivatelyHeldCompaniesMember_zygfI3UvOgDd"&gt;1.25
million&lt;/span&gt; shares of common stock in five privately held companies in connection with master services agreements for access to
the NexGenAI Affiliates Network platform. Additionally, to satisfy outstanding accounts receivables related to webinar services
rendered in the master services agreements, the Company received &lt;span id="xdx_904_eus-gaap--InvestmentOwnedBalanceShares_iI_dm_c20251231__us-gaap--TransactionTypeAxis__custom--NexGenAIAffiliatesNetworkPlatformMember__srt--CounterpartyNameAxis__custom--ThreePrivatelyHeldCompaniesMember_zWC2YVqGoTuk"&gt;82,500&lt;/span&gt;
shares of common stock in three of these privately held companies. The shares of common stock are carried as investments on the
Company&#x2019;s consolidated balance sheets at its initial cost basis of $1.00 per share. As the investments are in privately held
companies, the Company will assess the investments for impairment on an annual basis. As of December 31, 2025, the Company
recognized a $&lt;span id="xdx_906_eus-gaap--GainLossOnInvestments_iN_di_c20251101__20251231__us-gaap--TransactionTypeAxis__custom--NexGenAIAffiliatesNetworkPlatformMember_zTufr3C19kxa" title="Loss on investment"&gt;163,500&lt;/span&gt; unrealized loss due to impairment of one of these investments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In November 2025, the Company issued &lt;span id="xdx_906_ecustom--StockIssuedDuringPeriodSharesIssuedForInvestment_c20251101__20251130__srt--CounterpartyNameAxis__custom--PrivatelyHeldCompanyMember_zgMu2FyQdV0b"&gt;66,837&lt;/span&gt;
shares of common stock valued at $&lt;span id="xdx_90C_ecustom--StockIssuedDuringPeriodValueIssuedForInvestment_c20251101__20251130__srt--CounterpartyNameAxis__custom--PrivatelyHeldCompanyMember_zbJt0MC6xAQc"&gt;1,000,000&lt;/span&gt;,
in exchange for &lt;span id="xdx_90F_eus-gaap--InvestmentOwnedBalanceShares_iI_c20251130__srt--CounterpartyNameAxis__custom--PrivatelyHeldCompanyMember_zB2jpaoTdOW5"&gt;667,000&lt;/span&gt;
shares of a privately held company. The shares of common stock are carried as investments on the Company&#x2019;s consolidated
balance sheets at its initial cost basis of $1.50 per share. As the investments are in privately held companies, the Company
will assess the investments for impairment on an annual basis. As of December 31, 2025, &lt;span id="xdx_90C_eus-gaap--GainLossOnInvestments_iN_dio_c20251101__20251231__srt--CounterpartyNameAxis__custom--PrivatelyHeldCompanyMember_zsN8lh9OnHo1" title="Loss on investment"&gt;no&lt;/span&gt; impairment has been recorded
related to this investment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2025, the
Company entered into a one-year agreement with a customer to provide access to the NexGenAI Affiliates Network platform. The
contract fee paid by the customer consisted of &lt;span id="xdx_90C_ecustom--InvestmentCompanyFeePaidSharesIndirectly_c20250101__20251231_z4g8if05Rh8" title="Investment company fee paid shares indirectly"&gt;2,830,189&lt;/span&gt;
shares in the customer&#x2019;s publicly traded stock, or $&lt;span id="xdx_90D_eus-gaap--InvestmentCompanyFeePaidIndirectly_c20250101__20251231_zngxbOqC2Y3h" title="Investment company fee paid indirectly"&gt;600,000&lt;/span&gt;,
which the Company recorded as marketable securities on the consolidated balance sheets. The Company classified this marketable
security as a short-term asset as it is expected to be converted into cash within one year. During the year ended December 31, 2025,
the Company recorded an unrealized gain on marketable securities in the amount of $&lt;span id="xdx_90B_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20250101__20251231_zT5ZCztWTXj3" title="Unrealized gain on marketable securities"&gt;76,596&lt;/span&gt;.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:InvestmentTextBlock>
    <coep:SubscriptionReceivable
      contextRef="AsOf2024-08-31_custom_TwoPrivatelyHeldCompaniesMember"
      decimals="0"
      id="Fact001548"
      unitRef="USD">5700000</coep:SubscriptionReceivable>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2025-12-31_custom_NexGenAIAffiliatesNetworkPlatformMember_custom_FivePrivatelyHeldCompaniesMember"
      decimals="INF"
      id="Fact001549"
      unitRef="Shares">1250000</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2025-12-31_custom_NexGenAIAffiliatesNetworkPlatformMember_custom_ThreePrivatelyHeldCompaniesMember"
      decimals="INF"
      id="Fact001550"
      unitRef="Shares">82500</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:GainLossOnInvestments
      contextRef="From2025-11-012025-12-31_custom_NexGenAIAffiliatesNetworkPlatformMember"
      decimals="0"
      id="Fact001552"
      unitRef="USD">-163500</us-gaap:GainLossOnInvestments>
    <coep:StockIssuedDuringPeriodSharesIssuedForInvestment
      contextRef="From2025-11-012025-11-30_custom_PrivatelyHeldCompanyMember"
      decimals="INF"
      id="Fact001553"
      unitRef="Shares">66837</coep:StockIssuedDuringPeriodSharesIssuedForInvestment>
    <coep:StockIssuedDuringPeriodValueIssuedForInvestment
      contextRef="From2025-11-012025-11-30_custom_PrivatelyHeldCompanyMember"
      decimals="0"
      id="Fact001554"
      unitRef="USD">1000000</coep:StockIssuedDuringPeriodValueIssuedForInvestment>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2025-11-30_custom_PrivatelyHeldCompanyMember"
      decimals="INF"
      id="Fact001555"
      unitRef="Shares">667000</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:GainLossOnInvestments
      contextRef="From2025-11-012025-12-31_custom_PrivatelyHeldCompanyMember"
      decimals="0"
      id="Fact001557"
      unitRef="USD">-0</us-gaap:GainLossOnInvestments>
    <coep:InvestmentCompanyFeePaidSharesIndirectly
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact001559"
      unitRef="Shares">2830189</coep:InvestmentCompanyFeePaidSharesIndirectly>
    <us-gaap:InvestmentCompanyFeePaidIndirectly
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001561"
      unitRef="USD">600000</us-gaap:InvestmentCompanyFeePaidIndirectly>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001563"
      unitRef="USD">76596</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001567">&lt;p id="xdx_802_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z63rIQ88SQK6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 10 &#x2013; &lt;span id="xdx_82D_zK60r8rxyoR5"&gt;COMMITMENTS AND
CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Leases &#x2013;&lt;/b&gt; The Company leases
office space under an operating lease that commenced December 1, 2017 and was extended through multiple lease extensions. The third lease
extension extended the lease for twenty-four months, beginning on June 1, 2022 and ended on May 31, 2024. The fourth lease extension,
signed on January 30, 2024, extended the lease for twenty-four months, beginning June 1, 2024 and ending on May 31, 2026. The monthly
rent is $&lt;span id="xdx_90C_ecustom--MonthlyRent_uUSD_c20250101__20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FirstYearExtensionMember_zP97kLHgFb25" title="Monthly rent"&gt;3,805&lt;/span&gt;&#160;for the first year of the extension and increasing to $&lt;span id="xdx_907_ecustom--MonthlyRent_uUSD_c20250101__20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--SecondYearExtensionMember_zCbR59IAEgZd" title="Monthly rent"&gt;3,860&lt;/span&gt;&#160;for the second year of the extension.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company records rent expense associated with
this lease on the straight-line basis in conjunction with the terms of the underlying lease. During the year ended December 31, 2025,
rents paid totaled $&lt;span id="xdx_900_eus-gaap--OperatingLeaseExpense_c20250101__20251231_zSb7uE0KklXk" title="Operating lease expense"&gt;46,101&lt;/span&gt;. During the year ended December 31, 2024, rents paid totaled $&lt;span id="xdx_906_eus-gaap--OperatingLeaseExpense_c20240101__20241231_zwnXA6YZY4U" title="Operating lease expense"&gt;45,440&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Right of use asset is summarized below:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--LeaseCostTableTextBlock_zNurRGb4gJA9" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details - Lease cost)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_8B9_zfBMVeVu1fG1" style="display: none"&gt;Schedule of lease information&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;December 31, 2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;December 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 68%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Office lease&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--OperatingLeaseRightOfUseAssetGross_iI_c20251231_zTI5yKVpn9L7" style="width: 13%; text-align: right" title="Operating lease right of use asset, gross"&gt;&lt;span style="font-size: 10pt"&gt;243,550&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--OperatingLeaseRightOfUseAssetGross_iI_c20241231_zCNmIOx5AEda" style="width: 13%; text-align: right" title="Operating lease right of use asset, gross"&gt;&lt;span style="font-size: 10pt"&gt;243,550&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--OperatingLeaseRightOfUseAssetAccumulatedDepreciation_iNI_di_c20251231_zfjJ2CGRwWsd" style="border-bottom: Black 1pt solid; text-align: right" title="Operating lease right of use asset, accumulated depreciation"&gt;&lt;span style="font-size: 10pt"&gt;(225,151&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--OperatingLeaseRightOfUseAssetAccumulatedDepreciation_iNI_di_c20241231_zeEO5zVDrf14" style="border-bottom: Black 1pt solid; text-align: right" title="Operating lease right of use asset, accumulated depreciation"&gt;&lt;span style="font-size: 10pt"&gt;(183,767&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Right of use asset, net&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20251231_z3MqBXwIerud" style="border-bottom: black 2.25pt double; text-align: right" title="Operating lease right of use asset"&gt;&lt;span style="font-size: 10pt"&gt;18,399&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20241231_z29q7WIDxG68" style="border-bottom: black 2.25pt double; text-align: right" title="Operating lease right of use asset"&gt;&lt;span style="font-size: 10pt"&gt;59,783&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Operating lease liability is summarized below:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;December 31, 2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;December 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 68%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Office lease&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--OperatingLeaseLiability_iI_c20251231_z52hvCDNi538" style="width: 13%; text-align: right" title="Operating lease liability"&gt;&lt;span style="font-size: 10pt"&gt;18,875&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--OperatingLeaseLiability_iI_c20241231_z3X3UlzHpbR9" style="width: 13%; text-align: right" title="Operating lease liability"&gt;&lt;span style="font-size: 10pt"&gt;61,180&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_c20251231_zbwMKcGw5RS1" style="border-bottom: Black 1pt solid; text-align: right" title="Operating lease liability, current"&gt;&lt;span style="font-size: 10pt"&gt;(18,875&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_c20241231_zaYiadVVq5g1" style="border-bottom: Black 1pt solid; text-align: right" title="Operating lease liability, current"&gt;&lt;span style="font-size: 10pt"&gt;(42,305&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Long term portion&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_d0_c20251231_z5wk0aoUsIM" style="border-bottom: black 2.25pt double; text-align: right" title="Operating lease liability, noncurrent"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20241231_zrViZofdPv1h" style="border-bottom: black 2.25pt double; text-align: right" title="Operating lease liability, noncurrent"&gt;&lt;span style="font-size: 10pt"&gt;18,875&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A2_zqyctCikfcb8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Future minimum rental payments required under
the lease are as follows:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zhfD5xWoCW72" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details - Future minimum payments)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 84%"&gt;&lt;span id="xdx_8B8_zj1SoMqSanta" style="display: none"&gt;Schedule of future minimum rental payments&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49E_20251231_zvweQfOVXaz9" style="text-align: center; width: 13%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzRwJ_zcNnpXsH026b" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;2026&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;19,301&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzRwJ_zf9cpLG5IKMj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Total minimum lease payments:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;19,301&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zvJXonsH07G8" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;Less amount representing interest&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(426&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Present value of minimum lease payments:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;18,875&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AF_zHQkVCaIL2m2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Legal Matters&#160;&lt;/b&gt;&#x2013; The Company
is currently not a defendant in any litigation or threatened litigation that could have a material effect on the Company&#x2019;s consolidated
financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Employment Agreements with Directors and
Officers &#x2013;&lt;/b&gt; David Mehalick, our President and Chief Executive Officer, and Daniel Yerace, our Vice President of Operations, entered
into employment agreements with Coeptis Therapeutics, Inc. on February 21, 2022 (the &#x201c;Effective Date&#x201d;) covering Coeptis and
its subsidiary, Coeptis Pharmaceuticals. The employment agreements will remain in effect until the termination of the employment agreement
by either party in accordance with Section&#160;5 of the employment agreement. Under the employment agreements, the Company currently
pays both Mr. Mehalick and Mr. Yerace an annualized salary at the rate of $&lt;span id="xdx_904_ecustom--AnnualSalary_c20250101__20251231__srt--CounterpartyNameAxis__custom--MehalickMember_zvwLKWdDLC09" title="Annual salary"&gt;&lt;span id="xdx_90E_ecustom--AnnualSalary_c20250101__20251231__srt--CounterpartyNameAxis__custom--YeraceMember_zJfoP6lmzqT2" title="Annual salary"&gt;360,000&lt;/span&gt;&lt;/span&gt;. Mr. Mehalick and Mr. Yerace will also receive a guaranteed
bonus equal to twenty (20%) of the base salary for each calendar year, and will be eligible to receive merit bonuses, certain milestone
bonuses and awards of stock options, restricted stock units or other equity awards pursuant to any plans or arrangements that the Company
may have in effect from time to time.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;CAR T License &lt;/b&gt;&#x2013; On August 31,
2022, the Company entered into an exclusive license agreement with the University of Pittsburgh for certain intellectual property
rights related to the universal self-labeling SynNotch and CARs for programable antigen-targeting technology platform. The Company
paid the University of Pittsburgh a non-refundable fee in the amount of $75,000 for the exclusive patent rights to the licensed
technology. Under the terms of the agreement, the Company has been assigned the worldwide development and commercialization rights
to the licensed technology in the field of human treatment of cancer with antibody or antibody fragments using SNAP-CAR T-cell
technology, along with (i) an intellectual property portfolio consisting of issued and pending patents and (ii) options regarding
future add-on technologies and developments. In consideration of these rights, the Company paid an initial license fee of $&lt;span id="xdx_900_ecustom--InitialLicenseFee_iI_c20220831__us-gaap--TransactionTypeAxis__custom--CarTLicenseMember_z7ogeCkrL0E2" title="Initial license fee"&gt;75,000&lt;/span&gt;,
and will have &lt;span id="xdx_909_ecustom--AnnualMaintenanceFeeDescription_c20220829__20220831__us-gaap--TransactionTypeAxis__custom--CarTLicenseMember_z6zdmMaazNBh" title="Annual maintenance fee description"&gt;annual
maintenance fees ranging between $15,000 and $25,000&lt;/span&gt;, as well as developmental milestone payments (as defined in the
agreement) and royalties equal to 3.5% of net sales. On January 25, 2023, the Company entered into a Sponsored Research Agreement
(&#x201c;SRA&#x201d;) with the University of Pittsburgh for the pre- clinical development of SNAP-CAR T-cells targeting HER2. The
Company agreed to pay $&lt;span id="xdx_90A_eus-gaap--ContractualObligation_iI_c20251231__us-gaap--TransactionTypeAxis__custom--CarTLicenseMember_z2RYCefqhTW3" title="Contractual obligation"&gt;716,714&lt;/span&gt;
for performance-based milestones over a two-year term, all of which has been paid as of December 31, 2025. The Company&#x2019;s
liability was $&lt;span id="xdx_90F_eus-gaap--ContractualObligation_iI_c20251231_zKayGZDufN3d" title="Contractual obligation"&gt;0&lt;/span&gt;
and $&lt;span id="xdx_90C_eus-gaap--ContractualObligation_iI_c20241231_z1SCzeTXlzDl" title="Contractual obligation"&gt;507,535&lt;/span&gt; at
December 31, 2025 and 2024, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;To supplement the development work conducted under
the SRA, the Company&#x2019;s subsidiary SNAP Biosciences, in May 2025, entered into a grant agreement with the Alici Lab at the Karolinska
Institutet (&#x201c;KI&#x201d;). Under the terms of the grant agreement, KI will continue the pre-clinical and clinical development initially
started by Deverra under the terms of the Shared Services Agreement (&#x201c;SSA&#x201d;) described below. The grant agreement has an 18-month
term which the Company agreed to pay to KI quarterly payments equal to $105,000.&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Also in May 2025, the Company&#x2019;s subsidiary,
SNAP Biosciences, entered into a License Agreement with Monarch Therapeutics. The agreement grants SNAP Biosciences access to Monarch&#x2019;s
small-molecule adaptor-based technology platform for use with SNAP-CAR. Under the terms of the agreement, SNAP Biosciences agreed to pay
to Monarch a $50,000 upfront payment, a $10,000 annual license fee, and future success-based milestone payments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In September 2023, the Company expanded its exclusive
license agreement with the University of Pittsburgh to include SNAP-CAR technology platform in natural killer (NK) cells. The Company
paid $&lt;span id="xdx_903_ecustom--AgreementAmendmentFee_iI_c20230930_z7Ccz973ONKc" title="Agreement amendment fee"&gt;2,000&lt;/span&gt; to amend the agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Deverra Therapeutics, Inc.&#160;&lt;/b&gt;&#x2013;
On August 16, 2023, the Company entered into an exclusive licensing arrangement (the &#x201c;License Agreement&#x201d;) with Deverra Therapeutics
Inc. (&#x201c;Deverra&#x201d;), pursuant to which the Company completed the exclusive license of key patent families and related intellectual
property related to a proprietary allogeneic stem cell expansion and directed differentiation platform for the generation of multiple
distinct immune effector cell types, including natural killer (NK) and monocyte/macrophages. The License Agreement provides the Company
with exclusive rights to use the license patents and related intellectual property in connection with development and commercialization
efforts in the defined field of use (the &#x201c;Field&#x201d;) of (a) use of unmodified NK cells as anti-viral therapeutic for viral infections,
and/or as a therapeutic approach for treatment of relapsed/refractory AML and high-risk MDS; (b) use of Deverra&#x2019;s cell therapy platform
to generate NK cells for the purpose of engineering with Coeptis SNAP-CARs and/or Coeptis GEAR Technology; and (c) use of Deverra&#x2019;s
cell therapy platform to generate myeloid cells for the purpose of engineering with the Company&#x2019;s current SNAP-CAR and GEAR technologies.
In support of the exclusive license, the Company also entered into with Deverra (i) an asset purchase agreement (the &#x201c;APA&#x201d;)
pursuant to which the Company purchased certain assets from Deverra, including but not limited to two Investigational New Drug (IND) applications
and two Phase 1 clinical trial stage programs (NCT04901416, NCT04900454) investigating infusion of DVX201, an unmodified natural killer
(NK) cell therapy generated from pooled donor CD34+ cells, in hematologic malignancies and viral infections and (ii) a non-exclusive sublicense
agreement (the &#x201c;Sublicense Agreement&#x201d;), in support of the assets obtained by the exclusive license, pursuant to which the
Company sublicensed from Deverra certain assets which Deverra has rights to pursuant a license agreement (&#x201c;FHCRC Agreement&#x201d;)
by and between Deverra and The Fred Hutchinson Cancer Research Center (&#x201c;FHCRC&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In addition, in accordance with the terms of
the Sublicense Agreement, the Company agreed to pay FHCRC certain specified contingent running royalty payments and milestone payments
under the FHCRC Agreement, in each case to the extent such payments are triggered by the Company&#x2019;s development activities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Until December 2024, we operated under a SSA with Deverra, which provided Coeptis and Deverra to share resources and collaborate on the development
of Coeptis&#x2019; GEAR and SNAP-CAR platforms. The Company is continuing its development focus on both GEAR and SNAP-CAR, and will be
considering prospective strategic partners for such development.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Registration Rights&lt;/b&gt; &#x2013; Pursuant to
a registration rights agreement entered into on October 29, 2020, the holders of the founder shares, the Private Placement Warrants and
underlying securities, and any securities issued upon conversion of Working Capital Loans (and underlying securities) would be entitled
to registration rights pursuant to a registration rights agreement. The holders of at least a majority in interest of the then-outstanding
number of these securities were entitled to make up to three demands, excluding short form demands, that the Company register such securities.
In addition, the holders have certain &#x201c;piggy-back&#x201d; registration rights with respect to registration statements filed subsequent
to the consummation of a Business Combination. Notwithstanding the foregoing, Imperial, I-Bankers and Northland did not exercise their
demand and &#x201c;piggyback&#x201d; registration rights after five (5) and seven (7) years after the effective date of the registration
statement and did not exercise its demand rights on more than one occasion. The registration rights agreement did not contain liquidating
damages or other cash settlement provisions resulting from delays in registering the Company&#x2019;s securities. The Company would bear
the expenses incurred in connection with the filing of any such registration statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Finder&#x2019;s Fee and Indemnity Agreement
&lt;/b&gt;&#x2013; The Company entered into a finder&#x2019;s fee and indemnity agreement with a third party, pursuant to which the Company has
agreed to pay a fee in connection with the successful introduction and executive of the SEPA. Under the terms of the agreement, the Company
was obligated to pay a 4% fee upon the closing of the net funding amount of $1,350,000, equaling $54,000, and then 6% of the total cash
consideration received by the Company or the Company&#x2019;s creditors in connection with any follow on financing, and 0.5% on the amount
of any drawdown made by the Company on the SEPA. The Company also agreed to indemnify and hold harmless the third party from and against
any and all losses, claims, damages, obligations, penalties, judgments, any and all legal and other actions caused by or related to the
third party&#x2019;s engagement with the Company. As of December 31, 2025, the Company paid a total of $&lt;span id="xdx_90D_eus-gaap--PaymentsForFees_c20250101__20251231__us-gaap--TransactionTypeAxis__custom--FindersFeeAndIndemnityAgreementMember_z3ks7zv6MO9l" title="Payment for fees"&gt;103,500&lt;/span&gt; to the third party in connection
with this finder&#x2019;s fee and indemnity agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Master Services Agreements&lt;/b&gt;&#160;&#x2013;
On December 31,2024 and during the year ended December 31, 2025, the Company entered into one-year agreements with six customers to provide
access to the NexGenAI Affiliates Network platform. Under the terms of these agreements, the Company is obligated to deliver platform
access and related services over the contract period beginning in 2025. Revenue recognition will commence upon the start of services
in accordance with ASC 606,&#160;&lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt;. As these agreements represent future contractual obligations,
there was no impact on the Company&#x2019;s financial position, results of operations, or cash flows as of December 31, 2024. As of December
31, 2025, the Company has recognized $&lt;span id="xdx_904_eus-gaap--Revenues_c20250101__20251231__us-gaap--TransactionTypeAxis__custom--MasterServicesAgreementsMember_zPrrhccubqge"&gt;1,363,045&lt;/span&gt;
in revenue in connection with these contracts, with $&lt;span id="xdx_901_eus-gaap--ContractWithCustomerAssetNet_iI_c20251231__us-gaap--TransactionTypeAxis__custom--MasterServicesAgreementsMember_zR9QP5t796H4" title="Customer deposit receivable"&gt;599,455&lt;/span&gt;
remaining in customer deposits expected to be recognized in 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;GEAR&#x2122; Cell Therapy Platform &#x2013;&lt;/b&gt;
In March 2025, the Company reached an agreement with Vy-Gen-Bio, Inc. (&#x201c;Vy-Gen&#x201d;) to successfully license the exclusive worldwide
development and commercialization rights to the GEAR&#x2122; Cell Therapy Platform, representing a first-in-class approach to modifying
potent cancer-targeting immune cells to optimize the likelihood of deep remission in patients with hematologic malignancies and other
cancers. Coeptis had previously held limited co-development rights to GEAR. As part of this exclusive GEAR license agreement with VyGen-Bio,
Inc., the Company paid a total of $&lt;span id="xdx_908_eus-gaap--PaymentsForFees_c20250101__20251231__us-gaap--TransactionTypeAxis__custom--GearCellTherapyPlatformMember_zUy4rbi2jFEe" title="Payment for fees"&gt;400,000&lt;/span&gt; for license fees during the year ended December 31, 2025, which the company recorded as research
and development expense, and committed to pay other performance-based fees, milestone and royalty payments in 2026 and beyond.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <coep:MonthlyRent
      contextRef="From2025-01-012025-12-31_custom_FirstYearExtensionMember"
      decimals="0"
      id="Fact001569"
      unitRef="USD">3805</coep:MonthlyRent>
    <coep:MonthlyRent
      contextRef="From2025-01-012025-12-31_custom_SecondYearExtensionMember"
      decimals="0"
      id="Fact001571"
      unitRef="USD">3860</coep:MonthlyRent>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001573"
      unitRef="USD">46101</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001575"
      unitRef="USD">45440</us-gaap:OperatingLeaseExpense>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001577">&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--LeaseCostTableTextBlock_zNurRGb4gJA9" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details - Lease cost)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_8B9_zfBMVeVu1fG1" style="display: none"&gt;Schedule of lease information&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;December 31, 2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;December 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 68%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Office lease&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--OperatingLeaseRightOfUseAssetGross_iI_c20251231_zTI5yKVpn9L7" style="width: 13%; text-align: right" title="Operating lease right of use asset, gross"&gt;&lt;span style="font-size: 10pt"&gt;243,550&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--OperatingLeaseRightOfUseAssetGross_iI_c20241231_zCNmIOx5AEda" style="width: 13%; text-align: right" title="Operating lease right of use asset, gross"&gt;&lt;span style="font-size: 10pt"&gt;243,550&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--OperatingLeaseRightOfUseAssetAccumulatedDepreciation_iNI_di_c20251231_zfjJ2CGRwWsd" style="border-bottom: Black 1pt solid; text-align: right" title="Operating lease right of use asset, accumulated depreciation"&gt;&lt;span style="font-size: 10pt"&gt;(225,151&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--OperatingLeaseRightOfUseAssetAccumulatedDepreciation_iNI_di_c20241231_zeEO5zVDrf14" style="border-bottom: Black 1pt solid; text-align: right" title="Operating lease right of use asset, accumulated depreciation"&gt;&lt;span style="font-size: 10pt"&gt;(183,767&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Right of use asset, net&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20251231_z3MqBXwIerud" style="border-bottom: black 2.25pt double; text-align: right" title="Operating lease right of use asset"&gt;&lt;span style="font-size: 10pt"&gt;18,399&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20241231_z29q7WIDxG68" style="border-bottom: black 2.25pt double; text-align: right" title="Operating lease right of use asset"&gt;&lt;span style="font-size: 10pt"&gt;59,783&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Operating lease liability is summarized below:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;December 31, 2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;December 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 68%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Office lease&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--OperatingLeaseLiability_iI_c20251231_z52hvCDNi538" style="width: 13%; text-align: right" title="Operating lease liability"&gt;&lt;span style="font-size: 10pt"&gt;18,875&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--OperatingLeaseLiability_iI_c20241231_z3X3UlzHpbR9" style="width: 13%; text-align: right" title="Operating lease liability"&gt;&lt;span style="font-size: 10pt"&gt;61,180&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_c20251231_zbwMKcGw5RS1" style="border-bottom: Black 1pt solid; text-align: right" title="Operating lease liability, current"&gt;&lt;span style="font-size: 10pt"&gt;(18,875&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_c20241231_zaYiadVVq5g1" style="border-bottom: Black 1pt solid; text-align: right" title="Operating lease liability, current"&gt;&lt;span style="font-size: 10pt"&gt;(42,305&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Long term portion&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_d0_c20251231_z5wk0aoUsIM" style="border-bottom: black 2.25pt double; text-align: right" title="Operating lease liability, noncurrent"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20241231_zrViZofdPv1h" style="border-bottom: black 2.25pt double; text-align: right" title="Operating lease liability, noncurrent"&gt;&lt;span style="font-size: 10pt"&gt;18,875&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:LeaseCostTableTextBlock>
    <coep:OperatingLeaseRightOfUseAssetGross
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001579"
      unitRef="USD">243550</coep:OperatingLeaseRightOfUseAssetGross>
    <coep:OperatingLeaseRightOfUseAssetGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001581"
      unitRef="USD">243550</coep:OperatingLeaseRightOfUseAssetGross>
    <coep:OperatingLeaseRightOfUseAssetAccumulatedDepreciation
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001583"
      unitRef="USD">225151</coep:OperatingLeaseRightOfUseAssetAccumulatedDepreciation>
    <coep:OperatingLeaseRightOfUseAssetAccumulatedDepreciation
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001585"
      unitRef="USD">183767</coep:OperatingLeaseRightOfUseAssetAccumulatedDepreciation>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001587"
      unitRef="USD">18399</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001589"
      unitRef="USD">59783</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001591"
      unitRef="USD">18875</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001593"
      unitRef="USD">61180</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001595"
      unitRef="USD">18875</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001597"
      unitRef="USD">42305</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001599"
      unitRef="USD">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001601"
      unitRef="USD">18875</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001603">&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zhfD5xWoCW72" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details - Future minimum payments)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 84%"&gt;&lt;span id="xdx_8B8_zj1SoMqSanta" style="display: none"&gt;Schedule of future minimum rental payments&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49E_20251231_zvweQfOVXaz9" style="text-align: center; width: 13%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzRwJ_zcNnpXsH026b" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;2026&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;19,301&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzRwJ_zf9cpLG5IKMj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Total minimum lease payments:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;19,301&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zvJXonsH07G8" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;Less amount representing interest&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(426&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Present value of minimum lease payments:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;18,875&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001605"
      unitRef="USD">19301</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001607"
      unitRef="USD">19301</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001609"
      unitRef="USD">426</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001611"
      unitRef="USD">18875</us-gaap:OperatingLeaseLiability>
    <coep:AnnualSalary
      contextRef="From2025-01-012025-12-31_custom_MehalickMember"
      decimals="0"
      id="Fact001613"
      unitRef="USD">360000</coep:AnnualSalary>
    <coep:AnnualSalary
      contextRef="From2025-01-012025-12-31_custom_YeraceMember"
      decimals="0"
      id="Fact001615"
      unitRef="USD">360000</coep:AnnualSalary>
    <coep:InitialLicenseFee
      contextRef="AsOf2022-08-31_custom_CarTLicenseMember"
      decimals="0"
      id="Fact001617"
      unitRef="USD">75000</coep:InitialLicenseFee>
    <coep:AnnualMaintenanceFeeDescription
      contextRef="From2022-08-292022-08-31_custom_CarTLicenseMember"
      id="Fact001619">annual
maintenance fees ranging between $15,000 and $25,000</coep:AnnualMaintenanceFeeDescription>
    <us-gaap:ContractualObligation
      contextRef="AsOf2025-12-31_custom_CarTLicenseMember"
      decimals="0"
      id="Fact001621"
      unitRef="USD">716714</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001623"
      unitRef="USD">0</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001625"
      unitRef="USD">507535</us-gaap:ContractualObligation>
    <coep:AgreementAmendmentFee
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="Fact001630"
      unitRef="USD">2000</coep:AgreementAmendmentFee>
    <us-gaap:PaymentsForFees
      contextRef="From2025-01-012025-12-31_custom_FindersFeeAndIndemnityAgreementMember"
      decimals="0"
      id="Fact001632"
      unitRef="USD">103500</us-gaap:PaymentsForFees>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-12-31_custom_MasterServicesAgreementsMember"
      decimals="0"
      id="Fact001633"
      unitRef="USD">1363045</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="AsOf2025-12-31_custom_MasterServicesAgreementsMember"
      decimals="0"
      id="Fact001635"
      unitRef="USD">599455</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:PaymentsForFees
      contextRef="From2025-01-012025-12-31_custom_GearCellTherapyPlatformMember"
      decimals="0"
      id="Fact001637"
      unitRef="USD">400000</us-gaap:PaymentsForFees>
    <us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001639">&lt;p id="xdx_806_eus-gaap--CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_zMQNysjO24Da" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 11 - &lt;span id="xdx_825_zJCTDhq7YJi8"&gt;401(k) PROFIT-SHARING
PLAN&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company sponsors a qualified profit-sharing
plan with a 401(k) feature that covers all eligible employees. Participation in the 401(k) feature of the plan is voluntary. Participating
employees may defer up to 100% of their compensation up to the maximum prescribed by the Internal Revenue Code. The plan permits for employee
elective deferrals but has no contribution requirements for the Company. During the years ended December 31, 2025 and 2024,&#160;&lt;span id="xdx_904_eus-gaap--DefinedBenefitPlanContributionsByEmployer_pp0p0_do_c20250101__20251231_zIWhRsvwKX3" title="Employer contributions"&gt;&lt;span id="xdx_90A_eus-gaap--DefinedBenefitPlanContributionsByEmployer_pp0p0_do_c20240101__20241231_zed3SSxxssji" title="Employer contributions"&gt;no&lt;/span&gt;&lt;/span&gt;&#160;employer
contributions were made.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001641"
      unitRef="USD">0</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001643"
      unitRef="USD">0</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001645">&lt;p id="xdx_805_eus-gaap--IncomeTaxDisclosureTextBlock_zhwx7qezIYae" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;b&gt;NOTE
12 &#x2013; &lt;span id="xdx_820_zivfYEtOwphb"&gt;INCOME TAXES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;The Company
has established deferred tax assets and liabilities for the recognition of future deductions or taxable amounts and operating loss carry
forward. Deferred federal and state income tax expense or benefit is recognized as a result of the change in the deferred tax asset or
liability during the year using the currently enacted tax laws and rates that apply to the period in which they are expected to affect
taxable income. Valuation allowances are established, if necessary, to reduce deferred tax assets to the amount that will more likely
than not be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;During
the years ended December 31, 2025 and 2024, a reconciliation of income tax benefit at the statutory rate of 35% and 35%, respectively
to income tax benefit at the Company&#x2019;s effective tax rate is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zQRlzwnj8iTg" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - INCOME TAXES (Details - Reconcilation of income tax)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_8BB_zz5fIkO2LeJe" style="display: none"&gt;Schedule of effective income
    tax reconciliation&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49F_20250101__20251231_zEZKqKHR0Vr4" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49E_20240101__20241231_zw7wqMsWN7r" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_iN_di_zRJCLbPmId39" style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 68%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Income tax benefit at statutory rate&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,983,800&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,455,499&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_pp0p0_di_z7QukHZQwO7d" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(2,983,800&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(2,455,499&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;The income
tax provision differs from the expense that would result from applying federal statutory rates to income taxes as follows:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zuKJKVl0AiLb" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - INCOME TAXES (Details - Reconcilation of provision)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_8B7_zVCL0npBJ3ee" style="display: none"&gt;Schedule of income tax provision&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 44%"&gt;&lt;span style="font-size: 10pt"&gt;Excepted federal statutory income tax provision/rate&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ExpectedIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_iN_di_c20250101__20251231_zgJaatUK6x9c" style="width: 11%; text-align: right" title="Expected federal statutory income tax provision"&gt;&lt;span style="font-size: 10pt"&gt;(2,521,826&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--ExpectedEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pip0_dp_c20250101__20251231_zg0CG6XMikJi" style="font-size: 10pt"&gt;(21.0&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--ExpectedIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_iN_di_c20240101__20241231_zpLeMPaNqmn6" style="width: 11%; text-align: right" title="Expected federal statutory income tax provision/rate"&gt;&lt;span style="font-size: 10pt"&gt;(2,284,257&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_904_ecustom--ExpectedEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_c20240101__20241231_zBq80To0LlB4" style="font-size: 10pt"&gt;(21.0&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_iN_di_c20250101__20251231_zv8bhZNz8msi" style="text-align: right" title="State income taxes, net of federal benefit"&gt;&lt;span style="font-size: 10pt"&gt;(367,582&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pip0_dp_c20250101__20251231_zvrJZoK5FiEf" style="font-size: 10pt"&gt;(3.1&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_iN_di_c20240101__20241231_zQub2Ex3zNI1" style="text-align: right" title="State income taxes, net of federal benefit"&gt;&lt;span style="font-size: 10pt"&gt;(58,863&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_c20240101__20241231_zdkbDi8RN0lh" style="font-size: 10pt"&gt;(0.5&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Other&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--IncomeTaxReconciliationOtherAdjustments_d0_c20250101__20251231_zmxjFEVCrXpb" style="border-bottom: black 1pt solid; text-align: right" title="Other"&gt;&lt;span style="font-size: 10pt"&gt;(94,392&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_iN_pip0_dpi0_c20250101__20251231_zYh3smvTRDvl" style="font-size: 10pt"&gt;(0.8&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--IncomeTaxReconciliationOtherAdjustments_d0_c20240101__20241231_zw8VxXHZ5Shd" style="border-bottom: black 1pt solid; text-align: right" title="Other"&gt;&lt;span style="font-size: 10pt"&gt;(112,379)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_iN_pip0_dpi0_c20240101__20241231_zEBzGddw97je" style="font-size: 10pt"&gt;(1.0&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;%)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Income tax benefit at statutory rate&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maprovision2025_c20250101__20251231_zwemTfow8Awi" style="text-align: right" title="Income tax benefit at statutory rate"&gt;&lt;span style="font-size: 10pt"&gt;(2,983,800&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_pip0_dpi_marate2025_c20250101__20251231_zDODJ5rM56Qc" style="font-size: 10pt"&gt;(24.9&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c20240101__20241231_zMr9ZKcuNona" style="text-align: right" title="Income tax benefit at statutory rate"&gt;&lt;span style="font-size: 10pt"&gt;(2,455,499&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_dpi_c20240101__20241231_z4GVmULZyP7f" style="font-size: 10pt"&gt;(22.6&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maprovision2025_c20250101__20251231_zMUIjVGTqpLc" style="border-bottom: black 1pt solid; text-align: right" title="Change in valuation allowance"&gt;&lt;span style="font-size: 10pt"&gt;2,983,800&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_pip0_dpi_marate2025_c20250101__20251231_zHvwiCenaScl" style="font-size: 10pt"&gt;22.6&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c20240101__20241231_zdyr5v627Cmf" style="border-bottom: black 1pt solid; text-align: right" title="Change in valuation allowance"&gt;&lt;span style="font-size: 10pt"&gt;2,455,499&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_dpi_c20240101__20241231_z1TeO8BKFuMi" style="font-size: 10pt"&gt;22.6&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--IncomeTaxExpenseBenefit_d0_mtprovision2025_c20250101__20251231_z1RqDGAfPcNf" style="border-bottom: black 2.25pt double; text-align: right" title="Effective income tax rate reconciliation"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pip0_dp0_mtrate2025_c20250101__20251231_zhmLjvr2ewz7" style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--IncomeTaxExpenseBenefit_d0_c20240101__20241231_zAUFj5ujmvPi" style="border-bottom: black 2.25pt double; text-align: right" title="Effective income tax rate reconciliation"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pip0_dp0_c20240101__20241231_zstWZS4RSFbh" style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;The Company&#x2019;s
calculation of net operating loss carryforwards:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--SummaryOfOperatingLossCarryforwardsTextBlock_z9tlH1zytSh1" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - INCOME TAXES (Details - Operating loss carryforwards)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_8BB_zd0nrNFVfkUb" style="display: none"&gt;Schedule of net operating loss carryforwards&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49F_20251231_zzT8UvYvcx4f" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_499_20241231_zk929KRLf6K8" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0" style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 68%"&gt;&lt;span style="font-size: 10pt"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;28,184,213&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;24,971,010&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pp0p0" style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Section 174 R&amp;amp;D&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,084,044&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,275,054&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_pp0p0" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;PPE and intangible assets&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;974,646&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;915,327&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsStateTaxes_iNI_pp0p0_di_zxtLMq6E5fo9" style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;State taxes&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(1,667,634&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(1,569,922&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsGross_iI_pp0p0_zDPigNQka0d5" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;28,575,269&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;25,591,469&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_zxpC5d1kvps6" style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Valuation Allowance&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(28,575,269&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(25,591,469&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iI_pp0p0_d0_zNgvx6e3tjdf" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Net deferred tax assets (liabilities)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;At December
31, 2025, the Company had approximately $&lt;span id="xdx_90F_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20251231_zRiquT0WSzX" title="Net operating loss carry forwards"&gt;99,000,000&lt;/span&gt; of unused net operating loss carryforwards. Unused net operating loss carryforwards
may provide future benefits although there can be no assurance that these net operating losses will be realized in the future. The tax
benefits of these loss carryforwards have been fully offset by valuation allowance. These losses may be used to offset future taxable
income and will carryforward indefinitely.&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001647">&lt;table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zQRlzwnj8iTg" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - INCOME TAXES (Details - Reconcilation of income tax)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_8BB_zz5fIkO2LeJe" style="display: none"&gt;Schedule of effective income
    tax reconciliation&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49F_20250101__20251231_zEZKqKHR0Vr4" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49E_20240101__20241231_zw7wqMsWN7r" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_iN_di_zRJCLbPmId39" style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 68%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Income tax benefit at statutory rate&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,983,800&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,455,499&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_pp0p0_di_z7QukHZQwO7d" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(2,983,800&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(2,455,499&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001649"
      unitRef="USD">-2983800</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001650"
      unitRef="USD">-2455499</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001652"
      unitRef="USD">2983800</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001653"
      unitRef="USD">2455499</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001655">&lt;table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zuKJKVl0AiLb" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - INCOME TAXES (Details - Reconcilation of provision)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_8B7_zVCL0npBJ3ee" style="display: none"&gt;Schedule of income tax provision&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 44%"&gt;&lt;span style="font-size: 10pt"&gt;Excepted federal statutory income tax provision/rate&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ExpectedIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_iN_di_c20250101__20251231_zgJaatUK6x9c" style="width: 11%; text-align: right" title="Expected federal statutory income tax provision"&gt;&lt;span style="font-size: 10pt"&gt;(2,521,826&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--ExpectedEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pip0_dp_c20250101__20251231_zg0CG6XMikJi" style="font-size: 10pt"&gt;(21.0&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--ExpectedIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_iN_di_c20240101__20241231_zpLeMPaNqmn6" style="width: 11%; text-align: right" title="Expected federal statutory income tax provision/rate"&gt;&lt;span style="font-size: 10pt"&gt;(2,284,257&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_904_ecustom--ExpectedEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_c20240101__20241231_zBq80To0LlB4" style="font-size: 10pt"&gt;(21.0&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_iN_di_c20250101__20251231_zv8bhZNz8msi" style="text-align: right" title="State income taxes, net of federal benefit"&gt;&lt;span style="font-size: 10pt"&gt;(367,582&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pip0_dp_c20250101__20251231_zvrJZoK5FiEf" style="font-size: 10pt"&gt;(3.1&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_iN_di_c20240101__20241231_zQub2Ex3zNI1" style="text-align: right" title="State income taxes, net of federal benefit"&gt;&lt;span style="font-size: 10pt"&gt;(58,863&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_c20240101__20241231_zdkbDi8RN0lh" style="font-size: 10pt"&gt;(0.5&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Other&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--IncomeTaxReconciliationOtherAdjustments_d0_c20250101__20251231_zmxjFEVCrXpb" style="border-bottom: black 1pt solid; text-align: right" title="Other"&gt;&lt;span style="font-size: 10pt"&gt;(94,392&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_iN_pip0_dpi0_c20250101__20251231_zYh3smvTRDvl" style="font-size: 10pt"&gt;(0.8&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--IncomeTaxReconciliationOtherAdjustments_d0_c20240101__20241231_zw8VxXHZ5Shd" style="border-bottom: black 1pt solid; text-align: right" title="Other"&gt;&lt;span style="font-size: 10pt"&gt;(112,379)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_iN_pip0_dpi0_c20240101__20241231_zEBzGddw97je" style="font-size: 10pt"&gt;(1.0&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;%)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Income tax benefit at statutory rate&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maprovision2025_c20250101__20251231_zwemTfow8Awi" style="text-align: right" title="Income tax benefit at statutory rate"&gt;&lt;span style="font-size: 10pt"&gt;(2,983,800&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_pip0_dpi_marate2025_c20250101__20251231_zDODJ5rM56Qc" style="font-size: 10pt"&gt;(24.9&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c20240101__20241231_zMr9ZKcuNona" style="text-align: right" title="Income tax benefit at statutory rate"&gt;&lt;span style="font-size: 10pt"&gt;(2,455,499&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_dpi_c20240101__20241231_z4GVmULZyP7f" style="font-size: 10pt"&gt;(22.6&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maprovision2025_c20250101__20251231_zMUIjVGTqpLc" style="border-bottom: black 1pt solid; text-align: right" title="Change in valuation allowance"&gt;&lt;span style="font-size: 10pt"&gt;2,983,800&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_pip0_dpi_marate2025_c20250101__20251231_zHvwiCenaScl" style="font-size: 10pt"&gt;22.6&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c20240101__20241231_zdyr5v627Cmf" style="border-bottom: black 1pt solid; text-align: right" title="Change in valuation allowance"&gt;&lt;span style="font-size: 10pt"&gt;2,455,499&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_dpi_c20240101__20241231_z1TeO8BKFuMi" style="font-size: 10pt"&gt;22.6&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--IncomeTaxExpenseBenefit_d0_mtprovision2025_c20250101__20251231_z1RqDGAfPcNf" style="border-bottom: black 2.25pt double; text-align: right" title="Effective income tax rate reconciliation"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pip0_dp0_mtrate2025_c20250101__20251231_zhmLjvr2ewz7" style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--IncomeTaxExpenseBenefit_d0_c20240101__20241231_zAUFj5ujmvPi" style="border-bottom: black 2.25pt double; text-align: right" title="Effective income tax rate reconciliation"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pip0_dp0_c20240101__20241231_zstWZS4RSFbh" style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <coep:ExpectedIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001657"
      unitRef="USD">2521826</coep:ExpectedIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <coep:ExpectedEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact001658"
      unitRef="Pure">-0.210</coep:ExpectedEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <coep:ExpectedIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001660"
      unitRef="USD">2284257</coep:ExpectedIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <coep:ExpectedEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001661"
      unitRef="Pure">-0.210</coep:ExpectedEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001663"
      unitRef="USD">367582</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact001664"
      unitRef="Pure">-0.031</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001666"
      unitRef="USD">58863</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001667"
      unitRef="Pure">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001669"
      unitRef="USD">-94392</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact001670"
      unitRef="Pure">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001672"
      unitRef="USD">-112379</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001673"
      unitRef="Pure">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001675"
      unitRef="USD">-2983800</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact001676"
      unitRef="Pure">0.249</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001678"
      unitRef="USD">-2455499</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001679"
      unitRef="Pure">0.226</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001681"
      unitRef="USD">2983800</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact001682"
      unitRef="Pure">-0.226</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001684"
      unitRef="USD">2455499</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001685"
      unitRef="Pure">-0.226</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001687"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact001688"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001690"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001691"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001693">&lt;table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--SummaryOfOperatingLossCarryforwardsTextBlock_z9tlH1zytSh1" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - INCOME TAXES (Details - Operating loss carryforwards)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_8BB_zd0nrNFVfkUb" style="display: none"&gt;Schedule of net operating loss carryforwards&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49F_20251231_zzT8UvYvcx4f" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_499_20241231_zk929KRLf6K8" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0" style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 68%"&gt;&lt;span style="font-size: 10pt"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;28,184,213&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;24,971,010&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pp0p0" style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Section 174 R&amp;amp;D&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,084,044&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,275,054&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_pp0p0" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;PPE and intangible assets&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;974,646&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;915,327&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsStateTaxes_iNI_pp0p0_di_zxtLMq6E5fo9" style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;State taxes&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(1,667,634&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(1,569,922&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsGross_iI_pp0p0_zDPigNQka0d5" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;28,575,269&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;25,591,469&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_zxpC5d1kvps6" style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Valuation Allowance&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(28,575,269&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(25,591,469&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iI_pp0p0_d0_zNgvx6e3tjdf" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Net deferred tax assets (liabilities)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001698"
      unitRef="USD">28184213</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001699"
      unitRef="USD">24971010</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001701"
      unitRef="USD">1084044</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001702"
      unitRef="USD">1275054</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001704"
      unitRef="USD">974646</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001705"
      unitRef="USD">915327</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsStateTaxes
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001707"
      unitRef="USD">1667634</us-gaap:DeferredTaxAssetsStateTaxes>
    <us-gaap:DeferredTaxAssetsStateTaxes
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001708"
      unitRef="USD">1569922</us-gaap:DeferredTaxAssetsStateTaxes>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001710"
      unitRef="USD">28575269</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001711"
      unitRef="USD">25591469</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001713"
      unitRef="USD">28575269</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001714"
      unitRef="USD">25591469</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001716"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001717"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001719"
      unitRef="USD">99000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001723">&lt;p id="xdx_807_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zW3f44dxS5Bh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 13 &#x2013; &lt;span id="xdx_82B_zxTHs3KSiwRl"&gt;RELATED PARTY
TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In September 2023, the Company entered into a
transaction with AG Bio Life Capital I LP (&#x201c;AG&#x201d;), a Delaware limited partnership, where an employee of the Company is the
general partner. The Company agreed to issue &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesOther_c20230929__20230930__dei--LegalEntityAxis__custom--AGBioLifeCapitalILPMember_zR1n5s9xhjB" title="Shares issued"&gt;600,000&lt;/span&gt; shares (pre-reverse stock split) of common stock of the Company (&#x201c;AG Shares&#x201d;)
to AG, in exchange for $600,000, consisting of $&lt;span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230929__20230930__dei--LegalEntityAxis__custom--AGBioLifeCapitalILPMember_zzoClMlBNOr2" title="Proceeds from common stock"&gt;100,000&lt;/span&gt;&#160;payable in cash and the balance payable under a promissory note (&#x201c;AG
Note&#x201d;). The principal amount including all interest under the AG Note is due and payable by AG no later than August 30, 2024 (the
&#x201c;AG Maturity Date&#x201d;). The outstanding unpaid principal balance of the AG Note bears interest commencing as of the Company&#x2019;s
next registration statement at the rate of six (6%) percent per annum, which interest rate will increase to eighteen (18%) percent per
annum in the event an event of default occurs under the AG Note, computed on the basis of the actual number of days elapsed and a year
of 365 days. On August
12, 2024, AG transferred and assigned $&lt;span id="xdx_90D_eus-gaap--AccountsAndNotesReceivableNet_iI_c20240812__dei--LegalEntityAxis__custom--AGBioLifeCapitalILPMember_zt4MEzfZ3Vm5" title="Note receivable"&gt;522,667&lt;/span&gt; to the Company, the sum of principal and accrued interest owed, of shares of common stock
in a privately held company. As a result of this assignment agreement, the AG Note is considered paid in full, and $&lt;span id="xdx_901_eus-gaap--Investments_iI_pp0p0_c20241231__dei--LegalEntityAxis__custom--AGBioLifeCapitalILPMember_zJj2u1A5LDCj" title="Investment"&gt;&lt;span id="xdx_908_eus-gaap--Investments_iI_pp0p0_c20251231__dei--LegalEntityAxis__custom--AGBioLifeCapitalILPMember_zvYnXx4HlYfa" title="Investment"&gt;522,667&lt;/span&gt;&lt;/span&gt; is recorded
as an investment at December 31, 2025 and December 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2025, the Company accrued $&lt;span id="xdx_901_eus-gaap--AccruedProfessionalFeesCurrent_iI_c20251231__srt--CounterpartyNameAxis__custom--BoardOfDirectorsMember_zj2iVD9VrIYc" title="Accrued professional fees"&gt;32,500&lt;/span&gt;
of professional services expenses related to Board of Directors and Scientific Advisory Board compensation. These payments were completed
in the first quarter of 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2025, the Company holds investments
in certain privately held companies, recorded as investments on the Company&#x2019;s consolidated balance sheets. The Company&#x2019;s Chief
Executive Officer and Chief Financial Officer each hold ownership interests in these privately held companies. The investments were made
in the ordinary course of business and on terms management believes are consistent with those that would be negotiated on an arm&#x2019;s
length basis. As of December 31, 2025 and December 31, 2024, the Company&#x2019;s carrying value of these investments was $&lt;span id="xdx_900_eus-gaap--OtherInvestments_iI_c20251231_zd0uOhaLl93a" title="Other investments"&gt;7,023,583&lt;/span&gt; and
$&lt;span id="xdx_904_eus-gaap--OtherInvestments_iI_c20241231_zzZ8i5BALxYf" title="Other investments"&gt;5,691,084&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2023-09-292023-09-30_custom_AGBioLifeCapitalILPMember"
      decimals="INF"
      id="Fact001725"
      unitRef="Shares">600000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-09-292023-09-30_custom_AGBioLifeCapitalILPMember"
      decimals="0"
      id="Fact001727"
      unitRef="USD">100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:AccountsAndNotesReceivableNet
      contextRef="AsOf2024-08-12_custom_AGBioLifeCapitalILPMember"
      decimals="0"
      id="Fact001729"
      unitRef="USD">522667</us-gaap:AccountsAndNotesReceivableNet>
    <us-gaap:Investments
      contextRef="AsOf2024-12-31_custom_AGBioLifeCapitalILPMember"
      decimals="0"
      id="Fact001731"
      unitRef="USD">522667</us-gaap:Investments>
    <us-gaap:Investments
      contextRef="AsOf2025-12-31_custom_AGBioLifeCapitalILPMember"
      decimals="0"
      id="Fact001733"
      unitRef="USD">522667</us-gaap:Investments>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2025-12-31_custom_BoardOfDirectorsMember"
      decimals="0"
      id="Fact001735"
      unitRef="USD">32500</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherInvestments
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001737"
      unitRef="USD">7023583</us-gaap:OtherInvestments>
    <us-gaap:OtherInvestments
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001739"
      unitRef="USD">5691084</us-gaap:OtherInvestments>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001741">&lt;p id="xdx_80B_eus-gaap--IntangibleAssetsDisclosureTextBlock_znCU8q6tmIEc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 14 &#x2013; &lt;span id="xdx_82F_zGxZBhbJiuUi"&gt;INTANGIBLE ASSETS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 19, 2024, the Company acquired the
assets of NexGenAI Affiliates Network Platform (&#x201c;NexGenAI&#x201d;), from the seller NexGenAI Solutions Group, Inc., which contains
AI-powered marketing software and robotic process automation capabilities. The acquired assets include intellectual property, a domain
name and associated website, and the technology stack as defined in the agreement. As consideration for the purchase, the Company paid
the seller &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20241218__20241219__srt--CounterpartyNameAxis__custom--NexGenAISolutionsGroupIncMember_zxxpMjYJ7uMc" title="Stock issued for purchase of assets, shares"&gt;187,500&lt;/span&gt; shares of common stock, or $&lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_c20241218__20241219__srt--CounterpartyNameAxis__custom--NexGenAISolutionsGroupIncMember_zPXxYWvYHTBf" title="Stock issued for purchase of assets, value"&gt;541,875&lt;/span&gt;. In connection with the purchase, the Company entered into a Master Services Agreement
with the seller, for website development services and for services to enhance the existing technology.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company accounted for the NexGenAI
transaction as an asset acquisition in accordance with ASC 805-50, &lt;i&gt;Business Combinations &#x2013; Asset Acquisitions&lt;/i&gt;, and
recorded as intangible assets on the consolidated balance sheet, net of amortization, in the amount of $&lt;span id="xdx_907_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NexGenAIMember_zEZSlZrsouye"&gt;361,250&lt;/span&gt;
and $&lt;span id="xdx_907_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NexGenAIMember_zRwZr0OfhrS2"&gt;541,875&lt;/span&gt; as of December 31,
2025 and December 31, 2024, respectively. The Company recorded amortization expense of $&lt;span id="xdx_902_eus-gaap--AmortizationOfIntangibleAssets_c20250101__20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NexGenAIMember_zzOPVyxdJ9Xa" title="Amortization of intangible assets"&gt;180,625&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NexGenAIMember_zmayEPTz88A8" title="Amortization of intangible assets"&gt;0&lt;/span&gt; during the years ended
December 31, 2025 and 2024, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="From2024-12-182024-12-19_custom_NexGenAISolutionsGroupIncMember"
      decimals="INF"
      id="Fact001743"
      unitRef="Shares">187500</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2024-12-182024-12-19_custom_NexGenAISolutionsGroupIncMember"
      decimals="0"
      id="Fact001745"
      unitRef="USD">541875</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2025-12-31_custom_NexGenAIMember"
      decimals="0"
      id="Fact001746"
      unitRef="USD">361250</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2024-12-31_custom_NexGenAIMember"
      decimals="0"
      id="Fact001747"
      unitRef="USD">541875</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2025-01-012025-12-31_custom_NexGenAIMember206525843"
      decimals="0"
      id="Fact001749"
      unitRef="USD">180625</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-01-012024-12-31_custom_NexGenAIMember206525843"
      decimals="0"
      id="Fact001751"
      unitRef="USD">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001753">&lt;p id="xdx_80A_eus-gaap--SegmentReportingDisclosureTextBlock_zY5Niu9LSMA7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 15 &#x2013;&#160;&lt;span id="xdx_82A_zw6rAoezTV4k"&gt;SEGMENT REPORTING&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Operating segments are components of an enterprise
about which separate financial information is available and is evaluated regularly by management, namely the Chief Operating Decision
Maker (&#x201c;CODM&#x201d;) of an organization, in order to determine operating and resource allocation decisions. By this definition,
the Company has identified its Chief Executive Officer as the CODM. Effective in 2024, the Company began operating in &lt;span id="xdx_90B_eus-gaap--NumberOfReportableSegments_dxL_uInteger_c20250101__20251231_zb3RIjcYUnDb" title="Number of reportable segments::XDX::2"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1755"&gt;two&lt;/span&gt;&lt;/span&gt; segments: Biotechnology
and Technology. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Biotechnology Segment: This segment is non-revenue
generating and incurs expenses by developing its biotechnology product pipeline. The Biotechnology Segment had total assets of $&lt;span id="xdx_904_eus-gaap--Assets_iI_c20251231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologySegmentMember_zoqgt0yQYyVf" title="Total assets"&gt;13,783,575&lt;/span&gt;
and $&lt;span id="xdx_90B_eus-gaap--Assets_iI_c20241231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologySegmentMember_zXVZlhuEh8Rf" title="Total assets"&gt;8,366,785&lt;/span&gt; as of December 31, 2025 and December 31, 2024, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Technology Segment: This segment is revenue
generating and incurs expenses by acquiring technology assets to support and enhance operational capabilities through advanced technologies.
The Technology Segment had total assets of $&lt;span id="xdx_901_eus-gaap--Assets_iI_c20251231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologySegmentMember_zxE2wSUQ1rq3" title="Total assets"&gt;2,370,346&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--Assets_iI_c20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologySegmentMember_zPVZQ3Gu47Z9" title="Total assets"&gt;541,875&lt;/span&gt; as of December 31, 2025 and December 31, 2024, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company believes that this structure reflects
its current operational and financial management, and that it provides the best structure for the Company to focus on growth opportunities
while maintaining financial discipline. The factors used to identify the Biotechnology and Technology operating segments were the difference
in future potential revenue streams and customer base for each segment, the reporting structure for operational and performance information
within the Company, and management&#x2019;s decision to organize the Company around the different future potential revenue generating activities
of the segments.&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Segment information relating the Company's two operating segments
for the years ended December 31, 2025 and December 31, 2024 are as follows:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zjX9HX3W2cJ8" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - SEGMENT REPORTING (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span id="xdx_8B3_zhFTKBU63z7i" style="display: none"&gt;Schedule of segment information&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Year Ended December 31, 2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Biotechnology Segment&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Technology &lt;br/&gt;
Segment&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Consolidated&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 58%"&gt;&lt;span style="font-size: 10pt"&gt;Sales&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--Revenues_d0_c20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_zjOPg0dyozD" style="width: 11%; text-align: right" title="Sales"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--Revenues_c20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyMember_zuSi0ncYYfZ4" style="width: 11%; text-align: right" title="Sales"&gt;&lt;span style="font-size: 10pt"&gt;1,363,045&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--Revenues_c20250101__20251231_zt2l2Yxxzvah" style="width: 11%; text-align: right" title="Sales"&gt;&lt;span style="font-size: 10pt"&gt;1,363,045&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--CostOfRevenue_d0_c20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_z1mQVpjjabw5" style="text-align: right" title="Cost of goods sold"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--CostOfRevenue_c20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyMember_zQ2UtSYCMW95" style="text-align: right" title="Cost of goods sold"&gt;&lt;span style="font-size: 10pt"&gt;180,625&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--CostOfRevenue_c20250101__20251231_zdGumLwZcbV9" style="text-align: right" title="Cost of goods sold"&gt;&lt;span style="font-size: 10pt"&gt;180,625&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--OperatingExpenses_c20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_zRhfiiVMtsQj" style="border-bottom: black 1pt solid; text-align: right" title="Total operating expenses"&gt;&lt;span style="font-size: 10pt"&gt;13,540,971&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--OperatingExpenses_c20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyMember_zFIuUn47BtQg" style="border-bottom: black 1pt solid; text-align: right" title="Total operating expenses"&gt;&lt;span style="font-size: 10pt"&gt;684,947&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--OperatingExpenses_c20250101__20251231_zizQaAuvHgX8" style="border-bottom: black 1pt solid; text-align: right" title="Total operating expenses"&gt;&lt;span style="font-size: 10pt"&gt;14,225,918&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Net (loss) gain from operations&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--OperatingIncomeLoss_c20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_zvvYDj8S3lU" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss from operations"&gt;&lt;span style="font-size: 10pt"&gt;(13,540,971&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--OperatingIncomeLoss_c20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyMember_zHMKDyZHlpV5" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss from operations"&gt;&lt;span style="font-size: 10pt"&gt;497,473&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--OperatingIncomeLoss_c20250101__20251231_ziLj9kCiPnkj" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss from operations"&gt;&lt;span style="font-size: 10pt"&gt;(13,043,498&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - SEGMENT REPORTING (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Year Ended December 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Biotechnology Segment&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Technology &lt;/b&gt;&lt;/span&gt;&lt;br/&gt;
&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Segment&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Consolidated&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 61%"&gt;&lt;span style="font-size: 10pt"&gt;Sales&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--Revenues_d0_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_zRch71FsyVI1" style="width: 10%; text-align: right" title="Sales"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--Revenues_d0_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyMember_zUGb5ZvWrtNk" style="width: 10%; text-align: right" title="Sales"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--Revenues_d0_c20240101__20241231_zPccjbODzKA5" style="width: 10%; text-align: right" title="Sales"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--CostOfRevenue_d0_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_zIWFmPX2DPKj" style="text-align: right" title="Cost of goods sold"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--CostOfRevenue_d0_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyMember_zLUfAV0Y7P9a" style="text-align: right" title="Cost of goods sold"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--CostOfRevenue_d0_c20240101__20241231_zZD7MCnt0iKf" style="text-align: right" title="Cost of goods sold"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--OperatingExpenses_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_zO2St6XwO9Wa" style="border-bottom: black 1pt solid; text-align: right" title="Total operating expenses"&gt;&lt;span style="font-size: 10pt"&gt;10,054,488&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--OperatingExpenses_d0_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyMember_znnmn6cYX5D3" style="border-bottom: black 1pt solid; text-align: right" title="Total operating expenses"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--OperatingExpenses_c20240101__20241231_zOWjJnUP578e" style="border-bottom: black 1pt solid; text-align: right" title="Total operating expenses"&gt;&lt;span style="font-size: 10pt"&gt;10,054,488&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Net loss from operations&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--OperatingIncomeLoss_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_zxUQWwHKpD9k" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss from operations"&gt;&lt;span style="font-size: 10pt"&gt;(10,054,488&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--OperatingIncomeLoss_d0_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyMember_zYzKkFg1aHWd" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss from operations"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--OperatingIncomeLoss_c20240101__20241231_z1Se8kIKBQFh" style="border-bottom: Black 2.5pt double; text-align: right" title="Net (loss) gain from operations"&gt;&lt;span style="font-size: 10pt"&gt;(10,054,488&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A9_zz9cU8sRXl2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:Assets
      contextRef="AsOf2025-12-31_custom_BiotechnologySegmentMember"
      decimals="0"
      id="Fact001757"
      unitRef="USD">13783575</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31_custom_BiotechnologySegmentMember"
      decimals="0"
      id="Fact001759"
      unitRef="USD">8366785</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2025-12-31_custom_TechnologySegmentMember"
      decimals="0"
      id="Fact001761"
      unitRef="USD">2370346</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31_custom_TechnologySegmentMember"
      decimals="0"
      id="Fact001763"
      unitRef="USD">541875</us-gaap:Assets>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001768">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zjX9HX3W2cJ8" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - SEGMENT REPORTING (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span id="xdx_8B3_zhFTKBU63z7i" style="display: none"&gt;Schedule of segment information&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Year Ended December 31, 2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Biotechnology Segment&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Technology &lt;br/&gt;
Segment&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Consolidated&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 58%"&gt;&lt;span style="font-size: 10pt"&gt;Sales&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--Revenues_d0_c20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_zjOPg0dyozD" style="width: 11%; text-align: right" title="Sales"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--Revenues_c20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyMember_zuSi0ncYYfZ4" style="width: 11%; text-align: right" title="Sales"&gt;&lt;span style="font-size: 10pt"&gt;1,363,045&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--Revenues_c20250101__20251231_zt2l2Yxxzvah" style="width: 11%; text-align: right" title="Sales"&gt;&lt;span style="font-size: 10pt"&gt;1,363,045&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--CostOfRevenue_d0_c20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_z1mQVpjjabw5" style="text-align: right" title="Cost of goods sold"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--CostOfRevenue_c20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyMember_zQ2UtSYCMW95" style="text-align: right" title="Cost of goods sold"&gt;&lt;span style="font-size: 10pt"&gt;180,625&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--CostOfRevenue_c20250101__20251231_zdGumLwZcbV9" style="text-align: right" title="Cost of goods sold"&gt;&lt;span style="font-size: 10pt"&gt;180,625&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--OperatingExpenses_c20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_zRhfiiVMtsQj" style="border-bottom: black 1pt solid; text-align: right" title="Total operating expenses"&gt;&lt;span style="font-size: 10pt"&gt;13,540,971&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--OperatingExpenses_c20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyMember_zFIuUn47BtQg" style="border-bottom: black 1pt solid; text-align: right" title="Total operating expenses"&gt;&lt;span style="font-size: 10pt"&gt;684,947&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--OperatingExpenses_c20250101__20251231_zizQaAuvHgX8" style="border-bottom: black 1pt solid; text-align: right" title="Total operating expenses"&gt;&lt;span style="font-size: 10pt"&gt;14,225,918&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Net (loss) gain from operations&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--OperatingIncomeLoss_c20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_zvvYDj8S3lU" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss from operations"&gt;&lt;span style="font-size: 10pt"&gt;(13,540,971&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--OperatingIncomeLoss_c20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyMember_zHMKDyZHlpV5" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss from operations"&gt;&lt;span style="font-size: 10pt"&gt;497,473&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--OperatingIncomeLoss_c20250101__20251231_ziLj9kCiPnkj" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss from operations"&gt;&lt;span style="font-size: 10pt"&gt;(13,043,498&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - SEGMENT REPORTING (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Year Ended December 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Biotechnology Segment&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Technology &lt;/b&gt;&lt;/span&gt;&lt;br/&gt;
&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Segment&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Consolidated&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 61%"&gt;&lt;span style="font-size: 10pt"&gt;Sales&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--Revenues_d0_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_zRch71FsyVI1" style="width: 10%; text-align: right" title="Sales"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--Revenues_d0_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyMember_zUGb5ZvWrtNk" style="width: 10%; text-align: right" title="Sales"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--Revenues_d0_c20240101__20241231_zPccjbODzKA5" style="width: 10%; text-align: right" title="Sales"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--CostOfRevenue_d0_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_zIWFmPX2DPKj" style="text-align: right" title="Cost of goods sold"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--CostOfRevenue_d0_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyMember_zLUfAV0Y7P9a" style="text-align: right" title="Cost of goods sold"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--CostOfRevenue_d0_c20240101__20241231_zZD7MCnt0iKf" style="text-align: right" title="Cost of goods sold"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--OperatingExpenses_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_zO2St6XwO9Wa" style="border-bottom: black 1pt solid; text-align: right" title="Total operating expenses"&gt;&lt;span style="font-size: 10pt"&gt;10,054,488&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--OperatingExpenses_d0_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyMember_znnmn6cYX5D3" style="border-bottom: black 1pt solid; text-align: right" title="Total operating expenses"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--OperatingExpenses_c20240101__20241231_zOWjJnUP578e" style="border-bottom: black 1pt solid; text-align: right" title="Total operating expenses"&gt;&lt;span style="font-size: 10pt"&gt;10,054,488&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Net loss from operations&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--OperatingIncomeLoss_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_zxUQWwHKpD9k" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss from operations"&gt;&lt;span style="font-size: 10pt"&gt;(10,054,488&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--OperatingIncomeLoss_d0_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyMember_zYzKkFg1aHWd" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss from operations"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--OperatingIncomeLoss_c20240101__20241231_z1Se8kIKBQFh" style="border-bottom: Black 2.5pt double; text-align: right" title="Net (loss) gain from operations"&gt;&lt;span style="font-size: 10pt"&gt;(10,054,488&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-12-31_custom_BiotechnologyMember"
      decimals="0"
      id="Fact001770"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-12-31_custom_TechnologyMember"
      decimals="0"
      id="Fact001772"
      unitRef="USD">1363045</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001774"
      unitRef="USD">1363045</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="From2025-01-012025-12-31_custom_BiotechnologyMember"
      decimals="0"
      id="Fact001776"
      unitRef="USD">0</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2025-01-012025-12-31_custom_TechnologyMember"
      decimals="0"
      id="Fact001778"
      unitRef="USD">180625</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001780"
      unitRef="USD">180625</us-gaap:CostOfRevenue>
    <us-gaap:OperatingExpenses
      contextRef="From2025-01-012025-12-31_custom_BiotechnologyMember"
      decimals="0"
      id="Fact001782"
      unitRef="USD">13540971</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2025-01-012025-12-31_custom_TechnologyMember"
      decimals="0"
      id="Fact001784"
      unitRef="USD">684947</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001786"
      unitRef="USD">14225918</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-012025-12-31_custom_BiotechnologyMember"
      decimals="0"
      id="Fact001788"
      unitRef="USD">-13540971</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-012025-12-31_custom_TechnologyMember"
      decimals="0"
      id="Fact001790"
      unitRef="USD">497473</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001792"
      unitRef="USD">-13043498</us-gaap:OperatingIncomeLoss>
    <us-gaap:Revenues
      contextRef="From2024-01-012024-12-31_custom_BiotechnologyMember"
      decimals="0"
      id="Fact001794"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-01-012024-12-31_custom_TechnologyMember"
      decimals="0"
      id="Fact001796"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001798"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="From2024-01-012024-12-31_custom_BiotechnologyMember"
      decimals="0"
      id="Fact001800"
      unitRef="USD">0</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2024-01-012024-12-31_custom_TechnologyMember"
      decimals="0"
      id="Fact001802"
      unitRef="USD">0</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001804"
      unitRef="USD">0</us-gaap:CostOfRevenue>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-012024-12-31_custom_BiotechnologyMember"
      decimals="0"
      id="Fact001806"
      unitRef="USD">10054488</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-012024-12-31_custom_TechnologyMember"
      decimals="0"
      id="Fact001808"
      unitRef="USD">0</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001810"
      unitRef="USD">10054488</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-012024-12-31_custom_BiotechnologyMember"
      decimals="0"
      id="Fact001812"
      unitRef="USD">-10054488</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-012024-12-31_custom_TechnologyMember"
      decimals="0"
      id="Fact001814"
      unitRef="USD">0</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001816"
      unitRef="USD">-10054488</us-gaap:OperatingIncomeLoss>
    <coep:PendingMergerTransactionDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001818">&lt;p id="xdx_808_ecustom--PendingMergerTransactionDisclosureTextBlock_zLg0tYgYaVR8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 16 &#x2013; &lt;span id="xdx_823_zbJIHfzTMJCg"&gt;PENDING MERGER
TRANSACTION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 25, 2025, the Company (&#x201c;Coeptis&#x201d;
or the &#x201c;Purchaser&#x201d;), entered into an Agreement and Plan of Merger (the &#x201c;Merger Agreement&#x201d;) with CP Merger Sub
Inc., a Wyoming corporation and wholly-owned subsidiary of Coeptis (&#x201c;Merger Sub&#x201d;), and Z Squared, Inc., a Wyoming corporation
(&#x201c;Z Squared&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the Merger Agreement, subject to the
terms and conditions set forth therein, upon the consummation of the transactions contemplated by the Merger Agreement (the &#x201c;Closing&#x201d;),
(i) Merger Sub will merge with and into Z Squared (the &#x201c;Merger&#x201d;) and (ii) Coeptis will immediately prior to the Merger effect
a spin out of its biotechnology operations (the &#x201c;Spin Out&#x201d; and, together with Merger and the other transactions contemplated
by the Merger Agreement, the &#x201c;Transactions&#x201d;), with Z squared continuing as the surviving corporation in the Merger and becoming
a wholly-owned subsidiary of Coeptis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In the Merger, all shares of Z Squared common
stock issued and outstanding immediately prior to the effective time of the Merger (other than those properly exercising any applicable
dissenters rights under Wyoming law), will be converted into the right to receive a portion of the Merger Consideration (as defined below)
and (ii) any other outstanding securities with the right to convert into or acquire equity securities of Z Squared will be terminated.
At the Closing, Coeptis will change its name as mutually agreed upon by the Purchaser and Z Squared. &lt;span&gt;The
Merger is expected to close in the second quarter 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In connection with the Spin Out, all of Coeptis&#x2019;
assets comprising its biotechnology business will be assigned and contributed prior to Closing to one or more Spin Out Subsidiaries, which
will then spin out to Coeptis&#x2019; stockholders of record on the record date established for the Coeptis Special Meeting (as defined
below).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The aggregate Merger Consideration received by
Z Squared security holders from Coeptis at the Closing will be a number of shares of Purchaser Common Stock that represents at Closing
the Applicable Percentage of Purchaser&#x2019;s issued and outstanding shares of Purchaser Common Stock as calculated on a Fully-Diluted
Basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</coep:PendingMergerTransactionDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001820">&lt;p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_zf7swnmyJLMh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE
17 &#x2013; &lt;span id="xdx_820_zrwqph3Huiol"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Management has performed a review of all events
and transactions occurring after December 31, 2025 for items that would require adjustment to or disclosure in the accompanying consolidated
financial statements, noting no such items or transactions other than the following.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 12, 2026, the Company received a written
notice from The Nasdaq Stock Market (&#x201c;Nasdaq&#x201d;), indicating that the Company was not in compliance with Nasdaq Listing Rules
5620(a) and 5810(c)(2)G) due to the Company&#x2019;s failure to hold an annual meeting of shareholders within twelve months of the end
of the Company&#x2019;s fiscal year end of December 31, 2024. On February 9, 2026, the Company was notified by The Nasdaq Stock Market
that the Company has regained compliance with the annual meeting requirement for continued listing on The Nasdaq Capital Market. Accordingly,
the Company has regained compliance with Nasdaq Listing Rules and the matter is now closed.&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 12, 2026, 1,464 shares of common stock
were issued in connection the SEPA, resulting in net cash proceeds of $20,862.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 28, 2026, 13,809 shares of common stock
were issued in connection the SEPA, resulting in net cash proceeds of $180,942.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 5, 2026, 24,000 shares of common stock
were issued in connection the SEPA, resulting in net cash proceeds of $302,450.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 11, 2026, the Company implemented
an option repricing/exchange program pursuant to Option Repricing and Exchange Election Agreements (the Option/Exchange Agreements) with
its then current holders of options previously granted under the Company&#x2019;s 2022 Equity Incentive Plan, including each of the Company&#x2019;s
current officers and directors. These Option/Exchange Agreements provided a one-time opportunity for the option holders to elect to either
(i) have a one-time option repricing be applied to their respective options with exercise prices greater than the current fair market
value of the Company&#x2019;s common stock or (ii) surrender their outstanding options with exercise prices greater than the current fair
market value of the Company&#x2019;s common stock in exchange for restricted stock. In connection with the Option/Exchange Program, the
Company also accelerated vesting of all options including those with exercise prices greater than the current fair market value of the
Company&#x2019;s common stock, such that all options became fully vested.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s Board of Directors approved
the Option/Exchange program, including the accelerated vesting and the optionality of electing to reprice certain options or replace such
options with restricted stock. The Company&#x2019;s stockholders approved this one-time repricing or exchange event at its recent stockholders
meeting.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to these Option/Exchange Agreements,
officers and directors surrendered options to purchase a total of 112,500 shares of common stock, and received in exchange thereof 112,500
shares of restricted stock. Other option holders surrendered a total of 17,125 options to purchase shares of common stock and received
in exchange thereof 17,125 shares of restricted stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In addition, certain officers and directors of
the Company exercised their respective retained options in full, pursuant to which officers and directors exercised options to purchase
a total of 198,375 shares of restricted common stock. Other option holders exercised options to purchase a total of 9,000 shares of restricted
common stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Option/Exchange Agreements include customary
representations and warranties and acknowledgements by the participants. The foregoing description of the Option/Exchange Agreements does
not purport to be complete and is qualified in its entirety by reference to the full text of the Option/Exchange Agreements, a form of
which will be filed as an exhibit to a subsequent filing with the Securities and Exchange Commission.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On March 2, 2026, the holder of a standalone option exercised the option
to purchase 100,000 shares of the Company&#x2019;s common stock. Upon exercise of the option, the Company issued 100,000 shares of restricted
common stock in accordance with the terms of the option agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
